PRE-MEETING COURSES - American College of Rheumatology

B:11.125 in 

T:10.875 in 

S:9.875 in 

program 

B O O K 

Pre-meeting Courses: November 9-10, 2012 

opening lecture and awards, opening event: November 10, 2012 

Scientific Sessions: November 10-14, 2012

IMPORTANT LOCATIONS 

ACR Office ............................................102A; Telephone: (202) 249-4001 

Attendee Lounge.......................................Ballroom Pre-Function 

Business Center........................................L Street South Lobby (under escalator) 

Career Connection .....................................Exhibit Hall (Hall A), Booth 945 

Child Care.............................................Call for Location; Telephone: (202) 249-4008 

CME/Internet Center ...................................Concourse (near entrance to Hall A) 

Coat/Baggage Check....................................Registration (Salons G-H-I) 

Exhibit Hall............................................Hall A 

First Aid ..............................................Exhibit Hall (Hall A, bottom of escalator) 

Graffiti Walls ..........................................Exhibit Hall (Hall A) & Grand Lobby 

Hotel Reservations.....................................Registration (Salons G-H-I) 

Industry-Supported Symposia Information. ................L Street South Lobby (under escalator) 

Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall A, Booth 1451 

Lost and Found ........................................ACR Office (102A) 

Membership Booth.....................................Registration (Salons G-H-I) 

Newsroom. ...........................................203A-B; Telephone: (202) 249-4005 

Nursing Mothers’ Room.................................Salon D 

Poster Hall. ...........................................Hall B 

Prayer Room ..........................................Salon E (East Building, Street Level) 

Recharge Areas........................................Exhibit Hall (Hall A, main aisles), 

Attendee Lounge (Ballroom Pre-Function) 

and large meeting rooms 

Registration...........................................Salons G-H-I (Level 1) 

Resource Center .......................................L Street Bridge (Level 2) 

Restaurant Reservations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Grand Lobby 

Rheumatology Research Foundation 

5K Run/Walk Registration ...............................Registration (Salons G-H-I) 

Rheumatology Research Foundation Booth ................L Street Bridge (Level 2) 


Donors’ Lounge........................................East Overlook (2nd Floor) 

Ribbon Distribution. ....................................Registration (Salons G-H-I) 

SessionSelect Lounge ...................................West Overlook (2nd Floor) 

Shuttle Bus............................................L Street 

Speakers’ Lounge ......................................141 

Speaker Ready Room...................................156 

Visitor Information.....................................Grand Lobby 

Wheelchairs (complimentary-limited availability) ...........Information Desk (Grand Lobby) 

Wi-Fi Way ............................................Exhibit Hall (Hall A) 

Special Needs 

If you require special arrangements, please contact the ACR Office (102A); Telephone: (202) 249-4001. 

Emergency Contact Information 

Space is provided on the back of your badge to list name and telephone numbers of your emergency 

contacts. Please complete this information before inserting your badge in your badge holder. 

JF 7/17 

ENEBRO120 ACR JA AD 

TRIM: 8.375" x 10.875" 

BLEED: .125" 

LIVE: 6.875" x 9.875"

program 

B O O K 

ABOUT THE ANNUAL MEETING 

Participation Statement 

This annual meeting is sponsored by the American College of Rheumatology for educational purposes only. The material 

presented is not intended to represent the only or the best methods appropriate for the medical conditions being discussed, 

but rather is intended to present the opinions of the authors or presenters, which may be helpful to other healthcare 

professionals at arriving at their own conclusions and consequent application. Attendees participating in this medical 

education program do so with full knowledge that they waive any claim they may have against the College for reliance on 

any information presented during these educational activities. The College does not guarantee, warrant or endorse any 

commercial products or services. 

The ACR’s CME purpose is to provide comprehensive education to improve the knowledge and performance of physicians, 

scientists and other health professionals. The ACR will offer evidence-based educational activities designed to enhance 

practice performance and improve the quality of care in those with or at risk for arthritis and rheumatic and musculoskeletal 

diseases. 

Global Learning Objectives 

At the conclusion of the 2012 ACR/ARHP annual meeting, participants should be able to: 

• identify recent developments in the diagnosis and management of patients with rheumatic diseases 

• outline new technologies for the treatment of rheumatologic problems 

• describe potential challenges in the delivery of care to patients with rheumatic diseases and to specify 

possible solutions 

• utilize new research data to improve the quality of care of patients with rheumatic diseases 

• summarize recent rheumatology research findings 

The program is the result of a planning process that identified educational needs to change or enhance the knowledge, 

competence or performance of rheumatology professionals. The program’s content was derived from both needs assessment 

and practice gap analysis that took professional activities, practice setting, ABIM recertification requirements and physician 

attributes into account. 

Printing of this publication is supported by Amgen, Inc. and Pfizer, Inc. 

This publication was printed by an FSC validated printer on eco-friendly paper.

TABLE OF CONTENTS 

POLICIES 

Copyright Materials Policy .....................................11 

Media ......................................................11 

Embargo Policy ...............................................11 

MEETING INFORMATION 

Cell Phones, PDAs & Other Electronic Devices .....................12 

Children ....................................................12 

Child Care ...................................................12 

Nursing Mothers’ Room .......................................12 

Exhibit Hall ..................................................12 

Meeting Room Capacity/Important First Safety Information ..........12 

Photograpy and Videotaping ...................................12 

Name Badges ................................................12 

No Smoking .................................................12 

MEETING NAVIGATION GUIDE 

Track Icons ..................................................13 

Session Formats ..............................................13 

Abstract Formats .............................................13 

MEETING SERVICES 

My Annual Meeting ..........................................15 

Resource Center ..............................................15 

Membership Booth ...........................................15 

Lost and Found ...............................................15 

Newsroom ..................................................16 

Attendee Lounge .............................................16 

Announcement Boards ........................................16 

Career Connection ............................................16 

Registration Shuttle Bus .......................................16 

Speaker Ready Room ..........................................16 

Wi-Fi Way and Recharge Access .................................16 

Rheumatology Research Foundation Booth .......................17 

Rheumatology Research Foundation Donors’ Lounge ...............17 

Rheumatology Research Foundation 5K Run/Walk ..................17 

SPECIAL OFFERS 

SessionSelect ................................................18 

What Would Make the Meeting Better ...........................19 

Medical Bag .................................................19 

POSTER SESSIONS 

Poster Session Presenter Instructions ............................19 

ACR Poster Presenter No-show Policy ............................19 

Guided Poster Tours ...........................................19 

PRE-MEETING PROGRAM 

Friday, November 9, 2012 

ACR Musculoskeletal Ultrasound Course for Rheumatologists – 

Day One of Two ..............................................20 

ACR Certified Rheumatology Coder Course: Unlock the Mystery: 

A Roadmap for Rheumatology Coding – Day One of Two ............21 

ACR Basic Research Conference: Mesenchymal Cells in Rheumatic 

Diseases: Tissue Erosion/Invasion vs. Fibrosis – Day One of Two ......22 

ACR Clinical Research Conference: Pain Research: New Methods 

and Challenges – Day One of Two ...............................22 

ACR/ABIM Maintenance of Certification Learning Session – 

2012 Update in Rheumatology .................................21 

Saturday, November 10, 2012 

ACR Musculoskeletal Ultrasound Course for Rheumatologists – 

Day Two of Two ..............................................23 

ACR Review Course ...........................................24 

ACR Basic Research Conference: Mesenchymal Cells in Rheumatic 

Diseases: Tissue Erosion/Invasion vs. Fibrosis – Day Two of Two ......25 

ARHP Clinical Focus Course: Treating the Patient with 

Osteoarthritis: Interventions, Innovations and Clinical Insights .......26 

CORC Pre-meeting Course for Practice Managers: Helping You 

Manage A Profitable Practice ..................................27 

ACR Clinical Research Conference: Pain Research: New Methods 

and Challenges – Day Two of Two ...............................27 

ACR Certified Rheumatology Coder Course Examination: 

Unlock the Mystery: A Roadmap for Rheumatology Coding – 

Day Two of Two ..............................................29 

ACR/ARHP ANNUAL MEETING 

SCIENTIFIC PROGRAM 

Saturday, November 10, 2012 

ACR/ARHP Opening Lecture and Awards ..........................29 

Sunday, November 11, 2012 

ACR Sessions 

Modifying Causal Risk Factors that Influence the Incidence of Falls 

by Older Adults ..............................................29 

Year in Review ...............................................30 

Genetics as a Tool for Elucidating Autoimmune Disease 

Pathogenesis ................................................30 

Tips for Publishing Your Work in a Peer-Reviewed Medical 

Journal .....................................................30 

ARHP Sessions 

ARHP First-time Attendee Orientation ............................30 

ARHP Moderators Orientation ..................................30 

Meet the Professor Sessions 

Behçet’s Disease (001) ........................................31 

Controversies in Sjögren’s Syndrome (002) ........................31 

Infections with Biologics (003) ..................................31 

Pediatrics: Dermatomyositis (004) ...............................31 

Pediatrics: Difficult to Treat Juvenile Idiopathic Arthritis (005) ........31 

2 

2012 Program Book


Rheumatoid Arthritis: Biological Agents (006) ......................31 

Spondylarthropathy: An Update (007).............................31 

Systemic Arthritis and Still’s Disease (008) .........................31 

Systemic Lupus Erythematosus: Central Nervous System (009) ........31 

Vasculitis Mimics (010).........................................31 

ACR Workshops 

Basic Statistical Concepts for the Medical Researcher (201)...........31 

Clinical Anatomy and Physical Exam: Essential Tools in Lower 

Extremity Regional Pain Syndromes (202).........................31 

Dermatopathology of Rheumatic Diseases (203)....................31 

Musculoskeletal Exam Skills I: General Musculoskeletal 

Examination for Arthritis (204) ..................................31 

ACR Sessions 

Advances in the Biology of Aging.................................31 

CORC FORUM: Achieving Economic Goals in an Era of Healthcare 

Reform. .....................................................31 

New Therapies for Modulating Signaling in Rheumatoid Arthritis ......32 

The Plasticity of T Regulatory Cells and their Role in Autoimmunity. . . . 32 

Update on Stroke. .............................................32 

Extra-articular Involvement in Rheumatoid Arthritis.................32 

Medical Education: The Year in Review............................32 

ACR Poster Session A and Poster Tours 

Abstracts (#1-724).............................................32 

ARHP Session 

ARHP Keynote Address: It’s Not Child’s Play: Growing Up With 

and Mastering Juvenile Idiopathic Arthritis from the Child’s 

Perspective. .................................................33 

Rheumatology Research Foundation Special Session 

Oscar S. Gluck, MD, Memorial Lectureship: Bone Wasn’t 

Built in a Day: New Insights into Destruction and Repair in 

Rheumatic Disease............................................33 

Exhibits and Innovation Theater 

See page 316 of a complete listing of Innovation Theater.............33 

ACR Workshops 

Adult Musculoskeletal Upper Examinations (205) ...................33 

Musculoskeletal Ultrasound (206)................................33 

Renal Histopathology in Systemic Lupus Erythematosus and 

Vasculitis (207) ...............................................33 

ACR Plenary Session I: Discovery 2012 

Abstracts (#725-729)...........................................33 

ARHP Sessions 

Hands: Non-Surgical Management and Bracing – What You 

Don’t Know Can Hurt You. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 

New Medication Developments in Rheumatology...................37 

Rheumatic Disease Update: Vasculitis.............................37 

The 5A Approach to Physical Activity Counseling for 

Arthritis Patients. .............................................37 

ACR Session 

ACR Knowledge Bowl – Preliminary Round.........................37 

ARHP Networking Event 

Networking Forum.............................................37 

ACR Meet the Professor Sessions 

Adult Inflammatory Myopathy (011)..............................38 

Cutaneous Vasculitis (012) ......................................38 

Inflammatory Eye Disease/Uveitis (013)...........................38 

Myopathy: Issues in Diagnosis and Treatment (014) .................38 

Osteoporosis: Novel Treatments (015) ............................38 

Pediatrics: Periodic Fevers in Children (016)........................38 

Polymyalgia Rheumatica (017)...................................38 

Pregnancy in Rheumatic Diseases (018) ...........................38 

Systemic Lupus Erythematosus: Novel Treatments (019)..............38 

Vitamin D and Bone Health (020).................................38 

ACR Sessions 

Endoplasmic Reticulum Stress Unfolded Protein Response in 

Immunity and Inflammation....................................38 

Mechanisms of Pain in Rheumatic Diseases........................38 

Preoperative Assessment and Perioperative Management 

of the Patient with Rheumatic Disease: What Every 

Rheumatologist Should Know (Clinical Review).....................38 

ACR Workshops 

Designing a Website for Your Practice (208)........................39 

Muscle Involvement in Rheumatic Diseases (209)...................39 

Physical Examination Skills for Improved Detection of Synovitis 

and Cervical Thoracolumbar Disorders (210).......................39 

Renal Histopathology in Systemic Lupus Erythematosus and 

Vasculitis (211) ...............................................39 

ACR Sessions 

Complementary and Alternative Medicine: Evidence-based 

Options for Arthritis Patients....................................39 

Prospects for Prevention and Cure of Rheumatoid Arthritis...........39 

The Great Debate: In 2012 what are the Roles of Cyclophosphamide 

versus Rituximab in ANCA-Associated Vasculitis....................39 

Update on Treatment of Systemic Lupus Erythematosus..............39 

ACR Concurrent Abstract Sessions 

Biology and Pathology of Bone and Joint: Osteoarthritis 

(#730-735)...................................................40 

Cytokines, Mediators, and Gene Regulation I (#736-740) 

Includes 2011 Lee C. Howley, Sr. Prize for Arthritis Research 

Introductory Talk I.............................................40 

Epidemiology and Health Services Research I: Epidemiology 

and Outcomes in Rheumatic Disease (#741-746) ...................41 

Miscellaneous Rheumatic and Inflammatory Diseases: 

Periodic Fever Syndromes (#747-752) ............................41 

Muscle Biology, Myositis and Myopathies: Classification, 

Treatment and Outcome in Idiopathic Inflammatory 

Myopathies (# 753-758)........................................42 

Pediatric Rheumatology: Clinical and Therapeutic Disease I: 

Juvenile Idiopathic Arthritis I (#759-764)..........................42 

Rheumatoid Arthritis – Clinical Aspects I: Risk Factors and 

Prediction of Rheumatoid Arthritis (#765-770).....................43 

2012 Program Book 3


Rheumatoid Arthritis Treatment – Small Molecules, Biologics 

and Gene Therapy: Comparative Efficacy and Novel Treatment 

Strategies in Rheumatoid Arthritis (#771-776). . . . . . . . . . . . . . . . . . . . . 44 

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects 

and Treatment: Spondyloarthritis I (#777-782) ....................45 

Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s – 

Pathogenesis, Animal Models and Genetics (#783-788) .............45 

ARHP Sessions 

Non-pharmacological Management of Fibomyalgia: Your Toolbox .....46 

Practice Managers: Improving Access and Website Marketing 

(Practice Management Series) ..................................46 

Rheumatic Disease Update: Inflammatory Eye Disease ..............46 

ARHP Concurrent Abstract Sessions 

Foot and Gait Disorders (#789-794) ..............................47 

Osteoarthritis (#795-800) ......................................47 

ACR Workshops 

Dermatopathology of Rheumatic Diseases (212) ...................48 

Musculoskeletal Exam Skills II: Regional Musculoskeletal 

Examination of the Neck and Low Back (213) .....................48 

Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry 

and Clinical Risk Factors: The New Fracture Risk Assessment 

Algorithm (214)..............................................48 

Synovial Fluid Analysis and Crystal Identification (215) ..............48 

ACR Sessions 

Classification and Treatment of Sjögren’s Syndrome ................48 

Metabolic Abnormalities in Autoimmunity ........................48 

Puberty, Adolescence and Rheumatologic Disease .................48 

Thieves’ Market: Show Me Your Best Cases .......................49 

Update on Psoriatic Arthritis and the Spondylarthropathies .........49X 


Fibromyalgia and Soft Tissue Disorders I (#801-806) ................49 

Imaging of Rheumatic Diseases I: Ultrasound and X-ray (#807-812)....50 

Metabolic and Crystal Arthropathies: Clinical (#813-818) ............50 

Osteoporosis and Metabolic Bone Disease (#819-824) ..............51 

Rheumatoid Arthritis – Clinical Aspects II: Long-term Outcome 

of Rheumatoid Arthritis, Observational Studies (#825-830)..........51 

Rheumatoid Arthritis Treatment – Small Molecules, Biologics and 

Gene Therapy: Efficacy and Safety of Novel Entities (#831-836) ......52 

Systemic Lupus Erythematosus – Clinical Aspects and Treatment I: 

Renal (#837-842) ............................................53 

Systemic Lupus Erythematosus – Human Etiology and 

Pathogenesis I (#843-848) .....................................53 

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s – 

Clinical Aspects and Therapeutics I (#849-854) ....................54 

Vasculitis: Pathogenesis (#855-860)..............................55 


Ankylosing Spondylitis: 2012 Update (021)........................56 

Antiphospholipid Syndrome (022) ...............................56 

Crystal: Diagnosis and Management of Gout (023) .................56 

Immunodeficiency Syndromes (024) .............................56 

Pain: Evaluation and Treatment of Back Pain (025) .................56 

Psoriatic Arthritis (026) ........................................56 

Pulmonary Hypertension in the Rheumatic Diseases (027) ...........56 

Rheumatoid Arthritis: Challenging Cases (028).....................56 

Rheumatoid Arthritis: Outcome Measures in Clinical 

Practice (029) ...............................................56 

Temporal Arteritis (030) .......................................56 

ARHP Sessions 

Income Inequities Are Perilous to People with Arthritis ..............56 

Practice Management: Patients As Partners in Design and 

Delivery (Practice Management Series) ..........................56 


Pediatrics: Disease Flares (#861-865). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57 

Psychological Aspects of Rheumatologic Disease (#866-871) .........57 

Monday, November 12, 2012 

ACR Sessions 

Clinicopathologic Conference: A Patient with Hepatitis C 

and Inflammatory Polyarticular Arthritis .........................58 

Cross-Sectional Imaging Techniques for Rheumatology ..............58 

Immune Tolerance: From Theory and Clinical Practice ...............58 

Synovial Immunobiology and Response to Therapy in 

Rheumatoid .................................................58 

ARHP Sessions 

Disparities in the Use of Joint Arthroplasty: A Pervasive 

Matter Leading to Inequitable Care (Arthroplasty/Joint 

Replacement Series) ..........................................58 

Incorporating Physician Assistants and Nurse Practitioners 

into Rheumatology Practice ....................................59 

Infusion Room Information for Medical Professionals 

(Infusion Series) .............................................59 

New and Better Habits! Facilitating Patient Self-management 

with Proven Behavior Change Strategies .........................59 

ACR Session 

ILAR – The Current Rheumatology Workforce Across the Globe .......59 



Osteoarthritis: Update 2012 (032) ...............................60 

Pediatric Rheumatology for Adult Rheumatologists (033) ............60 

Pediatrics: Spondylarthritis in Children (034) ......................60 


Rheumatoid Arthritis: Difficult Cases (036) ........................60 

Rheumatoid Arthritis: Difficult Cases (037) ........................60 

Scleroderma: Systemic Sclerosis (038)............................60 


Vasculitis: Update (040)........................................60 

ACR/ARHP Workshops 

Joint Injections (Knee and Ankle Prosthetics) (216) .................60 

Musculoskeletal Ultrasound (217) ...............................60 

Peripheral Magnetic Resonance Imaging in Rheumatology 

Practice (218) ...............................................60 

X-ray Challenges in Rheumatic Diseases (219) .....................60 

4 

2012 Program Book


ACR Sessions 

Epigenetic Factors in Autoimmune Disease ........................60 

New Anticoagulants: What a Hematologist Thinks a 

Rheumatologist Needs to Know! ................................61 


Memorial Lectureship: Pathogenesis of Rheumatoid 

Arthritis: The Voyage from Pre-Rheumatoid Arthritis to Joint 

Destruction .................................................61 

ARHP Sessions 

Clinical Trials: Participation and Recruitment ......................61 

Infusion Reactions: Management and Prevention 

(Infusion Series) .............................................61 

Issues in the Management of Rheumatic Disease in 

Patients Undergoing Joint Replacement (Arthroplasty/Joint 

Replacement Series) ..........................................61 

Rheumatic Disease Update: Gout ................................61 

ACR Sessions 

Creating an Efficient Rheum Practice .............................61 

Legislative Update from Capitol Hill ..............................62 

Update on Safety Issues in the Treatment of Rheumatic 

Diseases – From the Food and Drug Administration and Beyond .....62 


ACR REF Special Session: Clinician Scholar Educator Presentations ....62 

ACR/ARHP Poster Session B, Thieves’ Market Posters and 

Poster Tours 

Abstracts (#872-1592) .........................................62 


See page 316 of a complete listing of Innovation Theater. ............63 

ARHP Session 

Distinguished Lecturer: Unraveling the “Go-Gene” .................63 

ACR Workshops 

Musculoskeletal Exam Skills III: Regional Musculoskeletal 

Examination of the Shoulder and Knee (220)......................63 

Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry 

and Clinical Risk Factors: The New Fracture Risk Assessment 

Algorithm (221)..............................................63 

ACR Plenary Session II: Discovery 2012 

(Abstracts #1593-1598) ........................................64 

ACR Sessions 

ACR Knowledge Bowl – Final Round ..............................68 

Career Opportunities in Rheumatology: Making a Choice ............69 

New Developments in Systemic Juvenile Idiopathic 

Arthritis Management ........................................69 

The Connected Rheumatology Practice: Electronic Health 

Record and Social Media Implementation and Customization ........69 


Networking at Noon ..........................................69 


Ankylosing Spondylitis: 2012 Update (041)........................70 

Basic Immunology for Clinical Rheumatologists (042) ...............70 

Challenging Cases in Osteoporosis Management (043) ..............70 

Dermatological Manifestations of Rheumatic Diseases (044) .........70 

Hereditary Angioedema (045) ..................................70 

Pulmonary Manifestations of Rheumatic Disease (046)..............70 

Raynaud’s and Digital Ischemia (047).............................70 

Scleroderma Mimics (048) .....................................70 

Vaccinations for Patients on Biologic Therapies (049) ...............70 


ACR Sessions 

Complex Regional Pain Syndrome/Reflex Sympathetic 

Dystrophy: Recent Advances, Current Thoughts ...................70 

Innovation in Musculoskeletal Curriculum Development: 

Lessons from New Medical Schools .............................70 

Pediatric Rheumatology Town Hall Meeting .......................71 

Scleroderma Bowel Disease: From Top to Bottom (Clinical Review) ....71 


Histopathology of Vasculitis (222) ...............................71 

Joint Injections (Shoulder and Wrist Prosthetics) (223) ..............71 

MRI in the Diagnosis and Management of Spondylarthritis: 

A Clinician’s Guide (224).......................................71 

ACR Sessions 

Curbside Consults – Ask the Professors ...........................71 

Macrophage and Dendritic cell Heterogeneity in Tissue 

Inflammation and Fibrosis .....................................71 

Mechanotransduction in Bone and Cartilage ......................72 

Neuropsychiatric Lupus in Children and Adolescents ................72 

Osteoporosis: From Bisphosphonates and Beyond. . . . . . . . . . . . . . . . . . 72 


Cell-cell Adhesion, Cell Trafficking and Angiogenesis (#1599-1603) 

Includes 2011 Lee C. Howley, Sr. Prize for Arthritis Research 

Introductory Talk II ...........................................72 

Epidemiology and Health Services Research II: Epidemiologic 

Risk Factors in the Development of Rheumatic Disease 

(#1604-1609)................................................73 

Genetics and Genomics of Rheumatic Diseases (#1610-1615) ........73 

Imaging of Rheumatic Diseases II: Magnetic Resonance 

Imaging (#1616-1621) ........................................74 

Infection-related Rheumatic Disease (#1622-1627) .................75 

Metabolic and Crystal Arthropathies: Basic Science (#1628-1633) .....76 

Rheumatoid Arthritis – Animal Models (#1634-1639) ...............76 


and Gene Therapy: Safety I (#1640-1645) ........................77 

Systemic Lupus Erythematosus – Clinical Aspects and 

Treatment II: Clinical Aspects/Pregnancy (#1646-1651) .............78 

Vasculitis: Clinical Trials (#1652-1657) ............................78 

ARHP Sessions 

Demystifying the Study Section: How Grants Are 

Reviewed and Scored .........................................79 

Depression in Rheumatic Diseases ...............................80 

Minimizing Falls in Geriatric Rheumatic Populations ................80 

Total Knee Arthroplasty Rehabilitation: Optimizing Functional 

Outcomes Through Examination of Patient Factors, Practice 

Variation and Best Practice Recommendations (Arthroplasty/ 

Joint Replacement Series) .....................................80 

2012 Program Book 5


ACR Workshops 

Getting Electronic Health Records Right (225) .....................80 

Musculoskeletal Ultrasonography: Basic (226) .....................80 

Patient Questionnaires: Multi-Dimensional Health Assessment 

Questionnaire/Routine Assessment of Patient Index Data 3 

and Beyond Toward a Standard, Scientific, Quantitative 

Patient History (227)..........................................81 

Systemic Sclerosis: How to Perform Skin Scores (228) ...............81 

ACR Sessions 

Aging and the Rheumatic Diseases ..............................81 

Dermatology Topics for Rheumatologists: What You Need to Know ....81 

Energetics, Metabolism and Osteoarthritis ........................81 

Gout and Hyperuricemia: Diseases Beyond the Joint ................81 

Preclinical Autoimmunity – Potential for Prevention ................82 


Cytokines, Mediators, and Gene Regulation II (#1658-1663). . . . . . . . . . 82 

Epidemiology and Health Services Research III: Rheumatic 

Diseases and Cardiovascular Disease and Risk Assessment 

(#1664-1669)................................................82 

Muscle Biology, Myositis and Myopathies: Pathogenesis in 

Idiopathic Inflammatory Myopathies (#1670-1675) ................83 

Pediatric Rheumatology: Clinical and Therapeutic Disease II: 

Juvenile Idiopathic Arthritis II (#1676-1681) ......................84 

Rheumatoid Arthritis – Clinical Aspects III: Rheumatoid Arthritis 

and Cardiovascular Disease (#1682-1687) ........................84 

Rheumatoid Arthritis – Human Etiology and Pathogenesis I: 

Early Pathogenesis of Rheumatoid Arthritis (#1688-1693) ...........85 


and Gene Therapy: Safety II (#1694-1699) ........................85 


and Treatment: Spondyloarthritis II (#1700-1705) .................86 

Systemic Lupus Erythematosus – Clinical Aspects and Treatment III: 

Cardiovascular (#1706-1711)...................................87 


Clinical Aspects and Therapeutics II (#1712-1717) .................87 


Adult Inflammatory Myopathy (051) .............................88 

Antiphospholipid Syndrome (052) ...............................88 

Controversies in Sjögren’s Syndrome (053) ........................88 

Dermatological Manifestations of Rheumatic Diseases (054) .........88 

Fibromyalgia and Dysautonomia (055) ...........................88 

Pain: Evaluation and Treatment of Back Pain (056) .................88 

Pediatric Systemic Lupus (057) ..................................88 


Rheumatoid Arthritis: Biological Agents (059) .....................88 

Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus 

Erythematosus (060) .........................................88 

ARHP Sessions 

Early Rehabilitation for Hip and Foot Osteoarthritis: 

Opportunities and Challenges ..................................88 

Novel Approaches to Pain Management in Juvenile 

Idiopathic Arthritis ...........................................88 

Promoting Participation: Where Is the Field and Where 

Do We Go Next? .............................................89 

ARHP Concurrent Abstract Session 

Care of Patients With Rheumatoid Arthritis (#1718-1723) ...........89 

ACR Study Groups .............................................90 

Tuesday, November 13, 2012 

ACR Sessions 

Chronic Recurrent Multifocal Osteomyelitis .......................90 

Molecular and Cellular Basis of Tissue Homing .....................91 

Update on Immune Mediated Glomerular Disease .................91 


Paul Klemperer, MD Memorial Lectureship: Serum 

Autoantibodies in Systemic Sclerosis: Usefulness in Diagnosis, 

Clinical Subsetting and Predicting Outcomes ......................91 

ARHP Sessions 

Clinical and Epidemiologic Study Designs in Rheumatic 

Disease Research ............................................91 

Don’t Let the Pink Sheets Make You Blue .........................91 

Fungal Infections and Tuberculosis in Patients with 

Rheumatologic Disease (Infection Series). . . . . . . . . . . . . . . . . . . . . . . . . 91 

ACR Meet the Professors Sessions 

Ankylosing Spondylitis: Disease Modification (061) .................91 


Infections with Biologics (063) ..................................92 

Osteoarthritis: Update 2012 (064) ...............................92 

Pain: Dealing with Patients with Refractory Pain in 

Musculoskeletal and Autoimmune Disorders (065).................92 

Pediatrics: Juvenile Idiopathic Arthritis for Adult 

Rheumatologists (066) ........................................92 

Pregnancy in Rheumatic Diseases (067) ..........................92 

Reactive Arthritis: An Update (068) ..............................92 




Adult Musculoskeletal Lower Examinations (229) ..................92 

Knee Braces and Foot Orthosis for Knee Osteoarthritis (230) .........92 

Peripheral Magnetic Resonance Imaging in Rheumatology 

Practice (231) ...............................................92 

Synovial Fluid Analysis and Crystal Identification (232) ..............92 

ACR Sessions 

Advances in Targeting of B cell Survival Factors ....................92 

Systems Immunology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92 

ARHP Sessions 

Hepatitis in Patients with Rheumatologic Disease 

(Infection Series) .............................................93 

Rheumatic Disease Update: The Approach to Low Back Pain .........93 

Threats to Validity: Confounding in Rheumatic Disease 

Research (Research Series) ....................................93 

ACR Sessions 

Contract Negotiations for Physicians .............................93 

Paradigm Shifts in Rheumatoid Arthritis ..........................93 

The Guide to Meaningful Use and Beyond ........................93 

6 

2012 Program Book



Disease Targeted Research .....................................94 


Physical/Occupational Therapy and Exercise in Patients 

with Rhematologic Disease (#2431-2436) ........................94 

Programs and Literacy in Patients with Rheumatolgic 

Diseases (#2437-2442) ........................................94 

ACR/ARHP Poster Session C, 

Thieves’ Market Posters and Poster Tours 

Abstracts (#1724-2430) ........................................95 


See page 316 of a complete listing of Innovation Theater. ............96 

ACR Session 

Gouty Inflammation ..........................................96 

ARHP Sessions 

Immunizations in Patients with Rheumatologic Disease 

(Infection Series) .............................................96 

Selection Bias in Rheumatic Disease Research – Risk Factor 

Paradox and Other Issues .....................................96 

ACR/ARHP Combined Abstract Session 

ACR/ARHP Combined Rehabilitation Abstract Session 

(#2443-2448) ................................................96 

ACR Workshops 

Histopathology of Vasculitis (233) ...............................97 

Joint Injection Techniques (234) .................................97 

ARHP Sessions 

A Practical Understanding of Function in Rheumatoid Arthritis: 

A Multidisciplinary Perspective .................................97 

Strategies to Enhance Office Efficiencies and Access to Care 

in Rheumatology Practice .....................................97 

ACR Plenary Session III: Discovery 2012 

Abstracts (#2449-2454) ........................................97 

ACR Sessions 

Microbiome Influence on Autoimmunity ........................101 

Polymyalgia Rheumatica – Recent Advances and Ongoing Questions ...101 

Top 10 Compliance Risks Facing Physicians .......................101 


Networking Break ...........................................102 


Basic Immunology for Clinical Rheumatologists (071) ..............102 

Fibromyalgia and Dysautonomia (072) ..........................102 

Myopathy: Issues in Diagnosis and Treatment (073) ...............102 

Rheumatoid Arthritis: Challenging Cases (074) ....................102 

Rheumatoid Arthritis: Safety of Novel Therapies (075) .............102 

Systemic Lupus Erythematosus: Central Nervous System (076) ......102 

Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus 

Erythematosus (077) ........................................102 

Systemic Lupus Erythematosus: Lupus Nephritis (078) .............102 

Temporal Arteritis (079) ......................................102 

Vasculitis: Update (080) .......................................102 

ACR Sessions 

Catastrophic Antiphospholipid Syndrome (Clinical Review) ..........102 

Osteoimmunology ...........................................102 

ACR Study Groups ............................................102 


Clinical Anatomy and Physical Exam: Essential Tools in 

Upper Extremity Regional Pain Syndromes (235) .................103 

MRI in the Diagnosis and Management of Spondyloarthritis: 

A Clinician’s Guide(236) ......................................103 

Synovial Fluid Analysis and Crystal Identification (237) .............103 

Web-based Tools for Enhancing and Managing Teaching 

and Clinical Practice (238) ....................................103 

ACR Session 

ACR Leadership Town Hall Meeting & Business Meeting ............103 

ACR Sessions 

Approach and Management of Back Pain in Older Adults ...........103 

Connective Tissue Disease Associated Interstitial Lung Disease ......104 

New Molecules in Joint Biology ................................104 

Visualizing the Immuno-inflammatory Response ..................104 


ACR Late-breaking Abstract Session .............................104 

Antiphospholipid Syndrome (#2455-2460) .......................104 

Epidemiology and Health Services Research IV: Outcomes 

and Costs in Rheumatic Disease (#2461-2466) ...................105 

Osteoarthritis – Clinical Aspects II: Structural Risks for 

Osteoarthritis End-points and Potential Treatments 

(#2467-2472)...............................................105 

Pediatric Rheumatology: Clinical and Therapeutic Disease III: 

Childhood Systemic Lupus Erythematosus and Other Vasculitides 

(#2473-2478)...............................................106 

Rheumatoid Arthritis – Clinical Aspects IV: Non-biologic Drugs 

for Rheumatoid Arthritis: New Insights on Comorbidities and 

Adverse Events (#2479-2484) .................................107 


and Gene Therapy: Safety & Efficacy of Janus Activated-Kinase 

(JAK) Inhibitors (#2485-2490) .................................108 

Spondyloarthritis and Psoriatic Arthritis – Pathogenesis, 

Etiology (#2491-2496) .......................................108 

Systemic Lupus Erythematosus – Human Etiology and 

Pathogenesis II (#2497-2502) .................................109 

T-cell Biology and Targets in Autoimmune Disease (#2503-2508).....109 

ACR/ARHP Combined Abstract Session 

ACR/ARHP Combined Epidemiology Abstract Session (#2509-2514) . . 110 

ARHP Sessions 

Myositis: Pathogenesis, Diagnosis and Management ...............110 

Rheumatic Disease Update: Systemic Lupus Erythematosus .........111 

Rheumatoid Arthritis Disease Activity Measures and Quality 

Indicators: Correct Use and Future Directions ....................111 

Transition Tools for Patients: Pediatric to Adults ...................111 

ACR Workshop 

Joint Injection Techniques (239) ................................111 

2012 Program Book 7


8 

ARHP Session 

Obesity: It is a Chronic Disease .................................111 

ACR Session 

Diagnostic Assessments in Myopathy ...........................111 

MicroRNA and the Rheumatic Diseases ..........................112 

Should Ultrasound be Used in Rheumatology Practice? ............112 

The Great Masqueraders: Malignancies in Rheumatic Disease .......112 


Biology and Pathology of Bone and Joint: Regulation of 

Bone Cells (#2515-2520) .....................................112 

Innate Immunity and Rheumatic Disease (#2521-2526) ............113 

Miscellaneous Rheumatic and Inflammatory I (#2527-2532) ........113 

Osteoarthritis – Clinical Aspects I: Weight, Activity, and 

Metabolic Effects on Osteoarthritis (#2533-2538) .................114 

Rheumatoid Arthritis – Clinical Aspects V: Comorbidities in 

Rheumatoid Arthritis (#2539-2544) ............................115 


and Gene Therapy: Efficacy of Approved Biologics (#2545-2550) ....115 

Sjögren’s Syndrome II – Clinical (#2551-2556) ....................116 


and Treatment: Psoriatic Arthritis (#2557-2562) ..................117 

Vasculitis: Clinical Aspects (#2563-2568) .........................118 


Central Nervous System Vasculitis (081) .........................119 

Crystal: Pseudogout (082) .....................................119 

Effective Use of Technology (083). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119 

Pulmonary Manifestations of Rheumatic Disease (084) .............119 

Raynaud’s and Digital Ischemia (085) ............................119 

Rheumatoid Arthritis: Safety of Novel Therapies (086) .............119 

Rheumatology Practice 101: Starting Out in Practice for 

The Graduating Fellow (087) ..................................119 

Systemic Lupus Erythematosus: Lupus Nephritis (088) .............119 

Systemic Lupus Erythematosus: Novel Treatments (089) ............119 

Vaccinations for Patients on Biologic Therapies (090) ..............119 


Edmond L. Dubois, MD Memorial Lectureship: 

Hydroxychloriquine Reduces Thrombosis in Systemic Lupus 

Erythematosis Particulerly in Antiphospholipid Positive Patients 

(#2569-2574) ...............................................119 

ARHP Sessions 

Arthritis and the Older Worker .................................120 

Best Practices for Ordering Diagnostic Imaging in Evaluating 

Rheumatologic Conditions ....................................120 

The Puzzle of Fatigue in Rheumatoid Arthritis: Putting the 

Pieces Together .............................................120 

Wednesday, November 14, 2012 

ACR Sessions 

Immunology of Pregnancy and Impact on Autoimmune 

Pathogenesis ...............................................121 

Neutrophil Extracellular Traps (NETosis) in Rheumatic Disease .......121 

Rheumatology Roundup: Highlights from the 2012 Annual 

Scientific Meeting ...........................................121 

2012 Program Book 

The Unintended Consequences of Health Information 

Technology ................................................121 

ARHP Sessions 

An Introduction to Immunology ................................121 

Beyond the Basics: A Real Life Example of Multiple Imputation 

for Missing Data Problems (Research Series) .....................121 

ACR Sessions 

Biosimilars Development: Food and Drug Administration 

Perspective ................................................122 

IgG4-Related Disease – Past Lessons and Future Directions .........122 

NIAMS-Sponsored Research in Rheumatology: 2012 Highlights ......122 

Osteoarthritis Therapeutics: Will This be the Decade for 

Breakthroughs? .............................................122 

Predictive Biomarkers: A Journey to Personalized Health Care .......123 


B-cell Biology and Targets in Autoimmune Disease (#2575-2580) ....123 

Imaging of Rheumatic Diseases III: Computed Tomography 

(#2581-2586)...............................................123 

Medical Education (#2587-2592) ...............................124 

Pediatric Rheumatology: Clinical and Therapeutic Disease IV: 

Childhood Therapeutics and Response (#2593-2598)..............124 

Quality Measures and Innovations in Practice Management 

and Care Delivery (#2599-2604) ...............................125 

Rheumatoid Arthritis – Clinical Aspects VI: Remission and Flare 

in Rheumatoid Arthritis (#2605-2610) ..........................126 


and Treatment: Psoriatic Arthritis and Spondylarthritis 

(#2611-2616)...............................................126 

Systemic Lupus Erythematosus – Clinical Aspects and Treatment IV: 

Therapeutics (#2617-2622) ...................................127 

ARHP Sessions 

Forming An Education and Support Group from the Ground Up .....128 

Osteoporosis: 2012 Update ...................................128 


Systemic Sclerosis, Vasculitis, Crohn’s and Spondylarthropathies 

(#2623-2628)...............................................128 

Clinical and Rehabilitative Aspects of Osteoarthritis (#2629-2634) ...129 

ACR Sessions 

Amyloidosis 2012 ............................................129 

Mechanisms of Autoinflammatory Diseases ......................129 

ACR Sessions 

Making Sense of Autoantibodies in the Diagnosis of Systemic 

Rheumatic Diseases .........................................129 

Rheumatoid Arthritis – Treating to Target: How to Incorporate 

Rheumatoid Arthritis Disease Activity Measures into Routine 

Practice ...................................................130 


Epidemiology and Health Services Research V: Rheumatoid 

Arthritis Management in the Treat-to-Target Era (#2635-2640)......130 

Fibromyalgia and Soft Tissue Disorders II (#2641-2646).............130 

Orthopedics, Low Back Pain, and Rehabilitation (#2647-2652).......131 

Pediatric Rheumatology – Pathogenesis and Genetics 

(#2653-2658)...............................................131


Rheumatoid Arthritis – Clinical Aspects VII: Prediction of 

Outcome in Rheumatoid Arthritis (#2659-2664) ..................132 

Rheumatoid Arthritis – Human Etiology and Pathogenesis II: Cellular 

Effectors of Rheumatoid Arthritis and Novel Rheumatoid Arthritis 

Genome-Wide Association Studies (#2665-2670) .................133 

Sjögren’s Syndrome I – Pathogenesis (#2671-2676) ................134 

Systemic Lupus Erythematosus – Animal Models (#2677-2682) ......135 

Systemic Lupus Erythematosus – Clinical Aspects and Treatment V: 

Clinical Aspects (#2683-2688) .................................135 

ARHP Sessions 

Highlights from the 2012 ARHP Sessions .........................136 

Shoulder Pain and Rotator Cuff Tear in Rheumatoid Arthritis ........136 


Factors Associated with Rheumatoid Arthritis (#2689-2694) ........136 

Systemic Lupus Erythematosus (#2695-2700).....................137 

ACR POSTER SESSION A 

(Abstracts # 1-724) 

Biology and Pathology of Bone and Joint 

(Abstracts # 1-51) ...........................................138 

Epidemiology and Health Services Research: Epidemiology and 

Outcomes of Rheumatic Disease I 

(Abstracts # 52-101) .........................................141 

Imaging of Rheumatic Diseases: Ultrasound, Nuclear Medicine and 

Fluorescence Imaging 

(Abstracts # 102-133) ........................................146 

Metabolic and Crystal Arthropathies 

(Abstracts # 134-170) ........................................149 

Infection-related Rheumatic Disease 

(Abstracts # 171-178) ........................................151 

Miscellaneous Rheumatic and Inflammatory Diseases: Periodic 

Fever Syndromes 

(Abstracts #179-204) ........................................152 

Muscle Biology, Myositis and Myopathies: Clinical and Therapeutic 

Aspects of Idiopathic Inflammatory Myopathies 

(Abstracts # 205-233) ........................................154 

Osteoarthritis – Clinical Aspects 

(Abstracts # 234-273) ........................................156 

Pediatric Rheumatology – Clinical and Therapeutic Aspects: Pediatric 

Systemic Lupus Erythematosus, Pediatric Vasculitis and Pediatric Myositis 

(Abstracts # 274-307) ........................................159 

Pediatric Rheumatology – Pathogenesis and Genetics 

(Abstracts # 308-325) ........................................162 

Rheumatoid Arthritis: Animal Models 

(Abstracts # 326-347) ........................................163 

Rheumatoid Arthritis – Clinical Aspects I: Drug Studies/Drug Safety/Drug 

Utilization/Disease Activity & Remission 

(Abstracts # 348-405) ........................................165 

Rheumatoid Arthritis – Human Etiology and Pathogenesis 

(Abstracts # 406-443) ........................................170 


Gene Therapy 

(Abstracts # 444-503) ........................................173 

Sjögren’s Syndrome – Pathogenesis 

(Abstracts # 504-530) ........................................179 

Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and 

Treatment 

(Abstracts # 531-579) ........................................181 

Spondylarthritis and Psoriatic Arthritis – Pathogenesis, Etiology 

(Abstracts # 580-601) ........................................186 

Systemic Lupus Erythematosus: Clinical Aspects 

(Abstracts # 602-657) ........................................187 

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis 

(Abstracts # 658-691) ........................................191 

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s – Clinical Aspects 

and Therapeutics 

(Abstracts # 692-724) ........................................194 

ACR/ARHP POSTER SESSION B 

(Abstracts # 872-1592) 

Cytokines, Mediators, and Gene Regulation 

(Abstracts # 872-903) ........................................198 

Epidemiology and Health Services Research: Epidemiology 

and Outcomes of Rheumatic Disease II 

(Abstracts # 904-951) ........................................200 

Fibromyalgia and Soft Tissue Disorders 

(Abstracts # 952-969) ........................................203 

Genetics and Genomics of Rheumatic Diseases 

(Abstracts # 970-1006) .......................................204 

Imaging of Rheumatic Diseases: Magnetic Resonance Imaging, 

Computed Tomography and X-ray 

(Abstracts # 1007-1054) ......................................209 

Innate Immunity and Rheumatic Disease 

(Abstracts # 1055-1081) ......................................213 

Orthopedics, Low Back Pain, and Rehabilitation Poster 

(Abstracts # 1082-1096) ......................................215 

Osteoarthritis – Clinical Aspects 

(Abstracts # 1097-1138) ......................................216 

Pediatric Rheumatology – Clinical and Therapeutic Aspects: 

Juvenile Idiopathic Arthritis 

(Abstracts # 1139-1174) ......................................219 

Rheumatoid Arthritis – Human Etiology and Pathogenesis 

(Abstracts # 1175-1212) ......................................222 

Rheumatoid Arthritis – Clinical Aspects II: Clinical Features & 

Comorbidity/Cardiovascular Disease 

(Abstracts # 1213-1270) ......................................225 

Rheumatoid Arthritis Treatment – Small Molecules, Biologics and Gene 

Therapy 

(Abstracts # 1271-1342) ......................................230 

Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects 

and Treatment 

(Abstracts # 1343-1385) ......................................238 


(Abstracts # 1386-1437) ......................................242 

Systemic Lupus Erythematosus – Animal Models 

(Abstracts # 1438-1457) ......................................246 


Clinical Aspects and Therapeutics 

(Abstracts # 1458-1489) ......................................247 

Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s – Pathogenesis, 

Animal Models and Genetics 

(Abstracts # 1490-1522) ......................................250 

2012 Program Book 9


Vasculitis 

(Abstracts # 1523-1552) ......................................252 

Clinical Practice/Patient Care 

(Abstracts # 1553-1578) ......................................255 

Rehabilitation Sciences 

(Abstracts # 1579-1592) ......................................257 

ACR/ARHP POSTER SESSION C 

(Abstracts # 1724-2430) 

Antiphospholipid Syndrome 

(Abstracts # 1724-1740) ......................................259 

B-cell Biology and Targets in Autoimmune Disease 

(Abstracts # 1741-1774) ......................................260 

Cell-cell Adhesion, Cell Trafficking and Angiogenesis 

(Abstracts # 1775-1781) ......................................263 


(Abstracts # 1782-1811) ......................................263 

Epidemiology and Health Services Research: Rheumatic Disease 

Pharmacoepidemiology 

(Abstracts # 1812-1856) ......................................265 


(Abstracts # 1857-1884) ......................................269 

Medical Education 

(Abstracts # 1885-1900) ......................................270 


(Abstracts # 1901-1916) ......................................272 

Miscellaneous Rheumatic and Inflammatory Diseases 

(Abstracts #1917-1934) ......................................273 

Muscle Biology, Myositis and Myopathies: Genetics, Autoantibodies 

and other Molecular Aspects of Idiopathic Inflammatory Myopathies 

and Models 

(Abstracts # 1935-1956) ......................................274 

Osteoporosis and Metabolic Bone Disease 

(Abstracts #1957-1998) ......................................276 

Pediatric Rheumatology – Clinical and Therapeutic Aspects: Juvenile 

Idiopathic Arthritis and Other Pediatric Rheumatic Diseases 

(Abstracts # 1999-2036) ......................................279 

Quality Measures and Innovations in Practice Management 

and Care Delivery 

(Abstracts # 2037-2068) ......................................283 


(Abstracts # 2069-2091) ......................................285 

Rheumatoid Arthritis – Clinical Aspects III: Infections/Risk Factors for 

Incident Rheumatoid Arthritis/Metrology/Classification/Biomarkers/ 

Predictors of Rheumatoid Arthritis Activity & Severity 

(Abstracts # 2092-2148) ......................................287 


Gene Therapy 

(Abstracts # 2149-2173) ......................................292 

Sjögren’s Syndrome – Clinical 

(Abstracts # 2174-2205) ......................................294 


and Treatment 

(Abstracts # 2206-2235) ......................................297 


(Abstracts # 2236-2266) ......................................300 

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis 

(Abstracts # 2267-2285) ......................................302 

Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s – Pathogenesis, 

Animal Models and Genetics 

(Abstracts # 2286-2309 ......................................304 

T-cell Biology and Targets in Autoimmune Disease 

(Abstracts # 2310-2346) ......................................306 

Vasculitis 

(Abstracts # 2347-2398) ......................................309 

Education/Community Programs 

(Abstracts # 2399-2407) ......................................313 

Epidemiology and Public Health 

(Abstracts # 2408-2419) ......................................314 

Pediatrics 

(Abstracts # 2420-2421) ......................................315 

Psychology/Social Sciences 

(Abstracts # 2422-2430) ......................................315 

INNOVATION THEATER LISTING ..................316 

INDUSTRY-SUPPORTED SYMPOSIA ..............322 

CERTIFICATES OF CME CREDIT OR 

PARTICIPATION 

Accreditation Statements .....................................317 

Meeting Evaluations, CME Credit/Certificates for Participation ......323 

Conflict of Interest /Disclosure Statements .......................323 

Disclosure Policy ............................................323 

RECOGNITION 

ACR/ARHP Annual Meeting Leadership ..........................324 

Exhibitors ..................................................331 

Supporter Acknowledgements .................................335 

INDICIES 

Invited Speaker Moderator Index ...............................337 

ACR/ARHP Abstract Author Index ...............................355 

ACR/ARHP Abstract Moderator Index ...........................407 

10 

2012 Program Book

The most comprehensive 

online collection of 

rheumatology-related images. 

Serving as a centralized resource for clinicians, researchers 

and health care professionals, the Rheumatology Image Bank 

provides invaluable assistance in self-study or the education 

of others. 

Start your visual exploration of rheumatology today 

at http://images.rheumatology.org! 

Stop by the acr Resource Center, located on the L Street 

Bridge (Level 2), and speak with staff to learn more about 

the Rheumatology Image Bank and all it can offer you. 

COPYRIGHT MATERIALS POLICY 

The annual meeting is a private event. Programs presented at 

the meeting are for the education of attendees and purchasers 

of recorded presentations as authorized by the ACR. The 

information and materials displayed and presented during this 

meeting are the property of the ACR and the presenter and 

cannot be photographed, copied, photocopied, transformed to 

electronic format, reproduced, or distributed without written 

permission of the ACR and the presenter. Any use of the program 

content for commercial purposes, which includes, but is not 

limited to oral presentations, audiovisual materials used by 

speakers, and program handouts without the written consent of 

the ACR is prohibited. This policy applies before, during and after 

the meeting. The ACR will enforce its intellectual property rights 

and penalize those who infringe upon it. 

The names, insignias, logos and acronyms of the ACR, the ARHP 

and the RRF are proprietary marks. Use of the names in any 

fashion, by any entity, for any purpose, is prohibited without the 

express written permission of the ACR. 

MEDIA 

Credentialed media attend the annual meeting to cover stories 

for consumer, trade and other media outlets, and are easily 

identified by their black press ribbons. Media has access to 

all general sessions and limited access (at the discretion of 

speakers) to meet the Professor and Workshop sessions. Media 

may use hand-held audio recorders and still cameras; moving 

video recording is also permitted with the permission of the 

presenter(s). The exception to this policy is that no photos 

or video are allowed in the exhibit hall. Press who would like 

general photos of the exhibit hall can obtain these after the 

meeting from the ACR. Attendees who have questions about 

the ACR’s media policies should contact Suzanne Forte at 

sforte@rheumatology.org. 

EMBARGO POLICY 

Accepted abstracts are made available to the public online 

in advance of the meeting and are published in a special 

supplement of Arthritis & Rheumatism. Information contained 

in those abstracts may not be released until the abstracts 

appear online. Academic institutions, private organizations and 

companies with products whose value may be influenced by 

information contained in an abstract may issue a press release 

2012 Program Book 11

to coincide with the availability of an ACR abstract on the ACR 

website. However, the ACR continues to require that information 

that goes beyond that contained in the abstract (e.g., discussion 

of the abstract done as part a scientific presentation or 

presentation of additional new information that will be available 

at the time of the meeting) is under embargo until 4:30 PM 

Eastern Time on Saturday, November 10, 2012. Violation of 

this policy may result in the abstract being withdrawn from 

the meeting and other measures deemed appropriate. Authors 

are responsible for notifying financial and other sponsors about 

this policy. 

MEETING INFORMATION 

Cell Phones, PDAs & Other Electronic Devices 

As a courtesy to meeting attendees, electronic devices must 

be operated in silent/vibrate mode within educational sessions; 

devices that beep, ring, etc. are prohibited. Cell phone 

conversations are not permitted in meeting rooms. 

Children 

For safety reasons, strollers are not permitted in the exhibit 

hall and all children must be accompanied by an adult. Only 

registered attendees will be permitted into meeting rooms. 

Child Care 

KiddieCorp is providing child care services for our attendees 

during meeting hours. If you did not reserve space in 

advance, you can inquire about space availability by calling 

(202) 249-4008. 

Nursing Mothers’ Room 

During scientific session hours, a staffed Nursing Mothers’ 

room will be available in Salon D. This room will have a private 

seating area, a refrigerator and a bulletin board for information 

exchange, advice and suggestions. 

Exhibit Hall 

The 2012 exhibit hall is located in Hall A. See page 331 for more 

information. 

Exhibit Hall hours: 

Sunday, November 11 .............. 10:00 AM – 5:00 PM 

Monday, November 12 ............. 10:00 AM – 5:00 PM 

Tuesday, November 13 ............. 10:00 AM – 5:00 PM 

Meeting Room Capacity/Important Fire Safety Information 

Attendance at scientific sessions is on a first-come, first-served 

basis. Rooms which have reached the maximum capacity may be 

closed according to local fire and safety regulations. Standing in 

the aisle or against the walls is not permitted. If overcrowding 

occurs, staff/security personnel will close the session. If space 

does not permit you to attend a session, the session may be 

available on SessionSelect or replayed in the SessionSelect 

Lounge located in the West Overlook (2nd Floor) of the 

convention center. 

Photography and Videotaping 

Photographers will be present at the meeting. Registration 

and attendance at, or participation in, ACR meetings and other 

activities constitutes an agreement by the registrant for the 

ACR’s use and distribution (both now and in the future) of 

the registrant or attendee’s image or voice in photographs, 

videotapes, electronic reproductions, and audio tapes of 

such events and activities. Visual reproduction of sessions is 

prohibited without prior written permission of the ACR. The ACR 

reserves the rights to audio and video reproduction at the 2012 

ACR/ARHP Annual Meeting. See copyrighted materials policy for 

more information on page 11. 

Name Badges 

For security reasons, your badge will be required for admittance 

to all sessions, exhibits, social events and shuttle buses. Please 

wear your badge so it can be easily seen at all times. Lost badges 

should be reported to the registration staff immediately. 

No Smoking 

All meeting facilities at the convention center, hotel meeting 

rooms and other venues have been designated as non-smoking 

areas. 

12 

2012 Program Book

PM 

PM 

PS 

MEETING NAVIGATION GUIDE 

Use PM the following PS track icons to help you identify the most 

relevant content based on your specialty. 

PM 

PS 

PM 

PS 

Basic Science 

Business/Administration 

Clinical Practice 

Clinical Science 

PAIN PS MANAGEMENT 

The ACR designates certain sessions for pain 

management credit as required by the Medical 

Board of California (AB487). This designation is 

identified by the icon shown and will be placed 

next to the session title. 

Exhibits and Industry-Supported Sessions provide attendees 

with an opportunity to learn about the latest technological 

advances in the treatment of rheumatic diseases within the 

exhibit hall via various exhibitions and non-CME sessions in 

the Innovation Theater, as well as evening and post-meeting 

symposia. 

Meet the Professor Sessions provide an opportunity for 

interaction and consultation with highly respected professionals 

who have expertise in a particular area. A separate registration 

is required. 

Networking Events provide unique opportunities to socialize and 

network with peers in smaller group settings. 

Pre-Meeting Courses offer attendees, with a specific interest, a 

unique learning opportunity. A separate registration is required. 

Study Groups bring together attendees with a common interest 

in one disease, a group of related disorders, or a specialized field 

of study for discussion and dissemination of information. 

PM PS PATIENT SAFETY 

The ACR designates certain sessions that 

will satisfy patient safety/risk management 

requirements of the Medical Board of 

Pennsylvania. This designation is identified by 

the icon shown and will be placed next to the 

session title. 

SESSION FORMATS 

Basic Science Symposia provide an update of the most recent 

scientific developments in the field of rheumatology. 

Clinical Symposia provide instruction to improve patient care. 

Developments from other specialties and practical patient 

management skills will be emphasized. Included are Clinical 

Reviews. 

Concurrent Sessions offer educational programs of interest to 

various health professionals. Concurrent sessions include invited 

speakers; peer-reviewed programs and lectures; research and 

special interest abstract sessions. 

Workshops foster hands-on learning, and provide an 

opportunity for interaction and consultation with highly 

respected professionals who have expertise in a particular area. 

A separate registration is required. 

ABSTRACT FORMATS 

Late-Breaking Session features truly late-breaking research. 

Oral Presentations are the main forum for didactic presentation 

of original research related to rheumatic diseases. 

Plenary Sessions highlight abstracts of significant novelty and 

importance. There will be three theme-based sessions offered. 

Poster Presentations feature poster displays of abstracts, while 

facilitating one-on-one interaction between the presenter and 

the audience. 

Poster Tours are small groups guided by experts in a particular 

field. Each tour will highlight selected posters of novel or recent 

developments within an abstract category. There is no additional 

cost to participate, although a separate registration is required. 


ACR Resource Center 

Stop by the acr Resource Center to 

see what’s new with the College! We’re 

located on the L Street Bridge (Level 2). 

Within the Resource Center you can: 

• Demo popular online products and receive daily giveaways 

• Get details about educational activities in 2013 

• Speak with key representatives from the ACR and ARHP journals 

• Learn about the latest advocacy efforts 

• Enroll in the new ACR Rheumatology Musculoskeletal Ultrasound 

Certification program 

• Get answers to your coding and billing questions 

• Collect complimentary product brochures, publications 

and patient education materials 

• Speak with ACR staff about health information 

technology, new initiatives, CME, MOC and much more 

Come discover all the College offers you, your patients and 

your practice at the Resource Center— where the resources 

you need are all in one place! 

Resource Center Hours: 

Saturday, November 10 

Sunday, November 11 

Monday, November 12 

Tuesday, November 13 

Wednesday, November 14 

7:00 am - 6:30 pm 

7:00 am - 6:30 pm 

7:00 am - 6:30 pm 

7:00 am - 6:30 pm 

7:00 am - 1:00 pm 

Located on the L Street Bridge (Level 2)

MEETING SERVICES 

My Annual Meeting – Everything You Need, in One Place 

Search the program, access syllabi, view abstracts, track your 

CME and retrieve recorded sessions on SessionSelect. See page 

18 for more information on SessionSelect. 

Resource Center – The Spot for All Things ACR! 

Resource Center Hours: 

Saturday, November 10 ............ 7:00 AM – 6:30 PM 




Wednesday, November 14 ..........7:00 AM – 1:00 PM 

Stop by the Resource Center, located on the L Street Bridge 

(Level 2), to learn more about the exceptional services the 

College has to offer and the exciting new initiatives under 

way. Staff will demonstrate popular online resources, provide 

information and answer any questions you may have. The 

Resource Center has it all in one place! See page 14 for more 

information. 

Look for these specific areas in the Resource Center: 

• Advocacy 

Get the most up-to-date information on the legislative and 

regulatory issues affecting your profession. We have talking 

points on all ACR legislative priorities and tips on how to get 

more involved with the ACR’s advocacy efforts. You can also 

receive information on RheumPAC – the ACR’s political action 

committee. 

• College Showcase 

Throughout the week, recordings of sessions will be replayed. 

ACR staff will also present interactive demonstrations of 

educational resources and practice tools. 

• Quality & Informatics 

Learn how enrollment in the Rheumatology Clinical Registry 

can benefit you by providing hands-on measurement tools 

and reports that enable you to comparatively assess the 

quality and outcome of rheumatologic care you provide. 

Plan on attending interactive demonstrations of this tool 

offered throughout the week. 

• Recertification 

Need help navigating Maintenance of Certification? We have 

answers to help steer your route to success with the American 

Board of Internal Medicine’s Maintenance of Certification 

program. An ABIM representative will be on-site throughout 

the week to help answer your questions. 

• Musculoskeletal Ultrasound Certification—NEW! 

Interested in certifying in ultrasound? The ACR is providing 

a voluntary pathway for physicians, physician assistants 

and nurse practitioners who perform ultrasound as part of 

their practice in rheumatology to demonstrate competence 

to patients, peers and payers through its first certification 

program. Stop by the ACR Rheumatology Musculoskeletal 

Ultrasound Certification kiosk to enroll in the first exam and 

learn more about the program. 

Membership Booth 

Located in the registration hall (Salons G-H-I ), this is the place 

to go if you want to become a member, pay dues, reinstate your 

membership, learn more about member benefits and awards, 

or volunteer to serve on a committee. 

Lost and Found 

Found items should be returned to the ACR Office, room 102A. 

If you are looking for a lost item, go to the ACR Office or call 

(202) 249-4001. 

• Lupus Initiative 

This educational initiative, designed to reduce health 

disparities in lupus based on gender, race and ethnicity, will 

offer demonstrations of educational resources for health 

professionals in training and in practice. Lupus experts are 

encouraged to drop by to participate in our online discussion. 

• Practice Management & Coding 

Visit with ACR certified coders and practice management 

experts for any coding, billing, insurance or practice 

management questions. We have all the resources you need 

for an efficient rheumatology practice. You can also pick up 

the latest copy of the ACR’s monthly RheumWATCH. 

• Publications 

The editorial office staff of the Arthritis & Rheumatism and 

Arthritis Care & Research journals will be available to answer 

questions concerning online article submission and article 

review processes for the journals. 


Newsroom 

Located in room 203A-B, use of the Newsroom is limited to 

media representatives with press passes. 

Attendee Lounge 

Across from the Ballroom, attendees are welcome to relax and 

enjoy seating while networking with colleagues, checking e-mail, 

and recharging their laptops or smartphones. 

Announcement Boards 

Located in the Ballroom South Prefunction (attendee lounge), 

display boards will be available for posting announcements and 

events of interest. Posted materials are limited to 8.5” x 11” in 

size. Job postings are not permitted. 

Career Connection 

Employers and candidates are encouraged to take advantage of 

the Career Connection located in the exhibit hall (Hall A, Booth 

945) to post position openings, search nationwide rheumatology 

career opportunities and much more. 

On Tuesday, November 13, potential employers and candidates 

can meet in the exhibit hall and enjoy a complimentary boxed 

lunch (provided to the first 100 participants) while discussing 

career opportunities. During this time employers can distribute 

handouts, flyers or business cards to potential candidates. 

Career Connection Hours: 

Sunday, November 11 ............. 10:00 AM – 5:00 PM 

Monday, November 12 ............ 10:00 AM – 5:00 PM 

Tuesday, November 13 ............ 10:00 AM – 5:00 PM 

Registration 

Registration counters are located in the registration hall 

(Salons G-H-I). 

Registration Hours: 

Friday, November 9 ................ 6:30 AM – 6:00 PM 






Shuttle Bus 

Shuttle service will be provided to and from the Walter E. 

Washington Convention Center and ACR hotels which are 

designated as non-walking hotels. On Friday, Saturday and 

Wednesday service operates continuously. On Sunday through 

Tuesday, service operates from 6:30 – 10:30 AM and 2:30 – 6:30 

PM. Special service will be provided on Saturday, November 10 to 

and from the Opening Event at the Newseum. Full shuttle service 

information will be posted in ACR hotel lobbies, at the shuttle 

bus entrance of the convention center and online. 

This service is complimentary for attendees and registered 

guests who booked their rooms through ACR Housing. Attendees 

who have booked their rooms on their own in contracted or noncontracted 

ACR hotels may purchase an ACR shuttle bus pass at 

the ACR registration counter for $40. 

Speaker Ready Room 

Located in room 156. Check-in is expected of all speakers. Plan to 

check in 3 hours prior to your presentation time. In the Speaker 

Ready Room, you can review your presentation and approve the 

file to be uploaded to the central server. Professional audiovisual 

technicians will be available to assist you. Computers in the 

Speaker Ready Room will be configured with hardware and 

software exactly like the ones in the meeting rooms and will 

allow you to preview your presentation, identify problems and 

make corrections as necessary before your presentation. 

Speaker Ready Room Hours: 

Friday, November 9 ................ 6:30 AM – 6:00 PM 






Wi-Fi Way and Recharge Access 

Complimentary Wi-Fi access is available in all rooms of the 

convention center. Recharge areas will be available in the exhibit 

hall (hall A), poster hall (Hall B), attendee lounge and in large 

meeting rooms. 

Park benches, banquet rounds and cocktail tables comprise 

seating in the new exhibit hall Wi-Fi Way where attendees can 

enjoy the flurry of activity while surfing the Internet, checking 

e-mail and recharging electronic items. 

16 

2012 Program Book

Rheumatology 

ReseARCh Foundation 

formerly the ACR Research and Education Foundation 

Visit our Booth 

Visit the Rheumatology Research Foundation booth located on 

the L Street Bridge (Level 2) to find out more about what we are 

doing to advance treatment and find cures for rheumatic disease. 

View and order the latest poster in the Rodnan Commemorative 

Gout Print poster series, learn more about our programs and 

initiatives, and even receive a gift just for stopping by! 

Foundation Booth Hours: 






Visit the Donors’ Lounge 

Plan to spend time in the Foundation Donors’ Lounge, located 

in the East Overlook (2nd Floor), and take advantage of special 

perks! Enjoy a hot breakfast each morning and gourmet 

afternoon coffee service; catch up on work and check e-mail at 

one of the private computer stations; or relax by watching some 

television and catching up with your colleagues. 

An official 2012 Donors’ Lounge Access Pass is required for entry 

and will be distributed to qualified donors at the meeting. A 

minimum cumulative donation of $500 to the Rheumatology 

Research Foundation during fiscal year 2012 (July 1, 2011 

through June 30, 2012) qualifies. 

Donors’ Lounge Hours: 

Saturday, November 10 ............ Noon – 5:00 PM 





Participate in the 5K Run/Walk 

Sunday, November 11 

6:00 – 7:30 AM 

The Yards Park 

www.yardspark.org 

We invite you to experience D.C.’s newest waterfront 

destination while supporting rheumatology training and career 

development. The 5K Run/Walk will take place at the Yards Park, 

the centerpiece of the Capitol Riverfront neighborhood located 

just south of Capitol Hill. 

Participants may register at the 5K Run/Walk Booth until 5:00 

PM on Saturday, November 10. Registration is $40 and subject 

to space availability. Complimentary shuttle service to and 

from the park is provided. Participants will receive an official 

Rheumatology Research Foundation 5K Run/Walk T-shirt. 

All proceeds support activities, grants and awards provided 

by the Foundation. 


Maximize Your 

Learning Opportunities 

with SessionSelect! 

VIP ACCESS! 

Annual meeting 

registration fee includes 

automatic access to 

SessionSelect. 

SessionSelect is a comprehensive digital library of presentations from the annual meeting. 

View hundreds of hours of fully-synchronized presentations with speaker slides and audio— 

just as if you were actually in the room. 

With SessionSelect you can: 

• Access sessions online within 24 hours of the live session 

• Review all or part of key educational sessions at your own pace 

• View content on your mobile device or download MP3 files for listening to audio on-the-go 

NEW for 2012! 

SessionSelect Lounges 

Got some down time between sessions? Kick-back while you replay sessions—on YOUR 

demand—in the new SessionSelect lounges, located in the West Overlook (2nd Floor) 

and Exhibit Hall (Hall A). 

CME Available 

Ten sessions from this year’s annual meeting are available for CME credit. 

Go to www.acrannualmeeting.org/SessionSelect for a list of sessions. 

To learn more about SessionSelect or to view a demo, 

stop by the Resource Center located on the L Street 

Bridge (Level 2).

SPECIAL OFFERS AT 

THE ANNUAL MEETING 

SessionSelect – no need to miss a session! 

Within 24 hours of virtually every live session at the annual 

meeting, video recordings of the presentations, including oral 

abstracts, will be available through SessionSelect, your source 

for ACR education, online. As a scientific attendee, you get 

FREE online access for one year to hundreds of hours of annual 

meeting content –over $500 of added value. 

Select sessions will be recorded and available to view as 

webcasts during and after the meeting. Therefore, if you missed 

one of the designated sessions, you can watch it the next day 

through SessionSelect. You can also catch replays of select 

sessions from SessionSelect in the new SessionSelect lounges 

located in the West Overlook (2nd Floor) and inside the exhibit 

hall, Hall A. Check these specific areas for a tentative schedule 

of sessions. 

Please note, recordings of individual sessions are subject to 

change. Ticketed sessions and pre-meeting courses are not 

included in this offer. 

What Would Make This Meeting Better? 

You’ve got ideas to share, and we’ve made it easy for you to 

share them. 

• Post a suggestion one of the graffiti walls for all to see. 

• Tweet your idea using the #ACR2012 hashtag. 

• Drop a comment into one of the idea boxes around the 

convention center. 

Medical Bag 

Don’t forget to pick up a Medical Bag prior to visiting the 

exhibits. Each bag contains special offers and invitations from 

our exhibitors and will be distributed from the exhibition 

entrance while supplies last. 

POSTER SESSIONS 

Poster presentations facilitate one-on-one interaction between 

the presenters and attendees. Posters are grouped by topic 

and will remain displayed in the poster hall (Hall B) of the 

convention center from 9:00 AM – 6:00 PM, Sunday, November 

11 – Tuesday, November 13. One poster session will be held each 

day. Presenting authors must be available at their poster from 

9:00 – 11:00 AM to answer questions from meeting attendees 

as well as poster tour participants. There is no poster session 

on Wednesday. The number on the poster boards refers to the 

abstract presentation number, and this number will change for 

each poster session. 

New 

this year! 

Thieves’ market poster sessions will be held on 

Sunday, November 11 and Monday, November 12. 

Poster Session Presenter Instructions 

Posters must be mounted by 8:30 AM and dismantled after 

6:00 PM during the designated poster session as outlined in the 

abstract acceptance notification. Posters not picked up after 6:00 

PM on Tuesday, November 13 will be recycled. In order to ensure 

a positive experience for both attendees and poster presenters, 

it is important to make sure that all posters are properly 

mounted and presenters are present from 9:00 – 11:00 AM for 

poster presentations. Poster presenter ribbons will be available 

in the Speaker Ready Room (room 156). If you elected to have 

your poster printed by the official ACR/ARHP poster printing 

service they will hang, take down and store your poster for you. 

ACR Poster Presenter No-show Policy 

Please note that the ACR will be monitoring posters during 

presentation hours in an effort to make certain that the ACR is 

meeting the educational needs and expectations of attendees. 

Poster Sessions – Sunday, November 11 through Tuesday, 

November 13 from 9:00 AM – 6:00 PM (Posters to remain up 

until 6:00 pm.) 

Set Up: .......................... 7:00 – 8:30 AM 

Presentation: . . . . . . . . . . . . . . . . . . . . . 9:00 – 11:00 AM 

Poster Tours: .....................9:00 – 9:45 AM 

10:15 – 11:00 AM 

Removal: ........................6:00 – 6:30 PM 

Guided Poster Tours 

Guided poster tours, led by experts in the field, will guide small 

groups of attendees during the poster presentation times 

to highlight novel or recent developments. Selected posters 

from various abstract categories will be included in the tours. 

Although there is no fee to participate, pre-registration is 

required and each tour is limited to 20 registered scientific 

attendees. 

If you would like to participate and have not registered you 

can check tour availability and request a ticket at registration, 

located in Salons G-H-I. If you registered in advance of the 

meeting, your ticket was included with your meeting materials. 

Once you have your ticket, plan to collect your headset and 

meet your group 10 minutes before your tour departs from 

the entrance of the poster hall, located in Hall B. 


FRIDAY 

November 9, 2012 

Call for Proposals and Study 

Group Applications 

Submission Deadline: Friday, 

December 14, 2012 at noon. 

This is your opportunity to share your ideas and make a contribution to the 

2013 Annual Meeting. To view instructions and submit a session proposal, 

visit www.ACRannualmeeting.org. 

Coordinate a study group and create a unique networking opportunity 

for your colleagues. To view the guidelines and submit an application, 

visit www.ACRannualmeeting.org. 

acr/arhp scientific sessions 

FRIDAY, NOVEMBER 9, 2012 

ACR/ARHP REGISTRATION 

6:30 am - 6:00 pm 

Registration Hall (Salons G-H-I) 

PM PS 

ACR MUSCULOSKELETAL ULTRASOUND 

COURSE FOR RHEUMATOLOGISTS - 

DAY ONE 

7:30 am - 5:30 pm 

207 A 

Admission to the ACR Musculoskeletal Ultrasound Course for 

Rheumatologists requires a separate registration. Registration 

includes complimentary continental breakfast and a boxed lunch. 

Faculty: Rany Al Haj, MD; David A. Bong, MD; George A.W. Bruyn, 

MD, PhD; Arnold Ceponis, MD, PhD; Paul J. DeMarco, MD; Amy 

M. Evangelisto, MD; Janak R. Goyal, MD; Jay B. Higgs, MD; Gurjit 

S. Kaeley, MBBS; Eugene Y. Kissin, MD; Minna J. Kohler, MD; Gary 

Kunkel, MD; Bethany A. Marston, MD; Esperanza Naredo, MD; 

Anthony M. Reginato, MD, PhD; Johannes Roth, MD; Jonathan 

Samuels, MD; Wolfgang A. Schmidt, MD; Richard J. Wakefield, 

BM, MD; Darren Tabechian, MD; Mihaela Taylor, MD; Nikolay 

Tzaribachev, MD; Alvin F. Wells, MD, PhD 

Upon completion of this session, participants should be able to: 

• demonstrate proper ultrasound exam technique and 

procedure guidance applying standardized protocols 

• identify and describe normal sonographic anatomy and 

fundamental pathology for rheumatology indications 

• explain the requirements for documentation related to 

musculoskeletal ultrasound 

7:00 - 7:30 AM 

Continental Breakfast 

Moderator: Amy M. Evangelisto, MD 

7:30 AM 

Opening Remarks 

Amy M. Evangelisto, MD 

Break Out Session: Adult Rheumatology 

7:45 AM 

Principles of Musculoskeletal Ultrasound for Rheumatologists 

Wolfgang A. Schmidt, MD 

8:15 AM 

Introduction to Typical Sonographic Findings in Rheumatology 

Esperanza Naredo, MD 

20 

2012 Program Book

8:45 AM 

Image Acquisition and Ultrasound Technique 

Richard J. Wakefield, BM, MD 

9:15 AM 

Hands-on Scanning: Image Acquisition and Ultrasound 

Technique 

Faculty 

Break Out Session: Pediatric Rheumatology 

7:45 AM 

Principles of Ultrasound in Pediatric Rheumatology 

Johannes Roth, MD 

8:15 AM 

Ultrasound and MRI in Pediatric Rheumatology 

Nikolay Tzaribachev, MD 

8:45 AM 

Sonographic Anatomy in Pediatric Rheumatology 

Johannes Roth, MD 

9:30 AM 

Hands-on Scanning: Image Acquisition and Ultrasound 

Technique 

Johannes Roth, MD; Nikolay Tzaribachev, MD; Bethany A. 

Marston, MD 

10:00 - 10:15 AM 

Break 

The Shoulder 

10:15 AM 

Lecture: Standard Scans, Sonographic Anatomy, and Basic 

Sonographic Pathology 

Gurjit S. Kaeley, MBBS 

10:45 AM 

Demonstration: Scanning of the Shoulder 

Esperanza Naredo, MD 

11:00 AM 

Hands-on Scanning: The Shoulder 

Faculty 

3:15 - 3:30 PM 

Break 

Hand and Wrist 

3:30 PM 



George A. W. Bruyn, MD, PhD 

4:00 PM 

Demonstration: Hand and Wrist 

Minna J. Kohler, MD 

4:15 PM 

Hands-on Scanning: Hand and Wrist 

Faculty 

ACR CERTIFIED RHEUMATOLOGY CODER 

PM PS 

COURSE: UNLOCK THE MYSTERY: A 

ROADMAP FOR RHEUMATOLOGY CODING – 

DAY ONE PM PS 

9:00 AM - 5:00 PM 

150 B 

Admission to the ACR Certified Rheumatology Coder Course 

requires a separate registration. Registration includes a boxed 

lunch. This course is not eligible for CME credit. 


• exhibit proficiency in adjudicating claims for accurate medical 

coding for diagnoses, procedures and services in physicianbased 

settings 

• display proficiency across a wide range of services, which 

include evaluation and management, surgical services, 

radiology, pathology and medicine 

• demonstrate knowledge of medical coding rules and 

regulations including compliance and reimbursement 

• distinguish how to integrate medical coding and 

reimbursement rule changes into a practice’s reimbursement 

process 

Speakers: Antanya Chung, CPC, CPC-I, CRHC, CCP and Melesia 

Tillman, CPC, CRHC, CHA 


FRIDAY 

12:30 - 1:30 PM 

Boxed Lunch 

Moderator: Gurjit S. Kaeley, MBBS 

The Elbow 

1:30 PM 




2:00 PM 

Demonstration: Scanning of the Elbow 

Jonathan Samuels, MD 

2:15 PM 

Hands-on Scanning: The Elbow 

PM PS 

ACR/ABIM MAINTENANCE OF CERTIFICATION 

LEARNING SESSION - 2012 UPDATE IN 

RHEUMATOLOGY 

1:00 - 6:00 PM 

146 C 

Admission to the ACR/ABIM MOC Learning Session requires a 

separate registration. Learn in an interactive environment as 

clinical experts lead you through 30 case-based questions from 

ABIM’s 2012 Update in Rheumatology Module. After the session, 

submit your answers online to the ABIM to receive 10 medical 

knowledge points for the Maintenance of Certification program. 

Moderator: Carol A. Langford, MD, MHS 


FRIDAY 


22 


• assess strengths and weaknesses in rheumatology medical 

base knowledge 

• state major developments in rheumatology over the past ten 

years 

• satisfy a self-evaluation requirement for the American Board 

of Internal Medicine Maintenance of Certification program 

Overview and Session I 

1:00 PM 

Questions from 2012 Update: 1, 9, 15, 16, 18, 19, 22, 26, 28, 29 

Carol A. Langford, MD, MHS 

2:40 - 3:00 PM 

Break 

Session II 

3:00 PM 


Mary Chester Wasko, MD, MSc 

Session III 

4:30 PM 


Seetha U. Monrad, MD 

6:00 PM 

Wrap-up 

ACR BASIC RESEARCH CONFERENCE: 

PM PS 

MESENCHYMAL CELLS IN RHEUMATIC 

DISEASES: TISSUE EROSION/INVASION VS. 

FIBROSIS – DAY ONE 

1:00 - 5:55 PM 

Ballroom A 

Admission to the ACR Basic Research Conference requires a 

separate registration. Registration includes complimentary 

continental breakfast and a boxed lunch. 

Moderator: Steffen Gay, MD 


• describe the role of mesenchymal cells in inflammatory 

arthritis 

• describe the role of mesenchymal cells in fibrosis 

• identify the factors modulating the function and development 

of mesenchymal cells 

Session I: The Biology of Mesenchymal Cells 

1:00 PM 

Mesenchymal Cells 

John Varga, MD 

1:20 PM 

Synovial Cells and the Development of the Synovial Lining 

Michael B. Brenner, MD 

1:50 PM 

Interaction of Synovial Fluid with T cells 

David A. Fox, MD 


2:15 PM 

Mesenchymal Cell Plasticity: EMT and Cancer 

Derek C. Radisky, PhD 

2:45 - 3:00 PM 

Break 

3:00 PM 

Cellular Plasticity and Lung Fibrosis 

Paul Noble, MD 

3:25 PM 

Biomechanical Sensing and Signaling 

Boris Hinz, PhD 

Session II: Core Signaling Mechanisms in Fibrosis 

3:40 PM 

Orbital Fibroblasts in Health and Disease 

Terry J. Smith, MD 

4:25 PM 

Morphogen Pathways or Stem Cell Pathways 

Joerg H. W. Distler, MD 

5:10 PM 

Novel Lipid Mediators and Eicosanoids Relevant in Synovial 

Biology 

Charles Serhan, PhD 

5:55 - 7:00 PM 

Networking Reception 

Networking reception combined with ACR Clinical Research 

Conference participants. 

PM PS 

ACR CLINICAL RESEARCH CONFERENCE: 

PAIN RESEARCH: NEW METHODS And 

CHALLENGES – DAY ONE OF TWO PM 

1:00 - 6:00 PM 

Ballroom C 

Admission to the ACR Clinical Research Conference requires 

a separate registration. Registration includes complimentary 


Moderator: Daniel J. Clauw, MD 


• discuss the latest clinical research techniques in the pain field, 

as well as the strengths and weaknesses of each technique 

• stimulate new interdisciplinary relationships, including 

mentor-mentee relationships in rheumatology community 

• disseminate the knowledge gained from this conference 

Introduction: State of the Field 

1:00 PM 

Introductory Remarks 

Daniel J. Clauw, MD 

1:30 PM 

Keynote Speaker: Neurophysiology and Preclinical Models 

Clifford Woolf, MB, BCh, PhD 

PS

2:20 PM 

Panel Discussion/Question and Answer 

Clinical Trials 

2:45 PM 

Academic Prospective 

Lesley M. Arnold, MD 

3:15 PM 

Accelerating the Development of Improved Analgesic 

Treatments: The ACTTION Public-private Partnership and 

Evidence-based Clinical Trial Design 

Robert H. Dworkin, PhD 

3:45 PM 


4:00 - 4:15 PM 

Break 

Special Issues in Pain Research 

4:15 PM 

Past, Present and Future-Regulatory Perspectives on Analgesics 

Sharon Hertz, MD 

4:45 PM 

Pediatric Pain Research 

Laura E. Schanberg, MD 

5:15 PM 

Ethics 

Joseph Ali, JD 

5:45 PM 

Wrap Up 

6:00 - 7:00 PM 

Networking Reception 

Networking reception combined with ACR Basic Research 

Conference participants. 

Faculty: Rany Al Haj, MD; David A. Bong, MD; George A.W. 

Bruyn, MD, PhD; Arnold Ceponis, MD, PhD; Paul J. DeMarco, 

MD; Amy M. Evangelisto, MD; Janak R. Goyal, MD; Jay B. 

Higgs, MD; Gurjit S. Kaeley, MBBS; Eugene Y. Kissin, MD; 

Minna J. Kohler, MD; Gary Kunkel, MD; Bethany A. Marston, 

MD; Esperanza Naredo, MD; Anthony M. Reginato, MD, PhD; 

Johannes Roth, MD; Jonathan Samuels, MD; Wolfgang A. 

Schmidt, MD; Richard J. Wakefield, BM, MD; Darren Tabechian, 

MD; Mihaela Taylor, MD; Nikolay Tzaribachev, MD; Alvin F. Wells, 

MD, PhD 


• demonstrate proper ultrasound exam technique and 

procedure guidance applying standardized protocols 

• identify and describe normal sonographic anatomy and 

fundamental pathology for rheumatology indications 

• explain the requirements for documentation related to 

musculoskeletal ultrasound 

6:45 - 7:15 AM 


Moderator: Alvin F. Wells, MD, PhD 

7:15 AM 

Opening Remarks 


7:20 AM 

Lecture: Billing Coding and Report Generation 

Alvin F. Wells, MD, PhD 

The Hip 

7:50 AM 

The Hip - Lecture: Standard Scans, Sonongraphic Anatomy, 

and Basic Sonographic Pathology 

Wolfgang A. Schmidt, MD 

8:20 AM 

Demonstration: Scanning of the Hip 


SATURDAY 


SATURDAY, NOVEMBER 10, 2012 


6:30 AM - 6:30 PM 


PM PS 

ACR MUSCULOSKELETAL ULTRASOUND 

COURSE FOR RHEUMATOLOGISTS – 

DAY TWO 

7:15 AM - 4:30 PM 

207 A 

Admission to the ACR Musculoskeletal Ultrasound Course for 

Rheumatologists requires a separate registration. Registration 

includes complimentary continental breakfast and a boxed 

lunch. 

8:35 AM 

Hands-on Scanning: The Hip 

Faculty 

9:30 - 9:40 AM 

Break 

The Knee 

9:40 AM 

The Knee - Lecture: Scans, Sonographic Anatomy, and Basic 


David A. Bong, MD 

10:10 AM 

Demonstration: Scanning of the Knee 

Jay B. Higgs, MD 

10:25 AM 

Hands-on Scanning: The Knee 

Faculty 


SATURDAY 


24 

11:30 AM - 12:30 PM 

Boxed Lunch 

Moderator: Eugene Y. Kissin, MD 

Foot and Ankle 

12:30 PM 

Foot and Ankle - Lecture: Standard Scans, Sonographic 

Anatomy, and Basic Sonographic Pathology 

Richard J. Wakefield, BM, MD 

1:00 PM 

Demonstration: Scanning of Foot and Ankle 

Paul J. DeMarco, MD 

1:15 PM 

Hands-on Scanning: Foot and Ankle 

Faculty 

2:30 - 2:45 PM 

Break 

Ultrasound Guidance 

2:45 PM 

Lecture: Evidence-base for Ultrasound Guidance of Procedures 

Eugene Y. Kissin, MD 

3:15 PM 

Lecture: Technique of Ultrasound Needle Guidance 

Janak R. Goyal, MD 

3:45 PM 

Hands-on Scanning: Ultrasound Injection Guidance with 

Phantoms 

Faculty 

ACR REVIEW COURSE 

8:00 AM - 4:00 PM 


PM 

Hall D 

Admission to the ACR Review Course requires a separate 

registration. Registration includes complimentary continental 

breakfast and a boxed lunch. 

Moderators: Gregory C. Gardner, MD and Virginia D. Steen, MD 

7:00 - 8:00 AM 


PS 

8:00 AM 

Review and Update of Ankylosing Spondylitis 

Speaker: Desiree M. van der Heijde, MD, PhD 


• describe to a patient or colleague the current understanding 

of the pathophysiology of ankylosing spondylitis 

• discuss the current criteria for diagnosis and the utility of 

imaging studies to confirm the diagnosis 

• discuss current recommendations for treating ankylosing 

spondylitis as well as potential agents that are soon to market 

that might have an impact on the disease 

• describe important extra-articular manifestations of the 

disease 

8:45 AM 

When Thick Skin is Not a Good Thing 

Speaker: Heidi Jacobe, MD, MSCS 


• describe what clinically distinguishes scleroderma-like 

diseases including localized scleroderma (morphea), 

eosinophilic fasciitis, scleredema, scleromyxedema, and 

nephrogenic systemic fibrosis from systemic sclerosis 

• discuss how laboratory testing, magnetic resonance imaging 

and pathology can help make the diagnosis and determine 

how active the disease is 

• discuss the best therapeutic options and what the role of 

phototherapy and physical therapy have on the long-term 

outcomes in these patients 

9:30 AM 

Inflammatory Myositis: 2012 

Speaker: Ingrid E. Lundberg, MD 


• discuss the best approach to the diagnosis of inflammatory 

muscle disease and how to differentiate it from other muscle 

and other connective tissue diseases 

• describe the important extra muscular problems in myositis, 

particularly the skin, joint and lung complications 

• recognize which patients are at greatest risk for developing 

malignancy 

• explain the different treatment approaches and the expected 

outcomes 

10:15 - 10:45 AM 

Break 

10:45 AM 

Lupus - More than Nephritis: Treatment of Non-Nephritis Lupus 

Problems 

Speaker: Susan Manzi, MD, MPH 


• describe the use of the laboratory in the management of nonnephritis 

lupus 

• discuss specific management issues in patients with skin, 

joint, hematologic, central nervous system, serositis, and lung 

involvement of lupus 

• describe what the different steroid sparing agents are, and 

when and who they should be used in, and what to expect 

from them 

11:30 AM 

Setting the Stage for Rheumatoid Arthritis 

Speaker: Hani S. El-Gabalawy, MD 


• describe the currently understood genetic and environmental 

factors that impact the development of autoimmunity, the 

clinical onset of synovitis, and the severity of rheumatoid 

arthritis 

• describe to a patient with rheumatoid arthritis the sub-clinical 

immunologic events that may have occurred just prior to 

disease onset and their relationship to their symptoms 

• discuss the utility of ACPA, RF, and other biomarkers in the 

diagnosis and prognosis of early rheumatoid arthritis 

• describe the potential utility of very early treatment strategies 

in changing the trajectory of rheumatoid arthritis, and 

impacting chronicity and persistence of the disease

12:15 - 1:15 PM 

Boxed Lunch 

7:00 - 8:00 AM 


1:15 PM 

Hypermobility, Diagnosis, Disease Associations, Treatment 

Speaker: Elizabeth B. Russell, MD 


• evaluate and clinically diagnose hypermobility in patients and 

know when to proceed with diagnostic testing 

• define the spectrum of disorders associated with 

hypermobility 

• describe to a patient with hypermobility the long-term 

management strategies, including surgical and non-surgical 

options 

2:00 PM 

Osteoporosis Update 

Speaker: Chad L. Deal, MD 


• describe the pathophysiology of osteoporosis 

• determine when and for how long patients should be treated 

with the different types of medication 

• discuss how the new biologic medications for osteoporosis 

will change management 

Session III: Fibroblasts as Invaders and Aggressors 

8:00 AM 

Overview of Synovial Cell Pathobiology 

Steffen Gay, MD 

8:20 AM 

Tumor Metastatis: Molecular Insights and Evolving Paradigms 

Scott J. Valastyan, PhD 

8:40 AM 

Syndecans and Fibroblast Response 

Thomas Pap, MD 

Session IV: Immunity and Mesenchymal Cells 

9:00 AM 

Fibroblasts as Tumor Suppressors 

Douglas T. Fearon, MD 

9:20 AM 

TLR Regulation of Fibroblast Function 

Cory M. Hogaboam, PhD 

SATURDAY 


2:45 - 3:15 PM 

Break 

3:15 PM 

Is It Central Nervous System Vasculitis or Something Else? 

Speaker: Leonard H. Calabrese, DO 


• describe to a colleague the evaluation for suspected central 

nervous system vasculitis and the pearls and pitfalls of 

imaging studies as well as brain biopsy 

• describe to a colleague why a patient does or does not have 

central nervous system vasculitis based on the results of the 

evaluation 

• discuss the conditions that mimic central nervous system 

vasculitis 

• discuss the current recommendations for treatment of central 

nervous system vasculitis 

ACR BASIC RESEARCH CONFERENCE: 

PM PS 

MESENCHYMAL CELLS IN RHEUMATIC 

DISEASES: TISSUE EROSION/INVASION VS. 

FIBROSIS – DAY TWO 

8:00 AM - 4:30 PM 

Ballroom A 

Admission to the ACR Basic Research Conference requires a 



Moderator: John Varga, MD 


• describe the role of mesenchymal cells in inflammatory 

arthritis 

• describe the role of mesenchymal cells in fibrosis 

• identify the factors modulating the function and development 

of mesenchymal cells 

9:40 AM 

Stromal Cell Modulation by Dendritic Cells 

Theresa T. Lu, MD, PhD 

10:00 AM 

Fibroblasts Maintain Inflammation 

Christopher D. Buckley, PhD 

10:20 AM 

Microparticles and Inflammation 

Astrid Jungel, PhD 

10:40 - 10:55 AM 

Break 

Session V: Therapeutic Aspects: Biomarkers and 

Targeting Fibrosis 

10:55 AM 

Fibrosis Biomarkers 

Robert Lafyatis, MD 

11:15 AM 

Macrophages and Matrix Remodeling 

Jeremy S. Duffield, MD, PhD 

11:35 AM 

Circulating Fibrocytes in Rheumatoid Arthritis 

Eleanor Fish, PhD 

12:05 - 12:45 PM 

Boxed Lunches 

12:45 PM 

Abstract Presentations 

1:40 PM 

Transforming Growth Factors Beta 

Shelia Violette, PhD 


2:05 PM 

Methylation and Acetylation in Resetting Fibroblast Function 

Gary S. Firestein, MD 

2:30 PM 

Fibroblast Reticular Cells in Inflammation 

Sanjiv Luther, PhD 

8:00 AM 

Introduction 

Marie D. Westby, PT, PhD 

8:15 AM 

Osteoarthritis as We Understand It Today 

Carla R. Scanzello, MD, PhD 

SATURDAY 


2:55 PM 

Adipokines and Mesenchymal Cell Activation 

Ulf Müller-Ladner, MD 

3:20 - 3:30 PM 

Break 

Session VI: Therapeutic Aspects: Biomarkers and 

Targeting Fibrosis (continued) 

3:30 PM 

Chemokines and Synovial Cell Activation 

Alisa E. Koch, MD 

9:00 AM 

Osteoarthritis Assessment: Thinking Outside of the Joint 

Charles R. Ratzlaff, BSc(PT), PhD, PT 

10:15 AM 

2012 ACR Guidelines on Osteoarthritis: A Focus on 

Pharmacologic Management 

Marc C. Hochberg, MD, MPH 

11:15 AM 

Addressing Risk Factors for Osteoarthritis through the Lifespan: 

Let’s Start with the Kids! 

Kristin M. Houghton, MD 

3:50 PM 

Mesenchymal Stem Cell Therapy 

Darwin J. Prockop, MD, PhD 

4:10 PM 

Purinergic Receptors Regulating Fibroblasts 

Bruce N. Cronstein, MD 

ARHP CLINICAL FOCUS COURSE: TREATING 

PM PS 

THE PATIENT WITH OSTEOARTHRITIS: 

INTERVENTIONS, INNOVATIONS And 

CLINICAL INSIGHTS 

8:00 AM - 4:30 PM 

143 A 

Admission to the ARHP Clinical Focus Course requires a separate 

registration. Registration includes complimentary continental 

breakfast and a boxed lunch. 

Moderator: Marie D. Westby, PT, PhD 


• conduct a comprehensive assessment that identifies 

impairments, activity limitations, participation restrictions and 

personal factors in a patient with osteoarthritis in order to 

inform a clinical treatment plan 

• integrate current evidence-based practice guidelines with 

patient needs and preferences to formulate pharmacological, 

non-pharmacological and complementary treatment 

strategies 

• incorporate the use of valid and clinically feasible 

osteoarthritis outcome measures in order to inform clinical 

practice 

• use a variety of professional and public resources and 

technology to engage patients in arthritis self-management 

7:00 - 8:00 AM 


Noon - 12:45 PM 

Boxed Lunch 

12:45 - 1:30 PM 

Breakout Session I 

What’s New in Fine Tuning the Care of the Osteoarthritic Hand? 

Moderator: Kathryn L. Lowenstein, OTR 

Speaker: Virginia O’Brien, OTD, OTR/L, CHT 

Neuromuscular Training and Joint Mobilizations: Do We Need 

Both to Optimize Lower Limb Function? 

Moderator: Marie Westby, PT, PhD 

Speaker: G. Kelley Fitzgerald, PhD, PT 

Managing Pain and Promoting Activity: It’s Not a Stretch to 

Suggest Complementary Movement Approaches 

Moderator: Jessica F. Farrell, PharmD 

Speaker: Steffany Moonaz, MFA, PhD 

1:45 - 2:30 PM 

Breakout Session II 

What’s New in Fine Tuning the Care of the Osteoarthritic Hand? 

Moderator: Kathryn L. Lowenstein, OTR 

Speaker: Virginia O’Brien, OTD, OTR/L, CHT 

Neuromuscular Training and Joint Mobilizations: Do We Need 

Both to Optimize Lower Limb Function? 

Moderator: Marie Westby, PT, PhD 

Speaker: G. Kelley Fitzgerald, PhD, PT 

Managing Pain and Promoting Activity: It’s Not a Stretch to 

Suggest Complementary Movement Approaches 

Moderator: Jessica F. Farrell, PharmD 

Speaker: Steffany Moonaz, PhD, RYT-500 

2:30 - 2:45 PM 

Break 

2:45 PM 

Using Outcome Measures to Inform Clinical Practice 

Gillian A. Hawker, MD, MSc 

26 

2012 Program Book

3:15 PM 

Obesity and Osteoarthritis: Clinicians Can Make a Difference in 

Promoting Healthier Lifestyles 

Susan J. Bartlett, PhD 

3:45 PM 

Osteoarthritis Chronic Disease Management in the Age of the 

Internet, Apps and Tweets 

Patricia D. Franklin, MBA, MD, MPH 

4:15 PM 

Concluding Remarks 


PM PS 

CORC PRE-MEETING COURSE FOR PRACTICE 

MANAGERS: HELPING YOU MANAGE A 

PROFITABLE PRACTICE 

8:00 AM - 4:30 PM 

152 A 

Admission to the CORC Pre-meeting Course for Practice 

Managers requires a separate registration fee. Fee includes a 

continental breakfast and boxed lunch. 

8:00 AM 

Keynote Address: The World’s Best Managers Do Manage 

Differently-Find Your Strengths for Efficiency! 

Moderator: Laura Wright, MBA, CMPE 

Speaker: To be announced 


• identify how to capitalize on the strengths of staff 

• develop techniques to help clarify staff roles, keeping them 

engaged and assisting with high performance 

• identify ways to understand and communicate effectively with 

different personality types 

• recognize the seven body language signs to watch for, and 

what they mean 

9:15 AM 

Improving Revenue Cycle Management Effectiveness and 

Optimize Cash Flow 


Speaker: Michael Fleischman, FAAHC 


• identify practical hands-on approach for handling denials to 

improve the bottom line 

• review standard spreadsheets that will help managing 

physicians and practice administrators monitor the accounts 

receivable for the practice 

• establish criteria to assess monthly accounts to streamline 

process 

• discuss tips and techniques to explore training on handling 

denial codes to save money 

10:00 - 10:15 AM 

Break 

10:15 AM 

Effective Marketing for Today’s Medical Practice 

Moderator: Cindy Gutierrez, MBA 

Speaker: Simon Sikorski, MD 


• discuss the importance of marketing in 2012 and the various 

marketing styles for physician practices 

• discuss the specifics and “do’s and dont’s” of web-based 

marketing 

• identify easy-to-implement tips and techniques to assist 

physicians in marketing their practices to prospective 

patients, including tips to increase the efficiency of marketing 

campaigns 

11:00 AM 

Transforming the Practice Front End 


Speaker: Sunjanel Avecilla, EMT-P, CPC, CMC, CMOM, CMIS, 

CMCO 


• identify the key issues on patient confidentiality and HIPAA 

compliance 

• discuss the necessity for training on charting and medical 

record keeping 

• identify areas for cross-training to enhance daily workflow 

• improve patient experience on scheduling appointments, 

minimize excessive wait time upon arrival 

Noon - 1:00 PM 

Networking Lunch 

1:00 PM 

Deal Breakers in Payer Contract Negotiations 


Speaker: Herbert S. B. Baraf, MD 


• identify specific contract language that pertains to areas such 

as recouPMent, carve-outs, limitations and clauses 

• evaluate and discuss the best way to negotiate specific 

requirements that should be included in a contract 

• determine when is the right time to begin new negotiations 

or sever ties with an insurance company 

• identify the top 10 “deal breakers” and “must have” in your 

contract 

2:00 PM 

Improving Accounts Receivable for Profitability 


Speaker: Sunjanel Avecilla, EMT-P, CPC, CMC, CMOM, CMIS, 

CMCO 


• identify the most common denials and rejection edits 

• discuss how your practice management system tools can 

directly assist in streamlining outstanding accounts to 

increase revenue 

• identify a tracking mechanism to secure accurate and timely 

reimbursement 

• review claim denials and appeals to minimize leaving money 

on the table 

SATURDAY 



SATURDAY 


28 

3:00 - 3:15 PM 

Break 

3:15 PM 

How to Maximize the Use of Your Practice Data 


Speakers: Heather McComas, PharmD; Steve Ellwing 


• discuss the importance of how insurance programs are using 

provider data to drive their decision-making process regarding 

new payment methodologies 

• discuss how physician data is used to rate quality and 

efficiency in physician practices 

• identify how physicians and their staff can access these data 

from payers 

• review how to use the data strategically to ensure practice 

efficiency and deliver quality patient care 

4:00 PM 

CORC Pre-meeting Course for Practice Managers - Innovations 

for the Office 


Speakers: Larry Garber, MD and Robert W. Warren, MD, PhD, MPH 


• describe how online communication can be used to support a 

more effective and efficient practice 

• employ strategies to encourage patient engagement per 

the provisions in the CMS EHR Incentive Program, while 

implementing efficient workflow processes to respond to 

patient requests for electronic access to health information 

• explain privacy and security requirements and best practices 

to ensure that electronic patient health information is secure 

PM PS 

ACR CLINICAL RESEARCH CONFERENCE: 

PAIN RESEARCH: NEW METHODS And 

CHALLENGES – DAY TWO PM PS 

8:30 AM - 4:15 PM 

Ballroom C 

Admission to the Clinical Research Conference requires a 


continental breakfast and a boxed lunch. Pre-conference courses 

require a separate registration fee. 

Moderator: Laura E. Schanberg, MD 


• discuss the latest clinical research techniques in the pain field, 

as well as the strengths and weaknesses of each technique 

• stimulate new interdisciplinary relationships, including 

mentor-mentee relationships in rheumatology community 

• disseminate the knowledge gained from this conference 

7:30 - 8:30 AM 


Day Two Introductory Remarks 

8:30 AM 

Importance of Pain Research in NIH/NIAMS Portfolio 

Stephen I. Katz, MD, PhD 


8:45 AM 

Importance of Pain Research to ACR 

David G. Borenstein, MD 

From Preclinical Models to Clinical Studies 

Moderator: Gary J. Macfarlane, BSc, MBChB, MD, PhD 

9:00 AM 

Genetic Studies 

William Maixner, DDS, PhD 

9:30 AM 

Epidemiological Studies 

John McBeth, PhD 

Methods for Phenotyping Pain-1 

10:00 AM 

Patient Reported Outcome Measures (including PROMIS) 

David A. Williams, PhD 

10:30 AM 

Quantitative Sensory Testing 

Roger B. Fillingim, PhD 

11:00 AM 

Functional, Structural, and Chemical Neuroimaging 

Irene Tracey, MA, (Oxon), PhD 

11:30 AM 


11:45 AM - 1:00 PM 

Boxed Lunch 

Methods for Phenotyping Pain-2 

1:00 PM 

Realtime Assessment and Objective Measures of Function 

Mark Connelly, PhD 

1:30 PM 

Using Large Databases 

Frederick Wolfe, MD 

2:00 PM 


2:15 PM 

Introduction to Breakout Groups 

Gary J. Macfarlane, BSc, MBChB, MD, PhD 

2:30 - 2:45 PM 

Break 

2:45 - 4:15 PM 

Break Out Groups 

Self-Report Outcomes Including PROMIS Measures 

Esi M. Morgan DeWitt, MD, MSCE, David A. Williams, PhD and 

James P. Witter, MD, PhD 

Quantitative Sensory Testing 

Roger B. Fillingim, PhD and Steven E. Harte, PhD 

Functional, Structural and Chemical Neuroimaging 

Dane B. Cook, PhD, Roland Staud, MD and Irene Tracey, Director

Real-time Assessment and Objective Measures of Function 

Mark Connelly, PhD, Susan L. Murphy, ScD and 

Jennifer N. Stinson, PhD, RN, CPNP 

Using Large Databases/Epidemiology 

Gary J. Macfarlane, BSc, MBChB, MD, PhD and John McBeth, 

PhD 

Genetics 

William Maixner, DDS, PhD 

Wrap up/Steps Forward 

Gary J. Macfarlane, BSc, MBChB, MD, PhD 

ACR CERTIFIED RHEUMATOLOGY CODER 

COURSE EXAMINATION: UNLOCK 

PM PS 

THE MYSTERY: A ROADMAP FOR 

RHEUMATOLOGY CODING – DAY TWO 

OF TWO PM PS 

11:00 AM - 5:00 PM 

150 B 

Admission to the ACR Certified Rheumatology Coder Course 

requires a separate registration. Registration includes CRHC 

review materials and a boxed lunch. This course is not eligible 

for CME credit. 


• exhibit proficiency in adjudicating claims for accurate medical 

coding for diagnoses, procedures and services in physicianbased 

settings 

• display proficiency across a wide range of services, which 

include evaluation and management, surgical services, 

radiology, pathology and medicine 

• demonstrate knowledge of medical coding rules and 

regulations including compliance and reimbursement 

• distinguish how to integrate medical coding and 

reimbursement rule changes into a practice’s reimbursement 

process 

Speaker: Melesia Tillman, CPC, CRHC, CHA 

PM 

PS 

ACR/ARHP OPENING LECTURE And 

AWARDS 

4:30 - 6:15 PM 

Hall E 

Moderators: James R. O’Dell, MD, ACR President; Audrey B. 

Uknis, MD, ACR President-elect; Benjamin J. Smith, PA-C, ARHP 

President 

4:30 PM 

Presidential Address 

James R. O’Dell, MD 

4:50 PM 

Rheumatology Research Foundation Announcement 

David I. Daikh, MD, PhD 

4:55 PM 

Recognition of 2012 ACR Masters 

Recognition of the 2012 Awards of Distinction Recipients 

Recognition of Presidential Gold Medal Award Recipient 

Recognition of ARHP Merit Awards Lifetime Achievement 

Award 

Recognition of Fellows Awards 

5:30 PM 

“Straight and Swift to My Wounded I Go”: The Reality 

of the American Civil War Medicine 

Speaker: Robert D. Hicks, PhD 


• describe the environment of emergency medical care at the 

outbreak of the American Civil War 

• outline the reforms to emergency medical care led by 

Surgeon General William Hammond and Medical director 

Jonathan Letterman 

• identify the chief tenets of medical ideology of the Civil War 

era, focusing on physiology and medicines 

• describe the nature of and limitations to surgery during the 

Civil War 

ACR/ARHP OPENING EVENT 

7:00 - 10:00 PM 

Newseum 

Admission to the ACR/ARHP Opening Event at the Newseum 

is ticketed and requires a separate registration. Purchase your 

tickets in the ACR/ARHP registration area before 6:30 PM (while 

supplies last) to ensure you have access to this VIP event. Tickets 

will not be available for purchase at the Newseum. 

SUNDAY, NOVEMBER 11, 2012 


6:30 AM - 6:00 PM 


RHEUMATOLOGY ReseARCH FOUNDATION 

5K RUN/WALK 

6:00 - 7:30 AM 

The Yards Park 

See page 17 for more information. 

ACR SESSIONS 

7:30 - 8:30 AM 

PM PS 

146 C 

Modifying Causal Risk Factors that Influence the 

Incidence of Falls by Older Adults 

Moderator: Joel A. Block, MD 

Speaker: Mark D. Grabiner, PhD 

SUNDAY 



SUNDAY 


30 


• summarize current knowledge regarding the prevalence and 

risk of falling among the elderly and infirm 

• discuss current thoughts regarding the neuromuscular basis of 

falls in the elderly 

• review potential therapeutic strategies leveraging recent 

knowledge about pathophysiology 

PM 

Hall D 

Year in Review 

Moderator: Chester V. Oddis, MD 


• discuss selected recent publications on the pathophysiological 

basis of rheumatic diseases by literature review of important 

publications 

• describe selected treatment modalities for rheumatic diseases 

from the recent published literature 

• enumerate how these new advances may impact the practice 

of rheumatology 


PS 

7:30 AM 

Clinical Perspective 

David A. Isenberg, MD 

8:00 AM 

Basic Science Perspective 

Daniel L. Kastner, MD, PhD 

ACR SESSIONS 

7:30 - 9:00 AM 

PM PS 

204 A 

Genetics as a Tool for Elucidating Autoimmune 

Disease Pathogenesis 

Moderator: Lindsey A. Criswell, MD, MPH 


• describe genome wide association study designs, including 

what they can and cannot tell us about genetic susceptibility 

factors for autoimmune and other complex human diseases 

• review the recently established genetic loci for several 

autoimmune diseases and which biologic pathways are most 

strongly implicated by these specific loci 

• describe the types of investigations that will be required to 

understand more specifically how specific genes operate, 

within biologic pathways, to influence disease susceptibility 

and expression 

• review and critique the current evidence that implicates 

specific genetic variants as predictors of rheumatoid arthritis 

treatment response 

7:30 AM 

Biologic Pathways Implicated by Recent GWAS of Systemic 

Autoimmune Disease 

Peter K. Gregersen, MD 

8:00 AM 

Identification of Genes that Influence Response to Rheumatoid 

Arthritis Treatment 

Robert M. Plenge, MD, PhD 

8:30 AM 

Functional Studies of Autoimmune Disease Genetic Risk Loci 

Patrick M. Gaffney, MD 

PM PS 

207 A 

Tips for Publishing Your Work in a Peer-Reviewed 

Medical Journal 

Moderator: Michael D. Lockshin, MD 


• assess whether their study findings are of sufficient novelty 

and significance to warrant submission for publication 

• identify peers and superiors who could provide critical 

feedback on their manuscripts prior to submission for formal 

review 

• determine the journal to which they should most 

appropriately submit their work 

• review how to prepare their manuscripts according to the 

journals’ specific requirements 

7:30 AM 

Publishing in Arthritis & Rheumatism 

Joan M. Bathon, MD 

8:15 AM 

Publishing in Arthritis Care & Research 

Marian T. Hannan, DSc, MPH 

ARHP SESSIONS 

7:45 - 9:00 AM 

201 

ARHP First-time Attendee Orientation 

First-time ARHP annual meeting attendees are invited to an 

orientation to learn the ‘ins and outs’ of the annual meeting. 

The ARHP Membership and Nominations Committee will assist 

you in planning how to get the most out of your first annual 

meeting. This session is not eligible for CME credit. Coffee and 

tea will be provided. 

Moderator: Nadine T. James, RN, PhD 

206 

ARHP Moderators Orientation 

This session is not eligible for CME credit. Coffee and tea will be 

provided. 

Moderators: Linda Ehrlich-Jones, PhD, RN and Afton Hassett, 

PsyD 

PM PS 

ACR MEET THE PROFESSOR SESSIONS 

7:45 - 9:15 AM 

Admission to Meet the Professor sessions requires a separate 

registration and ticket. To verify which session you registered for, 

the registration code on your ticket needs to match the 3-digit 

code in parentheses below. If you are interested in participating 

in one of these sessions or exchanging your ticket, visit the ACR 

registration desk to check space availability. View the session 

overview and learning objectives online in My Annual Meeting 

at www.ACRannualmeeting.org. 

* Sessions denoted with an asterisk were sold out as of 

September 14.

148 

Behçet’s Disease (001) 

Speaker: Hasan Yazici, MD 

153 

Controversies in Sjögren’s Syndrome (002) 

Speaker: Alan N. Baer, MD 

154 A 

Infections with Biologics (003) 

Speaker: John J. Cush, MD 

154 B 

Pediatrics: Dermatomyositis (004) 

155 

Speaker: Susan Kim, MD, MPH 

Pediatrics: Difficult to Treat Juvenile Idiopathic 

Arthiritis (005) 

Speaker: Murray H. Passo, MD 

158 A 

Rheumatoid Arthritis: Biological Agents (006) 

Speaker: Edward C. Keystone, MD 

158 B 

Spondylarthropathy: An Update (007) 

Speaker: Robert D. Inman, MD 

159 A 

Systemic Arthritis and Still’s Disease (008) 

Speaker: Rayfel Schneider, MBBCh 

159 B 

Systemic Lupus Erythematosus: Central Nervous 

System (009) 

Speaker: Cynthia Aranow, MD 

160 

Vasculitis Mimics (010) 

Speaker: John H. Stone, MD, MPH 

PM 

ACR WORKSHOPS 

7:45 - 9:45 AM 

PS 

Admission to Workshops requires a separate registration 

and ticket. To verify which session you registered for, the 

registration code on your ticket needs to match the 3-digit code 

in parentheses below. If you are interested in participating in 

one of these sessions or exchanging your ticket, visit the ACR 





September 14. 

149 A 

Basic Statistical Concepts for the Medical Researcher 

(201) 

Speakers: Dorothy D. Dunlop, PhD and JungHwa Lee, MD, PhD 

144 C 

Clinical Anatomy and Physical Exam: Essential Tools 

in Lower Extremity Regional Pain Syndromes (202) 

Speakers: Robert A. Kalish, MD and Pablo Villasenor Ovies, MD 

144 A 

Dermatopathology of Rheumatic Diseases (203) 

Speaker: Daniel Miller, MD 

144 B 

Musculoskeletal Exam Skills I: General 

Musculoskeletal Examination for Arthritis (204) 

Speakers: George V. Lawry, MD and Paul C. Utrie, MD 

ACR SESSIONS 

9:00 - 10:00 AM 

150 B 

Advances in the Biology of Aging 

Moderator: Peter A. Nigrovic, MD 

Speaker: Jan Vijg, PhD 


• review the role of telomere length in cell senescence, and 

the importance of this biology for the aging of the immune 

system 

• discuss the presence of senescent cells in tissues and this role 

in aging 

• discuss the possible implications of aging biology on 

rheumatic diseases 

PM PS 

147 A 

CORC FORUM: Achieving Economic Goals in An Era of 

Healthcare Reform 

Moderator: Edward L. Morris, MD 

Speaker: Kevin Lieb 


• identify effective compensation models to improve financial 

outcomes 

• develop key integration strategies for success in the practice 

• identify how new payment options will be used in promoting 

quality, efficiency and improved outcomes 

PM 

PS 

SUNDAY 



SUNDAY 


PM PS 

Hall E 

New Therapies for Modulating Signaling in 

Rheumatoid Arthritis 

Moderator: Gregg J. Silverman, MD 

Speaker: Mark C. Genovese, MD 


• define the basic factors and cell types involved in these 

pathways, and the inflammatory responses they control 

• describe the rationale for the development of new agents that 

target these pathways 

• review recent clinical trial results and appreciate the potential 

benefits and toxicities that have been reported 

PM PS 

152 A 

The Plasticity of T Regulatory Cells and their Role in 

Autoimmunity 

Moderator: Richard M. Pope, MD 

Speaker: Dario A. A. Vignali, PhD 


• define mechanisms which promote T regulatory cell plasticity 

• identify the mechanisms by which T regulatory cells promote 

immune homeostasis 

• identify mechanisms by which alterations of T regulatory cells 

promote autoimmune diseases such as rheumatoid arthritis 

and systemic lupus erythematosus 

PM 

PS 

Hall D 

Update on Stroke 

Moderator: Fernando E. Figueroa, MD 

Speaker: Harold Adams, MD 


• review the main types of acute cerebrovascular disease 

• analyze the current diagnostic tools in the management of 

stroke 

• review the contemporary therapies and strategies involved in 

the treatment of ischemic and hemorrhagic stroke 

ACR SESSIONS 

9:00 - 10:30 AM 

PM PS 

202 B 

Extra-articular Involvement in Rheumatoid 

Arthritis 

Moderator: Steven B. Abramson, MD 


• describe the association between periodontal disease and 

rheumatoid arthritis 

• examine the role of periodontal disease in the pathogenesis of 


• determine the role of specific oral flora in the pathogenesis of 

periodontal disease and rheumatoid arthritis 

9:00 AM 

Periodontal Disease as An Initiation or Propagation Factor for 


Ted R. Mikuls, MD, MSPH 

9:30 AM 

Does Rheumatoid Arthritis Start in the Lung? 

Kevin D. Deane, MD, PhD 

10:00 AM 

The Role of ACPA in the Pathogenesis of Rheumatoid Arthritis 

Patrick Venables, MD 

145 A 

Medical Education: The Year in Review 

Moderator: Michael J. Battistone, MD 

Speaker: Karen Szauter, MD 


• recognize the major research reports and scholarship in the 

field of medical education over the past year (2012) 

• translate results of educational research to their own 

educational programs 

• formulate ideas for educational research at their own 

institution 

ACR POSTER SESSION A And POSTER TOURS 

9:00 AM - 6:00 PM 

Poster presenters will be available from 9:00 - 11:00 AM 

(abstracts # 1 - 724). Poster tours will be held 9:00 - 9:45 AM and 

10:15 - 11:00 AM. Morning snacks will be available from 9:00 - 

10:30 AM. 

Poster Hall (Hall B) 


Guided poster tours allow scientific attendees to ask questions 

and gain insights from some of the best-known rheumatology 

leaders. Tours are complimentary; however, registration is 

required and is limited to scientific attendees. If you preregistered 

for a tour, you should have received a ticket with 

your meeting materials. Once you have your ticket, check in 

at the tour desk 15 minutes prior to the start of your tour to 

receive your headset. Your reservation will be held only until 

5 minutes prior to the start of the tour. After this time, your 

reservation is not guaranteed and may be released to standby 

attendees. If you did not pre-register, tickets may be available 

in the registration area (Salons G-H-I). Alternatively, you may 

go directly to the poster tour desk and wait for a standby ticket. 

Standby tickets will be assigned on a first-come, first served basis 

5 minutes prior to the start of each tour. Each tour participant 

will receive a wireless headset which will be registered against 

the participants’ registration ID. Participants will be charged $50 

if the headset is not returned within 15 minutes of the end of 

the tour. 

9:00 - 9:45 AM 

Fellows Only: How to Navigate the Poster Hall (301) 

Tour Guide: Calvin R. Brown, MD 

Osteoarthritis: Clinical Aspects (302) 

Tour Guide: Roy D. Altman, MD 

Pediatric Rheumatology: Clinical Aspects (303) 

Tour Guide: Carol A. Wallace, MD 

PM 

PS 

32 

2012 Program Book

Rheumatoid Arthritis: Clinical Aspects (304) 

Tour Guide: Inmaculada del Rincon, MD, MSc 

Rheumatoid Arthritis: Treatment: Small Molecules, Biologics 

and Gene Therapy (305) 

Tour Guide: S. Louis Bridges, MD, PhD 

Systemic Lupus Erythematosus: Clinical Aspects (306) 

Tour Guide: Barri J. Fessler, MD 

10:15 - 11:00 AM 

Osteoarthritis - Clinical Aspects (307) 

Tour Guide: Timothy E. McAlindon, MD, MPH 

Rheumatoid Arthritis Treatment - Small Molecules, Biologics 


Tour Guide: Martin Aringer, MD 


Tour Guide: Deborah P. Symmons, MD 


and Treatment (310) 

Tour Guide: Désirée van der Heijde, MD 


Tour Guide: David A. Isenberg, MD 

ARHP SESSION 

9:30 - 10:30 AM 

146 C 

PM PS 

ARHP Keynote Address: It’s Not Child’s Play: Growing 

Up With and Mastering Juvenile Idiopathic Arthritis 

from the Child’s Perspective 

Moderator: Linda S. Ehrlich-Jones, PhD, RN 

Speaker: Logan Graham 


• determine how health professionals can make an impact 

outside of the normal treatment process 

• discuss ways health professionals can exploit kids’ abilities for 

successful treatment 

• describe how health professionals can mobilize their “inner 

child” for better results 

RheumatoloGY Research Foundation 

SPECIAL SESSION 

10:00 - 11:00 AM 

Ballroom B 

PM PS 

Oscar S. Gluck, MD, Memorial Lectureship: Bone 

Wasn’t Built in a Day: New Insights into Destruction 

and Repair in Rheumatic Disease 

Moderator: Michael Maricic, MD 

Speaker: Ellen M. Gravallese, MD 


• describe mechanisms of articular bone loss in different 


• discuss the role of osteocytes in regulating key pathways of 

bone loss and formation 

• identify the potential for repair of articular erosions and the 

pathways implicated in this process 

EXHIBITS 

10:00 AM - 5:00 PM 

Exhibit Hall (Hall A) 

Join your colleagues in the Exhibit Hall for morning and 

afternoon refreshments from 10:00 - 11:00 AM and 2:00 - 

3:00 PM. 

(Booth #1451) 

Innovation Theater 

Non-CME accredited presentations have been planned and will 

be implemented in accordance with the requirements of the FDA 

and applicable standards of the PhRMA Code on Interactions 

with Healthcare Professionals. These presentations will be held 

from 10:30 - 11:15 AM, 12:30 - 1:15 PM and 2:30 - 3:15 PM. For 

a complete listing of Innovation Theater presentations, see 

PM PS 

page 316. 

ACR WORKSHOPS 

10:30 AM - 12:30 PM 










September 14. 

144 C 

*Adult Musculoskeletal Upper Examinations (205) 

Speaker: Arthur M. Mandelin II, MD, PhD 

144 B 

*Musculoskeletal Ultrasound (206) 

Speakers: Eugene Y. Kissin, MD and Amy M. Evangelisto, MD 

149 A 

*Renal Histopathology in Systemic Lupus 

Erythematosus and Vasculitis (207) 

Speaker: Megan Troxell, MD 

PM 

PS 

ACR PLENARY SESSION I – DISCOVERY 

2012 

11:00 AM - 12:30 PM 

Hall D 

Moderators: James R. O’Dell, MD and Benjamin J. Smith, PA-C 

11:00 AM 

Rheumatology Research Foundation Industry Roundtable Awards 

11:10 AM 

ACR Abstract Presentation and Commentaries 

2012 Program Book 33 

SUNDAY 

November 11, 2012

SUNDAY 


11:15 AM 

725. The Role of Interleukin-23 in Spondyloarthropathy 

Jonathan Sherlock 1 , Barbara Joyce-Shaikh 1 , Scott Turner 1 , Cheng- 

Chi Chao 1 , Manjiri Sathe 1 , Jeff Grein 1 , Dan Gorman 1 , Eddie P. 

Bowman 2 , Terrill McClanahan 1 , Jennifer Yearley 1 , Gerard Eberl 3 , 

Christopher D. Buckley 4 , Robert Kastelein 1 , Robert Pierce 1 , Drake 

LaFace 1 and Daniel Cua 5 , 1 Merck, Palo Alto, CA, 2 Merck, Palo 

Alto, 3 Institut Pasteur, Paris, France, 4 School of Immunity and 

Infection, MRC Center for Immune Regulation, Birmingham, 

United Kingdom, 5 Merck Research Laboratory, Palo Alto, CA 

Background/Purpose: Spondyloarthropathy is characterized by 

inflammation and bony pathology at the entheseal insertion of 

tendons to bone. Recent investigations have converged upon 

interleukin(IL)-23, demonstrating firstly that genetic variants 

in its receptor are associated with disease and secondly that 

HLA-B27, which is present in 90% of patients with ankylosing 

spondylitis, has a tendency to misfold and form cell surface 

homodimers resulting, respectively, in production of IL-23 and 

stimulation of IL-23R+ cells. However why such dysregulation of 

IL-23 should result in inflammation primarily at the enthesis has 

remained deeply enigmatic. 

We have hypothesized that tissue resident cells fundamentally 

determine disease localization (Cua and Sherlock, Nature 

Medicine 17(9):1055-6) and herein extend our previous 

observations (Sherlock et al. in press) to demonstrate the 

presence of IL-23R+ cells in the uvea and to further characterize 

these cells and their effects. 

Methods: We used GFP reporter mice to investigate the tissue 

distribution of IL-23R+ cells in the main tissues inflamed in 

spondyloarthropathy: the enthesis, aortic valve and uvea. Flow 

cytometric analysis and multiphoton microscopy was employed 

to characterize the location of such cells and the reactivity of this 

tissue to IL-23 was determined in vitro and in vivo. 

Results: Entheses, the aortic root and the uvea all contain 

a novel tissue resident IL-23R+ T lymphocyte, negative for 

both CD4 and CD8, which allows the tissue to respond to IL- 

23. Multiphoton microscopy confirms an extremely precise 

entheseal localization of the IL-23R+ cell type. These cells are 

RAG dependent, but express the PLZF transcription factor which 

confers an ‘innate like’ responsiveness on T cells, allowing them 

to immediately respond to cytokines. Entheses can respond 

within hours to IL-23 in vitro in the absence of further cellular 

recruitment. Moreover, IL-23 expression in mice is sufficient by 

itself to induce hallmark features of spondyloarthropathy, with 

severe inflammation developing very specifically at the enthesis 

and aortic root. Entheseal bone erosion, new bone formation 

and periostitis are likewise present. 

Conclusion: The highly restricted anatomical distribution 

of IL-23R+ cells explains both the exquisitely precise tissue 

localization of disease in spondyloarthropathy, as well as the 

known genetic associations with IL-23, and gives a very clear 

mechanism whereby HLA-B27 and its tendency to cause IL-23 

elaboration may predispose to pathology. These IL-23R+ tissue 

resident cells thus form the point of integration between the 

specific immunological dysregulations known to be associated 

with disease, and the very precise anatomical sites affected. 

The importance of these tissue resident cells is emphasized 

by the ability of IL-23 to drive enthesitis despite depletion of 

the conventional IL-23 responsive Th17 cells. Neutralization of 

IL-23 therefore represents an excellent therapeutic strategy 

in spondyloarthropathy since it will inhibit a potent molecule 

associated with known genetic factors, and do so directly at the 

site of pathology. 

Disclosure: J. Sherlock, Merck, 3; B. Joyce-Shaikh, Merck, 

3; S. Turner, Merck Pharmaceuticals, 3; C. C. Chao, Merck 

Pharmaceuticals, 3; M. Sathe, Merck, 3; J. Grein, Merck 

Pharmaceuticals, 3; D. Gorman, Merck Pharmaceuticals, 3; 

E. P. Bowman, Merck Pharmaceuticals, 3; T. McClanahan, 

Merck Pharmaceuticals, 3; J. Yearley, Merck Pharmaceuticals, 

3; G. Eberl, None; C. D. Buckley, None; R. Kastelein, Merck 

Pharmaceuticals, 3; R. Pierce, Merck Pharmaceuticals, 3; D. 

LaFace, Merck Pharmaceuticals, 3; D. Cua, Merck Research 

Laboratory, 3 

11:30 AM 

726. Dynamic in vivo Imaging of Th17-Mediated Osteoclastic 

Bone Resorption in Live Bones by Using Intravital Multiphoton 

Microscopy 

Junichi Kikuta and Masaru Ishii, Immunology Frontier Research 

Center, Osaka University, Osaka, Japan 

Background/Purpose: Rheumatoid arthritis (RA) is a 

chronic autoimmune disease characterized by joint synovial 

inflammation and progressive cartilage/bone destruction. 

Although various kinds of cell types, such as T/B lymphocytes, 

macrophages and synovial fibroblasts, are involved in the 

pathogenesis of chronic inflammation in RA, bone destruction 

is considered to be mainly mediated by enhanced activation of 

osteoclasts. Recently CD4+ T helper 17 (Th17) cells have been 

reported to express RANKL on the cell surface, which were 

suggested to be important for osteoclastic bone destruction in 

arthritic joints. However, the RANKL expressed on the surface of 

Th17 possesses little ability for inducing differentiation, and the 

practical function of RANKL and Th17 on bone erosion remained 

elusive. This study aimed to investigate how the bone-resorptive 

functions of osteoclasts are regulated in situ and how Th17 cells 

control the osteoclastic bone resorption in vivo. 

Methods: To examine in vivo behaviors of mature osteoclasts 

and Th17 cells, we utilized advanced imaging system for 

visualizing live bone tissues with intravital multiphoton 

microscopy that we have originally established. To identify 

mature osteoclasts in fluorescent microscopy, we utilized 

the mice in which GFP is expressed under the promoter of a 

vacuolar type H + -ATPase a3 subunit, those are preferentially 

and abundantly expressed in mature osteoclasts (a3-GFP 

mice). Polyclonally differentiated Th17 cells were labeled with 

fluorescent dye and then adoptively transferred into a3-GFP 

mice. We observed calvaria bone tissues of a3-GFP mice by using 

intravital multiphoton microscopy. 

Results: We succeeded in visualizing live mature osteoclasts on 

the bone surface in situ. By using this imaging system, we could 

identify different populations of live mature osteoclasts in terms 

of their motility and function, i.e., ‘static – bone resorptive (R)’ 

and ‘moving – non resorptive (N)’. Treatment with recombinant 

RANKL or bisphosphonate changed the composition of these 

populations as well as total number of mature osteoclasts. We 

also found that rapid RANKL injection converted the moving 

(N) osteoclasts to static (R) ones without any changes in total 

number of osteoclasts, suggesting a novel action of RANKL in 

controlling mature osteoclast function. Furthermore, we could 

demonstrate that Th17 cells had potency for inducing rapid N to 

34 

2012 Program Book

R conversion of mature osteoclasts by RANKL expressed on their 

cell surface in situ. 

Conclusion: By visualizing in vivo behaviors of mature 

osteoclasts, we for the first time identified different functional 

subsets of live osteoclasts on the bone surface, from ‘static – 

bone resorptive’ to ‘moving – non resorptive’. Furthermore, 

RANKL turned out not only to promote the differentiation of 

osteoclasts but also to regulate the bone-resorptive function 

of fully differentiated mature osteoclasts. RANKL-bearing 

Th17 cells were shown to control bone resorption of mature 

osteoclasts, demonstrating novel actions of Th17 that may be a 

novel therapeutic target in RA. 

Disclosure: J. Kikuta, None; M. Ishii, None. 

resorption, u-NTx/Cr, and significantly increased biomarkers of 

bone formation, s-P1NP and s-BSAP, compared to placebo. The 

increase observed for the bone resorption marker s-CTx with 

ODN treatment was unexpected. AEs were comparable between 

the 2 treatment arms. The overall safety profile appeared similar 

between ODN 50mg OW and placebo. 

Conclusion: In this study osteoporotic women treated with 

ODN following ALN treatment show incremental gains in BMD. 

Biomarker results suggest that ODN decreases bone resorption 

while preserving bone formation. 

ODN effects on BMD 

11:45 AM 

727. Effects of Odanacatib On BMD and Overall Safety in 

the Treatment of Osteoporosis in Postmenopausal Women 

Previously Treated with Alendronate 

Roland Chapurlat 1 , Sydney Bonnick 2 , Tobias De Villiers 3 , 

Alberto Odio 4 , Santiago Palacios 5 , Boyd Scott 6 , Celine Le Bailly 

De Tilleghem 7 , Carolyn DaSilva 6 , Albert Leung 8 and Deborah 

Gurner 8 , 1 Hôpital Edouard Herriot, Lyon, France, 2 Cooper Clinic, 

Dallas, TX, 3 Mediclinic Panorama, Cape Town, South Africa, 4 Alta 

California Medical Group, Simi Valley, CA, 5 Instituto Palacios, 

Madrid, Spain, 6 Merck Sharp & Dohme Corp., Whitehouse 

Station, NJ, 7 Merck Sharp & Dohme Corp., Brussels, Belgium, 

8 

Whitehouse Station, NJ 

Background/Purpose: Odanacatib (ODN) is a potent, orallyactive 

cathepsin K inhibitor being developed for the treatment 

of postmenopausal osteoporosis. This study evaluated 

the effects of ODN 50mg once weekly (OW) on BMD and 

biochemical markers of bone turnover in patients previously 

treated with alendronate (ALN) (dosed daily or weekly) for 

≥3years, as well as the safety and tolerability of ODN. 

Methods: This was a randomized, double-blind, placebocontrolled, 

24-month study. The primary endpoint was % change 

in femoral neck (FN) BMD from baseline at Month 24. 243 

postmenopausal women ≥60 years of age with low BMD T-score 

(T-score range ≤–2.5 but >-3.5) at the total hip, FN or trochanter 

but no history of hip fracture and who had been treated with 

ALN for ≥3years were randomized in a 1:1 ratio to receive ODN 

50mg OW or placebo OW for 24 months. All patients received 

vitamin D 3 5600 IU/wk and calcium supplementation (to 1200 

mg/day). BMD was assessed by DXA at baseline, 6, 12 and 24 

months. Biochemical markers of bone resorption (s-CTx, u-NTx) 

and bone formation (s-BSAP and s-P1NP) were measured at 

baseline and 3, 6, 12, 18 and 24 months. This study was not 

designed and did not have the power to evaluate the effect of 

ODN on fractures. 

Results: In the placebo group, FN and trochanter BMD were 

not significantly different from baseline levels for the first 12 

months, but declined significantly from baseline by Month 24 

(-0.94% and -1.35%, respectively). BMD at the total hip declined 

in a linear manner from baseline to month 24 (-1.87% at 24 

months). BMD at the lumbar spine (LS) was not significantly 

different from baseline for the entire 24 months of the study. 

BMD changes from baseline at 24 months in the ODN group 

were significant vs placebo at all 3 hip sites and the LS. The 

changes in BMD for the FN, trochanter, total hip and LS from 

baseline were 1.73%, 1.83%, 0.83% and 2.28%, respectively. 

ODN 50mg OW significantly decreased the biomarker of bone 

ODN effects on biomarkers 

Disclosure: R. Chapurlat, Merck Pharmaceuticals, 2, Merck 

Pharmaceuticals, 5; S. Bonnick, Merck Pharmaceuticals, 

5; T. De Villiers, None; A. Odio, Merck Pharmaceuticals, 

2; S. Palacios, None; B. Scott, Merck Pharmaceuticals, 3, 

Merck Pharmaceuticals, 1; C. Le Bailly De Tilleghem, Merck 

Pharmaceuticals, 3, Merck Human Health, 1; C. DaSilva, Merck 

Pharmaceuticals, 3, Merck Pharmaceuticals, 1; A. Leung, Merck 

Pharmaceuticals, 1, Merck Pharmaceuticals, 3; D. Gurner, Merck 

Pharmaceuticals, 1, Merck Pharmaceuticals, 3. 

Noon 

728. Does the Use of Angiotensin Converting Enzyme Inhibitors 

Prior to Scleroderma Renal Crisis Affect Prognosis? – Results of 

the International Scleroderma Renal Crisis Survey 

Marie Hudson 1 , Murray Baron 2 , Solene Tatibouet 1 , De Furst 3 , 

Dinesh Khanna4 and International Scleroderma Renal Crisis 

Study Investigaots 5 , 1 McGill University, Montreal, QC, 2 Jewish 

General Hospital, Montreal, QC, 3 University of California at Los 

Angeles, Los Angeles, CA, 4 University of Michigan, Ann Arbor, 

MI, 5 Montreal 

Background/Purpose: Scleroderma renal crisis (SRC) is an 

infrequent but life-threatening complication of systemic 

sclerosis (SSc). The outcome of SRC has improved considerably 

since the advent of angiotensin converting enzyme (ACE) 

inhibitors. The incidence of SRC has also appeared to have 

decreased, perhaps in part due to the more liberal use of ACE 

inhibitors in SSc. However, recent retrospective data suggests 

that patients with SRC exposed to ACE inhibitors prior to the 

onset of SRC may have worse outcomes. We undertook a 

prospective study to verify whether SSc patients with incident 

SRC on ACE inhibitors at the time of onset of SRC had worse 

outcomes compared to those who were not on these drugs at 

that time. 

SUNDAY 



SUNDAY 


Methods: We designed a prospective, observational cohort 

study of incident SRC subjects identified through a webbased 

survey. Every second week, an e-mail was sent to 589 

participating physicians from around the world to identify 

incident cases of SRC. Data on patient demographic and disease 

characteristics, as well as exposure to ACE inhibitors was 

collected. A one-year follow-up case report form was sent to all 

the physicians who identified a case. The primary outcome of 

interest was death or dialysis at one year after the onset of SRC, 

comparing patients exposed and unexposed to ACE inhibitors at 

the time of onset of SRC. 

Results: We identified 88 incident cases of SRC, of which 12 were 

lost to follow up (86% follow up rate). Mean age was 52 years, 

67% were women, 76% had diffuse SSc and median disease 

duration since the onset of the first non-Raynaud’s symptom 

was 1.5 years. The majority of cases had a hypertensive SRC 

(n=71/76) and only 5 had a normotensive SRC. Eighteen patients 

(24%) were on an ACE inhibitor immediately prior to the onset 

of the SRC. At one year follow up, 27 (36%) SRC patients had 

died and an additional 13 (17%) remained on dialysis. 

The crude one-year cumulative incidence of death in those 

exposed to ACE inhibitors at the time of onset of SRC compared 

to the unexposed was 1.56 (95% confidence interval [CI] 0.70- 

3.47) and the crude one-year cumulative incidence of dialysis 

was 0.61 (95% CI 0.18-2.09). The crude Cox proportional hazard 

ratio comparing the time to death of SRC patients exposed to 

ACE inhibitors prior to the onset of SRC to those unexposed 

was 1.95 (95% CI 0.87-4.35). After controlling for differences 

in prednisone exposure and history of systemic hypertension 

in the two groups, the adjusted Cox proportional hazard ratio 

comparing the time to death of SRC patients exposed to ACE 

inhibitors prior to the onset of SRC to those unexposed was 2.52 

(95% CI 1.05-6.05, p=0.0394). 

Conclusion: SRC was associated with poor one-year outcomes. 

Exposure to an ACE inhibitor prior to the onset of SRC was 

associated with an increased risk of death during the first year of 

follow up after SRC. Clinicians caring for patients with early SSc 

should use ACE inhibitors cautiously. 

Disclosure: M. Hudson, None; M. Baron, None; S. Tatibouet, 

None; D. Furst, Amgen, Janssen, Roche, and UCB, 2, Amgen, 

Janssen, Roche, and UCB, 5; D. Khanna, Actelion, BMS, Gilead, 

Genentech, ISDIN, and United Therapeutics, 2, Actelion, BMS, 

Gilead, Genentech, ISDIN, and United Therapeutics, 5, Actelion, 

BMS, Gilead, Genentech, ISDIN, and United Therapeutics, 8. 

12:15 PM 

729. Apolipoprotein L1 Risk Variants Underlie Racial Disparities 

in Lupus Nephritis-Induced End-Stage Renal Disease 

Robert P. Kimberly 1 , Barry I. Freedman 2 , Carl D. Langfeld 3 , 

Devin Absher 4 , Kelly K. Andringa 1 , Daniel Birmingham 5 , 

Elizabeth E. Brown 1 , Mary E. Comeau 6 , Karen H. Costenbader 7 , 

Lindsey A. Criswell 8 , Jeffrey C. Edberg 9 , John B. Harley 10 , Judith 

A. James 11 , Diane L. Kamen 12 , Joan T. Merrill 13 , Timothy B. 

Niewold 14 , Neha Patel 15 , Michelle A. Petri 16 , Rosalind Ramsey- 

Goldman 17 , Jane E. Salmon 18 , Mark Segal 19 , Kathy Moser 

Sivils 13 , Betty P. Tsao 20 , Bruce A. Julian9 and Lupus Nephritis- 

ESRD Consortium 21 , 1 University of Alabama at Birmingham, 

Birmingham, AL, 2 Department of Internal Medicine, Wake 

Forest School of Medicine, Winston-Salem, NC, 3 Wake Forest 

University Health Sciences, Winston-Salem, 4 HudsonAlpha 

Institute for Biotechnology, Huntsville, 5 Ohio State University 

Medical Center, Columbus, OH, 6 Wake Forest University Health 

Sciences, Winston-Salem, NC, 7 Brigham and Women’s Hospital, 

Harvard Medical School, Boston, MA, 8 University of California 

San Francisco, San Francisco, CA, 9 Department of Medicine, 

University of Alabama at Birmingham, Birmingham, AL, 

10 

Cincinnati Children’s Hospital Medical Center; US Department 

of Veterans Affairs Medical Center, Cincinnati, OH, 11 Oklahoma 

Medical Research Foundation and Oklahoma University Health 

Sciences Center, Oklahoma City, OK, 12 Arthritis & Clinical 

Immunology Program, Oklahoma Medical Research Foundation, 

Charleston, SC, 13 Oklahoma Medical Research Foundation, 

Oklahoma City, OK, 14 University of Chicago, Chicago, IL, 15 SUNY 

Downstate Medical Center, Brooklyn, NY, 16 Johns Hopkins 

University School of Medicine, Baltimore, MD, 17 Northwestern 

University Feinberg School of Medicine, Chicago, IL, 18 Hospital 

for Special Surgery, New York, NY, 19 University of Florida, 

Gainesville, FL, 20 UCLA School of Medicine, Los Angeles, CA, 

21 

Birmingham, AL 

Background/Purpose: The G1 and G2 coding variants in the 

apolipoprotein L1 gene (APOL1; G1: a compound missense 

allele (glycine-342/methionine-384) and G2: an in-frame 

deletion (deletion of asparagine-388 and tyrosine-389)), are 

strongly and reproducibly associated with focal segmental 

glomerulosclerosis (FSGS), HIV-associated collapsing 

glomerulopathy, and hypertension-attributed end-stage renal 

disease (ESRD) in African Americans (AAs) [Genovese G et al. 

Science 329:841,2010; Tzur S et al. Hum Genet 128:345,2010]. 

The role of APOL1 in lupus nephritis (LN) related ESRD is 

unexplored. We tested for association between APOL1risk 

variants and LN-ESRD in a national sample of unrelated AAs with 

systemic lupus erythematosus (SLE). 

Methods: The study sample included 668 AA cases with LN-ESRD 

(456 with kidney biopsy documentation; 212 physician-reported) 

and 697 AA patients with longstanding SLE lacking LN (mean 

duration of disease: 10.1 years). Genotyping was performed on 

a Sequenom platform. Allele frequency differences between 

LN-ESRD cases and SLE non-nephropathy cases were analyzed 

using multivariable logistic regression models, adjusting for 

non-muscle myosin heavy chain 9 gene single nucleotide 

polymorphism rs4821480 using a recessive genetic model. 

Results: In cases with LN-ESRD, 87.1% were female, 89% 

received cytotoxic therapy, mean + SD age at SLE onset was 

26.6 + 0.4 years, and duration of SLE to ESRD was 7.2 + 0.3 years 

with median at 5 years. In non-nephritis SLE patients, 93.5% 

were female with age at SLE onset 35.2 + 0.8 years. Contrasting 

all cases with and without ESRD, APOL1 risk variants were 

significantly associated with LN-ESRD (odds ratio 2.35 (1.77-3.3 

95% CI); p=4.25E-9); significant differences in association were 

not observed when comparing cases with or without kidney 

biopsy documentation to SLE patients without LN. The duration 

of SLE onset to ESRD for those with the G1/G2 variants was 

5.49+/-0.54 (median=4) years, while that for those without the 

variants was 7.78+/-0.37 (median=6) years, p

prevalence in individuals with African ancestry, may explain, in 

part, disparities in clinical outcomes in LN with there being a 

higher prevalence of severe LN in AA. 

Disclosure: R. P. Kimberly, None; B. I. Freedman, None; C. D. 

Langfeld, None; D. Absher, None; K. K. Andringa, None; D. 

Birmingham, None; E. E. Brown, None; M. E. Comeau, None; K. 

H. Costenbader, None; L. A. Criswell, None; J. C. Edberg, None; 

J. B. Harley, None; J. A. James, None; D. L. Kamen, None; J. T. 

Merrill, None; T. B. Niewold, None; N. Patel, None; M. A. Petri, 

None; R. Ramsey-Goldman, None; J. E. Salmon, None; M. Segal, 

None; K. Moser Sivils, None; B. P. Tsao, None; B. A. Julian, 

None. 

ARHP SESSIONS 

11:00 am - Noon 

206 

PM PS 

Hands: Non-Surgical Management and Bracing - 

What You Don’t Know Can Hurt You 

Moderator: Donna K. Everix, MPA, BS, PT 

Speaker: Tracey L. Airth-Edblom, OTR, CHT 


• describe why early intervention for conservative treatment is 

indicated for rheumatologic diagnoses 

• define how non-surgical methods can provide pain 

management techniques 

• identify at least five different strategies of a non-surgical 

comprehensive program for rheumatologic diagnoses 

143 A 

New Medication Developments in Rheumatology 

Moderator: Linda J. Pine, PharmD 

Speaker: Kam Nola, PharmD, MS 


• identify new molecular entities submitted and approved by 

the Food and Drug Administration used in rheumatology 

practice 

• discuss best practices in therapy for new molecular entities 

• report changes in safety of new and existing medications in 

rheumatology practice 

• explain medication shortage issues facing rheumatology 

practice 

204 A 

Rheumatic Disease Update: Vasculitis 

Moderator: James G. Freeman, MD 

Speaker: Philip Seo, MD, MHS 


• outline the classification of the major categories of vasculitis 

• explain the diagnostic approach to patients with suspected 

vasculitis 

• recognize the wide differential diagnosis and potential mimics 

of vasculitis 

• cite the data supporting the current treatment 

recommendations for the various forms of vasculitis 

PM 

PS 

PM 

PS 

201 

PM 

PS 

The 5A Approach to Physical Activity Counseling for 

Arthritis Patients 


Speaker: Jennifer M. Hootman, ATC, PhD 


• describe the history of the 5A model for brief behavior 

change 

• explain components of the 5A model as applied to physical 

activity counseling for arthritis patients 

• associate counseling strategies for each stage 

• identify tools to help incorporate the 5A model into clinical 

practice 

ACR SESSION 

12:30 - 1:45 PM 

202 B 

ACR Knowledge Bowl – Preliminary Round 

Moderator: Zsuzsanna H. McMahan, MD, MHS 


• identify key images that are important to recognize in clinical 

practice 

• recall factual information related to various rheumatic 

diseases 

• identify historical facts relevant to the field of rheumatology 

Duke University 

Lisa G. Criscione-Schreiber, MD, Eric Orlowsky, MD and 

Sara Wasserman, MD 

Ochsner Medical Center 

Robert Quinet, MD, Austin Fraser, MD and Sharon Ing, MD 

University of Colorado 

Jason R. Kolfenbach, MD, Christina Bright, MD and Kristen 

Demorouelle, MD 

University of Michigan 

David Fox, MD, Nezam Altorok, MD and Shailey Desai, MD 

University of Minnesota 

Bryce Binstadt, MD, PhD, Theresa Wampler, MD and Patricia 

Hobday, MD 

The University of Pittsburgh 

Marc Levesque, MD, Christine Peoples, MD and Ximena Ruiz, MD 

University of Vermont 

Bonita S. Libman, MD, Narandra Bethina, MD and Tatiana Keck, MD 

ARHP NETWORKING EVENT 

12:30 - 2:15 PM 

Renaissance Washington - Renaissance Ballroom, East & West 

Networking Forum 

All ARHP attendees are invited to this kick-off forum for the 

annual meeting. A box lunch will be provided for the first 250 

people. You will have an opportunity to meet and network with 

other health professionals and the ARHP leadership. This session 

is not eligible for CME credit. 

PM 

PS 

SUNDAY 



PM 

PS 

SUNDAY 



12:45 - 2:15 PM 










September 14. 

148 

Adult Inflammatory Myopathy (011) 

Speaker: Mary E. Cronin, MD 

153 

Cutaneous Vasculitis (012) 

Speaker: Nicole Fett, MD 

154 A 

Inflammatory Eye Disease/Uveitis (013) 

Speaker: Sergio Schwartzman, MD 

154 B 

Myopathy: Issues in Diagnosis and Treatment (014) 

Speaker: Lisa Christopher-Stine, MD, MPH 

155 

Osteoporosis: Novel Treatments (015) 

Speaker: Michael J. Maricic, MD 

158 A 

Pediatrics: Periodic Fevers in Children (016) 

Speaker: Daniel L. Kastner, MD, PhD 

158 B 

Polymyalgia Rheumatica (017) 

Speaker: Bhaskar Dasgupta, MD 

159 A 

Pregnancy in Rheumatic Diseases (018) 

Speaker: Eliza F. Chakravarty, MD 

159 B 

Systemic Lupus Erythematosus: Novel Treatments 

(019) 

Speaker: Mary Anne Dooley, MD, MPH 

160 

Vitamin D and Bone Health (020) 

Speaker: Nancy E. Lane, MD 

ACR SESSIONS 

1:00 - 2:00 PM 

PM PS 

204 A 

Endoplasmic Reticulum Stress Unfolded Protein 

Response in Immunity and Inflammation 

Moderator: Robert Lafyatis, MD 

Speaker: Randal J. Kaufman, PhD 


• describe the molecular pathways activated by the unfolded 

protein response 

• explain the relationship between endoplasmic reticulum 

stress and apoptosis 

• identify recent advances linking the endoplasmic reticulum 

PM PS 

stress to inflammation and immunity 

146 C 

Mechanisms of Pain in Rheumatic Diseases 

Moderator: Anne-Marie Malfait, MD, PhD 

Speaker: Clifford Woolf, MB, BCh, PhD 


• classify different types of pain, and how these relate to 

rheumatological diseases 

• review the neurobiology of pain 

• describe potential for targeting arthritis-related pain 

Hall E 

Preoperative Assessment and Perioperative 

PM PS 

Management of the Patient with Rheumatic Disease: 

What Every Rheumatologist Should Know (Clinical 

Review) 

Moderator: Elana J. Bernstein, MD 

Speaker: Linda Russell, MD 


• describe the important components of preoperative 

assessment of the patient with rheumatic disease undergoing 

elective surgery 

• discuss preoperative and perioperative management of 

biologic and non-biologic DMARD therapy 

• discuss preoperative and perioperative management of antiplatelet 

and anticoagulant therapy 

• identify perioperative complications of common orthopedic 

procedures 

ACR WORKSHOPS 

1:15 - 3:15 PM 










September 14. 

38 

2012 Program Book

PM 

PS 

PM 

149 B 

Designing a Website for Your Practice (208) 

Speaker: Peter J. Embi, MD, MS 

144 A 

Muscle Involvement in Rheumatic Diseases (209) 

Speaker: Sakir Humayun Gultekin, MD 

144 C 

PS 

Physical Examination Skills for Improved Detection of 

Synovitis and Cervical Thoracolumbar Disorders (210) 

PM 

PS 

2:30 PM 

ACPAs and the Prospects for Immunotherapy for Rheumatoid 

Arthritis 

Lars Klareskog, MD, PhD 

3:00 PM 

Is Rheumatoid Arthritis a Preventable Disease? 

V. Michael Holers, MD 

3:30 PM 

Novel Approaches to Rheumatoid Arthritis 

Michael B. Brenner, MD 


PM PS 

149 A 

Renal Histopathology in Systemic Lupus 

Erythematosus and Vasculitis (211) 

Speaker: Megan Troxell, MD 

ACR SESSIONS 

2:30 - 4:00 PM 

Ballroom A 

Complementary and Alternative Medicine: Evidencebased 

Options for Arthritis Patients PM PS 

Moderator: Sharon L. Kolasinski, MD 


• contrast traditional physical therapy with alternative exercise 

options 

• evaluate the literature supporting the use of alternative 

therapies 

• appreciate the role of tai chi and yoga among exercise options 

for patients 

2:30 PM 

Overview of Complementary and Alternative Medicine 

To be announced 

3:00 PM 

Tai Chi for Arthritis 

Chenchen Wang, MD, MSc 

3:30 PM 

Role of Yoga in the Management of Arthritis 


PM PS 

Salon B 

Prospects for Prevention and Cure of Rheumatoid 

Arthritis 

Moderators: Robert M. Plenge, MD, PhD and Peter A. Nigrovic, 

MD 


• define key limitations in our understanding of rheumatoid 

arthritis 

• consider diverse and novel approaches to the exploration of 


• review potential new points of intervention in the biology of 


PM 

PS 

Hall D 

PM PS 

The Great Debate: In 2012 What are the Roles of 

Cyclophosphamide versus Rituximab in ANCA- 

Associated Vasculitis 

Moderator: Robert F. Spiera, MD 


• describe the safety issues with cyclophosphamide versus 

rituximab in ANCA-associated vasculitis 

• identify what is known about remission induction and relapse 

with cyclophosphamide versus rituximab in ANCA-associated 

vasculitis 

• outline the advantages and disadvantages of 

cyclophosphamide versus rituximab in ANCA-associated 

vasculitis 

2:30 PM 

Does Cyclophosphamide Continue to Have a Role in Severe 

ANCA-Associated Vasculitis 

Carol A. Langford, MD, MHS 

3:15 PM 

Should Rituximab be the First Treatment of Choice in Severe 

ANCA-Associated Vasculitis? 

Ulrich Specks, MD 

PM PS 

Hall E 

Update on Treatment of Systemic Lupus 

Erythematosus 

Moderator: Virginia D. Steen, MD 


• describe the types of cutaneous manifestations of lupus and 

how to treat them 

• discuss how management of lupus nephritis has changed over 

the last five years 

• demonstrate the ability to use the newer treatments used in 

the management of lupus 

2:30 PM 

Cutaneous Problems in Lupus 

David Fiorentino, MD, PhD 

3:00 PM 

Update on Lupus Nephritis 

James E. Balow, MD 

3:30 PM 

Other Treatments in Lupus, the Role of New Agents 

Bevra H. Hahn, MD 


SUNDAY 

November 11, 2012

SUNDAY 


ACR CONCURRENT ABSTRACT SESSIONS 

2:30 - 4:00 PM 

150 B 

Biology and Pathology of Bone and Joint: 

Osteoarthritis 

Moderator: Hiroshi Asahara, MD and Mary B. Goldring, PhD 

2:30 PM 

730. Disease Modifying Effect of Strontium Ranelate in 

Experimental Dog Osteoarthritis: Inhibition of Major Catabolic 

Pathways 

Jean-Pierre Pelletier, Mohit Kapoor, Daniel Lajeunesse, Hassan 

Fahmi and Johanne Martel-Pelletier, Osteoarthritis Research 

Unit, University of Montreal Hospital Research Centre 

(CRCHUM), Notre-Dame Hospital, Montreal, QC 

2:45 PM 

731. A Systems Biology Approach to Elucidating Pathways 

Active During the Development of Osteoarthritis 

Richard F. Loeser 1 , Amy L. Olex 2 , Brian Westwood 2 , Margaret A. 

McNulty 3 , Cathy S. Carlson 3 , Michael Callahan 4 , Cristin Ferguson 4 

and Jacquelyn S. Fetrow 2 , 1 Wake Forest School of Medicine, 

Winston-Salem, NC, 2 Wake Forest University, Winston-Salem, 

NC, 3 University of Minnesota, St. Paul, MN, 4 Wake Forest School 

of Medicine, Winston-Salem 

3:00 PM 

732. Changes in Subchondral Bone Provide a Sensitive Marker 

for Osteoarthritis and Its Progression: Results From a Large 

Osteoarthritis Initiative Cohort 

Michael A. Bowes 1 , Christopher B. Wolstenholme 1 , Devan 

Hopkinson 1 , Graham R. Vincent 1 and Philip G. Conaghan 2 , 

1 

Imorphics Ltd, Manchester, United Kingdom, 2 University of 

Leeds, Leeds, United Kingdom 

3:15 PM 

733. Intra-Articular Injection of Adipose-Derived Stem Cells 

Inhibits Activation of the Synovium and Protects Against 

Cartilage Damage and Enthesophyte Formation in Murine 

Experimental Osteoarthritis 

Peter L.E.M. van Lent 1 , Menno C. ter Huurne 1 , Arjen B. Blom 1 , 

Rik Schelbergen 1 , Louis Casteilla 2 , Thomas Vogl 3 , Johannes 

Roth 3 , Roxane Blattes 2 , Christian Jorgensen 4 and Wim B. van den 

Berg 1 , 1 Radboud University Nijmegen Medical Centre, Nijmegen, 

Netherlands, 2 INSERM U1031, Toulouse, France, 3 University of 

Muenster, Munster, Germany, 4 Hospital Lapeyronie, Montpellier, 

France 

3:30 PM 

734. Chemokine (C-C Motif) Receptor 2 Signaling Mediates 

Persistent Pain in Experimental Osteoarthritis 

Rachel E. Miller 1 , Phuong Tran 1 , Rosalina Das 1 , Nayereh 

Ghoreishi-Haack 1 , Richard J. Miller 2 and Anne-Marie Malfait 1 , 

1 

Rush University Medical Center, Chicago, IL, 2 Northwestern 

University, Evanston, IL 

3:45 PM 

735. Mass Spectrometry Assays of Plasma Biomarkers to 

Predict Radiographic Progression of Knee Osteoarthritis 

Susan Y. Ritter 1 , William M. Reichmann 1 , Jamie E. Collins 1 , 

Alejandra Garces 2 , Bryan Krastins 2 , David Sarracino 2 , Mary 

Lopez 2 , Elena Losina 1 and Antonios O. Aliprantis 1 , 1 Brigham and 

Women’s Hospital, Boston, MA, 2 Thermo Fisher Scientific BRIMS 

Center, Cambridge, MA 

147 A 

Cytokines, Mediators, and Gene Regulation I 

Moderators: Erik Lubberts, PhD and Hendrik Schulze-Koops, MD, 

PhD 

2:30 PM 

2011 Lee C. Howley, Sr. Prize for Arthritis Research Introductory 

Talk I 

Speaker: Andrew D. Luster, MD, PhD 

2:45 PM 

736. Inhibition of Interleukin-17 Signaling Via De-Ubiquitinatio 

Sarah L. Gaffen and Abhishek Garg, University of Pittsburgh, 

Pittsburgh, PA 

3:00 PM 

737. Citrullination of ENA-78/CXCL5 Results in Conversion 

From a Non-Monocyte Recruiting to a Monocyte Recruiting 

Chemokine 

Ken Yoshida 1 , Olex Korchynskyi 2 , Paul P. Tak 3 , Takeo Isozaki 1 , 

Jeffrey H. Ruth 1 , Phillip Campbell 1 , Dominique L. Baeten 4 , 

Danielle M. Gerlag 4 , M. Asif Amin 1 and Alisa E. Koch 5 , 1 University 

of Michigan, Ann Arbor, MI, 2 Institute of Cell Biology, Lviv, 

Ukraine, 3 GlaxoSmithKline U.K. and Academic Medical Center/ 

University of Amsterdam, Amsterdam, Netherlands, 4 Academic 

Medical Center/University of Amsterdam, Amsterdam, 

Netherlands, 5 University of Michigan Medical School, Ann Arbor, 

MI 

3:15 PM 

738. A Novel Orally Active Phosphatidylinositol 3-Phosphate 

5-Kinase (PIKfyve) Inhibitor Ameliorates Mouse Psoriasis- 

Like Model by Inhibition of Interleukin-12 and Interleukin-23 

Production From Macrophages 

Ayatoshi Andou, Eviryanti Agung, Yukie Seki, Yoichiro Shima, 

Sen Takeshita, Takashi Yamamoto and Hiroyuki Eda, Ajinomoto 

Pharmaceuticals Co., Ltd., Kanagawa, Japan 

3:30 PM 

739. The Serine Arginine Protein SF2/ASF Is a Novel Regulator 

of IL-2 Transcription and Restores IL-2 Production in T 

Lymphocytes From SLE Patients 

Vaishali R. Moulton, Alexandros P. Grammatikos and George C. 

Tsokos, Beth Israel Deaconess Medical Center, Harvard Medical 

School, Boston, MA 

3:45 PM 

740. Select Soluble Inflammatory Mediators Are Detected Prior 

to and Increase At Systemic Lupus Erythematosus Classification 

Melissa E. Munroe 1 , Jourdan R. Anderson 1 , Julie M. Robertson 1 , 

Timothy B. Niewold 2 , George C. Tsokos 3 , Michael P. Keith 4 , John 

PM 

PS 

40 

2012 Program Book

B. Harley 5 and Judith A. James 6 , 1 Oklahoma Medical Research 

Foundation, Oklahoma City, OK, 2 University of Chicago, Chicago, 

IL, 3 Beth Israel Deaconess Medical Center, Harvard Medical 

School, Boston, MA, 4 Walter Reed National Military Medical 

Center, Bethesda, MD, 5 Cincinnati Children’s Hospital Medical 

Center; US Department of Veterans Affairs Medical Center, 

Cincinnati, OH, 6 Oklahoma Medical Research Foundation; 

Oklahoma University Health Sciences Center, Oklahoma City, OK 

202 B 

Epidemiology and Health Services Research I: 

Epidemiology and Outcomes in Rheumatic Disease 

Moderators: Liron Caplan, MD, PhD and Cheryl Barnabe, MD, 

MSc 

2:30 PM 

741. Increased Risk of Recurrent Gout Attacks During 

Hospitalization 

Yuqing Zhang 1 , Clara Chen 2 , Hyon K. Choi 3 , Christine E. Chaisson 2 , 

David J. Hunter 4 and Tuhina Neogi 5 , 1 Boston University, Boston, 

MA, 2 Boston University School of Public Health, Boston, MA, 

3 

Boston University School of Medicine, University of British 

Columbia, Arthritis Research Centre of Canada, Boston, MA, 

4 

University of Sydney, Sydney, Australia, 5 Boston Univ Schl of 

Med, Boston, MA 

2:45 PM 

742. Utility of HLA-B5801 Genotyping and Renal Dosing of 

the Starting Dose of Allopurinol in Preventing Allopurinol 

Hypersensitivity Syndrome: A Cost-Effectiveness Analysis 

Yanyan Zhu 1 , Ada Man 2 , Tuhina Neogi 3 and Hyon K. Choi 4 , 

1 

Boston University School of Medicine, Boston, MA, 2 Boston 

University, Boston, MA, 3 Boston Univ School of Medicine, 

Boston, MA, 4 Boston University School of Medicine, University 

of British Columbia, Arthritis Research Centre of Canada, 

Boston, MA 

3:00 PM 

743. Anemia and the Onset of Gout in a Population-Based 

Cohort of Adults: Atherosclerosis Risk in Communities Study 

Mara McAdams DeMarco 1 , Janet W. Maynard 2 , Josef Coresh 1 

and Alan N. Baer 2 , 1 Johns Hopkins Bloomberg School of Public 

Health, Baltimore, MD, 2 Johns Hopkins University School of 

Medicine, Division of Rheumatology, Baltimore, MD 

3:15 PM 

744. Racial Differences in Reported Knee Pain Severity Persist 

Even After Adjustment for Knee Examination and Radiographic 

Findings: Data From the Osteoarthritis Initiative 

Paige Luneburg 1 , Laura Yerges-Armstrong 2 , Braxton D. Mitchell 2 

and Marc C. Hochberg 1 , 1 University of Maryland, Baltimore, MD, 

2 

University of Maryland School of Medicine, Baltimore, MD 

3:30 PM 

745. Soft Drink Intake and Progression of Radiographic Knee 

Osteoarthritis: Data From the Osteoarthritis Initiative 

Bing Lu 1 , Jeffrey Driban 2 , Tim McAlindon 3 and Charles Eaton 4 , 

1 

Brigham and Women’s Hospital, Boston, MA, 2 Tufts Medical 

Center, MA, 3 Tufts Medical Center, Boston, MA, 4 Warren Alpert 

Medical School at Brown University, RI 

3:45 PM 

746. Increased Risk of Acute and Chronic Renal Comorbidity in 

Ankylosing Spondylitis: Results From a Population-Based Study 

Walter P. Maksymowych 1 , Shelagh Szabo 2 , Sumati Rao 3 , Mary A. 

Cifaldi 3 and Adrian R. Levy 4 , 1 University of Alberta, Edmonton, 

AB, 2 Oxford Outcomes, Vancouver, BC, 3 Abbott Laboratories, 

Abbott Park, IL, 4 Oxford Outcomes Ltd, Vancouver, BC 

145 A 

Miscellaneous Rheumatic and Inflammatory 

Diseases: Periodic Fever Syndromes 

Moderators: Kristine M. Lohr, MD, MS and Katherine K. 

Temprano, MD 

2:30 PM 

747. Familial Mediterranean Fever: Inhibition of IL-6 Signalling 

As a New Therapeutic Option in a Frequent Autoinflammatory 

Syndrome. 

Nicola Stein 1 , Matthias Witt 1 , Michael Baeuerle 2 , Fabian Proft 1 , 

Hendrik Schulze-Koops 3 and Mathias Gruenke 1 , 1 Medizinische 

Klinik und Poliklinik IV, Klinikum der Universität München, 

Munich, Germany, 2 Klinikum Nürnberg, Nuernberg, Germany, 

3 

University of Munich, Munich, Germany 

2:45 PM 

748. Efficacy and Safety of Canakinumab in Patients with 

Cryopyrin Associated Periodic Syndrome: Results From Meta- 

Analysis of 5 Studies 

Helen J. Lachmann 1 , Jasmin B. Kuemmerle-Deschner 2 , Toshio 

Heike 3 , Toshiro Hara 4 , Shumpei Yokota 5 , Phil Mckernan 6 , Albert 

Widmer 6 , Nicole Davis 7 and Eric Hachulla 8 , 1 University College 

London Medical School, London, United Kingdom, 2 Division of 

Pediatric Rheumatology, Department of Pediatrics, University 

Hospital Tuebingen, Tuebingen, Germany, 3 Department of 

Pediatrics, Graduate School of Medicine, Kyoto University, 

Kyoto, Japan, 4 Department of Pediatrics, Graduate School 

of Medical Science, Kyushu University, Fukuoka, Japan, 

5 

Department of Pediatrics, Yokohama City University, Graduate 

School of Medicine, Yokohama, Japan, 6 Novartis Pharma AG, 

Basel, Switzerland, 7 Novartis Pharmaceuticals Corporation, East 

Hanover, NJ, 8 Department of Internal Medicine, Claude Huriez 

Hospital, University of Lille, Lille CEDEX, France 

3:00 PM 

749. Efficacy and Safety of Canakinumab in Patients with TNF 

Receptor Associated Periodic Syndrome 

Marco Gattorno 1 , Laura Obici 2 , Antonella Meini 3 , Vincent 

Tormey 4 , Ken Abrams 5 , Nicole Davis 6 , Christopher Andrews 7 and 

Helen J. Lachmann 8 , 1 Istituto Giannina Gaslini, Genova, Italy, 

2 

IRCCS Policlinico San Matteo, Pavia, Italy, 3 Pediatric Immunology 

and Rheumatology, Brescia, Italy, 4 Galway University Hospitals, 

Galway, Ireland, 5 Novartis Pharmaceutical Corporation, East 

Hanover, NJ, 6 Novartis Pharmaceuticals Corporation, East 

Hanover, NJ, 7 Novartis Pharmaceuticals UK Limited, Surrey, 

United Kingdom, 8 University College London Medical School, 

London, United Kingdom 

3:15 PM 

750. Efficacy and Safety of Canakinumab in Adults with 

Colchicine Resistant Familial Mediterranean Fever 

A. Gul 1 , H. Ozdogan 2 , B. Erer 1 , S. Ugurlu 2 , Nicole Davis 3 , S. Sevgi 4 


SUNDAY 

November 11, 2012

SUNDAY 


and O. Kasapcopur 2 , 1 Istanbul University, Istanbul Faculty of 

Medicine, Istanbul, Turkey, 2 Istanbul University, Cerrahpasa 

Faculty of Medicine, Istanbul, Turkey, 3 Novartis Pharma Corp, 

East Hannover, 4 Novartis Pharma, Istanbul, Turkey 

3:30 PM 

751. Whole Transcriptome Analysis in Erdheim-Chester 

Disease: A Multicenter Collaborative Study of 58 Patients 

Laurent Arnaud 1 , Julien Haroche 1 , Lorenzo Dagna 2 , Augusto 

Vaglio 3 , Bruno Faivre 4 , Karim Dorgham 4 , Baptiste Hervier 1 , Fleur 

Cohen-Aubart 1 , Guy Gorochov 4 and Zahir Amoura 1 , 1 Hopital 

Pitié-Salpêtrière, AP-HP & UPMC Univ Paris 06, Paris, France, 

2 

Vita-Salute San Raffaele University School of Medicine and San 

Raffaele Scientific Institute, Milano, Italy, 3 University of Parma, 

Parma, Italy, 4 Institut National de la Santé et de la Recherche 

Médicale, INSERM UMR-S 945, Paris, France 

3:45 PM 

752. IFNg Production Is Intimately Associated with Clinical 

and Laboratory Features of CpG-Induced Secondary 

Hemophagocytic Lymphohistiocytosis (sHLH)/Macrophage 

Activating Syndrome (MAS) in Mice 

Vanessa Buatois, Laurence Chatel, Laura Cons, Maureen 

Deehan, Cristina de Min, Marie Kosco-Vilbois and Walter Ferlin, 

NovImmune S.A., Geneva, Switzerland 

152 A 

Muscle Biology, Myositis and Myopathies: 

Classification, Treatment and Outcome in Idiopathic 

Inflammatory Myopathies 

Moderators: Ingrid E. Lundberg, MD, PhD and Lisa G. Rider, MD 

2:45 PM 

754. The Functional Index-3 in Adult Dermatomyositis and 

Polymyositis: Validity and Reliability of an Outcome Measure 

for Muscle Endurance 

Christopher Chong 1 , Orla Ni Mhuircheartaigh 1 , Helene 

Alexanderson 2 , Tanaz A. Kermani 3 , Cynthia S. Crowson 4 , Abigail 

B. Green 4 , Ann M. Reed 4 and Floranne C. Ernste 5 , 1 Mayo Clinic, 

Rochester, 2 Karolinska Institutet, Stockholm, Sweden, 3 University 

of California Los Angeles, Los Angeles, 4 Mayo Clinic, Rochester, 

MN, 5 Mayo Clinic Rochester, Rochester, MN 

3:00 PM 

755. Sifalimumab, an Anti-IFN-Alpha Monoclonal Antibody 

Shows Target Suppression of a Type I IFN Signature in Blood 

and Muscle of Dermatomyositis and Polymyositis Patients 

Brandon W. Higgs 1 , Wei Zhu 1 , Chris Morehouse 1 , Wendy 

White 1 , Philip Brohawn 1 , Charles Le 1 , Anthony A. Amato 2 , David 

Fiorentino 3 , Steven A. Greenberg 2 , Laura Richman 1 , Warren 

Greth 1 , Bahija Jallal 1 and Yihong Yao 4 , 1 MedImmune, LLC, 

Gaithersburg, MD, 2 Brigham and Women’s Hospital and Harvard 

Medical School, Boston, MA, 3 Stanford University School of 

Medicine, Redwood City, CA, 4 MedImmune, Gaithersburg, MD 

3:15 PM 

756. Effect of B Cell Depletion Therapy with Rituximab 

On Myositis Associated Autoantibody Levels in Idiopathic 

Inflammatory Myopathy 

Rohit Aggarwal 1 , Chester V. Oddis 1 , Andriy Bandos 1 , Danielle 

Goudeau 2 , Diane Koontz 1 , Qi Zengbiao 1 , Ann M. Reed 3 , Dana P. 

Ascherman 4 and Marc C. Levesque 1 , 1 University of Pittsburgh, 

Pittsburgh, PA, 2 Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 

3 

Mayo Clinic, Rochester, MN, 4 University of Miami, Miami, FL 

42 

2:30 PM 

753. Progress Report On Development of Classification Criteria 

for Adult and Juvenile Idiopathic Inflammatory Myopathies 

Anna Tjärnlund 1 , Matteo Bottai 2 , Lisa G. Rider 3 , Victoria P. 

Werth 4 , Clarissa A. Pilkington 5 , Marianne de Visser 6 , Lars 

Alfredsson 7 , Anthony A. Amato 8 , Richard J. Barohn 9 , Matthew 

H. Liang 10 , Jasvinder A. Singh 11 , Frederick W. Miller 3 , Ingrid 

E. Lundberg 12 and the International Myositis Classification 

Criteria Project 13 , 1 Rheumatology Unit, Department of 

Medicine, Karolinska University Hospital, Solna, Karolinska 

Institutet, Stockholm, Sweden, Stockholm, Sweden, 2 Institute 

for Environmental Medicine, Karolinska Institutet, Stockholm, 

Sweden, Stockholm, Sweden, 3 NIEHS, NIH, Bethesda, MD, 

4 

University of Pennsylvania and Philadelphia V.A. Medical 

Center, Philadelphia, PA, 5 Great Ormond Street Hospital for 

Children NHS Trust, London, United Kingdom, 6 Department of 

Neurology, Academic Medical Centre, Amsterdam, Netherlands, 

Amsterdam, Netherlands, 7 Institute of Environmental 

Medicine, Karolinska Institutet, Stockholm, Sweden, 8 Brigham 

and Women’s Hospital and Harvard Medical School, Boston, 

MA, 9 Department of Neurology, University of Kansas Medical 

Center, Kansas City, USA, Kansas City, MO, 10 Brigham & Womens 

Hospital, Boston, MA, 11 University of Alabama at Birmingham, 

Birmingham, AL, 12 Karolinska Institutet, Stockholm, Sweden, 

13 

Stockholm 


3:30 PM 

757. Beneficial Role of Rapamycin in Experimental 

Autoimmune Myositis 

Nicolas Prevel 1 , Yves Allenbach 2 , David Klatzman 1 , Benoit 

Salomon 1 and Olivier Benveniste 2 , 1 UPMC Université Paris 06, 

UMR 7211, Paris, France, 2 Pitie-Salpetriere Hospital, Paris, 

France 

3:45 PM 

758. Cutaneous Ulceration in Dermatomyositis: Association 

with MDA-5 and Interstitial Lung Disease 

Neera Narang 1 , Livia Casciola-Rosen 2 , Antony Rosen 3 , David 

Fiorentino 4 and Lorinda Chung 5 , 1 Stanford Univ Medical Center, 

Stanford, CA, 2 Johns Hopkins University, Baltimore, MD, 3 The 

Johns Hopkins University, Baltimore, MD, 4 Stanford University 

School of Medicine, Redwood City, CA, 5 Stanford Univ Medical 

Center, Palo Alto, CA 

207 A 

Pediatric Rheumatology: Clinical and Therapeutic 

Disease I: Juvenile Idiopathic Arthritis I 

Moderators: Rayfel Schneider, MBBCh and Angelo Ravelli, MD 

2:30 PM 

759. Efficacy and Safety of Canakinumab in Patients with Active 

Systemic Juvenile Idiopathic Arthritis and Fever: Results From 

Two Pivotal Phase 3 Trials 

Hermine I. Brunner 1 , Nicolino Ruperto 2 , Pierre Quartier 3 , 

Tamás Constantin 2 , Nico Wulffraat 2 , Gerd Horneff 2 , Riva Brik 2 ,

Liza McCann 2 , Huri Ozdogan 2 , Lidia Rutkowska-Sak 2 , Rayfel 

Schneider 1 , Yackov Berkun 2 , Inmaculada Calvo 2 , Muferet 

Erguven 2 , Laurence Goffin 2 , Michael Hofer 2 , Tilmann Kallinich 2 , 

Karine Lheritier 4 , Ken Abrams 5 , Andrea Stancati 4 , D. J. Lovell 6 

and Alberto Martini 2 , 1 Pediatric Rheumatology Collaborative 

Study Group (PRCSG), Cincinnati, OH, 2 Paediatric Rheumatology 

International Trials Organisation (PRINTO)-Istituto Gaslini, 

Genova, Italy, 3 Necker-Enfants Malades Hospital, Paris, 

France, 4 Novartis Pharma AG, Basel, Switzerland, 5 Novartis 

Pharmaceutical Corporation, East Hanover, NJ, 6 Cincinnati 

Children’s Hospital, Cincinnati, OH 

2:45 PM 

760. Catch-up Growth During Tocilizumab Therapy for Systemic 

Juvenile Idiopathic Arthritis: 2-Year Data From a Phase 3 

Clinical Trial 

Fabrizio De Benedetti 1 , Nicolino Ruperto 2 , Graciela Espada 3 , 

Valeria Gerloni 3 , Berit Flato 3 , Gerd Horneff 4 , Barry L. Myones 5 , 

Karen Onel 5 , James Frane 6 , Andrew Kenwright 7 , Terri H. LiPMan 8 , 

Kamal N. Bharucha 6 , Alberto Martini 3 and D. J. Lovell 9 , 1 IRCCS 

Ospedale Pediatrico Bambino Gesù, Rome, Italy, 2 Paediatric 

Rheumatology International Trials Organisation [PRINTO], 

Genova, Italy, 3 Paediatric Rheumatology International Trials 

Organisation–IRCCS [PRINTO], Genova, Italy, 4 Centre of 

Pediatric Rheumatology, Sankt Augustin, Germany, 5 Pediatric 

Rheumatology Collaborative Study Group [PRSCG], Cincinnati, 

OH, 6 Genentech, South San Francisco, CA, 7 Roche, Welwyn 

Garden City, United Kingdom, 8 University of Pennsylvania School 

of Nursing, Philadelphia, PA, 9 Cincinnati Children’s Hospital, 

Cincinnati, OH 

3:00 PM 

761. Analysis of Biomarkers in Systemic Juvenile Idiopathic 

Arthritis Patients On Canakinumab Therapy 

Nico Wulffraat 1 , Hermine I. Brunner 2 , Nicolino Ruperto 1 , 

Pierre Quartier 3 , Riva Brik 1 , Liza McCann 1 , Huri Ozdogan 1 , Lidia 

Rutkowska-Sak 1 , Rayfel Schneider 2 , Valeria Gerloni 1 , Liora Harel 1 , 

Maria Hilário 2 , Kristin Houghton 2 , Rik Joos 1 , Daniel Kingsbury 2 , 

Arndt Brachat 4 , Stephan Bek 4 , Martin Schumacher 4 , Marie- 

Anne Valentin 4 , N.R Nirmala 5 , Hermann Gram 4 , Ken Abrams 6 , 

Alberto Martini 1 and D. J. Lovell 7 , 1 Paediatric Rheumatology 

International Trials Organization (PRINTO), Genova, Italy, 

2 

Pediatric Rheumatology Collaborative Study Group (PRCSG), 

Cincinnati, OH, 3 Necker-Enfants Malades Hospital, Paris, France, 

4 

Novartis Institutes for Biomedical Research, Basel, Switzerland, 

5 

Novartis Institutes for Biomedical Research, Cambridge, MA, 

6 

Novartis Pharmaceuticals Corporation, New Jersey, 7 Cincinnati 


3:15 PM 

762. Potentially Fatal Pulmonary Complications in Systemic 


Yukiko Kimura 1 , Jennifer E. Weiss 1 , Kathryn L. Haroldson 1 , 

Tzielan C. Lee 2 , Marilynn G. Punaro 3 , Sheila K. Feitosa de 

Oliveira 4 , Egla C. Rabinovich 5 , Meredith P. Riebschleger 6 , Jordi 

Anton 7 , Peter R. Blier 8 , Valeria Gerloni 9 , Melissa M. Hazen 10 , 

Elizabeth Kessler 11 , Karen Onel 12 , Murray H. Passo 13 , Robert 

M. Rennebohm 14 , Carol A. Wallace 15 , Patricia Woo 16 , Nico M. 

Wulffraat 17 and CARRAnet Investigators 18 , 1 JM Sanzari Children’s 

Hospital, Hackensack University Medical Center, Hackensack, 

NJ, 2 Stanford Univ School of Med, Stanford, CA, 3 Texas Scottish 

Rite Hospital, Dallas, TX, 4 Universidade Federal do Rio de 

Janeiro, Rio de Janeiro, Brazil, 5 Duke University Medical Center, 

Durham, NC, 6 University of Michigan Health System, Ann Arbor, 

MI, 7 Paediatric Rheumatology International Trials Organization 

(PRINTO), Istituto Giannina Gaslini, Genova, Italy, 8 Baystate 

Children’s Hospital, Springfield, MA, 9 Gaetano Pini Chair of 

Rheum, Milan, Italy, 10 Children’s Hospital Boston, Boston, MA, 

11 

Medical College of Wisconsin, Milwaukee, WI, 12 University 

of Chicago, Chicago, IL, 13 Medical University of South Carolina, 

Charleston, SC, 14 Alberta Children’s Hospital, University of 

Calgary, Calgary, AB, 15 Seattle Childrens Hospital, Seattle, 

WA, 16 University College London, London, United Kingdom, 

17 

University Medical Center Utrecht, Utrecht, Netherlands, 

18 

Durham 

3:30 PM 

763. Incidence of Selected Opportunistic Infections Among 

Children with Juvenile Idiopathic Arthritis 

Timothy Beukelman 1 , Fenglong Xie 1 , John Baddley 1 , Lang Chen 1 , 

Elizabeth S. Delzell 1 , Carlos Grijalva 2 , Melissa L. Mannion 1 , 

Nivedita M. Patkar 1 , Kenneth G. Saag 1 , Kevin L. Winthrop 3 

and Jeffrey R. Curtis 1 , 1 University of Alabama at Birmingham, 

Birmingham, AL, 2 Vanderbilt University, Nashville, TN, 3 Oregon 

Health & Science University, Portland, OR 

3:45 PM 

764. The Impact of Adalimumab On Growth in Patients with 


D. J. Lovell 1 , Nicolino Ruperto 2 , Katerina Jarosova 2 , Dana 

Nemcova 2 , Veronika Vargova 2 , Hartmut Michels 2 , Elizabeth 

Chalom 3 , Norman Ilowite 3 , Carine Wouters 2 , Hermine Brunner 2 , 

Karolyn Kracht 4 , Hartmut Kupper 5 , Edward Giannini 3 , Alberto 

Martini 2 and Neelufar Mozaffarian 4 , 1 Cincinnati Children’s 

Hospital, Cincinnati, OH, 2 Paediatric Rheumatology International 

Trials Organisation–IRCCS [PRINTO], Genova, Italy, 3 Pediatric 


OH, 4 Abbott, Abbott Park, IL, 5 Abbott GmbH and Co. KG, 

Ludwigshafen, Germany 

Ballroom C 

Rheumatoid Arthritis - Clinical Aspects I: Risk Factors 

and Prediction of Rheumatoid Arthritis 

Moderators: Vivian P. Bykerk, MD and Elizabeth Karlson, MD 

2:30 PM 

765. A Prediction Rule for the Development of Rheumatoid 

Arthritis: A Prospective Cohort Study of Seropositive Arthralgia 

Patients 

Lotte van de Stadt 1 , B. I. Witte 2 , W.H. Bos 1 and Dirkjan van 

Schaardenburg 1 , 1 Jan van Breemen Research Institute | Reade, 

Amsterdam, Netherlands, 2 VU University Medical Center, 

Amsterdam, Netherlands 

2:45 PM 

766. Anemia May Provide Clinically Relevant Information 

Beyond Conventional Disease Activity Assessment to Predict 

Radiographic Damage Progression in Rheumatoid Arthritis 

Burkhard Moller 1 , Frauke Förger 2 , Peter M. Villiger 3 and Axel 

Finckh 4 , 1 Inselspital University Hospital, Bern, Switzerland, 

2 

Inselspital University Hospital of Bern, Bern, Switzerland, 

3 

Inselspital-University Hospital of Bern, Bern, Switzerland, 

4 

Geneva University Hospitals, Geneva 14, Switzerland 


SUNDAY 

November 11, 2012

SUNDAY 


3:00 PM 

767. Patients with Early Inflammatory Arthritis Who Fulfil 

the 2010 American College Rheumatology/European League 

Against Rheumatism Classification Criteria for Rheumatoid 

Arthritis Have Increased Mortality Compared to Those Who Do 

Not: Results From the Norfolk Arthritis Register 

Jh Humphreys 1 , Suzanne Verstappen 2 , Mark Lunt 3 , Jackie 

Chipping 4 , Kimme Hyrich 5 , Tarnya Marshall 6 and Deborah 

Symmons 7 , 1 Arthritis Research UK Epidemiology Unit,, 

Manchester, United Kingdom, 2 University of Manchester, 

Manchester Academic Health Sciences Centre, Manchester, 

United Kingdom, 3 Arthritis Research UK Epidemiology Unit, 

The University of Manchester, Manchester, United Kingdom, 

4 

Norfolk Arthritis Register, School of Medicine Health Policy 

and Practice Faculty of Health UEA, Norwich, United Kingdom, 

5 

Arthritis Research UK Epidemiology Unit, University of 

Manchester, Manchester, United Kingdom, 6 Norfolk and Norwich 

University Hospitals Trust, Norwich, United Kingdom, 7 University 

of Manchester, Manchester Academy of Health Sciences, 

Manchester, United Kingdom 

3:15 PM 

768. An Easy to Use Referral Model for Arthritis From the 

Rotterdam Early Arthitis Cohort 

C. Alves 1 , Jolanda J. Luime 2 , Darian P. Shackleton 3 , P.J. 

Barendregt 4 , A.H. Gerards 5 and Johanna M.W. Hazes 6 , 1 Erasmus 

MC, Rotterdam, Netherlands, 2 Erasmus MC - University Medical 

Center, Rotterdam, Netherlands, 3 Medisch Centrum Parklaan, 

Netherlands, 4 Maasstad Hospital, Rotterdam, Netherlands, 

5 

Vlietland Hospital, Schiedam, Netherlands, 6 Erasmus Medical 

Center, Rotterdam, Netherlands 

3:30 PM 

769. 2010 ACR/EULAR Rheumatoid Arthritis Classification 

Criteria Predicts Radiogical, but Not Clinical Outcomes At 18 

Months Into Disease in a Canadian Early Arthritis Cohort 

Ariel Masetto 1 , Arthur J. Fernandes 2 , Patrick Liang 3 , Pierre 

Cossette 2 and Gilles Boire 4 , 1 CHUS, Fleurimont, QC, 2 Universite 

de Sherbrooke, Sherbrooke N, 3 CHUS, Sherbrooke, QC, 4 CHUS - 

Sherbrooke University, Sherbrooke, QC 

3:45 PM 

770. Is Late Onset Rheumatoid Arthritis (LORA) Really a Distinct 

Entity of RA? Results From the Swiss Observational Cohort 

Ruediger Mueller 1 , Toni Kaegi 1 , Axel Finckh 2 and Johannes 

von Kempis 1 , 1 MD, St. Gallen, Switzerland, 2 Geneva University 

Hospitals, Geneva 14, Switzerland 

Renaissance Washington - Grand Ballroom North 

Rheumatoid Arthritis Treatment - Small Molecules, 

Biologics and Gene Therapy: Comparative Efficacy and 

Novel Treatment Strategies in Rheumatoid Arthritis 

Moderators: Joseph A. Markenson, MD and Mark C. Genovese, 

MD 

2:30 PM 

771. Discontinuation of Adalimumab without Functional and 

Radiographic Damage Progression After Achieving Sustained 

Remission in Patients with Rheumatoid Arthritis (the HONOR 

study): 1-Year Results 

Yoshiya Tanaka, Shintaro Hirata, Shunsuke Fukuyo, Masao 

Nawata, Satoshi Kubo, Kunihiro Yamaoka and Kazuyoshi Saito, 

University of Occupational and Environmental Health, Japan, 

Kitakyushu, Japan 

2:45 PM 

772. Tocilizumab Monotherapy Compared with Adalimumab 

Monotherapy in Patients with Rheumatoid Arthritis: Results of 

a 24-Week Study 

Arthur Kavanaugh 1 , Paul Emery 2 , Ronald F. van Vollenhoven 3 , Ara 

H. Dikranian 4 , Rieke Alten 5 , Micki Klearman 6 , David Musselman 6 , 

Sunil Agarwal 6 , Jennifer Green 7 and Cem Gabay 8 , 1 UCSD School 

of Medicine, La Jolla, CA, 2 University of Leeds, Leeds, United 

Kingdom, 3 Karolinska Institute, Stockholm, Sweden, 4 San Diego 

Arthritis Medical Clinic, San Diego, CA, 5 Schlosspark Klinik, 

University Medicine Berlin, Berlin, Germany, 6 Genentech Inc, 

South San Francisco, CA, 7 Welwyn Garden City, United Kingdom, 

8 

Geneva University Hospitals, Geneva, Switzerland 

3:00 PM 

773. Remission Rates with Tofacitinib Treatment in Rheumatoid 

Arthritis: A Comparison of Various Remission Criteria 

J. S. Smolen 1 , D. Aletaha 1 , D. Gruben 2 , J. D. Bradley 2 , S. H. 

Zwillich 2 , S. Krishnaswami 2 , B. Benda 3 and C. Mebus 2 , 1 Medical 

University of Vienna, Vienna, Austria, 2 Pfizer Inc., Groton, CT, 

3 

Pfizer Inc., Collegeville, PA 

3:15 PM 

774. A CD4+ T-Cell Gene Expression Signature Predicts Drug 

Survival On Methotrexate Monotherapy in Early Rheumatoid 

Arthritis 

Arthur G. Pratt 1 , Philip M. Brown 1 , Simon J. Cockell 2 , Gillian 

Wilson 3 and John D. Isaacs 4 , 1 Newcastle University, Newcastle 

Upon Tyne, United Kingdom, 2 Newcastle University, Newcastleupon-Tyne, 

United Kingdom, 3 Freeman Hospital, Newcastleupon-Tyne, 

United Kingdom, 4 Musculoskeletal Research 

Group, Institute of Cellular Medicine, Newcastle University and 

Newcastle upon Tyne NHS Foundation Trust, Newcastle Upon 

Tyne, United Kingdom 

3:30 PM 

775. Long-Term Outcomes of Early Rheumatoid Arthritis 

Patients Initiated with Adalimumab Plus Methotrexate 

Compared with Methotrexate Alone Following a Targeted 

Treatment Approach 

Roy Fleischmann 1 , Ronald F. van Vollenhoven 2 , Josef S. Smolen 3 , 

Paul Emery 4 , Stefan Florentinus 5 , Suchitrita S. Rathmann 6 , 

Hartmut Kupper 7 and Arthur Kavanaugh 8 , 1 University of Texas 

Southwestern Medical Center, Dallas, TX, 2 Karolinska Institute, 

Stockholm, Sweden, 3 Medical University of Vienna and Hietzing 

Hospital, Vienna, Austria, 4 Leeds Musculoskeletal Biomedical 

Research Unit, Leeds, United Kingdom, 5 Abbott, Rungis, 

France, 6 Abbott, Abbott Park, IL, 7 Abbott GmbH and Co. KG, 

Ludwigshafen, Germany, 8 UCSD School of Medicine, La Jolla, CA 

3:45 PM 

776. A Multicenter, Randomized, Controlled, Open-Label Pilot 

Study of the Feasibility of Discontinuation of Adalimumab in 

Rheumatoid Arthritis Patients in Stable Clinical Remission 

Katerina Chatzidionysiou 1 , Carl Turesson 2 , Annika Teleman 3 , Ann 

Knight 4 , Elisabet Lindqvist 5 , Per Larsson 6 , Lars Cöster 7 , Barbro 

44 

2012 Program Book

Rydberg 8 , Ronald F. van Vollenhoven 9 and Mikael Heimbürger 10 , 

1 

Karolinska Institute, Stockholm, Sweden, 2 Lund University, 

Malmö, Sweden, 3 Department of Rheumatology, Spenshult 

Hospital, Oskarstrom, Sweden, 4 Institution for Medical Sciences, 

Uppsala University, Uppsala, Sweden, 5 Section for Rheumatology 

Lund University, Lund, Sweden, 6 Karolinska University Hospital, 

Stockholm, Sweden, 7 University Hospital, Linköping, Sweden, 

8 

Kärnsjukhuset, Skövde, Sweden, 9 The Karolinska Institute, 

Stockholm, Sweden, 10 Abbott Scandinavia, Stockholm, Sweden 

Ballroom B 

Spondylarthropathies and Psoriatic Arthritis - Clinical 

Aspects and Treatment: Spondyloarthritis I 

Moderators: Michael M. Ward, MD and Lianne S. Gensler, MD 

State Medical University, Kazan, Russia, 6 Catholic University of 

Korea, Seoul, South Korea, 7 Seoul National University, Seoul, 

South Korea, 8 Merck Sharp and Dohme, Kenilworth, NJ, 9 Merck 

Sharp and Dohme, Brussels, Belgium 

3:15 PM 

780. The Relationship of Inflammation, Fatty Degeneration 

and the Effect of Long-Term TNF-Blocker Treatment On 

the Development of New Bone Formation in Patients with 

Ankylosing Spondylitis 

Xenofon Baraliakos 1 , Frank Heldmann 2 , Joachim Listing 3 , 

Johanna Callhoff 3 , Juergen Braun 1 and EASIC 4 , 1 Rheumazentrum 

Ruhrgebiet, Herne, Germany, 2 Rheumazentrum Ruhrgebiet, 

Herne, Ghana, 3 German Rheumatism Research Center, Berlin, 

Germany, 4 Herne, Germany 

2:30 PM 

777. Effect of Certolizumab Pegol On Signs and Symptoms 

of Ankylosing Spondyltitis and Non-Radiographic 

Axial Spondyloarthritis: 24 Week Results of a Double 

Blind Randomized Placebo-Controlled Phase 3 Axial 

Spondyloarthritis Study 

Robert B. M. Landewé 1 , Martin Rudwaleit 2 , Désirée van der 

Heijde 3 , Maxime Dougados 4 , Walter P. Maksymowych 5 , Jurgen 

Braun 6 , Atul A. Deodhar 7 , Christian Stach 8 , Bengt Hoepken 8 , 

Geoffroy Coteur 9 , Danuta Kielar 9 , Andreas Fichtner 8 , Terri 

Arledge 10 and Joachim Sieper 11 , 1 Academic Medical Center/ 

University of Amsterdam & Atrium Medical Center, Amsterdam, 

Netherlands, 2 Endokrinologikum Berlin, Berlin, Germany, 3 Leiden 

University Medical Center, Leiden, Netherlands, 4 Paris-Descartes 

University, APHP, Cochin Hospital, Paris, France, 5 University of 

Alberta, Edmonton, AB, 6 Rheumazentrum Ruhrgebiet, Herne, 

Germany, 7 Oregon Health & Science University, Portland, 

OR, 8 UCB Pharma, Monheim am Rheim, Germany, 9 UCB 

Pharma, Brussels, Belgium, 10 UCB Pharma, Rtp, NC, 11 Charité 

Universitätesmedizin Berlin, Berlin, Germany 

2:45 PM 

778. Spinal MRI Has Little Incremental Diagnostic Value 

Compared with MRI of the Sacroiliac Joints Alone in Early 

Spondyloarthritis 

Ulrich Weber 1 , Veronika Zubler 1 , Zheng Zhao 2 , Robert GW 

Lambert 3 , Stanley Chan 3 , Susanne Juhl Pedersen 4 , Mikkel 

Ostergaard 5 and Walter P. Maksymowych 3 , 1 Balgrist University 

Hospital, Zurich, Switzerland, 2 Department of Rheumatology, 

University of Alberta and PLA General Hospital, Beijing, PR 

China, Beijing, China, 3 University of Alberta, Edmonton, AB, 

4 

Glostrup Hospital, Copenhagen, Denmark, 5 Copenhagen 

University Hospital at Glostrup, Glostrup, Denmark 

3:30 PM 

781. Ankylosing Spondylitis Is Associated with an Increased 

Risk of Osteoporotic Fractures: A Population-Based Cohort 

Study 

Juan Muñoz-Ortego 1 , Peter Vestergaard 2 , Josep Blanch 3 , Paul 

Wordsworth 4 , Andrew Judge 5 , M. Kassim Javaid 6 , Nigel K. Arden 6 , 

Cyrus Cooper 7 , Adolfo Díez-Pérez 8 and Daniel Prieto-Alhambra 9 , 

1 

Hospital Sagrat Cor, Barcelona (Spain), Barcelona, Spain, 

2 

Aarhus University Hospital THG, Aarhus (Denmark), Aarhus, 

Denmark, 3 Hospital del Mar, Parc de Salut Mar, Barcelona, 

Spain, 4 Nuffield Orthopaedic Centre, Oxford, United Kingdom, 

5 

Oxford University, Oxford, United Kingdom, 6 Oxford NIHR 

Musculoskeletal Biomedical Research Unit, University of Oxford, 

Oxford, UK, Oxford, United Kingdom, 7 University of Oxford; 

Southampton General Hospital, Southampton, United Kingdom, 

8 

Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, 

Barcelona; and RETICEF, ISCIII Madrid; Spain, Barcelona, Spain, 

9 

URFOA-IMIM, Parc de Salut Mar; Idiap Jordi Gol; University of 

Oxford; University of Southampton, Barcelona, Spain 

3:45 PM 

782. Anti-TNF Therapy Slows Radiographic Progression of 


Nigil Haroon 1 , Robert D. Inman 2 , Thomas J. Learch 3 , Michael H. 

Weisman 4 , Michael M. Ward 5 , John D. Reveille 6 and Lianne S. 

Gensler 7 , 1 University Health Network, Toronto Western Research 

Institute, University of Toronto, Toronto, ON, 2 Toronto Western 

Research Institute, University Health Network and University of 

Toronto, Toronto, ON, 3 Cedars-Sinai, Los Angeles, CA, 4 Cedars- 

Sinai Medical Center, Los Angeles, CA, 5 NIAMS/NIH, Bethesda, 

MD, 6 Univ of Texas Health Science Center at Houston, Houston, 

TX, 7 UCSF, San Francisco, CA 

SUNDAY 


3:00 PM 

779. Changes in Active Inflammatory Lesions Assessed by 

Magnetic Resonance Imaging: Results of the Infliximab 

As First Line Therapy in Patients with Early Active Axial 

Spondyloarthritis Trial 

Joachim Sieper 1 , Jan Lenaerts 2 , Jürgen Wollenhaupt 3 , Vadim 

Mazurov 4 , L. Myasoutova 5 , Sung-Hwan Park 6 , Yeong W. Song 7 , 

Ruji Yao 8 , Denesh Chitkara 8 and Nathan Vastesaeger 9 , 1 Charité, 

University Medicine Berlin, Berlin, Germany, 2 Reuma-instituut, 

Hasselt, Belgium, 3 Schön-Klinik, Hamburg, Germany, 4 St. 

Petersburg Medical Academy, St. Petersburg, Russia, 5 Kazan 

146 C 

Systemic Sclerosis, Fibrosing Syndromes and 

Raynaud’s – Pathogenesis, Animal Models and 

Genetics 

Moderators: John Varga, MD and Maria Trojanowska, PhD 

2:30 PM 

783. The Wnt Inhibitors DKK 1 and SFRP1 Are Downregulated by 

Promoter Hypermethylation in Systemic Sclerosis 

Clara Dees 1 , Inga Schlottmann 1 , Robin Funke 1 , Alfiya Distler 1 , 

Katrin Palumbo-Zerr 2 , Pawel Zerr 2 , Oliver Distler 3 , Georg A. 


SUNDAY 


Schett 2 and Joerg HW Distler 2 , 1 Department of Internal Medicine 

3 and Institute for Clinical Immunology, University of Erlangen- 

Nuremberg, Erlangen, Germany, 2 Department of Internal 

Medicine III and Institute for Clinical Immunology, University of 

Erlangen-Nuremberg, Erlangen, Germany, 3 University Hospital 

Zurich, Zurich, Switzerland 

2:45 PM 

784. Neutralization of Plasminogen Activator Inhibitor-1 

Resolves Skin Fibrosis and Vascular Injury in a Murine Model of 

Human Scleroderma 

Raphael Lemaire 1 , Tim Burwell 1 , Tracy Delaney 1 , Cindy Chen 1 , 

Julie Bakken 1 , Lily Cheng 1 , Philip Brohawn 1 , Isabelle de Mendez 2 , 

Dominic Corkill 2 , Anthony Coyle 3 , Ronald Herbst 1 and Jane 

Connor 1 , 1 MedImmune LLC, Gaithersburg, MD, 2 Medimmune, 

LLC, Cambridge, England, 3 Pfizer, Inc., Cambridge (formerly at 

MedImmune LLC, Gaithersburg, MD, USA) 

3:00 PM 

785. Resident Lung Fibroblast Gene Expression Signatures 

Predict Susceptibility or Resistance to Experimental Lung 

Fibrosis 

Emma Derrett-Smith 1 , Rachel Hoyles 1 , Korsa Khan 1 , David J. 

Abraham 1 and Christopher P. Denton 2 , 1 UCL Medical School, 

London, United Kingdom, 2 UCL, London, United Kingdom 

3:15 PM 

786. Crosstalk Between Integrins and TGFβ in the Pathogenesis 

and Treatment of Multiple Presentations of Scleroderma 

Elizabeth E. Gerber 1 , Fredrick M. Wigley 2 , Elaine C. Davis 3 , David 

L. Huso 1 and Harry C. Dietz 1 , 1 Johns Hopkins University School of 

Medicine, Baltimore, MD, 2 Johns Hopkins University, Baltimore, 

MD, 3 McGill University, Montreal, QC 

3:30 PM 

787. Aberrant Adipogenesis in the Pathogenesis of Scleroderma 

Roberta Goncalves Marangoni, Jun Wei, Monique E. Hinchcliff, 

Feng Fang, Warren Tourtellotte and John Varga, Northwestern 

University Medical School, Chicago, IL 

3:45 PM 

788. Tenofovir, a Potent Anti-Viral Agent, Is an Ecto- 

5’Nucleotidase (CD73) Inhibitor That Prevents Dermal Fibrosis 

in a Murine Model of Scleroderma 

Jessica L. Feig 1 , Doreen Tivon 1 , Miguel Perez-Aso 1 , Timothy 

Cardozo 1 and Bruce N. Cronstein 2 , 1 New York University School 

of Medicine, New York, NY, 2 NYU School of Medicine, Division of 

Rheumatology, New York, NY 

ARHP SESSIONS 

2:30 - 4:00 PM 

PM 

PS 

143 A 

Non-pharmacological Management of Fibromyalgia: 

Your Toolbox PM PS 

Moderator: Dane B. Cook, PhD 


• discuss the basic components of cognitive-behavioral therapy 

for chronic pain and the evidence base for associated 

effectiveness 

• provide the basic knowledge and associated materials needed 

to integrate multiple aspects of cognitive-behavioral therapy 

into practice 

• describe various forms of exercise and the evidence base for 

their use in the treatment of fibromyalgia 

• outline the basic knowledge and associated materials needed 

to educate patients in regard to exercise and enhance exercise 

persistence 

2:30 PM 

Cognitive-behavioral Therapy You Can Use 

David A. Williams, PhD 

3:15 PM 

Exercise Options and Motivating Persistence in Fibromyalgia 

Kim D. Jones, PhD 

PM PS 

204 A 

Practice Managers: Improving Access and Website 

Marketing (Practice Management Series) 



• recognize the importance of regular patient visits for viability 

of practice 

• evaluate practice strengths and weaknesses of a growing 

practice 

• outline ways to minimize barriers and opportunities by 

improving access and website marketing 

• determine how to effectively reach optimal patient target 

audiences 

• develop strategies for delivering advertised products (e.g., 

expertise, specialty, atmosphere, value) 

• outline a viable plan for maintaining and improving quality of 

services to new patients 

2:30 PM 

Marketing 

Chris Alonzo and John O’Toole, BA 

206 

3:15 PM 

Improving Access 

Michelle Hirschman 

PM 

PS 

Rheumatic Disease Update: Inflammatory Eye 

Disease 

Moderator: Deborah K. McCurdy, MD 

Speaker: Gary N. Holland, MD 


• discuss the associations between rheumatic disorders and 

inflammatory eye disease 

• recognize anatomical lesions of the eye as they relate to 

diagnosis 

• identify appropriate therapy options 

46 

2012 Program Book

ARHP CONCURRENT ABSTRACT SESSIONS 

2:30 - 4:00 PM 

140 A 

Foot and Gait Disorders 

Moderators: Shngpui Betty Chow, PT and Smita Rao, PhD, PT 

2:30 PM 

789. Foot Disorders Associated with Over-Pronated and Over- 

Supinated Foot Types: The Johnston County Osteoarthritis 

Project 

Yvonne M. Golightly 1 , Marian T. Hannan 2 , Alyssa B. Dufour 3 , 

Howard J. Hillstrom 4 and Joanne M. Jordan 5 , 1 University of North 

Carolina, Chapel Hill, NC, 2 Hebrew SeniorLife & Harvard Med 

Sch, Boston, MA, 3 Hebrew SeniorLife & Boston Univ, Boston, 

MA, 4 Hospital Special Surgery (HSS), New York, NY, 5 University of 

North Carolina Thurston Arthritis Research Center, Chapel Hill, 

NC 

2:45 PM 

790. Biomechanical Function Agrees with Clinical Implications 

of Foot Disorders in a Population-Based Study 

Thomas J. Hagedorn 1 , Alyssa B. Dufour 2 , Jody L. Riskowski 3 , 

Howard J. Hillstrom 4 , Virginia A. Casey 1 and Marian T. Hannan 5 , 

1 

Hebrew Senior Life, Boston, MA, 2 Hebrew SeniorLife & Boston 

Univ, Boston, MA, 3 Hebrew SeniorLife & Harvard Med School, 

Boston, MA, 4 Hospital Special Surgery (HSS), New York, NY, 

5 

Hebrew SeniorLife & Harvard Med Sch, Boston, MA 

3:00 PM 

791. Leg Muscle Mass Is Not Affected by Foot Pain, Structure 

or Function: The Framingham Foot Study 

Alyssa B. Dufour 1 , Marian T. Hannan 2 , Patricia P. Katz 3 , Jody L. 

Riskowski 4 , Thomas J. Hagedorn 5 , Virginia A. Casey 5 and Robert 

R. McLean 6 , 1 Hebrew SeniorLife & Boston Univ, Boston, MA, 

2 

Hebrew SeniorLife & Harvard Med Sch, Boston, MA, 3 Univercity 

of California San Francisco, San Francisco, CA, 4 Hebrew 

SeniorLife & Harvard Med School, Boston, MA, 5 Hebrew Senior 

Life, Boston, MA, 6 Hebrew Senior Life/Harvard Medical School, 

Boston, MA 

3:45 PM 

794. How Many Steps/Day Are Associated with a Community 

Level Gait Speed Among Older Adults with or At High Risk of 

Knee OA? 

Daniel K. White 1 , Roger Fielding 2 , Tuhina Neogi 3 , Michael P. 

LaValley 4 , K. Douglas Gross 5 , Michael C. Nevitt 6 , C.E. Lewis 7 , 

James Torner 8 and Catrine Tudor-Locke 9 , 1 Boston University, 

Boston, MA, 2 Tufts Medical Center, 3 Boston Univ School of 

Medicine, Boston, MA, 4 Boston University School of Public 

Health, Boston, MA, 5 MGH Institute of Health Professions, 

Boston, MA, 6 University of California-San Francisco, San 

Francisco, CA, 7 University of Alabama, Birmingham City, AL, 

8 

University of Iowa, Iowa City, Iowa City, IA, 9 Pennington 

Biomedical Research Center, Baton Rouge 

201 


Moderators: Charles G. Helmick, MD and Uyen Sa D.T. Nguyen, 

DSc, MPH 

2:30 PM 

795. Racial Differences in Pain Coping Efficacy in Patients with 

Hip and Knee Osteoarthritis 

Kelli D. Allen 1 , Hayden B. Bosworth 1 , Cynthia Coffman 1 , Jennifer 

H. Lindquist 1 , Nina R. Sperber 1 , Morris Weinberger 2 and Eugene 

Z. Oddone 1 , 1 Duke and Durham VA Medical Center, Durham, 

NC, 2 University of North Carolina at Chapel Hill & Durham VA 

Medical Center, Durham, NC 

2:45 PM 

796. African American Adults Less Willing to Undergo Joint 

Replacement Surgery: The Multicenter Osteoarthritis Study 

Julie J. Keysor 1 , Huan J. Chang 2 , Tianzhong Yang 3 , Cora E. Lewis 4 , 

James Torner 5 , Michael C. Nevitt 6 and David T. Felson 3 , 1 Boston 

Univ Sargent College, Boston, MA, 2 The Journal of the American 

Medical Association, Chicago, IL, 3 Boston Univ School of 

Medicine, Boston, MA, 4 University of Alabama, Birmingham City, 

Birmingham, AL, 5 University of Iowa, Iowa City, Iowa City, IA, 

6 

University of California-San Francisco, San Francisco, CA 

SUNDAY 


3:15 PM 

792. Associations of Foot Structure and Function to Low Back 

and Lower Extremity Pain 

Jody L. Riskowski 1 , Alyssa B. Dufour 2 , Thomas J. Hagedorn 3 , 

Howard J. Hillstrom 4 , Virginia A. Casey 3 and Marian T. Hannan 1 , 

1 

Hebrew SeniorLife & Harvard Medical School, Boston, MA, 

2 

Hebrew SeniorLife & Boston Univ, Boston, MA, 3 Hebrew 

SeniorLife, Boston, MA, 4 Hospital Special Surgery (HSS), New 

York, NY 

3:30 PM 

793. Associations of Foot Forces and Pressures to Regional 

Foot Pain: The Framingham Foot Study 

Jody L. Riskowski 1 , Thomas J. Hagedorn 2 , Alyssa B. Dufour 3 , 

Virginia A. Casey 4 and Marian T. Hannan 1 , 1 Hebrew SeniorLife & 

Harvard Med School, Boston, MA, 2 Hebrew SeniorLife, Boston, 

MA, 3 Hebrew SeniorLife & Boston Univ, Boston, MA, 4 Hebrew 

Senior Life, Boston, MA 

3:00 PM 

797. Clinical and Biomechanical Characteristics of Total Hip 

Arthroplasty Responders and Nonresponders 

Genna Waldman 1 and Kharma C. Foucher 2 , 1 Rush Medical 

College, Chicago, IL, 2 Rush University Medical Center, Chicago, IL 

3:15 PM 

798. A Rich Description of Clinical Exam Features in Patients 

with Knee Osteoarthritis and Their Correlation with Functional 

Outcomes 

Maura D. Iversen 1 , Kelli Sylvester 2 , Abigail Grader 2 , Michelle 

A. Frits 3 , Marie Boneparth 4 , Megan Whitmore 4 , Jane Lucas 5 , 

Fatima Shahzad 6 , Jeffrey B. Driban 6 and Chenchen Wang 6 , 

1 

Northeastern University, Department of Physical Therapy, and 

Brigham & Women’s Hospital, Harvard Medical School, Boston, 

MA, 2 Department of Physical Therapy, Northeastern University, 

Boston, MA, 3 Brigham and Women’s Hospital, Boston, MA, 4 Tufts 

Medical Center, Boston, 5 Back Bay Physical Therapy, Boston, 

6 

Tufts Medical Center, Boston, MA 


SUNDAY 


3:30 PM 

799. Does Unpredictable Intermittent Knee Pain Limit 

Functional Ability and Walking Frequency in Knee OA? 

Daniel K. White 1 , Gillian A. Hawker 2 , David T. Felson 1 , K. Douglas 

Gross 3 , Jingbo Niu 4 , Michael C. Nevitt 5 , C.E. Lewis 6 , James Torner 7 

and Tuhina Neogi 4 , 1 Boston University, Boston, MA, 2 Women’s 

College Research Institute, University of Toronto, Toronto, ON, 

3 

MGH Institute of Health Professions, Boston, MA, 4 Boston 

Univ School of Medicine, Boston, MA, 5 University of California- 

San Francisco, San Francisco, CA, 6 University of Alabama, 

Birmingham City, AL, 7 University of Iowa, Iowa City, Iowa City, IA 

3:45 PM 

800. BMI, Occupational Activity, and Leisure-Time Physical 

Activity: an Exploration of Risk Factors and Modifiers for Knee 


Kathryn Remmes Martin 1 , Diana Kuh 2 , Tamara B. Harris 1 , Jack 

M. Guralnik 3 , David Coggon 4 and Andrew K. Wills 5 , 1 NIA/NIH, 

Bethesda, MD, 2 Medical Research Council, London, United 

Kingdom, 3 University of Maryland, Baltimore, 4 University of 

Southampton, Southampton, United Kingdom, 5 University of 

Bristol, Bristol, United Kingdom 

PM 

ACR WORKSHOPS 

4:00 - 6:00 PM 

PS 










September 14. 

144 A 

Dermatopathology of Rheumatic Diseases (212) 

Speaker: Daniel Miller, MD 

144 B 

Musculoskeletal Exam Skills II: Regional 

Musculoskeletal Examination of the Neck and Low 

Back (213) 


ACR SESSIONS 

4:30 - 6:00 PM 

PM PS 

Ballroom C 

Classification and Treatment of Sjögren’s 

Syndrome 

Moderators: Lindsey A. Criswell, MD, MPH and Frederick B. 

Vivino, MD 


• describe how Sjögren’s syndrome has been both over 

diagnosed and under diagnosed 

• summarize the new ACR classification criteria for Sjögren’s 

syndrome 

• discuss the burden of illness in Sjögren’s syndrome 

• describe current efforts to develop clinical practice guidelines 

for Sjögren’s syndrome 

4:30 PM 

2012 ACR Classification Criteria for Sjögren’s Syndrome 

Steve Shiboski, PhD 

4:55 PM 

Rationale and Procedures for Guideline Development in 

Sjögren’s Syndrome 

Ann L. Parke, MD 

5:20 PM 

Preliminary Clinical Practice Guidelines for Sjögren’s Syndrome 

Steven E. Carsons, MD 

5:45 PM 

Questions & Answers 

143 A 

Metabolic Abnormalities in Autoimmunity 

Moderator: Andras Perl, MD, PhD 


• describe the close interconnection of metabolic responses 

with T cell function and autoimmunity 

• explain the scientific basis of therapeutic targets such as 

mammalian target of rapamycin that are under development 

• summarize how metabolic biomarkers of T cell function 

may contribute to a scientific understanding of disease 

exacerbation and remission 

4:30 PM 

Metabolic Control of T cell Differentiation 

Jonathan Powell, MD, PhD 

PM 

PS 

144 C 

Osteoporosis: Interpreting Dual Energy X-ray 

Absorptiometry and Clinical Risk Factors: The New 

Fracture Risk Assessment Algorithm (214) 

Speaker: Stuart L. Silverman, MD 

149 A 

Synovial Fluid Analysis and Crystal Identification (215) 

Speakers: Brian F. Mandell, MD, PhD, Lan Chen, MD, PhD, and 

Gilda M. Clayburne, MLT 

5:00 PM 

The Biology of Reactive Nitrogen Intermediates in Systemic 

Lupus Erythematosus 

Jim Oates, MD 

5:30 PM 

Metabolic Control of Systemic Autoimmunity 

Andras Perl, MD, PhD 

48 

2012 Program Book

PM 

PS 

207 A 

Puberty, Adolescence and Rheumatologic Disease 

Moderator: Kenneth N. Schikler, MD 


• recognize the psychosocial issues expected for early, middle 

and late adolescents 

• describe the effects of neuro-hormonal maturation on 

cognitive as well as somatic and pubertal physiologic growth 

• explain the challenges of dealing with the obstacles and 

challenges chronic diseases present to the adolescent and 

normative psychosocial development 

• demonstrate clearly and become adept at dealing with 

reproductive health issues of this population 

4:30 PM 

I’m Not a Little Kid Anymore and How and Why I Am Changing 

Frank M. Biro, MD 

5:00 PM 

Adolescent Sexuality 

Margaret Blythe, MD 

5:30 PM 

Reproductive Health Issues for Adolescents with 

Rheumatologic Disorders 

Susan Paige Hertweck, MD 

Hall D 

Thieves’ Market: Show Me Your Best Cases 

Moderator: Diane L. Kamen, MD, MS, Zsuzsanna H. McMahan, 

MD, MHS and Robert F. Spiera, MD 


• describe unique and challenging diagnostic dilemmas 

• discuss the differential diagnosis 

• review methods used to identify the underlying diagnosis 

• develop a treatment plan specific to the underlying diagnosis 

4:30 PM 

Temporal Arteritis with a “Twist” 

Ashima Makol, MD 

4:45 PM 

A Devastating Rash 

Andreea M. Harsanyi, MD 

5:00 PM 

Gout of Lumbar Spine 

Sangeetha Pabolu, MD 

5:15 PM 

Steroid-Resistant Systemic Lupus Erythematosus 

Cristina Arriens, MD 

PM 

PS 

PM PS 

Hall E 

Update on Psoriatic Arthritis and the 

Spondylarthropathies 

Moderators: Shelly P. Kafka, MD and Philip Mease, MD 


• review updated information on the assessment and treatment 

of psoriatic arthritis 

• describe the rationale and value of the new classification 

criteria for the spondylarthropathies including the new 

assessment criteria for axial spondylarthropathies and its 

utility in “treating to target” 

• identify the bone and enthesial pathology, including erosion, 

enthesial calcification, and syndesmophyte formation in 

spondylarthropathies, treatment implications, and the role 

imaging modalities 

4:30 PM 

Current State of the Art and Future Directions in the 

Assessment and Management of Psoriatic Arthritis 

Philip Mease, MD 

5:00 PM 

New Approaches for the Classification and Assessment of the 


Desiree Van Der Heijde, MD, PhD 

5:30 PM 

The Paradox of Pathologic Bone Erosions and Bone Formation 

in the Spondylarthropathies: Clinical Implications 

Christopher T. Ritchlin, MD, MPH 


4:30 - 6:00 PM 

202 B 

Fibromyalgia and Soft Tissue Disorders I 

Moderators: Daniel J. Clauw, MD and Dane Cook, PhD 

4:30 PM 

801. Symptom Improvement in Fibromyalgia Patients Is 

Related to Reduced Network Connectivity As Measured by EEG 

Coherence 

Jeffrey B. Hargrove 1 , Robert M. Bennett 2 , Daniel J. Clauw 3 , 

George Mashour 3 and Lauren Briggs 4 , 1 Kettering University, Flint, 

MI, 2 Oregon Health & Science Univ, Portland, OR, 3 University 

of Michigan, Ann Arbor, MI, 4 Grand Valley State University, 

Allendale, MI 

4:45 PM 

802. Milnacipran Reduces Brain Activity During Pain in 

Fibromyalgia 

Anson E. Kairys, Richard E. Harris, Eric Ichesco, Johnson P. 

Hampson, Steven Harte, Daniel J. Clauw and Tobias Schmidt- 

Wilcke, University of Michigan, Ann Arbor, MI 

SUNDAY 


5:30 PM 

A Boy with Monoarthritis 

Philip J. Hashkes, MD, MSc 

5:45 PM 

An Old Friend Revisited 

Shawn Rose, MD, PhD 

5:00 PM 

803. Frontal Brain Connectivity to the Default Mode Network 

Is Associated with Subjective Fatigue Irrespective of Pain and 

Depression 

Johnson P. Hampson 1 , Daniel J. Clauw 1 , Jieun Kim 2 , Vitaly 

Napadow 3 and Richard E. Harris 1 , 1 University of Michigan, 

Ann Arbor, MI, 2 Athinoula A. Martinos Center for Biomedical 

Imaging, Charlestown, MA, 3 Martinos Center for Biomedical 

Imaging, Charlestown, MA 


SUNDAY 


5:15 PM 

804. A Comparison of the Nociceptive Flexion Reflex, Pressure 

Algometry and Summated Widespread Pain in the Diagnosis of 

Fibromyalgia 

Robert M. Bennett 1 , Kim D. Jones 2 and Janice Hoffman 3 , 1 Oregon 

Health & Science Univ, Portland, OR, 2 Oregon Health Sciences 

University, Portland, OR, 3 Oregon Health & Science University, 

Portland, OR 

5:30 PM 

805. Milnacipran Increases Cortical to Brainstem Connectivity 

During Pain in Fibromyalgia 

Eric Ichesco, Tobias Schmidt-Wilcke, Anson E. Kairys, Johnson P. 

Hampson, Steven E. Harte, Daniel J. Clauw and Richard E. Harris, 

University of Michigan, Ann Arbor, MI 

5:45 PM 

806. Posterior Insula Combined Glutamate and Glutamine Is 

Associated with Pain in Fibromyalgia: A Replication Study 

Eric Ichesco, Daniel J. Clauw, Steven E. Harte, Anson E. Kairys, 

Johnson P. Hampson, Tobias Schmidt-Wilcke and Richard E. 

Harris, University of Michigan, Ann Arbor, MI 

Salon B 

Imaging of Rheumatic Diseases I: Ultrasound and 

X-ray 

Moderators: Ralf G. Thiele, MD and Wolfgang A. Schmidt, MD 

4:30 PM 

807. Predictors of Rheumatoid Arthritis: Quantitative and 

Semiquantitative Sonographic Measurements of Peripheral 

Joints 

Flavia S. Machado, Rita N.V. Furtado, Rogerio D. Takahashi, Ana 

Leticia P. de Buosi and Jamil Natour, Universidade Federal de São 

Paulo, São Paulo, Brazil 

4:45 PM 

808. Power Doppler Is Predictive of Treatment Failure in Early 

Rheumatoid Arthritis Patients: A One Year Follow-up Study 

Karine R. Luz, Rita N.V. Furtado, Marcelo M. Pinheiro, Giovanna 

S. Petterle and Jamil Natour, Universidade Federal de São Paulo, 

São Paulo, Brazil 

5:00 PM 

809. Ultrasonography Predicts Achievement of Deeper 

Remission After DAS28-Based Clinical Remission of Rheumatoid 

Arthritis 

Ryusuke Yoshimi, Maasa Hama, Daiga Kishimoto, Reikou 

Watanabe, Takeaki Uehara, Yukiko Asami, Atsushi Ihata, Atsuhisa 

Ueda, Mitsuhiro Takeno and Yoshiaki Ishigatsubo, Yokohama City 

University Graduate School of Medicine, Yokohama, Japan 

5:15 PM 

810. Assessment of Omeract Global Power Doppler 

Ultrasonography 44-Joint Scoring System and Reduced Joint 

Scoring Systems in Rheumatoid Arthritis Patients Treated with 

Abatacept Plus Background Methotrexate 

MA D’Agostino 1 , R. Wakefield 2 , H. Berner Hammer 3 , O. Vittecoq 4 , 

M. Galeazzi 5 , P. Balint 6 , E. Filippucci 7 , I. Moller 8 , A. Iagnocco 9 , 

E. Naredo 10 , Mikkel Ostergaard 11 , C. Gaillez 12 , K. Van Holder 13 , 

M. Le Bars 12 and OMERACT-US Task Force 14 , 1 AP-HP Ambroise 

Pare Hospital, Boulogne-Billancourt, France, 2 University of 

Leeds, Leeds, United Kingdom, 3 Diakonhjemmet Hospital, 

Oslo, Norway, 4 University Hospital, Rouen, France, 5 University 

of Siena, Siena, Italy, 6 National Institute, Budapest, Hungary, 

7 

University Politecnica delle Marche, Ancona, Italy, 8 Instituto 

Poal, Barcelona, Spain, 9 Sapienza Università di Roma, Roma, 

Italy, 10 Hospital Severo Ochoa, Madrid, Spain, 11 Copenhagen 

University Hospital at Glostrup, Glostrup, Denmark, 12 Bristol- 

Myers Squibb, Rueil Malmaison, France, 13 Bristol-Myers Squibb, 

Braine-L’Alleud, Belgium, 14 Paris 

5:30 PM 

811. The Relationship Between Power Doppler 

Ultrasonography Outcomes and Clinical Efficacy in Abatacept- 

Treated Patients with Rheumatoid Arthritis and in Inadequate 

Response to Methotrexate 

MA D’Agostino 1 , R. Wakefield 2 , H. Berner Hammer 3 , O. Vittecoq 4 , 

M. Galeazzi 5 , P. Balint 6 , E. Filippucci 7 , I. Moller 8 , A. Iagnocco 9 , E. 

Naredo 10 , Mikkel Ostergaard 11 , C. Gaillez 12 , K. Van Holder 13 , M. Le 

Bars 12 and OMERACT Ultrasound Task Force 14 , 1 AP-HP Ambroise 

Pare Hospital, Boulogne-Billancourt, France, 2 University of 

Leeds, Leeds, United Kingdom, 3 Diakonhjemmet Hospital, 

Oslo, Norway, 4 University Hospital, Rouen, France, 5 University 

of Siena, Siena, Italy, 6 National Institute, Budapest, Hungary, 

7 

University Politecnica delle Marche, Ancona, Italy, 8 Instituto 

Poal, Barcelona, Spain, 9 Sapienza Università di Roma, Roma, 

Italy, 10 Hospital Severo Ochoa, Madrid, Spain, 11 Copenhagen 

University Hospital at Glostrup, Glostrup, Denmark, 12 Bristol- 

Myers Squibb, Rueil Malmaison, France, 13 Bristol-Myers Squibb, 

Braine-L’Alleud, Belgium, 14 Paris 

5:45 PM 

812. Intravenous Golimumab Inhibits Radiographic Progression 

and Maintains Clinical Efficacy and Safety in Patients with 

Active Rheumatoid Arthritis Despite Methotrexate Therapy: 

1-Year Results of a Phase 3 Trial 

Michael Weinblatt 1 , Clifton O. Bingham III 2 , Alan Mendelsohn 3 , 

Lenore Noonan 3 , Shihong Sheng 3 , Lilianne Kim 3 , Kim Hung 3 , 

Jiandong Lu 3 , Daniel Baker 3 and Rene Westhovens 4 , 

1 

Rheumatology & Immunology, Brigham & Women’s Hospital, 

Boston, MA, 2 Johns Hopkins University, Baltimore, MD, 3 Janssen 

Research & Development, LLC, Spring House, PA, 4 University 

Hospital KU Leuven, Leuven, Belgium 

152 A 

Metabolic and Crystal Arthropathies: Clinical 

Moderators: Michael A. Becker, MD and Fernando Perez-Ruiz, 

MD, PhD 

4:30 PM 

813. Rilonacept for Gout Flare Prophylaxis in Patients with 

Chronic Kidney Disease: Analysis of 3 Clinical Trials 

Robert Terkeltaub 1 , Robert R. Evans 2 , Steven P. Weinstein 2 , 

Richard Wu 3 and H. Ralph Schumacher 4 , 1 VA Medical Ctr, San 

Diego, CA, 2 Regeneron Pharmaceuticals Inc, Tarrytown, NY, 

3 

Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 4 University of 

Pennsylvania and VA Medical Center, Philadelphia, PA 

50 

2012 Program Book

4:45 PM 

814. Familial Aggregation and Heritability of Gout in Taiwan: A 

Nationwide Population Study 

Chang-Fu Kuo 1 , Matthew J. Grainge 1 , Lai-Chu See 2 , Kuang- 

Hui Yu 3 , Shue-Fen Luo 3 , Ana M. Valdes 4 , Weiya Zhang 1 and 

Michael Doherty 1 , 1 University of Nottingham, Nottingham, 

United Kingdom, 2 Chang Gung University, Taoyuan, Taiwan, 

3 

Chang Gung Memorial Hospital, Taoyuan, Taiwan, 4 St. Thomas’ 

Hospital, King’s College London, London, United Kingdom 

5:00 PM 

815. Exploratory Analysis of Radiographic Change in Patients 

Treated with Intensive Urate-Lowering Therapy 

Nicola Dalbeth 1 , Anthony Doyle 1 , Fiona M. McQueen 1 , John 

S. Sundy 2 and Herbert S. B. Baraf 3 , 1 University of Auckland, 

Auckland, New Zealand, 2 Duke University Medical Center, 

Durham, NC, 3 Arthritis & Rheumatism Associates, Wheaton, MD 

5:15 PM 

816. Glomerular Filtration Rate, Chronic Kidney Disease and 

Incidence of Physician Diagnosed Gout 

Eswar Krishnan, Stanford University, Stanford, CA 

5:30 PM 

817. Feasibility of Using a Pharnacist-Based Gout Management 

Clinic to Improve Serum Uric Acid in Gout Patients an a Large 

Prepaid Health Plan 

Robert D. Goldfien 1 , Michele S. Ng 2 , Goldie M. Yip 2 , Alice 

Hwe 2 , Alice Pressman 2 and Andy L. Avins 2 , 1 Kaiser Permanente, 

Richmond, CA, 2 Kaiser Permanente, Oakland, CA 

5:45 PM 

818. Levotofisopam Has Uricosuric Activity and Reduces Serum 

Urate Levels in Patients with Gout 

Robert J. Noveck 1 , Zongyao Wang 1 , Ann Forsthoefel 1 , Kristina 

Sigmon 1 , Pauliana C. Hall 2 , John C. Keogh 3 and John S. Sundy 1 , 

1 

Duke University Medical Center, Durham, NC, 2 PCH Integrated 

Regulatory Services, Inc., Laguna Niguel, CA, 3 Keogh Medical 

Writing, Philadelphia, PA 

150 B 


Moderators: Willem F. Lems, MD and Chad L. Deal, MD 

4:30 PM 

819. Trajectories of Change in Physical Function: Effects On 

Fractures and Mortality 

Kamil E. Barbour 1 , Li-Yung Lui 2 , Deborah E. Barnes 3 , Kristine 

E. Ensrud 4 , Anne B. Newman 5 , Kristine Yaffe 3 , Steven R. 

Cummings 6 and Jane A. Cauley 5 , 1 Centers for Disease Control 

and Prevention, Atlanta, GA, 2 California Pacific Medical Center, 

San Francisco, CA, San Francisco, 3 University of California San 

Francisco, San Francisco, CA, San Francisco, CA, 4 University 

of Minnesota and Minneapolis VAHS, Minneapolis, MN, 

Minneapolis, MN, 5 University of Pittsburgh, Pittsburgh, PA, 6 San 

Francisco Coordinating Center, CPMC Research Institute, San 

Francisco, CA 

4:45 PM 

820. In Rheumatoid Arthritis Incident Fractures Are Associated 

with an Increased Risk of Cardiovascular Events 

Orla Ni Mhuircheartaigh, Cynthia S. Crowson, Sherine E. Gabriel, 

Veronique L. Roger, L. Joseph Melton III and Shreyasee Amin, 

Mayo Clinic, Rochester, MN 

5:00 PM 

821. Association of Serum Uric Acid and Incident Fractures in 

Elderly Men 

Nancy E. Lane 1 , Neeta Parimi 2 , Barton Wise 3 , Peggy Cawthon 4 , 

Eric Orwoll 5 and MrOS Investigators Group 6 , 1 UC Davis School 

of Medicine, Sacramento, CA, 2 CPMC Research Institute, SF, CA, 

3 

UC Davis, School of Medicine, Sacramento, CA, 4 CPMC Research 

Institute, San Francisco, CA, 5 Portland, OR, 6 Sacramento, CA 

5:15 PM 

822. Greater Than Expected Increased Mortality Following 

Fragility Fractures in Women and Men with Rheumatoid 

Arthritis 

Shreyasee Amin, Sherine E. Gabriel, Sara J. Achenbach, Elizabeth 

J. Atkinson and L. Joseph Melton III, Mayo Clinic, Rochester, MN 

5:30 PM 

823. Positive Effects of Tocilizumab On Bone Remodeling in 

Patients with Rheumatoid Arthritis 

Karine Briot 1 , Thierry Schaeverbeke 2 , Fabien Etchepare 3 , Philippe 

Gaudin 4 , Aleth Perdriger 5 , Muriel Vray 6 , Stephanie Rouanet 7 , 

Ghislaine Steinberg 7 and Christian Roux 1 , 1 Paris Descartes 

University, Paris, France, 2 Groupe Hospitalier Pellegrin, 

Bordeaux, France, 3 G.H. Pitié-Salpêtrière, Paris, France, 4 CHU 

Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, 

5 

Hôpital Sud, Rennes, France, 6 Paris, France, 7 Roche, Neuilly sur 

Seine, France 

5:45 PM 

824. Progressive Improvements in Cortical Mass and Thickness 

throughout the Hip Were Observed with Denosumab 

Treatment in the Freedom Trial 

Ken Poole 1 , Graham Treece 1 , Andrew Gee 1 , Jacques P. Brown 2 , 

Michael R. McClung 3 , Andrea Wang 4 and Cesar Libanati 4 , 

1 

University of Cambridge, Cambridge, United Kingdom, 2 CHUQ- 

CHUL Research Centre, Quebec City, QC, 3 Oregon Osteoporosis 

Center, Portland, OR, 4 Amgen Inc., Thousand Oaks, CA 


Rheumatoid Arthritis - Clinical Aspects II: Long-term 

Outcome of Rheumatoid Arthritis, Observational 

Studies 

Moderators: Eric M. Ruderman, MD and Lin A. Brown, MD 

4:30 PM 

825. Osteoporosis and Vertebral Fractures Are Important 

Determinants of Cardiovascular Disease in Rheumatoid 

Arthritis 

Ausaf Mohammad 1 , Derek Lohan 1 , Diane Bergin 1 , Sarah 

Mooney 1 , John Newell 2 , Martin O’Donnell 1 , Robert J. Coughlan 1 

and John J. Carey 1 , 1 Galway University Hospitals, Galway, Ireland, 

2 

National University of Ireland, Galway, Ireland 

SUNDAY 



SUNDAY 


4:45 PM 

826. Predictors of Return to Work During 3 Years After Start of 

First Tumor Necrosis Factor Antagonist in a National Cohort of 

Biologics-Treated Patients with Rheumatoid Arthritis 

Tor Olofsson 1 , Ingemar F. Petersson 2 , Jonas Eriksson 3 , Martin 

Englund 2 , Pierre Geborek 1 , Lennart T.H. Jacobsson 4 , Johan 

Askling 3 and Martin Neovius 3 , 1 Department of Clinical Sciences 

Lund, Section of Rheumatology, Lund University, Lund, 

Sweden, 2 Department of Orthopedics, Clinical Sciences Lund, 

Lund University, Lund, Sweden, 3 Clinical Epidemiology Unit, 

Department of Medicine, Karolinska Institutet, Stockholm, 

Sweden, 4 Department of Rheumatology and Inflammation 

Research, Sahlgrenska Academy at University of Gothenburg, 

Gothenburg, Sweden 

5:00 PM 

827. Sustained Development of Cardiovascular Disease in 

Rheumatoid Arthritis Despite Cardioprotective Treatment: The 

10-Year Prospective Carre-Study 

Alper M. van Sijl 1 , Inge A.M. van den Oever 1 , Mike J.L. Peters 2 , 

Vokko P. van Halm 3 , Alexandre E. Voskuyl 2 , Yvo M. Smulders 2 

and Mike T. Nurmohamed 1 , 1 Jan van Breemen Research Institute 

| Reade, Amsterdam, Netherlands, 2 VU University Medical 

Center, Amsterdam, Netherlands, 3 Academic Medical Centre, 


5:15 PM 

828. Association between Anti-Tumor Necrosis Factor Therapy 

and the Risk of Ischemic Stroke in Subjects with Rheumatoid 

Arthritis. Results From the British Society for Rheumatology 

Biologics Registers-Rheumatoid Arthritis (BSRBR-RA) 

Audrey S. Low 1 , Mark Lunt 2 , Louise K. Mercer 1 , James B. 

Galloway 1 , Rebecca Davies 3 , Kath D. Watson 4 , British Society 

for Rheumatology Biologics Register (BSRBR) control centre 

consortium 1 , Deborah P. Symmons 1 , William G. Dixon 1 , Kimme 

L. Hyrich 3 and On behalf of the BSRBR 5 , 1 Arthritis Research UK 

Epidemiology Unit, The University of Manchester, Manchester, 

United Kingdom, 2 University of Manchester, Manchester 

Academic Health Science Centre, Manchester, United Kingdom, 

3 

Arthritis Research UK Epidemiology Unit, Manchester, United 

Kingdom, 4 Arthritis Research UK Epidemiology Unit, University 

of Manchester, Manchester, United Kingdom, 5 British Society for 

Rheumatology, London, United Kingdom 

5:30 PM 

829. Subcutaneous Nodules Are Significantly Associated with 

Cardiovascular Events in Patients with Rheumatoid Arthritis: 

Results From a Very Large US Registry 

Prashant Kaushik 1 , Susan P. Messing 2 , Jyoti Arora 2 , George 

Reed 3 , Katherine C. Saunders 4 , Jeffrey D. Greenberg 5 and Joel 

M. Kremer 6 , 1 Sratton VAMC, Albany, NY, 2 University of Rochester 

School of Medicine and Dentistry, Rochester, NY, 3 UMass Medical 

School, Worcester, MA, 4 CORRONA, Inc., Southborough, MA, 

5 

New York University School of Medicine, New York, NY, 6 Albany 

Medical College and The Center for Rheumatology, Albany, NY 

5:45 PM 

830. Five-Year Favourable Outcome of Patients with Early 

Rheumatoid Arthritis in the 2000s: Data From the Espoir Cohort 

Bernard G. Combe 1 , Nathalie Rincheval 2 , Joelle Benessiano 3 , 

Francis Berenbaum 4 , Alain G. Cantagrel 5 , Jean-Pierre Daurès 2 , 

Maxime Dougados 6 , Patrice Fardellone 7 , Bruno Fautrel 8 , Rene- 

Marc Flipo 9 , Philippe M. Goupille 10 , Francis Guillemin 11 , Xavier X. 

Le Loet 12 , Isabelle Logeart 13 , Xavier Mariette 14 , Olivier Meyer 15 , 

Philippe Ravaud 16 , Alain Saraux 17 , Thierry Schaeverbeke 18 and 

Jean Sibilia 19 , 1 Hopital Lapeyronie, Montpellier, France, 2 Institut 

Universitaire de Recherche Clinique, Montpellier, France, 

3 

Rheumatology, Paris Unervisity Hospital BICHAT, Paris, France, 

4 

AP-HP, St Antoine Hospital, Paris, France, 5 Hopital Purpan, 

Toulouse CEDEX 9, France, 6 Paris-Descartes University, APHP, 

Cochin Hospital, Paris, France, 7 C.H.U. D’Amiens, Amiens, France, 

8 

APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, 9 Hopital 

R Salengro CHRU, Lille CEDEX, France, 10 Hopital Trousseau, 

Tours, France, 11 Faculte de Medecin/BP 184, Vandoeuvre-les- 

Nancy, France, 12 CHU de ROUEN, Rouen, France, 13 Pfizer, Paris, 

France, 14 Université Paris-Sud, Le Kremlin Bicetre, France, 

15 

Hopital Bichat, Paris, France, 16 Hotel Dieu University hospital, 

Paris, France, 17 CHU de la Cavale Blanche, Brest Cedex, France, 

18 

Groupe Hospitalier Pellegrin, Bordeaux, France, 19 CHU 

Hautepierre, Strasbourg, France 

Ballroom A 


Biologics and Gene Therapy: Efficacy and Safety of 

Novel Entities 

Moderators: Patrick Hoffstetter, MD and Andrew J. Head, MD 

4:30 PM 

831. A Randomized, Double-Blind, Placebo-Controlled, 

Multiple-Dose Study to Evaluate the Safety, Tolerability, and 

Efficacy of Brodalumab (AMG 827) in Subjects with Rheumatoid 

Arthritis and an Inadequate Response to Methotrexate 

Karel Pavelka 1 , Yun Chon 2 , Richard Newmark 2 , Ngozi Erondu 2 and 

Shao- Lee Lin 2 , 1 Institute and Clinical of Rheumatology, Charles 

University, Prague, Czech Republic, 2 Amgen Inc, Thousand Oaks, 

CA 

4:45 PM 

832. Peroxisome Proliferator-Activated Receptor Gamma 

Agonist Treatment for Rheumatoid Arthritis: A Proof-of- 

Concept Randomized Controlled Trial 

Michelle J. Ormseth, Annette M. Oeser, Andrew Cunningham, 

Aihua Bian, Ayumi Shintani, S. Bobo Tanner and C. Michael Stein, 

Vanderbilt Medical Center, Nashville, TN 

5:00 PM 

833. A Phase 1 , Randomized, Double-Blind, Placebo-Controlled 

Multiple-Dose Study of Intravenous Staphylococcal Protein A 

in Patients with Active Rheumatoid Arthritis On Methotrexate: 

Safety, Pharmacokinetics and Efficacy 

Edward Bernton 1 , Eduard Krantz 2 and William Gannon Jr. 3 , 

1 

Protalex Inc., Summit, NJ, 2 Parexel Clinical Pharmacology, 

Bloemfontein, South Africa, 3 Capital City Technical Consulting, 

Inc., Washington, DC 

5:15 PM 

834. Cetrorelix, a Gonadotropin-Releasing Hormone 

Antagonist, Significantly Reduces Tumour-Necrosis-Factor- 

Alpha and Demonstrates Efficacy in Patients with Active 

Rheumatoid Arthritis: A Proof-of-Concept, Double-Blind, 

Randomised Trial 

52 

2012 Program Book

Anita Kåss 1 , Øystein T. Førre 2 , Morten Fagerland 2 , Hans Christian 

Gulseth 3 , Peter Torjesen 4 and Ivana Hollan 5 , 1 University of Oslo, 

Oslo, Norway, 2 Oslo University Hospital, Oslo, Norway, 3 Betanien 

Hospital, Skien, Norway, 4 Oslo University Hospital, Norway, 

5 

Lillehammer Hospital for Rheumatic Diseases, Lillehammer, 

Norway 

5:30 PM 

835. Low Doses of Ocaratuzumab, a Fc- and Fab-Engineered 

Anti-CD20 Antibody, Result in Rapid and Sustained Depletion 

of Circulating B-Cells in Rheumatoid Arthritis Patients 

Adrienne O’Reilly, Tracy Davis and Vinay Jain, Mentrik Biotech, 

Dallas, TX 

5:45 PM 

836. Clinical Responses and Patient Reported Outcomes to 

NNC0109-0012 (anti-IL-20 mAb) in Rheumatoid Arthritis (RA) 

Patients Following 12-Weeks Dosing and 13 Weeks Follow up: 

Results From a Phase 2a Trial 

Ladislav ŠEnolt 1 , Marie Göthberg 2 , Xavier Valencia 3 and Eva 

Dokoupilova 4 , 1 Institute of Rheumatology, Prague, Czech 

Republic, 2 Novo Nordisk, A/S, Soeborg, Denmark, 3 Novo Nordisk, 

Inc., Princeton, NJ, 4 Medical Plus s.r.o, Uherske Hradiste, Czech 

Republic 

Ballroom B 

Systemic Lupus Erythematosus - Clinical Aspects and 

Treatment I: Renal 

Moderators: Jennifer M. Grossman, MD and Anca Askanase, 

MD, MPH 

4:30 PM 

837. Response to MMF Therapy for Lupus Nephritis Is 

Independent of Genetic Variation of Inosine Monophosphate 

Dehydrogenase 

Noa Schwartz 1 , Tejaskumar Patel 1 , Ellen M. Ginzler 2 , Neil 

Solomons 3 , Jill P. Buyon 4 and Robert M. Clancy 1 , 1 New York 

University School of Medicine, New York, NY, 2 SUNY-Downstate 

Medical Center, Brooklyn, NY, 3 Vifor Pharma, 4 NYU School of 

Medicine, New York, NY 

4:45 PM 

838. Association of Urinary and Serum Soluble Fn14 Levels and 

TWEAK Levels with Lupus Nephritis Disease Activity 

Irene Blanco 1 , Ping Wu 2 , Timothy S. Zheng 3 , Shawn Weng 4 , 

Jennifer S. Michaelson 5 , Linda C. Burkly 5 and Chaim Putterman 1 , 

1 

Albert Einstein College of Medicine, Bronx, NY, 2 Biogen Idec, 

Inc, Cambridge, MA, 3 Biogen Idec Inc, Cambridge, MA, 4 Biogen 

Idec, Inc., Cambridge, MA, 5 Biogen Idec, Cambridge, MA 

5:00 PM 

839. Urinary Levels of High Mobility Group Box 1 Protein Are 

Elevated in Patients with Active Lupus Nephritis, and Correlate 

with Renal Histopathology 

Irene Blanco 1 , Neelakshi Jog 2 , Chaim Putterman 1 , Iris Lee 2 and 

Roberto Caricchio 3 , 1 Albert Einstein College of Medicine, Bronx, 

NY, 2 Temple University, Philadelphia, PA, 3 Temple Univ Med 

Office Bldg, Philadelphia, PA 

5:15 PM 

840. Do Serum Hepcidin 25 Levels Predict SLE Renal or Non- 

Renal Flares? 

Alexandra Friedman 1 , Nicholas Young 1 , Paul Jensen 2 , Xiaolin 

Zhang 2 , Wael N. Jarjour 3 , Brad H. Rovin 2 , Daniel Birmingham 2 , 

Lee Hebert 2 and Stacy P. Ardoin 3 , 1 The Ohio State University 

Medical Center, Columbus, OH, 2 Ohio State University Medical 

Center, Columbus, OH, 3 Ohio State University, Columbus, OH 

5:30 PM 

841. Effect of Partial and Complete Proteinuria Recovery in 

Lupus Nephritis On Long Term Outcomes 

Zahi Touma, Murray B. Urowitz, Dominique Ibanez and D. D. 

Gladman, Toronto Western Hospital and University of Toronto, 

Toronto, ON 

5:45 PM 

842. Partial and Complete Recovery From Proteinuria in Lupus 

Nephritis Patients Receiving Standard of Care Treatment 

Zahi Touma, D. D. Gladman, Dominique Ibanez and Murray B. 

Urowitz, Toronto Western Hospital and University of Toronto, 

Toronto, ON 

145 A 

Systemic Lupus Erythematosus - Human Etiology and 

Pathogenesis I 

Moderators: Alessandra Pernis, MD and Vasileios C. Kyttaris, MD 

4:30 PM 

843. Interferon Regulatory Factor 5 Associates with Systemic 

Lupus Erythematosus Through Two Distinct and Independent 

Effects 

Erin Zoller 1 , Leah C. Kottyan 1 , Bahram Namjou 1 , Samuel 

Vaughn 1 , Miranda C. Marion 2 , Carl D. Langefeld 2 , Marta E. 

Alarcon-Riquelme 3 , Juan-Manuel Anaya 4 , Elizabeth E. Brown 

on behalf of PROFILE 5 , Sang-Cheol Bae 6 , Jeffrey C. Edberg 7 , 

Patrick M. Gaffney 8 , Diane L. Kamen 9 , Robert P. Kimberly 5 , Chaim 

O. Jacob 10 , Joan T. Merrill 11 , Kathy Moser Sivils 11 , Michelle A. 

Petri 12 , Rosalind Ramsey-Goldman 13 , John D. Reveille 14 , Anne M. 

Stevens 15 , Betty P. Tsao 16 , Luis M. Vila 17 , Timothy J. Vyse 18 and 

Kenneth M. Kaufman 1 , 1 Cincinnati Children’s Hospital Medical 

Center, Cincinnati, OH, 2 Wake Forest School of Medicine, 

Winston-Salem, NC, 3 Oklahoma Medical Research Foundation, 

Center for Genomics and Oncological Research Pfizer-University 

of Granada-Junta de Andalucia, Oklahoma City, OK, 4 Universidad 

del Rosario-Corporacion para Investigaciones Biologicas, Bogota, 

Colombia, 5 University of Alabama at Birmingham, Birmingham, 

AL, 6 Hanyang University Hospital for Rheumatic Diseases, Clinical 

Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South 

Korea, 7 Department of Medicine, University of Alabama at 

Birmingham, Birmingham, AL, 8 Arthritis & Clinical Immunology 

Program, Oklahoma Medical Research Foundation, Oklahoma 

City, OK, 9 Arthritis & Clinical Immunology Program, Oklahoma 

Medical Research Foundation, Charleston, SC, 10 Department 

of Medicine, Keck School of Medicine, University of Southern 

California, Los Angeles, CA, 11 Oklahoma Medical Research 

Foundation, Oklahoma City, OK, 12 Johns Hopkins University 

School of Medicine, Baltimore, MD, 13 Northwestern University 

Feinberg School of Medicine, Chicago, IL, 14 Univ of Texas 

SUNDAY 



Health Science Center at Houston, Houston, TX, 15 University 

of Washington, Seattle, WA, 16 UCLA School of Medicine, Los 

Angeles, CA, 17 University of PuertoRico Medical Sciences 

Campus, San Juan, PR, 18 Divisions of Genetics and Molecular 

Medicine and Immunology, King’s College London, London, 

United Kingdom 

Carolina, Charleston, SC, 14 Arthritis & Clinical Immunology 

Program, Oklahoma Medical Research Foundation, Charleston, 

SC, 15 Department of Biostatistical Sciences, Wake Forest 

University Health Sciences, Winston-Salem, NC, 16 National 

Defense Medical Center, Taipei, 17 Seoul National University 

Hospital, Seoul, South Korea 

SUNDAY 


4:45 PM 

844. Toll-Like Receptor 9-Independent and Immune Complex- 

Independent Interferon-α Production by Neutrophils Upon 

Netosis in Response to Circulating Chromatin 

Dennis Lindau 1 , Julie Mussard 2 , Armin Rabsteyn 1 , Matthieu 

Ribon 2 , Ina Kötter 3 , Annette Igney 3 , Gosse Adema 4 , Marie- 

Christophe Boissier 5 , Hans-Georg Rammensee 1 and Patrice 

Decker 2 , 1 University of Tübingen, Institute for Cell Biology, 

Tübingen, Germany, 2 University of Paris 13, Sorbonne Paris 

Cité, Bobigny, France, 3 Department of Internal Medicine II, 

Rheumatology Division, Tübingen, Germany, 4 Nijmegen Centre 

for Molecular Life Sciences, Nijmegen, Netherlands, 5 Avicenne 

Hospital, Rheumatology Department, Bobigny, France 

5:00 PM 

845. Systemic Lupus Erythematosus Immune Complexes 

Upregulate the Expression of CD319 and CD229 On 

Plasmacytoid Dendritic Cells 

Niklas Hagberg 1 , Jakob Theorell 2 , Gunnar V. Alm 3 , Maija-Leena 

Eloranta 1 , Yenan Bryceson 2 and Lars Rönnblom 1 , 1 Section of 

Rheumatology, Uppsala University, Uppsala, Sweden, 2 Center for 

Infectious Medicine, Karolinska Institutet, Stockholm, Sweden, 

3 

Swedish University of Agricultural Sciences, Uppsala, Sweden 

5:15 PM 

846. Preferential Binding to Elk-1 by SLE-Associated IL10 Risk 

Allele up-Regulates IL10 Expression 

Daisuke Sakurai 1 , Jian Zhao 1 , Yun Deng 1 , Jennifer A. Kelly 2 , Kathy 

Moser Sivils 2 , Kenneth M. Kaufman 3 , Elizabeth E. Brown on 

behalf of PROFILE 4 , Marta E. Alarcón-Riquelme on behalf of 

BIOLUPUS and GENLES network 5 , John B. Harley 6 , Sang-Cheol 

Bae 7 , Chaim O. Jacob 8 , Timothy J. Vyse 9 , Timothy B. Niewold 10 , 

Patrick M. Gaffney 11 , Judith A. James 12 , Robert P. Kimberly 4 , 

Gary S. Gilkeson 13 , Diane L. Kamen 14 , Carl D. Langefeld 15 , Deh- 

Ming Chang 16 , Yeong Wook Song 17 , Weiling Chen 1 , Jennifer M. 

Grossman 1 , Bevra H. Hahn 1 and Betty P. Tsao 1 , 1 David Geffen 

School of Medicine University of California Los Angeles, 

Los Angeles, CA, 2 Oklahoma Medical Research Foundation, 

Oklahoma City, OK, 3 Cincinnati Children’s Hospital Medical 

Center, Cincinnati, OH, 4 University of Alabama at Birmingham, 

Birmingham, AL, 5 Centro de Genómica e Investigación 

Oncológica Pfizer-Universidad de Granada-Junta de Andalucía 

(GENYO), Granada, Spain and Oklahoma Medical Research 

Foundation, Oklahoma City, OK, 6 Cincinnati Children’s Hospital 

Medical Center; US Department of Veterans Affairs Medical 

Center, Cincinnati, OH, 7 Hanyang University Hospital for 

Rheumatic Disease, Clinical Research Center for Rheumatoid 

Arthritis (CRCRA), Seoul, 8 Keck School of Medicine, University 

of Southern California, Los Angeles, CA, 9 King’s College London, 

London, United Kingdom, 10 University of Chicago, Chicago, IL, 

11 

Arthritis & Clinical Immunology Program, Oklahoma Medical 

Research Foundation, Oklahoma City, OK, 12 Oklahoma Medical 

Research Foundation and Oklahoma University Health Sciences 

Center, Oklahoma City, OK, 13 Medical University of South 

5:30 PM 

847. Enhanced ROCK Activation in Patients with Systemic Lupus 

Erythematosus 

Josephine Isgro 1 , Sanjay Gupta 2 , Tanya M. Pavri 2 , Roland 

Duculan 2 , Kyriakos A. Kirou 2 , Jane E. Salmon 2 and Alessandra 

B. Pernis 2 , 1 Morgan Stanley Children’s Hospital of New-York 

Presbyterian, Columbia University Medical Center, New York, NY, 

2 

Hospital for Special Surgery, New York, NY 

5:45 PM 

848. Targeting Glycosphingolipid Biosynthesis Normalises 

T Lymphocyte Function in Patients with Systemic Lupus 

Eyrthematosus 

Georgia McDonald 1 , Laura Miguel 1 , Cleo Hall 1 , David A. 

Isenberg 1 , Anthony I. Magee 2 , Terry Butters 3 and Elizabeth C. 

Jury 1 , 1 University College London, London, United Kingdom, 

2 

Imperial College London, London, United Kingdom, 3 University 

of Oxford, Oxford, United Kingdom 

146 C 

Systemic Sclerosis, Fibrosing Syndromes, and 

Raynaud’s – Clinical Aspects and Therapeutics I 

Moderators: Murray Baron, MD and Ami A. Shah, MD, MHS 

4:30 PM 

849. The Risk of Cardiovascular Disease in Systemic Sclerosis: A 

Population-Based Cohort Study 

Ada Man 1 , Yanyan Zhu 1 , Yuqing Zhang 2 , Maureen Dubreuil 1 , 

Young Hee Rho 1 , Christine Peloquin 1 , Robert W. Simms 1 and 

Hyon K. Choi 3 , 1 Boston University School of Medicine, Boston, 

MA, 2 Boston University, Boston, MA, 3 Boston University School 

of Medicine, University of British Columbia, Arthritis Research 

Centre of Canada, Boston, MA 

4:45 PM 

850. Elevation of KL-6 At Early Disease Course Predicts 

Subsequent Deterioration of Pulmonary Function in Patients 

with Systemic Sclerosis and Interstitial Lung Disease 

Masataka Kuwana 1 , Tsutomu Takeuchi 1 and Junichi Kaburaki 2 , 

1 

Keio University School of Medicine, Tokyo, Japan, 2 Shinakasaka 

Clinic, Tokyo, Japan 

5:00 PM 

851. An Evidence-Based Screening Algorithm for Pulmonary 

Arterial Hypertension in Systemic Sclerosis 

James R. Seibold 1 , Christopher D. Denton 2 , Ekkehard Grünig 3 , 

Diana Bonderman 4 , Oliver Distler 5 , Dinesh Khanna 6 , Ulf 

Müller-Ladner 7 , Janet E. Pope 8 , Madelon C. Vonk 9 , Martin 

Doelberg 10 , Harbajan Chadha-Boreham 10 , Harald Heinzl 4 , Daniel 

M. Rosenberg 10 , Vallerie McLaughlin 6 and John G. Coghlan 2 , 

1 

Scleroderma Research Consultants LLC, Avon, CT, 2 Royal 

Free Hospital, London, United Kingdom, 3 University Hospital, 

Heidelberg, Germany, 4 Medical University of Vienna, Vienna, 

54 

2012 Program Book

Austria, 5 University Hospital Zurich, Zurich, Switzerland, 

6 

University of Michigan, Ann Arbor, MI, 7 Kerckhoff-Klinik GmbH, 

Bad Nauheim, Germany, 8 Western University of Canada, 

St. Joseph’s Health Care, London, ON, 9 Radboud University 

Nijmegen Medical Centre, Nijmegen, Netherlands, 10 Actelion 

Pharmaceuticals Ltd, Allschwil, Switzerland 

5:15 PM 

852. C-Reactive Protein Predicts Long-Term Progression of 

Interstitial Lung Disease and Survival in Patients with Early 

Systemic Sclerosis 

Xiaochun Liu 1 , Maureen D. Mayes 1 , John D. Reveille 2 , Emilio 

B. Gonzalez 3 , Brock E. Harper 3 , Hilda T. Draeger 4 and Shervin 

Assassi 5 , 1 University of Texas Health Science Center at Houston, 

Houston, TX, 2 Univ of Texas Health Science Center at Houston, 

Houston, TX, 3 University of Texas Medical Branch, Galveston, TX, 

4 

Univ of TX Health Sci Ctr, San Antonio, TX, 5 Univ of Texas Health 

Science Houston, Houston, TX 

5:30 PM 

853. Systemic Sclerosis Classification Criteria: Developing 

Methods for Multi-Criteria Decision Analysis 

Sindhu R. Johnson 1 , Raymond P. Naden 2 , Jaap Fransen 3 , Frank 

H.J. van den Hoogen 4 , Janet E. Pope 5 , Murray Baron 6 , Alan G. 

Tyndall 7 , Marco Matucci-Cerinic 8 and Dinesh Khanna on behalf 

of ACR/EULAR Classification Criteria SSc 9 , 1 Toronto Western 

Hospital, Toronto, ON, 2 Auckland City Hospital, Auckland, New 

Zealand, Austria, 3 Radboud University Nijmegen Medical Centre, 

Nijmegen, Netherlands, 4 Department of Rheumatology, Sint 

Maartenskliniek, Nijmegen, Netherlands, 5 St. Joseph Health 

Care London, London, ON, 6 Jewish General Hospital, Montreal, 

QC, 7 University of Basel, Basel, Switzerland, 8 Univ Florence, 

Firenze, Italy, 9 University of Michigan, Ann Arbor, MI 

5:45 PM 

854. Anti-EIF2B: A Novel Interstitial Lung Disease Associated 

Autoantibody in Patients with Systemic Sclerosis 

Zoe Betteridge 1 , Felix Woodhead 2 , Christopher Bunn 3 , 

Christopher D. Denton 4 , David J. Abraham 5 , Sujal Desai 6 , Roland 

du Bois 7 , Athol U. Wells 8 and Neil McHugh 1 , 1 Royal National 

Hospital for Rheumatic Diseases, Bath, United Kingdom, 

2 

University Hospitals Coventry and Warwickshire, Coventry, 

United Kingdom, 3 Royal Free Hospital, London, United Kingdom, 

4 

Royal Free and University College Medical School, London, 

England, 5 UCL Medical School, London, United Kingdom, 6 Kings 

College Hosptial, London, United Kingdom, 7 National Jewish 

Health, Denver, 8 Royal Brompton Hospital, United Kingdom 

147 A 

Vasculitis: Pathogenesis 

Moderators: Paul A. Monach, MD, PhD and Maria C. Cid, MD 

4:30 PM 

855. Identification of a Burkholderia-Like Strain From Temporal 

Arteries of Subjects with Giant Cell Arteritis 

Curry L. Koening 1 , Bradley J. Katz 2 , Jose Hernandez-Rodriguez 3 , 

Marc Corbera-Bellalta 4 , Maria C. Cid 4 , Herbert P. Schweizer 5 , 

Dean Li 2 , Jerry Kaplan 2 , Gary S. Hoffman 6 and Ivana De 

Domenico 2 , 1 Salt Lake City Veterans Administration, Salt Lake 

City, UT, 2 University of Utah, Salt Lake City, UT, 3 Hospital Clínic. 

University of Barcelona. IDIBAPS, Barcelona, Spain, 4 Vasculitis 

Research Unit. Hospital Clínic. University of Barcelona. IDIBAPS, 

Barcelona, Spain, 5 Colorado State University, Fort Collins, CO, 

6 

Cleveland Clinic, Cleveland, OH 

4:45 PM 

856. Am80, a Retinoic Acid Receptor Agonist, Ameliorates 

Murine Vasculitisthrough the Suppression of Neutrophil 

Migration and Activation 

Chie Miyabe 1 , Yoshishige Miyabe 1 , Noriko Miura 2 , Kei Takahashi 3 , 

Yuya Terashima 4 , Etsuko Toda 4 , Fumiko Honda 1 , Tomohiro 

Morio 1 , Naohito Ohno 2 , Jun-ichi Suzuki 4 , Mitsuaki Isobe 1 , Kouji 

Matsushima 4 , Ryoji Tsuboi 5 , Nobuyuki Miyasaka 1 and Toshihiro 

Nanki 1 , 1 Tokyo Medical and Dental University, Tokyo, Japan, 

2 

School of Pharmacy, Tokyo University of Pharmacy and Life 

Science, Tokyo, Japan, 3 Toho University Ohashi Medical Center, 

Tokyo, Japan, 4 The University of Tokyo, Tokyo, Japan, 5 Tokyo 

Medical University, Tokyo, Japan 

5:00 PM 

857. Impairment of the Inhibitory PD-1-PD-L1 Axis in Giant Cell 

Arteritis (GCA) 

Mazen Nasrallah 1 , Augusto Vaglio 2 , Shalini Mohan 1 , Bjorn 

Hartmann 1 , Joyce Liao 3 , Kenneth J. Warrington 4 , Jorg J. Goronzy 5 

and Cornelia M. Weyand 6 , 1 Stanford University, Stanford, CA, 

2 

University of Parma, Parma, Italy, 3 Stanford University, Palo 

Alto, CA, 4 Mayo Clinic, Rochester, MN, 5 Stanford Univ School of 

Medicine, Stanford, CA, 6 Stanford University School of Medicine, 

Stanford, CA 

5:15 PM 

858. Dense Genotyping, Imputation, and Regression Analysis 

Identifies Multiple Independent Genetic Susceptibility Loci 

within the HLA Region in Behcet’s Disease 

Travis Hughes 1 , Adam Adler 2 , Patrick S. Coit 1 , Vuslat Yilmaz 3 , 

Kenan Aksu 4 , Nursen Duzgun 5 , Gokhan Keser 4 , Ayse Cefle 6 , 

Ayten Yazici 6 , Andac Ergen 7 , Erkan Alpsoy 8 , Carlo Salvarani 9 , 

Bruno Casali 10 , Ina Koetter 11 , Javier Gutierrez-Achury 12 , Cisca 

Wijmenga 12 , Haner Direskeneli 13 , Guher Saruhan-Direskeneli 14 

and Amr H. Sawalha 1 , 1 University of Michigan, Ann Arbor, MI, 

2 

Oklahoma Medical Research Foundation, Oklahoma City, OK, 

3 

Istanbul University, Istanbul Faculty of Medicine, Department 

of Physiology, Istanbul, Turkey, 4 Ege University, Izmir, Turkey, 

5 

Ankara University, Ankara, Turkey, 6 Kocaeli University, Kocaeli, 

Turkey, 7 Okmeydaný Research and Education Hospital, Istanbul, 

Turkey, 8 Akdeniz University, Antalya, Turkey, 9 Arcispedale S 

Maria Nuova. IRCCS, Reggio Emilia, Italy, 10 Molecular Biology 

Laboratory, Arcispedale S. Maria Nuova,, Reggio Emilia, Italy, 

11 

University Hospital, Tuebingen, Germany, 12 University Medical 

Hospital Groningen, University of Groningen, Groningen, 

Netherlands, 13 Marmara University, School of Medicine, 

Istanbul, Turkey, 14 Istanbul University, Istanbul Faculty of 

Medicine, Istanbul, Turkey 

5:30 PM 

859. WITHDRAWN 

5:45 PM 

860. Interleukin-21, B Cell Activating Factor and Unmethylated 

CpG Oligodeoxynucleotides Synergize in Promoting Anti- 

Proteinase 3 Autoantibody Production in vitro 


SUNDAY 

November 11, 2012

Nikola Lepse 1 , Judith Land 1 , Abraham Rutgers 1 , Cees G.M. 

Kallenberg 1 , Coen A. Stegeman 1 , Peter Heeringa 2 and Wayel H. 

Abdulahad 1 , 1 University Medical Center Groningen, Groningen, 

Netherlands, 2 University Medical Center Groningen, PM PS Netherlands 

160 

Temporal Arteritis (030) 

Speaker: Gene G. Hunder, MD 

SUNDAY 



4:30 - 6:00 PM 










September 14. 

148 

*Ankylosing Spondylitis: 2012 Update (021) 

Speaker: Michael H. Weisman, MD 

153 

*Antiphospholipid Syndrome (022) 

Speaker: Munther A. Khamashta, MD 

ARHP SESSIONS 

4:30 - 6:00 PM 

201 

PM 

PS 

Income Inequities Are Perilous to People with 

Arthritis 

Moderator: Charles G. Helmick, MD 


• characterize the social and economic burden of poverty 

among U.S. adults with arthritis 

• describe the characteristics of U.S. adults with arthritis with 

income insufficiency 

• explain the association between employment status and 

income 

• outline policies and interventions that can reduce the 

susceptibility to job loss and poverty and its adverse effects 

for U.S. adults with arthritis 

4:30 PM 

Introduction 

Charles G. Helmick, MD 

154 A 

Crystal: Diagnosis and Management of Gout (023) 

Speaker: Theodore R. Fields, MD 

154 B 

Immunodeficiency Syndromes (024) 

Speaker: Alton Melton, MD 

4:45 PM 

Magnitude of Socio-economic Inequities among People with 

Arthritis 

Louise Murphy, PhD 

5:10 PM 

Socio-economic Characteristics of People with Arthritis in the 

U.S. Medical Expenditure Panel Survey 

Edward H. Yelin, PhD 

155 

Pain: Evaluation and Treatment of Back Pain (025) PM 

Speaker: David G. Borenstein, MD 

PS 

5:35 PM 

Characteristics of U.S. Adults with Income Insufficiency 

Kristina A. Theis, BA, MPH 

56 

158 A 

*Psoriatic Arthritis (026) 

Speaker: Arthur Kavanaugh, MD 

158 B 

Pulmonary Hypertension in the Rheumatic Diseases 

(027) 

Speaker: Dinesh Khanna, MD, MSc 

159 A 

*Rheumatoid Arthritis: Challenging Cases(028) 

Speaker: Jonathan Kay, MD 

159 B 

*Rheumatoid Arthritis: Outcome Measures in Clinical 

Practice (029) 

Speaker: J. Timothy Harrington, MD 


PM PS 

204 A 

Practice Management: Patients as Partners in Design 

and Delivery (Practice Management Series) 



• outline the steps in establishing a Patient and Family Advisory 

Council 

• assess the benefits of engaging patients and family members 

in decision-making 

• describe the Patient and Family Advisory Council’s role in 

designing a safe, healing environment 

4:30 PM 


Delivery 

Janet Porter, PhD 

5:15 PM 


Delivery 

Martie Carnie, AS, PFAC


4:30 - 6:00 PM 

206 

Pediatrics: Disease Flares 

Moderators: Thuy T. Beam, RN and Janalee Taylor, MSN 

4:30 PM 

861. A Family Based Pedometer Walking Program in an 

Adolescent Population with Juvenile Idiopathic Arthritis 

Sara M. Stern, Jill R. Blitz, Amber Richards and Katherine AB 

Marzan, Children’s Hospital Los Angeles, Los Angeles, CA 

4:45 PM 

862. What Is the Impact of a Transition Program On 

Adolescents with Juvenile Idiopathic Arthritis and Their 

Parents ? 

Deborah Hilderson 1 , Rene Westhovens 2 , Rik Joos 3 , Carine H. 

Wouters 2 and Philip Moons 4 , 1 University Hospital Leuven, KU 

Leuven, Leuven, Belgium, 2 University Hospital KU Leuven, 

Leuven, Belgium, 3 University Hospital Gent, Ghent, Belgium, 4 KU 

Leuven, Leuven, Belgium 

5:00 PM 

863. Employment of a Needs Assessment Survey to Shape 

a Novel Web-Based Pediatric Rheumatology Curriculum for 

Primary Care Providers 

Amy L. Woodward and Z. Leah Harris, Vanderbilt University 

School of Medicine, Nashville, TN 

4:45 PM 

867. Events That Trigger the Onset of the Fibromyalgia 

Syndrome (FMS) 

Robert S. Katz 1 , Sharon M. Ferbert 2 , Alexandra Small 3 and 

Susan Shott 1 , 1 Rush University Medical Center, Chicago, IL, 

2 

Advocates for Funding Fibromyalgia Treatment, Education and 

Research(AFFTER), Libertyville, IL, 3 University of Illinois Medical 

School 

5:00 PM 

868. Illness Perceptions Among Patients with Different Forms 

of Vasculitis 

Peter C. Grayson 1 , Naomi Amudala 1 , Carol McAlear 2 , Renée 

Leduc 3 , Denise Shereff 3 , Rachel Richesson 3 , Liana Fraenkel 4 and 

Peter A. Merkel 5 , 1 Boston University Medical Center, Boston, 

MA, 2 Vasculitis Clinical Research Consortium, University of 

Pennsylvania, Philadelphia, 3 University of South Florida, 

Tampa, FL, 4 Yale University School of Medicine, Veterans Affairs 

Connecticut Healthcare System, New Haven, CT, 5 University of 

Pennsylvania, Philadelphia, PA 

5:15 PM 

869. Concepts Which Determine Health in a Positive Way 

Are Important to People with Rheumatoid Arthritis and Are 

Covered by Some Patient-Reported Outcome Instruments 

Mona Dür 1 , Michaela Coenen 2 , Josef S. Smolen 3 and Tanja A. 

Stamm 1 , 1 Medical University of Vienna, Vienna, Austria, 2 Ludwig- 

Maximilians-University, Munich, Germany, 3 Medical University 

of Vienna and Hietzing Hospital, Vienna, Austria 

SUNDAY 


5:15 PM 

864. Will I Waste Your Time? Delays in Help-Seeking for RA 

Flares 

Caroline A. Flurey 1 , Marianne Morris 1 , Jon Pollock 1 , Rodney 

A. Hughes 2 , Pamela Richards 3 and Sarah Hewlett 1 , 1 University 

of the West of England, Bristol, United Kingdom, 2 St. Peters 

Hospital, Chertsey Surrey, United Kingdom, 3 University of Bristol, 

Bristol, United Kingdom 

5:30 PM 

865. A Methodology for Estimating Disease State Transitions: 

Repeated Measures Markov Models with Covariate 

Dependence 

George W. Reed 1 , Andrew S. Koenig 2 , Katherine C. Saunders 3 , 

David H. Collier 4 , Joel M. Kremer 5 and Sameer Kotak 6 , 1 University 

of Massachusetts Medical School, Worcester, MA, 2 Pfizer Inc., 

Collegeville, PA, 3 CORRONA, Inc., Southborough, MA, 4 Amgen 

Inc., Thousand Oaks, CA, 5 Albany Medical College and The 

Center for Rheumatology, Albany, NY, 6 Pfizer Inc., New York, NY 

140 A 

Psychological Aspects of Rheumatologic Disease 

Moderators: Carol M. Greco, PhD and Karen L. Smarr, PhD 

4:30 PM 

866. Pain Is Associated with Telomere Shortening in Women 

with Fibromyalgia 

Afton L. Hassett 1 , Daniel J. Clauw 1 , Richard E. Harris 1 , Steven E. 

Harte 1 , Anson E. Kairys 1 , Steven Buyske 2 and David A. Williams 1 , 

1 

University of Michigan, Ann Arbor, MI, 2 Rutgers University, 

Piscataway, NJ 

5:30 PM 

870. To Love and to Hold: Men Describe Parenting in the 

Presence of Inflammatory Arthritis 

Catherine L. Backman 1 and Alana Longson 2 , 1 University of British 

Columbia, Vancouver, BC, 2 Arthritis Research Centre of Canada, 

Vancouver, BC 

5:45 PM 

871. Depression Predicts Mortality in RA 

Christina Bode 1 , Chris Tonner 2 , Laura Trupin 3 and Patricia P. 

Katz 4 , 1 University of Twente, Enschede, Netherlands, 2 UCSF, San 

Francisco, CA, 3 UC San Francisco, San Francisco, CA, 4 Univercity 

of California San Francisco, San Francisco, CA 

INDUSTRY-SUPPORTED SYMPOSIA 

6:30 - 9:30 PM 

These symposia are both CME-accredited and non-CME 

company-directed programs. For CME-accredited symposia, 

the sponsoring organization is responsible for planning and 

providing CME credit. All non-CME programs are wholly 

sponsored and supported by commercial entities. Please visit the 

organization’s exhibit booth, the industry-supported symposia 

booth or see page 317 for more information. 


MONDAY 


MONDAY, NOVEMBER 12, 2012 


6:30 am - 6:00 PM 


ACR SESSIONS 

7:30 - 8:30 AM 

Hall D 

PM PS 

Clinicopathologic Conference: A Patient with 

Hepatitis C and Inflammatory Polyarticular 

Arthritis 

Moderator: Victoria K. Shanmugam, MBBS 


• discuss the evaluation of patients with hepatitis C presenting 

with polyarticular inflammatory arthritis and review the 

differential diagnosis of inflammatory diseases seen in 

patients with hepatitis C 

• interpret synovial fluid findings in the context of the clinical 

care of complex patients 

• review the evaluation of immunosuppressed patients with 

inflammatory arthritis and the typical and atypical infections 

which should be considered 

7:30 AM 

Case Presentation 

Gail S. Kerr, MD 

7:40 AM 

Hepatitis C Associated Immune Diseases 


7:50 AM 

Gout in the Inpatient Setting 


8:00 AM 

Synovial Fluid Analysis 

Jack Lichy, MD 

8:10 AM 

Septic Arthritis in the Immunocompromised Host 

Debra Benator, MD 

8:20 AM 

Discussion 


PM PS 


Cross-Sectional Imaging Techniques for 

Rheumatology 

Moderator: Carol A. Langford, MD, MHS 

Speaker: John Carrino, MD, MPH 


• describe the physical basis underlying the cross-sectional 

imaging modalities 

• appreciate the relative strengths and weaknesses of each 

imaging modality 

• identify common clinical pathologies on each modality 

• know the current indications and potential future applications 

of computed tomography, magnetic resonance imaging and 

ultrasound 

PM PS 

Ballroom A 

Immune Tolerance: From Theory and Clinical 

Practice 

Moderator: Andrew P. Cope, MD, PhD 

Speaker: John D. Isaacs, MD, PhD 


• review the pivotal immunological studies that underpin our 

current understanding of immune tolerance 

• discuss the key molecular and cellular players responsible 

for maintaining a state of immunological tolerance, and 

how these are likely to form the basis for assays of immune 

tolerance in the clinical laboratory 

• review therapeutic approaches currently under evaluation for 

inducing a clinical state of operational tolerance in patients 

with autoimmune disease 

PM PS 

Salon B 

2012 Hench Lecture: Synovial Immunobiology and 

Response to Therapy in Rheumatoid 


Speaker: Paul P. Tak, MD, PhD 


• define mechanisms which promote synovial inflammation in 


• identify markers of clinical response, examining synovial tissue 

before and after therapy initiation 

• identify common mechanism(s) responsible for clinical 

response 

ARHP SESSIONS 

7:30 - 8:30 AM 

201 

Disparities in the Use of Joint Arthroplasty: A 

Pervasive Matter Leading to Inequitable Care 

(Arthroplasty/Joint Replacement Series) 

Moderator: Hazel L. Breland, PhD, OTR/L 

PM 

PS 

PM PS 


• describe the utilization of joint replacement across different 

demographic and sociocultural groups 

• identify conceptual models evaluating mediating factors 

leading to differential health services utilization 

• examine healthcare disparities in the use of joint arthroplasty: 

rates, determinants and the role of patients’ knowledge and 

preferences 

• compare conceptual models and interventions proposed to 

decrease disparities and improve equitable access to care for 

patients with arthritis with an indication for joint arthroplasty 

58 

2012 Program Book

7:30 AM 

Differences in the Utilization of Health Services: Disparity, 

Inequity or Preference? 

Maria E. Suarez-Almazor, MD, PhD 

7:40 AM 

Ethnic Variation in the Use of Joint Arthroplasty 

Said Ibrahim, MD, MPH 

8:00 AM 

Gender and Residence As Determinants of Variation in Joint 

Arthroplasty 

Gillian A. Hawker, MD, MSc 

8:20 AM 

Panel Discussion 

PM PS 

206 

Incorporating Physician Assistants and Nurse 

Practitioners into Rheumatology Practice PM PS 

Moderator: Victoria A. Merrell, MPT, PA-C 


• discuss the benefits of assimilating physician assistants and 

nurse practitioners into rheumatology practice 

• describe the scope of practice in various settings 

• review the approaches to training physician assistants and 

nurse practitioners with limited rheumatology experience 

• discuss the ACR/ARHP online rheumatology training program 

7:30 AM 

A Rheumatologist’s Perspective on Incorporating Advanced 

Practitioners into Rheumatology Practice 

John R. P. Tesser, MD 

7:45 AM 

Nurse Practitioners in Rheumatology 

Kori A. Dewing, DNP, ARNP 

8:00 AM 

Physician Assistants in Rheumatology 

Barbara A. Slusher, PA-C, MSW 

8:15 AM 


PM PS 

204 A 

Infusion Room Information for Medical Professionals 

(Infusion Series) 

Moderator: Aimee Wiener, ARNP, MSN 

Speaker: Sharon Manson, NP 


• describe processes required to ensure reimbursement of 

infusion therapies 

• establish skills required for infusion registered nurses and the 

impact on nursing practice 

• identify issues which impact scheduling and operations of 

infusion rooms 

143 A 

PM PS 

New and Better Habits! Facilitating Patient Selfmanagement 

with Proven Behavior Change 

Strategies PM PS 

Moderator: David A. Williams, PhD 


• compare key elements of behavior change and goal setting 

theories 

• identify and practice brief strategies that can be incorporated 

into clinical visits 

• outline components of Self-management and Recovery 

Training 

• propose strategies for using Self-management and Recovery 

Training 

7:30 AM 

Introduction 


7:36 AM 

Increasing Motivation to Change 


7:54 AM 

Guided Discovery 

Sarah Hewlett, MA, PhD, RN 

8:12 AM 

Goal Setting 

Emma Dures, PhD 

Acr SESSION 

7:30 - 9:00 AM 

PM PS 

202 B 

ILAR – The Current Rheumatology Workforce across 

the Globe 

Moderator: Peter Brooks, MD 


• recognize the shortage in the current rheumatology 

workforce across the globe and the impact it has on the 

patient population 

• describe programs funded by ILAR to address the need to 

advance the development of rheumatology by increasing the 

number of rheumatologists around the world 

7:30 AM 

Review of Current Workforce for Rheumatology in the United 

States 


7:45 AM 

Review of Current Workforce for Rheumatology in the 

Countries of the Americas 

John D. Reveille, MD 

8:00 AM 

Review of Current Workforce for Rheumatology in All 

Countries in Europe 

Maxime Dougados, MD 

MONDAY 



8:15 AM 

Review of Current Workforce for Rheumatology in All Countries 

in the Asia-Pacific 

Zhan-Guo Li, MD 

8:30 AM 

Review of Current Workforce for Rheumatology in All Countries 

in Africa 

Omondi G. Oyoo, MD, MMed 

8:45 AM 

Summary of the Global Rheumatology Workforce 

Peter Brooks, MD 

PM 

PS 

159 A 

Scleroderma: Systemic Sclerosis (038) 

Speaker: Robyn T. Domsic, MD, MPH 

159 B 


Speaker: Michael R. York, MD 

160 

Vasculitis: Update (040) 

Speaker: Paul A. Monach, MD, PhD 

PM 

PS 

MONDAY 



7:45 - 9:15 AM 










September 14. 

148 


Speaker: Michael A. Becker, MD 

153 

*Osteoarthritis: Update 2012 (032) 

Speaker: Joanne M. Jordan, MD, MPH 

ACR/ARHP WORKSHOPS 

7:45 - 9:45 AM 










September 14. 

144 C 

Joint Injections (Knee and Ankle Prosthetics) (216) 

Speakers: Gregory C. Gardner, MD and Kenneth R. Margules, MD 

144 B 

*Musculoskeletal Ultrasound (217) 

Speakers: Eugene Y. Kissin, MD and Amy M. Evangelisto, MD 

154 A 

Pediatric Rheumatology for Adult Rheumatologists 

(033) 

Speaker: Peter A. Nigrovic, MD 

154 B 

Pediatrics: Spondylarthritis in Children (034) 

Speaker: Thomas J. A. Lehman, MD 

155 

Psoriatic Arthritis (035) 

Speaker: M. Elaine Husni, MD, MPH 

158 A 

Rheumatoid Arthritis: Difficult Cases (036) 

Speaker: Stanley B. Cohen, MD 

158 B 

Rheumatoid Arthritis: Difficult Cases (037) 

Speaker: Nancy A. Shadick, MD, MPH 

144 A 

*Peripheral Magnetic Resonance Imaging in 

Rheumatology Practice (218) 

Speakers: Philip G. Conaghan, MD, PhD and Mikkel Ostergaard, 

MD, PhD, DMSc 

149 A 

*X-ray Challenges in Rheumatic Diseases (219) 

Speaker: Donald J. Flemming, MD 

ACR SESSIONS 

9:00 - 10:00 AM 

152 A 

Epigenetic Factors in Autoimmune Disease 

Moderator: Lindsey A. Criswell, MD, MPH 

Speaker: Bruce C. Richardson, MD, PhD 


• describe the different types of epigenetic modifications and 

how they are currently assessed 

PM 

PS 

60 

2012 Program Book

• recognize how epigenetic factors or changes may influence 

disease through changes in gene expression or other 

mechanisms 

• evaluate current and emerging evidence that implicates DNA 

methylation and other epigenetic changes in risk and severity 

of rheumatoid arthritis, systemic lupus erythematosus and 

related diseases 

PM PS 

Hall D 

New Anticoagulants: What a Hematologist Thinks a 

Rheumatologist Needs to Know! 

Moderator: Victoria K. Shanmugam, MBBS 

Speaker: Craig M. Kessler, MD 


• discuss the clinical indications for the various currently 

available anticoagulants 

• discuss the monitoring required for the various anticoagulants 

• describe some of the limitations of the various anticogaulants, 

and how clinicians should select appropriate therapy for their 

patients 



9:00 - 10:00 AM 

Hall E 

PM PS 

Memorial Lectureship: Pathogenesis of Rheumatoid 

Arthritis: The Voyage from Pre-Rheumatoid Arthritis 

to Joint Destruction 

Moderator: Shaun Ruddy, MD 

Speaker: Gary S. Firestein, MD 


• appreciate from a historic perspective the evolution of current 

theories on the causes of rheumatoid arthritis pathogenesis 

• describe how immunogenetic inheritance may lead to the 

development of inflammatory arthritis 

• explain the relationships between different rheumatoid 

arthritis associated autoantibodies and their target antigens 

during pathogenesis 

• describe how improved understanding of pathogenesis has 

led to progressive advancements in therapeutic interventions 

PM PS 

204 A 

Infusion Reactions: Management and Prevention 

(Infusion Series) 

Moderator: Karen Huisinga, MN, ARNP 

Speaker: Christine Elliott, RN 


• discuss the types of infusion reactions that may occur with 

medications used to manage rheumatic diseases 

• review the medications with higher propensity for infusion 

reactions 

• identify medications that require pretreatment and discuss 

measures that may be taken to assist with preventing infusion 

reactions 

• outline the management of infusion reactions from mild 

reactions to anaphylaxis 

201 

PM PS 

Issues in the Management of Rheumatic Disease 

in Patients Undergoing Joint Replacement 

(Arthroplasty/Joint Replacement Series) 


Speaker: Brian F. Mandell, MD, PhD 


• explain the major medical issues that should be assessed and 

optimized pre-operatively 

• recognize the rheumatology specific issues that must be 

addressed pre-operatively 

• discuss the data and current standard of care to help guide 

clinicians in the use of NSAIDs, DMARDs and biologics, as well 

as drugs for osteoporosis before and after surgery 

206 

Rheumatic Disease Update: Gout 

Moderator: Afton L. Hassett, PsyD 

Speaker: Naomi Schlesinger, MD 


• describe current conceptualizations of clinical manifestations, 

diagnostic procedures and pathophysiology of gout 

• identify common concerns of patients with gout 

• discuss evidence-based treatment strategies to promote 

optimal outcomes in patients with gout 

PM 

PS 

MONDAY 


ARHP SESSIONS 

9:00 - 10:00 AM 

143 A 

Clinical Trials: Participation and Recruitment 

Moderator: Meenakshi Jolly, MD, MS 

Speaker: Alan J. Kivitz, MD, CPI 


• identify challenges facing sponsors in recruiting patients 

• identify challenges facing sites in recruiting patients 

• describe what sponsors are doing in response to these 

challenges 

• discuss what sites can adopt to recruit patient for clinical trials 

PM 

PS 

ACR SESSIONS 

9:00 - 10:30 AM 

150 B 

Creating an Efficient Rheum Practice 

Moderator: C. Ryan Antolini, MD 

Speaker: Owen J. Dahl, MBA, FACHE, CHBC, LSSMBB 


• identify common opportunities to improve practice/ 

procedure efficiency 

• identify the person or process constraint in your office, and 

possible ways to leverage or manage that constraint 

• describe the concept of continuous flow 

• recognize strategies to reduce waste and inefficiency 

PM 

PS 


PM 

PS 

147 A 

Legislative Update from Capitol Hill 

This session is not eligible for CME credit. 

Moderator: Timothy Laing, MD 

Speaker: The Honorable Chris Van Hollen, U.S. Representative 

(MD – 8th District) 


• describe the latest developments in federal health policy 

• discuss legislative initiatives currently before Congress and 

how outcomes could affect the rheumatology community 

• recognize the value of engaging in grassroots advocacy with 

members of Congress 

• discuss new approaches to teaching in the rheumatic and 

musculoskeletal diseases 

• explain the unique and important roles of the clinician scholar 

educator in medical education and training 

9:00 AM 

A Web-based, Problem-based Learning: Rheumatology 

Curriculum for Medical Students, Internal Medicine Residents 

and Rheumatology Fellows 

Abby Abelson, MD 

9:18 AM 

Focusing on Basics: Regional Musculoskeletal Modules 

Jessica Berman, MD 

MONDAY 


207 A 

PM PS 

Update on Safety Issues in the Treatment of 

Rheumatic Diseases – From the Food and Drug 

Administration and Beyond PM PS 

Moderators: Arthur Kavanaugh, MD and Michael H. Weisman, 

MD 


• identify important safety issues in the drug treatment of 


• integrate knowledge of new safety issues into their treatment 

strategies 

• more fully advise patients about the safety issues related to 

treatments for rheumatic diseases 

• become aware of evolutions at the Food and Drug 

Administration that will affect drug safety monitoring and 

reporting 

9:00 AM 

Introduction – Update on Newly Identified Drug Safety Issues 

and Initiatives from the ACR Drug Safety Subcommittee 

John J. Cush, MD 

9:25 AM 

Update and Safety Issues of Recently Approved Agents for 

Rheumatic Diseases 

Larissa Lapteva, MD, MHS 

9:50 AM 

The Year in Review- Update on Safety Issues at the FDA for the 

Last 12 Months 

Sally M. Seymour, MD 

10:15 AM 

Question & Answer 



PM PS 

9:00 - 10:30 AM 

145 A 

Clinician Scholar Educator Presentations 

Moderators: Michael J. Battistone, MD and Kenneth S. O’Rourke, 

MD 


• discuss novel approaches to curriculum development for 

medical students and residents in the musculoskeletal and 


9:36 AM 

Web-based Interactive Rheumatology Experience (WIRE) 

Christopher E. Collins, MD 

9:54 AM 

Development of a Multimodal Rheumatology Elective: A 

Controlled Study 

Deana M. Lazaro, MD 

10:12 AM 

A Modular Curriculum in Pediatric Rheumatology for Residents, 

Pediatricians and Adult Specialists 

Amy L. Woodward, MD, MPH 

ACR/ARHP POSTER SESSION B, THIEVES’ 

MARKET POSTERS, AND POSTER TOURS 

9:00 AM - 6:00 PM 


(abstracts # 872 - 1592). Poster tours will be held 9:00 - 9:45 AM 

and 10:15 - 11:00 AM. Morning snacks will be available from 

9:00 - 10:30 AM. 


Thieves’ Market Posters 

Thieves’ Market posters feature cases with interesting imaging 

studies or pictorial displays of physical findings. 

A Case of Juvenile Arthritis 

Krati Chauhan, MD, MPH 

A Case of Perplexing Weakness 

Andreea Harsanyi, MD 

Development of Leprosy after Treatment with IL6 Blocker 

Basma Al Nahlawi, MD; Samina Hayat, MD; Mamatha Katikaneni, 

MD and Anita S. Mathew, MD 

Headaches and Heartaches 

Bansai Gujar, MD 

Mass Effect 

Bansai Gujar, MD 

Stridor 

Cristina Gale Arriens, MD 

Voriconazole-induced Periostitis 

Anna Gramling, MD 

62 

2012 Program Book





leaders. Tours are complimentary; however, registration 

is required and is limited to scientific attendees. If you 

preregistered for a tour, you should have received a ticket with 














the tour. 

9:00 - 9:45 AM 

ARHP Patient Care and Clinically-Focused Research (312) 

Tour Guide: Elizabeth G. Salt, PhD 

Orthopedics, Low Back Pain and Rehabilitation (313) 

Tour Guide: Jeffrey N. Katz, MD 


Tour Guide: Neal S. Birnbaum, MD 


and Treatment (315) 

Tour Guide: Atul A. Deodhar, MD 

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s: 

Clinical Aspects and Therapeutics (316) 

Tour Guide: Murray Baron, MD 

Vasculitis (317) 

Tour Guide: Alexandra Villa-Forte, MD, MPH 

10:15 - 11:00 AM 

Fibromyalgia and Soft Tissue Disorder (318) 

Tour Guide: Don L. Goldenberg, MD 

Osteoarthritis - Clinical Aspects (319) 

Tour Guide: Joanne M. Jordan, MD, MPH 

Rheumatoid Arthritis Treatment - Small Molecules, Biologics 


Tour Guide: Eric M. Ruderman, MD 


Tour Guide: Iain B. McInnes, PhD 


Tour Guide: Eliza F. Chakravarty, MD 

Rheumatology Research Foundation - Health Services/ 

Outcomes Research (323) 

Tour Guide: Michael M. Ward, MD 

Learn about the excellent work being done by Rheumatology 

Research Foundation-funded early career investigators. This is 

also an opportunity for division chiefs looking to recruit junior 

faculty to meet young productive investigators and vice versa. 

EXHIBITS 

10:00 AM - 5:00 PM 




3:00 PM. 

(Booth #1451) 






from 10:30 - 11:15 AM, 12:30 - 1:15 PM and 2:30 - 3:15 PM. 

For a complete listing of Innovation Theater presentations 

see page 316. 

ARHP SESSION 

10:30 - 11:30 AM 

206 

Distinguished Lecturer: Unraveling the “Go-Gene” 


Speaker: Basia Belza, PhD 


• describe the “go-gene” 

• identify facilitators and barriers to adopting and maintaining a 

physically active lifestyle for older adults 

• categorize strategies for adoption and maintenance of regular 

physical activity 

PM PS 

based on the socioecological model 

ACR WORKSHOPS 

10:30 AM - 12:30 PM 










September 14. 

144 B 

Musculoskeletal Exam Skills III: Regional 

Musculoskeletal Examination of the Shoulder and 

Knee (220) 


144 A 


Absorptiometry and Clinical Risk Factors: The New 

Fracture Risk Assessment Algorithm (221) 

Speaker: Stuart L. Silverman, MD 

PM 

PS 

MONDAY 



MONDAY 


PM 

PS 

ACR PLENARY SESSION II – DISCOVERY 

2012 

11:00 AM - 12:30 PM 

Hall E 

Moderators: Carol A. Langford, MD, MHS and Richard M. Pope, 

MD 

11:00 AM 

1593. The Risk of Lymphoma in Patients Receiving Anti-Tumor 

Necrosis Factor Therapy for Rheumatoid Arthritis: Results 

From the British Society for Rheumatology Biologics Register- 


Louise K. Mercer 1 , Mark Lunt 1 , Audrey S. Low 1 , James B. 

Galloway 1 , Kath Watson 1 , William G. Dixon 1 , BSRBR Control 

Centre Consortium 2 , Deborah P. Symmons 1 , Kimme L. 

Hyrich 3 and On behalf of the BSRBR 4 , 1 Arthritis Research UK 


United Kingdom, 2 Manchester, United Kingdom, 3 Arthritis 

Research UK Epidemiology Unit, Manchester, United Kingdom, 

4 

British Society for Rheumatology, London, United Kingdom 

Background/Purpose: The risk of lymphoma is increased in 

people with RA compared to the general population and is 

greatest in severe RA. Anti-TNF therapy is now widely used 

to treat RA, especially severe RA. The aim of this study was to 

determine whether anti-TNF influences the risk of lymphoma 

when used in routine UK clinical practice. 

Methods: The analysis was conducted in the BSRBR-RA, a 

national cohort study. Patients with RA starting treatment 

with the TNF inhibitors etanercept (ETA), infliximab (INF) or 

adalimumab (ADA) and a biologic-naïve comparison cohort 

exposed to non-biologic therapy (nbDMARD) were recruited 

between 2001-2009. Subjects were followed until 09/30/2010, 

first lymphoma or death, whichever came first. Subjects with a 

history of lymphoproliferative malignancy prior to registration 

were excluded. Incident cancers were identified in 3 ways; 

lifelong flagging with national cancer agencies; 6 monthly 

patient and physician questionnaires for 3 years and annual 

physician questionnaires thereafter. Only first lymphoma per 

subject, confirmed by histology or cancer agency, was analysed. 

The rates of lymphoma and non-Hodgkin lymphoma (NHL) in 

the nbDMARD cohort and in patients ever exposed to anti-TNF 

were compared using Cox proportional hazards models adjusted 

using deciles of propensity score (DP) which included baseline 

age, gender, DAS score, HAQ, disease duration, use of steroids, 

current/previous cyclophosphamide, smoking and registration 

date. The first 6 months of follow-up were excluded. There were 

too few Hodgkin lymphoma (HL) to compare rates. 

Results: 84 incident lymphomas were confirmed: 20 in 3465 

nbDMARD-treated subjects and 64 in 11987 anti-TNF (152 

versus 96 per 100000 person-years (pyrs); Table). After adjusting 

using DP there was no difference in risk of lymphoma between 

the cohorts; hazard ratio (HR) for anti-TNF 1.13 (95% CI 0.55, 

2.31). There were 5 (22%) HL in the nbDMARD cohort and 9 

(13%) in anti-TNF. Among 71 NHL, the most frequent subtype 

was diffuse large B cell lymphoma; 8 (50% of NHL) in nbDMARD 

and 25 (45%) anti-TNF. There was no significant difference in risk 

of NHL between the cohorts (table). 

Conclusion: There is no evidence that anti-TNF increases the risk 

of lymphoma over the background risk associated with RA, but 

further follow up is needed to establish if the picture changes 

with time. 

Table 

nbDMARD 

N=3465 

Anti-TNF 

N=11987 

Follow-up (pyrs) 13186 66353 

Median follow-up (pyrs; IQR) 4.5 (2.6, 5.9) 6.4 (4.8, 7.4) 

Age: (years) Mean (SD) 60 (12) 56 (12) 

Gender: N(%) female 2545 (73) 9145 (76) 

RA disease duration: (years) 

Median (IQR) 

6 (1, 15) 11 (6, 19) 

DAS28 score: mean (SD) 5.3 (1.1) 6.6 (1.0) 

HAQ: mean (SD) 1.5 (0.7) 2.0 (0.6) 

Lymphoma: N 20 64 

Lymphoma: Rate per 100000 

pyrs (95% CI) 

Lymphoma: Age and gender 

adjusted HR (95% CI) 

Lymphoma: DP adjusted HR 

(95% CI) 

152 (93, 234) 96 (74, 123) 

Referent 0.71 (0.43, 1.20) 

Referent 1.13 (0.55, 2.31) 

Hodgkin lymphoma: N 4 9 

Hodgkin lymphoma: Rate per 

100000 pyrs (95% CI) 

30 (8, 78) 14 (6, 26) 

Non-Hodgkin lymphoma: N 16 55 

NHL: Rate per 100000 pyrs 

(95% CI) 

NHL: Age and gender adjusted 

HR (95% CI) 

121 (69, 197) 83 (62, 108) 

Referent 0.79 (0.44, 1.40) 

NHL: DP adjusted HR (95% CI) Referent 1.26 (0.58, 2.72) 

Disclosure: L. K. Mercer, None; M. Lunt, None; A. S. Low, None; 

J. B. Galloway, None; K. Watson, None; W. G. Dixon, None; D. 

P. Symmons, None; K. L. Hyrich, None; O. B. O. T. BSRBR, BSR 

Biologcs Register, 2. 

11:15 AM 

1594. Clinical and Radiological Outcomes After One Year of 

Remission Steered Combination Treatment in Patients with 

Early Rheumatoid and Undifferentiated Arthritis 

L. Heimans 1 , K.V.C. Wevers-de Boer 1 , K. Visser 1 , H.K. Ronday 2 , M. 

van Oosterhout 3 , J. H. L. M. Van Groenendael 4 , A.J. Peeters 5 , G. 

Steup-Beekman 6 , G. Collee 7 , P.B.J Sonnaville 8 , B.A. Grillet 9 , Tom 

Huizinga 1 and C.F. Allaart 1 , 1 Leiden University Medical Center, 

Leiden, Netherlands, 2 Haga Hospital, The Hague, Netherlands, 

3 

Groene Hart Hospital, Gouda, Netherlands, 4 Franciscus 

Hospital, Roosendaal, Netherlands, 5 Reinier de Graaf Gasthuis, 

Delft, Netherlands, 6 Bronovo Hospital, Netherlands, 7 MCH, The 

Hague, Netherlands, 8 Admiraal de Ruyter Ziekenhuis, Goes, 

Netherlands, 9 Zorgsaam hospital, Terneuzen, Netherlands 

Background/Purpose: To evaluate the 1 year clinical and 

radiological outcomes of remission steered therapy in early 

arthritis patients treated aiming at remission (DAS

400mg/day, sulphasalazine 2000mg/day and prednisone 7.5mg/ 

day (arm 1) or to adalimumab (ADA) 40mg/2weeks with MTX 

25mg/wk (arm 2). If not in remission after 8 months, patients 

in arm 1 switched to ADA+MTX and patients in arm 2 increased 

ADA to 40mg/week. Proportions of remission and radiological 

progression measured by Sharp-van der Heijde scoring method 

after one year follow up were compared between the different 

treatment strategies. 

Results: After 4 months 375 patients (61%) achieved early 

remission and 221 (36%) did not, of which 161 patients were 

randomized, 83 to arm 1 and 78 to arm 2. In 62 (10%) patients 

the protocol was not followed, 12 were lost to follow up 

after 4 months and in total 34 after 1 year. Of those in early 

remission 361 (96%) tapered prednisone after 4 months and 

200 (53%) tapered MTX after 8 months. After 1 year, remission 

was achieved in 257 (69%) patients and 119 (32%, 20% of all 

patients) were in drug free remission. 

Patients in arm 1 and 2 achieved remission in similar 

proportions after 8 months (30 (36%) versus 27 (35%), p=1.0), 

but after 1 year patients in arm 2 more often achieved remission 

than in arm 1 (32 (41%) vs 21 (25%), p=0.01). Patients in arm 

2 who at 8 months tapered ADA+MTX combination to MTX 

monotherapy, more often remained in remission after one 

year than patients tapering poly-DMARDs+prednisone to MTX 

monotherapy in arm 1 (17/26 (65%) vs 11/30 (37%), p=0.02). 

After failing to achieve remission on poly-DMARDs+prednisone, 

6/24 patients (18%) who switched to ADA achieved remission 

after one year, compared to 8/27 (30%) who failed on ADA+MTX 

and increased ADA (p=0.2). Of the total study population 

53% were in remission after 1 year. Median (IQR) radiological 

damage progression after 1 year was 0(0-0) in patients who 

achieved early remission, and 0(0-0) and 0(0-0) in arms 1 and 2, 

respectively (p=0.2). 

Conclusion: After one year of remission steered combination 

treatment, 53% of the patients with early arthritis achieved 

remission. Patients in early remission after initial treatment 

with MTX and prednisone most often achieved remission after 

one year (69%) and 32% were in drug free remission. Patients 

who failed to achieve early remission benefited more from 

a treatment strategy with adalimumab than with multiple 

DMARDs+prednisone. In this treat-to-remission cohort, 

radiological damage progression after 1 year was negligible in all 

patients. 

Disclosure: L. Heimans, None; K. V. C. Wevers-de Boer, None; K. 

Visser, None; H. K. Ronday, None; M. van Oosterhout, None; J. 

H. L. M. Van Groenendael, None; A. J. Peeters, None; G. Steup- 

Beekman, None; G. Collee, None; P. B. J. Sonnaville, None; B. A. 

Grillet, None; T. Huizinga, None; C. F. Allaart, None. 

11:30 AM 

1595. Genome-Wide Association Study to High-Throughput 

Cell-Based Phenotypic Screen Identifies Novel Chemical 

Inhibitors of CD40 Signaling 

Gang Li 1 , Dorothee Diogo 1 , Di Wu 1 , Jim Spoonamore 2 , 

Rheumatoid Arthritis Consortium International (RACI) 3 , Eli 

Stahl 4 , Nicola Tolliday 2 and Robert M. Plenge 1 , 1 Brigham and 

Women’s Hospital, Boston, MA, 2 Broad Institute, Cambridge, 

MA, 3 Boston, 4 Brigham and Women’s Hospital 

Background/Purpose: Deriving therapeutic targets from human 

genetics linked with biological alterations of risk alleles may 

provide a more successful approach to drug development than 

traditional efforts that focus on biological insight alone. Here, 

we successfully translate a SNP association from a genome-wide 

association study (GWAS) in rheumatoid arthritis (RA) into a 

high-throughput screen (HTS) based on cellular phenotype in a 

human B cell line to identify inhibitors of CD40-mediated NF-κB 

signaling. 

Methods: We fine-map the CD40 risk locus in 7,222 seropositive 

RA patients and 15,870 controls genotyped on the Immunochip, 

together with deep sequencing of CD40 coding exons in 500 

RA cases and 650 controls. We use flow cytometry to measure 

CD40 protein levels on the surface of primary CD19+ from 90 

healthy control individuals. We use gene expression arrays to 

measure CD40 RNA levels in peripheral blood mononuclear 

cells from 1,469 healthy control individuals. We use retroviral 

shRNA infection to perturb the amount of CD40 on the surface 

of a human B lymphocyte cell line (BL2). We develop a highthroughput 

NF-κB luciferase reporter assay in BL2 cells activated 

with trimerized CD40 ligand (tCD40L), and conduct an HTS of 

1,982 chemical compounds and FDA-approved drugs. Counterscreens 

of the top “hit” compounds were performed in the BL2 

line activated with both tCD40L and LPS, and in an additional 

B cell line, Ramos, activated with tCD40L and TNF. Two known 

and two novel compounds were tested for inhibition of tCD40- 

NFkB signaling in primary human CD19+ B cells by measuring 

CD86 expression with flow cytometry. 

Results: A single common SNP at the CD40 locus explains the 

entire signal of association (rs4810485, P=1.4x10-9), without 

any evidence for independent rare variants contributing to 

RA risk. Subjects homozygous for the common RA risk allele 

have ~33% more CD40 on the surface of primary human 

CD19+ B lymphocytes than subjects homozygous for the 

non-risk allele (P=10-9), a finding corroborated by expression 

quantitative trait loci (eQTL) analysis in PBMC’s (P

MONDAY 


France, 3 CCBR, Ballerup, Denmark, 4 Radiology, Medicine and 

Orthopaedic Surgery University of California and Synarc, San 

Francisco, CA, 5 CONROD. The University of Queensland, Royal 

Brisbane and Women’s Hospital, Herston, Queensland, Australia, 

6 

St. Joseph’s Hospital and McMaster University, Hamilton, ON, 

7 

H. Universitario Virgen de la Macarena, Sevilla, Spain, 8 Center 

of Osteoporosis and Osteo-articular Diseases, Bialystock, 

Poland, 9 State Institute of Rheumatology, the Russian Academy 

of Medical Sciences, Moscow, Russia, 10 Hôpital Henri-Mondor, 

Creteil, France, 11 Royal North Shore Hospital, St Leonards, 

Australia, 12 King’s College London, St. Thomas Campus, London, 

United Kingdom, 13 University of Oxford; Southampton General 

Hospital, Southampton, United Kingdom 

Background/Purpose: Treatments for osteoarthritis focus 

on improving symptoms through non-pharmacological and 

pharmacological approaches. Strontium ranelate (SrRan), a 

treatment for osteoporosis, was shown to stimulate cartilage 

matrix formation in vitro, and to reduce radiographic spinal OA 

progression in osteoporotic women with spinal OA. 

The objective of SEKOIA phase III study was to compare 

the efficacy of SrRan with placebo for reducing radiological 

progression of knee OA. 

Methods: SEKOIA is a double-blind, placebo-controlled, 

randomized, 3-year study involving 1683 patients with 

symptomatic primary knee OA (Kellgren and Lawrence [KL] 

grade 2 or 3, joint space width [JSW] 2.5–5 mm) randomly 

allocated to SrRan 1 or 2g/day, or placebo. Primary endpoint 

was radiographic change in JSW of the medial tibiofemoral 

compartment from baseline to LOCF. Group comparisons were 

performed in the ITT using a general linear model with Dunnett’s 

multiple comparison procedure with baseline JSW, center and 

sex as covariates. JSW was measured yearly using a validated 

computer-assisted centralised reading method. Secondary 

endpoints included radiological progression (JSN≥0.5mm) 1 , 

radio-clinical progression (JSN≥0.5mm and WOMAC 

improvement≤20%)2, WOMAC scores, knee pain, and adverse 

events. 

Results: The ITT set included 1371 (82%) patients. Age was 

63±7 years, BMI was 30±5 kg/m2, JSW was 3.5±0.8 mm. 61% 

were KL II. 69% were female. SrRan was associated with less 

progression of cartilage degradation, decrease in JSW was 

–0.23±0.56 mm with 1g/day;–0.27±0.63 mm with 2g/day and 

–0.37±0.59 mm with placebo; estimated differences (SE) were 

0.14(0.04),p

Genova, Italy, 3 Paediatric Rheumatology International Trials 

Organisation–IRCCS [PRINTO], Genoa, Italy, 4 Roche, Welwyn 

Garden City, United Kingdom, 5 Paediatric Rheumatology 

International Trials Organization (PRINTO), Istituto Giannina 

Gaslini, Genova, Italy, 6 Scientific Research Institute of 

Rheumatology RAMS, Moskow, Moskow, Russia, 7 PRINTO, IRCCS 

G. Gaslini, Genoa, Italy, 8 International Investigator Consortium 

for MAS Diagnostic Criteria, Saint-Petersburg, Russia, 9 Centre 

of Pediatric Rheumatology, Sankt Augustin, Germany, 

10 

Necker-Enfants Malades Hospital, Paris, France, 11 Pediatric 


OH, 12 Cincinnati Children’s Hospital, Cincinnati, OH, 13 PRINTO 

and PRSCG, Genoa, Italy 

Background/Purpose: Elevated IL-6 levels are associated 

with disease activity in patients (pts) with juvenile idiopathic 

arthritis (JIA). 1 Tocilizumab (TCZ), an IL-6 receptor inhibitor, was 

evaluated for the treatment of polyarticular-course JIA (pcJIA; 

RF+ and RF– poly- and extended oligoarticular JIA; systemic JIA 

was excluded) in the CHERISH study. 

Methods: CHERISH is a 104-wk study in pts age 2-17 yrs with 

active pcJIA for ≥6 mo who failed MTX. In the first 16 wks, all pts 

received open-label (OL) TCZ every 4 wks (if body weight [BW] 

≥30 kg, 8 mg/kg [n = 119]; if BW

MONDAY 


Center, Kansas City, USA, Kansas City, MO, 5 The Hospital for Sick 

Children, Toronto, ON, 6 NIEHS, NIH, Bethesda, MD, 7 VA Medical 

Ctr, Washington, DC, 8 

Background/Purpose: The Rituximab in Myositis (RIM) Study 

evaluated 200 refractory myositis patients treated with 

rituximab, 83% of whom met the definition of improvement 

(DOI). The aim of this study was to identify the clinical and 

laboratory predictors of response in this cohort. 

Methods: All patients failed corticosteroids and at least 1 other 

immunosuppressive (IS) agent and received rituximab at weeks 

0/1 (Early) or 8/9 (Late). The 1° endpoint in this 44-week trial 

was time to achieve DOI [³20% improvement in 3 of 6 core set 

measures (CSM) (includes manual muscle testing (MMT), muscle 

enzymes, HAQ, patient/parent global, physician global disease 

activity and extramuscular disease activity) with no >2 CSM 

worsening by ³25% (excluding MMT)] at 2 consecutive visits. 

We analyzed the effect of the following baseline variables on 

the time to DOI: myositis subtype, demographics, laboratory 

[IgM, IgG, myositis-associated autoantibodies (MAA), CBC, 

creatinine], damage measures (global, muscle damage and 

atrophy and organ-related), disease activity and other clinical 

parameters (skeletal/GI/pulmonary/muscle disease activity, 

Raynaud, calcinosis, mechanic hands), CSM, medication (early 

vs. late rituximab, IS agents and corticosteroids) and MAA 

subset [anti-synthetase (anti-Syn), Mi-2, SRP, TIF1-γ, MJ, other 

autoantibodies and those without an MAA]. The Wilcoxon test 

was used to univariately evaluate the association of baseline 

variables with the time to DOI. A multivariate time-dependent 

proportional hazard model was built using forward selection 

(α=0.05) based on univariate variables with p

PM PS 

147 A 

Career Opportunities in Rheumatology: Making a 

Choice 

Moderator: Allan C. Gelber, MD 


• provide examples of different career choices available to 

young rheumatologists 

• discuss the pros and cons of the various career choices in 

rheumatology 

11:00 AM 

Basic Research 

Anne Davidson, MBBS 

11:20 AM 

Academic Rheumatology 

Richard Furie, MD 

11:40 AM 

Rheumatology Private Practice 

Joseph Flood, MD 

Noon 

Rheumatologists in Government 

Robert H. Carter, MD 

12:20 PM 

Discussion 

Ballroom C 

PM PS 

New Developments in Systemic Juvenile Idiopathic 

Arthritis Management 

Moderators: Alexei A. Grom, MD and Peter A. Nigrovic, MD 


• review current approaches to management of systemic 

juvenile idiopathic arthritis in North America 

• discuss the main results of the recent clinical trials in systemic 

juvenile idiopathic arthritis and their potential impact on 

systemic juvenile idiopathic arthritis management 

11:00 AM 

Current Practices in Systemic Juvenile Idiopathic Arthritis 

Management Based on the Childhood Arthritis & 

Rheumatology Research Alliance Registry 

Yukiko Kimura, MD 

11:30 AM 

Review of the Recent Phase III Clinical Trials of IL-6 and IL-1 

Inhibiting Biologic Agents in Systemic Juvenile Idiopathic 

Arthritis 

Ronald M. Laxer, MD 

Noon 

Role of New IL-1 and IL-6 Inhibiting Agents in Systemic Juvenile 

Idiopathic Arthritis 

Timothy Beukelman, MD, MSCE 

152 A 

PM PS 

The Connected Rheumatology Practice: Electronic 

Health Record and Social Media Implementation and 

Customization PM PS 

Moderator: Deborah S. Collier, MD 


• identify the key elements in current clinical processes and 

workflow to help select the features of an electronic health 

record that will be most useful for a rheumatology clinical 

practice 

• understand common obstacles in electronic health record 

implementation and identify strategies to mitigate those 

barriers 

• employ strategies to work effectively with an electronic 

health record vendor to incorporate rheumatology-specific 

templates into the electronic health record system 

• design successful marketing campaigns – online and 

traditional 

• examine the platforms, including Twitter, Facebook and 

YouTube and when it makes sense to use them to market your 

practice 

• identify resources for creating and utilizing a web site that 

patients can find and utilize successfully 

11:00 AM 

Things I Wish I Had Known about Implementing an Electronic 

Health Record System 

William M. McClatchey, MD 

11:30 AM 

Tips and Tricks to Optimize an Electronic Health Record System 

for Rheumatology 

Salahuddin Kazi, MD 

Noon 

Using Technology to Engage Patients and Promote Your 

Practice 

Simon Sikorski, MD 



Renaissance Washington - Renaissance Ballroom, East & West 

Networking at Noon 

Sit down with your colleagues over a complimentary lunch, and 

participate in open discussion on various research, practice, 

and clinical topics. Each roundtable discussion will be facilitated 

by a rheumatology expert. All ARHP attendees are welcome to 

participate in this event. 

This session is not eligible for CME credit. 

Roundtable Topics 

• Form Sharing – Adult 

• Form Sharing – Pediatric 

• Arthritis and Employment Issues 

• Clinical Research Coordinators 

• Physical Activity 

• Measurement of Disease Activity 

• Meeting the Needs of Underserved Populations –ECHO 

Program 

MONDAY 



MONDAY 


• Enhancing Patient Adherence 

• Epidemiology/Public Health 

• Advocacy 

• Patients Access to Medications 

• Issues in Healthcare Education 

• Post-surgical Interventions 

• Infusion and Injectable Therapies 

• Medications for Rheumatic Diseases 

• Physician Assistants 

• Nurse Practitioners – Adult 

• Nurse Practitioners – Pediatric 

• Office Nurse 

• Qualitative Research 

• Research Mentoring 

• ARHP Grant/Award Opportunities 

• Pain Management 

• Sleep/Fatigue 

• Social Media to Improve Patient Health Care Models 

• Tele Medicine 

• Electronic Health Records 

• Office Managers/Practice Managers 

• International Issues 

• ARHP Volunteering/Mentoring 

• ARHP Past Presidents 

PM PS 


12:45 - 2:15 PM 










September 14. 

148 

*Ankylosing Spondylitis: 2012 Update (041) 

Speaker: Michael H. Weisman, MD 

153 

*Basic Immunology for Clinical Rheumatologists (042) 

Speaker: Antony Rosen, MD 

154 A 

*Challenging Cases in Osteoporosis Management 

(043) 

Speaker: Kenneth G. Saag, MD, MSc 

154 B 

*Dermatological Manifestations of Rheumatic 

Diseases (044) 

Speaker: Ruth Ann Vleugels, MD 

155 

Hereditary Angioderma (045) 

Speaker: Peter Deane, MD 

158 A 

*Pulmonary Manifestations of Rheumatic Disease 

(046) 

Speaker: Kristin B. Highland, MD, MSCR 

158 B 

Raynaud’s and Digital Ischemia (047) 

Speaker: Janet E. Pope, MD, MPH 

159 A 

Scleroderma Mimics (048) 

Speaker: Faye N. Hant, DO, MSCR 

159 B 

Vaccinations for Patients on Biologic Therapies (049) 

Speaker: Clifton O. Bingham III, MD 

160 


Speaker: Peter A. Merkel, MD, MPH 

ACR SESSIONS 

1:00 - 2:00 PM 

Ballroom A 

PM PS 

Complex Regional Pain Syndrome/Reflex 

Sympathetic Dystrophy: Recent Advances, Current 

Thoughts PM PS 

Moderator: Joel A. Block, MD 

Speaker: Andreas Goebel, MSc, PhD 


• discuss the current thoughts regarding the etiopathogenesis 

of complex regional pain syndrome 

• summarize current knowledge regarding the appropriate 

evaluation of suspected complex regional pain syndrome 

• review potential therapeutic strategies leveraging recent 

knowledge about pathophysiology 

152 A 

PM 

Innovation in Musculoskeletal Curriculum 

Development: Lessons from New Medical Schools 

Moderator: Sharon L. Kolasinski, MD 


• explain the breadth of medical school curricular change 

• identify the goals and objectives of curricular redesign 

• outline expectations for evaluation of medical students 

enrolled in new schools 

1:00 PM 

Creating A New Medical School Curriculum at Hofstra North 

Shore-LIJ 

Veronica M. Catanese, MD, MBA 

PS 

70 

2012 Program Book

1:30 PM 

Creating A New Medical School Curriculum at the University of 

Central Florida 

Shazia Beg, MD 

201 

Pediatric Rheumatology Town Hall Meeting 

Moderator: Marisa S. Klein-Gitelman, MD, MPH 


• delineate the changes scheduled for implementation to the 

American Board of Pediatrics MOC program 

• recognize the current issues affecting the pediatric 

rheumatology community 

• identify various pediatric rheumatology organizations and 

their program of work 

1:00 PM 

Update on the American Board of Pediatrics MOC Program 

Barbara E. Ostrov, MD 

1:30 PM 

Update on ACR activities Involving Pediatric Rheumatology 

Marisa S. Klein-Gitelman, MD, MPH 

1:40 PM 

Update on Childhood Arthritis & Rheumatology Research 

Alliance 

Norman T. Ilowite, MD 

1:50 PM 

Update on Pediatric Rheumatology Collaborative Study Group 

Hermine I. Brunner, MD, MSc, MBA 

PM PS 

Hall E 

Scleroderma Bowel Disease: From Top to Bottom 

(Clinical Review) 

Moderator: Virginia D. Steen, MD 

Speaker: John Clarke, MD 


• review the available data involving the pathophysiology 

and associated complications of gastrointestinal disease in 

scleroderma 

• summarize the diagnostic and therapeutic strategies in the 

management of gastrointestinal dysmotility 

• discuss the management of challenging cases of scleroderma 

bowel disease including the role of parenteral nutrition and 

the data involving novel 

PM PS 

therapeutic targets 


1:15 - 3:15 PM 










September 14. 

PM 

PS 

149 B 

Histopathology of Vasculitis (222) 

Speaker: Allen Burke, MD 

144 C 

Joint Injections (Shoulder and Wrist Prosthetics) (223) 

Speakers: Gregory C. Gardner, MD and Kenneth R. Margules, MD 

144 B 

MRI in the Diagnosis and Management of 

Spondylarthritis: A Clinician’s Guide (224) 

Speaker: Walter P. Maksymowych, MD 

ACR SESSIONS 

2:30 - 4:00 PM 

Hall D 

Curbside Consults - Ask the Professors 

Moderators: Diane L. Kamen, MD, MS and Robert F. Spiera, MD 


• compare their personal management approaches to selected 

clinical problems with those of the presenters 

• describe therapeutic choices and management options for 

several common but difficult complications of Sjögren’s 

syndrome 

• develop an approach to evaluating and managing patients 

presenting with complications attributed to lyme disease 

• appraise the potential impact on fracture risk of various 

treatments for low bone density and when to consider a drug 

holiday 

2:30 PM 

Sjögren’s Syndrome: Challenges in Clinical Practice 

Frederick B. Vivino, MD 

3:00 PM 

Difficult Complications of Lyme Disease 

Robert A. Kalish, MD 

3:30 PM 

To Treat or Not to Treat When Faced with a Bone Density 

Dilemma 

Michael R. McClung, MD 

PM PS 


Macrophage and Dendritic cell Heterogeneity in 

Tissue Inflammation and Fibrosis 



• describe markers in mouse and human for macrophage and 

dendritic cell activation 

• explain the roles various cytokines play on macrophage 

activation 

• review macrophages and dendritic cell subpopulations 

implicated in inflammatory and fibrotic disease 

PM 

PS 


MONDAY 

NOVEMBER 12, 2012

MONDAY 


72 

2:30 PM 

Functional Consequences of Monocyte and Macrophage 

Heterogeneity in Normal and Inflammatory Conditions 

Frederic Geissmann, MD, PhD 

3:00 PM 

Dendritic Cell Subsets: Developmental Heterogeneity and Roles 

in Inflammatory Disease 

Kenneth M. Murphy, MD, PhD 

3:30 PM 

Macrophages and Dendritic Cells in Inflammatory Skin Disease 

Michelle Lowes, MD, PhD 

152 A 

Mechanotransduction in Bone and Cartilage 

Moderator: Richard F. Loeser, MD 


• define how mechanical stimulation of bone regulates 

bone cell function through cell signaling complexes called 

mechanosomes 

• review key mechanotransduction pathways in articular 

cartilage that regulate chondrocyte metabolism and survival 

• describe how knowledge of the biomechanics of joint tissues 

is being used to advance tissue engineering 

2:30 PM 

Mechanosomes as Mediators of Cell Signaling in Bone 

Fredrick Pavalko, PhD 

3:00 PM 

Mechanotransduction Pathways in Articular Cartilage 

Tonia Vincent, MD, PhD 

3:30 PM 

Role of Biomechanics in Tissue Engineering 

Lawrence Bonassar, PhD 

PM PS 

Ballroom C 

Neuropsychiatric Lupus in Children and Adolescents 

Moderator: Karen Onel, MD 


• describe the mechanisms for the development of 

neuropsychiatric lupus 

• summarize the utility of new imaging modalities in diagnosing 

neuropsychiatric 

• review the epidemiology, diagnosis and treatment of 

neuropsychiatric lupus in childhood 

2:30 PM 

Mechanisms of Neuropsychiatric Lupus 

Betty Diamond, MD 

3:00 PM 

Imaging in Neuropsychiatric Lupus 

Hermine I. Brunner, MD, MSc, MBA 


PM 

PS 

3:30 PM 

Epidemiology, Diagnosis and Therapy of Neuropsychiatric 

Lupus 

Eyal Muscal, MD, MS 

Ballroom A 

Osteoporosis: From Bisphosphonates and Beyond 

Moderators: Jeffrey R. Curtis, MD, MPH, MS and Margaret R. 

Wilkes, MD 


• describe current data regarding association of bisphosphonate 

therapy to osteonecrosis of the jaw and atypical fractures 

• discuss evidence and best data supporting duration of 

bisphosphonate therapy for osteoporosis 

• evaluate the data regarding increased infection risk in patients 

receiving denosumab 

• review potential treatment strategies for difficult to manage 

osteoporosis 

2:30 PM 

Osteoporosis and Bisphosphonates – How Long Should We 

Treat? 

Chad L. Deal, MD 

3:00 PM 

Denosumab: Is Infection a Real Concern? 

Nelson B. Watts, MD, MACE 

3:30 PM 

Diagnostic and Therapeutic Dilemmas in Osteoporosis 

Kenneth G. Saag, MD, MSc 


2:30 - 4:00 PM 

140 A 


Moderators: Shiva Shahrara, PhD and Douglas J. Veale, MD 

2:30 PM 

2011 Lee C. Howley, Sr. Prize for Arthritis Research Introductory 

Talk II 

Speaker: Alisa E. Koch, MD 

2:45 PM 

1599. NF-Kb Inducing Kinase (NIK) Is a Key Regulator of 

Inflammation-Induced Angiogenesis 

A.R. Noort 1 , K.P.M. van Zoest 1 , P. Koolwijk 2 , D.V. Novack 3 , M.J. 

Siemerink 1 , P. P. Tak 4 and S.W. Tas 1 , 1 Academic Medical Center/ 

University of Amsterdam, Amsterdam, Netherlands, 2 Institute 

for Cardiovascular Research (ICaR-VU)/VU University Medical 

Center, Amsterdam, Netherlands, 3 Washington University School 

of Medicine, St. Louis, MO, 4 Academic Medical Center/University 

of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands 

3:00 PM 

1600. Gene Targeting of an Integrin-Mediated Signaling 

Adaptor Molecule, Crk-Associated Substrate Lymphocyte Type 

Reduced the Severity of Collagen-Induced Arthritis. Its Possible 

Involvement in the Pathophysiology of Rheumatoid Arthritis 

Satoshi Iwata, Tomoki Katayose, Yoshiko Kichikawa, Hiromi 

Ichihara, Hiroshi Kawasaki, Osamu Hosono, Hirotoshi Tanaka 

PM 

PS

and Chikao Morimoto, The Institute of Medical Science, The 

University of Tokyo, Tokyo, Japan 

3:15 PM 

1601. Role of Focal Adhesion Kinase in Synovial Fibroblast 

Invasion and Arthritis 

Miriam A. Shelef, David Bennin and Anna Huttenlocher, Univ of 

Wisconsin Schl of Med, Madison, WI 

3:30 PM 

1602. Tie2 Signalling Induces a Pro-Inflammatory and 

Pro-Angiogenic Phenotype in Differentiated Macrophages, 

Independently of Macrophage Polarization Conditions, and 

Contributes to Production of Cytokines Elevated in Early 


Samuel Garcia 1 , Sarah Krausz 1 , Carmen A. Ambarus 2 , Bea Malvar 

Fernandez 1 , Dominique L. Baeten 1 , Paul P. Tak 3 and Kris A. 

Reedquist 1 , 1 Academic Medical Center, University of Amsterdam, 

Amsterdam, Netherlands, 2 Academic Medical Center/University 

of Amsterdam, Amsterdam, Netherlands, 3 Academic Medical 

Center, University of Amsterdam and GlaxoSmithKline, 


3:00 PM 

1606. Identifying a Link Between Uranium Exposure and 

Systemic Lupus Erythematosus in a Community Living near a 

Uranium Plant 

Pai-Yue Lu 1 , Leah C. Kottyan 1 , Susan M. Pinney 2 , Judith A. James 3 , 

Changchun Xie 2 , Jeanette M. Buckholz 2 and John B. Harley 4 , 

1 

Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 

2 

University of Cincinnati, Cincinnati, OH, 3 Oklahoma Medical 

Research Foundation and Oklahoma University Health Sciences 

Center, Oklahoma City, OK, 4 Cincinnati Children’s Hospital 


Center, Cincinnati, OH 

3:15 PM 

1607. The Association Between Thyroxin Substitution and 

Rheumatoid Arthritis; Results From the Swedish EIRA Study 

Camilla Bengtsson 1 , Henrik Källberg 1 , Leonid Padyukov 2 and 

Saedis Saevarsdottir 3 , 1 Institute of Environmental Medicine, 

Karolinska Institutet, Stockholm, Sweden, 2 Rheumatology Unit, 

Karolinska Institutet, Stockholm, Sweden, 3 Rheumatology unit, 

Karolinska University Hospital, Karolinska Institute, Stockholm, 

Sweden 

3:45 PM 

1603. Inhibitor of DNA Binding 1 As a Secreted Angiogenic 

Transcription Factor in Rheumatoid Arthritis 

Takeo Isozaki 1 , M. Asif Amin 1 , Alisa E. Koch 2 , Ali Arbab 3 , 

Stephanie A. Shuman 1 , Christine M. Ha 1 , G. Kenneth Haines III 4 

and Jeffrey H. Ruth 1 , 1 University of Michigan, Ann Arbor, MI, 

2 

University of Michigan Medical School, Ann Arbor, MI, 3 Henry 

Ford Hospital and Medical Centers, Detroit MI 48202, Detroit, 

MI, 4 Yale University, New Haven, CT 

Salon B 

Epidemiology and Health Services Research II: 

Epidemiologic Risk Factors in the Development of 

Rheumatic Disease 

Moderators: Evelyne Vinet, MD and Nasim A. Khan, MD 

2:30 PM 

1604. Parity and the Risk of Developing Rheumatoid Arthritis: 

Results From the Swedish Epidemiological Investigation of 

Rheumatoid Arthritis Study 

Cecilia Orellana 1 , Lars Klareskog 2 , Lars Alfredsson 1 and Camilla 

Bengtsson 1 , 1 Institute of Environmental Medicine, Karolinska 

Institutet, Stockholm, Sweden, 2 Rheumatology Unit, Karolinska 

Institutet, Stockholm, Sweden 

2:45 PM 

1605. Anti-Citrullinated Peptide Autoantibodies to Rheumatoid 

Synovium Epitopes in Women and Risk of Future Rheumatoid 

Arthritis 

Elizabeth V. Arkema 1 , Barbara L. Goldstein 2 , William H. 

Robinson 3 , Catriona Cramb 4 , Jeremy Sokolove 5 , Jing Cui 6 , Susan 

Malspeis 6 , Elizabeth W. Karlson 7 and Karen H. Costenbader 7 , 

1 

Harvard School of Public Health, Boston, MA, 2 Brigham and 

Women’s Hospital, Boston, MA, 3 Stanford University, Palo Alto, 

CA, 4 VA Palo Alto Heatlh Care System and Stanford University, 

Palo Alto, CA, 5 VA Palo Alto Health Care System and Stanford 

University, Palo Alto, CA, 6 Brigham and Womens Hospital, 

Boston, MA, 7 Brigham and Women’s Hospital, Harvard Medical 


3:30 PM 

1608. Overweight and Obesity Increase Risk of Rheumatoid 

Arthritis in Women in a Large Prospective Study 

Bing Lu 1 , Chia-Yen Chen 2 , Linda T. Hiraki 3 , Karen H. Costenbader 1 

and Elizabeth W. Karlson 1 , 1 Brigham and Women’s Hospital, 

Harvard Medical School, Boston, MA, 2 Harvard School of Public 

Health, Boston, MA, 3 Brigham and Women’s Hospital, Harvard 

School of Public Health, Boston, MA 

3:45 PM 

1609. Circulating 25-Hydroxyvitamin D Level and Risk of 

Developing Rheumatoid Arthritis 

Linda T. Hiraki 1 , Jing Cui 2 , Susan Malspeis 3 , Karen H. 

Costenbader 4 and Elizabeth W. Karlson 4 , 1 Brigham and Women’s 

Hospital, Harvard School of Public Health, Boston, MA, 2 Brigham 

and Women’s Hospital, Boston, MA, 3 Brigham and Womens 

Hospital, Boston, MA, 4 Brigham and Women’s Hospital, Harvard 

Medical School, Boston, MA 

145 A 


Moderators: Soumya Raychaudhuri, MD, PhD and Nan Shen, MD 

2:30 PM 

1610. The DNA Methylation Signature in Fibroblast-Like 

Synoviocytes (FLS) Defines Critical Pathogenic Pathways in 

Rheumatoid Arthritis (RA) 

David L. Boyle 1 , Robert Shoemaker 2 , David W. Anderson 2 , Wei 

Wang 3 and Gary S. Firestein 1 , 1 UCSD School of Medicine, La Jolla, 

CA, 2 NexDx, Inc., San Diego, CA, 3 UCSD, La Jolla, CA 

2:45 PM 

1611. Targeted Deep Re-Sequencing Implicates Rare and Low 

Frequency Coding Variants in IL23R, MEFV, TLR4, and NOD2 in 

Behçet’s Disease 

Yohei Kirino 1 , Qing Zhou 1 , Yoshiaki Ishigatsubo 2 , Nobuhisa 

Mizuki 2 , Ilknur Tugal-Tutkun 3 , Emire Seyahi 4 , Yilmaz Ozyazgan 4 , F. 

Sevgi Sacli 4 , Burak Erer 5 , Zeliha Emrence 6 , Atilla Cakar 7 , Duran 


MONDAY 

November 12, 2012

MONDAY 


Ustek 7 , Akira Meguro 2 , Atsuhisa Ueda 2 , Mitsuhiro Takeno 2 , 

Michael J. Ombrello 1 , Colleen Satorius 1 , Baishali Maskeri 8 , Jim 

Mullikin 8 , Hong-Wei Sun 9 , Gustavo Gutierrez-Cruz 9 , Yoonhee 

Kim 10 , Ahmet Gül 11 , Daniel L. Kastner 1 and Elaine F. Remmers 1 , 

1 

National Human Genome Research Institute, National Institutes 

of Health, Bethesda, MD, 2 Yokohama City University Graduate 

School of Medicine, Yokohama, Japan, 3 Istanbul, Turkey, 

4 

Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, 

Turkey, 5 Istanbul Faculty of Medicine, Istanbul University,, 

Istanbul, Turkey, 6 Institute for Experimental Medicine, Istanbul 

University, Istanbul, Turkey, 7 Institute of Experimental Medicine, 

Istanbul University, Istanbul, Turkey, 8 National Human Genome 

Research Institute, National Institutes of Health, Rockville, MD, 

9 

National Institute of Arthritis and Musculoskeletal and Skin 

Diseases, National Institutes of Health, Bethesda, MD, 10 National 

Human Genome Research Institute, National Institutes of 

Health, Baltimore, MD, 11 Istanbul Faculty of Medicine, Istanbul 

University, Istanbul, Turkey 

3:00 PM 

1612. Ankylosing Spondylitis Is Associated with Single 

Nucleotide Polymorphisms in Loci Implicating Four 

Aminopeptidases 

Philip Robinson 1 , Adrian Cortes 1 , Paul Leo 1 , Australian-Anglo- 

American Spondylitis Consortium (TASC) 2 , Wellcome Trust 

Case Control Consortium (WTCCC) . 3 , International Genetics of 

Ankylosing Spondylosis Consortium (IGAS) 4 , David Evans 5 and 

Matthew A. Brown 1 , 1 University of Queensland Diamantina 

Insititute, Brisbane, Australia, 2 Brisbane, Australia, 3 Wellcome 

Trust Case Control Consortium, Wellcome Trust Case Control 

Consortium, United Kingdom, 4 IGAS, Igas, Australia, 5 Bristol 

University, Bristol, United Kingdom 

3:15 PM 

1613. The SLE-Associated TLR7 Variant Confers Differential 

Gene Expression Modulated by Microrna-3148 

Yun Deng 1 , Jian Zhao 1 , Daisuke Sakurai 1 , Kenneth M. Kaufman 2 , 

Jeffrey C. Edberg 3 , Robert P. Kimberly 3 , Diane L. Kamen 4 , Gary 

S. Gilkeson 5 , Chaim O. Jacob 6 , Robert H. Scofield 7 , Carl D. 

Langefeld 8 , Jennifer A. Kelly 9 , Marta E. Alarcün-Riquelme on 

behalf of BIOLUPUS and GENLES networks 10 , John B. Harley 2 , 

Timothy J. Vyse 11 , Barry I. Freedman 12 , Patrick M. Gaffney 13 , 

Kathy Moser Sivils 9 , Judith A. James 13 , Timothy B. Niewold 14 , 

Rita M. Cantor 15 , Weiling Chen 1 , Bevra H. Hahn 1 , Elizabeth E. 

Brown on behalf of PROFILE 3 and Betty P. Tsao 1 , 1 David Geffen 

School of Medicine University of California Los Angeles, Los 

Angeles, CA, 2 Division of Rheumatology and The Center for 

Autoimmune Genomics & Etiology, Cincinnati Children’s Hospital 


Center, Cincinnati, OH, 3 Department of Medicine, University 

of Alabama at Birmingham, Birmingham, AL, 4 Arthritis & 

Clinical Immunology Program, Oklahoma Medical Research 

Foundation, Charleston, SC, 5 Medical University of South 

Carolina, Charleston, SC, 6 Department of Medicine, Keck School 

of Medicine, University of Southern California, Los Angeles, CA, 

7 

Arthritis & Clinical Immunology Program, Oklahoma Medical 

Research Foundation; Department of Medicine, University of 

Oklahoma Health Sciences Center; US Department of Veterans 

Affairs Medical Center, Oklahoma City, OK, 8 Department of 

Biostatistical Sciences, Wake Forest University Health Sciences, 

Winston-Salem, NC, 9 Oklahoma Medical Research Foundation, 

Oklahoma City, OK, 10 Centro de Genómica e Investigación 

Oncológica (GENYO) Pfizer-Universidad de Granada-Junta de 

Andalucia, Granada, Spain, 11 Divisions of Genetics and Molecular 

Medicine and Immunology, King’s College London, London, 

United Kingdom, 12 Department of Internal Medicine, Wake 

Forest School of Medicine, Winston-Salem, NC, 13 Arthritis & 


Foundation, Oklahoma City, OK, 14 Section of Rheumatology 

and Gwen Knapp Center for Lupus and Immunology Research 

University of Chicago, Chicago, IL, 15 Department of Human 

Genetics, University of California Los Angeles, Los Angeles, CA 

3:30 PM 

1614. Analysis of the Immunochip in a Large Cohort of Juvenile 

Idiopathic Arthritis Cases Identifies 17 Loci At Genome-Wide 

Significance 

Anne Hinks 1 , Joanna Cobb 1 , Miranda C. Marion 2 , Marc Sudman 3 , 

John Bowes 1 , Kathryn J. A. Steel 1 , Mehdi Keddache 4 , John F. 

Bohnsack 5 , Stephen Guthery 5 , Lucy R. Wedderburn 6 , Johannes 

Peter Haas 7 , David N. Glass 8 , Sampath Prahalad 9 , Carl D. 

Langefeld 2 , Wendy Thomson 1 and Susan D. Thompson 3 , 1 Arthritis 

Research UK Epidemiology Unit, University of Manchester, 

Manchester, United Kingdom, 2 Wake Forest School of Medicine, 

Winston-Salem, NC, 3 Cincinnati Children’s Hospital Medical 

Center, Cincinnati, OH, 4 Division of Human Genetics, Cincinnati 

Children’s Hospital Medical Center, Cincinnati, OH, 5 University 

of Utah, Salt Lake City, UT, 6 University College London (UCL), 

London, United Kingdom, 7 German Center for Pediatric and 

Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, 

8 

Cincinnati Childrens Hospital Medical Center, Cincinnati, OH, 

9 

Emory Children’s Center, Atlanta, GA 

3:45 PM 

1615. Evidence for Distinct Roles of Environmental and 

Genetic Factors in the Emergence of Anti Citrullinated-Protein 

Antibodies Positive Rheumatoid Arthritis-an Epidemiological 

Investigation in Twins 

Aase Haj Hensvold 1 , Patrik KE Magnusson 2 , Monika Hansson 1 , 

Lena Israelsson 3 , Cecilia Carlens 1 , Johan Askling 4 , Vivianne 

Malmström 1 , Lars Klareskog 3 and Anca Irinel Catrina 1 , 

1 

Rheumatology unit, Karolinska University Hospital, Karolinska 

Institute, Stockholm, Sweden, 2 Swedish Twin Registry Karolinska 

Institutet, Stockholm, Sweden, 3 Karolinska Institute, Stockholm, 

Sweden, 4 Rheumatology Unit & Clinical Epidemiology Unit, 

Stockholm, Sweden 

202 B 

Imaging of Rheumatic Diseases II: Magnetic 

Resonance Imaging 

Moderators: John Carrino, MD, MPH and Ali Guermazi, MD, PhD 

2:30 PM 

1616. Comparison of Conventional and Wholebody Magnetic 

Resonance Imaging for Assessing Inflammation and Structural 

Damage in Psoriatic Arthritis and Axial Spondyloarthritis 

René Panduro Poggenborg 1 , Susanne Juhl Pedersen 2 , Iris 

Eshed 3 , Inge Juul Sørensen 2 , Ole Rintek Madsen 4 , J.M. 

Møller 5 and Mikkel Østergaard 6 , 1 Copenhagen University 

Hospital in Glostrup, Copenhagen, Denmark, 2 Glostrup 

74 

2012 Program Book

Hospital, Copenhagen, Denmark, 3 Sheba Medical Center, Tel 

Hashomer, Israel, 4 Copenhagen University Hospital in Gentofte, 

Copenhagen, Denmark, 5 Copenhagen University Hospital in 

Herlev, Copenhagen, Denmark, 6 Copenhagen University Hospital 

Glostrup, Glostrup, Denmark 

2:45 PM 

1617. Whole-Body Magnetic Resonance Imaging of Disease 

Manifestations in Axial and Peripheral Joints and Entheses in 

Rheumatoid Arthritis Patients 

Mette Bjørndal Axelsen 1 , Anne Duer 2 , Iris Eshed 3 , Jakob M. 

Møller 4 , Susanne Juhl Pedersen 1 and Mikkel Østergaard 1 , 

1 

Glostrup Hospital, Copenhagen, Denmark, 2 Copenhagen 

University Hospital at Hvidovre, Hvidovre, Denmark, 3 Sheba 

Medical Center, Tel Hashomer, Israel, 4 Copenhagen University 

Hospital in Herlev, Copenhagen, Denmark 

3:00 PM 

1618. Prevalence of Inflammatory Sacroiliitis Assessed On MR 

Imaging of Inflammatory Bowel Disease: A Retrospective Study 

Performed On 186 Patients 

Sophie Leclerc-Jacob, Guillaume Lux, Anne-Christine Rat, Valérie 

Laurent, Alain Blum, Isabelle Chary-Valckenaere, Laurent Peyrin- 

Biroulet and Damien Loeuille, Nancy Teaching Hospital, Nancy, 

France 

3:15 PM 

1619. Quantification of Bone Marrow Edema by Using 

Magnetic Resonance Imaging for the Assessment of Neck Pain 

Only Marginally Reflects Clinical Evaluation in Patients with 

Rheumatoid Arthritis and Ankylosing Spondylitis 

Xenofon Baraliakos 1 , Frank Heldmann 2 , Ravi Suppiah 3 , Fiona M. 

McQueen 4 and Jurgen Braun 1 , 1 Rheumazentrum Ruhrgebiet, 

Herne, Germany, 2 Rheumazentrum Ruhrgebiet, Herne, Ghana, 

3 

Department of Rheumatology, Nuffield Orthopaedic Centre, 

Oxford, United Kingdom, 4 University of Auckland, Auckland, 

New Zealand 

3:30 PM 

1620. Early Magnetic Resonance Imaging Measures 

Independently Predict 1- and 2- Year X-Ray Progression: 

Results From a Large Clinical Trial 

Joshua Baker 1 , Mikkel Østergaard 2 , Paul Emery 3 , Elizabeth 

C. Hsia 4 , J. D. Lu 4 , Daniel Baker 5 and Philip G. Conaghan 6 , 

1 

University of Pennsylvania, Philadelphia, PA, 2 Glostrup Hospital, 

Copenhagen, Denmark, 3 Leeds Musculoskeletal Biomedical 

Research Unit, Leeds, United Kingdom, 4 Janssen Research & 

Development, LLC/U of Penn, Spring House/Phila, PA, 5 Janssen 

Research and Development, LLC, Spring House, PA, 6 University 

of Leeds, Leeds, United Kingdom 

3:45 PM 

1621. In vivo Synovial Oxygen Levels Are Inversely Related to 

Metabolic Turnover and Disease Activity in Rheumatoid and 

Psoriatic Arthritis Biologic Responders 

Leonard C. Harty 1 , John Ryan 2 , Chin Teck Ng 3 , Monika 

Biniecka 3 , Aisling Kennedy 3 , Eric J. Heffernan 4 , Ursula Fearon 5 

and Douglas J. Veale 1 , 1 Dublin Academic Medical Centre, St. 

Vincent’s University Hospital, Dublin, Ireland, 2 Ziltron, Unit 4 , 

Castletroy Business Park, Plassey, Limerick, Ireland, 3 Translation 

Rheumatology Research Group, Dublin, Ireland, 4 St. Vincent’s 

University Hospital, Dublin, Ireland, 5 Translation Research 

Group, Dublin Academic Medical Centre, St. Vincent’s University 

Hospital, Dublin, Ireland 

150 B 


Moderators: Leonard H. Calabrese, DO and James S. Louie, MD 

2:30 PM 

1622. Characteristics of Patients with Infectious 

Cryoglobulinemia Vasculitis in the Absence of HCV Infection: 

Results From the French Nationwide Cryovas Survey 

Benjamin Terrier Sr. 1 , Isabelle Marie 2 , Adeline Lacraz 3 , Pauline 

Belenotti 4 , Fabrice Bonnet 5 , Laurent Chiche Sr. 4 , Bruno 

Graffin Sr. 6 , Arnaud Hot Sr. 7 , Jean-Emmanuel Kahn 8 , Thomas 

Quemeneur 9 , Olivier Hermine Sr. 10 , Jean-Marc Léger 11 , Patricia 

Senet 12 , Emmanuelle Plaisier 13 , Xavier Mariette 14 and Patrice 

Cacoub Sr. 15 , 1 Cochin Hospital, Paris, France, 2 Service de 

médecine interne, CHU de Rouen, Rouen, France., Rouen, 

France, 3 Nephrology, CHU Bordeaux, Bordeaux, France, 4 Internal 

Medicine, CHU Marseille, Marseille, France, 5 Internal Medicine, 

CHU Bordeaux, Bordeaux, France, 6 Metz hospital, Metz, France, 

7 

Lyon hospital, Lyon, France, 8 Internal Medicine, Foch Hospital, 

Suresnes, France, 9 CHR de Valenciennes, Valenciennes, France, 

10 

Hôpital Necker, Paris, France, 11 Paris, France, 12 Tenon hospital, 

Paris, France, 13 Nephrology, Tenon Hospital, Paris, France, 

14 

Université Paris-Sud, Le Kremlin Bicetre, France, 15 CHU Pitié- 

Salpêtrière, Paris, France 

2:45 PM 

1623. Serum Biomarkers Signature Identifies Patients with 

Overt B-Cell Non-Hodgkin Lymphoma Associated with Mixed 

Cryoglobulinemia in Chronic HCV Infection 

Benjamin Terrier Sr. 1 , Wahiba Chaara 2 , Guillaume Geri 3 , 

David Saadoun 4 , Michelle Rosenzwajg Sr. 5 , Damien Sene Sr. 6 , 

Adrien Six 2 , David Klatzmann Sr. 5 and Patrice Cacoub Sr. 3 , 

1 

Cochin Hospital, Paris, France, 2 Laboratory I3 “Immunology, 

Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM 

U959, Groupe Hospitalier Pitié-Salpetrière, Paris, France, 

3 

CHU Pitié-Salpêtrière, Paris, France, 4 Department of Internal 

Medicine and Laboratory I3 “Immunology, Immunopathology, 

Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe 

Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, 

Paris 6 , Paris, France, Paris, France, 5 Laboratory I3 “Immunology, 

Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM 

U959, Paris, France, 6 Groupe Hospitalier Pitié-Salpétrière, 

Université Pierre et Marie Curie, Paris, France 

3:00 PM 

1624. Deletion of HLA-B27 T Cells Underlies the 

Immunodominant Response to Influenza Infection On Class I 

MHC Transgenic Mice 

Ali Akram 1 and Robert D. Inman 2 , 1 University of Toronto and 

University Health Network (UHN), Toronto, ON, 2 Toronto 

Western Research Institute, University Health Network and 

University of Toronto, Toronto, ON 

MONDAY 



MONDAY 


3:15 PM 

1625. With Chlamydia Infection the Macrophage Serves As 

Gate-Keeper for Dissemination and Induction of Host Immunity 

Eric Gracey 1 and R. D. Inman 2 , 1 Toronto Western Hospital, 

Toronto, ON, 2 Toronto Western Research Institute, University 

Health Network and University of Toronto, Toronto, ON 

3:30 PM 

1626. Frequent Conversion of Tuberculosis Screening Tests 

During Anti-Tumor Necrosis Factor Therapy in Patients with 


Chrisoula Hatzara, Emilia Hadziyannis, Anna Kandili, Stamatoula 

Tsikrika, Martha Minopetrou, Georgios Georgiopoulos and 

Dimitrios Vassilopoulos, Athens University School of Medicine, 

Athens, Greece 

3:45 PM 

1627. New Insights Into the Presentation and the Management 

of Hepatitis B Reactivation in Patients with Autoimmune 

Diseases and Inflammatory Arthritis 

Nina Droz 1 , Laurent Gilardin 2 , Patrice Cacoub Sr. 3 , Francis 

Berenbaum 4 , Daniel Wendling 5 , Bertrand Godeau 6 , Anne-Marie 

Piette 7 , Emmanuelle Dernis 8 , Mikael Ebbo 9 , Bruno Fautrel 10 , 

Arsène Meikinian 11 , Aude Rigolet 12 , Sophie Rivière 13 , Stanislas 

Pol 1 , Loic Guillevin 14 , Luc Mouthon Sr. 15 and Benjamin Terrier 

Sr. 1 , 1 Cochin Hospital, Paris, France, 2 Saint Antoine Hospital, 

Paris, France, 3 CHU Pitié-Salpêtrière, Paris, France, 4 AP-HP, St 

Antoine Hospital, Paris, France, 5 Minjoz University Hospital, 

Besancon, France, 6 Service de médecine interne, Université 

Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, 

France, 7 Foch Hospital, Suresnes, France, 8 Centre Hospitalier, Le 

Mans, France, 9 Conception Hospital, Marseille, France, 10 APHP- 

Pitie Salpetriere Hospital / UPMC, Paris, France, 11 Jean Verdier 

Hospital, Bondy, France, 12 Pitie-Salpetriere Hospital, APHP, 

UPMC Paris VI, Paris, France, 13 Lapeyronie, Montpellier, France, 

14 

Department of Internal Medicine, Referral Center for Rare 

Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, 

Université Paris Descartes, Paris, France, Paris, France, 15 Hopital 

Cochin, Paris, France 

147 A 

Metabolic and Crystal Arthropathies: Basic Science 

Moderators: Michael H. Pillinger, MD and John S. Sundy, MD, 

PhD 

2:30 PM 

1628. Epistatic Interaction Between Solute Carrier 2A9 

Genotype and Sugar-Sweetened Beverage Consumption in the 

Determination of Gout Risk 

Tony R. Merriman 1 , Nicola Dalbeth 2 , Peter J. Gow 3 , Andrew 

Harrison 4 , John Highton 5 , Peter B. B. Jones 6 , Lisa K. Stamp 7 , 

Murray Cadzow 1 , Marilyn E. Merriman 1 , Ruth Topless 1 , Michael 

A. Black 1 , Amanda Phipps-Green 1 and Caitlin M. Batt 1 , 1 University 

of Otago, Dunedin, New Zealand, 2 University of Auckland, 

Auckland, New Zealand, 3 Middlemore Hospital, Auckland, New 

Zealand, 4 Hutt Hospital, Lower Hutt, New Zealand, 5 Univ of 

Otago Med Sch, Dunedin, New Zealand, 6 Waikato Clinical School, 

Waikato Hospital, Hamilton, New Zealand, 7 University of Otago, 

Christchurch, Christchurch, New Zealand 

2:45 PM 

1629. Microarray Analysis of Acute and Intercritical Gout 

Alicia Rodriguez-Pla 1 , Lynda Bennett 1 , Kathryn H. Dao 2 , Edwardo 

Delgado 2 , Typhanie Maurouard 1 , M. Virginia Pascual 1 and John 

J. Cush 3 , 1 Baylor Institute for Immunology Research, Dallas, TX, 

2 

Arthritis Care and Research Center, Dallas, TX, 3 Baylor Research 

Institute, Dallas, TX 

3:00 PM 

1630. Genetic Variants of Serum Uric Acid and Gout: An 

Analysis of > 170,000 Individuals 

Hyon Choi 1 , Robert M. Plenge 2 , Anna Köttgen 3 , Veronique Vitart 4 , 

Murielle Bochud 5 , Christian Gieger 6 , Mark Caulfield 7 , Marina 

Ciullo 8 , Eva Albrecht 6 , Alexander Teumer 9 , Gary Curhan 10 , Jan 

Krumsiek 11 , Conall O’Seaghdha 12 , Caroline Fox 13 and The Global 

Urate Genetics Consortium (GUGC) 14 , 1 Boston University School 

of Medicine, Boston, MA, 2 Brigham and Women’s Hospital, 

Boston, MA, 3 Renal Division, Freiburg University Hospital, 

Freiburg, Germany, 4 Western General Hospital, Edinburgh, 

United Kingdom, 5 Lausanne University Hospital, Switzerland, 

6 

Neuherberg, Germany, 7 Barts and The London School of 

Medicine and Dentistry, Queen Mary University of London, 

London, United Kingdom, 8 “A. Buzzati-Traverso”, Italy, 9 Ernst- 

Moritz-Arndt- University Greifswald, Greifswald, Germany, 

10 

Harvard Medical School, Boston, 11 German Research Center 

for Environmental Health, Neuherberg, Germany, 12 NHLBI’s 

Framingham Heart Study and Center for Population Studies,, 

Neuherberg, 13 NHLBI’s Framingham Heart Study and Center for 

Population Studies,, MA, 14 Boston 

3:15 PM 

1631. Osteoarthritis-Associated Basic Calcium Phosphate 

Crystals Induce IL-1β, IL-18 and S100A8 Production in a 

Tyrosine Kinase Dependent Manner 

Geraldine M. McCarthy 1 , Evanna Mills 2 , Kingston Mills 2 and 

Aisling Dunne 2 , 1 Mater Misericordiae University Hospital, Dublin 

7, Ireland, 2 Trinity College Dublin, Dublin 2, Ireland 

3:30 PM 

1632. Arhalofenate Is a Novel Dual-Acting Agent with 

Uricosuric and Anti-Inflammatory Properties 

Yun-Jung Choi, Vanina Larroca, Annette Lucman, Vic Vicena, Noe 

Abarca, Tim Rantz, Brian E. Lavan and Charles A. McWherter, 

Metabolex, Inc., Hayward, CA 

3:45 PM 

1633. Ulodesine (BCX4208) Add-On Therapy to Allopurinol 

300mg Lowers Hypoxanthine and Xanthine Plasma Levels in a 

Dose-Dependent Fashion: Results From a 12-Week Randomized 

Controlled Trial in Patients with Gout 

Shanta Bantia 1 , Leigh Harman 1 , Cynthia Parker 1 , Damon Papac 2 , 

Andreas Maetzel 1 , Brian Taubenheim 1 and Alan S. Hollister 1 , 

1 

BioCryst Pharmaceuticals, Inc., Durham, NC, 2 Southern Research 

Institute, Birmingham, AL 

207 A 

Rheumatoid Arthritis - Animal Models 

Moderators: Charles S. Via, MD and Harris R. Perlman, PhD 

76 

2012 Program Book

2:30 PM 

1634. Delivering Mesenchymal Stem Cells to Arthritic Joints 

with Nano-Fiber Scaffold Resulted in Inhibition of Arthritis and 

Joint Damage in Arthritis Models 

Xiangmei Zhang 1 , Kunihiro Yamaoka 1 , Koshiro Sonomoto 1 , 

Masahiro Kondo 1 , Shunsuke Fukuyo 1 , Makoto Satake 2 , Hiroaki 

Kaneko 2 , Kazuhisa Nakano 1 , Shingo Nakayamada 1 , Yosuke 

Okada 1 and Yoshiya Tanaka 1 , 1 University of Occupational and 

Environmental Health, Japan, Kitakyushu, Japan, 2 Integrative 

Technology Research Institute, Teijin Limited, Tokyo, Japan 

2:45 PM 

1635. Polyarthritis Caused by TIARP (TNFAIP9) Deficiency 

Critically Dependent On Dysregulated STAT3, NF-κB Signaling 

and Cell Death in Macrophage 

Asuka Inoue 1 , Isao Matsumoto 1 , Naoto Umeda 1 , Yuki Tanaka 1 , 

Satoru Takahashi 2 and Takayuki Sumida 1 , 1 University of Tsukuba, 

Tsukuba city, Ibaraki, Japan, 2 Department of Anatomy and 

Embryology, Faculty of Medicine, University of Tsukuba, Tsukuba 

city, Ibaraki, Japan 

3:00 PM 

1636. Commensal Gut-Derived Bacteria As Therapy for 

Systemic Autoimmune Disease 

David Luckey 1 , Eric Marietta 1 , Harvinder S. Luthra 1 , Robin Patel 1 , 

Joseph A. Murray 1 , Ashutosh Mangalam 2 and Veena Taneja 1 , 

1 

Mayo Clinic, Rochester, MN, 2 Mayo Clinic, Rochester 

3:15 PM 

1637. A Novel Peptide Inhibiting the Binding Between C1q and 

Immunoglobulin Ameliorates Joint Destruction in Rats with 

Collagen-Induced Arthritis 

Yu Moriguichi and Tetsuya Tomita, Osaka University Graduate 

School of Medicine, Suita, Japan 

3:30 PM 

1638. Synovial Fibroblast Migration Is Modulated by the Focal 

Contact Protein Lasp-1 

Adelheid Korb-Pap 1 , Jan Hillen 1 , Marianne Heitzmann 1 , 

Catherine S. Chew 2 , Stefan Butz 3 , Dietmar Vestweber 3 , Hermann 

Pavenstädt 1 and Thomas Pap 1 , 1 University Hospital Muenster, 

Muenster, Germany, 2 Medical College of Georgia, Augusta, GA, 

3 

Max Planck Institute of Molecular Biomedicine, Muenster, 

Germany 

3:45 PM 

1639. FLIP in Macrophages Promotes the Progression of Serum 

Transfer-Induced Arthritis 

Qi Quan Huang 1 , Robert Birkett 2 , Renee E. Koessler 1 , G. 

Kenneth Haines III 3 , Harris R. Perlman 1 and Richard M. Pope 4 , 

1 

Northwestern University, Chicago, IL, 2 Northwestern University 

Feinberg School of Medicine, Chicago, IL, 3 Yale University, New 

Haven, CT, 4 Northwestern Univ Med School, Chicago, IL 

Hall E 


Biologics and Gene Therapy: Safety I 

Moderators: Josef S. Smolen, MD and Simon M. Helfgott, MD 

2:30 PM 

1640. Long-Term Safety of Tocilizumab in Patients with 

Rheumatoid Arthritis and a Mean Treatment Duration of 3.7 

Years 

Mark C. Genovese 1 , Anthony Sebba 2 , Andrea Rubbert-Roth 3 , 

Juan José Scali 4 , Rieke Alten 5 , Joel M. Kremer 6 , Laura Pitts 7 , 

Emma Vernon 7 and Ronald F. van Vollenhoven 8 , 1 Stanford 

University Medical Center, Palo Alto, CA, 2 University of South 

Florida, Tampa, FL, 3 University of Cologne, Cologne, Germany, 

4 

Durand University Hospital, Buenos Aires, Argentina, 

5 

Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, 

6 

Albany Medical College, Albany, NY, 7 Roche, Welwyn Garden 

City, United Kingdom, 8 Karolinska Institute, Stockholm, Sweden 

2:45 PM 

1641. When Can Biological Therapy Be Resumed in Patients 

with Rheumatic Conditions Who Develop Tuberculosis 

Infection During Tumour Necrosis Factors Antagonists 

Therapy? Study Based On the Biobadaser Data Registry 

Maria Victoria Hernández 1 , Miguel A. Descalzo 2 , Juan D. Cañete 1 , 

Raimon Sanmarti 1 and BIOBADASER Study Group 3 , 1 Hospital 

Clínic of Barcelona, Barcelona, Spain, 2 Spanish Society of 

Rheumatology, Madrid, Spain, 3 Madrid, Spain 

3:00 PM 

1642. Biologics and Mortality Risk in Rheumatoid Arthritis - 

Results of a Population Based Study 

Diane Lacaille 1 , Michal Abrahamowicz 2 , Eric C. Sayre 3 and John 

Esdaile 1 , 1 Arthritis Research Centre of Canada, University of 

British Columbia, Vancouver, BC, 2 McGill University, Montreal, 

QC, 3 Arthritis Research Centre of Canada, Vancouver, BC 

3:15 PM 

1643. Outcomes of Pregnancy in Subjects Exposed to 

Certolizumab Pegol 

Megan Clowse 1 , Douglas C. Wolf 2 , Christian Stach 3 , Gordana 

Kosutic 4 , Susan Williams 4 , Ido Terpstra 5 and Uma Mahadevan 6 , 

1 

Duke University Medical Center, Durham, NC, 2 Atlanta 

Gastroenterology Associates, Atlanta, GA, 3 UCB Pharma, 

Monheim, Germany, 4 UCB Pharma, Raleigh, NC, 5 UCB Pharma, 

Brussels, Belgium, 6 University of California, San Francisco, San 

Francisco, CA 

3:30 PM 

1644. Enhanced Pharmacovigilance Reporting of Malignancies 

in Children and Young Adults Taking Etanercept 

Michele Hooper 1 , Deborah Wenkert 1 , Bojena Bitman 1 , Virgil C. 

Dias 1 , Yessinia Bartley 2 , Julie Wang 3 and Julia R. Gage 4 , 1 Amgen 

Inc., Thousand Oaks, CA, 2 Assent Consulting, Solana Beach, CA, 

3 

One Amgen Center Drive, Thousand Oaks, CA, 4 Gage Medical 

Writing, LLC, Oak Park, CA 

3:45 PM 

1645. Combination of Isoniazid for Latent Tuberculosis with 

Traditional and/or Biologic Disease Modifying Anti-Rheumatic 

Drugs Is Well Tolerated in Patients with Rheumatic Diseases 

Dilrukshie Cooray 1 , Saleem A. Waraich 2 , Andrew Phan 1 , 

Rosalinda C. Moran 1 and George A. Karpouzas 1 , 1 Harbor-UCLA 

Medical Center, Torrance, CA, 2 Placentia, CA 

MONDAY 



MONDAY 


Ballroom B 


Treatment II: Clinical Aspects/Pregnancy 

Moderators: Meenakshi Jolly, MD, MS and Graciela S. Alarcon, 

MD, MPH 

2:30 PM 

1646. The Mechanism of Umbilical Cord Mesenchymal Stem 

Cells in the Upregulation of Regulatory T Cells by TGF-β1 in 

Systemic Lupus Erythematosus 

Lingyun Sun, Dandan Wang, Lin Lu and Xia Li, Department of 

Rheumatology and Immunology, the Affiliated Drum Tower 

Hospital of Nanjing University Medical School, Nanjing, China 

2:45 PM 

1647. Critical Management Decisions in Cardiac Neonatal 

Lupus: The Role of Fluorinated Steroids 

Peter M. Izmirly 1 , Sara Sahl 1 , Amit Saxena 1 , Nathalie Costedoat- 

Chalumeau 2 , Jean-Charles Piette 3 , Munther A. Khamashta 4 , 

Cecilia Pisoni 5 , Deborah Friedman 6 and Jill P. Buyon 1 , 1 New 

York University School of Medicine, New York, NY, 2 Assistance 

Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, 

France, 3 CHU Pitié-Salpêtrière, Paris, France, 4 Lupus Research 

Unit, The Rayne Institute, Kings College London School of 

Medicine, London, United Kingdom, 5 Médica e Investigaciones 

Clínicas (CEMIC), Buenos Aires, Argentina, 6 New York Medical 

College, Valhalla, NY 

3:00 PM 

1648. Lupus Anticoagulant At First Pregnancy Visit Is Predictive 

of Pregnancy Loss 

Michelle Petri 1 , Anil Mankee 1 , Ehtisham Akhter 1 , Hong Fang 1 

and Laurence S. Magder 2 , 1 Johns Hopkins University School of 

Medicine, Baltimore, MD, 2 University of Maryland, Baltimore, 

MD 

3:15 PM 

1649. French Cohort Study of 141 Cases of Autoimmune 

Congenital Heart Block 

Kateri Levesque 1 , Alice Maltret 2 , Mohamed Hamidou 3 , Moez 

Jallouli 4 , Jean Loup Pennaforte 5 , Pauline Orquevaux 5 , Jean- 

Charles Piette 6 , Zahir Amoura 4 , Francois Barriere 7 , Jérome Le 

Bidois 2 , Laurent Fermont 2 , Laurence Cohen 8 , Olivier Meyer 9 , 

Olivier Fain 10 , Arnaud Theulin 11 , Hugues Lucron 12 , Francois 

Sassolas 13 , Holly Bezanahary 14 , Gaëlle Guettrot-Imbert 15 , Pascal 

Seve 13 , Elizabeth Diot 16 , Nathalie Morel 1 , Christophe Deligny 17 , 

Elisabeth Villain 2 and Nathalie Costedoat-Chalumeau 18 , 1 Groupe 

Hospitalier Pitié-Salpétrière, Paris, France, 2 Groupe Hospitalier 

Necker - Enfants Malades, Paris, France, 3 Hôtel Dieu, Hôpital 

Universitaire de Nantes, Nantes, France, 4 CHU Pitié-Salpêtrière, 

Paris, France, 5 CHU Reims, Reims, France, 6 Paris, 7 CHU Nantes, 

Nantes, France, 8 Institut Jacques Cartier, 9 Hopital Bichat, Paris, 

France, 10 Service de médecine interne, Université Paris 13, AP- 

HP, Hôpital Jean Verdier, Bondy, France, 11 Strasbourg University 

Hospital, Strasbourg, France, 12 CHU Fort-de-France, Fort de 

France, Martinique, 13 CHU Lyon, Lyon, France, 14 University 

Hospital of Limoges, Limoges, France, 15 Hopital Gabriel 

Montpied, Clermont-Ferrand, France, 16 Department of Internal 

Medicine, Hôpital Bretonneau, Centre Hospitalier Régional 

Universitaire de Tours, Tours, France, Tours, France, 17 Centre 

hospitalier Universitaire de Fort de France, Fort de France, 

Martinique, 18 Assistance Publique-Hôpitaux de Paris, Hopital 

Pitié-Salpétrière, Paris, France 

3:30 PM 

1650. Abnormal Serologies in the Absence of Clinical Activity 

Do Not Predict New or Recurrent Lupus Nephritis During 

Pregnancy 

Jill Buyon 1 , Aanam Aslam 2 , Marta M. Guerra 2 , Michael D. 

Lockshin 2 , Carl A. Laskin 3 , Ware Branch 4 , Lisa R. Sammaritano 2 , 

Michelle Petri 5 , Joan T. Merrill 6 , Allen D. Sawitzke 7 and Jane E. 

Salmon 2 , 1 New York University School of Medicine, New York, 

NY, 2 Hospital for Special Surgery, New York, NY, 3 University 

of Toronto and LifeQuest Centre for Reproductive Medicine, 

Toronto, ON, 4 Univ of Utah, Salt Lake City, UT, 5 Johns Hopkins 

University School of Medicine, Baltimore, MD, 6 Oklahoma 

Medical Research Foundation, Oklahoma City, OK, 7 University of 

Utah Medical Ctr, Salt Lake City, UT 

3:45 PM 

1651. Higher Corticosteroid Doses Early in Disease Have A 

Long-Term Influence On Metabolic Syndrome in Systemic Lupus 

Erythematosus: Data from an International Inception Cohort 

Ben Parker 1 , Murray B. Urowitz 2 , Dafna D. Gladman Gladman 2 , 

Mark Lunt 3 , Ian N. Bruce 4 and Systemic Lupus International 

Collaborating Clinic (SLICC) 5 , 1 University of Manchester, 

Manchester, United Kingdom, 2 Toronto Western Hospital and 

University of Toronto, Toronto, ON, 3 Arthritis Research UK 


United Kingdom, 4 Arthritis Research UK Epidemiology Unit and 

NIHR Manchester Musculoskeletal Biomedical Research Unit, 

Manchester, United Kingdom, 5 Toronto 

146 C 

Vasculitis: Clinical Trials 

Moderators: Rula Hajj- Ali, MD and John Stone, MD, MPH 

2:30 PM 

1652. Rituximab Versus Azathioprine for Maintenance in 

Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated 

Vasculitis 

Loic Guillevin 1 , Christian Pagnoux 2 , Alexandre Karras 3 , Chahera 

Khoutra 4 , Olivier Aumaitre 5 , Pascal Cohen 6 , Francois Maurier 7 , 

Olivier Decaux 8 , Hélène Desmurs-Clavel 4 , Pierre Gobert 9 , 

Thomas Quemeneur 10 , Claire Blanchard-Delaunay 11 , Pascal 

Godmer 12 , Xavier Puechal 13 , Pierre-Louis Carron 14 , Pierre yves 

Hatron 15 , Nicolas Limal 16 , Mohamed Hamidou 17 , Maize Ducret 18 , 

Florence Vende 19 , Elisa Pasqualoni 19 , Bernard Bonnotte 20 , 

Philippe Ravaud 21 , Luc Mouthon Sr. 22 and French Vasculitis 

Study Group (FVSG) 23 , 1 Division of Internal Medicine, Hôpital 

Cochin, University Paris Descartes, Paris, France, 2 Mount Sinai 

Hospital, Toronto, ON, 3 Hôpital Européen Georges Pompidou, 

APHP, Paris, France, 4 Hospices Civils de Lyon, Hôpital Louis 

Pradel, Lyon, France, 5 Centre Hospitalier de Clermont-Ferrand, 

Clermont-Ferrand, France, 6 Service de médecine interne, Centre 

de Références des Vascularites, Université Paris Descartes, APHP, 

Hôpital Cochin, 75005 Paris, France., Paris, France, 7 Division 

of internal Medicine, CHR Metz, Metz, Metz, France, 8 Hôpital 

Sud, Rennes, France, 9 Centre Hospitalier d’Avignon, Avignon, 

France, 10 CHR de Valenciennes, Valenciennes, France, 11 Centre 

78 

2012 Program Book

Hospitalier, Niort, France, 12 Department of Internal Medicine, 

Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, 

France, 13 Hôpital Cochin, Paris, France, 14 Centre Hospitalier de 

Grenoble, Grenoble, France, 15 Hôpital Claude Huriez, Université 

Lille II, Lille, France, Paris, France, 16 Hôpital Henri Mondor, APHP, 

Creteil, France, 17 Hôtel Dieu, Hôpital Universitaire de Nantes, 

Nantes, France, 18 Centre Hospitalier d’Annecy, Annecy, France, 

19 

Hôpital Bicbat, APHP, Paris, France, 20 Centre Hospitalier de 

Dijon, Dijon, France, 21 Hopital Hotel Dieu, Paris Descartes 

University, Paris, France, 22 Hopital Cochin, Paris, France, 2 3Paris, 

France 

2:45 PM 

1653. Outcomes in Patients with Granulomatosis with 

Polyangiitis (Wegener’s) Treated with Short- Vs. Long-Term 

Maintenance Therapy 

Jason Springer, Benjamin Nutter, Carol A. Langford, Gary S. 

Hoffman and Alexandra Villa-Forte, Cleveland Clinic Foundation, 

Cleveland, OH 

3:00 PM 

1654. Primary Endpoint Failure in the Rituximab in ANCA- 

Associated Vasculitis Trial 

Eli Miloslavsky 1 , Ulrich Specks 2 , John H. Stone 3 and RAVE/ITN 

Research Group 4 , 1 Massachusetts General Hopsital, Boston, MA, 

2 

Mayo Clinic, Rochester, MN, 3 Massachusetts General Hospital, 

Boston, MA, 4 Bethesda 

3:15 PM 

1655. An Open-Label Trial of Abatacept in Mild Relapsing 

Granulomatosis with Polyangiitis (Wegener’s) 

Carol A. Langford 1 , David Cuthbertson 2 , Gary S. Hoffman 1 , 

Jeffrey Krischer 2 , Carol McAlear 3 , Paul A. Monach 4 , Philip Seo 5 , 

Ulrich Specks 6 , Steven R. Ytterberg 6 , Peter A. Merkel 3 and 

for the Vasculitis Clinical Research Consortium 3 , 1 Cleveland 

Clinic, Cleveland, OH, 2 University of South Florida, Tampa, FL, 

3 

University of Pennsylvania, Philadelphia, PA, 4 Boston University, 

Boston, MA, 5 Johns Hopkins Vasculitis Center, Baltimore, MD, 

6 


3:30 PM 

1656. Treatment of Systemic Necrotizing Vasculitides in 

Patients ≥65 Years Old: Results of the Multicenter Randomized 

Cortage Trial 

Christian Pagnoux 1 , Thomas Quemeneur 2 , Jacques Ninet 3 , Elodie 

Perrodeau 4 , Elizabeth Diot 5 , Xavier Kyndt 6 , Benoit de Wazières 7 , 

jean-Luc Reny 8 , Xavier Puéchal 9 , Pierre-Yves Leberruyer 10 , Olivier 

Lidove 11 , Philippe Vanhille 6 , Pascal Godmer 12 , Aimé Albath- 

Sadiki 13 , Boris Bienvenu 14 , Pascal Cohen 15 , Luc Mouthon Sr. 16 , 

Philippe Ravaud 4 , Loic Guillevin 17 and French Vasculitis Study 

Group (FVSG) 11 , 1 Department of Internal Medicine, National 

Referral Center for Necrotizing Vasculitides and Systemic 

Sclerosis, Hôpital Cochin, Assistance Publique – Hôpitaux de 

Paris, Université Paris – Descartes, Paris, France, Paris, France, 

2 

CHR de Valenciennes, Valenciennes, France, 3 Department of 

Nephrology and Internal Medicine, Hôpital Edouard Herriot, 

Lyon, France, Lyon, France, 4 Hopital Hotel Dieu, Paris Descartes 

University, Paris, France, 5 Department of Internal Medicine, 

Hôpital Bretonneau, Centre Hospitalier Régional Universitaire 

de Tours, Tours, France, Tours, France, 6 Valenciennes, France, 

7 

Department of Internal Medicine and Gerontology, Hôpital 

Universitaire Carémeau, Nîmes, France, Nimes, France, 8 Geneve, 

Switzerland, 9 Hôpital Cochin, AP-HP, Université Paris Descartes, 

Sorbonne Paris Cité, Paris, France, 10 Reims, France, 11 Paris, 

France, 12 Department of Internal Medicine, Centre Hospitalier 

Bretagne Atlantique de Vannes, Vannes, France, 13 Hôpital 

Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, 

27 rue du faubourg Saint Jacques, Paris, 750 14 , France, Paris, 

France, 14 Division of Internal Medicine, Centre Hospitalier 

Régional Universitaire de Caen, Côte de Nacre, Caen, Caen, 

France, 15 Service de médecine interne, Centre de Références des 

Vascularites, Université Paris Descartes, APHP, Hôpital Cochin, 

75005 Paris, France., Paris, France, 16 Hopital Cochin, Paris, 

France, 17 Cochin University Hospital, Paris, France 

3:45 PM 

1657. Peg-IFNa/Ribavirin/Protease Inhibitor Combination Is 

Highly Effective in HCV-Mixed Cryoglobulinemia Vasculitis 

David Saadoun 1 , Stanislas Pol 2 , Pascal Lebray Sr. 3 , François 

Blanc 4 , Gilles Pialoux 5 , Alexandre Karras 6 , Dorothée Bazin 7 , 

Emmanuelle Plaisier 8 and Patrice Cacoub Sr. 9 , 1 Assistance 


France, 2 Hepatology, Cochin Hospital, Paris, France, 3 Hôpital 

Pitié Salpétrière, Paris, France, 4 hôpital Montpellier, Montpellier, 

France, 5 hôpital Tenon, Paris, France, 6 Hôpital Européen Georges 

Pompidou, APHP, Paris, France, 7 Nouvel Hôpital Civil, Strasbourg, 

France, 8 Nephrology, Tenon Hospital, Paris, France, 9 CHU Pitié- 


ARHP SESSIONS 

2:30 - 4:00 PM 

PM PS 

143 A 


Reviewed and Scored 

Moderator: Jennifer M. Hootman, ATC, PhD 


• describe the basic process of how peer review sessions for 

grants are conducted 

• identify elements that lead to a strong early career grant 

application 

• identify common areas of weakness that can hurt a grant 

application 

2:30 PM 

Tips for an “Exceptional” Grant Review - National Institutes of 

Health Perspective 

Susan Marden, MD 

2:45 PM 

Tips for an “Exceptional” Grant Review – Research and 

Education Perspective 

Michael M. Ward, MD 

2:55 PM 

Overview of Study Section Process 

Kelli D. Allen, PhD 

3:00 PM 

Mock Study Section 

Kelli D. Allen, PhD, Patricia P. Katz, PhD, Susan Marden, MD and 



MONDAY 

November 12, 2012

MONDAY 


3:30 PM 

Summary of Grant Strengths and Weaknesses 

Robert R. McLean, DSc, MPH 

3:40 PM 


204 A 

Depression in Rheumatic Diseases 

Moderator: Karen L. Smarr, PhD 


• summarize the incidence of depression in various rheumatic 

diseases along with associated complications 

• describe the relationship between rheumatic disease and 

depression in the context pathophysiology 

• utilize diagnostic criteria and screening instruments to identify 

cases of depression 

• discuss pharmacological and non-pharmacological treatment 

options in consideration of other common treatments for 

rheumatic patients 

206 

2:30 PM 

Depression in Rheumatic Disease: An Overview 

Lesley M. Arnold, MD 

3:15 PM 

Pharmacological and Non-Pharmacological Treatment of 

Depression in Rheumatic Disease 

Jessica Farrell, PharmD 

PM 

PS 

Minimizing Falls in Geriatric Rheumatic 

Populations 

Moderator: Lori L. Cyr, BSc, OT 


• describe the incidence and contributing factors to falls in 

geriatric rheumatic populations 

• discuss medications associated with increased risk for falls and 

strategies to ameliorate the risk 

• identify physical and occupational therapies to prevent falls, 

as well as promote recovery after a fall 

2:30 PM 

Fractures and Falls in Geriatric Patients with Rheumatic 

Diseases 

Marian T. Hannan, DSc, MPH 

3:00 PM 

The Medication Connection to Falls in Elderly Rheumatic 

Patients 

Kam Nola, PharmD, MS 

PM 

3:30 PM 

After the Fall: The Rehabilitation Process 

Susan L. Murphy, ScD 

PS 

201 

Total Knee Arthroplasty Rehabilitation: Optimizing 

Functional Outcomes through Examination of 

PM PS 

Patient Factors, Practice Variation and Best Practice 

Recommendations (Arthroplasty/Joint Replacement 

Series) 



• describe patient-related factors influencing outcomes after 

total knee arthroplasty 

• identify screening and assessment tools that can identify 

patients at risk for poor outcomes 

• explain the variability in current rehabilitation practices after 

total knee arthroplasty 

• describe best practice recommendations for assessment and 

rehabilitation after total knee arthroplasty 

2:30 PM 

Variation in Functional Outcomes for Total Knee Arthroplasty 

and Tools to Screen for Patients at Risk for Poor Outcomes 

Patricia D. Franklin, MBA, MD, MPH 

2:50 PM 

Total Knee Arthroplasty Rehabilitation Practices: Wide 

Variation and Factors to Consider 

Carol A. Oatis, PhD, PT 

3:10 PM 

Best Practice Recommendations for Total Knee Arthroplasty 

Rehabilitation 


3:30 PM 

Panel Discussion and Case Study 

3:50 PM 

Question and Answer 

ACR WORKSHOPS 

4:00 - 6:00 PM 










September 14. 

149 B 

Getting Electronic Health Record Right (225) 

Speaker: Salahuddin Kazi, MD 

PM 

PS 

PM 

PS 

80 


144 B 

*Musculoskeletal Ultrasonography: Basic (226) 

Speakers: Janak R. Goyal, MD and Gurjit S. Kaeley, MBBS

144 A 

Patient Questionnaires: Multi-Dimensional Health 

PM PS 

Assessment Questionnaire/Routine Assessment of 

Patient Index Data 3 and Beyond toward a Standard, 

Scientific, Quantitative Patient History (227) 

Speaker: Theodore Pincus, MD 

PM PS 

144 C 

Systemic Sclerosis: How to Perform Skin 

Scores (228) 

Speaker: Daniel E. Furst, MD 

ACR SESSIONS 

4:30 - 6:00 PM 

150 B 

Aging and the Rheumatic Diseases 



• discuss updates in the biology of aging 

• review changes in the aging joint which may predispose to 

inflammation 

• discuss aging in the immune system and its potential 

relevance to rheumatic disease 

4:30 PM 

Update on the Biology of Aging 

Toren Finkel, MD, PhD 

5:00 PM 

Age-related Frailty: Age and Susceptibility to Disease 

Jeremy Walston, MD 

5:30 PM 

The Aging Immune System and Inflammatory Disease 

Cornelia M. Weyand, MD, PhD 

PM PS 

Hall D 

Dermatology Topics for Rheumatologists: What You 

Need to Know 

Moderator: Shelly P. Kafka, MD 


• describe nail pathology associated with common rheumatic 

diseases and be familiar with treatment options 

• review cutaneous reactions associated with biological agents, 

understand the pathology associated in treatment induced 

skin reactions 

• discuss options in regard to treatment and know when to stop 

and re-challenge certain agents 

• describe skin biopsies and discuss histopathology associated 

with autoimmune disorders 

• review procedures and techniques used in obtaining skin 

biopsies 

4:30 PM 

Nail Signs of Systemic Disease 

Richard K. Scher, MD, MS 

PM 

PS 

5:00 PM 

Cutaneous Reactions to Biologic Agents 

Jan P. Dutz, MD 

5:30 PM 

Interpreting the Dermatopathology Report: A Guide for 

Rheumatologists 

Soon Bahrami, MD 

152 A 

Energetics, Metabolism and Osteoarthritis 

Moderator: Richard F. Loeser, MD 


• describe the effects of a high fat diet and obesity on the 

development of osteoarthritis 

• define the role of Sirt1 in the regulation of chondrocyte 

anabolic and catabolic activity 

• review the changes found in AMPK activity in osteoarthritis 

and the effects on catabolic activity 

4:30 PM 

The Effects of High Fat Diet and Obesity on Joint Tissue 

Metabolism in Rodents 

Timothy M. Griffin, PhD 

5:00 PM 

Actions of the Metabolic Master Switch in Articular 

Chondrocytes 

Odile H. Gabay, PhD 

5:30 PM 

Altered AMP-activated kinase Activity in Osteoarthritis 

Ru Liu-Bryan, PhD 

PM PS 

Salon B 

Gout and Hyperuricemia: Diseases Beyond the 

Joint 

Moderators: Theodore R. Fields, MD and Jasvinder A. Singh, MD, 

MPH 


• describe the cardiovascular risks of hyperuricemia and data 

linking treatment of hyperuricemia with amelioration of the 

risk 

• summarize the renal and vascular effects of hyperuricemia 

and the effects of medications used for treatment of gout and 

hyperuricemia on kidneys and vascular system 

• discuss the indications and contraindications of new and old 

therapies for the treatment of gout, especially in patients 

with refractory disease and in those with renal failure 

4:30 PM 

Hyperuricemia and Atherothrombotic Vascular Disease-What 

to Do with the Evidence? 

Eswar Krishnan, MD 

5:00 PM 

Uric Acid as a Kidney Toxin: Revival of a 60-year Old Story 

Richard J. Johnson, MD 

PM 

PS 

MONDAY 



5:30 PM 

Gout Therapy: What to use in my Patient with Refractory Gout 

and Renal Disease? 

Ted R. Mikuls, MD, MSPH 

PM PS 

Ballroom C 

Preclinical Autoimmunity – Potential for 

Prevention 

Moderators: Kevin D. Deane, MD, PhD and Diane L. Kamen, MD, 

MS 


• identify the patterns of preclinical autoantibody positivity 

seen prior to the development of certain autoimmune 

diseases 

• describe potential mechanisms for gene x environment 

interactions in the development of autoimmunity 

• summarize findings from prospective studies and discuss 

proposed prevention strategies 

Seattle, 4 Sanford-Burnham Institute for Medical Research, La 

Jolla, CA 

5:00 PM 

1660. Development of a Bruton’s Tyrosine Kinase (Btk) 

Inhibitor, ONO-4059: Efficacy in a Collagen Induced Arthritis 

(CIA) Model Indicates Potential Treatment for Rheumatoid 

Arthritis (RA) 

Toshio Yoshizawa, Yuko Ariza, Yoshiko Ueda, Shingo Hotta, 

Masami Narita and Kazuhito Kawabata, Ono Pharmaceutical Co., 

Ltd., Osaka, Japan 

5:15 PM 

1661. CCR1 Potentiates Gouty Inflammation Following 

Initial CXCR2-Dependent Neutrophil Recruitment to Sites of 

Monosodium Urate Crystal Deposition in Mice 

Robert P. Friday 1 , Terry K. Means 2 , Melissa Tai 2 , Christian D. 

Sadik 2 and Andrew D. Luster 2 , 1 Massachusetts General Hospital, 

Boston, MA, 2 Massachusetts General Hospital, Charlestown, MA 

MONDAY 


4:30 PM 

The Epidemiology of Autoimmunity – Lessons from the 

Clustering of Cases and Factors Associated with a Rising 

Incidence 

Jill M. Norris, MPH, PhD 

5:00 PM 

Studying Genes, Environment and Biomarkers to Identify 

Targets to Prevent the Onset of Rheumatoid Arthritis 

Hani S. El-Gabalawy, MD 

5:30 PM 

The Age of Lost Tolerance - the Rise and Fall of Autoantibodies 

Prior to Onset of Clinical Disease 

Judith A. James, MD, PhD 

5:30 PM 

1662. Anti-IL-6 Therapy Impairs Intestinal Repair Through 

Inhibition of Epithelial Proliferation After Injury 

Kristine Kuhn, Hiroyuki Miyoshi, Nicholas A. Manieri, Nicole P. 

Malvin, Vinieth Bijanki, Paul Allen and Thaddeus S. Stappenbeck, 

Washington University School of Medicine, St. Louis, MO 

5:45 PM 

1663. G Protein Signaling Modulator 3 Is a Key Regulator of 

Monocyte-Driven Inflammatory Arthritis 

Matthew J. Billard, Patrick M. Giguére, Brian Buckley, Marcus W. 

McGinnis, Roman Timoshchenko, Peng Liu, David P. Siderovski 

and Teresa K. Tarrant, University of North Carolina at Chapel Hill, 

Chapel Hill, NC 

82 


4:30 - 6:00 PM 

140 A 

Cytokines, Mediators, and Gene Regulation II 

Moderators: Erik Lubberts, PhD and Michael Volin, PhD 

4:30 PM 

1658. Signal Transducer and Activator of Transcription 3 

Induced Synovial Invasion and Migration Is Mediated in Part 

Through the Notch/Hypoxia-Inducible Factor 1α Pathways 

Wei Gao 1 , Douglas J. Veale 2 and Ursula Fearon 3 , 1 Translational 

Rheumatology Research Group, Dublin, Ireland, 2 Dublin 

Academic Medical Centre, St. Vincent’s University Hospital, 

Dublin, Ireland, 3 Translation Rheumatology Research Group, 

Dublin, Ireland 

4:45 PM 

1659. Ptpome Profile of Rheumatoid Arthritis Fibroblast-Like 

Synoviocytes: A Novel Role for the Tyrosine Phosphatase SHP-2 

As a Modulator of Invasion and Survival 

Stephanie Stanford 1 , Michael Maestre 1 , Beatrix Bartok 2 , David L. 

Boyle 2 , Heather Arnett 3 , Tomas Mustelin 4 , Gary S. Firestein 2 and 

Nunzio Bottini 1 , 1 La Jolla Institute for Allergy and Immunology, La 

Jolla, CA, 2 UCSD School of Medicine, La Jolla, CA, 3 Amgen, Inc., 


Ballroom B 

Epidemiology and Health Services Research III: 

Rheumatic Diseases and Cardiovascular Disease and 

Risk Assessment 

Moderators: Laura L. Tarter, MD and Mariko L. Ishimori, MD 

4:30 PM 

1664. Autoantibodies Are Associated with Subclinical 

Atherosclerosis and Cardiovascular Endpoints in Caucasian and 

African American Women in a Prospective Study: the Multi- 

Ethnic Study of Atherosclerosis (MESA) 

Darcy S. Majka 1 , Rowland W. Chang 1 , Richard M. Pope 2 , Marius 

C. Teodorescu 3 , Elizabeth W. Karlson 4 , Thanh Huyen T. Vu 5 , 

Joseph Kang 6 and Kiang Liu 1 , 1 Northwestern University, Chicago, 

IL, 2 Northwestern Univ Med School, Chicago, IL, 3 TheraTest 

Laboratories Inc, Lombard, IL, 4 Brigham and Women’s Hospital, 

Harvard Medical School, Boston, MA, 5 Northwestern University, 

Feinberg School of Medicine, Chicago, 6 Northwestern University, 

Feinberg School of Medicine, Chicago, IL 

4:45 PM 

1665. Associations of Race and Ethnicity with Overall Mortality 

and Cardiovascular Events Among Patients with End-Stage 

Renal Disease Due to Lupus Nephritis 

Jose A. Gomez-Puerta 1 , Sushrut Waikar 2 , Graciela S. Alarcon 3 , 

Jun Liu 4 , Daniel H. Solomon 1 , Wolfgang C. Winkelmayer 5 and

Karen H. Costenbader 1 , 1 Division of Rheumatology, Immunology, 

and Allergy, Brigham and Women’s Hospital, Harvard Medical 

School, Boston, Boston, MA, 2 Division of Nephrology, Brigham 

and Women’s Hospital, Harvard Medical School, Boston, Boston, 

MA, 3 University of Alabama at Birmingham, Birmingham, AL, 

4 

Division of Pharmacoepidemiology and Pharmacoeconomics, 

Brigham and Women’s Hospital, Harvard Medical School, 

Boston, Boston, MA, 5 Stanford University School of Medicine, 

Stanford, CA 

5:00 PM 

1666. Short Term Use of Glucocorticoids Is Not Associated with 

Acute Risk of Myocardial Infarction 

Steven C. Vlad 1 , David T. Felson 1 , Donald R. Miller 2 and Yuqing 

Zhang 1 , 1 Boston University, Boston, MA, 2 Edith Nourse Rogers 

Memorial VA Hospital, Bedford, MA 

5:15 PM 

1667. Impact of Rheumatoid Arthritis On Recognition of 

Hypertension in a Medically Homed Population 

Christie M. Bartels 1 , Heather Johnson 2 , Katya Voelker 2 , Patrick 

Mc Bride 2 and Maureen Smith 1 , 1 Univ of Wisconsin School of 

Medicine and Public Health, Madison, WI, 2 Univ of Wisconsin 

School of Medicine and Public Health, Madison 

5:30 PM 

1668. Improving the Accuracy of Cardiovascular Risk Prediction 

in Rheumatoid Arthritis with a New Predictive Model Using the 

10-Year Prospective Carre-Study 

Alper M. van Sijl 1 , Inge A.M. van den Oever 1 , Mike J.L. Peters 2 , 

Vokko P. van Halm 3 , Alexandre E. Voskuyl 2 , Yvo M. Smulders 2 

and Mike T. Nurmohamed 1 , 1 Jan van Breemen Research Institute 

| Reade, Amsterdam, Netherlands, 2 VU University Medical 

Center, Amsterdam, Netherlands, 3 Academic Medical Centre, 


5:45 PM 

1669. Infection Risk After Orthopaedic Surgery in Patients 

with Inflammatory Rheumatic Diseases, with Focus On 

Discontinuation of TNF-Alpha-Inhibitors 

Catrina B. Scherrer 1 , Anne AF Mannion 1 , Diego Kyburz 2 , Markus 

Vogt 3 and Ines A. Kramers-de Quervain 1 , 1 Schulthess Clinic, 

Zürich, Switzerland, 2 Center of Exp. Rheumatology, Zurich, 

Switzerland, 3 Cantonal Hospital Zug, Baar, Switzerland 

202 B 


Pathogenesis in Idiopathic Inflammatory Myopathies 

Moderators: Lauren M. Pachman, MD and Jiri Vencovsky, MD, 

DSc 

4:30 PM 

1670. Microarray Analysis for miRNA Expression in Juvenile 

Dermatomyositis (JDM) 

Dong Xu 1 , Akadia Kachaochana 2 , Gabrielle A. Morgan 2 , Elio 

F. Vanin 3 , Marcelo Bento Soares 3 and Lauren M. Pachman 1 , 

1 

Division of Pediatric Rheumatology, Northwestern University 

Feinberg School of Medicine, Chicago, IL, 2 Children’s Hospital 

of Chicago Research Center, Cure JM Myositis Center, Chicago, 

IL, 3 Cancer Biology & Epigenomics Program, Department 

of Pediatrics, Northwestern University Feinberg School of 

Medicine, Chicago, IL 

4:45 PM 

1671. Characterization of Jo-1 Autoantibodies in Patients with 

Inflammatory Myopathy and Interstitial Lung Disease 

Kyle P. Chiang 1 , Varun Gauba 1 , Darin Lee 1 , Minh-Ha T. Do 1 , Jie J. 

Zhou 2 , Feng Wang 2 , Ying Buechler 1 , Leslie Nangle 1 , Zhiwen Xu 2 , 

John Mendlein 1 , Melissa Ashlock 1 and Jeffrey M. Greve 1 , 1 aTyr 

Pharma, San Diego, CA, 2 Hong Kong University of Science and 

Technology, Kowloon, Hong Kong 

5:00 PM 

1672. Myosin Skews Effector Immune Cells of Scurfy Mice to 

Target Muscles in an Adoptive Transfer Model of Myositis 

Nicholas Young 1 , Rahul Sharma 2 , Alexandra Friedman 1 , Benjamin 

Kaffenberger 1 and Wael N. Jarjour 3 , 1 The Ohio State University 

Medical Center, Columbus, OH, 2 University of Virginia Health 

System, Charlottesville, VA, 3 Ohio State University, Columbus, 

OH 

5:15 PM 

1673. Clinical Phenotypes of Caucasian Adult and Juvenile 

Dermatomyositis Patients with Anti-MDA5 Autoantibodies 

Zoe Betteridge 1 , Sarah Tansley 1 , Harsha Gunawardena 2 , Lucy 

R. Wedderburn 3 , Hector Chinoy 4 , Robert G. Cooper 5 , Jiri 

Vencovsky 6 , Lenka Plestilova 7 , Ingrid E. Lundberg 8 , Katalin 

Danko 9 , Melinda Vincze 9 , Neil McHugh 1 , UK JDRG 10 and 

EuMyoNet 11 , 1 Royal National Hospital for Rheumatic Diseases, 

Bath, United Kingdom, 2 North Bristol NHS Trust, Bristol, 

United Kingdom, 3 University College London (UCL), London, 

United Kingdom, 4 The University of Manchester, Manchester, 

United Kingdom, 5 Hope Hospital, Salford, United Kingdom, 

6 

Institute of Rheumatology, Prague, Czech Republic, 7 Institute of 

Rheumatology, Prague 2 , Czech Republic, 8 Karolinska Institutet, 

Stockholm, Sweden, 9 University of Debrecen, Debrecen, 

Hungary, Debrecan, Hungary, 10 London, United Kingdom, 

11 


5:30 PM 

1674. Myeloid Related Proteins Induce Muscle Derived 

Inflammatory Mediators in Juvenile Dermatomyositis 

Kiran Nistala 1 , Hemlata Varsani 1 , Helmut Wittkowski 2 , Thomas 

Vogl 3 , Petra Krol 4 , Vanita Shah 1 , Kamel Mamchaoui 5 , Paul 

Brogan 1 , Johannes Roth 3 and Lucy R. Wedderburn 1 , 1 University 

College London (UCL), London, United Kingdom, 2 Muenster, 

Germany, 3 University of Muenster, Muenster, Germany, 4 Prague, 

Czech Republic, 5 Paris, France 

5:45 PM 

1675. Myositis Autoimmunity and Muscle Weakness Are 

Linked to TNF-Alpha Suppression of Micrornas-1, 133, and 206 

in Myoblasts and Myocytes 

Robert Georgantas III 1 , Katie Streicher 1 , Steven A. Greenberg 2 , 

Lydia Greenlees V 3 , Wei Zhu 4 , Philip Brohawn 4 , Brandon W. 

Higgs 4 , Megan Czapiga 5 , Chris Morehouse 4 , Laura Richman 3 , 

Bahija Jallal 4 , Koustubh Ranade 5 and Yihong Yao 3 , 1 Medimmune, 

Inc, Gaithersburg, MD, 2 Brigham Women’s Hospital, Harvard 

Medical School, Boston, MA, 3 MedImmune, Gaithersburg, 

MD, 4 MedImmune, LLC, Gaithersburg, MD, 5 MedImmune, Inc, 

Gaithersburg, MD 

MONDAY 



MONDAY 


207 A 


Disease II: Juvenile Idiopathic Arthritis II 

Moderators: Daniel J. Kingsbury, MD and D. J. Lovell, MD, MPH 

4:30 PM 

1676. Abatacept As First Line Biological Treatment for Severe 

Juvenile Idiopathic Arthritis-Related Uveitis. A Multicenter 

Study 

Carolina Birolo 1 , Maria Elisabetta Zannin 1 , Svetlana Arsenyeva 2 , 

Rolando Cimaz 3 , Elisabetta Miserocchi 4 , Margarita Dubko 5 , 

Chantal Deslandre 6 , Fernanda Falcini 7 , Maria Alessio 8 , Francesco 

La Torre 9 , Ekaterina Denisova 10 , Irina Nikishina 11 and Francesco 

Zulian 12 , 1 University of Padua, Padua, Italy, 2 Scientific Research 

Institute of Rheumatology RAMS, Moskow, Russia, 3 A. Meyer 

Children’s Hospital, Florence, Italy, 4 Scientific Institute San 

Raffaele, University Vita-Salute, Milan, Italy, 5 Saint-Petersburg 

Pediatric Medical Academy, Saint-Petersburg, Russia, 6 Cochin 

Hospital, Paris, France, 7 Department of Internal Medicine, 

Rheumatology Section, University of Florence, Florence, 

Italy, 8 University of Naples Federico II, Naples, Italy, 9 DIMIMP- 

University, Rheumatologic Section, Bari, Italy, 10 Helmgoltz 

Moscow Recearch Institute of Eye Diseases, Moskow, Russia, 

11 

Scientific Research Institute of Rheumatology RAMS, Moskow, 

Moskow, Russia, 12 University of Padua, Padova, Italy 

4:45 PM 

1677. Safety and Efficacy of Intra-Articular Infliximab Therapy 

for Treatment Resistant Temporomandibular Joint Arthritis in 

Children 

Matthew L. Stoll, Anthony B. Morlandt, Suwat 

Teerawattanapong, Daniel Young, Peter D. Waite and Randy Q. 

Cron, University of Alabama at Birmingham, Birmingham, AL 

5:00 PM 

1678. Safety and Efficacy of Adalimumab in Children with 

Active Polyarticular Juvenile Idiopathic Arthritis Aged 2 to

5:30 PM 

1686. Vertebral Fracture Assessment-Detected Abdominal 

Aortic Calcification Enhances Cardiovascular Disease Risk 

Stratification of Rheumatoid Arthritis Patients 

Ausaf Mohammad 1 , Derek Lohan 1 , Diane Bergin 1 , Sarah 

Mooney 1 , John Newell 2 , Martin O’Donnell 1 , Robert J. Coughlan 1 

and John J. Carey 1 , 1 Galway University Hospitals, Galway, Ireland, 

2 

National University of Ireland, Galway, Ireland 

5:45 PM 

1687. The Risk of Atrial Fibrillation in Patients with 

Rheumatoid Arthritis Compared to the General Population: A 

Large Cohort Study 

Seoyoung C. Kim 1 , Jun Liu 2 and Daniel H. Solomon 3 , 1 Brigham 

and Women’s Hospital, Boston, MA, 2 Brigham and Women’s 

Hospital, Harvard Medical School, Boston, Boston, MA, 3 Brigham 

& Women’s Hospital and Harvard Medical School, Boston, MA 

146 C 

Rheumatoid Arthritis - Human Etiology and 

Pathogenesis I: Early Pathogenesis of Rheumatoid 

Arthritis 

Moderators: Hani S. El-Gabalawy, MD and Alisa E. Koch, MD 

4:30 PM 

1688. Evolution of Preclinical Autoimmunity in Individuals At 

Risk for Development of Rheumatoid Arthritis 

Hani S. El-Gabalawy 1 , David B. Robinson 1 , Irene Smolik 1 , Donna 

M. Hart 1 , Elizabeth D. Ferucci 2 , Marianna M. Newkirk 3 , Marvin 

J. Fritzler 4 , Catriona Cramb 5 , Jeremy Sokolove 5 and William H. 

Robinson 5 , 1 University of Manitoba, Winnipeg, MB, 2 Alaska 

Native Tribal Health Consortium, Anchorage, AK, 3 McGill 

University Health Centr, Montreal, QC, 4 University of Calgary, 

Calgary, AB, 5 Stanford University, Palo Alto, CA 

4:45 PM 

1689. Anti-Peptidylarginine Deiminase 3/4 Cross-Reactive 

Antibodies: A Novel Biomarker with Clinical and Mechanistic 

Implications in Rheumatoid Arthritis 

Erika Darrah 1 , Jon T. Giles 2 , Herbert Bull 3 , Felipe Andrade 1 

and Antony Rosen 1 , 1 The Johns Hopkins University School of 

Medicine, Baltimore, MD, 2 Columbia University Medical Center, 

New York, NY, 3 Consultant, Westfield, NJ 

5:00 PM 

1690. Citrullination within the Atherosclerotic Plaque: A New 

Potential Target for Anti-Citrullinated Protein Antibodies 

Jeremy Sokolove 1 , Orr Share 1 , Matthew Brennan 1 , Lauren J. 

Lahey 1 , Amy H. Kao 2 , Eswar Krishnan 3 , Mary Chester Wasko 4 

and William H. Robinson 5 , 1 VA Palo Alto Health Care System and 

Stanford University, Palo Alto, CA, 2 Allegheny Singer Research 

Institute, Pittsburgh, PA, 3 Stanford University, Stanford, CA, 

4 

Temple University School of Medicine, Pittsburgh, PA, 5 Stanford 

University, Palo Alto, CA 

5:15 PM 

1691. Early Signs of Subclinical Inflammation and Local 

Antibody Production in Early Rheumatoid Lungs 

Gudrun Reynisdottir 1 , Reza Karimi 2 , Jimmy Ytterberg 3 , Vijay 

Joshua 1 , Helga Olsen 2 , Aase Haj Hensvold 1 , Anders Harju 3 , Johan 

Grunewald 2 , Sven Nyren 4 , Anders Eklund 2 , Lars Klareskog 5 , 

Roman Zubarev 6 , Magnus Skold 2 and Anca Irinel Catrina 1 , 

1 

Rheumatology unit, Karolinska University Hospital, Karolinska 

Institute, Stockholm, Sweden, 2 Division of Respiratory Medicine, 


Sweden, 3 Rheumatology Unit, Karolinska University Hospital, 

Karolinska Institute, Stockholm, Sweden, 4 Karolinska University 

Hospital, Karolinska Institute, Stockholm, Sweden, Stockholm, 

Sweden, 5 Karolinska Institute, Stockholm, Sweden, 6 Karolinska 

Institutet, Stockholm, Sweden 

5:30 PM 

1692. Lung Microbiome Differs in Subjects with Rheumatoid 

Arthritis-Related Autoimmunity without Inflammatory 

Arthritis Compared to Healthy Seronegative Controls 

M. Kristen Demoruelle 1 , Jill M. Norris 2 , V. Michael Holers 1 , Kevin 

D. Deane 1 and J. Kirk Harris 3 , 1 University of Colorado School 

of Medicine, Aurora, CO, 2 Colorado School of Public Health, 

Aurora, CO, 3 Aurora, CO 

5:45 PM 

1693. Oncogenic Activation of MAPK in Rheumatoid Arthritis 

Synovial Fibroblasts 

Niloofar L. Farmani 1 , Keith K. Colburn 2 , Grace Chan 3 , Erica Li 3 , 

Emil Heinze 1 , Antonia Rubell 3 , Robert Nishimura 4 and Richard 

H. Weisbart 3 , 1 Olive View-UCLA Medical Center, Sylmar, CA, 

2 

Loma Linda Univ Medical Center, Loma Linda, CA, 3 VAGLAHS, 

Sepulveda, CA, 4 The David Geffen School of Medicine at UCLA, 

Los Angeles, CA 

Hall E 


Biologics and Gene Therapy: Safety II 

Moderators: Alan J. Kivitz, MD, and Joseph M. Grisanti, MD 

4:30 PM 

1694. Infection Risk in Patients with Low Immunoglobulins 

Following Rituximab Treatment in Rheumatoid Arthritis 

Ronald F. van Vollenhoven 1 , Gregg J. Silverman 2 , Clifton O. 

Bingham III 3 , Patrick Durez 4 , Patrica B. Lehane 5 , Nicola Tyson 5 

and Elena Fisheleva 5 , 1 Karolinska University Hospital, Stockholm, 

Sweden, 2 NYU School of Medicine, New York, NY, 3 Johns Hopkins 

University, Baltimore, MD, 4 University Hospital St Luc, UCL, 

Brussels, Belgium, 5 Roche Products Limited, Welwyn Garden 

City, United Kingdom 

4:45 PM 

1695. Prolonged Exposure to Subcutaneous and Intravenous 

Abatacept in Patients with Rheumatoid Arthritis Does Not 

Affect Rates of Infection, Malignancy and Autoimmune Events: 

Results From Pooled Clinical Trial Data 

M. C. Genovese 1 , M C. Hochberg 2 , R. B. Cohen 3 , M. E. Weinblatt 4 , 

J. Kaine 5 , E. Keystone 6 , P. Nash 7 , I. Delaet 8 and R. Alten 9 , 

1 

Stanford University, Palo Alto, CA, 2 Department of Medicine, 

University of Maryland, Baltimore, MD, 3 Perelman School 

of Medicine, University of Pennsylvania, Philadelphia, PA, 

4 


Boston, MA, 5 Sarasota Arthritis Research Center, Sarasota, FL, 

6 

Mount Sinai Hospital, Toronto, ON, 7 University of Queensland, 

Brisbane, Australia, 8 Bristol-Myers Squibb, Princeton, NJ 

and Bristol-Myers Squibb, Hopewell, VA, 9 Schlosspark-Klinik, 

University Medicine, Berlin, Germany 


MONDAY 

November 12, 2012

MONDAY 


86 

5:00 PM 

1696. Quantitative Evaluation of Dermal Atrophy by 

High-Resolution Ultrasonography, Comparing Between 

Patients Under Long-Term Treatment with Prednisolone or 

Methylprednisolone 

Tim Pottel 1 , Christoph Schäfer 2 and Gernot Keyßer 2 , 1 06114 Halle 

(Saale), Germany, 2 06120 Halle (Saale), Germany 

5:15 PM 

1697. Meta-Analysis of Malignancies, Serious Infections, and 

Serious Adverse Events with Tofacitinib or Biologic Treatment 

in Rheumatoid Arthritis Clinical Trials 

Sima Ahadieh 1 , Tina Checchio 1 , Thomas Tensfeldt 1 , Jonathan 

French 2 , Sriram Krishnaswami 1 , Richard Riese 1 , Sujatha Menon 1 , 

Mary G. Boy 1 and Jamie L. Geier 3 , 1 Pfizer Inc., Groton, CT, 

2 

Metrum Research Institute, Tariffville, CT, 3 Pfizer Inc., New York, 

NY 

5:30 PM 

1698. Predictors of Discontinuation of Biologics in 2,281 US 


Sofia Ramiro 1 , Frederick Wolfe 2 , David J. Harrison 3 , George 

Joseph 3 , David H. Collier 3 , Désirée van der Heijde 4 , Robert 

Landewé 5 and Kaleb Michaud 6 , 1 Academic Medical Center, 

University of Amsterdam, The Netherlands and Hospital Garcia 

de Orta, Almada, Portugal, 2 National Data Bank for Rheumatic 

Diseases, Wichita, KS, 3 Amgen Inc., Thousand Oaks, CA, 4 Leiden 

University Medical Center, Leiden, Netherlands, 5 Academic 

Medical Center, University of Amsterdam and Atrium Medical 

Center, Heerlen, Netherlands, 6 National Data Bank for Rheumatic 

Diseases & University of Nebraska Medical Center, Omaha, NE 

5:45 PM 

1699. Neutropenia After Rituximab in Rheumatoid Arthritis 

and Other Autoimmune Diseases Is a Rare Events: Date From 

the Autoimmunity and Rituximab Registry 

Jean Hugues Salmon 1 , Patrice P. Cacoub Sr. 2 , Bernard G. Combe 3 , 

Jean Sibilia 4 , Beatrice Pallot Prades 5 , Olivier Fain 6 , Alain G. 

Cantagrel 7 , Maxime Dougados 8 , Olivier Meyer 9 , Philippe Carli 10 , 

Edouard Pertuiset 11 , Isabelle Pane 12 , Philippe Ravaud 13 , Xavier 

Mariette 14 and Jacques-Eric Gottenberg 15 , 1 Rheumatology, 

Reims, France, 2 Assistance Publique-Hôpitaux de Paris, Hopital 

Pitié-Salpétrière, Paris, France, 3 Hopital Lapeyronie, Montpellier, 

France, 4 CHU Hautepierre, Strasbourg, France, 5 Saint Etienne 

university hospital, Saint Etienne, France, 6 Service de médecine 

interne, Université Paris 13, AP-HP, Hôpital Jean Verdier, 

93140, Bondy, France., Bondy, France, 7 Place du Docteur 

Baylac, Toulouse, France, 8 Paris-Descartes University, APHP, 

Cochin Hospital, Paris, France, 9 Hopital Bichat, Paris, France, 

10 

Toulon, France, 11 Ch Rene Dubos, Pontoise, France, 12 Hotel 

Dieu University Hospital Paris, France, 13 Hopital Hotel Dieu, 

Paris Descartes University, Paris, France, 14 Université Paris-Sud, 

Le Kremlin Bicetre, France, 15 Strasbourg University Hospital, 

Strasbourg, France 

145 A 


Aspects and Treatment: Spondyloarthritis II 

Moderators: Oliver M. FitzGerald, MD and Enrique R. Soriano, 

MD, MSc 


4:30 PM 

1700. Prevalence of Spondyloarthritis in Anterior Uveitis 

Patients: The Sentinel Study 

Miguel Cordero Coma 1 and Xavier Juanola 2 , 1 Unidad de Uveítis. 

Hospital Universitario de León, León, Spain, 2 Hospital Universitari 

de Bellvitge, Barcelona, Spain 

4:45 PM 

1701. Validation of the New ASAS Criteria for Classification of 

Early Spondyloarthritis in the Esperanza Cohort 

Eva Tomero 1 , Loreto Carmona 2 , Juan Mulero 3 , Eugenio De 

Miguel 4 , Milena Gobbo 5 , Carmen Martínez 6 , Miguel A. Descalzo 5 , 

Pedro Zarco 7 , Eduardo Collantes-Estevez 8 and Esperanza Group 9 , 

1 

Hospital Universitario La Princesa, Madrid, Spain, 2 Universidad 

Camilo José Cela, Villanueva de la Cañada, Spain, 3 Hospital 

Universitario Puerta de Hierro Majadahonda, Majadahonda 

(Madrid), Spain, 4 Hospital Universitario La Paz, Madrid, Spain, 

5 

Spanish Society of Rheumatology, Madrid, Spain, 6 Sociedad 

Española de Reumatología, Madrid, Spain, 7 Fundación Hospital 

Alcorcon, Alcorcon, Madrid, Spain, 8 IMIBIC-Reina Sofia Hospital, 

Cordoba 14012, Spain, 9 Madrid 

5:00 PM 

1702. Tumor Necrosis Factor Blocking Agents Inhibit the 

Progression of Preclinical Atherosclerosis in Patients with 


Alper M. van Sijl 1 , Izhar C. van Eijk 2 , Mike J.L. Peters 2 , Erik H. 

Serne 2 , Yvo M. Smulders 2 and Mike T. Nurmohamed 1 , 1 Jan van 

Breemen Research Institute | Reade, Amsterdam, Netherlands, 

2 

VU University Medical Center, Amsterdam, Netherlands 

5:15 PM 

1703. Relationship Between Tobacco Smoking and 

Radiographic Spinal Progression in Axial Spondyloarthritis: The 

Role of Inflammatory Activity 

Denis Poddubnyy 1 , Hildrun Haibel 1 , Joachim Listing 2 , Elisabeth 

Märker-Hermann 3 , Henning Zeidler 4 , Jürgen Braun 5 , Martin 

Rudwaleit 6 and Joachim Sieper 7 , 1 Charité Medical University, 

Campus Benjamin Franklin, Berlin, Germany, 2 German 

Rheumatism Research Center, Berlin, Germany, 3 Dr. Horst 

Schmidt Kliniken, Wiesbaden, Germany, 4 Medizinische 

Hochschule, Hannover, Germany, 5 Rheumazentrum Ruhrgebiet, 

Herne, Germany, 6 Endokrinologikum Berlin, Berlin, Germany, 

7 

Charité Universitätesmedizin Berlin, Berlin, Germany 

5:30 PM 

1704. New Threshold Values for Spinal Mobility Measures 

Based On a Large Nationally Representative Sample of U.S. 

Adults Ages 20-69 Years 

Shervin Assassi 1 , Michael H. Weisman 2 , Zhongxue Chen 1 , 

Mohammad Rahbar 1 and John D. Reveille 1 , 1 Univ of Texas Health 

Science Center at Houston, Houston, TX, 2 Cedars-Sinai Medical 

Center, Los Angeles, CA 

5:45 PM 

1705. Effect of Certolizumab Pegol On Inflammation of Spine 

and Sacroiliac Joints in Patients with Axial Spondyloarthritis: 

12 Week Magnetic Resonance Imaging results of a Phase 3 

Double Blind Randomized Placebo-Controlled Study 

Désirée van der Heijde 1 , Walter P. Maksymowych 2 , Robert B. M. 

Landewé 3 , Christian Stach 4 , Bengt Hoepken 4 , Andreas Fichtner 4 , 

Danuta Kielar 5 and Jurgen Braun 6 , 1 Leiden University Medical

Center, Leiden, Netherlands, 2 University of Alberta, Edmonton, 

AB, 3 Academic Medical Center/University of Amsterdam & 

Atrium Medical Center, Amsterdam, Netherlands, 4 UCB Pharma, 

Monheim am Rheim, Germany, 5 UCB Pharma, Brussels, Belgium, 

6 

Rheumazentrum Ruhrgebiet, Herne, Germany 



Treatment III: Cardiovascular 

Moderators: Susan Manzi, MD, MPH and Jose A. Gomez-Puerta, 

MD, PhD 

4:30 PM 

1706. Predictive Atherosclerotic Risk Factors At Inception in a 

Multicentre, Multinational Cohort 

Murray B. Urowitz 1 , Dominique Ibanez 1 , D. D. Gladman 1 and 

SLICC 2 , 1 Toronto Western Hospital and University of Toronto, 

Toronto, ON, 2 Toronto, ON 

2 

University of Pittsburgh, Pittsburgh, PA, 3 Allegheny Singer 

Research Institute, Pittsburgh, PA, 4 West Penn Allegheny Health 

System, Pittsburgh, PA 

147 A 


Raynaud’s – Clinical Aspects and Therapeutics II 

Moderators: Robyn T. Domsic, MD, MPH and Luc Mouthon Sr., 

MD 

4:30 PM 

1712. The Submaximal Heart and Pulmonary Evaluation: A 

Novel Noninvasive Test to Identify Pulmonary Hypertension in 

Patients with Systemic Sclerosis 

Elana J. Bernstein 1 , Jessica K. Gordon 1 , Robert F. Spiera 1 , Lisa A. 

Mandl 1 and Evelyn M. Horn 2 , 1 Hospital for Special Surgery, New 

York, NY, 2 New York Presbyterian Hospital/Weill Cornell Medical 

College, New York, NY 

4:45 PM 

1707. The Association of Serum Biomarkers and Metabolic 

Syndrome with Subclinical Atherosclerosis in Systemic Lupus 

Erythematosus: A Controlled Analysis in Patients with No 

Clinical Disease Activity 

Semra Ertan-Demir 1 , Ahmet Yasar Cizgici 1 , Gaye Erten 2 , Bahar 

Artim-Esen 1 , Yasemin Sahinkaya 1 , Özlem Pehlivan 1 , Nilüfer 

Alpay-Kanitez 1 , Kadri Atay 1 , Huseyin Oflaz 1 , Gunnur Deniz 2 and 

Murat Inanc 1 , 1 Istanbul University, Istanbul Faculty of Medicine, 

Istanbul, Turkey, 2 Istanbul University, Institute of Experimental 

Medicine (DETAE), Istanbul, Turkey 

5:00 PM 

1708. Systemic Lupus Erythematosus Cardiovascular Risk 

Equation 

Michelle Petri 1 and Laurence S. Magder 2 , 1 Johns Hopkins 

University School of Medicine, Baltimore, MD, 2 University of 

Maryland, Baltimore, MD 

5:15 PM 

1709. Biomarkers of Atherosclerosis Are Associated with 

Progression of Non-Cardiovascular Damage in Patients with 

SLE 

Sarah J. Kim, Jennifer M. Grossman, Brian Skaggs, Elaine 

Lourenco, Lori Sahakian, John D. FitzGerald, Nagesh Ragavendra, 

Christina Charles-Schoeman, Alan H. Gorn, Bevra H. Hahn and 

Maureen A. McMahon, UCLA David Geffen School of Medicine, 


5:30 PM 

1710. Increase in Vitamin D Improves Disease Activity and 

Systolic Blood Pressure in Systemic Lupus Erythematosus 

Kayode J. Bello 1 , Hong Fang 1 , Laurence S. Magder 2 and Michelle 

Petri 1 , 1 Johns Hopkins University School of Medicine, Baltimore, 

MD, 2 University of Maryland, Baltimore, MD 

5:45 PM 

1711. Association of Vascular Calcification and Perivascular 

Adipose Tissue of the Descending Aorta with Cardiovascular 

Events in SLE 

Kelly J. Shields 1 , Emma Barinas-Mitchell 2 , Amy H. Kao 3 , Susan 

Manzi 4 and Kim Sutton-Tyrrell 2 , 1 Lupus Center of Excellence/ 

ASRI/West Penn Allegheny Health System, Pittsburgh, PA, 

4:45 PM 

1713. Developing an Index for Disease Activity and Therapeutic 

Response in Connective Tissue Disease Related Interstitial 

Lung Disease: Results From A Delphi Exercise: Delivering A 

Consensus On Domains 

Lesley Ann Saketkoo 1 , Dörte Huscher 2 , Dinesh Khanna 3 , Paul F. 

Dellaripa 4 , Kevin Flaherty 3 , Chester V. Oddis 5 , Kristine Phillips 3 , 

Athol U. Wells 6 , Christopher P. Denton 7 , Oliver Distler 8 , Otylia 

M. Kowal-Bielecka 9 , Romy Christmann 10 , Nora Sandorfi 11 , 

David Pittrow 12 , Vibeke Strand 13 , James R. Seibold 14 , Kevin K. 

Brown 15 and Eric L. Matteson 16 , 1 Louisiana State University 

Health Science Center, New Orleans, LA, 2 German Rheumatism 

Research Centre and Charité University Medicine, Berlin, 

Germany, 3 University of Michigan, Ann Arbor, MI, 4 Brigham 

and Womens Hospital, Boston, MA, 5 University of Pittsburgh, 

Pittsburgh, PA, 6 Royal Brompton Hospital, United Kingdom, 

7 

UCL, London, United Kingdom, 8 Department of Rheumatology 

and Center of Experimental Rheumatology, University Hospital 

Zurich, Zurich, Switzerland, 9 Department of Rheumatology 

and Internal Medicine, Medical University in Bialystok, 

Bialystok, Poland, 10 Boston University, Boston, MA, 11 Thomas 

Jefferson Univ Med Coll, Philadelphia, PA, 12 Dresden, Germany, 

13 

Stanford University, Portola Valley, CA, 14 Scleroderma Research 

Consultants LLC, Avon, CT, 15 National Jewish Hospital, Denver, 

CO, 16 Mayo Clinic, Rochester, MN 

5:00 PM 

1714. Gender Differences in Systemic Sclerosis: Relationship to 

Disease Specific Clinical Manifestations and Estradiol Levels 

Christine Peoples, Mary Lucas, Zengbiao Qi, Thomas A. Medsger 

Jr. and Carol A. Feghali-Bostwick, University of Pittsburgh, 


5:15 PM 

1715. Imatinib Mesylate (Gleevec) in the Treatment of 

Diffuse Cutaneous Systemic Sclerosis: Results of a 24 Month 

Open Label, Extension Phase 

Jessica K. Gordon 1 , Morgana L. Davids 1 , Kamini Doobay 1 , Jamie 

N. Mersten 1 , Cynthia Magro 2 , Horatio F. Wildman 2 , Stephen 

L. Lyman 1 , Mary K. Crow 1 and Robert F. Spiera 1 , 1 Hospital for 

Special Surgery, New York, NY, 2 Weill-Cornell Medical Center, 

New York 


MONDAY 

November 12, 2012

5:30 PM 

1716. Outcomes Linked to Intensive Treatment Trials in 

Systemic Sclerosis 

Svetlana I. Nihtyanova 1 , Voon H. Ong 2 and Christopher P. 

Denton 3 , 1 Royal Free Hospital, Medical School, London, England, 

2 

UCL Medical School, London, England, 3 UCL, London, United 

Kingdom 

5:45 PM 

1717. Autologous Lipostructure in the Treatment of Fibrotic 

Perioral Changes in Systemic Sclerosis: A Pilot Study 

Nicoletta Del Papa 1 , Fabio Caviggioli 2 , Domenico Sambataro 1 , 

Eleonora Zaccara 1 , Gabriele Di Luca 1 , Valeriano Vinci 2 and Marco 

Klinger 3 , 1 G. Pini Hospital, Milano, Italy, 2 UOC Chirurgia Plastica, 

Multimedica Holding SpA, Università degli Studi di Milano, 

Milano, Italy, 3 Istituto Clinico Humanitas, Università degli Studi di 

Milano;, Milano, Italy 

PM 

PS 

158 B 

Pediatric Systemic Lupus (057) 

Speaker: Kelly A. Rouster-Stevens, MD, MSc 

159 A 

Psoriatic Arthritis (058) 

Speaker: M. Elaine Husni, MD, MPH 

159 B 

*Rheumatoid Arthritis: Biological Agents (059) 


160 

Systemic Lupus Erythematosus: Difficult to Treat 

Systemic Lupus Erythematosus (060) 

Speaker: Maria Dall’Era, MD 

MONDAY 



4:30 - 6:00 PM 










September 14. 

148 

Adult Inflammatory Myopathy (051) 

Speaker: Mary E. Cronin, MD 

153 

Antiphospholipid Syndrome (052) 

Speaker: Munther A. Khamashta, MD 

ARHP SESSIONS 

4:30 - 6:00 PM 

201 

PM 

Early Rehabilitation for Hip and Foot Osteoarthritis: 

Opportunities and Challenges 



• describe clinical presentation and assessment of individuals 

with early osteoarthritis 

• distinguish hip impingement from hip osteoarthritis 

• define how to assess pain, mechanics and physical function in 

foot osteoarthritis 

• interpret the results of subject specific motion analysis in 

individuals with hip or foot osteoarthritis 

• identify key components of rehabilitation intervention 

4:30 PM 

Early Hip Osteoarthritis: Clinical Presentation, Intervention 

Strategies and Implications for Treatment 

Shingpui Betty Chow, PT, MA, OCS 

PS 

154 A 

Controversies in Sjögren’s Syndrome (053) 

Speaker: Alan N. Baer, MD 

154 B 

Dermatological Manifestations of Rheumatic Diseases 

(054) 

Speaker: Ruth Ann Vleugels, MD 

155 

Fibromyalgia and Dysautonomia (055) 

Speaker: Manuel Martinez-Lavin, MD 

158 A 

Pain: Evaluation and Treatment of Back Pain (056) PM 

Speaker: David G. Borenstein, MD 

PS 

4:55 PM 

Hip Impingement: Clinical Presentation, Evaluation, Principles 

for Intervention and Implications for Treatment 

Scott Siverling, PT, OCS 

5:20 PM 

Foot Osteoarthritis: Clinical Presentation, Evaluation of 

Function and Footwear, Evidence-based Intervention and 

Implications for Treatment 

Smita Rao, PT, PhD 

5:45 PM 


PM 

PS 

204 A 

Novel Approaches to Pain Management in Juvenile 

Idiopathic Arthritis PM PS 

Moderator: Lynn R. Spiegel, MDCM 

88 

2012 Program Book


• explain how to design and evaluate interactive health 

communication applications for youth with musculoskeletal 

pain using an example from the “Teens Taking Charge: 

Managing Arthritis Online” program 

• summarize the use of smartphone health technology as a 

mode of assessing pain and coping as well as delivering pain 

management interventions in youth with juvenile idiopathic 

arthritis, and assess whether this modality may be suitable for 

their own research 

• appraise information that will help them to consider the 

inclusion of non-pharmacologic approaches, including 

complementary and alternative medicine interventions such 

as yoga, for targeting pain in juvenile idiopathic arthritis 

4:30 PM 

Harnessing the Potential of the Internet: Developing a 

Web-based Self-management Program for Adolescents with 

Arthritis 

Jennifer N. Stinson, PhD, RN, CPNP 

5:00 PM 

DVD-based Yoga Intervention for Adolescent Girls with 


Amanda B. Feinstein, MS 

5:30 PM 

Smartphone Delivery of Non-pharmacologic Interventions for 

Pain in Juvenile Idiopathic Arthritis 


PM PS 

143 A 

Promoting Participation: Where Is the Field and 

Where Do We Go Next? 

Moderator: Jillian A. Rose, LMSW 


• discuss the importance of examining participation outcomes 

for persons with rheumatic conditions 

• outline participation outcome measures for assessing work 

disability 

• identify community and social participant outcome measures 

for adults with rheumatic conditions 

• apply current evidence to intervening on participation 

4:30 PM 

Participation: Definition and Current Measurement 

Approaches 

Julie J. Keysor, PhD, PT 

4:45 PM 

Work Disability and Employment Retention 

Rawan Alheresh, OT, MSc 

5:05 PM 

Participation and Community Dwelling Adults with Arthritis 


ARHP CONCURRENT ABSTRACT SESSION 

4:30 - 6:00 PM 

206 

Care of Patients with Rheumatoid Arthritis 

Moderators: Jennifer M. Hootman, PhD and Joan C. McTigue, 

PA-C 

4:30 PM 

1718. Cost Effectiveness of Nurse-Led Care for People with 

Rheumatoid Arthritis: A Multicentre RCT 

Mwidimi Ndosi 1 , Martyn Lewis 2 , Claire Hale 1 , Howard Bird 1 , 

Sarah Ryan 2 , Helen Quinn 1 , Elizabeth McIvor 3 , Julia Taylor 4 , 

Gail Burbage 5 , Deborah Bond 6 , Jo White 7 , Debbie Chagadama 8 , 

Sandra Green 9 , Lesley Kay 10 , Adrian V. Pace 11 , Victoria Bejarano 12 , 

Paul Emery 13 and Jackie Hill 1 , 1 University of Leeds, Leeds, United 

Kingdom, 2 Keele University, Staffordshire, United Kingdom, 

3 

Stobhill Hospital, Glasgow, UK, Glasgow, United Kingdom, 

4 

Poole Hospital NHS Trust, Poole, United Kingdom, 5 King’s 

Mill Hospital, Mansfield, United Kingdom, 6 Queen Elizabeth 

Hospital King’s Lynn, King’s Lynn, United Kingdom, 7 Leeds 

Teaching Hospitals NHS Trust, Leeds, United Kingdom, 8 Royal 

London Hospital, London, United Kingdom, 9 Weston General 

Hospital, Weston-Super-Mare, United Kingdom, 10 Newcastle 

upon Tyne Hospitals NHS Foundation Trust, Newcastle upon 

Tyne, United Kingdom, 11 Russells Hall Hospital, Dudley, United 

Kingdom, 12 Barnsley Hospital, Barnsley, United Kingdom, 13 Leeds 

Musculoskeletal Biomedical Research Unit, Leeds, United 

Kingdom 

4:45 PM 

1719. What Do Patients Put up with for the Benefit They Get 

From Methotrexate? 

Sandra M. Robinson 1 , Peta S. Heslop 1 and David Walker 2 , 1 North 

Tyneside General Hospital, North Shields, United Kingdom, 

2 

Freeman Hospital, Newcastle Upon Tyne, United Kingdom 

5:00 PM 

1720. Cardiovascular Risk Management in Rheumatoid 

Arthritis Is Nurse Led Intervention Effective? 

Fiona Niddrie 1 and Gabor AC Major 2 , 1 Bone and Joint Institute; 

Royal Newcastle Centre, Newcastle, Australia, 2 Bone&Joint 

Institute; Royal Newcastle Centre, Newcastle, Australia 

5:15 PM 

1721. Development of User-Focused Standards of Care for 

Rheumatoid Arthritis the Www.Eumusc.Net Project - Work 

Package 5 

Michaela Stoffer 1 , Josef S. Smolen 2 , Anthony D. Woolf 3 , Tanja 

A. Stamm 4 and EUMUSC.net working group WP 5 5 , 1 Medical 

University of Vienna, A – 1090 Vienna, Austria, 2 Medical 

University of Vienna and Hietzing Hospital, Vienna, Austria, 

3 

Royal Cornwall Hospital, Truro Cornwall, United Kingdom, 

4 

Medical University of Vienna, Vienna, Austria, 5 Truro Cornwall, 

MONDAY 


5:25 PM 

Participation and Adults Post Total Knee Joint Replacement 

Jessica L. Maxwell, DPT, PT 


5:45 PM 



5:30 PM 

1722. Exploring How Patients with Rheumatoid Arthritis Use a 

Methotrexate Decision Aid for Making Treatment Choices 

Linda C. Li 1 , Anne F. Townsend 2 , Paul M. Adam 3 , Catherine L. 

Backman 1 , Sydney Brooks 4 , Gwen A. Ellert 5 , Allyson Jones 6 , 

Otto Kamensek 2 , Cheryl Koehn 7 , Diane Lacaille 2 , Jenny Leese 8 , 

Colleen Maloney 2 , Elaine Yacyshyn 6 , Charlene Yousefi 2 and Dawn 

Stacey 9 , 1 University of British Columbia, Vancouver, BC, 2 Arthritis 

Research Centre of Canada, Vancouver, BC, 3 Mary Pack Arthritis 

Centre, Vancouver, BC, 4 The Arthritis Society, Ontario Division, 

Toronto, 5 Trelle Enterprises Inc, Vancouver, BC, 6 University of 

Alberta, Edmonton, AB, 7 Vancouver, BC, 8 Arthritis Research 

Centre, Vancouver, BC, 9 University of Ottawa, Ottawa, ON 

5:45 PM 

1723. The Development of the Rheumatoid Arthritis Patient 

Priorities in Pharmacological Intervention Outcome Measures 

Tessa Sanderson 1 , John R. Kirwan 2 , Marianne Morris 1 , Jon 

Pollock 1 , Robert Noddings 2 , Anne Watts 2 and Sarah Hewlett 1 , 

1 

University of the West of England, Bristol, United Kingdom, 

2 

Bristol Royal Infirmary, Bristol, United Kingdom 

ACR STUDY GROUPS 

6:30 - 7:45 PM 

Study Groups are non-CME activities, open to all attendees. 

See page 102 for additional Study Group offerings. View 

Study Group session details online in My Annual Meeting 


145 A 

ACR-EULAR Study Group - Signal Transduction in the 


206 

Gout Classification Criteria 

143 A 

Hypermobility 

204 A 

Interstitial Lung Disease 

154 B 

(JAW) Juvenile Arthritis Workgroup 

146 C 

Macrophage Activation Syndrome 

207 A 

Musculoskeletal Ultrasound 

202 B 

Myositis: New Developments on Myositis Therapies 

140 A 

Neuro Endocrine Immunology 

154 A 

Osteoarthritis - Synovial Inflammation 

155 

Pediatric Rheumatologists Interested in Medical 

Education 

209 B 

Pediatric Rheumatology Imaging 

TUESDAY 


147 A 


150 B 

Autoantibodies in Diagnosis and Follow-up of 


153 

Skin 

TUESDAY, NOVEMBER 13, 2012 

90 

152 A 

Childhood Vasculitis 

158 A 

Clinical Research Methodology 

151 A or B 

Degos Disease and Other Atypical Vasculopathies 

158 B 

Geriatric Rheumatology 

201 

Global Health Initiatives 



6:30 AM - 6:00 PM 


ACR SESSIONS 

7:30 - 8:30 AM 

Ballroom B 

Chronic Recurrent Multifocal Osteomyelitis 


Speaker: Polly J. Ferguson, MD 


• discuss the clinical presentation and diagnosis of chronic 

recurrent multifocal osteomyelitis 

• review the potential pathophysiologic mechanisms of chronic 

recurrent multifocal osteomyelitis and related inflammatory 

diseases of bone 

• identify and evaluate therapeutic options for chronic recurrent 

multifocal osteomyelitis 

PM 

PS

PM 

PS 

152 A 

Molecular and Cellular Basis of Tissue Homing 


Speaker: William Agace, PhD 


• review the main cell surface and soluble factors that regulate 

migratory behavior of cells 

• discuss the role of external cues in programming dendritic 

cells to promote tissue specific T cell migration 

• discuss how this knowledge may inform aberrant migratory 

pathways of cells in the context of chronic immune mediated 

inflammatory diseases 

Hall D 

Update on Immune Mediated Glomerular Disease 


Speaker: Derek M. Fine, MD 


• develop a differential diagnosis for causes of glomerular 

disease 

• discuss the most recent literature involving the mechanisms 

of immune-mediated glomerular injury 

• define the approach to screening, diagnosis, and 

management of these patients 



7:30 - 8:30 AM 

Ballroom C 

Paul Klemperer, MD Memorial Lectureship: Serum 

PM PS 

Autoantibodies in Systemic Sclerosis: Usefulness 

in Diagnosis, Clinical Subsetting and Predicting 

Outcomes 

Moderator: David I. Daikh, MD, PhD 

Speaker: Thomas A. Medsger Jr., MD 


• describe and interpret laboratory reports on systemic 

sclerosis serum autoantibodies 

• use autoantibody test results to classify systemic sclerosis 

patients into meaningful clinical subsets 

• design clinically relevant and cost-effective followup plans for 

individual systemic sclerosis patients 

ARHP SESSIONS 

7:30 - 8:30 AM 

201 

PM 

Clinical and Epidemiologic Study Designs in 

Rheumatic Disease Research 

Moderator: Marian T. Hannan, DSc, MPH 

Speaker: Tuhina Neogi, MD, PhD 


• discuss measures of disease occurrence (e.g., prevalence, risk, 

and rate) and measures of effects (e.g., relative risk, rate ratio 

and odds ratio) 

PS 

PM 

PS 

• explain basic epidemiologic study designs including 

observational (e.g., cross-sectional, cohort and case-control) 

and clinical trials, as well as the advantages and disadvantages 

of each design 

• identify other study designs in rheumatology research such 

as case-cross over, self-control case series and examples of 

research using each design 

143 A 

Don’t Let the Pink Sheets Make You Blue 

Moderator: Leigh F. Callahan, PhD 

Speaker: Nelson Chao, MD 


• describe the review process using the National Institutes of 

Health as an example including resubmission success funding 

rates 

• identify a plan to break down comments and develop a high 

level strategy to submit a comprehensive response 

• utilize strategies to respond to each reviewer’s concerns that 

will be viewed as thorough and friendly 

• discuss the need to manage expectations and skills to multiply 

success 

PM PS 

145 A 

Fungal Infections and Tuberculosis in Patients with 

Rheumatologic Disease (Infection Series) 

Moderator: Elizabeth G. Salt, PhD 

Speaker: Neil M. Ampel, MD 


• identify the risks of fungal infections and tuberculosis in 

patients with rheumatologic disease 

• review screening for tuberculosis and fungal infections in 

patients with rheumatic disease 

• outline treatment of rheumatologic disease in areas with high 

incidence of fungal infections and describe the treatment of 

rheumatologic disease in the presence of fungal disease 

• discuss treatment of rheumatic disease in the presence of 

tuberculosis 

PM PS 


7:45 - 9:15 AM 










September 14. 

148 

*Ankylosing Spondylitis: Disease Modification (061) 

Speaker: Joachim Sieper, MD 

PM 

PS 

TUESDAY 



153 


Speaker: Michael A. Becker, MD 

144 C 

Adult Musculoskeletal Lower Examinations (229) 

Speaker: Arthur M. Mandelin II, MD, PhD 

TUESDAY 


154 A 

*Infections with Biologics (063) 

Speaker: John J. Cush, MD 

154 B 

Osteoarthritis: Update 2012 (064) 

155 

Speaker: Joanne M. Jordan, MD, MPH 

Pain: Dealing with Patients with Refractory Pain in 

Musculoskeletal and Autoimmune 

Disorders (065) PM PS 

Speaker: Stephen A. Paget, MD 

158 A 


Rheumatologists (066) 

Speaker: Mara L. Becker, MD, MSCE 

158 

*Pregnancy in Rheumatic Diseases (067) 

Speaker: Eliza F. Chakravarty, MD 

159 A 

Reactive Arthritis: An Update (068) 

Speaker: John D. Reveille, MD 

159 B 


Speaker: Robyn T. Domsic, MD, MPH 

160 


Speaker: Peter A. Merkel, MD, MPH 

PM 


7:45 - 9:45 AM 










September 14. 

PS 

144 A 

Knee Braces and Foot Orthosis for Knee Osteoarthritis 

(230) 

Speakers: Howard J. Hillstrom, PhD and Kelly Krohn, MD 

144 B 

Peripheral Magnetic Resonance Imaging in 

Rheumatology Practice (231) 

Speakers: Philip G. Conaghan, MD, PhD and Mikkel Ostergaard, 

MD, PhD, DMSc 

149 A 

Synovial Fluid Analysis and Crystal Identification (232) 

Speakers: Brian F. Mandell, MD, PhD, Lan Chen, MD, PhD and 


ACR SESSIONS 

9:00 - 10:00 AM 

Ballroom A 

Advances in Targeting of B cell Survival Factors 

Moderator: William Stohl, MD, PhD 

Speaker: Eline T. Luning Prak, MD, PhD 


• identify the ligands and receptors involved in B cell survival 

pathways 

• explain basic signaling pathways 

• describe emerging approaches and newly developed agents 

for the targeting of B cells by interruption of survival factor 

pathways 

• summarize results from recent clinical trials and the new 

therapeutic opportunities now available for the treatment of 

autoimmune rheumatic diseases 

147 A 

Systems Immunology 

Moderator: Richard J. Bucala, MD, PhD 

Speaker: David A. Hafler, MD 

PM 


• describe how new developments in systems approaches, 

or the broad-based examination of hundreds to thousands 

of genetic or phenotypic characteristics, is enhancing our 

understanding of autoimmune diseases 

• identify how mathematically-based, bioinformatic approaches 

are enabling a better understanding of RNA expression and 

genetic data and allowing for the definition of sub-phenotypes 

of autoimmune disease 

• explain how systems immunology will suggest new 

approaches to therapy by tailoring drugs for the treatment of 

particular immune profiles 

PS 

PM 

PS 

92 

2012 Program Book

ARHP SESSIONS 

9:00 - 10:00 AM 

PM PS 

145 A 

Hepatitis in Patients with Rheumatologic Disease 

(Infection Series) 


Speaker: Daniel E. Furst, MD 


• describe the risks of treatment of rheumatologic conditions in 

the presence of concomitant hepatitis infection 

• review screening for hepatitis B and C in patients with 

rheumatic disease 

• discuss treatment of rheumatologic disease in patients with 

hepatitis B and C infections 

PM 

PS 

143 A 

Rheumatic Disease Update: The Approach to Low 

Back Pain PM PS 


Speaker: Jeffrey N. Katz, MD 


• recognize the critical items in the history and exam of a 

patient with low back pain 

• identify appropriate diagnostic testing in the evaluation of 

low back pain 

• determine treatment options for patients with low back pain 

201 

Threats to Validity: Confounding in Rheumatic 

Disease Research (Research Series) 

Moderators: Hyon K. Choi, DrPH, MD and Yuqing Zhang, DSc, 

MPH 

Speaker: Til Stürmer, MD, MPH 


• define and describe the concept of confounding 

• identify design methods to reduce confounding (e.g., 

randomization, restriction, matching) 

• examine analytic methods to adjust for confounding (e.g., 

stratification, matching, multivariate analyses 

• explain propensity scores and their appropriate uses 

ACR SESSIONS 

9:00 - 10:30 AM 

150 B 

Contract Negotiations for Physicians 

Moderator: Seth M. Berney, MD 


• explain the value of legal advice prior to signing a contract 

and the legal ramifications of the contract 

• identify a fair private practice or hospital practice contract 

and how to successfully modify it to correspond with their 

individual needs 

• negotiate a fair academic or industrial letter of offer/contract 

9:00 AM 

Contract Negotiations for Academics: How to Optimize Your 

PM 

PS 

PM 

PS 

Academic Offer Letter/Contract 


9:20 AM 

Contract Negotiations with Industry: How to Optimize Your 

Industry Offer Letter/Contract 

Gregory J. Dennis, MD 

9:40 AM 

Contract Negotiations for Private Practice: How to Identify 

a Fair Private or Hospital Practice Contract and How to 

Successfully Modify It to Correspond to Your Individual Needs 

Herbert S. B. Baraf, MD 

10:00 AM 

The Legal Ramifications of the Contract: How to Optimize Your 

Contract and Protect Yourself 

Joan M. Roediger, JD, LLM 

10:20 AM 


Hall D 

Paradigm Shifts in Rheumatoid Arthritis 

Moderators: Elana J. Bernstein, MD and Jasvinder A. Singh, MD, 

MPH 


• outline the arguments for and against a window of 

opportunity in rheumatoid arthritis 

• apply comparative safety and efficacy data from metaanalyses 

of biologic agents to patient care 

• describe the data supporting tapering of therapy in selected 

patients with rheumatoid arthritis 

9:00 AM 

Window of Opportunity in Rheumatoid Arthritis - Myth or 

Reality? 

Vivian P. Bykerk, MD 

9:30 AM 

Biologics in 2012: Making Sense of the Data 

Joel Kremer, PsyD 

10:00 AM 

My Patient Feels Great! Can I Taper Therapy? 

Stanley B. Cohen, MD 


The Guide to Meaningful Use and Beyond 

Moderator: Steven K. Magid, MD 


• describe the requirements and criteria for receiving the 

incentive payments under the CMS electronic health record 

incentive program (meaningful use) 

• identify the electronic health record incentive program’s 

impact on the practice of rheumatology, including best 

practices from early experiences and how operations must be 

modified to successfully achieve meaningful use 

• describe the functionality objectives and clinical quality 

measures most relevant to rheumatology providers 

• understand the implications of future stages of the program, 

PM 

PM 

PS 

PS 


TUESDAY 

November 13, 2012

specifically how to adopt the second stage of meaningful use 

9:00 AM 

Implementing Stage I of Meaningful Use While Keeping Stage 

II in Mind 

Robert W. Warren, MD, PhD, MPH 

9:40 AM 

Attestation Best Practices From Early Adopters 

Craig W. Carson, MD 

10:20 AM 


Hospital Vienna Speising, 1130 Wien, Austria, 3 University of 

Western Ontario, London, ON, 4 Medical University of Vienna 

and Hietzing Hospital, Vienna, Austria, 5 Royal Cornwall Hospital, 

Truro Cornwall, United Kingdom, 6 Medical University of Vienna, 

Vienna, Austria 

9:15 AM 

2432. Arthritis Foundation’s Tai Chi Program for People with 

Arthritis: One Year Follow-up 

My-Linh Luong 1 , Rebecca J. Cleveland 1 , Betsy Hackney 1 and Leigh 

F. Callahan 2 , 1 University of North Carolina at Chapel Hill, Chapel 

Hill, NC, 2 University of North Carolina, Chapel Hill, NC 

TUESDAY 




9:00 AM - 10:30 PM 

PM PS 

207 A 

Disease Targeted Research 

Moderator: Anne Davidson, MBBS 


• explain the role of carboxypeptidase B in the pathogenesis of 


• determine the potential for therapeutic intervention targeting 

specific WNT inhibitors to prevent bone destruction and/or 

promote bone repair in rheumatoid arthritis 

• report the genetic basis of measures of rheumatoid arthritis 

severity 

9:00 AM 

The Role of Carboxypeptidase B and its Substrates in 


William H. Robinson, MD, PhD 

9:30 AM 

The Role of sFRP1 and WNT Signaling in Formation and Repair 

of Erosions in Rheumatoid Arthritis 

Ellen M. Gravallese, MD 

10:00 AM 

Genome Wide Predictors of Quantitative Phenotypes in 


Jing Cui, PhD 


9:00 - 10:30 AM 

206 

Physical/Occupational Therapy and Exercise in 

Patients with Rhematologic Disease 

Moderators: Jill R. Blitz, DPT, PT and Maura D. Iverson, DPT, MPH 

9:00 AM 

2431. Are Occupational Therapy Interventions Included in the 

Most Commonly Used European Clinical-Practice Guidelines for 

the Management of Osteoarthritis? 

Michaela Stoffer 1 , Doris Taurok 2 , Birgit Prodinger 3 , Josef S. 

Smolen 4 , Anthony D. Woolf 5 and Tanja A. Stamm 6 , 1 Medical 

University of Vienna, A – 1090 Vienna, Austria, 2 Orthopaedic 

9:30 AM 

2433. Integration of a Healthy Aging Program Into the Arthritis 

Foundation Exercise Program: Six-Month Results 

Elizabeth A. Schlenk 1 , Joni Vander Bilt 1 , Wei-Hsuan Lo-Ciganic 1 , 

Sarah E. Woody 1 , Janice C. Zgibor 1 , Molly B. Conroy 2 , C. Kent 

Kwoh 3 and Anne B. Newman 1 , 1 University of Pittsburgh, 

Pittsburgh, PA, 2 University of Pittsburgh, PIttsburgh, PA, 

3 

University of Pittsburgh and VA Healthcare System, Pittsburgh, 

PA 

9:45 AM 

2434. Effects of Interventions That Aim to Increase Exercise 

Adherence in People with Arthritis: A Best Evidence Synthesis 

Katie, E. MacPherson 1 , Allison M. Ezzat 2 , Jenny Leese 3 and Linda 

C. Li 2 , 1 New Westminster, BC, 2 University of British Columbia, 

Vancouver, BC, 3 Arthritis Research Centre, Vancouver, BC 

10:00 AM 

2435. Lumbrical Splinting and Stretching Versus Standard 

Treatment On Grip, Pinch, and Dexterity in People with Carpal 

Tunnel Syndrome 

Nancy A. Baker 1 , Krissy Moehling 2 , Elaine Rubinstein 3 , Norman 

Gustafson 1 and Mark Baratz 4 , 1 University of Pittsburgh, 

Pittsburgh, PA, 2 Pittsburgh, PA, 3 University of Pittsburgh, 

Pittsburgh, 4 Alleghancy General Hospital, Pittsburgh, PA 

10:15 AM 

2436. Clinical Effectiveness and Costs of an Integrated 

Rehabilitation Programme Compared with Outpatient 

Physiotherapy for Chronic Knee Pain 

Mike Hurley 1 , Dr Nicola E. Walsh 2 and Sally Jessep 3 , 1 St George’s 

University of London, London, United Kingdom, 2 University of 

the West of England Bristol, Bristol, United Kingdom, 3 Kent, 


204 A 

Programs and Literacy in Patients with Rheumatologic 

Diseases 

Moderators: Susan J. Blalock, PhD and Victoria Gall, PT, MEd 

9:00 AM 

2437. Initiating an Innovative Training Programme to Improve 

Access to Musculoskeletal Health Care in Kenya 

Anthony D. Woolf 1 , Jo Erwin 2 , Omondi G. Oyoo 3 , Lillian Mwaniki 4 , 

Ingrid Cederlund 5 , Paul Etau 6 and Katie Edwards 7 , 1 Royal Cornwall 

Hospital, Truro Cornwall, United Kingdom, 2 Royal Cornwall 

Hospital, Teliske, United Kingdom, 3 University of Nairobi, Nairobi, 

94 

2012 Program Book

Kenya, 4 Association for Arthritis & Rheumatic Diseases of Kenya, 

Nairobi, Kenya, 5 Reumatikerforbundet, Stockholm, Sweden, 

6 

University of Nairobi, Nairobi, Kuwait, 7 Royal Cornwall Hospital, 

Truro, United Kingdom 

9:15 AM 

2438. The Effect of a Systematic, Personalized Computer 

Workstation Redesign On Musculoskeletal Symptoms 

Nancy A. Baker and Krissy Moehling, University of Pittsburgh, 


9:30 AM 

2439. A Brief Exercise and Self Management Programme 

Improves Upper Limb Disability in People with Early 


Lindsay M. Bearne 1 , Victoria L. Manning 1 , David L. Scott 2 , Ernest 

Choy 3 and Michael V. Hurley 4 , 1 Kings College London, London, 

United Kingdom, 2 King’s College London, London, United 

Kingdom, 3 Cardiff University School of Medicine, Cardiff, United 

Kingdom, 4 St George’s University of London, London, United 

Kingdom 

9:45 AM 

2440. Decisional Conflict Among Vulnerable Patient 

Populations with Rheumatoid Arthritis Is Associated with 

Limited Health Literacy and Non-English Language 

Laura Trupin, Jennifer Barton, Gina Evans-Young, John B. 

Imboden, Andrew J. Gross, Dean Schillinger and Edward H. Yelin, 

UCSF, San Francisco, CA 

10:00 AM 

2441. Readability and Suitability Assessment of Patient 

Education Materials in Rheumatic Diseases 

Rennie L. Rhee 1 , Joan Marie Von Feldt 2 , H. Ralph Schumacher 3 

and Peter A. Merkel 1 , 1 University of Pennsylvania, Philadelphia, 

PA, 2 Univ of Pennsylvania/Philadelphia VAMC, Philadelphia, PA, 

3 

University of Pennsylvania and VA Medical Center, 

Philadelphia, PA 

10:15 AM 

2442. Screening of Osteoporosis in Men Age 70 and Older: A 

Need for Increased Awareness 

Sian Yik Lim, Kenneth Nugent, Joon Hee Lim, Hoda Mojazi Amiri, 

Rie Okamura and Dan Nguyen, Texas Tech University Health 

Sciences Center, Lubbock, TX 

ACR/ARHP POSTER SESSION C, THIEVES’ 

MARKET POSTERS AND POSTER TOURS 

9:00 AM - 6:00 PM 


(abstracts # 1724 - 2430). Poster tours will be held 9:00 - 9:45 

AM and 10:15 - 11:00 AM. Morning snacks will be available from 

9:00 - 10:30 AM. 


Thieves’ Market Posters 

Thieves’ Market posters feature cases with interesting imaging 

studies or pictorial displays of physical findings. 

A Wolf in Sheep’s Clothing 

Reeti Joshi, MBBS 

Behçet’s Disease with Pulmonary Artery Aneurysms 

Claudia B. Hubbe, MD 

Medical Re-vascularisation 

Mark Richard Williams, MD 

Myalgias: Out of Proportion to Exam 

Julie Paik, MD 

Neonate with Sclerodermatous Limbs 

Murray H. Passo, MD 

Treatment of Fulminant Myocarditis and Macrophage 

Activation Syndrome Secondary to Adult Onset Still’s Disease 

Eimear Savage, BAO, BCh, MB 





leaders. Tours are complimentary; however, registration 

is required and is limited to scientific attendees. If you 

preregistered for a tour, you should have received a ticket with 














the tour. 

9:00 - 9:45 AM 

ARHP Epidemiology and Public Health (324) 

Tour Guide: Leigh F. Callahan, PhD 

Miscellaneous Rheumatic and Inflammatory Diseases (325) 

Tour Guide: W. Winn Chatham, MD 


Tour Guide: Merete L. Hetland, MD, PhD, DMSc 

Systemic Lupus Erythematosus: Human Etiology and 

Pathogenesis (327) 

Tour Guide: Mary K. Crow, MD 

Vasculitis (328) 

Tour Guide: Philip Seo, MD, MHS 

10:15 - 11:00 AM 

Antiphospholipid Syndrome (329) 

Tour Guide: Pier Luigi Meroni, MD 

Fibromyalgia and Soft Tissue Disorder (330) 

Tour Guide: Daniel J. Clauw, MD 

Metabolic and Crystal Arthropathies (331) 

Tour Guide: N. Lawrence Edwards, MD 


TUESDAY 

November 13, 2012

Osteoporosis and Metabolic Bone Disease: Clinical Aspects and 

Pathogenesis (332) 

Tour Guide: Nancy E. Lane, MD 

Sjögren’s Syndrome (333) 

Tour Guide: Jacques-Eric Gottenberg, PhD 

Rheumatology Research Foundation - Pathogenic Mechanisms 

in Rheumatic Diseases (334) 

Tour Guide: Michael H. Pillinger, MD 

Learn about the excellent work being done by Rheumatology 

Research Foundation-funded early career investigators. This is 

also an opportunity for division chiefs looking to recruit junior 

faculty to meet young productive investigators and vice versa. 

EXHIBITS 

10:00 AM - 5:00 PM 




3:00 PM. 

(Booth #1451) 






from 10:30 - 11:15 AM, 12:30 - 1:15 PM and 2:30 - 3:15 PM. 

For a complete listing of Innovation Theater presentations 

see page 316. 

201 


• indentify underlying immune dysregulation and 

immunosuppressive treatments 

• discuss effective methods of infection prevention in patients 

with autoimmune disease 

• review recommendations for vaccines in adult patients with 

rheumatic disease 

Selection Bias in Rheumatic Disease Research – 

Risk Factor Paradox and Other Issues 

Moderator: Sherine E. Gabriel, MD, MSc 


• discuss selection bias due to conditioning on an intermediate 

variable 

• identify major types of selection bias 

• associate design and analytic methods to minimize selection 

bias 

10:30 AM 

Risk Factor Paradox in Rheumatic Diseases-Selection Bias? 

Hyon K. Choi, DrPH, MD 

10:50 AM 

Other Major Types of Selection Bias in Rheumatic Disease 

Research 

Yuqing Zhang, DSc, MPH 

11:10 AM 

Minimizing Selection Bias through Study Design and Analytic 

Methods – Panel Discussion 

Hyon K. Choi, DrPH, MD and Yuqing Zhang, DSc, MPH 

PM 

PS 

TUESDAY 


ACR SESSION 

10:30 - 11:30 AM 

PM 

146 C 

Gouty Inflammation 

Moderator: Richard J. Bucala, MD, PhD 

Speaker: Stephen E. Malawista, MD 


• describe evolving knowledge of the pathogenetic setting in 

which urate crystals lead to acute gout 

• review biochemical and cellular determinants that lead to the 

initiation of gouty inflammation 

• discuss biochemical and cellular determinants that lead to 

resolution of gouty inflammation 

PS 

ACR/ARHP COMBINED ABSTRACT SESSION 

10:30 AM - Noon 

140 A 

ACR/ARHP Combined Rehabilitation Abstract Session 

Moderators: Nancy A. Baker, MPH, OTR, OTR/L; Julie J. Keysor, 

PhD, PT 

10:30 AM 

2443. Pain and Function Outcomes in Systemic Lupus 

Erythematosus Hip and Knee Arthroplasty 

Ummara Shah 1 , Lisa A. Mandl 2 , Mark P. Figgie 2 , Michael 

Alexiades 2 and Susan M. Goodman 2 , 1 New York University School 

of Medicine, NYC, NY, 2 Hospital for Special Surgery, New York, NY 

ARHP SESSIONS 

10:30 - 11:30 AM 

PM PS 

145 A 

Immunizations in Patients with Rheumatologic 

Disease (Infection Series) 


Speaker: Gil Y. Melmed, MD 

10:45 AM 

2444. Restricting Back Pain Is Associated with Disability in 

Community-Living Older Persons 

Una E. Makris 1 , Liana Fraenkel 2 , Ling Han 3 , Linda Leo-Summers 3 

and Thomas M. Gill 4 , 1 UT Southwestern Medical Center, Dallas, 

TX, 2 Yale University School of Medicine, Veterans Affairs 

Connecticut Healthcare System, New Haven, CT, 3 Department of 

Medicine, New Haven, CT, 4 Yale University, New Haven 

96 

2012 Program Book

11:00 AM 

2445. Ipsilateral Lower Extremity Joint Involvement Increases 

the Risk of Poor Pain and Function Outcomes After Hip or Knee 

Arthroplasty 

Jasvinder A. Singh 1 and David Lewallen 2 , 1 University of Alabama 

at Birmingham, Birmingham, AL, 2 Mayo Clinic college of 

medicine, Rochester 

11:15 AM 

2446. Activity Limitations Experienced by People with 

Rheumatoid Arthritis On Biologic Medications and Their Use of 

Ergonomic Methods 

Alison Hammond 1 and Sarah Tyson 2 , 1 University of Salford, 

Salford, United Kingdom, 2 University of Salford, Manchester, 


11:30 AM 

2447. Accuracy of Sensewear MiniTM and Actigraph GT3XTM 

Accelerometers for Differentiating Sedentary and Light Physical 

Activities in a Controlled Laboratory Setting 

April Y. F. Leung 1 , Lynne M. Feehan 2 , Cynthia Macdonald 1 , Jenny 

Leese 3 , Erin Carruthers 3 and Linda C. Li 1 , 1 University of British 

Columbia, Vancouver, BC, 2 Arthritis Research Centre of Canada 

and University of British Columbia, Vancouver, BC, 3 Arthritis 

Research Centre of Canada, Vancouver, BC 

ARHP SESSIONS 

11:00 AM – Noon 

PM PS 

204 A 

A Practical Understanding of Function in Rheumatoid 

Arthritis: A Multidisciplinary Perspective 

Moderator: Jillian A. Rose, LMSW 


• discuss pathophysiologic mechanisms of rheumatoid arthritis 

and their effect on functional activity 

• review the tools for assessing functional activity and how they 

can be used in the clinical setting and for research 

• discuss common strategies patients with rheumatoid arthritis 

use to ensure optimal functioning in the home, at work, and 

in the community 

• discuss educational strategies to help patients with 

rheumatoid arthritis improve communication of functional 

capabilities to health care providers being cognizant of 

patients’ level of health literacy 

11:00 AM 

Integrating Impairment and Functional Activity: Using Patient 

Self-report Measures to Inform Medial Practice for Patients 

with Rheumatoid Arthritis 

Terence W. Starz, MD 

11:45 AM 

2448. Sustained Improvement Physical Function Following an 

Integrated Rehabilitation Programme for Chronic Knee Pain 

Mike Hurley 1 and Dr Nicola E. Walsh 2 , 1 St George’s University 

of London, London, United Kingdom, 2 University of the West of 

England Bristol, Bristol, United Kingdom 

PM 

ACR WORKSHOPS 

PS 

10:30 AM - 12:30 PM 










September 14. 

149 B 

Histopathology of Vasculitis (233) 

Speaker: Allen Burke, MD 

144 C 

*Joint Injection Techniques (234) 

Speakers: Atul A. Deodhar, MD and Kenneth S. O’Rourke, MD 

11:20 AM 

Strategies to Promote Functional Activity in the Home, at 

Work, and in the Community for Clients with Rheumatoid 

Arthritis 

Nancy A. Baker, MPH, OTR, OTR/L 

11:40 AM 

The Role of Nursing in the Management of Rheumatoid 

Arthritis 

Elizabeth A. Schlenk, PhD, RN 

143 A 

Strategies to Enhance Office Efficiencies and Access 

to Care in Rheumatology Practice PM PS 


Speaker: Eric D. Newman, MD 


• review some of the problems with traditional practice models 

that impede efficiency and increase waiting times for new 

referrals 

• explore alternative models that may improve access to care 

and triage of new referrals 

• discuss options for improving practice scheduling, workflow 

and efficiencies 

PM 

PS 

ACR PLENARY SESSION III – DISCOVERY 

2012 

11:00 AM - 12:30 PM 

Hall E 

Moderators: Chester V. Oddis, MD and Richard M. Pope, MD 

PM 

PS 

TUESDAY 



TUESDAY 


11:00 AM 

2449. Head to Head Comparison of Subcutaneous Abatacept 

Versus Adalimumab in the Treatment of Rheumatoid Arthritis: 

Key Efficacy and Safety Results From the Ample (Abatacept 

Versus Adalimumab Comparison in Biologic-Naive RA Subjects 

with Background Methotrexate) Trial 

Michael E. Weinblatt 1 , Michael H. Schiff 2 , Roy Fleischmann 3 , 

Robert Valente 4 , Désirée van der Heijde 5 , Gustavo Citera 6 , 

Cathy Zhao 7 and Michael A. Maldonado 7 , 1 Rheumatology 

& Immunology, Brigham & Women’s Hospital, Boston, MA, 

2 

University of Colorado, Denver, CO, 3 University of Texas 

Southwestern Medical Center, Dallas, TX, 4 Arthritis Center of 

Nebraska, Lincoln, NE, 5 Leiden University Medical Center, Leiden, 

Netherlands, 6 Instituto de Rehabilitación Psicofísica., Buenos 

Aires, Argentina, 7 Bristol-Myers Squibb, Princeton, NJ 

Background/Purpose: The availability of multiple biologic 

agents to treat rheumatoid arthritis (RA) has created a need for 

comparative assessment. AMPLE (Abatacept Versus Adalimumab 

Comparison in Biologic-Naive RA Subjects with Background 

Methotrexate) is the first head-to-head study powered to 

compare SC abatacept (ABA) and adalimumab (ADA) on a 

background of methotrexate (MTX). Here, we report key 1 year 

data from AMPLE including ACR core component data. 

Methods: AMPLE is an ongoing, phase IIIb, randomized, 

investigator-blinded study of 24 months duration with a 12 

month primary efficacy endpoint. Biologic-naïve RA patients 

with an inadequate response to MTX were randomized to 125 

mg ABA weekly or 40 mg ADA bi-weekly, in combination with 

MTX. The primary end point was non-inferiority (NI) of ABA to 

ADA based on ACR 20 at 12 months; key secondary endpoints 

were rates of radiographic non-progression, safety, injection site 

reactions and retention. ACR core component data were also 

analyzed. 

Results: A total of 646 patients were randomized and treated; 

86.2% of ABA patients and 82.0% of ADA patients completed 

12 months. Baseline characteristics were balanced across both 

arms (mean DAS28-CRP of 5.5 and disease duration ~1.8 yrs). 

At 1 year, 64.8% of ABA patients and 63.4% of ADA patients 

achieved an ACR 20 response, with an estimated difference 

between the two arms (95% CI) of 1.8 (-5.6, 9.2) supporting 

NI of ABA to ADA. The kinetics of response across ACR scores 

were comparable overall, with an ACR50 of 46.2% and 46% 

and ACR70 of 29.2% and 26.2% for ABA and ADA, respectively, 

at 1 year. Similar responses over time were seen in some ACR 

core components (Figure). At 1 year, the rates of radiographic 

non-progression were comparable, as were mean changes in van 

der Heijde-modified total Sharp scores (0.58 vs. 0.38, for ABA 

vs. ADA respectively). The rates of AEs, SAEs, serious infections 

and malignancies were comparable. There were more patients 

with autoimmune AEs (3.1% vs. 0.9%) in the ABA arm; however, 

none were serious. One patient discontinued in each arm due to 

an autoimmune event. There were fewer discontinuations with 

ABA due to AEs (3.5% vs. 6.1%) and due to serious infections (0% 

vs. 1.5%). Injection site reactions occurred in significantly fewer 

ABA-treated patients (3.8% vs. 9.1% [p=0.006]). 

Conclusion: This first head-to-head study in RA patients 

comparing biologic agents on background MTX demonstrated 

that subcutaneous abatacept is comparable to adalimumab by 

most efficacy measures, including radiographic progression. 

Safety was generally similar with fewer discontinuations and 

injection site reactions observed with abatacept. 

Disclosure: M. E. Weinblatt, Bristol-Myers Squibb, Abbott, 2, 

Bristol-Myers Squibb, Abbott, 5; M. H. Schiff, Bristol-Myers 

Squibb, 5, Abbott Laboratories, 8; R. Fleischmann, Genentech 

Inc, Roche, Abbott, Amgen, UCB, Pfizer, BMS, Lilly, Sanofi 

Aventis, Lexicon, MSD, Novartis, BiogenIdec, Astellas, Astra- 

Zeneca, Jansen, 2, Roche, Abbott, Amgen, UCB, Pfizer, BMS, Lilly, 

Sanofi Aventis, Lexicon, Novartis, Astellas, Astra-Zeneca, Jansen, 

HGS, 5; R. Valente, UCB,Pfizer,Novartis,Eli Lilly,Takeda, Centocor, 

2; D. van der Heijde, Abbott, Amgen, AstraZeneca, BMS, 

Centocor, Chugai, Eli-Lilly, GSK, Merck, Novartis, Otsuka, Pfizer, 

Roche, Sanofi-Aventis, Schering-Plough, UCB, Wyeth, 5, Owner 

of Imaging Rheumatology bv, 4; G. Citera, Pfizer Inc, 2, Pfizer, 

Bristol-Myers Squib, Astra Zeneca, 5; C. Zhao, Bristol-Myers 

Squibb, 1, Bristol-Myers Squibb, 3; M. A. Maldonado, Bristol- 

Myers Squibb, 3, Bristol-Myers Squibb, 1. 

11:15 AM 

2450. Evoked Pain Brain Response Is Associated with Reduced 

μ-Opioid Receptor Binding in Fibromyalgia 

Heng Wang 1 , Daniel J. Clauw 2 , Jon-Kar Zubieta 1 and Richard 

E. Harris 2 , 1 University of Michigan, Ann Arbor, 2 University of 

Michigan, Ann Arbor, MI 

Background/Purpose: Previous studies indicate that 

fibromyalgia (FM) patients have augmented clinical and brain 

responses to painful stimuli (i.e. hyperalgesia/allodynia), as 

well as increased production of endogenous opioids, and 

reduced μ-opioid receptor (MOR) binding. However, it is not 

known if these factors co-occur within the same individual or if 

these factors act independently. We performed a longitudinal 

investigation using functional magnetic resonance imaging 

(fMRI) and positron emission tomography (PET) in chronic pain 

patients diagnosed with FM to address this question. If these 

factors operate in the same individual, we expected an inverse 

correlation between changes in fMRI evoked pain activity and 

MOR binding potential (BP). 

Methods: fMRI and PET imaging sessions were performed 

on 18 female opioid-naïve FM patients (age 45.4+/- 13.0). 

Each participant underwent 4 weeks of non-pharmacological 

treatment. Before and after treatment, each patient underwent 

98 

2012 Program Book

an fMRI scan with varying levels of pressure pain applied to 

the thumb as well as a 90-minute [11C]carfentanil PET scan 

under resting conditions. After quantification of the PET data 

with Logan plots, fMRI images and preprocessing of PET data 

were performed with statistical parametric mapping (SPM5). 

fMRI and PET scans were normalized to the same template. 

Difference images before and after treatment were calculated 

for both the fMRI contrast and PET images. A whole-brain 

voxel-by-voxel correlation analysis between the fMRI and 

PET difference images were carried out using the Biological 

Parametric Mapping toolbox. Activation clusters were defined 

based on a correlation coefficient, with |R|>=0.6 uncorrected. 

Clinical pain was assessed with Short Form McGill Pain 

Questionnaire (SFMPQ). 

Results: Negative correlations between the change in the fMRI 

blood oxygenation level dependent (BOLD) signal and MOR BP 

were observed in multiple regions involved in pain processing 

and modulation: right posterior insula R=-0.82,P=0.0004; left 

medial insula R=-0.82, P=0.0003; left orbital frontal cortex 

R=-0.75, P=0.0004; right amygdala R=-0.68, P=0.002; brainstem 

R=-0.71, P=0.0009. Positive correlations were observed in right 

DLPFC R=0.66, P=0.003; posterior cingulate R=0.62, P=0.006; 

right putamen R=0.72, P=0.0008. Changes in both functional 

imaging outcomes were negatively associated with changes in 

clinical pain: BOLD in right DLPFC and clinical pain SFMPQ; R=- 

0.52, P=0.03; MOR BP in left medial insula and SFMPQ present 

pain R=-0.51, P=0.03. 

Conclusion: We find strong longitudinal associations between 

evoked pain activations suggestive of hyperalgesia, and µ-opioid 

receptor availability (binding potential, BP) within the same 

brain regions, in individual FM patients. Positive associations 

were also observed between BOLD responses, and μ-opioid 

receptor BP (in opposive directions) with respect to clinical 

pain. These data suggest that the µ-opioid system is somehow 

involved in the pathogenesis of FM, and may even help explain 

why these patients are generally not felt to respond to narcotic 

analgesics, and may even be made worse when these drugs are 

used therapeutically. 

Disclosure: H. Wang, None; D. J. Clauw, Pfizer Inc, Forest 

Laboratories, Merck, Nuvo , 2, Pfizer, Forest, Lilly, Merck, Nuvo, 

J and J , 5; J. K. Zubieta, None; R. E. Harris, Pfizer Inc, 2, Pfizer 

Inc, 5. 

11:30 AM 

2451. Laquinimod (LAQ) Is Equivalent to Mycophenolate 

Mofetil (MMF) in Preventing and Suppressing Murine Lupus 

Nephritis and Has Greater Effects On Myeloid/Monocyte/ 

Macrophage Cells 

Bevra H. Hahn, Maida Wong, Elaine Lourenco and Brian Skaggs, 

UCLA David Geffen School of Medicine, Los Angeles, CA 

Background/Purpose: Lupus nephritis (LN) depends on autoAb 

deposition and activation of multiple cell types that infiltrate 

kidneys and promote inflammation – monocytes/macrophages 

(MM), DCs, T and B cells. Laquinimod (LAQ) administered to 

humans downregulates Ag presentation, decreases chemokine 

production, decreases MHC expression on MM, and induces 

apoptotic pathways in PBMC (Gurevich M et al 2010). LAQ 

reduces progression of relapsing remitting multiple sclerosis 

(Comi G et al NEJM 2012); it is currently in clinical trials in SLE. 

MMF targets primarily lymphocytes; it is effective in many LN 

patients 

Methods: We compared clinical and immune cell changes in 

groups of 10-12 BWF1 female mice treated orally 3 times a week 

for 24 weeks with a) water; b) LAQ 1 mg/kg; c) LAQ 25 mg/kg; d) 

MMF 30 mg/kg; e) MMF100 mg/kg. 

Results: Survival was better in both LAQ groups and the 

MMF100 group vs controls (p=0.028). LAQ at both doses 

was equivalent to MMF100 in preventing proteinuria in mice 

treated before disease appeared. At 32 wks of age 50% of mice 

on water had proteinuria vs zero in LAQ and MMF100 groups 

(p

TUESDAY 


PTPN22 might modulate TLR signaling and attendant innate 

immune responses. 

Methods: We studied TLR signaling and type 1 IFN-mediated 

antiviral responses and immunoregulation in Ptpn22-deficient 

myeloid cells and mice, in transgenic mice harboring human 

LypW or LypR (major allele protein product), and in human LypW 

carrier peripheral blood mononuclear cells (PBMC). 

Results: We found markedly decreased induction of type 1 IFN 

after TLR3/4/7/9 activation in Ptpn22 -/- macrophages, DC, and 

plasmacytoid DC. Interestingly, Ptpn22 was dispensable for 

induction of proinflammatory cytokines, including TNFα, IL- 6 , 

and IL-1β, after TLR2/3/4/7/9 stimulation. The selective TLR 

signalling defect in Ptpn22 -/- cells was associated with impaired 

type 1 IFN-dependent immunity, manifested by reduced serum 

type 1 IFN, impaired dendritic cell activation, and diminished T 

cell responses after lymphocytic choriomeningitis virus (LCMV) 

infection of Ptpn22 -/- mice. In the K/BxN serum transfer model 

of rheumatoid arthritis, treatment with type 1 IFN-inducing TLR 

ligands suppresses disease. However, we observed significantly 

decreased TLR ligand-mediated suppression of inflammatory 

arthritis in Ptpn22 -/- mice. RA-associated LypW carrier human 

PBMC and myeloid cells derived from LypW transgenic mice 

displayed defective induction of type 1 IFN after TLR stimulation. 

LypR directly associated with TNF receptor-associated factor 3 

(TRAF3), a key TLR signaling mediator upstream of type 1 IFN 

induction. LypR, but not LypW promoted TRAF3 K63-linked 

polyubiquitinylation, which is required for TLR-induced type 1 

IFN production. 

Conclusion: PTPN22 is a key positive regulator of TLR-driven 

upregulation of type 1 IFN. LypW, product of the RAassociated 

PTPN22 allele, exhibits “loss of function” in type 

1 IFN dependent processes, including antiviral host defense 

and amelioration of inflammatory arthritis. Our findings 

strongly suggest that PTPN22 could regulate severity of joint 

inflammation in RA through modulation of TLR signaling in 

innate immune cells. 

Disclosure: Y. Wang, None; S. Stanford, None; W. Zhou, None; 

J. L. Auger, None; G. Cheng, None; A. Campbell, None; F. M. 

Shoyama, None; H. H. Balfour Jr., None; A. C. Chan, None; B. A. 

Binstadt, None; N. Bottini, None; E. J. Peterson, None. 

Noon 

2453. The Role of Bob1 in Rheumatoid Arthritis: Potential 

Implications for Autoimmunity 

Nataliya Yeremenko 1 , Tineke Cantaert 1 , Melissa N. van Tok 1 , 

Ioana Gofita 1 , Juan D. Canete 2 , Paul P. Tak 1 , Hergen Spits 3 and 

Dominique L. Baeten 1 , 1 Division of Clinical Immunology and 

Rheumatology and Department of Experimental Immunology, 

Academic Medical Center / University of Amsterdam, 

Amsterdam, Netherlands, 2 Rheumatology Department, Hospital 

Clinic, Barcelona, Spain, 3 Tytgat Institute for Liver and Intestinal 

Research, Academic Medical Center / University of Amsterdam, 


Background/Purpose: Rheumatoid arthritis (RA) is a prototypic 

autoimmune disease characterized by a prominent humoral 

autoimmunity. Of particular relevance is the local production 

of autoantibodies such as rheumatoid factor and anticitrullinated 

protein antibodies in the inflamed synovial tissue. 

The mechanisms underlying break of B cell tolerance and local 

autoantibody production remains poorly understood. This 

study was conducted in order to identify cellular and molecular 

pathways implicated in RA-specific humoral autoimmunity. 

Methods: Synovial tissue samples were obtained by arthroscopy 

from untreated individuals with RA (n=33) and inflammation 

matched SpA controls (n=58). Gene expression profiling was 

performed on tissue samples of patients with established 

arthritis using 44K Whole Genome Human microarrays 

(Agilent). Top differentially expressed genes were validated 

on three independent cohorts by Taqman based RT-qPCR and 

immunohistochemistry. Collagen-induced arthritis (CIA) and 

Experimental autoimmune encephalomyelitis (EAE) experiments 

were conducted using Bob1 knockout mice and their littermate 

controls. 

Results: Microarray screening for genes differentially expressed 

in the inflamed synovium, the key target of the disease process 

in RA, revealed a prominent and disease-specific B cell/plasma 

cell signature with the B cell-specific transcriptional co-activator 

Bob 1 and its transcriptional target BCMA among the most 

upregulated genes. Validation by RT-qPCR on two independent 

cohorts representing early and established arthritis confirmed 

microarray data and demonstrated elevated expression of Bob 1 

and BCMA not only in established RA, but also at the early phase 

of the disease. Quantitative evaluation of immunohistochemical 

stainings of synovial tissue with monoclonal antibody for 

Bob1 revealed significant increase in Bob1 positive cells in 

RA synovium (p

eal-time RT-PCR and/or flow cytometry. Next, linear regression 

analysis was employed to correlate expression of TLR5 with 

levels of TNF-a and DAS28 score in RA monocytes from 43- 

48 patients. Finally, the mechanism by which TLR5 ligation 

mediates RA pathogenesis was determined by endothelial 

chemotaxis and tube formation. 

Results: We performed microarray studies to identify 

differentially regulated genes in RA synovial fluid macrophages 

from active patients and identified Toll like receptor (TLR)5 as 

one of the most highly upregulated genes in RA synovial fluid 

macrophages compared to normal macrophages. Using realtime 

RT-PCR and FACS analysis we confirmed that expression of 

TLR5 is significantly elevated in RA synovial fluid macrophages 

(35 fold) and RA monocytes (7 fold) compared to normal 

counterpart cells. Interestingly, we found that blockade of TLR5 

on RA peripheral blood (PB) monocytes greatly reduces RA 

synovial fluid mediated TNF-a transcription by 80% suggesting 

that there are endogenous TLR5 ligands expressed in the RA 

synovial fluid that are crucial for joint TNF-a modulation. Since 

TNF-a stimulation is also capable of upregulating TLR5 levels 

there is a positive feedback modulation in RA monocytes 

between TNF-a and TLR5 ligation and expression. We found that 

patients with higher expression of TNF-a expressed elevated 

levels of TLR5 (R 2 =0.79, p=3.6x10 -7 ) in RA monocytes and the 

concentrations of TLR5 and TNF-a strongly correlated with 

increased disease activity as determined by examination of 28 

defined joints (DAS28) (correlation of TLR5 with DAS28; R 2 =0.75) 

(correlation of TNF-a with DAS28; R 2 =0.58). Since our previous 

studies demonstrated that TLR5 expression is elevated on RA 

synovial tissue endothelial cells compared to control tissue we 

asked whether ligation of this receptor induces angiogenesis 

and if TLR5 endogenous ligands present in RA synovial fluid 

play a role in this process. We found that when endothelial cells 

were exposed to a dose response of flagellin, a TLR5 agonist, 

migration of endothelial cells was induced at concentrations 

ranging from 0.1 to 100 ng/ml (p

• identify tracking mechanism to respond timely to auditors for 

“additional documentation requests” 

• recognize the new targeted reviews of EMR cloned notes and 

documentation that are triggering audits 



Renaissance Washington - Congressional Hall B 

Networking Break 

All ARHP attendees are invited to an informal networking event. 

Bring your lunch and enjoy an opportunity to meet with health 

professionals. Soft drinks will be provided. This session is not 

eligible for CME credit. 

PM 

PS 

158 B 

*Systemic Lupus Erythematosus: Difficult to Treat 

Systemic Lupus Erythematosus (077) 

Speaker: Maria Dall’Era, MD 

159 A 

*Systemic Lupus Erythematosus: Lupus Nephritis 

(078) 

Speaker: Brad H. Rovin, MD 

159 B 

Temporal Arteritis (079) 

Speaker: Gene G. Hunder, MD 

TUESDAY 



12:45 - 2:15 PM 










September 14. 

148 

*Basic Immunology for Clinical Rheumatologists (071) 

Speaker: Antony Rosen, MD 

153 

Fibromyalgia and Dysautonomia (072) 

Speaker: Manuel Martinez-Lavin, MD 

154 A 

Myopathy: Issues in Diagnosis and Treatment (073) 

Speaker: Lisa Christopher-Stine, MD, MPH 

154 B 

Rheumatoid Arthritis: Challenging Cases (074) 


155 

*Rheumatoid Arthritis: Safety of Novel Therapies 

(075) 

Speaker: Lee S. Simon, MD 

158 A 


System (076) 

Speaker: Cynthia Aranow, MD 

160 


Speaker: Paul A. Monach, MD, PhD 

ACR SESSIONS 

1:00 - 2:00 PM 

PM PS 

Hall D 

Catastrophic Antiphospholipid Syndrome (Clinical 

Review) 

Moderator: Fernando E. Figueroa, MD 

Speaker: Doruk Erkan, MD 


• review the current classification criteria for catastrophic 

antiphospholipid syndrome 

• analyze proposed diagnostic algorithms for catastrophic 


• describe current treatment guidelines for catastrophic 


PM 

PS 

Ballroom B 

Osteoimmunology 

Moderator: S. Louis Bridges Jr., MD, PhD 

Speaker: Georg A. Schett, MD, PhD 


• describe the relationship between osteoclasts and the 

immune system 

• identify inflammation-associated changes in bone 

homeostasis 

• appreciate the mechanisms of bone destruction in rheumatoid 

arthritis and other forms of inflammatory arthritis 

ACR STUDY GROUPS 

1:00 - 2:00 PM 

Study Groups are non-CME activities, open to all attendees. 

204 A 

A Primer on Educational Theory for Medical Educators 

206 

Capillaroscopy in Rheumatic Diseases 

102 

2012 Program Book

207 A 

Crystal Group 

146 C 

Decision Aids 

140 A 

Latin American 

202 B 

Lupus 

PM PS 

149 A 

Synovial Fluid Analysis and Crystal Identification 

(237) 

Speakers: Brian F. Mandell, MD, PhD, Lan Chen, MD, PhD, and 


PM PS 

149 B 

Web-based Tools for Enhancing and Managing 

Teaching and Clinical Practice (238) 

Speaker: Laura E. Ray, MA 

PM 

201 

Magnetic Resonance Imaging 

147 A 

Polymyalgia Rheumatica 

145 A 

Scleroderma Biomarkers 

150 B 

Shaping the Future of Psoriatic Disease Care: Current 

Controversies and Progress 

143 A 

Sjögren’s Syndrome 

152 A 

Veterans Affairs Rheumatology 


1:15 - 3:15 PM 










September 14. 

144 C 

PS 

Clinical Anatomy and Physical Exam: Essential Tools 

in Upper Extremity Regional Pain Syndromes (235) 

Speakers: Robert A. Kalish, MD and Pablo Villasenor Ovies, MD 

PM PS 

144 B 


Spondylarthritis: A Clinician’s Guide (236) 

Speakers: Walter P. Maksymowych, MD 

ACR SESSION 

1:30 - 2:30 PM 

Ballroom A 

ACR Leadership Town Hall Meeting & Business 

Meeting 

This session is not eligible for CME Credit. 

Moderator: James R. O’Dell, MD 


• have interacted with ACR leadership by asking questions and 

voicing concerns 

• recognize ACR initiatives 

• summarize what the ACR is doing to address various practice 

and other issues 

1:30 PM 

Leadership Town Hall Meeting 

James R. O’Dell, MD, Audrey B. Uknis, MD, Joseph Flood, MD, 

E. William St.Clair, MD, David I. Daikh, MD, PhD, Benjamin J. 

Smith, PA-C and David G. Borenstein, MD 

2:00 PM 

Business Meeting 

James R. O’Dell, MD, Audrey B. Uknis, MD, Joseph Flood, MD, 

E. William St.Clair, MD, David I. Daikh, MD, PhD, Benjamin J. 

Smith, PA-C and David G. Borenstein, MD 

ACR SESSIONS 

2:30 - 4:00 PM 

PM 

PS 

Hall E 

Approach and Management of Back Pain in Older 

Adults PM PS 

Moderator: Una E. Makris, MD 


• review the painful structures associated with back pain in 

older persons 

• describe the epidemiological differences, including impact, of 

back pain in younger vs. older adults 

• discuss the approach to diagnosis of back pain in older adults 

• discuss the pharmacological, non-pharmacological, and 

surgical management of back pain in older adults 

2:30 PM 

Where Does the Pain Come From? A Surgeon’s Perspective on 

Back Pain in Older Adults 

A. Jay Khanna, MD 

TUESDAY 

NOVEMBER 13, 2012 


PM 

PS 

TUESDAY 


3:15 PM 

Back Pain in Older Adults: Fundamental Differences 

Between Younger and Older Adults and How Our Approach/ 

Management Should Differ 


PM PS 

Hall D 

Connective Tissue Disease Associated Interstitial Lung 

Disease 

Moderators: Jessica K. Gordon, MD, MSc and Robert F. Spiera, 

MD 


• describe basic pathophysiologic principles underlying 

interstitial lung disease in association with connective tissue 

diseases 

• explain diagnostic and therapeutic approaches to these 

patients and evolving concepts in such approaches 

2:30 PM 

Connective Tissue Disease Associated Interstitial Lung Disease- 

Clinical and Pathological Aspects 

Aryeh Fischer, MD 

3:00 PM 

Connective Tissue Disease Associated Interstitial Lung Disease: 

Approach to Therapy 

Richard M. Silver, MD 

3:30 PM 

Interstitial Lung Disease Associated Secondary Pulmonary 

Hypertension: Implications for Diagnosis and Treatment 

Stephen C. Mathai, MD, MHS 

152 A 

New Molecules in Joint Biology 

Moderator: Anne-Marie Malfait, MD, PhD 


• describe form and function of extracellular matrix molecules, 

with emphasis on novel molecules or roles in joint 

homeostasis 

• review newly discovered mutations in TRPV4 that cause an 

inherited arthropathy of hands and feet 

• discuss sclerostin biology in bone and cartilage 

• recognize implications for the pathogenesis of age- and injuryrelated 

osteoarthritis 

2:30 PM 

Proteoglycans and More- From Molecules to Biology of 

Articular Cartilage 

Dick Heinegard, PhD 

3:00 PM 

A Role for TRPV4 in Cartilage Homeostasis 

Shireen Lamande, PhD 

3:30 PM 

Sclerostin in Bone and Cartilage 

Di Chen, MD, PhD 

PM 

PS 

150 B 

Visualizing the Immuno-inflammatory Response 


2:30 PM 

The Immunological Synapse and its Aberrations in 

Inflammatory Disease 

Alexandra Zanin-Zhorov, PhD 

3:00 PM 

In vivo Imaging of Immunity and Infection 

Paul Garside, PhD 

3:30 PM 

The Dynamics of Monocyte Migration in Immune-mediated 

Inflammatory Disease in Humans 

Danielle M. Gerlag, MD 


2:30 - 4:00 PM 

Ballroom A 

ACR Late-breaking Abstract Session 


147 A 


Moderators: Pier Luigi Meroni, MD and Roger Levy, MD 

2:30 PM 

2455. Establishment of Standardized International Units for IgG 

Anti-β2glycoprotein Antibody Measurement 

Rohan Willis 1 , Claudia Grossi 2 , Gabriella Lakos 3 , Pier Luigi 

Meroni 4 , Maria Borghi 2 , Luis R. Lopez 5 , Corina Dima 6 , Marius C. 

Teodorescu 7 , Nicholas Ozarka 7 , Matthias Kast 8 , Nina Olschowka 8 , 

Alfredo Villarreal 9 , Maria Crisostomo 10 , Mike Watkins 9 , 

Wendy Vandam 11 , Tony Prestigiacomo 10 , Josep Puig 12 , Kerrie 

Jaskal 13 , Roger Walker 10 , Sarah Paul 9 , T. Buckner 14 , Fernando S. 

Cavalcanti 12 and Silvia S. Pierangeli 1 , 1 University of Texas Medical 

Branch, Galveston, TX, 2 Lab of immunology, IRCCS Istituto 

Auxologico Italiano, Milano, Italy, 3 INOVA Diagnostics, Inc., San 

Diego, CA, 4 Division of Rheumatology - Istituto G. Pini, University 

of Milan, Milano, Italy, 5 Corgenix Inc, Broomfield, CO, 6 Theratest 

Laboratories Inc, Lombard, IL, 7 TheraTest Laboratories Inc, 

Lombard, IL, 8 Phadia Thermofisher, Freiburg, Germany, 9 Bio-Rad 

Laboratories, Benicia, CA, 10 Bio-Rad Laboratories, Hercules, CA, 

11 

Bio-Rad Laboratories, Hercules, 12 Biokit, Barcelona, Spain, 

13 

Instrumentation Laboratories, Bedford, MA, 14 Corgenix, 

Broomfield, CO 

2:45 PM 

2456. Pro-Inflammatory and Pro-Thrombotic Markers in 

Persistently Antiphospholipid Antibody-Positive Patients with/ 

without Systemic Lupus Erythematosus 

Gurjot Basra 1 , Doruk Erkan 2 , Rohan Willis 1 , JoAnn Vega 2 , Ana 

Laura Carrera Marin 1 , Patricia Ruiz Limon 1 , Vijaya L. Murthy 1 , 

Shraddha Jatwani 1 , Neha Dang 1 , Emilio B. Gonzalez 1 and Silvia S. 

Pierangeli 1 , 1 University of Texas Medical Branch, Galveston, TX, 

2 


104 

2012 Program Book

3:00 PM 

2457. An Open-Label Prospective Pilot Mechanistic Study of 

Fluvastatin in Persistently Antiphospholipid Antibody-Positive 

Patients 

Doruk Erkan 1 , Rohan Willis 2 , JoAnn Vega 1 , Vijaya L. Murthy 2 , 

Ana Laura Carrera Marin 2 , Gurjot Basra 2 , Patricia Ruiz Limon 2 , 

Emilio B. Gonzalez 2 and Silvia S. Pierangeli 2 , 1 Hospital for Special 

Surgery, New York, NY, 2 University of Texas Medical Branch, 

Galveston, TX 

3:15 PM 

2458. The Estimated Prevalence of Antiphospholipid 

Antibodies in General Population Patients with Pregnancy Loss, 

Stroke, Myocardial Infarction, and Deep Vein Thrombosis 

Laura Andreoli 1 , Alessandra Banzato 2 , Cecilia B. Chighizola 3 , 

Guillermo J. Pons-Estel 4 , Guilherme Ramires de Jesus 5 , Michael 

D. Lockshin 6 , Doruk Erkan 6 and On Behalf of APS Action 7 , 

1 

Rheumatology and Clinical Immunology, University of Brescia, 

Brescia, Italy, 2 Department of Cardiac Thoracic and Vascular 

Sciences, University of Padua, Padua, Italy, 3 Istituto Auxologico 

Italiano, University of Milan, Milan, Italy, 4 Department 

of Autoimmune Diseases, Institut Clìnic de Medicina i 

Dermatologia, Hospital Clìnic, Barcelona, Spain, 5 Department 

of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de 

Janeiro, Brazil, 6 Hospital for Special Surgery, New York, NY, 7 . 

3:30 PM 

2459. Efficacy of Aspirin for the Prevention of the First 

Thrombo-Embolic Events in Patients with Antiphospholipid 

Antibodies: A Metanalysis of Literature Data 

Laurent Arnaud 1 , Alexis Mathian 1 , Amelia Ruffatti 2 , Maria 

Tecktonidou 3 , Ricard Cervera 4 , Ricardo Forastiero 5 , Vittorio 

Pengo 6 , Marc Lambert 7 , Stephane Zuily 8 , Denis Wahl 8 and Zahir 

Amoura 1 , 1 Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 

& French National Reference Center For Systemic Lupus and 

Antiphospholipid Syndrome, Paris, France, 2 Rheumatology Unit, 

Department of Clinical and Experimental Medicine, University 

of Padua, Padua, Italy, 3 First Department of Internal Medicine, 

School of Medicine, National University of Athens, Athens, 

Greece, 4 Hospital Clínic of Barcelona, Barcelona, Spain, 5 Favaloro 

University, Argentina, 6 Clinical Cardiology, Department of 

Cardiac Thoracic and Vascular Sciences, University of Padova, 

Padova, Italy, 7 Internal Medicine Department, Universitary 

hospital, Lille, France, 8 Nancy University Hospital, Université de 

Lorraine & INSERM U961, Vandoeuvre-Les-Nancy, France 

3:45 PM 

2460. Dual Antiplatelet Therapy As Prophylaxis of Recurrent 

Arterial Thrombosis in Patients with antiphospholipid 

Syndrome 

Yuichiro Fujieda, Olga Amengual, Toshiyuki Watanabe, Michihito 

Kono, Yusaku Kanetsuka, Takashi Kurita, Toshio Odani, Kotaro 

Otomo, Toshiyuki Bohgaki, Tetsuya Horita, Shinsuke Yasuda and 

Tatsuya Atsumi, Hokkaido University, Sapporo, Japan 

202 B 

Epidemiology and Health Services Research IV: 

Outcomes and Costs in Rheumatic Disease 

Moderators: Kaleb Michaud, PhD and Elena Losina, PhD 

2:30 PM 

2461. Cost-Effectiveness of Systemic Therapies for Acute Gouty 

Arthritis 

Kimberly Reiter 1 , Jeremy Goldhaber-Fiebert 2 and Eswar 

Krishnan 3 , 1 Stanford University School of Medicine, Palo Alto, 

CA, 2 Stanford, Stanford, CA, 3 Stanford University, Stanford, CA 

2:45 PM 

2462. Projecting the Direct Cost Burden of Osteoarthritis in 

Canada Using a Population-Based Microsimulation Model 

From [2010-2031] 

Behnam Sharif 1 , Jacek A. Kopec 1 , Mushfiqur Rahman 1 , Nick 

Bansback 2 , Eric C. Sayre 1 , Philippe Finès 3 , Hubert Wong 2 and 

Aslam H. Anis 2 , 1 Arthritis Research Centre of Canada, Vancouver, 

BC, 2 St Paul’s Hospital, University of British Columbia, Vancouver, 

V6Z 1Y6, Canada, Vancouver, BC, 3 Statistics Canada, 150 

Tunney’s Pasture Driveway, Ottawa, ON, Canada, Ottawa, ON 

3:00 PM 

2463. Cost-Effectiveness of Tocilizumab Monotherapy Vs. 

Adalimumab Monotherapy in the Treatment of Severe Active 


Josh J. Carlson 1 , Sarika Ogale 2 , Fred Dejonckheere 3 and Sean 

Sullivan 1 , 1 University of Washington, Seattle, WA, 2 Genentech, 

South San Francisco, CA, 3 F. Hoffmann-La Roche Ltd, Basel, 

Switzerland 

3:15 PM 

2464. Cost-Sharing and Utilization of Biologic and Non-Biologic 

Dmards Among U.S. Medicare Beneficiaries with Rheumatoid 

Arthritis 

Chris Tonner, Gabriela Schmajuk and Jinoos Yazdany, University 

of California, San Francisco, San Francisco, CA 

3:30 PM 

2465. Seroresponse Rates After Influenza Vaccination in 

Rheumatoid Arthritis Patients Treated with Biological Agents 

During the 2011–2012 Flu Season 

Masatoshi Hayashi 1 , Toshihisa Kojima 2 , Naoki Ishiguro 3 , 

Tomonori Kobayakawa 1 and Toshihisa Kanamono 1 , 1 Nagano Red 

Cross Hospital, Nagano, Japan, 2 Nagoya Univeristy, School of 

Medicine, Nagoya, Japan, 3 Nagoya University, Graduate School 

& Faculty of Medicine, Nagoya, Aichi, Japan 

3:45 PM 

2466. Pregnancy Outcome in Women Treated with 

Adalimumab for the Treatment of Rheumatoid Arthritis: The 

OTIS Autoimmune Diseases in Pregnancy Project 

Christina D. Chambers 1 , Diana L. Johnson 1 , Yunjun Luo 1 , Janina 

L. Jimenez 1 , Nicole Mirrasoul 1 , Elizabeth Salas 1 , Kenneth Lyons 

Jones 1 and OTIS Research Group 2 , 1 University of California, San 

Diego, La Jolla, CA, 2 La Jolla 


Osteoarthritis - Clinical Aspects II: Structural Risks for 

Osteoarthritis End-points and Potential Treatments 

Moderators: Tuhina Neogi, MD, PhD and Martin Englund, MD, 

PhD 

TUESDAY 



2:30 PM 

2467. Tissue Lesions in Osteoarthritis Initiative Participants 

with Normal X-Rays and Risk Factors for Incident Cartilage 

Damage 

Leena Sharma 1 , Ali Guermazi 2 , Orit Almagor 1 , Michel Crema 3 , 

Dorothy D. Dunlop 1 , Frank Roemer 4 , Marc C. Hochberg 5 , 

Charles Eaton 6 , Joan M. Bathon 7 , Rebecca D. Jackson 8 , W.J. 

Mysiw 8 , C. Kent Kwoh 9 , Michael C. Nevitt 10 and Joan S. Chmiel 1 , 

1 

Northwestern University, Chicago, IL, 2 Boston University 

School of Medicine, Boston, MA, 3 Boston University, Boston, 

MA, 4 Klinikum Augsburg, Augsburg, Germany, 5 University of 

Maryland, Baltimore, MD, 6 Warren Alpert Medical School at 

Brown University, RI, 7 Columbia University Medical Center, New 

York, NY, 8 Ohio State University, Columbus, OH, 9 University of 

Pittsburgh and VA Healthcare System, Pittsburgh, PA, 10 University 

of California-San Francisco, San Francisco, CA 

2:45 PM 

2468. Incident Symptomatic Hip Osteoarthritis Is Associated 

with Differences in Hip Shape by Active Shape Modeling: The 

Johnston County Osteoarthritis Project 

Amanda E. Nelson 1 , Felix Liu 2 , John A. Lynch 2 , Jordan B. Renner 3 , 

Todd A. Schwartz 4 , Nancy E. Lane 5 and Joanne M. Jordan 1 , 

1 

University of North Carolina Thurston Arthritis Research Center, 

Chapel Hill, NC, 2 University of California at San Francisco, San 

Francisco, CA, 3 University of North Carolina at Chapel Hill Dept of 

Radiology, Chapel Hill, NC, 4 University of North Carolina Gillings 

School of Global Public Health, Dept of Biostatistics, Chapel Hill, 

NC, 5 UC Davis School of Medicine, Sacramento, CA 

3:30 PM 

2471. Oral Glucosamine Sulphate for the Prevention of Knee 

Osteoarthritis in Overweight Females; The First Ever Preventive 

Randomized Controlled Trial 

Jos Runhaar 1 , Marienke van Middelkoop 1 , Max Reijman 1 , Edwin 

Oei 1 , Dammis Vroegindeweij 2 , Gerjo van Osch 1 , Bart Koes 1 and 

Sita Bierma-Zeinstra 1 , 1 Erasmus MC, Rotterdam, Netherlands, 

2 

Maasstad Hospital, Rotterdam, Netherlands 

3:45 PM 

2472. A Randomized, Multicentre, Double Blind, Placebo- 

Controlled Trial of Anti TNF Alpha (adalimumab) in Refractory 

Hand Osteoarthritis: The Dora Study 

Xavier Chevalier 1 , Philippe Ravaud 2 , Emmanuel Maheu 3 , Gabriel 

Baron 4 , Amandine Rialland 5 , Philippe Vergnaud 6 , Christian 

Roux 7 , Yves Maugars 8 , Denis Mulleman 9 , Bernard Combe 10 , 

Daniel Wendling 11 , Pierre Laforgue 12 , Damien Loeuille 13 , Violaine 

Foltz 14 and Pascal Richette 15 , 1 Department of Rheumatology 

Hopital Henri Mondor, Créteil, France, 2 Hopital Hotel Dieu, Paris 

Descartes University, Paris, France, 3 AP-HP, St Antoine Hospital, 

Paris, France, 4 Epidemiology, Paris, France, 5 Unité de recherche 

clinique Henri Mondor, Créteil, France, 6 CCRB Synarc Lyon, 

Lyon, France, 7 CHU L’ Archet University Nice, Nice, France, 8 CHU 

Nantes, Nantes, France, 9 CHU Trousseau Tours, Tours, France, 

10 

Lapeyronie Hospital, Montpellier, France, 11 Minjoz University 

Hospital, Besancon, France, 12 CHU la conception Marseille, 

Marseille, France, 13 CHU Brabois, Vandoeuvre les Nancy, France, 

14 

Pitié Salpétrière Hospital, Paris, France, 15 Lariboisière Hospital, 

Paris, France 

TUESDAY 


106 

3:00 PM 

2469. A Virtual Knee Joint Replacement Clinical Endpoint Based 

On Longitudinal Trends and Thresholds in Koos Knee Pain and 

Function in Osteoarthritis Initiative Participants 

Robert M. Boudreau 1 , David J. Hunter 2 , Zhijie Wang 3 , Frank 

Roemer 4 , Felix Eckstein 5 , Michael J. Hannon 3 , Ali Guermazi 4 

and C. Kent Kwoh 6 , 1 University of Pittsburgh, Pittsburgh, PA, 

2 

University of Sydney, Sydney, Australia, 3 University of Pittsburgh 

School of Medicine, Pittsburgh, PA, 4 Boston University School of 

Medicine, Boston, MA, 5 Paracelsus Medical University, Salzburg, 

Austria, 6 University of Pittsburgh and VA Healthcare System, 


3:15 PM 

2470. Does Structural Progression of Knee Osteoarthritis 

Measured with Magnetic Resonance Imaging or Radiography 

Predict Knee Replacement? - Data From the Osteoarthritis 

Initiative 

Felix Eckstein 1 , C. Kent Kwoh 2 , Robert M. Boudreau 3 , Zhijie 

Wang 4 , Michael J. Hannon 4 , Wolfgang Wirth 1 , Ali Guermazi 5 , 

Frank Roemer 6 , Michael C. Nevitt 7 , Markus R. John 8 , Leena 

Sharma 9 , Jeffrey W. Duryea 10 , David J. Hunter 11 and Osteoarthritis 

Initiative Investigators 12 , 1 Paracelsus Medical University, 

Salzburg, Austria, 2 University of Pittsburgh and VA Healthcare 

System, Pittsburgh, PA, 3 University of Pittsburgh, Pittsburgh, 

PA, 4 University of Pittsburgh School of Medicine, Pittsburgh, PA, 

5 

Boston University, Boston, MA, 6 Klinikum Augsburg, Augsburg, 

Germany, 7 University of California-San Francisco, San Francisco, 

CA, 8 Novartis Pharma AG, Basel, Switzerland, 9 Northwestern 

University, Chicago, IL, 10 Brigham & Women, Boston, MA, 

11 

University of Sydney, Sydney, Australia, 12 San Francisco 


207 A 


Disease III: Childhood Systemic Lupus Erythematosus 

and Other Vasculitides 

Moderators: Emily von Scheven, MD and Karen Onel, MD 

2:30 PM 

2473. A Randomized Trial in New Onset Juvenile 

Dermatomyositis: Prednisone Versus Prednisone Plus 

Cyclosporine Versus Prednisone Plus Methotrexate 

Nicolino Ruperto, Angela Pistorio, Sheila Oliveira, Rubén J. 

Cuttica, Angelo Ravelli, Michel Fischbach, Stefan Hagelberg, 

Tadej Avcin, Emanuel Cheuret, Fabrizia Corona, Gerard 

Couillault, Frank Dressler, Valeria Gerloni, Gary Sterba, Francesco 

Zulian, Maria Teresa Apaz, Adriana Cespedes-Cruz, Rolando 

Cimaz, Fabrizio De Benedetti, Pierre Quartier, Ricardo Russo, 

Nico Wulffraat, Simona Angioloni and Alberto Martini, Paediatric 

Rheumatology International Trials Organization (PRINTO), 

Istituto Giannina Gaslini, Genova, Italy 

2:45 PM 

2474. Urine Biomarkers Distinguish Between Proliferative and 

Membranous Lupus Nephritis in Childhood Onset Systemic 


Rina Mina 1 , Michael Bennett 2 , Lining Qi 3 , Shannen Nelson 4 , 

Jessica Hummel 5 , Pavel Shiyanov 3 , John Schlager 3 , Prasad 

Devarajan 2 and Hermine I. Brunner 4 , 1 Cincinnati Children’s 

Hospital Medical Center/University of Cincinnati, Cincinnati, 

OH, 2 Cincinnati Children’s Med Ctr, Cincinnati, OH, 3 US Air Force 

Research Lab, Wright-Patterson Air Force Base, OH, 4 Cincinnati 

Children’s Hospital, Cincinnati, OH, 5 Cincinnati Children’s 

Hospital Medical Center, Cincinnati, OH

3:00 PM 

2475. Cancer in Pediatric-Onset Systemic Lupus: What Is the 

Role of Disease Duration and Other Factors on Risk? 

Sasha Bernatsky 1 , Ann E. Clarke 1 , Jeremy Labrecque 2 , Emily von 

Scheven 3 , Laura E. Schanberg 4 , Earl D. Silverman 5 , Hermine I. 

Brunner 6 , Kathleen A. Haines 7 , Randy Q. Cron 8 , Kathleen M. 

O’Neil 9 , Kiem Oen 10 , Alan M. Rosenberg 11 , Ciaran M. Duffy 12 , 

Jennifer LF Lee 13 , Mruganka Kale 13 , Elizabeth M. Turnbull 2 and 

Rosalind Ramsey-Goldman 14 , 1 McGill University, Montreal, QC, 

2 

Research Institute of the McGill Univ. Health Ctre, Montreal, 

QC, 3 UC San Francisco, San Francisco, CA, 4 Duke University 

Medical Center, Durham, NC, 5 PRSCG, Cincinnati, OH, 6 Cincinnati 

Children’s Hospital Medical Center, Cincinnati, OH, 7 Hackensack 

Univ Med Ctr, Hackensack, NJ, 8 Univ of Alabama-Birmingham, 

Birmingham, AL, 9 Okla Univ Health Science Ctr, Oklahoma City, 

OK, 10 University of Manitoba, Winnipeg, MB, 11 Royal University 

Hospital, Saskatoon, SK, 12 Children’s Hospital of Eastern 

Ontario, Ottawa, ON, 13 RI McGill Univ Health Ctr, Montreal, 

QC, 14 Northwestern University Feinberg School of Medicine, 

Chicago, IL 

3:15 PM 

2476. Role of Whole-Body Magnetic Resonance Imaging in the 

Assessment of Disease Activity in Juvenile Dermatomyositis. A 

Pilot Study. 

Clara Malattia 1 , Annalisa Madeo 1 , Silvia Pederzoli 1 , Anna 

Providenti 2 , Marta Mazzoni 1 , Agnese Beltramo 1 , Alessandro 

Consolaro 1 , Stefania Viola 1 , Antonella Buoncompagni 1 and A. 

Martini 1 , 1 Istituto G Gaslini, Pediatria II, Reumatologia, Genova, 

Italy, 2 Istituto G Gaslini, Genova, UO Fisioterapia, Genova, Italy 

3:30 PM 

2477. The Comparison of Childhood Polyarteritis Nodosa and 

Cutaneous Polyarteritis Nodosa and a New Set of Diagnostic 

Criteria for Cut-Polyarteritis Nodosa 

Erkan Demirkaya, Seza Ozen, Turker Turker, Rubén J. Cuttica, 

Paul Brogan, Pierre Quartier, Jordi Anton, Nuray Aktay Ayaz, 

Stella Maris Garay, Graciela Espada, Raju Khubchandani, 

Francesco Zulian, Arvind Bagga, Alexandre Belot, Clovis Artur 

Silva, Sulaiman Al-Mayouf, Amparo Ibanez Estrella, Sheila 

Oliveira, Cengizhan Acikel, Claudia Saad-Magalhães, Alberto 

Martini and Nicolino Ruperto, Paediatric Rheumatology 


Gaslini, Genova, Italy 

3:45 PM 

2478. Identification of Disease-Specific Neuroimaging 

Phenotypes in Childhood Inflammatory Brain Diseases 

Tania Cellucci, Pascal N. Tyrrell, Shehla Sheikh, Suzanne Laughlin 

and Susanne M. Benseler, The Hospital for Sick Children, 

Toronto, ON 

Ballroom B 

Rheumatoid Arthritis - Clinical Aspects IV: Nonbiologic 

Drugs for Rheumatoid Arthritis: New Insights 

on Comorbidities and Adverse Events 

Moderators: Jonathan Kay, MD and Neal S. Birnbaum, MD 

2:30 PM 

2479. Rheumatoid Arthritis Does Not Increase Risk of Short 

Term Total Knee Replacement (TKR) Adverse Events (AE) 

Zachary J. LoVerde 1 , Lisa A. Mandl 2 , Beverly K. Johnson 2 , Mark P. 

Figgie 2 , Friedrich Boettner 2 and Susan M. Goodman 2 , 1 New York 

Medical College, Valhalla, NY, 2 Hospital for Special Surgery, New 

York, NY 

2:45 PM 

2480. Disease-Modifying Antirheumatic Drug Use and 

Toxicities Among Elderly Patients with Rheumatoid Arthritis 

Rebecca L. Manno 1 , Dimitrios A. Pappas 2 , Katherine C. 

Saunders 3 , George Reed 4 , Shannon Grant 5 and Clifton O. 

Bingham III 1 , 1 Johns Hopkins University, Baltimore, MD, 

2 

Columbia University, College of Physicians & Surge, New York, 

NY, 3 CORRONA, Inc., Southborough, MA, 4 UMass Medical 

School, Worcester, MA, 5 Axio Research LLC, Seattle, WA 

3:00 PM 

2481. Time Trends in Corticosteroid Use in Rheumatoid 

Arthritis: Results From a Population Based Inception Cohort 

1980–1994 Vs. 1995–2007 

Ashima Makol, John M. Davis III, Cynthia S. Crowson, Terry M. 

Therneau, Sherine E. Gabriel and Eric L. Matteson, Mayo Clinic, 

Rochester, MN 

3:15 PM 

2482. Hydroxychloroquine Has Lipid-Lowering Effects in US 

Veterans with Rheumatoid Arthritis 

Nicole A. Kieffer 1 , Gail S. Kerr 2 , J. Steuart Richards 3 , Lisa A. Davis 4 , 

Liron Caplan 5 , Jeffrey Huang 6 , Grant W. Cannon 7 , Harlan Sayles 8 

and Kaleb Michaud 9 , 1 Georgetown University, Washington, DC, 

2 

Washington DC VAMC, Georgetown and Howard University, 

Washington, DC, 3 Washington DC VA and Georgetown 

University, Washington, DC, 4 Denver VA and Univ of Colorado 

School of Med, Aurora, CO, 5 Denver VA and Univ of Colorado 

School of Medicine, Aurora, CO, 6 Washington DC VA and Howard 

University Hospital, Washington, DC, 7 George E. Wahlen VA 

Medical Center, Salt Lake City, UT, 8 University of Nebraska 

Medical School, Omaha, NE, 9 National Data Bank for Rheumatic 

Diseases & University of Nebraska Medical Center, Omaha, NE 

3:30 PM 

2483. Folic Acid Pathway Single Neucelotide Polymorphisms 

Associated with Methotrexate-Related Significant Adverse 

Events 

Lisa A. Davis 1 , Brooke Ivan Polk 2 , Alyse D. Mann 3 , Roger K. Wolff 4 , 

Gail S. Kerr 5 , Andreas M. Reimold 6 , Grant W. Cannon 7 , Ted R. 

Mikuls 8 and Liron Caplan 9 , 1 Univ of Colorado School of Med, 

Aurora, CO, 2 University of Colorado Medical School, Aurora, CO, 

3 

Denver VA Medical Center, Denver, CO, 4 University of Utah, 

Salt Lake City, UT, 5 Washington DC VAMC, Georgetown and 

Howard University, Washington, DC, 6 Dallas VA and University of 

Texas Southwestern, Dallas, TX, 7 George E. Wahlen VA Medical 

Center, Salt Lake City, UT, 8 Omaha VA and University of Nebraska 

Medical Center, Omaha, NE, 9 Denver VA and University of 

Colorado School of Medicine, Aurora, CO 

3:45 PM 

2484. Hepatic Steatosis in Rheumatoid Arthritis: Associations 

with Disease Characteristics, Pharmacotherapies, and 

Atherosclerosis 

Jon T. Giles and Joan M. Bathon, Columbia University Medical 

Center, New York, NY 


TUESDAY 

November 13, 2012

TUESDAY 


108 

Ballroom C 


Biologics and Gene Therapy: Safety & Efficacy of 

Janus Activated-Kinase (JAK) Inhibitors 

Moderators: Daniel Aletaha, MD, MSc and Martin Aringer, MD 

2:30 PM 

2485. Tofacitinib, an Oral Janus Kinase Inhibitor: Analyses of 

Efficacy and Safety of 10 versus 5mg Twice Daily in a Pooled 

Phase 3 and Long-Term Extension Rheumatoid Arthritis 

Population 

S. Cohen 1 , S. Krishnaswami 2 , B. Benda 3 , R. Riese 2 , M.G. Boy 2 , D. 

Gruben 2 , G. Wallenstein 2 , C. A. Mebus 2 , S. H. Zwillich 2 and J. D. 

Bradley 2 , 1 Metroplex Clinical Research Centre, Dallas, TX, 2 Pfizer 

Inc., Groton, CT, 3 Pfizer Inc., Collegeville, PA 

2:45 PM 

2486. Radiographic, Clinical and Functional Comparison 

of Tofacitinib Monotherapy Versus Methotrexate in 

Methotrexate-Naïve Patients with Rheumatoid Arthritis 

Eun Bong Lee 1 , Roy M. Fleischmann 2 , Stephen Hall 3 , Ronald F. 

van Vollenhoven 4 , John Bradley 5 , David Gruben 5 , Tamas Koncz 6 , 

Sriram Krishnaswami 5 , Gene Wallenstein 5 , Samuel H. Zwillich 5 , 

Bethanie E. Wilkinson 5 and the ORAL Start Investigators 7 , 

1 

Seoul National University, Seoul, South Korea, 2 Metroplex 

Clinical Research Center, Dallas, TX, 3 Cabrini Health and 

Monash University, Melbourne, Australia, 4 Karolinska Institute, 

Stockholm, Sweden, 5 Pfizer Inc., Groton, CT, 6 Pfizer Inc., New 

York, NY, 7 Groton, CT 

3:00 PM 

2487. 24-Week Results of a Blinded Phase 2b Dose-Ranging 

Study of Baricitinib, an Oral Janus Kinase 1/ Januse Kinase 2 

Inhibitor, in Combination with Traditional Disease Modifying 

Antirheumatic Drugs in Patients with Rheumatoid Arthritis 

Mark C. Genovese 1 , Edward Keystone 2 , Peter Taylor 3 , Edit 

Drescher 4 , Pierre-Yves Berclaz 5 , Chin H. Lee 5 , Douglas E. 

Schlichting 5 , Scott D. Beattie 5 , Rosanne K. Fidelus-Gort 6 , Monica 

E. Luchi 6 and William Macias 5 , 1 Stanford University Medical 

Center, Palo Alto, CA, 2 University of Toronto, Toronto, ON, 

3 

University of Oxford, Oxford, United Kingdom, 4 Veszprém 

Csolnoky Ferenc County Hospital, Department of Rheumatology 

and Physical Rehabilitation, Veszprém, Hungary, 5 Eli Lilly and 

Company, Indianapolis, IN, 6 Incyte Corporation, Wilmington, DE 

3:15 PM 

2488. Magnetic Resonance Imaging Substudy in a Phase 2b 

Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus 

Kinase 2 Inhibitor, in Combination with Traditional Disease- 

Modifying Antirheumatic Drugs in Patients with Rheumatoid 

Arthritis 

Charles G. Peterfy 1 , Paul Emery 2 , Mark C. Genovese 3 , Edward 

Keystone 4 , Peter Taylor 5 , Pierre-Yves Berclaz 6 , Julie C. DiCarlo 1 , 

Chin H. Lee 6 , Douglas E. Schlichting 6 , Scott D. Beattie 6 , Monica 

E. Luchi 7 and William Macias 6 , 1 Spire Sciences LLC, Kentfield, 

CA, 2 University of Leeds, Leeds, United Kingdom, 3 Stanford 

University Medical Center, Palo Alto, CA, 4 University of Toronto, 

Toronto, ON, 5 University of Oxford, Oxford, United Kingdom, 

6 

Eli Lilly and Company, Indianapolis, IN, 7 Incyte Corporation, 

Wilmington, DE 


3:30 PM 

2489. Selective JAK1 Inhibition in the Treatment of Rheumatoid 

Arthritis: Proof of Concept with GLPG0634 

Frédéric Vanhoutte 1 , Minodora Mazur 2 , Annegret Van der 

Aa 1 , Piet Wigerinck 1 and Gerben van ‘t Klooster 1 , 1 Galapagos 

NV, Mechelen, Belgium, 2 State Medical and Pharmaceutical 

University “Nicolae Testemitanu”, Chisinau, Moldova 

3:45 PM 

2490. Herpes Zoster and Tofacitinib Therapy in Patients with 


K. L. Winthrop 1 , H. Valdez 2 , E. Mortensen 3 , R. Chew 4 , S. 

Krishnaswami 4 , T. Kawabata 4 and R. Riese 4 , 1 Division of Infectious 

Diseases, Oregon Health and Science University, Portland, OR, 

2 

Pfizer Inc., New York, NY, 3 Pfizer Inc., Collegeville, PA, 4 Pfizer 

Inc., Groton, CT 

Salon B 

Spondyloarthritis and Psoriatic Arthritis - 

Pathogenesis, Etiology 

Moderators: Shervin Assassi, MD, MS and Dominique L. Baeten, 

MD, PhD 

2:30 PM 

2491. IL-17 Expression Is Low in Psoriatic Arthritis Synovium 

Compared to Expression in Matched Skin Lesions 

Jennifer Belasco 1 , Hiroshi Mitsui 1 , Mayte Suarez-Farinas 1 , 

James S. Louie 2 , Nathan Wei 3 , Nicholas Gulati 1 and James G. 

Krueger 1 , 1 The Rockefeller University, New York, NY, 2 UCLA 

School of Medicine, Los Angeles, CA, 3 Arthritis Treatment Center, 

Frederick, MD 

2:45 PM 

2492. Protective and Pathogenic Effects of the IL-23 Family of 

Cytokines in Spondyloarthropathy in SKG Mice 

Helen Benham 1 , Linda Rehaume 1 , Merja Ruutu 1 , Jared 

Velasco 1 , Kristine Kikly 2 , Geoffrey Strutton 3 , Michael McGuckin 4 

and Ranjeny Thomas 1 , 1 Diamantina Institute University of 

Queensland, Brisbane, Australia, 2 Biotechnology Discovery 

Research, Eli Lilly and Co., Indianapolis, 3 Department of 

Pathology, Princess Alexandra Hospital, Brisbane, Australia, 

4 

Mater Medical Research Institute, Brisbane, Australia 

3:00 PM 

2493. The Presence of HLA-B27 Shapes Gut Microbiome 

Composition in Rats 

Mary H. Bach 1 , Russell N. Van Gelder 1 , Joel D. Taurog 2 and James 

T. Rosenbaum 3 , 1 University of Washington Medical Center, 

Seattle, WA, 2 UT Southwestern Medical Center, Dallas, TX, 

3 

Oregon Health & Science University, Portland, OR 

3:15 PM 

2494. Incidence and Severity of Spondyloarthritis and Crohn’s 

Ileitis Are Determined by Interaction Between the Microbiota 

and Genetic Susceptibility in Beta-Glucan-Treated SKG Mice 

Ranjeny Thomas 1 , Linda Rehaume 1 , Daniel Aguirre de Cárcer 2 , 

Stan Mondot 2 , Jared Velasco 1 , Helen Benham 1 , Merja Ruutu 1 , 

Mark Morrison 2 and Michael McGuckin 3 , 1 University of 

Queensland Diamantina Institute, Brisbane, Australia, 2 CSIRO 

Livestock Industries, Brisbane, Australia, 3 Mater Medical 

Research Institute, Brisbane, Australia

3:30 PM 

2495. Dense Genotyping of Candidate Genes Identifies 16 New 

Susceptibility Loci in Ankylosing Spondylitis 

Adrian Cortes 1 , Philip Robinson 1 , International Spondyloarthritis 

Genetics Consortium 2 and Matthew A. Brown 1 , 1 The University 

of Queensland Diamantina Insititute, Brisbane, Australia, 

2 

Brisbane, Australia 

Rheumatology - Faculdade de Medicina da Universidade de 

São Paulo, São Paulo, Brazil, 2 Division of AnatomoPathology 

- Faculdade de Medicina da Universidade de São Paulo, São 

Paulo, Brazil, 3 Faculdade de Medicina da Universidade de São 

Paulo, São Paulo, Brazil, 4 Division of Nephrology - Faculdade 

de Medicina da Universidade de São Paulo, São Paulo, Brazil, 

5 

University of Sao Paulo, São Paulo, Brazil 

3:45 PM 

2496. Elevated Serum Level of the Vascular Endothelial Growth 

Factor Is Highly Predictive for New Syndesmophytes Formation 

in Patients with Ankylosing Spondylitis 

Denis Poddubnyy 1 , Kristina Conrad 1 , Uta Syrbe 1 , Hildrun 

Haibel 1 , Heiner Appel 1 , Martin Rudwaleit 2 and Joachim Sieper 3 , 

1 

Charité Medical University, Campus Benjamin Franklin, Berlin, 

Germany, 2 Endokrinologikum Berlin, Berlin, Germany, 3 Charité 


146 C 


Pathogenesis II 

Moderators: Mary K. Crow, MD and Mariana J. Kaplan, MD 

2:30 PM 

2497. Altered Circulating Follicular Helper T Cell Phenotype 

and Subset Composition Are Associated with Disease Activity 

in Patients with Systemic Lupus Erythematosus 

Hsi-en Ho 1 , Jin Young Choi 2 , Viviane M. Bunin 2 , Sandra G. 

Pasoto 3 , Solange Carrasco 3 , Eduardo F. Borba 3 , Celio R. 

Goncalves 3 , Priscila R. Costa 4 , Esper G. Kallas 4 , Eloisa Bonfa 3 

and Joseph E. Craft 2 , 1 Yale University School of Medicine, 

New Haven, CT, 2 Yale University School of Medicine, 

Internal Medicine, Section of Rheumatology, New Haven, 

CT, 3 Universidade de São Paulo, Division of Rheumatology, 

Faculdade de Medicina, Sao Paulo, Brazil, 4 Universidade de São 

Paulo, Division of Immunology, Faculdade de Medicina, Sao 

Paulo, Brazil 

2:45 PM 

2498. Biomarkers of Mitochondrial Dysfunction Correlate with 

Disease Activity in SLE 

Zhi-Wei Lai 1 , Tiffany Telarico 2 , Robert Hanczko 1 , Adam Bartos 1 , 

Lisa Francis 3 , Hajra I. Tily 4 , Ricardo Garcia 1 , Maha M. Dawood 5 , 

Jianghong Yu 2 , Ashwini Shadakshari 2 , Paul E. Phillips 6 and Andras 

Perl 7 , 1 SUNY, Syracuse, NY, 2 SUNY Upstate Medical University, 

Syracuse, NY, 3 SUNY upstate medical university, Syracuse, NY, 

4 

SUNY, NY, 5 SUNY Upstate, Syracuse, NY, 6 SUNY-Upstate Medical 

Univ, Syracuse, NY, 7 Upstate Medical University, Syracuse, NY 

3:00 PM 

2499. The Peroxisome-Proliferator Activated Receptor-γ 

Agonist Pioglitazone Modulates Aberrant T-Cell Responses in 


Wenpu Zhao 1 , Celine C. Berthier 1 , Matthias Kretzler 2 and 

Mariana J. Kaplan 1 , 1 University of Michigan, Ann Arbor, MI, 

2 

University of Michigan, MI 

3:15 PM 

2500. Podocyte Injury in Membranous and Proliferative Lupus 

Nephritis: Distinct Underlying Mechanisms? 

Gabriela M. Rezende 1 , Vilma S. T. Viana 1 , Denise M. Malheiros 2 , 

Elaine P. Leon 3 , Eduardo F. Borba 1 , Neila AS Silva 2 , Irene L. 

Noronha 4 , Cleonice Silva 4 and Eloisa Bonfá 5 , 1 Division of 

3:30 PM 

2501. Mirorna Mir-150 Contributes to Chronic Kidney Injury in 

Lupus Nephritis by Increasing the Synthesis of Fibrotic Proteins 

Via Downregulation of SOCS1 

Hua Zhou 1 , Sarfaraz A. Hasni 2 , Mayank Tandon 1 , Shyh-Ing Jang 1 , 

Howard A. Austin 3 , James E. Balow 3 , Ilias Alevizos 1 and Gabor G. 

Illei 1 , 1 NIDCR/NIH, Bethesda, MD, 2 NIAMS/NIH, Bethesda, MD, 

3 

NIDDK/NIH, Bethesda, MD 

3:45 PM 

2502. Neutrophil Extracellular Trap-Associated Protein 

Activation of the Inflammasome Is Enhanced in Lupus M1 

Macrophages 

J. Michelle Kahlenberg, Carolyne K. Smith, Carmelo Carmona- 

Rivera and Mariana J. Kaplan, University of Michigan, Ann Arbor, 

MI 

204 A 


Moderators: Cornelia M. Weyand, MD, PhD and George C. 

Tsokos, MD 

2:30 PM 

2503. CD8+Foxp3-CD103+ Regulatory T Cells Generated Ex Vivo 

with TGF-β Suppress Autoimmunity Through IL-10-Dependet 

Mechanism 

Ya Liu 1 , An-Ping Xu 2 , David A. Horwitz 3 and Song G. Zheng 3 , 

1 

USC Keck School of Medicine, Los Angeles, CA, 2 2nd Affiliated 

Hospital of Sun Yat-sen University, 3 Keck School of Medicine of 

USC, Los Angeles, CA 

2:45 PM 

2504. SOCS1 Is One of the Key Molecules to Prevent the 

Plasticity of Regulatory T Cells and the Development of 

Autoimmunity 

Reiko Takahashi 1 , Kenji Itoh 1 , Fumihiko Kimura 1 and Akihiko 

Yoshimura 2 , 1 National Defense Medical College, Tokorozawa, 

Japan, 2 Keio University School of Medicine, Tokyo, Japan 

3:00 PM 

2505. Involvment of CD4+ FoxP3+ Regulatory T Cells in 

Interleukin-6 Receptor Targeted Treatment in Murine Arthritis 

and Rheumatoid Arthritis 

Allan Thiolat 1 , Jerome Biton 1 , Luca Semerano 1 , Yves-Marie 

Pers 2 , Pierre Portales 2 , Delphine Lemeiter 1 , Patrice Decker 1 , 

Christian Jorgensen 2 , Pascale Louis-Plence 2 , Natacha Bessis 1 

and Marie-Christophe Boissier 1 , 1 EA4222, Li2P, University 

Paris 13, Sorbonne Paris Cité and Rheumatology Department, 

Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP- 

HP), Bobigny, 93009, France, Bobigny, France, 2 Inserm U844, 

CHU saint-Eloi, Université Montpellier 1, CHU Lapeyronie, 

Montpellier, France 


TUESDAY 

November 13, 2012

3:15 PM 

2506. Expression of Helios Facilitates Distinction Between 

FoxP3+ Treg and FoxP3+ Activated T Conventional Cells in 

Patients with Systemic Lupus Erythematosus 

Amit Golding 1 , Sarfaraz A. Hasni 2 , Gabor G. Illei 3 and Ethan M. 

Shevach 4 , 1 NIAID/National Institutes of Health, Bethesda, MD, 

2 

National Institutes of Health, Bethesda, MD, 3 NIDCR/ NIH, 

Bethesda, MD, 4 NIAID/NIH, Bethesda, MD 

3:30 PM 

2507. Activated Cullin-Ring Ubiquitin Ligases (CRLs) Dampen T 

Cell Signaling and Inactivation of Crls Arrests the Progression of 

Inflammatory Arthritis 

Leonard L. Dragone 1 , Lisa K. Peterson 1 , Allison Berger 2 and 

Samantha F. Friend 1 , 1 National Jewish Health, Denver, CO, 

2 

Millennium Pharmaceuticals, Inc, Cambridge, MA 

3:45 PM 

2508. miR142-3p Interfers with T Cell Proliferation by Targeting 

the Expression of Garp in Patients with Rheumatoid Arthritis 

Qihui Zhou, Sonja Haupt, Johannes Thomas Kreuzer, Hendrik 

Schulze-Koops and Alla Skapenko, University of Munich, Munich, 

Germany 

ACR/ARHP COMBINED ABSTRACT SESSION 

2:30 - 4:00 PM 

201 

ACR/ARHP Combined Epidemiology Abstract Session 

Moderators: Yuqing Zhang, DSc, MPH and Tuhina Neogi, MD, 

PhD 

of the McGill University Health Ctre, Montreal, QC, 4 Southlake 

Regional Health Centre, Newmarket, ON, 5 William Osler Health 

Center, Mississauga, ON 

3:15 PM 

2512. Changes in Bone Marrow Lesion Volume Relate to 

Changes in Knee Pain. Data From the Osteoarthritis Initiative 

Jeffrey B. Driban 1 , Lori Lyn Price 1 , Grace H. Lo 2 , Jincheng Pang 3 , 

Eric Miller 3 , Charles Eaton 4 , John A. Lynch 5 and Timothy E. 

McAlindon 1 , 1 Tufts Medical Center, Boston, MA, 2 Michael E. 

DeBakey Veterans Affairs Medical Center, Houston, TX, 3 Tufts 

University, Medford, MA, 4 Warren Alpert Medical School at 

Brown University, RI, 5 University of California at San Francisco, 

San Francisco, CA 

3:30 PM 

2513. Association of Arthritis and Joint Pain with 

Accelerometer-Measured Physical Activity in Adults Aged 50 

and Older in the United States: Findings From the National 

Health and Nutrition Examination Survey (2003-2004) 

Kathryn Remmes Martin 1 , Dane Van Domelen 1 , Matthew 

Pantell 1 , Ming-yang Hung 1 , Tamara B. Harris 1 and Kushang Patel 2 , 

1 

NIA/NIH, Bethesda, MD, 2 University of Washington, Seattle, WA 

3:45 PM 

2514. Racial/Ethnic Trends in Incidence and Prevalence of 

Rheumatoid Arthritis in a Large Multi-Ethnic Managed Care 

Population 

Aniket A. Kawatkar 1 , Cecilia Portugal 1 , Li-Hao Chu 2 and Rajan 

Iyer 1 , 1 Kaiser Permanente Southern California, Pasadena, CA, 

2 

Kaiser Permanente Southern California, Pasadena 

TUESDAY 


2:30 PM 

2509. Cost-Effectiveness of Training Rural Providers to Perform 

Joint Injections 

Michael J. Battistone, Richard E. Nelson, William D. Ashworth, 

Andrea Barker, Marissa Grotzke, Timothy A. Huhtala, Robert Z. 

Tashjian and Grant W. Cannon, Salt Lake City VA and University 

of Utah, Salt Lake City, UT 

2:45 PM 

2510. Patient and Provider Factors Associated with Compliance 

with Rheumatoid Arthritis Treatment Recommendations 

Leslie R. Harrold 1 , George W. Reed 2 , Katherine C. Saunders 3 , Ying 

Shan 1 , Tanya Spruill 4 and Jeffrey D. Greenberg 5 , 1 UMass Medical 

School, Worcester, MA, 2 University of Massachusetts Medical 

School, Worcester, MA, 3 CORRONA, Inc., Southborough, MA, 

4 

NYU School of Medicine, New York, NY, 5 New York University 

School of Medicine, New York, NY 

3:00 PM 

2511. Potential Barriers That Limit Access to Rheumatologists 

Among Patients with Early Rheumatoid Arthritis in a Universal 

Access Health Care System 

Jessica Widdifield 1 , J. Michael Paterson 2 , Sasha Bernatsky 3 , 

Karen Tu 2 , Nadia Gunraj 2 , Noah Ivers 1 , Debra Butt 2 , R. Liisa 

Jaakkimainen 1 , J. Carter Thorne 4 , Vandana Ahluwalia 5 and Claire 

Bombardier 1 , 1 University of Toronto, Toronto, ON, 2 Institute for 

Clinical Evaluative Sciences, Toronto, ON, 3 Research Institute 

ARHP SESSIONS 

2:30 - 4:00 PM 

206 

PM 

PS 

Myositis: Pathogenesis, Diagnosis and 

Management 

Moderator: Maura D. Iversen, BSc, DPT, SD, MPH 


• review the pathogenesis of myositis versus other myopathies 

• discuss the diagnostic approach to myositis including specific 

objective measures in the clinical setting, laboratory studies, 

imaging, electromyogram and muscle biopsy 

• identify medications currently being used to treat myositis and 

emerging therapies 

• summarize the therapeutic approach to myositis and identify 

specific precautions 

2:30 PM 

Pathogenesis, Diagnosis and Medication Management of 

Myositis 

Dana P. Ascherman, MD 

3:15 PM 

Exercise in Patients with Idiopathic Inflammatory Myopathies 

Helene Alexanderson, PhD, RPT 

110 

2012 Program Book

PM 

PS 

PM PS 

145 A 

Rheumatic Disease Update: Systemic Lupus 

Erythematosus 


Speaker: Michelle Petri, MD, MPH 


• review current knowledge of the pathophysiology and biology 

of lupus 

• discuss the major manifestations of lupus 

• identify the recently recognized cardiovascular co-morbidities 

associated with lupus 

• explain the use of laboratory testing in lupus 

• explore the role for newer biological agents in the treatment 

of lupus 

143 A 

PM PS 

Rheumatoid Arthritis Disease Activity Measures 

and Quality Indicators: Correct Use and Future 

Directions 

Moderator: Barbara A. Slusher, PA-C, MSW 


• define the term disease activity in patients with rheumatoid 

arthritis 

• describe the importance of the measuring disease activity in 

patients with rheumatoid arthritis 

• describe measures of disease activity used in patients with 


• apply the use of measures of disease activity to clinical 

scenarios 

• describe quality indicators of rheumatoid arthritis 

• discuss the role of quality inidcators in the health care system 

2:30 PM 

Disease Activity Measures 

Arthur M. Mandelin II, MD, PhD 

3:15 PM 

Quality Indicators 

Jeffrey R. Curtis, MD, MPH, MS 

140 A 

Transition Tools in Youth with Chronic Illness 

Moderator: Thuy T. Beam, RN, BSN 

Speaker: Mary R. Ciccarelli, MD 


• develop an approach to supporting teens and young adults 

into adult care 

• establish practice skills in motivational interviewing 

• establish practical skills in the management and adherence of 

the teens and young adults 

PM 

PS 

ACR WORKSHOP 

4:00 - 6:00 PM 










September 14. 

144 C 

*Joint Injection Techniques (239) 

Speaker: Atul A. Deodhar, MD and Kenneth S. O’Rourke, MD 


• discuss indications and contraindications for joint aspirations 

and injections 

• identify and avoid common mistakes in joint injection 

procedures 

• perform common joint and soft tissue injections on upper and 

lower extremities 

ARHP SESSION 

4:30 - 5:30 PM 

140 A 

Obesity: It IS a Chronic Disease 


Speaker: Mary R. Ciccarelli, MD 

PM 


• review secondary co-morbidities associated with obesity 

across the lifespan 

• develop skills to communicate the importance of weight 

management 

• develop strategies for selfmanagement for the obese patient 

ACR SESSIONS 

4:30 - 6:00 PM 

Hall D 

Diagnostic Assessments in Myopathy 

Moderators: Christina Charles-Schoeman, MD and Chester V. 

Oddis, MD 


• recognize the clinical and prognostic factors associated with 

the more recently identified autoantibodies in patients with 

myositis 

• identify the nuances of interpreting an electromyogram 

report in patients presenting with myopathic features 

• interpret accurately the muscle biopsy report received from a 

neuromuscular pathologist in patients with myopathy 

PS 

PM 

PS 

TUESDAY 



TUESDAY 


4:30 PM 

Clinical and Prognostic Correlations of Newly Identified 

Myositis-Associated Autoantibodies 

Hector Chinoy, MD, PhD 

5:00 PM 

Electromyography for the Rheumatologist 

Devon I. Rubin, MD 

5:30 PM 

Interpretation of the Muscle Biopsy Report in Patients with 

Myopathy 

David Lacomis, MD 

Ballroom B 

MicroRNA and the Rheumatic Diseases 



• identify the mechanisms regulating the expression and 

function of MicroRNA 

• define the role of MicroRNA in innate and antigen specific 

inflammatory responses 

• describe the role of MicroRNA in altered chondrocyte function 

in osteoarthritis 

4:30 PM 

MicroRNA Control of Cellular Homeostasis: Basic Mechanisms 

Judy Lieberman, MD, PhD 

5:00 PM 

MicroRNA in the Regulation of Innate and Adaptive Immunity 

Ryan M. O’Connell, PhD 

5:30 PM 

MicroRNA and the Regulation of Chondrocyte Gene Expression 

in Osteoarthritis 

Martin K. Lotz, MD 

PM PS 

Salon B 

Should Ultrasound be Used in Rheumatology 

Practice? 

Moderator: Timothy E. McAlindon, MD, MPH 


• describe the capability of ultrasound scanning to image 

pathophysiological changes in and around joints and other 

anatomical sites pertinent to rheumatology practice 

• identify how musculoskeletal ultrasound might be utilized in 

typical rheumatology practice 

• assess the use of ultrasound in clinical management of 

rheumatic diseases with a balanced perspective on its risks 

and benefits 

• identify when to use musculoskeletal ultrasonography in 

appropriate clinical scenarios 

4:30 PM 

Possible Uses of Ultrasound in Rheumatology Practice 

Paul J. DeMarco, MD 

PM 

PS 

4:40 PM 

Methods Used to Develop Appropriateness Criteria 

John Esdaile, MD, MPH 

4:50 PM 

Overview of Literature Review 

John D. FitzGerald, MD, PhD 

5:00 PM 

Presentation of Recommendations 

Timothy E. McAlindon, MD, MPH 

5:40 PM 


PM PS 

146 C 

The Great Masqueraders: Malignancies in Rheumatic 

Disease 



• describe the biologic mechanisms associated with neoplastic 

and paraneoplastic syndromes 

• define the risks of malignancy in patients with rheumatic 

disease 

• distinguish the features of occult malignancies that distinguish 

them from rheumatic diseases 

4:30 PM 

Myositis Associated with Neoplastic and Paraneoplastic 

Syndromes 

Andrew L. Mammen, MD, PhD 

5:00 PM 

Vasculitis Associated with Neoplastic and Paraneoplastic 

Syndromes 

Simon Carette, MD 

5:30 PM 

Malignancies and Scleroderma 

Ami A. Shah, MD, MHS 


4:30 - 6:00 PM 

201 

Biology and Pathology of Bone and Joint: Regulation 

of Bone Cells 

Moderators: Antonios O. Aliprantis, MD and Tariq M. Haqqi, PhD 

4:30 PM 

2515. Low Density Lipoprotein Receptor Deficiency Results 

in Osteophyte Formation During Experimental Osteoarthritis 

Which Is Enhanced Under High Cholesterol Conditions 

Wouter de Munter, Birgitte Walgreen, Monique M. Helsen, 

Annet W. Sloëtjes, Wim B. van den Berg and Peter L.E.M. van 

Lent, Radboud University Nijmegen Medical Centre, Nijmegen, 

Netherlands 

112 

2012 Program Book

4:45 PM 

2516. Adenosine Receptors Stimulate Bone Regeneration by 

Targeting Osteoclasts 

Aranzazu Mediero 1 , Tuere Wilder 1 and Bruce N. Cronstein 2 , 1 NYU 

School of Medicine, New York, NY, 2 NYU School of Medicine, 

Division of Rheumatology, New York, NY 

5:00 PM 

2517. Inhibition of Notch Signaling Increases the Severity of 

Experimental Osteoarthritis 

Neng-Yu Lin 1 , Alfiya Distler 2 , Christian Beyer 2 , Clara Dees 2 , 

Jingang Huang 3 , Francesco Dell’Accio 4 , Oliver Distler 5 , Georg A. 

Schett 1 and Joerg HW Distler 1 , 1 Department of Internal Medicine 

III and Institute for Clinical Immunology, University of Erlangen- 

Nuremberg, Erlangen, Germany, 2 Department of Internal 

Medicine 3 and Institute for Clinical Immunology, University 

of Erlangen-Nuremberg, Erlangen, Germany, 3 University of 

Erlangen-Nuremberg, Erlangen, Germany, 4 William Harvey 

Research Institute, Barts and the London Queen Mary’s School 

of Medicine and Dentistry, Centre for Experimental Medicine 

and Rheumatology, London, United Kingdom, 5 Department 

of Rheumatology and Center of Experimental Rheumatology, 

University Hospital Zurich, Zurich, Switzerland 

5:15 PM 

2518. The Sphingosine-1-Phosphate Pathway Is a Key Regulator 

of Bone Substrate-Mediated Osteoclast Differentiation in 

Inflammatory Arthritis 

P. Edward Purdue 1 , Jon Hill 2 , Steven R. Goldring 3 , Nikolaus, B. 

Binder 3 , Jennifer L. Swantek 4 , Zhenxin Shen 5 , Tania N. Crotti 5 , 

Gerald H. Nabozny 4 and Kevin P. McHugh 5 , 1 Hospital for Special 

Surgery, Weill Cornell Medical Center, New York, NY, 2 Boehringer 

Ingelheim Pharmaceuticals Inc, Ridgefield, CT, 3 Hospital 

for Special Surgery, New York, NY, 4 Boehringer Ingelheim 

Pharmaceuticals Inc., Ridgefield, CT, 5 Center for Advanced 

Orthopedic Studies, Beth Israel Deaconess Medical Center, 

Boston, MA 

5:30 PM 

2519. IL-1β and TNF-α Regulate the Global and Locus-Specific 

hydroxymethylation of Genomic DNA by Modulating the 

Expression and Activity of Tet-1 in Human OA Chondrocytes 

Abdul Haseeb 1 and Tariq M. Haqqi 2 , 1 Case Western Reserve 

University, Cleveland, OH, 2 Metro Health Medical Center, 

Cleveland, OH 

5:45 PM 

2520. Suppressor of Cytokine Signaling 3 Is Reduced in Obese 

Patients with Osteoarthritis and Regulates Leptin Responses in 

Chondrocytes 

Anna Koskinen 1 , Katriina Vuolteenaho 1 , Riku Korhonen 1 , Teemu 

Moilanen 2 and Eeva Moilanen 1 , 1 The Immunopharmacology 

Research Group, University of Tampere School of Medicine and 

Tampere University Hospital, Tampere, Finland, 2 Coxa Hospital 

for Joint Replacement, Tampere, Finland 

143 A 


Moderators: Diego Kyburz, MD and Mariana J. Kaplan, MD 

4:30 PM 

2521. Immunoglobulin G Fc Receptor Activity in vivo Is Under 

Complement Control 

Eveline Y. Wu, Haixiang Jiang, C. Garren Hester and Michael M. 

Frank, Duke Univ Med Ctr, Durham, NC 

4:45 PM 

2522. M-Ficolin, an Activator of the Complement System, Is the 

Strongest Predictor of Both DAS28 Remission and Low Disease 

Activity in a Cohort of 180 Early DMARD Naïve Rheumatoid 

Arthritis Patients Followed in the Opera-Study 

Christian G. Ammitzbøll 1 , Jens Christian Jensenius 2 , Torkell 

Ellingsen 3 , Steffen Thiel 2 , Kim Hørslev-Petersen 4 , Merete L. 

Hetland 5 , Peter Junker 6 , Julia Johansen 7 , Mikkel Østergaard 8 , 

Jan Pødenphant 9 and Kristian Stengaard-Pedersen 1 , 1 Arhus 

University Hospital, Aarhus, Denmark, 2 Aarhus University, 

Aarhus, Denmark, 3 Silkeborg Regional Hospital, Silkeborg, 

Denmark, 4 University of Southern Denmark, Graasten, Denmark, 

5 

Copenhagen University and Glostrup Hospital, Copenhagen, 

Denmark, 6 Odense University Hospital, Odense, Denmark, 

7 

Glostrup Hospital, Glostrup, Denmark, 8 Copenhagen University 

Hospital Glostrup, Glostrup, Denmark, 9 Gentofte Hospital 

5:00 PM 

2523. Periodontal Pathogens Directly Promote Autoimmune 

Experimental Arthritis by Inducing a Toll-Like Receptor 2 and 

Interleukin-1 Driven Th17 Response 

Shahla Abdollahi-Roodsaz 1 , Sabrina Garcia de Aquino 2 , Marije 

I. Koenders 1 , Fons A. van de Loo 1 , Ger J. Pruijn 3 , Mario J. Avila 

Campos 4 , Fernando Q. Cunha 5 , Joni A. Cirelli 2 and Wim B. van 

den Berg 1 , 1 Rheumatology Research and Advanced Therapeutics, 

Department of Rheumatology, Radboud University Nijmegen 

Medical Centre, Nijmegen, Netherlands, 2 Department of 

Diagnosis and Oral Surgery, Periodontic Division, Araraquara 

Dental School, Sao Paolo, Brazil, 3 Radboud University Nijmegen, 

Nijmegen, Netherlands, 4 Department of Microbiology, Institute 

of Biomedical Sciences—ICB/USP, Sao Paulo, Brazil, 5 Department 

of Pharmacology, School of Medicine of Ribeirao Preto, Sao 

Paolo, Brazil 

5:15 PM 

2524. Snapin Is Critical for the Maturation of Autophagosome 

and Phagosome in Macrophages 

Bo Shi, Qiquan Huang, Robert Birkett, Renee E. Koessler, 

Andrea Dorfleutner, Christian Stehlik and Richard M. Pope, 

Northwestern University Feinberg School of Medicine, Chicago, 

IL 

5:30 PM 

2525. Bruton’s Tyrosine Kinase Inhibition Suppresses 

Inflammatory Cytokine Production and Affects Gene 

Expression in Human Macrophages and RA Synovial Tissue 

Explants 

Linda M. Hartkamp 1 , Inge E. van Es 1 , Jay S. Fine 2 , Michael Smith 2 , 

John Woods 2 , Satwant Narula 2 , Julie DeMartino 2 , Paul P. Tak 3 and 

Kris A. Reedquist 1 , 1 Academic Medical Center, University 

TUESDAY 



of Amsterdam, Amsterdam, Netherlands, 2 Hoffmann-La Roche, 

Nutley, NJ, 3 Academic Medical Center / University of Amsterdam 

and GlaxoSmithKline, Amsterdam, Netherlands 

5:45 PM 

2526. Bruton′s Tyrosine Kinase and Calreticulin: A Novel 

Interaction with Implications for Inflammatory and 

Autoimmune Disease 

Jennifer C. Byrne 1 , Joan Ní Gabhann 1 , Kevin Stacey 1 , Barbara 

M. Coffey 1 , Eoghan M. McCarthy 2 , Warren Thomas 3 , Eamonn 

S. Molloy 4 , Grainne M. Kearns 2 and Caroline Jefferies 1 , 1 Royal 

College of Surgeons in Ireland, Dublin, Ireland, 2 Beaumont 

Hospital, Dublin 9 , Ireland, 3 Royal College of Surgeons in Ireland, 

Dublin 9 , Ireland, 4 Dublin Academic Medical Centre, St. Vincent’s 

University Hospital, Dublin, Ireland 

Laurent Arnaud 1 , Hervé Devilliers 2 , Stanford L. Peng 3 , Zahir 

Amoura 4 and the RPDAI study group 5 , 1 Assistance Publique- 

Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 2 CHU 

Dijon, Dijon, France, 3 Virginia Mason Medical Center, Seattle, 

WA, 4 CHU Pitié-Salpêtrière, Paris, France, 5 Paris 

5:45 PM 

2532. Whole Transcriptome Analysis in Relapsing 

Polychondritis: A Single-Center Analysis of 35 Patients 

Laurent Arnaud 1 , Alexis Mathian 1 , Bruno Faivre 2 , Karim 

Dorgham 2 , Julien Haroche 1 , Nathalie Costedoat-Chalumeau 1 , 

Jean-Charles Piette 1 , Guy Gorochov 2 and Zahir Amoura 1 , 1 Hôpital 

Pitié-Salpêtrière, AP-HP & UPMC Univ Paris 06, Paris, France, 

2 

Institut National de la Santé et de la Recherche Médicale, 

INSERM UMR-S 945, Paris, France 

TUESDAY 


145 A 

Miscellaneous Rheumatic and Inflammatory I 

Moderators: W. Winn Chatham, MD and Richard M. Keating, MD 

4:30 PM 

2527. Prozone Phenomenon Leads to Low IgG4 Concentrations 

in IgG4-Related Disease 

Arezou Khosroshahi 1 , Lynn A. Cheryk 2 , Mollie Carruthers 1 , 

Judith A. Edwards 2 , Donald B. Bloch 1 and John H. Stone 1 , 

1 

Massachusetts General Hospital, Boston, MA, 2 Mayo Medical 

Laboratories, Andover 

4:45 PM 

2528. Hypertrophic Pachymeningitis: IgG4-Related Disease Is A 

Common Etiology 

Zachary S. Wallace, Mollie Carruthers, Arezou Khosroshahi, 

Robert Carruthers, Shweta Shinagare, Anat Stemmer- 

Rachamimov, Vikram Deshpande and John H. Stone, 

Massachusetts General Hospital, Boston, MA 

5:00 PM 

2529. Molecular Mechanism of IgG4 Class Switch 

Recombination in IgG4-Related Disease 

Hiroto Tsuboi 1 , Mana Iizuka 1 , Hiromitsu Asashima 1 , Sayaka 

Tsuzuki 1 , Yuya Kondo 1 , Akihiko Tanaka 2 , Masafumi Moriyama 2 , 

Isao Matsumoto 1 , Seiji Nakamura 2 and Takayuki Sumida 1 , 

1 

University of Tsukuba, Tsukuba, Japan, 2 Kyushu University, 

Fukuoka, Japan 

5:15 PM 

2530. Anti-Ribosomal P Antibodies in a Large Cohort of 

Autoimmune Hepatitis with No Evidence of Lupus: A Common 

Underlying Mechanism Targeting Liver? 

Ana Luisa Calich 1 , Vilma S. T. Viana 1 , Eduardo L. Cançado 1 , 

Débora R. Terrabuio 1 , Francisco Tustumi 1 , Elaine P. Leon 1 , 

Clovis Artur Silva 2 , Eduardo F. Borba Neto 1 and Eloisa Bonfa 1 , 

1 

Faculdade de Medicina da Universidade de São Paulo, São 

Paulo, Brazil, 2 Paediatric Rheumatology International Trials 

Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy 

5:30 PM 

2531. The Relapsing Polychondritis Disease Activity Index: 

International Development and Initial Validation of the First 

Disease Activity Score for Relapsing Polychondritis 

152 A 

Osteoarthritis - Clinical Aspects I: Weight, Activity, 

and Metabolic Effects on Osteoarthritis 

Moderators: Joanne M. Jordan, MD, MPH and Leena Sharma, 

MD 

4:30 PM 

2533. Weight Loss Is Associated with Structure Modification 

in Subjects with Radiographic Osteoarthritis of the Knee: Data 

From the Osteoarthritis Initiative 

Marc C. Hochberg 1 , Danuta I. Bujak 1 , Jeffrey W. Duryea 2 , 

Knachelle Favors 3 and John D. Sorkin 4 , 1 University of Maryland, 

Baltimore, MD, 2 Brigham & Women, Boston, MA, 3 VA Maryland 

Health Care System, Baltimore, 4 VA Maryland Health Care 

System, Baltimore, MD 

4:45 PM 

2534. The Intensive Diet and Exercise for Arthritis Trial (IDEA): 

18-Month Radiographic and MRI Outcomes 

David J. Hunter 1 , D. Beavers 2 , Felix Eckstein 3 , Ali Guermazi 4 , 

Richard F. Loeser 5 , Barbara J. Nicklas 6 , Shannon Mihalko 7 , Gary 

D. Miller 7 , Mary Lyles 8 , Paul DeVita 9 , Claudine Legault 8 , J. Jeffery 

Carr 8 , Jeff D. Williamson 8 and Stephen P. Messier 7 , 1 University 

of Sydney, Sydney, Australia, 2 Winston Salem, NC, 3 Paracelsus 

Medical University, Salzburg, Austria, 4 Boston University, Boston, 

MA, 5 Wake Forest School of Medicine, Winston-Salem, NC, 

6 

Winston-Salem, NC, 7 Wake Forest University, Winston-Salem, 

NC, 8 Wake Forest University School of Medicine, Winston-Salem, 

NC, 9 East Carolina University, Greenville, NC 

5:00 PM 

2535. Childhood Physical Fitness Predicts Adulthood Knee 

Cartilage Volume and Bone Area: A 25-Year Cohort Study 

Benny Samuel Eathakkattu Antony 1 , Graeme Jones 1 , Alison 

Venn 1 , Leigh Blizzard 2 , Flavia Cicuttini 3 , L. March 4 , Terry Dwyer 5 

and Changhai Ding 6 , 1 Menzies Research Institute Tasmania, 

Hobart, Australia, 2 Hobart, Australia, 3 Monash University, Central 

and Eastern Clinical School, Melbourne, Australia, 4 University of 

Sydney, Insitute of Bone and Joint Research, Royal North Shore 

Hospital, St Leonards - Sydney, Australia, 5 Murdoch Children’s 

Research Institute, Melbourne, Australia, 6 Menzies research 

institute & Monash University, Hobart, Australia 

114 

2012 Program Book

5:15 PM 

2536. The Effects of Intensive Diet and Exercise On Bone 

Density in Older Adults with Knee Osteoarthritis: The Intensive 

Diet and Exercise for Arthritis (IDEA) Trial 

Nicole R. Walton 1 , Richard F. Loeser 2 , Daniel Beavers 3 , Barbara 

J. Nicklas 4 , Mary Lyles 3 and Stephen P. Messier 5 , 1 Wake Forest 

University School of Medicine, Winston Salem, NC, 2 Wake Forest 

School of Medicine, Winston-Salem, NC, 3 Wake Forest University 

School of Medicine, Winston-Salem, NC, 4 Winston-Salem, NC, 

5 

Wake Forest University, Winston-Salem, NC 

5:30 PM 

2537. Cross-Sectional and Longitudinal Associations Between 

Circulating Leptin and Knee Cartilage Thickness in Older Adults 

Oliver Stannus 1 , Yuelong Cao 2 , Benny Samuel Eathakkattu 

Antony 1 , Graeme Jones 3 and Changhai Ding 4 , 1 Menzies Research 

Institute Tasmania, Hobart, Australia, 2 Menzies Research 

Institute Tasmania, Research Institute of Orthopaedics, 

Shuguang Hospital Affiliated to Shanghai University of 

Traditional Chinese Medicine, Hobart, Australia, 3 Menzies 

Research institute Tasmania, University of Tasmania, Hobart, 

7000, Australia, 4 Menzies research institute & Monash 

University, Hobart, Australia 

5:45 PM 

2538. The Association of Fat Mass and Skeletal Muscle 

Mass with Clinical and Structural Knee Osteoarthritis: The 

Netherlands Epidemiology of Obesity Study 

A. Willemien Visser, Marieke Loef, Martin den Heijer, Monique 

Reijnierse, Frits R. Rosendaal and Margreet Kloppenburg, Leiden 

University Medical Center, Leiden, Netherlands 

Ballroom A 

Rheumatoid Arthritis - Clinical Aspects V: 

Comorbidities in Rheumatoid Arthritis 

Moderators: Eric L. Matteson, MD and Paul F. Dellaripa, MD 

4:30 PM 

2539. Fine-Specificity of Anti-Citrullinated Peptide Auto- 

Antibodies: Associations with Cardiac Structure and Function 

in Rheumatoid Arthritis 

Laura Geraldino-Pardilla 1 , Jon T. Giles 1 , Jeremy Sokolove 2 , 

William H. Robinson 3 and Joan M. Bathon 1 , 1 Columbia University 

Medical Center, New York, NY, 2 VA Palo Alto Health Care System 

and Stanford University, Palo Alto, CA, 3 Stanford University, Palo 

Alto, CA 

5:00 PM 

2541. High Risk of Intensive Care Unit Admission in 

Rheumatoid Arthritis Patients: A Population Based Study 

Christine Peschken, Carol A. Hitchon, Allan Garland, Charles N. 

Bernstein, Randy Fransoo and Ruth Ann Marrie, University of 

Manitoba, Winnipeg, MB 

5:15 PM 

2542. The Association Between Inflammatory Markers and 

Hyperlipidemia and the Risk of Myocardial Infarction in 


Jie Zhang 1 , Lang Chen 1 , Elizabeth S. Delzell 1 , Paul M. Muntner 1 , 

William B. Hillegass 2 , Monika M. Safford 1 , Iris E. Navarro 1 

and Jeffrey R. Curtis 3 , 1 University of Alabama at Birmingham, 

Birmingham, AL, 2 Birmingham, AL, 3 Univ of Alabama- 

Birmingham, Birmingham, AL 

5:30 PM 

2543. Hospitalized Bacterial Infections Among U.S. Veterans 

with Rheumatoid Arthritis Initiating TNF Antagonist and Newer 

Biologic Agents 

Jeffrey Curtis 1 , Shuo Yang 1 , Nivedita M. Patkar 2 , Lang Chen 1 , 

Jasvinder A. Singh 1 , Grant W. Cannon 3 , Ted R. Mikuls 4 , Elizabeth 

S. Delzell 1 , Kenneth G. Saag 2 , Monika M. Safford 1 , Scott DuVall 5 , 

Kimberly Alexander 6 , Pavel Napalkov 6 , Aaron Kamauu 7 and John 

Baddley 1 , 1 University of Alabama at Birmingham, Birmingham, 

AL, 2 Univ of Alabama-Birmingham, Birmingham, AL, 3 George E. 

Wahlen VA Medical Center, Salt Lake City, UT, 4 Omaha VA and 

University of Nebraska Medical Center, Omaha, NE, 5 VA Salt 

Lake City Health Care System and University of Utah School 

of Medicine, Salt Lake City, UT, 6 Genentech, Inc., South San 

Francisco, CA, 7 Anolinx, Bountiful, UT 

5:45 PM 

2544. Widening Gap Between Cardiovascular Specific Mortality 

in Patients with Inflammatory Polyarthritis Compared to the 

General Population? 

Alexander J. Warner 1 , Jh Humphreys 2 , Mark Lunt 3 , Tarnya 

Marshall 4 , Deborah P. M. Symmons 1 and Suzanne Verstappen 5 , 

1 

Arthritis Research UK Epidemiology Unit, The University of 

Manchester, Manchester, United Kingdom, 2 Arthritis Research 

UK Epidemiology Unit,, Manchester, United Kingdom, 

3 

University of Manchester, Manchester Academic Health Science 

Centre, Manchester, United Kingdom, 4 Norfolk and Norwich 

University Hospitals Trust, Norwich, United Kingdom, 5 University 

of Manchester, Manchester Academic Health Sciences Centre, 


TUESDAY 


4:45 PM 

2540. Prescription of Tumour Necrosis Factor α Antagonists Is 

Strongly Associated with a Reduction in Hospital Admissions 

and in Musculoskeletal Surgical Procedures for Rheumatoid 

Arthritis Based On a 16 Year Analysis of Nationwide Data 

Leonard C. Harty 1 , Gary O’Toole 2 , Kathleen Bennett 3 and Oliver 

M. FitzGerald 4 , 1 Department of Rheumatology, St. Vincent’s 

University Hospital, Dublin, Ireland, 2 Department of Orthopaedic 

Surgery, St. Vincent’s University Hospital, Dublin, Ireland, 3 2. 

Department of Pharmacology & Therapeutics, Trinity centre for 

Health Sciences, St James’s Hospital, Dublin, Ireland, 4 Dublin 



Hall E 


Biologics and Gene Therapy: Efficacy of Approved 

Biologics 

Moderators: Richard W. Martin, MA, MD and Aaron T. 

Eggebeen, MD 

4:30 PM 

2545. A Randomized, Double-Blind, Parallel Group Study of 

the Safety and Efficacy of Tocilizumab SC Versus Tocilizumab 

IV, in Combination with Traditional Dmards in Patients with 

Moderate to Severe RA 


TUESDAY 


G. R. Burmester 1 , Andrea Rubbert-Roth 2 , Alain G. Cantagrel 3 , 

Stephen Hall 4 , Piotr Leszczynski 5 , Daniel Feldman 6 , Madura 

J. Rangaraj 7 , Georgia Roane 8 , Charles L. Ludivico 9 , Francesco 

Ramirez 10 and Min Bao 11 , 1 Charité-Universitätsmedizin Berlin, 

Berlin, Germany, 2 Klinikum der Universität zu Köln, Köln, 

Germany, 3 Centre Hospitalier Universitaire de Toulouse, 

Toulouse, France, 4 Cabrini Medical Centre, Malvern, Australia, 

5 

Hospital J. Strusia, Poznan, Poland, 6 Universidade Federal de de 

São Paulo, Sao Paulo, Brazil, 7 Arthritis & Diabetes Clinic, Monroe, 

LA, 8 Rheumatology Associates, P.A., Charleston, SC, 9 East Penn 

Rheumatology Assoc, Bethlehem, PA, 10 Roche Products Limited, 

Welwyn, United Kingdom, 11 Genentech, South San Francisco, CA 

4:45 PM 

2546. Tofacitinib Inhibits Radiographic Progression in Patients 

with Rheumatoid Arthritis Prone to Develop Structural 

Damage: A Post-Hoc Analysis of a Phase 3 Trial 

Désirée van der Heijde 1 , Robert B. M. Landewé 2 and David 

Gruben 3 , 1 Leiden University Medical Center, Leiden, Netherlands, 

2 

Academic Medical Center/University of Amsterdam & Atrium 

Medical Center, Amsterdam, Netherlands, 3 Pfizer Inc., Groton, CT 

5:00 PM 

2547. Weekly Subcutaneous Abatacept Confers Comparable 

Onset of Treatment Response and Magnitude of Efficacy 

Improvement Over 6 Months When Administered with or 

without an Intravenous Abatacept Loading Dose 

M. Schiff 1 , R. Alten 2 , M. Weinblatt 3 , P. Nash 4 , R. Fleischmann 5 , 

P. Durez 6 , J. Kaine 7 , I. Delaet 8 , S. Kelly 8 , M. Maldonado 8 , S. 

Patel 8 and M. C. Genovese 9 , 1 University of Colorado, Denver, 

CO, 2 Schlosspark-Klinik, University Medicine, Berlin, Germany, 

3 


Boston, MA, 4 University of Queensland, Brisbane, Australia, 

5 

University of Texas Southwestern Medical Center, Dallas, TX, 

6 

Université Catholique de Louvain, Brussels, Belgium, 7 Sarasota 

Arthritis Research Center, Sarasota, FL, 8 Bristol-Myers Squibb, 

Princeton, NJ, 9 Stanford University, Palo Alto, CA 

5:15 PM 

2548. Global Molecular Effects of Tocilizumab Therapy in 

Synovial Biopsies of Early Rheumatoid Arthritis Patients 

Julie Ducreux, Adrien Nzeusseu Toukap, Frédéric A. Houssiau, 

Patrick Durez and Bernard Lauwerys, Université catholique de 

Louvain, Brussels, Belgium 

5:30 PM 

2549. Induction of Remission in Patients with up to 12 Months 

of Moderate-to-Severe Rheumatoid Arthritis Symptoms 

Treated with Etanercept Plus Methotrexate Over 52 Weeks 

Paul Emery 1 , Mohammed Hamoudeh 2 , Oliver M. FitzGerald 3 , 

Bernard Combe 4 , Stefanie Gaylord 5 , Theresa Williams 5 , Jack 

Bukowski 5 , Ronald Pedersen 5 , Andrew S. Koenig 5 and Bonnie 

Vlahos 5 , 1 Leeds General Infirmary, Leeds, United Kingdom, 

2 

Hamad Medical Corporation, Doha, Qatar, 3 St. Vincent’s 

University Hospital, Dublin, Ireland, 4 Lapeyronie Hospital, 

Montpellier, France, 5 Pfizer Inc., Collegeville, PA 

5:45 PM 

2550. Clinical, Radiographic, and Immunogenic Effects After 

1 Year of Tocilizumab-Based Treatment Strategy with and 

without Methotrexate in Rheumatoid Arthritis: The ACT-RAY 

Study 

Maxime Dougados 1 , Karsten Kissel 2 , Philip G. Conaghan 3 , Emilio 

Martin-Mola 4 , Georg A. Schett 5 , Howard Amital 6 , Ricardo M. 

Xavier 7 , OM Troum 8 , Corrado Bernasconi 9 and T.W.J. Huizinga 10 , 

1 

Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 

2 

F. Hoffmann-La Roche Ltd, Basel, Switzerland, 3 University of 

Leeds, Leeds, United Kingdom, 4 Hospital Universitario La Paz, 

Madrid, Spain, 5 Department of Internal Medicine III and Institute 

for Clinical Immunology, University of Erlangen-Nuremberg, 

Erlangen, Germany, 6 Center for Autoimmune Diseases, Sheba 

Medical Center, Tel-hashomer, Israel, Tel-hashomer, Israel, 

7 

Universidade Federal do Rio Grande do Sul, Porto Alegre, 

Brazil, 8 USC Keck School of Medicine, Santa Monica, CA, 9 Roche, 

Basel, Switzerland, 10 Leiden University Medical Center, Leiden, 

Netherlands 

207 A 

Sjögren’s Syndrome II - Clinical 

Moderators: E. William St.Clair, MD and Athanasios G. Tzioufas, 

MD 

4:30 PM 

2551. Validation of EULAR Primary Sjögren’s Syndrome Disease 

Activity and Patient Indexes 

Raphaèle Seror 1 , Elke Theander 2 , Johan G. Brun 3 , Manel Ramos- 

Casals 4 , Valeria Valim 5 , T. Dorner 6 , Xavier Mariette 7 , Hendrika 

Bootsma 8 , Athanasios G. Tzioufas 9 , Roser Solans-Laqué 10 , 

Jacques-Eric Gottenberg 11 , Eric Hachulla 12 , Wan-Fai NG 13 , Stefano 

Bombardieri 14 , Roberto Gerli 15 , Takayuki Sumida 16 , Alain Saraux 17 , 

Matija Tomsic 18 , Roberto Caporali 19 , Roberta Priori 20 , Kathy 

Moser Sivils 21 , A.A. Kruize 22 , Cristina F. Vollenweider 23 , Claudio 

Vitali 24 and Simon J. Bowman 25 , 1 Bicetre university hospital, 

LE Kremlin-Bicetre, France, 2 Skane University Hospital, Lund 

University, Malmö, Sweden, 3 Haukeland University Hospital, 

Bergen, Norway, 4 Hospital Clínic, Barcelona, Spain, 5 Universidade 

Federal do Espírito Santo, Vitória, Brazil, 6 Charité University 

Medicine Berlin, Berlin, Germany, 7 Université Paris-Sud, Le 

Kremlin Bicetre, France, 8 University Medical Center Groningen, 

Groningen, Netherlands, 9 School of Medicine, National 

University of Athens, Athens, Greece, 10 Senior Consultant, 

Barcelona, Spain, 11 Strasbourg University Hospital, Strasbourg, 

France, 12 Department of Internal Medicine, Claude Huriez 

Hospital, University of Lille, Lille CEDEX, France, 13 Departement 

of rheumatology, New-Castle University Hospital, UK, Newcastle, 

England, 14 Rheumatology Unit, University of Pisa, Pisa, Italy, 

15 

Rheumatology Unit, University of Perugia, Perugia, Italy, 

16 

University of Tsukuba, Tsukuba City, Japan, 17 Université Brest 

Occidentale, Brest, France, 18 University Medical Centre Ljubjana, 

Ljubljana, Slovenia, 19 Division of Rheumatology, IRCCSPoliclinico 

S. Matteo Foundation, Pavia, Italy, 20 Rheumatology Unit, 

Sapienza University of Rome, Rome, Italy, 21 Oklahoma Medical 

Research Foundation, Oklahoma City, OK, 22 University Medical 

Center Utrecht, Utrecht, Netherlands, 23 German Hospital, 

Buenos Aires, Argentina, 24 Casa di Cura di Lecco, Lecco, Italy, 

25 

Queen Elizabeth Hospital Birmingham, Birmingham, United 

Kingdom 

116 

2012 Program Book

4:45 PM 

2552. Clinically Significant and Biopsy-Documented Renal 

Involvement in Primary Sjögren’s Syndrome: Clinical 

Presentation and Outcome 

Andreas V. Goules 1 , Ioanna P. Tatouli 1 , Alexandros A. Drosos 2 , 

Fotini N. Skopouli 3 , Haralampos M. Moutsopoulos 4 and 

Athanasios G. Tzioufas 5 , 1 National University of Athens, Athens, 

Greece, 2 Professor of Medicine/Rheumatology, Ioannina, 

Greece, 3 Harokopion University, Athens, Greece, 4 School of 

Medicine, University of Athens, Athens, Greece, 5 School of 

Medicine, National University of Athens, Athens, Greece 

5:00 PM 

2553. Histological, Serological and Clinical Changes in Response 

to Abatacept Treatment of Sjögren’s Syndrome 

Sabine Adler 1 , Meike Koerner 1 , Frauke Foerger 2 , Marco- 

Domenico Caversaccio 3 and Peter M. Villiger 4 , 1 University 

Hospital Bern, Bern, Switzerland, 2 Inselspital-University Hospital, 

Bern, Switzerland, 3 University Hospital Bern, Inselspital, Bern, 

Switzerland, 4 Inselspital-University Hospital of Bern, Bern, 

Switzerland 

5:15 PM 

2554. Tolerance and Efficacy of Rituximab in Primary Sjogren 

Syndrome: Final Results of a Randomized Controlled Trial 

Valerie Devauchelle-Pensec 1 , Xavier Mariette 2 , Sandrine Jousse- 

Joulin 3 , Jean-Marie Berthelot 4 , Aleth Perdriger 5 , Eric Hachulla 6 , 

Xavier Puechal 7 , Véronique Le Guern 8 , Jean Sibilia 9 , Jacques- 

Eric Gottenberg 10 , Laurent Chiche Sr. 11 , Vincent Goeb 12 , Gilles 

Hayem 13 , Jacques Morel 14 , Charles Zarnitsky 15 , JJ Dubost 16 , 

Jacques-Olivier Pers 17 , Emmanuel Nowak 18 and Alain Saraux 19 , 

1 

Brest Occidentale university, Brest, France, 2 Université Paris- 

Sud, Le Kremlin Bicetre, France, 3 Brest university medical 

school, EA 22 16 , UBO and CHU de la Cavale Blanche,, Brest, 

France, 4 Nantes University Hospital, Nantes, France, 5 Hôpital 

Sud, Rennes, France, 6 Department of Internal Medicine, Claude 

Huriez Hospital, University of Lille, Lille CEDEX, France, 7 Hôpital 

Cochin, Paris, France, 8 Cochin Hospital, Paris, France, 9 EA4438 

Laboratoire Physiopathologie des Arthrites, Illkirch-Strasbourg, 

France, 10 Strasbourg University Hospital, Strasbourg, France, 

11 

Internal Medicine, CHU Marseille, Marseille, France, 12 Rouen 

University Hospital, Rouen, France, 13 Bichat Hospital, Paris, 

France, 14 Hopital Lapeyronie, Montpellier, France, 15 CH du 

Havre, Le Havre, France, 16 CHU CLERMONT-FERRAnd, Clermont- 

Ferrand, France, 17 Brest Occidentale University, Brest, France, 

18 

CHU Brest, Brest, France, 19 Université Brest Occidentale, Brest, 

France 

5:45 PM 

2556. Allogenic Mesenchymal Stem Cells Transplantation 

Alleviates Clinical Sjögren’s Syndrome 

Lingyun Sun 1 , Dandan Wang 1 , Junji Xu 2 and Songlin Wang 2 , 

1 

Department of Rheumatology and Immunology, the Affiliated 

Drum Tower Hospital of Nanjing University Medical School, 

Nanjing, China, 2 Salivary Gland Disease Center and Molecular 

Laboratory for Gene Therapy & Tooth Regeneration, Beijing Key 

Laboratory of Tooth Regeneration and Function Reconstruction, 

Capital Medical University School of Stomatology, Beijing, China 

Ballroom C 


Aspects and Treatment: Psoriatic Arthritis 

Moderators: Jeffrey R. Lisse, MD and Andreas M. Reimold, MD 

4:30 PM 

2557. Ustekinumab in Active Psoriatic Arthritis Including 

Patients Previously Treated with Anti-TNF Agents: Results of a 

Phase 3 , Multicenter, Double-Blind, Placebo-Controlled Study 

Christopher T. Ritchlin 1 , Alice B. Gottlieb 2 , Iain B. McInnes 3 , 

Lluis Puig 4 , Proton Rahman 5 , Shu Li 6 , Yuhua Wang 6 , Mittie K. 

Doyle 7 , Alan Mendelsohn 8 and Arthur Kavanaugh 9 , 1 University of 

Rochester Medical Center, Rochester, NY, 2 Tufts Medical Center, 

Boston, MA, 3 University of Glasgow, Glasgow, United Kingdom, 

4 

Universitat Autònoma de Barcelona, 5 Memorial University, 

St. Johns, NF, 6 Janssen Research and Development, LLC, PA, 

7 

Janssen Research and Development, LLC/U of Penn, Spring 

House/Phila, PA, 8 Janssen Research & Development, LLC, Spring 

House, PA, 9 UCSD School of Medicine, La Jolla, CA 

4:45 PM 

2558. Clinical Response, Drug Survival and Predictors Thereof 

Among 548 Switchers of Tumor Necrosis Factor Alpha Inhibitor 

Therapy in Psoriatic Arthritis. Results From the Danish 

Nationwide Danbio Registry 

Bente Glintborg 1 , Mikkel Østergaard 2 , Niels Steen Krogh 3 , 

Martin Dehn Andersen 4 , Ulrik Tarp 4 , Anne Gitte Loft 4 , Hanne 

M. Lindegaard 4 , Mette Holland-Fischer 4 , Henrik Nordin 4 , Dorte 

Vendelbo Jensen 4 and Merete L. Hetland 5 , 1 Copenhagen 

University Hospital Gentofte, Copenhagen, Denmark, 2 Glostrup 

Hospital, Copenhagen, Denmark, 3 ZiteLab ApS, Copenhagen, 

Denmark, 4 DANBIO, On behalf of Depts of Rheumatology, 

North, South, Central, Zealand and Capital Region, Copenhagen, 

Denmark, 5 Copenhagen University and Glostrup Hospital, 

Copenhagen, Denmark 

TUESDAY 


5:30 PM 

2555. Results of the Beliss Study, the First Open Phase 2 Study 

of Belimumab in Primary Sjogren’s Syndrome 

Xavier Mariette 1 , Luca Quartuccio 2 , Raphaèle Seror 3 , Sara Salvin 2 , 

Frederic Desmoulins 1 , Martina Fabris 4 , Sara Villeneuve 5 , Philippe 

Ravaud 6 and Salvatore De Vita 7 , 1 Université Paris-Sud, Le Kremlin 

Bicetre, France, 2 Rheumatology Clinic, DSMB, University of 

Udine, Italy, Udine, Italy, 3 Bicetre university hospital, LE Kremlin- 

Bicetre, France, 4 Institute of Clinical Pathology, Udine, Italy, 

5 

Hospital Hotel dieu, Paris, France, 6 Hopital Hotel Dieu, Paris 

Descartes University, Paris, France, 7 Rheumatology Clinic, DSMB, 

University of Udine, Udine, Italy 

5:00 PM 

2559. Mortality in Patients with Psoriatic Arthritis Compared 

to Patients with Rheumatoid Arthritis, Psoriasis Alone, and the 

General Population 

Alexis Ogdie 1 , Kevin Haynes 2 , Andrea Troxel 2 , Thorvardur Love 3 , 

Hyon K. Choi 4 and Joel Gelfand 2 , 1 University of Pennsylvania, 

Philadelphia, PA, 2 University of Pennsylvania., Philadelphia, 

PA, 3 Labspitali University Hospital, Reykjavik, Iceland, 4 Boston 

University School of Medicine, University of British Columbia, 

Arthritis Research Centre of Canada, Boston, MA 


TUESDAY 


118 

5:15 PM 

2560. Response and Drug Survival of 1st TNF-Inhibitor in 440 

Patients with Psoriatic Arthritis - What Is the Role of Co- 

Medication with Methotrexate? 

Karen M. Fagerli 1 , Elisabeth Lie 1 , Désirée van der Heijde 2 , Marte 

S. Heiberg 3 , Erik Rødevand 4 , Åse S. Lexberg 5 , Synnøve Kalstad 6 , 

Knut Mikkelsen 7 and Tore K. Kvien 1 , 1 Diakonhjemmet Hospital, 

Oslo, Norway, 2 Leiden University Medical Center, Leiden, 

Netherlands, 3 Diakonhjemmet hospital, Oslo, Norway, 4 St. Olavs 

Hospital, Trondheim, Norway, 5 Drammen Hospital, Drammen, 

Norway, 6 Tromsø, Norway, 7 Lillehammer Hospital for Rheumatic 

Diseases, Lillehammer, Norway 

5:30 PM 

2561. Switching Between TNF-Inhibitors in Psoriatic Arthritis: 

Data From the NOR-DMARD Study 

Karen M. Fagerli 1 , Elisabeth Lie 1 , Désirée van der Heijde 2 , Marte 

S. Heiberg 3 , Åse S. Lexberg 4 , Knut Mikkelsen 5 , Erik Rødevand 6 , 

Synnøve Kalstad 7 and Tore K. Kvien 1 , 1 Diakonhjemmet Hospital, 

Oslo, Norway, 2 Leiden University Medical Center, Leiden, 

Netherlands, 3 Diakonhjemmet hospital, Oslo, Norway, 4 Vestre 

Viken, Drammen, Norway, 5 Lillehammer Hospital for Rheumatic 

Diseases, Lillehammer, Norway, 6 St. Olavs Hospital, Trondheim, 

Norway, 7 Tromsø, Norway 

5:45 PM 

2562. Ustekinumab in Patients with Active Psoriatic Arthritis: 

Results of the Phase 3, Multicenter, Double-Blind, Placebo- 

Controlled Psummit I Study 

Arthur Kavanaugh 1 , Iain B. McInnes 2 , Alice B. Gottlieb 3 , Lluis 

Puig 4 , Proton Rahman 5 , Christopher T. Ritchlin 6 , Shu Li 7 , Yuhua 

Wang 7 , Alan Mendelsohn 7 and Mittie K. Doyle 7 , 1 UCSD School 

of Medicine, La Jolla, CA, 2 University of Glasgow, Glasgow, 

United Kingdom, 3 Tufts Medical Center, Boston, MA, 4 Universitat 

Autònoma de Barcelona, 5 Memorial University, St. Johns, NF, 

6 

University of Rochester Medical Center, Rochester, NY, 7 Janssen 

Research & Development, LLC, Spring House, PA 

202 B 

Vasculitis: Clinical Aspects 

Moderators: Loic Guillevin, MD and David Jayne, MD 

4:30 PM 

2563. Factors Associated with Major Cardiovascular Events 

in Patients with Primary Systemic Necrotizing Vasculitides: 

Results of a Longitudinal Long-Term Follow-up Study 

Benjamin Terrier Sr. 1 , Christian Pagnoux 2 , Gilles Chironi 3 , Alain 

Simon 3 , Luc Mouthon Sr. 4 , Loic Guillevin 5 and French Vasculitis 

Study Group (FVSG) 6 , 1 Cochin Hospital, Paris, France, 2 Mount 

Sinai Hospital, Toronto, ON, 3 HEGP, Paris, France, 4 Hopital Cochin, 

Paris, France, 5 Division of Internal Medicine, Hôpital Cochin, 

University Paris Descartes, Paris, France, 6 Paris 

4:45 PM 

2564. A Risk Score for Predicting Short-Term Incidence of Death 

or Relapse in Anti-Neutrophil Cytoplasmic Antibody-Associated 

Vasculitis 

Carla Maldini 1 , Matthieu Resche-Rigon 1 , David Jayne 2 , Kerstin 

Westman 3 and Alfred Mahr 1 , 1 Hospital Saint-Louis, Paris, France, 

2 

Addenbrookes Hospital University of Cambridge, Cambridge, 


United Kingdom, 3 Skåne University Hospital Malmö, Lund 

University, Malmö, Sweden 

5:00 PM 

2565. Prevalence of Anti-Neutrophil Cytoplasmic Antibodies in 

Infective Endocarditis: An Analysis of 109 Cases 

Alfred Mahr 1 , Frédéric Batteux 2 , Sarah Tubiana 3 , Michel Wolff 3 , 

Claire Goulvestre 2 , Thomas Papo 3 , François Vrtovsnik 3 , Isabelle 

Klein 3 , Bernard Iung 3 and Xavier Duval 3 , 1 Hospital Saint-Louis, 

Paris, France, 2 Hospital Cochin, Paris, France, 3 Hospital Bichat, 

Paris, France 

5:15 PM 

2566. Aβ-Related Angiitis: Comparison with Patients with 

Amyloid Cerebral Angiopathy without Inflammation 

Carlo Salvarani 1 , Caterina Giannini 2 , Robert D. Brown Jr. 2 , Teresa 

J. H. Christianson 2 and Gene G. Hunder 2 , 1 Arcispedale S Maria 

Nuova. IRCCS, Reggio Emilia, Italy, 2 Mayo Clinic, Rochester, MN 

5:30 PM 

2567. Predictive Value of Selected Markers of Inflammation 

and Platelet Activation for Complete Remission in ANCA – 

Associated Vasculitis 

Gunnar Tomasson 1 , Paul A. Monach 2 , Kahraman Tanriverdi 3 , 

Ulrich Specks 4 , John H. Stone 5 , Linna Ding 6 , Fernando Fervenza 4 , 

Gary S. Hoffman 7 , Cees G.M. Kallenberg 8 , Carol A. Langford 7 , 

Deborah J. Phippard 9 , Philip Seo 10 , Robert F. Spiera 11 , E. 

William St. Clair 12 , Nadia Tchao 9 , Jane E. Freedman 3 and 

Peter A. Merkel 13 , 1 University of Iceland, Reykjavik, Iceland, 

2 

Boston University, Boston, MA, 3 University of Massachusetts, 

Wochester, 4 Mayo Clinic, Rochester, MN, 5 Massachusetts 

General Hospital, Boston, MA, 6 NIAID, Bethesda, MD, 7 Cleveland 

Clinic, Cleveland, OH, 8 University Medical Center Groningen, 

Groningen, Netherlands, 9 Immune Tolerance Network, Bethesda, 

MD, 10 Johns Hopkins Vasculitis Center, Baltimore, MD, 11 Hospital 

for Special Surgery, New York, NY, 12 Duke University Medical 

Center, Durham, NC, 13 University of Pennsylvania, Philadelphia, 

PA 

5:45 PM 

2568. The Risk of Pulmonary Embolism and Deep Vein 

Thrombosis in Giant Cell Arteritis: A Population-Based Cohort 

Study 

J. Antonio Avina-Zubieta 1 , Diane Lacaille 1 , Eric C. Sayre 1 , Jacek A. 

Kopec 1 and Hyon K. Choi 2 , 1 Arthritis Research Centre of Canada/ 

University of British Columbia, Richmond, BC, 2 Boston University 

School of Medicine, Arthritis Research Centre of Canada/ 

University of British Columbia, Boston, MA 


4:30 - 6:00 PM 










September 14. 

PM 

PS

148 

Central Nervous System Vasculitis (081) 

Speaker: Rula Hajj-Ali, MD 

153 

Crystal: Pseudogout (082) 

Speaker: Ann K. Rosenthal, MD 

154 B 

Pulmonary Manifestations of Rheumatic Disease 

(084) 

Speaker: Kristin B. Highland, MD, MSCR 

155 

Raynaud’s and Digital Ischemia (085) 

Speaker: Janet E. Pope, MD, MPH 

158 A 

Rheumatoid Arthritis: Safety of Novel Therapies (086) 

Speaker: Lee S. Simon, MD 

158 B 

Rheumatology Practice 101: Starting Out in Practice 

for The Graduating Fellow (087) 

Speaker: Michael J. Maricic, MD 

159 A 

Systemic Lupus Erythematosus: Lupus Nephritis (088) 

Speaker: Brad H. Rovin, MD 

159 B 

*Systemic Lupus Erythematosus: Novel Treatments 

(089) 

Speaker: Robert G. Lahita, MD, PhD 

160 

Vaccinations for Patients on Biologic Therapies (090) 

Speaker: Clifton O. Bingham III, MD 



4:30 - 6:00 PM 

147 A 

Edmond L. Dubois, MD Memorial Lectureship: 

PM PS 

Hydroxychloriquine Reduces Thrombosis is Systemic 

Lupus Erythematosis Particularly in Antiphosholipid 

Positive Patients 

Moderators: Francisco P. Quismorio Jr. , MD and Lindsy J. 

Forbess, MD 

4:30 PM 

2569. Hydroxychloroquine Reduces Thrombosis in Systemic 

LUPUS Erythematosus, Particularly in Antiphospholipid 

Positive Patients 

Speaker: Genevieve Law, MD 

Genevieve Law 1 , Laurence S. Magder 2 , Hong Fang 3 and Michelle 

Petri 3 , 1 University of British Columbia, Vancouver, BC, 2 University 

of Maryland, Baltimore, MD, 3 Johns Hopkins University School 

of Medicine, Baltimore, MD 

4:45 PM 

2570. Lymphoma Risk in Systemic Lupus: Effects of Disease 

Activity Versus Treatment 

Sasha Bernatsky 1 , Ann E. Clarke 2 , Karen H. Costenbader 3 , Murray 

B. Urowitz 4 , Dafna D. Gladman 5 , Paul R. Fortin 6 , Michelle Petri 7 , 

Susan Manzi 8 , D.A. Isenberg 9 , Anisur Rahman 10 , Daniel Wallace 11 , 

Caroline Gordon 12 , Christine Peschken 13 , Mary Anne Dooley 14 , 

E.M. Ginzler 15 , Cynthia Aranow 16 , Steven M. Edworthy 17 , Ola 

Nived 18 , Søren Jacobsen 19 , Guillermo Ruiz-Irastorza 20 , Edward 

Yelin 21 , Susan G. Barr 22 , Irene Blanco 23 , Candace H. Feldman 24 

and R. Ramsey-Goldman 25 , 1 Systemic Lupus International 

Collaborating Clinics, Montreal, QC, 2 Research Institute of 

the McGill University Health Centre, Montreal, QC, 3 Brigham 

and Women’s Hospital, Harvard Medical School, Boston, MA, 

4 

Toronto Western Hospital and University of Toronto, Toronto, 

ON, 5 Toronto Western Hospital and University of Toronto, 

Toronto, ON, 6 University of Laval, Quebec, 7 Johns Hopkins 

University School of Medicine, Baltimore, MD, 8 West Penn 

Allegheny Health System, Pittsburgh, PA, 9 University College of 

London, London, United Kingdom, 10 University College London, 

London, United Kingdom, 11 Cedars-Sinai/UCLA, Los Angeles, 

CA, 12 University of Birmingham, Birmingham, United Kingdom, 

13 

University of Manitoba, Winnipeg, MB, 14 University of North 

Carolina at Chapel Hill, Chapel Hill, NC, 15 SUNY-Downstate 

Medical Center, Brooklyn, NY, 16 Feinstein Institute for Medical 

Research, Manhasset, NY, 17 The University of Calgary, Calgary, 

AB, 18 University Hospital - Lund, Lund, Sweden, 19 Copenhagen 

University Hospital, Copenhagen, Denmark, 20 Hospital de 

Cruces, UPV/EHU, Barakaldo, Spain, Bizkaia, Spain, 21 University 

of California San Francisco, San Francisco, CA, 22 University of 

Calgary, Calgary, AB, 23 Albert Einstein College of Medicine, 

Bronx, NY, 24 Brigham and Women’s Hospital, Boston, MA, 

25 

Northwestern University Feinberg School of Medicine, Chicago, 

IL 

5:00 PM 

2571. Lack of Control of Hypertension in Systemic Lupus 

Erythematosus 

Hong Fang 1 , Raheel Ahmad 1 , Laurence S. Magder 2 and Michelle 

Petri 1 , 1 Johns Hopkins University School of Medicine, Baltimore, 

MD, 2 University of Maryland, Baltimore, MD 

5:15 PM 

2572. Molecular Signatures in SLE: Flare Vs. Infection 

Meggan Mackay 1 , Michaela Oswald 1 , Jorge Sanchez-Guerrero 2 , 

Juan J. Lichuaco 3 , Cynthia Aranow 1 , Sean Kotkin 1 , Peter K. 

Gregersen 1 and Betty Diamond 1 , 1 The Feinstein Institute for 

Medical Research, Manhasset, NY, 2 Mount Sinai Hospital, 

University Health Network, Toronto, ON, 3 St. Luke’s Medical 

Center, Quezon City, Philippines 

TUESDAY 



TUESDAY 


5:30 PM 

2573. Arthoplasty Rates Increased Among US Patients with 

Systemic Lupus Erythematosus: 1991-2005 

Christina Mertelsmann-Voss 1 , Ting Jung Pan 2 , Huong Do 2 , Mark P. 

Figgie 2 and Lisa A. Mandl 2 , 1 Hospital for Special Surgery, Cornell 

University, New York, NY, 2 Hospital for Special Surgery, New York, 

NY 

5:45 PM 

2574. Smoking, Autoantibodies and Vascular Events in Systemic 


Johanna Gustafsson 1 , Iva Gunnarsson 2 , Susanne Pettersson 3 , 

Agneta Zickert 1 , Anna Vikerfors 4 , Erik Hellbacher 4 , Sonia Möller 3 , 

Kerstin Elvin 4 , Henrik Källberg 4 , Julia F. Simard 5 and Elisabet 

Svenungsson 1 , 1 Rheumatology Unit, Karolinska Institutet, 

Stockholm, Sweden, 2 Department of Medicine, Rheumatology 

Unit, Karolinska Institute, Stockholm, Sweden, 3 Karolinska 

University Hospital, Stockholm, Sweden, 4 Karolinska Institutet, 

Stockholm, Sweden, 5 Clinical Epidemiology Unit, Dept of 

Medicine, Karolinska Institutet, Stockholm, Sweden 

ARHP SESSIONS 

4:30 - 6:00 PM 

204 A 

Arthritis and the Older Worker 

Moderator: Kristina A. Theis, BA, MPH 


• describe the current trends of employment among older 

adults and specifically those with arthritis 

• identify one CMS policy or service affected by growing 

numbers of workers aged 65 years and older 

• discuss interventions applicable to helping older workers with 

arthritis gain or maintain employment 

• describe the public health approach to addressing 

employment needs for older workers with arthritis 

4:30 PM 

Overview of Demographic Trends of Older Workers 

Terence McMenamin, MA 

5:00 PM 

Impact of Older Workers on Medicare/Medicaid 

Shari M. Ling, MD 

PM 

PS 

206 


• review common rheumatologic conditions that can be 

diagnosed with the aid of imaging 

• describe the differences between X-ray, MRI, CT scan and 

ultrasound for evaluating conditions 

• discuss when and why a specific imaging modality is preferred 

over another for certain conditions 

• recognize when it is appropriate to order MRI imaging with 

and without contrast instead of plain X-rays 

PM 

PS 

The Puzzle of Fatigue in Rheumatoid Arthritis: Putting 

the Pieces Together 

Moderator: Ann Vincent, MD 


• recognize the impact of the disease process and behavioral 

factors in the manifestation of fatigue, and the therapeutic 

implications for patients with rheumatic diseases 

• identify potential psychological and physiological sources of 

fatigue 

• utilize traditional and novel methods (e.g., computer adaptive 

testing) of measuring fatigue from the patient perspective 

• cite evidence supporting psychological and physical activity 

interventions for rheumatoid arthritis fatigue, and some of the 

questions that remain to be answered 

4:30 PM 

Fatigue in Rheumatic Disease from a Psychophysiological 

Perspective 

Rinie Geenen, PhD 

4:50 PM 

Sources of Fatigue: Body, Mind, or Both? 

Patricia P. Katz, PhD 

5:10 PM 

Novel Methods to Measure Fatigue from the Patient 

Perspective 

Christina Bode, PhD 

5:30 PM 

Non-pharmacological Interventions for Rheumatoid Arthritis 

Fatigue 

Sarah Hewlett, MA, PhD, RN 

5:30 PM 

The Public Health Perspective on Older Workers with Arthritis 

Sylvia Furner, PhD 

PM PS 

150 B 

Best Practices for Ordering Diagnostic Imaging in 

Evaluating Rheumatologic Conditions 


Speaker: Mark D. Murphey, MD 


6:30 - 9:30 PM 

These symposia are both CME-accredited and non-CME 

company-directed programs. For CME-accredited symposia, 

the sponsoring organization is responsible for planning and 

providing CME credit. All non-CME programs are wholly 

sponsored and supported by commercial entities. Please visit the 

organization’s exhibit booth, the industry-supported symposia 

booth or see page 317 for more information. 

120 

2012 Program Book

WEDNESDAY, NOVEMBER 14, 2012 


7:00 AM - 1:00 PM 


ACR SESSIONS 

7:30 - 8:30 AM 

PM PS 

Ballroom A 

Immunology of Pregnancy and Impact on 

Autoimmune Pathogenesis 

Moderator: Gregg Silverman, MD 

Speaker: J. Lee Nelson, MD 


• summarize the immunobiology of pregnancy and immune 

tolerance to the fetus 

• discuss advances in methods to survey the immune status in 

pregnant women without and with rheumatic diseases 

• discuss the pathogenesis of toxemia of pregnancy in 

predisposed individuals such as lupus patients 

• consider whether insights into the immunology of pregnancy 

may offer new therapeutic approaches 

PM PS 

145 A 

Neutrophil Extracellular Traps (NETosis) in Rheumatic 

Disease 

Moderator: Cong-Qiu Chu, MD 

Speaker: Arturo Zychlinsky, PhD 


• describe neutrophil extracellular traps, their components, and 

the process of NETosis 

• identify that NETosis is one of the first lines of defense against 

pathogens 

• review current data implicating NETosis in autoimmune 

disease, particularly ANCA-associated vasculitis and systemic 

lupus erythematosus 

PM PS 

Hall D 

Rheumatology Roundup: Highlights from the 2012 

Annual Scientific Meeting 


Speakers: John J. Cush, MD and Arthur Kavanaugh, MD 


• list research highlights from the scientific presentations 

• discuss the clinical impact of selected research reports 

presented at the meeting 

• evaluate the therapeutic potential of selected clinical trials 

presented at the meeting 

PM 

PS 

143 A 

The Unintended Consequences of Health Information 

Technology PM PS 

Moderator: Christi Joy Inman, MD, MS 

Speaker: Dean F. Sittig, PhD 


• discuss the potential unintended consequences of health 

information technology including workflow errors, changes in 

communication patterns and practices, overdependence on 

technology, and paper persistence 

• identify best practices and potential solutions to mitigate 

unintended consequences of health information technology in 

the rheumatology practice, including human, organizational, 

and environmental factors that can significantly improve 

clinical practice 

• describe potential causative factors of health information 

technology related errors specific to their practice and then 

develop appropriate preventative measures 

ARHP SESSIONS 

7:30 - 8:30 AM 

201 

An Introduction to Immunology 

Moderator: Afton L. Hassett, PsyD 

Speaker: Leonard H. Sigal, MD 


• distinguish the differences between the innate immune 

system and the adaptive immune response and how they 

interact 

• develop insights into the functions of B cells and T cells 

• recognize mechanisms whereby auto-immunity may occur 

• identify the many “yins and yangs” that cooperate to 

modulate the immune response 

206 

PM PS 

Beyond the Basics: A Real Life Example of Multiple 

Imputation for Missing Data Problems (Research 

Series) 

Moderator: Sunny Kim, PhD 


• identify the causes of missing data and how it affects 

interpretation and analysis of research studies 

• describe statistical principals behind multiple imputation of 

missing data and why it is preferred over single imputation 

techniques 

• discuss the analytic techniques (imputation, analysis, pooling) 

required for multiple imputation 

• apply real-life analyses using multiple imputation in popular 

statistical packages 

7:30 AM 

How Does Loss to Missing Data Happen and What Are the 

Implications? 


7:45 AM 

Overview of Multiple Imputation for Missing Data 

Alyssa B. Dufour, MA and Robert R. McLean, DSc, MPH 

7:55 AM 

Using SAS and R to Perform Multiple Imputation 

Alyssa B. Dufour, MA 

PM 

PS 

WEDNESDAY 



8:10 AM 

Introduction to the Johnston County Osteoarthritis Project 

Dataset 

Yvonne M. Golightly, MS, PhD, PT 

8:25 AM 

Reporting Results in Manuscripts/Take Home Message 


ACR SESSIONS 

9:00 - 10:30 AM 

Ballroom C 

Biosimilars Development: Food and Drug 

Administration Perspective 

Moderator: Nikolay P. Nikolov, MD 


• summarize the statutory paradigm for the 351(k) biosimilar 

pathway 

• discuss the Food and Drug Administration’s approach to the 

development of the biosimilar pathway 

• discuss the role analytical similarity assessments and clinical 

considerations play in biosimilar product development 

9:00 AM 

Regulatory Framework of Biosimilars Development 

Leah Christl, PhD 

PM 

PS 

10:00 AM 

Diagnosis and Pathophysiology of IgG4-Related Disease 

Yoh Zen, MD, PhD 

PM PS 

152 A 

NIAMS-Sponsored Research in Rheumatology: 2012 

Highlights 

Moderator: Robert H. Carter, MD 


• explain funding mechanisms available to rheumatology 

investigators 

• describe the role of genetics in predicting response to 

treatment 

• explain the future of juvenile idiopathic arthritis treatment 

and what the pipeline looks like 

• identify the extent to which the poorer outcomes of those of 

low socioeconomic status may be due to the quality of care 

they receive 

• express the importance of patient reported outcomes, and 

how these outcomes are being evaluated through the PROMIS 

system 

9:00 AM 

Funding Opportunities Available in Rheumatology 


WEDNESDAY 


9:15 AM 

Biosimilars Development: The Role of Analytics 

Marjorie Shapiro, PhD 

9:45 AM 

Biosimilars Development: Clinical Considerations 

Nikolay P. Nikolov, MD 

10:10 AM 


Badrul Chowdhury, MD, PhD, Leah Christl, PhD, Sarah K. Okada- 

Yim, MD and Marjorie Shapiro, PhD 

PM PS 

Hall D 

IgG4-Related Disease – Past Lessons and Future 

Directions 

Moderators: Diane L. Kamen, MD, MS and Arezou Khosroshahi, 

MD 


• summarize the current nomenclature and diagnostic criteria 

for retroperitoneal fibrosis and IgG4-related disease 

• identify the patterns of organ involvement and clinical 

manifestations of retroperitoneal fibrosis and IgG4-related 

disease 

• describe potential treatment options for retroperitoneal 

fibrosis and IgG4-related disease 

9:00 AM 

Retroperitoneal Fibrosis – Past Lessons and Future Directions 

Gary S. Gilkeson, MD 

9:30 AM 

Emerging Concepts in IgG4-Related Disease 

John H. Stone, MD, MPH 

9:20 AM 

Improved Understanding of the Biology and Use of Tumor 

Necrosis Factor Inhibition in Juvenile Idiopathic Arthritis 

D. J. Lovell, MD, MPH 

9:40 AM 

Health Systems, Quality of Care, and Outcomes 

Edward H. Yelin, PhD 

10:00 AM 

Patient Reported Outcomes Measurement Information System 

(PROMIS) 

James P. Witter, MD, PhD 

10:20 AM 

Break 

PM PS 

Ballroom B 

Osteoarthritis Therapeutics: Will This be the Decade 

for Breakthroughs? 

Moderators: Tuhina Neogi, MD, PhD and Jasvinder A. Singh, MD, 

MPH 


• review the evidence in the literature regarding current 

therapies for osteoarthritis 

• describe the rationale of new therapies for osteoarthritis, 

including stem cells and other innovative therapies 

• describe the new approaches to treatment of osteoarthritis 

and promising new therapies on the horizon 

• recognize how new treatments compliment the current 

therapies in management of patients with osteoarthritis 

122 

2012 Program Book

9:00 AM 

What’s Effective in Osteoarthritis? Appraisal of Current 

Therapies 


9:30 AM 

Stem cells in Osteoarthritis: They Give Them to My Dog, Are 

we There Yet for Use in Humans? 

Rocky S. Tuan, PhD 

10:00 AM 

Future of Osteoarthritis Treatment: Therapeutics in the 

Pipeline 

David J. Hunter, MBBS, PhD 

PM PS 

150 B 

Predictive Biomarkers: A Journey to Personalized 

Health Care 

Moderator: Wael N. Jarjour, MD 


• critically review predictive biomarkers in cardiology and 

hematology/oncology 

• define the status of predictive biomarkers in systemic lupus 

erythematosus 

• identify models that were used to develop validated 

predictive biomarkers in cardiology (and other disciplines) and 

their potential applicability in systemic lupus erythematosus 

9:00 AM 

Predictive Biomarkers in Cardiovascular Disease 

Alan S. Maisel, MD 

9:15 AM 

2576. Production of Citrullinated Filaggrin-Specific IgG in 

Rheumatoid Arthritis Patients Is Associated with an Expansion 

of Citrullinated Filaggrin Tetramer-Binding Switched Memory 

Blood B Cells 

Philip Titcombe, Laura O. Barsness, Lauren Giacobbe, Emily 

Baechler Gillespie, Erik J. Peterson and Daniel L. Mueller, 

University of Minnesota Medical School, Minneapolis, MN 

9:30 AM 

2577. Characterization of Circulating Human B Cells That 

Bind Cyclic Citrullinated Peptide Antigens in Clinically Active 


Gregg J. Silverman 1 , John Jung 2 , Jeffrey D. Greenberg 3 , Adam 

J. Pelzek 1 , Caroline Gronwall 1 and Jaya Vas 1 , 1 NYU School 

of Medicine, New York, NY, 2 NYU, New York, NY, 3 New York 

University School of Medicine, New York, NY 

9:45 AM 

2578. Monoclonal IgG Antibodies (ACPAs) From Synovial Fluid 

B Cells of Rheumatoid Arthritis Patients – Antigen-Driven 

Affinity Maturation and Cross Reactivity 

Khaled Amara 1 , Johanna Steen 1 , Fiona Murray 1 , Henner 

Morbach 2 , Blanca Fernandez-Rodriguez 3 , Vijay Balasingh 1 , 

Marianne Engström 1 , Omri Snir 1 , Lena Israelsson 1 , Anca. I. 

Catrina 1 , Hedda Wardemann 4 , Davide Corti 3 , Eric Meffre Sr. 2 , 

Lars Klareskog 1 and Vivianne Malmström 1 , 1 Rheumatology unit, 


Sweden, 2 Yale University School of Medicine, New Haven, CT, 

3 

Institute for Research in Biomedicine, Bellinzona, Switzerland, 

4 

Max Planck Institute for Infection Biology, Berlin, Germany 

9:30 AM 

Moving from Prognostic to Predictive Factors in Oncology 

Neil E. Kay, MD 

10:00 AM 

Predictive Biomarkers in Systemic Lupus Erythematosus: 

Where are We? 

Mary K. Crow, MD 


9:00 -10:30 AM 

147 A 


Moderators: Robert A. Eisenberg, MD and William Stohl, MD, 

PhD 

9:00 AM 

2575. Inhibition of Pathogenic Autoantibodies by Accelerating 

the Exit of Germinal Center B Cells Via Manipulation of 

Regulator of G-Protein Signaling 

John D. Mountz 1 , John H. Wang 2 , James S. New 3 , PingAr Yang 3 , Qi 

Wu 3 , Bao Luo 3 , Jun Li 3 , Kirk M. Druey 4 and Hui-Chen Hsu 3 , 1 Univ 

of Alabama at Birmingham and Birmingham VA Medical Center, 

Birmingham, AL, 2 Cedars Sinai Medical Center, Los Angeles, CA, 

3 

University of Alabama at Birmingham, Birmingham, AL, 4 National 

Institute of Allergy and Infectious Diseases, Bethesda, MD 

10:00 AM 

2579. Novel Autoantibodies to 14-3-3 Eta Are Highly Specific 

for Rheumatoid Arthritis 

Walter P. Maksymowych 1 , Désirée van der Heijde 2 , R. Landewe 3 , 

Vivian P. Bykerk 4 and Anthony Marotta 5 , 1 University of Alberta, 

Edmonton, AB, 2 Leiden University Medical Center, Leiden, 

Netherlands, 3 Academic Medical Center / University of 

Amsterdam, Amsterdam, Netherlands, 4 Hospital for Special 

Surgery, New York, NY, 5 Augurex Life Sciences Corp, North 

Vancouver, BC 

10:15 AM 

2580. Marginal Zone Defects in Wiskott-Aldrich Syndrome Are 

Dependent On B Cell Intrinsic Toll-Like Receptor Signals 

Shaun W. Jackson 1 , Nikita Kolhatkar 2 , Marc A. Schwartz 2 , 

Socheath Khim 3 and David J. Rawlings 4 , 1 Seattle Children’s 

Hospital, Seattle, WA, 2 Department of Immunology, University of 

Washington, Seattle, WA, 3 Seattle Children’s Research Institute, 

Seattle, WA, 4 Washington, Seattle, WA 

145 A 

Imaging of Rheumatic Diseases III: Computed 

Tomography 

Moderators: Georg A. Schett, MD, PhD and Fiona M. McQueen, 

MBChB, MD 

WEDNESDAY 



9:00 AM 

2581. Anti- Citrullinated Protein Antibodies but Not 

Rheumatoid Factor Are Associated with Larger Bone Erosions 

in rheumatoid arthritis patients- a Cross-Sectional Micro 

Computed Tomography Study 

Carolin Hecht 1 , Stephanie Finzel 1 , Matthias Englbrecht 1 , Sarah 

Schmidt 1 , Juergen Rech 1 , Elizabeth Araujo 1 and Georg Schett 2 , 

1 

University of Erlangen-Nuremberg, Erlangen, Germany, 

2 

Institute for Clinical Immunology, University of Erlangen- 

Nuremberg, Erlangen, Germany 

9:15 AM 

2582. Bone Anabolic Changes Progress in Psa Patients Despite 

Treatment with Methotrexate or Tumour Necrosis Factor 

Inhibitors 

Stephanie Finzel 1 , Sebastian Kraus 1 , Sarah Schmidt 1 , Axel J. 

Hueber 1 , Juergen Rech 1 , Klaus Engelke 1 , Matthias Englbrecht 1 

and Georg Schett 2 , 1 University of Erlangen-Nuremberg, Erlangen, 

Germany, 2 Institute for Clinical Immunology, University of 

Erlangen-Nuremberg, Erlangen, Germany 

9:30 AM 

2583. Bone Structure and Perfusion Quantification of Bone 

Marrow Edema and Pannus Tissue Areas in the Wrist of 

Patients with RA 

Jose R. Teruel Antolin, Andrew J. Burghardt, Julien Rivoire, 

Waraporn Srikhum, Susan M. Noworolski, Thomas M. Link, 

John B. Imboden and Xiaojuan Li, University of California, San 

Francisco, San Francisco, CA 

9:00 AM 

2587. Practice Makes Perfect: Assessment of Proficiency of 

Rheumatology Fellows in Specific Joint Procedural Skills 

Tara J. Rizvi, Min Xu and Nancy Searle, Baylor College of 

Medicine, Houston, TX 

9:15 AM 

2588. Standardized Patient Simulation Improves Internal 

Medicine Resident Musculoskeletal Examination Skills 

Floranne C. Ernste 1 , Uma Thanarajasingam 1 , Courtney Shourt 2 , 

Andrew Halvorsen 3 and Furman S. McDonald 3 , 1 Mayo Clinic, 

Rochester, MN, 2 Mayo Clinic Rochester, Rochester, 3 Mayo Clinic, 

Rochester 

9:30 AM 

2589. From Novice to Expert: Competency Milestones for 

Musculoskeletal Ultrasound 

Karina D. Torralba 1 , Jay B. Higgs 2 , Amy C. Cannella 3 and Gurjit 

S. Kaeley 4 , 1 Keck School of Medicine, University of Southern 

California, Los Angeles, CA, 2 San Antonio Military Medical Center, 

Fort Sam Houston, TX, 3 University of Nebraska Med Ctr, Omaha, 

NE, 4 University of Florida, Ponte Vedra Beach, FL 

9:45 AM 

2590. Consolidating Knowledge, Comprehension, Application 

and Analysis in Rheumatology Education by Use of an in-House 

Electronic Module (Web-based Rheumatology Case Scenarios) 

David A. Kandiah, Diana Jonas-Dwyer and Astrid Davine, 

University of Western Australia, Crawley, Australia 

WEDNESDAY 


9:45 AM 

2584. Quantitative and Semi-Quantitative Bone Erosion 

Assessment On High-Resolution Peripheral Quantitative 

Computed Tomography in Rheumatoid Arthritis 

Waraporn Srikhum, Warapat Virayavanich, Andrew J. Burghardt, 

Andrew Yu, Thomas M. Link, John B. Imboden and Xiaojuan Li, 

University of California, San Francisco, San Francisco, CA 

10:00 AM 

2585. Magnetic Resonance Imaging Versus Dual Energy 

Computed Tomography for Detection of Joint Pathology in 

Gout 

Fiona M. McQueen 1 , Anthony Doyle 1 , Quentin Reeves 2 , 

Angela Gao 2 , Amy Tsai 2 , Gregory Gamble 1 , Barbara Curteis 1 , 

Megan Williams 2 and Nicola Dalbeth 1 , 1 University of Auckland, 

Auckland, New Zealand, 2 Auckland District Health Board, 

Auckland, New Zealand 

10:15 AM 

2586. Tendon and Ligament Involvement in Gout: A Dual 

Energy Computed Tomography Study 

Nicola Dalbeth 1 , Ramanamma Kalluru 2 , Opetaia Aati 1 , Fiona 

M. McQueen 1 and Anthony Doyle 1 , 1 University of Auckland, 

Auckland, New Zealand, 2 Department of Rheumatology, 

Auckland District Health Board, Auckland, New Zealand 

143 A 


Moderators: Michael H. Pillinger, MD and Michael J. Battistone, 

MD 

10:00 AM 

2591. Assessment of Examination Skills of 4th Year Medical 

Students Using a Novel Objective Structured Clinical 

Examination 

Seetha U. Monrad, Lisa DiPonio, Cliff Craig, John Zeller and R. 

Brent Stansfield, Univ of Michigan Med Ctr, Ann Arbor, MI 

10:15 AM 

2592. Musculoskeletal Ultrasound Objective Structured Clinical 

Examination : An Assessment of the Test 

Eugene Y. Kissin 1 , Peter C. Grayson 2 , Amy C. Cannella 3 , Amy M. 

Evangelisto 4 , Janak R. Goyal 5 , Rany Al Haj 6 , Jay B. Higgs 7 , Daniel 

G. Malone 8 , Midori Jane Nishio 9 , Darren Tabechian 10 and Gurjit 

S. Kaeley 11 , 1 Boston University, Boston, MA, 2 Boston University 

Medical Center, Boston, MA, 3 University of Nebraska Med Ctr, 

Omaha, NE, 4 Arthritis, Rheumatic and Back Disease Associates, 

Voorhees, NJ, 5 Raritan Bay Medical Center, Perth Amboy, NJ, 

6 

Jersey Shore Arthritis & Rheumatism A, Ocean, NJ, 7 San Antonio 

Military Medical Center, Fort Sam Houston, TX, 8 Family & 

Sports Orthopaedic Center, Beaver Dam, WI, 9 Adjunct Assistant 

Professor of Medicine/ Stanford University, Walnut Creek, CA, 

10 

Univ of Rochester Schl of Med, Rochester, NY, 11 University of 

Florida, Ponte Vedra Beach, FL 

146 C 


Disease IV: Childhood Therapeutics and Response 

Moderators: Suzanne C. Li, MD, PhD and Taunton R. Southwood, 

MD 

124 

2012 Program Book

9:00 AM 

2593. Predictive Markers of Therapeutical Outcome and Their 

Role in the Ethiopathology of Juvenile Idiopathic Arthritis 

Maura Rossetti 1 , Roberto Spreafico 1 , Hong Zhang 1 , Maryam 

Moshref 1 , Nora G. Singer 2 , D. J. Lovell 3 , Carol A. Wallace 4 and 

Salvatore Albani 1 , 1 Sanford-Burnham Medical Research Institute, 

La Jolla, CA, 2 MetroHealth Medical Center, Cleveland, OH, 

3 

Cincinnati Children’s Hospital, Cincinnati, OH, 4 Seattle Childrens 

Hospital, Seattle, WA 

9:15 AM 

2594. Epigenetic Signature of the Response to Anti-TNF in 


Roberto Spreafico 1 , Maura Rossetti 1 , Hong Zhang 1 , Maryam 

Moshref 1 , Carol Wallace 2 , D. J. Lovell 3 and Salvatore Albani 1 , 

1 

Sanford-Burnham Medical Research Institute, La Jolla, CA, 

2 

Childrens Hosp & Regional Med, Seattle, WA, 3 Cincinnati 


9:30 AM 

2595. S100A12 At Baseline May Be Useful for Predicting 

Inactive Disease within 12 Months in Polyarticular Juvenile 

Idiopathic Arthritis 

Gali Malul 1 , Joy M. Whitbred 1 , MaryAnn O’Riordan 2 , Sarah 

Ringold 3 , Susan D. Thompson 4 , Carol Wallace 5 , Salvatore Albani 6 

and Nora G. Singer 7 , 1 MetroHealth Medical Center, Cleveland, 

OH, 2 Case Medical Center, Cleveland, OH, 3 Seattle Children’s 

Hospital, Seattle, WA, 4 Cincinnati Children’s Hospital Medical 

Center, Cincinnati, OH, 5 Childrens Hosp & Regional Med, Seattle, 

WA, 6 Sanford-Burnham Medical Research Institute, La Jolla, 

CA, 7 Director, Division of Rheumatology, MetroHealth Medical 

Center, Case Western Reserve University, Cleveland, OH 

9:45 AM 

2596. Rituximab Treatment for Antineutrophil Cytoplasmic 

Antibody - Associated Vasculitis in Children 

Katharine F. Moore 1 , Leonard L. Dragone 2 , Jennifer B. Soep 3 and 

J. Roger Hollister 3 , 1 Seattle Children’s Hospital / University of 

Washington, Seattle, WA, 2 National Jewish Health, Denver, CO, 

3 

Children’s Hospital Colorado, Aurora, CO 

10:00 AM 

2597. Degree of Initial Intracellular Folate Depletion May 

Predict Methotrexate Response in Juvenile Idiopathic Arthritis 

Leon van Haandel 1 , Ryan S. Funk 1 , Maria F. Ibarra 1 , Mark F. 

Hoeltzel 1 , Andrew Lasky 2 , Daisy Dai 1 , Rodger Gaedigk 1 , J. Steven 

Leeder 1 and Mara L. Becker 1 , 1 Children’s Mercy Hospital, Kansas 

City, MO, 2 Childrens Mercy Hospital, Kansas City, MO 

10:15 AM 

2598. Anti-Drug Antibodies Are Associated with Diminished 

Drug Levels and Treatment Failure 

Miha Kosmac 1 , Natasa Toplak 2 , Gabriele Simonini 3 , Ilaria 

Pagnini 3 , Rolando Cimaz 4 , Vladka Curin Serbec 1 and Tadej Avcin 4 , 

1 

Blood Transfusion Centre of Slovenia, Ljubljana, Slovenia, 

2 

University Children’s Hospital Ljubljana Slovenia, Ljubljana, 

Slovenia, 3 Anna Meyer Children’s Hospital, Department of 

Pediatrics, University of Florence, Florence, Italy, 4 Paediatric 



207 A 

Quality Measures and Innovations in Practice 

Management and Care Delivery 

Moderators: Andreas M. Reimold, MD 

9:00 AM 

2599. Quality of Care for Medicare Recipients with 

Rheumatoid Arthritis: Vulnerable Populations More Likely to 

Receive Therapy with Glucocorticoids Alone 

Chris Tonner 1 , Gabriela Schmajuk 1 , Amal N. Trivedi 2 , Grace 

Lin 3 and Jinoos Yazdany 3 , 1 UCSF, San Francisco, CA, 2 Brown 

University, Providence, RI, 3 University of California San 


9:15 AM 

2600. Assessment of Quality of Care for Incident Lupus 

Nephritis in the U.S. Medicaid Population 

Jinoos Yazdany 1 , Candace H. Feldman 2 , Jun Liu 3 , Michael 

M. Ward 4 , Michael A. Fischer 2 and Karen H. Costenbader 5 , 

1 

University of California San Francisco, San Francisco, CA, 

2 

Brigham and Women’s Hospital, Boston, MA, 3 Brigham and 

Women’s Hospital, Harvard Medical School, Boston, Boston, 

MA, 4 NIAMS/NIH, Bethesda, MD, 5 Brigham and Women’s 

Hospital, Harvard Medical School, Boston, MA 

9:30 AM 

2601. Improving Delivery of Care for JIA Across a Multi- 

Center Network Using a Shared Data Registry and Quality 

Improvement Science: The Pediatric Rheumatology Care and 

Outcomes Improvement Network 

Catherine A. Bingham 1 , Lynn M. Darbie 2 , Keith Marsolo 2 , Jennifer 

E. Weiss 3 , Stacy P. Ardoin 4 , Ronald M. Laxer 5 , D. J. Lovell 2 , 

Murray H. Passo 6 , Sheetal Vora 7 , Beth S. Gottlieb 8 , Timothy 

Beukelman 9 , Nancy Griffin 10 , Jason A. Stock 11 , Michael L. Miller 12 , 

Karen Onel 13 , Tova Ronis 14 , Peter Margolis 2 and Esi M. Morgan 

DeWitt 11 , 1 Hershey Medical Center, Hershey, PA, 2 Cincinnati 

Children’s Hospital, Cincinnati, OH, 3 Joseph M. Sanzari Children’s 

Hospital, Hackensack University Medical Center, Hackensack, 

NJ, 4 Ohio State University, Columbus, OH, 5 The Hospital for Sick 

Children, Toronto, ON, 6 Medical University of South Carolina, 

Charleston, SC, 7 Medical College of Wisconsin, Milwaukee, WI, 

8 

Cohen Children’s Medical Center of New York, New Hyde Park, 

NY, 9 Univ of Alabama-Birmingham, Birmingham, AL, 10 Cincinnati 

Children’s Hospital Medical Center, Cincinnati, 11 Cincinnati 

Children’s Hospital Medical Center, Cincinnati, OH, 12 Childrens 

Memorial Hospital, Chicago, IL, 13 University of Chicago, Chicago, 

IL, 14 Stanford University Hospital, Palo Alto, CA 

9:45 AM 

2602. The Rheumatology Informatics System for Effectiveness 

(RISE): Enabling Data Access Across Disparate Sites for Quality 

Improvement and Research 

Peter J. Embi 1 , Itara Barnes 2 , Rachel Myslinski 2 , David Ervin 1 , 

William Stevens 1 , Tara Borlawsky 1 and Philip R.O. Payne 1 , 1 The 

Ohio State University, Columbus, OH, 2 American College of 

Rheumatology, Atlanta, GA 

WEDNESDAY 



WEDNESDAY 


126 

10:00 AM 

2603. Moving Into the Electronic Age: Validation of 

Rheumatology Self-Assessment Questionnaires On Tablet 

Computers 

Jessica M. Sage 1 , Arshia Ali 2 , Jennifer Farrell 1 , Jennifer L. 

Huggins 1 , Kara Covert 1 , Diane Eskra 1 , Rina Mina 3 , Shweta 

Srivastava 1 , Janalee Taylor 1 , Tracy V. Ting 1 , Esi M. Morgan DeWitt 1 

and Hermine I. Brunner 1 , 1 Cincinnati Children’s Hospital Medical 

Center, Cincinnati, OH, 2 University of Cincinnati, Cincinnati, OH, 

3 

Cincinnati Children’s Hospital Medical Center/University of 

Cincinnati, Cincinnati, OH 

10:15 AM 

2604. Ask a Doc – Rheumatologic Care Delivered Just in Time 

Eric D. Newman 1 , Chelsea Cedeno 1 , Thomas M. Harrington 1 , 

Thomas P. Olenginski 1 , Alfred E. Denio 1 , Androniki Bili 1 , Brian 

DelVecchio 1 , Carolyn Houk 2 and Paul F. Simonelli 1 , 1 Geisinger 

Medical Center, Danville, PA, 2 Geisinger Health System, 

Frackville, PA 

Ballroom A 

Rheumatoid Arthritis - Clinical Aspects VI: Remission 

and Flare in Rheumatoid Arthritis 

Moderators: Ernest Choy, MD and Shahin Jamal, MD, MSc 

9:00 AM 

2605. Exploration of Possible Preliminary Descriptions of 

Remission Based On RAPID3, without Laboratory Tests or 

Formal Joints Counts but with Careful Joint Examinations, in 

the Etude Et Suivi Des Polyarthrites Indifférenciées Récentes 

(ESPOIR) Cohort of Early Rheumatoid Arthritis Patients 

Isabel Castrejón 1 , Maxime Dougados 2 , Bernard Combe 3 , Bruno 

Fautrel 4 and Theodore Pincus 1 , 1 NYU Hospital for Joint Diseases, 

New York, NY, 2 Paris-Descartes University, APHP, Cochin Hospital, 

Paris, France, 3 Hopital Lapeyronie, Montpellier, France, 4 APHP- 

Pitie Salpetriere Hospital / UPMC, Paris, France 

9:15 AM 

2606. Patient Reported Outcomes in Early Arthritis Patients 

L. Heimans 1 , K.V.C. Wevers-de Boer 1 , K. Visser 1 , R. Goekoop 2 , 

T.H.E. Molenaar 3 , B.A. Grillet 4 , Tom Huizinga 1 and C.F. Allaart 1 , 

1 

Leiden University Medical Center, Leiden, Netherlands, 2 Haga 

Hospital, The Hague, 3 Groene Hart Hospital, Netherlands, 

4 

Zorgsaam hospital, Terneuzen, Netherlands 

9:30 AM 

2607. Adherence to a Treat-to-Target Strategy in Early 

Rheumatoid Arthritis: Results of the Dutch Rheumatoid 

Arthritis Monitoring Remission Induction Cohort 

Marloes Vermeer 1 , Ina H. Kuper 2 , Hein J. Bernelot Moens 3 , 

Monique Hoekstra 4 , Marcel D. Posthumus 5 , Piet L.C.M. van Riel 6 

and Mart A.F.J. van de Laar 1 , 1 University of Twente & Medisch 

Spectrum Twente, Enschede, Netherlands, 2 Medisch Spectrum 

Twente, Enschede, Netherlands, 3 Ziekenhuisgroep Twente, 

Hengelo, Netherlands, 4 Isala Klinieken, Zwolle, Netherlands, 

5 

University Medical Center Groningen, Groningen, Netherlands, 

6 

Radboud University Nijmegen Medical Centre, Nijmegen, 

Netherlands 


9:45 AM 

2608. Time in Remission Is Important for Improvement of 

Physical Function in Patients with Rheumatoid Arthritis (RA) 

Helga Radner 1 , Farideh Alasti 2 , Josef S. Smolen 3 and Daniel 

Aletaha 2 , 1 Medical University Vienna, Vienna, Austria, 2 Medical 

University of Vienna, Vienna, Austria, 3 Medical University of 

Vienna and Hietzing Hospital, Vienna, Austria 

10:00 AM 

2609. Construct and Criterion Validity of Several Proposed 

DAS28 Based Rheumatoid Arthritis Flare Criteria: A Cohort 

Validation Study 

Aatke van der Maas 1 , Elisabeth Lie 2 , Robin Christensen 3 , 

Ernest Choy 4 , Yaël A. de Man 5 , Piet L.C.M. van Riel 6 , Thasia G. 

Woodworth 7 and Alfons A. den Broeder 1 , 1 Sint Maartenskliniek, 

Nijmegen, Netherlands, 2 Diakonhjemmet Hospital, Oslo, 

Norway, 3 Musculoskeletal Statistics Unit, The Parker Institute, 

Copenhagen University Hospital, Copenhagen, Denmark, 

4 

Cardiff University School of Medicine, Cardiff, United Kingdom, 

5 

Erasmus Medical Centre, Rotterdam, Netherlands, 6 Radboud 

University Nijmegen Medical Centre, Nijmegen, Netherlands, 

7 

Visiting Clinical Researcher, Geffen School of Medicine, UCLA, 


10:15 AM 

2610. Predictors of Sustained Clinical Remissionin Early 

Rheumatoid Arthritis - Results From the Canadian Early 

Arthritis Cohort 

Bindee Kuriya 1 , Juan Xiong 2 , Gilles Boire 3 , Boulos Haraoui 4 , 

Carol A. Hitchon 5 , Janet E. Pope 6 , J. Carter Thorne 7 , Diane Tin 7 , 

Edward Keystone 1 , Vivian P. Bykerk 8 and CATCH 9 , 1 University 

of Toronto, Toronto, ON, 2 Mount Sinai Hospital, Toronto, ON, 

3 

CHUS - Sherbrooke University, Sherbrooke, QC, 4 Osteoarthritis 

Research Unit, University of Montreal Hospital Research Centre 

(CRCHUM), Montreal, QC, 5 University of Manitoba, Winnipeg, 

MB, 6 St. Joseph’s Health Care London, London, ON, 7 Southlake 

Regional Health Centre, Newmarket, ON, 8 Hospital for Special 

Surgery, New York, NY, 9 Toronto, ON 

Salon B 


Aspects and Treatment: Psoriatic Arthritis and 

Spondyloarthritis 

Moderators: Rafael Valle-Oñate, MD and Dirk Elewaut, MD, PhD 

9:00 AM 

2611. Do Patients with Psoriatic Arthritis Fall Into Distinct 

Clinical Sub-Groups- a Cluster Analysis? 

Arane Thavaneswaran 1 , Vinod Chandran 2 and Dafna Gladman 1 , 

1 

Toronto Western Hospital and University of Toronto, Toronto, 

ON, 2 Toronto Western Hospital, University of Toronto, Toronto, 

ON 

9:15 AM 

2612. Localisation of Bone Marrow Edema in Sacroiliac Joints 

in Spondyloarthritis Patients: Does the Site of Lesions Change 

Over a 3-Month Period? 

Manouk de Hooge, Rosaline van den Berg, Monique Reijnierse, 

Victoria Navarro-Compán, Floris van Gaalen, Tom Huizinga 

and Désirée van der Heijde, Leiden University Medical Center, 

Leiden, Netherlands

9:30 AM 

2613. Effect of Certolizumab Pegol On Signs and Symptoms 

in Patients with Psoriatic Arthritis with and without Prior 

Anti-TNF Exposure: 24 Week Results of a Phase 3 Double-Blind 

Randomized Placebo-Controlled Study 

Philip Mease 1 , Roy M. Fleischmann 2 , Jürgen Wollenhaupt 3 , Atul 

A. Deodhar 4 , Danuta Kielar 5 , Franz Woltering 6 , Christian Stach 6 , 

Bengt Hoepken 6 , Terri Arledge 7 and Désirée van der Heijde 8 , 

1 

Seattle Rheumatology Associates, Seattle, WA, 2 University of 

Texas Southwestern Medical Center at Dallas, Dallas, TX, 3 Schön- 

Klinik, Hamburg, Germany, 4 Oregon Health & Science University, 

Portland, OR, 5 UCB Pharma, Brussels, Belgium, 6 UCB Pharma, 

Monheim am Rheim, Germany, 7 UCB Pharma, Rtp, NC, 8 Leiden 


9:45 AM 

2614. The Risk of Diabetes in Psoriatic Arthritis and 


Maureen Dubreuil 1 , Young Hee Rho 1 , Ada Man 2 , Yanyan Zhu 3 , 

Yuqing Zhang 2 , Thorvardur Love 4 , Alexis Ogdie 5 , Joel Gelfand 6 

and Hyon Choi 1 , 1 Boston University School of Medicine, 

Boston, MA, 2 Boston University, Boston, MA, 3 Department 

of Biostatistics, Boston University School of Public Health, 

Boston, MA, 4 Labspitali University Hospital, Reykjavik, Iceland, 

5 

University of Pennsylvania, Philadelphia, PA, 6 University of 

Pennsylvania., Philadelphia, PA 

10:00 AM 

2615. Circulating Levels of Citrullinated Vimentin Fragments 

Are Diagnostic and Prognostic in Ankylosing Spondylitis; 

Evidence for Disease-Related Citrullination 

Anne C. Bay-Jensen 1 , Morten Asser Karsdal 1 , Efstathios 

Vassiliadis 2 , Stephanie Wichuk 3 , Zheng Zhao 4 , Robert GW 

Lambert 3 , Rik Lories 5 , Claus Christiansen 6 and Walter P. 

Maksymowych 3 , 1 Nordic Bioscience A/S, Herlev, Denmark, 

2 

Nordic Bioscience, Herlev, Denmark, 3 University of Alberta, 

Edmonton, AB, 4 Department of Rheumatology, University of 

Alberta and PLA General Hospital, Beijing, PR China, Beijing, 

China, 5 KU Leuven, Leuven, Belgium, 6 CCBR, Ballerup, Denmark 

Dennis 2 , Alan Oglesby 4 , Mark B. McGuire 5 , Ramesh Pappu 6 , 

Charles T. Molta 7 and Greg Keenan 2 , 1 Washington Hospital Ctr, 

Washington, DC, 2 Human Genome Sciences, Inc., Rockville, 

MD, 3 University of California, San Francisco, San Francisco, CA, 

4 

GlaxoSmithKline, Research Triangle Park, NC, 5 Medical Data 

Analytics, Parsippany, NJ, 6 GlaxoSmithKline, USA, Philadelphia, 

PA, 7 GlaxoSmithKline, Philadelphia, PA 

9:15 AM 

2618. Lupus Disease Activity Severely Impairs Pandemic 

Influenza A/H1N1 Vaccine Immune Response in Patients 

without Therapy 

Eduardo F. Borba 1 , Sandra G. Pasoto 1 , Ana L. Calich 1 , Ricardo 

Fuller 1 , Vilma S.T. Viana 1 , Margareth Vendramini 1 , Joao Miraglia 2 , 

Maria A. Ishida 3 and Eloisa Bonfa 4 , 1 University of Sao Paulo, Sao 

Paulo, Brazil, 2 Fundação Butantan, São Paulo, Brazil, 3 Adolfo Lutz 

Institute, Sao Paulo, Brazil, 4 University of São Paulo, São Paulo, 

Brazil 

9:30 AM 

2619. A Double-Blind Randomized Placebo-Controlled Trial of 

the Effect of vitamin D 3 On the Interferon Signature in Patients 

with Systemic Lupus Erythematosus 

Cynthia Aranow 1 , Maria Dall’Era 2 , Elena M. Massarotti 3 , Meggan 

C. Mackay 4 , Andreea Coca 5 , Fotios Koumpouras 6 , Marc C. 

Levesque 7 , W. Winn Chatham 8 , Megan E. B. Clowse 9 , Lisa G. 

Criscione-Schreiber 9 , Sherri Callahan 10 , Ellen A. Goldmuntz 10 , 

Lynette Keyes-Elstein 11 , Betty Diamond 12 and Diane L. Kamen 13 , 

1 

Feinstein Institute for Medical Research, Manhasset, NY, 

2 

University of California, San Francisco, San Francisco, CA, 

3 


Boston, MA, 4 The Feinstein Institute, Manhasset, NY, 5 University 

of Rochester, Rochester, NY, 6 West Penn Hospital, Pittsburgh, PA, 

7 

University of Pittsburgh, Pittsburgh, PA, 8 University of Alabama 

at Birmingham, Birmingham, AL, 9 Duke University Medical 

Center, Durham, NC, 10 NIAID/NIH Rm 6807, Bethesda, MD, 11 Rho 

Federal Systems, Inc., Chapel Hill, NC, 12 Feinstein Institute Med 

Rsch, Manhasset, NY, 13 Arthritis & Clinical Immunology Program, 

Oklahoma Medical Research Foundation, Charleston, SC 

10:15 AM 

2616. The Transition From Psoriasis (Ps) to Psoriatic Arthritis 

(PsA) Is Associated with Elevated Circulating Osteoclast 

Precursors (OCP) and Increased Expression of DC-STAMP 

Ya-Hui Chiu 1 , Edward M. Schwarz 1 , Dafna Gladman 2 , Sharon 

Moorehead 1 , Michelle Smith 1 , Rick Barrett 1 and Christopher 

T. Ritchlin 3 , 1 University of Rochester, Rochester, NY, 2 Toronto 

Western Hospital and University of Toronto, Toronto, ON, 

3 

University of Rochester Medical Center, Rochester, NY 

Hall E 


Treatment IV: Therapeutics 

Moderators: Jose A. Gomez-Puerta, MD, PhD and 

Daniel Wallace, MD 

9:00 AM 

2617. Outcomes Associated with Belimumab in Black/African 

American Patients with Systemic Lupus Erythematous in 

Clinical Practice Settings in the United States 

Christopher E. Collins 1 , Siva Narayanan 2 , Maria Dall’Era 3 , Greg 

9:45 AM 

2620. Randomized, Double-Blind, Placebo-Controlled 

Studies of P140 Peptide in Mannitol (Lupuzor) and Trehalose 

(Forigerimod) in Patients with SLE 

Robert Zimmer 1 , Daniel J. Wallace 2 and Sylviane Muller 3 , 

1 

ImmuPharma France, Mulhouse, France, 2 Cedars-Sinai Medical 

Center, Los Angeles, CA, 3 CNRS, Strasbourg, France 

10:00 AM 

2621. Sustained Disease Improvement and Safety Profile Over 

1745 Patient-Year Experience (7 years) with Belimumab in 

Systemic Lupus Erythematosus Patients 

Joan T. Merrill 1 , Richard A. Furie 2 , Daniel J. Wallace 3 , William 

Stohl 4 , W. Winn Chatham 5 , Arthur Weinstein 6 , James D. McKay, 

Ellen M. Ginzler 8 , Z. John Zhong 9 , William W. Freimuth 9 and 

Michelle A. Petri 10 , 1 Oklahoma Medical Research Foundation, 

Oklahoma City, OK, 2 North Shore-LIJ Health System, Lake 

Success, NY, 3 Cedars-Sinai Medical Center, Los Angeles, CA, 

4 

University of Southern California Keck School of Medicine, 

Los Angeles, CA, 5 University of Alabama at Birmingham, 

Birmingham, AL, 6 Washington Hospital Center, Washington, 

DC, 7 SUNY-Downstate Medical Center, Brooklyn, NY, 8 Human 


WEDNESDAY 

November 14, 2012

WEDNESDAY 


128 

Genome Sciences, Inc., Rockville, MD, 9 Johns Hopkins University 

School of Medicine, Baltimore, MD 

10:15 AM 

2622. Efficacy and Safety of Rontalizumab (Anti-Interferon 

Alpha) in SLE Subjects with Restricted Immunosuppressant 

Use: Results of A Randomized, Double-Blind, Placebo- 

Controlled Phase 2 Study 

K. Kalunian 1 , Joan T. Merrill 2 , R. Maciuca 3 , Wenjun Ouyang 3 , 

J. M. McBride 3 , Michael J. Townsend 3 , E. Park 3 , J. Li 3 , X. Wei 3 , 

A. Morimoto 3 , R. Boismenu 3 , John C. Davis Jr. 3 and William P. 

Kennedy 3 , 1 UCSD School of Medicine, La Jolla, CA, 2 Oklahoma 

Medical Research Foundation, Oklahoma City, OK, 3 Genentech, 

Inc, South San Francisco, CA 

ARHP SESSIONS 

9:00 - 10:30 AM 

206 

PM 

PS 

Forming an Education and Support Group from the 

Ground up 



• review the literature of the value of support and education 

groups for both teens and their parents 

• analyze identified barriers and how to overcome them 

• analyze and evaluate the success of a collaborative effort 

• discuss the development of three programs models, their pro 

and cons 

• identify options and resources available to develop a strong 

community program 

9:00 AM 

Getting Started: From Concept to Program Development 

Sandra J. Watcher, BSN 

9:25 AM 

Building the Community and Engaging Partners to Fulfill the 

Vision 

Elyse M. Leon-Reyes, BA, MPA 

9:50 AM 

Bringing It All Together: Patient Impact and Resource Building 

Jennifer A. Ziegler 

10:15 AM 


201 

Osteoporosis: 2012 Update 

Moderator: Hazel L. Breland, PhD, OTR/L 


• review osteoporosis treatments and recommendations for 

duration of therapy 

• describe the importance and effectiveness of medical 

management post-hip fracture to reduce risk of subsequent 

fracture 

• cite the evidence for exercise and other non-pharmacologic 

therapeutic interventions for fracture prevention and 

hyperkyphosis 


PM 

PS 

9:00 AM 

Update on Imaging and Medications: When, Who, and How 

Long 

Nancy E. Lane, MD 

9:25 AM 

Post Fracture Management 

Michael R. McClung, MD 

9:50 AM 

Best Posture, Movement and Exercise for Vertebral Fracture 

Prevention and Hyperkyphosis 

Wendy Katzman, DSc, PT 

10:15 AM 



9:00 - 10:30 AM 

140 A 

Systemic Sclerosis, Vasculitis, Crohn’s and 


Moderators: Elizabeth G. Salt, PhD and Emily C. Somers, PhD 

9:00 AM 

2623. Taking Charge of Systemic Sclerosis: A Pilot Study of an 

Internet Self-Management Program 

Janet L. Poole 1 , Dinesh Khanna 2 , Betty Skipper 3 and Cindy F. 

Mendelson 1 , 1 University of New Mexico, Albuquerque, NM, 

2 

University of Michigan, Ann Arbor, MI, 3 University of New 

Mexico, NM 

9:15 AM 

2624. Changes in Leisure Participation in Persons with Systemic 

Sclerosis 

Cindy F. Mendelson, Jessica Greaves and Janet L. Poole, 

University of New Mexico, Albuquerque, NM 

9:30 AM 

2625. The Impact of Sexual Difficulties in Women with 

Scleroderma and Interpersonal Relationships 

Tanaka Ngcozana 1 , Louise Parker 1 , Christopher P. Denton 2 and 

Voon Ong 3 , 1 UCL Medical School and Royal Free Hosp, London, 

United Kingdom, 2 UCL, London, United Kingdom, 3 UCL Medical 

School, London, England 

9:45 AM 

2626. The Utility of the Patient Health Questionnaire-9 to 

Assess Suicide Risk in Patients with Systemic Sclerosis 

Ilya Razykov 1 , Marie Hudson 1 , Murray Baron 2 and Brett D. 

Thombs 1 , 1 McGill University, Montreal, QC, 2 Jewish General 

Hospital, Montreal, QC 

10:00 AM 

2627. Gender Differences of Concepts Important to People 

Living with Crohn’s Disease and Their Coverage by Commonly 

Used Patient-Reported Outcome Instruments: Patient’s 

Perspective Elevated by a Qualitative Study 

Mona Dür 1 , Michaela Coenen 2 , Josef S. Smolen 3 , Clemens 

Dejaco 1 and Tanja A. Stamm 1 , 1 Medical University of Vienna,

Vienna, Austria, 2 Ludwig-Maximilians-University, Munich, 

Germany, 3 Medical University of Vienna and Hietzing Hospital, 


10:15 AM 

2628. The Lumbo-Pelvic Muscles and Axial Spondyloarthritis: A 

Pilot Observational Study 

Janet Millner 1 , Julie A. Hides 2 , Patricia Lewis 3 and Jane Zochling 3 , 

1 

Royal Hobart Hospital, Hobart, Australia, 2 Australian Catholic 

University, Brisbane, Australia, 3 Menzies Research Institute 

Tasmania, Hobart, Australia 

204 A 

Clinical and Rehabilitative Aspects of Osteoarthritis 

Moderators: Leigh F. Callahan, PhD and Dorothy D. Dunlop, PhD 

9:00 AM 

2629. Associations of Current and Early-Life Socioeconomic 

Positions with Risk of Self-Reported Doctor-Diagnosed Arthritis 

in a Family-Medicine Cohort of North-Carolinians 

Antoine A. Baldassari 1 , Rebecca J. Cleveland 1 and Leigh F. 

Callahan 2 , 1 University of North Carolina at Chapel Hill, Chapel 

Hill, NC, 2 University of North Carolina, Chapel Hill, NC 

9:15 AM 

2630. Rheumatoid Arthritis and Osteoarthritis in the 

Population: How Different Is the Impact? 

Christina H. Chan 1 , Mayilee Canizares 1 and E.M. Badley 2 , 

1 

Division of Healthcare Outcomes and Research, Toronto 

Western Research Institute, Toronto, ON, 2 Division of Health 

Care and Outcomes Research, Toronto Western Research 

Institute; Dalla Lana School of Public Health, University of 

Toronto, Toronto, ON 

9:30 AM 

2631. Radiographic Osteoarthritis Severity Is Associated with 

an Increased Risk of Developing Knee Pain: Findings From the 

Osteoarthritis Initiative 

Jingbo Niu, David T. Felson, Tuhina Neogi and Yuqing Zhang, 

Boston Univ School of Medicine, Boston, MA 

9:45 AM 

2632. Doing Is Believing: Health Beliefs Before and After an 

Exercised-Based Rehabilitation Programme for Chronic Knee 

Pain 

Mike Hurley 1 and Dr Nicola E. Walsh 2 , 1 St George’s University 

of London, London, United Kingdom, 2 University of the West of 


10:00 AM 

2633. Independence At Home: Real or Perceived 

Hazel L. Breland, Medical University of South Carolina, 

Charleston, SC 

10:15 AM 

2634. Physical Disability, Perceived Dependence and 

Depression in Older Women with Osteoarthriti 

Kisoo Park 1 , Monique A. Gignac 2 and E. M. Badley 3 , 1 Gyeongsang 

National University, Jinju, South Korea, 2 Arthritis Community 

Research and Evaluation Unit , Toronto Western Research 

Institute and University of Toronto, Toronto, ON, 3 Division of 

Health Care and Outcomes Research,Toronto Western Research 



ACR SESSIONS 

11:00 AM - Noon 

PM 

Hall D 

Amyloidosis 2012 

Moderator: Gregory C. Gardner, MD 


PS 


• describe to a colleague the immunology of various forms of 

amyloidosis 

• compare and contrast the clinical manifestation of 

amyloidosis 

• order appropriate laboratory/diagnostic testing 

• explain the current therapeutic approaches to amyloidosis 

150 B 

Mechanisms of Autoinflammatory Diseases 


Speaker: Richard M. Siegel, MD, PhD 


• describe the clinical presentation of patients with TRAPs and 

other auto-inflammatory diseases 

• explain recent advances in understanding pathogenesis of 

these diseases 

ACR SESSIONS 

11:00 AM - 12:30 PM 

PM PS 

Ballroom C 

Making Sense of Autoantibodies in the Diagnosis of 

Systemic Rheumatic Diseases 

Moderator: Luis Eduardo C. Andrade, MD, PhD 


• review the technical basis of the several methodological 

platforms for autoantibody determination 

• discuss the pros and cons of each methodological platform 

• assess the clinical performance of autoantibodies determined 

by different methodological platforms 

• recognize the perspectives for optimum autoantibody testing 

in the globalized world 

11:00 AM 

Elements for Discriminating a Positive ANA-HEp-2 Test in 

Patients with and without Systemic Rheumatic Disease 

Luis Eduardo C. Andrade, MD, PhD 

11:30 AM 

Antinuclear Antibody Screening: Indirect Immunofluorescence 

on HEp-2 Cells versus ELISA and Related Platforms 

Donald B. Bloch, MD 

Noon 

How May the Choice of the Laboratory Technique Influence 

Results in the Lab: Critical Analysis of Different Autoantibody 

Assays and Proposition of Algorithms for Optimal Clinical Value 

Johan Ronnelid, MD 

PM 

PS 


WEDNESDAY 

November 14, 2012

WEDNESDAY 


130 

Hall E 

PM PS 

Rheumatoid Arthritis – Treating to Target: How to 

Incorporate Rheumatoid Arthritis Disease Activity 

Measures into Routine Practice 

Moderator: Mark L. Robbins, MD, MPH 


• explain which measure(s) best fits your practice setting 

• describe the time required to administer and score each 

measure 

• discuss how to locate the forms/scoring sheets 

• review the strengths and weaknesses of each measure that 

have practical implications for following patients 

• outline the usefulness of a registry when implementing 

measures in a practice setting 

11:00 AM 

Rheumatoid Arthritis – Treating to Target: Why the Time 

has Come For All Rheumatologists to Routinely Measure 

Rheumatoid Arthritis Disease Activity in their Practices 

James R. O’Dell, MD 

11:20 AM 

Which Rheumatoid Arthritis Disease Activity Measures to Use 

in Practice and Why 

Charles M. King II, MD 

11:40 AM 

Accessing and Using Rheumatoid Arthritis Disease Activity 

Measures 

Kaleb Michaud, PhD 

Noon 

Using the ACR Rheumatology Clinical Registry to Document 

Rheumatoid Arthritis Disease Activity 

Salahuddin Kazi, MD 


11:00 AM - 12:30 PM 

207 A 

Epidemiology and Health Services Research V: 

Rheumatoid Arthritis Management in the Treat-to- 

Target Era 

Moderators: Lee S. Simon, MD and Jeffrey R. Curtis, MD, MPH 

11:00 AM 

2635. Exploring the Influence of Patient Perceptions On 

Medication Escalation in Daily Practice 

Jos Hendrikx, Wietske Kievit, Jaap Fransen and Piet L.C.M. van 

Riel, Radboud University Nijmegen Medical Centre, Nijmegen, 

Netherlands 

11:15 AM 

2636. Understanding Why Treat-to-Target Strategies Are 

Difficult to Follow 

Liana Fraenkel 1 , Meaghan Cunningham 2 and Paul Falzer 3 , 1 Yale 

University School of Medicine, Veterans Affairs Connecticut 

Healthcare System, New Haven, CT, 2 Yale University School of 

Medicine, New Haven, CT, 3 VA Connecticut Healthcare System, 

New Haven, CT 


11:30 AM 

2637. Cost-Effectiveness and Cost-Utility Analysis of Treat-to- 

Target Versus Usual Care in Early Rheumatoid Arthritis: Results 

of the Dutch Rheumatoid Arthritis Monitoring Registry 

Marloes Vermeer 1 , Wietske Kievit 2 , Ina H. Kuper 3 , Annemarie 

Braakman-Jansen 4 , Hein J. Bernelot Moens 5 , Theo R. Zijlstra 6 , 

Alfons A. den Broeder 7 , Piet L.C.M. van Riel 2 , Jaap Fransen 2 

and Mart A.F.J. van de Laar 1 , 1 University of Twente & Medisch 

Spectrum Twente, Enschede, Netherlands, 2 Radboud University 

Nijmegen Medical Centre, Nijmegen, Netherlands, 3 Medisch 

Spectrum Twente, Enschede, Netherlands, 4 University of 

Twente, Enschede, Netherlands, 5 Ziekenhuisgroep Twente, 

Hengelo, Netherlands, 6 Isala Klinieken, Zwolle, Netherlands, 

7 

Maartenskliniek, Nijmegen, Netherlands 

11:45 AM 

2638. Biologic Switching Among Patients with Rheumatoid 

Arthritis in the United States, 2004-2011 

Ozgur Tunceli 1 , Jeffrey R. Curtis 2 , Tatia C. Woodward 3 , Siting 

Zhou 1 , Yen-Wen Chen 1 and Ancilla W. Fernandes 4 , 1 HealthCore, 

Inc, Wilmington, DE, 2 Univ of Alabama-Birmingham, 

Birmingham, AL, 3 MedImmune, LLC, Gaithersburg, MD, 

4 

MedImmune LLC, Gaithersburg, MD 

Noon 

2639. Residual Disease Activity in Patients with Early 

Rheumatoid Arthritis Who Were Classified As Being in 

Remission According to 8 Different Descriptions: Post Hoc 

Analysis of the Etude Et Suivi Des Polyarthrites Indifférenciées 

Récentes (ESPOIR) Cohort 

Isabel Castrejón 1 , Maxime Dougados 2 , Bernard Combe 3 , Francis 

Guillemin 4 , Bruno Fautrel 5 and Theodore Pincus 1 , 1 NYU Hospital 

for Joint Diseases, New York, NY, 2 Paris-Descartes University, 

APHP, Cochin Hospital, Paris, France, 3 Hopital Lapeyronie, 

Montpellier, France, 4 Faculte de Medecin/BP 184, Vandoeuvreles-Nancy, 

France, 5 APHP-Pitie Salpetriere Hospital / UPMC, 

Paris, France 

12:15 PM 

2640. Methotrexate Adverse Events in a Cohort of US Veterans 

with Rheumatoid Arthritis 

Lisa A. Davis 1 , Brooke Ivan Polk 2 , Alyse D. Mann 3 , Gail S. Kerr 4 , 

Andreas M. Reimold 5 , Grant W. Cannon 6 , Ted R. Mikuls 7 and 

Liron Caplan 8 , 1 Univ of Colorado School of Med, Aurora, CO, 

2 

University of Colorado Medical School, Aurora, CO, 3 Denver VA 

Medical Center, Denver, CO, 4 Washington DC VAMC, Georgetown 

and Howard University, Washington, DC, 5 Dallas VA and 

University of Texas Southwestern, Dallas, TX, 6 George E. Wahlen 

VA Medical Center, Salt Lake City, UT, 7 Omaha VA and University 

of Nebraska Medical Center, Omaha, NE, 8 Denver VA and 

University of Colorado School of Medicine, Aurora, CO 

202 B 

Fibromyalgia and Soft Tissue Disorders II 

Moderators: Mary-Ann Fitzcharles, MBChB, MD and Dennis Ang, 

MD 

11:00 AM 

2641. Time-to-Improvement of Pain and Sleep in Clinical Trials 

of Pregabalin Treatment of Fibromyalgia 

Lesley M. Arnold 1 , Andrew Clair 2 , Birol Emir 2 , Lynne Pauer 2 and

E. Malca Resnick 2 , 1 University of Cincinnati College of Medicine, 

Cincinnati, OH, 2 Pfizer Inc, New York, NY 

11:15 AM 

2642. Rate and Predictors of Work Disability in Fibromyalgia 

Frederick Wolfe 1 , Brian T. Walitt 2 , Robert S. Katz 3 and Winfried 

Häuser 4 , 1 National Data Bank for Rheumatic Diseases, Wichita, 

KS, 2 Washington Hospital Center, Washington, DC, 3 Rush 

University Medical Center, Chicago, IL, 4 Technische Universität 

München, Munich, Germany 

11:30 AM 

2643. Grey Matter Decrease in Fibromyalgia Is Related to Pain 

Catastrophizing and Pain Sensitivity 

Marta Ceko, Mary-Ann Fitzcharles, M. Catherine Bushnell and 

Petra Schweinhardt, McGill University, Montreal, QC 

11:45 AM 

2644. Functional Magnetic Resonance Imaging of Working 

Memory in Fibromyalgia: Support for a “Competing Demands” 

Theory of Cognitive Function in Chronic Pain 

Anson E. Kairys, Gabriela Ramirez, Eric Ichesco, Johnson P. 

Hampson, Richard E. Harris, Daniel J. Clauw, Tobias Schmidt- 

Wilcke and Jennifer M. Glass, University of Michigan, Ann Arbor, 

MI 

Noon 

2645. The Transcription Factor Mohawk Plays an Important 

Role for Maintaining Human Anterior Cruciate Ligament 

Homeostasis 

Hiroyuki Nakahara, Akihiko Hasegawa, Fumiaki Ayabe, Tetsuya 

Matsukawa, Koji Otabe, Tomo Yonezawa, Martin K. Lotz and 

Hiroshi Asahara, The Scripps Research Institute, La Jolla, CA 

12:15 PM 

2646. Cost-Effectiveness of Tai Chi Mind-Body Exercise for the 

Treatment of Fibromyalgia 

John B. Wong and Chenchen Wang, Tufts Medical Center, 

Boston, MA 

11:30 AM 

2649. Trends in US Arthroplasty Rates 1991-2005: Patients with 

Inflammatory Arthritis Continue to Require Joint Replacement 

Christina Mertelsmann-Voss 1 , Ting Jung Pan 2 , Stephen L. Lyman 3 , 

Mark P. Figgie 2 and Lisa A. Mandl 2 , 1 Hospital for Special Surgery, 

Cornell University, New York, NY, 2 Hospital for Special Surgery, 

New York, NY, 3 Hospital Special Surgery, New York, NY 

11:45 AM 

2650. The Meteor Trial: Preliminary Results of an RCT of 

Arthroscopic Partial Meniscectomy Vs. Physical Therapy in 

Patients greater Than 45 

Jeffrey N. Katz 1 , Christine E. Chaisson 2 , Brian Cole 3 , Laurel 

Donnell-Fink 1 , Morgan Jones 4 , Bruce Levy 5 , Lisa A. Mandl 6 , Scott 

Martin 1 , Robert Marx 6 , Anthony Miniaci 4 , Joseph Palmisano 7 , 

Emily Reinke 8 , Clare Safran-Norton 1 , Debra J. Skoniecki 9 , Daniel 

Hal Solomon 9 , Kurt P. Spindler 8 , John Wright 1 , Rick Wright 10 and 

Elena Losina 1 , 1 Brigham and Women’s Hospital, Boston, MA, 

2 

Boston University School of Public Health, Boston, MA, 3 Rush 

University, Chicago, IL, 4 Cleveland Clinic, Cleveland, OH, 5 Mayo 

Clinic, Rochester, MN, 6 Hospital for Special Surgery, New York, 

NY, 7 Boston University School of Public Health, 8 Vanderbilt 

University, Nashville, TN, 9 Brigham & Womens Hospital, Boston, 

MA, 10 Washington University, MO 

Noon 

2651. Associations Between Body Mass Index and Physical 

Activity Following Total Knee Replacement 

Carol A. Oatis 1 , Wenjun Li 2 , Milagros Rosal 2 , David Ayers 2 

and Patricia D. Franklin 2 , 1 Arcadia University, Glenside, PA, 

2 

University of Massachusetts Medical School, Worcester, MA 

12:15 PM 

2652. Benefits of Aerobic Training in Patients with Ankylosing 

Spondylitis Are Not Coupled by Effects On Cytokines: A 

Randomized Controlled Trial 

Fabio Jennings, Hilda A. Oliveira, Marcelo C. Sousa, Vaneska G. 

Cruz, Fabio S. Lira and Jamil Natour, Universidade Federal de Sao 

Paulo, Sao Paulo, Brazil 

145 A 

Orthopedics, Low Back Pain, and Rehabilitation 

Moderators: Leena Sharma, MD and Agustin Escalante, MD 

11:00 AM 

2647. Effects of Pain Expectations On Neuromuscular Control 

of the Spine in Patients with Chronic Low Back Pain and 

Healthy Participants 

Yves Henchoz, Charles Tétreau, Jacques Abboud, Mathieu Piché 

and Martin Descarreaux, Université du Québec à Trois-Rivières, 

Trois-Rivières, QC 

11:15 AM 

2648. Randomized Placebo-Controlled Trial of Local Steroid 

Injection for Moderately Severe Carpal Tunnel Syndrome 

Isam Atroshi 1 , Magnus Flondell 2 and Manfred Hofer 3 , 1 Lund 

University, Hässleholm, Sweden, 2 Lund University, Malmö, 

Sweden, 3 Kristianstad Hospital, Kristianstad, Sweden 

143 A 

Pediatric Rheumatology - Pathogenesis and Genetics 

Moderators: Anthony R. French, MD and James W. Verbsky, MD, 

PhD 

11:00 AM 

2653. A Subset of up-Regulated IFN Regulated Genes in Candle 

Patients Decrease with Treatment with a JAK Inhibitor 

Adriana Almeida de Jesus 1 , Yin Liu 2 , Gina A. Montealegre 2 , Adam 

L. Reinhardt 3 , Diane Brown 4 , Antonio Torrelo 5 , Angel V. Casano 6 , 

Lena Das 7 , Yongqing Chen 8 , Yan Huang 8 , Deborah Stone 9 , Dawn 

C. Chapelle 2 , Nicole Plass 10 , Steven H. Zuckerman 11 , William 

Macias 12 and Raphaela T. Goldbach-Mansky 13 , 1 National 

Institute of Arthritis Musculoskeletal and Skin Disease, National 

Institutes of Health, Bethesda, MD, 2 NIAMS, Bethesda, MD, 

3 

Children’s Hosp of Omaha/UNMC, Omaha, NE, 4 Children’s 

Hospital Los Angeles, Los Angeles, CA, 5 Departments of Pediatric 

Dermatology, Hospital Niño Jesús, Madrid, Spain, Madrid, Spain, 

6 

Meditex Spain, Malaga, Spain, 7 KK Women’s and Children’s 

Hospital, Singapore, Singapore, 8 Translational Autoinflammatory 

WEDNESDAY 



Disease Section, Office of the Clinical Director NIAMS, 

Bethesda, MD, 9 National Institutes of Health, Bethesda, MD, 

10 

National Institutes of Health Clinical Center, Bethesda, MD, 

11 

Lilly Research Labs, Indianapolis, IN, 12 Eli Lilly and Company, 

Indianapolis, IN, 13 Translational Autoinflammatory Diseases 

Section NIAMS NIH, Bethesda, MD 

11:15 AM 

2654. Genome-Wide Association Study of Methotrexate 

Response Identifies Novel Genes in a Large Cohort of European 

Juvenile Idiopathic Arthritis Cases 

Joanna Cobb 1 , Erika Cule 2 , Halima Moncrieffe 3 , Edward Flynn 4 , 

Anne Hinks 1 , Fiona Patrick 3 , Laura Kassoumeri 3 , Simona Ursu 3 , 

Maja Bulatovic 5 , Marek Bohm 6 , Bertrand D. van Zelst 7 , Pavla 

Dolezalova 6 , Robert De Jonge 7 , Nico M. Wulffraat 5 , Stanton 

Newman 8 , Maria de Iorio 3 , Lucy R. Wedderburn 3 and Wendy 

Thomson 1 , 1 Arthritis Research UK Epidemiology Unit, University 

of Manchester, Manchester, United Kingdom, 2 Imperial College 

London, United Kingdom, 3 University College London, London, 

United Kingdom, 4 University of Manchester, Manchester 

Academy of Health Sciences, Manchester, United Kingdom, 

5 

University Medical Centre Utrecht, Utrecht, Netherlands, 6 First 

Faculty of Medicine and General Faculty Hospital, Prague, Czech 

Republic, 7 Erasmus Medical Center, Rotterdam, Netherlands, 

8 

City University London, London, United Kingdom 

11:30 AM 

2655. Rapid and Effective Response to Immunosuppression in 

Treating Macrophage Activation Syndrome Associated with a 

Heterozygous Dominant Negative Mutation in RAB27a Leading 

to Decreased Cytolytic Activity 

Randy Q. Cron, Mingce Zhang, Christina J. Bemrich-Stolz and 

Timothy Beukelman, Univ of Alabama-Birmingham, Birmingham, 

AL 


Health, Bethesda, MD, 2 National Institutes of Health, National 

Human Genome Research Institute, Bethesda, MD, 3 Cincinnati 

Children’s Hospital Medical Center, Cincinnati, OH, 4 Arthritis 

Research UK Epidemiology Unit, Manchester, United Kingdom, 

5 

University of Genova, Genova, Italy, 6 Istituto Giannina Gaslini, 

Genova, Italy, 7 Hacettepe University, Ankara, Turkey, 8 Emory 

Children’s Center, Atlanta, GA, 9 University of Utah, Salt Lake City, 

UT, 10 The Cleveland Clinic, Cleveland, OH, 11 Children’s Hospital 

Montefiore, Bronx, NY, 12 Stanford University Med Ctr, Stanford, 

CA, 13 Hospital de Pediatria Garrahan, Buenos Aires, Argentina, 

14 

Universidade Federal de São Paulo / UNIFESP, Sao Paulo, 

Brazil, 15 Instituto de Pediatria e Puericultura Martagão Gesteira 

(IPPMG) da Universidade Federal do Rio de Janeiro (UFRJ), Rio 

de Janeiro, Brazil, 16 Hospital for Sick Children, Toronto, ON, 

17 

University College London (UCL), London, United Kingdom, 

18 

University Childrenxs Hospital, Barcelona, Spain, 19 National 

Human Genome Research Institute, Nationsl Institutes of 

Health, Bethesda, MD, 20 The Wellcome Trust Sanger Institute, 

Cambridge, United Kingdom, 21 Wake Forest School of Medicine, 

Winston-Salem, NC, 22 University College London, London, United 

Kingdom 

12:15 PM 

2658. Correlation Between Mefv Genotype and Interleukin 

(IL)1β secretion and Role of the nlr Family Pyrin Domain 

Containing 3 (Nlrp3) Inflammasome in Patients with Familial 

Mediterranean Fever (FMF) 

Alessia Omenetti 1 , Sonia Carta 2 , Delfino Laura 2 , Alberto Martini 3 , 

Anna Rubartelli 4 and Marco Gattorno 1 , 1 Pediatrics II Unit G 

Gaslini Institute, Genoa, Italy, 2 Cell Biology, lST-San Martino, 

Genoa, Italy, 3 Pediatrics ll Unit, G Gaslini lnstitute and University 

of Genoa, Genoa, Italy, 4 lST-San Martino, Genoa, Italy, Genoa, 

Italy 

WEDNESDAY 


11:45 AM 

2656. Elevated Serum Follistatin-Like Protein 1 Suggests 

an Interleukin-1 Independent Pathway for Inflammation in 

Patients with Cryopyrin Associated Periodic Syndromes 

Mark Gorelik 1 , Daniel Bushnell 2 , Raphaela T. Goldbach-Mansky 3 , 

Hal M. Hoffman 4 and Raphael Hirsch 5 , 1 Univ of Pittsburgh Med 

Ctr Children’s Hospital, Pittsburgh, PA, 2 Childrens Hospital 

Pittsburgh, Pittsburgh, PA, 3 Translational Autoinflammatory 

Diseases Section NIAMS NIH, Bethesda, MD, 4 University of 

California at San Diego, La Jolla, CA, 5 Childrens Hosp Pittsburgh, 


Noon 

2657. Genome-Wide Association Meta-Analysis of Eight 

Independent Systemic Juvenile Idiopathic Arthritis 

Collections Reveals Regional Association Spanning the Major 

Histocompatibility Complex Class II and III Gene Cluster 

Michael J. Ombrello 1 , Elaine Remmers 2 , Alexei A. Grom 3 , Wendy 

Thomson 4 , Alberto Martini 5 , Marco Gattorno 6 , Seza Ozen 7 , 

Sampath Prahalad 8 , John F. Bohnsack 9 , Andrew Zeft 10 , Norman 

T. Ilowite 11 , Elizabeth D. Mellins 12 , Ricardo A. G. Russo 13 , Claudio 

Len 14 , Sheila K. Oliveira 15 , Rae SM Yeung 16 , Lucy R. Wedderburn 17 , 

Jordi Anton Lopez 18 , Colleen Satorius 19 , Ioanna Tachmazidou 20 , 

Carl D. Langefeld 21 , Eleftheria Zeggini 20 , Susan D. Thompson 3 , 

Patricia Woo 22 and Daniel L. Kastner 1 , 1 National 

Ballroom A 

Rheumatoid Arthritis - Clinical Aspects VII: Prediction 

of Outcome in Rheumatoid Arthritis 

Moderators: Merete L. Hetland, MD, PhD, DMSc and Yvonne C. 

Lee, MD, MMedSc 

11:00 AM 

2659. An Expanded Repertoire of Anti-Citrullinated Peptide 

Antibodies Is Associated with Interstitial Lung Disease in 


Jon T. Giles 1 , Sonye Danoff 2 , Jeremy Sokolove 3 , Robert 

Winchester 4 , Dimitrios A. Pappas 5 , Catriona Cramb 6 , Geoffrey 

Connors 7 , Stanley S. Siegelman 8 , William H. Robinson 9 and Joan 

M. Bathon 1 , 1 Columbia University Medical Center, New York, 

NY, 2 Johns Hopkins School of Medicine, Baltimore, MD, 3 VA 

Palo Alto Health Care System and Stanford University, Palo Alto, 

CA, 4 Columbia University, New York, NY, 5 Columbia University, 

College of Physicians and Surgeons, New York, NY, 6 VA Palo 

Alto Heatlh Care System and Stanford University, Palo Alto, 

CA, 7 Division of Pulmonary and Critical Care Medicine, Yale 

University, New Haven, CT, 8 Department of Radiology, Johns 

Hopkins University, Baltimore, MD, 9 Stanford University, Palo 

Alto, CA 

132 

2012 Program Book

11:15 AM 

2660. Progressive Radiographic Joint Damage in Established 

Rheumatoid Arthritis: Common and Strongly Associated with 

Seropositivity 

Siri Lillegraven 1 , Nancy A. Shadick 2 , Zarif Jabbar-Lopez 3 , Anna 

Potapov 3 , Michelle A. Frits 2 , Christine K. Iannaccone 2 , Espen A. 

Haavardsholm 1 , Tore K. Kvien 1 , Michael Weinblatt 2 and Daniel 

H. Solomon 2 , 1 Diakonhjemmet Hospital, Oslo, Norway, 2 Brigham 

and Women’s Hospital, Boston, MA, 3 Harvard School of Public 

Health, Boston, MA 

11:30 AM 

2661. Disease Activity Score 28-Joint Count: Are Erythrocyte 

Sedimentation Rate and C-Reactive Protein Versions 

Comparable? 

Roy M. Fleischmann 1 , Désirée van der Heijde 2 , Andrew S. 

Koenig 3 , Ronald Pedersen 3 , Annette Szumski 3 , Lisa Marshall 3 

and Eustratios Bananis 3 , 1 University of Texas, Dallas, TX, 2 Leiden 

University Medical Center, Leiden, Netherlands, 3 Pfizer Inc., 

Collegeville, PA 

11:45 AM 

2662. Tightening up: Musculoskeletal Ultrasound Could 

Further Individualise Treatment Decisions in Early Rheumatoid 

Arthritis Patients Treated by a Step-up DMARD Escalation 

Regimen 

James Dale 1 , David Purves 1 , Alex McConnachie 1 , Duncan Porter 2 

and Iain B. McInnes 1 , 1 University of Glasgow, Glasgow, United 

Kingdom, 2 Gartnavel General Hosp, Glasgow, United Kingdom 

Noon 

2663. A Variant in the Osteoprotegerin Gene Is Associated 

with Coronary Atherosclerosis in Patients with Rheumatoid 

Arthritis: Results From a Candidate Gene Study 

Cecilia P. Chung 1 , Joseph F. Solus 1 , Annette Oeser 1 , Chun Li 1 , 

Paolo Raggi 2 , Jeffrey R. Smith 1 and C. Michael Stein 1 , 1 Vanderbilt 

University, Nashville, TN, 2 Emory University, Atlanta, GA 

12:15 PM 

2664. A Multi-Biomarker Disease Activity (VECTRA DA 

Algorithm) Score Reflects Clinical Disease Activity and Tracks 

Responses in Patients with Rheumatoid Arthritis Treated with 

Either Adalimumab, Etanercept, and Infliximab 

Shintaro Hirata 1 , Douglas J. Haney 2 , Guy Cavet 2 , Rebecca Bolce 2 , 

Wanying Li 2 , Nadine Defranoux 2 , David Chernoff 2 , Kunihiro 

Yamaoka 1 , Kazuyoshi Saito 1 and Yoshiya Tanaka 1 , 1 University 

of Occupational and Environmental Health, Japan, Kitakyushu, 

Japan, 2 Crescendo Bioscience Inc., South San Francisco, CA 

146 C 


Pathogenesis II: Cellular Effectors of Rheumatoid 

Arthritis and Novel Rheumatoid Arthritis Genome- 

Wide Association Studies 

Moderators: David S. Pisetsky, MD, PhD and Pierre Miossec, MD, 

PhD 

11:00 AM 

2665. Metabolic Reprogramming of Autoimmune T Cells in 


Zhen Yang 1 , Hiroshi Fujii 2 , Shalini Mohan 1 , Jorg J. Goronzy 1 and 

Cornelia M. Weyand 1 , 1 Stanford University School of Medicine, 

Stanford, CA, 2 Tohoku University, Sendai, Japan 

11:15 AM 

2666. A Link Between B Cells and Bone Erosion in RA: RANKL 

Production by Memory B Cells 

Nida Meednu, Teresa Owen, Hengwei Zhang, Christopher A. 

Cistrone, Lianping Xing and Jennifer H. Anolik, University of 

Rochester, Rochester, NY 

11:30 AM 

2667. Activated Memory B Cell Compartment in Rheumatoid 

Arthritis: Impact of B Cell Depletion Therapy 

Diana G. Adlowitz 1 , Jennifer Hossler 1 , Jamie Biear 1 , Christopher 

A. Cistrone 1 , Teresa Owen 1 , Wensheng Wang 1 , Arumugam 

Palanichamy 1 , Ignacio Sanz 2 and Jennifer H. Anolik 1 , 1 University 

of Rochester Medical Center, Rochester, NY, 2 Emory University, 

Atlanta, GA 

11:45 AM 

2668. Interferon and B-Cell Gene Signatures Contribute to 

Diagnosis of pre-Clinical Rheumatoid Arthritis 

Joyce Lubbers 1 , Lotte A. van de Stadt 2 , Saskia Vosslamber 1 , 

John G. Wesseling 1 , Dirkjan van Schaardenburg 2 and Cornelis 

L. Verweij 1 , 1 VU University Medical Center, Amsterdam, 

Netherlands, 2 Jan van Breemen Research Institute | Reade, 


Noon 

2669. TLR7 Ligation Contributes to Monocyte Migration in 


Nathan D. Chamberlain 1 , Seung-jae Kim 1 , Michael Volin 2 , William 

Swedler 1 , Suncica Volkov 3 and Shiva Shahrara 1 , 1 University of 

Illinois at Chicago, Chicago, IL, 2 Chicago College of Osteopathic 

Medicine Midwestern University, Downers Grove, IL, 3 University 

of Illinios at Chicago, Chicago, IL 

12:15 PM 

2670. Genome-Wide Association Study On the Severity of Joint 

Destruction in Autoantibody Positive Rheumatoid Arthritis 

Identifies a Role for Sperm Associated Antigen 16 

Rachel Knevel 1 , Kerstin Klein 2 , Klaartje Somers 3 , Caroline 

Ospelt 4 , Jeanine J. Houwing-Duistermaat 5 , Jessica van Nies 1 , 

Diederik P.C. de Rooy 1 , Laura de Bock 3 , Joris Schonkeren 1 , Gerrie 

Stoeken-Rijsbergen 1 , Jenna Kiridly 6 , Luis Rodriguez-Rodriguez 6 , 

Quinta Helmer 5 , Piet Sinissen 3 , Tom W. J. Huizinga 1 , René 

E.M. Toes 7 , Steffen Gay 8 , Peter K. Gregersen 9 , Veerle Somers 3 

and Annette H.M. van der Helm - van Mil 1 , 1 Leiden University 

Medical Center, Leiden, Netherlands, 2 Center of Experimental 

Rheumatology, University Hospital Zurich and Zurich Center 

of Integrative Human Physiology (ZIHP), Zurich, Switzerland, 

3 

Hasselt University, Biomedical Research Institute, Belgium, 

4 

Center of Experimental Rheumatology, University Hospital 

Zurich and Zurich Center of Integrative Human Physiology 

(ZIHP), Switzerland, Zurich, Switzerland, 5 Department of Medical 

Statistics and Bioinformatics, Leiden, Netherlands, 6 Feinstein 

Institute for Medical Research and North Shore–Long Island 

WEDNESDAY 



WEDNESDAY 


Jewish Health System, Manhasset, New York, 7 Leiden University 

Medical Centre, Leiden, Netherlands, 8 Center of Experimental 

Rheumatology, University Hospital Zurich, Zurich, Switzerland, 

9 

Feinstein Institute Medical Research and North Shore-Long 

Island Jewish Health System, Manhasset, NY 

147 A 

Sjögren’s Syndrome I - Pathogenesis 

Moderators: Xavier Mariette, MD, PhD and Lindsey A. Criswell, 

MD, MPH 

11:00 AM 

2671. A Genome-Wide Association Study Establishes Multiple 

Susceptibility Loci for Sjögren’s Syndrome 

Christopher J. Lessard 1 , He Li 2 , Indra Adrianto 3 , John A. Ice 3 , 

Roland Jonsson 4 , Gabor G. Illei 5 , Maureen Rischmueller 6 , Gunnel 

Nordmark 7 , Xavier Mariette 8 , Corinne Miceli-Richard 9 , Marie 

Wahren-Herlenius 10 , Torsten Witte 11 , Michael T. Brennan 12 , 

Roald Omdal 13 , Patrick M. Gaffney 14 , James A. Lessard 15 , Wan-Fai 

Ng 16 , Nelson L. Rhodus 17 , Barbara M. Segal 18 , R. Hal Scofield 3 , 

Judith A. James 19 , Juan-Manuel Anaya 20 , John B. Harley 21 , 

Courtney G. Montgomery 3 and Kathy Moser Sivils 3 , 1 Oklahoma 

Medical Research Foundation; University of Oklahoma Health 

Sciences Center, Oklahoma City, OK, 2 Oklahoma Medical 

Research Foundation, Oklahoma CIty, 3 Oklahoma Medical 

Research Foundation, Oklahoma City, OK, 4 University of Bergen, 

Bergen, Norway, 5 NIDCR/ NIH, Bethesda, MD, 6 Queen Elizabeth 

Hospital, Adelaide, Australia, 7 Rheumatology, Uppsala, Sweden, 

8 

Université Paris-Sud, Le Kremlin Bicetre, France, 9 Hopital 

Bicêtre, Le Kremlin Bicêtre, France, 10 Karolinska Institutet, 

Stockholm, Sweden, 11 Hannover Medical School, Hanover, 

Germany, 12 Carolinas Medical Center, Charlotte, NC, 13 Clinical 

Immunology Unit, Department of Internal Medicine, Stavanger 

University Hospital, Stavanger, Norway, 14 Arthritis & Clinical 


Oklahoma City, OK, 15 Valley Bone & Joint Clinic, Grand Forks, 

ND, 16 Newcastle University, Newcastle, England, 17 University 

of Minnesota, Minneapolis, MN, 18 Hennepin County Medical 

Center, Minneapolis, MN, 19 Oklahoma Medical Research 

Foundation and Oklahoma University Health Sciences Center, 

Oklahoma City, OK, 20 Universidad del Rosario-Corporacion 

para Investigaciones Biologicas, Bogota, Colombia, 21 Cincinnati 

Children’s Hospital Medical Center; US Department of Veterans 

Affairs Medical Center, Cincinnati, OH 

11:15 AM 

2672. Genome-Wide Association Analysis Reveals Genetic 

Heterogeneity of Sjögren’s Syndrome (SS) According to Specific 

Subphenotypes and Ancestry 

Lindsey A. Criswell 1 , Kimberly E. Taylor 1 , Caitlin McHugh 2 , Cathy 

Laurie 2 , Kimberly Doheny 3 , Mi Y. Lam 1 , Joanne Nititham 4 , Laura 

Bierut 5 , Emily L. Harris 6 , Alan N. Baer 7 , Stephen Challacombe 8 , 

Yi Dong 9 , Hector Lanfranchi 10 , Morten Schiodt 11 , M. Srinivasan 12 , 

Susumu Sugai 13 , Hisanori Umehara 14 , Frederick B. Vivino 15 , 

Zhao Yan 16 , Steve Shiboski 1 , Troy Daniels 17 , John S. Greenspan 1 , 

Caroline Shiboski 1 and SICCA 18 , 1 University of California, San 

Francisco, San Francisco, CA, 2 University of Washington, Seattle, 

WA, 3 Center for Inherited Disease Research, Baltimore, MD, 

4 

Rosalind Russell Medical Research Center for Arthritis, San 

Francisco, CA, 5 Washington University, St. Louis, MO, 6 National 

Institute of Dental and Craniofacial Research, Bethesda, MD, 

7 

Johns Hopkins University, Baltimore, MD, 8 Kings College London, 

London, United Kingdom, 9 Peking Univ Med Coll Hospital, East 

City Beijing, China, 10 University of Buenos Aires, Buenos Aires, 

Argentina, 11 Righospitalet, Copenhagen, Denmark, 12 Aravind 

Eye Hospital, Madurai, India, 13 Kanazawa Medical University, 

Ishikawa, Japan, 14 Kanazawa Medical University, Kanazawa, 

Japan, 15 Penn Presbyt Med Ctr, Philadelphia, PA, 16 Peking Union 

Medical College Hospital, Beijing, China, 17 UCSF Schools of 

Medicine & Dentistry, San Francisco, CA, 18 San Francisco 

11:30 AM 

2673. Sibling Relative Risk and Heritability of Sjögren’s 

Syndrome: A Nationwide Population Study in Taiwan 

Chang-Fu Kuo 1 , Matthew J. Grainge 1 , Kuang-Hui Yu 2 , Lai-Chu 

See 3 , Shue-Fen Luo 2 , Ana M. Valdes 4 , I-Jun Chou 2 , Hsiao-Chun 

Chang 2 , Weiya Zhang 1 and Michael Doherty 1 , 1 University of 

Nottingham, Nottingham, United Kingdom, 2 Chang Gung 

Memorial Hospital, Taoyuan, Taiwan, 3 Chang Gung University, 

Taoyuan, Taiwan, 4 Dept of Twin Research and Genetic 

Epidemiology, St. Thomas’ Hospital, King’s College London, 


11:45 AM 

2674. Cis-Expression Quantitative Trait Loci Analysis of 

Dysregulated Interferon-Pathway Genes Identifies HLA-C 

and OAS1 As Novel Candidates for Susceptibility to Sjögren’s 

Syndrome 

He Li 1 , John A. Ice 2 , Jennifer A. Kelly 2 , Indra Adrianto 2 , Stuart B. 

Glenn 2 , Kimberly S. Hefner 3 , Evan G. Vista 4 , Donald U. Stone 5 , 

Raj Gopalakrishnan 6 , Glen D. Houston 5 , David M. Lewis 5 , 

Michael Rohrer 6 , Pamela Hughes 6 , John B. Harley 7 , Courtney G. 

Montgomery 2 , James Chodosh 5 , James A. Lessard 8 , Juan-Manuel 

Anaya 9 , Barbara M. Segal 10 , Nelson L. Rhodus 6 , Lida Radfar 5 , 

Mark B. Frank 2 , R. Hal Scofield 2 , Christopher J. Lessard 1 and 

Kathy Moser Sivils 2 , 1 Oklahoma Medical Research Foundation; 

University of Oklahoma Health Sciences Center, Oklahoma 

City, OK, 2 Oklahoma Medical Research Foundation, Oklahoma 

City, OK, 3 Hefner Eye Care and Optical Center, Oklahoma 

City, OK, 4 University of Santo Tomas, Taguig City, Philippines, 

5 

University of Oklahoma Health Sciences Center, Oklahoma City, 

OK, 6 University of Minnesota, Minneapolis, MN, 7 Cincinnati 

Children’s Hospital Medical Center; US Department of Veterans 

Affairs Medical Center, Cincinnati, OH, 8 Valley Bone & Joint 

Clinic, Grand Forks, ND, 9 Universidad del Rosario-Corporacion 

para Investigaciones Biologicas, Bogota, Colombia, 10 Hennepin 

County Medical Center, Minneapolis, MN 

Noon 

2675. Oral and Gut Microbiota Influence Immune Responses to 

Sjogren’s Syndrome Associated Antigen Ro60 

Agnieszka Szymula, Barbara Szczerba, Harini Bagavant, Shu-Man 

Fu and Umesh Deshmukh, University of Virginia, Charlottesville, 

VA 

12:15 PM 

2676. Long-Term Humoral Autoimmunity to Ro60 in Primary 

Sjögren’s Syndrome Is Driven by Clonal Succession 

Rhianna Lindop 1 , Isabell Bastian 1 , Georgia Arentz 1 , Lauren 

134 

2012 Program Book

Thurgood 1 , Andrew Whyte 1 , Tim, K. Chataway 2 , Michael Jackson 1 

and Tom Gordon 1 , 1 Flinders Medical Centre and Flinders 

University, Adelaide, Australia, 2 Flinders University, Adelaide, 

Australia 

152 A 

Systemic Lupus Erythematosus - Animal Models 

Moderators: Keith B. Elkon, MBBCh and Ram P. Singh, PhD 

12:15 PM 

2682. Calcium/Calmodulin-Dependent Protein Kinase IV 

Suppresses IL-2 Production and Regulatory T Cell Activity in 


Tomohiro Koga 1 , Kunihiro Ichinose 2 , Masayuki Mizui 1 , José C. 

Crispín 1 and George C. Tsokos 1 , 1 Beth Israel Deaconess Medical 

Center, Harvard Medical School, Boston, MA, 2 Nagasaki 

University Graduate School of Biomedical Sciences, Nagasaki, 

Japan 

11:00 AM 

2677. IL-23 Controls Autoimmunity by Facilitating Clearance of 

Apoptotic Bodies in the Marginal Zone in Lupus-Prone BXD2 

Mice 

Hao Li 1 , Hui-Chen Hsu 1 , Qi Wu 1 , PingAr Yang 1 , Jun Li 1 , Daniel 

Cua 2 , Mohamed Oukka 3 and John D. Mountz 4 , 1 University of 

Alabama at Birmingham, Birmingham, AL, 2 Merck Research 

Laboratory, Palo Alto, CA, 3 Seattle, WA, 4 University of 

Alabama at Birmingham and Birmingham VA Medical Center, 


11:15 AM 

2678. Novel Nuclear Export Inhibitors Deplete Autoreactive 

Plasma Cells and Protect Mice with Lupus-Like Disease From 

Nephritis 

Teresa Owen 1 , Wensheng Wang 1 , Dilara McCauley 2 , Laura 

Strojny 1 , Jennifer Hossler 1 , Javier Rangel-Moreno 1 , Michael 

Kauffman 2 , Sharon Shacham 2 and Jennifer H. Anolik 1 , 1 University 

of Rochester Medical Center, Rochester, NY, 2 Karyopharm, 

Therapeutics Inc., Natick, MA 

11:30 AM 

2679. Loss of Caspase 8 in Dendritic Cells Induces a Systemic 

Lupus Erythematosus-Like Disease That Is Independent of the 

Necroptosome 

Carla M. Cuda 1 , Alexander V. Misharin 2 , Rana Saber 2 , G. 

Kenneth Haines III 3 , Jack Hutcheson 4 , Chandra Mohan 4 and 

Harris R. Perlman 2 , 1 Northwestern University Feinberg School 

of Medicine, Chicago, IL, 2 Northwestern University, Chicago, 

IL, 3 Yale University, New Haven, CT, 4 University of Texas 

Southwestern Medical Center, Dallas, TX 

11:45 AM 

2680. Soluble Receptor for Advanced Glycation End Products 

Alleviates Nephritis in NZB/WF1 Mice 

Sang-Won Lee 1 , Kyu-Hyoung Park 1 , Sungha Park 2 , Ji-Hye Kim 1 , 

Sung-You Hong 2 , Soo Kon Lee 1 , Donghoon Choi 2 and Yong-Beom 

Park 1 , 1 Yonse University College of Medicine, Seoul, South Korea, 

2 

Yonsei University College of Medicine, Seoul, South Korea 

Noon 

2681. Blocking the Serum Protease Inhibitor Activity of 

Plasminogen Activator Inhibitor-1 Protects Mice From 

Development of Glomerulonephritis in a Model of Lupus 

Nephritis 

Brian Naiman 1 , Tracy Delaney 1 , Lily Cheng 1 , Philip Brohawn 1 , 

Chris Morehouse 1 , Christopher Groves 1 , Isabelle de-Mendez 2 , 

Dominic Corkill 2 , Anthony Coyle 3 , Ronald Herbst 1 and Jane 

Connor 1 , 1 MedImmune, LLC, Gaithersburg, MD, 2 MedImmune, 

LLC, Cambridge, United Kingdom, 3 Pfizer, Inc. (formerly 

MedImmune LLC, Gaithersburg, MD, USA), Cambridge, MA 

Ballroom B 


Treatment V: Clinical Aspects 

Moderators: Kenneth C. Kalunian, MD and Maureen A. 

McMahon, MD 

11:00 AM 

2683. Interferon-Associated Cytokine and Chemokine 

Expression in Patients with Serologically Active Clinically 

Quiescent (SACQ) Systemic Lupus Erythematosus (SLE) 

Amanda J. Steiman 1 , Murray B. Urowitz 1 , Dominique Ibanez 1 , 

Carolina Landolt-Marticorena 2 , Dafna D. Gladman 3 and Joan E. 

Wither 4 , 1 Toronto Western Hospital and University of Toronto, 

Toronto, ON, 2 University of Toronto, Toronto, ON, 3 Toronto 

Western Research Institute, University of Toronto, University 

Health Network, Toronto, ON, 4 Toronto Western Research 

Institute, University Health Network, Toronto, ON 

11:15 AM 

2684. Cerebrospinal Fluid IL-6 and Anti-NMDA Receptor NR2 

Antibodies As Surrogate Markers for CNS Disease Severity in 

SLE 

Shunsei Hirohata, Yoshiyuki Arinuma and Eisuke Ogawa, Kitasato 

University School of Medicine, Sagamihara, Japan 

11:30 AM 

2685. Overall and Cause Specific Mortality in Patients 

with Systemic Lupus Erythematosus. A Meta-Analysis of 

Observational Studies 

Marko Yurkovich 1 , Kateryna Vostretsova 2 and J. Antonio 

Avina-Zubieta 3 , 1 University of British Columbia, Vancouver, BC, 

2 

University of British Columbia, Vancouver, 3 Arthritis Research 

Centre of Canada/University of British Columbia, Richmond, BC 

11:45 AM 

2686. Difference in Clinical Features and Mortality 

Between Pediatric-Onset and Adult-Onset Systemic Lupus 

Erythematosus 

So-Yeon Park 1 , Jeeseon Shim 2 , Dam Kim 1 , Ji-Young Choi 1 , So- 

Young Bang 3 , Chan-Bum Choi 4 and Sang-Cheol Bae 4 , 1 Hanyang 

University Hospital for Rheumatic Diseases, Seoul, South Korea, 

2 

Clinical Research Center for Rheumatoid Arthritis (CRCRA), 

Seoul, South Korea, 3 Hanyang University Guri Hospital, Guri, 

South Korea, 4 Hanyang University Hospital for Rheumatic 

Diseases, Clinical Research Center for Rheumatoid Arthritis 

(CRCRA), Seoul, South Korea 

WEDNESDAY 



WEDNESDAY 


Noon 

2687. Modular Microarray Analysis Fails to Reveal a Significant 

Biological Effect of Vitamin D 3 Treatment in Patients 

Participating in a Double-Blind Randomized Placebo-Controlled 

Trial of the Effect of Vitamin D 3 On the Interferon Signature in 

Patients with Systemic Lupus Erythematosus 

Michaela Oswald 1 , Cynthia Aranow 2 , Diane L. Kamen 3 , Meggan 

C. Mackay 4 , Ellen A. Goldmuntz 5 , Betty Diamond 6 , Peter K. 

Gregersen 7 and ALE02 Study Team 8 , 1 The Feinstein Institute 

for Medical Research, Manhasset, NY, 2 Feinstein Institute 

for Medical Research, Manhasset, NY, 3 Arthritis & Clinical 


Charleston, SC, 4 The Feinstein Institute, Manhasset, NY, 5 NIAID/ 

NIH Rm 6807, Bethesda, MD, 6 Feinstein Institute Med Rsch, 

Manhasset, NY, 7 Feinstein Institute Medical Research and 

North Shore-Long Island Jewish Health System, Manhasset, NY, 

8 

Bethesda, MD 

12:15 PM 

2688. The Health Improvement and Prevention Program in 

Systemic Lupus Erythematosus Demonstrates Improvement in 

Mental Health and Framingham Risk Score At One Year 

Paul R. Fortin 1 , Ellie Aghdassi 2 , Anne Cymet 3 , Stacey Morrison 4 , 

Willy Wynant 5 , Janet E. Pope 6 , Sara Hewitt 7 , Christian A. 

Pineau 8 , Carolyn Neville 9 , Paula Harvey 10 , Jean-Claude Tardif 11 , 

Michal Abrahamowicz 12 and Deborah DaCosta 13 , 1 Division of 

Rheumatology, Centre de recherche du centre hospitalier 

universitaire de Québec, Faculté de médecine de L’université 

Laval, Quebec City, QC, 2 University Health Network Research 

Institute - Western Division, Toronto, ON, 3 University Health 

Network - Western Division, Toronto, ON, 4 The Toronto Western 

Hospital, Toronto, ON, 5 McGill University Health Centre and 

McGill University, Montreal, QC, 6 Western University of Canada, 

St. Joseph’s Health Care, London, ON, 7 St. Joseph’s Health Care, 

University of Western Ontario, London, ON, 8 McGill University 

Health Centre, Montreal, QC, 9 Royal Victoria Hospital, Montreal, 

QC, 10 Women’s College Hospital, Toronto, ON, 11 Universite de 

Montreal endowed research chair in atherosclerosis, Quebec, 

QC, 12 McGill University, Montreal, QC, 13 Montreal General 

Hospital, Montreal 

ARHP SESSIONS 

11:00 AM - 12:30 PM 

201 

Highlights from the 2012 ARHP Sessions 

Moderator: To be announced 

Speakers: Donah Z. Crawford, BS, MA and Robert R. McLean, 

DSc, MPH 


• list the highlights from the 2012 ARHP abstracts, presentations 

and sessions 

• gain better awareness of the diversity of ARHP presentations 

• assess the most important trends in ARHP research 

PM 

PS 

206 

PM 

PS 

Shoulder Pain and Rotator Cuff Tear in Rheumatoid 

Arthritis 



• review a basic overview of the anatomic structure and 

function of the shoulder 

• describe how rheumatologic conditions result in an abnormal 

physiologic state 

• summarize the clinical assessment of shoulder pain and the 

use of diagnostic testing 

• evaluate the management of shoulder pain (with special focus 

on rotator cuff tears) from the orthopedic surgeon, physical 

therapy and physiatrist perspective 

11:00 AM 

Shoulder Pain: Pathophysiology, Assessment, and Medical 

Management 

Nitin Jain, MD, MSPH 

11:45 AM 

Shoulder Pain Management from the Physical Therapy 

Perspective 

Robert Gillanders, PT, DPT 


11:00 AM - 12:30 PM 

140 A 

Factors Associated with Rheumatoid Arthritis 

Moderators: Beatriz Y. Hanaoka, MD and Afton L. Hassett, PsyD 

11:00 AM 

2689. Quality of Sleep, Physical Activity and Fatigue in Patients 

with Rheumatoid Arthritis. A Cross-Sectional Study 

Katrine Loeppenthin 1 , Bente Appel Esbensen 1 , Poul Jennum 2 , 

Mikkel Østergaard 3 , Tanja Thomsen 1 and Julie Midtgaard 4 , 

1 

Nursing and Health Science Research Unit, DK-2600 Glostrup, 

Denmark, 2 Danish Centre for Sleep Medicine, Department of 

Clinical Neurophysiology, DK-2600 Glostrup, Denmark, 3 Glostrup 

Hospital, Copenhagen, Denmark, 4 Health Care Research Centre, 


11:15 AM 

2690. Assessment of Sleep Quality in Patients with Rheumatoid 

Arthritis 

Ulku Ucar and Mehmet Tuncay Duruöz, Celal Bayar University 

Medical School, Manisa, Turkey 

11:30 AM 

2691. Factors Related to Objectively Measured Physical Activity 

in the Rheumatoid Arthritis Population 

Marie Tierney 1 , Alexander D. Fraser 2 and Norelee M. Kennedy 1 , 

1 

University of Limerick, Limerick, Ireland, 2 Mid Western Regional 

Hospital, Limerick, Ireland 

136 

2012 Program Book

11:45 AM 

2692. Diet and Other Lifestyle Related Factors and the Risk of 

Developing Rheumatoid Arthritis 

Björn Sundström 1 , Ingegerd Johansson 2 and Solbritt Rantapää 

Dahlqvist 3 , 1 Umeå University, Umeå, Sweden, 2 Umeå Universitet, 

Umeå, Sweden, 3 Umeå University Hospital, Umeå, Sweden 

Noon 

2693. Factors Associated with Person-Perceived Disability in 

Adults Aged 18+ with Rheumatoid Arthritis 

Yeliz Greenhill, Alison Hammond and Sarah Tyson, University of 

Salford, Manchester, United Kingdom 

12:15 PM 

2694. Examination of a Multidimensional Model of Disability 

and Role Functioning in Patients with Rheumatoid Arthritis 

Sarah R. Ormseth 1 , Taylor Draper 1 , M. Custodio 2 , M.H. 

Weisman 3 , M.R. Irwin 2 and Perry M. Nicassio 2 , 1 Loma Linda 

University, Loma Linda, CA, 2 UCLA, Los Angeles, CA, 3 Cedars- 

Sinai Medical Center, Los Angeles, CA 

204 A 


Moderators: Atul A. Deodhar, MD and Carol M. Greco, PhD 

Noon 

2699. Psychosocial Stress and Complement Activation 

Product C4d On Reticulocytes in Patients with Systemic Lupus 

Erythematosus 

Xiaotian Chen 1 , Yu Cheng 1 , Chau Ching Liu 2 , Amy H. Kao 2 , Susan 

Manzi 3 , Joseph M. Ahearn 3 and Carol M. Greco 1 , 1 University of 

Pittsburgh, Pittsburgh, PA, 2 Allegheny Singer Research Institute, 

Pittsburgh, PA, 3 West Penn Allegheny Health System, Pittsburgh, 

PA 

12:15 PM 

2700. A Multi-Center Study of the Appropriateness of Anti- 

Neutrophilic Cytoplasmic Antibody Testing 

Tarun S. Sharma, Vikash Sinha, Vino Unson, Saurav Acharya, 

Sahar Mohammadi and Amer Syed, Mount.Sinai School of 

Medicine-Jersey City Medical Center, Jersey City, NJ 

INDUSTRY-SUPPORTED POST SYMPOSIA 

1:00 - 4:00 PM 

For CME-accredited symposia, the sponsoring organization 

is responsible for planning and providing CME credit. Please 

visit the organization’s exhibit booth, the industry-supported 

symposia booth or see page 317 for more information. 

11:00 AM 

2695. Benefits of the Chronic Disease Self-Management 

Program in Low-Income African American Women with 

Systemic Lupus Erythematosus: Results of a Pilot Test 

Cristina Drenkard 1 , Charmayne M. Dunlop-Thomas 1 , Kirk 

Easley 1 , Gaobin Bao 1 , S. Sam Lim 1 and Teresa J. Brady 2 , 1 Emory 

University, Atlanta, GA, 2 Centers for Disease Control and 

Prevention, Atlanta, GA 

11:15 AM 

2696. The Mary Kirkland Center for Lupus Care General Health 

Assessment Initiative for Systemic Lupus Erythematosus 

Patients 

Monica C. Richey, Doruk Erkan and Kyriakos A. Kirou, Hospital 

for Special Surgery, New York, NY 

11:30 AM 

2697. The Short Term Effect of Individualized Nutrition 

Counseling On Nutrients and Select Cardiovascular Risk Factors 

in Patients with Systemic Lupus Erythematosus 

Sotiria Everett, Virginia Haiduc, Monica C. Richey and Doruk 

Erkan, Hospital for Special Surgery, New York, NY 

11:45 AM 

2698. FMS and SLE Patients Have Higher Treatment 

Expectations Than RA Patients 

Robert S. Katz 1 , Hannah Bond 2 , Jessica L. Polyak 2 , Lauren Kwan 2 

and Susan Shott 1 , 1 Rush University Medical Center, Chicago, IL, 

2 

Rheumatology Associates, Chicago, IL 

WEDNESDAY 




138 

Sunday, NOVEMBER 11, 2012 


Biology and Pathology of Bone and Joint 

1. Evaluation of Synovial Inflammation Assessed by 

Macroscopic and Histological Criteria in Patients with Knee 

Osteoarthritis. Montserrat Romera-Baures Sr. 1 , Ramon 

Valls-Garcia Sr. 2 , Antonio Rozadilla Sr. 3 , Marta Terricabras 

Sr.4 and Joan Miquel Nolla Sr. 5 , 1 Hospital Universitari 

Bellvitge, Barcelona, Spain, 2 Hospital de Palamos, Girona, 

Palamos (Girona), Spain, 3 Hospital Universitari de Bellvitge, 

Barcelona, Spain, 4 Hospital Universitari de Bellvitge., 

Barcelona, Spain, 5 Hospital Universitario de Bellvitge, 

Barcelona, Spain 

2. Microrna-558 Regulates the Expression of 

Cyclooxygenase-2 and IL-1beta Responses in Human 

Articular Chondrocytes. Su Jin Park, Eun-Jeong Cheon and 

Hyun Ah Kim, Hallym University Sacred Heart Hospital, 

Kyunggi, South Korea 

3. Mesenchymal Stem Cells Differentiate Into Osteoblasts in 

Response to Inflammation. Koshiro Sonomoto, Kunihiro 

Yamaoka, Koichi Oshita, Shunsuke Fukuyo, Xiangmei Zhang, 

Kazuhisa Nakano, Yosuke Okada and Yoshiya Tanaka, 

University of Occupational and Environmental Health, 

Kitakyushu, Japan 

4. Pro-Inflammatory Effect of Extracellular RNA on Synovial 

Fibroblasts From Patients with Rheumatoid Arthritis. 

Birgit Zimmermann 1 , Silvia Fischer 2 , Markus Rickert 3 , Stefan 

Rehart 4 , Angela Lehr 4 , Ulf Müller-Ladner 1 , Klaus T. Preissner 2 

and Elena Neumann 1 , 1 Justus-Liebig-University of Giessen, 

Kerckhoff-Klinik, Bad Nauheim, Germany, 2 Justus-Liebig- 

University of Giessen, Medical School, Giessen, Germany, 

3 

University Hospital Giessen and Marburg, Giessen, 

Germany, 4 Markus-Hospital, Frankfurt, Germany 

5. Adalimumab Inhibits TNF-Enhanced Human Osteoclast 

Development More Effectively Than Other Biologic Agents 

Under in Vitro Conditions of Chronic TNF Exposure. Bohdan 

P. Harvey 1 and Zehra Kaymakcalan 2 , 1 Abbott Laboratories, 

Worcester, MA, 2 Abbott, Worcester, MA 

6. The Effect of Hydrogen Sulfide Donors on Inflammatory 

Mediators in Human Articular Osteoarthritic Chondrocytes. 

Elena F. Burguera 1 , Angela Vela Anero 2 , Rosa Meijide 

Failde 2 and Francisco J. Blanco 1 , 1 Rheumatology Service, 

INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, 

2 

Department of Medicine, University of A Coruña, A Coruña, 

Spain 

7. Lamin A Deregulation in Human Mesenchymal STEM CELLS 

Promotes an Impairment in Their Chondrogenic Potential 

and Imbalance in Their Response to Oxidative Stress. 

Jesus Mateos 1 , Alexandre De La Fuente 2 , Ivan A. Lesende- 

Rodriguez 2 , Maria Carmen Arufe 2 and Francisco J. Blanco 1 , 

1 

Rheumatology Division, Proteomics Unit-ProteoRed/ISCIII, 

INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, 

2 

Department of Medicine, Area of Anatomy and Human 

Embryology, University of A Coruña-INIBIC, A Coruña, Spain 


8. Supercharged Sox9 Protein Induces Chondrogenic 

Differentiation of Bone Marrow-Derived Mesenchymal 

Stem Cells. Yuan K. Chou 1 , Shili Wu 2 , Camilo Avendano 2 , Tom 

Caldwell 2 , Brian Maniaci 2 , Kentaro Yomogida 1 , Yong Zhu 2 

and Cong-Qiu Chu 3 , 1 Oregon Health & Science University, 

Portland, OR, 2 VivoScript, Inc, Costa Mesa, CA, 3 Oregon 

Health & Science Univ and Portland VA Medical Center, 

Portland, OR 

9. Function of the Chondrocyte PI-3 Kinase-Akt Signaling 

Pathway Is Stimulus Dependent. Richard F. Loeser and 

Meredith Greene, Wake Forest School of Medicine, 

Winston-Salem, NC 

10. Fibronectin Fragment Induces Procatabolic Effects Through 

TLR-2 Signaling Pathway in Human Articular Chondrocytes. 

Su Jin Park 1 , Eun-Jeong Cheon 1 and Hyun Ah Kim 2 , 1 Hallym 

University Sacred Heart Hospital, Kyunggi, South Korea, 

2 

Hallym university sacred heart hospital, Kyunggi, South 

Korea 

11. Cartilage Tissue Engineering Using Collagen Scaffolds and 

Human Mesenchymal Stem Cells. Clara Sanjurjo-Rodriguez 1 , 

Adela Helvia Martinez-Sanchez 1 , Silvia Diaz-Prado 2 , Emma 

Muiños-Lopez 1 , Isaac M. Fuentes-Boquete 2 , Francisco J. De 

Toro 2 and Francisco J. Blanco 1 , 1 Osteoarticular and Aging 

Res. Lab. CIBER-BBN. Rheumatology Div. INIBIC-Complejo 

Hosp. Univ. A Coruña, A Coruña, Spain, 2 Osteoarticular and 

Aging Res. Lab. CIBER-BBN. INIBIC- University of A Coruña, A 

Coruña, Spain 

12. Articular Cartilage Expresses the IL-15 Receptor Alpha- 

Chain and Responds to IL-15 with Increased Matrix 

Metalloproteinase Release. Anjali Nair 1 , Michael Huvard 2 , 

Madeline Rollins 3 , Arnavaz Hakimiyan 1 , Lev Rappaport 1 , 

Arkady Margulis 1 , Susanna Chubinskaya 1 and Carla R. 

Scanzello 1 , 1 Rush University Medical Center, Chicago, IL, 

2 

University of Illinois at Chicago, Chicago, IL, 3 Northwestern 

University, Chicago, IL 

13. Visfatin/Nampt in Osteoarthritis: Sites of Production in 

Human Joints and Role of Its Enzymatic Activity. Marie- 

Charlotte Laiguillon 1 , Carole Bougault 1 , Xavier Houard 1 , 

Marjolaine Gosset 2 , Geoffroy Nourissat 1 , Sabrina Priam 1 , 

Zvezdana Mladenovic 1 , Claire Jacques 1 , Francis Berenbaum 3 

and Jeremie Sellam 4 , 1 Pierre et Marie Curie University Paris 

VI, Paris, France, 2 Paris Descartes University, Montrouge, 

France, 3 AP-HP, St Antoine Hospital, Paris, France, 4 Hopital 

Saint-Antoine, Pierre et Marie Curie University Paris 6, AP- 

HP, 75012, France 

14. EPAC1 Activation Is Required for NFkB Nuclear 

Translocation and Osteoclast Differentiation. Aranzazu 

Mediero 1 and Bruce N. Cronstein 2 , 1 NYU School of Medicine, 

New York, NY, 2 NYU School of Medicine, Division of 

Rheumatology, New York, NY 

15. Adenosine A 2A Receptor Stimulation Inhibits OC Formation 

by Suppressing NFkB Translocation to the Nucleus by A 

PKA-ERK1/2 Mediated Mechanism. Aranzazu Mediero 1 and 

Bruce N. Cronstein 2 , 1 NYU School of Medicine, New York, NY, 

2 

NYU School of Medicine, Division of Rheumatology, New 

York, NY


16. Adenosine A 2A Receptor Diminishes Bone Destruction At 

Inflamed Sites, in Part, Via Downregulating Semaphorin4D- 

PlexinB 1 Communication Between Osteoclasts and 

Osteoblasts. Aranzazu Mediero 1 and Bruce N. Cronstein 2 , 

1 

NYU School of Medicine, New York, NY, 2 NYU School of 

Medicine, Division of Rheumatology, New York, NY 

17. Synovial Overexpression of Wnt and Wnt-1-Induced 

Secreted Protein 1 Induces Cartilage Damage by Skewing of 

TGF-Beta Signaling and Reduction of the Anti-Hypertrophy 

Factor Sox9. Martijn H. van den Bosch 1 , Arjen B. Blom 1 , 

Peter L. van Lent 1 , Henk M. van Beuningen 1 , Fons A. van 

de Loo 2 , Esmeralda N. Blaney Davidson 1 , Peter M. van der 

Kraan 1 and Wim B. van den Berg 2 , 1 Radboud University 

Nijmegen Medical Centre, Nijmegen, Netherlands, 

2 

Rheumatology Research and Advanced Therapeutics, 

Department of Rheumatology, Radboud University 

Nijmegen Medical Centre, Nijmegen, Netherlands 

18. Identification of 14-3-3å As a New Subchondral Bone 

Mediator Involved in Cartilage Degradation During 

Osteoarthritis. Sabrina Priam Jr. 1 , Carole Bougault 1 , Xavier 

Houard 1 , Marjolaine Gosset 2 , Colette Salvat 3 , Francis 

Berenbaum 4 and Claire Jacques 1 , 1 Pierre et Marie Curie 

University Paris VI, Paris, France, 2 Paris Descartes University, 

Montrouge, France, 3 University Pierre and Marie Curie, 

Paris, France, 4 AP-HP, St Antoine Hospital, Paris, France 

19. Stress-Induced Cartilage Degradation Does Not Depend On 

NLRP3-Inflammasome in Osteoarthritis. Carole Bougault 1 , 

Marjolaine Gosset 2 , Xavier Houard 1 , Colette Salvat 3 , Lars 

Godmann 4 , Thomas Pap 4 , Claire Jacques 1 and Francis 

Berenbaum 5 , 1 Pierre et Marie Curie University Paris VI, Paris, 

France, 2 Paris Descartes University, Montrouge, France, 

3 

University Pierre and Marie Curie, Paris, France, 4 University 

Hospital Münster, Münster, Germany, 5 AP-HP, St Antoine 

Hospital, Paris, France 

20. Osteoclastogenesis Is Inhibited by Immune Complexes 

Through Activating Fcγ Receptors. Lilyanne C. Grevers 1 , 

Peter L.E.M. van Lent 1 , Teun J. de Vries 2 , Vincent Everts 2 , 

J. Sjef Verbeek 3 and Wim B. van den Berg 4 , 1 Radboud 

University Nijmegen Medical Centre, Nijmegen, 

Netherlands, 2 ACTA, UVA, VU University Amsterdam, 

Amsterdam, Netherlands, 3 Leiden University Medical 

Center, Leiden, Netherlands, 4 Rheumatology Research and 

Advanced Therapeutics, Department of Rheumatology, 


Netherlands 

21. IL-32 and IL-17 Interact and Aggravate Osteoclastogenesis 

in Rheumatoid Arthritis . Bo Young Yoon 1 , Young-Mee 

Moon 2 , Yang-Mi Her 2 , Hye Jwa Oh 2 , Jae-Seon Lee 2 , Kyoung- 

Woon Kim 3 , Seon-Yeong Lee 2 , Yun-Ju Woo 2 , Kyung-Su 

Park 2 , Sung-Hwan Park 2 , Ho-Youn Kim 2 and Mi-La Cho 2 , 

1 

Inje University Ilsan Paik Hospital, Goyang, South Korea, 

2 

Catholic University of Korea, Seoul, South Korea, 3 The 

Catholic University of Korea, Seoul St. Mary’s Hospital, 

Seoul, South Korea 

22. Protective Properties of Conditioned Media from 

Adipose Stem Cells On Osteoarthritic Chondrocytes. 

Maria Isabel Guillén 1 , Julia Platas 1 , Vicente Mirabet 2 , 

Miguel Angel Castejón 3 , Francisco Gomar 4 and Maria Jose 

Alcaraz 1 , 1 University of Valencia, Burjasot, Valencia, Spain, 

2 

Generalitat Valenciana, Valencia, Spain, 3 De la Ribera 

University Hospital, Alzira, Spain, 4 University of Valencia and 

University Hospital, Valencia, Spain 

23. Differential Effects of Bone Morphogenetic Protein 2 and 

9 On Chondroprotective Transforming Growth Factor 

β Signaling. Arjan P. van Caam 1 , Esmeralda N. Blaney 

Davidson 1 , Elly L. Vitters 1 , Laurie de Kroon 1 , Ellen W. van 

Geffen 1 , Peter ten Dijke 2 , Wim B. van den Berg 1 and Peter 

M. van der Kraan 1 , 1 Radboud University Nijmegen Medical 

Centre, Nijmegen, Netherlands, 2 Leiden University Medical 

Center, Leiden, Netherlands 

24. The Negative Effects of Glucocorticoids On Bone Are 

Primarily Mediated by Genes Involved in Osteoblast 

Differentiation and Bone Remodelling. Katharina 

Blankenstein 1 , Tara C. Brennan-Speranza 1 , Karin Lyon 1 , Colin 

R. Dunstan 1 , Frank Buttgereit 2 , Hong Zhou 3 and Markus J. 

Seibel 3 , 1 Bone Research Program, Sydney, Australia, 2 Charite 

University Med-Berlin, Berlin, Germany, 3 ANZAC Research 

Institute, The University of Sydney, Concord, Australia 

25. Activation of the Canonical Wnt Signaling Pathway 

Is Tissue-Dependent in Osteoarthritic Joints: Distinct 

Mechanisms of Regulation by Wnt Antagonists. Thomas 

Funck-Brentano, Wafa Bouaziz, Hilene Lin, Valerie Geoffroy, 

Eric Hay and Martine Cohen-Solal, INSERM U606 Paris 7 

university, Paris, France 

26. Quantitative Analysis of Bone Damage/Morphological 

Changes in the Citrullinated Collagen Induced Arthritis 

Mouse Model Using Micro-CT. Anand Dusad 1 , Michael 

J. Duryee 1 , Dong Wang 2 , James R. O’Dell 3 , Ted R. Mikuls 4 , 

Geoffrey M. Thiele 3 and Lynell W. Klassen 3 , 1 University of 

Nebraska Medical Center, Omaha, NE, 2 Univ of Nebraska 

Medical Ctr, Omaha, NE, 3 Univ of Nebraska Med Ctr, Omaha, 

NE, 4 Omaha VA and University of Nebraska Medical Center, 

Omaha, NE 

27. Anti-Citrullinated Protein Antibodies As an Indicator 

of Bone Damage in the Citrullinated Collagen Induced 

Arthritis Model. Anand Dusad 1 , Michael J. Duryee 1 , Dong 

Wang 2 , Carlos D. Hunter 1 , Bartlett C. Hamilton III 3 , James R. 

O’Dell 4 , Ted R. Mikuls 5 , Lynell W. Klassen 4 and Geoffrey M. 

Thiele 4 , 1 University of Nebraska Medical Center, Omaha, 

NE, 2 Univ of Nebraska Medical Ctr, Omaha, NE, 3 University 

of Nebraska Medical Centre and Omaha VA Medical Center, 

Omaha, 4 Univ of Nebraska Med Ctr, Omaha, NE, 5 Omaha VA 

and University of Nebraska Medical Center, Omaha, NE 



140 

28. Role of Microrna-455 Networks in Mesenchymal Cell 

Differentiation and Osteoarthritis. Fumiaki Ayabe 1 , Shigeru 

Miyaki 2 , Diana Brinson 1 , Satoshi Yamashita 3 , Hiroyuki 

Nakahara 1 , Koji Otabe 1 , Stuart Duffy 1 , Shawn Grogan 1 , Shuji 

Takada 3 , Martin K. Lotz 1 and Hiroshi Asahara 1 , 1 The Scripps 

Research Institute, La Jolla, CA, 2 Hiroshima University, 

Hiroshima, Japan, 3 National Research Institute for Child 

Health and Development, Tokyo, Japan 

29. Level of IL-1â-Induced Epigenetic Modifications Differ in 

Chondrocytes From Different Histological Zones of Human 

Cartilage. Nahid Akhtar 1 and Tariq M. Haqqi 2 , 1 Case Western 

Reserve University/Metrohealth Medical Center, Cleveland, 

OH, 2 Metro Health Medical Center, Cleveland, OH 

30. A Mouse Myeloid Precursor with Osteoclastogenic 

Function in Vivo. Julia F. Charles 1 , Erene Niemi 2 , Mary 

C. Nakamura 3 and Antonios O. Aliprantis 4 , 1 Brigham and 

Women’s Hospital, Harvard Medical School, Boston, MA, 

2 

University of California, San Francisco; VA Medical Center, 

San Francisco, 3 SFVAMC/UCSF, San Francisco, CA, 4 Brigham 

and Women’s Hospital, Boston, MA 

31. Anti Citrullinated Protein Antibodies from Synovial Fluid of 

Rheumatoid Arthritis Patients Enhance Osteoclastogenesis. 

Akilan Krishnamurthy 1 , Nancy Vivar Pomiano 1 , Catia 

Cerqueira 1 , Elena Ossipova 1 , Karin Lundberg 1 , Ulrike Harre 2 , 

Vivianne Malmström 1 , Per Johan Jakobsson 1 , Lars Klareskog 3 , 

Georg Schett 2 and Anca Irinel Catrina 1 , 1Rheumatology 

Unit, Karolinska University Hospital, Karolinska Institute, 

Stockholm, Sweden, 2 Institute for Clinical Immunology, 


3 

Karolinska Institute, Stockholm, Sweden 

32. Development of a Quantitative Model of Endotoxin- 

Induced Calvarial Bone Erosion Utilizing Micro-Computed 

Tomography and Pax-It Imaging Analysis Software. Diane 

Thome, Donald Souza, Aruna Behera, Jie Zheng, Jennifer 

Swantek and Gerald H. Nabozny, Boehringer Ingelheim 

Pharmaceuticals Inc., Ridgefield, CT 

33. Novel Targets for Blocking Osteoclast-Mediated Resorption 

in Inflammatory Disorders. Kevin P. McHugh 1 , Tania N. 

Crotti 1 , Jun Li 2 , Jon Hill 3 , Gerald H. Nabozny 2 , Steven R. 

Goldring 4 and P. Edward Purdue 5 , 1 Center for Advanced 

Orthopedic Studies, Beth Israel Deaconess Medical Center, 

Boston, MA, 2 Boehringer Ingelheim Pharmaceuticals Inc., 

Ridgefield, CT, 3 Boehringer Ingelheim Pharmaceuticals Inc, 

Ridgefield, CT, 4 Hospital for Special Surgery, New York, NY, 

5 

Hospital for Special Surgery, Weill Cornell Medical Center, 

New York, NY 

34. Rebamipide Attenuates Pain Severity and Cartilage 

Degeneration in a Rat Model of Osteoarthritis by 

Downregulating Oxidative Damage and Catabolic Activity 

in Chondrocytes. Su-Jin Moon 1 , Mi-La Cho 2 , Yeon-Sik 

Hong 3 , Sung-Hwan Park 2 and Jun-Ki Min 1 , 1 Division of 

Rheumatology, Department of Internal Medicine, School 

of Medicine, The Catholic University of Korea, Seoul, South 

Korea, 2 Catholic University of Korea, Seoul, South Korea, 

3 

Our Lady of Mercy Hospital, Inchon, South Africa 


35. Changes in Tibial Bone and Cartilage Structure in a Mouse 

Surgical Model of Osteoarthritis. Brett A. Tonkin 1 , Evange 

Romas 2 , Natalie A. Sims 1 and Nicole C. Walsh 1 , 1 St Vincent’s 

Institute of Medical Research, Melbourne, Australia, 2 St 

Vincent’s Hospital, Melbourne, Australia 

36. Role of FK506 Binding Protein 5 in Osteoclast 

Differentiation. Miho Kimura 1 , Tatsuo Nagai 1 , Reiko 

Matsushita 1 , Atsushi Hashimoto 2 , Toshiyuki Miyashita 3 and 

Shunsei Hirohata 1 , 1 Kitasato University School of Medicine, 

Sagamihara, Japan, 2 Sagamihara National Hospital, National 

Hospital Organization, Sagamihara, Kanagawa, Japan, 

3 

Kitasato University School of Medicine, Sagamihara 

37. Development of a Mouse Model of Natural Osteoarthritis 

of Knee by Induction of obesity and Bipedal Walking. Hyun 

Ah Kim 1 , Su Jin Park 2 , Eun-Jeong Cheon 2 , Hyun A. Jung 1 and 

Kyeong Min Son 3 , 1 Hallym university sacred heart hospital, 

Kyunggi, South Korea, 2 Hallym University Sacred Heart 

Hospital, Kyunggi, South Korea, 3 Hallym university Chunchun 

sacred heart hospital, Chunchun, South Korea 

38. Bone Marrow Lesions On Magnetic Resonance Imaging 

Are Not Associated with Regions of Hypermetabolism in 

an Animal Model of Osteoarthritis. Arash Panahifar, Jacob 

Jaremko, Robert GW Lambert, Walter P. Maksymowych and 

Michael R. Doschak, University of Alberta, Edmonton, AB 

39. SDF-1 Induces Osteoclastogenesis in Rheumatoid 

Arthritis by Upregulating of RANKL Expression in Synovial 

Fibroblasts and CD4+ T Cells. Hae-Rim Kim 1 , Kyoung-Woon 

Kim 2 , Bo-Mi Kim 1 , Mi La Cho 3 and Sang-Heon Lee 4 , 1 Konkuk 

University School of Medicine, Seoul, South Korea, 2 The 

Catholic University of Korea, Seoul St. Mary’s Hospital, 

Seoul, South Korea, 3 Catholic University of Korea, Seoul, 

South Korea, 4 Konkuk University Hospital, Seoul, South 

Korea 

40. Syndecan-4 Regulates Activation of WNT Signaling 

in Chondrocytes. Jessica Bertrand 1 , Richard Stange 1 , 

Giovanna Nalesso 2 , Joanna Sherwood 2 , Lars Godmann 1 , 

Frank Echtermeyer 3 , Francesco Dell’Accio 4 and Thomas 

Pap 1 , 1 University Hospital Münster, Münster, Germany, 

2 

Queen Mary University London, London, United Kingdom, 

3 

University hospital Hanover, Hanover, Germany, 4 William 

Harvey Research Institute, Barts and the London Queen 

Mary’s School of Medicine and Dentistry, Centre for 

Experimental Medicine and Rheumatology, London, United 

Kingdom 

41. Long-Distance Physical Connections between 

Chondrocytes; Cell-to-Cell Communication within Articular 

Cartilage. Maria Dolores Mayan 1 , Raquel Gago-Fuentes 1 , 

Paula Carpintero-Fernandez 1 , Patricia Fernandez-Puente 1 , 

Purificacion Filgueira-Fernandez 1 , Virgin Valiunas 2 , Peter 

Brink 2 , Gary Goldberg 3 and Francisco J. Blanco Garcia 1 , 

1 

Osteoarticular and Aging Research Group. Rheumatology 

Division, Biomedical Research Center (INIBIC). Hospital 

Universitario A Coruña, As Xubias de Arriba 84, 15006, A 

Coruña, Spain, 2 Department of Physiology and Biophysics. 

State University of New York, Stony Brook, New York,


SC, 3 Department of Molecular Biology. Medical Center 

Drive, University of Medicine and Dentistry of New Jersey, 

Stratford, NJ 

42. Role of Stromal Cell-Derived Factor-1 Alpha through 

Smad and MAPK Pathway On Endochondral Ossification. 

Gunwoo Kim 1 , Seungwoo Han 1 , Younkwan Jung 2 , Eunju Lee 2 , 

Hyeri Park 2 , Shirine E. Usmani 3 , Veronica Ulici 3 and Frank 

Beier 3 , 1 Daegu Fatima Hospital, Daegu, South Korea, 2 Fatima 

research institute, Daegu Fatima Hospital, Daegu, South 

Korea, 3 Schulich School of Medicine and Dentistry, London, 

ON 

43. Serum Amyloid A Level in Knee Osteoarthritis: Systemic 

and/or Local Production and Pro-Inflammatory Properties 

On Human Chondrocytes and Fibroblast-Like Synoviocytes. 

Dominique de Seny 1 , Gaël Cobraiville 1 , Sophie Neuville 1 , 

Edith Charlier 1 , Biserka Relic 1 , Florence Quesada Calvo 1 , 

Olivier Malaise 1 , Denis Malaise 2 , Laurence Lutteri 3 , Jean- 

Paul Chapelle 3 and Michel G. Malaise 1 , 1 GIGA Research - 

University of Liège - CHU Liège, Liège, Belgium, 2 University 

of Liège, Liège, Belgium, 3 Medical Chemistry - CHU Liège, 

Liège, Belgium 

44. Inhibition of WNT Signaling Pathway by Sclerostin 

Maintains Cartilage Homeostasis. Wafa Bouaziz, Thomas 

Funck-Brentano, Hilene Lin, Eric Hay and Martine Cohen- 

Solal, INSERM U606 Paris 7 university, Paris, France 

45. The Effects of Apremilast On Osteoclasts, Osteoblasts, 

and Osteocytes. Mary Adams and Peter Schafer, Celgene 

Corporation, Summit, NJ 

46. Synovitis in Secondary Osteoarthritis Due to Rheumatoid 

Arthritis: A Proof-of-Concept Study. Stefan Vordenbäumen 1 , 

Tim Lögters 1 , Philipp Sewerin 1 , Thomas Pauly 2 , Ellen 

Bleck 1 , Paulina Philippski 1 , Matthias Schneider 1 , Michael 

Schädel-Höpfner 1 and Benedikt Ostendorf 1 , 1 Heinrich- 

Heine-University, Düsseldorf, Germany, 2 Rheinisches 

Rheumazentrum St. Elisabeth-Hospital, Meerbusch, 

Germany 

47. Accumulation of CD34+ Hematopoietic Stem Cells in 

the Initial Inflammatory Human Fracture Hematoma Is 

Mediated Via Chemokine Receptor Type 3 Ligands. Paula 

Hoff 1 , Timo Gaber 1 , Martin Hahne 1 , Cindy Strehl 1 , Katharina 

Schmidt-Bleek 1 , Gerd R. Burmester 2 , Gerhard Schmidmaier 3 , 

Georg Duda 1 , Carsten Perka 1 and Frank Buttgereit 4 , 

1 

Charité University Medicine, Berlin, Germany, 2 Charité - 

Universitätsmedizin Berlin, Berlin, Germany, 3 Heidelberg 

University Hospital, Heidelberg, Germany, 4 Charite 

University Med-Berlin, Berlin, Germany 

48. Tissue Engineering for Articular Cartilage Repair, Culturing 

Bone Marrow Mesenchymal STEM CELLS On Collagen 

and Heparan Sulphate Scaffolds. Adela Helvia Martinez- 

Sanchez 1 , Clara Sanjurjo-Rodriguez 1 , Silvia Diaz-Prado 2 , 

Emma Muiños 1 , Isaac M. Fuentes 2 , Francisco J. De Toro 2 , 

Julia Bujan 3 and Francisco J. Blanco 1 , 1 Osteoarticular 

and Aging Res. Lab. CIBER-BBN. Rheumatology Div. 

INIBIC-Complejo Hosp. Univ. A Coruña, A Coruña, Spain, 

2 

Osteoarticular and Aging Res. Lab. CIBER-BBN. INIBIC- 

University of A Coruña, A Coruña, Spain, 3 Department of 

Medical Specialties. University of Alcala de Henares, Madrid, 

Spain 

49. The Spatial Energy Expenditure Configuration and Possible 

Applications in an Experimental Model of Arthritis. 

Susanne Klatt 1 and Rainer H. Straub 2 , 1 Laboratory of Exp. 

Rheumatology and Neuroendocrine Immunology, University 

Hospital, Regensburg, Germany, 2 University Hospital 

Regensburg, Regensburg, Germany 

50. Human Chondrocyte Dedifferentiation Is Accompagnied 

by CD105 Endoglin Expression, ALK-1/Smad1/5 

Phosphorylation and Leptin Production - Stimulation by 

Prednisolone and Aldosterone Through the Glucocorticoid 

Receptor. Olivier Malaise, Biserka Relic, Mustapha Zeddou, 

Edith Charlier, Florence Quesada Calvo, Sophie Neuville, 

Dominique de Seny and Michel G. Malaise, GIGA Research - 

University of Liège - CHU Liège, Liège, Belgium 

51. Phosphodiesterase 4 Expression in Rheumatoid Arthritis 

Synovium and Anti-Inflammatory Effects of Apremilast On 

Synovial Fibroblasts. Lei Wu, Mary Adams, Stacey Parton 

and Peter Schafer, Celgene Corporation, Summit, NJ 


Outcomes of Rheumatic Disease I 

52. The Validity of the Diagnosis Inflammatory Arthritis in 

Primary Care. Markus M.J. Nielen 1 , Jennie Ursum 1 , François 

G. Schellevis 2 and Joke C. Korevaar 1 , 1 NIVEL (Netherlands 

Institute for Health Services Research), Utrecht, 

Netherlands, 2 VU University Medical Centre, Amsterdam, 

Netherlands 

53. Comparison of Decision Rules for Identifying Patients with 

Rheumatoid Arthritis (RA) in Administrative Healthcare 

Databases. John G. Hanly, Kara Thompson and Chris 

Skedgel, Dalhousie University and Capital Health, Halifax, NS 

54. Use of Health Plan Data to Assess Feasibility of Large 

Pragmatic Clinical Trials in Rheumatoid Arthritis. Jeffrey 

Curtis 1 , Lang Chen 1 , Fenglong Xie 1 , Jie Zhang 1 , Kenneth 

G. Saag 2 , Stacey Cofield 3 , Kevin L. Winthrop 4 , Nicole C. 

Wright 1 and Elizabeth S. Delzell 1 , 1 University of Alabama 

at Birmingham, Birmingham, AL, 2 Univ of Alabama- 

Birmingham, Birmingham, AL, 3 Univ of Alabama at 

Birmingham,, Birmingham, AL, 4 Oregon Health & Science 

University, Portland, OR 

55. Accuracy of Canadian Health Administrative Databases 

in Identifying Patients with Rheumatoid Arthritis Seen by 

Rheumatologists. Jessica Widdifield 1 , Sasha Bernatsky 2 , J. 

Michael Paterson 3 , Karen Tu 3 , Ryan Ng 3 , J. Carter Thorne 4 , 

Janet E. Pope 5 and Claire Bombardier 1 , 1 University of 

Toronto, Toronto, ON, 2 Research Institute of the McGill 

University Health Ctre, Montreal, QC, 3 Institute for Clinical 

Evaluative Sciences, Toronto, ON, 4 Southlake Regional 

Health Centre, Newmarket, ON, 5 St. Joseph Health Care 

London, University of Western Ontario, London, ON 



56. A Validated Mathematical Model Using Electronic Health 

Records to Identify Rheumatoid Arthritis Patients for 

Observational Studies. Aarat M. Patel 1 , Ilinca D. Metes 2 , 

Larry W. Moreland 3 , Melissa Saul 3 , Stephen R. Wisniewski 4 

and Marc C. Levesque 3 , 1 Univ of Pittsburgh Med Ctr / 

Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 

2 

University of Pittsburgh School of Medicine, Pittsburgh, 

PA, 3 University of Pittsburgh, Pittsburgh, PA, 4 University of 

Pittsburgh, Graduate School of Public Health, Pittsburgh, PA 

57. A British Survey of Time to Presentation and Treatment 

of Rheumatoid Arthritis in Subjects of Black and Minority 

Ethnic Origin. Sonia Panchal 1 , Ash Samanta 1 , Arumugam 

Moorthy 1 , Sawson Hayat 2 , Ira Pande 2 , Adewale O. Adebajo 3 

and Kuntal Chakravarty 4 , 1 University Hospitals of Leicester, 

Leicester, United Kingdom, 2 Nottingham University 

Hospitals, Nottingham, United Kingdom, 3 Academic 

Rheumatology Group, D, Sheffield, United Kingdom, 

4 

University of Bedfordshire Post Graduate Medical School, 

Romford, United Kingdom 

58. 5 Million Patients and Not 0.34% Is Worrisome: Burden of 

Rheumatoid Arthritis in India Based On a Bone and Joint 

Decade India Community Oriented Program for Control 

of Rheumatic Disease. Arvind Chopra 1 , R. Ghorpade 1 , S. 

Sarmukkadam 2 , VL Joshi 1 , AJ. Mathews 3 , L. Gauri 4 , A. Rahim 5 , 

K. Datta 6 , S. Chaturvedi 7 , B. Thakuria 8 , A. Mahajan 9 , R. 

Singh 10 , A. Ghosh 11 , R. Handa 12 , M. Saluja 1 , A. Venugopalan 1 , 

V. Kunjeer 1 , B. Paul 5 , S. Pal 6 , K. Wangjam 10 , T. Kumar 11 and 

K. Mahendranath 13 , 1 Center for Rheumatic Diseases, Pune, 

India, 2 BJMC, Pune, India, 3 Government Medical College 

Hospital, Trivandrum, India, 4 SP Medical College, Bikaner, 

India, 5 Calicut Medical College, Calicut, India, 6 Advance 

Rheumatology Clinic, Hyderabad, India, 7 FRCH, Pune, 

India, 8 Guwahati Medical College & Hospital, Guwahati, 

India, 9 Government Medical College, Jammu, India, 

10 

Regional Institute of Medical Sciences, Imphal, Manipur, 

India, 11 Institute of Post Graduate Medical Education 

and Research, Kolkata, India, 12 AIIMS, New Delhi, India, 

13 

Rheumatology Clinic, Bangalore, India 

59. A Staggering Burden of Pain and Rheumatic Disorders in 

India: A National Bone & Joint Decade India Community 

Oriented Program for Control of Rheumatic Disease 

Survey 2006-2011. Arvind Chopra 1 , R. Ghorpade 1 , S. 

Sarmukkadam 2 , VL Joshi 1 , AJ. Mathews 3 , L. Gauri 4 , A. Rahim 5 , 

K. Datta 6 , S. Chaturvedi 7 , B. Thakuria 8 , A. Mahajan 9 , R. 

Singh 10 , A. Ghosh 11 , R. Handa 12 , M. Saluja 1 , A. Venugopalan 1 , 

V. Kunjeer 1 , B. Paul 5 , S. Pal 6 , K. Wangjam 10 , T. Kumar 11 , CP 

Rajendran 13 , V. Gajalakshmi 14 and K. Mahendranath1 5 , 

1 

Center for Rheumatic Diseases, Pune, India, 2 B J Medical 

College, Pune, India, 3 Government Medical College 

Hospital, Trivandrum, India, 4 SP Medical College, Bikaner, 

India, 5 Calicut Medical College, Calicut, India, 6 Advance 

Rheumatology Clinic, Hyderabad, India, 7 FRCH, Pune, 

India, 8 Guwahati Medical College & Hospital, Guwahati, 

India, 9 Government Medical College, Jammu, India, 

10 

Regional Institute of Medical Sciences, Imphal, Manipur, 

India, 11 Institute of Post Graduate Medical Education and 

Research, Kolkata, India, 12 AIIMS, New Delhi, India, 13 Madras 

Medical College, Chennai, India, 14 ERC Unit, Chennai, India, 

15 

Rheumatology clinic, Bangalore, India 

60. The Burden of Early Arthritis in Latin America: Utility 

Analysis Using Patient-Level Data From the Argentinian 

Consortium for Early Arthritis. Christian A. Waimann 1 , 

Gustavo Citera 2 , Hernan Maldonado Ficco 3 , Oscar L. Rillo 4 , 

Mariana Benegas 5 , Rafael Chaparro del Moral 6 , Antonio 

Catalan Pellet 7 , Anastasia Secco 8 , Lucila Marino 9 , Alberto 

Berman 10 , Horacio Berman 10 , Ana Lucía Barbaglia 11 , Juan 

Carlos Marcos 12 , Josefina Marcos 12 , Francisco Caeiro 13 , 

Maria Haye Salinas 14 , Ana C. Alvarez 15 , Enrique Soriano 16 , 

Zaida Bedran 17 , Sergio Paira 18 , Federico Ceccato 18 , Gabriela 

Salvatierra 19 , Ana Quinteros 20 , Emilio Buschiazzo 21 and Edson 

Javier Velozo2 2 , 1 Instituto de Rehabilitación Psicofísica, 

Buenos Aires, Argentina, 2 Instituto de Rehabilitación 

Psicofísica., Buenos Aires, Argentina, 3 Instituto de 

Rehabilitacion Psicofisica, Buenos Aires, Argentina, 

4 

Hospital Tornú, Buenos Aires, Argentina, 5 Hospital Tornu, 

Buenos Aires, Argentina, 6 CONAART, Argentina., Buenos 

Aires, Argentina, 7 Hospital Rivadavia, Buenos Aires, 

Argentina, 8 Rivadavia Hospital, Buenos aires, Argentina, 

9 

Rivadavia Hospital, Buenos Aires, Argentina, 10 Centro 

Medico Privado de Reumatologia, Tucuman, Argentina, 

11 

Hospital Padilla, Tucuman, Argentina, 12 Hospital San 

Martin, La Plata, Argentina, 13 Hospital privado de Cordoba, 

Cordoba, Argentina, 14 Hospital Privado de Cordoba, 

Córdoba, Argentina, 15 Hospital Privado, Córdoba, Argentina, 

16 

Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 

17 

Rheumatology Section, Hospital Italiano de Buenos 

Aires, Buenos Aires, Argentina, 18 Hospital Jose Maria 

Cullen, Santa Fe, Argentina, 19 Centro de enfermedades 

Reumaticas, Santiago Del Estero, Argentina, 20 Centro Integral 

de Reumatología San Miguel de Tucumán, San Miguel de 

Tucumán, Argentina, 21 Hospital Señor del Milagro, Salta, 

Argentina, 22 Sanatorio Adventista del Plata, Entre Rios, 

Argentina 

61. Role of Health Literacy in Population Estimates of 

Musculoskeletal Disorders. Catherine L. Hill 1 , Sarah L. 

Appleton 2 , Tiffany K. Gill 3 , Julie Black 4 , Rima E. Rudd 5 and 

Robert J. Adams 2 , 1 The Queen Elizabeth Hospital, Woodville, 

Australia, 2 University of Adelaide, Woodville South, South 

Australia, Australia, 3 University of Adelaide, Adelaide, South 

Australia, Australia, 4 Arthritis SA, Marleston, Australia, 

5 

Harvard School of Public Health, Boston, MA 

62. Clinical Implication of Rheumatoid Factor Formation 

According to Various Hepatitis B Virus Infection Status and 

Vaccination. Sang Tae Choi 1 , Hyun Woong Lee 1 , Jung-Soo 

Song 2 , Soo Kon Lee 3 and Yong-Beom Park 3 , 1 Chung-Ang 

University School of Medicine, Seoul, South Korea, 2 Chung- 

Ang University College of Medicine, Seoul, South Korea, 

3 

Yonse University College of Medicine, Seoul, South Korea 

142 

2012 Program Book


63. The Association between Silica and the Risk of Anti- 

Citrullinated Protein Antibody Positive RA in the Malaysian 

and Swedish Epidemiological Investigation of Rheumatoid 

Arthritis Studies. Abqariyah Yahya 1 , Camilla Bengtsson 1 , 

Lars Klareskog 2 , Chun Lai Too 3 , Shahnaz Murad 4 and 

Lars Alfredsson 1 , 1 Institute of Environmental Medicine, 

Karolinska Institutet, Stockholm, Sweden, 2 Karolinska 

Institute, Stockholm, Sweden, 3 Karolinska Institutet, 

Stockholm, Sweden, 4 Institute for Medical Research, Kuala 

Lumpur, Kuala Lumpur, Malaysia 

64. Use of Moist Snuff and the Risk of Developing Rheumatoid 

Arthritis; Results from the Swedish Epidemiological 

Investigation of Rheumatoid Arthritis Study. Lars 

Alfredsson 1 , Lars Klareskog 2 and Camilla Bengtsson 1 , 

1 

Institute of Environmental Medicine, Karolinska Institutet, 

Stockholm, Sweden, 2 Karolinska Institute, Stockholm, 

Sweden 

65. Serum Inflammatory Biomarkers Correlated Stronger with 

a Panel of Serum Steroid and Pituitary Hormones in a 

Cohort of Pre-Rheumatoid Arthritis (pre-RA) Than in Non- 

RA Control (CN) Subjects. Alfonse T. Masi 1 , Kevin B. Elmore 1 , 

Azeem A. Rehman 1 , Jean C. Aldag 1 and Robert T. Chatterton 2 , 

1 

University of Illinois College of Medicine at Peoria, Peoria, 

IL, 2 Northwestern University, Chicago, IL 

66. Pre-Rheumatoid Arthritis (pre-RA) Subjects Had a Minority 

Excess with Clearly Low Serum Cortisol Levels and Females 

Had Lower Mean androstenedione Levels than Control 

(CN) Cohorts in Analysis of a Large Panel of Serum Steroids 

and Pituitary Hormones. Alfonse T. Masi 1 , Kevin B. Elmore 1 , 

Azeem A. Rehman 1 , Jean C. Aldag 1 and Robert T. Chatterton 2 , 

1 

University of Illinois College of Medicine at Peoria, Peoria, 

IL, 2 Northwestern University, Chicago, IL 

67. Increased Prevalence of Hypothyroidism Preceding 

Rheumatoid Arthritis – an Epidemiological Study. Anne 

M. Kerola 1 , Tuomo Nieminen 2 , Markku J. Kauppi 3 , Hannu 

Kautiainen 4 , Kari Puolakka 5 , Lauri J. Virta 6 and Tuomas 

Kerola 3 , 1 Medical School, University of Helsinki, Helsinki, 

Finland, 2 Division of Cardiology, Helsinki University Central 

Hospital, Helsinki, Finland, 3 Department of Internal 

Medicine, Päijät-Häme Central Hospital, Lahti, Finland, 4 Unit 

of Primary Health Care, Kuopio University Hospital, Kuopio, 

Finland, 5 Department of Medicine, South Karelia Central 

Hospital, Lappeenranta, Finland, 6 Research Department, the 

Social Insurance Institution, Turku, Finland 

68. Cardiovascular Comorbidities Antedating the Diagnosis of 

Rheumatoid Arthritis. Anne M. Kerola 1 , Tuomas Kerola 2 , 

Markku J. Kauppi 2 , Hannu Kautiainen 3 , Lauri J. Virta 4 , 

Kari Puolakka 5 and Tuomo Nieminen 6 , 1 Medical School, 

University of Helsinki, Helsinki, Finland, 2 Department of 

Internal Medicine, Päijät-Häme Central Hospital, Lahti, 

Finland, 3 Unit of Primary Health Care, Kuopio University 

Hospital, Kuopio, Finland, 4 Research Department, the 

Social Insurance Institution, Turku, Finland, 5 Department 

of Medicine, South Karelia Central Hospital, Lappeenranta, 

Finland, 6 Division of Cardiology, Helsinki University Central 

Hospital, Helsinki, Finland 

69. The Presence of Asymptomatic Carotid Plaques in Patients 

with Inflammatory Joint Disease Results in Inadequate 

Treatment to Lipid Targets in Cardiovascular Disease 

Prevention. Anne G. Semb 1 , Silvia Rollefstad 2 , Inge C. Olsen 2 , 

Desiree van der Heijde 3 and Tore K. Kvien 2 , 1 Diakonhjemmet 

Hospital, Olso, Norway, 2 Diakonhjemmet Hospital, Oslo, 

Norway, 3 Leiden University Medical Center, Leiden, 

Netherlands 

70. The Impact of Systemic Autoimmune Rheumatic Disease 

on One-Year Mortality in Congestive Heart Failure Patients: 

A Population-Level Analysis. Stephanie O. Keeling, Asvina 

Bissonauth, Becky Leung and Padmaja Kaul, University of 

Alberta, Edmonton, AB 

71. The Association between Preclinical Markers for 

Cardiovascular Disease and Rheumatoid Arthritis- 

Related Autoantibodies in First-Degree Relatives without 

Rheumatoid Arthritis. Ryan W. Gan 1 , Jan M. Hughes-Austin 2 , 

Kevin D. Deane 3 , Elaine M. Urbina 4 , Peter K. Gregersen 5 , 

Michael H. Weisman 6 , V. Michael Holers 3 and Jill M. Norris 1 , 

1 

Colorado School of Public Health, Aurora, CO, 2 Colorado 

School of Public Health / University of Colorado Anschutz 

Medical Campus, Aurora, CO, 3 University of Colorado School 

of Medicine, Aurora, CO, 4 Cincinnati Children’s Hospital 

Medical Center, Cincinnati, OH, 5 Feinstein Institute Medical 

Research and North Shore-Long Island Jewish Health 

System, Manhasset, NY, 6 Cedars-Sinai Medical Center, Los 

Angeles, CA 

72. Relationships between Air Pollution and Presence of 

Rheumatoid Arthritis-Related Autoantibodies in Individuals 

without Rheumatoid Arthritis: Studies of the Etiology 

of Rheumatoid Arthritis. Ryan W. Gan 1 , Kevin D. Deane 2 , 

Gary O. Zerbe 3 , Michael H. Weisman 4 , Jane H. Buckner 5 , P. 

K. Gregersen 6 , Ted R. Mikuls 7 , James R. O’Dell 8 , Richard M. 

Keating 9 , V. Michael Holers 2 and Jill M. Norris 1 , 1 Colorado 

School of Public Health, Aurora, CO, 2 University of Colorado 

School of Medicine, Aurora, CO, 3 Colorado School of Public 

Health / University of Colorado Anschutz Medical Campus, 

Aurora, CO, 4 Cedars-Sinai Medical Center, Los Angeles, CA, 

5 

Benaroya Research Institute at Virginia Mason, Seattle, WA, 

6 


Island Jewish Health System, Manhasset, NY, 7 Omaha VA 

and University of Nebraska Medical Center, Omaha, NE, 

8 

Univ of Nebraska Med Ctr, Omaha, NE, 9 The University of 

Chicago, Chicago, IL 

73. Trends in 21st century Health Care Utilization in a 

Rheumatoid Arthritis Cohort Compared to the General 

Population. Sofia Hagel 1 , Ingemar F. Petersson 2 , Ann B. I. 

Bremander 3 , Elisabet Lindqvist 1 , Charlotte Bergknut 4 and 

Martin Englund 2 , 1 Department of Clinical Sciences, Lund, 

Section for Rheumatology, Lund University and Skåne 

University Hospital, Lund, Lund, Sweden, 2 Department of 

Orthopedics, Clinical Sciences Lund, Lund University, Lund, 



Sweden, 3 Halmstad University School of Business and 

Engineering,, Halmstad, Sweden, 4 Lund University, Lund, 

Sweden 

74. Length of Stay for Rheumatoid Arthritis Related 

Orthopedic Surgery Has Improved Over the Past 3 Decades 

and Is Related to Disease Markers. Results From Two UK 

Multicentre Inception Cohorts (1986-2011) Compared with 

National Data. Elena Nikiphorou 1 , Stephen Morris 2 , David 

James 3 , Patrick D. Kiely 4 , David Walsh 5 and Adam Young 6 , 

1 

ERAS, St Albans City Hospital and University College London 

(UCL), St Albans, United Kingdom, 2 Research Department 

of Epidemiology and Public Health, 1-19 Torrington Place, 

United Kingdom, 3 Diana Princess of Wales Hospital, Grimsby, 

United Kingdom, 4 St. Georges Hospital, London, United 

Kingdom, 5 City Hospital, Nottingham, United Kingdom, 6 St 

Albans City Hospital, St Albans, United Kingdom 

75. Patient-Reported Outcomes Associated with Achieving and 

Maintaining Low Disease Activity in Rheumatoid Arthritis. 

Martin J. Bergman 1 , James W. Shaw 2 , Mary Cifaldi 2 , Gourab 

De 3 , Tony He 4 , Rajeev Ayyagari 4 and James Signorovitch 4 , 

1 

Taylor Hospital, Ridley Park, PA, 2 Abbott Laboratories, 

Abbott Park, IL, 3 Analysis Group, Inc., New York, NY, 4 Analysis 

Group, Inc., Boston, MA 

76. The Difference in Performance of DAS28 and RADAI During 

Pregnancy Might Explain Discrepancies Between Older 

and More Recent Studies On the Impact of Pregnancy On 

Rheumatoid Arthritis. Jan Naterop 1 , Johanna M.W. Hazes 2 

and Radboud J.E.M. Dolhain 2 , 1 Erasmus Medical Center, 

University Medical Center Rotterdam, Rotterdam, The 

Netherlands, Rotterdam, Netherlands, 2 Erasmus Medical 


77. Comorbid Conditions Do Not Explain Divergent Patient 

Assessments of Disease Activity and Global Health in 

Patients with Rheumatoid Arthritis. Dörte Huscher 1 , 

Katja Thiele 2 , Sascha Bischoff 2 , Ulrich von Hinüber 3 , Guido 

Hoese 4 , Kirsten Karberg 5 , Wolfgang Ochs 6 and Angela 

Zink 1 , 1 German Rheumatism Research Centre and Charité 

University Medicine, Berlin, Germany, 2 German Rheumatism 

Research Centre, Berlin, Germany, 3 Rheumatologist in 

Private Practice, Hildesheim, Germany, 4 Rheumatologist in 

Private Practice, Stadthagen, Germany, 5 Rheumatologist in 

Private Practice, Berlin, Germany, 6 Rheumatologist in Private 

Practice, Bayreuth, Germany 

78. Factors Influencing on the Discordance Between 2011 

ACR/EULAR Criteria and Physician’s Clinical Judgment for 

Remission in Rheumatoid Arthritis Patients. Yoon-Kyoung 

Sung 1 , Bo Young Yoon 2 , Soo-Kyung Cho 1 , Chan-Bum Choi 1 , 

Dae-Hyun Yoo 1 , Jae-Bum Jun 1 , Tae-Hwan Kim 1 , Shin-Seok 

Lee 3 , Tae-Jong Kim 3 , Jisoo Lee 4 , Jung-Yoon Choe 5 , Sung-Hoon 

Park 5 , Seung-Jae Hong 6 , Yeon-Ah Lee 6 , Jinseok Kim 7 , Eun-Mi 

Koh 8 , Hoon-Suk Cha 8 , Jaejoon Lee 8 , Won-Tae Chung 9 , Sung 

Won Lee 9 , Choong-Ki Lee 10 , Hye-Soon Lee 11 , Wan-Hee Yoo 12 , 

Young Mo Kang 13 and Sang-Cheol Bae 14 , 1 Hanyang University 

Hospital for Rheumatic Diseases, Seoul, South Korea, 

2 

Inje University Ilsan Paik Hospital, Goyang, South Korea, 

3 

Chonnam National University Medical School, Gwangju, 

South Korea, 4 Ewha Womans University Mokdong Hospital, 

Seoul, South Korea, 5 Catholic University of Daegu School of 

Medicine, Daegu, South Korea, 6 Kyung Hee University, Seoul, 

South Korea, 7 Jeju National University, Jeju, Korea, South 

Korea, 8 Samsung Medical Center, Sungkyunkwan University 

School of Medicine, Seoul, South Korea, 9 Dong-A University 

Hospital, Busan, South Korea, 10 Yeungnam University 

Hospital, Daegu, South Korea, 11 Hanyang University Guri 

Hospital, Guri, South Korea, 12 Department of Internal 

Medicine, Chonbuk National University Medical School and 

Research Institute of Clinical Medicine, Jeonju, South Korea, 

13 

Kyungpook National University School of Medicine, Daegu, 




79. Physician’s Global Assessment Is Affected by Physician’s 

Age and Gender, but Not by Patient Age and Gender in 

Rheumatoid Arthritis Patients Treated in Routine Care. 

Data from the Danish Nationwide Danbio Registry. Cecilie 

Lindstrom Egholm 1 , Theodore Pincus 2 , Lene Dreyer 3 , 

Torkell Ellingsen 4 , Bente Glintborg 3 , Marcin Kowalski 5 , 

Tove Lorenzen 4 , Ole Rintek Madsen 3 , Henrik Nordin 6 , 

Claus Rasmussen 7 and Merete L. Hetland 8 , 1 Copenhagen 

University Hospital / DANBIO at Glostrup, Copenhagen, 

Denmark, 2 NYU Hospital for Joint Diseases, New York, NY, 

3 

Copenhagen University Hospital at Gentofte, Gentofte, 

Denmark, 4 Region Hospital Silkeborg, Silkeborg, Denmark, 

5 

Aalborg Hospital, Aalborg, Denmark, 6 Rigshospitalet, 

Copenhagen, Denmark, 7 Vendsyssel Hospital, Hjoerring, 

Denmark, 8 Copenhagen University and Glostrup Hospital, 


80. Validation of Remission of Rheumatoid Arthritis by 

Traditional Disease Activity Score and Provisional Criteria 

by American College of Rheumatology and European 

League Against Rheumatism: Patient Reported Outcomes 

Analyzed From 3 Phase III Golimumab Trials. Chenglong 

Han 1 , E. Keystone 2 , Roy Fleischmann 3 , Josef S. Smolen 4 , Paul 

Emery 5 , Mark C. Genovese 6 , Mittie K. Doyle 7 and Elizabeth 

C. Hsia 7 , 1 Johnson & Johnson Pharmaceutical Services, LLC, 

Malvern, PA, 2 University of Toronto, Toronto, ON, 3 University 

of Texas Southwestern Medical Center, Dallas, TX, 4 Medical 


5 

Leeds Musculoskeletal Biomedical Research Unit, Leeds, 

United Kingdom, 6 Stanford University Medical Center, Palo 

Alto, CA, 7 Janssen Research and Development, LLC, Spring 

House, PA 

81. Transitions among Disease Activity States: Estimates and 

Models of Covariate Associations. George W. Reed 1 , David 

H. Collier 2 , Andrew S. Koenig 3 , Katherine C. Saunders 4 , 

Joel M. Kremer 5 and Sameer Kotak 6 , 1 University of 

Massachusetts Medical School, Worcester, MA, 2 Amgen Inc., 

Thousand Oaks, CA, 3 Pfizer Inc., Collegeville, PA, 4 CORRONA, 

144 

2012 Program Book


Inc., Southborough, MA, 5 Albany Medical College and The 

Center for Rheumatology, Albany, NY, 6 Pfizer Inc., New York, 

NY 

82. Variability of the SF-6D Determinants over Time in Early 

Arthritis: Results From the Espoir Cohort. Cécile Gaujoux- 

Viala 1 , Bruno Fautrel 2 , Kossar Hosseini 3 , Francis Guillemin 3 , 

René-Marc Flipo 4 and Anne-Christine Rat 5 , 1 Lorraine 

University, Paris Descartes University, APEMAC, EA 4360, 

F- 54 000, Nancy; Paris 6 – Pierre et Marie Curie University; 

Rheumatology, Pitié-Salpêtrière Hospital, Paris, France, 

2 

Paris 6 – Pierre et Marie Curie University; Rheumatology, 

Pitié-Salpêtrière Hospital, Paris, France, 3 Lorraine University, 

Paris Descartes University, APEMAC, EA 4360, F- 54 000, 

Nancy, France, 4 Rheumatology Department, Lille University 

Hospital, Lille, France, 5 Université de Lorraine, Paris 

Descartes University, APEMAC, EA 4360, F- 54 000, Nancy, 

France 

83. Substantial Functional Disability Is the Key Determinant of 

Discrepancies Between EQ-5D and SF-6D Utility Measures 

in Early Arthritis: Results From the Espoir Cohort. 

Cécile Gaujoux-Viala 1 , Bruno Fautrel 2 , Kossar Hosseini 3 , 

Francis Guillemin 4 , René-Marc Flipo 5 and Anne-Christine 

Rat 4 , 1 Université de Lorraine, Paris Descartes University, 

APEMAC, EA 4360, F- 54 000, Nancy; Paris 6 – Pierre et 

Marie Curie University; Rheumatology, Pitié-Salpêtrière 

Hospital, Paris, France, 2 Paris VI University, Paris, France, 

3 

Lorraine University, Paris Descartes University, APEMAC, 

EA 4360, F- 54 000, Nancy, France, 4 Université de Lorraine, 

Paris Descartes University, APEMAC, EA 4360, F- 54 000, 

Nancy, France, 5 Rheumatology Department, Lille University 

Hospital, Lille, France 

84. Benefits of Treat-to-Target Guideline Compliance in 

Patients with Rheumatoid Arthritis: A Retrospective 

Claims Analysis. Martin J. Bergman 1 , James W. Shaw 2 , 

Mary A. Cifaldi 2 , Annie Guerin 3 , Pooja Chopra 3 and James 

Signorovitch 4 , 1 Taylor Hospital, Ridley Park, PA, 2 Abbott 

Laboratories, Abbott Park, IL, 3 Analysis Group, Inc., 

Montreal, QC, 4 Analysis Group, Inc., Boston, MA 

85. WITHDRAWN. 

86. Longitudinal Hypertension Diagnosis and Control among 

a Primary Care Medically Homed Population with 

Rheumatoid Arthritis. Katya Voelker 1 and Christie M. 

Bartels 2 , 1 Univ of Wisconsin School of Medicine and Public 

Health, Madison, 2 Univ of Wisconsin School of Medicine and 

Public Health, Madison, WI 

87. Prediction of Mortality in Rheumatoid Arthritis Using 

a Serum Cytokine Profile. Agustin Escalante 1 , Roy W. 

Haas 1 , Daniel F. Battafarano 2 and Inmaculada Del Rincon 1 , 

1 

University of Texas Health Science Center at San Antonio, 

San Antonio, TX, 2 Brooke Army Medical Ctr, San Antonio, TX 

88. The Effect of Weather on Patient Symptoms in Rheumatoid 

Arthritis: A Systematic Review of the Literature and 

Exploration of “weather sensitivity”. Annika Cutinha 1 , 

Frederick Wolfe 2 and Kaleb Michaud 3 , 1 University of 

Nebraska Medical Center, Omaha, NE, 2 National Data Bank 

for Rheumatic Diseases, Wichita, KS, 3 National Data Bank 

for Rheumatic Diseases & University of Nebraska Medical 

Center, Omaha, NE 

89. Poor to Moderate Performance of Patient Self-Report in 

Indentifying Periodontitis in Patients with Rheumatoid 

Arthritis. Ted R. Mikuls 1 , Jeffrey Payne 2 , Harlan Sayles 3 , 

Shawneen Gonzalez 2 , Jeffrey Markt 4 , Mark Beatty 2 , Grant W. 

Cannon 5 , David McGowan 5 , Gail S. Kerr 6 , Robert Redman 7 , 

Andreas M. Reimold 8 and Garth Griffiths 8 , 1 Omaha VA 

and University of Nebraska Medical Center, Omaha, NE, 

2 

University of Nebraska Medical Center, Lincoln, NE, 

3 

University of Nebraska Medical Center, Omaha, NE, 

4 

Omaha, NE, 5 George E. Wahlen VA Medical Center, Salt 

Lake City, UT, 6 Washington DC VAMC, Georgetown and 

Howard University, Washington, DC, 7 Washington DC VA, 

Georgetown and Howard University, Washington, DC, 

8 

Dallas VA and University of Texas Southwestern, Dallas, TX 

90. Physical Function, Pain and Fatigue Are Related to 

Sleep Disturbance in Females with Rheumatoid 

Arthritis. Cathrine Austad 1 , Tore K. Kvien 2 and Till Uhlig 2 , 

1 

Diakonhjemmet Hospital, Norway, Oslo, Norway, 

2 

Diakonhjemmet Hospital, Oslo, Norway 

91. Correlations of Single Item Health Literacy Screening 

Questions with Established Measures of Health Literacy 

in Subjects with Rheumatoid Arthritis. Itziar Quinzanos 1 , 

Joel M. Hirsh 1 and Liron Caplan 2 , 1 Denver Health Med Ctr, 

Denver, CO, 2 Denver VAMC and Univ of Colorado School of 

Medicine, Aurora, CO 

92. Combined Response Index in Diffuse Systemic Sclerosis 

(CRISS)—Which External Anchors to Use When Developing 

the Index? Baseline Analysis. Dinesh Khanna 1 , Veronica 

Berrocal 1 , James R. Seibold 2 , Peter A. Merkel 3 , Maureen 

D. Mayes 4 , Kristine Phillips 1 , Robert W. Simms 5 , Shervin 

Assassi 4 , Philip J. Clements 6 and Daniel E. Furst 7 , 1 University 

of Michigan, Ann Arbor, MI, 2 Scleroderma Research 

Consultants LLC, Avon, CT, 3 University of Pennsylvania, 

Philadelphia, PA, 4 University of Texas Health Science Center 

at Houston, Houston, TX, 5 Boston University School of 

Medicine, Boston, MA, 6 UCLA School of Medicine, Los 

Angeles, CA, 7 UCLA Medical School, Los Angeles, CA 

93. Health State Utilities in Systemic Sclerosis: Results 

From the UCLA Scleroderma Quality of Life Study. 

Mohsen Sadatsafavi 1 , Dinesh Khanna 2 , Paul Maranian 3 , 

D. Furst 4 , Amir Khakban 1 and Carlo A. Marra 1 , 1 Univ of 

British Columbia, Vancouver, BC, 2 University of Michigan, 

Ann Arbor, MI, 3 UCLA Medical School, Los Angeles, CA, 

4 

University of California at Los Angeles, Los Angeles, CA 



146 

94. Medical Costs and Health Care Resource Use in Patients 

with Systemic Sclerosis in an Insured Population. 

Daniel E. Furst 1 , Ancilla W. Fernandes 2 , Serban R. Iorga 3 , 

Warren Greth 4 and Tim Bancroft 3 , 1 UCLA Medical School, 

Los Angeles, CA, 2 MedImmune LLC, Gaithersburg, MD, 

3 

OptumInsight, Eden Prairie, MN, 4 MedImmune, LLC, 

Gaithersburg, MD 

95. Smoking Is Associated with Worse and More Widespread 

Pain, Worse Disease Activity, Function, Fatigue and 

Health Related Quality of Life in Patients with Axial 

Spondyloarthritis – Results From a Population Based 

Cohort. Ann B. I. Bremander 1 , Ingemar F. Petersson 2 , Emma 

Haglund 3 , Stefan Bergman 4 and Lennart TH Jacobsson 5 , 

1 

Halmstad University School of Business and Engineering, 

Halmstad, Sweden, 2 Department of Orthopedics, Clinical 

Sciences Lund, Lund University, Lund, Sweden, 3 Spenshult 

Hospital for Rheumatic Diseases, Halmstad, Sweden, 4 R&D 

Center Spenshult, Oskarström, Sweden, 5 Department of 

Rheumatology and Inflammation Research, Sahlgrenska 

Academy at University of Gothenburg, Gothenburg, Sweden 

96. Quality of Care: Reference and Counter Reference from 

Family Physicians and Rheumatologists’ perspectives– A 

Pilot Study. Thiago D. Baumgratz 1 , Raphael Battisti 1 , Mirella 

Cuziol 1 , Ana Carolina Reiff Janini 1 , R.A. Levy 2 and Mirhelen 

M. Abreu 3 , 1 Medical Student at Universidade Federal de 

São Carlos, São Carlos, Brazil, 2 Hospital Universitário Pedro 

Ernesto, Rio de Janeiro, Brazil, 3 Universidade Federal de São 

Carlos, São Carlos, Brazil 

97. Systematic Review of Explanatory and Predictive Models 

in Rheumatology: Lack of Adhearance to Methodologic 

Standards. Daniel A. Albert, Dartmouth-Hitchcock Med Ctr, 

Lebanon, NH 

98. How to Assess Risks for Pulmonary Infection in Patients 

Receiving Immunosuppressive Treatment for Rheumatic 

Diseases? A Report from a Large-Scale Prospective 

Cohort Study. Hayato Yamazaki 1 , Ryoko Sakai 1 , Ryuji 

Koike 1 , Yasunari Miyazaki 1 , Michi Tanaka 1 , Toshihiro Nanki 1 , 

Kaori Watanabe 1 , Shinsuke Yasuda 2 , Takashi Kurita 2 , Yuko 

Kaneko 3 , Yoshiya Tanaka 4 , Yasuhiko Nishioka 5 , Yoshinari 

Takasaki 6 , Kenji Nagasaka 7 , Koichi Amano 8 , Shigeto Tohma 9 , 

Makoto Dohi 10 , Takahiko Sugihara 11 , Haruhito Sugiyama 12 , 

Yasushi Kawaguchi 13 , Naohiko Inase 1 , Sae Ochi 14 , Hiroyuki 

Hagiyama 15 , Nobuyuki Miyasaka 1 and Masayoshi Harigai 1 , 

1 

Tokyo Medical and Dental University, Tokyo, Japan, 

2 

Hokkaido University, Sapporo, Japan, 3 Keio Univ School of 

Medicine, Tokyo, Japan, 4 University of Occupational and 

Environmental Health, Kitakyushu, Japan, 5 The Univeristy of 

Tokushima Graduate School, Tokushima, Japan, 6 Juntendo 

University School of Medicine, Tokyo, Japan, 7 Ome 

Municipal General Hospital, Ome, Japan, 8 Department 

of Rheumatology and Clinical Immunology, Saitama 

Medical Center, Saitama Medical University, Saitama, 

Japan, 9 Sagamihara National Hospital, Sagamihara, Japan, 

10 

Graduate School of Medicine, The University of Tokyo, 

Tokyo, Japan, 11 Tokyo Metropolitan Geriatric Hospital, Tokyo, 


Japan, 12 National Center for Global Health and Medicine, 

Tokyo, Japan, 13 Institute of Rheumatology, Tokyo Women’s 

Medical University, Tokyo, Japan, 14 Tokyo Metropolitan 

Bokutoh Hospital, Tokyo, Japan, 15 Yokohama-city Bay Red 

Cross Hospital, Yokohama, Japan 

99. Cancer Iincidence and Type of Malignancy in 

Rrheumatologic Ddiseases in Korea: Head-to-Head 

Comparison. Sung Hae Chang, Jin Kyun Park and Eun Bong 

Lee, Seoul National University Hospital, Seoul, South Korea 

100. Further Evidence on Biased Cancer Risk Estimation in 

Studies Comparing A Subpopulation to the General 

Population. Koray Tascilar 1 and Hasan Yazici 2 , 1 Istanbul 

University Cerrahpasa Medical Faculty, Istanbul, Turkey, 

2 

Istanbul University, Cerrahpasa Medical School, 

Rheumatology, Istanbul, Turkey 

101. Kidney Function and the Risk of Incident Gout in A 

Population-Based Cohort of Adults: Atherosclerosis Risk 

in Communities Study. Mara McAdams DeMarco 1 , Anna 

Kottgen 2 , Andrew Law 3 , Janet W. Maynard 4 , Josef Coresh 1 

and Alan N. Baer 5 , 1 Johns Hopkins Bloomberg School of 

Public Health, Baltimore, MD, 2 University Hospital Freiburg, 

Freiburg, Germany, 3 Johns Hopkins, Baltimore, MD, 

4 

Johns Hopkins University School of Medicine, Division of 

Rheumatology, Baltimore, MD, 5 Johns Hopkins University, 

Baltimore, MD 

Imaging of Rheumatic Diseases: Ultrasound, Nuclear Medicine 

and Fluorescence Imaging 

102. Sonographic Assessment of Normal Peripheral Joints: 

Evaluation According to Demographics Parameters. Flavia 

S. Machado, Rita N.V. Furtado, Rogerio D. Takahashi, Ana 

Leticia P. de Buosi and Jamil Natour, Universidade Federal de 

São Paulo, São Paulo, Brazil 

103. A Pragmatic Musculoskeletal Ultrasound Screening 

Protocol Does Not Add to a Predictive Algorithm for 

Persistent Inflammatory Arthritis in a UK Early Arthritis 

Clinic. Arthur G. Pratt 1 , Alice R. Lorenzi 2 , Gillian Wilson 2 , 

Philip N. Platt 2 and John D. Isaacs 3 , 1 Newcastle University, 

Newcastle Upon Tyne, United Kingdom, 2 Freeman Hospital, 

Newcastle upon Tyne, United Kingdom, 3 Musculoskeletal 

Research Group, Institute of Cellular Medicine, Newcastle 

University and Newcastle upon Tyne NHS Foundation Trust, 

Newcastle Upon Tyne, United Kingdom 

104. The Usefulness of A NEW Musculoskeletal ULTRASOUND 

Scoring System of the Hands and Wrist Joints (US10) for 

Evaluation of EARLY Rheumatoid Arthritis Patients. Karine 

R. Luz, Rita N.V. Furtado, Marcelo M. Pinheiro, Giovanna 

S. Petterle and Jamil Natour, Universidade Federal de São 


105. Combined Synovial and Structural Ultrasound Score for 

the Diagnosis of RA. Gary A. Kunkel 1 , Grant W. Cannon 2 and 

Daniel O. Clegg 2 , 1 George Wahlen Veterans Affairs Medical 

Center, Salt Lake City, UT, 2 George E. Wahlen VA Medical 

Center, Salt Lake City, UT


106. Development of a 6 Joint Simplified Ultrasonographic 

Score to Assess Disease Activity in Patients with 

Rheumatoid Arthritis. Tomas Cazenave 1 , Christian A. 

Waimann 2 , Gustavo Citera 3 and Marcos G. Rosemffet 1 , 

1 

Instituto de Rehabilitacion Psicofisica, Buenos Aires, 

Argentina, 2 Instituto de Rehabilitación Psicofísica, Buenos 

Aires, Argentina, 3 Instituto de Rehabilitación Psicofísica., 

Buenos Aires, Argentina 

107. Sensitivity to Change of the Ultrasound synovitis SONAR 

Score in RA Patients: Results of the Scqm Cohort. Pascal 

Zufferey 1 , Almut Scherer 2 , Hans Rudolf Ziswiler 3 , Giorgio 

Tamborrini 4 , Laure Brulhart 5 and Burkhard Moeller 6 , 

1 

Lausanne University Hospital, Lausanne, Switzerland, 

2 

SCQM Foundation, Zurich, Switzerland, 3 Inselspital, 

University of Bern, Bern, Switzerland, 4 University Hospital, 

Zurich, Switzerland, 5 Geneva, Switzerland, 6 Inselspital Bern, 

Bern, Switzerland 

108. Disparity Between Sonographic and Clinical Criteria 

of Remission in Psoriasis Arthritis. Christian Dejaco 1 , 

Rusmir Husic 1 , Judith Gretler 2 , Winfried B. Graninger 1 and 

Josef Hermann 1 , 1 Medical University Graz, Graz, Austria, 

2 

Auenbruggerplatz 15 , Graz, Austria 

109. Does Joint Sonography Really Add Clinically Important 

Information Beyond Clinical Joint Examination? Miriam 

Gärtner 1 , Helga Radner 1 , Gabriela Supp 1 , Peter Mandl 1 , 

Daniel Aletaha 1 , Klaus P. Machold 1 and Josef S. Smolen 2 , 

1 

Medical University of Vienna, Vienna, Austria, 2 Medical 

University of Vienna and Hietzing Hospital, Vienna, Austria 

110. Comparing Palmar and Dorsal Ultrasound Assessment 

of Small Joint Synovitis in Rheumatoid Arthritis: Dorsal 

Greyscale Mode Yields Significantly Better Concordance 

with Power Doppler. Matthias Witt 1 , Felix Mueller 1 , 

Hendrik Schulze-Koops 2 and Mathias Grunke 1 , 1 Division 

of Rheumatology, Medizinische Klinik und Poliklinik IV, 

University of Munich, Munich, Germany, 2 Division of 

Rheumatology, Medizinische Klinik and Poliklinik IV, 

University of Munich, Munich, Germany 

111. Ultrasound Measurement of Metacarpal Cartilage 

Thickness Correlates with Joint Space Narrowing in the 

Metacarphalangeal Joints of Patients with Rheumatoid 

Arthritis. Peter Mandl 1 , Helga Radner 1 , Gabriela Supp 1 , Peter 

V. Balint 2 , Daniel Aletaha 1 and Josef S. Smolen 3 , 1 Medical 

University of Vienna, Vienna, Austria, 2 National Institute 

of Rheumatology and Physiotherapy, Budapest, Hungary, 

3 

Medical University of Vienna and Hietzing Hospital, Vienna, 

Austria 

112. Time-Integrated Synovitis Activity Assessed by Power 

Doppler Ultrasound Significantly Correlates with 

Radiographic Progression in Rheumatoid Arthritis Patients 

Treated with Methotrexate Alone but Not in Those Treated 

with TNF Antagonists. Kei Ikeda, Daiki Nakagomi, Yoshie 

Sanayama, Mieko Yamagata, Ayako Okubo, Taro Iwamoto, 

Hirotoshi Kawashima, Kentaro Takahashi and Hiroshi 

Nakajima, Chiba University Hospital, Chiba, Japan 

113. Power Doppler Signal Is Frequently Positive Among 

Patients with Rheumatoid Arthritis in Clinical Remission 

and Normal Serum Matrix Metalloproteinase-3 (MMP- 

3) Levels. Tadashi Okano, Tatsuya Koike, Masahiro Tada, 

Kenji Mamoto, Yuko Sugioka, Atsuko Kamiyama and Hiroaki 

Nakamura, Osaka City University Medical School, Osaka, 

Japan 

114. US Examination of Wrists and Hands: A Comparison 

between Rheumatoid Arthritis and Psoriatic Arthritis. 

Andrea Delle Sedie 1 , Elisa Cioffi 1 , Linda Carli 1 , Elena 

Sardano 2 , Stefano Bombardieri 1 and Lucrezia Riente 1 , 

1Rheumatology Unit, University of Pisa, Pisa, Italy, 

2 

Immunology Unit, University of Pisa, Italy 

115. Composite Ultrasound Score in Spondyloarthropathies. 

Maria L. Acosta Felquer 1 , Cristian Quiroz 1 , Santiago 

Ruta 2 , Javier Rosa 1 , Marina Scolnik 2 , Leandro Ferreyra 

Garrott 1 , Ricardo Garcia-Monaco 3 and Enrique R. Soriano 4 , 

1 

Rheumatology Section, Hospital Italiano de Buenos Aires, 

Buenos Aires, Argentina, 2 Rheumatology Unit, Internal 

Medical Services, Hospital Italiano de Buenos Aires, Buenos 

Aires, Argentina, 3 Radiology and Imagenology Department, 

Hospital italiano de Buenos Aires, Buenos Aires, 

4 

Rheumatology Unit, Internal Medical Services, Hospital 

Italiano de Buenos Aires, Instituto Universitario Hospital 

Italiano de Buenos Aires, and Fundacion PM Catoggio, 


116. Correlation between Clinical and Ultrasonographic 

Examination of the Calcaneal Enthesis in Patients with 

Ankylosing Spondylitis: A Controlled Study. Suellen 

Narimatsu 1 , Rita N.V. Furtado 1 , andre Rosenfeld 2 , Germana. 

B. Q. Estrela 1 , Jorge E. P. Proglhof 3 and Jamil Natour 4 , 

1 

Universidade Federal de São Paulo - UNIFESP, São Paulo, 

Brazil, 2 Universidade Federal de Sao Paulo, Sao Paulo, Brazil, 

3 

Universidade Federal de São Paulo - UNIFESP, Sao Paulo, 

Brazil, 4 Universidade Federal de São Paulo, São Paulo, Brazil 

117. Ultrasound for Diagnosis of Carpal Tunnel Syndrome – 

Comparison of Different Methods to Determine Median 

Nerve Volume and Value of Power Doppler Sonography. 

Christian Dejaco, Martin Stradner, Dorothea Zauner, 

Werner Seel, Nicole E. Simmet, Alexander Klammer, Kerstin 

Brickmann, Judith Gretler, Florentine Moazedi-Fürst, 

Rene Thonhofer, Rusmir Husic, Josef Hermann and Stefan 

Quasthoff, Medical University Graz, Graz, Austria 

118. Colour Doppler Sonography of the Knee Joint: A Useful 

Tool to Discriminate Arthritis From Osteoarthritis? 

Wolfgang Hartung 1 , Nelly Beitinger 1 , Boris P. Ehrenstein 1 , 

Christian Lüring 2 , Joachim Grifka 3 , Benno Schreiner 3 , Martina 

Müller 4 and Martin Fleck 1 , 1 Asklepios Klinikum Bad Abbach, 

Bad Abbach, Germany, 2 Universitiy Clinic Aachen, Aachen, 

Germany, 3 University of Regensburg, Bad Abbach, Germany, 

4 

University Clinic Regensburg, Regensburg 



119. Ultrasound (US) Findings in Patients with Knee Pain: 

Sensitivity and Specificity for the Diagnosis of Knee 

Osteoarthritis and Development of an US Prediction 

Score. Erika Catay 1 , Santiago Ruta 2 , Javier Rosa 1 , David A. 

Navarta 1 , Ricardo Garcia-Monaco 3 and Enrique R. Soriano 4 , 

1 


Buenos Aires, Argentina, 2 Rheumatology Unit, Internal 

Medical Services, Hospital Italiano de Buenos Aires, Buenos 

Aires, Argentina, 3 Radiology and Imagenology Department, 

Hospital italiano de Buenos Aires, Buenos Aires, 

4 



Italiano de Buenos Aires and Fundacion PM Catoggio, 


120. Evaluation of Joint Involvement in Patients Suffering From 

Early Polymyalgia Rheumatica Using High Resolution 

Ultrasound. Sandra Balser 1 , Emmanuelle LeBras 1 , Boris P. 

Ehrenstein 1 , Martina Müller 2 , Martin Fleck 1 and Wolfgang 

Hartung 1 , 1 Asklepios Klinikum Bad Abbach, Bad Abbach, 

Germany, 2 University Clinic Regensburg, Regensburg 

121. The Diagnostic Value of Color Doppler Ultrasonography 

in Giant Cell Arteritis. Merete L. Hetland 1 , Geirmund 

Myklebust 2 , Glenn Haugeberg 2 and Andreas P. 

Diamantopoulos 2 , 1 Copenhagen University and Glostrup 

Hospital, Copenhagen, Denmark, 2 Hospital of Southern 

Norway HF, Kristiansand, Norway 

122. Grey-Scale Ultrasonography with Power Doppler 

Technique: An Available Tool for the Assessment of 

Subclinical Joint Inflammatory Activity in Juvenile 

Idiopathic Arthritis. Paz Collado 1 , Rosa Merino 2 , J. Graña 

Sr. 3 , Sagrario Bustabad-Reyes 4 , MariLuz Gamir 5 , Mari Luz 

García 6 and Inmaculada Calvo 7 , 1 Severo Ochoa University 

Hospital, Madrid, Spain, 2 Hospital Universitario La Paz, 

Madrid, Spain, 3 Hospital Juan Canalejo, Spain, 4 Hospital 

Universitario de Canarias, La Laguna. Tenerife, Spain, 

5 

Ramon y Cajal University Hospital, Madrid, Spain, 6 Hospital 

de Basurto, Bilbao, Spain, 7 Hospital de La Fe, Valencia, Spain 

123. Detection of Synovitis in Clinically Inactive Juvenile 

Idiopathic Arthritis Patients by Ultrasonography with 

POWER Doppler. Paz Collado 1 , MariLuz Gamir 2 , Rosa 

Merino 3 , Consuelo Modesto 4 , Indalecio Monteagudo 5 and 

Juan Carlos Lopez-Robledillo 6 , 1 Severo Ochoa University 

Hospital, Madrid, Spain, 2 Ramon y Cajal University Hospital, 

Madrid, Spain, 3 Hospital Universitario La Paz, Madrid, Spain, 

4 

Hospital Valle de Hebron, Barcelona, Spain, 5 Gregorio 

Marañón Hospital, Madrid, Spain, 6 Hospital Niño Jesus, 

Madrid, Spain 

124. Reliability of an Ultrasound Scoring Measure for Juvenile 

Localized Scleroderma (jLS). Suzanne C. Li 1 , Melissa S. 

Liebling 2 , Andrea S. Doria 3 , Molly Dempsey-Robertson 4 , 

Carsten Hamer 5 , Sven Opitz 5 , Faridali Ramji 6 , Stephanie 

Edgerton 6 , Jose Jarrin 3 , Tanicka Kornyat 2 , Michael Malone 6 , 

Arun Mohanta 3 , Shuzhen Zhang 4 and Knut M. Wittkowski 7 , 

1 

Joseph M Sanzari Children’s Hospital, Hackensack University 

Medical Center, Hackensack, NJ, 2 Hackensack University 

Medical Center, Hackensack, NJ, 3 Hospital for Sick Children, 

Toronto, ON, 4 Texas Scottish Rite Hospital, Dallas, TX, 5 Schon 

Klinik Hamburg Eilbek, Hamburg, Germany, 6 University of OK 

Health Science Center, Okc, OK, 7 Rockefeller University, New 

York, NY 

125. Borderline Right Ventricular Involvement in Patients with 

Systemic Sclerosis without Pulmonary Hypertension. Luna 

Gargani 1 , Piotr Gosciniak 2 , Cosimo Bruni 3 , Serena Guiducci 3 , 

Silvia Bellando Randone 3 , Lorenza Pratali 1 , Gergely Agoston 4 , 

Alberto Moggi Pignone 5 , Albert Varga 4 , Rosa Sicari 1 , Eugenio 

Picano 1 and Marco Matucci Cerinic 3 , 1 Institute of Clinical 

Physiology, National Research Council, Pisa, Italy, 2 WSZ, 

Department of Cardiology, Szczecin, Poland, 3 Department 

of Biomedicine, Division of Rheumatology AOUC, Excellence 

Centre for Research, Florence, Italy, 4 University of Szeged, 

Faculty of Medicine, 2 nd Dept of Internal Medicine & 

Cardiology Center, Szeged, Hungary, 5 University of Florence, 

Department of Medicine, Division of Rheumatology, 

Florence, Italy 

126. Ultrasonography of Salivary Glands: Diagnostic and 

Prognostic Value in Primary Sjögren’s Syndrome. Nicoletta 

Luciano 1 , Chiara Baldini 1 , Rachele Pascale 2 , Francesco Ferro 1 , 

Alessandro Paolicchi 2 , Davide Caramella 2 and Stefano 

Bombardieri 1 , 1Rheumatology Unit, University of Pisa, Pisa, 

Italy, 2 Diagnostic and Interventional Radiology, University of 

Pisa, Pisa, Italy 

127. Ultrasonographic Evaluation of the Hands of Patients 

with Primary and Secondary Sjögren´s Syndrome. Cristina 

Hernández-Díaz 1 , Luis M. Amezcua-Guerra 2 , Angélica 

Vargas 2 , Alberto Lopez-Reyes 3 and Carlos Pineda 1 , 1 Instituto 

Nacional de Rehabilitación, Mexico City, Mexico, 2 Instituto 

Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, 

3 

Instituto Nacional de Rehabilitacion, Mexico City, Mexico 

128. Quantitative Assessment of Synovitis in Patients with 

Rheumatoid Arthritis Using Fluorescence Optical Imaging. 

Valentin S. Schäfer 1 , Wolfgang Hartung 1 , Patrick Hoffstetter 1 , 

Jörn Berger 2 , Martina Müller 3 , Martin Fleck 1 and Boris P. 

Ehrenstein 1 , 1 Asklepios Klinikum Bad Abbach, Bad Abbach, 

Germany, 2 mivenion GmbH, Berlin, Germany, 3 University 

Clinic Regensburg, Regensburg 

129. Comparison of Automated, Computer-Based Assessment 

and Visually Assessed Disease Activity Scores in ICG- 

Enhanced Fluorescence Optical Imaging in Patients with 

Rheumatic Disorders: A Feasibility Study. Stephanie G. 

Werner 1 , Michael Schirner 2 , Hans-Eckhard Langer 3 , Mathias 

Cziumplik 2 , Jörn Berger 2 , Marina Backhaus 4 and Malte 

Bahner 2 , 1 RHIO (Rheumatology, Immunology, Osteology) 

Duesseldorf, Duesseldorf, Germany, 2 mivenion GmbH, 

Berlin, Germany, 3 Duesseldorf, Germany, 4 Charite University 

Hospital, Berlin, Germany 

148 

2012 Program Book


130. Is Bone Scintigraphy Still Useful to Diagnose Rheumatoid 

Arthritis After the Appearance of 2010 ACR/EULAR 

Classification Criteria? Ji Young Kim 1 , Soo-Kyung Cho 2 , 

Min-Kyung Han 2 , Yun Young Choi 1 and Yoon-Kyoung Sung 2 , 

1 

Hanyang University College of Medicine, Seoul, South 

Korea, 2 Hanyang University Hospital for Rheumatic Diseases, 


131. Subclinical Arthritis Visualised by Positron Emission 

Tomography and Macrophage Targeting Precedes Clinical 

Flare in Rheumatoid Arthritis Patients in DAS28 Remission. 

Y.Y.J. Gent, A.E. Voskuyl, N. Ahmadi, N. Hoetjes and C.J. 

van der Laken, VU University Medical Center, Amsterdam, 

Netherlands 

132. FDG-PET Evaluation of Axillary Lymph Nodes and Large 

Joints of Patients with Rheumatoid Arthritis Treated with 

Anti-TNF Drugs. Koichi Okamura 1 , Yukio Yonemoto 1 , Tetsuya 

Kaneko 1 , Kimihiko Takeuchi 2 , Tsutomu Kobayashi 1 and Kenji 

Takagishi 1 , 1 Gunma University Graduate School of Medicine, 

Maebashi, Gunma, Japan, 2 Isesaki Fukushima Hospital, 

Isesaki, Gunma, Japan 

133. Utility of PET-CT Imaging in IgG4-Related Disease. Arezou 

Khosroshahi, Leslie Lee, Mollie Carruthers, Rusen Acu, 

Pietro Bonaffini, Vikram Deshpande, Dushyant Sahani and 

John H. Stone, Massachusetts General Hospital, Boston, MA 


134. Co-Existence of Gout in Rheumatoid Arthritis: It Does 

Happen! A Population Based Study. Adlene Jebakumar, 

Cynthia S. Crowson, P. Deepak Udayakumar and Eric L. 

Matteson, Mayo Clinic, Rochester, MN 

135. A Pilot Study of the Efficacy of IL1 Blockade by Anakinra 

in Acute Calcific Periarthritis of the Rotator Cuff. Pascal 

Zufferey, Melanie Faucherre, Pierre A. Varisco, Berengere 

Aubry Sr., Isabelle Fabreguet and Alexander K. So Sr., CHUV, 

Lausanne, Switzerland 

136. A Delphi Exercise to Identify Characteristic Features of 

Gout – A Study of Opinions From Patients and Physicians 

to Inform New Classification Criteria. Rebecca Prowse 1 , 

Nicola Dalbeth 2 , H. R. Schumacher 3 , Tuhina Neogi 4 , Tim L. 

Jansen 5 , Jaap Fransen 6 and William Taylor 1 , 1 University of 

Otago, Wellington, New Zealand, 2 University of Auckland, 

Auckland, New Zealand, 3 University of Pennsylvania and VA 

Medical Center, Philadelphia, PA, 4 Boston Univ School of 

Medicine, Boston, MA, 5 St Radboud University Nijmegen 

Medical Centre, Netherlands, 6 Radboud University Nijmegen 

Medical Centre, Nijmegen, Netherlands 

137. Monosodium Urate Crystals Inhibit Tenocyte Viability 

and Function: Implications for Periarticular Involvement 

in Chronic Gout. Ashika Chhana 1 , Karen E. Callon 1 , 

Bregina Pool 1 , Dorit Naot 1 , Gregory Gamble 1 , Brendan 

Coleman 2 , Fiona M. McQueen 1 , Jillian Cornish 1 and Nicola 

Dalbeth 1 , 1 University of Auckland, Auckland, New Zealand, 

2 

Middlemore Hospital, Auckland, New Zealand 

138. Evaluating Appropriate Use of Prophylactic Colchicine and 

Urate Lowering Therapy in Gout. Michael George 1 , Sally 

W. Pullman-Mooar 2 and H. Ralph Schumacher 3 , 1 Hospital of 

the University of Pennsylvania, Philadelphia, PA, 2 University 

of Pennsylvania and Philadelphia Veterans Hospital, 

Philadelphia, PA, 3 University of Pennsylvania and VA Medical 

Center, Philadelphia, PA 

139. Lack of Effect of Supplemental Vitamin C On Serum 

Urate in Patients with Gout. Lisa K. Stamp 1 , Christopher 

Frampton 1 , John L. O’Donnell 2 , Jill Drake 3 and Peter T. 

Chapman 3 , 1 University of Otago, Christchurch, Christchurch, 

New Zealand, 2 Canterbury Health Laboratories, 

Christchurch, New Zealand, 3 Christchurch Hospital, 

Christchurch, New Zealand 

140. Patients That Continue to Flare Despite Apparent Optimal 

Urate Lowering Therapy. Dinesh Khanna 1 , Puja Khanna 1 , 

David Hagerty 2 , Chris Storgard 2 , Robert Mischler 2 and Robert 

Morlock 2 , 1 University of Michigan, Ann Arbor, MI, 2 Ardea 

Bioscience, San Diego, CA 

141. Effectiveness of Prophylaxis with Anti-Gout Medications 

on Risk of Gout Attacks. Tuhina Neogi 1 , Clara Chen 2 , Jingbo 

Niu 1 , Christine E. Chaisson 2 , David J. Hunter 3 , Hyon K. Choi 1 

and Yuqing Zhang 4 , 1 Boston University School of Medicine, 

Boston, MA, 2 Boston University School of Public Health, 

Boston, MA, 3 Royal North Shore Hospital, Sydney, Australia, 

4 

Boston University, Boston, MA 

142. Efficacy of Canakinumab versus Triamcinolone Acetonide 

According to Multiple Gouty Arthritis-Related Health 

Outcomes Measures. Ari Gnanasakthy 1 , Andrew Sarkin 2 , 

Rachel Lale 2 , Kyle Choi 2 and Jan D. Hirsch 3 , 1 Novartis 

Pharmaceuticals Corporation, East Hanover, NJ, 2 Health 

Services Research Center, University of California, San Diego, 

CA, 3 Skaggs School of Pharmacy & Pharmaceutical Sciences, 

University of California, San Diego, CA 

143. Proposed Gout Treatment Guidelines and Meeting Serum 

Urate and Flare Goals. Jasvinder A. Singh 1 , David Hagerty 2 , 

Chris Storgard 2 , Robert Mischler 2 and Robert Morlock 2 , 

1 


2 

Ardea Bioscience, San Diego, CA 

144. Long-Term Safety of Canakinumab in Patients with Gouty 

Arthritis. Alexander So 1 , Reike Alten 2 , H. Ralph Schumacher 3 , 

Mark Bloch 4 , Thomas Bardin 5 , Markus R. John 6 , Gerhard 

Krammer 6 , Jan Michael Nebesky 6 , Aiyang Tao 7 and 

Naomi Schlesinger 8 , 1 CHUV, Univ of Lausanne, Lausanne, 

Switzerland, 2 Charité Univ Medicine, Berlin, Germany, 

3 

Department of Medicine, University of Pennsylvania and 

VA Medical Center, Philadelphia, PA, 4 Holdsworth House 

Medical Practice, Sydney, Australia, 5 Hôpital Lariboisière, 

Paris, France, 6 Novartis Pharma AG, Basel, Switzerland, 

7 

Novartis Pharmaceuticals Corporation, East Hanover, NJ, 

8 

UMDNJ-RWJMS, New Brunswick, NJ 



150 

145. Prevalence of Non-Gout Arthritis in Patients with Gout: 

Not As Sparing As Previously Thought. Fernando Perez- 

Ruiz 1 and Ana M. Herrero-Beites 2 , 1 Hospital Universitario 

Cruces, Baracaldo, Spain, 2 Hospital de Gorliz, Gorliz, Spain 

146. The Treatment of Acute Gouty Arthritis in Complex 

Hospitalized Patients with Anakinra. Mary Bach, Jane Park, 

Pradipta Ghosh, Peter A. Simkin and Gregory C. Gardner, 

University of Washington, Seattle, WA 

147. Improvements in Long-Term Health-Related Quality of 

Life in Chronic Gout Patients Refractory to Conventional 

Therapies Treated with Pegloticase: Results From 

Responder Cohort. Dinesh Khanna 1 , Puja Khanna 1 and Faith 

D. Ottery 2 , 1 University of Michigan, Ann Arbor, MI, 2 Savient 

Pharmaceuticals, Inc., East Brunswick, NJ 

148. Towards a Preliminary Definition of Remission from 

Gout. William Taylor 1 , Nicola Dalbeth 2 , Jasvinder A. Singh 3 , 

Kenneth G. Saag 4 and H. R. Schumacher 5 , 1 University 

of Otago, Wellington, New Zealand, 2 University of 

Auckland, Auckland, New Zealand, 3 University of Alabama 


Birmingham, Birmingham, AL, 5 University of Pennsylvania 

and VA Medical Center, Philadelphia, PA 

149. Natural Language Processing in the Evaluation of Gout 

Quality Indicators. Gail S. Kerr 1 , J. Steuart Richards 2 , 

Carl A. Nunziato 3 , Olga V. Patterson, Scott L. DuVall 5 , 

David D. Maron 3 and Richard L. Amdur 6 , 1 Washington DC 

VAMC, Georgetown and Howard University, Washington, 

DC, 2 Washington DC VA and Georgetown University, 

Washington, DC, 3 Washington, DC, 4 VA Salt Lake City Health 

Care System and University of Utah School of Medicine, 

Salt Lake City, UT, 5 Washington DC VA and Georgetown 

Unviversity, Washington, DC 

150. Ulodesine (BCX4208) Long-Term Safety When Added to 

Allopurinol in the Chronic Management of Gout: A Phase 2 

24-Week Blinded Safety Extension and Vaccine Challenge 

Study. Alan S. Hollister 1 , Andreas Maetzel 1 , Michael A. 

Becker 2 , Robert Terkeltaub 3 , David Fitz-Patrick 4 , Valerie 

Smith 5 and William P. Sheridan 1 , 1 BioCryst Pharmaceuticals, 

Inc., Durham, NC, 2 University of Chicago, Chicago, IL, 3 VA 

Medical Ctr, San Diego, CA, 4 East-West Medical Research 

Institute, Honolulu, HI, 5 Pharpoint Research, Inc., Durham, 

NC 

151. Management of Gout Attacks in the Community. Tuhina 

Neogi 1 , Clara Chen 2 , Christine E. Chaisson 2 , David J. Hunter 3 , 

Hyon Choi 1 and Yuqing Zhang 4 , 1 Boston University School of 

Medicine, Boston, MA, 2 Boston University School of Public 

Health, Boston, MA, 3 Royal North Shore Hospital, Sydney, 

Australia, 4 Boston University, Boston, MA 

152. Rilonacept for Gout Flare Reduction: Estimation of Number 

Needed to Treat to Benefit (NNTB). Robert R. Evans 1 , Steven 

P. Weinstein 1 , George D. Yancopoulos 2 and Yuhwen Soo 2 , 

1 

Regeneron Pharmaceuticals Inc, Tarrytown, NY, 2 Regeneron 

Pharmaceuticals, Inc., Tarrytown, NY 


153. Prevention of Recurrent Calcium Stones in Subjects 

with Hyperuricosuria: A Randomized Controlled Trial of 

Febuxostat Vs Allopurinol. David S. Goldfarb 1 , Patricia A. 

MacDonald 2 , Lhanoo Gunawardhana 3 , Solomon Chefo 3 

and Lachy McLean 4 , 1 New York Universtiy Langone Medical 

Center, New York, NY, 2 Takeda Pharmaceuticals USA, Inc., 

Deerfield, IL, 3 Takeda Global Research & Development 

Center, Inc., Deerfield, IL, 4 Takeda Global Research & 

Development Center, Inc, Deerfield, IL 

154. Dual-Energy Computed Tomography as a Diagnostic Tool 

for Gout during Intercritical Periods. Gabriel S. Breuer 1 , 

Naama Bogot 2 and Gideon Nesher 1 , 1 Shaare Zedek Medical 

Center, Jerusalem, Israel, 2 Shaare Zedek Medical Center p o 

box 3235 Jerusalem, Israel, Israel 

155. Accuracy of International Classification of Disease Codes 

for Calcium Pyrophosphate Disease in the Veterans 

Adminstration Healthcare System. Karri A. Huber 1 , 

Lawrence M. Ryan 2 and Ann K. Rosenthal 2 , 1 MCW Froedtert 

Hospital, Milwaukee, WI, 2 Medical College of Wisconsin, 

Milwaukee, WI 

156. Menopause and the Prevalence of Gout and 

Hyperuricemia: An Age-Matched Case Control Study. Eswar 

Krishnan 1 and Mihoko Bennett 2 , 1 Standford University, Palo 

Alto, CA, 2 Stanford University, Palo Alto, CA 

157. Prevalence of Gout among Adults with Chronic Kidney 

Disease in the United States, 2009-10. Eswar Krishnan, 

Standford University, Palo Alto, CA 

158. Focus Groups Reveal Knowledge Gaps in Patients with 

Gout-A Qualitative Study. Puja Khanna 1 , Veronica Berrocal 1 , 

Tonya Hays 2 , Daniel J. Clauw 1 and David A. Williams 3 , 

1 

University of Michigan, Ann Arbor, MI, 2 UCLA, Los Angeles, 

CA, 3 Univ of MI Hlth System-Lobby M, Ann Arbor, MI 

159. Clinical Efficacy Outcomes with up to 3 Years of Pegloticase 

Treatment for Refractory Chronic Gout. Michael A. Becker 1 , 

Herbert S. B. Baraf 2 , Robert A. Yood 3 , Aileen M. Dillon 4 , 

Janitzia Vazquez-Mellado 5 , Faith D. Ottery 6 , Dinesh Khanna 7 

and John S. Sundy 8 , 1 University of Chicago, Chicago, IL, 

2 

Arthritis & Rheumatism Associates, Wheaton, MD, 3 Reliant 

Medical Group, Worcester, MA, 4 Kaiser Foundation Hospital, 

San Francisco, CA, 5 Hospital General de Mexico, Mexico city, 

Mexico, 6 Savient Pharmaceuticals, Inc., East Brunswick, NJ, 

7 

University of Michigan, Ann Arbor, MI, 8 Duke University 


160. Pegloticase Long-Term Safety: Data from the Open-Label 

Extension Trial. Michael A. Becker 1 , Herbert S. B. Baraf 2 , 

Robert A. Yood 3 , Aileen M. Dillon 4 , Janitzia Vazquez- 

Mellado 5 , Faith D. Ottery 6 , Dinesh Khanna 7 and John S. 

Sundy 8 , 1 University of Chicago, Chicago, IL, 2 Arthritis & 

Rheumatism Associates, Wheaton, MD, 3 Reliant Medical 

Group, Worcester, MA, 4 Kaiser Foundation Hospital, San 

Francisco, CA, 5 Hospital General de Mexico, Mexico city, 

Mexico, 6 Savient Pharmaceuticals, Inc., East Brunswick, NJ, 

7 

University of Michigan, Ann Arbor, MI, 8 Duke University 

Medical Center, Durham, NC


161. Increased Serum Uric Acid: Consequence or Cause of 

Increased Cardiovascular Risk. Inger L. Meek 1 , Harald E. 

Vonkeman 1 and Mart A.F.J. van de Laar 2 , 1 Rheumatology 

Center Twente, Medisch Spectrum Twente & Twente 

University, Enschede, Netherlands, 2 Medisch Spectrum 

Twente & University of Twente, Enschede, Netherlands 

162. Metabolic Syndrome: The Genesis of Nephrolithiasis in 

Gout Patients. Filipi M. Mello 1 , Rafael B. Tomita 2 , Ricardo 

Fuller 2 , Marco Antonio G. P. Filho 2 , Thiago B. M. Barros 2 , 

Leandro L. do Prado 2 , Kristopherson L. Augusto 2 and Claudia 

Goldenstein-Schainberg 2 , 1 Faculdade de Medicina da 

Universidade de São Paulo, São Paulo, Brazil, 2 Rheumatology 

Division - University of São Paulo, São Paulo, Brazil 

163. Evaluating Allopurinol Therapy and Serum Uric Acid Levels 

in Medicare Beneficiaries with Gout. Melea Ward 1 , Anthony 

M. Louder 2 , Keith A. Szymanski 3 and Leonardo Tamariz 4 , 

1 

Competitive Health Analytics, Louisville, KY, 2 Competitive 

Health Analytics, Inc., Louisville, KY, 3 Takeda Pharmaceuticals 

America, Inc., Deerfield, IL, 4 University of Miami, Miami, FL 

164. The Prevalence of Gout in a Large Tertiary Hospital and 

the Impact of in-Hospital Attacks of Acute Gout On Patient 

Outcomes and Health Resource Utilisation – a Nested Case- 

Control Study. John HY Moi 1 , Mark Tacey 1 , Carol Roberts 2 , 

Caroline Brand 1 , Alexandra Gorelik 2 and Sharon Van 

Doornum 1 , 1 The Royal Melbourne Hospital, The University 

of Melbourne, Melbourne, Australia, 2 The Royal Melbourne 

Hospital, Melbourne, Australia 

165. Colchicine Is Associated with a Decreased Rate of 

Myocardial Infarction in Gout Patients: Interim Results 

From a Retrospective Cohort Study. Daria B. Crittenden 1 , 

Cilian J. White 1 , Michael DeBerardine 1 , Grace Kim 1 , Binita 

Shah 2 , Jessica C. Kimmel 1 , Rima D. Patel 1 , Steven P. Sedlis 2 , 

Jeffrey D. Greenberg 1 , Craig T. Tenner 3 , Bruce N. Cronstein 1 

and Michael H. Pillinger 1 , 1 NYU School of Medicine, Division 

of Rheumatology, New York, NY, 2 NYU School of Medicine, 

Division of Cardiology, New York, NY, 3 NYU School of 

Medicine, Department of Internal Medicine, New York, NY 

166. Low-Dose Allopurinol Promotes Greater Serum Urate 

Lowering in Gout Patients with Chronic Kidney Disease 

Vs Normal Renal Function. Michael DeBerardine 1 , Mark 

C. Fisher 2 , Robert T. Keenan 3 , Michael H. Pillinger 1 and 

Daria B. Crittenden 1 , 1 NYU School of Medicine, Division 

of Rheumatology, New York, NY, 2 Massachusetts General 

Hospital, Boston, MA, 3 Duke University, Durham, NC 

167. Serum Uric Acid Control and Risk of Flare According to 

Different Cut-Offs in Patients with Gout: Longitudinal 

Analysis from the King Study of the Italian Society for 

Rheumatology. Maria Manara 1 , Carlo Alberto Scirè 2 , 

Marco A. Cimmino 3 , Marcello Govoni 4 , Fausto Salaffi 5 , 

Greta Carrara 1 , Carlomaurizio Montecucco 6 , Marco 

Matucci-Cerinic 7 , Giovanni Minisola 8 and Kick-off of 

the Italina Network for Gout (KING) Study Group 9 , 

1 

Epidemiology Unit -Italian Society for Rheumatology, 

Milano, Italy, 2 Epidemiology Unit -Italian Society for 

Rheumatology, Milan, Italy, 3 Rheumatology - Department 

of Internal Medicine - University of Genoa, Genova, Italy, 

4 

Section of Rheumatology - Department of Clinical and 

Experimental Medicine - University of Ferrara, Ferrara, 

Italy, 5 Rheumatology Unit - Polytechnic University of the 

Marche, Jesi, Italy, 6 Division of Rheumatology - University 

of Pavia School of Medicine, IRCCS Policlinico San Matteo 

Foundation, Pavia, Italy, 7 Department of Biomedicine & 

Division of Rheumatology AOUC - University of Florence, 

Florence, Italy, 8 Rheumatology Unit - San Camillo Forlanini 

Hospital, Rome, Italy, 9 SIR, Italy 

168. Allopurinol Use Is Associated with a Decreased Risk 

of Myocardial Infarction. Lamiae Grimaldi-Bensouda 1 , 

Annick Alpérovitch 2 , Elodie Aubrun 1 , Nicolas Danchin 3 , 

Michel Rossignol 4 , Lucien Abenhaim 5 , Pascal Richette 6 

and PGRx MI Group 7 , 1 LA-SER, Paris, France, 2 Inserm 

U708-Neuroepidemiology, La Pitié-Salpêtrière Hospital, 

Paris, France, 3 Coronary disease unit, Georges Pompidou 

European Hospital, Assistance Publique-Hôpitaux de Paris 

and Paris-Descartes University, Paris, France, 4 LA-SER, Centre 

for Risk Research, Montreal, 5 LA-SER Europe Ltd, London, 

United Kingdom, 6 Lariboisière Hospital, Paris, France, 7 Paris, 

France 

169. Post-Marketing Safety Surveillance Data Reveals Patterns 

of Use for Pegloticase in Refractory Chronic Gout. Kenneth 

M. Bahrt, Anthony E. Yeo, Tina L. Howson and Faith D. 

Ottery, Savient Pharmaceuticals, Inc., East Brunswick, NJ 

170. Relative Risk of Infusion Reactions with KRYSTEXXA® 

(pegloticase) From Post-Approval Safety Data: Results 

From Sept 2010 to June 2012. Raymond L. Malamet, Tina 

L. Howson, Anthony E. Yeo, Kenneth M. Bahrt and Marsha 

Wolfson, Savient Pharmaceuticals, Inc., East Brunswick, NJ 


171. Disease Modifying Agents Combined with Isoniazid for 

Latent Tuberculosis in Patients with Rheumatic Diseases. 

Josiane Bourré-Tessier 1 , Mireia Ariño i Torregrosa 2 and 

Denis Choquette 3 , 1 Institut de Rhumatologie de Montréal, 

Université de Montréal, Montréal, QC, 2 Universitat de 

Valencia, Massanassa, Spain, 3 University of Montreal 

Hospital Research Centre (CRCHUM), Montreal, QC 

172. A Systematic Review and Meta-Analysis of Antibiotic 

Treatment for Reactive Arthritis. Claire E. Barber 1 , Joseph 

Kim 2 , R. D. Inman 3 , John Esdaile 4 and Matthew T. James 5 , 

1 

University of Calgary, Calgary, AB, 2 University of Calgary, 

Calgary, 3 Toronto Western Research Institute, University 

Health Network and University of Toronto, Toronto, ON, 

4 

University of British Columbia, Vancouver, BC, 5 Univeristy of 

Calgary, Calgary 

173. Latent Tuberculosis Screening and Treatment in 

Rheumatoid Arthritis Patients Eligible for Anti-TNF Therapy 

in Endemic Areas: Does It Work? Ieda Laurindo, Ana C. M. 

Ribeiro, Julio C. B. Moraes, Carla G.S. Saad, Karina Rossi 



152 

Bonfiglioli, Fernando H.C. Souza, Ana L. G. Calich, Mariana G. 

Waisberg, Lissiane K. N. Guedes and Eloisa Bonfa, Faculdade 

de Medicina da Universidade de São Paulo, São Paulo, Brazil 

174. Prevalence, Risk Factors, and Functional Impact of 

Arthralgias among Patients with Chronic Hepatitis C Virus 

Infection. Samir Bhangle 1 , Vincent Lo Re 1 , W. Gina Pang 1 , 

Kyong-Mi Chang 2 , Valerianna Amorosa 2 , Jay Kostman 1 , 

H. Ralph Schumacher 3 and Alexis Ogdie 1 , 1 University of 

Pennsylvania, Philadelphia, PA, 2 Philadelphia VA Medical 

Center, Philadelphia, PA, 3 University of Pennsylvania and VA 

Medical Center, Philadelphia, PA 

175. The Impact of Hepatitis Screening On Diagnosis and 

Treatment in Rheumatoid Arthritis. Richard Conway, 

Michele Doran, Finbar (Barry) D. O’Shea and Gaye Cunnane, 

St James’s Hospital, Dublin, Ireland 

176. Prevalence and Associations of Hepatitis C Arthritis in 

Chronic Hepatitis C Virus Infection. Elizabeth D. Ferucci 1 , 

Holly S. Ryan 1 , Tammy L. Choromanski 1 , Lisa J. Townshend- 

Bulson 1 , Stephen E. Livingston 1 , Brian J. McMahon 1 and 

Mark H. Wener 2 , 1 Alaska Native Tribal Health Consortium, 

Anchorage, AK, 2 University of Washington, Seattle, WA 

177. Antibodies to Citrullinated Peptides in Tuberculosis. 

Isabella Lima 1 , Rodrigo Oliveira 2 , Ajax Atta 2 , Samyra Marchi 3 , 

Lúcio Barbosa 3 , Eliana Reis 3 , Mitermayer G. Reis 3 and 

Mittermayer Santiago 1 , 1 Escola Bahiana de Medicina e 

Saúde Pública, Salvador, Brazil, 2 Universidade Federal da 

Bahia, Salvador, Brazil, 3 Fundação Oswaldo Cruz, Salvador, 

Brazil 

178. Intravenous Immunoglobulin in Parvovirus B19 Mediated 

Pure Red Cell Aplasia: A Retrospective Study in 10 Patients 

and a Review of 123 Cases. Yoann Crabol, Hôpital Cochin, 

Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France 

Miscellaneous Rheumatic and Inflammatory Diseases: Periodic 

Fever Syndromes 

179. Evaluation of Anakinra Therapy in Seven Adults After 

Suboptimal Response to Etanercept Therapy for Tumor 

Necrosis Factor Receptor-Associated Periodic Fever 

Syndrome. Amanda K. Ombrello 1 , Patrycja M. Hoffmann 1 , 

Anne Jones 1 , Karyl S. Barron 2 and Daniel L. Kastner 1 , 

1 

National Human Genome Research Institute, National 

Institutes of Health, Bethesda, MD, 2 NIAID-NIH, Bethesda, 

MD 

180. Safety of Canakinumab in a Large Cohort of Patients with 

Cryopyrin-Associated Periodic Syndrome: Results From 

the ß-Confident Registry. H. Hoffman 1 , J. B. Kuemmerle- 

Deschner 2 , P. Hawkins 3 , T. van der Poll 4 , Ulrich A. Walker 5 , 

B. Rauer 6 , J. M. Nebesky 6 and H. Tilson 7 , 1 University of 

California at San Diego, San Diego, CA, 2 University Hospital 

Tuebingen, Tuebingen, Germany, 3 University College London 

Medical School, London, United Kingdom, 4 Academic 

Medical Center, University of Amsterdam, Amsterdam, 

Netherlands, 5 Universitäts-Poliklinik, Felix-Platter Spital, 

Basel, Switzerland, 6 Novartis Pharma AG, Basel, Switzerland, 


7 

The University of North Carolina Gillings School of Global 

Public Health, Chapel Hill, North Carolina 

181. Thiopurine S-Methyltransferase Levels in Patients 

with Behçet’s Disease. Hakan Emmungil 1 , Melike Kalfa 1 , 

Raika Durusoy 2 , Figen Yargucu Zihni 1 , Gokhan Keser 1 and 

Kenan Aksu 1 , 1 Dept. of Internal Medicine, Division of 

Rheumatology, Ege University, Izmir, Turkey, 2 Department of 

Public Health, Ege University, Izmir, Turkey 

182. Comprehensive Analysis of Protein Expression in 

Peripheral Blood Mononuclear Cells From Patients with 

Behcet’s Disease. Takuya Yoshioka 1 , Manae Kurokawa 1 , 

Yukiko Takakuwa 1 , Hiromasa Nakano 2 , Seido Ooka 2 , Nobuko 

Iizuka 1 , Toshiyuki Sato 1 , Mitsumi Arito 1 , Kouhei Nagai 3 , 

Kazuki Okamoto 1 , Naoya Suematsu 1 , Noboru Suzuki 1 , Shoichi 

Ozaki 2 and Tomohiro Kato 1 , 1 St. Marianna Univ School 

Med, Kawasaki, Japan, 2 St. Marianna University School of 

Medicine, Kawasaki, Japan, 3 Kinki Univ., Kinokawa, Japan 

183. A Strong Association Between HLA-A*26 and Behçet’s 

Syndrome in Japanese Patients: From Two-Center Cohort 

Study of Behçet’s Syndrome. Tatsuo Kobayashi 1 , Mitsumasa 

Kishimoto 2 , Kazuki Yoshida 1 , Yuri Ohara 2 , Hiroto Nakano 1 , 

Masahiro Minoda 1 , Hideto Oshikawa 1 and Kazuo Matsui 1 , 

1 

Kameda Medical Center, Kamogawa City, Chiba, Japan, 2 St. 

Luke’s International Hospital, Chuo-ku, Tokyo, Japan 

184. The Retrospective Review of 39 Intestinal Behcet’s Disease 

Focusing On the Requirement for the Immunosuppresive 

Drugs Other Than Corticosteroid. Yoshitaka Kimura 1 , Kurumi 

Asako 1 , Hirotoshi Kikuchi 2 , Akiteru Takeuchi 3 and Hajime 

Kono 4 , 1 Department of Internal Medicine, Teikyo University 

school of medecine, Tokyo, Japan, 2 Teikyo University, Tokyo, 

Japan, 3 6-7-8 Arakawa, Tokyo, Japan, 4 Teikyo University 

School of Medicine, Tokyo, Japan 

185. Long-Term Efficacy and Safety of Tumour Necrosis Factor 

Antagonists for Patients with Behçet’s Disease with Uveitis 

As Main Involvement. M. Victoria Hernández, Marina 

Mesquida, Gerard Espinosa, Victor Llorens, Laura Pelegrin, 

Juan D. Cañete, Ricard Cervera, Alfredo M. Adan and 

Raimon Sanmarti, Hospital Clínic of Barcelona, Barcelona, 

Spain 

186. Long-Term Infliximab Therapy in Patients with Behcet’s 

Disease Is Well Tolerated without Increasing Risk of Serious 

Infections. Sho Ueda 1 , Hiroshi Tsukamoto 1 , Yasushi Inoue 1 , 

Masahiro Ayano 1 , Satomi Hisamoto 1 , Naoko Ueki 1 , Atsushi 

Tanaka 1 , Shun-ichiro Ohta 1 , Naoyasu Ueda 1 , Yojiro Arinobu, 

Hiroaki Niiro 1 , Takahiko Horiuchi 1 and Koichi Akashi 1 , 

1 

Department of Medicine and Biosystemic Science, Kyushu 

University Graduate School of Medical Sciences, Fukuoka, 

Japan 

187. Effect of Colchicine On Cholesterol Levels in Patients with 

Familial Mediterranean Fever and Behçet’s Syndrome. 

SerdaL Ugurlu 1 , Emire Seyahi 2 , Idil Hanci 1 , Huri Ozdogan 3 , 

Seval Masatlioglu-Pehlivan 4 and Hasan Yazici 5 , 1 MD, Istanbul, 

Turkey, 2 Cerrahpasa Faculty of Medicine, Istanbul University, 

Istanbul, Turkey, 3 MD,Division of Rheumatology, Department


of Medicine, Cerrahpasa Medical Faculty, University of 

Istanbul, Istanbul, Turkey, 4 MD,Rheumatology, Istanbul, 

Turkey, 5 Istanbul University, Cerrahpasa Medical School, 

Rheumatology, Istanbul, Turkey 

188. Etiology of Uveitis: A Hospital-Based Study in a Referral 

Centre. Claudia Ferrari 1 , Rosaria Talarico 1 , Michele Figus 2 , 

Chiara Stagnaro 1 , Anna d’Ascanio 1 and Stefano Bombardieri 1 , 


2 

Ophthalmology Unit, University of Pisa, Pisa, Italy 

189. Pedal Swelling As a Characteristic Phenotype of the New 

Category of Autoinflammatory Disease Associated with 

NOD2 Gene Mutations. Qingping Yao, Cleveland Clinic, 

Cleveland, OH 

190. NLRP3 Gene Analysis for Patients with Schnitzler’s 

Syndrome. Cong-Qiu Chu 1 , Carrie R. Austin 2 , Trudy M. 

Doyle 2 , Kelley A. Goodwin 2 , Noha El Torgomen 2 , Regina 

Treudler 3 and Tammy M. Martin 4 , 1 Oregon Health & 

Science Univ and Portland VA Medical Center, Portland, 

OR, 2 Oregon Health & Science University, Portland, OR, 

3 

Universitätsklinikum Leipzig AöR, Leipzig, Germany, 4 Oregon 

Health & Science Univ, Portland, OR 

191. Analysis of Genes Involved in Autoinflammatory Diseases 

in Adult Onset Still’s Disease. Emma Garcia-Melchor 1 , 

Dolors Grados 2 , Eva Gonzalez-Roca 1 , Elena Riera 3 , Manel 

Juan 1 , Jordi Yagüe 1 , Juan Ignacio Aróstegui 1 , Javier Narváez 4 

and Alejandro Olivé 2 , 1 Hospital Clinic Barcelona, Barcelona, 

Spain, 2 Hospital Universitario Germans Trias i Pujol, 

Badalona, Spain, 3 Hospital Mutua de Terrassa, Terrassa, 

Spain, 4 Hospital Universitari de Bellvitge, L’Hospitalet de 

Llobregat, Spain 

192. Clinical and Laboratory Findings in A Cohort of Italian 

Patients with Adult Onset Still’S Disease: The Role of 

IL-18 As A Disease Biomarker. Roberta Priori 1 , Serena 

Colafrancesco 1 , Carlo Perricone 1 , Antonina Minniti 1 , 

Cristiano Alessandri 2 , Giancarlo Iaiani 3 and Guido Valesini 1 , 

1Rheumatology Unit, Sapienza University of Rome, 

Rome, Italy, 2 Sapienza University of Rome, Rome, Italy, 

3 

Department of Infectious Diseases and Tropical Medicine, 

Sapienza University of Rome, Rome, Italy 

193. Tocilizumab in Adult Still’s Disease: The Israeli Experience. 

Ori Elkayam 1 , Nizar Jiries 2 , Zvi Dranitzki 3 , Shaye Kivity 4 , 

Merav Lidar 5 , Ofer Levy 6 , Mahmoud Abu-Shakra 7 , Hagit 

Sarvagil-Maman 1 , Hagit Padova 1 , Dan Caspi 8 and Itzhak 

Rosner 9 , 1 Tel Aviv Sourasky Medical Center and the Sackler 

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 2 Bnai 

Zion Medical Center, Israel, 3 Hadassah hebrew university, 

Jerusalem, Israel, 4 Center for Autoimmune Diseases, Sheba 

Medical Center, Tel-hashomer, Israel, Tel-Hashomer, Israel, 

5 

Sheba Medical Center, Ramat Gan, Israel, 6 Asaf Harofe 

Medical Center, 7 Soroka Medical Centre and Ben Gurion 

University, Beer-Sheva, Israel, 8 Tel Aviv, Israel, 9 Bnai Zion 

Medical Center / Technion Faculty of Medicine, Haifa, Israel 

194. LONG-TERM Efficacy of Tocilizumab in A Patient with 

Amyloidosis and Interstitial Pneumonia Secondary to 

Multicentric Castleman’s Disease (MCD). Michihito 

Katayama 1 , Soichiro Tsuji 1 , Satoshi Teshigawara 1 , Eriko 

Kudo-Tanaka 1 , Maiko Yoshimura 1 , Akane Watanabe 1 , Akiko 

Yura 2 , Yoshinori Harada 2 , Yoshinori Katada 2 , Jun Hashimoto 1 , 

Masato Matsushita 3 , Yukihiko Saeki 1 and Shiro Ohshima 1 , 

1 

Osaka-Minami Medical Center, Kawachinagano City, Japan, 

2 

Kawachinagano City, Japan, 3 Osaka Minami Medical Center, 

Osaka, Japan 

195. Inflammatory Arthritis in Patients with Myelodysplastic 

Syndrome: French Multicenter Retrospective Study. 

Arsene Mekinian 1 , Olivier Decaux 2 , Geraldine Falgarone 3 , 

Thorsten Braun Sr. 4 , Eric Toussirot 5 , Loic Raffray 6 , Bruno 

Gombert 7 , Bruno de Wazieres 8 , Anne Laure Buchdaul 9 , 

Jean-Marc Ziza 10 , David Launay 11 , Guillaume Denis 12 , Serge 

Madaule 13 , Pierre Fenaux 14 and Olivier Fain 15 , 1 Jean Verdier 

Hospital, Bondy, France, 2 Hôpital Sud, Rennes, France, 

3 

Hopital avicenne, Paris, France, 4 Avicenne hospital, Bobigny, 

France, 5 CIC Biotherapy 50 6 and Rheumatology and EA 

4266 Pathogens and Inflammation, Besançon, France, 6 CHU 

de Bordeaux, Bordeaux, France, 7 La Rochelle hospital, La 

Rochelle, France, 8 CHU de Nimes, Nimes, France, 9 Douai 

hospital, Douai, France, 10 Hopital Croix Saint Simon, Paris, 

France, 11 Internal Medicine, CHRU Claude Huriez, Lille, 

France, 12 Rochefoucault hospital, Rochefoucault, France, 

13 

Albi hospital, Albi, France, 14 Avicenne Hospital, France, 

15 

Service de médecine interne, Université Paris 13, AP-HP, 

Hôpital Jean Verdier, 93140, Bondy, France., Bondy, France 

196. Sarcoidosis in Northern New England. Clinical 

Characteristics and Predictive Factors for More Aggressive 

Therapy. Alireza Meysami 1 , Kevin F. Spratt 2 and Christopher 

M. Burns 3 , 1 Dartmouth Hitchcock Medical Center, Lebanon, 

NH, 2 Geisel School of Medicine at Dartmouth, Lebanon, NH, 

3 

Dartmouth Medical School, Lebanon, NH 

197. Collapsing Glomerulopathy in Collagen Vascular-Like 

Disease. Rawad Nasr 1 , Christine Johns 2 and Elie Gertner 3 , 

1 

University of Minnesota, Minneapolis, MN, 2 Regions 

Hospital, St Paul, MN, 3 Regions Hospital and University of 

Minnesota Medical School, St. Paul, MN 

198. Diagnostic Predictors and Clinical Outcomes in Patients 

Presenting Solely with Lymphadenopathy. Huifang Lu, 

Xerxes Pundole and Khanh Vu, UT MD anderson Cancer 

Center, Houston, TX 

199. Joint, Hand and Feet Swelling As a Presenting Symptom of 

Hereditary Angioedema. Maria J. Gutierrez 1 and Timothy 

J. Craig 2 , 1 Penn State College of Medicine Milton S. Hershey 

Medical Center, Hershey, PA, 2 Penn State College of 

Medicine Milton S. Hershey Medical Cente, Hershey, PA 



200. Rheumatic Manifestations and Connective Tissue Diseases 

in Autoimmune Hepatitis of the Child and the Adult. 

Federico Zazzetti 1 , Nora C. Fernandez 1 , Javier Benavidez 1 , 

Luis A. Colombato 1 , Graciela R. Rodriguez 2 , Graciela Nardi 2 , 

Carolina Bru Morón 3 , Oscar L. Rillo 4 , Nelo A. Quadrini 3 , 

Stella M. Garay 5 , Mariana Fabi 5 , Teresita Gonzalez 5 and 

Juan C. Barreira 1 , 1 Buenos Aires British Hospital, Buenos 

Aires, Argentina, 2 Hospital Dr. Ignacio Pirovano, Buenos 

Aires, Argentina, 3 Hospital Dr. Enrique Tornú, Buenos 

Aires, Argentina, 4 Hospital Tornú, Buenos Aires, Argentina, 

5 

Hospital IAEP Sor María Ludovica, La Plata, Argentina 

201. High Rate of Autoimmune Manifestations during Idiopathic 

CD4 Lymphocytopenia. Alexis Régent 1 , Brigitte Autran 2 , 

Guislaine Carcelain 2 , Benjamin Terrier 3 , Alain Krivitzky 4 , Eric 

Oksenhendler 5 , Nathalie Costedoat-Chalumeau 6 , Pascale 

Hubert 2 , Olivier Lortholary 7 , Nicolas Dupin 8 , Patrice Debré 2 , 

Loic Guillevin 9 and Luc Mouthon 1 , 1 Hopital Cochin, Paris, 

France, 2 Laboratoire d’Immunologie Cellulaire Et Tissulaire, 

Paris, France, 3 Cochin Hospital, Paris, France, 4 Département 

de médecine interne, Hôpital Avicenne, AP-HP, Bobigny, 

France, 5 Département d’Immunologie Clinique, Hôpital 

Saint-Louis, AP-HP, Paris, France, 6 Assistance Publique- 

Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 

7 

Service de maladies infectieuses, Hôpital Necker-Enfants 

malades, AP-HP, Paris, France, 8 Service de Dermatologie, 

Hôpital Cochin, AP-HP, Paris, France, 9 Department of 

Internal Medicine, Referral Center for Rare Autoimmune 

and Systemic Diseases, Hôpital Cochin, AP–HP, Université 

Paris Descartes, Paris, France, Paris, France 

202. Diseases Associated with Markedly Elevated Ferritin 

Levels. Reshma Marri, Payal J. Patel, Amita Thakkar, Rochella 

A. Ostrowski, Eric McBride and Rodney Tehrani, Loyola Univ 

Medical Ctr, Maywood, IL 

203. Clinical Course Factors Associated with Outcome of 

Monoarthritis: A Retrospective Study of 173 Cases. Hyemin 

Jeong 1 , Eun-Jung Park 2 , Jiwon Hwang 2 , Ji Young Chai 3 , Joong 

Kyong Ahn 4 , Eun-Mi Koh 5 and Hoon-Suk Cha 6 , 1 Samsung 

Medical Center, Seoul, South Korea, 2 Samsung Medical 

Center, Sungkyunkwan University School of Medicine, Seoul, 

South Korea, 3 Jesang Hospital, Seongnam-si Gyeonggi-do, 

South Korea, 4 Kangbuk Samsung hospital, Sungkyunkwan 

University School of Medicine, Seoul, South Korea, 

5 

Samsung Medical Center, Sungkyunkwan University School 

of Medicine, Seoul, Seoul, South Korea, 6 Samsung Medical 

Center, Sunkyunkwan University School of Medicine, Seoul, 

South Korea 

204. Characterization of Joint Disease in Mucopolysaccharidosis 

Type I Mice and the Effects of Enzyme Replacement 

Therapy. Patricia Oliveira 1 , Guilherme Baldo 2 , Fabiana 

Mayer 2 , Barbara Martinelli 2 , Luise Meurer 2 , Roberto 

Giugliani 2 , Ursula Matte 2 and Ricardo M. Xavier 3 , 1 Hospital 

de Clinicas de Porto Alegre, Porto Alegre, Brazil, 2 Hospital 

de Clinicas de Porto Alegre, 3 Universidade Federal do Rio 

Grande do Sul, Porto Alegre, Brazil 

Muscle Biology, Myositis and Myopathies: Clinical and 

Therapuetic Aspects of Idiopathic Inflammatory Myopathies 

205. Idiopathic Inflammatory Myositis Is Associated with an 

Increased Incidence of Systemic Sclerosis. Shreyas H. 

Chaudhary 1 , Susanna Proudman 2 and Vidya S. Limaye 2 , 

1 

Medical Student University of Adelaide, Adelaide, Australia, 

2 

Royal Adelaide Hospital, Adelaide, Australia 

206. Clinical, Laboratory, and Cellular Responses in the 

Rituximab in Myositis Trial in Patients Enrolled At the 

National Institutes of Health. Lisa G. Rider 1 , Adrienne L. 

Yip 1 , Iren Horkayne-Szakaly 2 , Rita Volochayev 1 , Joseph A. 

Shrader 3 , Maria L. Turner 4 , Heidi H. Kong 4 , Minal S. Jain 3 , 

Anna V. Jansen 1 , Chester V. Oddis 5 , Thomas A. Fleisher 6 and 

Frederick W. Miller 1 , 1 National Institute of Environmental 

Health Sciences, National Institutes of Health, Bethesda, 

MD, 2 Joint Pathology Center, Silver Spring, MD, 3 Rehab 

Medicine, NIH Clinical Center, Bethesda, MD, 4 NCI, NIH, 

Bethesda, MD, 5 University of Pittsburgh, Pittsburgh, PA, 

6 

Laboratory Medicine, NIH Clinical Center, Bethesda, MD 

207. Interferon-Driven Chemokines Are Associated with 

Changes in Disease Activity Among Rituximab-Treated 

Refractory Myositis Patients with Pulmonary Involvement 

- the RIM Study. Cynthia S. Crowson 1 , Ann M. Reed 1 , Molly 

Hein 1 , Abigail B. Green 1 , Consuelo Lopez de Padilla 1 , Rohit 

Aggarwal 2 , Dana P. Ascherman 3 , Marc C. Levesque 4 and 

Chester V. Oddis 4 , 1 Mayo Clinic, Rochester, MN, 2 University 

of Pittsburgh Medical Center, Pittsburgh, PA, 3 University of 

Miami, Miami, FL, 4 University of Pittsburgh, Pittsburgh, PA 

208. Outcome of Muscle Function and Disease Activity in 

Patients Recently Diagnosed with Polymyositis and 

Dermatomyositis – Preliminary Results of a 1-Year 

Follow-up Registry Study. Helene Alexanderson 1 , Jenny 

Bergegård 2 , Christina Ottosson 3 , Maryam Dastmalchi 4 

and Ingrid E. Lundberg 1 , 1 Karolinska Institutet, Stockholm, 

Sweden, 2 Karolinska University Hospital, Solna, Stockholm, 

Sweden, 3 Rheumatology Unit, Karolinska University 

Hospital, Stockholm, Sweden, 4 Rheumatology Unit, 

Karolinska University Hospital in Solna, Karolinska Institutet., 


209. Clinical Study of Determination of Myositis-Associated 

Autoantibodies in Japanese Patients with Connective 

Tissue Diseases except Autoimmune Myositis. Toshio 

Kawamoto 1 , Masakazu Matsushita 1 , Ken Yamaji 1 , 

Naoto Tamura 1 and Yoshinari Takasaki 2 , 1 Juntendo 

University School of Medicine, Tokyo, Japan, 2 Division of 

Rheumatology, Department of Internal Medicine, Juntendo 

University, Tokyo, Japan 

210. An Analysis of Metabolic Syndrome in Adult 

Dermatomyositis with a Focus On Cardiovascular Disease. 

Mariana T. Moraes, Fernando H.C. Souza, Thiago B. M. 

Barros and Samuel K. Shinjo, Faculdade de Medicina da 

Universidade de São Paulo, São Paulo, Brazil 

154 

2012 Program Book


211. Efficacy and Safety of Disease Modifying Drugs, Biologic 

Therapies and Immunoglobulin in Patients with 

Polymyositis and Dermatomyositis: A Systematic Literature 

Review. JA Martinez-Lopez Sr. 1 , J. Graña Sr. 2 , Santiago 

Muñoz-Fernandez 3 , I. Rua-Figueroa 4 , José M. Pego-Reigosa 5 , 

Estíbaliz Loza Sr. 6 and SER group for the study of systemic 

autoimmune diseases 7 , 1 Fundacion Jimenez Diaz, Madrid, 

Spain, 2 Hospital Juan Canalejo, Spain, 3 Hospital Infanta Sofía, 

Madrid, Spain, 4 Hospital de GC Dr Negrin, Las Palmas GC, 

Spain, 5 Hospital do Meixoeiro, Vigo, Spain, 6 Research Unit. 

Sociedad Española de Reumatología, Madrid, Spain, 7 Madrid 

212. Distinctive Characteristics of Anti-Mi-2 and –p155/140 

Autoantibody Production in Two Cohorts of Mexican 

Patients with Dermatomyositis. Monica Vazquez-Del 

Mercado 1 , Marcelo Petri 2 , Luis J. Jara-Quezada 3 , Miguel 

A. Saavedra-Salinas 4 , Claudia Cruz-Reyes 5 , Olga-Lidia 

Vera-Lastra 6 , Lilia andrade 7 , Mario Salazar-Paramo 8 , 

Laura Gonzalez-Lopez 9 , Jorge Gamez-Nava 10 , Rosa E. 

Prieto-Parra 8 , Teresita Martin Marquez 1 , Jason Y.F. Chan 11 , 

Edward K.L. Chan 11 and Minoru Satoh 11 , 1 Universidad 

de Guadalajara, Guadalajara, Mexico, 2 Universidad de 

Guadalajara, Guadalajara, Jalisco, Mexico, Mexico, 3 Hospital 

de Especialidades Centro Médico La Raza, IMSS, Mexico 

City, Mexico, 4 Centro Médico Nacional, México, Mexico, 

5 

Centro Medico La Raza Instituto Mexicano del Seguro Social 

Mexico D.F., Mexico D. F., Mexico, 6 Inst Mexicano Seguro 

Social, Mexico City, Mexico, 7 CMN 20 Noviembre ISS STE, 

Mexico, Mexico, 8 Instituto Mexicano Del SS, Guadalajara, 

Mexico, 9 Hospital Regional de Zona 110, Instituto Mexicano 

del Seguro Social (IMSS), Guadalajara, Jalisco, Mexico, 

Guadalajara, Jalisco, Mexico, Mexico, 10 Centro Medico de 

Occidente, Guadalajara Jal, Mexico, 11 University of Florida, 

Gainesville, FL 

213. Nsaids Suppress the Inflammatory Reaction Related 

to Muscle Soreness but May Delay Recovery. Matthias 

Rother 1 , Egbert J. Seidel 2 , Alexander Fischer 2 and Ilka 

Rother 1 , 1 IMR Partner GmbH, Graefelfing, Germany, 

2 

Sophien- and Hufeland Clinic, Weimar, Germany 

214. Inflammatory Muscle Disease Associated Pulmonary 

Hypertension - Clinical Features and Survival At a National 

Referral Centre. Matthew Webber 1 , D. Dobarro 1 , Clive 

Handler 2 , Christopher P. Denton 3 , Benjamin E. Schreiber 2 

and John G. Coghlan 2 , 1 Royal Free Hospital, London, United 

Kingdom, 2 Royal Free Hospital, London, London, United 

Kingdom, 3 UCL, London, United Kingdom 

215. Abnormal Videofluoroscopy Swallow Study Finding 

in Inflammatory Myopathy Patient with Dysphagia As 

Predictor of Prognosis. Hye Won Kim, Hwang Kim, Sung 

Hae Chang, Hye Jin Oh, Myeong Jae Yoon, Bong Seung Ku, 

Byeong Mo Oh and Eun Young Lee, Seoul National University 

College of Medicine, Seoul, South Korea 

216. Clinical and Serological Associations of Malignancy in 

Adult Patients with Polymyositis and Dermatomyositis. 

Yuji Hosono, Ran Nakashima, Yoshitaka Imura, Naoichiro 

Yukawa, Hajime Yoshifuji, Motomu Hashimoto, Koichiro 

Ohmura, Takao Fujii and Tsuneyo Mimori, Graduate School 

of Medicine, Kyoto University, Kyoto, Japan 

217. Myositis-Associated Usual Interstitial Pneumonia Has 

Better Survival Than Idiopathic Pulmonary Fibrosis. 

Christine McBurney 1 , Rohit Aggarwal 2 , Kevin Gibson 3 , 

Kathleen Lindell 4 , Carl Fuhrman 1 , Diane Koontz 1 , Frank 

Schneider 4 , Naftali Kaminski 4 and Chester V. Oddis 1 , 

1 

University of Pittsburgh, Pittsburgh, PA, 2 University of 

Pittsburgh Medical Center, Pittsburgh, PA, 3 University of 

Pittsburgh School of Medicine, Pittsburgh, PA, 4 Pittsburgh, 

PA 

218. Proteomics Study of a Phase 1b Trial with an Anti-IFN-α 

Monoclonal Antibody Indicates Association of Soluble 

Interleukin 2 Receptor with Type I Interferon Activity in 

Patients with Dermatomyositis or Polymyositis. Xiang Guo, 

Brandon W. Higgs, Wei Zhu, Yihong Yao and Wendy White, 

MedImmune, LLC, Gaithersburg, MD 

219. Significant Functional Improvement Using Aggressive 

Immunomodulatory Therapy in Patients with Inflammatory 

Myopathy and Interstitial Lung Disease. Ramona Mihu 1 , 

Roger D. Rossen 1 , Jovan Popovich 2 and Sandra L. Sessoms 1 , 

1 

Baylor College of Medicine, Houston, TX, 2 The Methodist 

Hospital, Houston, TX 

220. Efficacy of Rituximab for the Treatment of Refractory 

Inflammatory Myopathies Associated with Anti-HistidyltRNA 

Synthetase Antibodies (the FORCE Jo1 Study). 

Yves Allenbach 1 , Aude Rigolet 1 , Marguerite Guiguet 2 , 

Isabelle Marie 3 , Eric Hachulla 4 , Dominique Farge 5 , 

Kuberaka Mariampillai 1 , Serge Jacquot 6 , Fabienne Jouen 7 , 

Olivier Boyer 8 , Lucile Musset 9 , Serge Herson 1 and Olivier 

Benveniste 1 , 1 Pitie-Salpetriere Hospital, Paris, France, 2 Paris, 

France, 3 Service de médecine interne, CHU de Rouen, 

Rouen, France., Rouen, France, 4 Department of Internal 

Medicine, Claude Huriez Hospital, University of Lille, Lille 

CEDEX, France, 5 EBMT, Paris, France, 6 INSERM U905, 

Université de Rouen, Rouen, France, 7 Rouen University 

Hospital, Rouen Cedex, France, 8 INSERM U905, University of 

Rouen, Rouen, France, 9 CHU Pitié-Salpêtrière, Paris, France 

221. Expanding the Clinical and Serological Spectrum of MDA5- 

Associated Dermatomyositis. John C. Hall 1 , Livia Casciola 

Rosen 1 , Sonye K. Danoff 2 , Lesly-Anne Samedy 1 and Lisa 

Christopher-Stine 1 , 1 Johns Hopkins University, Baltimore, 

MD, 2 Johns Hopkins School of Medicine, Baltimore, MD 

222. Lung Nodules in Patients with Idiopathic Inflammatory 

Myopathies. Laura C. Cappelli 1 , Andrew L. Mammen 2 , 

Sonye K. Danoff 3 , Grant H. Louie 1 , Thomas E. Lloyd 2 and Lisa 

Christopher-Stine 1 , 1 Johns Hopkins University, Baltimore, 

MD, 2 Johns Hopkins, Baltimore, MD, 3 Johns Hopkins School 




223. High Prevalence and Clustering Over Time of Anti- 

PL-7 Autoantibody-Positive Idiopathic Inflammatory 

Myopathies. Yoshioki Yamasaki 1 , Minoru Satoh 2 , Hidehiro 

Yamada 1 , Machiko Mizushima 1 , Takahiro Okazaki 1 , Hiroko 

Nagafuchi 1 , Seido Ooka 1 , Tomohiko Shibata 1 , Hiromasa 

Nakano 1 , Hitoshi Ogawa 1 , Kohei Azuma 1 , Akihiko Maeda 1 , 

Hirofumi Mitomi 1 , Tomofumi Kiyokawa 1 , Kosei Tsuchida 1 , 

Hidenori Mikage 1 , Jason Y.F. Chan 2 and Shoichi Ozaki 1 , 1 St. 

Marianna University School of Medicine, Kawasaki, Japan, 

2 

University of Florida, Gainesville, FL 

224. Standardized Incidence Ratios and Predictors of 

Malignancies in 215 Southern Chinese Patients with 

Inflammatory Myopathies. Chi Chiu Mok 1 , Chi Hung To 1 , 

ML Yip 2 and King Yee Ying 3 , 1 Tuen Mun Hospital, Hong Kong, 

Hong Kong, 2 Kwong Wah Hospital, Kowloon, Hong Kong, 

3 

Princess Margaret Hospital, Hong Kong, Hong Kong 

225. Polymyositis in HIV+ Patients Is Associated to Uncontrolled 

Viral Load. Yves Allenbach 1 , Odile Dubourg 1 , Thierry 

Maisonobe 1 , Anthony Behin 2 , Charles Duyckaerts 1 , 

Guillaume Breton 1 , Olivier Fain 3 , Marie-Caroline Meyhoas 4 , 

Catherine Leport 5 , Marc-Antoine Valentin 6 , Daniel Vittecoq 7 , 

Jean-François Bergmann 8 , Thomas Anslik 9 , Marie-Paule 

Chauveheid 10 , Zahir Amoura 11 , Thomas de Broucker 12 , Pierre 

Bourgeois 1 , Bruno Eymard 2 , Serge Herson 1 and Olivier 

Benveniste 1 , 1 Pitie-Salpetriere Hospital, Paris, France, 

2 

Institute of Myology, Pitie-Salpetriere Hospital, Paris, 

France, 3 Service de médecine interne, Université Paris 13, 

AP-HP, Hôpital Jean Verdier, 93140, Bondy, France., Bondy, 

France, 4 Department of Infectious Diseases, Saint Antoine 

Hospital, Paris, France, 5 Paris, France, 6 Department of 

Infectious Diseases, Pitié-Salpetriere Hospital, Paris, France, 

7 

Department of Infectious Diseases, K Bicetre Hospital, 

Kremlin-Bicetre, France, 8 Internal Medicine, Lariboisiere 

Hospital, Paris, France, 9 Internal Medicine, Ambroise Pare 

Hospital, Boulogne Billancourt, France, 10 Internal Medicine, 

Bichat Hospital, Paris, France, 11 CHU Pitié-Salpêtrière, Paris, 

France, 12 Department of Neurology, Delafontaine Hospital, 

Saint Denis, France 

226. Autoantibodies to Small Ubiquitin-Like Modifier Activating 

Enzymes in Japanese Patients with Dermatomyositis. 

Manabu Fujimoto, Takashi Matsushita, Yasuhito Hamaguchi, 

Kenzo Kaji, Minoru Hasegawa and Kazuhiko Takehara, 

Kanazawa University Graduate School of Medical Sciences, 

Kanazawa, Japan 

227. Long Term Outcome of Interstitial Lung Disease in 

Idiopathic Inflammatory Myopathies and Amyopathic 

Dermatomyositis. Machiko Mizushima 1 , Hidehiro Yamada 2 , 

Yoshioki Yamasaki 1 , Masaomi Yamasaki 3 , Minoru Satoh 4 and 

Shoichi Ozaki 5 , 1 St. Marianna University School of Medicine, 

Kawasaki, Japan, 2 St. Marianna University, Kawasaki, Japan, 

3 

St Marianna University, Yokohama City Seibu Hospital, 

Yokohama, Japan, 4 University of Florida, Gainesville, FL, 5 St. 

Marianna University School of Medicine., Kawasaki, Japan 

228. Simultaneous Initiating of Glucocorticoids and disease- 

Modifying Antirheumatic Drug Therapy in Polymyositis and 

Dermatomyositis Patients Results in the Opportunity to 

Taper Dosage of Glucocorticoids Early. Kavish J. Bhansing 1 , 

Piet LCM Van Riel 1 , Sigrid Pillen 2 , Baziel G.M. van Engelen 1 

and Madelon C. Vonk 1 , 1 Radboud University Nijmegen 

Medical Centre, Nijmegen, Netherlands, 2 Catharina 

Wilhemina Hospital, Nijmegen, Netherlands 

229. Clinical Differences between Adult and Juvenile 

Dermatomyositis Associated with Anti-NXP2 

Autoantibodies. Sarah Tansley 1 , Zoe Betteridge 1 , Harsha 

Gunawardena 2 , Lucy R. Wedderburn 3 , Hector Chinoy 4 , 

Robert G. Cooper 5 , Jiri Vencovsky 6 , Lenka Plestilova 7 , 

Ingrid E. Lundberg 8 , Katalin Danko 9 , Melinda Vincze 9 , Neil 

McHugh 1 , UK JDRG 10 and EuMyoNet 11 , 1 Royal National 

Hospital for Rheumatic Diseases, Bath, United Kingdom, 

2 

North Bristol NHS Trust, Bristol, United Kingdom, 

3 

University College London (UCL), London, United 

Kingdom, 4 The University of Manchester, Manchester, 

United Kingdom, 5 Hope Hospital, Salford, United Kingdom, 

6 

Institute of Rheumatology, Prague, Czech Republic, 

7 

Institute of Rheumatology, Prague 2 , Czech Republic, 

8 

Karolinska Institutet, Stockholm, Sweden, 9 University 

of Debrecen, Debrecen, Hungary, Debrecan, Hungary, 

10 

London, United Kingdom, 11 Stockholm, Sweden 

230. Hydroxy-3-Methylglutaryl-Coenzyme A Reductase 

(HMGCoR) Antibody in Necrotizing Myopathy and the Role 

of Statins. Ashima Malik 1 , Rohit Aggarwal 1 , Zengbiao Qi 1 , 

Noreen Fertig 1 , Diane Koontz 1 , Rufus W. Burlingame 2 , David 

Lacomis 3 and Chester V. Oddis 1 , 1 University of Pittsburgh, 

Pittsburgh, PA, 2 INOVA Diagnostics, Inc., San Diego, CA, 

3 

University of Pittsburgh Medical Ctr, Pittsburgh, PA 

231. Pulmonary Hypertension in the Antisynthetase Syndrome. 

Helena andersson 1 , T. Mogens Aalokken 2 , Torhild Garen 3 , 

Oyvind Molberg 4 and Jan Tore Gran 1 , 1 Oslo University 

Hospital, Oslo, Norway, 2 Oslo, Norway, 3 Oslo University 

Hospital Rikshospitalet, Oslo, Norway, 4 Department of 

Rhematology, Oslo University hospital, Rikshospitalet, Oslo, 

Norway 

232. The Natural History of Sporadic Inclusion Body Myositis 

– an Observational Longitudinal Study. Pedro Machado 1 , 

Andrea Cortese 1 , Jasper Morrow 1 , Liz Dewar 1 , andy 

Hiscock 1 , Adrian Miller 1 , Stefen Brady 2 , David Hilton- 

Jones 2 , Matt Parton 1 and Michael G. Hanna 1 , 1 MRC Centre 

for Neuromuscular Diseases, UCL Institute of Neurology, 

London, United Kingdom, 2 Oxford Muscle and Nerve Centre, 

John Radcliffe Hospital, Oxford, United Kingdom 

233. IFN Signature Is Associated with Autoantibody Profiles 

in Patients with Idiopathic Inflammatory Myopathies. 

Saskia Vosslamber 1 , Louise Ekholm 2 , Anna Tjarnlund 3 , Clio 

P. Mavragani 4 , Lenka Plestilova 5 , Martin Klein 5 , Mary K. 

Crow 6 , Peter J. Charles 7 , Leonid Padyukov 8 , Jiri Vencovsky 5 , 

Ingrid E. Lundberg 3 and Cornelis L. Verweij 1 , 1 VU University 

Medical Center, Amsterdam, Netherlands, 2 1Rheumatology 

156 

2012 Program Book


Unit, Department of Medicine, Karolinska University 

Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 

Stockholm, Sweden, 3 Rheumatology Unit, Department of 

Medicine, Karolinska University Hospital, Solna, Karolinska 

Institutet, Sweden, Stockholm, Sweden, 4 School of 

Medicine, University of Athens, Athens, Greece, Athens, 

Greece, 5 Institute of Rheumatology, Prague, Czech Republic, 

6 

Hospital for Special Surgery, New York, NY, 7 Oxford 

University, London, United Kingdom, 8 Rheumatology Unit, 

Karolinska Institutet, Stockholm, Sweden 

Osteoarthritis - Clinical Aspects 

234. Central Sensitization Is Associated with Spontaneous 

Pain in Knee Osteoarthritis. Anisha B. Dua 1 , Tuhina Neogi 2 , 

Rachel A. Mikolaitis 3 , Joel A. Block 3 and Najia Shakoor 3 , 

1 

Rush Universtiy Medical Center, Chicago, IL, 2 Boston Univ 

School of Medicine, Boston, MA, 3 Rush University Medical 

Center, Chicago, IL 

235. Peripheral and Central Sensitization in Patients with 

Different Degree of Knee Osteoarthritis. Lars Arendt- 

Nielsen 1 , Thomas Navndrup Eskehave 2 , Morten Asser 

Karsdal 3 , Anne C. Bay-Jensen 3 , Hans Christian Hoeck 4 and 

Ole Simonsen 5 , 1 Aalborg University, Aalborg, Denmark, 

2 

Ålborg University, Ålborg, Denmark, 3 Nordic Bioscience A/S, 

Herlev, Denmark, 4 C4Pain, Ålborg, Denmark, 5 Frederikshavn 

Hospital, Frederikshavn, Denmark 

236. The Relationship between Vibratory Sense and 

Somatosensory Pain Measures in Knee Osteoarthritis. 

Anisha B. Dua 1 , Rachel A. Mikolaitis 2 , Tuhina Neogi 3 , Joel A. 

Block 2 and Najia Shakoor 2 , 1 Rush Universtiy Medical Center, 

Chicago, IL, 2 Rush University Medical Center, Chicago, IL, 

3 

Boston Univ School of Medicine, Boston, MA 

237. Association between Pain Threshold, Symptoms and 

Radiographic Knee and Hip Osteoarthritis: The Johnston 

County Osteoarthritis Project. Adam P. Goode 1 , Xiaoyan A. 

Shi 2 , Jordan Renner 3 , Richard Gracely 4 , Mehrnaz Maleki- 

Fischbach 5 and Joanne M. Jordan 6 , 1 Duke University, 

Durham, NC, 2 SAS Institute, Inc, Cary, NC, 3 University of 

North Carolina, Chapel Hill, NC, 4 Chapel Hill, NC, 5 National 

Jewish Health, Denver, CO, 6 University of North Carolina 

Thurston Arthritis Research Center, Chapel Hill, NC 

238. Inevitable Deterioration? Trajectories and Risk Profiles 

of Pain in Patients with Radiographic, Symptomatic Knee 

Osteoarthritis. Jamie E. Collins 1 , William M. Reichmann 2 , 

Jeffrey N. Katz 1 and Elena Losina 1 , 1 Brigham and Women’s 

Hospital, Boston, MA, 2 Brigham and Womens Hospital, 

Boston, MA 

239. Knee Osteoarthritis Symptom Assessments That Combine 

Pain and Physical Activity Are Superior to Pain Alone. 

Grace H. Lo 1 , Timothy E. McAlindon 2 , Gillian A. Hawker 3 , 

Jeffrey B. Driban 2 , Lori Lyn Price 2 , Jing Song 4 , Charles Eaton 5 , 

Marc C. Hochberg 6 , Rebecca D. Jackson 7 , C. Kent Kwoh 8 , 

Michael C. Nevitt 9 and Dorothy D. Dunlop 4 , 1 Michael E. 

DeBakey Veterans Affairs Medical Center / Baylor College of 

Medicine, Houston, TX, 2 Tufts Medical Center, Boston, MA, 

3 

Women’s College Research Institute, University of Toronto, 

Toronto, ON, 4 Northwestern University, Chicago, IL, 5 Warren 

Alpert Medical School at Brown University, RI, 6 University of 

Maryland, Baltimore, MD, 7 Ohio State University, Columbus, 

OH, 8 University of Pittsburgh and VA Healthcare System, 

Pittsburgh, PA, 9 University of California-San Francisco, San 

Francisco, CA 

240. Degenerative Changes in Patients with Knee Pain: A 

Comparative Study between Ultrasound and Conventional 

Radiology. Santiago Ruta 1 , Erika Catay 2 , Javier Rosa 2 , 

David A. Navarta 2 , Ricardo Garcia-Monaco 3 and Enrique R. 

Soriano 4 , 1Rheumatology Unit, Internal Medical Services, 


2 


Buenos Aires, Argentina, 3 Radiology and Imagenology 

Department, Hospital italiano de Buenos Aires, Buenos 

Aires, 4 Rheumatology Unit, Internal Medical Services, 

Hospital Italiano de Buenos Aires, Instituto Universitario 

Hospital Italiano de Buenos Aires, and Fundacion PM 

Catoggio, Buenos Aires, Argentina 

241. Excess Body Weight and 4-Year Function Outcomes: 

Comparison of African-Americans and Caucasians in the 

Osteoarthritis Initiative. Carmelita J. Colbert, Orit Almagor, 

Joan S. Chmiel, Jing Song, Dorothy D. Dunlop, Karen W. 

Hayes and Leena Sharma, Northwestern University, Chicago, 

IL 

242. Relationship of Objective to Self-Reported Physical 

Activity Measures Among Adults in the Osteoarthritis 

Initiative. Grace E. Ahn 1 , Jing Song 1 , Jungwha Lee 1 , Pamela 

A. Semanik 1 , Rowland W. Chang 1 , Leena Sharma 1 , Charles 

Eaton 2 , Rebecca Jackson 3 , Alex Mysiw 4 and Dorothy D. 

Dunlop 1 , 1 Northwestern University, Chicago, IL, 2 Warren 

Alpert Medical School at Brown University, RI, 3 Ohio State 

University, Columbus, OH, 4 Denison University, Granville 

243. Relationship of Physical Activity with Health Utility in the 

Osteoarthritis Initiative. Dorothy D. Dunlop 1 , Jing Song 1 , 

Rowland W. Chang 1 , Jungwha Lee 1 , Pamela A. Semanik 2 , 

Linda S. Ehrlich-Jones 3 , Kai Sun 1 , Leena Sharma 1 , C. Kent 

Kwoh 4 , Charles Eaton 5 and Larry Manheim 1 , 1 Northwestern 

University, Chicago, IL, 2 Rehabilitation Institute Chicago, 

Oak Park, IL, 3 Rehabilitation Institute Chicago, Chicago, 

IL, 4 University of Pittsburgh and VA Healthcare System, 

Pittsburgh, PA, 5 Warren Alpert Medical School at Brown 

University, RI 

244. Minimal Clinically Important Difference and Patient 

Acceptable Symptom State for the Oarsi-Omeract 

Intermittent and Constant OA Pain (ICOAP) Measure. Z. 

Anna Liu, Tetyana Kendzerska, Joy Elkayam, Shefali Ram 

and Gillian A. Hawker, Women’s College Research Institute, 


245. Similarities of Patient Self-Report Scores From a 

Multidimensional Health Assessment Questionnaire 

(MDHAQ), Laboratory Tests, Physician Global Assessment, 



and Polyarticular Involvement in Patients with 

Osteoarthritis and Rheumatoid Arthritis. Isabel Castrejón, 

Yusuf Yazici and Theodore Pincus, NYU Hospital for Joint 

Diseases, New York, NY 

246. Routine Assessment of Patient Index Data 3 (RAPID3) Is a 

Valid Index for Routine Care in Patients with Osteoarthritis. 

Alfredomaria Lurati 1 , Luca Bertani 1 , Daniela Bompane 1 , 

Mariagrazia Marrazza 1 , Katia Angela Re 1 and Magda 

Scarpellini 2 , 1Rheumatology Unit, Magenta, Italy, 2 Ospedale 

Fornaroli, Magenta, Italy 

247. Meager Depression Screening and Mental Health Referral 

Rates for Patients with Arthritis in a National Sample. 

Mary Margaretten, Patricia P. Katz, Laura Trupin, Gabriela 

Schmajuk, Jennifer Barton, Jinoos Yazdany and Edward Yelin, 

UCSF, San Francisco, CA 

248. Synovial Fluid Leptin Level Is Associated with Residual 

Pain and Functional Disability One Year After Total Joint 

Arthroplasty. Anne Lübbeke 1 , Gabor J. Puskas 1 , Axel Finckh 2 , 

Domizio Suva 1 , Sylvette Bas 3 , Cem Gabay 1 , Daniel Fritschy 1 

and Pierre Hoffmeyer 1 , 1 Geneva University Hospitals, 

Geneva, Switzerland, 2 Geneva University Hospitals, Geneva 

14 

, Switzerland, 3 Geneva University Hospitals, Switzerland 

249. Medial Subchondral Bone Marrow Lesions Increase 

the Odds of Knee Joint Replacement – Data From the 

Osteoarthritis Initative. Frank Roemer 1 , C. Kent Kwoh 2 , 

David Hunter 3 , Michael J. Hannon 4 , Robert M. Boudreau 5 , 

Felix Eckstein 6 , Zhijie Wang 4 , Markus R. John 7 and Ali 

Guermazi 8 , 1 Klinikum Augsburg, Augsburg, Germany, 

2 

University of Pittsburgh and VA Healthcare System, 

Pittsburgh, PA, 3 University of Sydney, Sydney, Australia, 

4 

University of Pittsburgh School of Medicine, Pittsburgh, PA, 

5 

University of Pittsburgh, Pittsburgh, PA, 6 Paracelsus Medical 

University, Salzburg, Austria, 7 Novartis Pharma AG, Basel, 

Switzerland, 8 Boston University School of Medicine, Boston, 

MA 

250. Incident and Worsening Cartilage Damage in the Lateral 

Compartment and Multiple Subregions Worsening in 

the Medial Compartment Increase the Risk for Knee 

Replacement - Data From the Osteoarthritis Initiative. 

Frank Roemer 1 , C. Kent Kwoh 2 , Michael J. Hannon 3 , Robert 

M. Boudreau 4 , Felix Eckstein 5 , David J. Hunter 6 , Zhijie Wang 3 , 

Markus R. John 7 and Ali Guermazi 8 , 1 Klinikum Augsburg, 

Augsburg, Germany, 2 University of Pittsburgh and VA 

Healthcare System, Pittsburgh, PA, 3 University of Pittsburgh 

School of Medicine, Pittsburgh, PA, 4 University of Pittsburgh, 

Pittsburgh, PA, 5 Paracelsus Medical University, Salzburg, 

Austria, 6 Royal North Shore Hospital, Sydney, Australia, 

7 

Novartis Pharma AG, Basel, Switzerland, 8 Boston University 

School of Medicine, Boston, MA 

251. Smaller Baseline and Follow-up Quadriceps Muscle Cross- 

Sectional Area Increases the Odds of Knee Replacement 

in Knee Osteoarthritis. Serter Gumus 1 , Michael J. Hannon 2 , 

Diana Kaya 1 , C. Kent Kwoh 3 and Kyongtae Ty Bae 1 , 1 University 

of Pittsburgh, Pittsburgh, PA, 2 University of Pittsburgh School 

of Medicine, Pittsburgh, PA, 3 University of Pittsburgh and VA 

Healthcare System, Pittsburgh, PA 

252. Presence of Severe Medial Mensical Pathology Increases 

the Odds for Knee Replacement: Data From the 

Osteoarthritis Initiative. Frank Roemer 1 , C. Kent Kwoh 2 , 

David J. Hunter 3 , Robert M. Boudreau 4 , Michael J. Hannon 5 , 

Markus R. John 6 , Felix Eckstein 7 , Michel Crema 8 , Zhijie 

Wang 5 and Ali Guermazi 9 , 1 Klinikum Augsburg, Augsburg, 

Germany, 2 University of Pittsburgh and VA Healthcare 

System, Pittsburgh, PA, 3 Royal North Shore Hospital, 

Sydney, Australia, 4 University of Pittsburgh, Pittsburgh, PA, 

5 


PA, 6 Novartis Pharma AG, Basel, Switzerland, 7 Paracelsus 

Medical University, Salzburg, Austria, 8 Boston University, 

Boston, MA, 9 Boston University School of Medicine, Boston, 

MA 

253. Incidence of Osteoarthritis-Related Knee and Hip Joint 

Surgery in Southern Sweden. Aleksandra Turkiewicz, 

Ingemar F. Petersson, Leif E. Dahlberg and Martin Englund, 

Department of Orthopedics, Clinical Sciences Lund, Lund 

University, Lund, Sweden 

254. Effects of Strontium Ranelate on Knee Osteoarthritis Pain: 

A Responder Analysis. JY. Reginster 1 , Roland Chapurlat 2 , 

N. Bellamy 3 , E. Czerwinski 4 , JP Devogelaer 5 , L. March 6 , K. 

Pavelka 7 and Cyrus Cooper 8 , 1 University of Liège, Liège, 

Belgium, 2 Hôpital Edouard Herriot, Lyon, France, 3 CONROD. 

The University of Queensland, Royal Brisbane and Women’s 

Hospital, Herston, Queensland, Australia, 4 Krakow Medical 

Centre, Kraków, Poland, 5 Cliniques Universitaires St. Luc, 

Brussels, Belgium, 6 University of Sydney, Institute of Bone 

and Joint Research, Royal North Shore Hospital, St Leonards 

- Sydney, Australia, 7 Institute of Rheumatology, Prague 2 , 

Czech Republic, 8 University of Oxford; Southampton General 

Hospital, Southampton, United Kingdom 

255. Clinically Meaningful Effect of Strontium Ranelate on 

Knee Osteoarthritis Symptoms. O. Bruyere 1 , N. Bellamy 2 , J. 

Brown 3 , P. Richette 4 , L. Punzi 5 , X. Chevalier 6 , Cyrus Cooper 7 

and Jean-Yves Reginster 1 , 1 University of Liège, Liège, 

Belgium, 2 CONROD. The University of Queensland, Royal 

Brisbane and Women’s Hospital, Herston, Queensland, 

Australia, 3 Rheumatology Centre,, Quebec City, QC, 4 Hôpital 

Lariboisière, Paris, France, 5 Azienda Ospedaliera di Padova, 

Padova, Italy, 6 Hôpital Henri-Mondor, Creteil, France, 

7 

University of Oxford; Southampton General Hospital, 

Southampton, United Kingdom 

256. Strontium Ranelate Decreases the Level of Urinary CTX-II 

in Patients with Knee Osteoarthritis. Julien Collette 1 , Olivier 

Bruyere 2 and Jean-Yves Reginster 3 , 1 Labo Ria Chu Sart 

Tilman, Liege, Belgium, 2 Universite De Liege, Liege, Belgium, 

3 

University of Liège, Liège, Belgium 

257. Meta-Analysis of Four 12-Week Phase III Clinical Trials 

Investigating the Effect of TDT 064, a Transdermal Gel, in 

Osteoarthritis of the Knee. Matthias Rother 1 , Johannes C. 

Vester 2 , Wolfgang W. Bolten 3 and Philip G. Conaghan 4 , 1 IMR 

158 

2012 Program Book


Partner GmbH, Graefelfing, Germany, 2 IDV Data Analysis and 

Study Planning, Krailling, Germany, 3 Klaus-Miehlke-Klink, 

Wiesbaden, Germany, 4 University of Leeds, Leeds, United 

Kingdom 

258. Efficacy and Safety of the Chinese Herbal Compound 

Hou-Lou-Xiao-Ling Dan in Patients with Osteoarthritis of 

the Knee: Results of a Phase II International Study. Marc 

C. Hochberg 1 , Lixing Lao 1 , Patricia Langenberg 1 , Harry H. S. 

Fong 2 , David Y-W. Lee 3 and Brian Berman 1 , 1 University of 

Maryland, Baltimore, MD, 2 University of Illinois at Chicago, 

Chicago, IL, 3 Harvard Medical School, Boston, MA 

259. Long-Term Tanezumab Treatment for Osteoarthritis: 

Efficacy and Safety Results. Alfonso E. Bello 1 , Evan F. 

Ekman 2 , David Radin 3 , Isabelle Davignon 4 , Michael D. Smith 4 , 

Mark T. Brown 4 , Christine R. West 5 and Kenneth M. Verburg 4 , 

1 

Illinois Bone & Joint Institute, Glenview, IL, 2 Southern 

Orthopaedic Sports Medicine, Columbia, SC, 3 Stamford 

Therapeutics Consortium, Stamford, CT, 4 Pfizer, Groton, CT, 

5 

Pfizer, Williamston, MI 

260. Adjudication of Reported Serious Adverse Joint Events 

in the Tanezumab Clinical Development Program. Marc 

C. Hochberg 1 , Steven B. Abramson 2 , David S. Hungerford 3 , 

Edward McCarthy 4 , Eric P. Vignon 5 , Michael D. Smith 6 , 

Leslie Tive 7 , Kenneth M. Verburg 6 and Christine R. West 8 , 

1 

University of Maryland, Baltimore, MD, 2 NYU Hospital for 

Joint Diseases, New York, NY, 3 Johns Hopkins University, 

Baltimore, MD, 4 The Johns Hopkins University School of 

Medicine, Baltimore, MD, 5 Centre Hospitalier, Pierre Benite, 

France, 6 Pfizer, Groton, CT, 7 Pfizer Inc, New York, NY, 8 Pfizer, 

Williamston, MI 

261. Effect of Advancing Age on the Gastrointestinal Safety 

of Celecoxib versus Nonselective Nonsteroidal Anti- 

Inflammatory Drugs: A Post Hoc Analysis of GI-Reasons. 

Lee S. Simon 1 , Byron Cryer 2 , Gurkirpal Singh 3 , Chunming 

Li 4 and Margaret Noyes Essex 5 , 1 SDG LLC Consulting, West 

Newton, MA, 2 University of Texas Southwestern Medical 

Center, Dallas, TX, 3 Stanford University School of Medicine, 

Palo Alto, CA, 4 Pfizer Inc, New York, NY, 5 Pfizer, Inc, New 

York, NY 

262. Flexible Footwear Reduces Dynamic Joint Loads in 

Knee Osteoarthritis: Results of a 6 Month Randomized 

Controlled Trial Najia Shakoor 1 , Roy H. Lidtke 1 , Louis F. 

Fogg 2 , Rachel A. Mikolaitis 1 , Markus A. Wimmer 1 , Kharma 

C. Foucher 1 , Laura E. Thorp 1 and Joel A. Block 1 , 1 Rush 

University Medical Center, Chicago, IL, 2 Rush University 

Medical Center 

263. Efficacy of Ketoprofen Vs Ibuprofen and Diclofenac: A 

Systematic Review of the Literature and Meta-Analysis. 

Fabiola Atzeni 1 , Pier Carlo Sarzi-Puttini 1 , Luigi Lanata 2 and 

Michela Bagnasco 2 , 1 University Hospital L Sacco, Milan, Italy, 

2 

Dompé SpA, Milan, Italy 

264. Specialized Footwear Decreases Medial Tibial Bone 

Mineral Density Over 48 Weeks in Knee Osteoarthritis. 

Justin B. Gan, Laura E. Thorp, Roy H. Lidtke, Rachel A. 

Mikolaitis, Louis F. Fogg, Joel A. Block and Najia Shakoor, 

Rush University Medical Center, Chicago, IL 

265. Reducing Loads in the Contralateral Side in Medial Knee 

Osteoarthritis; A 3-Year Follow-up Study. Roy H. Lidtke and 

Joel A. Block, Rush University Medical Center, Chicago, IL 

266. Knee Joint Stabilization Therapy in Patients with 

Osteoarthritis of the Knee: A Randomized, Controlled 

Trial. Jesper Knoop 1 , Joost Dekker 2 , Marike van der Leeden 3 , 

Martin van der Esch 1 , Carina A. Thorstensson 4 , Martijn 

Gerritsen 1 , Ramon E. Voorneman 1 , Wilfred FH Peter 1 , 

Mariette de Rooij 1 , Suzanne Romviel 1 , Willem F. Lems 5 , Leo 

D. Roorda 3 and Martijn P.M. Steultjens 6 , 1 Reade, centre for 

rehabilitation and rheumatology, Amsterdam, Netherlands, 

2 

VU University Medical Centre, Department of Rehabilitation 

Medicine, EMGO Institute and Department of Psychiatry, 

Amsterdam, Netherlands, 3 Reade, Amsterdam, Netherlands, 

4 

University of Gothenburg, Institute of Neuroscience and 

Physiology, Gothenburg, Sweden, 5 VU University Medical 

Center, Amsterdam, Netherlands, 6 Glasgow Caledonian 

University, Glasgow, Scotland 

267. Osteopontin in Patients with Primary Knee Osteoarthritis: 

Relation to Disease Severity. Ramy Abdelnaby, Ain Shams 

University, Cairo, Egypt 

268. Knee Osteoarthritis and Serum Uric Acid Concentration: 

The Third National Health and Examination Survey. Tony 

Ning, Carl Pieper, Virginia B. Kraus, William E. Kraus and Kim 

M. Huffman, Duke University Medical Center, Durham, NC 

269. Differences Between Patients with Hip and Knee 

Osteoarthritis. Kim F. Le Marshall 1 , Bradley Yee 2 , Paul A. 

Dieppe 2 , Albert Leung 1 , Carolyn Page 3 , Peter F. Choong 3 , 

Michelle Dowsey 3 and Keith K. Lim 1 , 1 Western Hospital, 

Melbourne, Australia, 2 University of Plymouth Campus, 

Plymouth, United Kingdom, 3 St Vincent’s Hospital, 

Melbourne, Australia 

270. Use of Drug Combinations in Patients with Osteoarthritis: 

A Population-Based Cohort Study. Daniel Prieto-Alhambra 1 

and Rosa Morros 2 , 1 URFOA-IMIM, Parc de Salut Mar; Idiap 

Jordi Gol; University of Oxford; University of Southampton, 

Barcelona, Spain, 2 IDIAP Jordi Gol; Institut Català de la Salut, 

Spain 

271. Bone Marrow Lesions in Knees with Osteoarthritis: Can 

Parameters From Dynamic Contrast Enhancement Predict 

Change in Bone Marrow Lesion Volume or Knee Pain 

Change? Andrew D. Gait 1 , Timothy F. Cootes 1 , Elizabeth J. 

Marjanovic 1 , Matthew J. Parkes 1 , Charles E. Hutchinson 2 and 

David T. Felson 1 , 1 University of Manchester, Manchester, 

United Kingdom, 2 University of Warwick, Coventry, United 

Kingdom 



160 

272. Interim Safety Analysis of a Phase 2 , Multicenter, 

Randomized, Double-Blind, Placebo-Controlled, Parallel- 

Group, Efficacy Study of Apremilast (CC10004) in Subjects 

with Erosive Hand Osteoarthritis. Juergen Rech 1 , Wolfgang 

Ochs 2 , Wolfgang Spieler 3 , Herbert Kellner 4 , Ulf Müller- 

Ladner 5 , Mathias Grunke 6 , Matthias Schneider 7 and Georg 

Schett 8 , 1 University of Erlangen-Nuremberg, Erlangen, 

Germany, 2 Rheumatology Practice, Bayreuth, Bayreuth, 

Germany, 3 Rheumatology Specialty Practice, Zerbst, 

Germany, 4 Centre for Inflammatory Joint Diseases, Munich, 

Germany, 5 Kerckhoff-Klinik GmbH, Bad Nauheim, Germany, 

6 

Medizinische Klinik und Poliklinik IV, University of Munich, 

Munich, Germany, 7 Heinrich-Heine-University, Duesseldorf, 



273. The Prevalence of Periarticular Lesions On Magnetic 

Resonance Imaging and Its Relation to Knee Pain in the 

Community Residents in Korea. In Je Kim 1 , Kyeong Min 

Son 2 , DH Kim 3 , Yeong Wook Song 4 , Ali Guermazi 5 and Hyun 

Ah Kim 6 , 1 Hallym University Kangdong Sacred Heart hospital, 

Seoul, South Korea, 2 Hallym university Chunchun sacred 

heart hospital, Chunchun, South Korea, 3 Chunchon, South 

Korea, 4 Seoul National University Hospital, Seoul, South 

Korea, 5 Boston University School of Medicine, Boston, MA, 

6 

Hallym University Sacred Heart Hospital, Kyunggi, South 

Korea 

Pediatric Rheumatology - Clinical and Therapeutic Aspects: 

Pediatric Systemic Lupus Erythematosus, Pediatric Vasculitis and 

Pediatric Myositis 

274. Childhood Onset Angiitis of the Central Nervous System: 

What Outcomes Can We Expect? Lena Das, Sook Fun Hoh, 

Terrence Thomas and Thaschawee Arkachaisri, KK Women’s 

and Children’s Hospital, Singapore, Singapore 

275. Pediatric Rheumatology Practitioners Experience with 

Biologics in Juvenile Dermatomyositis: Survey Results. 

Anjali Patwardhan 1 , Kelly Rouster-Stevens 2 , Harry L. 

Gewanter 3 , Grant D. Syverson 4 , Renee F. Modica 5 , Kara M. 

Schmidt 6 and Charles H. Spencer 1 , 1 Nationwide Childrens 

Hospital, Columbus, OH, 2 Emory-Children’s Center, Atlanta,, 

GA, 3 Pediatric & Adolescent HP, Midlothian, VA, 4 Medical 

College of Wisconsin, Wauwatosa, WI, 5 University of Florida, 

Gainesville, FL, 6 Univ of Louisville, Louisville, KY 

276. Development of a Longitudinal, Propective Cohort of 

Young Adults with Childhood-Onset Systemic Lupus 

Erythematosus. Aimee O. Hersh 1 , Erica F. Lawson 2 , Emily von 

Scheven 2 , Edward Yelin 3 and John F. Bohnsack 1 , 1 University 

of Utah, Salt Lake City, UT, 2 UC San Francisco, San Francisco, 

CA, 3 University of California San Francisco, San Francisco, CA 

277. Dyslipidemia in Juvenile Dermatomyositis: The Role of 

Disease Activity. Katia T. Kozu 1 , Clovis Artur Silva 2 , Eloisa 

Bonfa 1 , Adriana M. Sallum 3 , Rosa M.R. Pereira 4 , Vilma 

S. Viana 1 , Eduardo F. Borba 5 and Lucia M. A. Campos 1 , 

1 


Paulo, Brazil, 2 Paediatric Rheumatology International Trials 


Organization (PRINTO), Istituto Giannina Gaslini, Genova, 

Italy, 3 Faculdade de Medicina da Universidade de São Paulo, 

São Paulo-SP, Brazil, 4 University of São Paulo, São Paulo, 

Brazil, 5 University of Sao Paulo, Sao Paulo, Brazil 

278. Evaluating Cardiovascular Risk Factors of Impaired Glucose 

Tolerance, Diabetes Mellitus, and Metabolic Syndrome in 

a Primarily Latino Population with Pediatric Rheumatic 

Diseases Associated with Vasculitis. Sara M. Stern, Jamie 

Wood, Katherine AB Marzan, Andreas Reiff, Bracha Shaham 

and Diane Brown, Children’s Hospital Los Angeles, Los 

Angeles, CA 

279. Distribution of Vasculitides in Childhood Arthritis and 

Rheumatology Research Alliance-Affiliated Pediatric 

Rheumatology Centers in the United States. Melissa A. 

Lerman 1 , Peter A. Merkel 2 and for the CARRA Registry 

Investigators 3 , 1 Children’s Hospital of Philadelphia, 

Philadelphia, PA, 2 University of Pennsylvania, Philadelphia, 

PA, 3 Stanford 

280. Pediatric Automated Neuropsychological Assessment 

Metrics As a Screening Tool for Neuropsychiatric 

Childhood-Onset Systemic Lupus Erythematosus. Patricia 

Vega-Fernandez 1 , Eyal Muscal 2 , Natasha M. Ruth 3 , Frank 

Zelko 4 , Andrea Vincent 5 , Erin C. Thomas 6 , Marisa S. Klein- 

Gitelman 7 , Debra Canter 8 , Alison Tian 9 , Lisa Ravindra 10 , 

HaiMei Liu 11 , Jessica Hummel 12 , Deborah M. Levy 9 , Hermine 

Brunner 13 and Tresa Roebuck-Spencer 5 , 1 Cincinanti Children’s 

Hospital Medical Center, Cincinnati, OH, 2 Baylor College 

of Medicine, Houston, TX, 3 Medical University of South 

Carolina, Charleston, SC, 4 Children’s Memorial Hospital, 

Chicago, IL, 5 University of Oklahoma, Norman, OK, 6 Anne 

and Robert C Lurie Hospital, Feinstein School of Medicine, 

Northwestern University, Chicago, IL, 7 Ann & Robert H. Lurie 

Children’s Hospital of Chicago, Chicago, IL, 8 Baylor College 

of Medicine, Texas Children’s Hospital, Houston, TX, 9 The 

Hospital for Sick Children, Toronto, ON, 10 University Hospital, 

Cincinnati, Cincinnati, OH, 11 Children’s Hospital of Fundan 

University, Shanghai, China, 12 Cincinnati Children’s Hospital 

Medical Center, Cincinnati, OH, 13 Cincinnati Children’s 

Hospital Medical Center and PRSCG, Cincinnati, OH 

281. The Pediatric Automated Neuropsychological Assessment 

Metrics - Reproducibility and Responsive to Change 

in Cognition in Childhood-Onset Lupus. Patricia Vega- 

Fernandez 1 , Marisa S. Klein-Gitelman 2 , Jessica Hummel 3 , 

Erin C. Thomas 4 , Jennifer L. Huggins 3 , Frank Zelko 5 , Tresa 

Roebuck-Spencer 6 , Jun Ying 7 and Hermine Brunner 8 , 

1 

Cincinanti Children’s Hospital Medical Center, Cincinnati, 

OH, 2 Ann & Robert H. Lurie Children’s Hospital of Chicago, 

Chicago, IL, 3 Cincinnati Children’s Hospital Medical Center, 

Cincinnati, OH, 4 Anne and Robert C Lurie Hospital, Feinstein 

School of Medicine, Northwestern University, Chicago, IL, 

5 

Children’s Memorial Hospital, Chicago, IL, 6 University of 

Oklahoma, Norman, OK, 7 University of Cincinnati, Cincinnati, 

OH, 8 Cincinnati Children’s Hospital Medical Center and 

PRSCG, Cincinnati, OH


282. Clinical and Laboratory Features Distinguishing Juvenile 

Polymyositis and Muscular Dystrophy in Children. Gulnara 

Mamyrova 1 , James D. Katz 1 , Robert V. Jones 1 , Peter A. 

Lachenbruch 2 , Mona Shah 2 , Olcay Y. Jones 1 , Anupam 

Chahal 1 , Seema Agrawal 1 , Frederick W. Miller 2 , Lisa G. Rider 2 

and the Childhood Myositis Heterogeneity Group 3 , 1 George 

Washington University, Washington, DC, 2 NIEHS, NIH, 

Bethesda, MD, 3 Bethesda, MD 

283. Hospitalizations for Patients with Chilhood-Onset Systemic 

Lupus Erythematosus in the Pediatric Health Information 

System Databse. Aimee O. Hersh, Charlie Casper, Tellen D. 

Bennett, Susan L. Bratton, John F. Bohnsack and Rajendu 

Srivastava, University of Utah, Salt Lake City, UT 

284. Treatment and Outcome of ANCA-Associated Vasculitis 

in Children: A Pilot Study. Marinka Twilt 1 , Audrey Bell- 

Peter 1 , Ronald M. Laxer 1 , Christian Pagnoux 2 , Diane Hebert 3 , 

Elizabeth Harvey 3 , Shehla Sheikh 1 and Susanne M. Benseler 1 , 

1 

The Hospital for Sick Children, Toronto, ON, 2 Mount Sinai 

Hospital, Toronto, ON, 3 Hospital for Sick Children, Toronto, 

ON 

285. Rituximab for Severe Disease Flares in Childhood ANCA 

Vasculitides. Marinka Twilt 1 , Rayfel Schneider 1 , Audrey 

Bell-Peter 1 , Sharon Dell 2 and Susanne M. Benseler 1 , 1 The 

Hospital for Sick Children, Toronto, ON, 2 the Hospital for Sick 

Children, Toronto, ON 

286. The Association of N-Methyl-D-Aspartate Receptor 

Antibodies and Neurocognitive Dysfunction in Pediatric 

Lupus Patients and in the Offspring of Adult Patients 

with Lupus. Natasha M. Ruth 1 , Mary C. Kral 2 , Stephanie 

Slan 3 , Tamara K. Nowling 1 , Murray H. Passo 1 and Gary S. 

Gilkeson 1 , 1 Medical University of South Carolina, Charleston, 

SC, 2 MUSC, Charleston, SC, 3 Medical University of South 

Carolina, Charlestons, SC 

287. Variation in Healthcare Utilization by Region and 

Number of Rheumatologists Per State Among Pediatric 

Medicaid Patients with Lupus Nephritis Prior to End-Stage 

Renal Disease in the United States, 2000-2004. Linda T. 

Hiraki 1 , Candace H. Feldman 2 , Graciela S. Alarcon 3 , Jun 

Liu 4 , Michael A. Fischer 2 , Wolfgang C. Winkelmayer 5 and 

Karen H. Costenbader 6 , 1 Brigham and Women’s Hospital, 

Harvard School of Public Health, Boston, MA, 2 Brigham and 

Women’s Hospital, Boston, MA, 3 University of Alabama 

at Birmingham, Birmingham, AL, 4 Brigham and Women’s 

Hospital, Harvard Medical School, Boston, Boston, MA, 

5 

Stanford University School of Medicine, Stanford, CA, 

6 


Boston, MA 

288. Validation of Promis Modules for Use in Childhood- 

Onset Lupus. Alexandria J. Greenler 1 , Laura E. Schanberg 2 , 

Michael P. Flannery 1 , Shannen Nelson 1 , Janet Wootton 2 , Esi 

M. Morgan DeWitt 1 and Hermine I. Brunner 1 , 1 Cincinnati 

Children’s Hospital Medical Center, Cincinnati, OH, 2 Duke 

University Medical Center, Durham, NC 

289. Mycophenolate Mofetil and Abatacept Combination 

Therapy in Refractory Pediatric Systemic Lupus 

Erythematosus Nephritis. Rhina Castillo 1 , Suhas M. 

Radhakrishna 2 , Andreas O. Reiff 1 and Katherine AB Marzan 1 , 

1 

Children’s Hospital Los Angeles, Los Angeles, CA, 2 Kaiser 

Permananete Medical Group, Oakland, CA 

290. Long-Term Outcomes in Neonatal Lupus. Amit Saxena 1 , 

Peter M. Izmirly 2 , Deborah Friedman 3 and Jill P. Buyon 2 , 

1 

New York University School of Medicine, New York, NY, 

2 

NYU School of Medicine, New York, NY, 3 New York Medical 

College, Valhalla, NY 

291. Illness Features Associated with an Increased Risk of 

Mortality in Children with Juvenile Idiopathic Inflammatory 

Myopathies. Adam M. Huber 1 , Gulnara Mamyrova 2 , Julia 

A. Lee 3 , Peter A. Lachenbruch 4 , Ira N. Targoff 5 , Frederick W. 

Miller 4 , Lisa G. Rider 4 and Childhood Myositis Heterogeneity 

Study Group 6 , 1 Dalhousie University, Halifax, NS, 2 George 

Washington University, Washington, DC, 3 NIEHS, Bethesda, 

MD, 4 NIEHS, NIH, Bethesda, MD, 5 Oklahoma Medical 

Research Foun, Oklahoma City, OK, 6 Bethesda 

292. Clinical Utility of Anti-CADM-140/Melanoma 

Differentiation-Associated Gene 5 Autoantibody Titers 

in Patients with Juvenile Dermatomyositis and Rapidly 

Progressive Interstitial Lung Disease. Shinji Sato 1 , Norimoto 

Kobayashi 2 , Kazuko Yamazaki 3 and Yasuo Suzuki 1 , 1 Tokai 

University School of Medicine, Isehara, Japan, 2 Shinshu 

University School of Medicine, Matsumoto, Japan, 

3 

Yokohama City University Hospital, Yokohama, Japan 

293. Usefulness of Cardiac Magnetic Resonance in the 

Assessment of Myocardial Inflammation and Fibrosis in 

Children Born to Mothers with Anti-SSA/Ro Antibodies: 

A Prospective Study of 23 Cases and 6 Controls. Nathalie 

Costedoat-Chalumeau 1 , Alice Maltret 2 , Kateri Levesque 1 , 

Shelby Kutty 3 , Elisabeth Villain 2 , Phalla Ou 2 and Gaëlle 

Guettrot-Imbert 4 , 1 Assistance Publique-Hôpitaux de Paris, 

Hopital Pitié-Salpétrière, Paris, France, 2 Groupe Hospitalier 

Necker - Enfants Malades, Paris, France, 3 Division of 

Pediatric Cardiology, university of Nebraska Medical Center 

and Children’s Hospital ans Medical Center, Omaha, NE, 

USA, Omaha, 4 Hopital Gabriel Montpied, Clermont-Ferrand, 

France 

294. Effects of Obesity On Health-Related Quality of Life in 

Childhood-Onset Systemic Lupus Erythematosus. Rina 

Mina 1 , Marisa S. Klein-Gitelman 2 , Shannen Nelson 3 , Lori 

B. Tucker 4 , B. Anne Eberhard 5 , Nora G. Singer 6 , Deborah 

M. Levy 7 , Kathleen A. Haines 8 , Karen Onel 9 , Marilynn G. 

Punaro 10 , Kathleen M. O’Neil 11 , Michael Henrickson 12 , 

Jun Ying 13 and Hermine I. Brunner 3 , 1 Cincinnati Children’s 

Hospital Medical Center/ University of Cincinnati, Cincinnati, 

OH, 2 Ann & Robert H. Lurie Children’s Hospital of Chicago, 

Chicago, IL, 3 Cincinnati Children’s Hospital, Cincinnati, OH, 

4 

BC Childrens Hospital, Vancouver, BC, 5 Cohen Children’s 

Hospital Medical Center, New Hyde Park, NY, 6 Director, 

Division of Rheumatology, MetroHealth Medical Center, 

Case Western Reserve University, Cleveland, OH, 7 The 



Hospital for Sick Children, Toronto, ON, 8 Hackensack Univ 

Med Ctr, Hackensack, NJ, 9 University of Chicago, Chicago, IL, 

10 

Texas Scottish Rite Hospital, Dallas, TX, 11 Riley Hospital for 

Children, Indianapolis, IN, 12 Cincinnati Children’s Hospital 

Medical Center, Cincinnati, OH, 13 University of Cincinnati, 


295. Brain Biopsy Diagnosis in Magnetic Resonance Imaging 

Negative Childhood Primary Angiitis of the Central Nervous 

System. Senq-J Lee, Cynthia Hawkins, Suzanne Laughlin, 

Shehla Sheikh and Susanne M. Benseler, The Hospital for 

Sick Children, Toronto, ON 

296. A Brazilian Multicenter Study of 71 Children and 

Adolescents with Takayasu’s Arteritis. Maria Teresa 

Terreri 1 , Gleice Clemente 2 , Clovis Silva 3 , Silvana Sacchetti 4 , 

Adriana M. Sallum 5 , Lucia M. A. Campos 6 , Maria Carolina 

Santos 4 , Flavio Sztajnbok 7 , Rozana Gasparello de Almeida 7 , 

Virginia P. Ferriani 8 , Blanca E. Bica 9 , Teresa Robazzi 10 , 

Marcia Bandeira 11 , andre Cavalcanti 12 , Marise Lessa 13 , 

Sheila K. Feitosa de Oliveira 13 and Maria Odete Hilario 14 , 

1 

Universidade Federal de São Paulo / UNIFESP, Sao Paulo, 

Brazil, 2 Universidade Federal de São Paulo - Unifesp, São 

Paulo, Brazil, 3 MD; PhD, São Paulo-SP, Brazil, 4 Santa Casa 

de Misericórdia de São Paulo, São Paulo, Brazil, 5 Faculdade 

de Medicina da Universidade de São Paulo (FMUSP), São 

Paulo-SP, Brazil, 6 University of São Paulo Medical School, 

São Paulo, Brazil, 7 Universidade do Estado do Rio de Janeiro, 

Rio de Janeiro, Brazil, 8 FMUSP-Ribeirao Preto, Ribeirao 

Preto, Brazil, 9 International Investigator Consortium for MAS 

Diagnostic Criteria, Rio de Janeiro, Brazil, 10 Universidade 

Federal da Bahia, 11 Hospital Infantil Pequeno Príncipe, 

Curitiba, Brazil, 12 Universidade Federal de Pernambuco, 

Recife, Brazil, 13 Universidade Federal do Rio de Janeiro, Rio 

de Janeiro, Brazil, 14 Universidade Federal de Sao Paulo / 

UNIFESP, Sao Paulo, Brazil 

297. Effectiveness of Intravenous Cyclophosphamide in Severe 

or Refractory Juvenile Dermatomyositis - A National Cohort 

Study: UK and Ireland. Elena Moraitis 1 , Katie Arnold 2 , 

Clarissa Pilkington 1 and Juvenile Dermatomyositis Research 

Group 3 , 1 Great Ormond Street Hospital, London, United 

Kingdom, 2 UCL Institute of Child Health, London, United 

Kingdom, 3 London, United Kingdom 

298. Childhood-Onset Predicts Increased Disease Damage 

and Steroid Toxicity in a Cohort of Adults with Systemic 

Lupus Erythematosus. Erica F. Lawson 1 , Laura Trupin 1 , 

Jinoos Yazdany 1 , Aimee O. Hersh 2 , Emily von Scheven 1 and 

Edward H. Yelin 1 , 1 University of California San Francisco, San 

Francisco, CA, 2 University of Utah, Salt Lake City, UT 

299. Reduction of Cerebral and Corpus Callosum Volumes 

in Childhood-Onset Systemic Lupus Erythematosus. A 

Volumetric Magnetic Resonance Imaging Analysis. Aline 

T. Lapa 1 , Wesley G. Ferreira 1 , Mariana Postal 1 , Nailu A. 

Sinicato 1 , Roberto Marini 2 , Fernando Cendes 1 and Simone 

Appenzeller 3 , 1 State University of Campinas, Campinas, 

Brazil, 2 Universidade Estadual de Campinas, Sao Paulo, 

Brazil, 3 State University of Campinas, São Paulo, Brazil 

300. Prevalence and Clinical Significance of Hippocampal 

Atrophy in Childhood-Onset Systemic Lupus 

Erythematosus. Aline T. Lapa 1 , Renata Brabosa 2 , Mariana 

Postal 1 , Nailu A. Sinicato 1 , Roberto Marini 3 , Fernando 

Cendes 1 and Simone Appenzeller 4 , 1 State University 

of Campinas, Campinas, Brazil, 2 Faculdade de Ciencias 

Medicas, Universidade Estadual de Campinas, Campinas, 

Germany, 3 Universidade Estadual de Campinas, Sao Paulo, 

Brazil, 4 State University of Campinas, São Paulo, Brazil 

301. Decreased Frequency of Dystrophic Calcifications in 

Children with Juvenile Dermatomyositis: A 10-Year Study. 

Lauren M. Pachman 1 , Gabrielle A. Morgan 2 , Megan L. 

Curran 1 , Lori J. Ferguson 2 and Chiang-Ching Huang 3 , 1 Division 

of Pediatric Rheumatology, Northwestern University 

Feinberg School of Medicine, Chicago, IL, 2 Children’s 

Hospital of Chicago Research Center, Cure JM Myositis 

Center, Chicago, IL, 3 Department of Preventive Medicine, 

Northwestern University Feinberg School of Medicine, 

Chicago, IL 

302. Accuracy of Systemic Lupus International Collaborating 

Clinics Classiffication Criteria Applied to Juvenile Systemic 

Lupus Erythematosus Patients. Marìa M. Katsicas 1 , 

Ezequiel Borgia 2 , Ileana Villarroel 2 and Ricardo Russo 3 , 1 MD, 

Buenos Aires, Argentina, 2 MD, Caba, Argentina, 3 Paediatric 



303. Ancestral Group Differences in Pediatric SLE Early Disease 

Severity: An Analysis of the Carranet Registry. Jennifer 

M.P. Woo 1 , Alice DC Hoftman 1 , Emily von Scheven 2 , 

Deborah K. McCurdy 1 , Ornella J. Rullo 1 and CARRA Registry 

Investigators 3 , 1 Mattel Children’s Hospital, University of 

California, Los Angeles, Los Angeles, CA, 2 UC San Francisco, 

San Francisco, CA, 3 Durham 

304. Burden of Childhood Central Nervous System Vasculitis: 

Identifying High Risk Factors for Poor Cognitive Outcome. 

Peter J. Gowdie, Marinka Twilt, Pascal N. Tyrrell, Robyn 

Westmacott, Tania Cellucci, Shehla Sheikh, Nick Blancette 

and Susanne M. Benseler, The Hospital for Sick Children, 

Toronto, ON 

305. Clinicopathologic Correlates for Activity and Damage 

of Lupus Nephritis in Childhood-Onset Systemic Lupus 

Erythematosus. Ravi Nunna 1 , Rina Mina 1 , Michael Bennett 2 , 

Shannen Nelson 3 , Jessica Hummel 4 , Prasad Devarajan 2 , 

David Witte 3 and Hermine I. Brunner 3 , 1 Cincinnati Children’s 

Hospital Medical Center/University of Cincinnati, Cincinnati, 

OH, 2 Cincinnati Children’s Med Ctr, Cincinnati, OH, 

3 

Cincinnati Children’s Hospital, Cincinnati, OH, 4 Cincinnati 

Children’s Hospital Medical Center, Cincinnati, OH 

306. Children with Probable SLE by ACR Criteria May Need More 

Aggressive Lupus Treatment Early in the Disease Course. 

Anjali Patwardhan 1 , Igor Dvorchik 2 and Charles H. Spencer 1 , 

1 

Nationwide Childrens Hospital, Columbus, OH, 2 Nationwide 

Children’s Hospital,, Columbus, OH 

162 

2012 Program Book


307. Risk Factors for Poor Outcomes in Hospitalized Patients 

with Pediatric Systemic Lupus Erythematosus. Mary 

Beth F. Son 1 , Victor M. Johnson 2 , Mindy S. Lo 2 and Karen 

H. Costenbader 3 , 1 Children Hospital Boston, Boston, MA, 

2 

Children’s Hospital Boston, Boston, MA, 3 Brigham and 

Women’s Hospital, Harvard Medical School, Boston, MA 

Pediatric Rheumatology - Pathogenesis and Genetics 


309. Cell Type Specific Transcriptome Analysis in Patients with 

Enthesitis Related Arthritis Category of Juvenile Idiopathic 

Arthritis (JIA-ERA). Amita Aggarwal, Arpita Myles and 

Priyanka Gaur, Sanjay Gandhi Postgraduate Institute of 

Medical Sciences, Lucknow, India 

310. STAT3 Plays a Central Role in NLRP3 Inflammasome- 

Mediated IL-1β Production and Pyronecrosis. Jehad 

H. Edwan 1 , Tri M. Tran 1 , Mones Abu-Asab 2 , Raphaela 

T. Goldbach-Mansky 3 and Robert A. Colbert 1 , 1 NIAMS 

NIH, Bethesda, MD, 2 NEI NIH, Bethesda, 3 Translational 

Autoinflammatory Diseases Section NIAMS NIH, Bethesda, 

MD 

311. The DEK Autoantigen Regulates Formation of Neutrophil 

Extracellular Traps and Zymosan Induced Arthritis in Mice. 

Nirit Mor-Vaknin 1 , Anjan K. Saha 1 , Maureen Legendre 1 , 

Marta J. Gonzalez-Hernandez 1 , M. Asif Amin 2 , Bradley J. 

Rabquer 2 , Julie M. Jorns 3 , Mariana J. Kaplan 1 , Barbara S. 

Adams 4 , David A. Fox 5 , Alisa E. Koch 2 and David Markovitz 1 , 

1 

University of Michigan, Ann Arbor, MI, 2 University of 

Michigan Medical School, Ann Arbor, MI, 3 Ann Arbor, MI, 

4 

Univ of Michigan Health System, Ann Arbor, MI, 5 Univ of 

Michigan Med Ctr, Ann Arbor, MI 

312. Blood-Based Biomarkers of Neurocognitive Dysfunction 

in Childhood-Onset Systemic Lupus Erythematosus. 

Hermine I. Brunner 1 , Jessica Hummel 1 , Shannen Nelson 2 , 

Erin C. Thomas 3 , Jennifer L. Huggins 1 , Megan L. Curran 4 , Jun 

Ying 5 and Marisa S. Klein-Gitelman 6 , 1 Cincinnati Children’s 

Hospital Medical Center, Cincinnati, OH, 2 Cincinnati 

Children’s Hospital, Cincinnati, OH, 3 Anne and Robert C 

Lurie Hospital, Feinstein School of Medicine, Northwestern 

University, Chicago, IL, 4 Division of Pediatric Rheumatology, 


Chicago, IL, 5 University of Cincinnati, Cincinnati, OH, 6 Ann & 

Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL 

313. Epigenetic Changes in Fibrosis and Myocyte Repair Genes 

May Contribute to Pathogenesis in Monozygotic Twins 

Discordant for Cardiac Manifestations of Neonatal Lupus. 

Paula S. Ramos 1 , Timothy D. Howard 2 , Miranda C. Marion 2 , 

Satria Sajuthi 2 , Robert M. Clancy 3 , Jill P. Buyon 3 and Carl 

D. Langefeld 2 , 1 Medical University of South Carolina, 

Charleston, SC, 2 Wake Forest School of Medicine, Winston- 

Salem, NC, 3 New York University School of Medicine, New 

York, NY 

314. Transcriptome and Surface Phenotype Analyses 

Suggest an Alternatively Activated (M2) Function for 

Hemophagocytes. Scott W. Canna 1 , Ana Patrícia Costa 

Reis 2 , William E. Bernal 3 , Kathleen E. Sullivan 3 , Michele 

E. Paessler 1 and Edward M. Behrens 3 , 1 Childrens Hospital 

of Philadelphia, Philadelphia, PA, 2 Childrenxs Hospital 

of Philadelphia, Philadelphia, PA, 3 Children’s Hospital of 

Philadelphia, Philadelphia, PA 

315. Pediatric Lupus Nephritis: Micrornas – Macro 

Inflammation. Patrícia Costa Reis, Pierre Russo and Kathleen 

E. Sullivan, Children’s Hospital of Philadelphia, Philadelphia, 

PA 

316. The Interleukin-10 (IL-10) Producing Regulatory B Cell 

(“B10 cell”) Compartment Expands with Disease Activity 

in Juvenile Dermatomyositis (JDM) and Pediatric-Onset 

Systemic Lupus Erythematosus (pSLE). Ioannis Kalampokis, 

Jeffrey A. Dvergsten and Thomas Tedder, Duke University 


317. Fatty Acid Profiling: Potential New Biomarkers in Juvenile 

Idiopathic Arthritis (pilot study). Weng Tarng Cham 1 , 

Enzo Ranieri 2 , Janice Fletcher 2 and Christina A. Boros 3 , 

1 

Women’s and Children’s Hospital, North Adelaide, SA 5006, 

Australia, 2 SA Pathology, North Adelaide, SA 5006, Australia, 

3 

University of Adelaide/Women’s and Children’s Hospital, 

Adelaide, Australia 

318. Replication Analysis of Non-HLA Gene Variants with Prior 

Evidence of Association with Juvenile Idiopathic Arthritis. 

Justine Ellis 1 , Raul Chavez 1 , Anne-Louise Ponsonby 1 , Angela 

Pezic 1 , Roger Allen 2 , Jonathan Akikusa 2 and Jane Munro 2 , 

1 

Murdoch Childrens Research Institute, Parkville, Australia, 

2 

Royal Childrens Hospital, Parkville, Australia 

319. Gamma Interferon-Induced Protein-10 (IP-10) As a 

Potential Biomarker for Disease Activity in Pediatric 

Localized Scleroderma. Katherine Kurzinski 1 , Carol A. 

Feghali-Bostwick 2 , Christina Kelsey 1 , Kelsey Magee 2 and 

Kathryn S. Torok 1 , 1 Univ of Pittsburgh Med Ctr, Pittsburgh, 

PA, 2 University of Pittsburgh, Pittsburgh, PA 

320. Evaluation of Anti-Citrullinated Type II Collagen and Anti- 

Citrullinated Vimentin Antibodies in Patients with Juvenile 

Idiopathic Arthritis. Brooke Gilliam, Anil K. Chauhan and 

Terry L. Moore, Saint Louis University, St. Louis, MO 

321. Glycosylation of Vitamin D Binding Protein Reduced in 

Juvenile Idiopathic Arthritis Patients At Risk of Disease 

Extension. David S. Gibson 1 , Sorcha Finnegan 2 , Gwen 

Manning 3 , Mark Duncan 4 , Stephen R. Pennington 5 , Terry 

L. Moore 6 and Madeleine Rooney 7 , 1 Arthritis Research 

Group, Queens University Belfast, Belfast, United Kingdom, 

2 

Queen’s University, Belfast, Belfast, United Kingdom, 

3 

Proteome Research Centre, University College Dublin, 

Dublin, Ireland, 4 Division of Endocrinology, University of 

Colorado, Denver, 5 UCD Conway Institute of Biomolecular 

and Biomedical Research, University College Dublin, Dublin 

4 

, Ireland, 6 Saint Louis University, St. Louis, MO, 7 Queens 

University Belfast, Belfast, United Kingdom 



322. Immune Response to Porphyromonas Gingivalis 

Citrullinated α-Enolase Cross-Reacts with Human 

α-Enolase in Polyarticular JIA Patients. Peggy Lee 1 , Rebecca 

Howsmon 2 , Claire Murphy 2 , Sarah Ringold 1 and Anne M. 

Stevens 1 , 1 University of Washington, Seattle, WA, 2 Seattle 

Children’s Research Institute, Seattle, WA 

323. Immunoprecipitation and Advanced Proteomics for the 

Discovery of Novel Antigenic Targets in Juvenile Idiopathic 

Arthritis. Ginger L. Janow 1 , Cristina Clement 2 , Norman 

T. Ilowite 3 , Laura Santambrogio 2 and Steven A. Porcelli 4 , 

1 

Children’s Hospital at Montefiore, Bronx, NY, 2 Albert 

Einstein College of Medicine, Bronx, NY, 3 Children’s Hospital 

Montefiore, Bronx, NY, 4 Albert Eistein College of Medicine, 

Bronx, NY 

324. Measurement and Evaluation of Isotypes of Anti- 

Citrullinated Fibrinogen and Anti-Citrullinated Alpha- 

Enolase Antibodies in Juvenile Idiopathic Arthritis Patients. 

Brooke Gilliam, Sandra Crespo-Pagnussat, Anil K. Chauhan 

and Terry L. Moore, Saint Louis University, St. Louis, MO 

325. Anti-Cyclic Citrullinated Peptide Antibody Isotyping and 

Identification of Citrullinated Proteins in the Synovial Fluid 

of Juvenile Idiopathic Arthritis Patients. Brooke Gilliam, 

Sandra Crespo-Pagnussat, Anil K. Chauhan, Reema H. Syed 

and Terry L. Moore, Saint Louis University, St. Louis, MO 


326. Silencing Intraarticular Snail Expression Ameliorates 

Rat Collagen-Induced Arthritis Through Induction of 

Mesenchymal-Epithelial Transition in Synovial Fibroblasts. 

Chrong-Reen Wang, Shih-Yao Chen, Ai-Li Shiau, Yuan-Tsung 

Li, Ming-Fei Liu and Chao-Liang Wu, College of Medicine, 

National Cheng Kung University, Tainan, Taiwan 

327. Tolerogenic Dendritic Cells Ameliorates the Disease 

Severity of Murine Collagen-Induced Arthritis. Bin Ning 1 , 

Shang-You Yang 2 , Jianlu Wei 1 , Weiming Gong 1 and Paul H. 

Wooley 2 , 1 Shandong University Jinan Central Hospital, Jinan, 

China, 2 Via Christi Wichita Hospitals, Wichita, KS 

328. IL-7; An Important Pro-Inflammatory Factor That 

Affects Myeloid Cell Function in RA and CIA. Nathan D. 

Chamberlain 1 , Seung-jae Kim 1 , Michael Volin 2 , Anjali Mehta 1 , 

Nadera J. Sweiss 1 and Shiva Shahrara 1 , 1 University of Illinois 

at Chicago, Chicago, IL, 2 Chicago College of Osteopathic 

Medicine Midwestern University, Downers Grove, IL 

329. The SYK Inhibitor, Fostamatinib, Administered Alone 

or in Combination with Methotrexate in Rat Collagen- 

Induced Arthritis, Reduces Bone Erosions, Biomarkers of 

Cartilage/Bone Destruction, and Synovial Osteoclastogenic 

Cytokines. Polly Pine 1 , Ayodele Apatira 1 , Betty Y. Chang 1 , 

Nathan Schoettler 2 , Elliott B. Grossbard 1 and Ernest Brahn 2 , 

1 

Rigel Pharmaceuticals, So San Francisco, CA, 2 UCLA School 

of Medicine, Los Angeles, CA 

330. Fut1 Plays A Unique Role in K/BxN Serum Transfer Arthritis 

by Regulating Angiogenesis and Adhesion Molecule 

Expression. M. Asif Amin, Phillip L. Campbell, Takeo Isozaki, 

Jeffrey H. Ruth, Jonathan Vargo, Steven E. Domino and Alisa 

E. Koch, University of Michigan Medical School, Ann Arbor, 

MI 

331. PDL24 1 , a Novel Humanized Monoclonal Antibody, Reveals 

CD319 As a Therapeutic Target for Rheumatoid Arthritis. 

Michel P.M. Vierboom 1 , Jacky Woo 2 , Hakju Kwon 2 , Debra 

Chao 2 , Shiming Ye 2 , Jianmin Li 2 , Karen Lin 2 , Irene Tang 2 , 

Nicole Belmar 2 , Taymar Hartman 2 , Elia Breedveld 1 , Bert A. 

‘t Hart 1 and Gary C. Starling 2 , 1 Biomedical Primate Research 

Centre, Rijswijk, Netherlands, 2 Abbott Biotherapeutics, 

Redwood City, CA 

332. Blockade of CTGF Restores Aberrant Ostoclastgenesis in 

Collagen Induced Arthritis (CIA) Mice Through Inhibition 

of Th-17 Differentiation. Kazuhisa Nozawa 1 , Maki Fujishiro 2 , 

Ayako Yamaguchi 3 , Mikiko Kawasaki 2 , Shouzou Ichinose 2 , 

Mitsuaki Yanagida 2 , Kazuhisa Iwabuchi 2 , Keigo Ikeda 4 , Shinji 

Morimoto 5 , Megumi Morioka 6 , Yoshinari Takasaki 1 and 

Iwao Sekigawa 4 , 1 Juntendo University School of Medicine, 

Tokyo, Japan, 2 Juntendo University Graduate School of 

Medicine, Chiba, Japan, 3 Juntendo University Graduate 

School of Medicine, Tokyo, Japan, 4 Juntendo University 

Urayasu Hospital, Tomioka, Urayasu, Chiba, Japan, 5 Juntendo 

University Urayasu Hospital, Tokyo kyo, Japan, 6 Nihon Nosan 

Corporation, Kanagawa, Japan 

333. Pressure and Blood Flow Measurements in Efferent 

Lymphatics As Biomarkers of Arthritic Flare. Echoe M. 

Bouta 1 , Ronald Wood 2 , Christopher T. Ritchlin 3 , Lianping 

Xing 1 and Edward M. Schwarz 1 , 1 University of Rochester, 

Rochester, NY, 2 University of Rochester School of Medicine 

and Dentistry, Rochester, NY, 3 University of Rochester 

Medical Center, Rochester, NY 

334. Selective iNOS Inhibition Increases the Lymphatic Pulse 

and Drainage from Arthritic Joints in TNF-Tg Mice. Yawen 

Ju, Ronald Wood, Lianping Xing, Christopher T. Ritchlin and 

Edward M. Schwarz, University of Rochester Medical Center, 

Rochester, NY 

335. Treatment with Bgp-15, a Novel Insulin Sensitizer 

Attenuates Collagen-Induced Arthritis in DBA/1 Mice. Peter 

Mandl 1 , Silvia Hayer 1 , Stephan Blüml 1 , Victoria Saferding 1 , 

Despoina Sykoutri 1 , Kurt Redlich 1 and Josef S. Smolen 2 , 

1 

Medical University of Vienna, Vienna, Austria, 2 Medical 

University of Vienna and Hietzing Hospital, Vienna, Austria 

336. Preclinical Development of ALX-0061, an Anti-IL-6R 

Nanobody® For Therapeutic Use in Rheumatoid Arthritis 

with a High in Vitro Affinity and Potency and a Competitive 

in Vivo Pharmacological Profile. Maarten Van Roy 1 , Hans 

Ulrichts 1 , Stefaan Rossenu 1 , Sandy Jacobs 1 , Sofie Poelmans 1 , 

Gert Verheyden 1 , Michel Vierboom 2 , Bert ‘t Hart 2 , Judith 

Baumeister 1 and Josefin-Beate Holz 1 , 1 Ablynx N.V., 

Zwijnaarde, Belgium, 2 Biomedical Primate Research Centre, 

Rijswijk, Netherlands 

164 

2012 Program Book


337. In Vivo Quantification of Joint Inflammation in a Murine 

Arthritis Model by Anato-Molecular Imaging. Smriti K. 

Raychaudhuri 1 , Anupam Mitra 1 , Kuang Gong 2 , Jian Zhou 2 , 

Jinyi Qi 2 , Siba P. Raychaudhuri 1 and Abhijit J. Chaudhari 3 , 1 UC 

Davis School of Medicine/VA Sacramento Medical Center, 

Mather, CA, 2 University of California, Davis, Davis, CA, 3 UC 

Davis School of Medicine, Sacramento, CA 

338. The Potent Phosphoinositide-3-Kinase-(δ,γ) Inhibitor 

IPI-145 Is Active in Preclinical Models of Arthritis and Well 

Tolerated in Healthy Adult Subjects. James R. Porter, Janid 

Ali, Jonathan P. DiNitto, Joi Dunbar, Kerrie Faia, Jennifer 

Hoyt, Brianne Leary, Alice R. Lim, Christian Martin, Charlotte 

McKee, Patrick O’Hearn, Melissa Pink, Jennifer Proctor, John 

Soglia, Bonnie Tillotson, Kerry White, David G. Winkler and 

Vito J. Palombella, Infinity Pharmaceuticals, Inc., Cambridge, 

MA 

339. Differences between Juvenile and Adult Rodents with 

Collagen Induced Arthritis. Tracy D. Wilson-Gerwing 1 , Isaac 

V. Pratt 1 , David M.L. Cooper 1 , Tawni I. Silver 1 and Alan M. 

Rosenberg 2 , 1 University of Saskatchewan, Saskatoon, SK, 

2 

Royal University Hospital, Saskatoon, SK 

340. Myeloid Deletion of SIRT1 Aggravates Inflammatory 

Arthritis Via Nuclear Factor-Kappab Activation in Animal 

Model of Rheumatoid Arthritis. Sang-il Lee and Yun-Hong 

Cheon, Gyeongsang National University School of Medicine, 

Jinju, South Korea 

341. Oral Administration of a Novel Small Molecule BET 

Bromodomain Inhibitor, RVX-297, Reduces Disease 

Severity in a Rat Collagen-Induced Arthritis Model. R. 

Jahagirdar 1 , S. Attwell 1 , E.M. Gesner 1 , K.G. McLure 1 , H.C. 

Hansen 1 , J. Chen 2 , J. Wu 1 , K. Norek 1 , N. Shenoy 2 , G.S. 

Wagner 1 and P. R. Young 1 , 1 Resverlogix Corporation, Calgary, 

AB, 2 Aravasc Inc., Sunnyvale, CA 

342. Novel Combination Therapy of Existing Repurposed 

Therapies, Designed by Predictive Software Modeling, 

Shows Profound Impact On Disease Progression in a 

Murine Collagen-Induced Arthritis Model. Shireen Vali 1 , 

Canio Refino 2 , Jay Dela Cruz 2 , Robinson Vidva 1 , Prashant 

Nair 1 , Saumya Radhakrishnan 1 , Pradeep Fernandes 1 , Taher 

Abbasi 1 and Gurkirpal Singh 3 , 1 CellWorks Group, Saratoga, 

CA, 2 InTouch Bio, Alameda, CA, 3 Stanford University School 

of Medicine, Palo Alto, CA 

343. Functional Impairment in an Animal Model for 

Rheumatoid Arthritis Assessed As Changes in Gait Is Due 

to Joint Destruction but Not Synovial Inflammation Per Se. 

Gregor Bauer 1 , Constantin Aschauer 1 , Birgit Niederreiter 1 , 

Josef S. Smolen 2 , Kurt Redlich 1 and Silvia Hayer 1 , 1 Medical 

University of Vienna, Vienna, Austria, 2 Medical University of 

Vienna and Hietzing Hospital, Vienna, Austria 

344. Non Classical Monocytes Are Required for Initiation Phase 

While Macrophages Are Necessary for the Resolution 

Phase in the K/BxN Murine of Inflammatory Arthritis. 

Alexander V. Misharin 1 , G. Kenneth Haines III 2 and Harris 

R. Perlman 1 , 1 Northwestern University, Chicago, IL, 2 Yale 

University, New Haven, CT 

345. Predictive Software-Based Mathematical Modeling: A 

Novel Approach to Development of Oral Therapies for 

Rheumatoid Arthritis – Validation in a Murine Collagen 

Induced Arthritis Model. Gurkirpal Singh 1 , Robinson 

Vidva 2 , Prashant Nair 2 , Saumya Radhakrishnan 2 , Pradeep 

Fernandes 2 , Taher Abbasi 2 , Canio Refino 3 , Jay Dela Cruz 3 

and Shireen Vali 2 , 1 Stanford University School of Medicine, 

Palo Alto, CA, 2 CellWorks Group, Saratoga, CA, 3 InTouch Bio, 

Alameda, CA 

346. Sclerostin Protects against Inflammatory Bone Loss by 

Regulating Tnfalpha Mediated p38-Mapkinase Activation. 

Corinna Wehmeyer 1 , Christina Wunrau 1 , Athanasios 

Stratis 1 , Ina Kramer 2 , Michaela Kneissel 2 , Thomas Pap 1 and 

Berno Dankbar 1 , 1 University Hospital Muenster, Muenster, 

Germany, 2 CH-4056 Basel, Switzerland 

347. The Loss of S100A4 Prevents Induction of Experimental 

Arthritis in Human Tumour Necrosis Factor Transgenic 

Mouse Model. Michal Tomcik 1 , Christine Boehm 2 , Carina 

Scholtysek 3 , Lucie andres Cerezo 1 , Wolfgang Baum 3 , Clara 

Dees 3 , Christian Beyer 3 , Jerome Avouac 4 , Pawel Zerr 3 , Katrin 

Palumbo-Zerr 3 , Alfiya Akhmetshina 3 , Radim Becvar 1 , Oliver 

Distler 5 , Mariam Grigorian 6 , Gerhard Kroenke 3 , Georg A. 

Schett 3 , Joerg HW Distler 3 and Ladislav Senolt 1 , 1 Institute 

of Rheumatology, Department of Clinical and Experimental 

Rheumatology, 1 st Faculty of Medicine, Charles University, 

Prague, Czech Republic, 2 Medical University of Vienna, 

Vienna, Austria, 3 Department of Internal Medicine III and 


Nuremberg, Erlangen, Germany, 4 Paris Descartes University, 

Rheumatology A department, Cochin Hospital, Paris, France, 

5 

Department of Rheumatology and Center of Experimental 

Rheumatology, University Hospital Zurich, Zurich, 

Switzerland, 6 Institute of Cancer Biology, Danish Cancer 

Society, Copenhagen, Denmark 

Rheumatoid Arthritis - Clinical Aspects I: Drug Studies/Drug 

Safety/Drug Utilization/Disease Activity & Remission 

348. Liver Fibrosis Evaluated by Shearwave Elastograpy Is 

Associated with Body Mass Index and Serum AST, but Not 

Methotrexate Cumulative Dose and Duration in Patients 

with Rheumatoid Arthritis. Tae Yeob Kim, So-Young Bang, 

Joo Hyun Sohn and Hye-Soon Lee, Hanyang University Guri 

Hospital, Guri, South Korea 

349. Preliminary Results From a Controlled Study Assessing the 

Humoral Immune Response to Vaccines in Rheumatoid 

Arthritis Patients Treated with Tocilizumab. CO Bingham 

III 1 , Warren C. Rizzo 2 , Micki Klearman 3 , Azra Hassanali 4 , Ruchi 

Upmanyu 5 and Alan J. Kivitz 6 , 1 Johns Hopkins University, 

Baltimore, MD, 2 Advanced Arthritis Care & Research, 

Scottsdale, AZ, 3 Genentech Inc, South San Francisco, CA, 

4 

Genentech Inc, San Francisco, CA, 5 Roche, Welwyn Garden 

City, United Kingdom, 6 Altoona Center for Clinical Research, 

Duncansville, PA 



166 

350. Reduction of Inflammation with Abatacept and Tocilizumab 

Results in Lower N-Terminal Pro Brain Natriuretic Peptide 

Levels in Patients with Rheumatoid Arthritis: Results from 

Prospective Cohort Studies. Inge A.M. van den Oever and 

Mike T. Nurmohamed, Jan van Breemen Research Institute | 

Reade, Amsterdam, Netherlands 

351. Prospective Follow-up of Tocilizumab Treatment in 764 

Patients with Refractory Rheumatoid Arthritis: Tolerance 

and Efficacy Data From the French Registry Regate 

(REGistry –RoAcTEmra). Jacques Morel 1 , Marie-Odile 

Duzanski 2 , Thomas Bardin 3 , Alain G. Cantagrel 4 , Bernard 

Combe 1 , Maxime Dougados 5 , Rene-Marc Flipo 6 , Jacques- 

Eric Gottenberg 7 , Xavier Mariette 8 , Martin Soubrier 9 , Olivier 

Vittecoq 10 , Alain Saraux 11 , Thierry Schaeverbeke1 2 and Jean 

Sibilia 13 , 1 Hopital Lapeyronie, Montpellier, France, 2 Hôpitaux 

Universitaires de Strasbourg, Strasbourg, France, 3 Hôpital 

Lariboisière, Paris, France, 4 Centre Hospitalier Universitaire 

de Toulouse, Toulouse, France, 5 Paris-Descartes University, 

APHP, Cochin Hospital, Paris, France, 6 Hopital R Salengro 

CHRU, Lille CEDEX, France, 7 Strasbourg University Hospital, 

Strasbourg, France, 8 Université Paris-Sud, Le Kremlin Bicetre, 

France, 9 CHU CLERMONT-FERRAnd, Clermont-Ferrand, 

France, 10 Rouen University Hospital & Inserm905, University 

of Rouen, Rouen Cedex, France, 11 CHU de la Cavale Blanche, 

Brest Cedex, France, 12 Groupe Hospitalier Pellegrin, 

Bordeaux, France, 13 CHU Hautepierre, Strasbourg, France 

352. Meta-Analysis: Influence of Methotrexate, Anti-TNF and 

Rituximab On the Immune Response to Influenza and 

Pneumococcal Vaccines in Patients with Rheumatoïd 

Arthritis. Charlotte Hua 1 , Thomas Barnetche 2 , Bernard 

Combe 3 and Jacques Morel 3 , 1 Hôpital Lapeyronie, 

Montpellier, France, 2 CHU Bordeaux Pellegrin, Bordeaux, 

France, 3 Hopital Lapeyronie, Montpellier, France 

353. The Effect of Combination Therapy and Prednisolone On 

Haemostatic Markers in Rheumatoid Arthritis. Inge A.M. 

van den Oever 1 , Danka J.F. Stuijver 2 , Debby den Uyl 3 , Bregje 

van Zaane 4 , Marieke M. ter Wee 5 , Willem F. Lems 5 , D. van 

Schaardenburg 1 , Joost C.M. Meijers 4 , Victor E.A. Gerdes 4 and 

M. T. Nurmohamed 6 , 1 Jan van Breemen Research Institute | 

Reade, Amsterdam, Netherlands, 2 Academic Medical Center, 

Amsterdam, Netherlands, 3 VU University medical centre, 

Amsterdam, Netherlands, 4 Slotervaart Hospital, Amsterdam, 

Netherlands, 5 VU University Medical Center, Amsterdam, 

Netherlands, 6 VU University Medical Center/Jan van Bremen 

Research Institute, Amsterdam, Netherlands 

354. Delayed Onset of Hepatitis and/or Neutropenia in Patients 

with Rheumatoid Arthritis Treated with Combination 

Therapy of Methotrexate and Leflunomide. Seung Won 

Choi 1 , Ji Seon Oh 1 , You Jae Kim 2 , Bon San Koo 3 , Min Wook 

So 3 , Yong-Gil Kim 3 , Chang-Keun Lee 3 and Bin Yoo 3 , 1 University 

of Ulsan College of Medicine, Ulsan University Hospital, 

Ulsan, South Korea, 2 Asan Medical Center, University of Ulsan 

College of Medicine, Seoul, South Korea, 3 University of Ulsan 

College of Medicine, Asan Medical Center, Seoul, South Korea 


355. Metaanalysis of 5-Aminoimidazole-4-Carboxamide 

Ribonucleotide Transformylase (ATIC) 347C>G 

Polymorphism Affecting Methotrexate Efficacy and Toxicity 

in Rheumatoid Arthritis Patients. Fardina Malik 1 and 

Prabha Ranganathan 2 , 1 Alton Memorial Hospital, Alton, IL, 

2 

Washington Univ School of Med, St. Louis, MO 

356. Safety of Abatacept in Rheumatoid Arthritis with Chronic 

Hepatitis B VIRUS Infection. Melissa Padovan 1 , Elisabetta 

Lanciano 2 , Oscar Epis 3 , Alessandro Mathieu 4 , Giulia Erba 5 , 

Leopoldo Ciani 6 , Sarah Giacuzzo 1 and Marcello Govoni 1 , 

1 

Section of Rheumatology, Ferrara, Italy, 2 Rheumatology Unit, 

Bari, Italy, 3 Rheumatology Unit, Milano, Italy, 4 Rheumatology 

Unit, Cagliari, Italy, 5 Medical Clinics, Monza, Italy, 6 Unit of 

Internal Medicine, Legnano, Italy 

357. Is the Impact of Methotrexate On Mortality in Rheumatoid 

Arthritis Independent of Its Effect On Disease Activity? 

Dietmar MJ Krause 1 , Bernadette Gabriel 2 , Gertraud Herborn 3 

and Rolf Rau 3 , 1 Internistische und rheumatologische 

Gemeinschaftspraxis, Gladbeck, Germany, 2 Private Practice, 

Gladbeck, Germany, 3 Evangelisches Fachkrankenhaus, 

Ratingen, Germany 

358. Six Months of an Attenuated Cobra Regimen (‘COBRA-light’) 

Is Clinically Noninferior to the Original Cobra Regimen: 

An Open-Label Randomized Trial in Early Rheumatoid 

Arthritis. Debby den Uyl 1 , Marieke M. ter Wee 1 , Maarten 

Boers 1 , Alexandre Voskuyl 1 , P.J.S.M. Kerstens 2 , Mike T. 

Nurmohamed 3 , Hennie G. Raterman 1 , D. van Schaardenburg 3 , 

N. van Dillen 2 , B.A.C Dijkmans 1 and W.F. Lems 1 , 1 VU University 

Medical Center, Amsterdam, Netherlands, 2 Reade | Jan 

van Breemen Research Institute, Amsterdam, Netherlands, 

3 

Jan van Breemen Research Institute | Reade, Amsterdam, 

Netherlands 

359. Improved Radiological Outcome of Rheumatoid Arthritis: 

Early Treatment with methotrexate might be a key 

Prognostic Factor. Christoph Fiehn 1 , Elisabeth Belke-Voss 1 , 

Dietmar Krause 2 , Siegfried Wassenberg 3 and Rolf Rau 4 , 

1 

ACURA Centre for Rheumatic Diseases, Baden-Baden, 

Germany, 2 Dept. for Medical Informatics, Biometry 

and Epidemiology, Ruhr University, Bochum, Germany, 

3 

Evangelisches Fachkrankenhaus Ratingen, Rheumazentrum, 

Ratingen, Germany, 4 Düsseldorf, Germany 

360. Initial Introduction of Treat-to-Target Strategy in Patients 

with Recent Onset Rheumatoid Arthritis Is More Effective 

Than Delayed Introduction of Strategy with More Clinical 

and Functional Remission Achieved for 2-Years: Results of 

the Treating to Twine Targets (T-4) Study. Yukitomo Urata 1 , 

Yoshihide Nakamura 2 and Ken-ichi Furukawa 3 , 1 Seihoku 

Central Hospital, Gosyogawara, Japan, 2 Hirosaki University 

Graduate School of Medicine, Hirosaki, Japan, 3 Hirosaki, 

Japan 

361. Impact of Tumour Necrosis Factor Inhibitor Treatment On 

Hand Bone Loss in Rheumatoid Arthritis Patients Treated in 

Clinical Practice. Results from the Nationwide Danish Danbio 

Registry. Lykke Midtbøll Ørnbjerg 1 , Mikkel Østergaard 1 , 

Pernille Bøyesen 2 , Trine David Jensen 3 , Anja Thormann 1 ,


Ulrik Tarp 1 , Wolfgang Bøhme 1 , Ditte Dencker 1 , Hanne M. 

Lindegaard 1 , Uta Engling Poulsen 1 , Annette Hansen 1 , Vibeke 

Stevenius Ringsdal 1 , Annette Schlemmer 1 , Niels Graudal 1 , 

Anne Rødgaard andersen 1 , Jakob Espesen 1 , Gina Kollerup 1 , 

Torben Grube Christensen 1 , Randi Pelck 1 , Bente Glintborg 1 , 

Ole Rintek Madsen 1 , Dorte Vendelbo Jensen 1 , Ole Majgaard 1 

and Merete L. Hetland 4 , 1 DANBIO, On behalf of Depts of 

Rheumatology, North, South, Central, Zealand and Capital 

Region, Copenhagen, Denmark, 2 Diakonhjemmet Hospital, 

Olso, Norway, 3 Dept. of Endocrinology, Hvidovre Hospital, 

Copenhagen, Denmark, 4 Copenhagen University and Glostrup 

Hospital, Copenhagen, Denmark 

362. Response to Etanercept, but Not Infliximab or Adalimumab, 

Is Inversely Associated with Body Mass Index. James R. 

Maxwell 1 , Darren Plant 2 , Anne Barton 3 , Kimme L. Hyrich 3 , Ann 

W. Morgan 4 , John Isaacs 5 and Anthony G. Wilson 6 , 1 University 

of Sheffield, Sheffield, United Kingdom, 2 University of 

Manchester, Manchester, United Kingdom, 3 Arthritis 


Manchester Academy of Health Sciences, Manchester, 

United Kingdom, 4 NIHR-Leeds Musculoskeletal Biomedical 

Research Unit and Leeds Institute of Molecular Medicine, 

University of Leeds, Leeds, United Kingdom, 5 Newcastle 

University, Newcastle upon Tyne, United Kingdom, 6 Section 

of Musculoskeletal Sciences, University of Sheffield, Sheffield, 


363. Risk Factors for Radiographic Progression During TNF- 

Inhibitor Treatment in 932 Rheumatoid Arthritis Patients 

Treated in Clinical Practice: Results from the Nationwide 

Danish Danbio Registry. Lykke Midtbøll Ørnbjerg 1 , Mikkel 

Østergaard 1 , Pernille Bøyesen 2 , Anja Thormann 1 , Ulrik Tarp 1 , 

Wolfgang Bøhme 1 , Ditte Dencker 1 , Hanne M. Lindegaard 1 , 

Uta Engling Poulsen 1 , Annette Hansen 1 , Vibeke Stevenius 

Ringsdal 1 , Annette Schlemmer 1 , Niels Graudal 1 , Anne 

Rødgaard andersen 1 , Jakob Espesen 1 , Gina Kollerup 1 , Torben 

Grube Christensen 1 , Randi Pelck 1 , Bente Glintborg 1 , Ole 

Rintek Madsen 1 , Dorte Vendelbo Jensen 1 , Ole Majgaard 1 

and Merete L. Hetland 3 , 1 DANBIO, On behalf of Depts of 


Region, Copenhagen, Denmark, 2 Diakonhjemmet Hospital, 

Olso, Norway, 3 Copenhagen University and Glostrup Hospital, 


364. Moderate Rheumatoid Arthritis Despite Methotrexate 

Treatment: Risk of Radiographic Progression. Bruno 

Fautrel 1 , Gaia Gallo 2 , Yves Brault 3 and Henk Nab 4 , 1 APHP- 

Pitie Salpetriere Hospital / UPMC, Paris, France, 2 Pfizer, 

Rome, Italy, 3 Pfizer, Paris, France, 4 Pfizer Europe, Rome, Italy 

365. Improvement of Health-Related Quality of Life in RA 

Patients Treated with Biologics - One-Year Follow-up 

Data of the German Biologics Register Rabbit. Kerstin 

Gerhold 1 , Adrian Richter 1 , Matthias Schneider 2 , Hans 

Joachim Bergerhausen 3 , Winfried Demary 4 , Anke Liebhaber 5 , 

Joachim Listing 1 , Angela Zink 1 and Anja Strangfeld 1 , 1 German 

Rheumatism Research Center, a Leipniz Institute, Berlin, 

Germany, 2 Heinrich-Heine-University Düsseldorf, Düsseldorf, 

Germany, 3 Wedau Kliniken - Klinikum Duisburg, Duisburg, 

Germany, 4 Private Practice, Hildesheim, Germany, 5 Private 

Practice, Halle, Germany 

366. Efficacy of Methotrexate (MTX) According to Anti- 

Citrullinated Protein Antibody (ACPA) Status in an Early 

Inflammatory Arthritis Cohort. Sarah C. Horton, David 

Pickles, Paul Emery, Maya H. Buch and Jane E. Freeston, 

University of Leeds, Leeds, United Kingdom 

367. Improved Fatigue-Related Quality of Life in CAPRA-2, 

a 12 Week Study of 5-Mg Modified (Delayed) Release 

Prednisone in Rheumatoid Arthritis. Rieke Alten 1 , Amy 

Grahn 2 , Patricia Rice 3 and Frank Buttgereit 4 , 1 Schlosspark- 

Klinik, University Medicine, Berlin, Germany, 2 Horizon 

Pharma, Deerfield, IL, 3 CliniRx Research, Naperville, IL, 

4 

Charite University Med-Berlin, Berlin, Germany 

368. Impact of Etanercept-Methotrexate Therapy On Patient- 

Reported Outcomes in Rheumatoid Arthritis Patients with 

up to 12 Months of Symptoms. Paul Emery 1 , Piotr Wiland 2 , 

Wolfgang Spieler 3 , Jean Dudler 4 , Stefanie Gaylord 5 , Theresa 

Williams 5 , Ronald Pedersen 5 , Andrew S. Koenig 5 , Bonnie 

Vlahos 5 and Sameer Kotak 6 , 1 Leeds General Infirmary, Leeds, 

United Kingdom, 2 Wroclaw Medical University, Wroclaw, 

Poland, 3 Rheumatology Specialty Practice, Zerbst, Germany, 

4 

University Hospital of Lausanne, Lausanne, Switzerland, 

5 

Pfizer Inc., Collegeville, PA, 6 Pfizer Inc., New York, NY 

369. Differences in Short-Term Radiographic Progression 

Following Early Response to Adalimumab Plus 

Methotrexate Vs. Methotrexate Alone. Ronald F. van 

Vollenhoven 1 , James W. Shaw 2 , Mary A. Cifaldi 2 , James 

Signorovitch 3 , Eric Q. Wu 3 , Thomas Samuelson 3 , Elizabeth 

Faust 3 and Paul Emery 4 , 1 Karolinska Institute, Stockholm, 

Sweden, 2 Abbott Laboratories, Abbott Park, IL, 3 Analysis 

Group, Inc., Boston, MA, 4 University of Leeds, Leeds, United 

Kingdom 

370. Characteristic of the Japanese Patients with Rheumatoid 

Arthritis (RA) of Rapid Radiographic Progression (RRP) 

Treated with Synthetic Disease Modifying Anti-Rheumatic 

Drugs (DMARDs) in Daily Practice: A Large-Scale 

Prospective Longitudinal Cohort Study (the 1st report 

of Apple Survey). Akitomo Okada 1 , Atsushi Kawakami 1 , 

Takaaki Fukuda 2 , Toshihiko Hidaka 3 , Tomonori Ishii 4 , Yukitaka 

Ueki 5 , Takao Kodera 6 , Munetoshi Nakashima 7 , Yuichi 

Takahashi 8 , Seiyo Honda 9 , Yoshiro Horai 1 , Tomohiro Koga 1 , 

Ryu Watanabe 10 , Hiroshi Okuno 10 and Katsumi Eguchi 11 , 

1 

Nagasaki University Graduate School of Biomedical 

Sciences, Nagasaki, Japan, 2 Kurume University Medical 

Center, Kurume, Japan, 3 Zenjinkai Shimin-No-Mori-Hospital, 

Miyazaki, Japan, 4 Tohoku University, Sendai, Japan, 5 Sasebo, 

Japan, 6 Tohoku Kosei Nenkin Hospital, Sendai, Japan, 

7 

Japanese Red Cross Nagasaki Genbaku Hospital, Nagasahi, 

Japan, 8 Yu Family Clinic, Sendai, Japan, 9 Kurume University 

School of Medicene, Kurume, Japan, 10 Tohoku University 

Hospital, Sendai, Japan, 11 Sasebo City General Hospital, 

Sasebo, Nagasaki, Japan 



371. Treat-to-Target Strategy Aiming At Achievement of 

Structural and Functional Remission in Patients with 

Active Elderly-Onset Rheumatoid Arthritis. Takahiko 

Sugihara 1 , Tatsuro Ishizaki 2 , Tadashi Hosoya 1 , Shoko Iga 1 , 

Waka Yokoyama 1 , Fumio Hirano 1 , Nobuyuki Miyasaka 3 and 

Masayoshi Harigai 3 , 1 Tokyo Metropolitan Geriatric Hospital, 

Tokyo, Japan, 2 Tokyo Metropolitan Institute of Gerontology, 

Tokyo, Japan, 3 Tokyo Medical and Dental University, Tokyo, 

Japan 

372. TRAF1/C5 Locus Is Associated with Response to Anti-Tumor 

Necrosis Factor Therapy in Patients with Rheumatoid 

Arthritis. Helena Canhao 1 , Ana M. Rodrigues 2 , Maria José 

Santos 3 , Diana Carmona-Fernandes 4 , Bruno Bettencourt 5 , 

Jing Cui 6 , Fabiana Rocha 5 , Jose canas Silva 3 , Joaquim Polido 

Pereira 4 , Jose Alberto Pereira Silva 7 , José Antonio Costa 8 , 

Domingos Araujo 9 , Candida Silva 10 , Helena Santos 11 , Catia 

Duarte 12 , Fernando Pimentel-Santos 13 , Jaime C. Branco 13 , 

Robert M. Plenge 6 , Daniel H. Solomon 6 , Jacome Bruges 

Armas 5 , José A. P. Da Silva 14 , João E. Fonseca 15 and Elizabeth 

W. Karlson 16 , 1 Instituto de Medicina Molecular, Lisbon, 

Portugal, 2 Instituto de Medicina Molecular, Faculdade 

de Medicina da Universidade de Lisboa, Lisbon, Lisbon, 

Portugal, 3 Hospital Garcia de Orta, E.P.E., Almada, Portugal, 

4 

Instituto Medicina Molecular, Lisbon, Portugal, 5 Hospital 

de Santo Espirito da Ilha Terceira, Ilha Terceira, Portugal, 

6 

Brigham and Women’s Hospital, Boston, MA, 7 Santa 

Maria Hospital, Lisbon, Portugal, 8 Centro Hospitalar do 

Alto Minho, Hospital de Ponte de Lima, Ponte de Lima, 

Portugal, 9 Unidade Local de Saude, Ponte de Lima, Portugal, 

10 

Instituto Portugues Reumatologia, Lisbon, Portugal, 

11 

Instituto Português de Reumatologia, Lisboa, Portugal, 

12 

Hospitais da Universidade de Coimbra, Coimbra, Portugal, 

13 

Centro Hospitalar de Lisboa Ocidental, Hospital Egas 

Moniz, Lisboa, Portugal, 14 Centro Hospitalar e Universitário 

de Coimbra – Hospitais da Universidade de Coimbra, E.P.E., 

Coimbra, Portugal, 15 Instituto de Medicina Molecular, 

Faculdade de Medicina da Universidade de Lisboa and 

Rheumatology Department, Centro Hospitalar de Lisboa 

Norte, EPE, Hospital de Santa Maria, Lisboa, Portugal, 

16 


Boston, MA 

373. Patient-Reported Outcomes in Early Rheumatoid Arthritis 

Patients Failing to Achieve Stable Low Disease Activity: 

Comparing Addition of Adalimumab to Methotrexate 

Monotherapy with Maintenance On Adalimumab 

Plus Methotrexate. Arthur Kavanaugh 1 , Ronald F. van 

Vollenhoven 2 , Paul Emery 3 , James W. Shaw 4 , Mary A. Cifaldi 4 , 

Stefan Florentinus 5 and Josef S. Smolen 6 , 1 UCSD School of 

Medicine, La Jolla, CA, 2 Karolinska Institute, Stockholm, 

Sweden, 3 University of Leeds, Leeds, United Kingdom, 

4 

Abbott Laboratories, Abbott Park, IL, 5 Abbott, Rungis, 

France, 6 Medical University of Vienna and Hietzing Hospital, 


374. Prevalence of Biologic Utilization over Calendar Time 

Among Medicare Beneficiaries with Rheumatoid Arthritis. 

Jie Zhang 1 , Fenglong Xie 1 , Elizabeth S. Delzell 1 , Lang Chen 1 , 

James Lewis 2 , Kevin Haynes 3 , Kenneth G. Saag 4 and Jeffrey 

Curtis 1 , 1 University of Alabama at Birmingham, Birmingham, 

AL, 2 University of Pennsylvania, 3 University of Pennsylvania., 

Philadelphia, PA, 4 Univ of Alabama-Birmingham, 


375. Cell Phone Based Automated Monitoring of Patients with 

Early Rheumatoid Arthritis. Kari Puolakka 1 , Tuulikki Sokka 2 

and Hannu Kautiainen 3 , 1 Department of Medicine, South 

Karelia Central Hospital, Lappeenranta, Finland, 2 Jyvaskyla 

Central Hospital, Jyvaskyla, Finland, 3 Orton Rehabilitation, 

Helsinki, Finland 

376. Strategies for Use of Prednisolone in Rheumatoid Arthritis 

Have Changed Over the Past Decade: Data From the NOR- 

DMARD Register. Anna-Birgitte Aga, Elisabeth Lie, Till Uhlig, 

Tore K. Kvien and Espen A. Haavardsholm, Diakonhjemmet 

Hospital, Oslo, Norway 

377. Use and Long Term Use of Complementary and Alternative 

Medicine in Rheumatoid Arthritis Patients. Peri H. 

Pepmueller 1 , Ramzy Jandali 1 , Anu Sharma 2 , Shannon Grant 3 

and Katherine C. Saunders 4 , 1 Saint Louis University, St. Louis, 

MO, 2 Center for Rheumatic Diseases, Bethesda, MD, 3 Axio 

Research LLC, Seattle, WA, 4 CORRONA, Inc., Southborough, 

MA 

378. Use of Anti-Tumor Necrosis Factor Monotherapy and 

Adherence with Non-Biologic Disease-Modifying Anti- 

Rheumatic Drugs in Combination with Anti-Tumor Necrosis 

Factor Therapy among Rheumatoid Arthritis Patients in 

a Real-World Setting. Nicole M. Engel-Nitz 1 , Sarika Ogale 2 

and Mahesh Kulakodlu 1 , 1 OptumInsight, Eden Prairie, MN, 

2 

Genentech, South San Francisco, CA 

379. Persistency and Predictors of Persistency of Adalimumab 

among Rheumatoid Arthritis (RA) Patients in a US Registry. 

Allan Gibofsky 1 , Katherine C. Saunders 2 , Arijit Ganguli 3 , 

Mary Cifaldi 3 , Shannon Grant 4 , Jerry Clewell 3 , Neelufar 

Mozaffarian 3 , James Shaw 5 , Reva McCaskill 3 , George W. 

Reed 6 and Jeffrey D. Greenberg 7 , 1 Hospital for Special 

Surgery, New York, NY, 2 CORRONA, Inc., Southborough, 

MA, 3 Abbott Laboratories, Abbott Park, IL, 4 Axio Research 

LLC, Seattle, WA, 5 Abbott, Abbott Park, IL, 6 University of 

Massachusetts Medical School, Worcester, MA, 7 NYU 

Hospital for Joint Diseases, New York, NY 

380. DMARD and Biologic Use During Pregnancy Among 

Rheumatoid and Psoriatic Arthritis Patients in the 

Corrona Registry. John J. Cush 1 , George Reed 2 , Katherine 

C. Saunders 3 , Joel M. Kremer 4 , Jeffrey D. Greenberg 5 and 

Arthur Kavanaugh 6 , 1 Baylor Research Institute, Dallas, TX, 

2 

UMass Medical School, Worcester, MA, 3 CORRONA, Inc., 

Southborough, MA, 4 Albany Medical College, Albany, NY, 

5 

NYU Hospital for Joint Diseases, New York, NY, 6 UCSD 

School of Medicine, La Jolla, CA 

168 

2012 Program Book


381. DAS Does Not Predict Increasing Treatment in Early 

Rheumatoid Arthritis: Results From the CATCH Study. 

Lonnie Pyne 1 , Vivian P. Bykerk 2 , Carol A. Hitchon 3 , Edward 

Keystone 4 , J. Carter Thorne 5 , Boulos Haraoui 6 , Ashley 

Bonner 7 , Janet E. Pope 8 and CATCH Investigators 9 , 1 Western 

University, London, ON, 2 Hospital for Special Surgery, New 

York, NY, 3 University of Manitoba, Winnipeg, MB, 4 University 

of Toronto, Toronto, ON, 5 Southlake Regional Health Centre, 

Newmarket, ON, 6 Osteoarthritis Research Unit, University 

of Montreal Hospital Research Centre (CRCHUM), Montreal, 

QC, 7 McMaster University, Hamilton, ON, 8 St. Joseph Health 

Care London, University of Western Ontario, London, ON, 

9 

Toronto, ON 

382. Does Biased Risk Perception Explain the Underuse of 

Disease Modifying Anti-Rheumatic Drugs? Richard W. 

Martin 1 , Andrew J. Head 2 , James D. Birmingham 1 and Aaron 

T. Eggebeen 1 , 1 Michigan State University College of Human 

Medicine, Grand Rapids, MI, 2 College of Human Medicine, 

Michigan State University, Grand Rapids, MI 

383. 2002-04 Vs.2007-09: Initiation of Combination, and 

Tapering/Discontinuation (DC) Patterns of TNFi and MTX 

in a US (RA) Patient Registry: Analysis with CDAI Scores. 

Deborah Wenkert 1 , Shannon Grant 2 , David H. Collier 1 , 

Andrew S. Koenig 3 and Joel M. Kremer 4 , 1 Amgen Inc., 

Thousand Oaks, CA, 2 Axio Research LLC, Seattle, WA, 3 Pfizer 

Inc., Collegeville, PA, 4 Albany Medical College, Albany, NY 

384. Treating Rheumatoid Arthritis to Target: A Canadian 

Patient Survey. Boulos Haraoui 1 , William G. Bensen 2 , J. 

Carter Thorne 3 , John P. Wade 4 , Melissa Deamude 5 , Jane 

M. Prince 6 and Jean Legare 7 , 1 Institut de Rhumatologie 

de Montréal, Montreal, QC, 2 St. Joseph’s Hospital and 

McMaster University, Hamilton, ON, Hamilton, ON, 

3 

Southlake Regional Health Centre, Newmarket, ON, 

4 

University of British Columbia, Vancouver, BC, 5 Dr. William 

G. Bensen Medicine Professional Corporation, Hamilton, 

ON, 6 Vancouver Coastal Health, Vancouver, BC, 7 Arthritis 

Alliance of Canada, Montreal, QC 

385. The Wide Variation in Corticosteroid Use in Early 

Rheumatoid Arthritis - There Is Need for Guidelines. A. 

Bharadwaj and Carol Alves, Basildon & Thurrock University 

Hospital NHS Trust, Basildon, United Kingdom 

386. Costs of Tumor Necrosis Factor Blockers Per Treated 

Rheumatoid Arthritis Patient Using Real-World Drug Data 

in a US Managed Care Population. Vernon F. Schabert 1 , 

Crystal Watson 2 , George Joseph 2 , Paige Iversen 1 , Chakkarin 

Burudpakdee 1 and David J. Harrison 2 , 1 IMS Health, 

Alexandria, VA, 2 Amgen Inc., Thousand Oaks, CA 

387. Medication Choices and Medication Survival in a National 

Multicentre Community Based Rheumatoid Arthritis 

Cohort. Lynden Roberts 1 , Kathleen Tymms 2 , Julien P. de 

Jager 3 , Geoffrey O. Littlejohn 4 , Hedley Griffiths 5 , Dave 

Nicholls 6 , Paul Bird 7 , Julie Hill 8 , Philip McCloud 8 , James C. 

Scott 9 , Jane Zochling 10 and OPAL Consortium 11 , 1 James Cook 

University, Townsville, Australia, 2 Canberra Rheumatology, 

Canberra, Australia, 3 Suite 2 , Osler House, Southport, 

Australia, 4 Monash Medical Center, Melbourne, Australia, 

5 

Barwon Rheumatology Service, Geelong, Australia, 

6 

Coast Joint Care, Maroochydore, Australia, 7 Combined 

Rheumatology Practice, Sydney, Australia, 8 McCloud 

Consulting Group, Sydney, Australia, 9 Roche Products Pty 

Limited, Sydney, Australia, 10 Menzies Research Institute 

Tasmania, Hobart, Australia, 11 Melbourne, Australia 

388. Retention Rate of the Anti-TNF Biologics in the Treatment 

of Rheumatic Diseases and Predictive Factors for Drug 

Withdrawal: Data from the Hong Kong Biologics Registry. 

Chi Chiu Mok 1 , Cherry Kwan 1 , Helen Chan 2 , Ka Lai Lee 3 and 

Lai-Shan Tam 4 , 1 Tuen Mun Hospital, Hong Kong, Hong Kong, 

2 

Kowloon Hospital, Hong Kong, Hong Kong, Hong Kong, 

3 

Pamela Youde Eastern Hospital, Hong Kong, Hong Kong, 

4 

The Chinese University of Hong Kong, Hong Kong, China 

389. Oral Glucocorticoid Sparing Effects of Rituximab in 

Rheumatoid Arthritis Patients Who Have Switched from 

an Anti-TNF Therapy - an Administrative Claims Database 

Analysis. Stephen Johnston 1 , Tripthi Kamath 2 , Nianwen Shi 1 , 

Robert Fowler 1 , Bong-Chul Chu 1 and William Reiss 3 , 1 Truven 

Health Analytics, Washington, DC, 2 Genentech, Inc., South 

San Francisco, CA, 3 Genentech Inc., South San Francisco, CA 

390. Performance of Criteria for Remission in a Long-Term 

Observational Study of Patients with Early Rheumatoid 

Arthritis. Bjorn Svensson 1 , Maria LE andersson 2 , Sidona- 

Valentina Bala 1 , Kristina Forslind 3 and Ingiäld Hafström 4 , 

1 

Lund University, Lund, Sweden, 2 R&D Center, Spenshult 

Hospital, Oskarström, Sweden, 3 Helsingborgs Lasarett and 

Lund University Hospital, Helsingborg, Sweden, 4 Karolinska 

University Hospital, Stockholm, Sweden 

391. DAS28 Is Not a Sufficient Disease Activity Measure for 

Obese Rheumatoid Arthritis Patients - Don’t Leave the Feet 

Behind. Vikram Garg 1 , Paul Maranian 2 , Mihaela B. Taylor 3 , 

Harold E. Paulus 4 , David Elashoff 4 and Veena K. Ranganath 5 , 

1 

UCLA David Geffen School of Medicine, VA Greater 

Los Angeles Healthcare System, Los Angeles, CA, 2 UCLA 

Medical School, Los Angeles, CA, 3 University of California 

Los Angeles, Los Angeles, CA, 4 University of California, Los 

Angeles, Los Angeles, CA, 5 University of California, Los 

Angeles, Western Consortium of Practicing Rheumatologists, 


392. Analysis of Factors Impact on Patient Global Assessment 

in Daily Practice Based On Observational Cohort IORRA 

(Institute of Rheumatology, Rheumatoid Arthritis). Yasushi 

Inoue, Eiichi Tanaka, Ayako Nakajima, Eisuke Inoue, Akiko 

Kobayashi, Daisuke Hoshi, Naoki Sugimoto, Kumi Shidara, 

Yohei Seto, Atsuo Taniguchi, Shigeki Momohara and Hisashi 

Yamanaka, Institute of Rheumatology, Tokyo Women’s 

Medical University, Tokyo, Japan 

393. Defining Criteria for Rheumatoid Arthritis Patient-Derived 

Disease Activity Score That Corrresponds to Disease 

Activity Score 28 and Clnical Disease Activity Index Based 

Statuses and Response Criteria. Alexander MH Leung 1 , 



Daniel Farewell 2 , Chak S. Lau 3 and Ernest Choy 4 , 1 Institute 

of Infection and Immunity, Cardiff University School of 

Medicine, Cardiff, United Kingdom, 2 Cardiff, ENGLAnd, 

United Kingdom, 3 Queen Mary Hospital, Hong Kong, Hong 

Kong, 4 Cardiff University School of Medicine, Cardiff, United 

Kingdom 

394. Remission after One Year in ACPA Positive and ACPA 

Negative Patients with Early Arthritis. K.V.C. Wevers-de 

Boer 1 , L. Heimans 1 , K. Visser 1 , A.A. Schouffoer 2 , T.H.E. 

Molenaar 3 , J.B. Harbers 4 , C. Bijkerk 5 , I. Speyer 6 , M. de 

Buck 7 , P.B. de Sonnaville 8 , B.A. Grillet 9 , Tom Huizinga 1 and 

C.F. Allaart 1 , 1 Leiden University Medical Center, Leiden, 

Netherlands, 2 Haga Hospital, The Hague, Netherlands, 

3 

Groene Hart Hospital, Netherlands, 4 Franciscus Hospital, 

Roosendaal, 5 Reinier de Graaf Gasthuis, Delft, Netherlands, 

6 

Bronovo Hospital, Den Haag, Netherlands, 7 MCH, The 

Hague, 8 Admiraal de Ruyter hospital, Goes, 9 Zorgsaam 

hospital, Terneuzen, Netherlands 

395. Trends in Disease Activity, Response and Remission 

Rates in Rheumatoid Arthritis during the Last Decade: 

Results from the NOR-DMARD Register. Anna-Birgitte Aga, 

Elisabeth Lie, Karen M. Fagerli, Till Uhlig, Tore K. Kvien and 

Espen A. Haavardsholm, Diakonhjemmet Hospital, Oslo, 

Norway 

396. Prevalence, Concordance and Predictors of Early and 

Sustained Remission Assessed by Various Indices in the 

French Early Arthritis Espoir Cohort. Cédric Lukas 1 , Ihsane 

Hmamouchi 2 , Xavier Le Loet 3 , Bruno Fautrel 4 and Bernard 

Combe 5 , 1 Montpellier 1 University, Lapeyronie Hospital, 

Montpellier, France, 2 El Ayachi Hospital, Rabat, Morocco, 

3 

CHU de ROUEN, Rouen, France, 4 APHP-Pitie Salpetriere 

Hospital / UPMC, Paris, France, 5 Hopital Lapeyronie, 


397. Assessment of Global Disease Activity in Rheumatoid 

Arthritis Patients Monitored in the Measurement 

of Efficacy of Treatment in the Era of Rheumatology 

Database: The patient’s versus the rheumatologist’s 

Opinion. E. Gvozdenovic 1 , R. Koevoets 1 , R. Wolterbeek 1 , 

Désirée van der Heijde 1 , T.W.J. Huizinga 1 , C.F. Allaart 1 and 

Robert B. M. Landewé 2 , 1 Leiden University Medical Center, 

Leiden, Netherlands, 2 Academic Medical Center/University 

of Amsterdam & Atrium Medical Center, Amsterdam, 

Netherlands 

398. Basal Metabolic Rate As an Indicator of Rheumatoid 

Arthritis Disease Activity and Predictor of Remission. 

Heather Jones 1 , Annette Szumski 2 and Andrew S. Koenig 2 , 

1 

Pfizer Inc, Collegeville, PA, 2 Pfizer Inc., Collegeville, PA 

399. Can Sustained Remission of Rheumatoid Arthritis Be 

Predicted? an Analysis From the Japanese National 

Database of Rheumatic Disease (NinJa). Yoichiro Haji 1 , 

Mitsumasa Kishimoto 1 , Ryo Rokutanda 1 , Sachiko Ohde 2 , 

Gautam A. Deshpande 2 , Yuri Ohara 1 , Chisun Min 1 , Yasuhiro 

Suyama 1 , Hisanori Shimizu 1 , Ken-ichi Yamaguchi 1 , Akira 

Takeda 1 , Yukio Matsui 1 , Masato Okada 1 and Shigeto Tohma 3 , 

1 

St. Luke’s International Hospital, Tokyo, Japan, 2 St.Luke’s 

Life of Science Institute, Tokyo, Japan, 3 Sagamihara National 

Hospital, Sagamihara City, Japan 

400. High Patient Global Assessment Scores Associate with 

the Residual Disease Activity Unidentified by a 28-Joint 

Examination in Rheumatoid Arthritis Patients Approaching 

Clinical Remission. Yasushi Inoue, Eiichi Tanaka, Ayako 

Nakajima, Eisuke Inoue, Akiko Kobayashi, Daisuke Hoshi, 

Naoki Sugimoto, Kumi Shidara, Yohei Seto, Atsuo Taniguchi, 

Shigeki Momohara and Hisashi Yamanaka, Institute of 

Rheumatology, Tokyo Women’s Medical University, Tokyo, 

Japan 

401. Can We Improve Outcomes in Early Rheumatoid Arthritis 

by Determining Best Practices? An Analysis of the 

Canadian Early Rheumatoid Arthritis Cohort (CATCH). 

Jamie Harris 1 , Vivian P. Bykerk 2 , Carol A. Hitchon 3 , Edward 

Keystone 4 , J. Carter Thorne 5 , Gilles Boire 6 , Boulos Haraoui 7 , 

Glen S. Hazlewood 4 , Ashley Bonner 8 , Janet E. Pope 9 and 

CATCH Investigators 10 , 1 Western University, London, ON, 

2 

Hospital for Special Surgery, New York, NY, 3 University of 

Manitoba, Winnipeg, MB, 4 University of Toronto, Toronto, 

ON, 5 Southlake Regional Health Centre, Newmarket, 

ON, 6 CHUS - Sherbrooke University, Sherbrooke, QC, 

7 

Osteoarthritis Research Unit, University of Montreal 

Hospital Research Centre (CRCHUM), Montreal, QC, 

8 

McMaster University, Hamilton, ON, 9 St. Joseph Health 


10 

Toronto, ON 

402. Discordant Inflammatory Markers in Veterans with 

Rheumatoid Arthritis: Baseline Characteristics and 

Relationship with Disease Activity. Rebecca Belsom 1 , 

Archana Jain 1 , Jeffrey Curtis 2 , Shuo Yang 2 , Ted R. Mikuls 3 , 

Lang Chen 2 and Angelo L. Gaffo 4 , 1 University of Alabama, 

Birmingham, AL, 2 University of Alabama at Birmingham, 

Birmingham, AL, 3 Omaha VA and University of Nebraska 

Medical Center, Omaha, NE, 4 Birmingham VA Medical Center 

and University of Alabama at Birmingham, Birmingham, AL 

403. The Impact of Reaching Low Disease Activity in the First 

Year on Future Disability and Damage in Patients with 

Early Rheumatoid Arthritis. Pooneh Akhavan 1 , George 

A. Tomlinson 2 , Paul R. Fortin 3 and Claire Bombardier 1 , 

1 

University of Toronto, Toronto, ON, 2 Toronto General 

Hospital, Toronto, ON, 3 Division of Rheumatology, Centre 

de recherche du centre hospitalier universitaire de Québec, 

Faculté de médecine de L’université Laval, Quebec City, QC 

404. Remission is a Difficult Target in Clinical Practice When 

RA Disease Is Established. Till Uhlig 1 , Elisabeth Lie 1 , Cecillie 

Kaufmann 2 , Erik Rødevand 3 , Knut Mikkelsen 4 , Synnøve 

Kalstad 5 and Tore K. Kvien 1 , 1 Diakonhjemmet Hospital, 

Oslo, Norway, 2 Vestre Viken, Drammen, Norway, 3 St. Olavs 

Hospital, Trondheim, Norway, 4 Lillehammer Hospital for 

Rheumatic Diseases, Lillehammer, Norway, 5 Tromsø, Norway 

170 

2012 Program Book


405. Frequencies of Boolean and Index Based ACR-EULAR 

Remissions Differ Slightly Depending On the Method of 

Patient Global Assessment. Paul Studenic, Josef S. Smolen 

and Daniel Aletaha, Medical University Vienna, Vienna, 

Austria 

Rheumatoid Arthritis - Human Etiology and Pathogenisis 

406. βig-h3 Regulates the Inflammatory Arthritis by Mediating 

Selective Recruitment of Effector/Memory T Cells. Keum 

Hee Sa, Jin Hee Kang, Mahmudul Md Alam, Kyung Hwa Lee, 

Churl Hyun Im, Eon Jeong Nam, In San Kim and Young Mo 

Kang, Kyungpook National University School of Medicine, 

Daegu, South Korea 

407. The I50V IL4R SNP Is Associated with Increased Th17 Cell 

Frequency and Poor Clinical Outcome in Rheumatoid 

Arthritis. Jan Leipe 1 , Iryna Prots 2 , Markus A. Schramm 1 , 

Matthias Witt 1 , Axel P. Nigg 1 , Christiane S. Reindl 1 , Claudia 

Dechant 1 , Mathias Grunke 1 , Hendrik Schulze-Koops 1 and Alla 

Skapenko 1 , 1 University of Munich, Munich, Germany, 2 Junior 

Research Group III, Interdisciplinary Center for Clinical 

Research Nikolaus-Fiebiger Center for Molecular Medicine, 

Erlangen 

408. Alpha-Enolase Facilitates Migration of Fibroblast-Like 

Synoviocytes in Rheumatoid Arthritis. Kichul Shin 1 , Ji Ah 

Park 2 , Seyeon Bae 1 , Jae Seung Kang 1 and Yeong Wook Song 3 , 

1 

College of Medicine, Seoul National University, Seoul, South 

Korea, 2 Seoul National Hospital, Seoul, South Korea, 3 Seoul 

National University Hospital, Seoul, South Korea 

409. Pathway Analysis of Genome-Wide Association Studies 

On Rheumatoid Arthritis. Young Ho Lee 1 , Sung Jae Choi 1 , 

Jong Dae Ji 1 and Gwan Gyu Song 2 , 1 Korea University Medical 

Center, Seoul, South Korea, 2 Korea Univ College of Med, 

Seoul 

410. Early Growth Response-1 (EGR-1) Controls Synoviocyte 

Apoptosis, and Its Expression Is Regulated by the Direct 

Binding of Fibroblast Growth Factor-1 (FGF1) or Insulin-Like 

Growth Factor-1 (IGF1) to Integrin αvβ3. Shino Tanaka 1 , 

Jun Saegusa 1 , Seiji Kawano 1 , Yoshikazu Takada 2 , Shunichi 

Kumagai 3 and Akio Morinobu 1 , 1 Kobe University Graduate 

School of Medicine, Kobe, Japan, 2 University of California, 

Davis, School of Medicine, Sacramento, CA, 3 Shinko Hospital, 

Kobe, Japan 

411. Early Menopause, Smoking and Circulating Antibodies 

against Citrullinated Peptides in the Pre-Clinical Phase 

of Rheumatoid Arthritis. Mitra Pikwer 1 , Johan Rönnelid 2 , 

Monika Hansson 3 , Ulf Bergström 1 , Lennart T.H. Jacobsson 1 , 

Linda Mathsson 2 , Per Johan Jakobsson 3 , Guy B. Serre 4 , 

Rikard Holmdahl 5 , Lars Klareskog 6 and Carl Turesson 1 , 1 Lund 

University, Malmö, Sweden, 2 Uppsala University, Uppsala, 

Sweden, 3 Rheumatology unit, Karolinska University Hospital, 

Karolinska Institute, Stockholm, Sweden, 4 Centre National 

de la Recherche Scientifique - Université de Toulouse, 

Toulouse, France, 5 Department of Medical Biochemistry 

and Biophysics, Karolinska Institutet, Stockholm, Sweden, 

6 

Karolinska Institute, Stockholm, Sweden 

412. Single Nucleotide Polymorphisms within the HLA-DRB1 

Gene in Relation to Antibodies Against Citrullinated 

Peptides in Individuals Prior to the Development of 

Rheumatoid Arthritis. Lisbeth Arlestig 1 , Mikael Brink 2 , 

Monika Hansson 3 , Per Johan Jakobsson 3 , Rikard Holmdahl 4 , 

Linda Mathsson 5 , Johan Ronnelid 5 , Lars Klareskog 6 and 

Solbritt M. Rantapaa-Dahlqvist 7 , 1 Umeå University, Umea, 

Sweden, 2 Umea University, Umea, Sweden, 3 Rheumatology 

unit, Karolinska University Hospital, Karolinska Institute, 

Stockholm, Sweden, 4 Department of Medical Biochemistry 


5 

Uppsala University, Uppsala, Sweden, 6 Karolinska Institute, 

Stockholm, Sweden, 7 Institution of Public health and clinical 

medicine/ Rheumatology, University of Umeå, Umea, 

Sweden 

413. α(1,2)-Linked Fucosylated Cytokines Are Upregulated in 

Rheumatoid Arthritis. Takeo Isozaki 1 , Jeffrey H. Ruth 1 , M. 

Asif Amin 1 , Phillip L. Campbell 1 , Christine M. Ha 1 and Alisa E. 

Koch 2 , 1 University of Michigan, Ann Arbor, MI, 2 University of 

Michigan Medical School, Ann Arbor, MI 

414. First-Degree Relatives without Rheumatoid Arthritis Exhibit 

Reactivity to Multiple Anti-Citrullinated Protein Antibodies 

in Association with Rheumatoid Arthritis-Related Clinical 

Characteristics: Studies of the Etiology of Rheumatoid 

Arthritis. Kendra A. Young 1 , Kevin D. Deane 2 , Lezlie A. 

Derber 3 , Jan M. Hughes-Austin 4 , Michael H. Weisman 5 , 

Jane H. Buckner 6 , Ted R. Mikuls 7 , James R. O’Dell 8 , Richard 

M. Keating 9 , Peter K. Gregersen 10 , V. Michael Holers 2 and 

Jill M. Norris 1 , 1 Colorado School of Public Health, Aurora, 

CO, 2 University of Colorado School of Medicine, Aurora, 

CO, 3 University of Colorado Anschutz Medical Campus, 

Aurora, CO, 4 Colorado School of Public Health / University of 

Colorado Anschutz Medical Campus, Aurora, CO, 5 Cedars- 

Sinai Medical Center, Los Angeles, CA, 6 Benaroya Research 

Institute at Virginia Mason, Seattle, WA, 7 Omaha VA and 

University of Nebraska Medical Center, Omaha, NE, 8 Univ of 

Nebraska Med Ctr, Omaha, NE, 9 The University of Chicago, 

Chicago, IL, 10 Feinstein Institute Medical Research and North 

Shore-Long Island Jewish Health System, Manhasset, NY 

415. Hypoxia-Induced Endogenous Prostaglandin E2 Negatively 

Regulates Hypoxia-Enhanced Aberrant Overgrowth of 

Rheumatoid Synovial Tissue. Hirofumi Mitomi 1 , Hidehiro 

Yamada 1 , Toshiko Nozaki Shibata 1 , Hiroshi Ito 1 , Yoshioki 

Yamasaki 1 , So Nomoto 2 , Atsushi Kusaba 3 , Hiroki Yamashita 3 

and Shoichi Ozaki 1 , 1 St. Marianna University, Kawasaki, 

Japan, 2 Saiseikai Yokohamashi Tobu Hospital, Yokohama, 

Japan, 3 Ebina General Hospital, Ebina, Japan 

416. Dyslipidaemia in Early Rheumatoid Arthritis Patients Is 

Common and Not Influenced by Two Years of Effective 

DMARD Therapy. The Opera Study. Torkell Ellingsen 1 , Kim 

Horslev-Petersen 2 , Merete L. Hetland 3 , Peter Junker 4 , Jan 

Podenphant 5 , Mikkel Ostergaard 5 and Kristian Stengaard- 

Pedersen 6 , 1 Regional Hospital, Silkeborg, Denmark, 

2 

Southern University, Denmark, 3 Copenhagen University 

and Glostrup Hospital, Copenhagen, Denmark, 4 Odense 



172 

University Hospital, Denmark, 5 Copenhagen University 

Hospital at Glostrup, Denmark, 6 Arhus University Hospital, 

Denmark 

417. The Potential Role of PTPRD Gene Copy Number Variation 

in Susceptibility to Rheumatoid Arthritis. Seung Cheol 

Shim, Donghyuk Sheen, Mi Kyoung Lim and Hyo Park, Eulji 

University Hospital, Daejeon, South Korea 

418. Immediate Early Response Gene X-1 Is Over-Expressed 

and Regulates Apoptosis and Cytokine Production in 

Rheumatoid Arthritis Synovial Fibroblasts. Akio Morinobu 1 , 

Masaaki Fujita 2 , Shino Tanaka 3 , Jun Saegusa 2 and Shunichi 

Kumagai 4 , 1 Kobe university graduate school of medicine, 

Kobe 650-0017, Japan, 2 Kobe University Graduate School 

of Medicine, Kobe, Japan, 3 Rheumatology and Clinical 

Immunology, Kobe, Japan, 4 Shinko hospital, Kobe, Japan 

419. Epigenome Analysis of Rheumatoid Arthritis Synovial 

Fibroblasts Revealed TBX-5 As a Novel Transcription Factor 

in Chemokine Regulation. Emmanuel Karouzakis, Michelle 

Trenkmann, Renate E. Gay, Beat A. Michel, Steffen Gay and 

Michel Neidhart, Center of Experimental Rheumatology, 


420. Loss-of-Co-Homozygosity Mapping and Exome Sequencing 

of a Syrian Pedigree Identified the Candidate Causal 

Mutation Associated with Rheumatoid Arthritis. Yukinori 

Okada 1 , Namrata Gupta 2 , Daniel Mirel 3 , Stacey Gabriel 3 , 

Thurayya Arayssi 4 , Faten Mouassess 5 , Walid AL Achkar 5 , 

Layla Kazkaz 6 and Robert M. Plenge 7 , 11 .Brigham and 

Women’s Hospital, Harvard Medical School, 2 .Program in 

Medical and Population Genetics, Broad Institute, Boston, 

MA, 2 The Broad Institute, Cambridge, 3 The Broad Institute, 

Cambridge, MA, 4 Weill Cornell Medical College-Qatar, Doha, 

Qatar, 5 Molecular Biology and Biotechnology, Damascus, 

Syria, 6 Tishreen Hospital and the Syrian Association for 

Rheumatology, Damascus, Syria, Damascus, Syria, 7 Brigham 


421. Rheumatoid Factor, Not Antibodies to Citrullinated 

Proteins, Are Associated with High Disease Activity. Josef 

S. Smolen 1 , Farideh Alasti 2 and Daniel Aletaha 2 , 1 Medical 


2 

Medical University of Vienna, Vienna, Austria 

422. Antibodies to Citrulline from Rheumatoid Arthritis Patients 

Also Bind Homocitrulline. Mathias Scinocca, Radha Joseph, 

David A. Bell, Ewa Cairns and Lillian J. Barra, Schulich School 

of Medicine and Dentistry, Western University, London, ON 

423. Sputa Autoantibodies in Patients with Established 

Rheumatoid Arthritis and Subjects At-Risk for Future 

Clinically Apparent Disease. Van C. Willis 1 , M. Kristen 

Demoruelle 1 , Lezlie A. Derber 1 , Catherine J. Chartier-Logan 1 , 

Mark Parish 1 , Isabel Pedraza 2 , Michael H. Weisman 3 , Jill M. 

Norris 4 , V. Michael Holers 1 and Kevin D. Deane 1 , 1 University 

of Colorado School of Medicine, Aurora, CO, 2 Cedars Sinai 

Med Ctr, Los Angeles, 3 Cedars-Sinai Medical Center, Los 

Angeles, CA, 4 Colorado School of Public Health, Aurora, CO 


424. Influence of Pregnancy on Disease Activity-Associated 

Genes in Rheumatoid Arthritis. Erik J. Peterson 1 , Shreyasee 

Amin 2 , Hatice Bilgic 1 , Emily Baechler Gillespie 1 , Jane 

E. Salmon 3 , Ann M. Reed 2 , Weihua Guan 4 and Daniel 

L. Mueller 1 , 1 University of Minnesota Medical School, 

Minneapolis, MN, 2 Mayo Clinic, Rochester, MN, 3 Hospital 

for Special Surgery, New York, NY, 4 University of Minnesota 

School of Public Health, Minneapolis, MN 

425. Slug Is Induced by Benzo(a)Pyrene and EGF Through 

PI3K/Akt/mTOR Pathway and Is Closely Involved in the 

Regulation of the Invasive Properties of FLS in Rheumatoid 

Arthritis. Jaejoon Lee 1 , Jiwon Hwang 2 , Chan Hong Jeon 3 , 

Joong Kyong Ahn 4 , Hoon-Suk Cha 1 and Eun-Mi Koh 5 , 

1 

Samsung Medical Center, Sunkyunkwan University School 

of Medicine, Seoul, South Korea, 2 Samsung Medical Center, 

Sungkyunkwan University School of Medicine, Seoul, South 

Korea, 3 Soonchunhyang University College of Medicine, 

Bucheon, South Korea, 4 Kangbuk Samsung hospital, 


Korea, 5 Samsung Medical Center, Sungkyunkwan University 

School of Medicine, Seoul, Seoul, South Korea 

426. Dickkopf-1 Stimulates Fibroblast-Like Synoviocyte 

Migration Through Janus Kinase Activation. Yubin Luo 1 , 

Bryan Dieffenbach 2 , Jung-Soo Song 3 , Jinseok Kim 4 , David 

L. Boyle 1 , Michael Karin 1 , Gary S. Firestein 1 and Maripat 

Corr 5 , 1 UCSD School of Medicine, La Jolla, CA, 2 UCSD School 

of Medicine, la Jolla, CA, 3 Chung-Ang University College of 

Medicine, Seoul, South Korea, 4 Jeju National University, Jeju, 

Korea, South Korea, 5 Univ of California-San Diego, La Jolla, 

CA 

427. Epigenetic Features as Predictive Markers of 

Responsiveness to Epitope-Specific Therapy in Rheumatoid 

Arthritis. Roberto Spreafico, Maura Rossetti, Theodorus Van 

Der Broek, Olivia Morrow and Salvatore Albani, Sanford- 

Burnham Medical Research Institute, La Jolla, CA 

428. TNFα Modulates the Expression of Circadian Clock 

Gene, Per 2 , Via D-Box Motif in the Promoter Region 

in Rheumatoid Synovial Cells. Kohsuke Yoshida 1 , Akira 

Hashiramoto 2 , Takaichi Okano 3 , Nao Shibanuma 4 and 

Shunichi Shiozawa 5 , 1 Hyogo Prefectural Rehabilitation Center 

at Nishi-harima, Tatsuno, Japan, 2 Department of Internal 

Medicine, Kobe University Graduate School of Medicine 

/ The Center for Rheumatic Diseases, Kobe University 

Hospital, Kobe, Japan, 3 Kobe University Hospital, Kobe, 

Japan, 4 The Center for Rheumatic Diseases, Kobe University 

Hospital / Departmant of Orthopaedic Surgery, Kobe Kaisei 

Hospital, Kobe, Japan, 5 Kyushu University Beppu Hospital, 

Beppu, Japan 

429. The Significance of the Apoptosis Level and the Apoptosis 

Related Signal Proteins of CD4+t ACD4+Foxp3+t Cell in 

Patients with Rheumatoid Arthritis. Ning Li 1 , Tianrui Ma 2 , 

Jie Han 1 , Jieru Zhou 1 and Songguo Zheng 3 , 1 Shanghai East 

Hospital, Shanghai, China, 2 Ningbo Pediatric Hospital, 

Ningbo, China, 3 Keck School of Medicine of the University of 

Southern California, Los Angeles, CA


430. Comprehensive Microrna Analysis Identifies Mir-2 4 , 

Mir-26a, and Mir-125a-5p As Plasma Biomarkers for 

Rheumatoid Arthritis. Koichi Murata, Moritoshi Furu, 

Hiroyuki Yoshitomi, Masahiro Ishikawa, Hideyuki Shibuya, 

Hiromu Ito and Shuichi Matsuda, Kyoto University Graduate 

School of Medicine, Kyoto, Japan 

431. Basic and Clinical Significance of Interleukin 6 (IL-6) in AA 

Amyloidosis with RA. Kazuyuki Yoshizaki, Prabha Tiwari, 

Lokesh P. Tripathi, Shandar Ahmad, Kenji Mizuguchi, Teppei 

Nishikawa-Matsumura, Tomoyasu Isobe and Soken- 

Nakazawa J. Song, Osaka University, Osaka, Japan 

432. Identification and Characterization of Fibrinogen-Specific 

T Cells in Patients with Rheumatoid Arthritis. Laura Su and 

Mark M. Davis, Stanford University School of Medicine, 

Stanford, CA 

433. Genome Wide Association Analysis of Pain Reduction 

in Rheumatoid Arthritis Patients Treated with Anti-TNF 

Medication. Results of the DREAM and Danbio Registries. 

Marieke J.H. Coenen 1 , Masha Umicevic-Mirkov 1 , Hans 

Scheffer 1 , Sophine B. Krintel 2 , Sita H. Vermeulen 1 , Julia S. 

Johansen 2 , Wietske Kievit 1 , Mart A.F.J. van de Laar 3 , Piet 

L.C.M. van Riel 1 , Barbara Franke 1 and Merete L. Hetland 4 , 

1 


Netherlands, 2 Copenhagen University Hospital at Glostrup, 

Glostrup, Denmark, 3 Medisch Spectrum Twente & Twente 

University, Enschede, Netherlands, 4 Copenhagen University 

and Glostrup Hospital, Copenhagen, Denmark 

434. IL-22 Mediated Pannus Formation in Autoimmune Arthritis 

Is PI3K/Akt/mTOR Dependent. Siba P. Raychaudhuri 1 , 

Anupam Mitra 1 , Ananya Datta Mitra 2 , Christine Abria 2 and 

Smriti K. Raychaudhuri 2 , 1 VA Sacramento Medical Center\ 

UC Davis School of Medicine, Mather, CA, 2 VA Sacramento 

Medical Center, Mather, CA 

435. CIP2A Facilitates Apoptotic Resistance of Fibroblast-Like 

Synoviocytes in Rheumatoid Arthritis Independent of 

c-Myc Expression. Jaejoon Lee 1 , Jiwon Hwang 2 , Jinseok 

Kim 3 , Joong Kyong Ahn 4 , Hoon-Suk Cha 1 and Eun-Mi Koh 5 , 

1 

Samsung Medical Center, Sunkyunkwan University School 

of Medicine, Seoul, South Korea, 2 Samsung Medical Center, 


Korea, 3 Jeju National University Hospital, Jeju, South Korea, 

4 

Kangbuk Samsung hospital, Sungkyunkwan University 

School of Medicine, Seoul, South Korea, 5 Samsung Medical 

Center, Sungkyunkwan University School of Medicine, Seoul, 


436. Synthetic Anti-CCP Antibody Aggravated Severity of Animal 

Arthritis and Captured Citrullinated Antigen in the Serum 

of Patients with Rheumatoid Arthritis. Youngkyun Kim 1 , Su- 

Jin Moon 1 , Hyoju Yi 1 and Ji Hyeon Ju 2 , 1 College of Medicine, 

The Catholic University of Korea, Seoul, South Korea, 

2 

College of Medicine, The Catholic University of Korea & 

Stanford University, Seoul & Palo Alto, CA 

437. SIRT6 Regulates Cigarette Smoke Induced MMP1 

Expression in Rheumatoid Arthritis Synovial Fibroblasts. 

Anna Engler, Renate E. Gay, Beat A. Michel, Steffen Gay and 

Caroline Ospelt, Center of Experimental Rheumatology, 

University Hospital Zurich and Zurich Center of Integrative 

Human Physiology (ZIHP), Zurich, Switzerland 

438. Methyl Supplementation of Rheumatoid Arthritis Synovial 

Fibroblasts Regulates the Expression of Transcription 

Factors and Matrix Metalloproteinases. Edvardas Bagdonas, 

Emmanuel Karouzakis, Astrid Jungel, Caroline Ospelt, Renate 

E. Gay, Steffen Gay, Beat A. Michel and Michel Neidhart, 

Center of Experimental Rheumatology, University Hospital 

Zurich, Zurich, Switzerland 

439. Interaction of Antibodies against Citrullinated Peptides 

with HLA Shared Epitope, PTPN22 1858T Variant, and 

Smoking in Individuals Prior to and After the Development 

of Rheumatoid Arthritis. Heidi Kokkonen 1 , Mikael Brink 2 , 

Monika Hansson 3 , Linda Mathsson 4 , Ewa Lassen 5 , Per 

Johan Jakobsson 3 , Rikard Holmdahl 6 , Johan Rönnelid 4 , 

Lars Klareskog 7 and Solbritt M. Rantapaa-Dahlqvist 8 , 

1 

Umeå University, Umea, Sweden, 2 Umea University, 

Umea, Sweden, 3 Rheumatology unit, Karolinska University 

Hospital, Karolinska Institute, Stockholm, Sweden, 

4 

Uppsala University, Uppsala, Sweden, 5 Umeå University, 

Umeå, Sweden, 6 Department of Medical Biochemistry 


7 

Karolinska Institute, Stockholm, Sweden, 8 Institution 

of Public health and clinical medicine/ Rheumatology, 

University of Umeå, Umea, Sweden 

440. Effects of Fetal Microchimerisms on Disease Onset 

and Severity in Women with Rheumatoid Arthritis and 

Systemic Lupus Erythematosus. Marianne Kekow 1 , Sara Fill 

Malfertheiner 2 , Maria Barleben 1 , Susanne Drynda 3 , Joern 

Kekow 3 and Thomas Brune 1 , 1 Univ of Magdeburg, Children’s 

Hospital, Magdeburg, Germany, 2 Univ of Magdeburg, 

Department of Obstetrics and Gynecology, Magdeburg, 

Germany, 3 Univ of Magdeburg, Vogelsang-Gommern, 

Germany 

441. Performance of Anti-Cyclic Citrullinated Peptide Assays 

Differs in Healthy Subjects At Elevated Risk for Future 

Rheumatoid Arthritis and Subjects with Established 

Disease. M. Kristen Demoruelle 1 , Mark Parish 2 , Lezlie 

A. Derber 2 , Michael H. Weisman 3 , William R. Gilliland 4 , 

Jess Edison 4 , James R. O’Dell 5 , Ted R. Mikuls 5 , Richard M. 

Keating 6 , Peter K. Gregersen 7 , Jane H. Buckner 8 , Jill M. 

Norris 9 , V. Michael Holers 1 and Kevin D. Deane 1 , 1 University 

of Colorado School of Medicine, Aurora, CO, 2 University of 

Colorado Anschutz Medical Campus, Aurora, CO, 3 Cedars- 

Sinai Medical Center, Los Angeles, CA, 4 Walter Reed National 

Military Medical Center, Bethesda, MD, 5 University of 

Nebraska Medical Center, Omaha, NE, 6 The University 

of Chicago, Chicago, IL, 7 North Shore University Hospital 

Research Center, Manhasset, NY, 8 Benaroya Research 

Institute at Virginia Mason, Seattle, WA, 9 Colorado School of 

Public Health, Aurora, CO 



442. Joint Effects of Known Genetic Markers of Rheumatoid 

Arthritis Risk and 25-Hydroxyvitamin D On Rheumatoid 

Arthritis Risk. Linda T. Hiraki 1 , Chia-Yen Chen 2 , Jing Cui 3 , 

Susan Malspeis 4 , Karen H. Costenbader 5 and Elizabeth W. 

Karlson 5 , 1 Brigham and Women’s Hospital, Harvard School of 

Public Health, Boston, MA, 2 Harvard School of Public Health, 

Boston, MA, 3 Brigham and Women’s Hospital, Boston, MA, 

4 

Brigham and Womens Hospital, Boston, MA, 5 Brigham and 


443. Secreted Frizzled-Related Protein 5 Exerts the Anti- 

Inflammatory Role in Rheumatoid Arthritis Via Down- 

Regulation of c-Jun N-Terminal Kinase. Yong-Jin Kwon, 

Tae-Yeon Kim, Sang-Won Lee, Yong-Beom Park, Soo Kon Lee 

and Min-Chan Park, Yonse University College of Medicine, 


Rheumatoid Arthritis Treatment - Small Molecules, Biologics and 

Gene Therapy 

444. Tocilizumab Improves Bone Mineral Density Compared 

with Abatacept in Patients with TNF Blockers-Resistant 

Active Rheumatoid Arthritis. An Open Label Randomized 

Controlled Trial. Kensuke Kume 1 , Kanzo Amano 1 , Susumu 

Yamada 1 , Kazuhiko Hatta 2 , Kuniki Amano 3 , Noriko Kuwaba 4 

and Hiroyuki Ohta 5 , 1 Hiroshima Clinic, Hiroshima, Japan, 

2 

Hatta Clinic, Kure, Japan, 3 Sky Clinic, Hiroshima, Japan, 

4 

Sanki Clinical Link, Hiroshima, Japan, 5 Hiroshima, Japan 

445. Combination of Intra-Articular Steroid Injection and 

Infliximab More Effective Than Infliximab in Rapid 

Radiographic Progression Patients with Rheumatoid 

Arthritis: A Randomized, Open Label, x Ray Reader Blinded 

Study. Kensuke Kume 1 , Kanzo Amano 1 , Susumu Yamada 1 , 

Kazuhiko Hatta 2 , Kuniki Amano 3 , Hiroyuki Ohta 4 and Noriko 

Kuwaba 5 , 1 Hiroshima Clinic, Hiroshima, Japan, 2 Hatta Clinic, 

Kure, Japan, 3 Sky Clinic, Hiroshima, Japan, 4 Hiroshima, 

Japan, 5 Sanki Clinical Link, Hiroshima, Japan 

446. Clinical Remission and Rate of Relapse after Tocilizumab 

Withdrawal in Rheumatoid Arthritis Patients. Cesar 

Vargas-Serafin 1 , Luis Aguilar-Lozano 1 , Jorge Padilla-Ibarra 1 , 

Carlos Sandoval-Castro 1 , Jose Dionisio Castillo-Ortiz 1 , Jorge 

Morales-Torres 2 , Claudia Hernandez 2 and Cesar Ramos- 

Remus 1 , 1 Unidad de Investigacion en Enfermedades Cronico- 

Degenerativas, Guadalajara, Mexico, 2 Hospital Aranda de la 

Parra, Leon, Mexico 

447. Long-Term Safety and Efficacy of Tabalumab, an Anti-B- 

Cell Activating Factor Monoclonal Antibody, in Patients 

with Rheumatoid Arthritis: A 52-Week, Open-Label 

Extension Study. Maria W. Greenwald 1 , Leszek Szczepanski 2 , 

Alastair C. Kennedy 3 , Chin H. Lee 4 , Emery Polasek 5 , Melissa 

Veenhuizen 5 , Rebecca Jones-Taha 6 and Pierre-Yves Berclaz 5 , 

1 

Desert Medical Advances, Palm Desert, CA, 2 Wydz. 

Fizjoterapii, Wyzsza Skola Spoleczno-Przyrodnicza, Poland, 

3 

Alastair C. Kennedy, MD, Vero Beach, FL, 4 Eli Lilly and 

Company, Indianapolis, IN, 5 Eli Lilly & Company, Indianapolis, 

IN, 6 PharmaNet/i 3 , Blue Bell, PA 

448. Sustained and Cumulated Response Over Time in 

Rheumatoid Arthritis Patients Treated with Rituximab 

After Initial Failure of Anti Tumor Necrosis Factor Agents. 

Ioan Ancuta 1 , Catalin Codreanu 2 , Ruxandra Ionescu 3 , Magda 

Parvu 4 and Mihai Bojinca 1 , 1 “Dr. I. Cantacuzino” Hospital, 

Bucharest, Romania, 2 “Dr. I. Stoia” Center for Rheumatic 

Diseases, Bucharest, Romania, 3 Clinic Hospital “Sf. Maria”, 

Bucharest, Romania, 4 “N.Gh. Lupu” Clinical Hospital, 

Bucharest, Romania 

449. Rituximab After First Anti Tumor Necrosis Factor Failure 

Is More Efficient with High Impact in Reducing Time 

and Costs to Achieve Superior Rates of Low Disease 

Activity and Remission. Ioan Ancuta 1 , Catalin Codreanu 2 , 

Ruxandra Ionescu 3 , Magda Parvu 4 and Mihai Bojinca 1 , 1 “Dr. 

I. Cantacuzino” Hospital, Bucharest, Romania, 2 “Dr. I. Stoia” 

Center for Rheumatic Diseases, Bucharest, Romania, 3 Clinic 

Hospital Sf. Maria, Bucharest, Romania, 4 “N.Gh. Lupu” 

Clinical Hospital, Bucharest, Romania 

450. Late Onset Neutropenia after Rituximab Treatment for 

Rheumatological Conditions. Gabriel S. Breuer 1 , Michael 

Z. Ehrenfeld 2 , Itzhak Rosner 3 , Alexandra Balbir-Gurman 4 , 

Devy Zisman 5 and Daphna Paran 6 , 1 Shaare Zedek Medical 

Center, Jerusalem, Israel, 2 Chaim Sheba Medical Center, 

Tel HaShomer, Israel, 3 Bnai Zion Medical Center / Technion 

Faculty of Medicine, Haifa, Israel, 4 Rambam Health Care 

Campus, Haifa, Israel, 5 Carmel Medical Center, Haifa, Israel, 

6 

Tel Aviv Sourasky Medical Ctr, Tel Aviv, Israel 

451. Pilot Study of Stimulation of the Cholinergic Anti- 

Inflammatory Pathway with an Implantable Vagus Nerve 

Stimulation Device in Patients with Rheumatoid Arthritis. 

Frieda A. Koopman 1 , Sanda Miljko 2 , Simeon Grazio 3 , Sekib 

Sokolovic 4 , Kevin Tracey 5 , Yaakov Levine 6 , Ralph Zitnik 6 and 

Paul-Peter Tak 7 , 1 Academic Medical Center/University of 

Amsterdam, Amsterdam, Netherlands, 2 University Clinical 

Hospital, Mostar, Bosnia, 3 Clinical Hospital Center Sestre 

Milosrdnice, Zagreb, Croatia, 4 University Clinical Center, 

Sarajevo, Bosnia, 5 Feinstein Institute for Medical Research, 

Manhasset, NY, 6 SetPoint Medical Corporation, Valencia, CA, 

7 

Academic Medical Center/GlaxoSmithKline, Amsterdam, 

Netherlands 

452. Effectiveness and Tolerance Infiltration Intraarticular 

Corticosteroid According to Dose. Daniele F. Pereira 1 , 

Rita N.V. Furtado 2 , Natalia P. Machado 3 and Jamil Natour 3 , 

1 

Universidade Federal de São Paulo (UNIFESP), São Paulo, 

Brazil, 2 Universidade Federal de São Paulo - UNIFESP, São 

Paulo, Brazil, 3 Universidade Federal de São Paulo, São Paulo, 

Brazil 

453. Fish Oil in Rheumatoid Arthritis: A Randomised, Double 

Blind Trial Comparing High Dose with Low Dose. Susanna 

Proudman 1 , Llew Spargo 1 , Cindy Hall 1 , Leah McWilliams 1 , 

Anita Lee 1 , Maureen Rischmueller 2 , Robert Gibson 3 , Michael 

James 1 and Leslie G. Cleland 1 , 1 Royal Adelaide Hospital, 

Adelaide, Australia, 2 Queen Elizabeth Hospital, Adelaide, 

Australia, 3 University of Adelaide, Adelaide, Australia 

174 

2012 Program Book


454. Long-Term Efficacy of Tocilizumab Monotherapy in Patients 

with Rheumatoid Arthritis Previously Methotrexate 

Naive or Methotrexate Free for 6 Months. Graeme Jones 1 , 

Anthony Sebba 2 , Denise Lepley 3 , Jenny Devenport 3 , Corrado 

Bernasconi 4 , Devi Smart 5 , Chiedzo Mpofu 4 and Juan J. 

Gomez-Reino 6 , 1 Menzies Research Institute Tasmania, 

Hobart, Australia, 2 University of South Florida, Tampa, 

FL, 3 Genentech, South San Francisco, CA, 4 Roche, Basel, 

Switzerland, 5 Roche Products Ltd, Welwyn Garden City, 

United Kingdom, 6 Hospital Clinico Universitario, Santiago, 

Spain 

455. Lack of Additive Benefits of Concomitant Methotrexate 

Use to Tocilizumab Monotherapy for Rheumatoid Arthritis 

in Daily Clinical Practice. Keisuke Izumi 1 , Yuko Kaneko 2 , 

Hidekata Yasuoka 2 , Noriyuki Seta 3 , Hideto Kameda 1 , 

Masataka Kuwana 1 and Tsutomu Takeuchi 1 , 1 Keio University 

School of Medicine, Tokyo, Japan, 2 Keio Univ School of 

Medicine, Shinjuku-ku, Japan, 3 Keio university, Tokyo, Japan 

456. Factors Influencing Choice of Rituximab Versus an 

Alternative Tumor Necrosis Factor Inhibitor Following 

Tumor Necrosis Factor Inhibitor Failure in Patients 

with Rheumatoid Arthritis: Sub-Analysis of a Global, 

Observational Comparative Effectiveness Study. Axel 

Finckh 1 , Jacques-Eric Gottenberg 2 , Chiedzo Mpofu 3 , William 

G. Bensen 4 , Andrea Rubbert-Roth 5 , Fedra Irazoque 6 , Victor 

Martínez Taboada 7 , Carol Chung 8 , Lykke Hinsch-Gylvin 3 , 

Clodoveo Ferri 9 and Paul Emery 10 , 1 University Hospital of 

Geneva, Geneva, Switzerland, 2 CHU Strasbourg, Strasbourg, 

France, 3 F Hoffmann-La Roche Ltd, Basel, Switzerland, 4 St. 

Joseph’s Hospital and McMaster University, Hamilton, ON, 

5 

University of Cologne, Cologne, Germany, 6 Hospital Angeles 

Mocel, Mexico City, Mexico, 7 Hospital Universitario Marqués 

de Valdecilla, Santander, Spain, 8 Genentech Inc., South San 

Francisco, CA, 9 University of Modena and Reggio Emilia, 

Modena, Italy, 10 University of Leeds, Leeds, United Kingdom 

457. Biologic Disease-Modifying Anti-Rheumatic Drugs and the 

Risk of Non-Vertebral Osteoporotic Fractures in Patients 

with Rheumatoid Arthritis Aged 50 Years and Over. 

Jean-Pascal Roussy 1 , Louis Bessette 2 , Sasha Bernatsky 3 , 

Elham Rahme 3 and Jean Lachaine 1 , 1 University of Montreal, 

Montreal, QC, 2 Centre Hospitalier Universitaire de Québec, 

pavillon CHUL, Sainte-Foy, QC, 3 McGill University, Montreal, 

QC 

458. Better Retention RATE At 5 YEARS of ANTI-TNF Agents 

USED in Conjonction with Methotrexate Over Time in 

Patients with Rheumatoid Arthritis: REAL-Life DATA From 

Rhumadata Computarized Database. Denis Choquette 1 , 

Diane Sauvageau 2 , Boulos Haraoui 2 and Jean-Pierre 

Raynauld 2 , 1 Institut de Rhumatologie De Montréal, 

Montreal, QC, 2 Institut de Rhumatologie de Montréal, 

Montreal, QC 

459. Long-Term Safety of Rituximab: 10-Year Follow-up in the 

Rheumatoid Arthritis Global Clinical Trial Program. Ronald 

F. van Vollenhoven 1 , Paul Emery 2 , Clifton O. Bingham III 3 , 

Edward Keystone 4 , Roy M. Fleischmann 5 , Daniel E. Furst 6 , 

Nicola Tyson 7 , Abdul Mehbob 7 and Patrica B. Lehane 7 , 

1 

Karolinska University Hospital, Stockholm, Sweden, 

2 

University of Leeds, Leeds, United Kingdom, 3 Johns Hopkins 

University, Baltimore, MD, 4 Mount Sinai Hospital, Toronto, 

ON, 5 University of Texas Southwestern Medical Center 

and Metroplex Clinical Research Center, Dallas, TX, 6 UCLA 

Medical School, Los Angeles, CA, 7 Roche Products Limited, 

Welwyn Garden City, United Kingdom 

460. Real-World Efficacy and Safety of Abatacept Treatment 

for Rheumatoid Arthritis: 12-Month Interim Analysis of 

the Action Study. H. Nüßlein 1 , R. Alten 2 , M. Galeazzi 3 , H. 

M. Lorenz 4 , Dimitrios Boumpas 5 , M. T. Nurmohamed 6 , 

W. Bensen 7 , G. R. Burmester 8 , H.-H. Peter 9 , F. Rainer 10 , 

Karel Pavelka 11 , M. Chartier 12 , C. Poncet 13 , C. Rauch 14 and 

M. Le Bars 15 , 1 University Erlangen, Nürnberg, Germany, 

2 

Schlosspark-Klinik, University Medicine, Berlin, Germany, 

3 

University of Siena, Siena, Italy, 4 University Hospital 

Heidelberg, Heidelberg, Germany, 5 Panepistimio Kritis, 

Rethymnon, Greece, 6 VU University Medical Center/Jan 

van Bremen Research Institute, Amsterdam, Netherlands, 

7 

St. Joseph’s Hospital and McMaster University, Hamilton, 

ON, 8 Charité-Universitätsmedizin, Berlin, Germany, 

9 

University Medical Center Freiburg, Freiburg, Germany, 

10 

Hospital Barmherzige Brueder, Graz, Austria, 11 Institute 

of Rheumatology, Prague, Czech Republic, 12 Chiltern 

International, Neuilly, France, 13 Docs International, Sévres, 

France, 14 Bristol-Myers Squibb, Munich, Germany, 15 Bristol- 

Myers Squibb, Rueil Malmaison, France 

461. Patterns of Tocilizumab Use, and Dosing Among Patients 

with Rheumatoid Arthritis in the Clinical Practice. 

Preliminary Analyses of ACT-Life Study. J.V. Tovar Beltrán 1 , 

M.A. Guzmán Úbeda 2 , I. Mateo Bernardo 3 , Rosario 

García-Vicuña 4 , M. Rodríguez-Gómez 5 , M. Belmonte- 

Serrano 6 , C. Marras 7 , E. Loza Cortina 8 , E. Pérez Pampin 9 , V. 

Vila Fayos 10 , A.B. Romero Silva 11 and A. Balsa 12 , 1 Hospital 

General Universitario de Elche, Alicante, Spain, 2 Hospital 

Universitario Virgen de las Nieves, Granada, Spain, 3 Hospital 

Universitario 12 de Octubre, Madrid, Spain, 4 Hospital 

Universitario La Princesa, Madrid, Spain, 5 Complejo 

Hospitalario Universitario de Ourense, Ourense, Spain, 

6 

Hospital General de Castellón, Castellón, Spain, 7 Hospital 

Universitario Virgen de la Arrixaca, Murcia, Spain, 8 Hospital 

de Navarra, Navarra, Spain, 9 Complejo Hospitalario 

Universitario de Santiago, Santiago de Compostela, Spain, 

10 

Hospital Comarcal de Vinaroz, Castellón, Spain, 11 Roche 

Farma, Madrid, Spain, 12 Hospital La Paz, Madrid, Spain 

462. Subcutaneous Abatacept: Long-Term Data From the 

Acquire Trial. M. C. Genovese 1 , C. Pacheco-Tena 2 , A. 

Covarrubias 3 , G. Leon 4 , E. Mysler 5 , M. Keiserman 6 , R. 

Valente 7 , P. Nash 8 , J. A. Simon-Campos 9 , J. Box 10 , C. Legerton 

III 11 , E. Nasonov 12 , P. Durez 13 , I. Delaet 14 and R. Alten 15 , 

1 

Stanford University, Palo Alto, CA, 2 Universidad Autónoma 

de Chihuahua, Chihuahua, Mexico, 3 Centro Medico De 

Las Americas, Merida, Mexico, 4 Instituto De Ginecologia 

Y Reproduccion, Lima, Peru, 5 Organización Médica de 

Investigación, Buenos Aires, Argentina, 6 Pontificial Catholic 



176 

University School of Medicine, Porto Alegre, Brazil, 7 Arthritis 

Center of Nebraska, Lincoln, NE, 8 University of Queensland, 

Brisbane, Australia, 9 Centro De Especialidades Médicas/ 

Universidad Marista, Merida, Mexico, 10 Box Arthritis & 

Rheumatology of the Carolinas, Charlotte, NC, 11 Low Country 

Rheumatology, Charleston, SC, 12 Institute of Rheumatology, 

Moscow, Russia, 13 Université Catholique de Louvain, 

Brussels, Belgium, 14 Bristol-Myers Squibb, Princeton, NJ, 

15 

Schlosspark-Klinik, University Medicine, Berlin, Germany 

463. Drug Survival, Efficacy and Predictors for Survival on 

Tocilizumab in Real-Life Patients with Rheumatoid 

Arthritis; Results From the Swedish Biologics Register. 

Helena Forsblad-d’Elia 1 , Karin Bengtsson 1 , Lars-Erik 

Kristensen 2 and Lennart TH Jacobsson 1 , 1 Department of 


Academy at University of Gothenburg, Gothenburg, 

Sweden, 2 Department of Rheumatology, University Hospital 

of Skåne, Lund, Sweden 

464. Rituximab for Treatment of Rheumatoid Arthritis: 

Treatment Effectiveness in the Corrona Database. Leslie 

R. Harrold 1 , George W. Reed 1 , Robert P. Magner 1 , Katherine 

C. Saunders 2 , Jeffrey D. Greenberg 3 , Joel M. Kremer 4 , 

Ani John 5 , William Reiss 5 , Steve Zlotnick 5 and Ashwini 

Shewade 5 , 1 University of Massachusetts Medical School, 

Worcester, MA, 2 CORRONA, Inc., Southborough, MA, 3 New 

York University School of Medicine, New York, NY, 4 Albany 

Medical College, Albany, NY, 5 Genentech Inc., South San 

Francisco, CA 

465. The Comparative Effectiveness of Oral Methotrexate 

versus Subcutaneous Methotrexate for the Treatment of 

Early Rheumatoid Arthritis. Glen S. Hazlewood 1 , J. Carter 

Thorne 2 , Janet Pope 3 , Gilles Boire 4 , Boulos Haraoui 5 , Carol A. 

Hitchon 6 , Edward Keystone 1 , Diane Tin 2 , CATCH Investigators 7 

and Vivian P. Bykerk 8 , 1 University of Toronto, Toronto, 

ON, 2 Southlake Regional Health Centre, Newmarket, ON, 

3 

Schulich School of Medicine and Dentistry, Western 

University, London, ON, 4 CHUS - Sherbrooke University, 

Sherbrooke, QC, 5 Osteoarthritis Research Unit, University of 

Montreal Hospital Research Centre (CRCHUM), Montreal, 

QC, 6 University of Manitoba, Winnipeg, MB, 7 Toronto, ON, 

8 


466. Synovialitis Plus Articular Cartilage Monitoring Via 

Magnetic Resonance Imaging and Ultrasound Under 

Tocilizumab Therapy in Patients with Rheumatoid Arthritis. 

Maria Hoehle 1 and Michael Finkenstaedt 2 , 1 Rheumatology, 

Hamburg, Germany, 2 Private Practice for Radiology and 

Neuroradiology, Hamburg, Germany 

467. Seropositive Rheumatoid Arthritis Patients with an 

Inadequate Response to Tumor Necrosis Factor Inhibitors 

Achieve Improved Clinical Effectiveness After Switching 

to Rituximab Versus Switching to an Alternative Tumor 

Necrosis Factor Inhibitor. Andrea Rubbert-Roth 1 , Axel 

Finckh 2 , Piercarlo Sarzi-Puttini 3 , Jacques-Eric Gottenberg 4 , 

Denis Choquette 5 , Victor Martínez Taboada 6 , Leonor 

Barile-Fabris 7 , Carol Chung 8 , Lykke Hinsch-Gylvin 9 and 


Paul Emery 10 , 1 University of Cologne, Cologne, Germany, 

2 

University Hospital of Geneva, Geneva 14 , Switzerland, 3 L 

Sacco University Hospital, Milan, Italy, 4 CHU Strasbourg, 

Strasbourg, France, 5 University of Montreal, Notre-dame 

Hospital, Montreal, QC, 6 Hospital Universitario Marqués 

de Valdecilla, Santander, Spain, 7 Hospital de Especialidades 

Centro Médico Nacional Siglo XXI, Mexico City, Mexico, 

8 

Genentech Inc., South San Francisco, CA, 9 F Hoffmann-La 

Roche Ltd, Basel, Switzerland, 10 University of Leeds, Leeds, 


468. Adalimumab Treatment Is Associated with Decreased 

Concomitant Rheumatoid Arthritis Medication Use Over 

24 Months. Daniel E. Furst 1 , Neelufar Mozaffarian 2 , Shannon 

Grant 3 , Mary Cifaldi 2 , Jerry Clewell 2 , Joel M. Kremer 4 and 

James Shaw 2 , 1 UCLA Medical School, Los Angeles, CA, 

2 

Abbott Laboratories, Abbott Park, IL, 3 Axio Research LLC, 

Seattle, WA, 4 Albany Medical College and The Center for 

Rheumatology, Albany, NY 

469. Intra Articular Injections in Patients with Rheumatoid 

Arthritis: Analyses from the Behandelstrategiën Study. E. 

Gvozdenovic 1 , L. Dirven 1 , M. van den Broek 1 , Kh Han 2 , T.H.E. 

Molenaar 3 , R. Landewe 4 , W.F. Lems 5 and C.F. Allaart 1 , 1 Leiden 

University Medical Center, Leiden, Netherlands, 2 Maasstad 

hospital, Rotterdam, Netherlands, 3 Groene Hart Hospital, 


Amsterdam, Amsterdam, Netherlands, 5 VU University 

medical center, Amsterdam, Netherlands 

470. Concomitant Assessment of Clinical and Ultrasound 

Efficacy and Safety of Tocilizumab in Patients with 

Moderate to Severe Rheumatoid Arthritis: The Torpedo 

Study. Thierry Schaeverbeke 1 , Philippe Gaudin 2 , Aleth 

Perdriger 3 , Christian Roux 4 , Muriel Vray 5 , Stephanie 

Rouanet 6 , Ghislaine Steinberg 6 and Fabien Etchepare 7 , 

1 


Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, 

3 

Hôpital Sud, Rennes, France, 4 Paris Descartes University, 

Paris, France, 5 Paris, France, 6 Roche, Boulogne, France, 7 G.H. 

Pitié-Salpêtrière, Paris, France 

471. Efficacy and Safety of Golimumab as Add-On Therapy 

to Disease-Modifying Antirheumatic Drugs. Bernard 

Combe 1 , Bhaskar Dasgupta 2 , Ingrid Louw 3 , Sarvajeet Pal 4 , 

Jürgen Wollenhaupt 5 , Cristiano Zerbini 6 , andre D. Beaulieu 7 , 

Hendrik Schulze-Koops 8 , Patrick Durez 9 , Ruji Yao 10 , Nathan 

Vastesaeger 11 and Holly Weng 10 , 1 Hôpital Lapeyronie-Service 

d’Immuno-rhumatologie, Montpellier, France, 2 Southend 

University Hospital, Westcliff-on-Sea, United Kingdom, 

3 

Panorama Medical Centre, Cape Town, South Africa, 

4 

Advance Rheumatology Clinic, Hyderabad, India, 5 Schön- 

Klinik, Hamburg, Germany, 6 Centro Paulista de Investigações, 

Sao Paulo, Brazil, 7 Centre de Rhumatologie, St. Louis, QC, 

8 

University of Munich, Munich, Germany, 9 UCL Saint-Luc, 

Brussels, Belgium, 10 Merck Sharp and Dohme, Kenilworth, 

NJ, 11 Merck Sharp and Dohme, Brussels, Belgium


472. More Positive Expectations of Treatment with Golimumab 

for Rheumatoid Arthritis Are Associated with Greater 

Improvement in Clinical Outcomes. Bhaskar Dasgupta 1 , 

Bernard Combe 2 , Ingrid Louw 3 , Sarvajeet Pal 4 , Jürgen 

Wollenhaupt 5 , Cristiano Zerbini 6 , andre D. Beaulieu 7 , Hendrik 

Schulze-Koops 8 , Patrick Durez 9 , W. Bensen 10 , V. Wolff 11 , Ruji 

Yao 12 , Holly Weng1 2 and Nathan Vastesaeger 13 , 1 Southend 

University Hospital, Westcliff-on-Sea, United Kingdom, 

2 

Hôpital Lapeyronie-Service d’Immuno-rhumatologie, 

Montpellier, France, 3 Panorama Medical Centre, Cape Town, 

South Africa, 4 Advance Rheumatology Clinic, Hyderabad, 

India, 5 Schön-Klinik, Hamburg, Germany, 6 Centro Paulista de 

Investigações, Sao Paulo, Brazil, 7 Centre de Rhumatologie, 

St. Louis, QC, 8 University of Munich, Munich, Germany, 9 UCL 

Saint-Luc, Brussels, Belgium, 10 St. Joseph’s Hospital and 

McMaster University, Hamilton, ON, 11 Hospital del Salvador, 

Santiago, Chile, 12 Merck Sharp and Dohme, Kenilworth, NJ, 

13 

Merck Sharp and Dohme, Brussels, Belgium 

473. The Addition of Another Disease-Modifying Anti- 

Rheumatic Drug to Methotrexate in Place of Infliximab 

Reduces the Flare Rate During 2 Years After Infliximab 

Discontinuation in Patients with Rheumatoid Arthritis. 

Hideto Kameda 1 , Takahiko Kurasawa 1 , Hayato Nagasawa 2 , 

Koichi Amano 3 and Tsutomu Takeuchi 1 , 1 Keio University 

School of Medicine, Tokyo, Japan, 2 Saitama Medical Ctr, 

Kawagoe, Japan, 3 Department of Rheumatology and Clinical 

Immunology, Saitama Medical Center, Saitama Medical 

University, Saitama, Japan 

474. Dose Reduction in Rituximab Retreatment May Delay 

Achievement of Optimal Responses. Mohammed I. Sharif 1 , 

Sudipto Das 2 , Paul Emery 3 , Helen MacIver 1 , Wendy Shingler 1 , 

Philip S. Helliwell 2 , Katharina Sokoll 1 and Edward M. Vital 2 , 

1 

Bradford Teaching Hospitals NHS Foundation Trust, 

Bradford, United Kingdom, 2 NIHR Leeds Biomedical Research 

Unit, University of Leeds and Leeds Teaching Hospitals 

NHS Trust, Leeds, United Kingdom, 3 Leeds Musculoskeletal 

Biomedical Research Unit, Leeds, United Kingdom 

475. Immunologic Responsiveness in Patients with Juvenile 

Idiopathic Arthritis On Methotrexate and Etanercept: 

23 Valent Pneumococcal Vaccination. Ankur A. Kamdar 1 , 

Patricia C. Giclas 2 and Barry L. Myones 3 , 1 University of Texas 

Medical School at Houston, Houston, TX, 2 National Jewish 

Health, Denver, CO, 3 Baylor College of Medicine, Houston, 

TX 

476. Effects of Vitamin D Repletion and Maintenance Therapy 

on Clinical Indicators of Disease Activity in Rheumatoid 

Arthritis. Uzma J. Haque 1 , Clifton O. Bingham III 2 and Susan 

J. Bartlett 3 , 1 Johns Hopkins Hospital, Baltimore, MD, 2 Johns 

Hopkins University, Baltimore, MD, 3 McGill University, 

Montreal, QC 

477. Impact of Etanercept On Incident Cancer in Taiwanese 

Patients with Rheumatoid Arthritis. Jiunn Horng Chen 1 

and Wen-Miin Liang 2 , 1 China Medical University Hospital, 

Taichung City, Taiwan, 2 China Medical University, Taichung, 

Taiwan 

478. Body Mass Index Negatively Influences the Response to 

Infliximab in Rheumatoid Arthritis. Sébastien Ottaviani 1 , 

Anais Gardette 2 , Emilie Quintin 2 , Karen Dawidowicz 2 , 

Ghislaine Gill 2 , Elisabeth Palazzo 3 , Olivier Meyer 3 and 

Philippe Dieude 2 , 1 APHP, Paris, France, 2 APHP, Hopital Bichat, 

Paris, France, 3 Hopital Bichat, Paris, France 

479. Active Immunization with TNF-Kinoid in Rheumatoid 

Arthritis Patients with Secondary Resistance to 

Tumor Necrosis Factor-Alpha Antagonists Is Safe and 

Immunogenic. Patrick Durez 1 , Pedro Miranda 2 , Antoaneta 

Toncheva 3 , Alberto Berman Sr. 4 , Oscar L. Rillo 5 , Yves 

Boutsen 6 , Tatjana Kehler 7 , Eugenia Mociran 8 , LiAn Soto 

Saez 9 , Bruno Fautrel 10 , Xavier Mariette 11 , Panayot Solakov 12 , 

Eleonora Lucero 13 , Tonko Vlak 14 , Simeon Grazio 15 , Ksenija 

Mastrovic 16 , Rodica Chiriac 17 , Géraldine Grouard-Vogel 18 , 

Olivier Dhellin 18 , Stéphane Ouary 18 , Pierre Vandepapeliere 18 

and Marie-Christophe Boissier 19 , 1 Université Catholique 

de Louvain, Brussels, Belgium, 2 Centro de Estudios 

Reumatologicos, Santiago de Chile, Chile, 3 National 

Multiprofile Transport Hospital, Sofia, Bulgaria, 4 Hospital 

Padilla, Tucuman, Argentina, 5 Hospital Tornú, Buenos 

Aires, Argentina, 6 UCL Mont-Godinne, Godinne, Belgium, 

7 

Thalassotherapia Opatija, Opatija, Croatia, 8 Emergency 

County Hospital Dr Constantin Opis, Maramures, Romania, 

9 

Sociedad Medica del Aparato Locomotor SA, Santiago 

de Chile, Chile, 10 APHP-Pitie Salpetriere Hospital / UPMC, 

Paris, France, 11 Université Paris-Sud, Le Kremlin Bicetre, 

France, 12 Diagnostic and Consulting Center, Plovdiv, Bulgaria, 

13 

Centro Investigaciones Reumatológicas, Tucumán, 

Argentina, 14 University Hospital Split, Split, Croatia, 15 Clinical 

Hospital Center Sestre Milosrdnice, Zagreb, Croatia, 16 Clinical 

Hospital Sveti Duh, Zagreb, Croatia, 17 Rehabilitation clinical 

Hospital Iasi, Iasi, Romania, 18 NEOVACS SA, Paris, France, 

19 

Hopital Avicenne, Bobigny, France 

480. Etanercept Induces A Significant Decrease of Oxidative 

Stress and Osteoprotegerin Compared with Sdmard in 

Patients with Rheumatoid Arthritis. Claire I. Daien 1 , Anne- 

Marie Dupuy Gorce 1 , Edith Pinot 1 , Thibault Mura 2 , Jean- 

Paul Cristol 1 , Bernard Combe 1 and Jacques Morel 1 , 1 Hopital 

Lapeyronie, Montpellier, France, 2 Hopital Gui De Chauliac, 


481. Duration of Sustained Remission and Differences in 

Responce Between Medications, in Tumor Necrosis factor 

inhibitor Treated Rheumatoid Arthritis Patients. Jon T. 

Einarsson 1 , Pierre Geborek 2 , Tore Saxne 3 and Meliha C. 

Kapetanovic 4 , 1 Dept of Clinical Sciences, Lund, Section of 

Rheumatology, Lund University, Sweden, Lund, Sweden, 

2 

Lund University, Lund, Sweden, 3 Dept of Clinical Sciences 

Lund, Section of Rheumatology, Lund, Sweden, 4 Dept of 

Clinical Sciences Lund, Lund, Sweden 

482. B-Lymphocyte Count Is Not Associated with an Increased 

Risk of Infection in Patients Treated with Rituximab for 

Auto-Immune Diseases. Ilias Lazarou, Axel Finckh, Lara 

Fischer, Camillo Ribi, Joerg Seebach and Pierre A. Guerne, 

University Hospitals of Geneva, Geneva, Switzerland 



483. An Evaluation of Literature on Discontinuation Rates of 

Biologics in Rheumatoid Arthritis. Setareh A. Williams 1 , 

Victoria Porter 2 , Victoria Zarotsky 3 , Sujatha Sundaram 4 , 

Elisabeth Nyman 5 , Cassie K. Gregson 6 and Paul S. J. Miller 6 , 

1 

AstraZeneca LP, Wilmington, DE, 2 OptumInsight, Mastic 

Beach, NY, 3 OptumInsight, Calabasas, CA, 4 OptumInsight, 

Hanover, NH, 5 AstraZeneca, Mölndal, Sweden, 6 AstraZeneca, 

Macclesfield, United Kingdom 

484. Comparison of Rheumatoid Arthritis-Related Health 

Care Resource Use and Comorbidities Among Patients 

with Rheumatoid Arthritis Treated with Adalimumab Vs. 

Etanercept. Jipan Xie 1 , Arijit Ganguli 2 , Hongbo Yang 1 , Kejal 

Parikh 1 , Eric Q. Wu 1 and Mary Cifaldi 2 , 1 Analysis Group Inc., 

Boston, MA, 2 Abbott Laboratories, Abbott Park, IL 

485. Immunogenicity of Infliximab Is Related to Reduction of 

Frequency of Infliximab Administration in Rheumatoid 

Arthritis and Spondyloarthritis Patients. Mathieu Verdet 1 , 

Clément Guillou 2 , Marie-Laure Potier 2 , Martine Hiron 2 , 

Fabienne Jouen 3 , Olivier Boyer 4 , Thierry Lequerré 5 and 

Olivier Vittecoq 6 , 1 Rouen University Hospital, Bois Guillaume, 

France, 2 Inserm 905 & Institute for Biomedical Research, 

University of Rouen, Rouen, France, 3 Rouen University 

Hospital, Rouen Cedex, France, 4 INSERM U905, University 

of Rouen, Rouen, France, 5 Department of Rheumatology, 

Rouen University Hospital & Inserm 905, Institute for 

Biomedical Research, University of Rouen, Rouen, France, 

6 

Rouen University Hospital & Inserm905, University of 

Rouen, Rouen Cedex, France 

486. Impact of Adalimumab Therapy on Laboratory Parameters 

of Interest in Patients with Early or Long-Standing 

Rheumatoid Arthritis. De Furst 1 , Ana P. Lacerda 2 , Nupun 

andhivarothai 3 , Jasmina Kalabic 4 and Neelufar Mozaffarian 3 , 

1 

University of California at Los Angeles, Los Angeles, CA, 

2 

Abbott Laboratories, São Paulo, Brazil, 3 Abbott Laboratories, 

Abbott Park, IL, 4 Abbott GmbH & Co. KG, Ludwigshafen, 

Germany 

487. Functional Disability in Early Rheumatoid Arthritis - 

Contributions of Disease Activity and Structural Damage, 

and the Impact of Different Treatment Strategies. Josef 

S. Smolen 1 , Roy Fleischmann 2 , Paul Emery 3 , Ronald F. van 

Vollenhoven 4 , Stefan Florentinus 5 , Freddy Faccin 6 , Suchitrita 

S. Rathmann 7 , Hartmut Kupper 8 and Arthur Kavanaugh 9 , 

1 


Austria, 2 University of Texas Southwestern Medical Center, 

Dallas, TX, 3 Leeds Musculoskeletal Biomedical Research 

Unit, Leeds, United Kingdom, 4 The Karolinska Institute, 

Stockholm, Sweden, 5 Abbott, Rungis, France, 6 Abbott, 

Abbott Park, IL, 7 Abbott Laboratories, Abbott Park, IL, 

8 

Abbott GmbH and Co. KG, Ludwigshafen, Germany, 9 UCSD 

School of Medicine, La Jolla, CA 

488. Patient Preferences for Biologic Treatments in Rheumatoid 

Arthritis. Beenish Nafees 1 , Andrew Lloyd 1 , Carol L. Gaich 2 , 

Julie Birt 2 and Rodney A. Hughes 3 , 1 Oxford Outcomes, 

Oxford, United Kingdom, 2 Eli Lilly and Company, 

Indianapolis, IN, 3 St. Peters Hospital, Chertsey Surrey, United 

Kingdom 

489. The Comparative Effectiveness of Anti-TNF Medications 

among Older and Disabled Rheumatoid Arthritis Patients 

in the U.S. Medicare Population. Huifeng Yun 1 , Fenglong 

Xie 2 , Elizabeth S. Delzell 2 , Lang Chen 2 , Shuo Yang 2 , Kenneth 

G. Saag 3 and Jeffrey Curtis 2 , 1 University of Alabama- 

Birmingham, Birmingham, AL, 2 University of Alabama 



490. 12- and 24-Week Patient-Reported Outcomes From a 

Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus 

Kinase 1/ Janus Kinase 2 Inhibitor, in Combination with 

Traditional Disease-Modifying Antirheumatic Drugs in 

Patients with Rheumatoid Arthritis. Josef S. Smolen 1 , 

Douglas E. Schlichting 2 , Kimberly L. Sterling 2 , Edward 

Keystone 3 , Peter Taylor 4 , Mark C. Genovese 5 , Louise 

Johnson 6 , Juan C. Rizo Rodriguez 7 , Chin H. Lee 2 and Carol L. 

Gaich 2 , 1 Medical University of Vienna and Hietzing Hospital, 

Vienna, Austria, 2 Eli Lilly and Company, Indianapolis, IN, 

3 

University of Toronto, Toronto, ON, 4 Kennedy Institute 

of Rheumatology, London, United Kingdom, 5 Stanford 

University Medical Center, Palo Alto, CA, 6 PharmaNet/ 

i 3 , Eden Prairie, MN, 7 Centro de Alta Especialidad en 

Reumatología e Investigación del Potosí, San Luis Potosi, San 

Luis Potosi, Mexico 

491. Predictors of Initiating Biologic Monotherapy in Biologic 

Naïve Patients with Rheumatoid Arthritis (RA) in a US 

Registry Population. Dimitrios A. Pappas 1 , George W. Reed 2 , 

Ani John 3 , Ashwini Shewade 3 , Katherine C. Saunders 4 , Jenny 

Devenport 5 , Jeffrey D. Greenberg 6 and Joel M. Kremer 7 , 

1 

Columbia University, College of Physicians and Surgeons, 

New York, NY, 2 University of Massachusetts Medical School, 

Worcester, MA, 3 Genentech Inc., South San Francisco, CA, 

4 

CORRONA, Inc., Southborough, MA, 5 Genentech, South 

San Francisco, CA, 6 NYU Hospital for Joint Diseases, New 

York, NY, 7 Albany Medical College and The Center for 

Rheumatology, Albany, NY 

492. Divergent Toxicity of TNF Inhibitors on Demyelinating 

Disorders and Neurological Events. Sergio Schwartzman 1 , 

John Clark 2 and John J. Cush 3 , 1 Hosp for Special Surgery, 

New York, NY, 2 RiskBenefits LLC, Flourtown, PA, PA, 3 Baylor 

Research Institute, Dallas, TX 

493. Effect of Infliximab on Employment Status in Patients 

with Rheumatoid Arthritis or Ankylosing Spondylitis. W. 

Bensen 1 , J. Carter Thorne 2 , Saeed A. Shaikh 3 , Maqbool K. 

Sheriff 4 , Susan M. Otawa 5 , Allen J. Lehman 6 and Hayssam 

Khalil 7 , 1 St. Joseph’s Hospital and McMaster University, 

Hamilton, ON, 2 Southlake Regional Health Centre, 

Newmarket, ON, 3 McMaster University, St Catharines, ON, 

4 

Nanaimo Regional General Hospital, Nanaimo, BC, 5 Janssen 

Canada Inc, Mississauga, ON, 6 Janssen Inc, Toronto, ON, 

7 

Janssen Canada Inc, Toronto, ON 

178 

2012 Program Book


494. Are There Gender Specific Differences in Patient 

Characteristics At Initiation of Biologic Treatment in 

Rheumatoid Arthritis? William Bensen 1 , Denis Choquette 2 , 

Isabelle Fortin 3 , Alice V. Klinkhoff 4 , Susan M. Otawa 5 and 

Hayssam Khalil 6 , 1 St. Joseph’s Hospital and McMaster 

University, Hamilton, ON, 2 University of Montreal, Notredame 

Hospital, Montreal, QC, 3 Centre de Rhumatologie de 

l’Est du Québec, Rimouski, QC, 4 The Mary Pack Arthritis 

Ctr, Vancouver, BC, 5 Janssen Canada Inc, Mississauga, ON, 

6 

Janssen Canada Inc, Toronto, ON 

495. Comparison of Discontinuation Rates by Biologic Since 

1998 in US Patients with Rheumatoid Arthritis. Sofia 

Ramiro 1 , Frederick Wolfe 2 , David J. Harrison 3 , George 

Joseph 3 , David H. Collier 3 , Désirée van der Heijde 4 , Robert 

Landewé 5 and Kaleb Michaud 6 , 1 Academic Medical 

Center, University of Amsterdam, The Netherlands and 

Hospital Garcia de Orta, Almada, Portugal, 2 National Data 

Bank for Rheumatic Diseases, Wichita, KS, 3 Amgen Inc., 

Thousand Oaks, CA, 4 Leiden University Medical Center, 

Leiden, Netherlands, 5 Academic Medical Center, University 

of Amsterdam and Atrium Medical Center, Heerlen, 

Netherlands, 6 National Data Bank for Rheumatic Diseases & 

University of Nebraska Medical Center, Omaha, NE 

496. Real-World Effectiveness of Infliximab in Improving 

Routine Assessment of Patient Index Data 3 Outcomes: The 

Canadian Experience. Andrew Chow 1 , Majed M. Khraishi 2 , 

Jude F. Rodrigues 3 , Susan M. Otawa 4 and Hayssam Khalil 5 , 

1 

Credit Valley Rheumatology, Mississauga, ON, 2 Memorial 

University of Newfoundland, St Johns, NF, 3 Windsor, ON, 

4 

Janssen Canada Inc, Mississauga, ON, 5 Janssen Canada Inc, 

Toronto, ON 

497. Golimumab Drug Utilization Patterns in Canada – Higher 

Retention Rate in Golimumab Treated Rheumatoid 

Arthritis Patients Compared to Etanercept and 

Adalimumab. Hayssam Khalil 1 and Amir Tahami 2 , 1 Janssen 

Canada Inc, Toronto, ON, 2 Janssen Canada Inc., Toronto, ON 

498. LIGHT (TNFSF14), Cathepsin-K, DKK- 1 and Sclerostin in 

Rheumatoid Arthritis Patients: Effect of ANTI TNF-α 

Treatment in the WNT/β-Catenin Network Signaling. 

Alberto Cauli, Grazia Dessole, Giovanni Porru, Matteo 

Piga, Alessandra Vacca, Valentina Ibba, Pietro Garau and 

Alessandro Mathieu, University of Cagliari, Cagliari, Italy 

499. What Is the Right Dose to Start Methotrexate (7.5 or 15mg) 

in Rheumatoid Arthritis? (A Randomized Controlled Trial). 

Varun Dhir, Mandeep Singla, Palvi Goyal, Vinay Sagar, Aman 

Sharma and Shefali K. Sharma, Post Graduate Institute of 

Medical Education and Research, Chandigarh, India 

500. Comparison of Tolerability between Tumor Necrosis 

Factor-Inhibitors and Tocilizumab for the Treatment 

of Rheumatoid Arthritis. Yoshihiro Hishitani, Yoshihito 

Shima, Toru Hirano, Keisuke Hagihara, Kosuke Ebina, Yasuo 

Kunugiza, Kenrin Shi, Masashi Narazaki, Atsushi Ogata, 

Tetsuya Tomita, Toshio Tanaka and Atsushi Kumanogoh, 

Osaka University Graduate School of Medicine, Suita, Japan 

501. TNF Inhibitor Treatment in Rheumatoid Arthritis (RA) 

Patients with Moderate versus High Disease Activity At 

Baseline: A Comparison of Utility Gains, Response and 

Remission Rates. Elisabeth Lie, Siri Lillegraven, Karen M. 

Fagerli, Till Uhlig and Tore K. Kvien, Diakonhjemmet Hospital, 

Oslo, Norway 

502. Safety and Efficacy of Rituximab in Patients with 

Rheumatoid Arthritis and Lung Involvement. Elena Becerra, 

Geraldine Cambridge and Maria J. Leandro, University 

College London, London, United Kingdom 

503. Safety Update On Certolizumab Pegol in Patients with 

Active Rheumatoid Arthritis with Long Term Exposure. 

Xavier Mariette 1 , RF. van Vollenhoven 2 , Vivian P. Bykerk 3 , 

Marc de Longueville 4 , Catherine Arendt 4 , Kristel Luijtens 5 

and John J. Cush 6 , 1 Université Paris-Sud, Le Kremlin Bicetre, 

France, 2 The Karolinska Institute, Stockholm, Sweden, 

3 

Hospital for Special Surgery, New York, NY, 4 UCB Pharma, 

Brussels, Belgium, 5 UCB, Brussels, Belgium, 6 Baylor Research 

Institute, Dallas, TX 

Sjögren’s Syndrome - Pathogenesis 

504. Pathogenic Autoantibodies to the Anti-Muscarinic Type 3 

Receptor Act by Competitive Inhibition of Acetylcholine- 

Mediated Receptor Signalling in Sjögren’s Syndrome. 

Michael W. Jackson 1 , Isabell Bastian 2 and Thomas P. 

Gordon 3 , 1 Flinders University, Adelaide, Australia, 2 Flinders 

University and Flinders Medical Centre, Adelaide, Australia, 

3 

Flinders Medical Centre, Bedford Park, Australia 

505. Characterization of an in Vitro Model of Human Salivary 

Gland for Studying Sjögren Syndrome (SS). M. Jesus 

Dominguez-Luis 1 , M.Teresa Arce-Franco 1 , Estefania 

Armas-Gonzalez 1 , Ada Herrera-Garcia 1 , Teresa Giraldez 2 , 

Pablo Miranda 2 , Diego Alvarez de la Rosa 3 , Jose Garcia- 

Verdugo 4 , Carlos Martinez-Jimeno 5 and Federico Diaz- 

Gonzalez 1 , 1 Rheumatology Service. Hospital Universitario 

de Canarias., La Laguna, Spain, 2 Unidad de Investigación 

of Hospital Universitario Nuestra Señora de Candelaria, 

Santa Cruz de Tenerife, Spain, 3 Department of Physiology. 

Universidad de La Laguna,, La Laguna, Spain, 4 Cellular 

Morphology Laboratory, Centro de Investigación Príncipe 

Felipe., Valencia, Spain, 5 Maxilofacial Department, Hospital 

Universitario de Canarias,, La Laguna, Spain 

506. Ebv-Mir-Bart13 Affects the Expression of AQP5 in Human 

Salivary Gland Cell Lines Contributing to the Pathogenesis 

of Sjögren’s Syndrome. Alessia Gallo 1 , Mayank Tandon 1 , 

Shyh-Ing Jang 1 , Hwei Ling Ong 1 , Indu Ambudkar 1 , Gabor G. 

Illei 2 and Ilias Alevizos 3 , 1 NIDCR, Bethesda, MD, 2 NIDCR/ NIH, 

Bethesda, MD, 3 NIDCR/ NIH #10 1N110, Bethesda, MD 

507. Expression of Micrornas (miRNAs) Predicted to Target Ro/ 

SSA and La/SSB Autoantigens in Sjögren’s Syndrome (SS). 

Vasiliki C. Gourzi 1 , Efstathia K. Kapsogeorgou 1 , Nikolaos C. 

Kyriakidis 1 , Menelaos N. Manoussakis 1 , Haralampos M. 

Moutsopoulos 2 and Athanasios G. Tzioufas 3 , 1 School of 

Medicine, National University of Athens, Greece, Athens, 



180 

Greece, 2 School of Medicine, University of Athens, Athens, 

Greece, 3 School of Medicine, National University of Athens, 


508. TLR3-Signaling Induces the Expression of Ro/SSA and La/ 

SSB Autoantigens in Salivary Gland Epithelial Cells (SGECs). 

Nikolaos C. Kyriakidis 1 , Efstathia K. Kapsogeorgou 1 , Vasiliki 

C. Gourzi 1 , Haralampos M. Moutsopoulos 2 and Athanasios 

G. Tzioufas 3 , 1 School of Medicine, National University of 

Athens, Greece, Athens, Greece, 2 School of Medicine, 

University of Athens, Athens, Greece, 3 School of Medicine, 

National University of Athens, Athens, Greece 

509. IL- 7 and Toll-Like Receptor 7 Synergistically Increase Th1/ 

Th17/Th22 Cytokine Secretion and Activity of B Cells. 

A. Bikker 1 , A.A. Kruize 1 , F. Redegeld 2 , W. de Jager 3 , F.P.J.G. 

Lafeber 1 and J.A.G. van Roon 1 , 1 University Medical Center 

Utrecht, Utrecht, Netherlands, 2 Dept Pharmacology UU, 

Utrecht, Netherlands, 3 Dept Immunology, UMC Utrecht, 

Utrecht, Netherlands 

510. IL- 7 and IL-7 Receptor Blockade to Selectively Inhibit TLR7- 

Induced B Cell Activation in Primary Sjögren’s Syndrome. 

A. Bikker 1 , C.R. Willis 2 , A.A. Kruize 1 , J.W.J. Bijlsma 1 , F.P.J.G. 

Lafeber 1 and J.A.G. van Roon 1 , 1 University Medical Center 

Utrecht, Utrecht, Netherlands, 2 Amgen Inc., Seattle, WA 

511. A New Pathogenic Role of Salivary Gland Epithelial Cells in 

the Costimulation of T Lymphocytes in Primary Sjögren’s 

Syndrome: 0X40 Ligand Expression, T-Cell Induction of 

OX40 and Promotion of T-Cell Survival, Proliferation 

and Activation. Yazhuo Gong, Ghada Alsaleh, Jean 

Sibilia and Jacques-Eric Gottenberg, EA4438 Laboratoire 

Physiopathologie des Arthrites, Illkirch-Strasbourg, France 

512. Memory B Cell Phenotypic and Gene Expression Profiling 

in Primary Sjogren’s Syndrome: Implications for Disease 

Diagnosis. Mustimbo E. P. Roberts 1 , Craig Maguire 1 , Alex 

Rosenberg 2 , andreea Coca 3 , Jennifer H. Anolik 2 and Inaki 

Sanz 4 , 1 University of Rochester School of Medicine and 

Dentistry, Rochester, NY, 2 University of Rochester, Rochester, 

NY, 3 Univ of Rochester, Rochester, NY, 4 Rochester, Rochester, 

NY 

513. Regulatory B Cells in Primary Sjögren’s Syndrome. 

Gabriela Hernandez-Molina, Janette Furusawa-Carballeda, 

Guadalupe Lima, Yahaira Rivera and Luis Llorente, Instituto 

Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, 

Mexico City, Mexico 

514. Frequencies and Numbers of Circulating IL-10 Producing 

Regulatory B Cells Are Not Disturbed in Pss-Patients but 

Correlate Negatively with the EULAR Sjögren Syndrome 

Disease Activity Score (ESSDAI). Wayel H. Abdulahad, 

Gwenny Verstappen, Arjan Vissink, Minke G. Huitema, Petra 

M. Meiners, Hendrika Bootsma and Frans Kroese, University 

Medical Center Groningen, Groningen, Netherlands 

515. Stages of Sjögren’s Syndrome Defined by Immune 

Mediators. Lakshmanan Suresh 1 , Julian Ambrus Jr. 2 and 

Long Shen 3 , 1 IMMCO Diagnostics Inc., Amherst, NY, 2 State 


University of New York at Buffalo, Buffalo, NY, 3 SUNY at 

Buffalo, Buffalo, NY 

516. Characterization of Dominant B- and Plasma Cell Clones 

in Patients with Primary Sjögren’s Syndrome and Patients 

with Sicca Syndrome. Marieke E. Doorenspleet 1 , Erlin 

Haecke 2 , Paul L. Klarenbeek 1 , Annie Visser 3 , Rebecca 

E. Esveldt 1 , Fred Spijkervet 3 , Paul-Peter Tak 1 , Hendrika 

Bootsma 3 , Niek de Vries 1 and Frans Kroese 3 , 1 Academic 

Medical Center of the University of Amsterdam, Amsterdam, 

Netherlands, 2 University Medical Center Groningen, 

University of Groningen, Groningen, Netherlands, 

3 

University Medical Center Groningen, Groningen, 

Netherlands 

517. Overexpression of BMP6 Is Associated with Loss of Salivary 

Gland Activity in Sjögren’s Syndrome Patients and Mice. 

Hongen Yin 1 , Javier Cabrera-Perez 1 , Zhennan Lai 1 , Drew 

Michael 1 , Melodie Weller 1 , Bill Swaim 1 , Noreen Rana 1 , Xibao 

Liu 1 , Ilias Alevizos 2 , Indu Ambudkar 3 and John A. Chiorini 1 , 

1 

NIH/NIDCR, Bethesda, MD, 2 NIDCR/ NIH #10 1N110, 

Bethesda, MD, 3 NIDCR, Bethesda, MD 

518. Spontaneous Sialadenitis like Sjögren’s Syndrome in 

Orphan Nuclear Receptor γt (RORγt) Transgenic Mice. 

Mana Iizuka 1 , Hiroto Tsuboi 1 , Hiromitsu Asashima 1 , Yuya 

Kondo 1 , Satoru Takahashi 2 , Isao Matsumoto 1 and Takayuki 

Sumida 1 , 1 Department of Internal Medicine, Faculty 

of Medicine, University of Tsukuba, Tsukuba, Japan, 

2 

Department of Anatomy and Embryology, Faculty of 

Medicine, University of Tsukuba, Tsukuba, Japan 

519. Sex-Specific Regulatory T Cell Dysfunction in a Mouse 

Model of Sjögren Syndrome. Scott M. Lieberman 1 , 

Portia A. Kreiger 2 and Gary A. Koretzky 3 , 1 The Children’s 

Hospital of Philadelphia, Philadelphia, PA, 2 Nemours/A.I. 

DuPont Hospital for Children, Wilmington, DE, 3 University 


520. Genetic Associations to Germinal Centre Formation in 

Primary Sjögren’s Syndrome. Tove Ragna Reksten 1 , Malin 

V. Jonsson 2 , Roland Jonsson 1 , Gunnel Nordmark 3 and 

The Swedish-Norwegian Sjögren’s syndrome Network 4 , 

1 

Broegelmann Research Laboratory, the Gade Institute, 

University of Bergen, Bergen, Norway, 2 University of Bergen, 

Bergen, Norway, 3 Rheumatology, Uppsala, Sweden, 4 Bergen 

521. Differences in Genome-Wide DNA Methylation Profiles 

across Multiple Cell and Tissue Types in Sjögren’s 

Syndrome (SS). Lindsey A. Criswell 1 , Diana Quach 2 , Hong 

L. Quach 2 , Emon Elboudwarej 2 and Lisa F. Barcellos 2 , 

1 


2 

University of California, Berkeley, Berkeley, CA 

522. Genetic Variation in the NCR3 Locus Is Associated with 

Anti-SSA⁄SSB Positive Primary Sjögren′s Syndrome in 

Scandinavian Samples. Gunnel Nordmark 1 , Maija-Leena 

Eloranta 1 , Per Eriksson 2 , Elke Theander 3 , Helena Forsbladd’Elia 

4 , Roald Omdal 5 , Marie Wahren-Herlenius 6 , Roland 

Jonsson 7 and Lars Rönnblom 1 , 1 Rheumatology, Department 

of Medical Sciences, Uppsala University, Uppsala,


Sweden, 2 Rheumatology/AIR, Department of Clinical and 

Experimental Medicine, Linköping University, Linköping, 

Sweden, 3 Skane University Hospital, Lund University, 

Malmö, Sweden, 4 Sahlgrenska Academy at University of 

Gothenburg, Gothenburg, Sweden, 5 Clinical Immunology 

Unit, Department of Internal Medicine, Stavanger University 

Hospital, Stavanger, Norway, 6 Karolinska Institutet, 

Stockholm, Sweden, 7 Broegelmann Research Laboratory, the 

Gade Institute, University of Bergen, Bergen, Norway 

523. Use of Global Gene Expression Profiling to Characterize 

Sjögren’s Patients Who Underexpress Interferon- 

Inducible Genes. John A. Ice 1 , He Li 2 , Jennifer A. Kelly 1 , 

Indra Adrianto 1 , Stuart B. Glenn 1 , Kimberly S. Hefner 3 , Evan 

G. Vista 4 , Donald U. Stone 2 , Raj Gopalakrishnan 5 , Glen 

D. Houston 2 , David M. Lewis 2 , Michael Rohrer 5 , Pamela 

Hughes 5 , John B. Harley 6 , Courtney G. Montgomery 1 , James 

Chodosh 7 , James A. Lessard 8 , Juan-Manuel Anaya 9 , Barbara 

M. Segal 10 , Nelson L. Rhodus 5 , Lida Radfar 2 , Mark B. Frank 1 , 

R. Hal Scofield 1 , Christopher J. Lessard 11 and Kathy Moser 

Sivils 1 , 1 Oklahoma Medical Research Foundation, Oklahoma 

City, OK, 2 University of Oklahoma Health Sciences Center, 

Oklahoma City, OK, 3 Hefner Eye Care and Optical Center, 

Oklahoma City, OK, 4 University of Santo Tomas, Taguig 

City, Philippines, 5 University of Minnesota, Minneapolis, 

MN, 6 Cincinnati Children’s Hospital Medical Center; US 

Department of Veterans Affairs Medical Center, Cincinnati, 

OH, 7 Harvard Clinical and Translational Science Center, 

Boston, MA, 8 Valley Bone & Joint Clinic, Grand Forks, ND, 

9 

Universidad del Rosario-Corporacion para Investigaciones 

Biologicas, Bogota, Colombia, 10 Hennepin County Medical 

Center, Minneapolis, MN, 11 Oklahoma Medical Research 

Foundation; University of Oklahoma Health Sciences Center, 

Oklahoma City, OK 

524. RNA-Sequencing Identifies Novel Differentially Expressed 

Coding and Non-Coding Transcripts in Sjögren’s Syndrome. 

Indra Adrianto 1 , Graham B. Wiley 1 , John A. Ice 1 , He Li 1 , 

Jennifer A. Kelly 1 , Astrid Rasmussen 1 , Stuart B. Glenn 1 , 

Kimberly Hefner 2 , Donald U. Stone 3 , Raj Gopalakrishnan 4 , 

Glen D. Houston 3 , David M. Lewis 3 , Michael Rohrer 4 , James 

A. Lessard 5 , Juan-Manuel Anaya 6 , Barbara M. Segal 7 , Nelson 

L. Rhodus 4 , Lida Radfar 3 , John B. Harley 8 , Judith A. James 9 , 

Courtney G. Montgomery 1 , R. Hal Scofield 1 , Patrick M. 

Gaffney 10 , Kathy Moser Sivils 1 and Christopher J. Lessard 11 , 

1 

Oklahoma Medical Research Foundation, Oklahoma City, 

OK, 2 Hefner Eye Care and Optical Center, Oklahoma City, OK, 

3 


City, OK, 4 University of Minnesota, Minneapolis, MN, 

5 

Valley Bone & Joint Clinic, Grand Forks, ND, 6 Universidad 

del Rosario-Corporacion para Investigaciones Biologicas, 

Bogota, Colombia, 7 Hennepin County Medical Center, 

Minneapolis, MN, 8 Cincinnati Children’s Hospital Medical 


Cincinnati, OH, 9 Oklahoma Medical Research Foundation 

and Oklahoma University Health Sciences Center, Oklahoma 

City, OK, 10 Arthritis & Clinical Immunology Program, 


OK, 11 Oklahoma Medical Research Foundation; University of 

Oklahoma Health Sciences Center, Oklahoma City, OK 

525. Gene Expression Profiling in a Large Cohort of Europeans 

with Sjögren’s Syndrome Reveals Candidate Genes in Viral, 

Immune, and Interferon-Related Pathways. He Li 1 , John 

A. Ice 2 , Jennifer A. Kelly 2 , Indra Adrianto 2 , Stuart B. Glenn 2 , 

Kimberly S. Hefner 3 , Evan G. Vista 4 , Donald U. Stone 5 , 

Raj Gopalakrishnan 6 , Glen D. Houston 5 , David M. Lewis 5 , 

Michael Rohrer 6 , Pamela Hughes 6 , John B. Harley 7 , Courtney 

G. Montgomery 2 , James Chodosh 5 , James A. Lessard 8 , 

Juan-Manuel Anaya 9 , Barbara M. Segal 10 , Nelson L. Rhodus 6 , 

Lida Radfar 5 , Mark B. Frank 2 , R. Hal Scofield 2 , Christopher 

J. Lessard 1 and Kathy Moser Sivils 2 , 1 Oklahoma Medical 

Research Foundation; University of Oklahoma Health 

Sciences Center, Oklahoma City, OK, 2 Oklahoma Medical 

Research Foundation, Oklahoma City, OK, 3 Hefner Eye Care 

and Optical Center, Oklahoma City, OK, 4 University of Santo 

Tomas, Taguig City, Philippines, 5 University of Oklahoma 

Health Sciences Center, Oklahoma City, OK, 6 University 

of Minnesota, Minneapolis, MN, 7 Cincinnati Children’s 

Hospital Medical Center; US Department of Veterans Affairs 

Medical Center, Cincinnati, OH, 8 Valley Bone & Joint Clinic, 

Grand Forks, ND, 9 Universidad del Rosario-Corporacion para 

Investigaciones Biologicas, Bogota, Colombia, 10 Hennepin 

County Medical Center, Minneapolis, MN 

526. Use of a Novel Probe to Demonstrate Granzyme B 

Activity in Sjögren’s Syndrome Salivary Glands. Kimberly 

Doering Maurer 1 , Laura Gutierrez-Alamillo 1 , Efstathia K. 

Kapsogeorgou 2 , Athanasios G. Tzioufas 3 , Livia Casciola- 

Rosen 4 and Antony Rosen 5 , 1 Johns Hopkins University School 

of Medicine, Baltimore, MD, 2 School of Medicine, National 

University of Athens, Greece, Athens, Greece, 3 School of 

Medicine, National University of Athens, Athens, Greece, 

4 

Johns Hopkins University, Baltimore, MD, 5 The Johns 

Hopkins University, Baltimore, MD 

527. Multiplexed Nanostring Screening for Salivary Gland Viral 

Elements in Sjögren’s Syndrome. Kristin Haffizulla 1 , Glen 

Barber 1 , Juan Chen 2 and Eric L. Greidinger 3 , 1 University 

of Miami Miller School of Medicine, Miami, FL, 2 The First 

Afflicted Hospital of Xiamen University, China, Miami, FL, 

3 

University of Miami, Miami, FL 

528. Mxa As a Biomarker for Systemic Interferon Type I 

Activation in Primary Sjögren′s Syndrome. Naomi I. 

Maria 1 , Zana Brkic 1 , Matti Waris 2 , Cornelia G. van Helden- 

Meeuwsen 1 , Kim Heezen 1 , Joop P. van de Merwe 1 , Paul 

L. van Daele 1 , Virgil A. Dalm 1 , Hemmo A. Drexhage 1 and 

Marjan A. Versnel 1 , 1 Erasmus Medical Center, Rotterdam, 

Netherlands, 2 University of Turku, Turku, Finland 

529. The Axis P2X7 Receptor-Inflammasome: A Role in 

Modulating Inflammatory Response in Primary Sjögren’s 

Syndrome? Chiara Baldini 1 , Chiara Rossi 1 , Eleonora 

Santini 1 , Francesco Ferro 1 , Alessia Gallo 2 , Daniela Martini 1 , 

Francesca Sernissi 1 , Valentina Donati 1 , Camillo Giacomelli 1 , 



Nicoletta Luciano 1 , Anna Solini 1 and Stefano Bombardieri 1 , 

1 

Rheumatology Unit, University of Pisa, Pisa, Italy, 2 NIDCR, 

Bethesda, MD 

530. S100A8/A9 Is Upregulated and Triggers the Secretion 

of Pro-Inflammatory Cytokines in Primary Sjögren’s 

Syndrome. Laura Weichselbaum 1 and Muhammad S. 

Soyfoo 2 , 1 Department of rheumatology ,Hôpital Erasme, 

Brussels, Belgium, 2 Hôpital Erasme,Université Libre de 

Bruxelles, Brussels, Belgium 


and Treatment 

531. Developmen and Validation of a New Instrument to 

Asess Health Related Quality of Life in Psoriasis Arthritis: 

The Vitacora Questionnaire. Juan Carlos Torre-Alonso 1 , J. 

Santos-Rey 2 , JM Ruiz-Martin 3 , P. Valdazo-De Diego 4 , Mireia 

Moreno 5 and Juan-Antonio Fernández 6 , 1 Hospital Monte 

Naranco, Oviedo, Spain, 2 Rheumatology, Toledo, Spain, 

3 

Rheumatology, Viladecans, Spain, 4 Rheumatology, Zamora, 

Spain, 5 Corporació Sanitària Parc Taulí, Sabadell, Spain, 6 MP, 

Oviedo, Spain 

532. The Prevalance of Autoimmune Thyroid Disfunction 

in Ankylosing Spondylitis. Hakan Emmungil 1 , Mehmet 

Erdogan 2 , Melike Kalfa 1 , Gonca Karabulut 1 , Hayriye 

Kocanaogullari 1 , Vedat Inal 1 , Yasemin Kabasakal 3 , Fahrettin 

Oksel 3 , Kenan Aksu 4 and Gokhan Keser 1 , 1 Dept. of Internal 

Medicine, Division of Rheumatology, Ege University, Izmir, 

Turkey, 2 Dept. of Internal Medicine, Division of Endocrinolgy, 

Ege University, Izmir, Turkey, 3 Ege University, Izmir, Turkey, 

4 

Dept. Of Internal Medicine, Division of Rheumatology, Ege 

University, Izmir, Turkey 

533. NT-Probnp and Inflammation in Active Ankylosing 

Spondylitis Receiving TNF Blockers: Is There a Link? 

Julio C. B. Moraes 1 , Ana C. M. Ribeiro 2 , Carla G.S. Saad 3 , 

Alessandro C. Lianza 4 , Nadia E. Aikawa 2 , Clovis Artur Silva 5 

and Eloisa Bonfa 1 , 1 Faculdade de Medicina da Universidade 

de São Paulo, São Paulo, Brazil, 2 Faculdade de Medicina da 

Universidade de São Paulo, Sao Paulo, Brazil, 3 University of 

Sao Paulo, São Paulo, Brazil, 4 Radiology Division, Faculdade 

de Medicina da Universidade de São Paulo, São Paulo, Brazil, 

5 

Paediatric Rheumatology International Trials Organization 

(PRINTO), Istituto Giannina Gaslini, Genova, Italy 

534. WITHDRAWN 

535. Reduced Joint Counts Misclassify Psoriatic Arthritis 

Patients with Oligoarthritis and Miss Significant Active 

Disease. Laura C. Coates 1 , Oliver M. FitzGerald 2 , Dafna 

D. Gladman Gladman 3 , Neil J. McHugh 4 , Philip Mease 5 , 

Vibeke Strand 6 , Philip S. Helliwell 7 and GRAPPA Composite 

Exercise (GRACE) collaboration 8 , 1 Division of Rheumatic 

and Musculoskeletal Disease, Leeds, United Kingdom, 2 St. 

Vincent’s Univ Hospital, Dublin, Ireland, 3 Toronto Western 

Hospital and University of Toronto, Toronto, ON, 4 Royal 

National Hospital for Rheumatic Diseases, Bath, United 

Kingdom, 5 Swedish Medical Center, Seattle, WA, 6 Stanford 

University, Portola Valley, CA, 7 NIHR Leeds Biomedical 

Research Unit, University of Leeds and Leeds Teaching 

Hospitals NHS Trust, Leeds, United Kingdom, 8 Leeds 

536. Psoriasis and Psoriatic Arthritis in a Diverse Ethnic Cohort. 

Gail S. Kerr 1 , Seema Qaiyumi 2 , John S. Richards 2 , Chesahna 

Kindred 3 , Sean A. Whelton 4 and Florina M. Constantinescu 5 , 

1 

Washington DC VAMC, Georgetown and Howard University, 

Washington, DC, 2 Washington DC VA and Georgetown 

University, Washington, DC, 3 Howard University Hospital, 

Washington, DC, 4 Georgetown University, Washington, DC, 

5 

Washington Hospital Center, Washington, DC 

537. The Association of alpha7 Nicotinic Acetylcholine Receptor 

Polymorphisms with Psoriatic Arthritis and Its Interaction 

with Smoking. Lihi Eder 1 , Vinod Chandran 2 , Fawnda Pellett 2 , 

Remy Pollock 2 , Fatima Abji 2 , Adele Carty 2 , Sutharshini 

Shanmugarajah 2 , Cheryl Rosen 2 and D. D. Gladman 2 , 1 Carmel 

Medical Center, Haifa, Israel, 2 Toronto Western Hospital and 


538. Association between Biomarkers (Metalloproteinase- 3 , 

Dikkopf- 1 and Sclerostin) with Disease Activity and 

Prediction of Anti-TNFá Therapy Response in Patients with 

Ankylosing Spondylitis. Victoria Navarro-Compán, Rafael 

Ariza, Rufino Mondéjar-García, Virginia Moreira-Navarrete, 

Enrique Melguizo-Madrid, Blanca Hernández-Cruz, 

Concepción González-Rodríguez and Federico Navarro- 

Sarabia, University Hospital Virgen Macarena, Sevilla, Spain 

539. Efficacy and Safety of Adalimumab for the Treatment of 

Peripheral Arthritis in Spondyloarthritis Patients without 

Ankylosing Spondylitis or Psoriatic Arthritis. Jacqueline 

E. Paramarta, Leen De Rycke, Tanja F. Heijda, Carmen 

A. Ambarus, Koen Vos, Huib J. Dinant, Paul P. Tak and 

Dominique L. Baeten, Academic Medical Center/University 

of Amsterdam, Amsterdam, Netherlands 

540. The Predictors of Reduced Work Productivity in Patients 

with Psoriatic Arthritis. Anjali Papneja 1 , Matthew Kennedy 2 , 

Arane Thavaneswaran 3 , Daniel Pereira 3 , Vinod Chandran 3 

and Dafna D. Gladman 3 , 1 University of Toronto, Toronto, 

ON, 2 University of Toronto, TOronto, ON, 3 Toronto Western 

Hospital and University of Toronto, Toronto, ON 

541. Prevalence of Sacroiliitis in the General Population: 

Comparative Analysis with Cutaneous Psoriasis and 

Psoriatic Arthritis. Jose Luis Fernandez-Sueiro 1 , Carlos 

Fernandez-Lopez 1 , S. Pertega-Diaz 1 , JA Pinto 1 , E. Gonzalez 1 , 

Francisco J. de Toro-Santos 1 and Francisco J. Blanco 2 , 

1 

Complejo Hospitalario Universitario La Coruña, La Coruña, 

Spain, 2 INIBIC-Hospital Universitario A Coruña, A Coruña, 

Spain 

182 

2012 Program Book


542. Validation of a Reference Imaging Module for Calibration 

of Readers Scoring with the Modified Stoke Ankylosing 

Spondylitis Spine Score. Walter P. Maksymowych 1 , Thomas 

J. Learch 2 , Robert GW Lambert 1 , Michael M. Ward 3 , Nigil 

Haroon 4 , David Salonen 5 , Robert D. Inman 6 and Michael 

H. Weisman 7 , 1 University of Alberta, Edmonton, AB, 

2 

Cedars-Sinai, Los Angeles, CA, 3 NIAMS/NIH, Bethesda, MD, 

4 

University Health Network, Toronto Western Research 

Institute, University of Toronto, Toronto, ON, 5 University 

Health Network, Toronto, ON, 6 Toronto Western Research 

Institute, University Health Network and University of 

Toronto, Toronto, ON, 7 Cedars-Sinai Medical Center, Los 

Angeles, CA 

543. Wnt Pathway Inhibitors in Patients with Psoriatic and 

Rheumatoid Arthritis Treated with Anti-TNF Therapy. 

Agnes Szentpetery 1 , Harjit P. Bhattoa 2 , Peter Antal-Szalmas 2 , 

Zoltan Szekanecz 3 and Oliver M. FitzGerald 4 , 1 Department 

of Rheumatology, St. Vincent’s University Hospital, Dublin, 

Ireland, 2 Department of Laboratory Medicine, University of 

Debrecen, Medical and Health Science Center, Debrecen, 

Hungary, 3 Department of Rheumatology, University of 

Debrecen Medical and Health Sciences Center, Debrecen, 

Hungary, 4 Dublin Academic Medical Centre, St. Vincent’s 

University Hospital, Dublin, Ireland 

544. Anterior Chest Wall Pain in Recent Inflammatory Back Pain. 

Data From the DESIR Cohort. Daniel Wendling 1 , Clément 

Prati 2 , Christophe Demattei 3 , Damien Loeuille 4 , P. Richette 5 

and Maxime Dougados 6 , 1 Minjoz University Hospital, 

Besancon, France, 2 CHU J Minjoz, Besancon, France, 3 CHU, 

Nimes, France, 4 CHU Brabois, Vandoeuvre les Nancy, 

France, 5 Hôpital Lariboisière, Paris, France, 6 Paris-Descartes 

University, APHP, Cochin Hospital, Paris, France 

545. Correlates of Inflammatory Back Pain in a Nationally 

Representative Sample of the US Population. Shervin 

Assassi 1 , Michael H. Weisman 2 , Zhongxue Chen 1 , 

Mohammad Rahbar 1 , Daniel O. Clegg 3 , Robert A. Colbert 4 , 

Atul A. Deodhar 5 , Laurie M. Savage 6 , Tiffany Graham 1 , 

James P. Witter 7 and John D. Reveille 1 , 1 Univ of Texas Health 

Science Center at Houston, Houston, TX, 2 Cedars-Sinai 

Medical Center, Los Angeles, CA, 3 George E. Wahlen VA 

Medical Center, Salt Lake City, UT, 4 NIAMS NIH, Bethesda, 

MD, 5 Oregon Health & Science University, Portland, OR, 

6 

Spondylitis Association of America, Van Nuys, CA, 7 NIH, 

Bethesda, MD 

546. The Immunogenicity to the First Anti-TNF Therapy 

Determines the Outcome of Switching to a Second Anti- 

TNF in Spondyloarthritis Patients. Chamaida Plasencia 1 , 

Dora Pascual-Salcedo 2 , Sara Garcia-Carazo 1 , Gema Bonilla 3 , 

Leticia Lojo 1 , Laura Nuño 3 , Alejandro Villalba 1 , Diana 

Peiteado 1 , Concepcion Castillo-Gallego Jr. 4 , Florencia 

Arribas 2 , Daniel Nagore 5 , E. Martin-Mola 4 and Alejandro 

Balsa 6 , 1Rheumatology Unit, Spain, Spain, 2 Hospital La Paz. 

IdiPaz, Madrid, Spain, 3 Hospital La Paz-IdiPaz, Madrid, Spain, 

4 

Hospital Universitario La Paz, Madrid, Spain, 5 Proteomika 

S.L., 6 Hospital La Paz, Madrid, Spain 

547. Comparison and Validation of Screening Questionnaires for 

Psoriatic Arthritis in Patients with Psoriasis. Devy Zisman 1 , 

Lihi Eder 1 , Bosmat Zamir 2 , Arie Laor 1 and Joy Feld 1 , 1 Carmel 

Medical Center, Haifa, Israel, 2 Clalit Health Services, Haifa 

and Western Galilee District, Haifa, Israel 

548. Assessment of the T1-Weighted Sequence Is Essential 

in Defining a Positive MRI Scan of the Sacroiliac Joints 

in Spondyloarthritis. Ulrich Weber 1 , Veronika Zubler 1 , 

Susanne Juhl Pedersen 2 , Kaspar Rufibach 3 , Robert GW 

Lambert 4 , Stanley Chan 4 , Mikkel Ostergaard 5 and Walter 

P. Maksymowych 4 , 1 Balgrist University Hospital, Zurich, 

Switzerland, 2 Glostrup Hospital, Copenhagen, Denmark, 

3 

University of Zurich, Zurich, Switzerland, 4 University of 

Alberta, Edmonton, AB, 5 Copenhagen University Hospital at 


549. A Randomized, Open-Label Study of Maintenance of 

Partial Remission with Naproxen Vs No Treatment: 

Results of the Infliximab As First Line Therapy in Patients 

with Early Active Axial Spondyloarthritis Trial, Part II. 

Joachim Sieper 1 , Jan Lenaerts 2 , Jürgen Wollenhaupt 3 , Vadim 

Mazurov 4 , L. Myasoutova 5 , Sung-Hwan Park 6 , Yeong W. 

Song 7 , Ruji Yao 8 , Denesh Chitkara 8 and Nathan Vastesaeger 9 , 

1 

Charité, University Medicine Berlin, Berlin, Germany, 

2 

Reuma-instituut, Hasselt, Belgium, 3 Schön-Klinik, Hamburg, 

Germany, 4 St. Petersburg Medical Academy, St. Petersburg, 

Russia, 5 Kazan State Medical University, Kazan, Russia, 

6 

Catholic University of Korea, Seoul, South Korea, 7 Seoul 

National University, Seoul, South Korea, 8 Merck Sharp and 

Dohme, Kenilworth, NJ, 9 Merck Sharp and Dohme, Brussels, 

Belgium 

550. Differences in the Prevalence of Inflammatory Articular 

Disease in Psoriatic Patients, Applying Clinical, Ultrasound 

and/or Radiological Data. Implications in the Classification 

of Psoriatic Arthritis according to Caspar Criteria. Jose Luis 

Fernandez-Sueiro, S. Pertega-Diaz, JA Pinto and E. Gonzalez, 


Spain 

551. Prevalence of Enthesitis in Psoriatic Patients: Agreement 

between Clinical and Power Doppler Ultrasonography 

Exploration and Its Implications for the Classification 

of Psoriatic Arthritis. Jose Luis Fernandez-Sueiro 1 , JA 

Pinto 1 , S. Pertega-Diaz 1 and Carlos Fernandez-Lopez 2 , 

1 


Spain, 2 INIBIC- Complejo Hospitalario Universitario La 

Coruña(CHUAC). Rheumatology Division., La Coruña, Spain 

552. Simple Questions in the Dermatology Office May 

Reasonably Exclude, but Do Not Reliably Identify Psoriatic 

Arthritis Patients: Results From the Center of Excellence 

for Psoriasis and Psoriatic Arthritis. Neha Garg 1 , Atul A. 

Deodhar 2 , Benjamin Ehst 1 , Andrew Blauvelt 1 , Jennifer Ku 1 

and Brian Truong 1 , 1 Oregon Health and Sciences University, 

Portland, OR, 2 Oregon Health & Science University, Portland, 

OR 



184 

553. Identification of Axial Spondyloarthritis Among Patients 

with Chronic Back Pain in Primary Care – How Does 

Determination of HLA B27 Influence the Performance 

of Clinical Assessments of Inflammatory Back Pain? 

Annalina Braun 1 , Holger Gnann 2 , Ertan Saracbasi 1 , Joachim 

Grifka 3 , Uta Kiltz 1 , J. Schnittker 4 , Katrin Letschert 5 and 

Juergen Braun 1 , 1 Rheumazentrum Ruhrgebiet, Herne, 

Germany, 2 Abteilung Biostatistik, GKM Gesellschaft für 

Therapieforschung mbH, München, Germany, 3 University of 

Regensburg, Bad Abbach, Germany, 4 Institut für angewandte 

Statistik Dr. Jörg Schnitker GmbH, Bielefeld, Germany, 

5 

Abbott Inc., Wiesbaden, Germany 

554. A Reduction in Ultrasound Synovitis Score Discriminates 

Between Clinical Responders and Non-Responders and 

Is Predictive for a Favourable Clinical Outcome in Early 

Psoriartic Arthritis. Axel P. Nigg 1 , Anna M. Malchus 1 , Joerg 

C. Prinz 2 , Mathias Gruenke 1 and Hendrik Schulze-Koops 1 , 

1 

Medizinische Klinik IV, University of Munich, Munich, 

Germany, 2 Department of Dermatology, University of 

Munich, Munich, Germany 

555. Performances of the ASAS Axial Spondyloarthritis Criteria 

for Diagnosis and Classification Purposes in Patients 

Visiting a Rheumatologist Because of Chronic Back Pain: 

The Declic Study. Anna Moltó 1 , Simon Paternotte 1 , Denis 

Comet 2 , Cécile Hacquard-Bouder 3 , Martin Rudwaleit 4 , 

Pascal Claudepierre 5 , Désirée van der Heijde 6 and Maxime 

Dougados 1 , 1 Paris-Descartes University, APHP, Cochin 

Hospital, Paris, France, 2 Axonal, Nanterre, France, 3 Abbott 

France, Rungis, France, 4 Endokrinologikum Berlin, Berlin, 

Germany, 5 Université Paris Est, Laboratoire d’Investigation 

Clinique (LIC) EA 4393, AP-HP, Hôpital Henri-Mondor, 

Rheumatology department, Creteil, France, 6 Leiden 


556. Eos Imaging Could Replace Conventional Computed 

Radiography for Ankylosis Assessment in Axial 

Spondyloarthritis. Anna Moltó 1 , Veronique Freire 2 , Antoine 

Feydy 2 , Simon Paternotte 1 , Walter P. Maksymowych 3 , 

Mathilde Benhamou 4 , François Rannou 4 , Maxime Dougados 1 

and Laure Gossec 1 , 1 Rheumatology B Department, Paris- 

Descartes University, Cochin Hospital, Paris, France, 

2 

Radiology B Department, Paris Descartes University, Cochin 

Hospital, APHP, Paris, France, Paris, France, 3 University 

of Alberta, Edmonton, AB, 4 Physical Medicine and 

Rehabilitation Service, Paris-Descartes University, Cochin 

Hospital, Paris, France 

557. Effect of Certolizumab Pegol On the Multiple Facets of 

Psoriatic Arthritis As Reported by Patients: 24 Week 

Patient Reported Outcome Results of a Phase 3 Double 

Blind Randomized Placebo-Controlled Study. Dafna D. 

Gladman 1 , Roy M. Fleischmann 2 , Geoffroy Coteur 3 , Franz 

Woltering 4 and Philip Mease 5 , 1 Toronto Western Research 

Institute, University of Toronto, University Health Network, 

Toronto, ON, 2 University of Texas Southwestern Medical 

Center at Dallas, Dallas, TX, 3 UCB Pharma, Brussels, Belgium, 

4 

UCB Pharma, Monheim, Germany, 5 Seattle Rheumatology 

Associates, Seattle, WA 


558. Rapid Improvements in Patient Reported Outcomes 

with Certolizumab Pegol in Patients with Axial 

Spondyloarthritis, Including Ankylosing Spondylitis and 

Non-Radiographic Axial Spondyloarthritis: 24 Week 

Results of a Phase 3 Double Blind Randomized Placebo- 

Controlled Study. Joachim Sieper 1 , Alan J. Kivitz 2 , A.M. 

Van Tubergen 3 , Atul A. Deodhar 4 , Geoffroy Coteur 5 , Franz 

Woltering 6 and Robert B. M. Landewé 7 , 1 Charité University 

Medicine, Berlin, Germany, 2 Altoona Center for Clinical 

Research, Duncansville, PA, 3 Maastricht University Medical 

Center, Maastricht, Netherlands, 4 Oregon Health & Science 

University, Portland, OR, 5 UCB Pharma, Brussels, Belgium, 

6 

UCB Pharma, Monheim, Germany, 7 Academic Medical 

Center/University of Amsterdam & Atrium Medical Center, 

Heerlen, Netherlands 

559. Utility of Dual-Energy X-Ray absorptiometry Scanning 

and Risk of Osteoporosis in Ankylosing Spondylitis; A 

Prospective Study. Marina N. Magrey 1 and Muhammad 

Asim Khan 2 , 1 Case Western Reserve University School of 

Medicine at MetroHealth Medical Center, Cleveland, OH, 

2 

CASE at MetroHealth Med Center, Cleveland, OH 

560. Proteomic Profiling of Synovial Fluid Reveals Candidate 

Psoriatic Arthritis Biomarkers. Daniela Cretu 1 , Ihor 

Batruch 2 , Punit Saraon 1 , Dafna Gladman 3 , Fawnda Pellett 3 , 

Eleftherios Diamandis 2 and Vinod Chandran 4 , 1 Department 

of Laboratory Medicine and Pathobiology, University of 

Toronto, Toronto, ON, 2 Mount Sinai Hospital, Toronto, 


Toronto, ON, 4 Toronto Western Hospital, University of 


561. Performance of Magnetic Resonance Imaging in 

Detection of Chronic Structural Changes in Sacroiliac 

Joints As Compared to Conventional X-Rays in Axial 

Spondyloarthritis. Denis Poddubnyy 1 , Inna Gaydukova 2 , 

Hildrun Haibel 1 , In-Ho Song 1 and Joachim Sieper 1 , 1 Charité 

Medical University, Campus Benjamin Franklin, Berlin, 

Germany, 2 Saratov State Medical University, Saratov, Russia 

562. Prevalence and Predictors of Significant Liver Fibrosis in 

Methotrexate Treated Rheumatoid and Psoriatic Arthritis 

Patients Using Transient Elastography (fibroscan). WC 

Chan, ML Yip and CK Loo, Kwong Wah Hospital, Kowloon, 

Hong Kong 

563. In Ankylosing Spondylitis, a Decrease in MRI Spinal 

Inflammation Predicts Improvement in Spinal Mobility 

Independently of Patient Reported Symptomatic 

Improvement. Pedro Machado 1 , Robert Landewé 2 , Jürgen 

Braun 3 , Xenofon Baraliakos 3 , Kay-Geert A. Hermann 4 , 

Benjamin Hsu 5 , Daniel Baker 5 and Désirée van der Heijde 1 , 

1 

Leiden University Medical Center, Leiden, Netherlands, 

2 

Academic Medical Center, University of Amsterdam 

and Atrium Medical Center, Heerlen, Netherlands, 

3 

Rheumazentrum Ruhrgebiet, Herne, Germany, 4 Charité 

Medical School, Berlin, Germany, 5 Centocor Inc., Malvern/ 

Philadelphia, PA


564. Almost 40% of Patients with Chronic Back Pain 

Starting Before the Age of 45 Fulfill the ASAS Axial 

Spondyloarthritis Criteria. Manouk de Hooge, Rosaline 

van den Berg, Floris van Gaalen, Monique Reijnierse, Tom 

Huizinga and Désirée van der Heijde, Leiden University 

Medical Center, Leiden, Netherlands 

565. Fetuin A: A New Biomarker Related with Syndesmophytes 

in Patients with Ankylosing Spondylitis. Tugba Tuylu 1 , Dilek 

Solmaz 1 , Ismail Sari 1 , Didem L. Kozaci 2 , Servet Akar 3 , Necati 

Gunay 2 and Nurullah Akkoc 4 , 1 Dokuz Eylul University School 

of Medicine, Izmir, Turkey, 2 Adnan Menderes University 

School of Medicine, Aydin, Turkey, 3 Dokuz Eylul University 

School of Medicine Department of Internal Medicine 

Division of Rheumatology, Izmir, Turkey, 4 Dokuz Eylul 

University School Of Medicine, Department Of Internal 

Medicine, Division Of Rheumatology, Izmir, Turkey 

566. Effect of TNF Antagonists On Radiographic Progression in 

Psoriatic Arthritis: Systematic Review and Meta-Analysis 

of Randomized Controlled Trials. Radjiv Goulabchand 1 , 

Gael Mouterde 1 , Cédric Lukas 1 , Thomas Barnetche 2 , Jacques 

Morel 1 and Bernard Combe 1 , 1 Montpellier 1 University, 

Lapeyronie Hospital, Montpellier, France, 2 CHU Bordeaux 

Pellegrin, Bordeaux, France 

567. Prevalence of Psoriasis and Psoriatic Arthritis in a Northern 

Population of Spain. Jose Luis Fernandez-Sueiro 1 , JA Pinto 1 , 

S. Pertega-Diaz 1 , Manuel Acasuso 2 and Ignacio Herrero de 

Padura 2 , 1 Complejo Hospitalario Universitario La Coruña, La 

Coruña, Spain, 2 Centro de Salud, San José, La Coruña, Spain 

568. 14-3-3 Eta Is a Modifiable Serum Biomarker That Marks 

Adalimumab Response in Psoriatic Arthritis. Anthony 

Marotta 1 , A. W van Kuijk 2 , Walter P. Maksymowych 3 and Paul 

Peter Tak 4 , 1 Augurex Life Sciences Corp, North Vancouver, 

BC, 2 Academic Medical Centre/University of Amsterdam, 

Amsterdam, Netherlands, 3 University of Alberta, Edmonton, 

AB, 4 Academic Medical Center/University of Amsterdam, 


569. Ustekinumab Improves Arthritis-Related and Skin-Related 

Quality of Life in Patients with Active Psoriatic Arthritis: 

Patient Reported Outcomes From Randomized and Double 

Blinded Phase III Psummit I Trial. Arthur Kavanaugh 1 , Iain 

B. McInnes 2 , Alice B. Gottlieb 3 , Lluis Puig 4 , Proton Rahman 5 , 

Christopher T. Ritchlin 6 , Shu Li 7 , Yuhua Wang 7 , Chenglong 

Han 8 , Alan Mendelsohn 7 and Mittie K. Doyle 7 , 1 UCSD 

School of Medicine, La Jolla, CA, 2 University of Glasgow, 

Glasgow, United Kingdom, 3 Tufts Medical Center, Boston, 

MA, 4 Universitat Autònoma de Barcelona, 5 Memorial 

University, St. Johns, NF, 6 University of Rochester Medical 

Center, Rochester, NY, 7 Janssen Research & Development, 

LLC, Spring House, PA, 8 Johnson & Johnson Pharmaceutical 

Services, LLC., Malvern, PA 

570. Randomized Controlled Trial of Adalimumab in Patients 

with Peripheral Spondyloarthritis. Philip Mease 1 , Joachim 

Sieper 2 , Filip Van den Bosch 3 , Proton Rahman 4 , Katie 

Obermeyer 5 and Aileen L. Pangan 5 , 1 Swedish Medical Center, 

Seattle, WA, 2 Charité Universitätesmedizin Berlin, Berlin, 

Germany, 3 Ghent University Hospital, Ghent, Belgium, 

4 

Memorial University, St. Johns, NF, 5 Abbott Laboratories, 

Abbott Park, IL 

571. Description of Distribution of Active Inflammatory Lesions 

On Magnetic Resonance Imaging of the Sacroiliac Joints 

and the Spine in Patients with Early Axial Spondyloarthritis 

– Analysis of the Esther Trial Baseline Data. In-Ho Song 1 , 

Christian Althoff 2 , Hildrun Haibel 1 , Joachim Listing 3 , Anja 

Weiß 4 , Bruce Freundlich 5 , Martin Rudwaleit 6 and Joachim 

Sieper 7 , 1 Charité Medical University, Campus Benjamin 

Franklin, Berlin, Germany, 2 Charite Medical School, Berlin, 

Germany, 3 German Rheumatism Research Center, Berlin, 

Germany, 4 German Rheumatism Research Centre, Berlin, 

Germany, 5 Villanova, PA, 6 Endokrinologikum Berlin, Berlin, 

Germany, 7 Charité Universitätesmedizin Berlin, Berlin, 

Germany 

572. Radiographic Damage in Ankylosing Spondylitis Over 12 

Years of Follow-up: A Longitudinal Analysis. Sofia Ramiro 1 , 

Carmen Stolwijk 2 , A.M. Van Tubergen 2 , Désirée van der 

Heijde 3 and Robert Landewé 4 , 1 Academic Medical Center, 

University of Amsterdam, The Netherlands and Hospital 

Garcia de Orta, Almada, Portugal, 2 Maastricht University 

Medical Center, Maastricht, Netherlands, 3 Leiden University 

Medical Center, Leiden, Netherlands, 4 Academic Medical 

Center, University of Amsterdam and Atrium Medical Center, 

Heerlen, Netherlands 

573. Differential Association between Human Leukocyte 

Antigen (HLA) Alleles and Joint Subluxation and Ankylosis 

in Patients with Psoriatic Arthritis. Vinod Chandran, Arane 

Thavaneswaran, Amir Haddad, Fawnda Pellett and Dafna 

Gladman, Toronto Western Hospital and University of 


574. Long Term Inhibition of Interleukin (IL)-17A with 

Secukinumab Improves Clinical Symptoms and Reduces 

Spinal Inflammation As Assessed by Magnetic Resonance 

Imaging in Patients with Ankylosing Spondylitis. Xenofon 

Baraliakos 1 , Jurgen Braun 1 , D. D. Laurent 2 , D. Baeten 3 , D. 

van der Heijde 4 , J. Sieper 5 , Paul Emery 6 , Iain B. McInnes 7 , 

J. van Laar 8 , R. Landewe 9 , Paul Wordsworth 10 , Jurgen 

Wollenhaupt 11 , Herbert Kellner 12 , Andrew Wright 2 , Francois 

Vandenhende 13 , Kath Radford 14 , Babul Borah 14 and Hueber 

Wolfgang 14 , 1 Rheumazentrum Ruhrgebiet, Herne, Germany, 

2 

Novartis Pharma AG, Basel, Switzerland, 3 Academic Medical 

Center, University of Amsterdam, Amsterdam, Netherlands, 

4 


5 

Charitè Berlin, Campus Benjamin Franklin, Berlin, Germany, 

6 

University of Leeds, Leeds, United Kingdom, 7 University of 

Glasgow, Glasgow, United Kingdom, 8 Newcastle University, 

Newcastle upon Tyne, United Kingdom, 9 Academic Medical 

Center / University of Amsterdam, Amsterdam, Netherlands, 

10 

Nuffield Orthopaedic Centre, Oxford, United Kingdom, 

11 

Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the 

University of Hamburg, Hamburg, Germany, 12 Centre for 

Inflammatory Joint Diseases, Munich, Germany, Munich, 

Germany, 13 Clinbay, Genappe, Belgium, Genappe, Belgium, 

14 

Novartis Institutes for BioMedical Research, Basel, 

Switzerland 



575. Profiling of Response to Anti-TNFα Therapy by Serum 

Markers of Tissue Degradation End Products in Ankylosing 

Spondylitis Patients. Anne Sofie Siebuhr 1 , Anne C. Bay- 

Jensen 2 , Morten Asser Karsdal 2 , Efstathios Vassiliadis 1 , 

Stephanie Wichuk 3 , Claus Christiansen 4 and Walter P. 

Maksymowych 3 , 1 Nordic Bioscience, Herlev, Denmark, 

2 

Nordic Bioscience A/S, Herlev, Denmark, 3 University of 

Alberta, Edmonton, AB, 4 CCBR, Ballerup, Denmark 

576. Reference Intervals of Spinal Mobility Measures in Normal 

Individuals – the Mobility Study. Sofia Ramiro 1 , Carmen 

Stolwijk 2 , A.M. Van Tubergen 2 , Patrick Royston 3 , Désirée 

van der Heijde 4 and Robert Landewé 5 , 1 Academic Medical 

Center, University of Amsterdam, The Netherlands and 

Hospital Garcia de Orta, Almada, Portugal, 2 Maastricht 

University Medical Center, Maastricht, Netherlands, 3 MRC 

Clinical Trials Unit, University College of London, London, 

United Kingdom, 4 Leiden University Medical Center, 

Leiden, Netherlands, 5 Academic Medical Center, University 


Netherlands 

577. MRI of the Spine for Detection of Bone Spurs and Ankylosis 

in Patients with Ankylosing Spondylitis: Does MRI 

Offer Any Advantages Over Radiography? Susanne Juhl 

Pedersen 1 , Mikkel Østergaard 1 , Robert GW Lambert 2 and 

Walter P. Maksymowych 2 , 1 Glostrup Hospital, Copenhagen, 

Denmark, 2 University of Alberta, Edmonton, AB 

578. Assessment of the Link between Inflammation and Fat 

Metaplasia in Patients with Spondyloarthritis On Non- 

Biological Therapy: A Long Term Magnetic Resonance 

Imaging Study. Zheng Zhao 1 , Susanne Juhl Pedersen 2 , Robert 

GW Lambert 3 , Stephanie Wichuk 3 , Mikkel Ostergaard 4 and 

Walter P. Maksymowych 3 , 1 Department of Rheumatology, 

University of Alberta and PLA General Hospital, Beijing, 

PR China, Beijing, China, 2 Glostrup Hospital, Copenhagen, 

Denmark, 3 University of Alberta, Edmonton, AB, 

4 

Copenhagen University Hospital at Glostrup, Glostrup, 

Denmark 

579. Prevalence of Psoriatic Arthritis in Psoriasis Patients 

According to Newer Classification Criteria. Hernan 

Maldonado-Ficco 1 , Gustavo Citera 1 , Ana Alba Porrini 2 and 

Jose A. Maldonado-Cocco 1 , 1 Instituto de Rehabilitacion 

Psicofisica - Fundacion Reumatologica Argentina Dr. Osvaldo 

Garcia-Morteo, Buenos Aires, Argentina, 2 Hospital Argerich, 


Spondylarthritis and Psoriatic Arthritis - Pathogenesis, Etiology 

580. Changes in Sclerostin, Dickkopf-1 and Serum Markers of 

Inflammation, Cartilage and Bone Turnover in Patients 

with Axial Spondyloarthritis Treated with Adalimumab. 

Susanne Juhl Pedersen 1 , Inge Juul Sørensen 2 , Julia S. 

Johansen 3 , Patrick Garnero 4 , Anne Gitte Loft 5 , Jens Skoedt 6 , 

Gorm Thamsborg 1 , Karsten Asmussen 7 , Elka Kluger 8 , Jesper 

Nørregaard 9 , Torben Grube Christensen 10 and Mikkel 

Østergaard 1 , 1 Glostrup Hospital, Copenhagen, Denmark, 

2 

Hvidovre Hospital, Copenhagen, Denmark, 3 Herlev 

Hospital, Herlev, Denmark, 4 INSERM, Lyon, France, 5 Sygehus 

Lillebaelt, Vejle, Copenhagen, Denmark, 6 Gentofte Hospital, 

Copenhagen, Denmark, 7 Bispebjerg Hospital, Copenhagen, 

Denmark, 8 King Christian 10th Rheumatism Hospital at 

Gråsten, Denmark, 9 Hørsholm Hospital, Denmark, 10 Slagelse 

Hospital, Slagelse, Denmark 

581. Examining a Role for Th17 Regulation and Toll-Like 

Receptor Signaling in Psoriatic Arthritis. Fatima Abji, 

Remy Pollock, Fawnda Pellett, Vinod Chandran and Dafna 

D. Gladman, Toronto Western Hospital and University of 


582. Proteomic Analysis of Synovial Tissue: A Unique Tool to 

Predict Response to Anti-TNF Alpha Therapy in Patients 

with Inflammatory Arthritis. Opeyemi S. Ademowo 1 , 

Emily S. Collins 1 , Cathy Rooney 1 , A. W van Kuijk 2 , Danielle 

M. Gerlag 3 , Paul P. Tak 2 , Oliver M. FitzGerald 4 and Stephen 

R. Pennington 1 , 1 UCD Conway Institute of Biomolecular 

and Biomedical Research, University College Dublin, 

Dublin 4 , Ireland, 2 Academic Medical Centre/University of 

Amsterdam, Amsterdam, Netherlands, 3 Academic Medical 


4 

St. Vincent’s University Hospital, Dublin, Ireland 

583. Familial Aggregation and Heritability of Ankylosing 

Spondylitis in Taiwan: A Nationwide Population Study. 


Hui Yu 3 , Shue-Fen Luo 3 , Ana M. Valdes 4 , I-Jun Chou 3 , Weiya 

Zhang 1 and Michael Doherty 1 , 1 University of Nottingham, 

Nottingham, United Kingdom, 2 Chang Gung University, 

Taoyuan, Taiwan, 3 Chang Gung Memorial Hospital, Taoyuan, 

Taiwan, 4 St. Thomas’ Hospital, King’s College London, 


584. Association of Platelet Endothelial Cell Adhesion 

Molecule-1 and â1 Integrin Gene Polymorphisms with 

Uveitis Development in Ankylosing Spondylitis. Seung 

Cheol Shim, Donghyuk Sheen, Mi Kyoung Lim and Hyo Park, 

Eulji University Hospital, Daejeon, South Korea 

585. Relative Overexpression of Membrane-Bound versus 

Soluble TNF in Human and Experimental Spondyloarthritis. 

Carmen Ambarus 1 , Leonie M. van Duivenvoorde 1 , Huriatul 

Masdar 1 , Melissa N. van Tok 1 , Paul P. Tak 1 , Nataliya 

Yeremenko 1 and Dominique L. Baeten 2 , 1 Academic Medical 


2 

Academic Medical Center/University of Amsterdam, 


586. High Prevalence of Anti-CD-74 Antibodies with Specificity 

for the Class II-Associated Invariant Chain Peptide in 

Patients with Axial Spondyloarthritis but Not in Controls. 

Xenofon Baraliakos 1 , Niklas T. Baerlecken 2 , Frank Heldmann 3 , 

Torsten Witte 4 and Jügen Braun 1 , 1 Rheumazentrum 

Ruhrgebiet, Herne, Germany, 2 MD, Hannover, Germany, 

3 

Rheumazentrum Ruhrgebiet, Herne, Ghana, 4 Hannover 

Medical School, Hanover, Germany 

186 

2012 Program Book


587. Brain MRI and Psychophysics Analysis Demonstrate 

Neuropathic Pain to Be a Component of Back Pain in 

Ankylosing Spondylitis. Q. Wu 1 , R. D. Inman 2 and Karen 

Davis 1 , 1 Toronto Western Research Institute, Toronto, ON, 

2 

Toronto Western Research Institute, University Health 

Network and University of Toronto, Toronto, ON 

588. Discovery of Two Public T Cell Receptor Clonotypes in 

B27+ Ankylosing Spondylitis by Deep Repertoire Sequence 

Analysis. Malek Faham 1 , Victoria Carlton 1 and R. D. Inman 2 , 

1 

Sequenta, Inc., South San Francisco, CA, 2 Toronto Western 

Research Institute, University Health Network and University 

of Toronto, Toronto, ON 

589. NGF and Trka: A Novel Therapeutic Target in Chronic 

Inflammation. Siba P. Raychaudhuri 1 , Ananya Datta Mitra 2 

and Smriti K. Raychaudhuri 2 , 1 VA Sacramento Medical 

Center/UC Davis School of Medicine, Mather, CA, 2 VA 

Sacramento Medical Center, Mather, CA 

590. The Association between KIR3DL1 Alleles and Psoriatic 

Arthritis. Remy Pollock, Jeffrey Berinstein, Arane 

Thavaneswaran, Fawnda Pellett, Dafna Gladman and Vinod 

Chandran, Toronto Western Hospital and University of 


591. Structural Progression of Ankylosing Spondylitis Associated 

with Elevation in Two NOVEL, Inflammatory Biomarkers; 

Matrix Metalloproteinase and Cathepsin-Derived. Anne 

C. Bay-Jensen 1 , Morten Asser Karsdal 1 , Stephanie Wichuk 2 , 

Zheng Zhao 3 , Robert GW Lambert 2 , Per Qvist 4 and Walter P. 


2 

University of Alberta, Edmonton, AB, 3 Department of 

Rheumatology, University of Alberta and PLA General 

Hospital, Beijing, PR China, Beijing, China, 4 Nordic 

Bioscience, Herlev, Denmark 

592. Two Novel Diagnostic Biomarkers of Cartilage Degradation 

and Connective Tissue Inflammation Are Predictive of 

Disease Progression in Ankylosing Spondylitis. Anne C. Bay- 

Jensen 1 , Stephanie Wichuk 2 , Inger Byrjalsen 3 , Zheng Zhao 4 , 

Robert GW Lambert 2 , Morten Asser Karsdal 1 and Walter P. 


2 

University of Alberta, Edmonton, AB, 3 Nordic Bioscience, 

Herlev, Denmark, 4 Department of Rheumatology, University 

of Alberta and PLA General Hospital, Beijing, PR China, 

Beijing, China 

593. DKK1 Serum Level Is Increased in Recent Spondyloarthritis 

and Is Associated with Higher Prevalence of 

Syndesmophytes. Sclerostin Is Highly Correlated with Age. 

Data From the DESIR Cohort. Gaetane Nocturne 1 , Stephan 

Pavy 2 , Désirée van der Heijde 3 , Philipe M. Goupille 4 , Maxime 

Dougados 5 , Christian Roux 6 , Xavier Mariette 7 and Corinne 

Miceli-Richard 2 , 1 Université Paris Descartes, Paris, France, 

2 

Université Paris Sud, Le Kremlin Bicêtre, France, 3 Leiden 

University Medical Center, Leiden, Netherlands, 4 Hopital 

Trousseau, Tours, France, 5 Paris-Descartes University, APHP, 

Cochin Hospital, Paris, France, 6 Paris Descartes University, 

Paris, France, 7 Université Paris-Sud, Le Kremlin Bicetre, 

France 

594. Evidence of Human Leucozyte Antigen-B27 in Healthy 

Individuals and Patients with Uveitis Is a Risk Factor for 

Alterations in Bone Metabolism. Sarah Schmidt 1 , Stephanie 

Finzel 1 , Jürgen Rech 1 , Matthias Englbrecht 1 , Silke Winkler 1 , 

Isabel Schmidt 1 , Roula Said-Nahal 2 , Maxime A. Breban 2 

and Georg A. Schett 3 , 1 University of Erlangen-Nuremberg, 

Erlangen, Germany, 2 Ambroise Paré Hospital (AP-HP), and 

Versailles Saint Quentin en Yvelines University, Boulogne- 

Billancourt, France, 3 Department of Internal Medicine III and 


Nuremberg, Erlangen, Germany 

595. A Genomewide Association Study of Anterior Uveiti. Dorith 

Claushuis 1 , Adrian Cortes 2 , Linda A. Bradbury 1 , Tammy 

M. Martin 3 , James T. Rosenbaum 4 , John D. Reveille 5 , Paul 

Wordsworth 6 , Jennifer Pointon 6 , Australo-Anglo-American 

Spondyloarthritis Consortium 7 , David Evans 8 , Paul Leo 2 , 

Pamela Mukhopadhyay 2 and Matthew A. Brown 2 , 1 The 

University of Queensland Diamantina Institute, Brisbane, 

Australia, 2 The University of Queensland Diamantina 

Insititute, Brisbane, Australia, 3 Oregon Health & Science 

Univ, Portland, OR, 4 Oregon Health & Science University, 

Portland, OR, 5 Univ of Texas Health Science Center at 

Houston, Houston, TX, 6 Nuffield Orthopaedic Centre, Oxford, 

United Kingdom, 7 Houston, TX, 8 Bristol University, Bristol, 


596. Evolution of Atherosclerosis in Psoriatic Arthritis: Is the 

Former an Independent Inflammatory Process?Roberta 

Ramonda 1 , Massimo Puato 2 , Valentina Modesti 1 , 

Mariagrazia Lorenzin 1 , Paola Frallonardo 1 , Augusta Ortolan 1 , 

Carla Campana 1 , Alessandro Lo Nigro 1 and Leonardo Punzi 3 , 

1 

Unit of Rheumatology, University of Padova, Padova, Italy, 

2 

Department of Internal Medicine, University of Padova, 

Padova, Italy, 3 Rheumatology Unit - University of Padova, 

Padova, Italy 

597. Investigating the Genetic Association between ERAP 1 and 

Spondyloarthritis. Amir Kadi 1 , Brigitte Izac 1 , Roula Said- 

Nahal 2 , Ariane Leboime 2 , Kurt L. de Vlam 3 , Dirk Elewaut 4 , 

Gilles Chiocchia 1 and Maxime A. Breban 2 , 1 Institut Cochin - 

INSERM U1016 - CNRS (UMR 8104), Paris, France, 2 Ambroise 

Paré Hospital (AP-HP), and Versailles Saint Quentin en 

Yvelines University, Boulogne-Billancourt, France, 3 University 

Hospitals Leuven, Leuven, Belgium, 4 Ghent University 

Hospital, Ghent, Belgium 

598. The Non-Synonymous Polymorphism IL23R Arg381Gln 

Is Associated with Ankylosis in Spondyloarthritis. Amir 

Kadi 1 , Félicie Costantino 1 , Brigitte Izac 1 , Ariane Leboime 2 , 

Roula Said-Nahal 2 , Gilles Chiocchia 1 and Maxime A. Breban 2 , 

1 

Institut Cochin - INSERM U1016 - CNRS (UMR 8104), Paris, 

France, 2 Ambroise Paré Hospital (AP-HP), and Versailles 

Saint Quentin en Yvelines University, Boulogne-Billancourt, 

France 

599. LIGHT (TNFSF14), Cathepsin K, DKK- 1 and Sclerostin 

in Ankylosing Spondylitis: Osteoclast/OSTEOBLAST 

Imbalance Unrelated to Disease Activity and Effect of 

ANTI-TNFα Treatment On the WNT/β Catenin Pathway. 

Alberto Cauli, Grazia Dessole, Giovanni Porru, Matteo 



Piga, Alessandra Vacca, Valentina Ibba, Pietro Garau and 

Alessandro Mathieu, University of Cagliari, Cagliari, Italy 

600. Regulatory T Cells in Spondyloarthritis (SpA) Animal Model 

and Modulatory Role of Inducible Costimulator (ICOS). 

Luiza Krause 1 , Ingrid Fert 1 , Karine Labroquère 2 , Muriel 

andrieu 2 , Gilles Chiocchia 1 and Maxime A. Breban 3 , 1 Institut 

Cochin - INSERM U1016 - CNRS (UMR 8104)-Université 

Paris Descartes (UMR-S 1016), Paris, France, 2 Cochin 

Immunobiology Facility, Paris, France, 3 Ambroise Paré 

Hospital (AP-HP), and Versailles Saint Quentin en Yvelines 

University, Boulogne-Billancourt, France 

601. Bath Ankylosing Spondylitis Functional Index (BASFI) 

Is a Better Indicator of Poor Quality of Life Than Bath 

Ankylosing Spondylitis Disease Activity Index (BASDAI) in 

Ankylosing Spondylitis: Results From SIRAS – the Scotland 

and Ireland Registry for Ankylosing Spondylitis. Gareth T. 

Jones 1 , Linda E. Morton 1 , Gary J. Macfarlane 1 and Scotland 

and Ireland Registry for Ankylosing Spondylitis 2 , 1 University 

of Aberdeen, Aberdeen, United Kingdom, 2 Aberdeen 


602. Sexual and Reproductive Health Counseling Among 

Adolescents with Systemic Lupus Erythematosus. Xue 

Tian, Murray H. Passo, Janice D. Key, Thomas C. Hulsey and 

Natasha M. Ruth, The Medical University of South Carolina, 


603. Cell Bound Complement Activation Products Are 

Associated with Disease Activity in Systemic Lupus 

Erythematosus. Kenneth C. Kalunian 1 , W. Winn Chatham 2 , 

Elena M. Massarotti 3 , Joyce Reyes-Thomas 4 , Richard Furie 5 , 

Jill P. Buyon 6 , Emily C. Somers 7 , Chaim Putterman 8 , Rachel 

L. Gross 9 , Kyriakos A. Kirou 10 , Rosalind Ramsey-Goldman 11 , 

Christine Hsieh 12 , Thierry Dervieux 13 and A. Weinstein 14 , 

1 

UCSD School of Medicine, La Jolla, CA, 2 University of 

Alabama at Birmingham, Birmingham, AL, 3 Brigham and 

Women’s Hospital, Harvard Medical School, Boston, MA, 

4 

Albert Einstein College of Med, Bronx, NY, 5 North Shore- 

LIJ Health System, Lake Success, NY, 6 New York University 

School of Medicine, New York, NY, 7 University of Michigan, 

Ann Arbor, MI, 8 Albert Einstein College of Medicine, Bronx, 

NY, 9 Albert Einstein College of Medicine, New York, NY, 

10 

Hospital for Special Surgery, New York, NY, 11 Northwestern 

University Feinberg School of Medicine, Chicago, IL, 

12 

University of Chicago, Chicago, IL, 13 Exagen Diagnostics, 

Albuquerque, NM, 14 Washington Hospital Center, 

Washington, DC 

604. Comparing the ACR and the SLICC Criteria for the 

Classification of SLE Patients Using Data from an Existing 

Multi-Ethnic Cohort. Graciela S. Alarcon 1 , Gerald McGwin 

Jr. 1 , Larry Madger 2 and Michelle Petri 3 , 1 University of 

Alabama at Birmingham, Birmingham, AL, 2 University of 

Maryland, Baltimore, MD, 3 Johns Hopkins University School 


605. Increased Incidence of Herpes Zoster Among Patients with 

Systemic Lupus Erythematosus. Eliza F. Chakravarty 1 , Kaleb 

Michaud 2 , Robert S. Katz 3 and Frederick Wolfe 4 , 1 Oklahoma 

Medical Research Foundation, Oklahoma City, CA, 2 National 

Data Bank for Rheumatic Diseases & University of Nebraska 

Medical Center, Omaha, NE, 3 Rush University Medical 

Center, Chicago, IL, 4 National Data Bank for Rheumatic 

Diseases, Wichita, KS 

606. Risk Factors Associated with Cervical Human 

Papillomavirus Infection in Women with Systemic Lupus 

Erythematosus: The Role of Rituximab. Mario Garcia- 

Carrasco 1 , Claudia Mendoza Pinto 1 , Alejandro Taboada- 

Cole 1 , Verónica Vallejo-Ruiz 2 , Julio Reyes-Leyva 2 and Aurelio 

Lopez-Colombo 3 , 1 HGR 36 CMN Manuel Ávila Camacho, 

Instituto Mexicano del Seguro Social, Puebla, Mexico, 

2 

Centro de Investigación Biomédica de Oriente, Instituto 

Mexicano del Seguro Social, Hospital General de Zona No. 5 , 

Puebla, Mexico, 3 Delegación Estatal, Instituto Mexicano del 

Seguro Social, Puebla, Mexico 

607. Activity Index after Renal Failure in a Cohort of 32 Patients 

with Lupus Nephritis. Cristina Gonzalez-Pulido 1 , Sara Croca 2 

and D.A. Isenberg 3 , 1 University Hospital Virgen del Rocio, 

Seville, Spain, 2 University College London, London, United 

Kingdom, 3 University College of London, London, United 

Kingdom 

608. Association of Discoid Lupus with Other Clinical 

Manifestations Among Patients with Systemic Lupus 

Erythematosus. Joseph F. Merola, Christina Iversen, Jose 

A. Gomez-Puerta, Tabatha Norton, Hsun Tsao, Peter H. 

Schur, Elena M. Massarotti, Bonnie L. Bermas and Karen 

H. Costenbader, Brigham and Women’s Hospital, Harvard 

Medical School, Boston, MA 

609. Peripheral Neuropathy in Systemic Lupus Erythematosus. 

Amin Oomatia 1 , Hong Fang 2 , Michelle Petri 2 and Julius 

Birnbaum 3 , 1 University of Cambridge, Cambridge, United 

Kingdom, 2 Johns Hopkins University School of Medicine, 

Baltimore, MD, 3 Johns Hopkins University, Baltimore, MD 

610. B Lymphocyte Stimulator Levels Are Higher in Caucasian 

SLE Patients Earlier in Disease Course and Predict Damage 

Accumulation. Eoghan M. McCarthy 1 , Ruth Lee 1 , Joan Ni 

Gabhann 2 , Siobhan Smith 2 , Michele Doran 3 , Gaye Cunnane 3 , 

Donough G. Howard 1 , Paul G. O’Connell 1 , Grainne M. 

Kearns 1 and Caroline Jefferies 2 , 1 Beaumont Hospital, Dublin 

9 

, Ireland, 2 Royal College of Surgeons in Ireland, Dublin, 

Ireland, 3 St. James Hospital, Dublin, Ireland 

611. Impaired Diffusion Tensor Imaging Findings in the Corpus 

Callosum and Cingulum May Underlie Impaired Learning 

and Memory Abilities in Systemic Lupus Erythematosus. 

Daphna Paran 1 , Elissa Ash 1 , Ira Litinsky 1 , Valerie Aloush 1 , 

Marina Anouk 1 , Dan Caspi 2 , Talma Hendler 3 and Irit Shapira- 

Lichter 3 , 1 Tel Aviv Sourasky Medical Ctr, Tel-Aviv University, 

Tel Aviv, Israel, 2 Tel Aviv, Israel, 3 Tel-Aviv Sourasky Medical 

Ctr, Tel-Aviv University, Tel Aviv, Israel 

188 

2012 Program Book


612. Thrombosis Recurrence in Systemic Lupus Erythematosus 

Patients with and without Antiphospholipid Antibodies. 

Ibrahim AlHomood, D. D. Gladman, Dominique Ibanez and 

Murray B. Urowitz, Toronto Western Hospital and University 

of Toronto, Toronto, ON 

613. Serum Level of Syndecan-1 Is Associated with Disease 

Activity in Patients with Systemic Lupus Erythematosus. In- 

Woon Baek 1 , Ki-Jo Kim 2 , Ji-Young Kim 3 , Su-Jung Park 3 , Chong- 

Hyeun Yoon 4 , Wan-Uk Kim 5 and Chul Soo Cho 6 , 1 Internal 

medicine, Catholic University of Korea, Callege of Medicine, 

Seoul, South Korea, 2 College of Medicine, Catholic University 

of Korea, Seoul, South Korea, 3 Research Institute of Bone 

& Joint Diseases, Catholic University of Korea, Seoul, 

South Korea, 4 College of Medicine, The Catholic University 

of Korea, Seoul, South Korea, 5 College of Medicine, The 

Catholic University of Korea, Suwon, South Korea, 6 St Marys 

Hospital, Seoul, South Korea 

614. Predictors of Systemic Lupus Erythematosus Flares: 

Baseline Disease Activity and Demographic Characteristics 

from the Combined Placebo Groups in the Phase 3 

Belimumab Trials. Ronald F. van Vollenhoven 1 , Michelle 

A. Petri 2 , Roger A. Levy 3 , Sandra V. Navarra 4 , Jill P. Buyon 5 , 

Z. John Zhong 6 , William W. Freimuth 6 and Ricard Cervera 7 , 

1 

Karolinska University Hospital, Stockholm, Sweden, 2 Johns 

Hopkins University School of Medicine, Baltimore, MD, 3 Univ 

Estado Do Rio De Janeiro, Rio de Janeiro, Brazil, 4 University 

of Santo Tomas Hospital, Manila, Philippines, 5 New York 

University School of Medicine, New York, NY, 6 Human 

Genome Sciences, Inc., Rockville, MD, 7 Hospital Clínic of 

Barcelona, Barcelona, Spain 

615. Baseline Laboratory Characteristics From the Combined 

Placebo Groups in the Phase 3 Belimumab Trials Are 

Predictive of Severe Flare At 52 Weeks. Michelle A. Petri 1 , 

Ronald F. van Vollenhoven 2 , Roger A. Levy Sr. 3 , Sandra 

V. Navarra 4 , Ricard Cervera 5 , Z. John Zhong 6 , William W. 

Freimuth 6 and Jill P. Buyon 7 , 1 Johns Hopkins University 

School of Medicine, Baltimore, MD, 2 Karolinska University 

Hospital, Stockholm, Sweden, 3 Hospital Universitário Pedro 

Ernesto, Rio de Janeiro, Brazil, 4 University of Santo Tomas 

Hospital, Manila, Philippines, 5 Hospital Clinic, Barcelona, 

Spain, 6 Human Genome Sciences, Inc., Rockville, MD, 7 New 

York University School of Medicine, New York, NY 

616. Bioavailability, Pharmacokinetics, and Safety of Belimumab 

Administered Subcutaneously in Healthy Subjects. Wendy 

Cai 1 , Cecil Chen 1 , Z. John Zhong 1 , William W. Freimuth 1 , 

William Lewis 2 and David Subich 3 , 1 Human Genome 

Sciences, Inc., Rockville, MD, 2 Covance Clinical Research 

Unit, Inc., Dallas, TX, 3 Covance Clinical Research Unit, Inc., 

Daytona Beach, FL 

617. Soluble Urokinase Plasminogen Activator Receptor 

(suPAR) Levels Reflect Organ Damage in Systemic Lupus 

Erythematosus. Helena Enocsson 1 , Jonas Wetterö 2 , Thomas 

Skogh 2 and Christopher Sjöwall 1 , 1 Linkoping University, 

Linkoping, Sweden, 2 Linköping University, Linköping, Sweden 

618. BAFF/BLyS Gene Expression Predicts Disease Activity in 

Systemic Lupus Erythematosis Over One Year. Eric Zollars 1 , 

Hong Fang 1 , Jadwiga Bienkowska 2 , Norm Allaire 2 , Susan 

Kalled 2 and Michelle Petri 1 , 1 Johns Hopkins University School 

of Medicine, Baltimore, MD, 2 Biogen Idec Inc., Cambridge, 

MA 

619. Elevated Plasma Levels of CXCL 2 and CXCL10 Have Distinct 

Predictive Value in Systemic Lupus Erythematosus. Felipe 

andrade 1 , Ehtisham Akhter 2 , Hong Fang 2 and Michelle 

Petri 2 , 1 The Johns Hopkins University School of Medicine, 

Baltimore, MD, 2 Johns Hopkins University School of 

Medicine, Baltimore, MD 

620. Development of A Quantitative PCR Method to Determine 

Interferon Signature Metric Status in SLE Patients: 

Distribution and Clinical & Serological Associations in 

Two Lupus Clinical Trials. Bruce C. Richardson 1 , William P. 

Kennedy 2 , John C. Davis Jr. 2 , R. Maciuca 2 , A. Morimoto 2 , J. 

M. McBride 2 , Alexander R. Abbas 2 , Timothy W. Behrens 2 and 

Michael J. Townsend 2 , 1 University of Michigan, Ann Arbor, 

MI, 2 Genentech, Inc, South San Francisco, CA 

621. Prolonged Improvement of Systemic Lupus Erythematosus 

Following Systematic Administration of Rituximab and 

Cyclophosphamide. Thomas J. A. Lehman 1 , Emily Baird 2 , 

Anusha Ramanathan 3 , Risa Alperin 3 , Emma J. MacDermott 3 , 

Alexa B. Adams 3 , Laura V. Barinstein 4 and Lakshmi N. 

Moorthy 5 , 1 Hosp for Special Surgery, New York, NY, 2 Hospital 

for Special Surgery, NY, 3 Hospital for Special Surgery, New 

York, NY, 4 Maimonides Medical Center, Brooklyn, NY, 5 Robert 

Wood Johnson-UMDNJ, New Brunswick, NJ 

622. Headache in Systemic Lupus Erythematosus (SLE): Results 

from a Prospective, International, Inception Cohort 

Study. John G. Hanly 1 and Systemic Lupus International 

Collaborating Clincs 2 , 1 Dalhousie University and Capital 

Health, Halifax, NS, 2 (SLICC) 

623. Endothelial Microparticles As a Biomarker for Endothelial 

Dysfunction in Active Systemic Lupus Erythematosus. Ben 

Parker 1 , Awal Zaki 2 , M. Yvonne Alexander 3 and Ian N. Bruce 4 , 

1 

Arthritis Research UK Epidemiology Unit,, Manchester, 

United Kingdom, 2 Arthritis Research UK Epidemiology 

Unit, Manchester, United Kingdom, 3 The University of 

Manchester, Manchester, United Kingdom, 4 Arthritis 

Research UK Epidemiology Unit and NIHR Manchester 

Musculoskeletal Biomedical Research Unit, Manchester, 


624. Excess Health Care Utilization Prior to Diagnosis of 

Systemic Lupus Erythematosus in England. Amy Steffey 1 , 

Trung N. Tran 1 , Jie Li 1 and Herve Caspard 2 , 1 MedImmune, 

Gaithersburg, MD, 2 MedImmune LLC, Gaithersburg, MD 

625. Control of Hypertension and Hypercholesterolemia Is 

Not Associated with a Decreased Rate of Atherosclerotic 

Vascular Events in Patients with Systemic Lupus 

Erythematosus. Joanna Ueng, D. D. Gladman, Dominique 



Ibanez and Murray B. Urowitz, Toronto Western Hospital 

and University of Toronto, Toronto, ON 

626. The Interferon Alpha Gene Signature Is Not Associated 

with nor Does It Predict Progression of Coronary Artery 

Calcium (CAC) or Carotid Intima-Media Thickness (IMT) in 

Systemic Lupus Erythematosus (SLE). Adnan Kiani, Hong 

Fang, Jie Xu, Ehtisham Akhter and Michelle Petri, Johns 

Hopkins University School of Medicine, Baltimore, MD 

627. Zostavax Vaccine Is Safe in Lupus Patients with Low 

Disease Activity. Eliza F. Chakravarty 1 , Joel M. Guthridge 2 , 

Joan T. Merrill 2 , Abigail Cogman 2 , Tiny Powe 1 , Virginia C. 

Roberts 3 and Judith A. James 4 , 1 Oklahoma Medical Research 

Foundation, Oklahoma City, CA, 2 Oklahoma Medical 

Research Foundation, Oklahoma City, OK, 3 OMRF, Oklahoma 

City, OK, 4 Oklahoma Medical Research Foundation and 

Oklahoma University Health Sciences Center, Oklahoma City, 

OK 

628. Urinary Heparanase Activity Is Elevated in Patients with 

Lupus Nephritis and Correlate with Protein Excretion. Ki-Jo 

Kim 1 , In-Woon Baek 2 , Chong-Hyeun Yoon 1 , Wan-Uk Kim 3 and 

Chul-Soo Cho 1 , 1 College of Medicine, The Catholic University 

of Korea, Seoul, South Korea, 2 Callege of Medicine, The 

Catholic University of Korea, Seoul, South Korea, 3 College of 

Medicine, The Catholic University of Korea, Suwon, South 

Korea 

629. Inflammatory Biomarkers of Atherosclerosis and Oxidative 

Stress Are Associated with Disease Flare in SLE. Maureen 

A. McMahon 1 , Jennifer M. Grossman 1 , Brian Skaggs 1 , 

Elaine Lourenco 1 , Cheryl Lee 1 , Lori Sahakian 1 , John D. 

FitzGerald 1 , Christina Charles-Schoeman 2 , Alan H. Gorn 1 , 

George A. Karpouzas 3 , Michael H. Weisman 4 , Daniel J. 

Wallace 4 , Weiling Chen 1 and Bevra H. Hahn 1 , 1 UCLA David 

Geffen School of Medicine, Los Angeles, CA, 2 University of 

California, Los Angeles, CA, 3 Harbor-UCLA Medical Center, 

Torrance, CA, 4 Cedars-Sinai Medical Center, Los Angeles, CA 

630. Risk Factors Associated with Early Central Nervous System 

Damage Detected Through Diffusion Tensor Imaging (DTI) 

in Patients with Systemic Lupus Erythematosus. Paola 

Tomietto 1 , Federica Casagrande 2 , Maja Ukmar 3 , Luca Weis 2 , 

Pia Morassi 4 , Rita Moretti 2 , Gianni Biolo 2 , Carlo Giansante 2 

and Maria Assunta Cova 2 , 1 AOU Ospedali Riuniti, Trieste, 

Italy, 2 University of Trieste, Trieste, Italy, 3 University of 

Trieste, Trieste, 4 AOU Ospedali Riuniti di Trieste, Trieste, Italy 

631. Peripheral Neuropathy Due to Systemic Lupus 

Erythematosus (SLE) Itself: Incidence, Disease Risk Factors 

and Outcome. Simone Fargetti 1 , Samuel K. Shinjo 2 , Sandra 

G. Pasoto 1 , Ana L. Calich 1 , Eloisa Bonfa 3 and Eduardo 

F. Borba 1 , 1 University of Sao Paulo, Sao Paulo, Brazil, 

2 

Faculdade de Medicina da Universidade de São Paulo, Sao 

Paulo, Brazil, 3 University of São Paulo, São Paulo, Brazil 

632. The Effects of Co-Existing Proliferative Histopathology on 

Membranous Lupus Nephritis. Jennifer L. Graybill, Catarina 

Vila-Inda, Chaim Putterman and Irene Blanco, Albert 

Einstein College of Medicine, Bronx, NY 

633. Missed Work Days in Systemic Lupus Erythematosus. Jie 

Xu, Hong Fang and Michelle Petri, Johns Hopkins University 

School of Medicine, Baltimore, MD 

634. Adherence to Adult Treatment Panel III Guidelines for 

Systemic Lupus Patients. Matthew Basiaga and Lisabeth 

Scalzi, Penn State Univ/ Hershey, Hershey, PA 

635. Elevated Transglutaminase Levels On Microparticles From 

Systemic Lupus Erythematosus Patients. Leslie Harris, 

Ratnesh Chopra, Ann K. Rosenthal and Mary E. Cronin, 

Medical College of Wisconsin, Milwaukee, WI 

636. Retrospective Study of Allogenic Mesenchymal Stem Cells 

Transplantation in Active and Refractory Lupus Nephritis 

for Induction Therapy. Lingyun Sun, Dandan Wang, Xia Li 

and Huayong Zhang, Department of Rheumatology and 

Immunology, the Affiliated Drum Tower Hospital of Nanjing 

University Medical School, Nanjing, China 

637. Anti-Mullerian Hormone and Ovarian Reserve in Systemic 

Lupus Erythematosus. Chi Chiu Mok 1 , Pak To Chan 2 and 

Chi Hung To 2 , 1 Tuen Mun Hospital, Hong Kong, Hong Kong, 

2 

Hong Kong, Hong Kong 

638. The Progression of Brain MRI Biomarker of Cognitive 

Impairment (White Matter Hyperintensity) in Systemic 

Lupus: A Clinical and Imaging Longitudinal Study. Jamal 

Mikdashi and Umran Ashruf, University of Maryland School 


639. Safety and Efficacy of Epratuzumab in an Open-Label 

Extension Study (SL0006). K. Hobbs 1 , D.J. Wallace 2 , V. 

Strand 3 , K. Kalunian 4 , B. Kilgallen 5 , S. Bongardt 6 , W.A. 

Wegener 7 and D.M. Goldenberg 7 , 1 Denver Arthritis Clinic, 

Denver, CO, 2 Cedars-Sinai Medical Center, Los Angeles, 

CA, 3 Stanford University, Palo Alto, CA, 4 UCSD School of 

Medicine, La Jolla, CA, 5 UCB Pharma, Smyrna, GA, 6 UCB 

Pharma, Brussels, Belgium, 7 Immunomedics Inc, Morris 

Plains, NJ 

640. Association of Body Weight with Cardiovascular Events 

in Systemic Lupus Erythematosus. George Stojan 1 , Homa 

Timlin 2 , Hong Fang 1 , Laurence S. Magder 3 and Michelle 

Petri 1 , 1 Johns Hopkins University School of Medicine, 

Baltimore, MD, 2 West Drayton, United Kingdom, 3 University 

of Maryland, Baltimore, MD 

641. Study of Anti-Müllerian Hormone and Probability of 

Pregnancy in 112 Systemic Lupus Erythematosus Patients 

Exposed or Not to Cyclophosphamide. Nathalie Morel 1 , 

Anne Bachelot 1 , Zeina Chakhtoura 1 , Zahir Amoura 1 , Olivier 

Aumaitre 2 , Jean-Emmanuel Kahn 3 , Du Boutin 1 , Pierre 

Duhaut 4 , Dominique Farge 5 , Camille Francès 1 , Lionel 

Galicier 6 , Gaëlle Guettrot-Imbert 2 , Jean-Robert Harlé 7 , 

Olivier Lambotte 8 , Véronique Le Guern 9 , Jean-Charles 

Piette 1 , Jacques Pourrat 7 , Karim Sacre 10 , Damien Sene 11 , 

Salim Trad 12 , Elisabeth Vidal 13 , Lamiae Grimaldi 14 , Christiane 

Coussieu 1 , Nathalie Costedoat-Chalumeau 1 and PLUS 15 , 

1 

Groupe Hospitalier Pitié-Salpétrière, Paris, France, 2 Centre 

Hospitalier de Clermont-Ferrand, Clermont-Ferrand, France, 

190 

2012 Program Book


3 

Internal Medicine, Foch Hospital, Suresnes, France, 4 CHU 

Nord, Amiens, France, 5 EBMT, Paris, France, 6 Hopital Saint 

Louis, Paris, France, 7 CHU Toulouse, Toulouse, France, 

8 

Hopital Kremlin Bicêtre, Kremlin Bicêtre, France, 9 Cochin 

Hospital, Paris, France, 10 Bichat Hospital, University Paris- 7 , 

APHP, Paris, France, 11 Hopital Lariboisière, Paris, France, 

12 

Hopital Ambroise Paré, Paris, France, 13 Hopital de Limoges, 

Limoges, France, 14 Société Laser, Paris, France, 15 Paris, 

France 

642. Effects of Treatment on the Expression of CCL 2 and 

CXCL10 in Systemic Lupus Erythematosus Patients. Paul R. 

Dominguez-Gutierrez, Angela Ceribelli, Minoru Satoh, Eric S. 

Sobel, Westley H. Reeves and Edward K.L. Chan, University 

of Florida, Gainesville, FL 

643. Clinical Characteristics for Future Development of Systemic 

Lupus Erythematosus in Korean Patients with Idiopathic 

Thrombocytopenic Purpura. Yeon-Ah Lee 1 , Somi Kim 1 , 

Ran Song 2 and Sang-Hoon Lee 2 , 1 Kyung Hee University, 

Seoul, South Korea, 2 Hospital at GANGDONG, Kyung Hee 

University, Seoul, South Korea 

644. Pulmonary Hypertension in Systemic Lupus 

Erythematosus: A 6-Year Follow-up Study Cohort. Claudia 

Hübbe-Tena, Selma Gallegos-Nava, Rafael Bojalil and Luis M. 

Amezcua-Guerra, Instituto Nacional de Cardiología Ignacio 

Chávez, Mexico City, Mexico 

645. Altered Soluble Inflammatory Mediators Mark Impending 

Systemic Lupus Erythematosus Disease Flare in European- 

American Lupus Patients Who Receive Influenza 

Vaccination. Melissa E. Munroe 1 , Jourdan R. anderson 1 , 

Joan T. Merrill 1 , Joel M. Guthridge 1 , Virginia C. Roberts 1 , 

Gillian M. Air 1 , Linda F. Thompson 1 and Judith A. James 2 , 

1 


OK, 2 Oklahoma Medical Research Foundation; University of 


646. Comparison of the Lupusqol and SF-36 Scores As Valid 

Measures of Change in Health Related Quality of Life. Zahi 

Touma, Murray B. Urowitz, Dominique Ibanez, Shahrzad 

Taghavi-Zadeh and D. D. Gladman, Toronto Western Hospital 


647. Adjusted Framingham Risk Factor Scoring for Systemic 

Lupus Erythematosus: Results from an Inception Cohort 

Followed for Eight Years. Murray B. Urowitz 1 , Dominique 

Ibanez 1 , D. D. Gladman 1 , SLICC 2 and Systemic Lupus 

International Collaborating Clinics (SLICC) 2 , 1 Toronto 


2 

Toronto, ON 

648. Atherosclerotic Vascular Events in a Multinational 

Inception Cohort of Systemic Lupus Erythematosus: 

Incidence over a Ten Year Period. D. D. Gladman 1 , 

Dominique Ibanez 1 , Murray B. Urowitz 1 and SLICC 2 , 1 Toronto 


2 

Toronto, ON 

649. Increased Male-to-Female Ratio in Children Born to 

Women with Systemic Lupus Erythematosus. Evelyne 

Vinet 1 , Sasha Bernatsky 2 , Mohammed Kaouache 2 , Emil 

P. Nashi 1 , Christian A. Pineau 1 , Ann E. Clarke 3 , Robert W. 

Platt 4 , Meggan C. Mackay 5 and Cynthia Aranow 6 , 1 McGill 

University Health Centre, Montreal, QC, 2 Research Institute 

of the McGill University Health Ctre, Montreal, QC, 3 MUHC, 

Montreal, QC, 4 McGill University, Montreal, QC, 5 The 

Feinstein Institute, Manhasset, NY, 6 Feinstein Institute for 

Medical Research, Manhasset, NY 

650. Clinical Variables Associated with Thrombosis At Systemic 

Lupus Erythematosus Diagnosis. Differences between 

Patients with Positive/Negative Lupus Anticoagulant. 

Andrea Hinojosa-Azaola 1 , Alba Cicero-Casarrubias 1 , Mario 

César Ocampo-Torres 1 , Juanita Romero-Díaz 1 and Jorge 

Sánchez-Guerrero 2 , 1 Instituto Nacional de Ciencias Médicas 

y Nutrición Salvador Zubirán, Mexico City, Mexico, 2 Mount 

Sinai Hospital and University Health Network, Toronto 

Canada 

651. Suicidal Ideation in Patients with Systemic Lupus 

Erythematosus: Incidence and Relationship with Anxiety/ 

Depression Score, Disease Activity and Organ Damage. Chi 

Chiu Mok 1 , Kelly Chan 1 and Paul Yip 2 , 1 Tuen Mun Hospital, 

Hong Kong, Hong Kong, 2 University of Hong Kong, Hong 

Kong, Hong Kong 

652. Serum Rituximab Levels and Efficiency of B-Cell Depletion: 

Differences between Patients with Systemic Lupus 

Erythematosus and Rheumatoid Arthritis. Venkat Reddy 1 , 

Sara Croca 1 , Delia Gerona 2 , Inmaculada De La Torre 

Ortega 2 , David A. Isenberg 1 , Maria Leandro 1 and Geraldine 

Cambridge 1 , 1 University College London, London, United 

Kingdom, 2 Gregorio Marañón Hospital, Madrid, Spain 

653. Longitudinal Analysis of Plasma Factors and Disease 

Activity Identifies Von Willebrand Factor As A Biomarker 

of LUPUS FLARE. Mikhail Olferiev 1 , Kyriakos A. Kirou 2 , Elena 

Gkrouzman 3 , Dorthe Lundsgaard 4 , Klaus S. Frederiksen 5 , 

Jan Fleckner 5 and Mary K. Crow 2 , 1 Mary Kirkland Center for 

Lupus Research, Hospital for Special Surgery, New York, NY, 

2 

Hospital for Special Surgery, New York, NY, 3 Mary Kirkland 

Center for Lupus Research, Hospital for Special Surgery, New 

York, New York, NY, 4 Novo Nordisk A/S, Måløv, Denmark, 

5 

NovoNordisk, Copenhagen, Denmark 

654. Incidence Studies of Systemic Lupus Erythematosus 

in Southern Sweden. Have the Tides Turned? Ragnar 

Ingvarsson 1 , Andreas Jönsen 2 , Ola Nived 3 , Gunnar Sturfelt 1 

and anders Bengtsson 4 , 1 Department of Clinical Sciences 

Lund, Section of Rheumatology, Lund, Sweden, 2 Section of 

Rheumatology, Lund, Sweden, 3 University Hospital - Lund, 

Lund, Sweden, 4 University Hospital Lund, Lund, Sweden 

655. Non-White Race, Younger Age, and Use of Primary and 

Gynecologic Care Are Associated with Higher Rates of 

Cervical Cancer Screening in Systemic Lupus Erythematosus 

Patients At a Public Hospital. Jennifer Stichman 1 , Angela 

Keniston 1 , Joann Zell 2 , Jinoos Yazdany 3 , Itziar Quinzanos 1 



and Joel M. Hirsh 1 , 1 Denver Health Med Ctr, Denver, CO, 

2 

National Jewish Health, Denver, CO, 3 University of California 

San Francisco, San Francisco, CA 

656. Effects of Nelfinavir on Anti-dsDNA Antibody Binding 

and Pro-Inflammatory Cytokine Gene Expression. Maria 

Espinosa 1 , Julisa Patel 2 , Meggan Mackay 3 , Cynthia Aranow 4 

and Betty Diamond 5 , 1 Cohen Children’s Hospital-North Shore 

LIJ, New Hyde Park, NY, 2 Cohen Children’s Hospital, New 

Hyde Park, NY, 3 The Feinstein Institute for Medical Research, 

Manhasset, NY, 4 Feinstein Institute for Medical Research, 

Manhasset, NY, 5 Feinstein Institute Med Rsch, Manhasset, 

NY 

657. Serial Screening Shows That 28% of Systemic Lupus 

Erythematosus Adult Patients Carry an Underlying Primary 

Immunodeficiency. Sandro F. Perazzio 1 , Reinaldo Salomao 1 , 

Neusa P. Silva 2 , Magda Carneiro-Sampaio 3 and Luis Eduardo 

C. andrade 4 , 1 Federal University of Sao Paulo, Sao Paulo, 

Brazil, 2 Escola Paulista de Medicina - Universidade Federal 

de São Paulo, Sao Paulo, Brazil, 3 Instituto da Criança da 

Faculdade de Medicina da Universidade de São Paulo 

(FMUSP), Sao Paulo, Brazil, 4 Universidade Federal de São 

Paulo, Sao Paulo, Brazil 


Pathogenesis 

658. Up-Regulation of A Disintegrin and Metalloprotease 

with Thrombospondin Type I Repeats-13 Correlates with 

Ischemic Cerebrovascular Disease in Systemic Lupus 

Erythematosus Patients. Consuelo Lopez de Padilla 1 , Molly 

Hein 1 , Cynthia S. Crowson 1 , Christopher Choo 2 , Abigail 

B. Green 1 , Michelle Petri 3 , Hatice Bilgic 4 , Emily Baechler 

Gillespie 4 and Ann M. Reed 1 , 1 Mayo Clinic, Rochester, 

MN, 2 Rochester, MN, 3 Johns Hopkins University School of 

Medicine, Baltimore, MD, 4 University of Minnesota Medical 

School, Minneapolis, MN 

659. The Small Molecule Activator to ACE2 Prevents the 

Inhibition of ACE2 Activity by Autoantibodies. Shiori 

Haga 1 , Yuko Takahashi 2 , Yukihito Ishizaka 1 and Akio Mimori 2 , 

1 

National Center for Global Health and Medicine, Research 

Institute, Tokyo, Japan, 2 National Center for Global Health 

and Medicine, Tokyo, Japan 

660. Abnormal Neutrophil Development in Human Systemic 

Lupus Erythematosus. Namrata Singh 1 , Mariana J. Kaplan 2 , 

Philip L. Cohen 1 and Michael F. Denny 1 , 1 Temple University, 

Philadelphia, PA, 2 University of Michigan, Ann Arbor, MI 

661. Co-Localization of C - reactive protein, Immunoglobulin 

G and Complement in Renal Subendothelial Immune 

Deposits of Proliferative Lupus Nephritis Detected Using 

Immunogold Electron Microscopy. Christopher Sjöwall 1 , 

anders I. Olin 2 , Thomas Skogh 3 , Jonas Wetterö 3 , Mattias 

Mörgelin 2 , Ola Nived 4 , Gunnar Sturfelt 5 and anders A. 

Bengtsson 5 , 1 Linkoping University, Linkoping, Sweden, 

2 

Infection Medicine, Department of Clinical Sciences, 

Lund University, Lund, Sweden, Lund, Sweden, 3 Linköping 

University, Linköping, Sweden, 4 University Hospital Lund, 

Lund, Sweden, 5 Department of Clinical Sciences Lund, 

Section of Rheumatology, Lund, Sweden 

662. Increased C1q, C 4 and C3 Deposition on Platelets in 

Patients with Systemic Lupus Erythematosus – A Possible 

Link to Venous Thrombosis? Christian Lood 1 , Sam Eriksson 1 , 

Birgitta Gullstrand 2 , Andreas Jönsen 1 , Gunnar Sturfelt 1 , 

Lennart Truedsson 2 and anders A. Bengtsson 1 , 1 Department 

of Clinical Sciences Lund, Section of Rheumatology, Lund, 

Sweden, 2 Department of Laboratory Medicine, Section of 

Microbiology, Immunology and Glycobiology, Lund, Sweden 

663. The Clinical Significance and Expression of P2X7 Purinergic 

Receptor in Peripheral Blood from Patients with New- 

Oneset Systemic Lupus Erythematosus. Xiangpei Li, Meiyun 

Wang, Jinhui Tao, Xiaomei Li and Ning Yu, Anhui Medical 

University Affiliated Provincial Hospital, Hefei, Anhui, China 

664. Estrogen Upregulates Interleukin-21 Production of Clusters 

of Differentiation 4 Positive T Lymphocytes in Patients with 

Systemic Lupus Erythematosus. Jennifer Lee 1 , Daejun Kim 1 , 

Jae Ho Lee 1 , Seung Min Jung 1 , Mi-La Cho 2 , Seung-Ki Kwok 1 , 

Ji Hyeon Ju 1 , Kyung-Su Park 1 , Sung-Hwan Park 1 and Ho-Youn 

Kim 1 , 1 Division of Rheumatology, Department of Internal 

Medicine, School of Medicine, The Catholic University of 

Korea, Seoul, South Korea, 2 Rheumatic research center, 

Catholic University of Korea, Seoul, South Korea 

665. Cytokines and Their Relation to Autoantibodies before 

Disease Onset in Systemic Lupus Erythematosus. Catharina 

Eriksson 1 and Solbritt Rantapää Dahlqvist 2 , 1 Department of 

Clinical Immunology/clinical microbiology, Umeå, Sweden, 

2 

Umeå University Hospital, Umeå, Sweden 

666. Leukadherin 1, a CR3 Mimetic, Negatively Regulates Toll 

Like Receptor (TLR) Dependent Inflammatory Responses 

via Degradation of an Adaptor Protein. Kristen Lee 1 , Joanne 

H. Reed 1 , Vineet Gupta 2 , Tejaskumar Patel 1 , Jill P. Buyon 3 and 

Robert M. Clancy 1 , 1 New York University School of Medicine, 

New York, NY, 2 Division of Nephrology and Hypertension, 

Department of Medicine, University of Miami, Miami, FL 

3313 6 , U.S.A., Miami, FL, 3 NYU School of Medicine, New 

York, NY 

667. Interferon-Alpha Impairs the Survival and Function of 

Circulating Angiogenic Cells in Vitro: A Model of Failed 

Endothelial Repair in SLE. John A. Reynolds 1 , David W. 

Ray 2 , Terence O’Neill 2 , M. Yvonne Alexander 1 and Ian N. 

Bruce 3 , 1 The University of Manchester, Manchester, United 

Kingdom, 2 University of Manchester, Manchester, United 

Kingdom, 3 Arthritis Research UK Epidemiology Unit and 

NIHR Manchester Musculoskeletal Biomedical Research 

Unit, Manchester, United Kingdom 

668. Markers of Nitric Oxide and Hydroxyl Radical Formation 

Are Increased in Proliferative Lupus Nephritis and May 

Emanate From Increased Nitric Oxide Synthase and NADPH 

Oxidase Production and Reduced Endothelial Nitric Oxide 

192 

2012 Program Book


Synthase-Derived NO Scavenging. Jim Oates, Ahmad 

Mashmoushi, Thomas Fleury, Ann Hofbauer and Gary S. 

Gilkeson, Medical University of South Carolina, Charleston, 

SC 

669. Serum Anti N-Methyl-D-Aspartate Receptor Subunit 1 

Antibodies Are Elevated in SLE. Ogawa Eisuke, Nagai Tatsuo, 

Arinuma Yoshiyuki and Hirohata Shunsei, Kitasato University 

School of Medicine, Kanagawa, Japan 

70. Prolidase Deficiency Induces Antibodies to Sm, Ro60 and 

Double Stranded DNA. Biji T. Kurien 1 , Anil D’souza 2 , Skyler 

P. Dillon 1 , Benjamin F. Bruner 3 , Timothy Gross 4 , Judith A. 

James 5 , Ira N. Targoff 6 , Jacen S. Maier-Moore 1 , Isaac T.W. 

Harley 7 , Heng Wang 8 and Robert H. Scofield 1 , 1 Arthritis 

& Clinical Immunology Program, Oklahoma Medical 

Research Foundation; Department of Medicine, University 

of Oklahoma Health Sciences Center; US Department 

of Veterans Affairs Medical Center, Oklahoma City, OK, 

2 


City, OK, 3 Harding University, Searcy, AR, 4 Oklahoma Medical 

Research Foundation, Oklahoma City, OK, 5 Oklahoma 

Medical Research Foundation and Oklahoma University 

Health Sciences Center, Oklahoma City, OK, 6 Oklahoma 

Medical Research Foun, Oklahoma City, OK, 7 Cincinnati 

Children’s Hospital Research Foundation, Cincinnati, OH, 

8 

Das Deutsch Center Clinic for Special Needs Children, 

Middlefield, OH 

671. Differences in the SLE Clinical Phenotype by Age of 

Diagnosis. T. Clark Powell 1 , Elizabeth E. Brown on behalf 

of PROFILE 1 , Gerald McGwin Jr. 1 , Luis M. Vila 2 , Yesenia 

C. Santiago-Casas 3 , Michelle Petri 4 , Rosalind Ramsey- 

Goldman 5 , John D. Reveille 6 , Sergio Duran 7 , Sergio M.A. 

Toloza 8 , Robin L. Brey 9 , Agustin Escalante 10 , Randy Q. Cron 11 , 

Robert P. Kimberly on behalf of PROFILE investigators 12 and 

Graciela S. Alarcon 1 , 1 University of Alabama at Birmingham, 

Birmingham, AL, 2 University of PuertoRico Medical Sciences 

Campus, San Juan, PR, 3 University of Puerto Rico Medical 

Sciences Campus, San Juan, PR, 4 Johns Hopkins University 

School of Medicine, Baltimore, MD, 5 Northwestern 

University Feinberg School of Medicine, Chicago, IL, 6 Univ 

of Texas Health Science Center at Houston, Houston, TX, 

7 

UIECD, Guadalajara, Mexico, Guadalajara, Mexico, 8 Hospital 

San Juan Bautista, Catamarca, Argentina, 9 UTHSCSA, San 

Antonio, TX, 10 University of Texas Health Science Center 

at San Antonio, San Antonio, TX, 11 Univ of Alabama- 

Birmingham, Birmingham, AL, 12 Department of Medicine, 

University of Alabama at Birmingham, Birmingham, AL 

672. Immune Complexes and Autoantibodies to Oxidized Lipids 

in Systemic Lupus Erythematosus. Yujin Ye, Tianfu Wu and 

Chandra Mohan, University of Texas, Southwestern Medical 

Center at Dallas, Dallas, TX 

673. Altered Soluble Mediators in Individuals with Incomplete 

Lupus (ILE) in the Lupus Autoimmunity in Relatives 

(LAUREL) Study. Melissa E. Munroe 1 , Jill M. Norris 2 , Joel M. 

Guthridge 1 , Diane L. Kamen 3 , Kathy Moser Sivils 1 , Timothy B. 

Niewold 4 , Gary S. Gilkeson 5 , Michael H. Weisman 6 , Mariko 

L. Ishimori 6 , Daniel J. Wallace 6 , David R. Karp 7 , John B. 

Harley 8 and Judith A. James 9 , 1 Oklahoma Medical Research 

Foundation, Oklahoma City, OK, 2 Colorado School of 

Public Health, Aurora, CO, 3 Arthritis & Clinical Immunology 

Program, Oklahoma Medical Research Foundation, 

Charleston, SC, 4 University of Chicago, Chicago, IL, 5 Medical 

University of South Carolina, Charleston, SC, 6 Cedars-Sinai 

Medical Center, Los Angeles, CA, 7 UT Southwestern Medical 

Center, Dallas, TX, 8 Cincinnati Children’s Hospital Medical 


Cincinnati, OH, 9 Oklahoma Medical Research Foundation; 


City, OK 

674. Altered Response to B Cell Receptor (BCR) Crosslinking in 

SLE: Correlation with Genetic Risk Variants Predicted to 

Impact BCR Signaling. Nan-Hua Chang 1 , Timothy Li 1 , Paul R. 

Fortin 2 , Dafna D. Gladman 3 , Carolina Landolt-Marticorena 4 , 

Jorge Sanchez-Guerrero 5 , Murray B. Urowitz 4 and Joan E. 

Wither 3 , 1 Toronto Western Research Institute, University 

Health Network, Toronto, ON, 2 University of Laval, Quebec, 

3 

Toronto Western Research Institute, University of Toronto, 

University Health Network, Toronto, ON, 4 University Health 

Network, University of Toronto, Toronto, ON, 5 Mount Sinai 

Hospital, University Health Network, Toronto, ON 

675. Differential Impairment of Serum Cholesterol Efflux 

Capacity in Patients with Rheumatoid Arthritis and 

Systemic Lupus Erythematosus. Pier Luigi Meroni 1 , Nicoletta 

Ronda 2 , Elda Favari 3 , Orietta Borghi 4 , Francesca Zimetti 3 , 

Mariapia Adorni 5 , Francesca Ingegnoli 6 , Maria Gerosa 7 , 

Claudia Grossi 8 and Franco Bernini 5 , 1 Istituto G. Pini, 

University of Milan, Milano, Italy, 2 Parma, Italy, 3 University 

of Parma, Parma, Italy, 4 University of Milan, Milan, Italy, 5 39- 

02-58318176, Parma, Italy, 6 Rheumatology, Istituto G. Pini, 

University of Milan, Milano, Italy, 7 Division of Rheumatology, 

Istituto Ortopedico Gaetano Pini, Milan, Italy, 8 Lab of 

immunology, IRCCS Istituto Auxologico Italiano, Milano, Italy 

676. A Novel Biomarker: Nucleotide-Binding Oligomerization 

Domain 27 in Systemic Lupus Erythematosus. Annika 

Cutinha 1 , Yangsheng Yu 2 , Kaihong Su 2 , James R. O’Dell 1 , 

Lynell W. Klassen 1 , Amy C. Cannella 1 , Ted R. Mikuls 1 , Alan R. 

Erickson 3 , Gerald F. Moore 1 and Michelene Hearth-Holmes 1 , 

1 

University of Nebraska Medical Center, Omaha, NE, 

2 

Department of Pathology and Microbiology, Omaha, NE, 

3 

UNMC Physicians - Brentwood, LaVista, NE 

677. Antibodies to Oxidized Low Density Lipoprotein or Anti- 

Lipoprotein Lipase May Lead to More Atherosclerotic 

Plaque in a Sub-Set of SLE Patients. Biji T. Kurien 1 , James 

Fesmire 2 , Skyler P. Dillon 3 , Marianne Reichlin 4 , Morris 

Reichlin 5 and Robert H. Scofield 6 , 1 University of Oklahoma 

Health Sciences Center, Arthritis & Clinical Immunology 

Program, Oklahoma Medical Research Foundation; US 

Department of Veterans Affairs Medical Center, Oklahoma 

City, OK, 2 Oklahoma Medical Research Foundation, 

3 




194 

City, OK, 4 Oklahoma Medical Res Fndn, Oklahoma City, 

OK, 5 Oklahoma Medical Research Foun, Oklahoma City, 

OK, 6 Arthritis & Clinical Immunology Program, Oklahoma 

Medical Research Foundation; Department of Medicine, 

University of Oklahoma Health Sciences Center; US 

Department of Veterans Affairs Medical Center, Oklahoma 

City, OK 

678. Estrogen Modulation of ZAS3 Is Mediated Through 

Estrogen Receptor α: An Underlying Mechanism of Gender- 

Bias in Systemic Lupus Erythematosus? Nicholas Young 1 , 

Alexandra Friedman 1 , Lai-Chu Wu 1 and Wael N. Jarjour 2 , 

1 

The Ohio State University Medical Center, Columbus, OH, 

2 

Ohio State University, Columbus, OH 

679. ZAP70+ B Cells and Plasmablasts as Markers of Disease 

Activity and Remission in Systemic LUPUS Erythematosus 

Nephritis. Elisa Gremese, Barbara Tolusso, Laura 

Messuti, Marcin Nowik, Silvia Canestri, Luca Petricca, 

Maria Rita Gigante and Gianfranco Ferraccioli, Division 

of Rheumatology, Institute of Rheumatology and Affine 

Sciences, Catholic University of the Sacred Heart, Rome, 

Italy 

680. Plasma Level of Galectin-3 Binding Protein Reflects Type 

I Interferon Activity and Is Highly Increased in Patients 

with Systemic Lupus Erythematosus. Christoffer T. Nielsen 1 , 

Ole Østergaard 2 , Line V. Iversen 1 , Christian Lood 3 , anders 

A. Bengtsson 4 , Anne Voss 5 , Søren Jacobsen 6 and Niels 

H. H. Heegaard 1 , 1 Statens Serum Institut, Copenhagen 

S, Denmark, 2 Statens Serum Institute, Copenhagen S, 

Denmark, 3 Department of Clinical Sciences Lund, Lund, 

Sweden, 4 Department of Clinical Sciences Lund, Section of 

Rheumatology, Lund, Sweden, 5 Odense University Hospital, 

Odense C, Denmark, 6 Copenhagen University Hospital, 


681. Interferon Alpha Decreases Endothelial Nitric Oxide 

Synthase Function and Expression in Human Umbilical 

Vein Endothelial Cells. Joy Buie and Jim Oates, Medical 

University of South Carolina, Charleston, SC 

682. IL-12p70 Levels Play a Role in Damage Accrual in SLE 

Patients. Eoghan M. McCarthy 1 , Ruth Lee 1 , Joan Ni 

Gabhann 2 , Siobhan Smith 2 , Michele Doran 3 , Gaye Cunnane 3 , 

Donough G. Howard 1 , Paul G. O’Connell 1 , Caroline Jefferies 2 

and Grainne M. Kearns 1 , 1 Beaumont Hospital, Dublin 9 , 

Ireland, 2 Royal College of Surgeons in Ireland, Dublin, 

Ireland, 3 St. James’s Hospital, Dublin, Ireland 

683. Prevalence of Inhibitory or Non-Inhibitory Autoantibodies 

to Angiotensin Converting Enzyme 2 (ACE2) in Patients 

with Systemic Lupus Erythematosus. Yuko Takahashi 1 , Shiori 

Haga 2 , Yukihito Ishizaka 2 and Akio Mimori 1 , 1 National Center 

for Global Health and Medicine, Tokyo, Japan, 2 Research 

Institute, National Center for Global Health and Medicine, 

Tokyo, Japan 

684. Correlation of Signal Transducers and Activators of 

Transcription- 1 and Microrna-146a with Anaemia and 

Other Clinical Features in Systemic Lupus Erythematosus 


Patients. Paul R. Dominguez-Gutierrez, Angela Ceribelli, 

Minoru Satoh, Eric S. Sobel, Yi Li, Westley H. Reeves and 

Edward K.L. Chan, University of Florida, Gainesville, FL 

685. Using a Library of Synthetic Autoantigen Mimics to 

Discover Biomarkers of Systemic Lupus Erythematosus. 

Akshai Lakhanpal 1 , Jiexia Quan 1 , Sayed Zaman 1 , Nancy 

J. Olsen 2 and David R. Karp 1 , 1 UT Southwestern Medical 

Center, Dallas, TX, 2 Penn State MS Hershey Medical Center, 

Hershey, PA 

686. Cell-Type Specific Type I Interferon Signatures in 

Autologous Stem Cell Transplanted Lupus Patients: 

Different Molecular Behavior between CD4+ T Cells and 

Monocytes. Chieko Kyogoku 1 , Joachim R. Grün 1 , Tobias 

Alexander 2 , Robert Biesen 2 , Falk Hiepe 2 , Thomas Häupl 2 , 

Andreas Radbruch 1 and Andreas Grützkau 1 , 1 German 

Rheumatism Research Centre Berlin (DRFZ), an institute of 

the Leibniz Association, Berlin, Germany, 2 Charité University 

Hospital Berlin, Berlin, Germany 

687. Gammadelta T Cells and Their Intracellular Cytokine 

Profile in Peripheral Blood of Patients with Systemic 

Lupus Erythematosus. Lingyun Sun, Xia Li and Zhimin 

Lu, Department of Rheumatology and Immunology, the 

Affiliated Drum Tower Hospital of Nanjing University 

Medical School, Nanjing, China 

688. Expression of the Mer Receptor Tyrosine Kinase on 

Peripheral Blood Mononuclear Cells from Systemic Lupus 

Erythematosus Patients. Brendan A. Hilliard 1 , Gaetano 

Zizzo 1 , Margaret K. Linan 1 and Philip L. Cohen 2 , 1 Temple 

University School of Medicine, Philadelphia, PA, 2 Temple 

University, Philadelphia, PA 

689. Activation of the Interferon Pathway Is Dependent Upon 

Autoantibodies in African-American SLE Patients, but 

Not in European-American SLE Patients. Kichul Ko, Yelena 

Koldobskaya, Elizabeth Rosenzweig and Timothy B. Niewold, 

University of Chicago, Chicago, IL 

690. Molecular Analysis of 9G4+ Antibodies in Systemic Lupus 

Erythematosus. Christopher Richardson 1 , Asiya Seema 

Chida 2 , Erin Fox 1 , Lin Silver 1 , Diana G. Adlowitz 1 , Scott 

Jenks 2 , Elise Palmer 1 , Christopher Tipton 2 and Ignacio Sanz 2 , 

1 

University of Rochester, Rochester, NY, 2 Emory University, 

Atlanta, GA 

691. Characterization of Pro-Inflammatory Cytokines and 

Vitamin D Levels in a Lupus Cohort and Correlation with 

Disease Activity. Rohan Willis 1 , Praveen Jajoria 1 , Brock 

E. Harper 1 , Emilio B. Gonzalez 1 , Michelle Petri 2 , Ehtisham 

Akhter 2 , Hong Fang 2 and Silvia S. Pierangeli 1 , 1 University 

of Texas Medical Branch, Galveston, TX, 2 Johns Hopkins 

University School of Medicine, Baltimore, MD 



692. A Phase 1 Multicenter, Open-Label Study of MEDI-546, 

a Human Anti-Type I Interferon Receptor Monoclonal 

Antibody, in Adults with Scleroderma. Avram Z. Goldberg 1 ,


Thomas D. Geppert 2 , Elena Schiopu 3 , Tracy M. Frech 4 , 

Vivien M. Hsu 5 , Robert W. Simms 6 , Stanford L. Peng 7 , Yihong 

Yao 8 , Nairouz Elgeioushi 8 , Bing Wang 9 , Linda Chang 9 and 

Stephen Yoo 8 , 1 North Shore-LIJ Health System, Lake Success, 

NY, 2 Metroplex Clinical Research Center, LLC, Dallas, TX, 

3 

University of Michigan, Ann Arbor, MI, 4 University of Utah 

School of Medicine, SLC, UT, 5 RWJ Med Schl Scleroderma 

Prog, New Brunswick, NJ, 6 Boston University School of 

Medicine, Boston, MA, 7 Benaroya Research Institute at 

Virginia Mason Medical Center, Seattle, WA, 8 MedImmune, 

Gaithersburg, MD, 9 MedImmune, Hayward, CA 

693. A Placebo-Controlled Phase II Study of Hyperimmune 

Caprine Serum in Diffuse Cutaneous Systemic Sclerosis: 

Safety and Potential Efficacy. Niamh P. Quillinan 1 , 

Deirdre McIntosh 2 , Syed Haq 2 and Christopher P. Denton 3 , 

1 

UCL Medical School, London, United Kingdom, 2 Daval 

International Ltd, Eastbourne, East Sussex, United Kingdom, 

3 

UCL, London, United Kingdom 

694. Nilotinib (Tasigna) in the Treatment of Early Diffuse 

Systemic Sclerosis: A Single Group, Open Label Pilot 

Clinical Trial. Jessica K. Gordon 1 , Morgana L. Davids 1 , Kamini 

Doobay 1 , Cynthia Magro 2 , Horatio F. Wildman 3 , Stephen L. 

Lyman 1 , Mary K. Crow 1 and Robert F. Spiera 1 , 1 Hospital for 

Special Surgery, New York, NY, 2 Weill-Cornell Medical Center, 

New York, NY, 3 Weill-Cornell Medical Center, New York 

695. Comparison of Intense Pulsed Light and Laser Treatment 

of Telangiectases in Systemic Sclerosis. Graham Dinsdale 1 , 

Andrea Murray 1 , Tonia Moore 1 , Janice E. Ferguson 2 , Holly 

Ennis 1 , Christopher E.M Griffiths 3 and Ariane Herrick 4 , 

1 

School of Translational Medicine, University of Manchester, 

Manchester Academic Health Science Centre, Salford 

Royal NHS Foundation Trust, Manchester, United Kingdom, 

2 

Dermatology Centre, Salford Royal NHS Foundation 

Trust, Manchester, United Kingdom, 3 Dermatology Centre, 

University of Manchester, Manchester Academic Health 

Science Centre, Salford Royal NHS Foundation Trust, 


Salford, United Kingdom 

696. Risk Factors for EARLY Mortality in Scleroderma Patients: 

A Report From the EULAR Scleroderma Trials and Research 

Group (EUSTAR) Database. Patricia E. Carreira 1 , Loreto 

Carmona 2 , Beatriz E. Joven 3 , Christopher P. Denton 4 , Yannick 

Allanore 5 , Ulrich A. Walker 6 , Marco Matucci-Cerinic 7 , Ulf 

Müller-Ladner 8 and Eustar 9 , 1 Hospital Universitario 12 de 

Octubre, Madrid, Spain, 2 Universidad Camilo José Cela, 

Villanueva de la Cañada, Spain, 3 HOSPITAL UNIVERSITARIO 

12 DE OCTUBRE, Madrid, Spain, 4 UCL, London, United 

Kingdom, 5 Paris Descartes University, Rheumatology A 

department, Cochin Hospital, Paris, France, 6 Universitäts- 

Poliklinik, Felix-Platter Spital, Basel, Switzerland, 7 University 

of Florence, Florence, Italy, 8 Kerckhoff-Klinik GmbH, Bad 

Nauheim, Germany, 9 Florence 

697. Demographic, Clinical, Serologic and Socioeconomic 

Measures Each Predict Mortality in Scleroderma. Allan C. 

Gelber, Rebecca L. Manno, Adrianne Woods, Ami A. Shah, 

Francesco Boin, Laura K. Hummers and Fredrick M. Wigley, 

Johns Hopkins University, Baltimore, MD 

698. External Validation of a Two-Year Mortality Risk Prediction 

Rule in Early Diffuse Systemic Sclerosis Patients. Robyn 

T. Domsic 1 , Svetlana Nihtyanova 2 , Stephen R. Wisniewski 3 , 

Michael J. Fine 4 , C. Kent Kwoh 5 , Christopher P. Denton 6 

and Thomas A. Medsger Jr. 7 , 1 University of Pittsburgh, 

Pittsburgh, PA, 2 Royal Free Hospital, Medical School, 

London, England, 3 University of Pittsburgh, Graduate School 

of Public Health, Pittsburgh, PA, 4 University of Pittsburgh 

and Center for Health Equity Research and Promotion, VA 

Pittsburgh Healthcare, Pittsburgh, 5 University of Pittsburgh 

and VA Healthcare System, Pittsburgh, PA, 6 UCL, London, 

United Kingdom, 7 Univ of Pittsburgh, Pittsburgh, PA 

699. Endothelial Dysfunction and Vascular Stiffness in Early 

Diffuse Systemic Sclerosis. Robyn T. Domsic 1 , Dana Ivanco 1 , 

Hunter C. Champion 1 , Ali Shoushtari 1 and Thomas A. 

Medsger Jr. 2 , 1 University of Pittsburgh, Pittsburgh, PA, 2 Univ 

of Pittsburgh, Pittsburgh, PA 

700. Clinical Correlation of Flow-Mediated Endothelium- 

Dependent Vasodilatation in Systemic Sclerosis. Takehiro 

Takahashi 1 , Yoshihide Asano 1 , Eisuke Amiya 2 , Masaru 

Hatano 2 , Atsuko Ozeki 2 , Aya Watanabe 2 , Shuichi Kawarasaki 2 , 

Tomoko Nakao 2 , Zenshiro Tamaki 1 , Takashi Taniguchi 1 , Yohei 

Ichimura 1 , Tetsuo Toyama 1 , Masafumi Watanabe 2 , Yasunobu 

Hirata 2 , Ryozo Nagai 2 and Shinichi Sato 1 , 1 Department 

of Dermatology, University of Tokyo Graduate School of 

Medicine, Tokyo, Japan, 2 Department of Cardiovascular 

Medicine, University of Tokyo Graduate School of Medicine, 

Tokyo, Japan 

701. Vascular Differences Associated to Genetic Polymorphisms 

of Endothelial Nitric Oxide Synthase in Mexican Patients 

with Systemic Sclerosis. A Preliminary Report. Maria Pilar 

Cruz-Dominguez 1 , Maria Angeles Martinez-Godinez 2 , Angel 

Miliar-Garcia 2 , Daniel Hector Montes-Cortes 3 , Olga Vera- 

Lastra 4 , Luis J. Jara-Quezada 5 and Anabel Reyes-Salazar 6 , 

1 

Hospital de Especialidades Centro Medico Nacional La 

Raza., Mexico, DF, Mexico, 2 Escuela Superior de Medicina. 

IPN,, Mexico, D.F., Mexico, 3 Hospital General CMN La 

Raza, IMSS, Mexico DF, Mexico, 4 MD, Mexico City, Mexico, 

5 

Hospital de Especialidades Centro Médico La Raza, IMSS, 

Mexico City, Mexico, 6 Hospital de especialidades Centro 

Medico National “La Raza”, IMSS, Mexico, D.F., Mexico 

702. Arterial Stiffness Is Increased in Systemic Sclerosis: A 

Cross-Sectional Comparison with Matched Controls. 

Gene-Siew Ngian 1 , Joanne Sahhar 2 , Ian Wicks 3 and Sharon 

Van Doornum 4 , 1 The University of Melbourne, Parkville, 

Australia, 2 Monash Medical Centre, Clayton, Australia, 3 Royal 

Melbourne Hospital, Parkville, Australia, 4 The University 

of Melbourne, The Royal Melbourne Hospital, Melbourne, 

Australia 



703. Vascular Ischemic Events in Systemic Sclerosis - A Cross- 

Sectional Comparision with Population-based Controls. 

Annica Nordin 1 , Kerstin Jensen-Urstad 2 , Lena Björnådal 1 

and Elisabet Svenungsson 1 , 1Rheumatology Unit, Karolinska 

Institutet, Stockholm, Sweden, 2 Department of Clinical 

Physiology, Södersjukhuset, Karolinska Institutet, Stockholm, 

Sweden 

704. Decreased Number of Endothelial Progenitor Cells in 

Systemic Sclerosis Patients with Early Disease. Fernando 

V. andrigueti, Maria I. Arismendi, Pâmela C.C. Ebbing and 

Cristiane Kayser, Universidade Federal de São Paulo, São 

Paulo, Brazil 

705. Adipose Derived Stem Cells As an Alternative Source 

of Cellular Repair for Vascular Dysfunction in Systemic 

Sclerosis. Nevin Hammam 1 and Hazem Orabi 2 , 1 Assiut 

University, Assiut, Egypt, 2 Knuppe Molecular Laboratory, San 

Francisco, CA 

706. Excess Mortality From Atherosclerotic Cardiovascular 

Disease in Systemic Sclerosis Compared to Lupus and 

Rheumatoid Arthritis. Amish J. Dave 1 , Bharathi Lingala 2 , 

David Fiorentino 3 , Eswar Krishnan 4 and Lorinda Chung 5 , 

1 

Stanford University, Stanford, CA, 2 Stanford University, 

Redwood City, CA, 3 Stanford University School of Medicine, 

Redwood City, CA, 4 Standford University, Palo Alto, CA, 

5 

Stanford Univ Medical Center, Palo Alto, CA 

707. Risk of Cancer in Systemic Sclerosis: Meta-Analysis of 

Population-Based Cohort Studies. Akira Onishi 1 , Daisuke 

Sugiyama 2 , Akio Morinobu 1 and Shunichi Kumagai 3 , 1 Kobe 

University Graduate School of Medicine, Kobe, Japan, 

2 

School of Medicine, Keio University, Tokyo, Japan, 3 Shinko 

Hospital, Kobe, Japan 

708. Histological Features of Localized Scleroderma’en Coup De 

Sabre’: A Study of 16 Cases. Takashi Taniguchi, Yoshihide 

Asano, Zenshiro Tamaki, Kaname Akamata, Naohiko Aozasa, 

Shinji Noda, Takehiro Takahashi, Yohei Ichimura, Tetsuo 

Toyama, Miki Sugita, Hayakazu Sumida, Yoshihiro Kuwano, 

Miki Miyazaki, Koichi Yanaba and Shinichi Sato, University of 

Tokyo Graduate School of Medicine, Tokyo, Japan 

709. Fingertip Skin Hardness in Limited Scleroderma: Durometry 

versus Manual Assessment. Thomas Osborn 1 , Eric 

Matteson 1 , Floranne Ernste 2 , Cynthia S. Crowson 1 , Deana 

D. Hoganson 3 and Irene Z. Whitt 4 , 1 Mayo Clinic, Rochester, 

MN, 2 Mayo Clinic Rochester, Rochester, MN, 3 Mercy Arthritis 

and Osteoporosis Center, Urbandale, IA, 4 NIH/NIEHS/ 

Environmental Autoimmunity Group, Bethesda, MD 

710. Optical Density Measure of the Papillary Dermis 

Discriminates As Abnormal Clinically Uninvolved Skin 

in Systemic Sclerosis and Correlates with Severity of 

Skin Thickness. Giuseppina Abignano 1 , Sibel Z. Aydin 2 , 

Concepcion Castillo-Gallego Jr. 3 , Daniel Woods 4 , Adam 

Meekings 4 , Dennis McGonagle 1 , Paul Emery 1 and Francesco 

Del Galdo 1 , 1 University of Leeds, Leeds Institute of Molecular 

Medicine and LMBRU, Leeds, United Kingdom, 2 Medeniyet 

University, Goztepe Training and Research Hospital, Istanbul, 

Turkey, 3 Hospital Universitario La Paz, Madrid, Spain, 

4 

Michelson Diagnostics Ltd, Kent, United Kingdom, Kent, 


711. Myopathy Is a Poor Prognostic Feature in Systemic 

Sclerosis: Results From the Canadian Scleroderma Research 

Group. MIchelle Jung 1 , Murray Baron 2 , Marie Hudson 3 , 

Ashley Bonner 4 , Janet E. Pope 5 and Canadian Scleroderma 

Research Group 6 , 1 Western University, London, ON, 

2 

Jewish General Hospital, Montreal, QC, 3 McGill University, 

Montreal, QC, 4 McMaster University, Hamilton, ON, 5 St. 

Joseph Health Care London, University of Western Ontario, 

London, ON, 6 Montreal, QC 

712. Autoantibodies to Survival of Motor Neuron (SMN) 

Complex Are Common in Patients with Anti-U1RNP/Sm 

and Are Associated with Features of Scleroderma and 

Myopathy. Jason YF Chan, Yi Li, Angela Ceribelli, Eric S. 

Sobel, Westley H. Reeves, Edward K.L. Chan and Minoru 

Satoh, University of Florida, Gainesville, FL 

713. Rpp25 Is a Major Target of Autoantibodies to the 

Th/to Complex As Measured by ELISA and a New 

Chemilumiscence Assay. Michael Mahler 1 , Cristina Gascon 1 , 

Sima Patel 1 , Angela Ceribelli 2 , Edward K.L. Chan 2 and Minoru 

Satoh 2 , 1 INOVA Diagnostics, Inc., San Diego, CA, 2 University 


714. Line Blot Assay, a Screening Test for Autoantibodies 

in Systemic Sclerosis (SSc). Kae Takagi 1 , Yasushi 

Kawaguchi 1 , Sayuri Kataoka 2 , Yuko Ota 3 , Yuko Okamoto 2 , 

Masanori Hanaoka 1 , Hisae Ichida 1 , Takahisa Gono 1 , 

Yasuhiro Katsumata 2 and Hisashi Yamanaka 1 , 1 Institute 

of Rheumatology, Tokyo Women’s Medical University, 

Tokyo, Japan, 2 Tokyo Women’s Medical University, Tokyo, 

Japan, 3 Institute of Rheumatology,Tokyo Women’s Medical 



716. Utility of Novel Patient-Reported Outcome Instruments 

in Predicting Cardiac Involvement and Pulmonary 

Hypertension in Patients with Systemic Sclerosis. Monique 

E. Hinchcliff, Mary A. Carns, Sofia Podlusky, John Varga and 

Sanjiv J. Shah, Northwestern University Feinberg School of 

Medicine, Chicago, IL 

717. Results From a Multi-Tiered Item Collection On Linking 

Systemic Sclerosis to the International Classification of 

Functioning, Disability and Health: A EULAR Scleroderma 

Trials and Research Initiative. Lesley Ann Saketkoo 1 , Reuben 

Escorpizo 2 , Kevin J. Keen 3 , Kim Fligelstone 4 and Oliver 

Distler 5 , 1 Louisiana State University Health Science Center, 

New Orleans, LA, 2 ICF Research Branch in cooperation 

with the WHO Collaborating Centre for the Family of 

International Classifications Department of Health Sciences; 

and Health Policy, University of Lucerne, Switzerland, 

3 

University of Northern British Columbia, Prince George, 

BC, 4 Royal Free Hospital, Scleroderma Unit and Scleroderma 

196 

2012 Program Book


Society, London, United Kingdom, 5 Department of 

Rheumatology and Center of Experimental Rheumatology, 


718. Worsening Carbon Monoxide Diffusing Capacity Predicts 

Mortality in Patient with Systemic Sclerosis and Pulmonary 

Arterial Hypertension Enrolled in the Pulmonary 

Hypertension Assessment and Recognition of Outcomes 

in Scleroderma Registry. Elena Schiopu 1 , Dinesh Khanna 1 , 

Virginia D. Steen 2 and PHAROS Investigators 3 , 1 University of 

Michigan, Ann Arbor, MI, 2 Georgetown Univ Medical Center, 

Washington, DC, 3 Washington DC 

719. Biomarkers of Pulmonary Hypertension in Patients 

with Scleroderma: A Case-Control Study. Zsuzsanna H. 

McMahan 1 , Florian Schoenhoff 2 , Jennifer van Eyk 1 , Fredrick 

M. Wigley 1 and Laura K. Hummers 1 , 1 Johns Hopkins 

University, Baltimore, MD, 2 Berne, Switzerland 

720. Left-Heart Disease Is a Frequent Cause of Pulmonary 

Hypertension in Systemic Sclerosis, Is Associated with 

Increased Levels of MR-ProANP and MR-ProADM but Is 

Unrelated to Elevated NT-ProBNP Levels: A Retrospective 

Cohort Analysis. Lada Miller 1 , Sandra Chartrand 1 , 

Martial Koenig 2 , Jean-Richard Goulet 2 , Eric Rich 1 , Michal 

Abrahamowicz 3 , Jean-Luc Senécal 1 and Tamara Grodzicky 1 , 

1 

Hôpital Notre-Dame du CHUM, Montreal, QC, 2 Hôpital 

Notre-Dame du CHUM, Montréal, QC, 3 Centre Universitaire 

de Santé McGill (CUSM), Montreal, QC 

721. Measurement of Pulmonary Arteries by Cardiac Magnetic 

Resonance Imaging: A Simple and Useful Tool for the 

Detection of Pulmonary Hypertension in Systemic Sclerosis 

Patients without Overt Cardiac Microvascular Perfusion 

Defects or Fibrosis. Sandra Chartrand 1 , Lada Miller 1 , Martial 

Koenig 1 , Jean-Richard Goulet 1 , Eric Rich 1 , Anne S. Chin 2 , Yves 

Provost 2 , Carl Chartrand-Lefebvre 2 , Pauline Gou 1 , Jean-Luc 

Senécal 1 and Tamara Grodzicky 1 , 1 Hôpital Notre-Dame du 

CHUM, Montréal, QC, 2 Hôtel-Dieu de Montréal du CHUM, 

Montréal, QC 

722. Systemic Sclerosis Associated Pulmonary Hypertension - Is 

Pulmonary Veno-Occlusive Disease As Common As They 

Say? Benjamin E. Schreiber 1 , Greg Keir 2 , D. Dobarro 3 , Clive 

Handler 1 , Svetlana Nihtyanova 4 , Jay Suntharaligam 5 , Nicola 

Sverzelatti 6 , Graham Robinson 5 , David Hansell 7 , Athol U. 

Wells 2 , Christopher P. Denton 8 and John G. Coghlan 1 , 1 Royal 

Free Hospital, London, London, United Kingdom, 2 Royal 

Brompton Hospital, United Kingdom, 3 Royal Free Hospital, 

London, United Kingdom, 4 Royal Free Hospital, Medical 

School, London, England, 5 Royal United Hospital, Bath, 

United Kingdom, 6 University of Parma, Parma, Italy, 7 Royal 

Brompton Hospital, London, United Kingdom, 8 UCL, London, 


723. Renal Dysfunction and Disease Severity in Scleroderma- 

Associated Pulmonary Arterial Hypertension. Stephen C. 

Mathai 1 , Laura K. Hummers 1 and Virginia D. Steen 2 , 1 Johns 

Hopkins University, Baltimore, MD, 2 Georgetown Univ 

Medical Center, Washington, DC 

724. Survival, Hospitalization or Need for Combination Therapy 

at One Year in Patients with Scleroderma-Associated 

Pulmonary Arterial Hypertension. Robyn T. Domsic 1 , 

Lorinda Chung 2 , Jessica K. Gordon 3 , Yona Cloonan 1 , Virginia 

D. Steen 4 and PHAROS Investigators 5 , 1 University of 

Pittsburgh, Pittsburgh, PA, 2 Stanford Univ Medical Center, 

Palo Alto, CA, 3 Hospital for Special Surgery, New York, 

NY, 4 Georgetown Univ Medical Center, Washington, DC, 

5 



ACR POSTER SESSION B 

Monday, NOVEMBER 12, 2012 



872. Monocyte Chemoattractant Protein- 1 and Eotaxin Are 

Associated with Parameters of Cardiac Dysfunction 

in Juvenile Dermatomyositis. Thomas Schwartz 1 , Ivar 

Sjaastad 2 , Berit Flatø 1 , Maria Vistnes 1 , Geir Christensen 1 and 

Helga Sanner 1 , 1 Institute for Clinical Medicine, University 

of Oslo, Oslo, Norway, 2 Institute for Experimental Medical 

Research, Oslo University Hospital, Oslo, Norway 

873. Imbalance between Histone Acetyl Transferase and 

Histone Deacteylase Activities and Modulation of HDAC 

Activity and Tnfa Production by HDAC Inhibitors in Patients 

with Ankylosing Spondylitis or Rheumatoid Arthritis. 

Eric Toussirot 1 , Wasim Abbas 2 , Kashif Aziz Khan 3 , Marion 

Tissot 2 , Alicia Jeudy 2 , Lucile Baud 2 , Ewa Bertolini 4 , Daniel 

Wendling 5 , Georges Herbein 6 and CIC Biotherapy 7 , 1 CIC 

Biotherapy 50 6 and Rheumatology and EA 4266 Pathogens 

and Inflammation, Besançon, France, 2 EA 4266 Pathogens 

and Inflammation, Besançon, France, 3 EA Pathogens and 

Inflammation, Besançon, France, 4 Rheumatology, Besançon, 

France, 5 Minjoz University Hospital, Besancon, France, 

6 

Virology and EA 4266 Pathogens and Inflamamtion, 

Besançon, France, 7 University Hospital, Besançon, France 

874. TNFα Induces Sustained Signaling and a Prolonged 

and Unremitting Inflammatory Response in Synovial 

Fibroblasts. Angela Lee, Galina Grigoriev, Janice Chen, Lionel 

B. Ivashkiv and George D. Kalliolias, Hospital for Special 

Surgery, New York, NY 

875. Discovery of Pharmacologic MIF Antagonists by Structure- 

Based Molecular Design. William L. Jorgensen 1 , Alissa A. 

Hare 1 , Zoe Cournia 1 , Sunilkumar Gandavadi 1 , Xin Du 1 , Lin 

Leng 1 and Richard J. Bucala 2 , 1 Yale University, New Haven, 

CT, 2 Yale University School of Med, New Haven, CT 

876. Xanthine Oxidase-Derived ROS Direct Context-Dependent 

Action of NFAT5 Toward Inflammatory Response in 

Macrophages. Nam Hoon Kim, Catholic university of Korea, 

Seoul of Korea, Seoul, South Korea 

877. Aberrant Expression of BAFF Receptor (BR3) in Peripheral 

Monocytes of Patients with Primary Sjögren’s Syndrome 

Impacts Abnormal Activation of BAFF Signaling Through 

IKK-Alphaand IKK-Beta. Keiko Yoshimoto 1 , Maiko Tanaka 1 , 

Masako Kojima 1 , Hideko Ogata 1 , Hideto Kameda 1 , Katsuya 

Suzuki 1 , Tohru Abe 2 and Tsutomu Takeuchi 1 , 1 Keio University 

School of Medicine, Tokyo, Japan, 2 Saitama Medical School, 

Kawagoe-shi Saitama, Japan 

878. Differential Regulation of Cytokines by Extracellular- 

Signal Regulated Kinase and c-Jun N-Terminal Kinase in 

Map Kinase Kinase- 3 and -6 Deficiency. Deepa Hammaker, 

Katharyn Topolewski, Monica Guma, David L. Boyle and Gary 

S. Firestein, UCSD School of Medicine, La Jolla, CA 

879. Fucosyltransferase 1 (fut1) is Overexpressed in Rheumatoid 

Arthritis Synovial Tissue and Modifies Cytokine Production. 

Takeo Isozaki 1 , Jeffrey H. Ruth 1 , M. Asif Amin 1 , Phillip L. 

Campbell 1 , Steven E. Domino 1 , G. Kenneth Haines III 2 and 

Alisa E. Koch 3 , 1 University of Michigan, Ann Arbor, MI, 2 Yale 

University, New Haven, CT, 3 University of Michigan Medical 

School, Ann Arbor, MI 

880. Interferon Regulatory Factor 8 Regulates BAFF Production 

in Murine Macrophages and Is a Nexus for Cross Talk 

Between IFN-γ and TGF-β. Weijia Yuan, Sanjay Gupta, Jane 

E. Salmon and Alessandra B. Pernis, Hospital for Special 

Surgery, Weill Cornell Medical College, New York, NY 

881. Microrna-155 Regulates Chemokines and Chemokine 

Receptors in Rheumatoid Arthritis Monocyte. Aziza 

Elmesmari, Derek S. Gilchrist, Alasdair R. Fraser, Diane 

Vaughan, Ross McQueenie, Gerard J. Graham, James 

Brewer, Iain B. McInnes and Mariola Kurowska-Stolarska, 

Institute of Infection,Immunity and Inflammation, College of 

Medical, Veterinary and Life Sciences, University of Glasgow, 

Glasgow, United Kingdom 

882. Anti-Inflammatory Effects of Phosphodiesterase 4 

Inhibition Are Mediated by Mitogen-Activated Protein 

Kinase Phosphatase-1. Riku Korhonen, Tuija Hömmö, 

Mirka Laavola, Tiina Keränen, Mari Hämäläinen and Eeva 

Moilanen, University of Tampere School of Medicine and 

Tampere University Hospital, Tampere, Finland 

883. Role of Phospholipase D1 (PLD1) in the Expression of 

Proinflammatory Genes in Rheumatoid Arthritis Synovial 

Fibroblasts (RASF). Sean C. Friday 1 and David A. Fox 2 , 1 The 

University of Michigan, Ann Arbor, MI, 2 Univ of Michigan 

Med Ctr, Ann Arbor, MI 

884. Receptor Activator of Nuclear Factor ÊB Ligand-Mediated 

Osteoclastogenesis Is Augmented by Interleukin-1â via 

up-Regulation of Endoplasmic Reticulum Stress Signals. 

Myong-Joo Hong 1 , Myung-Soon Sung 1 , Eun-Gyeong Lee 1 , 

Yoon Kyung Hong 1 , Chang-Hoon Lee 2 , Myeung Su Lee 3 and 

Wan-Hee Yoo 1 , 1 Department of Internal Medicine, Chonbuk 

National University Medical School and Research Institute 

of Clinical Medicine, Jeonju, South Korea, 2 Department 

of Internal Medicine, School of medicine, Wonkwang 

university, Iksan, Chonbuk, South Korea, 3 Reumatology, 

Iksan, Chonbuk, South Korea 

885. Interferon α and Self-Organized Criticality Theory. Shunichi 

Shiozawa 1 , Yumi Miyazaki 2 and Ken Tsumiyama 1 , 1 Kyushu 

University Beppu Hospital, Beppu, Japan, 2 Kyushu University 

Beppu Hospital/ Kobe University Graduate School of Health 

Sciences, Beppu/ Kobe, Japan 

886. Association between Neutrophil Gene Signature and 

Disease Characteristics in Systemic Lupus Erythematosus 

Patients. Michelle Petri 1 , Hong Fang 1 , Jadwiga Bienkowska 2 , 

Norm Allaire 2 , Jeff Browning 2 and Susan Kalled 2 , 1 Johns 

Hopkins University School of Medicine, Baltimore, MD, 

2 

Biogen Idec Inc., Cambridge, MA 

198 

2012 Program Book



888. Plasma Cells Express the Novel Cytokine Interleukin-36α in 

Psoriatic and Rheumatoid Arthritis Synovium. Anja Derer 1 , 

Silke Frey 1 , Maria-Elena Messbacher 1 , Serena Bugatti 2 , D. 

Baeten 3 , Carlomaurizio Montecucco 4 , Georg A. Schett 5 and 

Axel J. Hueber 1 , 1 University of Erlangen, Erlangen, Germany, 

2 

Division of Rheumatology, University of Pavia School of 

Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, 

Italy, 3 Academic Medical Center, University of Amsterdam, 

Amsterdam, Netherlands, 4 University of Pavia School of 


Italy, 5 Department of Internal Medicine III and Institute for 

Clinical Immunology, University of Erlangen-Nuremberg, 

Erlangen, Germany 

889. Modeling Environmental and Genetic Determinants 

to Identify the Association of Risk Genes in Anti-Ro60- 

Mediated Injury: Relaxin Receptor I and Tumor Necrosis 

Factor. Joanne H. Reed 1 , Paula S. Ramos 2 , Jiri Zavadil 1 , Jill P. 

Buyon 1 and Robert M. Clancy 1 , 1 New York University School 

of Medicine, New York, NY, 2 Medical University of South 

Carolina, Charleston, SC 

890. The Role of Adipocytokines in Osteophyte Formation 

in Osteoarthritis. Susann Junker 1 , Grit Krumbholz 1 , Klaus 

Frommer 1 , Angela Lehr 2 , Stefan Rehart 2 , Jürgen Steinmeyer 3 , 

Markus Rickert 4 , Georg A. Schett 5 , Ulf Müller-Ladner 1 and 

Elena Neumann 6 , 1 Justus-Liebig-University of Giessen, 

Kerckhoff-Klinik, Bad Nauheim, Germany, 2 Markus-Hospital, 

Frankfurt, Germany, 3 University Hospital Gießen and 

Marburg, Gießen, Germany, 4 University Hospital Giessen 

and Marburg, Giessen, Germany, 5 Department of Internal 

Medicine III and Institute for Clinical Immunology, University 

of Erlangen-Nuremberg, Erlangen, Germany, 6 Justus- 

Liebig-University of Gießen, Kerckhoff-Klinik, Bad Nauheim, 

Germany 

891. Fatty Acids Promote Secretion of Proinflammatory and 

Prodestructive Factors by Synovial Fibroblasts. Klaus W. 

Frommer 1 , Andreas Schäffler 2 , Stefan Rehart 3 , Angela Lehr 3 , 

Ulf Müller-Ladner 1 and Elena Neumann 1 , 1 Justus-Liebig- 

University of Gießen, Bad Nauheim, Germany, 2 University 

of Regensburg, Regensburg, Germany, 3 Markus-Hospital, 

Frankfurt, Germany 

892. The Epigenetically Repressed Long Noncoding RNA Hotair 

Influences the Expression of Matrix Metalloproteases in 

Synovial Fibroblasts. Michelle Trenkmann 1 , Matthias Brock 2 , 

Renate E. Gay 1 , Beat A. Michel 3 , Lars C. Huber 2 and Steffen 

Gay 1 , 1 Center of Experimental Rheumatology, University 

Hospital Zurich, Zurich, Switzerland, 2 Department of Internal 

Medicine, University Hospital Zurich, Zurich, Switzerland, 

3 

Department of Rheumatology, University Hospital Zurich, 

Zurich, Switzerland 

893. Nuclear Factor-κB Activation by Type II Collagen Peptide in 

Osteoarthritic Chondrocytes: Its Inhibition by Hyaluronan 

Via CD44. Tadashi Yasuda, Tenri University, Tenri, Japan 

894. Genetic Variants in the IL- 4 and IL-4 Receptor Genes 

in Association with the Severity of Joint Damage in 

Rheumatoid Arthritis: A Study in Seven Cohorts. A. 

Krabben 1 , A. G. Wilson 2 , R. Knevel 1 , A. Zhernakova 3 , E. 

Brouwer 3 , E. Lindqvist 4 , T. Saxne 4 , G. Stoeken-Rijsbergen 1 , 

J. A. B. van Nies 1 , D. P. C. de Rooy 1 , T.W.J. Huizinga 1 , B. P. 

C. Koeleman 5 , R. E. M. Toes 1 , P. K. Gregersen 6 and A. H. M. 

van der Helm-van Mil 1 , 1 Leiden University Medical Center, 

Leiden, Netherlands, 2 University of Sheffield, Sheffield, 

United Kingdom, 3 University of Groningen, University 

Medical Center, Groningen, Netherlands, 4 Lund University, 

Lund, Sweden, 5 University Medical Center Utrecht, Utrecht, 

Netherlands, 6 Feinstein Institute Medical Research and 

North Shore-Long Island Jewish Health System, Manhasset, 

NY 

895. Transcriptomics of Synovial Tissue of Early Human (CHECK) 

and Experimental OA Identify Pathways Associated with 

Cartilage Damage. Arjen B. Blom 1 , Peter L.E.M. van Lent 1 , 

Martijn H. van den Bosch 1 , Hans Cats 2 , Peter M. van der 

Kraan 1 and Wim B. van den Berg 3 , 1 Radboud University 

Nijmegen Medical Centre, Nijmegen, Netherlands, 2 Sint 

Maartenskliniek, Nijmegen, Netherlands, 3 Rheumatology 

Research and Advanced Therapeutics, Department of 

Rheumatology, Radboud University Nijmegen Medical 

Centre, Nijmegen, Netherlands 

896. Tyro 3 , Axl, MerTK-Receptor Activation by Gas6 or Pros1 

Gene Delivery, ameliorates Collagen-induced arthritis. Fons 

A.J. van de Loo 1 , Ben T. van Den Brand 1 , Shahla Abdollahi- 

Roodsaz 1 , Eline A. Vermeij 2 , Miranda B. Bennink 2 , Onno 

J. Arntz 2 and Wim B. van den Berg 1 , 1 Radboud University 

Nijmegen Medical Centre, Nijmegen, Netherlands, 

2 

Nijmegen, Netherlands 

897. IL-33 Promotes Mast Cell Survivial Via Inhibition of 

Apoptosis Associated with Enhanced Expression of Bcl-XL. 

Shinjiro Kaieda 1 , Jun-Xia Wang 1 and Peter A. Nigrovic 2 , 

1 


Boston, MA, 2 Brigham and Women’s Hospital, Boston, MA 

898. Nuclear Receptor Related 1 Induces Synovial Hyperplasia 

via Transcriptional Regulation of Novel Target Genes. 

Kimberlee S. Mix, Loyola University New Orleans, New 

Orleans, LA 

899. A Role for Soluble Interleukin-6 Receptor as an Antagonist 

of Interleukin-27 Signaling. Misato Hashizume, Keiko Esaki 

and Yoshihiro Matsumoto, Chugai Pharmaceutical Co., Ltd., 

Gotemba, Japan 

900. Deletion of RBP-J in a Murine Model of Inflammatory 

Arthritis Reveals Differential Pro-Inflammatory Cytokine 

and FoxP3 Gene Expression. Soumya D. Chakravarty, 

Karmen Au, Xiaoyu Hu and Lionel B. Ivashkiv, Hospital for 

Special Surgery, New York, NY 

901. Colony-Stimulating Factor (CSF) Receptor 1 Blockade 

Overcomes Overlapping Effects of M-CSF and 

Interleukin-34 On Myeloid Differentiation and Gene 



200 

Expression to Reduce Inflammation in Human and 

Murine Models of Rheumatoid Arthritis. Samuel 

Garcia 1 , Linda M. Hartkamp 1 , Inge E. van Es 1 , Haishan 

Lin 2 , Li Long 2 , Emma L. Masteller 2 , Brian R. Wong 2 , Paul 

P. Tak 3 and Kris A. Reedquist 1 , 1 Academic Medical Center, 

University of Amsterdam, Amsterdam, Netherlands, 

2 

Five Prime Therapeutics, Inc., South San Francisco, CA, 

3 

Academic Medical Center, University of Amsterdam and 

GlaxoSmithKline, Amsterdam, Netherlands 

902. Activation of NF-Kb Via Poly(I:C)-Induced Monocyte- 

Derived Microparticles Decreases TRAIL-Induced Apoptosis 

of Rheumatoid Arthritis Synovial Fibroblasts. Mojca 

Frank Bertoncelj 1 , Blaz Rozman 2 , Beat A. Michel 3 , Renate 

E. Gay 1 , David S. Pisetsky 4 , Oliver Distler 5 , Steffen Gay 6 and 

Astrid Juengel 1 , 1 Center of Experimental Rheumatology, 

University Hospital Zurich and Zurich Center of Integrative 

Human Physiology (ZIHP), Zurich, Switzerland, 2 Department 

of Rheumatology, University Medical Centre Ljubljana, 

Ljubljana, Slovenia, 3 Department of Rheumatology, 

University Hospital Zurich, Zurich, Switzerland, 4 Duke 

University Medical Center, Durham, NC, 5 Department of 

Rheumatology and Center of Experimental Rheumatology, 

University Hospital Zurich, Zurich, Switzerland, 6 Center of 

Experimental Rheumatology, University Hospital Zurich 

and Zurich Center of Integrative Human Physiology (ZIHP), 

Zurich, CH-809 1 , Switzerland 

903. NR4A1 Mediates Anti-Inflammatory Effects of Apoptotic 

Cells. Natacha Ipseiz 1 , Stefan Uderhardt 1 , Georg A. Schett 2 

and Gerhard Kronke 1 , 1 University of Erlangen, Erlangen, 

Germany, 2 Department of Internal Medicine III and Institute 




Outcomes of Rheumatic Disease II 

904. Perinatal Characteristics, Maternal Reproductive History 

and Juvenile Idiopathic Arthritis: A Case-Control Study. 

Samantha W. Bell 1 , Beth A. Mueller 1 , J. Lee Nelson 2 , Parveen 

Bhatti 1 and Susan Shenoi 3 , 1 University of Washington, 

Seattle, WA, 2 Fred Hutchinson Cancer Rsch, Seattle, WA, 

3 

Seattle Children’s Hospital, University of Washington, 

Seattle, WA 

905. The Association between Lower Body Mass Index and 

Increased Risk of Giant Cell Arteritis Is Not Explained by 

Differences in Physical Activity. Karin Jakobsson 1 , Lennart 

T.H. Jacobsson 1 , Kenneth J. Warrington 2 , Eric L. Matteson 2 , 

Kimberly P. Liang 3 , Olle Melander 1 and Carl Turesson 1 , 1 Lund 

University, Malmö, Sweden, 2 Mayo Clinic, Rochester, MN, 

3 

University of Pittsburgh, Pittsburgh, PA 

906. Patient-Rheumatologist Communication Concerning 

Medication and Disease Risks. Susan J. Blalock, University 

of North Carolina at Chapel Hill, Chapel Hill, NC 


907. Use of Patient Preferences to Inform the Development 

of Disease Modifying Drugs for Osteoarthritis. Liana 

Fraenkel 1 , Charles Cunningham 2 , Gillian A. Hawker 3 and 

Lisa G. Suter 4 , 1 Yale University School of Medicine, Veterans 

Affairs Connecticut Healthcare System, New Haven, CT, 

2 

McMaster University, Hamilton, ON, 3 Women’s College 

Research Institute, University of Toronto, Toronto, ON, 4 Yale 

University, New Haven, CT 

908. Race, Gender and Total Knee Replacement Consideration: 

The Role of Social Support. Ernest R. Vina 1 , Yona Cloonan 2 , 

Said Ibrahim 3 , Michael J. Hannon 4 , Robert M. Boudreau 2 and 

C. Kent Kwoh 1 , 1 University of Pittsburgh and VA Healthcare 


PA, 3 University of Pennsylvania Perelman School of 

Medicine, Philadelphia, PA, 4 University of Pittsburgh School 

of Medicine, Pittsburgh, PA 

909. Determinants of Patient Preferences for Total Knee 

Replacement: A Comparison of Whites and African- 

Americans. C. Kent Kwoh 1 , Robert M. Boudreau 2 , Yona 

Cloonan 2 , Michael J. Hannon 3 , Ernest R. Vina 2 and Said 

Ibrahim 4 , 1 University of Pittsburgh and VA Healthcare 


PA, 3 University of Pittsburgh School of Medicine, Pittsburgh, 

PA, 4 University of Pennsylvania Perelman School of 

Medicine, Philadelphia, PA 

910. The Cost-Effectiveness of Total Joint Arthroplasty: A 

Systematic Review of Published Literature. Meghan E. 

Daigle, Alexander M. Weinstein, Jeffrey N. Katz and Elena 

Losina, Brigham and Women’s Hospital, Boston, MA 

911. Race- and Sex-Specific Estimates of 10-, 20 -, 3 0-Year, 

and Lifetime Risk of Diagnosed Symptomatic Knee 

Osteoarthritis and the Need for TKR in the US. Elena 

Losina, Meghan E. Daigle, Sara A. Burbine and Jeffrey N. 

Katz, Brigham and Women’s Hospital, Boston, MA 

912. Clinical Features Associated with Progression of Knee 

Radiographic Osteoarthritis: Data From the Osteoarthritis 

Initiative. Michelle S. Yau 1 , Laura Yerges-Armstrong 1 , 

Braxton D. Mitchell 1 and Marc C. Hochberg 2 , 1 University of 

Maryland School of Medicine, Baltimore, MD, 2 University of 

Maryland, Baltimore, MD 

913. Consultation Prevalence of Osteoarthritis in Southern 

Sweden. Aleksandra Turkiewicz 1 , Ingemar F. Petersson 1 , 

Jonas Björk 2 , Leif E. Dahlberg 1 and Martin Englund 1 , 

1 


University, Lund, Sweden, 2 Division of Occupational and 

Environmental Medicine, Lund University, Lund, Sweden, 

Lund, Sweden 

914. Prognosis for the Year 2030: The Consultation Prevalence 

of Osteoarthritis in Sweden May Increase by 50%. 

Aleksandra Turkiewicz 1 , Ingemar F. Petersson 1 , Jonas Björk 2 , 

Leif E. Dahlberg 1 and Martin Englund 1 , 1 Department of 

Orthopedics, Clinical Sciences Lund, Lund University, Lund, 

Sweden, 2 Division of Occupational and Environmental 

Medicine, Lund University, Lund, Sweden, Lund, Sweden


915. Incidence of Knee, Hip, and Hand Clinical Osteoarthritis: A 

Population-Based Cohort Study. Daniel Prieto-Alhambra 1 , 

Aina Pagès-Castellà 2 , M. Kassim Javaid 3 , Andrew Judge 4 , 

Cyrus Cooper 5 , Nigel K. Arden 3 and Adolfo Díez-Pérez 6 , 

1 

URFOA-IMIM, Parc de Salut Mar; Idiap Jordi Gol; University 

of Oxford; University of Southampton, Barcelona, Spain, 

2 

IDIAP Jordi Gol; Institut Català de la Salut, Barcelona, Spain, 

3 

Oxford NIHR Musculoskeletal Biomedical Research Unit, 

University of Oxford, Oxford, UK, Oxford, United Kingdom, 

4 

Oxford University, Oxford, United Kingdom, 5 University 

of Oxford; Southampton General Hospital, Southampton, 

United Kingdom, 6 Hospital del Mar-IMIM, Universitat 

Autònoma de Barcelona, Barcelona; and RETICEF, ISCIII 

Madrid; Spain, Barcelona, Spain 

916. Population Incidence of Soft Tissue Knee Injury: Estimates 

From a Swedish Health Care Register. Charlotte Bergknut 1 , 

George Peat 2 , Richard Frobell 1 and Martin Englund 3 , 1 Lund 

University, Lund, Sweden, 2 Arthritis Research UK Primary 

Care Centre, Keele University, United Kingdom, 3 Department 

of Orthopedics, Clinical Sciences Lund, Lund University, 

Sweden, Sweden 

917. Feasibility of Remote Activity and Functional Status 

Monitoring of Patients with Hip or Knee Pain. Pim 

Jetanalin 1 , Hyeon Eui Kim 1 , Zia Agha 2 , Nathaniel Heintzman 1 , 

Lucila Ohno-Macado 1 and Susan J. Lee 1 , 1 University of 

California, San Diego, La Jolla, CA, 2 San Diego Veterans 

Affairs Medical Center, San Diego, CA 

918. Impact of Comorbidities On Measuring Indirect Utility by 

the Medical Outcomes Study Short Form 6D in Lower-Limb 

Osteoarthritis. Kossar Hosseini 1 , Cécile Gaujoux-Viala 2 , Joel 

Coste 1 , Jacques Pouchot 1 , Bruno Fautrel 3 , Anne-Christine 

Rat 1 and Francis Guillemin 1 , 1 Université de Lorraine, Paris 

Descartes University, APEMAC, EA 4360, F- 54 000, France, 

Nancy, France, 2 Université de Lorraine, Paris Descartes 

University, APEMAC, EA 4360, F- 54 000, Nancy; Paris 6 

– Pierre et Marie Curie University; Rheumatology, Pitié- 

Salpêtrière Hospital, Paris, France, 3 Paris VI University, Paris, 

France 

919. Sedentary Time, Physical Activity, and Concurrent Blood 

Pressure in Osteoarthritis Initiative Participants. Min- 

Woong Sohn 1 , Rowland W. Chang 1 , Grace Ahn 1 , Linda S. 

Ehrlich-Jones 2 , Marc C. Hochberg 3 , Jungwha Lee 1 , Michael 

C. Nevitt 4 , Pamela A. Semanik 5 , Jing Song 1 , Kai Sun 6 and 

Dorothy D. Dunlop 1 , 1 Northwestern University, Chicago, IL, 

2 

Rehabilitation Institute Chicago, Chicago, IL, 3 University 

of Maryland, Baltimore, MD, 4 University of California-San 

Francisco, San Francisco, CA, 5 Northwestern University, IL, 

6 

Northwestern University, Feinberg School of Medicine, 

Chicago, IL 

920. A Multimodal Intervention to Improve Osteoporosis 

Care in Home Health Settings: Results from a Cluster 

Randomized Trial. Meredith Kilgore 1 , Kenneth G. Saag 2 , 

Jeroan Allison 3 , Elizabeth Kitchin 4 , Julie L. Locher 1 , Amy 

Mudano 4 , Ryan C. Outman 1 and Jeffrey R. Curtis 2 , 1 University 

of Alabama at Birmingham, Birmingham, AL, 2 Univ of 

Alabama-Birmingham, Birmingham, AL, 3 University of 

Massachusetts Medical School, 4 Birmingham, AL 

921. Association between Metabolic Syndrome and Bone 

Mineral Density in a Community-Dwelling Older Women: 

The São Paulo Ageing & Health Study (SPAH). Luana G. 

Machado, Diogo S. Domiciano, Jaqueline B. Lopes, Camille P. 

Figueiredo, Valéria Caparbo, Liliam Takayama and Rosa M.R. 

Pereira, University of São Paulo, São Paulo, Brazil 

922. Risk of Fracture among Treated and Untreated Men 

with Osteoporosis. Karen Tomic 1 , Joanne Lafleur 2 , Liisa 

Palmer 1 , David M. Smith 1 , Carly J. Paoli 3 , Irene Agodoa 3 and 

Nicole Yurgin 3 , 1 Truven Health Analytics, Washington, DC, 

2 

University of Utah College of Pharmacy, Salt Lake City, UT, 

3 

Amgen Inc, Thousand Oaks, CA 

923. Low Bone Mineral Density and Higher Parathyroid 

Hormone Levels As Independent Factors to All-Cause 

Mortality in Community-Dwelling Older Adults: the São 

Paulo Ageing & Health Study (SPAH). Diogo S. Domiciano, 

Luana G. Machado, Jaqueline B. Lopes, Camille P. Figueiredo, 

Valéria Caparbo, Liliam Takayama, Eloisa Bonfa and Rosa 

M.R. Pereira, University of São Paulo, São Paulo, Brazil 

924. Methods to Link a U.S. Arthritis Cohort with Medicare 

Administrative Claims Data. Jeffrey R. Curtis 1 , Lang Chen 2 , 

Timothy Beukelman 1 , Aseem Bharat 2 , Fenglong Xie 2 , 

Kenneth G. Saag 1 and Elizabeth S. Delzell 2 , 1 Univ of Alabama- 

Birmingham, Birmingham, AL, 2 University of Alabama at 


925. Use of Rheumatology Services for Arthritis: The Role of 

SES and Geographic Availability of Rheumatologists and 

Primary Care Physicians. E. M. Badley 1 , Mayilee Canizares 2 

and Aileen M. Davis 3 , 1 Division of Health Care and Outcomes 

Research,Toronto Western Research Institute; Dalla Lana 

School of Public Health, University of Toronto, Toronto, ON, 

2 

Division of Health Care and Outcomes Research,Toronto 

Western Research Institute, Toronto, ON, Toronto, ON, 

3 

Division of Health Care and Outcomes Research, Toronto 

Western Research Institute, Departments of Rehabilitation 

Science and Health Policy, Management and Evaluation, 


926. Accuracy of Canadian Health Administrative Databases 

in Identifying Patients with Rheumatoid Arthritis Using 

a Random Sample of 7500 Patients Seen in Primary 

Care. Jessica Widdifield 1 , Claire Bombardier 1 , Sasha 

Bernatsky 2 , J. Michael Paterson 3 , Jacqueline Young 3 , Diane 

Green 3 , J. Carter Thorne 4 , Noah Ivers 1 , Debra Butt 3 , R. 

Liisa Jaakkimainen 1 , Myra Wang 3 , Vandana Ahluwalia 5 , 

George A. Tomlinson 6 and Karen Tu 3 , 1 University of Toronto, 

Toronto, ON, 2 Research Institute of the McGill University 

Health Ctre, Montreal, QC, 3 Institute for Clinical Evaluative 

Sciences, Toronto, ON, 4 Southlake Regional Health Centre, 

Newmarket, ON, 5 William Osler Health Center, Mississauga, 

ON, 6 Toronto General Hospital, Toronto, ON 



927. Shared Decision Making in Secondary Care: Rheumatologic 

Patient’s Perspective. Raphael Battisti 1 , Thiago D. 

Baumgratz 1 , Mirella Cuziol 2 , Ana Carolina Reiff Janini 2 , Roger 

A. Levy Sr. 3 and Mirhelen M. Abreu 4 , 1 Medical Student, São 

Carlos, Brazil, 2 Medical Student at Universidade Federal de 

São Carlos, São Carlos, Brazil, 3 Hospital Universitário Pedro 

Ernesto, Rio de Janeiro, Brazil, 4 Universidade Federal de São 

Carlos, São Carlos, Brazil 

928. Is There an Optimal Treatment Strategy for Disease- 

Modifying-Antirheumatic-Drug Naïve Patients with 

Rheumatoid Arthritis? Roopa Akkineni 1 and Daniel A. 

Albert 2 , 1 Dartmouth Hitchcock Medical Center, Lebanon, NH, 

2 

Dartmouth-Hitchcock Med Ctr, Lebanon, NH 

929. Epidemiology of the US National Burden of Pediatric Lupus 

Hospitalization From 2000-2009. Andrea Knight 1 , Pamela 

Weiss 2 , Knashawn Morales 3 and Ron Keren 1 , 1 Children’s 

Hospital of Philadelphia, Philadelphia, PA, 2 The Children’s 

Hospital of Philadelphia, Philadelphia, PA, 3 University of 


930. Disease Burden and Cost of Illness in SLE During 8 

Years Follow up. Andreas Jönsen 1 , anders A. Bengtsson 2 , 

Frida Hjalte 3 , Minna Willim 2 , Ragnar Ingvarsson 2 , Ulf 

Persson 3 , Ingemar F. Petersson 4 and Ola Nived 5 , 1 Section 

of Rheumatology, Lund, Sweden, 2 Department of Clinical 

Sciences Lund, Section of Rheumatology, Lund, Sweden, 

3 

Lund, Sweden, 4 Musculoskeletal Scienes, Department of 

Orthopedics, Clinical Sciences, Lund, Sweden, 5 University 

Hospital - Lund, Lund, Sweden 

931. Health Care Utilization among Medicaid Enrollees with 

Systemic Lupus Erythematosus Preceding the Development 

of End-Stage Renal Disease: Sociodemographic Variation. 

Candace H. Feldman 1 , Linda T. Hiraki 2 , Graciela S. Alarcon 3 , 

Jinoos Yazdany 4 , Jun Liu 5 , Michael A. Fischer 1 , Wolfgang C. 

Winkelmayer 6 and Karen H. Costenbader 7 , 1 Brigham and 

Women’s Hospital, Boston, MA, 2 Brigham and Women’s 

Hospital/ Harvard School of Public Health, Boston, MA, 

3 


4 

University of California San Francisco, San Francisco, 

CA, 5 Brigham and Women’s Hospital, Harvard Medical 

School, Boston, Boston, MA, 6 Stanford University School of 

Medicine, Stanford, CA, 7 Brigham and Women’s Hospital, 

Harvard Medical School, Boston, MA 

932. Medical Costs and Health Care Resource Use in Patients 

with Systemic Lupus Erythematosus in an Insured 

Population. Daniel E. Furst 1 , Ann E. Clarke 2 , Ancilla W. 

Fernandes 3 , Tim Bancroft 4 , Kavita Gajria 3 , Warren Greth 5 

and Serban R. Iorga 4 , 1 UCLA Medical School, Los Angeles, 

CA, 2 McGill University, Montreal, QC, 3 MedImmune LLC, 

Gaithersburg, MD, 4 OptumInsight, Eden Prairie, MN, 

5 

MedImmune, LLC, Gaithersburg, MD 

933. Economic Burden of Systemic Lupus Erythematosus by 

Flare Severity in a Commercially Insured Population in 

the United States. Siva Narayanan 1 , Emily Durden 2 , Alan 

Oglesby 3 , Paul Juneau 4 and Kathleen L. Wilson 5 , 1 Human 

Genome Sciences, Inc., Rockville, MD, 2 Thomson Reuters, 

Austin, TX, 3 GlaxoSmithKline, Research Triangle Park, NC, 

4 

Truven Health Analytics, Washington, DC, 5 Thomson 

Reuters Healthcare, Cambridge, MA 

934. Direct Medical Cost Associated with Organ System 

Involvement in a Commercially Insured Population with 

Systemic Lupus Erythematosus in the United States. Alan 

Oglesby 1 , Emily Durden 2 , Siva Narayanan 3 , Paul Juneau 4 and 

Kathleen L. Wilson 5 , 1 GlaxoSmithKline, Research Triangle 

Park, NC, 2 Thomson Reuters, Austin, TX, 3 Human Genome 

Sciences, Inc., Rockville, MD, 4 Truven Health Analytics, 

Washington, DC, 5 Thomson Reuters Healthcare, Cambridge, 

MA 

935. Primary Care Preventive Services in Patients with Systemic 

Lupus Erythematosus Compared to Others in Their 

Community. Cristina Drenkard 1 , Kimberley Rask 1 , Gaobin 

Bao 1 , Gnanesh Patel 1 , Suparna Bagchi 2 and S. Sam Lim 1 , 

1 

Emory University, Atlanta, GA, 2 Georgia Department of 

Public Health, Atlanta, GA 

936. Autoimmune Diseases: Declining Mortality Between 199 9 

and 2008 However Continuing to be a Leading Cause of 

Death in Children-A 10-Year Retrospective Review. Eric Y. 

Yen 1 and Deborah K. McCurdy 2 , 1 Mattel Children’s Hospital, 


2 

Mattel Children’s Hospital, University of California, Los 

Angeles, Los Angeles, CA 

937. Changes in Ten Year Survival among SLE Patients at an 

Academic Center in North America (1970-2011). Joseph F. 

Merola, Bonnie L. Bermas, Bing Lu, Peter Hsun Tsao, Tabatha 

Norton, Christina Iversen, Elizabeth W. Karlson, Peter H. 

Schur and Karen H. Costenbader, Brigham and Women’s 


938. Hospitalizations in Systemic Lupus Erythematosus: A 

Longitudinal Study. Hong Fang, Jie Xu and Michelle Petri, 

Johns Hopkins University School of Medicine, Baltimore, MD 

939. Shared High Risk of Intensive Care Unit Admission in Three 

Autoimmune Inflammatory Diseases. Christine Peschken, 

Carol A. Hitchon, Allan Garland, Charles N. Bernstein, Randy 

Fransoo and Ruth Ann Marrie, University of Manitoba, 

Winnipeg, MB 

940. Incidence of Systemic Lupus Erythematosus in England, 

1998-2010. Herve Caspard 1 , Amy Steffey 2 , Jie Li 2 and 

Trung N. Tran 2 , 1 MedImmune LLC, Gaithersburg, MD, 

2 

MedImmune, Gaithersburg, MD 

941. Validity and Reliability of the Systemic Lupus Activity 

Questionnaire (SLAQ): A Prospective Study. Yuko Okamoto, 

Yasuhiro Katsumata, Yasushi Kawaguchi, Sayumi Baba, Kae 

Takagi, Hisae Ichida, Takahisa Gono, Masanori Hanaoka, 

Yuko Ota and Hisashi Yamanaka, Tokyo Women’s Medical 


942. Validity and Reliability of the Lupus Damage Index 

Questionnaire (LDIQ): A Prospective Study. Yuko Okamoto, 

Yasuhiro Katsumata, Yasushi Kawaguchi, Sayumi Baba, Kae 

202 

2012 Program Book


Takagi, Hisae Ichida, Takahisa Gono, Masanori Hanaoka, 

Yuko Ota and Hisashi Yamanaka, Tokyo Women’s Medical 


943. Impact of Systemic Lupus Erythematosus on Work 

Productivity and Income in the United States. Alan 

Oglesby 1 , Ellen Sulcs 2 , Siva Narayanan 3 , Mechele Lee 2 and 

Cindy Garris 1 , 1 GlaxoSmithKline, Research Triangle Park, 

NC, 2 Harris Interactive Inc., Rochester, NY, 3 Human Genome 

Sciences, Inc., Rockville, MD 

944. Job-Related Burden and Effort-Reward Imbalance in 

Patients with Systemic Lupus Erythematosus. Jutta G. 

Richter, Thomas Muth, Ralph Brinks, Tobias Koch, Johannes 

Siegrist, Nicole Hoffmann, Peter Angerer and Matthias 

Schneider, Heinrich-Heine-University, Duesseldorf, Germany 

945. Work Loss in Systemic Lupus Erythematosus, the 

General Public, and Other Chronic Conditions. S. Sam 

Lim 1 , Greg Dennis 2 , Hong Kan 3 , Priti M. Jhingran 4 , Charles 

T. Molta 5 , Gaobin Bao 1 and Cristina Drenkard 1 , 1 Emory 

University, Atlanta, GA, 2 Human Genome Sciences, Inc., 

Rockville, MD, 3 GlaxoSmithKline, Research Triangle Park, 

NC, 4 GlaxoSmithKline R&D, Research Triangle Park, NC, 

5 

GlaxoSmithKline, Philadelphia, PA 

946. Self-Reported Disease Activity and Health-Related Quality 

of Life in a Longitudinal Cohort of Patients with Systemic 

Lupus Erythematosus. Siva Narayanan 1 , Ellen Sulcs 2 , Alan 

Oglesby 3 , Cindy Garris 4 and Mechele Lee 2 , 1 Human Genome 

Sciences, Inc., Rockville, MD, 2 Harris Interactive Inc., 

Rochester, NY, 3 GlaxoSmithKline, Research Triangle Park, NC, 

4 

GlaxoSmithKline R&D, Research Triangle Park, NC 

947. The Impact of Dyspigmentation and Scarring in Cutaneous 

Lupus On Quality of Life. Saroj M. Verma 1 , Joyce Okawa 2 , 

Kathleen Propert 1 and Victoria P. Werth 3 , 1 University 

of Pennsylvania, Philadelphia, PA, 2 Perelman School of 

Medicine at the University of Pennsylvania and Philadelphia 

V.A. Medical Center, Philadelphia, PA, 3 University of 

Pennsylvania and Philadelphia V.A. Medical Center, 


948. Antibody-Based Prediction Rules for Connective Tissue 

Disease: Analysis of 12,555 Patients with Antinuclear 

Antibody Testing. Ryo Rokutanda 1 , Mitsumasa Kishimoto 1 , 

Yasuharu Tokuda 2 , Ken-ichi Yamaguchi 1 , Hisanori Shimizu 1 , 

Yasuhiro Suyama 1 , Yuri Ohara 1 , Yoichiro Haji 1 , Chisun Min 1 , 

Akira Takeda 1 , Yukio Matsui 1 and Masato Okada 1 , 1 St. Luke’s 

International Hospital, Tokyo, Japan, 2 University of Tsukuba, 

Ibaraki, Japan 

949. The Inverse Association between Obesity and Anti-Nuclear 

Antibodies Is Modified by Systemic Inflammation and 

Maybe Associated with Body Composition. Irene Blanco, 

Monalyn Labitigan and Matthew Abramowitz, Albert 

Einstein College of Medicine, Bronx, NY 

950. Performance of Various Anti-Nuclear Antibody 

Methodologies in the Assessment of Autoimmune 

Connective Tissue Diseases. Xiaoli Deng, Cynthia S. 

Crowson, Helen Khun, Melissa R. Snyder and Kevin G. 

Moder, Mayo Clinic, Rochester, MN 

951. A Systematic Review of Quality of Prognosis Studies 

in Systemic Lupus Erythematosus. Lily Siok Hoon Lim 1 , 

Senq-J Lee 1 , Brian M. Feldman 2 , D. D. Gladman 3 , Eleanor 

Pullenayegum 4 and Earl D. Silverman 5 , 1 Hospital for Sick 

Children, Toronto, ON, 2 The Hospital for Sick Children, 

Toronto, ON, 3 Toronto Western Hospital and University of 

Toronto, Toronto, ON, 4 McMaster University, Hamilton, 

ON, 5 Pediatric Rheumatology Collaborative Study Group 

(PRSCG), Toronto, ON 


952. Cognitive Behavioral Therapy and Milnacipran in 

Combination Appears to Be More Efficacious Than Either 

Therapy Alone. Dennis C. Ang 1 , Mark P. Jensen 2 , Jennifer 

L. Steiner 3 , Janna Hilligoss 1 , Richard Gracely 4 and Chandan 

Saha 5 , 1 Indiana University, Indianapolis, IN, 2 Seattle, WA, 

3 

Indianapolis, IN, 4 Chapel Hill, NC, 5 Indiana University 

953. Comparative Symptom Severity of Patients Satisfying 

Chronic Widespread Pain and Fibromyalgia Criteria. 

Frederick Wolfe 1 , Brian Wallitt 2 , Robert S. Katz 3 and Winfried 

Häuser 4 , 1 National Data Bank for Rheumatic Diseases, 

Wichita, KS, 2 Washington Hospital Center, Baltimore, MD, 

3 

Rush University Medical Center, Chicago, IL, 4 Klinikum 

Saarbrücken, Saarbrücken, Germany 

954. Diagnosis of Secondary Fibromyalgia in an Established 

Rheumatoid Arthritis Cohort. Yvonne C. Lee 1 , Christine K. 

Iannaccone 1 , Michelle A. Frits 1 , M. Weinblatt 2 and Nancy 

A. Shadick 3 , 1 Brigham and Women’s Hospital, Boston, 

MA, 2 Rheumatology & Immunology, Brigham & Women’s 

Hospital, Boston, MA, 3 Department of Medicine, Division 

of Rheumatology, Immunology and Allergy, Brigham and 

Women’s Hospital, Boston, MA 

955. Post – Surgical Outcome Is Correlated with Pre – Surgical 

Symptoms of Fibromyalgia in Patients Undergoing Spinal 

Surgery. Jacob N. Ablin 1 , Mark Berman 1 , Eyal Behrbalk 2 , 

Dan Buskila 3 , Gilad Regev 2 and Zvi Lidar 2 , 1 Tel Aviv 

Sourasky Medical Center, Tel Aviv, Israel, 2 Department of 

Neurosurgery and Orthopedic, Tel Aviv Sourasky Medical 

Center, Tel Aviv, Israel, 3 Beer-Sheva, Israel 

956. Learning Disability in Fibromyalgia Patients: FMS Patients 

Report More Language and Spatial Difficulties. Robert S. 

Katz 1 , Alexandra Small 2 , Carlen Katz 3 and Susan Shott 1 , 1 Rush 

University Medical Center, Chicago, IL, 2 University of Illinois 

Medical School, 3 Rheumatology Associates, Chicago, IL 

957. Key Psychological Processes Associated with the 

Fibromyalgia Phenotype Exist On a Continuous Spectrum 

with Asymptomatic People. Katrina Malin 1 and Geoffrey O. 

Littlejohn 2 , 1 Monash University, Clayton, Australia, 2 Monash 

Medical Centre and Monash University, Clayton, Victoria, 

Australia 



958. Prevelance of Spondyloarthropathy in Fibromyalgia 

Patients. A.Eftal Yucel, Derya Kaskari and Muhtesem 

Agýldere, Baskent University, Ankara, Turkey 

959. Treatment of Lateral Epicondylitis with Injection of 

Platelet-Rich Plasma or Corticosteroid Versus Saline: A 

Randomized, Double-Blind, Placebo-Controlled Trial. 

Thoger Krogh 1 , Ulrich Fredberg 1 , Kristian Stengaard- 

Pedersen 2 , Pia Jensen 1 , Robin Christensen 3 and Torkell 

Ellingsen 1 , 1 Diagnostic Centre Region Hospital Silkeborg 

Denmark, Silkeborg, Denmark, 2 Arhus University Hospital, 

Aarhus, Denmark, 3 Copenhagen University Hospital at 

Frederiksberg, Copenhagen, Denmark 

960. Cyclobenzaprine (CBP) and Its Major Metabolite 

Norcyclobenzaprine (nCBP) Are Potent Antagonists 

of Human Serotonin Receptor 2a (5HT2a), Histamine 

Receptor H- 1 and á-Adrenergic Receptors: Mechanistic and 

Safety Implications for Treating Fibromyalgia Syndrome by 

Improving Sleep Quality. Bruce Daugherty, Leland Gershell 

and Seth Lederman, Tonix Pharmaceuticals, Inc., New York, 

NY 

961. Cerebral Grey and White Matter Changes in Fibromyalgia 

Depend On Patients’ Age. Marta Ceko, Mary-Ann 

Fitzcharles, M. Catherine Bushnell and Petra Schweinhardt, 

McGill University, Montreal, QC 

962. Pain, Sleep Disturbance, and Depression Mediate the 

Association Between Body Mass Index and Fatigue in 

Fibromyalgia. Mary O. Whipple 1 , Loren L. Toussaint 2 , 

Daniel J. Clauw 3 , David A. Williams 4 , Terry H. Oh 1 , Jeffrey 

M. Thompson 1 , Connie A. Luedtke 1 and Ann Vincent 1 , 

1 

Mayo Clinic, Rochester, MN, 2 Luther College, Decorah, IA, 

3 

University of Michigan, Ann Arbor, MI, 4 Univ of MI Hlth 

System-Lobby M, Ann Arbor, MI 

963. Efficacy of Long-Term Milnacipran Treatment in Patients 

Meeting Different Thresholds of Clinically Relevant Pain 

Relief: Subgroup Analysis of a Double-Blind, Placebo- 

Controlled Discontinuation Study. Daniel J. Clauw 1 , Philip 

Mease 2 , Robert H. Palmer 3 , Joel M. Trugman 3 and Yimin Ma 3 , 

1 

University of Michigan, Ann Arbor, MI, 2 Swedish Medical 

Center and University of Washington, Seattle, WA, 3 Forest 

Research Institute, Jersey City, NJ 

964. High-Energy Extracorporeal Shock Wave Therapy Is 

Effective for Treating Chronic Calcific Tendonitis of the 

Shoulder: A Meta-Analysis. Nina E. Flavin, Raveendhara R. 

Bannuru, William F. Harvey and Timothy E. McAlindon, Tufts 

Medical Center, Boston, MA 

965. Increased Number of Painful Body Sites Is Associated with 

Worse Pain and Disability-Associated Outcomes Among 

Returning Operations Enduring Freedom/Operation Iraqi 

Freedom Service Members. Dennis C. Ang 1 , Jingwei Wu 2 , 

Samantha Outcalt 2 , Zhangsheng Yu 2 and Matthew Bair 2 , 

1 

Indiana University, Indianapolis, IN, 2 Indiana University 

School of Medicine 

966. A Systematic Review of Evidence for the Effectiveness 

of Practitioner-Based Complementary and Alternative 

Therapies in the Management of Fibromyalgia. Gareth 

T. Jones 1 , Priya Paudyal 2 , Gary J. Macfarlane 1 and the 

Arthritis Research UK Working Group on Complementary 

and 3 , 1 University of Aberdeen, Aberdeen, United Kingdom, 

2 

University of Plymouth, Plymouth, United Kingdom, 

3 

Aberdeen 

967. Haplotypes of GTP Cyclophydrolase Gene Polymorphisms 

Are Protective in the Susceptibility of Fibromyalgia 

Syndrome. Hwajeong Lee 1 , Shin-Seok Lee 2 , Seong-Kyu 

Kim 3 , Jung-Yoon Choe 1 , Seong-Ho Kim KIM 4 , Seong-Su Nah 5 , 

Ji Hyun Lee 6 , Seung-Jae Hong 7 , Hyun-Sook Kim 8 , Hye- 

Soon Lee 9 , Hyun Ah Kim 10 and Chung-Il Joung 11 , 1 Catholic 

University of Daegu School of Medicine, Daegu, South 

Korea, 2 Chonnam National University Medical School, 

Gwangju, South Korea, 3 and Autoimmunity Research Center, 

Catholic University of Daegu School of Medicine, Daegu, 

South Korea, 4 Inje University Haeundae Paik Hospital, 

Busan, South Korea, 5 Soonchunhyang University, College 

of Medicine, Cheonan, South Korea, 6 Maryknoll Medical 

Center, Busan, South Korea, 7 Kyung Hee University, Seoul, 

South Korea, 8 Internal Medicine, Chosun University Hospital, 

Gwangju, South Korea, 9 Hanyang University Guri Hospital, 

Guri, South Korea, 10 Hallym university sacred heart hospital, 

Kyunggi, South Korea, 11 Konyang University Medical School, 

Daejeon, South Korea 

968. Sympathetic Nervous System Dysfunction in Fibromyalgia 

and in Overlapping Central Sensitivity Syndromes. A 

Systematic Review of Controlled Studies. Laura Aline 

Martinez, Tania Mora, Angelica Vargas, Mario Fuentes and 

Manuel Martinez-Lavin, National Institute of Cardiology, 


969. Presence of Small Fiber Neuropathy in a Cohort of Patients 

with Fibromyalgia. Todd Levine 1 , Victoria Lawson 2 , Aidan 

Levine 1 , Kevin V. Hackshaw 3 and David Saperstein 1 , 1 Phoenix 

Neurological Associates, Phoenix, AZ, 2 Ohio State University, 

Columbus, OH, 3 Ohio State Univ/Wm Davis Res, Columbus, 

OH 


970. Genetic Interactions between SNP Variants in C3 Receptor 

Subunits in Patients with SLE. Jeffrey C. Edberg 1 , Christine 

W. Duarte 2 , Amit Patki 2 , Elizabeth E. Brown MPH 2 , Kenneth 

M. Kaufman 3 , Jennifer A. Kelly 4 , Mary E. Comeau 5 , Marta 

E. Alarcon-Riquelme on behalf of BIOLUPUS and GENLES 6 , 

Sang-Cheol Bae 7 , Lindsey A. Criswell 8 , Barry I. Freedman 9 , 

Patrick M. Gaffney 10 , Gary S. Gilkeson 11 , Chaim O. Jacob 12 , 

Judith A. James 13 , Diane L. Kamen 14 , Kathy Moser Sivils 4 , 

Timothy B. Niewold 15 , Robert H. Scofield 16 , Betty P. Tsao 17 , 

Timothy J. Vyse 18 , John B. Harley 19 , Carl D. Langefeld 20 , 

Hemant Tiwari 2 and Robert P. Kimberly 2 , 1 Department 

of Medicine, University of Alabama at Birmingham, 


Birmingham, AL, 3 Cincinnati Children’s Hospital Medical 

204 

2012 Program Book


Center, Cincinnati, OH, 4 Oklahoma Medical Research 

Foundation, Oklahoma City, OK, 5 Wake Forest University 

Health Sciences, Winston-Salem, NC, 6 Oklahoma Medical 

Research Foundation, Center for Genomics and Oncological 

Research Pfizer-University of Granada-Junta de andalucia, 

Oklahoma City, OK, 7 Hanyang University Hospital for 

Rheumatic Disease, Clinical Research Center for Rheumatoid 

Arthritis (CRCRA), Seoul, 8 University of California San 

Francisco, San Francisco, CA, 9 Department of Internal 

Medicine, Wake Forest School of Medicine, Winston- 

Salem, NC, 10 Arthritis & Clinical Immunology Program, 


OK, 11 Medical University of South Carolina, Charleston, 

SC, 12 Department of Medicine, Keck School of Medicine, 

University of Southern California, Los Angeles, CA, 

13 

Oklahoma Medical Research Foundation and Oklahoma 

University Health Sciences Center, Oklahoma City, OK, 

14 

Arthritis & Clinical Immunology Program, Oklahoma 

Medical Research Foundation, Charleston, SC, 15 University 

of Chicago, Chicago, IL, 16 Arthritis & Clinical Immunology 

Program, Oklahoma Medical Research Foundation; 

Department of Medicine, University of Oklahoma Health 

Sciences Center; US Department of Veterans Affairs Medical 

Center, Oklahoma City, OK, 17 UCLA School of Medicine, Los 

Angeles, CA, 18 Divisions of Genetics and Molecular Medicine 

and Immunology, King’s College London, London, United 

Kingdom, 19 Cincinnati Children’s Hospital Medical Center; US 


OH, 20 Wake Forest School of Medicine, Winston-Salem, NC 

971. Association of adam33 Polymorphisms with Systemic 

Lupus Erythematosus. Seung Cheol Shim, Mi Kyoung Lim, 

Donghyuk Sheen and Hyo Park, Eulji University Hospital, 

Daejeon, South Korea 

972. Associations of Genetic Polymorphisms of Microrna-146a 

and Its Target Interleukin-1-Receptor-Associated Kinase 1 

with Ankylosing Spondylitis. Chun-Huang Huang 1 , Jia-Yan 

Zhan 1 , Kai-Jieh Yeo 2 , James C. Wei 3 , Chih-Shien Chuang 1 

and Ruey-Hong Wong 1 , 1 Chung Shan Medical University, 

Taichung, Taiwan, 2 Chung Shan Medical University Hospital, 

Taichung, Taiwan, 3 Chung Shan Med Univ Hospital, Taichung, 

Taiwan 

973. New Genetic Risk Loci for the Radiographic Severity 

of Rheumatoid Arthritis. Diederik P.C. de Rooy 1 , Sacha 

Zhernakova 1 , Roula Tsonaka 2 , Fina Kurreeman 1 , René E.M. 

Toes 1 , Tom W. J. Huizinga 1 , Jeanine Houwing-Duistermaat 2 , 

Peter K. Gregersen 3 and Annette H.M. van der Helm-van 

Mil 1 , 1 Rheumatology, Leiden University Medical Center, 

Leiden, Netherlands, 2 Statistics, Leiden University Medical 

Center, Leiden, Netherlands, 3 Feinstein Institute Medical 

Research and North Shore-Long Island Jewish Health 

System, Manhasset, NY 

974. Identification of Susceptibility Loci for Inflammatory 

Arthritis. K. J. A. Steel 1 , Anne Hinks 1 , John Bowes 1 , Joanna 

Cobb 1 , Edward Flynn 2 , Carl D. Langefeld 3 , Sampath 

Prahalad 4 , Johannes Peter Haas 5 , John F. Bohnsack 6 , Stephen 

Guthery 6 , Anne Barton 1 , Susan D. Thompson 7 and Wendy 

Thomson 1 , 1 Arthritis Research UK Epidemiology Unit, 

University of Manchester, Manchester, United Kingdom, 

2 

University of Manchester, Manchester Academy of Health 

Sciences, Manchester, United Kingdom, 3 Wake Forest 

School of Medicine, Winston-Salem, NC, 4 Emory Children’s 

Center, Atlanta, GA, 5 Childrens Hospital, Erlangen, Germany, 

6 

University of Utah, Salt Lake City, 7 Cincinnati Children’s 

Hospital Medical Center, Cincinnati, OH 

975. Dense Genotyping of Risk Loci in Black South Africans with 

Rheumatoid Arthritis: An Association Study. Nimmisha 

Govind 1 , Ananyo Choudhury 2 , Bridget Hodkinson 1 , Claudia 

Ickinger 1 , Jacqueline Frost 3 , Annette T. Lee 4 , Peter K. 

Gregersen 4 , Richard J. Reynolds 5 , S. Louis Bridges Jr. 5 , Scott 

Hazelhurst 2 , Michèle Ramsay 3 and Mohammed Tikly 1 , 

1 

Division of Rheumatology, University of the Witwatersrand, 

Johannesburg, South Africa, 2 Wits Bioinformatics 

Department, University of the Witwatersrand, 

Johannesburg, South Africa, 3 Division of Human Genetics, 

National Health Laboratory Service, University of the 

Witwatersrand, Johannesburg, South Africa, 4 Feinstein 

Institute for Medical Research, Manhasset, NY, 5 Division 

of Clinical Immunology and Rheumatology, University of 

Alabama at Birmingham, Birmingham, AL 

976. Effect of Interactions between Validated Rheumatoid 

Arthritis Genetic Factors and Environmental Factors On 

Rheumatoid Arthritis Risk. Chia-Yen Chen 1 , Linda T. Hiraki 2 , 

Susan Malspeis 3 , Jing Cui 4 , Bing Lu 4 , Robert M. Plenge 3 , 

Karen H. Costenbader 4 and Elizabeth W. Karlson 4 , 1 Harvard 

School of Public Health, Boston, MA, 2 Brigham and Women’s 

Hospital, Harvard School of Public Health, Boston, MA, 

3 



977. 14-3-3 Eta Is a Novel Citrullination Target in Rheumatoid 

Arthritis That Enhances Diagnostic Utility in Anti-CCP 

Negative Patients. Walter P. Maksymowych 1 , Vivian P. 

Bykerk 2 , Désirée van der Heijde 3 , R. Landewe 4 and Anthony 

Marotta 5 , 1 University of Alberta, Edmonton, AB, 2 Hospital for 

Special Surgery, New York, NY, 3 Leiden University Medical 

Center, Leiden, Netherlands, 4 Academic Medical Center 

/ University of Amsterdam, Amsterdam, Netherlands, 

5 

Augurex Life Sciences Corp, North Vancouver, BC 

978. A Genome-Wide Interaction Study with Smoking Suggests 

New Risk Loci for Two Different Subsets of Rheumatoid 

Arthritis; Results From Swedish Epidemiological 

Investigation of Rheumatoid Arthritis Study. Xia Jiang 1 , 

Henrik Källberg 1 , Leonid Padyukov 2 , Lars Klareskog 2 and 

Lars Alfredsson 1 , 1 Karolinska Institutet, Stockholm, Sweden, 

2 

Rheumatology Unit, Karolinska Institutet, Stockholm, 

Sweden 

979. Cell-Type Specific Type I Interferon Signatures in Systemic 

Lupus Erythematosus and Viral Infection: What Makes 

the Difference? Chieko Kyogoku 1 , Joachim R. Grün 1 , Tobias 

Alexander 2 , Robert Biesen 2 , Falk Hiepe 2 , Thomas Häupl 2 , 



Andreas Radbruch 1 and Andreas Grützkau 1 , 1 German 

Rheumatism Research Centre Berlin (DRFZ), an institute of 

the Leibniz Association, Berlin, Germany, 2 Charité University 


980. Genomewide Association Study in Systemic Lupus 

Erythematosus: Known Loci. Antonio Fernandez-Nebro 1 , 

Patricia E. Carreira 2 , Ricardo Blanco 3 , Victor M. Martinez- 

Taboada 4 , Luis Carreño 5 , Alejandro Olive 6 , José Luis 

andreu 7 , Mª Angeles Aguirre 8 , Paloma Vela 9 , Jose Javier 

Pérez Venegas 10 , Jose Luís Marenco 7 , Joan Miquel Nolla 11 , 

Antonio Zea 12 , José M. Pego-Reigosa 13 , Mercedes Freire 

González 14 , Gabriela Ávila 15 , María América López-Lasanta 15 , 

Raül Tortosa 15 , Antonio Julià 15 and Sara Marsal 15 , 1 Hospital 

Regional Universitario Carlos Haya, Málaga, Spain, 2 Instituto 

de Investigación Hospital 12 de Octubre, Madrid, Spain, 

3 

Hospital Universitario Marques De Valdecilla, Santander, 

Spain, 4 Hospital Universitario Marques de Valdecilla. IFIMAV, 

Santander, Spain, 5 Gregorio Marañón Hospital, Madrid, 

Spain, 6 Germans Trias Pujol Hospital, Barcelona, Spain, 7 HU 

Puerta de Hierro Majadahonda, Madrid, Spain, 8 IMIBIC- 

Reina Sofia Hospital, Cordoba, Spain, 9 Hospital General 

Universitario de Alicante, Alicante, Spain, 10 Hospital del 

SAS de Jerez de la Frontera, Jerez De La Frontera, Spain, 

11 

Hospital Universitari de Bellvitge, Barcelona, Spain, 

12 

Hospital Universitario Ramon y Cajal, Madrid, Spain, 

13 

Hospital do Meixoeiro, Vigo, Spain, 14 Complejo Hospitalario 

Universitario de La Coruña,, La Coruña, Spain, 15 Vall 

d’Hebron Hospital Research Institute, Barcelona, Spain 

981. Aggregated Genetic Information Explains Variations On 

Hand Radiographic Scores in Rheumatoid Arthritis Patient. 

Jing Cui 1 , Nancy A. Shadick 2 , Katherine P. Liao 1 , Michael 

Weinblatt 3 , Robert M. Plenge 1 and Elizabeth W. Karlson 4 , 

1 

Brigham and Women’s Hospital, Boston, MA, 2 Department 

of Medicine, Division of Rheumatology, Immunology and 

Allergy, Brigham and Women’s Hospital, Boston, MA, 

3 

Rheumatology & Immunology, Brigham & Women’s 

Hospital, Boston, MA, 4 Brigham and Women’s Hospital, 

Harvard Medical School, Boston, MA 

982. Genetic Variants near Insulin-Like Growth Factor 

Binding Protein 3 (IGFBP3) Are Associated with Hip 

Osteoarthritis. Daniel S. Evans 1 , Neeta Parimi 1 , Ana M. 

Valdes 2 , Hanneke J.M Kerkhof 3 , Frederic Cailotto 4 , Michael 

C. Nevitt 5 , Steven R. Cummings 1 , Rik J. Lories 4 , Timothy D. 

Spector 2 , Nigel K. Arden 6 , Joyce B. van Meurs 3 and Nancy 

E. Lane 7 , 1 California Pacific Medical Center Research 

Institute, San Francisco, CA, 2 Dept of Twin Research and 

Genetic Epidemiology, St. Thomas’ Hospital, King’s College 

London, London, United Kingdom, 3 Department of Internal 

Medicine, Erasmus Medical Center and The Netherlands 

Genomics Initiative-Sponsored Netherlands Consortium 

for Healthy Aging, Rotterdam, Netherlands, 4 Laboratory 

for Skeletal Development and Joint Disorders, Department 

of Development and Regeneration, KU Leuven, Leuven, 

Belgium, 5 University of California-San Francisco, San 

Francisco, CA, 6 Oxford NIHR Musculoskeletal Biomedical 

Research Unit, University of Oxford, Oxford, UK, Oxford, 

United Kingdom, 7 UC Davis School of Medicine, Sacramento, 

CA 

983. Genome-Wide Association Study and Gene Expression 

Analysis Identifies CD84 As a Predictor of Response to 

Etanercept Therapy in Rheumatoid Arthritis. Jing Cui 1 

and International RA Consortium on Therapy (InteRACT) 2 , 

1 

Brigham and Women’s Hospital, Boston, MA, 2 Boston, MA 

984. Association of Elevated C5a Levels, but Not the Presence 

of Anti-Cfh IgG Autoantibodies, with the Deletion of CFHR 3 

and CFHR1 in SLE. Jian Zhao 1 , Seema Kamble 1 , Yun Deng 1 , 

Magdangal Erika 1 , Daisuke Sakurai 1 , Rongqun Li 1 , Weiling 

Chen 1 , Jennifer M. Grossman 1 , Bevra H. Hahn 2 and Betty P. 

Tsao 1 , 1 Division of Rheumatology, David Geffen School of 

Medicine, University of California Los Angeles, Los Angeles, 

CA, 2 UCLA David Geffen School of Medicine, Los Angeles, CA 

985. Inverse Relation Between the tumor Necrosis Factor 

Promoter Methylation and Trascript Leveles in Leukocytes 

from Patients with Rheumatoid Arthritis. James R. 

Maxwell 1 , Lyndsey H. Taylor 2 , Richardo A. Pachecho 2 , Neil 

Lawrence 2 , Gordon W. Duff 3 , M. Dawn. Teare 2 and Anthony 

G. Wilson 4 , 1 University of Sheffield, Sheffield, United 

Kingdom, 2 University of Sheffield, United Kingdom, 3 Royal 

Hallamshire Hospital, Sheffield, United Kingdom, 4 Section of 

Musculoskeletal Sciences, University of Sheffield, Sheffield, 


986. Genome Wide Association Studies of Knee Osteoarthritis 

in 2 Large North American Cohorts: A Meta-Analysis with 

2667 Cases. Marc C. Hochberg 1 , Laura Yerges-Armstrong 2 , 

Changwan (Larry) Lu 2 , Michelle S. Yau 1 , Braxton D. Mitchell 2 , 

Joanne M. Jordan 3 , Youfang Liu 4 , Jordan B. Renner 5 , T. 

McSherry 6 , D.M. Taverna 6 , David Duggan 6 , W.J. Mysiw 7 and 

Rebecca D. Jackson 8 , 1 University of Maryland, Baltimore, 

MD, 2 University of Maryland School of Medicine, Baltimore, 

MD, 3 University of North Carolina Thurston Arthritis 

Research Center, Chapel Hill, NC, 4 University of North 

Carolina, Chapel Hill, NC, 5 University of North Carolina 

at Chapel Hill Dept of Radiology, Chapel Hill, NC, 6 TGen, 

Pheonix, AZ, 7 Ohio State University, Columbus, 8 Ohio State 

University, Columbus, OH 

987. Autoimmune Susceptibility Genes Are Regulators of Gene 

Expression Response to ER Stress. William E. Bernal 1 , 

Michael P. Morley 2 and Vivian G. Cheung 3 , 1 The Children’s 

Hospital of Philadelphia, Philadelphia, PA, 2 University of 

Pennsylvania, Philadelphia, PA, 3 Howard Hughes Medical 

Institute, Chevy Chase, MD; University of Pennsylvania, 


988. Zone-Specific Protein Profiles in Human Cartilage 

Unraveled by a Quantitative Proteomic Approach. Patricia 

Fernandez-Puente 1 , Lucia Lourido 2 , Valentina Calamia 2 , 

Jesus Mateos 2 , Cristina Ruiz-Romero 2 , Martin K. Lotz 3 and 

Francisco J. Blanco 2 , 1 Osteoarticular and Aging Research 

Group. Rheumatology Division, Biomedical Research Center 

(INIBIC). Hospital Universitario A Coruña, As Xubias de 

206 

2012 Program Book


Arriba 84, 15006, A Coruña, Spain, 2 Rheumatology Division, 

Proteomics Group/ProteoRed-ISCIII, INIBIC-C. Hospitalario, A 

Coruña, Spain, 3 Department of Molecular and Experimental 

Medicine, The Scripps Research Institute, La Jolla, CA 

989. Genome-Wide Analysis Reveals a Recessive Association 

of ERAP1 Variants with Behçet’s Disease and Epistasis 

between ERAP 1 and HLA-B*51. Elaine F. Remmers 1 , Yohei 

Kirino 1 , George Bertsias 1 , Yoshiaki Ishigatsubo 2 , Yoonhee 

Kim 3 , Michael J. Ombrello 1 , Ilknur Tugal-Tutkun 4 , Emire 

Seyahi 5 , Yilmaz Ozyazgan 5 , F. Sevgi Sacli 5 , Burak Erer 4 , Zeliha 

Emrence 6 , Atilla Cakar 6 , Neslihan Abaci 6 , Duran Ustek 6 , 

Colleen Satorius 1 , Mitsuhiro Takeno 2 , Ahmet Gül 4 and Daniel 

L. Kastner 1 , 1 National Human Genome Research Institute, 

National Institutes of Health, Bethesda, MD, 2 Yokohama City 

University Graduate School of Medicine, Yokohama, Japan, 

3 

National Human Genome Research Institute, National 

Institutes of Health, Baltimore, MD, 4 Istanbul Faculty of 

Medicine, Istanbul University, Istanbul, Turkey, 5 Cerrahpasa 

Faculty of Medicine, Istanbul University, Istanbul, Turkey, 

6 

Institute of Experimental Medicine, Istanbul University, 

Istanbul, Turkey 

990. Proteomic Shotgun Analysis of Mesenchymal Stem Cells 

Reveals an Alterated Regulation of Proteosomal Proteins in 

Osteoarthritis Patients. Jose Ramon Lamas, Hospital clinico 

San Carlos, Madrid, Spain 

991. MTHFR Polymorphisms in Systemic Lupus Erythematosus 

and Rheumatoid Arthritis: Associations with Intima Media 

Thickness Scores. Clio P. Mavragani 1 , Maira Giannelou 2 , 

Ioanna Papadaki 3 , Eleni Antypa 4 , Dimitrios Ioakeimidis 5 , 

Haralampos M. Moutsopoulos 2 and Michael Koutsilieris 1 , 

1 

School of Medicine, University of Athens, Athens, 

Greece, Athens, Greece, 2 School of Medicine, University 

of Athens, Athens, Greece, 3 General Hospital of Athens 

“G.Gennimatas”, Athens, Greece, 4 General Hospital of 

Athens, Greece, 5 General Hospital, Greece 

992. Functional Genomics of the Human ITGAM Locus. Yebin 

Zhou 1 , Dan C. Bullard 1 , Alexander Szalai 2 , Jianming Wu 3 and 

Jeffrey C. Edberg 4 , 1 University of Alabama at Birmingham, 

Birmingham, AL, 2 University of alabama at birmingham, 

Birmingham, AL, 3 University of minnesota, St. Paul, MN, 

4 

Department of Medicine, University of Alabama at 


993. A Genome-Wide DNA Methylation Analysis Reveals 

Different Methylation Patterns in the OA Disease. Ignacio 

Rego-Pérez 1 , Juan Fernandez-Tajes 1 , Mercedes Fernandez- 

Moreno 1 , Maria Tamayo Novas 2 , Alejandro Mosquera 

Rey 2 , Natividad Oreiro 1 , Carlos Fernandez-Lopez 1 , Jose Luis 

Fernandez Garcia 2 and Francisco J. Blanco 1 , 1 INIBIC-Hospital 

Universitario A Coruña. Rheumatology Division. Genomic 

Group, A Coruña, Spain, 2 INIBIC-Hospital Universitario A 

Coruña. Genetic Deparment., A Coruña, Spain 

994. The Genome-Wide Expression of Human Osteoarthritic 

Cartilage Shows A Differential Pattern Between Two 

Subgroups of OA Patients. Ignacio Rego-Perez, Juan 

Fernandez-Tajes, Angel Soto-Hermida, Mercedes 

Fernandez Moreno, Maria Eugenia Vazquez Mosquera, 

Natividad Oreiro, Carlos Fernandez-Lopez, Estefania Cortes 

Pereira, Sara Relaño-Fernandez and Francisco J. Blanco, 

INIBIC-Hospital Universitario A Coruña. Genomic Group. 

Rheumatology Division., A Coruña, Spain 

995. Genetic Effects of HLA-DRB 1 , IL4R, and FcγRIIb On 

Long-Term Treatment Responses in Patients with Early 

Rheumatoid Arthritis: 78-Week Results of a Phase 4 

Study. Alla Skapenko 1 , Josef S. Smolen 2 , Arthur Kavanaugh 3 , 

Vipin Arora 4 , Hartmut Kupper 5 and Hendrik Schulze- 

Koops 1 , 1 University of Munich, Munich, Germany, 2 Medical 


3 

UCSD School of Medicine, La Jolla, CA, 4 Abbott, Abbott 

Park, IL, 5 Abbott GmbH and Co. KG, Ludwigshafen, Germany 

996. Genetic Predictors of Methotrexate Efficacy and Toxicity 

in Early Rheumatoid Arthritis: Results From the Treatment 

of Early Aggressive Rheumatoid Arthritis Trial. Stella 

Aslibekyan 1 , Elizabeth Brown 2 , Richard J. Reynolds 1 , David T. 

Redden 1 , Sarah L. Morgan 3 , Joseph Baggott 1 , Jin Sha 1 , Larry 

W. Moreland 4 , James R. O’Dell 5 , Jeffrey R. Curtis 6 , S. Louis 

Bridges Jr. 7 and Donna K. Arnett 1 , 1 University of Alabama 

at Birmingham, Birmingham, AL, 2 Univ of Alabama at 

Birmingham, Birmingham, AL, Birmingham, AL, 3 University 

of Alabama Birmingham, Birmingham, AL, 4 University of 

Pittsburgh, Pittsburgh, PA, 5 Univ of Nebraska Med Ctr, 

Omaha, NE, 6 Univ of Alabama-Birmingham, Birmingham, 

AL, 7 Marguerite Jones Harbert-Gene V. Ball, MD Professor 

of Medicine, and Director, Division of Clinical Immunology 

and Rheumatology, University of Alabama at Birmingham, 


997. Evidence of Novel Genetic Predictors of Methotrexate 

Efficacy in Rheumatoid Arthritis. Stella Aslibekyan 1 , Maria 

I. Danila 2 , Jin Sha 1 , David T. Redden 1 , Richard J. Reynolds 1 , 

Elizabeth Brown 3 , Laura B. Hughes 1 , Molly S. Bray 1 , Sarah 

L. Morgan 4 , Larry W. Moreland 5 , James R. O’Dell 6 , Jeffrey 

R. Curtis 2 , Robert P. Kimberly 1 , Lindsey A. Criswell 7 , Robert 

M. Plenge 8 , S. Louis Bridges Jr. 9 and Donna K. Arnett 1 , 

1 


2 

Univ of Alabama-Birmingham, Birmingham, AL, 3 Univ of 

Alabama at Birmingham, Birmingham, AL, Birmingham, 

AL, 4 University of Alabama Birmingham, Birmingham, AL, 

5 

University of Pittsburgh, Pittsburgh, PA, 6 Univ of Nebraska 

Med Ctr, Omaha, NE, 7 University of California San Francisco, 

San Francisco, CA, 8 Brigham and Women’s Hospital, Boston, 

MA, 9 Marguerite Jones Harbert-Gene V. Ball, MD Professor 

of Medicine, and Director, Division of Clinical Immunology 

and Rheumatology, University of Alabama at Birmingham, 


998. Association Study of Genetic Risk Variants for Psoriasis 

in a Large Cohort of Psoriatic Arthritis, Psoriasis and 

Controls of the Spanish Population and Association with 

Relevant Clinical Subphenotypes. J. D. Cañete 1 , Jose Luis 

Fernandez-Sueiro 2 , Raimon Sanmarti 3 , Jesus Rodriguez 4 , 

Jordi Gratacós 5 , Rubén Queiro 6 , Juan Carlos Torre-Alonso 7 , 



208 

Jose Perez Venegas 8 , Santiago Muñoz-Fernandez 9 , Carlos 

Gonzalez 10 , Carlos Montilla 11 , Daniel Roig 12 , Alba Erra 13 , 

Isabel Acosta 14 , Antonio Fernández-Nebro 15 , Pedro Zarco 16 , 

Arnald Alonso 17 , María América López-Lasanta 17 , Antonio 

Julià 17 , Raül Tortosa 17 and Sara Marsal 18 , 1 Hospital Clínic 

de Barcelona,, Barcelona, Spain, 2 Complejo Hospitalario 

Universitario La Coruña, La Coruña, Spain, 3 Hospital Clínic 

of Barcelona, Barcelona, Spain, 4 Hospital Universitari de 

Bellvitge, Barcelona, Spain, 5 Hospital Parc Taulí, Sabadell 

(Barcelona), 6 Hospital Universitario Central de Asturias, 

Oviedo, Spain, 7 Hospital Monte Naranco, Oviedo, Spain, 

8 

Hospital del SAS de Jerez de la Frontera, Jerez De La 

Frontera, Spain, 9 Hospital Infanta Sofía, Madrid, Spain, 

10 

Hospital Gregorio Marañon, Madrid, Spain, 11 Hospital 

Universitario de Salamanca, Salamanca, Spain, 12 Hospital 

Universitari de Bellvitge, Hospitalet de Llobregat- Barcelona, 

Spain, 13 Hospital San Rafael, Barcelona, Spain, 14 Hospital 

Universitari Vall d’Hebron, Barcelona, Spain, 15 Hospital 

Regional Universitario Carlos Haya, Málaga, Spain, 

16 

Fundación Hospital Alcorcon, Alcorcon, Madrid, Spain, 

17 

Vall d’Hebron Hospital Research Institute, Barcelona, 

Spain, 18 University Hospital Vall d’Hebron, Barcelona, Spain 

999. Identification of New Epistatic Interactions with the HLA 

Region in the Genetic Etiology of Psoriasis and Psoriatic 

Arthritis. Sara Marsal 1 , Juan D. Cañete 2 , Jose Luis Fernandez- 

Sueiro 3 , Raimon Sanmarti 2 , Jesus Rodriguez Moreno 4 , Jordi 

Gratacós 5 , Rubén Queiro 6 , Carlos Montilla 7 , Juan Carlos 

Torre-Alonso 8 , Jose Perez Venegas 9 , Santiago Muñoz- 

Fernández 10 , Carlos M. Gonzalez 11 , Daniel Roig 12 , Alba 

Erra 13 , Isabel Acosta 1 , Antonio Fernández-Nebro 14 , Pedro 

Zarco 15 , Arnald Alonso 16 , María América López-Lasanta 16 , 

Raül Tortosa 16 and Antonio Julià 16 , 1 Hospital Universitari Vall 

d’Hebron, Barcelona, Spain, 2 Hospital Clínic of Barcelona, 

Barcelona, Spain, 3 Complejo Hospitalario Universitario 

La Coruña, La Coruña, Spain, 4 Hospital Universitario de 

Bellvitge., Barcelona, Spain, 5 Hospital Parc Taulí, Sabadell 

(Barcelona), 6 Hospital Universitario Central de Asturias, 

Oviedo, Spain, 7 Hospital Universitario de Salamanca, 

Salamanca, Spain, 8 Hospital Monte Naranco, Oviedo, 

Spain, 9 Hospital del SAS de Jerez de la Frontera, Jerez De La 

Frontera, Spain, 10 Hospital Universitario Infanta Sofía, San 

Sebastián de los Reyes (Madrid), Spain, 11 Hospital Gregorio 

Maranon, Madrid, Spain, 12 Hospital Universitari de Bellvitge, 

Hospitalet de Llobregat- Barcelona, Spain, 13 Hospital San 

Rafael, Barcelona, Spain, 14 Hospital Regional Universitario 

Carlos Haya, Málaga, Spain, 15 Fundación Hospital Alcorcon, 

Alcorcon, Madrid, Spain, 16 Vall d’Hebron Hospital Research 

Institute, Barcelona, Spain 

1000. Epistatic Interaction between BANK 1 and BLK in 

Rheumatoid Arthritis: Results From a Large Trans-Ethnic 

Meta-Analysis. Emmanuelle Genin 1 , Baptiste Coustet 2 , 

Yannick Allanore 3 , Maria Teruel 4 , Arnaud L. Constantin 5 , 

Shigeto Tohma 6 , O. Vittecoq 7 , Hiroshi Furukawa 8 , Alejandro 

Balsa 9 , Thierry Schaeverbeke 10 , Miguel Angel González- 

Gay 11 , Gilles Chiocchia 12 , Naoyuki Tsuchiya 13 , Javier Martin 14 

and Philippe Dieude 15 , 1 INSERM UMR-S946, Paris, France, 


2 

Université Paris Descartes, Hopital Cochin, Paris, France, 

3 

Paris Descartes University, Rheumatology A department, 

Cochin Hospital, Paris, France, 4 Instituto de Parasitologia y 

Biomedicina Lopez-Neyra, CSIC, Granada, Spain, 5 Purpan 

University Hospital, Toulouse Cedex 9 , France, 6 Sagamihara 

National Hospital, Sagamihara City, Japan, 7 University 

Hospital, Rouen, France, 8 Clinical Research Center for 

Allergy and Rheumatology, Sagamihara National Hospital, 

National Hospital Organization, Sagamihara, Japan, 9 La 

Paz Hospital. IdiPaz, Madrid, Spain, 10 Groupe Hospitalier 

Pellegrin, Bordeaux, France, 11 Hospital Universitario 

Marqués de Valdecilla. IFIMAV, Santander, Spain, 12 Institut 

Cochin - INSERM U1016 - CNRS (UMR 8104), Paris, 

France, 13 Molecular and Genetic Epidemiology Laboratory, 

University of Tsukuba, Tsukuba, Japan, 14 Instituto de 

Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, 

Spain, 15 APHP, Hopital Bichat, Paris, France 

1001. CNstream2: Improved SNP and CNV Genotyping Reveals 

New Loci Associated with Rheumatic Diseases. Arnald 

Alonso, Antonio Julià, Raül Tortosa and Sara Marsal, Vall 

d’Hebron Hospital Research Institute, Barcelona, Spain 

1002. Microrna Expression Profiles in Peripheral Blood 

Mononuclear Cells of Early Onset Psoriatic Arthritis. 

G. Ciancio 1 , Manuela Ferracin 2 , Barbara Zagatti 2 , Elena 

Saccenti 2 , Valentina Bagnari 1 , Ilaria Farina 1 , Matteo 

Colina 3 , Marco Seri 4 , Francesco Trotta 1 , Massimo Negrini 2 

and Marcello Govoni 1 , 1Rheumatology Unit-Azienda 

Ospedaliera-Universitaria Sant’Anna, Ferrara, Italy, 

2 

Laboratory for Technologies of Advanced Therapies (LTTA), 

University of Ferrara, Ferrara, Italy, 3 Section of Internal 

Medicine A.Ospedale Maggiore, Bologna, Italy, 4 Medical 

Genetics Unit, Bologna, Italy 

1003. Role of Particular Class I MHC Haplotypes in Determining 

Different Traits within the Psoriatic Arthritis Phenotypes. 

Muhammad Haroon 1 , Jon T. Giles 2 , Robert Winchester 3 and 

Oliver M. FitzGerald 1 , 1 Dublin Academic Medical Center, St. 

Vincent’s University Hospital, Dublin, Ireland, 2 Columbia 

University Medical Center, New York, NY, 3 Columbia 

University, New York, NY 

1004. A Unique Single Nucleotide Polymorphism in the 3’ UTR 

of the MED29 Gene On Chromosome 19 Is Associated 

with the Clinical Outcome of Different Biologic Response 

Modifiers. Susanne Drynda, David Leesch, Marietta 

Gloetzner and Joern Kekow, Univ of Magdeburg, Vogelsang- 

Gommern, Germany 

1005. The Identification of Pathway Markers in Behcet’s Disease 

Using Genomewide Association Data from Two Different 

Populations. Burcu Bakir-Gungor 1 , Elaine Remmers 2 , Daniel 

L. Kastner 3 , Akira Meguro 4 , Nobuhisa Mizuki 4 , Ahmet 

Gul 5 and Osman Ugur Sezerman 6 , 1 Bahcesehir University, 

Istanbul, Turkey, 2 National Institutes of Health, National 

Human Genome Research Institute, Bethesda, MD, 3 National 


Health, Bethesda, MD, 4 Yokohama City University Graduate


School of Medicine, Yokohama, Japan, 5 Istanbul University, 

Istanbul Faculty of Medicine, Istanbul, Turkey, 6 Sabancı 

University, Istanbul, Turkey 

1006. Dynamic Gene Expression of Wnt Signaling Pathway 

during Osteogenic Stimulation in Vitro of Osteoarthritis 

Mesenchymal Stem Cells. A. Peralta-Sastre 1 , M. Hernandez- 

Molinero 2 , P. Tornero-Esteban 2 , E. Villafuertes 2 , B. 

Fernandez-Gutierrez 3 and Jose Ramon Lamas 4 , 11 UGC de 

Reumatología, Hospital Clínico San Carlos, Instituto de 

Investigación Sanitaria del Hospital Clínico San Carlos 

(IdISSC), Madrid, Spain., 2 Hospital Clinico San Carlos, 

Madrid, Spain, 3 Department of Rheumatology, Hospital 

Clinico San Carlos, Madrid, Spain, 4 Hospital clinico San 

Carlos, Madrid, Spain 

Imaging of Rheumatic Diseases: Magnetic Resonance Imaging, 

Computed Tomography and X-ray 

1007. High Resolution Peripheral Quantitative CT Detects Marked 

Differences in Metacarpal Head and Shaft and Ultra-Ultra- 

Distal Radius Bone Volumetric Density and Microstructure 

in Early Rheumatoid Arthritis. Lynne M. Feehan 1 , Helen R. 

Buie 2 , Linda C. Li 1 , Kamran Shojania 3 , Cheryl Barnabe 2 and 

Heather A. McKay 3 , 1 Arthritis Research Centre of Canada and 

University of British Columbia, Vancouver, BC, 2 University 

of Calgary, Calgary, AB, 3 University of British Columbia, 

Vancouver, BC 

1008. Segmentation and Quantification of Bone Erosions in the 

Hands of Patients with Rheumatoid Arthritis Using High 

Resolution Computed Tomography. Dominique Toepfer 1 , 

Stephanie Finzel 1 , Oleg Museyko 1 , Klaus Engelke 1 and Georg 

A. Schett 2 , 1 University of Erlangen-Nuremberg, Erlangen, 

Germany, 2 Department of Internal Medicine III and Institute 



1009. A New Approach for Detecting Progressive Joint Damage 

Using 3D Imaging From High-Resolution Peripheral 

Quantitative Computed Tomography: Measuring 

Reproducibility. Cheryl Barnabe, Helen R. Buie, Michelle 

Kan, Susan G. Barr, Liam Martin and Steven K. Boyd, 

University of Calgary, Calgary, AB 

1010. Bone Loss before Clinical Onset of Rheumatoid Arthritis 

o Subjects with Anti-Citrullinated Protein Antibodies. 

Stephanie Finzel 1 , Veronika Lang 2 , Arnd Kleyer 1 , Juergen 

Rech 1 , Bernhard Manger 1 , Elizabeth Araujo 1 , Axel J. Hueber 1 , 

Ulrike Harre 3 and Georg Schett 3 , 1 University of Erlangen- 

Nuremberg, Erlangen, Germany, 2 University of Erlangen- 

Nuremberg, Germany, 3 Institute for Clinical Immunology, 

University of Erlangen-Nuremberg, Erlangen, Germany 

1011. Structural Damage Is Reduced by Early Achievement of 

Clinical Remission. Paul Emery 1 , Vibeke Strand 2 , Andrew S. 

Koenig 3 , Ronald Pedersen 3 and Eustratios Bananis 3 , 1 Leeds 


Kingdom, 2 Stanford University, Portola Valley, CA, 3 Pfizer 

Inc., Collegeville, PA 

1012. Radiographic Deformity of the Foot Is Starting From the 

Early Stage of Rheumatoid Arthritis. Kenji Mamoto, Tatsuya 

Koike, Tadashi Okano, Atsuko Kamiyama, Yuko Sugioka, 

Masahiro Tada and Hiroaki Nakamura, Osaka City University 

Graduate School of Medicine, Osaka, Japan 

1013. The Influence of Vertebral Fractures On the Functional 

Disability of Patients with Rheumatoid Arthritis. Soo-Kyung 

Cho 1 , Joo-Hyun Lee 2 , Min-Kyung Han 3 , Seunghun Lee 4 , Ji 

Young Kim 4 , Jeong Ah Ryu 4 , Yun Young Choi 4 , Sang-Cheol 

Bae 5 and Yoon-Kyoung Sung 5 , 1 Hanyang University Hospital 

for Rheumatic Diseases, Seoul, South Korea, 2 Ilsan Paik 

Hospital, Inje University, Goyang, South Korea, 3 Hanyang 

University Hospital for Rheumatic Disease, Seoul, South 

Korea, 4 Hanyang University College of Medicine, Seoul, 




1014. Trimmed Analyses, a New Approach to the Analysis of 

Sharp Score Data in the Assessment of Progression in 

Patients with Rheumatoid Arthritis. Robert B. M. Landewé 1 , 

Désirée van der Heijde 2 , Carol Connell 3 , John Bradley 3 , 

David Gruben 3 and Michael Brown 3 , 1 Academic Medical 


Amsterdam, Netherlands, 2 Leiden University Medical Center, 

Leiden, Netherlands, 3 Pfizer Inc., Groton, CT 

1015. Analysis of Integrated Radiographic Data for Two Long- 

Term, Open-Label Extension Studies of Adalimumab. 

Désirée van der Heijde 1 , Robert Landewé 2 , Edward C. 

Keystone 3 , Ferdinand C. Breedveld 1 , Shufang Liu 4 and 

Neelufar Mozaffarian 4 , 1 Leiden University Medical 

Center, Leiden, Netherlands, 2 Academic Medical Center, 

Amsterdam, Netherlands, 3 Professor of Medicine, Toronto, 

ON, 4 Abbott, Abbott Park, IL 

1016. The Effect of Evaluation Variability At the Unit of 

Measurement On the Reliability of Omeract Ramris and 

Van Der Heijde-Modified Sharp Score. Ruben Tavares 1 , 

Naveen Parasu 2 , Karen Finlay 2 , Erik Jurriaans 2 , Hao Wu 1 , 

Karen A. Beattie 1 , Maggie Larche 1 , Lawrence E. Hart 3 , 

William G. Bensen 4 , Raja S. Bobba 1 , Alfred A. Cividino 1 , Colin 

E. Webber 5 , Jean-Eric Tarride 6 and Jonathan D. Adachi 7 , 

1 

McMaster University, Hamilton, ON, 2 Hamilton Health 

Sciences, Hamilton, 3 St. Joseph’s Health Care, Hamilton, ON, 

4 


ON, Hamilton, ON, 5 Hamilton Health Sciences, Hamilton, 

ON, 6 Programs for Assessment of Technology in Health 

(PATH) Research Institute, Hamilton, ON, 7 Charlton Medical 

Centre, Hamilton, ON 

1017. Bye Bye Biopsy: Diffusion Tensor and Dynamic Contrast 

Enhance Magnetic Resonance Imaging Parameters Reflect 

Molecular Events of Inflammation in the Synovium. 

Vikas Agarwal 1 , Rishi Awasthi 2 , Deepak Tripathi 3 , Vinita 

Agrawal 3 , Ram Kishore Singh Rathore 4 , Kusum Sharma 5 , 

CM Pandey 3 and Rakesh K. Gupta 3 , 1 Sanjay Gandhi Post 

Graduate Institute of Medical Sciences, Lucknow, Lucknow, 



India, 2 Sanjay Gandhi Post Graduate Institute of Medical 

Sciences, Lucknow, India,, Lucknow, India, 3 Sanjay Gandhi 

Postgraduate Institute of Medical Sciences, Lucknow, 

Lucknow, India, 4 Indian Institute of Technology, Kanpur, 

India, 5 Postgraduate Institute of Medical Education and 

Research, Chandigarh, India 

1018. Reliability of the Early Erosions in Rheumatoid Arthritis 

Software When Quantifying Bone Loss. Melissa XP. Koh 1 , 

Joshua WJ. Barbosa 1 , Ruben Tavares 1 , Stephen Tytus 1 , 

Patrick Emond 1 , Chris Gordon 1 , George Ioannidis 1 , Karen 

A. Beattie 1 , William G. Bensen 2 , Raja S. Bobba 1 , Alfred A. 

Cividino 1 , Lawrence E. Hart 3 , Maggie Larche 1 , Arthur N. Lau 1 

and Jonathan D. Adachi 4 , 1 McMaster University, Hamilton, 

ON, 2 St. Joseph’s Hospital and McMaster University, 

Hamilton, ON, 3 St. Joseph’s Health Care, Hamilton, ON, 4 St. 

Joseph’s Health Care and McMaster University, Hamilton, 

ON 

1019. Visualization of Cartilage in High-Resolution Magnetic 

Resonance Imaging Is a New Imaging Biomarker for the 

Quantification of Joint Damage in Rheumatoid Arthritis. 

Barbara Herz 1 , Stephanie Finzel 1 , Andreas Albrecht 1 , Juergen 

Rech 1 , Matthias Englbrecht 1 , Goetz Welsch 2 and Georg 

Schett 3 , 1 University of Erlangen-Nuremberg, Erlangen, 

Germany, 2 Department of Traumatic Surgery, University 

Clinic of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, 



1020. Location of Erosions At the Metatarsophalangeal Joints 

in Patients with Rheumatoid Arthritis. Heidi J. Siddle 1 , 

Richard J. Hodgson 2 , Andrew J. Grainger 3 , Anthony C. 

Redmond 4 , Richard J. Wakefield 4 and Philip S. Helliwell 5 , 

1 

University of Leeds, Leeds, United Kingdom, 2 NIHR Leeds 


Kingdom, 3 Leeds Teaching Hospitals NHS Trust and NIHR 

Leeds Musculoskeletal Biomedical Research Unit, Leeds, 

United Kingdom, 4 University of Leeds and NIHR Leeds 


Kingdom, 5 NIHR Leeds Biomedical Research Unit, University 

of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, 


1021. Magnetic Resonance Imaging in Follow-up of Clinical 

Remission in Juvenile Idiopathic Arthritis. Mira van 

Veenendaal 1 , Robert Hemke 2 , Marjolein I. Bos 1 , Mario 

Maas 2 , Marion A. J. Van Rossum 1 and Taco W. Kuijpers 1 , 

1 

Emma Children’s Hospital / Academic Medical Center 

(AMC), Amsterdam, Netherlands, 2 Academic Medical Center 

(AMC), Amsterdam, Netherlands 

1022. Imaging of Ankle Joints by MRI in Murine Models of 

Inflammatory Arthritis. Shawn M. Rose 1 , Harris R. Perlman 1 , 

Emily Alex Waters 2 and Thomas Meade 2 , 1 Northwestern 

University, Chicago, IL, 2 Northwestern University, Evanston, 

IL 

1023. Scoring Radiographic Progression in Axial Spa: Should 

We Use the Modified Stoke in Ankylosing Spondylitis 

Spine Score or the Radiographic Ankylosing Spondylitis 

Spinal Score? Sofia Ramiro1, A.M. Van Tubergen 2 , Carmen 

Stolwijk 2 , Robert Landewé 3 and Désirée van der Heijde 4 , 

1 

Academic Medical Center, University of Amsterdam, 

The Netherlands and Hospital Garcia de Orta, Almada, 

Portugal, 2 Maastricht University Medical Center, Maastricht, 

Netherlands, 3 Academic Medical Center, University 


Netherlands, 4 Leiden University Medical Center, Leiden, 

Netherlands 

1024. What Constitutes the Characteristic Fat Lesion On MRI 

of the Sacroiliac Joints in Early Spondyloarthritis? Ulrich 

Weber 1 , Susanne Juhl Pedersen 2 , Veronika Zubler 1 , Kaspar 

Rufibach 3 , Stanley Chan 4 , Robert GW Lambert 4 , Mikkel 

Ostergaard 5 and Walter P. Maksymowych 4 , 1 Balgrist 

University Hospital, Zurich, Switzerland, 2 Copenhagen 

University Hospital Glostrup, Copenhagen, Denmark, 

3 

University of Zurich, Zurich, Switzerland, 4 University of 

Alberta, Edmonton, AB, 5 Copenhagen University Hospital at 


1025. Spinal Inflammation in the Absence of SI Joint 

Inflammation on MRI in Patients with Active Non- 

Radiographic Axial Spondyloarthritis. Désirée van der 

Heijde 1 , Joachim Sieper 2 , Walter P. Maksymowych 3 , 

Matthew A. Brown 4 , Suchitrita S. Rathmann 5 and Aileen 

L. Pangan 5 , 1 Leiden University Medical Center, Leiden, 

Netherlands, 2 Charité Universitätesmedizin Berlin, Berlin, 

Germany, 3 University of Alberta, Edmonton, AB, 4 University 

of Queensland Diamantina Insititute, Brisbane, Australia, 

5 

Abbott Laboratories, Abbott Park, IL 

1026. Psoriatic Arthritis and Spondyloarthritis: Inflammation 

Assessed by “Head to Toe” Wholebody Magnetic 

Resonance Imaging - A Comparison with Clinical Joint 

Examination. René Panduro Poggenborg 1 , Susanne Juhl 

Pedersen 2 , Iris Eshed 3 , Inge Juul Sørensen 2 , Ole Rintek 

Madsen 4 , J.M. Møller 5 and Mikkel Østergaard 6 , 1 Copenhagen 

University Hospital in Glostrup, Copenhagen, Denmark, 

2 

Glostrup Hospital, Copenhagen, Denmark, 3 Sheba Medical 

Center, Tel Hashomer, Israel, 4 Copenhagen University 

Hospital in Gentofte, Copenhagen, Denmark, 5 Copenhagen 

University Hospital in Herlev, Copenhagen, Denmark, 

6 

Copenhagen University Hospital Glostrup, Glostrup, 

Denmark 

1027. Frequency of MRI-Detected Hip Osteoarthritis Features 

in Persons with Chronic Hip Pain and the Diagnostic 

Performance of Radiography Using MRI as the Reference. Li 

Xu 1 , Daichi Hayashi 1 , Ali Guermazi 1 , David J. Hunter 2 , Anton 

Winterstein 3 , Ling Li 4 , Klaus Bohndorf 3 and Frank Roemer 3 , 

1 

Boston University School of Medicine, Boston, MA, 2 Royal 

North Shore Hospital, Sydney, Australia, 3 Klinikum Augsburg, 

Augsburg, Germany, 4 New England Baptist Hospital, Boston, 

MA 

210 

2012 Program Book


1028. Semi-Quantitative Assessment of Bone Marrow Edema 

and Synovitis-Effusion in Osteoarthritis with the Knee 

Inflammation MRI Scoring System: A Target Lesion Based 

Methodology. Walter P. Maksymowych 1 , Ulrich Weber 2 , 

Marcus Pianta 3 and Robert GW Lambert 1 , 1 University of 

Alberta, Edmonton, AB, 2 Balgrist University Hospital, Zurich, 

Switzerland, 3 University of Alberta, AB 

1029. Frequency of Mediopatellar Plica in Persons with Chronic 

Knee Pain and Its Cross-Sectional Association with 

Patellofemoral Cartilage Damage and Bone Marrow 

Lesions: Data From the Joints On Glucosamine Study. Li 

Xu 1 , Daichi Hayashi 1 , Ali Guermazi 1 , C. Kent Kwoh 2 , Michael 

J. Hannon 3 , Mohamed Jarraya 1 , Carolyn E. Moore 4 , John M. 

Jakicic 5 , Stephanie M. Green 6 and Frank Roemer 7 , 1 Boston 

University School of Medicine, Boston, MA, 2 University 

of Pittsburgh and VA Healthcare System, Pittsburgh, PA, 

3 


PA, 4 Texas Women’s University, Houston, TX, 5 University 

of Pittsburgh, PA, 6 University of Pittsburgh, Pittsburgh, PA, 

7 

Klinikum Augsburg, Augsburg, Germany 

1030. Frequency and Fluctuation of Susceptibility Artifacts in the 

Tibio-Femoral Joint Space in Painful Knees On 3T MRI and 

Association with Meniscal Tears, Radiographic Joint Space 

Narrowing and Calcifications. Daichi Hayashi 1 , Mohamed 

Jarraya 1 , Ali Guermazi 1 , C. Kent Kwoh 2 , Michael J. Hannon 3 , 

Carolyn E. Moore 4 , John M. Jakicic 5 , Stephanie M. Green 6 

and Frank Roemer 7 , 1 Boston University School of Medicine, 

Boston, MA, 2 Univ of Pittsburgh, Pittsburgh, PA, 3 University 

of Pittsburgh School of Medicine, Pittsburgh, PA, 4 Texas 

Women’s University, Houston, TX, 5 University of Pittsburgh, 

PA, 6 University of Pittsburgh, Pittsburgh, PA, 7 Klinikum 

Augsburg, Augsburg, Germany 

1031. High Degree of Symmetricity of MRI-Detected Articular 

Tissue Damage in Subjects with Knee Pain: A within- 

Person Analysis From the JOG Study. Frank Roemer 1 , C. 

Kent Kwoh 2 , Michael J. Hannon 3 , Robert M. Boudreau 4 , 

Stephanie M. Green 4 , John M. Jakicic 5 , Carolyn E. Moore 6 

and Ali Guermazi 7 , 1 Klinikum Augsburg, Augsburg, Germany, 

2 

University of Pittsburgh and VA Healthcare System, 

Pittsburgh, PA, 3 University of Pittsburgh School of Medicine, 

Pittsburgh, PA, 4 University of Pittsburgh, Pittsburgh, PA, 

5 

University of Pittsburgh, PA, 6 Texas Women’s University, 

Houston, TX, 7 Boston University School of Medicine, Boston, 

MA 

1032. Medial Meniscal Root Tears and the Association with 

Meniscal Extrusion, Prevalent Cartilage Damage and 

Longitudinal Cartilage Loss: The MOST Study. Mohamed 

Jarraya 1 , David T. Feslon 1 , Daichi Hayashi 1 , Frank Roemer 2 , 

Yuqing Zhang 1 , Jingbo Niu 1 , Michel Crema 1 , Martin Englund 3 , 

John A. Lynch 4 , Michael C. Nevitt 5 , James Torner 6 , C.E. 

Lewis 7 and Ali Guermazi 1 , 1 Boston University, Boston, MA, 

2 

Klinikum Augsburg, Augsburg, Germany, 3 Lund University, 

Lund, Sweden, 4 University of California at San Francisco, San 

Francisco, CA, 5 University of California-San Francisco, San 

Francisco, CA, 6 University of Iowa, Iowa City, IA, 7 University 

of Alabama at Birmingham, Birmingham City, AL 

1033. Reliability and Responsiveness of Two Methods for 

Assessment of Magnetic Resonance Imaging Abnormalities 

in Hip Osteoarthritis in a Placebo-Controlled Trial of 

Intra-Articular Steroid Injection. Walter P. Maksymowych 1 , 

Jolanda Cibere 2 , Ulrich Weber 3 , Jacob Jaremko 1 , Damien 

Loeuille 4 , Veronika Zubler 3 , Frank Roemer 5 , Eric C. Sayre 6 

and Robert GW Lambert 1 , 1 University of Alberta, Edmonton, 

AB, 2 Arthritis Research Ctr of CA, Vancouver, BC, 3 Balgrist 

University Hospital, Zurich, Switzerland, 4 CHU Brabois, 

Vandoeuvre les Nancy, France, 5 Klinikum Augsburg, 

Augsburg, Germany, 6 Arthritis Research Centre of Canada, 

Vancouver, BC 

1034. Changing Osteoarthritis Treatment Assessment Paradigms: 

Subchondral Bone Is a More Responsive Measure of 

Progression Than the Current Radiographic Standard. 

Michael A. Bowes 1 , Christopher B. Wolstenholme 1 , Devan 

Hopkinson 1 , Graham R. Vincent 1 and Philip G. Conaghan 2 , 

1 

Imorphics Ltd, Manchester, United Kingdom, 2 University of 

Leeds, Leeds, United Kingdom 

1035. Characterisation of New Bone Formation in Gout: A 

Quantitative Site-by-Site Analysis Using Plain Radiography 

and Computed Tomography. Nicola Dalbeth 1 , Aaron 

Milligan 2 , Barnaby Clark 2 , Fiona M. McQueen 1 and Anthony 

Doyle 1 , 1 University of Auckland, Auckland, New Zealand, 

2 

Department of Radiology, Auckland District Health Board, 

Auckland, New Zealand 

1036. The Prevalence of Chondrocalcinosis of the 

Acromioclavicular Joint On Chest Radiographs and 

correlation with Calcium Pyrophosphate Dihydrate Crystal 

Deposition Disease. Konstantinos M. Parperis, Guillermo F. 

Carrera, Keith E. Baynes, Alan P. Mautz, Melissa S. DuBois, 

Ross M. Cerniglia and Lawrence M. Ryan, Medical College of 

Wisconsin, Milwaukee, WI 

1037. Magnetic Resonance Imaging (MRI) Assessment of 

Inflammatory Myopathy: Quantitative Fat-Corrected 

Muscle T2 and Conventional T2 Measurement Versus 

Standard MRI and Clinical Metrics. Lawrence Yao 1 , Adrienne 

L. Yip 2 , Sepehr Mesdaghinia 3 , Ashkan Shademan 3 , Joseph 

A. Shrader 1 , Anna V. Jansen 2 , Frederick W. Miller 2 and Lisa 

G. Rider 2 , 1 Clinical Center, NIH, Bethesda, MD, 2 NIEHS, NIH, 

Bethesda, MD, 3 NIEHS, NIH, Bethesda 

1038. Assessment of Aortic Stiffness by Cardiac Magnetic 

Resonance Imaging in Systemic Autoimmune Rheumatic 

Diseases. Galia Karp 1 , Arik Wolak 2 , Nina Baram 3 , Victor 

Novack 4 , Philip Rosen 3 , Yael Perl 5 , Talia Wolak 6 , Ilan Shelef 3 

and Mahmoud Abu-Shakra 7 , 1 Department of Medicine, 

Soroka Medical Centre and Ben Gurion University, Beer- 

Sheva, Israel, 2 Dept. of Cardiology, Cardiac MRI unit, Soroka 

University Medical Center, and Ben Gurion University, 

Beer-Sheva, Israel, 3 Radiology division, Soroka University 

Medical Center and Ben Gurion University, 4 Department 

of Medicine, Clinical Research center, Soroka University 

Medical Center and Ben Gurion University, 5 Clinical Research 

center, Soroka University Medical Center and Ben Gurion 

University, 6 Department of Medicine and Hypertension 



unit, Soroka University Medical Center and Ben-Gurion 

University, 7 Department of Medicine and Rheumatology, 

Soroka Medical Centre and Ben Gurion University, Beer- 

Sheva, Israel 

1039. Cardiac Involvement in Systemic Sclerosis: The Added 

Value of Magnetic Resonance Imaging. Luna Gargani 1 , 

Alessandro Pingitore 2 , Daniele De Marchi 2 , Serena Guiducci 3 , 

Giancarlo Todiere 2 , Silvia Bellando Randone 3 , Cosimo Bruni 3 , 

Marica Doveri 4 , Laura Bazzichi 4 , Stefano Bombardieri 4 , 

Massimo Lombardi 2 , Eugenio Picano 1 and Marco Matucci 

Cerinic 3 , 1 Institute of Clinical Physiology, National Research 

Council, Pisa, Italy, 2 Gabriele Monasterio Foundation, CNR- 

Regione Toscana, Pisa, Italy, 3 Department of Biomedicine, 

Division of Rheumatology AOUC, Excellence Centre for 

Research, Florence, Italy, 4 Rheumatology Unit, University of 

Pisa, Pisa, Italy 

1040. Combined High-Resolution Single Photon Emission 

Computed Tomography and Magnetic Resonance Imaging 

for Therapy Monitoring in Rheumatoid Arthritis. Philipp 

Sewerin 1 , Christian Buchbender 1 , Katalin Mattes-György 1 , 

Falk Miese 1 , Hans-Jörg Wittsack 1 , Christof Specker 2 , 

Gerald Antoch 1 , Matthias Schneider 3 , Axel Scherer 1 and 

Ben Ostendorf 1 , 1 Heinrich-Heine-University, Düsseldorf, 

Germany, 2 Hospital Essen Sued, Essem, Germany, 3 Heinrich- 

Heine-University, Duesseldorf, Germany 

1041. Whole-Body Magnetic Resonance Imaging - A New 

Diagnostic Tool in the Assessment of Activity in Juvenile 

Dermatomyositis Patients? Tania Monteiro de Castro 1 , 

Henrique Lederman 1 , Maria Teresa Terreri 1 , Wanda I. 

Caldana 1 , Edmar Zanoteli 2 and Maria Odete Hilario 1 , 1 Federal 

University of São Paulo, São Paulo, Brazil, 2 University of São 


1042. Psoriatic Arthritis Patients Assessed by Dynamic Contrast- 

Enhanced MRI in High Disease Versus Minimal Disease 

Activity State - a Cross-Sectional Study Correlating 

Conventional MRI and Clinical Composite Measures. 

René Panduro Poggenborg 1 , Pernille Bøyesen 2 , Charlotte 

Wiell 3 , Susanne Juhl Pedersen 4 , Inge Juul Sørensen 5 , 

Ole Rintek Madsen 6 , Ole Slot 1 , Jakob M. Møller 7 , Mikael 

Boesen 8 , Henning Bliddal 9 , Olga Kubassova 10 and Mikkel 

Østergaard 11 , 1 Copenhagen University Hospital in Glostrup, 

Copenhagen, Denmark, 2 Diakonhjemmet Hospital, Olso, 

Norway, 3 Copenhagen University Hospital in Gentofte, 

Copenhagen, Denmark, 4 Copenhagen University Hospital 

Glostrup, Copenhagen, Denmark, 5 Glostrup Hospital, 

Copenhagen, Denmark, 6 DANBIO, On behalf of Depts of 


Region, Copenhagen, Denmark, 7 Copenhagen University 

Hospital in Herlev, Copenhagen, Denmark, 8 Copenhagen 

University Hospital at Frederiksberg, Copenhagen, Denmark, 

9 

Copenhagen University Hospital at Frederiksberg, 

Frederiksberg, Denmark, 10 Image Analysis Ltd., Leeds, 

United Kingdom, 11 Glostrup Hospital, Glostrup, Denmark 

1043. Assessment of Rheumatoid Arthritis Disease Activity by 

Power Doppler Ultrasonography: Association with Routine 

Clinical Indices and Its Usefulness in Detecting Remission. 

Hiroaki Taguchi, Kazuo Nishi, Takeo Kudo and Yutaka Okano, 

Kawasaki Municipal Kawasaki Hospital, Kawasaki, Japan 

1044. Ultrasound Scores of Enthesitis and Dactylitis Do Not 

Correlate with Corresponding Clinical Findings in Psoriasis 

Arthritis. Rusmir Husic 1 , Josef Hermann 1 , Judith Gretler 2 , 

Winfried B. Graninger 1 and Christian Dejaco 1 , 1 Medical 

University Graz, Graz, Austria, 2 Auenbruggerplatz 15 , Graz, 

Austria 

1045. Dynamic Contrast-Enhanced Magnetic Resonance Imaging 

of the Wrist in Rheumatoid Arthritis Patients Treated 

with Methotrexate, Intra-Articular Glucocorticoid and 

Adalimumab/Placebo. Mette Bjørndal Axelsen 1 , Merete 

L. Hetland 2 , Kim Hørslev-Petersen 3 , Kristian Stengaard- 

Pedersen 4 , Peter Junker 5 , Jan Pødenphant 6 , Jakob M. 

Møller 7 , Henning Bliddal 8 , Olga Kubassova 9 , Mikael 

Boesen 10 and Mikkel Østergaard 1 , 1 Copenhagen University 

Hospital at Glostrup, Copenhagen, Denmark, 2 Copenhagen 

University and Glostrup Hospital, Copenhagen, Denmark, 

3 

University of Southern Denmark, Graasten, Denmark, 

4 

Arhus University Hospital, Aarhus, Denmark, 5 Odense 

University Hospital, Odense C, Denmark, 6 Copenhagen 

University at Gentofte, Hellerup, Denmark, 7 Copenhagen 

University Hospital in Herlev, Copenhagen, Denmark, 

8 

The Parker Institute, Copenhagen University Hospital at 

Frederiksberg, Copenhagen, Denmark, 9 Image Analysis Ltd., 

Leeds, United Kingdom, 10 Copenhagen University Hospital at 

Frederiksberg, Copenhagen, Denmark 

1046. Automated Breast Volume Scanner (ABVS), a New 

Automated Ultrasonic Device, Is Useful to Examine Joint 

Injury in Patients with Rheumatoid Arthritis. Shin-ya 

Kawashiri 1 , Takahisa Suzuki 1 , Yoshikazu Nakashima 1 , Akitomo 

Okada 1 , Naoki Iwamoto 1 , Kunihiro Ichinose 1 , Mami Tamai 1 , 

Kazuhiko Arima 2 , Hideki Nakamura 2 , Tomoki Origuchi 1 , 

Masataka Uetani 1 , Kiyoshi Aoyagi 1 and Atsushi Kawakami 1 , 

1 

Nagasaki University Graduate School of Biomedical 

Sciences, Nagasaki, Japan, 2 Nagasaki University, Nagasaki, 

Japan 

1047. Evaluation of Ankle Swelling Due to Löfgren´s Syndrome: 

A Pilot Study Using B –mode and Power Doppler 

Ultrasonography. Emmanuelle LeBras 1 , Sandra Balser 1 , 

Valentin S. Schäfer 1 , Boris P. Ehrenstein 1 , Patrick Hoffstetter 1 , 

Martina Müller 2 , Martin Fleck 1 and Wolfgang Hartung 1 , 

1 

Asklepios Klinikum Bad Abbach, Bad Abbach, Germany, 

2 

University Clinic Regensburg, Regensburg 

1048. Tenosynovitis in Carpal Tunnel Syndrome – Prevalence 

and Comparison between Ultrasonography, Surgery 

and Histology. David F. Ten Cate 1 , Nick Glaser 1 , Jolanda 

J. Luime 2 , K.H. Lam 3 , Johannes W.G. Jacobs 4 , Ruud W. 

Selles 2 , Johanna Hazes 5 and M. Bertleff 6 , 1 Erasmus Medical 

Center, Rotterdam, Netherlands, 2 Erasmus MC - University 

Medical Center, Rotterdam, Netherlands, 3 Erasmus 

212 

2012 Program Book


University Medical Center, Netherlands, 4 University Medical 

Center Utrecht, Utrecht, Netherlands, 5 Erasmus Medical 

Centre Rotterdam, Rotterdam, Netherlands, 6 Xpert Clinic, 

Rotterdam, Netherlands 

1049. The Prevalence of the Ultrasonographic Positive Power 

Doppler Synovitis Is High and Predicts the Risk of Relapse 

and Structural Progression in Rheumatoid Arthritis 

in Clinical Remission: A Systematic Literature Review 

and Meta Analysis. Huong Nguyen 1 , Adeline Ruyssen- 

Witrand 1 , Arnaud L. Constantin 1 , Violaine Foltz 2 , Frédérique 

Gandjbakhch 2 and Alain G. Cantagrel 1 , 1 Purpan University 

Hospital, Toulouse, France, 2 Pitié Salpétrière Hospital, Paris, 

France 

1050. Assessment of Validity of Magnetic Resonance Imaging 

Measures of Joint Inflammation and Damage in 

Rheumatoid Arthritis Wrist/Hand – a Systematic Literature 

Review. TG Woodworth 1 , O. Morgacheva 2 , OM Troum 3 , 

OL Pimienta 3 , P. Maranian 2 , V.K. Ranganath 2 and D.E. 

Furst 2 , 1 Visiting Clinical Researcher, David Geffen School 

of Medicine, UCLA, Los Angeles, CA, 2 David Geffen School 

of Medicine, UCLA, Los Angeles, CA, 3 USC Keck School of 

Medicine, Santa Monica, CA 

1051. Magnetic Resonance Imaging in Inflammatory Bowel 

Disease Patients with Arthralgia. W. Stomp 1 , L.K.P.M. 

Brakenhoff 1 , F.A. van Gaalen 1 , D. van der Heijde 1 , H.H. 

Fidder 2 , D.W. Hommes 3 , M. Reijnierse 1 and J.L Bloem 1 , 

1 


2 

University Medical Center Utrecht, Utrecht, Netherlands, 

3 

University of California Los Angeles, Los Angeles, CA 

1052. Systematic Review of the Association between Magnetic 

Resonance Imaging and Radiographic Detection of Erosions 

in Rheumatoid Arthritis. Ruben Tavares 1 , Stephen R. Tytus 2 , 

Karen A. Beattie 1 , Maggie Larche 1 , Naveen Parasu 3 , Colin 

E. Webber 4 , Lawrence E. Hart 5 and Jonathan D. Adachi 6 , 

1 

McMaster University, Hamilton, ON, 2 Northern Ontario 

School of Medicine, Sudbury, Qatar, 3 Hamilton Health 

Sciences, Hamilton, 4 Hamilton Health Sciences, Hamilton, 

ON, 5 St. Joseph’s Health Care, Hamilton, ON, 6 Charlton 

Medical Centre, Hamilton, ON 

1053. Severe Joint Injury Assessed by Musculoskeletal 

Ultrasonography (MSKUS) Predicts the Presence of MRI- 

Proven Osteitis in Patients with Rheumatoid Arthritis. 

Shin-ya Kawashiri 1 , Takahisa Suzuki 1 , Yoshikazu Nakashima 1 , 

Yoshiro Horai 1 , Naoki Iwamoto 2 , Kunihiro Ichinose 1 , Kazuhiko 

Arima 2 , Mami Tamai 2 , Hideki Nakamura 2 , Tomoki Origuchi 1 , 

Kiyoshi Aoyagi 1 and Atsushi Kawakami 1 , 1 Nagasaki University 

Graduate School of Biomedical Sciences, Nagasaki, Japan, 

2 

Nagasaki University, Nagasaki, Japan 

1054. Diffusion Tensor and Dynamic Contrast Enhanced Perfusion 

Imaging Metrics Discriminate Chronic Tubercular Synovitis 

From Chronic Inflammatory Synovitis of the Knee. Vikas 

Agarwal 1 , Rakesh K. Gupta 2 , Rishi Awasthi 2 , Deepak Tripathi 2 , 

Prativa Sahoo 3 , Vinita Agrawal 2 , Kusum Sharma 4 , Rungmei 

Marak 5 , Ram Kishore Singh Rathore 3 and CM Pandey 2 , 

1 

Sanjay Gandhi Post Graduate Institute of Medical Sciences, 

Lucknow, Lucknow, India, 2 Sanjay Gandhi Postgraduate 

Institute of Medical Sciences, Lucknow, Lucknow, India, 

3 

Indian Institute of Technology, Kanpur, India, 4 Postgraduate 

Institute of Medical Education and Research, Chandigarh, 

India, 5 Microbiology, Sanjay Gandhi Postgraduate Institute 

of Medical Sciences, Lucknow, Lucknow, India 


1055. Sec61 Is Indispensable for Antigen Cross-Presentation 

and the Development of Lupus Nephritis: A Novel ‘Self- 

Organized Criticality Theory’ Explaining the Cause of 

Systemic Lupus Erythematosus (SLE). Ken Tsumiyama 

and Shunichi Shiozawa, Kyushu University Beppu Hospital, 

Beppu, Japan 

1056. Fc Receptor Gamma-Dependent Autoimmune Endocarditis 

in K/BxN Mice. Patricia M. Hobday 1 , Jennifer L. Auger 1 , J. 

Sjef Verbeek 2 , Jeffrey V. Ravetch 3 and Bryce A. Binstadt 1 , 

1 

University of Minnesota, Minneapolis, MN, 2 Leiden 

University Medical Center, Leiden, Netherlands, 3 The 

Rockefeller University, New York, NY 

1057. A Specific Inhibitor of Spleen Tyrosine Kinase, PRT06260 7 , 

Is a Potent Modulator of Innate Immune Cell Function. 

Lynn A. Kamen, Gillian Stephens, Anjali Pandey and Uma 

Sinha, Portola Pharmaceuticals, South San Francisco, CA 

1058. Fulminant Toll-Like Receptor 9-Induced Macrophage 

Activation Syndrome and Hemophagocytosis Occur 

Independently of Interferon Gamma. Scott W. Canna 1 , 

Julia Wrobel 2 , Portia A. Kreiger 3 , Michele E. Paessler 1 and 

Edward M. Behrens 4 , 1 Childrens Hospital of Philadelphia, 

Philadelphia, PA, 2 The Children’s Hospital of Philadelphia, 

Philadelphia, PA, 3 Nemours/A.I. DuPont Hospital for 

Children, Wilmington, DE, 4 Children’s Hospital of 


1059. Endogenous Complement Factor H Plays an Important Role 

in Controlling Immune Complex-Induced Inflammatory 

Arthritis. Nirmal K. Banda 1 , Gaurav Mehta 1 , Viviana P. 

Ferreira 2 , Claudio Cortes 2 , Michael K. Pangburn 3 , William 

P. Arend 1 and V. Michael Holers 1 , 1 University of Colorado 

School of Medicine, Aurora, CO, 2 University of Toledo Health 

Science Campus, Toledo, OH, 3 University of Texas Health 

Sciences Center, Tyler, TX 

1060. Protein Kinase C Inhibitor Generates Human Tolerogenic 

Dendritic Cells That Induce Tr 1 and Foxp3+ Regulatory T 

Cells. Takuya Matsumoto, Hitoshi Hasegawa, Jun Ishizaki, 

Koichiro Suemori, Sachiko Onishi and Masaki Yasukawa, 

Ehime University Graduate School of Medicine, Toon, Japan 

1061. Generation of Myeloid-Derived Suppressor Cells in Vitro 

from Murine Bone Marrow Precursors. Julia Kurko, Beata 

Tryniszewska, Tibor A. Rauch, Colt Egelston, Tibor T. Glant 

and Katalin Mikecz, Rush University Medical Center, Chicago, 

IL 



1062. Identification of Highly Potent and Selective Interleukin-1 

Receptor-Associated Kinase 4 Inhibitors for the Treatment 

of Rheumatic Diseases. Divya Chaudhary 1 , Shaughnessy 

Robinson 2 , Craig E. Masse 1 , Matthew D. Wessel 2 , Shawn 

Watts 2 , Jeremy Greenwood 2 , Mee Shelley 2 , Mark Brewer 2 , 

Geraldine Harriman 1 , Leah L. Frye 2 , Ronald T. Wester 1 , 

Rosana Kapeller 1 and Donna Romero 1 , 1 Nimbus Discovery, 

Inc., Cambridge, MA, 2 Schrödinger, Inc., New York, NY 

1063. Dysfunction of Natural Killer and Natural Killer T Cells in 

Patients with Adult Onset Still’s Disease. Young-Nan Cho 1 , 

Sung-Ji Lee 1 , Tae-Jong Kim 2 , Hye-Mi Jin 1 , Dong-Jin Park 2 , 

Seung-Jung Kee 1 and Yong-Wook Park 1 , 1 Chonnam National 

University Medical School and Hospital, Gwangju, South 

Korea, 2 Chonnam National University Medical School, 

Gwangju, South Korea 

1064. CD1c-Expressing Myeloid Dendritic Cells From Joints of 

Rheumatoid Arthritis Patients Produce Increased Levels 

of T Cell-Attracting Chemokines and Strongly Activate 

Autologous T Cells. F.M. Moret, C.E. Hack, F.P.J.G. Lafeber, 

T.R.D.J. Radstake and J.A.G. van Roon, University Medical 

Center Utrecht, Utrecht, Netherlands 

1065. Hypoxia-Inducible Factor-1α: Trigger of Toll-Like Receptor 

Signalling-Engaged Inflammation in Rheumatoid Arthritis. 

Fanlei Hu 1 , Rong Mu 1 , Jiaxin Zhu 1 , Wenwei Shao 2 , Lianjie 

Shi 1 , Philip L. Cohen 3 , Xiaoyan Qiu 2 and Zhanguo Li 1 , 1 Peking 

University People’s Hospital, Beijing, China, 2 School of Basic 

Medical Science, Peking University, Beijing, China, 3 Temple 


1066. Extrathymic Autoimmune Regulator (AIRE) Expression in 

Rheumatoid Arthritis. A.R. Noort 1 , K.P.M. van Zoest 1 , M.C. 

Lebre 1 , P. P. Tak 2 and S.W. Tas 1 , 1 Academic Medical Center 


2 

Academic Medical Center / University of Amsterdam and 


1067. Spontaneous Aggregation of the Anti-Viral Mavs Protein 

in Certain Systemic Lupus Erythematosus Patients May 

Explain Excessive Type I Interferon Production. Philip L. 

Cohen 1 and Wen-Hai Shao 2 , 1 Temple University, Philadelphia, 

PA, 2 Temple University School of Medicine, Philadelphia, PA 

1068. A Selective Inhibitor of Endosomal Toll-Like Receptors, 

IMO-8400, Suppresses Activation of Multiple Cytokines, 

Th17 Response and Inflammasome Activation. Weiven 

Jiang, Fugang Zhu, Dong Yu, Ekambar R. Kandimalla, Nicola 

La Monica and Sudhir Agrawal, Idera Pharmaceuticals, 

Cambridge, MA 

1069. The Effects of TNF Stimulation on Control of Apoptosis in 

Neutrophils. Direkrit Chiewchengchol, Connie Lam, Kate 

Roberts, Helen Wright, Huw Thomas, Robert Moots and 

Steven Edwards, University of Liverpool, Liverpool, United 

Kingdom 

1070. CD11c+ Dendritic Cells Play an Important Proinflammatory 

Role in Inflammatory Arthritis. Antonia Puchner 1 , Stephan 

Blüml 2 , Harald Leiss 2 , Victoria Saferding 2 and Kurt Redlich 2 , 

1 

Medical University Vienna, Vienna, Austria, 2 Medical 

University of Vienna, Vienna, Austria 


1072. Enzymatic Lipid Oxidation Contributes to the Maintenance 

of Self-Tolerance by Regulating Antigen Clearance and 

Dendritic Cell Function. Stefan Uderhardt 1 , Tobias Rothe 1 , 

Elisabeth Zinser 1 , Olga Oskolkova 2 , Martin Herrmann 3 , 

Alexander Steinkasserer 4 , Valery Bochkov 2 , Georg Schett 5 

and Gerhard Kronke 1 , 1 University of Erlangen, Erlangen, 

Germany, 2 Department of Vascular Biology and Thrombosis 

Research, Center for Physiology and Pharmacology, 

Medical University of Vienna, Vienna, Austria, Vienna, 

Austria, 3 PhD, Erlangen, Germany, 4 Department of Immune 

Modulation at the Department of Dermatology, University 

Hospital Erlangen, Erlangen, Germany, 5 Institute for Clinical 

Immunology, University of Erlangen-Nuremberg, Erlangen, 

Germany 

1073. Increased Oxidative Burst in Neutrophils but Not 

Monocytes in Systemic Lupus Erythematosus. Sandro 

F. Perazzio 1 , Reinaldo Salomao 1 , Neusa P. Silva 2 and Luis 

Eduardo C. andrade 3 , 1 Federal University of Sao Paulo, Sao 

Paulo, Brazil, 2 Escola Paulista de Medicina - Universidade 

Federal de São Paulo, Sao Paulo, Brazil, 3 Universidade 

Federal de São Paulo, Sao Paulo, Brazil 

1074. TLR2 Deletion Promotes Arthritis and Joint Destruction 

Through Reduction of IL-10. Qi Quan Huang 1 , Renee E. 

Koessler 1 , Robert Birkett 2 , Harris R. Perlman 1 , Lianping Xing 3 

and Richard M. Pope 4 , 1 Northwestern University, Chicago, 

IL, 2 Northwestern University Feinberg School of Medicine, 

Chicago, IL, 3 University of Rochester, Rochester, NY, 

4 

Northwestern Univ Med School, Chicago, IL 

1075. Effects of siRNA Depletion of Interferon Regulatory Factor 

5 on Pro-Inflammatory Cytokine Production and IgG 

Secretion by Primary Human Immune Cells in Response to 

TLR7/8 Stimulation. Dinesh Srinivasan 1 , Sandip Panicker 2 , 

Gang Lu 1 , Yajuan Gu 1 , Rothschild Soto 2 , Seng-Lai Tan 1 

and Julie Demartino 1 , 1 Hoffmann-La Roche, Nutley, NJ, 

2 

Hoffmann La Roche, Nutley, NJ 

1076. FLIP in Dendritic Cells May Regulate Hematopoietic 

Homeostasis and Modulating Inflammation and Immunity. 

Qi Quan Huang 1 , Robert Birkett 2 , Harris R. Perlman 1 and 

Richard M. Pope 3 , 1 Northwestern University, Chicago, IL, 

2 


Chicago, IL, 3 Northwestern Univ Med School, Chicago, IL 

1077. p21 Promotes Inflammatory Arthritis Resolution by 

Facilitating Alternative Activation of Macrophages. 

Angelica K. Gierut 1 , Carla M. Cuda 2 , Alexander V. Misharin 3 , 

Rana Saber 3 and Harris R. Perlman 3 , 1 Northwestern Med 

Faculty Found, Chicago, IL, 2 Northwestern University 

Feinberg School of Medicine, Chicago, IL, 3 Northwestern 


214 

2012 Program Book


1078. Prolactin Is Increased in Responders to Anti-TNFá 

Treatment and the Role of the Prolactin Receptor in 

Rheumatoid Arthritis. Man Wai Tang 1 , Danielle Marie 

Gerlag 2 , Veronica Codullo 3 , Elsa Vieira-Sousa 4 , Anne Q. 

Reuwer 5 , Marcel T. Twickler 5 , Robert B. M. Landewé 6 and 

Paul Peter Tak 7 , 1 Academic Medical Center / University of 

Amsterdam, Amsterdam, Netherlands, 2 Academic Medical 

Center, Amsterdam, Netherlands, 3 Academic Medical 

Center/Univeristy of Amsterdam / University of Pavia, IRCCS 

Policlinico San Matteo Foundation, Amsterdam / Pavia, 

Netherlands, 4 Instituto de Medicina Molecular, Faculdade 

de Medicina da Universidade de Lisboa, Lisbon, Portugal, 

5 

Academic Medical Center/University of Amsterdam, 

Amsterddam, Netherlands, 6 Academic Medical Center/ 

University of Amsterdam & Atrium Medical Center, 

Amsterdam, Netherlands, 7 Academic Medical Center/ 

University of Amsterdam, Amsterdam, Netherlands 

1079. Polyclonal CD4+Foxp3+ treg Cells Induce TGFb-Dependent 

Tolerogenic Dendritic Cells That Suppress Murine Lupus- 

Like Syndrome. Qin Lan 1 and Song G. Zheng 2 , 1 University 

of Southern California, Los Angeles, CA, 2 Keck School of 

Medicine of USC, Los Angeles, CA 

1080. Effect of Anti-NKG2A Antibody Treatment on NK Cell 

Receptor Expression in Rheumatoid Arthritis Patients. 

Joseph Wahle, John Bui and Kristen Bontadelli, Novo 

Nordisk, Seattle, WA 

1081. Toll-Like Receptor 7, 8 and 9 Activation of Primary Human 

Cells by Lupus Immune Complexes Is Dependent On 

Interleukin 1 Receptor Associated Kinase 4 Activity. Aaron 

Winkler, Weiyong Sun, Ken Dower, Elizabeth A. Murphy, 

Julia Shin, Michael Luong, Michael J. Primiano, Varenka 

A. Rodriguez, Tatyana Souza, Lih-Ling Lin, J. Perry Hall, 

Katherine Lee, Vikram R. Rao and Margaret Fleming, Pfizer, 

Cambridge, MA 

Orthopedics, Low Back Pain, and Rehabilitation Poster 

1082. Predictors of Persistence in People with Subacute Low 

Back Pain. Souraya Torbey, Ali Mansour, Kristina Herrmann, 

Marwan Baliki, Thomas J. Schnitzer and A. Vania Apkarian, 

Northwestern University, Chicago, IL 

1083. Physicians’ Recommendations for Total Knee Arthroplasty 

in Younger Persons with Moderate Osteoarthritis. 

Liana Fraenkel 1 , Lawrence Weis 2 and Lisa G. Suter 2 , 1 Yale 


Healthcare System, New Haven, CT, 2 Yale University, New 

Haven, CT 

1084. In Vivo Kinematics of Three-Component Mobile-Bearing 

Total Ankle Replacement for Rheumatoid Arthritis. Keiji 

Iwamoto 1 , Tetsuya Tomita 1 , Takaharu Yamazaki 2 , Kenrin Shi 1 , 

Norimasa Shimizu 1 , Masahiro Kurita 1 , Kazuma Futai 1 , Yasuo 

Kunugiza 1 , Hideki Yoshikawa 1 and Kazuomi Sugamoto 1 , 

1 

Osaka University Graduate School of Medicine, Osaka, 

Japan, 2 Osaka University, Osaka, Japan 

1085. Differences in Baseline Characteristics between TKR 

and THR Patients: Results from a National Research 

Consortium. Patricia D. Franklin 1 , Benjamin Snyder 1 , 

Jeroan Allison 2 , Wenjun Li 1 , Milagros Rosal 1 , Leslie R. 

Harrold 3 , Bruce Barton 2 and David Ayers 1 , 1 University of 

Massachusetts Medical School, Worcester, MA, 2 University 

of Massachusetts Medical School, 3 UMass Medical School, 

Worcester, MA 

1086. Has the Level of Disability At Time of TKR Changed Over 

the Past 10 Years?: Results From Two National Cohorts. 

Patricia D. Franklin 1 , Wenjun Li 1 , Benjamin Snyder 1 , 

Courtland Lewis 2 , Philip Noble 3 and David Ayers 1 , 1 University 

of Massachusetts Medical School, Worcester, MA, 2 CT Joint 

Replacement Institute, St. Francis Hospital, Hartford, CT, 

3 

Baylor College of Medicine, Houston, TX 

1087. Do Younger TKR Patients Have Similar Disability At Time 

of Surgery As Older Adults? Patricia D. Franklin 1 , Wenjun 

Li 1 , Leslie R. Harrold 2 , Benjamin Snyder 1 , Courtland Lewis 3 , 

Philip Noble 4 and David Ayers 1 , 1 University of Massachusetts 

Medical School, Worcester, MA, 2 UMass Medical School, 

Worcester, MA, 3 CT Joint Replacement Institute, St. Francis 

Hospital, Hartford, CT, 4 Baylor College of Medicine, Houston, 

TX 

1088. Factors Influencing Long-Term Recovery of Total Knee 

Arthroplasty. C. Allyson Jones 1 , Gian S. Jhangri 2 and Maria 

E. Suarez-Almazor 3 , 1 Departments of Physical Therapy and 

School of Public Health, University of Alberta, Edmonton, 

AB, 2 School of Public Health, University of Alberta, 

Edmonton, AB, 3 University of Texas MD anderson Cancer 


1089. The Number of Ruptured Tendons as a Prognostic Factor 

for Reconstructing Extensor Tendon Rupture in Patients 

with Rheumatoid Arthritis. Yu Sakuma, Kensuke Ochi, 

Takuji Iwamoto, Shinji Yoshida, Asami Saitou, Katsunori Ikari 

and Shigeki Momohara, Institute of Rheumatology, Tokyo 

Women’s Medical University, Tokyo, Japan 

1090. A Comparison of Patient-Reported and Measured Range 

of Motion in a Cohort of Total Knee Replacement Patients. 

Jamie E. Collins, Benjamin N. Rome, Vladislav Lerner, Jeffrey 

N. Katz and Elena Losina, Brigham and Women’s Hospital, 

Boston, MA 

1091. Trends in Patient Physical Activity before and After Primary 

Total Hip Arthroplasty. Anne Lübbeke, Dorith Zimmermann, 

Constantinos Roussos, Alexis Bonvin, Robin Peter and 

Pierre Hoffmeyer, Geneva University Hospitals, Geneva, 

Switzerland 

1092. Effect of FULL Contact FOOT Orthosis On Plantar Fasciitis. 

Hilda A. Oliveira 1 , Anamaria Jones 1 , Emilia Moreira 1 , Fabio 

Jennings 1 and Jamil Natour 2 , 1 Universidade Federal de Sao 

Paulo, Sao Paulo, Brazil, 2 Universidade Federal de São Paulo, 




1093. Obesity Is Not a Risk Factor for Poor Pain and Function Two 

Years after Total Knee Replacement. Lisa A. Mandl, Mark 

P. Figgie, Alejandro Gonzalez Della Valle, Michael Alexiades 

and Susan M. Goodman, Hospital for Special Surgery, New 

York, NY 

1094. The Relationship between Lumbar Spine Individual 

Radiographic Features and Low Back Symptoms with and 

without Associated Leg Symptoms: The Johnston County 

Osteoarthritis Project. Adam P. Goode 1 , Janet K. Freburger 2 , 

Timothy S. Carey 3 , Chad E. Cook 4 , Jordan Renner 5 , Sean D. 

Rundell 6 and Joanne M. Jordan 7 , 1 Duke University, Durham, 

NC, 2 University of NC CB 7590, Chapel Hill, NC, 3 Cecil G. 

Sheps Center for Health Services Research University of 

North Carolina, Chapel Hill, NC, 4 Walsh University, OH, 

5 

University of North Carolina, Chapel Hill, NC, 6 University 

of Washington, Seatle, WA, 7 University of North Carolina 


1095. Metal Concentrations in Patients with Failed Metal- 

On-Metal Hip Prostheses Determine the Inflammatory 

Phenotype in Peri-Implant Tissue. Erja-Leena Paukkeri 1 , 

Riku Korhonen 1 , Antti Eskelinen 2 , Marko Pesu 3 , Kaija 

Vasama 4 , Teemu Moilanen 2 and Eeva Moilanen 1 , 1 The 

Immunopharmacology Research Group, University of 

Tampere School of Medicine and Tampere University 

Hospital, Tampere, Finland, 2 Coxa Hospital for Joint 

Replacement, Tampere, Finland, 3 Immunoregulation, 

Institute of Biomedical Technology, University of Tampere, 

Tampere, Finland, 4 Fimlab Laboratories, Tampere, Finland 

1096. Lower Income Paradoxically Associated with Better 

Patient-Reported Outcomes After Knee Arthroplasty in the 

U.S. Jasvinder A. Singh 1 and David Lewallen 2 , 1 University 

of Alabama at Birmingham, Birmingham, AL, 2 Mayo Clinic 

college of medicine, Rochester 

Osteoarthritis - Clinical Aspects 

1097. The Association of Fat Distribution and Clinically Defined 

Hand Osteoarthritis: The Netherlands Epidemiology of 

Obesity Study. A. Willemien Visser, Marieke Loef, andreea 

Ioan-Fascinay, Martin den Heijer, Frits R. Rosendaal and 

Margreet Kloppenburg, Leiden University Medical Center, 

Leiden, Netherlands 

1098. Knee Osteoarthritis and Frailty in Older Adults: 

Findings from the Multicenter Osteoarthritis Study and 

Osteoarthritis Initiative. Devyani Misra 1 , Michael C. Nevitt 2 , 

Cora E. Lewis 3 , James Torner 4 , David T. Felson 1 and Tuhina 

Neogi 1 , 1 Boston University School of Medicine, Boston, MA, 

2 

University of California-San Francisco, San Francisco, CA, 

3 

University of Alabama, Birmingham City, Birmingham, AL, 

4 

University of Iowa, Iowa City, Iowa City, IA 

1099. Whole Blood Lead Is Associated with Symptoms, but 

Not Radiographic Osteoarthritis, in Multiple Joint Sites: 

The Johnston County Osteoarthritis Project. Amanda 

E. Nelson 1 , Xiaoyan A. Shi 2 , Todd A. Schwartz 3 , Jordan B. 

Renner 4 , Kathleen L. Caldwell 5 , Charles G. Helmick 5 and 

Joanne M. Jordan 1 , 1 University of North Carolina Thurston 

Arthritis Research Center, Chapel Hill, NC, 2 SAS Institute, 

Inc, Cary, NC, 3 University of North Carolina Gillings School of 

Global Public Health, Dept of Biostatistics, Chapel Hill, NC, 

4 

University of North Carolina School of Medicine, Dept of 

Radiology, Chapel Hill, NC, 5 Centers for Disease Control and 

Prevention, Atlanta, GA 

1100. A Functional Growth Hormone Receptor Polymorphism, 

Exon 3 Deleted Ghr, Is Associated with Radiographic Knee 

Osteoarthritis in Females with Familial Osteoarthritis 

At Multiple Sites: The Garp Study. Kim M.J.A. Claessen 1 , 

Margreet Kloppenburg 2 , H.M. Kroon 1 , Jessica Bijsterbosch 1 , 

Alberto M. Pereira 1 , Hans A. Romijn 1 , Tahar Straaten 

van der 1 , Marian Beekman 1 , P.E. Slagboom 1 , Nienke R. 

Biermasz 1 and Ingrid Meulenbelt 3 , 1 Leiden University 

Medical Center, Leiden, Netherlands, 2 Department 

Rheumatology and Department of Clinical Epidemiology, 

Leiden University Medical Centre, Leiden, The Netherlands, 

Leiden, Netherlands, 3 The Netherlands Genomics Initiative- 

Sponsored Netherlands Consortium for Healthy Aging, 


1101. Condroitin Sulfate Decreases Chemokine Levels and 

Synovitis in knee osteoarthritis Patients. Jordi Monfort 1 , 

Paula Escudero 2 , Cristobal Orellana 3 , Laura Piqueras 4 , 

Laura Tio 5 , Francisco Montañés 1 , Natalia García 5 , Chantal 

Company 2 , Pere Benito 1 and Maria Jesús Sanz 2 , 1 Hospital del 

Mar, Barcelona, Spain, 2 Universitary Clinic Hospital Research 

Foundation-INCLIVA, University of Valencia, Valencia, Spain, 

3 

Corporació Sanitaria Parc Taulí, Sabadell, Spain, 4 University 

Clinic Hospital Research Foundation-INCLIVA, University of 

Valencia, Valencia, Spain, 5 GRICIC. FIMIM, Barcelona, Spain 

1102. Immunoreactive Collagen Type II Cleavage Products 

and Their Nitrated Forms in Rheumatoid Arthritis and 

Osteoarthritis: An Outpatient Cross-Sectional Study. 

Ruediger Mueller 1 , Axel Finckh 2 , Guy Heynen 3 and Johannes 

von Kempis 4 , 1 Cantonal Hospital, St. Gallen, Switzerland, 

2 

Geneva University Hospitals, Geneva 14 , Switzerland, 

3 

Consulting, CH-6300 Zug, Switzerland, 4 MD, St. Gallen, 

Switzerland 

1103. Cumulative Occupational Physical Load as Risk Factor for 

Knee Osteoarthritis. Allison M. Ezzat 1 , Jolanda Cibere 2 , 

Mieke Koehoorn 1 , Eric C. Sayre 2 and Linda C. Li 1 , 1 University 

of British Columbia, Vancouver, BC, 2 Arthritis Research 

Centre of Canada, Vancouver, BC 

1104. The Association of Demographic, Modifiable, Structural 

and Biomechanical Risk Factors with Medial and Lateral 

Patellofemoral Joint Structural Damage on MRI: The 

Multicenter Osteoarthritis Study. Joshua J. Stefanik 1 , Ke 

Wang 1 , K. Douglas Gross 2 , Frank Roemer 3 , John A. Lynch 4 , 

Neil Segal 5 , Cora E. Lewis 6 , Michael C. Nevitt 4 , Ali Guermazi 1 

and David T. Felson 1 , 1 Boston University, Boston, MA, 2 MGH 

Institute of Health Professions, Boston, MA, 3 Klinikum 

Augsburg, Augsburg, Germany, 4 University of California-San 

Francisco, San Francisco, CA, 5 University of Iowa, Iowa City, 

6 

University of Alabama, Birmingham City, Birmingham, AL 

216 

2012 Program Book


1105. Lateral Tibio-Femoral Shift Related to Medial Knee 

Osteoarthritis. Roy H. Lidtke 1 , Berna Goker 2 , Abdurrahman 

Tufan 2 , Laura E. Thorp 1 and Joel A. Block 1 , 1 Rush University 

Medical Center, Chicago, IL, 2 Gazi University Medical School, 

Ankara, Turkey 

1106. Evaluation of Foot Posture and Plantar Pressure Changes 

in Knee Osteoarthritis: Preliminary Report. Necati Balci 

and Lale Cerrahoglu, Celal Bayar University Medical School, 

Manisa, Turkey 

1107. Baseline Knee Flexion Pain, Age and Joint Line Tenderness 

Predict the Progression of Asymptomatic, Radiographic 

Knee Osteoarthritis to Symptomatic Knee Osteoarthritis 

Over 5 Years. Abhiram Gande 1 and James J. Irrgang 2 , 

1 

University of Pittsburgh School of Medicine, Pittsburgh, PA, 

2 


1108. A Randomized Controlled Trial of Hylan G-F 20 for the 

Treatment of Carpometacarpal Osteoarthritis. Lisa A. 

Mandl 1 , Scott Wolfe 2 , Aaron Daluiski 2 , Robert N. Hotchkiss 1 , 

Stephen L. Lyman 3 and Jeffrey N. Katz 4 , 1 Hospital for Special 

Surgery, New York, NY, 2 Hospital For Special Surgery, New 

York, NY, 3 Hospital Special Surgery, New York, NY, 4 Brigham 


1109. Effects of Strontium Ranelate On Hand Osteoarthritis 

– Analysis of Data From the Sekoia Trial. E. Maheu 1 , C. 

Cadet 2 and F. Berenbaum 1 , 1 AP-HP St Antoine Hospital, Paris, 

France, 2 Paris, France 

1110. Radiologic Progression in Hand Osteoarthritis (OA) Over 

2.6 Years - Data from the Sekoia Trial. Emmanuel Maheu 1 , 

Christian Cadet 2 and Francis Berenbaum 1 , 1 AP-HP, St Antoine 

Hospital, Paris, France, 2 Rheumatology, Paris, France 

1111. Erosive Evolution in Hand Osteoarthritis Is Associated with 

Incident Joint Tenderness Independent of MRI-Defined 

Bone Marrow Lesions and Synovitis. Ida K. Haugen 1 , 

Barbara Slatkowsky-Christensen 1 , Pernille Boyesen 1 , Sølve 

Sesseng 1 , Désirée van der Heijde 2 and Tore K. Kvien 1 , 

1 

Diakonhjemmet Hospital, Oslo, Norway, 2 Leiden University 


1112. Patients with Erosive Osteoarthritis Have Less Extensive 

Synovitis Than Patients with Rheumatoid Arthritis On 

Histopathology. Allen P. Anandarajah 1 , Stephen Kates 2 , 

Kate Burns 3 and Ellen Giampoli 4 , 1 Univ of Rochester 

Medical Ctr, Rochester, NY, 2 University of Rochester Medical 

Center, Rochester, 3 University of Rochester, Rochester, NY, 

4 

University of Rochester Medical Ctr, Rochester, NY 

1113. Characterization of Lumbar Spine Individual Radiographic 

Features in African American and White Women and 

Men: The Johnston County Osteoarthritis Project. Adam P. 

Goode 1 , Amanda E. Nelson 2 , Kelli D. Allen 3 , Jordan Renner 4 , 

Timothy S. Carey 5 and Joanne M. Jordan 2 , 1 Duke University, 

Durham, NC, 2 University of North Carolina Thurston Arthritis 

Research Center, Chapel Hill, NC, 3 Duke and Durham VA 

Medical Center, Durham, NC, 4 University of North Carolina, 

Chapel Hill, NC, 5 Cecil G. Sheps Center for Health Services 

Research University of North Carolina, Chapel Hill, NC 

1114. Prevalence of Radiographic and Symptomatic Hip 

Osteoarthritis in an Urban US Population: The Framingham 

Osteoarthritis Study. Katherine D. Linsenmeyer 1 , Ali 

Guermazi 2 , Kyu-Chan Kim 1 , David T. Felson 2 , Mary M. Clancy 2 

and Steven C. Vlad 2 , 1 Boston Medical Center, Boston, MA, 

2 

Boston University, Boston, MA 

1115. Relation between Hip Dysplasia, Pain, and Osteoarthritis in 

a Cohort of Patients with Hip Symptoms. Johanne Morvan 1 , 

Ronan Bouttier 2 , Bernard Mazieres 3 , Evelyne Verrouil 3 , 

Jacques Pouchot 4 , Anne-Christine Rat 5 , Joel Coste 6 and Alain 

Saraux 7 , 1 CH Quimper, Quimper, France, 2 CHU Brest, Brest, 

3 

Hopital de Rangueil, Toulouse, FRANCE, France, 4 Hopital 

Louis Mourier, Colombes, FRANCE, France, 5 Nancy Teaching 

Hospital, Nancy, France, 6 Université de Lorraine, Paris 

Descartes University, APEMAC, EA 4360, F- 54 000, France, 

Nancy, France, 7 Université Brest Occidentale, Brest, France 

1116. Diagnostic Value of Internal Rotation Measurement in 

Patients with Cam- and Pincer-Type Deformities of the Hip. 

Stephan Reichenbach 1 , Michael Leunig 2 , Stefan Werlen 3 , 

Andreas Limacher 1 , Christian W. Pfirrmann 4 , Reinhold Ganz 1 

and Peter Jüni 1 , 1 University of Bern, Bern, Switzerland, 

2 

Schulthess Clinic, Zurich, Switzerland, 3 Hospital Sonnenhof, 

Bern, Switzerland, 4 Balgrist University Hospital, Zurich, 

Switzerland 

1117. Association between Hip Bone Marrow Lesions (BMLs) and 

Bone Mineral Density: A Cross-Sectional and Longitudinal 

Population-Based Study. Harbeer Ahedi 1 , Dawn Dore 1 , Leigh 

Blizzard 1 , Flavia Cicuttini 2 and Graeme Jones 1 , 1 Menzies 

Research institute Tasmania, University of Tasmania, 

Hobart, 7000, Australia, 2 Department of Epidemiology and 

Preventive Medicine, Monash University, Melbourne, 3004, 

Australia 

1118. Association Between Hip and Knee Cartilage Measured 

Using Radiographs and Magnetic Resonance Imaging: The 

Tasmanian Older Adult Cohort Study. Hussain Ijaz Khan 1 , 

Dawn Dore 1 , Guangju Zhai 2 , Changhai Ding 3 , Jean Pierre 

Pelletier 4 , Johanne Martel-Pelletier 4 , Flavia Cicuttini 5 and 

Graeme Jones 1 , 1 Menzies Research institute Tasmania, 

University of Tasmania, Hobart, 7000, Australia, 2 Discipline 

of Genetics, Faculty of Medicine, Memorial University of 

Newfoundland, St John’s, NL, 3 Menzies research institute 

& Monash University, Hobart, Australia, 4 Osteoarthritis 

Research Unit, University of Montreal Hospital Research 

Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, 

5 

Department of Epidemiology and Preventive Medicine, 

Monash University, Melbourne, 3004, Australia 

1119. Prediction of MRI-Detected Cartilage Loss Over 30 Months 

Using Simplified Radiographic and Clinical Stratification: 

The MOST Study. Frank Roemer 1 , David T. Felson 2 , Jingbo 

Niu 2 , Yuqing Zhang 3 , Michael C. Nevitt 4 , Michel Crema 3 , 

Cora E. Lewis 5 , James Torner 6 and Ali Guermazi 7 , 1 Klinikum 

Augsburg, Augsburg, Germany, 2 Boston Univ School of 

Medicine, Boston, MA, 3 Boston University, Boston, MA, 

4 

University of California-San Francisco, San Francisco, CA, 

5 

University of Alabama, Birmingham City, Birmingham, 



218 

AL, 6 University of Iowa, Iowa City, Iowa City, IA, 7 Boston 

University School of Medicine, Boston, MA 

1120. Cartilage Volume Loss Occurs in Most Older Adults and 

the Rate of Loss Increases with Age. andreea M. Harsanyi 1 , 

Dawn Dore 2 , Changhai Ding 2 , Jean-Pierre Pelletier 3 , Johanne 

Martel-Pelletier 3 , Flavia Cicutinni 4 and Graeme Jones 2 , 

1 

Menzies Research Institute Tasmania, Hobart, Australia, 

2 

Menzies Research institute Tasmania, University of 

Tasmania, Hobart, 7000, Australia, 3 Osteoarthritis Research 

Unit, University of Montreal Hospital Research Centre 

(CRCHUM), Notre-Dame Hospital, Montreal, QC, 4 Monash 

University, Melbourne, Australia, Melbourne, Australia 

1121. Degenerative Medial Meniscal Pathology May Initiate in 

the Posterior Horn: Data From the Osteoarthritis Initiative. 

Robert J. Ward 1 , Jeffrey B. Driban 1 , Eric E. Wong 1 , Jonathan 

W. Pack 1 , Kunal K. Kothari 2 , Grace H. Lo 3 and Timothy E. 

McAlindon 1 , 1 Tufts Medical Center, Boston, MA, 2 Tufts 

University School of Medicine, Boston, MA, 3 Michael E. 

DeBakey Veterans Affairs Medical Center, Houston, TX 

1122. Identifying Radiographic Phenotypes of Early Knee 

Osteoarthritis Using Separate Quantitative Features Might 

Improve Patient Selection for More Targeted Treatment. 

Margot B. Kinds 1 , Anne C. A. Marijnissen 1 , Max A. 

Viergever 1 , P.J. Emans 2 , J.W.J. Bijlsma 1 , F.P.J.G. Lafeber 1 and 

P.M.J. Welsing 1 , 1 University Medical Center Utrecht, Utrecht, 

Netherlands, 2 Maastricht University Medical Center, 

Maastricht, Netherlands 

1123. Comparison of Anatomic Knee Alignment On Physical 

Examination and Radiographs. Iman Hemmati 1 , Eric C. 

Sayre 2 , Ali Guermazi 3 , Savvakis Nicolaou 1 , Anona Thorne 4 , 

Joel Singer 1 and Jolanda Cibere 2 , 1 University of British 

Columbia, Vancouver, BC, 2 Arthritis Research Centre of 

Canada, Vancouver, BC, 3 Boston University, Boston, MA, 

4 

Canadian Institutes of Health Research HIV Trials Network, 

Vancouver, BC 

1124. Total Knee Replacement As an Osteoarthritis Study 

Outcome: Predictors Derived From Long-Term Observation 

Following a Randomized Clinical Trial. Jean-Pierre 

Raynauld 1 , Johanne Martel-Pelletier 1 , Marc Dorais 2 , Boulos 

Haraoui 1 , Denis Choquette 1 , François Abram 3 , andré 

Beaulieu 4 , Louis Bessette 5 , Frédéric Morin 6 , Lukas M. Wildi 1 

and Jean Pierre Pelletier 7 , 1 Osteoarthritis Research Unit, 

University of Montreal Hospital Research Centre (CRCHUM), 

Montreal, QC, 2 StatSciences Inc., Notre-Dame de l’Île 

Perrot, QC, 3 Imaging Research & Development, ArthroLab 

Inc., Montreal, QC, 4 Faculty of Medicine, Laval University, 

Quebec, QC, 5 Centre Hospitalier Universitaire de Québec, 

pavillon CHUL, Sainte-Foy, QC, 6 Centre de Recherche 

Musculo-squelettique, Trois-Rivières, QC, 7 Osteoarthritis 


Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC 

1125. Three Trajectories of Activity Limitations in Early 

Symptomatic Knee Osteoarthritis: A 5-Year Follow-up 

Study. Jasmijn F. M. Holla 1 , Marike van der Leeden 1 , Leo D. 


Roorda 1 , Martijn W. Heymans 2 , Sita M.A. Bierma-Zeinstra 3 , 

Maarten Boers 2 , Willem F. Lems 2 , Martijn P.M. Steultjens 4 

and Joost Dekker 2 , 1 Reade, Amsterdam, Netherlands, 

2 

VU University Medical Center, Amsterdam, Netherlands, 

3 

Erasmus MC - University Medical Center, Rotterdam, 

Netherlands, 4 Glasgow Caledonian University, Glasgow, 

Scotland 

1126. Comparison between Osteoartritis Initiative and CHECK 

study (Cohort Hip & Cohort Knee); Development of pain 

and function during 4 years follow-up. Janet Wesseling 1 , 

Sita M.A. Bierma-Zeinstra 2 , Margreet Kloppenburg 3 , 

Johannes WJ Bijlsma 1 and CHECK steering group 4 , 1 University 

Medical Center Utrecht, Utrecht, Netherlands, 2 Erasmus 

MC - University Medical Center, Rotterdam, Netherlands, 

3 

Department Rheumatology and Department of Clinical 

Epidemiology, Leiden University Medical Centre, Leiden, The 

Netherlands, Leiden, Netherlands, 4 Utrecht 

1127. Dynamic Stereo X-Ray Evaluation of Knee Joint 

Mechanics during Downhill Walking in Subject with Knee 

Osteoarthritis. Shawn Farrokhi 1 , Carrie A. Rainis 1 , G. Kelley 

Fitzgerald 2 and Scott Tashman 1 , 1 University of Pittsburgh, 

Pittsburgh, PA, 2 Univ of Pittsburgh, Pittsburgh, PA 

1128. Different of Patterns Knee Pain Trajectories: Longitudinal 

Data from the Osteoarthritis Initiative (OAI). Joseph Devich 

Jr. 1 , Michael J. Hannon 2 , Zhijie Wang 2 , Robert M. Boudreau 3 

and C. Kent Kwoh 4 , 1 UPMC Shadyside, Pittsburgh, PA, 

2 


PA, 3 University of Pittsburgh, Pittsburgh, PA, 4 University of 

Pittsburgh and VA Healthcare System, Pittsburgh, PA 

1129. Prevalence of Symptomatic Basilar Thumb Joint 

Osteoarthritis in the General Population. Jennifer Moriatis 

Wolf 1 , Aleksandra Turkiewicz 2 , Isam Atroshi 3 and Martin 

Englund 2 , 1 University of Connecticut Health Center, 

Farmington, CT, 2 Department of Orthopedics, Clinical 

Sciences Lund, Lund University, Lund, Sweden, 3 Lund 

University, Hässleholm, Sweden 

1130. The Effect of Age On the Number of Osteoarthritis Flares 

with Continuous Versus Intermittent Celecoxib Treatment. 

George H. Sands, Pritha Bhadra and Margaret Noyes Essex, 

Pfizer, Inc, New York, NY 

1131. Intraarticular Infliximab for Knee Osteoarthritis: High 

Baseline Levels of Synovial Cellularity and High MRI 

Cartilage Injury At the Lateral Tibial Plateau Predict 

Improvement in Total WOMAC Score. Jeremy R. Schue 1 , 

Ossama Tawfik 1 , Rebecca Bolce 2 , Donald D. Smith 1 , Gary 

Hinson 1 , Jo A. Wick 1 and Herbert B. Lindsley 1 , 1 Kansas 

University Med Ctr, Kansas City, KS, 2 Crescendo Bioscience 

Inc., South San Francisco, CA 

1132. Prevalence of Knee Pain in Ultramarathon Runners. 

Victoria M. Kelly 1 , Martin Hoffman 2 , Bharathi Lingala 1 , 

Mihoko Bennett 1 and Eswar Krishnan 1 , 1 Stanford University, 

Palo Alto, CA, 2 Department of Veteran’s Affairs, Northern 

California Health Care System and University of California 

Davis Medical Center, Sacramento, CA


1133. Gait Differences Are Present in Subjects with Symptomatic 

Vs. Asymptomatic Mild Radiographic Hip Osteoarthritis. 

Samir S. Chabra 1 , Najia Shakoor 2 and Kharma C. Foucher 2 , 

1 

University of Illinois at Chicago, Chicago, IL, 2 Rush University 

Medical Center, Chicago, IL 

1134. What Are the Levels of Physical Activities and Their 

Associations with Quality of Life in Patients with 

Symptomatic Hip and/or Knee Osteoarthritis? Irawati 

Lemonnier 1 , Anne Vuillemin 2 and Anne-Christine Rat 3 , 

1 

Lorraine Université Paris Descartes University, EA 4360 

Apemac, Nancy, France, Nancy, France, 2 Universite de 

Lorraine, Paris Descartes University, EA 4360 Apemac, 

Nancy, France, Nancy, France, 3 Université de Lorraine, Paris 

Descartes University, APEMAC, EA 4360, F- 54 000, Nancy, 

France 

1135. Combined Glucosamine and Chondroitin Sulfate, Once of 

Three Times Daily, Provide Clinically Relevant Analgesia in 

Knee Osteoarthritis. Jose R. Provenza 1 , Samuel K. Shinjo 2 , 

Joyce M. Silva 3 , Carla RGS. Peron 4 and Francisco AC Rocha 5 , 

1 

Pontifícia Universidade Católica de Campinas, Campinas, 

Brazil, 2 Faculdade de Medicina da Universidade de São 

Paulo, Sao Paulo, Brazil, 3 Sao Paulo, Brazil, 4 Laboratórios 

Aché Ltda, Sao Paulo, Brazil, 5 Federal University of Ceara, 

Fortaleza, Brazil 

1136. Aesthetic Dissatisfaction in Hand Osteoarthritis Patients, 

Its Impact and Risk Factors. R. Liu, L.J.J. Beaart-van de 

Voorde, T.W.J. Huizinga and M. Kloppenburg, Leiden 


1137. Clinimetric Properties of a New Outcome Measure: The 

Hand-Osteoarthritis Aesthetic Damage Index. N. Bellamy 

and Joan Hendrikz, The University of Queensland, Herston, 

Queensland, Australia 

1138. Nonpharmacologic and Pharmacologic Therapy Utilization 

by Primary Care Providers for Hand Osteoarthritis- 

Comparative Review by Electronic Health Record Data 

Mining and in-Home Visit Verification. Gale A. McCarty, 

President, Rheum.Ed Consulting, Harborside, ME 



1139. Inhaled Nitrous Oxide Facilitates Access to Intra-Articular 

Corticosteroid Injections in Children with Juvenile 

Idiopathic Arthritis. Mercedes O. Chan 1 , Ruth Wyllie 2 and 

H. E. Foster 3 , 1 University of British Columbia and British 

Columbia’s Children’s Hospital, Vancouver, BC, 2 Newcastle 

Hospitals, NHS Foundation Trust, Newcastle Upon Tyne, 

United Kingdom, 3 Newcastle Hospitals NHS Foundation 

Trust, Great North Children’s Hospital and Newcastle 

University, Newcastle Upon Tyne, United Kingdom 

1140. Response to Adalimumab in 40 Patients with refractory 

juvenile Idiopathic Arthritis-Associated Uveitis. A 

Multicenter Study. Vanesa Calvo-Río 1 , Ricardo Blanco 1 , 

Manuel Díaz-Llopis 2 , David Salom 3 , Carmen García-Vicuña 4 , 

Miguel Cordero-Coma 5 , Norberto Ortego 6 , Marta Suarez-de- 

Figueroa 7 , J. Carlos Fernandez-Cid 8 , A. Fonollosa Calduch 9 , 

Ángel M. García-Aparicio 10 , Jose M. Benítez-del-Castillo 11 , 

Jose L. Olea 12 , Javier Loricera 13 and Miguel Angel González- 

Gay 13 , 1 Hospital Universitario Marqués de Valdecilla-IFIMAV, 

Santander, Spain, 2 Hospital Universitario La Fe de Valencia, 

Valencia, 3 Hospital Universitario La Fe de Valencia, Valencia, 

Spain, 4 Hospital Sant Joan de Déu, Barcelona, Barcelona, 

5 

Hospital de León, León, Spain, 6 Hospital Santa Cecilio, 

Granada, Spain, 7 Hospital Ramon y Cajal, Madrid, Spain, 

8 

Hospital de Pontevedra, Pontevedra, Spain, 9 Hospital de 

Cruces, Barakaldo, Spain, 10 Hospital Virgen Salud, Toledo, 

Toledo, 11 Hospital Clínico San Carlos, Madrid, 12 Hospital Son 

Dureta, Palma de Mallorca, Spain, 13 Hospital Universitario 

Marqués de Valdecilla. IFIMAV, Santander, Spain 

1141. Safety of Celecoxib and Non-Selective Non-Steroidal 

Anti-Inflammatory Drugs in Juvenile Idiopathic Arthritis. 

Rachel E. Sobel 1 , D. J. Lovell 2 , Hermine I. Brunner 3 , Jennifer 

E. Weiss 4 , Paula W. Morris 5 , Beth S. Gottlieb 6 , Elizabeth C. 

Chalom 7 , Lawrence K. Jung 8 , Karen Onel 9 , Lisa Petinoit 10 , 

Donald P. Goldsmith 11 , Staci Abramsky-Risman 12 , James 

P., Young 13 and Edward H. Giannini 14 , 1 Pfizer, Inc., New 

York, NY, 2 Cincinnati Children’s Hospital, Cincinnati, OH, 

3 

Cincinnati Children’s Hospital Medical Center, Cincinnati, 

OH, 4 Hackensack Univ Med Ctr, Hackensack, NJ, 5 Univ of 

Arkansas for Med Sci, Little Rock, AR, 6 Cohen Children’s 

Medical Center of New York, New Hyde Park, NY, 7 St. 

Barnabas Medical Center, Livingston, NJ, 8 Children’s National 

Medical Center, Washington, DC, 9 University of Chicago, 

Chicago, IL, 10 ’Specially for Children, Dell Children’s Medical 

Center, Austin, TX, 11 St Christopher’s Hospital for Children/ 

Drexel College of Medicine, Philadelphia, PA, 12 Pfizer Inc, 

New York, NY, 13 United BioSource Corporation, Ann Arbor, 

MI, 14 PRCSG-Cincinnati Children’s Hospital Medical Center, 


1142. Efficacy of Biologic Agents in Juvenile Idiopathic Arthritis: 

A Systematic Review Using Indirect Comparisons. Janneke 

Anink 1 , Marieke H. Otten 1 , Sandra Spronk 2 and Lisette 

W.A. Van Suijlekom-Smit 1 , 1 Erasmus MC Sophia Children’s 

Hospital, Rotterdam, Netherlands, 2 Erasmus MC, Rotterdam, 

Netherlands 

1143. Tocilizumab Therapy in Children with Systemic Onset 

Juvenile Idiopathic Arthritis. Russian Experience. Ekaterina 

Alekseeva, Rina Denisova, Saniya Valieva, Tatyana Bzarova, 

Kseniya Isayeva, Alexandra Chomakhidze, Evgeniya 

Chistyakova, Tatyana Sleptsova and Elena Mitenko, Scientific 

Center of Children’s Health, Moscow, Russia 

1144. Phenotypic Characterization of Childhood Onset 

Rheumatoid Arthritis. Emily G. Ferrell 1 , Lori Ponder 2 , Lauren 

Minor 3 , Sheila T. Angeles-Han 3 , Christine W. Kennedy 2 , Kelly 

A. Rouster-Stevens 4 , Mina Pichavant 2 , Larry B. Vogler 4 and 

Sampath Prahalad 2 , 1 Emory University School of Medicine, 

Atlanta, GA, 2 Emory Children’s Center, Atlanta, GA, 3 Emory 

University, Atlanta, GA, 4 Emory Univ School of Medicine, 

Atlanta, GA 



1145. Use of Non-Etanercept Biologics in Children with Juvenile 

Idiopathic Arthritis: Results from the Biologics for Children 

with Rheumatic Diseases Study. Lianne Kearsley-Fleet 1 , 

Eileen Baildam 2 , Michael Beresford 3 , Rebecca Davies 1 , 

Helen E. Foster 4 , Katy Mowbray 1 , Taunton R. Southwood 5 , 

Wendy Thomson 1 and Kimme L. Hyrich 6 , 1 Arthritis Research 

UK Epidemiology Unit, Manchester Academic Health 

Science Centre, Manchester, United Kingdom, 2 Alder Hey 

Children’s Foundation NHS Trust, Liverpool, United Kingdom, 

3 

Institute of Translational Medicine (Child Health), Alder Hey 

Children’s Foundation NHS Trust, Liverpool, United Kingdom, 

4 

Musculoskeletal Research Group, Newcastle upon Tyne, 

United Kingdom, 5 University of Birmingham and Birmingham 

Children’s Hospital, Birmingham, United Kingdom, 6 Arthritis 


Manchester Academy of Health Sciences, Manchester, 


1146. Choice of Systemic JIA Treatment among Childhood 

Arthritis and Rheumatology Research Alliance (CARRA) 

Rheumatologists. Jennifer E. Weiss 1 , Esi M. Morgan DeWitt 2 , 

Timothy Beukelman 3 , Laura E. Schanberg 4 , Rayfel Schneider 5 

and Yukiko Kimura 1 , 1 Joseph M. Sanzari Children’s Hospital, 

Hackensack University Medical Center, Hackensack, NJ, 

2 

Cincinnati Children’s Hospital Medical Center, Cincinnati, 

OH, 3 Univ of Alabama-Birmingham, Birmingham, AL, 4 Duke 

University Medical Center, Durham, NC, 5 The Hospital for 


1147. Definition of Improvement Thresholds in Juvenile 

Idiopathic Arthritis Using the JADAS. Gerd Horneff 1 

and Ingrid Kaul 2 , 1 Centre of Pediatric Rheumatology, 

Sankt Augustin, Germany, 2 Institute of Medical Statistics, 

Informatics and Epidemiology, University of Cologne, 

Cologne, Germany 

1148. Adalimumab - Effective Control under Refractory JIA 

Associated Uveitis. Ekaterina Alekseeva, Elena Mitenko, 

Tatyana Bzarova, Saniya Valieva, Kseniya Isayeva, Alexandra 

Chomakhidze, Evgeniya Chistyakova, Tatyana Sleptsova 

and Rina Denisova, Scientific Center of Children’s Health, 

Moscow, Russia 

1149. Long-Term Safety of Etanercept in Patients with Juvenile 

Idiopathic Arthritis (JIA). Kirsten Minden 1 , Martina 

Niewerth 2 , Jens Klotsche 3 , Michael Hammer 4 , Johannes 

Peter Haas 5 , Gerd Ganser 6 and Gerd Horneff 7 , 1 German 

Rheumatism Research Center, a Leibniz Institute, Berlin, 

Germany, 2 German Rheumatism Research Centre, Berlin, 

Germany, 3 German Rheumatism Research Center, a Leibniz 

institute, Berlin, Germany, 4 St. Josef-Stift, Sendenhorst, 

Germany, 5 German Center for Pediatric and Adolescent 

Rheumatology, Garmisch-Partenkirchen, Germany, 6 Sankt 

Josef Stift, Sendenhorst, Germany, 7 Centre of Pediatric 

Rheumatology, Sankt Augustin, Germany 

1150. Adverse Events in Juvenile Idiopathic Arthritis: Results 

From the Enhanced Drug Safety Surveillance (EDSS) Pilot 

Project. Sarah Ringold 1 , Audrey F. Hendrickson 1 , Carol A. 

Wallace 2 and Rachel E. Sobel 3 , 1 Seattle Children’s Hospital, 

Seattle, WA, 2 Seattle Childrens Hospital, Seattle, WA, 3 Pfizer, 

Inc., New York, NY 

1151. Low-Dose Methotrexate and the Selective Accumulation of 

Intracellular Aminoimidazolecarboxamide Ribotide. Ryan 

S. Funk, Leon van Haandel, Mara L. Becker and J.S. Leeder, 

Children’s Mercy Hospital, Kansas City, MO 

1152. Improvement in Health-Related Quality of Life for Children 

with Juvenile Ideopathic Arthritis after Start of Treatment 

with Etanercept. Jens Klotsche 1 , Kirsten Minden 2 and Gerd 

Horneff 3 , 1 German Rheumatism Research Center, a Leibniz 

institute, Berlin, Germany, 2 German Rheumatism Research 

Center, a Leibniz Institute, Berlin, Germany, 3 Centre of 

Pediatric Rheumatology, Sankt Augustin, Germany 

1153. Perceived Health-Related Quality of Life and Its 

Determining Factors in Children with Recent-Onset JIA. 

Jens Klotsche 1 , Ina Liedmann 1 , Martina Niewerth 2 , Gerd 

Horneff 3 , Johannes Peter Haas 4 and Kirsten Minden 5 , 

1 

German Rheumatism Research Center, a Leibniz institute, 

Berlin, Germany, 2 German Rheumatism Research Centre, 

Berlin, Germany, 3 Centre of Pediatric Rheumatology, 

Sankt Augustin, Germany, 4 German Center for Pediatric 

and Adolescent Rheumatology, Garmisch-Partenkirchen, 

Germany, 5 German Rheumatism Research Center, a Leibniz 

Institute, Berlin, Germany 

1154. Impact of FokI VDR and TNFalpha–308 Polymorphism 

on Disease Severity and Long Term Outcome in JIA 

Patients On Anti-TNF Treatment. Jelena Vojinovic 1 , Jelena 

Basic 2 , Gordana Susic 3 , Dragana Lazarevic 2 and Nemanja 

Damjanov 4 , 1 Prof, Nis, Serbia, 2 Dr, Nis, Serbia, 3 Dr, Belgrade, 

Serbia, 4 Prof, Belgrade, Serbia 

1155. A New Measure of Visual Function for Children with 

Juvenile Idiopathic Arthritis-Associated Uveitis. Sheila T. 

Angeles-Han 1 , Steven Yeh 1 , Courtney McCracken 1 , Larry B. 

Vogler 1 , Kelly A. Rouster-Stevens 1 , Christine W. Kennedy 2 , 

Kirsten Jenkins 3 , Matthew Kent 1 , Scott Lambert 1 , Carolyn 

Drews-Botsch 4 and Sampath Prahalad 2 , 1 Emory Univ School 

of Medicine, Atlanta, GA, 2 Emory Children’s Center, Atlanta, 

GA, 3 Children’s Healthcare of Atlanta, Atlanta, GA, 4 Emory 

University School of Public Health, Atlanta, GA 

1156. Effectivity of Methotrexate in Therapy of Juvenile 

Idiopathic Enthesitis-Related Arthritis. Katharina Geitz 

and Ivan Foeldvari, Hamburger Zentrum Kinder-und 

Jugendrheumatologie, Hamburg, Germany 

1157. The Phenotypic Characterization of Juvenile Idiopathic 

Arthritis in African American Children. Lauren Minor 1 , Lori 

Ponder 2 , Emily G. Ferrell 1 , Sheila Angeles-Han 1 , Christine W. 

Kennedy 2 , Kelly Rouster-Stevens 1 , Mina Pichavant 2 , Larry B. 

Vogler 1 and Sampath Prahalad 1 , 1 Emory University School of 

Medicine, Atlanta, GA, 2 Emory Children’s Center, Atlanta, GA 

1158. Development of Cut-off Values for High Disease Activity in 

Juvenile Idiopathic Arthritis Based On the Juvenile Arthritis 

Disease Activity Score. Alessandro Consolaro 1 , Stefano 

220 

2012 Program Book


Lanni 1 , Sara Verazza 1 , Maria C. Gallo 1 , Marta Bertamino 1 , 

Giulia C. Varnier 1 , Serena Calandra 2 , Nicolino Ruperto 3 , 

Alberto Martini 4 and Angelo Ravelli 5 , 1 Istituto Giannina 

Gaslini, Genova, Italy, 2 University of Genova, Genova, Italy, 

3 

Paediatric Rheumatology International Trials Organisation 

[PRINTO], Genova, Italy, 4 Pediatric Rheumatology 

Collaborative Study Group [PRSCG], Cincinnati, OH, 

5 

Paediatric Rheumatology International Trials Organization 

(PRINTO), Istituto Giannina Gaslini, Genova, Italy 

1159. Reasons and Predictors of Methotrexate Discontinuation 

in Children with JIA: Results From the Childhood Arthritis 

Prospective Study (CAPS). Suzanne Verstappen 1 , Lucy 

R. Wedderburn 2 , H. E. Foster 3 , Eileen Baildam 4 , Janet 

Gardner-Medwin 5 , Joyce Davidson 5 , Alice Chieng 6 , Wendy 

Thomson 7 and Kimme L. Hyrich 8 , 1 University of Manchester, 

Manchester Academic Health Sciences Centre, Manchester, 

United Kingdom, 2 University College London (UCL), London, 

United Kingdom, 3 Newcastle Hospitals NHS Foundation Trust 

and Great North Children’s Hospital, Newcastle Upon Tyne, 

United Kingdom, 4 Alder Hey Children’s Foundation NHS 

Trust, Liverpool, United Kingdom, 5 Royal Hospital for Sick 

Children, Glasgow, United Kingdom, 6 Manchester Children’s 

Hospital, Manchester, United Kingdom, 7 Arthritis Research 

UK Epidemiology Unit, Manchester, United Kingdom, 

8 

Arthritis Research UK Epidemiology Unit, University of 

Manchester, Manchester Academy of Health Sciences, 


1160. Assessment of Subclinical Synovitis by Power Doppler 

Ultrasonography in Patients with Juvenile Idiopathic 

Arthritis. Maria Teresa Terreri 1 , Vanessa M. Bugni 2 , Claudio 

A. Len 2 , Sônia de A.V. Mitraud 3 , Rita NV. Furtado 4 and Jamil 

Natour 5 , 1 Universidade Federal de São Paulo / UNIFESP, Sao 

Paulo, Brazil, 2 Universidade Federal de São Paulo / UNIFESP, 

São Paulo, Brazil, 3 Universidade Federal de São Paulo / 

UNIFESP, São Paulo, 4 Universidade Federal de Sao Paulo, Sao 


Brazil 

1161. Current Evidence of Anti-TNFα Treatment Efficacy in 

Childhood Chronic Uveitis: A Systematic Review and 

Meta-Analysis Approach Comparing the Different Drugs. 

Gabriele Simonini 1 , Kate Druce 2 , Rolando Cimaz 1 , Gary J. 

Macfarlane 2 and Gareth T. Jones 2 , 1 Anna Meyer Children’s 

Hospital-University of Florence, Firenze, Italy, 2 University of 

Aberdeen, Aberdeen, United Kingdom 

1162. Patients with Juvenile Idiopathic Arthritis From a Low 

Socio-Economic Background Perceive Their Disease Activity 

and Physical Limitations Higher Than Patients from a High 

Socio-Economic Background. Suzanne Verstappen 1 , Joanna 

Cobb 2 , H. E. Foster 3 , Eileen Baildam 4 , Lucy R. Wedderburn 5 , 

Janet Gardner-Medwin 6 , Alice Chieng 7 , Joyce Davidson 6 , 

Wendy Thomson 8 and Kimme L. Hyrich 9 , 1 University of 

Manchester, Manchester Academic Health Sciences Centre, 

Manchester, United Kingdom, 2 Arthritis Research UK 

Epidemiology Unit, University of Manchester, Manchester, 

United Kingdom, 3 Newcastle Hospitals NHS Foundation 

Trust and Great North Children’s Hospital, Newcastle Upon 

Tyne, United Kingdom, 4 Alder Hey Children’s Foundation 

NHS Trust, Liverpool, United Kingdom, 5 University College 

London (UCL), London, United Kingdom, 6 Royal Hospital 

for Sick Children, Glasgow, United Kingdom, 7 Manchester 

Children’s Hospital, Manchester, United Kingdom, 8 Arthritis 

Research UK Epidemiology Unit, Manchester, United 

Kingdom, 9 Arthritis Research UK Epidemiology Unit, 

University of Manchester, Manchester Academy of Health 

Sciences, Manchester, United Kingdom 

1163. Risk Factors for Radiologic Progression in Polyarticular 

Juvenile Idiopathic Arthritis Patients Treated with Biologic 

Agents. Tomohiro Kubota 1 , Tsuyoshi Yamatou 1 , Yukiko 

Nonaka 1 , Harumi Akaike 2 , Tomokazu Nagakura 3 , Yuichi 

Yamasaki 1 , Tomoko Takezaki 1 , Yasuhito Nerome 1 , Hiroyuki 

Imanaka 1 and Syuji Takei 1 , 1 Kagoshima University, Kagoshima 

City, Japan, 2 Kagoshima University, Kagoshima, Japan, 

3 

House of Meguminoseibo, Usuki, Japan 

1164. Orofacial Anomalies in Children with Confirmed Juvenile 

Idiopathic Arthritis. Bernd Koos 1 , Franka Stahl de Castrillon 2 , 

Robert Ciesielski 1 and Nikolay Tzaribachev 3 , 1 University 

Medical Center Schleswig-Holstein, Campus Kiel, Kiel, 

Germany, 2 Department of Orthodontics, University of 

Rostock, Germany, Rostock, Germany, 3 Center for Rheumatic 

Diseases, Bad Bramstedt, Germany 

1165. Factors Associated with Achievement of Inactive Disease 

in Children with Juvenile Idiopathic Arthritis Treated with 

Etanercept. Nicoletta Solari 1 , Elena Palmisani 1 , Alessandro 

Consolaro 1 , Sara Dalprà 1 , Benedetta Schiappapietra 1 , 

Giulia Bracciolini 1 , Silvia Rosina 1 , Giorgia Negro 1 , Alberto 

Martini 2 and Angelo Ravelli 3 , 1 Istituto Giannina Gaslini, 

Genova, Italy, 2 Pediatric Rheumatology Collaborative Study 

Group [PRSCG], Cincinnati, OH, 3 Paediatric Rheumatology 


Gaslini, Genova, Italy 

1166. Clinical and Therapeutic Features of 312 Patients 

with Macrophage Activation Syndrome Enrolled in a 

Multinational Survey. Sergio Davì 1 , Francesca Minoia 1 , 

Erkan Demirkaya 2 , Chiara Suffia 1 , Mario Abinun 3 , Amita 

Aggarwal 4 , Nuray Aktay Ayaz 5 , Maria Alessio 6 , Jordi Anton 5 , 

Maria Apaz 5 , Tadej Avcin 7 , Patrizia Barone 8 , Blanca E. Bica 9 , 

Isabel Bolt 10 , Luciana Breda 11 , Vyacheslav Chasnyk 12 , Rolando 

Cimaz 5 , Fabrizia Corona 5 , Ruben Cuttica 13 , Gianfranco 

D’Angelo 14 , AnnaCarin Horne 15 , Nicola Ruperto 1 , Alberto 

Martini 16 , Randy Q. Cron 17 and Angelo Ravelli 5 , 1 Istituto 

di Ricovero e Cura a Carattere Scientifico G. Gaslini, 

Genova, Italy, 2 International Investigator Consortium for 

MAS Diagnostic Criteria, Ankara, Turkey, 3 International 

Investigator Consortium for MAS Diagnostic Criteria, 

Newcastle upon Tyne, United Kingdom, 4 Sanjay Gandhi 

Postgraduate Institute of Medical Sciences, Lucknow, 

India, 5 Paediatric Rheumatology International Trials 


Italy, 6 University of Naples Federico II, Naples, Italy, 

7 

International Investigator Consortium for MAS Diagnostic 



Criteria, Ljubljana, Slovenia, 8 International Investigator 

Consortium for MAS Diagnostic Criteria, Catania, Italy, 

9 


Criteria, Rio de Janeiro, Brazil, 10 International Investigator 

Consortium for MAS Diagnostic Criteria, Zurich, Switzerland, 

11 


Criteria, Chieti, Italy, 12 International Investigator Consortium 

for MAS Diagnostic Criteria, Saint-Petersburg, Russia, 

13 


Criteria, Buenos Aires, Argentina, 14 International Investigator 

Consortium for MAS Diagnostic Criteria, Ancona, Italy, 

15 

Karolinska Institutet, Karolinska University Hospital Solna, 

Stockholm, Sweden, 16 Pediatric Rheumatology Collaborative 

Study Group [PRSCG], Cincinnati, OH, 17 Univ of Alabama- 


1167. Golimumab in 25 Young Adults Affected by Juvenile 

Idiopathic ARTHRITIS NON Responders to OTHER Biological 

Agents: Preliminary DATA. Irene Pontikaki 1 , Orazio De 

Lucia 1 , Maurizio Gattinara 1 , Alessandra Salmaso 1 , Pier Luigi 

Meroni 2 and Valeria Gerloni 1 , 1 Orthopedic Institute Gaetano 

Pini, Milano, Italy, 2 Istituto G. Pini, University of Milan, 

Milano, Italy 

1168. Cost-Effectiveness Analysis of Early Biologic Treatment 

in Polyarticular Juvenile Idiopathic Arthritis. Nadia Luca 1 , 

Heather Burnett 2 , Wendy Ungar 2 , Timothy Beukelman 3 , 

Brian M. Feldman 2 , Gwen Schwartz 4 and Ahmed Bayoumi 5 , 

1 

Hospital for Sick Children, Toronto, ON, 2 The Hospital for 

Sick Children, Toronto, ON, 3 Univ of Alabama-Birmingham, 

Birmingham, AL, 4 St. Michael’s Hospital, Toronto, ON, 

5 

Keenan Research Centre of the Li Ka Shing Knowledge 

Institute of St. Michael’s Hospital, Toronto, ON 

1169. Obstetrical Complications in Women with Juvenile 

Idiopathic Arthritis. Evelyne Vinet 1 , Sasha Bernatsky 2 , 

Mohammed Kaouache 2 , Christian A. Pineau 1 , Ann E. 

Clarke 3 , Elizabeth Hazel 1 , Ciaran M. Duffy 4 , Anick Bérard 5 

and Debbie Ehrmann Feldman 6 , 1 McGill University Health 

Centre, Montreal, QC, 2 Research Institute of the McGill 

University Health Ctre, Montreal, QC, 3 MUHC, Montreal, 

QC, 4 Children’s Hospital of Eastern Ontario, Ottawa, 

ON, 5 Université de Montréal, 6 Université de Montréal, 

Hampstead, QC 

1170. Folate Usage in Methotrexate -Treated Juvenile Idiopathic 

Arthritis Patients Is Inconsistent and Highly Variable. Gil 

Amarilyo 1 , Ornella J. Rullo 1 , Deborah K. McCurdy 1 , Jennifer 

M.P. Woo 1 and De Furst 2 , 1 Mattel Children’s Hospital, 

University of California, Los Angeles, Los Angeles, CA, 

2 


1171. Validation of BASDAI and BASFI in Children with 

Spondyloarthritis. Alisa C. Rachlis 1 , Bertha Wong 2 , Kristi J. 

Whitney-Mahoney 2 , Michelle Batthish 2 , Michelle anderson 2 , 

JoAnne Marcuz 2 , Margaret Reaume 2 , Ashley DeLaurier 2 , 

Ronald M. Laxer 2 , Brian M. Feldman 2 and Shirley M. Tse 2 , 

1 

Hospital for Sick Children, Toronto, ON, 2 The Hospital for 


1172. Delineating the Role of Multiple Corticosteroid Joint 

Injections in the Management of Juvenile Idiopathic 

Arthritis in the Biologic Era. Charalampia Papadopoulou 1 , 

Maria I. Gonzalez 1 , Juan C. Nieto 1 , Mikhail Kostik 1 , Marek 

Bohm 1 , Stefano Lanni 1 , Valentina Muratore 2 , Alessandro 

Consolaro 1 , Alberto Martini 3 and Angelo Ravelli 4 , 1 Istituto 

Giannina Gaslini, Genova, Italy, 2 Fondazione IRCCS 

Policlinico San Matteo, Pavia, Italy, 3 Pediatric Rheumatology 

Collaborative Study Group [PRSCG], Cincinnati, OH, 

4 

University of Genova, Genova, Italy 

1173. Targeting Remission in Juvenile Idiopathic Arthritis in 

Routine Clinical Care: Experience in 175 Newly-Diagnosed 

Patients. Alessandro Consolaro 1 , Giorgia Negro 1 , Nicoletta 

Solari 1 , Cristina Ferrari 1 , Sergio Davì 1 , Silvia Pederzoli 1 , Giulia 

Bracciolini 1 , Maria C. Gallo 1 , Alberto Martini 2 and Angelo 

Ravelli 3 , 1 Istituto Giannina Gaslini, Genova, Italy, 2 Pediatric 

Rheumatology Collaborative Study Group [PRSCG], 

Cincinnati, OH, 3 Paediatric Rheumatology International Trials 


Italy 

1174. Severe Adverse Events Associated with Use of Biologic 

Therapy in Juvenile Idiopathic Arthritis: A Single-Center 

Study. Ricardo A. G. Russo 1 and Marìa M. Katsicas 2 , 1 Hospital 

de Pediatria Garrahan, Buenos Aires, Argentina, 2 Hospital de 

Pediatrìa Garrahan, Buenos Aires, Argentina 

Rheumamtoid Arthritis - Human Etiology and Pathogenesis 

1175. Decreased Frequency of Th17 Cells in Early Rheumatoid 

Arthritis. Irene Arroyo-Villa 1 , M. Belén Bautista-Caro 1 , 

Alejandro Balsa 1 , Pilar Aguado 1 , Laura Nuño 1 , Gema Bonilla 1 , 

Amaya Puig-Kröger 2 , Emilio Martín-Mola 1 and M. Eugenia 

Miranda-Carús 1 , 1 Hospital La Paz-IdiPaz, Madrid, Spain, 

2 

Hospital Gregorio Marañon, Madrid, Spain 

1176. Galactosylation, and Not Sialylation, of Immunoglobulin G 

Is Associated with Improvement of Rheumatoid Arthritis 

During Pregnancy. Albert Bondt 1 , Maurice H.J. Selman 2 , 

andré M. Deelder 2 , Johanna M.W. Hazes 1 , Manfred Wuhrer 2 

and Radboud J.E.M. Dolhain 1 , 1 Erasmus University Medical 

Center, Rotterdam, Netherlands, 2 Leiden University Medical 


1177. Talin Is Cleaved and Expressed As a Short Form in Patients 

with Rheumatoid Arthritis. Kensei Tsuzaka 1 , Masako Takao 1 , 

Naoshi Shinozaki 2 and Jiro Nishida 1 , 1 Ichikawa General 

Hospital,TDC, Ichikawa, Chiba, Japan, 2 Ichikawa, Japan 

1178. IL-6 and IL-21 in Rheumatoid Arthritis. Gustavo Carbone 1 , 

Augusta Wilson 1 , Sean Diehl 2 , Janice Bunn 3 , Sheldon Cooper 4 

and Mercedes Rincon 1 , 1 University of Vermont College of 

Medicine, Burlington, VT, 2 University of Vermont College of 

Medicine, 3 University of Vermont, Burlington, 4 Univ Vermont 

College of Med, Burlington, VT 

1179. Vitamin D Receptor Polymorphisms Are Associated 

with Clinical Outcomes and IgM Responses to Common 

Pathogens but Not Baseline Disease Activity in Early 

Inflammatory Arthritis. Carol A. Hitchon 1 , Linda Larcombe 1 , 

222 

2012 Program Book


Neeloffer Mookherjee 1 , Christine A. Peschken 1 , Marianna M. 

Newkirk 2 and Hani S. El-Gabalawy 1 , 1 University of Manitoba, 

Winnipeg, MB, 2 McGill University Health Centre, Montreal, 

QC 

1180. The Sex-Determining Region Y Box 6 Locus: Shared 

Genetic Susceptibility Between Rheumatoid Arthritis and 

Psychotic Disorder. Tony R. Merriman 1 , Nicola Dalbeth 2 , 

Andrew Harrison 3 , John Highton 4 , Lisa K. Stamp 5 , Malcolm D. 

Smith 6 , Benedicte A. Lie 7 , Tore K. Kvien 8 , Timothy Radstake 9 , 

Marieke J.H. Coenen 10 , Barbara Franke 10 , Jasper Broen 11 , 

Piet Van Riel 10 , Pilar Barrera 10 , Sophia Steer 12 , Marilyn E. 

Merriman 1 , Amanda Phipps-Green 1 , Ruth Topless 1 , Mansour 

Zamanpoor 1 and Wan Rohani Wan Tain 13 , 1 University of 

Otago, Dunedin, New Zealand, 2 University of Auckland, 

Auckland, New Zealand, 3 Hutt Hospital, Lower Hutt, New 

Zealand, 4 Univ of Otago Med Sch, Dunedin, New Zealand, 

5 

University of Otago, Christchurch, Christchurch, New 

Zealand, 6 Rheumatologist, Adelaide, Australia, 7 Oslo 

University Hospital, Oslo, Norway, 8 Diakonhjemmet Hospital, 

Oslo, Norway, 9 Radboud University Nijmegen Medical 

Centre, University Medical Center Utrecht, Nijmegen, 

Utrecht, Netherlands, 10 Radboud University Nijmegen 


Rheumatology & Clinical Immunology, University Medical 

Center, Utrecht, Netherlands, 12 1 Sloane Ct East Flat 7 , 

London, United Kingdom, 13 Universiti Sains Malaysia, 

Malaysia 

1181. The Role of á-Defensin-1 and Its Signal Transduction 

Mechanisms in the Production of IL-6, IL-8 and MMPs in 

Rheumatoid Fibroblast-Like Synoviocytes. Joong Kyong 

Ahn 1 , Bo Huang 2 , Eun-Jung Park 2 , Jiwon Hwang 2 , Jaejoon 

Lee 2 , Chan Hong Jeon 3 , Eunmi Koh 2 and Hoon-Suk Cha 2 , 

1 

Kangbuk Samsung hospital, Sungkyunkwan University 

School of Medicine, Seoul, South Korea, 2 Samsung Medical 

Center, Sungkyunkwan University School of Medicine, 

Seoul, South Korea, 3 Soonchunhyang University College of 

Medicine, Bucheon, South Korea 

1182. Familial Aggregation and Heritability of Rheumatoid 

Arthritis in Taiwan: A Nationwide Population Study. Chang- 

Fu Kuo 1 , Matthew J. Grainge 1 , Kuang-Hui Yu 2 , Lai-Chu See 3 , 

Shue-Fen Luo 2 , Ana M. Valdes 4 , I-Jun Chou 2 , Hsiao-Chun 

Chang 2 , Weiya Zhang 1 and Michael Doherty 1 , 1 University 

of Nottingham, Nottingham, United Kingdom, 2 Chang 

Gung Memorial Hospital, Taoyuan, Taiwan, 3 Chang Gung 

University, Taoyuan, Taiwan, 4 St. Thomas’ Hospital, King’s 


1183. Podoplanin-Mediated Interaction of Rheumatoid Arthritis 

Synovial Fibroblasts with Platelets Modulates IL-8 

Expression. Manuel J. Del Rey 1 , Elena Izquierdo 1 , Regina 

Faré 1 , Alicia Usategui 1 , Vanessa Miranda 1 , Gabriel Criado 1 , 

J. D. Cañete 2 and Jose L. Pablos 1 , 1 Instituto de Investigación 

Hospital 12 de Octubre (I+12), Madrid, Spain, 2 Hospital 

Clínic de Barcelona,, Barcelona, Spain 

1184. Negative Association Between Testosterone Levels and 

Risk of Future Rheumatoid Factor Negative Rheumatoid 

Arthritis in Men. Mitra Pikwer 1 , Aleksander Giwercman 2 , Ulf 

Bergström 1 , Jan-Åke Nilsson 1 , Lennart T.H. Jacobsson 1 and 

Carl Turesson 1 , 1 Lund University, Malmö, Sweden, 2 Skåne 

University Hospital, Malmö, Sweden 

1185. Regulatory Role of 1, 25 Dihydroxyvitamin D3 in 

the Pathogenesis of Autoimmune Arthritis. Siba P. 

Raychaudhuri 1 , Ananya Datta Mitra 2 , Anupam Mitra 1 , 

Christine Abria 2 and Smriti K. Raychaudhuri 2 , 1 VA 

Sacramento Medical Center/UC Davis School of Medicine, 

Mather, CA, 2 VA Sacramento Medical Center, Mather, CA 

1186. A Single Nucleotide Polymorphism of Tumor Necrosis 

Factor Receptor-Associated Factor 1 Predicts Clinical 

Response to Anti-Tumor Necrosis Factor Treatments in 

Japanese Patients with Rheumatoid Arthritis. Tetsuya 

Nishimoto 1 , Noriyuki Seta 1 , Ryusuke Anan 1 , Tatsuya 

Yamamoto 1 , Yuko Kaneko 2 , Masataka Kuwana 3 and Tsutomu 

Takeuchi 3 , 1 Keio university, Tokyo, Japan, 2 Keio Univ School 

of Medicine, Shinjuku-ku, Japan, 3 Keio University School of 

Medicine, Tokyo, Japan 

1187. Smoking Status Is Associated with Inflammatory Cytokine 

Profile and Disease Activity in Anti-Citrullinated Protein 

Antibody Positive Rheumatoid Arthritis: Decreased 

Inflammation and Disease Improvement with Smoking 

Cessation? Catriona Cramb 1 , Jeremy Sokolove 2 , Geoffrey 

M. Thiele 3 , Gail S. Kerr 4 , Grant W. Cannon 5 , Andreas M. 

Reimold 6 , Ted R. Mikuls 7 and William H. Robinson 8 , 1 VA 

Palo Alto Heatlh Care System and Stanford University, Palo 

Alto, CA, 2 VA Palo Alto Health Care System and Stanford 

University, Palo Alto, CA, 3 Univ of Nebraska Med Ctr, Omaha, 

NE, 4 Washington DC VAMC, Georgetown and Howard 

University, Washington, DC, 5 Salt Lake City VA and Univeristy 

of Utah, Salt Lake City, UT, 6 Dallas VA and University of Texas 

Southwestern, Dallas, TX, 7 Omaha VA and University of 

Nebraska Medical Center, Omaha, NE, 8 Stanford University, 

Palo Alto, CA 

1188. Fibrinogen Induced Inhibition of Osteoclastogenesis 

Is Reversed by Citrullination of Fibrinogen by 

Peptidylarginine Deiminase. Eun Young Lee 1 , Ji Soo Kim 1 , 

Hye Won Kim 1 , Sung Hae Chang 1 , Jin-Su Song 2 , Hie-Joon 

Kim 2 , Kyung-Hyun Park-Min 3 , Lionel B. Ivashkiv 3 , Eun Bong 

Lee 2 and Yeong Wook Song 1 , 1 Seoul National University 

College of Medicine, Seoul, South Korea, 2 Seoul National 

University, Seoul, South Korea, 3 Hospital for Special Surgery, 

New York, NY 

1189. Stromal Cell Markers in the Synovial Tissue of Patients 

with Early Arthritis and Preclinical Rheumatoid Arthritis. 

Yuen Kei Choi 1 , Olga N. Karpus 1 , Paul Peter Tak 2 , Jörg 

Hamann 1 , Christopher D. Buckley 3 , Andrew Filer 4 and 

Danielle M. Gerlag 5 , 1 Academic Medical Center, Amsterdam, 

Netherlands, 2 Division of Clinical Immunology and 

Rheumatology, Department of Experimental Immunology, 

Academic Medical Center / University of Amsterdam 



224 

and GlaxoSmithKline, Amsterdam, Netherlands, 3 School 

of Immunity and Infection, MRC Center for Immune 

Regulation, Birmingham, United Kingdom, 4 Rheumatology 

Department, Birmingham, United Kingdom, 5 Academic 

Medical Center / University of Amsterdam, Amsterdam, 

Netherlands 

1190. Fine Specificity of Anti-Citrullinated Peptide Antibodies 

Discloses a Heterogeneous Antibody Population in 

Rheumatoid Arthritis (RA). John D. Goules, Andreas V. 

Goules and Athanasios G. Tzioufas, School of Medicine, 

National University of Athens, Athens, Greece 

1191. Nicotinamide Adenine Dinucleotide Phosphate Oxidase 

Mediated Angiogenesis and Inflammation in the Arthritic 

Joint. Monika Biniecka 1 , Wei Gao 2 , Chin Teck Ng 2 , Emese 

Balogh 2 , Douglas J. Veale 2 and Ursula Fearon 2 , 1 Translation 

Research Group, Dublin Academic Medical Centre, St. 

Vincent’s University Hospital, Dublin, Ireland, 2 Translation 

Rheumatology Research Group, Dublin, Ireland 

1192. IL-21 Regulates B Cell Proliferation and Differentiation 

in Rheumatoid Arthritis. Lingyun Sun, Rui Liu and Xia 

Li, Department of Rheumatology and Immunology, the 

Affiliated Drum Tower Hospital of Nanjing University 

Medical School, Nanjing, China 

1193. Podoplanin Expression in Rheumatoid Stroma Correlates 

with Lymphoid Neogenesis and Is Downregulated by Anti- 

TNF-α Therapy. Regina Faré 1 , Elena Izquierdo 1 , Manuel J. 

Del Rey 1 , Raquel Celis 2 , Alicia Usategui 1 , Juan D. Cañete 2 and 

Jose L. Pablos 1 , 1 Instituto de Investigación Hospital 12 de 

Octubre (I+12), Madrid, Spain, 2 Hospital Clínic of Barcelona, 

Barcelona, Spain 

1194. Prevalence of Anti-Peptidylarginine Deiminase Type 

4 Antibodies in Rheumatoid Arthritis and Unaffected 

First-Degree Relatives in Indigenous North American 

Populations. Elizabeth D. Ferucci 1 , Irene Smolik 2 , Tammy L. 

Choromanski 1 , David B. Robinson 2 , Marianna M. Newkirk 3 , 

Marvin J. Fritzler 4 , Antony Rosen 5 , Erika Darrah 5 and Hani 

S. El-Gabalawy 2 , 1 Alaska Native Tribal Health Consortium, 

Anchorage, AK, 2 University of Manitoba, Winnipeg, MB, 

3 

McGill University Health Centr, Montreal, QC, 4 University 

of Calgary, Calgary, AB, 5 The Johns Hopkins University, 

Baltimore, MD 

1195. Identification of Follicular Helper T Cells As a Novel Cell 

Population Potentially Involved in the Pathogenesis of 

Rheumatoid Arthritis. Sharon Ing 1 , Anika Alarakhia 1 , Elvira 

Lindwall 1 , Austin Fraser 1 , Jerald M. Zakem 2 , William E. Davis 2 , 

Tamika A. Webb-Detiege 3 , Robert Quinet 4 and Xin Zhang 5 , 

1 

Ochsner Medical Center, New Orleans, LA, 2 Ochsner Clinic, 

New Orleans, LA, 3 Ochsner Medical Ctr, New Orleans, LA, 

4 

Ochsner Medical Center - New Orleans, New Orleans, LA, 

5 

Ochsner Clinic Foundation, New Orleans, LA 

1196. Analysis of Gene Expression Patterns in Rheumatoid 

Arthritis (RA) Synovial Macrophages from Patients 

Undergoing Disease Flare. Karen L. Berg 1 , Adedayo Hanidu 1 , 

Jon Hill 2 , Xiaoyu Jiang 1 , Tom Freeman 2 , Jennifer Swantek 1 , 


Anna Yarlina 3 , George D. Kalliolias 3 , Lionel B. Ivashkiv 3 and 

Gerald H. Nabozny 1 , 1 Boehringer Ingelheim Pharmaceuticals 

Inc., Ridgefield, CT, 2 Boehringer Ingelheim Pharmaceuticals 

Inc, Ridgefield, CT, 3 Hospital for Special Surgery, New York, 

NY 

1197. Porphyromonas Gingivalis and the Pathogenesis of 

Rheumatoid Arthritis: Analysis of the Synovial Tissue and 

of Other Compartments. Michele C. Totaro 1 , Sara D’Onghia 2 , 

Elisa Gremese 1 , Luca Petricca 1 , Simona Marchetti 2 , 

Silvia Canestri 1 , Barbara Tolusso 1 , Stefano Alivernini 1 , 

Paola Cattani 2 and Gianfranco Ferraccioli 1 , 1 Division of 

Rheumatology, Institute of Rheumatology and Affine 

Sciences, Catholic University of the Sacred Heart, Rome, 

Italy, 2 Laboratory of Clinical Analyses CIC, Catholic University 

of the Sacred Heart, Rome, Italy 

1198. Cardiovascular Risk Factors and Events Are More Frequent 

Prior to the Onset of Rheumatoid Arthritis Than in the 

General Population. Helen Pahau 1 , Vibeke Videm 2 , Sanjoy 

Paul 3 and Ranjeny Thomas 1 , 1 University of Queensland 

Diamantina Institute, Brisbane, Australia, 2 Department 

of Laboratory Medicine, Children’s and Women’s Health, 

Norwegian University of Science and Technology, and 

Department of Immunology and Transfusion Medicine, 

Trondheim University Hospital,, Trondheim, Norway, 

3 

University of Queensland School of Population Health, 

Brisbane, Australia 

1199. Proteases Produced by Porphyromonas Gingivalis Can 

Cleave and Citrullinate Substrates Found in the Joint 

and Oral Mucosa: Implications for Autoimmunity in 

Rheumatoid Arthritis. Nidhi Sofat 1 , Saralili Robertson 1 and 

Robin Wait 2 , 1 St. George’s University of London, London, 

United Kingdom, 2 University of Oxford, Oxford, United 

Kingdom 

1200. Anti-Cyclic Citrullinated Peptide Antibodies in Idiopathic 

Pulmonary Fibrosis Are Not Citrulline-Specific: Implications 

for the Pathogenesis of Rheumatoid Arthritis. Elena B. 

Lugli 1 , Muslima Chowdhury 1 , Peter J. Charles 1 , Michael G. 

Crooks 2 , Simon P. Hart 2 , Patrick J. Venables 1 and Benjamin 

A. Fisher 3 , 1 Oxford University, London, United Kingdom, 

2 

Hull York Medical School, Cottingham, United Kingdom, 

3 

University of Birmingham, Birmingham, United Kingdom 

1201. Anti-Citrullinated Protein Antibody Specific Fc 

Glycosylation Patterns in Arthralgia Patients. Hans Ulrich 

Scherer 1 , Yoann Rombouts 2 , Ewoud Ewing 2 , Lotte van de 

Stadt 3 , Maurice H.J. Selman 2 , andré M. Deelder 2 , Tom W.J. 

Huizinga 2 , Manfred Wuhrer 2 , D. van Schaardenburg 3 and 

René E.M. Toes 1 , 1 Leiden University Medical Centre, Leiden, 




1202. Antibodies against Porphyromonas Gingivalis Correlate 

with Rheumatoid Arthritis-Specific Auto-Immunity in 

Arthralgia Patients. M. J. de Smit 1 , L. A. van de Stadt 2 , 

J. Westra 1 , B. Doornbos-van der Meer 1 , K.M.J. Janssen 1 ,


A. Vissink 1 , A. J. van Winkelhoff 1 , E. Brouwer 1 and D. van 

Schaardenburg 2 , 1 University of Groningen, University 

Medical Center, Groningen, Netherlands, 2 Jan van Breemen 

Research Institute | Reade, Amsterdam, Netherlands 

1203. High Expression of Genes in the Toll-Like Receptor and 

Interferon Pathways Are Associated with Radiographic 

Damage in African-Americans with ACPA-Positive RA. 

Maria I. Danila 1 , A. D. Steg 2 , Xiangqin Cui 2 , David Redden 3 , 

M. R. Johnson 2 , Richard J. Reynolds 3 , D. van der Heijde 4 , 

Doyt L. Conn 5 , Beth L. Jonas 6 , Leigh F. Callahan 7 , Larry W. 

Moreland 8 , P. K. Gregersen 9 and S. Louis Bridges Jr. 10 , 1 Univ 

of Alabama-Birmingham, Birmingham, AL, 2 University 

of Alabama at Birmingham, 3 University of Alabama at 

Birmingham, Birmingham, AL, 4 Leiden University Medical 

Center, Leiden, Netherlands, 5 Emory Univ School of 

Medicine, Atlanta, GA, 6 University of North Carolina at 

Chapel Hill, Chapel Hill, NC, 7 University of North Carolina, 

Chapel Hill, NC, 8 University of Pittsburgh, Pittsburgh, PA, 

9 


Island Jewish Health System, Manhasset, NY, 10 Marguerite 

Jones Harbert-Gene V. Ball, MD Professor of Medicine, and 

Director, Division of Clinical Immunology and Rheumatology, 


1204. Porphyromonas Gingivalis Antibody Responses and Clinical 

Associations in Patients with Early Rheumatoid Arthritis. 

Sheila L. Arvikar 1 , Klemen Strle 1 , Deborah S. Collier 1 , Mark C. 

Fisher 1 , Gail McHugh 1 , Toshihisa Kawai 2 , Alpdogan Kantarci 2 

and Allen C. Steere 1 , 1 Massachusetts General Hospital, 

Boston, MA, 2 Forsyth Institute, Cambridge, MA 

1205. Study of Association of CD40-CD154 Gene Polymorphisms 

with Disease Susceptibility and Cardiovascular Risk in 

Spanish Rheumatoid Arthritis Patients. Mercedes García- 

Bermúdez 1 , Carlos González-Juanatey 2 , Alfonso Corrales 3 , 

Raquel López-Mejías 4 , Maria Teruel 5 , Jose A. Miranda-Filloy 6 , 

Santos Castañeda-Sanz 7 , Alejandro Balsa 8 , B. Fernández- 

Gutierrez 9 , Isidoro González-Álvaro 10 , Carmen Gómez- 

Vaquero 11 , R. Blanco Alonso 12 , Javier Llorca 13 , Javier Martin 1 

and Miguel Angel González-Gay 4 , 1 Instituto de Parasitologia 

y Biomedicina Lopez-Neyra (IPBLN-CSIC), Granada, Spain, 

2 

Hospital Xeral-Calde, Lugo, Spain, 3 Hospital Universitario 

Marques de Valdecilla. IFIMAV, Santander, Spain, 4 Hospital 

Universitario Marqués de Valdecilla. IFIMAV, Santander, 

Spain, 5 Instituto de Parasitologia y Biomedicina Lopez- 

Neyra, CSIC, Granada, Spain, 6 Hospital Universitario Lucus 

Augusti, Lugo, Spain, 7 Hospital de La Princesa, Madrid, 

Spain, 8 La Paz Hospital. IdiPaz, Madrid, Spain, 9 Department 

of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, 

10 

Reumatología (Hospital Universitario de La Princesa), 

Madrid, Spain, 11 Hospital Universitario de Bellvitge, IDIBELL, 

Barcelona, Spain, 12 Hospital Universitario Marques de 

Valdecilla, Santander, Spain, 13 Department of Epidemiology 

and Computational Biology, School of Medicine, University 

of Cantabria, and CIBER Epidemiología y Salud Pública 

(CIBERESP), Santander, Spain 

1206. Gp96 Exacerbate the Inflammation of Rheumatoid 

Arthritis. Qi Quan Huang 1 , Robert Birkett 2 , J.-P. Jin 3 and 

Richard M. Pope 4 , 1 Northwestern University, Chicago, IL, 

2 


Chicago, IL, 3 Wayne State University, Detroit, MI, 

4 

Northwestern Univ Med School, Chicago, IL 

1207. Impact of Anti Tumor Necrosis Factor-Alpha Therapy 

in Rheumatoid Arthritis On Osteoclast Activation and 

B Cells. Ezinma Ezealah 1 , Jennifer Hossler 1 , Jamie Biear 1 , 

Christopher A. Cistrone 1 , Teresa Owen 1 , Nida Meednu 1 , Kelly 

Callahan 1 , Arumugam Palanichamy 1 , Ignacio Sanz 2 , Allen P. 

Anandarajah 1 , Ralf G. Thiele 1 , Darren Tabechian 3 , R. John 

Looney 1 and Jennifer H. Anolik 1 , 1 University of Rochester 

Medical Center, Rochester, NY, 2 Emory University, Atlanta, 

GA, 3 Univ of Rochester Schl of Med, Rochester, NY 

1208. Stable Synovial Fluid Phenotype for Anti Citrullinated- 

Protein Antibodies in Established Rheumatoid Arthritis. 

Vijay Joshua 1 , Lena Israelsson 2 , Lars Klareskog 2 , Anca 

Irinel Catrina 1 and Vivianne Malmström 1 , 1Rheumatology 

Unit, Karolinska University Hospital, Karolinska Institute, 


Sweden 

1209. Functional Role of Chondrogenic Progenitor Cells in 

Rheumatoid Arthritis. Sabine Blaschke 1 , Sandra Trautmann 1 , 

Alexander W. Beham 2 , Burkhard Mai 3 , Sebastian Koelling 1 , 

Caroline Breysach 4 , Gabriele Wolf 1 , Gerhard A. Mueller 1 and 

Nicolai Miosge 5 , 1 University Medical Center Goettingen, 

Goettingen, Germany, 2 Department of Surgery, Germany, 

3 

Vitos Orthopaedic Clinic Kassel, Kassel, Germany, 

4 

Department of Surgery, Goettingen, Germany, 5 Dept. of 

Prosthodontics, Goettingen, Germany 

1210. Effect of HLA-DRB1*0901 Suggest Distinctive Mechanisms 

of Rheumatoid Arthritis Susceptibility. So-Young Bang 1 , 

Hye-Soon Lee 2 , Kyung Wha Lee 3 and Sang-Cheol Bae 4 , 

1 

Hanyang University Hospital for Rheumatic Diseases, Seoul, 

South Korea, 2 Hanyang University Guri Hospital, Guri, South 

Korea, 3 Hallym Institute for Genome Application,Hallym 

University Sacred Heart Hospital, Anyang, South Korea, 

4 

Hanyang University Hospital for Rheumatic Diseases, 

Clinical Research Center for Rheumatoid Arthritis (CRCRA), 


1211. ANTI-Cyclic Citrullinated Protein Antibodies Induce 

Inflammation and Oxidative Stress in WHITE Blood CELLS 

of Rheumatoid Arthritis Patients. Chary Lopez-Pedrera 1 , 

Carlos Perez-Sanchez 2 , Patricia Ruiz-Limon 1 , Mª Angeles 

Aguirre 1 , Rosario M. Carretero-Prieto 1 , Antonio Rodriguez- 

Ariza 1 , Nuria Barbarroja 3 , Pilar Font 1 , Francisco Martinez 1 , 

Inmaculada Gomez-Gracia 1 , Mª Jose Cuadrado 4 and Eduardo 

Collantes-Estevez 1 , 1 IMIBIC-Reina Sofia Hospital, Cordoba, 

Spain, 2 Research Unit, IMIBIC-Reina Sofia Hospital, Cordoba, 

Spain, 3 IMABIS and Virgen de la Victoria Hospital, Malaga, 

Spain, 4 The Rayne Institute, London, United Kingdom 



1212. Elevated Fecal Secretory Immunoglobulin A, Anti-Cyclic 

Citrullinated Peptide Antibodies, and Cytokine Levels in 

Rheumatoid Arthritis Patients. Sam Dalvi, Jose U. Scher*, 

Mukundan Attur, Jyoti Patel and Steven B. Abramson, NYU 

Hospital for Joint Diseases, New York, NY 

Rheumatoid Arthritis - Clinical Aspects II: Clinical Features and 

Comorbidity/Cardiovascular Disease 

1213. The Serum Cytokine Profile of Interstitial Lung Disease 

in Rheumatoid Arthritis. Jose Felix Restrepo 1 , Inmaculada 

del Rincon 2 , Roy Haas 3 , Daniel F. Battafarano 4 and Agustin 

Escalante 5 , 1 University of Texas Health Science Center, San 

Antonio, TX, 2 University Of Texas, Health Science Center, San 

Antonio, TX, 3 TX, 4 Brooke Army Medical Ctr, San Antonio, TX, 

5 

University of Texas Health Science Center at San Antonio, 

San Antonio, TX 

1214. The Impact of Periodontal Disease On Early Inflammatory 

Arthritis Persists Even After All Teeth Are Lost. Gisela 

Westhoff 1 , Paola de Pablo 2 , Thomas Dietrich 3 , Georg 

Schett 4 and Angela Zink 5 , 1 German Rheumatism Research 

Center Berlin, Berlin, Germany, 2 University of Birmingham, 

Birmingham, United Kingdom, 3 The School of Dentistry, 

University of Birmingham, Birmingham, UK, Birmingham, 

United Kingdom, 4 Institute for Clinical Immunology, 


5 

German Rheumatism Research Center and Charité 

University Medicine, Berlin, Germany 

1215. Rates of Orthopaedic Interventions for Rheumatoid 

Arthritis Have Changed Over the Last 25 Years. A Report 

From Two UK Inception Cohorts Reflecting Treatment 

Changes From Sequential DMARD Monotherapy to Anti-TNF 

Agents (1986-2011). Elena Nikiphorou 1 , Lewis Carpenter 2 , 

Sam Norton 3 , David James 4 , Patrick D. Kiely 5 , David Walsh 6 , 

Richard Williams 7 and Adam Young 3 , 1 ERAS, St Albans City 

Hospital and University College London (UCL), London, 

United Kingdom, 2 University of Hertfordshire, Hatfield, 

United Kingdom, 3 ERAS, St Albans City Hospital, St Albans, 

United Kingdom, 4 Diana Princess of Wales Hospital, Grimsby, 

United Kingdom, 5 St. Georges Hospital, London, United 

Kingdom, 6 City Hospital, Nottingham, United Kingdom, 

7 

County Hospital, Hereford, United Kingdom 

1216. Flare Self Management Strategies Used by Patients 

with Rheumatoid Arthritis. Susan J. Bartlett 1 , Clifton O. 

Bingham III 2 , Juan Xiong 3 , Ernest Choy 4 , Gilles Boire 5 , Carol 

A. Hitchon 6 , Janet E. Pope 7 , J. Carter Thorne 8 , Diane Tin 8 , 

Boulos Haraoui 9 , E. Keystone 10 , Vivian P. Bykerk 11 , OMERACT 

Flare Working Group1 2 and CATCH 13 , 1 McGill University, 

Montreal, QC, 2 Johns Hopkins University, Baltimore, MD, 

3 

Mount Sinai Hospital, Toronto, ON, 4 Cardiff University 

School of Medicine, Cardiff, United Kingdom, 5 CHUS - 

Sherbrooke University, Sherbrooke, QC, 6 University of 

Manitoba, Winnipeg, MB, 7 St. Joseph Health Care London, 

University of Western Ontario, London, ON, 8 Southlake 

Regional Health Centre, Newmarket, ON, 9 Osteoarthritis 


Centre (CRCHUM), Montreal, QC, 10 University of Toronto, 

Toronto, ON, 11 Hospital for Special Surgery, New York, NY, 

12 

Ottawa, 13 Toronto, ON 

1217. Decreased Survival in Rheumatoid Arthritis Complicated 

with Bronchiectasis: A Family-Based Cohort Study. Xavier 

Puéchal 1 , Emmanuelle Génin 2 , Thierry Bienvenu 1 and 

Daniel J. Dusser 1 , 1 Hôpital Cochin, AP-HP, Université Paris 

Descartes, Sorbonne Paris Cité, Paris, France, 2 INSERM 

UMR-S946, Université Paris Diderot, Paris, France 

1218. Genetic Markers of Functional Stress Response in Patients 

with Rheumatoid Arthritis. Olga Malysheva and Christoph 

G. Baerwald, University Hospital, Leipzig, Germany 

1219. Periodontal Disease Is Associated with Rheumatoid 

Arthritis but Its Severity Is Not Correlated with 

Rheumatoid Arthritis Disease Activity. In Ah Choi 1 , Jin-Hee 

Kim 2 , Kyung Hwa Kim 2 , Hye Won Kim 1 , Myeong Jae Yoon 1 , 

Bon Seung Ku 1 , Hyejin Oh 1 , Joo Youn Lee 1 , Eun Young Lee 1 , 

Eun Bong Lee 1 , Yong-Moo Lee 2 and Young Wook Song 1 , 

1 

Department of Internal Medicine, School of Medicine, 

Seoul National University, Seoul, South Korea, 2 Department 

of Periodontology, School of Dentistry, Seoul National 

University, Seoul, South Korea 

1220. Occurrence and Morbidity of Lower Extremity Ulcer in 

Rheumatoid Arthritis - A Population Based Study. Adlene 

Jebakumar, Cynthia S. Crowson, Prabhu D. Udayakumar, 

Sherine E. Gabriel and Eric L. Matteson, Mayo Clinic, 

Rochester, MN 

1221. Low Muscle Density in Rheumatoid Arthritis and Modified 

Association with Total Fat Mass, Results of a Pilot Study. 

Joshua Baker 1 , Joan Marie Von Feldt 2 and Mary Beth 

Leonard 3 , 1 University of Pennsylvania, Philadelphia, PA, 

2 

Univ of Pennsylvania/Philadelphia VAMC, Philadelphia, PA, 

3 

The Children’s Hospital of Philadelphia, Philadelphia, PA 

1222. Incidence and Time Trends of Malignancy in Rheumatoid 

Arthritis: A Population Based Study 1980-2007. Kerry 

Wright, Cynthia S. Crowson, Sherine E. Gabriel and Eric L. 

Matteson, Mayo Clinic, Rochester, MN 

1223. Frequency of Deep Vein Thromboses and Pulmonary 

Emboli in Rheumatoid Arthritis. Christian A. Pineau 1 , 

Evelyne Vinet 1 and Sasha Bernatsky 2 , 1 McGill University 

Health Centre, Montreal, QC, 2 Research Institute of the 

McGill University Health Ctre, Montreal, QC 

1224. Rheumatoid Arthritis Disease Activity During Pregnancy 

Affects the Postnatal Catch-up Growth of the Child. 

Florentien D.O. de Steenwinkel 1 , Anita C.S. Hokken-Koelega 2 , 

Maria A.J. de Ridder 1 , Johanna M.W. Hazes 1 and Radboud 

J.E.M. Dolhain 1 , 1 Erasmus Medical Center, Rotterdam, 

Netherlands, 2 Erasmus Medical Center- Sophia Children’s 

Hospital, Rotterdam, Netherlands 

1225. Self Reported Comorbidity Is Common in Early 

Inflammatory Arthritis and Associated with Poorer 

Function and Quality of Life and Greater Disease Activity: 

Results From the Canadian Early Arthritis Cohort. Carol A. 

226 

2012 Program Book


Hitchon 1 , Gilles Boire 2 , Boulos Haraoui 3 , Edward Keystone 4 , 

Janet E. Pope 5 , Vivian P. Bykerk 6 and Canadian Early Arthritis 

Cohort (CATCH) Investigators 7 , 1 University of Manitoba, 

Winnipeg, MB, 2 CHUS - Sherbrooke University, Sherbrooke, 

QC, 3 Osteoarthritis Research Unit, University of Montreal 


4 

University of Toronto, Toronto, ON, 5 St. Joseph Health 


6 

Hospital for Special Surgery, New York, NY, 7 Toronto 

1226. Transition Time to Osteoporosis in Patients with 

Rheumatoid Arthritis. Jiwon Hwang 1 , Joong Kyong Ahn 2 , 

Ji Young Chai 3 , Hoon-Suk Cha 1 , Jaejoon Lee 1 and Eunmi 

Koh 1 , 1 Samsung Medical Center, Sungkyunkwan University 

School of Medicine, Seoul, South Korea, 2 Kangbuk Samsung 

hospital, Sungkyunkwan University School of Medicine, 

Seoul, South Korea, 3 Jesang Hospital, Seongnam-si 

Gyeonggi-do, South Korea 

1227. Rheumatoid Arthritis-Associated Interstitial LUNG Disease: 

Clinical Spectrum of A Large Cohort From A Respiratory 

Referral Center. Joshua J. Solomon 1 , Gloria M. Russell 2 , Jill B. 

Ketzer 3 , Amy L. Olson 4 , Evans R. Fernandez-Perez 4 , Tristan J. 

Huie 4 , Jeffrey J. Swigris 4 , Kevin K. Brown 5 and Aryeh Fischer 4 , 

1 

Denver, 2 Pontificia Universidad Católica Madre y Maestra, 

Santiago, Dominican Republic, 3 National Jewish Health, 

Denver, 4 National Jewish Health, Denver, CO, 5 National 

Jewish Hospital, Denver, CO 

1228. Contributions of Inflammation, Inactivity, and Low Dose 

Prednisone Use to Skeletal Muscle Insulin Resistance in 

Well-Controlled Rheumatoid Arthritis. Hiba Abouassi, Lori 

Bateman, Gary E. McDaniel, Lorraine Elliott-Penry, Michael 

Muehlbauer, E. William St. Clair, William E. Kraus and Kim M. 

Huffman, Duke University Medical Center, Durham, NC 

1229. Rheumatoid Arthritis and Risks of Malignant Lymphoma 

- Are Risks Still Increased? Karin Hellgren 1 , Eva Baecklund 2 , 

Karin E Smedby 3 , Carin Backlin 4 , Christer Sundstrom 5 

and Johan Askling 6 , 1 Unit of Rheumatology, Stockholm, 

Sweden, 2 Unit of Rheumatology,, Uppsala, Sweden, 3 Clinical 

Epidemiology Unit, Stockholm, Sweden, 4 Department 

of Medical Sciences,, Uppsala, Sweden, 5 Department of 

Genetics and Pathology, Uppsala, Sweden, 6 Rheumatology 

Unit & Clinical Epidemiology Unit, Stockholm, Sweden 

1230. The Role of Sleep Problems in Conditioned Pain 

Modulation in Rheumatoid Arthritis. Yvonne C. Lee 1 , Bing 

Lu 2 , Robert R. Edwards 3 , Ajay Wasan 4 , Nicholas Nassikas 1 , 

Daniel J. Clauw 5 , Daniel H. Solomon 1 and Elizabeth W. 

Karlson 2 , 1 Brigham and Women’s Hospital, Boston, MA, 

2 


Boston, MA, 3 Brigham & Womens Hospital, Chestnut Hill, 

MA, 4 Brigham and Women’s Hospital, Chestnut Hill, MA, 

5 


1231. Rheumatoid Arthritis Is Associated with Likelihood of 

Being Overweight in Women. Irum-Mona Idrees 1 , H. Lester 

Kirchner 2 and androniki Bili 1 , 1 Geisinger Medical Center, 

Danville, PA, 2 Geisinger Health System, Danville, PA 

1232. Association of Actometer Assessed Physical Activity and 

Fatigue in Patients with Rheumatoid Arthritis: Patients 

with a Lower Daily Activity Have More Fatigue. Sanne van 

Dartel, Han Repping-Wuts, Dewy van Hoogmoed, Hans 

Knoop, Gijs Bleijenberg, Piet L.C. van Riel and J. Fransen, 


Netherlands 

1233. Effect of Insoles on the Rheumatoid Foot. Emilia Moreira 1 , 

Anamaria Jones 1 , Hilda A. Oliveira 1 , Fabio Jennings 1 , Artur 

R.C. Fernandes 2 and Jamil Natour 3 , 1 Universidade Federal de 

Sao Paulo, Sao Paulo, Brazil, 2 Universidade Federal de São 

Paulo, Sao Paulo, Brazil, 3 Universidade Federal de São Paulo, 


1234. Barriers, Benefits and Preferences for Exercise in RA 

Patients: A Cross Sectional Study. Yves Henchoz 1 , Pascal 

Zufferey 2 and Alexander So 3 , 1 Université du Québec à Trois- 

Rivières, Trois-Rivières, QC, 2 Lausanne University Hospital, 

Lausanne, Switzerland, 3 CHUV, Univ of Lausanne, Lausanne, 

Switzerland 

1235. Orthopedic Surgery Among Patients with Rheumatoid 

Arthritis 1980-2007: A Population-Based Study to Identify 

Predictors of Large Joint Vs Small Joint Surgeries. Ashima 

Makol, Cynthia S. Crowson and Eric L. Matteson, Mayo 

Clinic, Rochester, MN 

1236. Important Prognostic Factor in Rheumatoid Arthritis 

Patients with Interstitial Lung Disease Is Not Usual 

Interstitial Pneumonia Pattern but Interstitial Lung Disease 

Extent On Chest High-Resolution Computed Tomography. 

Hwajeong Lee 1 , Jung-Yoon Choe 1 , Seong-Kyu Kim 1 , Sung 

Hoon Park 1 , Ji Hun Kim 1 , Dae Sung Hyun 2 , Kyung Jae Jung 3 

and Jisuk Bae 4 , 1 Division of Rheumatology, Department of 

Internal Medicine, Catholic University of Daegu School of 

Medicine, Daegu, South Korea, 2 Division of Pulmonology, 

Department of Internal Medicine, Catholic University of 

Daegu School of Medicine, South Korea, 3 Radiology, Catholic 

University of Daegu School of Medicine, South Korea, 

4 

Department of Preventive Medicine, Catholic University of 

Daegu School of Medicine, South Korea 

1237. Baseline Evaluation of Insulin Resistance in Patients with 

early Non-Treated Rheumatoid Arthritis. Sara Manrique- 

Arija 1 , María América López-Lasanta 1 , Pilar Espiño- Lorenzo 1 , 

Pedro Valdivielso 2 , José Rioja 2 , Inmaculada Ureña 1 , 

Francisco Gabriel Jimenez- Núñez 1 , Carmen M. Romero- 

Barco 1 , Veronica Rodríguez-García 1 , Laura Nieves 1 , Mari 

Carmen Ordoñez-Cañizares 1 , Laura Cano 1 , Maria Victoria 

Irigoyen 1 and Antonio Fernández-Nebro 1 , 1 Hospital Carlos 

Haya. University of Malaga, Malaga, Spain, 2 Department of 

Medicine. University of Malaga, Malaga, Spain 

1238. Effects of Stress on Clinical Presentation of Patients with 

Early Rheumatoid Arthritis. Yun A. Kim 1 , Jane E. Salmon 2 , 

Juan Xiong 3 , Boulos Haraoui 4 , Carol A. Hitchon 5 , Edward 

Keystone 6 , Janet Pope 7 , Diane Tin 8 , J. Carter Thorne 8 , Gilles 

Boire 9 , Vivian P. Bykerk 2 and CATCH 10 , 1 Hospital for Special 

Surgery (and Kwangju Christian Hospital, Gwangju, Korea), 



New York, NY, 2 Hospital for Special Surgery, New York, 

NY, 3 Mount Sinai Hospital, Toronto, ON, 4 Osteoarthritis 


Centre (CRCHUM), Montreal, QC, 5 University of Manitoba, 

Winnipeg, MB, 6 University of Toronto, Toronto, ON, 

7 

Schulich School of Medicine and Dentistry, Western 

University, London, ON, 8 Southlake Regional Health 

Centre, Newmarket, ON, 9 CHUS - Sherbrooke University, 

Sherbrooke, QC, 10 Toronto 

1239. Soluble Glycoprotein VI: A Novel Risk Marker for 

Thrombosis in Patients with Inflammatory Arthritis. Leann 

Bell 1 , Anne M. Madigan 1 , Paul A. MacMullan 1 , Eimear 

Dunne 2 , Dermot Kenny 2 and Geraldine M. McCarthy 1 , 

1 

Mater Misericordiae University Hospital, Dublin 7 , Ireland, 

2 

RCSI, Dublin 2, Ireland 

1240. Serum Anti-Müllerian Hormone Can Be Used to Determine 

Ovarian Reserve in Women with Rheumatoid Arthritis. 

Jenny Brouwer, Johanna M.W. Hazes, Joop S.E. Laven, Izaäk 

Schipper and Radboud J.E.M. Dolhain, Erasmus Medical 


1241. Glucocorticoid Use is associated with increase in HDL 

in Rheumatoid Arthritis Patients. Lisa L. Schroeder 1 , 

Xiaoqin Tang 2 , Mary Chester M. Wasko 3 and androniki Bili 4 , 

1 

Geisinger Health System, Danville, PA, 2 Geisinger Center 

for Health Research, Danville, PA, 3 Temple University School 

of Medicine, Pittsburgh, PA, 4 Geisinger Medical Center, 

Danville, PA 

1242. Use of Anti-Tumor Necrosis Factor Therapy Is Associated 

with Reduced Cardiovascular Event Risk in Rheumatoid 

Arthritis. Mike Nurmohamed 1 , Yanjun Bao 2 , James 

Signorovitch 3 , Parvez M. Mulani 2 and Daniel E. Furst 4 , 1 VU 

University Medical Center & Jan van Breemen Research 

Institute, Amsterdam, Netherlands, 2 Abbott Laboratories, 

Abbott Park, IL, 3 Analysis Group, Inc., Boston, MA, 4 UCLA 

Medical School, Los Angeles, CA 

1243. Effect of Tocilizumab Treatment On Regional Left 

Ventricular Function, As Assessed by Cardiac Magnetic 

Resonance Imaging, in Rheumatoid Arthritis Patients 

without Cardiac Symptoms. Hitomi Kobayashi 1 , Isamu 

Yokoe 1 , Hiroshi Sato 1 and Yasuyuki Kobayashi 2 , 1 Itabashi 

Chuo Medical Center, Tokyo, Japan, 2 St Marianna Univ Sch of 

Med, Kawasaki, Japan 

1244. Group Cycling in Rheumatoid Arthritis: Positive Effects 

On Aerobic Capacity and Blood Pressure. Lars Ångström, 

Kristina Hörnberg and Solveig Wållberg Jonsson, Dept of 

Rheumatology, Umeå, Sweden 

1245. Age-Specific Association between Disease-Related 

Measures and Incident Cardiovascular Events and All-Cause 

Mortality in Early Rheumatoid Arthritis. Sofia Ajeganova 1 , 

Maria LE andersson 2 , Johan Frostegård 3 and Ingiäld 

Hafström 1 , 1 Karolinska Institutet, Unit of Rheumatology, 

Department of Medicine Huddinge, Stockholm, Sweden, 

2 

R&D Center, Spenshult Hospital, Oskarström, Sweden, 

3 

Karolinska Institutet, Section of Immunology and chronic 

disease, Institute of Environmental Medicine, Stockholm, 

Sweden 

1246. Cardiovascular Risk Assessment in Rheumatoid Arthritis 

(RA) Patients Treated by Biologic Response Modifiers. 

Majed M. Khraishi 1 , Rana Aslanov 2 and Katie Doyle 1 , 

1 

Memorial University of Newfoundland, St Johns, NF, 

2 

Memorial University of Newfoundland, St.John’s, NF 

1247. Delay in Diagnosis of Rheumatoid Arthritis Increases 

the Cardiovascular Risk. Chan-Bum Choi 1 , Yoon-Kyoung 

Sung 2 , Soo-Kyung Cho 2 , Dae-Hyun Yoo 2 , Shin-Seok Lee 3 , 

Jisoo Lee 4 , Jinseok Kim 5 , Hye-Soon Lee 6 , Tae-Hwan Kim 2 , Bo 

Young Yoon 7 , Wan-Hee Yoo 8 , Jung-Yoon Choe 9 , Sang-Heon 

Lee 10 , Seung-Cheol Shim 11 , Won-Tae Chung 12 , Seung-Jae 

Hong 13 , Choong Ki Lee 14 , Eunmi Koh 15 , Jae-Bum Jun 16 , So- 

Young Bang 6 , Seong-Kyu Kim 17 , Hoon-Suk Cha 18 , Jeeseon 

Shim 19 , Sang-Cheol Bae 20 and Korean Observational Study 

Network for Arthritis (KORONA) 21 , 1 Hanyang University 

Hospital for Rheumatic Diseases, Clinical Research Center 

for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 

2 

Hanyang University Hospital for Rheumatic Diseases, 

Seoul, South Korea, 3 Chonnam National University 

Medical School, Gwangju, South Korea, 4 Ewha Womans 

University Mokdong Hospital, Seoul, South Korea, 5 Jeju 

National University Hospital, Jeju, South Korea, 6 Hanyang 

University Guri Hospital, Guri, South Korea, 7 Inje University 

Ilsan Paik Hospital, Goyang, South Korea, 8 Department of 

Internal Medicine, Chonbuk National University Medical 

School and Research Institute of Clinical Medicine, Jeonju, 

South Korea, 9 Catholic university of Daegu School of 

mediine, Arthritis and autoimmunty research center, 

Daegu, 10 Konkuk University School of Medicine, Seoul, 

South Korea, 11 Eulji University Hospital, Daejeon, South 

Korea, 12 Dong-A University Hospital, Busan, South Korea, 

13 

Kyung Hee University, Seoul, South Korea, 14 Yeungnam 

University, Daegu, South Korea, 15 Samsung Medical Center, 


Korea, 16 Hanyang University Hospital for Rheumatic Disease, 

Seoul, South Korea, 17 and Autoimmunity Research Center, 

Catholic University of Daegu School of Medicine, Daegu, 

South Korea, 18 Samsung Medical Center, Sunkyunkwan 

University School of Medicine, Seoul, South Korea, 19 Clinical 

Research Center for Rheumatoid Arthritis (CRCRA), Seoul, 


Disease, Clinical Research Center for Rheumatoid Arthritis 

(CRCRA), Seoul, South Korea, 21 Seoul 

1248. Accelerated Aging Influences Cardiovascular Disease 

Risk in Rheumatoid Arthritis. Cynthia S. Crowson, Terry 

M. Therneau, John M. Davis III, Veronique L. Roger, Eric L. 

Matteson and Sherine E. Gabriel, Mayo Clinic, Rochester, MN 

1249. The Impact of Statin Use On Lipid Levels in Statin-Naive 

Patients with Rheumatoid Arthritis (RA) Vs. Non-RA Subjects: 

Results From a Population-Based Study. Elena Myasoedova, 

Cynthia S. Crowson, Abigail B. Green, Eric L. Matteson and 

Sherine E. Gabriel, Mayo Clinic, Rochester, MN 

228 

2012 Program Book


1250. Heightened Aortic Wall Inflammation in Patients with 

Rheumatoid Arthritis Versus Patients with Established 

Coronary Artery Disease without Autoimmune Disease. 

Jeffrey D. Greenberg 1 , Zahi Fayad 2 , Victoria Furer 3 , Michael 

Farkouh 2 , Michael J. Colin 3 , Pamela B. Rosenthal 3 , Jonathan 

Samuels 3 , Svetlana Krasnokutsky Samuels 4 , Soumya M. 

Reddy 3 , Peter M. Izmirly 3 , Cheongeun Oh 3 , Manish Jain 3 and 

Venkatesh Mani 2 , 1 New York University School of Medicine, 

New York, NY, 2 Mount Sinai School of Medicine, New York, 

NY, 3 NYU School of Medicine, New York, NY, 4 NYU School of 

Medicine, New York 

1251. Vulnerability Features Are Common in Coronary Plaques 

of Asymptomatic Patients with Rheumatoid Arthritis 

Compared to Controls: Associations with Lipid and 

Oxidative Stress Biomarkers. George A. Karpouzas 1 , Jennifer 

Malpeso 2 , Tae-Young Choi 2 , Silvia Munoz 1 and Matthew 

Budoff 2 , 1 Harbor-UCLA, Torrance, CA, 2 Harbor-UCLA Medical 

Center, Torrance, CA 

1252. Association of Paraoxonase 1 Gene Polymorphisms and 

Enzyme Activity with Carotid Plaque in Rheumatoid 

Arthritis. Christina Charles-Schoeman, Yuen Yin Lee, 

Veena K. Ranganath, John D. FitzGerald, Mihaela B. Taylor, 

Maureen A. McMahon, David Elashoff and Srinivasa T. 

Reddy, University of California, Los Angeles, CA 

1253. Identifying Vulnerable Plaque in Rheumatoid Arthritis: A 

Pilot Study Using Novel Microbubble-Contrast Enhanced 

Carotid Ultrasonography. Kimberly P. Liang, Douglas P. 

Landsittel, Suresh R. Mulukutla, Steven E. Reis, Marc C. 

Levesque, Flordeliza S. Villanueva, Hunter C. Champion and 

Larry W. Moreland, University of Pittsburgh, Pittsburgh, PA 

1254. In Treatment-Naive Early RA the Left Ventricular Function 

Is Correlated to CRP, Doctors Global and Anti-CCP Status. 

BB Løgstrup 1 , LD Kristensen 1 , A. Hedemann-Andersen 1 

and Torkell Ellingsen 2 , 1 Diagnostic Centre Region Hospital 

Silkeborg Denmark, Silkeborg, Denmark, 2 Diagnostic Centre 

Regional Hospital Silkeborg, 8 600 Silkeborg, Denmark 

1255. Vascular Calcification on Hand and Feet X-Rays, VFA 

Imaging of the Spine, and Cardiovascular Disease in 

Rheumatoid Arthritis. Ausaf Mohammad 1 , Collette English 1 , 

Derek Lohan 1 , Diane Bergin 1 , Sarah Mooney 1 , John Newell 2 , 

Martin O’Donnell 1 , Robert J. Coughlan 1 and John J. Carey 1 , 

1 

Galway University Hospitals, Galway, Ireland, 2 National 

University of Ireland, Galway, Ireland 

1256. High Inflammation May Condition the Antiatherogenic 

Function of Small, Dense HDL in Patients with Active 

Rheumatoid Arthritis. Carla Saucedo 1 , Leonardo gomez 

Rosso 2 , Tomas Meroño 2 , Fernando Brites 2 , Anatol Kontush 3 , 

Luis J. Catoggio 1 , Enrique Soriano 4 , Laurent Camont 5 , 

Marie Lhomme 5 , Veronica Malah 6 , Patricia Sorroche 7 , 

Sandrine Chantepie 5 , Paul Robillard 8 and John Chapman 5 , 

1 

Rheumatology Section, Hospital Italiano de Buenos 

Aires, Buenos Aires, Argentina, 2 Laboratory of Lipids and 

Lipoproteins, School of Pharmacy and Biochemistry, Buenos 

Aires, Argentina, 3 Université Pierre et Marie Curie-Paris, 

Paris, France, 4 Hospital Italiano de Buenos Aires, Buenos 

Aires, Argentina, 5 Université Pierre et Marie Curie, Paris, 

France, 6 Rheumatology section, Hospital de Clínicas “José de 

San Martín”, Buenos Aires, Argentina, 7 Central Laboratory , 


8 

Université Pierre et Marie Curie, Paris, Argentina 

1257. Subclinical Atherosclerosis in Hispanic Patients with 

Rheumatoid Arthritis. Correlation with the Presence of 

Anti-Oxidized LDL Antibodies and Serum Levels of CD40L. 

Yurilis Fuentes-Silva 1 , Soham Al Snih 2 , Natali Serra-Bonett 1 , 

Juan De Sanctis 3 and Martin A. Rodriguez 4 , 1 Centro Nacional 

de Enfermedades Reumáticas, Caracas, Venezuela, 

2 

University of Texas Medical Branch, Galveston, TX, 3 Instituto 

de Inmunología, Caracas, Venezuela, 4 Hospital Universitario 

de Caracas, Caracas, Venezuela 

1258. Association between Low Vitamin D Levels and Indicators 

of Osteoporosis and Atherosclerosis. Barry J. Sheane 1 , 

Ruth Dunne 2 , Ken Scott 3 , Mary Hall 2 , Michelle O’Connor 2 , 

Martin Healy 2 , John Feely 2 , J.B. Walsh 2 and Gaye Cunnane 2 , 

1 

St. James’s Hospital, Dublin, Ireland, 2 St James’s Hospital, 

Dublin, Ireland, 3 Trinity College Dublin, Dublin 8, Ireland 

1259. Association between Subclinical Atherosclerosis and Bone 

Mineral Density in Rheumatoid Arthritis. Barry J. Sheane 1 , 

Ruth Dunne 2 , Ken Scott 3 , Mary Hall 2 , Michelle O’Connor 2 , 

Martin Healy 4 , John Feely 2 , J.B. Walsh 5 and Gaye Cunnane 6 , 

1 

St. James Hospital, Dublin, Ireland, 2 St James’s Hospital, 

Dublin 8, Ireland, 3 Trinity College Dublin, Dublin 8, Ireland, 

4 

Central Pathology Laboratory, Dublin 8, Ireland, 5 Medicine 

for the Elderly, Dublin 8, Ireland, 6 St James’s Hospital, 


1260. Hydroxychloroquine Reduces the Risk of Coronary 

Artery Disease in Patients with Rheumatoid Arthritis. 

Li Chun 1 , Mu Rong 1 , Su Yin 1 , Li Xiaofeng 2 , Wang Yongfu 3 , 

Wang Guochun 4 , Zhu Ping 5 , Liu Xiangyuan 4 , Chen Haiying 6 , 

Cui Liufu 7 , Zhang Zhuoli 4 , Li Zhenbin 6 , Li Junfang 8 , Zhang 

Fengxiao 9 , Han Shuling 4 , Lin Jinying 10 , Liu Xiaomin 4 , Hu 

Shaoxian 11 , Yang Xiuyan 12 , Huang Cibo Sr. 13 , Li Xingfu 14 , Wang 

Yi 15 and Li Zhanguo 1 , 1 Peking University People’s Hospital, 

Beijing, China, 2 Taiyuan, China, 3 Baotou, China, 4 Beijing, 

China, 5 Xian, China, 6 Shijiazhuang, China, 7 Tangshan, China, 

8 

Handan, China, 9 China, 10 Nanning, China, 11 Wuhan, China, 

12 

Guangzhou, China, 13 Beijing Hospital, Ministry of Health, 

Beijing, China, 14 Jinan, China, 15 Lanzhou, China 

1261. Epicardial Adipose Tissue Is Associated with 

Cardiometabolic Risk and the Metabolic Syndrome in 

Patients with Rheumatoid Arthritis. Michelle J. Ormseth 1 , 

Aliza Lipson 2 , Nikolaos Alexopoulos 2 , Gregory R. Hartlage 2 , 

Annette M. Oeser 1 , Aihua Bian 1 , Tebeb Gebretsadik 1 , Ayumi 

Shintani 1 , Paolo Raggi 2 and C. Michael Stein 1 , 1 Vanderbilt 

Medical Center, Nashville, TN, 2 Emory University, Atlanta, GA 

1262. Rheumatoid Arthritis Patients with Higher Disease 

Severity and Subclinical Carotid Plaque Experience More 

Cardiovascular Events Despite a Favorable Conventional 

Cadiovascular Risk Profiles. Yeon-Ah Lee 1 , Somi Kim 1 , Sang- 



Hoon Lee 2 , Ran Song 2 , Hyung In Yang 2 and Seung-Jae Hong 1 , 

1 

Kyung Hee University, Seoul, South Korea, 2 Hospital at 

GANGDONG, Kyung Hee University, Seoul, South Korea 

1263. Carotid Arterial Wall Inflammation Is Associated with a 

Specific Profile of Inflammatory Biomarkers and Anti- 

Citrullinated Protein Antibodies in Rheumatoid Arthritis 

Patients. Caroline Grönwall 1 , Gregg Silverman 1 , Zahi Fayad 2 , 

Venkatesh Mani 2 , Victoria Furer 1 , Michael Farkouh 2 , Manish 

Jain 1 , Cheongeun Oh 1 , John Todd 3 , Mukundan Attur 4 , 

Steven B. Abramson 4 and Jeffrey D. Greenberg 5 , 1 NYU 

School of Medicine, New York, NY, 2 Mount Sinai Hospital, 

New York, NY, 3 Singulex, Alameda, California, Alameda, CA, 

4 

NYU Hospital for Joint Diseases, New York, NY, 5 New York 


1264. Vascular Age in Rheumatoid Arthritis Patients. Jl Rosales- 

Alexander, César Magro Checa, Juan Salvatierra, Silvia 

Montes García, Jesús Cantero Hinojosa and Enrique Raya 

Álvarez, University Hospital San Cecilio, Granada, Spain 

1265. Lipoprotein Subclass Particles and Small Vessel Elasticity As 

a Potential Marker for Early Atherosclerosis in Rheumatoid 

Arthritis: a Prospective, Controlled Study. Marty T. 

Mertens 1 and Elie Gertner 2 , 1 University of Minnesota, 

Minneapolis, MN, 2 Regions Hospital and University of 

Minnesota Medical School, St. Paul, MN 

1266. Evaluation of Metabolic Syndrome in 97 Patients with 

Rheumatoid Arthritis. Fernanda G. G Chaer 1 , Juliana 

Lucena 1 , Rogerio Castro Reis 1 , Fabiola Brasil 1 , Murilo Melo 2 , 

Amanda Callegari 2 and Branca Souza 2 , 1 Irmandade da 

Santa Casa de Misericordia de Sao Paulo, São Paulo, Brazil, 

2 

Irmandade da Santa Casa de Misericordia de São Paulo, São 

Paulo, Brazil 

1267. Inflammatory Burden Predicts Progression of Carotid 

Plaque in Rheumatoid Arthritis: A 24-Month Longitudinal 

Analysis. Churl Hyun Im, Na Ri Kim, Jong Wan Kang, Young 

Ji Kim, Kyung Hye Kim, Eon Jeong Nam and Young Mo Kang, 

Kyungpook National University School of Medicine, Daegu, 

South Korea 

1268. Lipid Alterations and Measurement of Arterial Stiffness 

in Rheumatoid Arthritis. Marina Scolnik 1 , Carla Saucedo 1 , 

David A. Navarta 1 , Leandro Ferreyra Garrott 1 , Erika 

Catay 1 , Maria L. Acosta Felquer 1 , Eliana Lancioni 1 , Cristian 

Quiroz 1 , Federica Varela Guidetti 1 , Zaida Bedran 1 , Mirtha 

Sabelli 1 , Javier Rosa 1 , Maria Victoria Garcia 1 , Patricia 

M. Imamura 1 , Patricia Sorroche 2 , Jose Alfie 3 , Margarita 

Morales 3 , Gabriel Waisman 3 , Luis J. Catoggio 1 and Enrique 

Soriano 4 , 1 Rheumatology Section, Hospital Italiano de 

Buenos Aires, Buenos Aires, Argentina, 2 Central Laboratory 

, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 

3 

Hypertension Unit, Hospital Italiano de Buenos Aires, 

Buenos Aires, Argentina, 4 Hospital Italiano de Buenos Aires, 


1269. Serum Cytokines Associated with Carotid Atherosclerosis 

in Rheumatoid Arthritis. Inmaculada del Rincon 1 , Roy 

W. Haas 1 , Daniel H. O’Leary 2 , Joseph F. Polak 2 , Daniel F. 

Battafarano 3 and Agustin Escalante 1 , 1 University of Texas 

Health Science Center at San Antonio, San Antonio, TX, 

2 

Tufts University-Boston Campus, Boston, MA, 3 Brooke Army 

Medical Ctr, San Antonio, TX 

1270. Role of Inflammation, Serologic Status and Low Density 

Lipoprotein in Coronary Heart Disease Among Patients 

with Rheumatoid Arthritis: Data From the National 

Veterans Health Administration. Iris Navarro-Millan 1 , 

Shuo Yang 2 , Scott L. DuVall 3 , Lang Chen 2 , John Baddley 2 , 

Grant W. Cannon 4 , Elizabeth S. Delzell 2 , Jie Zhang 2 , Monika 

M. Safford 2 , Nivedita M. Patkar 5 , Ted R. Mikuls 6 , Jasvinder 

A. Singh 2 and Jeffrey Curtis 2 , 1 University of Alabama 

Birmingham, Birmingham, AL, 2 University of Alabama at 

Birmingham, Birmingham, AL, 3 VA Salt Lake City Health 

Care System and University of Utah School of Medicine, Salt 

Lake City, UT, 4 Salt Lake City VA and Univeristy of Utah, Salt 

Lake City, UT, 5 Univ of Alabama-Birmingham, Birmingham, 

AL, 6 Omaha VA and University of Nebraska Medical Center, 

Omaha, NE 


Gene Therapy 

1271. Two-Year Drug Survival and Treatment Effect of Abatacept 

and Tocilizumab in the Treatment of Rheumatoid Arthritis 

in Routine Care. Results from the Nationwide Danish Danbio 

Registry. HC Leffers 1 , Mikkel Østergaard 1 , Bente Glintborg 2 , 

Niels Steen Krogh 3 , Ulrik Tarp 4 , Tove Lorenzen 5 , Annette 

Hansen 2 , Michael Sejer Hansen 2 , Lene Dreyer 2 , Martin S. 

Jakobsen 2 and Merete L. Hetland 6 , 1 DANBIO, On behalf of 

Depts of Rheumatology, North, South, Central, Zealand and 

Capital Region, Glostrup, Denmark, 2 DANBIO, On behalf 

of Depts of Rheumatology, North, South, Central, Zealand 

and Capital Region, Copenhagen, Denmark, 3 ZiteLab ApS, 

Copenhagen, Denmark, 4 DANBIO, On behalf of Depts of 


Region, Aarhus, Denmark, 5 DANBIO, On behalf of Depts of 


Region, Silkeborg, Denmark, 6 Copenhagen University and 

Glostrup Hospital, Copenhagen, Denmark 

1272. Rheumatoid Arthritis (RA) Incomplete Secondary 

Responders to TNF-Alpha Safely Achieve Efficacy by 

Switching to Certolizumab Pegol in a 24-Week Study: A 

Phase IV, Randomized Multicenter, Double-Blind, Twelve- 

Week Study Followed by a 12 -Week Open-Label Phase. M. 

Schiff 1 , Ronald Goldblum 2 and John RP Tesser 3 , 1 University of 

Colorado, Denver, CO, 2 CPC, Inc, Carlsbad, CA, 3 AZ Arthritis 

Rheum Assoc, Paradise Valley, AZ 

1273. Can Response Duration After the First Rituximab 

Treatment Be Used in Timing of Rituximab Retreatment? 

Noortje van Herwaarden 1 , Aatke van der Maas 1 , Tim L. 

Jansen 2 , Ellen Dutmer 3 , andre Hartkamp 4 , Piet L.C.M. van 

Riel 2 , Wietske Kievit 2 , Bart J.F. van den Bemt 1 and Alfons A. 

230 

2012 Program Book


den Broeder 1 , 1 Sint Maartenskliniek, Nijmegen, Netherlands, 

2 


Netherlands, 3 Gelderse Vallei Hospital, Ede, Netherlands, 

4 

Jeroen Bosch Hospital, ‘s-Hertogenbosch, Netherlands 

1274. Relationship between Morning Stiffness Duration and 

Severity, Pain Intensity, and Measures of Disease Activity 

in a 12 Week Efficacy Study of a Modified (Delayed- 

Release) Prednisone Plus Disease-Modifying Antirheumatic 

Drugs in Rheumatoid Arthritis. Frank Buttgereit 1 , John 

R. Kirwan 2 , Kenneth G. Saag 3 , Reike Alten 4 , Amy Grahn 5 , 

Patricia Rice 6 and Maarten Boers 7 , 1 Charite University 

Med-Berlin, Berlin, Germany, 2 Bristol Royal Infirmary, 

Bristol, United Kingdom, 3 Univ of Alabama-Birmingham, 

Birmingham, AL, 4 Charité Univ Medicine, Berlin, Germany, 

5 

Horizon Pharma, Deerfield, IL, 6 CliniRx Research, Naperville, 

IL, 7 VU University Medical Center, Amsterdam, Netherlands 

1275. Fast Remission Response to Etanercept At Week 4 Predicts 

Better Long-Term Outcomes in Early and Established 

Rheumatoid Arthritis Compared to Slower Response At 

Week 12. Bernd Raffeiner, Costantino Botsios, Francesca 

Ometto, Mariagrazia Canova, Livio Bernardi, Cristiana 

Vezzari, Silvano Todesco, Paolo Sfriso and Leonardo Punzi, 

Rheumatology Unit - University of Padova, Padova, Italy 

1276. Changes in B Cell Populations and Serum Immunoglobulins 

and Their Relationship to Infections in a One Year, 

Uncontrolled Open Label Study of Tabalumab. Maria 

W. Greenwald 1 , Melissa Veenhuizen 2 , Wendy Komocsar 2 , 

Rebecca Jones-Taha 3 , Chin H. Lee 2 and Pierre-Yves Berclaz 2 , 

1 

Desert Medical Advances, Palm Desert, CA, 2 Eli Lilly & 

Company, Indianapolis, IN, 3 PharmaNet/i 3 , Blue Bell, PA 

1277. Tofacitinib, an Oral Janus Kinase Inhibitor, in Combination 

with Methotrexate Reduced the Progression of Structural 

Damage in Patients with Rheumatoid Arthritis: Year 2 

Efficacy and Safety Results From a 24-Month Phase 3 

Study. D. van der Heijde 1 , Y. Tanaka 2 , R. M. Fleischmann 3 , 

E. Keystone 4 , J. M. Kremer 5 , C. Zerbini 6 , M. H. Cardiel 7 , S. B. 

Cohen 8 , P. T. Nash 9 , Y. Song 10 , D. Tegzova 11 , B. Wyman 12 , D. 

Gruben 12 , B. Benda 13 , G. Wallenstein 12 , S. Krishnaswami 12 , 

S. H. Zwillich 12 , J. Bradley 12 , C. A. Connell1 2 and ORAL Scan 

Investigators 14 , 1 Leiden University Medical Center, Leiden, 

Netherlands, 2 University of Occupational and Environmental 

Health, Kitakyushu, Japan, 3 Metroplex Clinical Research 

Center, Dallas, TX, 4 Mount Sinai Hospital, Toronto, ON, 

5 

Albany Medical College, Albany, NY, 6 CEPIC – Centro 

Paulista de Investigação Clínica, São Paulo-SP, Sao Paulo, 

Brazil, 7 Centro de Investigacion Clinica de Morelia, Morelia, 

Mexico, 8 Metroplex Clinical Research Centre, Dallas, TX, 

9 

Nambour Hospital, Sunshine Coast, Australia, 10 Seoul 

National University Hospital, Seoul, South Korea, 11 Institute 

of Rheumatology, Prague, Czech Republic, 12 Pfizer Inc., 

Groton, CT, 13 Pfizer Inc., Collegeville, PA, 14 Groton 

1278. Tuberculosis and Tofacitinib Therapy in Patients with 

Rheumatoid Arthritis. Kevin L. Winthrop 1 , S.-H. Park 2 , A. 

Gul 3 , M. Cardiel 4 , JJ Gomez-Reino 5 , D. Ponce de Leon 6 , 

R. Riese 7 , R. Chew 7 , T. Kawabata 7 , E. Mortensen 6 and H. 

Valdez 8 , 1 Oregon Health & Science University, Portland, 

OR, 2 The Catholic University of Korea, Seoul, South 

Korea, 3 Istanbul University, Istanbul, Turkey, 4 Centro de 

Investigación Clínica de Morelia SC, Morelia, Mexico, 

5 

Hospital Clinico Universitario de Santiago, Santiago de 

Compostela, Spain, 6 Pfizer Inc., Collegeville, PA, 7 Pfizer Inc., 

Groton, CT, 8 Pfizer Inc., New York, NY 

1279. First in Human Study with Recombinant Anti-IL-21 

Monoclonal Antibody in Healthy Subjects and Patients 

with Rheumatoid Arthritis. Stanislav Ignatenko 1 , Birte 

K. Skrumsager 2 , Adam Steensberg 2 and Ulrik Mouritzen 2 , 

1 

Charité Research Organization GmbH, Berlin, Germany, 

2 

Novo Nordisk A/S, Copenhagen, Denmark 

1280. Sustained Efficacy Responses and a Consistent Safety 

Profile with Rituximab Repeat Treatment Over 5 Years in 

Patients with Rheumatoid Arthritis and an Inadequate 

Response to Tumour Necrosis Factor Inhibitors. Edward 

Keystone 1 , Stanley B. Cohen 2 , Paul Emery 3 , Joel M. Kremer 4 , 

Maxime R. Dougados 5 , James E. Loveless 6 , Carol Chung 7 , 

Pamela Wong 7 , Patrica B. Lehane 8 and Helen Tyrrell 8 , 

1 

Mount Sinai Hospital, Toronto, ON, 2 Metroplex Clinical 

Research Center, Dallas, TX, 3 University of Leeds, Leeds, 

United Kingdom, 4 Albany Medical College, Albany, NY, 5 René 

Descartes University, Paris, France, 6 St Luke’s Rheumatology, 

Boise, ID, 7 Genentech, Inc., South San Francisco, CA, 8 Roche 

Products Limited, Welwyn Garden City, United Kingdom 

1281. IL-6 Signaling Inhibition Improves Abnormal Bone 

Homeostasis in Active Rheumatoid Arthritis. Masayasu 

Kitano 1 , Sachie Kitano 1 , Chieri Sato 1 , Kazuyuki Fujita 1 , 

Takahiro Yoshikawa 1 , Yuki Katashima 1 , Masahiro Sekiguchi 1 , 

Naoto Azuma 1 , Naoaki Hashimoto, Shinichiro Tsunoda 1 , 

Kiyoshi Matsui 1 and Hajime Sano 1 , 1 Hyogo College of 

Medicine, Nishinomiya-city, Japan 

1282. Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment 

of Rheumatoid Arthritis: Open-Label, Long-Term Extension 

Safety and Efficacy up to 48 Months. Jurgen Wollenhaupt 1 , 

Joel C. Silverfield 2 , Eun Bong Lee 3 , Susan P. Wood 4 , Koshika 

Soma 4 , Lisy Wang 4 , Hiroyuki Nakamura 5 , Yoshihiro Komuro 5 , 

Chudi I. Nduaka 4 , David Gruben 4 , Birgitta Benda 6 , Samuel 

H. Zwillich 4 , Richard Riese 4 and John D. Bradley 4 , 1 Schoen- 

Klinik Hamburg-Eilbek Teaching Hospital of the University 

of Hamburg, Hamburg, Germany, 2 Tampa Medical Group, 

Tampa, FL, 3 Seoul National University, Seoul, South Korea, 

4 

Pfizer Inc., Groton, CT, 5 Pfizer Japan Inc., Tokyo, Japan, 

6 

Pfizer Inc., Collegeville, PA 

1283. Effects of Tofacitinib On Patient-Reported Outcomes in 

Patients with Active Rheumatoid Arthritis Receiving Stable- 

Dose Methotrexate: Results of Two Phase 3 Studies. Gerd 

R. Burmester 1 , Désirée van der Heijde 2 , Vibeke Strand 3 , 

Cristiano A. F. Zerbini 4 , Carol A. Connell 5 , Charles A. Mebus 5 , 

Samuel H. Zwillich 5 , John D. Bradley 5 , David Gruben 5 and 

Gene Wallenstein 5 , 1 Charité – University Medicine Berlin, 

Berlin, Germany, 2 Leiden University Medical Center, Leiden, 



232 

Netherlands, 3 Stanford University, Palo Alto, CA, 4 Centro 

Paulista de Investigação Clinica, Sao Paulo, Brazil, 5 Pfizer Inc., 

Groton, CT 

1284. Evaluation of Influenza and Pneumococcal Vaccine 

Responses in Patients with Rheumatoid Arthritis Receiving 

Tofacitinib. K. L. Winthrop 1 , A. Racewicz 2 , E. B. Lee 3 , B. 

Wilkinson 4 , S. H. Zwillich 4 , K. Soma 4 , S. Rottinghaus 4 , 

T. Kawabata 4 , R. Riese 4 , S. Wood 4 , J. Bradley 4 and C. O. 

Bingham III 5 , 1 Oregon Health and Science University, 

Portland, OR, 2 Department of Internal Medicine and 

Osteoarthrology, Bialystok Regional Hospital, Bialystok, 

Poland, 3 Seoul National University, Seoul, South Korea, 

4 

Pfizer Inc., Groton, CT, 5 Johns Hopkins University, Baltimore, 

MD 

1285. Short-Term Efficacy of Etanercept Plus Methotrexate 

Vs.Various Disease-Modifying Anti-Rheumatic 

Combinations with Methotrexate in Established 

Rheumatoid Arthritis. Roy Fleischmann 1 , Andrew S. Koenig 2 , 

Annette Szumski 2 , Henk Nab 3 , Lisa Marshall 2 and Eustratios 

Bananis 2 , 1 University of Texas Southwestern Medical Center, 

Dallas, TX, 2 Pfizer Inc., Collegeville, PA, 3 Pfizer Europe, Rome, 

Italy 

1286. Antibodies to Etanercept and Adalimumab in Rheumatoid 

Arthritis Inadequate Responders and Clinical Outcomes 

After an Active Switch to Infliximab. Chad Pool 1 , Gopi 

Shankar 2 , Allen Schantz 2 , George Gunn 2 , Rebecca Bolce 3 , 

Marjatta Leirisalo-Repo 4 , Jim Wang 5 , John A. Goldman 6 , 

Raphael J. DeHoratius 1 , Roy M. Fleischmann 7 and Dennis 

Decktor 1 , 1 Janssen Services, LLC, Horsham, PA, 2 Janssen 

R&D, LLC, PA, 3 Crescendo Bioscience Inc., South San 

Francisco, CA, 4 Helsinki University Central Hospital, Helsinki, 

Finland, 5 Janssen Services, LLC, Horsham, 6 Medical Quarters 

#29 3 , Atlanta, GA, 7 University of Texas Southwestern Medical 

Center and Metroplex Clinical Research Center, Dallas, TX 

1287. Rheumatoid Arthritis Comparison of Active Therapies 

in Methotrexate Suboptimal Responders: Validation of 

the Strategy of Conventional Disease Modifying Anti- 

Rheumatic Drugs Before Biologicals. James R. O’Dell 1 , 

Ted R. Mikuls 1 , Thomas Taylor 2 , Vandana Ahluwalia 3 , Mary 

Brophy 4 , Stuart Warren 5 , Robert Lew 6 , Ciaran Phibbs 7 , 

Aslam H. Anis 8 , Amy C. Cannella 1 , Gary A. Kunkel 9 , Alan 

R. Erickson 10 , Edward Keystone 11 and the CSP551 RACAT 

Research Group 12 , 1 Omaha VA and University of Nebraska 

Medical Center, Omaha, NE, 2 VA Medical Center, White River 

Junction, VT, 3 William Osler Health Center, Mississauga, ON, 

4 

VA Boston Healthcare System, Boston, MA, 5 VA CSP Clinical 

Research Pharmacy Coordinating Center, Albuquerque, 

NM, 6 VA Boston HealthCare System, Boston, MA, 7 Palo Alto 

VA Health Care System, Menlo Park, CA, 8 Univ of British 

Columbia, Vancouver, BC, 9 George Wahlen Veterans Affairs 

Medical Center, Salt Lake City, UT, 10 UNMC Physicians - 

Brentwood, LaVista, NE, 11 University of Toronto, Toronto, 

ON, 12 Boston 


1288. A Significant Number of Patients with Chronic Arthritis 

Received a Reduced Dosage of Biological Drugs: an 

Observational Study in Clinical Practice. Jose Inciarte- 

Mundo 1 , Maria Victoria Hernández 1 , Violeta Rosario 1 , Sonia 

Cabrera 2 , Virginia Ruiz-Esquide 1 , Maria Eugenia Gomez- 

Caballero 1 , Jose A. Gómez-Puerta 1 , Julio Ramirez 1 , Juan D. 

Cañete 1 and Raimon Sanmarti 1 , 1 Hospital Clínic of Barcelona, 

Barcelona, Spain, 2 Hospital Clínic of Barcelona., Barcelona, 

Spain 

1289. Abatacept Biologic-Free Remission Study in Established 

Rheumatoid Arthritis Patients. Orion Study. Tsutomu 

Takeuchi 1 , Tsukasa Matsubara 2 , Shuji Ohta 3 , Masaya Mukai 4 , 

Koichi Amano 5 , Shigeto Tohma 6 , Yoshiya Tanaka 7 , Hisashi 

Yamanaka 8 and Nobuyuki Miyasaka 9 , 1 Keio University 

School of Medicine, Tokyo, Japan, 2 Matsubara Mayflower 

Hospital, Hyogo, Japan, 3 Taga General Hospital, Ibaraki, 

Japan, 4 Sapporo City General Hospital, Sapporo, Japan, 

5 

Department of Rheumatology and Clinical Immunology, 

Saitama Medical Center, Saitama Medical University, 

Saitama, Japan, 6 Sagamihara National Hospital, Sagamihara 

City, Japan, 7 University of Occupational and Environmental 

Health, Kitakyushu, Japan, 8 Institute of Rheumatology, Tokyo 

Women’s Medical University, Tokyo, Japan, 9 Tokyo Medical 

and Dental University, Tokyo, Japan 

1290. Effects of Tofacitinib On Lipid Profiles and Cholesterol and 

Lipoprotein Kinetics in Patients with Rheumatoid Arthritis. 

Christina Charles-Schoeman 1 , Roy M. Fleischmann 2 , Jean 

Davignon 3 , Howard Schwartz 4 , Scott Turner 5 , Carine Beysen 5 , 

Mark Milad 6 , Zheng Luo 7 , John Bradley 7 , Irina Kaplan 7 , 

Richard Riese 7 , Andrea Zuckerman 7 and Iain B. McInnes 8 , 

1 

University of California, Los Angeles, CA, 2 Metroplex 

Clinical Research Center, Dallas, TX, 3 University of Montreal, 

Montreal, 4 Miami Research Associates, Miami, FL, 5 KineMed 

Inc., Emeryville, CA, 6 Milad Pharmaceutical Consulting 

LLC, Plymouth, MI, 7 Pfizer Inc., Groton, CT, 8 University of 

Glasgow, Glasgow, United Kingdom 

1291. A Phase Ib Clinical Trial with F8-IL10, an Anti-Inflammatory 

Immunocytokine for the Treatment of Rheumatoid 

Arthritis (RA), Used in Combination with Methotrexate 

(MTX). Mauro Galeazzi 1 , Caterina Baldi 1 , Elena Prisco 2 , 

Marco Bardelli 1 , Dario Neri 3 , Leonardo Giovannoni 4 , 

Enrico Selvi 1 and Roberto Caporali 2 , 1 University of Siena, 

Siena, Italy, 2 University of Pavia, IRCCS Policlinico San 

Matteo Foundation, Pavia, Italy, 3 Swiss Federal Institute of 

Technology Zurich, Zurich, Switzerland, 4 Philogen S.p.A., 

Siena, Italy 

1292. Fatigue Is an Independent Variable Predicting Physical 

Function and Disease Activity Score-28 Remission 

for Patients with Rheumatoid Arthritis Treated with 

Intravenously Administered Golimumab: Results 

From Phase 3 , Placebo Controlled Clinical Trial. Rene 

Westhovens 1 , Michael Weinblatt 2 , Chenglong Han 3 , Tim 

Gathany 3 , Lilianne Kim 4 , Michael Mack 5 , Jiandong Lu 5 , 

Daniel Baker 5 , Alan Mendelsohn 5 and Clifton O. Bingham 

III 6 , 1 University Hospital KU Leuven, Leuven, Belgium,


2 


Hospital, Boston, MA, 3 Johnson & Johnson Pharmaceutical 

Services, LLC, Malvern, PA, 4 Janssen Research & 

Development, LLC, Malvern, PA, 5 Janssen Research & 

Development, LLC, Spring House, PA, 6 Johns Hopkins 

University, Baltimore, MD 

1293. Importance of Steady-State Trough Concentrations after 

Intravenous Golimumab with Concomitant Methotrexate 

in Subjects with Active Rheumatoid Arthritis. J. H. Leu, Z. 

Xu, C. Hu, Alan Mendelsohn, J. Ford, Hugh M. Davis and 

H. Zhou, Janssen Research and Development, LLC, Spring 

House, PA 

1294. A Phase Ib Multiple Ascending Dose Study Evaluating 

Safety, Pharmacokinetics, and Early Clinical Response 

of Brodalumab (AMG 827), a Human Anti-Interleukin 

17 Receptor (IL-17R) Antibody, in Rheumatoid Arthritis. 

Melvin A. Churchill 1 , Luis F. Flores-Suarez 2 , Daniel J. 

Wallace 3 , Kristine Phillips 4 , Richard W. Martin 5 , Mario H. 

Cardiel 6 , Jeffrey Kaine 7 , Edgar Bautista 8 , David H. Salinger 9 , 

Erin Stevens 9 , Christopher B. Russell 9 and David A. Martin 9 , 

1 

Arthritis Center of Nebraska, Lincoln, NE, 2 Instituto Nacional 

de Enfermedades Respiratorias, Mexico City, Mexico, 

3 

Cedars-Sinai Medical Center, Los Angeles, CA, 4 University 

of Michigan Medical School, Ann Arbor, MI, 5 Michigan State 

University College of Human Medicine, Grand Rapids, MI, 

6 

Hospital, Morelia, Mexico, 7 Sarasota Arthritis Research 

Center, Sarasota, FL, 8 Amgen, Thousand Oaks, CA, 9 Amgen, 

Seattle, WA 

1295. Effectiveness and Tolerability of Subcutaneous Tocilizumab 

in Rheumatoid Arthritis Patients Switched From 

Intravenous Tocilizumab: Results From the Extension 

Period of the Musashi Study. Atsushi Ogata 1 and the 

MUSASHI study group 2 , 1 Osaka University Graduate School 

of Medicine, Suita, Japan, 2 Japan 

1296. An Interim Analysis of the Efficacy of Abatacept in 

Japanese Biologics-naïve Rheumatoid Arthritis Patients 

(results from ABROAD study): Comparison of CRP and 

MMP-3 Level after Treatment with Abatacept Versus Anti- 

TNF Agents. Masahiro Sekiguchi 1 , Kiyoshi Matsui 1 , Masayasu 

Kitano 1 , Mitsuo Namiki 1 , Koichiro Ohmura 2 , Takao Fujii 2 , 

Hideko Nakahara 3 , Keiji Maeda 3 , Hideo Hashimoto 4 , Takanori 

Kuroiwa 5 , Kenji Miki 6 , Masanori Funauchi 7 , Kazuhiro Hatta 8 , 

Kenshi Higami 9 , Shunzo Namiuchi 10 , Ichiro Yoshii 11 , Teruyuki 

Nakatani 12 , Takashi Ikawa 13 , Takaji Matsutani 14 , Kosaku 

Murakami 15 , Satoshi Morita 16 , Yutaka Kawahito 17 , Norihiro 

Nishimoto 14 , Tsuneyo Mimori 2 and Hajime Sano 1 , 1 Hyogo 

College of Medicine, Nishinomiya, Japan, 2 Kyoto University, 

Kyoto, Japan, 3 NTT West Osaka Hospital, Osaka, Japan, 

4 

Rinku Hashimoto Rheumatology, Osaka, Japan, 5 Yukioka 

Hospital, Osaka, Japan, 6 Amagasaki Central Hospital, 

Amagasaki, Japan, 7 Kinki University Faculty of Medicine, 

Osaka, Japan, 8 Tenri Yorozu Sodansyo Hospital, Nara, 

9 

Higami Hospital, Nara, Japan, 10 Saiseikai Nakatsu Hospital, 

Osaka, Japan, 11 Yoshii Hospital, Shimanto, Japan, 12 Kishiwada 

City Hospital, Osaka, Japan, 13 Kobe-Konan Yamate Clinic, 

Kobe, Japan, 14 Wakayama Medical University, Ibaraki, Japan, 

15 

Osaka Red Cross Hospital, Osaka, Japan, 16 Yokohama City 

University, Kanagawa, Japan, 17 Graduate School of Medical 

Science, Kyoto Prefectural University of Medicine, Kyoto, 

Japan 

1297. Tofacitinib and Adalimumab Achieve Similar Rates of 

Low Disease Activity in Rheumatoid Arthritis — Lack 

of Improvement in Disease Activity Score by 3 Months 

Predicts Low Likelihood of Low Disease Activity At 1 Year. 

Ronald F. van Vollenhoven 1 , Sriram Krishnaswami 2 , Birgitta 

Benda 3 , David Gruben 2 , Bethanie Wilkinson 2 , Charles A. 

Mebus 2 , Samuel H. Zwillich 2 and John Bradley 2 , 1 Karolinska 

Institute, Stockholm, Sweden, 2 Pfizer Inc., Groton, CT, 3 Pfizer 

Inc., Collegeville, PA 

1298. Improvement of Treatment Outcome of Rheumatoid 

Arthritis with Salazosulfapyridine by Pharmacogenetic 

Approach. Shunichi Kumagai 1 , Yoshiaki Hagiwara 2 , Yoshihide 

Ichise 1 , Sho Sendo 1 , Nobuhiko Okada 1 , Jun Saegusa 2 and 

Goh Tsuji 3 , 1 Shinko hospital, Kobe, Japan, 2 Kobe University 

Graduate School of Medicine, Kobe, Japan, 3 Shinko Hospital, 

Kobe, Japan 

1299. Rituximab versus Abatacept in Rheumatoid Arthritis 

Patients with an Inadequate Response to Prior Biologic 

Therapy: A Retrospective, Single-Center Study. Edward 

Keystone, Juan Xiong, Deborah Weber and Ye Sun, Mount 

Sinai Hospital, Toronto, ON 

1300. Characteristics Associated with Biologic Initiation As 

Monotherapy Versus Combination Therapy in Patients with 

Rheumatoid Arthritis (RA) in a US Registry Population. 

Dimitrios A. Pappas 1 , George W. Reed 2 , Katherine C. 

Saunders 3 , Ani John 4 , Ashwini Shewede 5 , Jenny Devenport 6 , 

Jeffrey D. Greenberg 7 and Joel M. Kremer 8 , 1 Columbia 

University, College of Physicians and Surgeons, New York, 

NY, 2 University of Massachusetts Medical School, Worcester, 

MA, 3 CORRONA, Inc., Southborough, MA, 4 Genentech 

Inc., South San Francisco, CA, 5 Genentech Inc., South San 

Francisco, 6 Genentech, South San Francisco, CA, 7 NYU 

Hospital for Joint Diseases, New York, NY, 8 Albany Medical 

College and The Center for Rheumatology, Albany, NY 

1301. Predictors of Significant Disease Activity Score-28 (Using 

C-reactive protein) Remission Achieved with Intravenous 

Golimumab in Patients with Active Rheumatoid Arthritis 

Despite Methotrexate Therapy: Results of the Phase 3 , 

Multicenter, Double-Blind, Placebo-Controlled Trial. Clifton 

O. Bingham III 1 , Michael Weinblatt 2 , Alan Mendelsohn 3 , 

Lilianne Kim 3 , Michael Mack 3 , Jiandong Lu 3 , Daniel Baker 3 

and Rene Westhovens 4 , 1 Johns Hopkins University, 

Baltimore, MD, 2 Rheumatology & Immunology, Brigham 

& Women’s Hospital, Boston, MA, 3 Janssen Research & 

Development, LLC, Spring House, PA, 4 University Hospital KU 

Leuven, Leuven, Belgium 

1302. Early Neutropenia Is Associated with Clinical Response 

in Patients Receiving Tocilizumab in Rheumatoid 

Arthritis. Marie Kostine 1 , Thomas Barnetche 2 , Elodie 



234 

Ardouin 3 , Marlene Joly 4 , Emilie Rabois 5 , Baptiste Glace Sr. 6 , 

Delphine Nigon 7 , Thierry Schaeverbeke 8 and Christophe 

Richez 9 , 1 Rheumatology, CHU Pellegrin, Bordeaux, 

France, 2 CHU Bordeaux Pellegrin, Bordeaux, France, 

3 

Rheumatology, Limoges University Hospital, Limoges, 

France, 4 Rheumatology, Montpellier University Hospital, 

Montpellier, France, 5 CHU Gabriel Montpied, Clermont- 

Ferrand, France, 6 Rheumatology CHU Gabriel Montpied, 

Clermont-Ferrand, France, 7 CHU Purpan, Toulouse, France, 

8 

Groupe Hospitalier Pellegrin, Bordeaux, France, 9 Hôpital 

Pellegrin and Université Victor Segalen Bordeaux, France 

1303. Achieving Comprehensive Disease Control in Long- 

Standing or Early Rheumatoid Arthritis Patients Treated 

with Adalimumab Plus Methotrexate Versus Methotrexate 

Alone. Edward C. Keystone 1 , Ferdinand C. Breedveld 2 , 

Désirée van der Heijde 2 , Ronald F. van Vollenhoven 3 , Stefan 

Florentinus 4 , Freddy Faccin 5 , Shufang Liu 5 , Hartmut Kupper 6 

and Arthur Kavanaugh 7 , 1 Professor of Medicine, Toronto, 

ON, 2 Leiden University Medical Center, Leiden, Netherlands, 

3 

Karolinska Institute, Stockholm, Sweden, 4 Abbott, Rungis, 

France, 5 Abbott, Abbott Park, IL, 6 Abbott GmbH and Co. KG, 

Ludwigshafen, Germany, 7 UCSD School of Medicine, La Jolla, 

CA 

1304. Long-Term Use of Adalimumab as Monotherapy Following 

Attainment of Low Disease Activity with Adalimumab 

Plus Methotrexate. Edward C. Keystone 1 , Ferdinand C. 

Breedveld 2 , Hartmut Kupper 3 , Shufang Liu 4 and Stefan 

Florentinus 5 , 1 Professor of Medicine, Toronto, ON, 2 Leiden 

University Medical Center, Leiden, Netherlands, 3 Abbott 

GmbH and Co. KG, Ludwigshafen, Germany, 4 Abbott, Abbott 

Park, IL, 5 Abbott, Rungis, France 

1305. Three-Year Follow-up of Rituximab in Rheumatoid 

Arthritis: Results From the Belgian MIRA (MabThera in 

Rheumatoid Arthritis) Registry. Filip De Keyser 1 , Patrick 

Durez 2 , Rene Westhovens 3 , marie-Joelle Kaiser 4 and Ilse 

Hoffman 5 , 1 Universitair Ziekenhuis Gent, Gent, Belgium, 

2 

Université Catholique de Louvain, Brussels, Belgium, 

3 

University Hospital KU Leuven, Leuven, Belgium, 4 Dept 

Rheumatology, University Hospital Liege, Belgium, Belgium, 

5 

Dept Rheumatology, GZA St-Augustinus Hospital Antwerp, 

Belgium 

1306. How Well Do Patients with Rheumatoid and Psoriatic 

Arthritis Tolerate Methotrexate? A Retrospective Review 

of Discontinuation Data from a Large UK Cohort. Calum T. 

Goudie 1 , John D. Fitzpatrick 1 , Anshuman P. Malaviya 2 and 

Andrew J. Ostor 2 , 1 University of Cambridge Medical School, 

Cambridge, United Kingdom, 2 Addenbrooke’s Hospital, 

Cambridge, United Kingdom 

1307. Anti-IL-6 Receptor Nanobody (ALX-0061) Seamless 

“First-in-Human” Phase I/II POC Study in Patients with 

Active RA On Stable MTX Treatment. Steven De Bruyn 1 , 

Béla Gachályi 2 , Bernadette Rojkovich 3 , Slavomir Bruk 4 , 

Petr Sramek 5 , Mariusz Korkosz 6 , Krzysztof Krause 7 , Pieter 

Schoen 1 , Laura Sargentini-Maier 1 , Joke D’Artois 1 , Katrien 


Verschueren 1 , Katelijne De Swert 1 , Gerhard Arold 8 and 

Josefin-Beate Holz 1 , 1 Ablynx N.V., Zwijnaarde, Belgium, 

2 

Péterfy Sándor Utcai Kórház, Budapest, Hungary, 3 Budai 

Irgalmasrendi Kórház Kht., Budapest, Hungary, 4 Nemocnice 

Trinec, Trinec, Czech Republic, 5 Pharmaceutical Research 

Associates CZ, Praha, Czech Republic, 6 Szpital Uniwersytecki 

w Krakowie, Krakow, Poland, 7 Wojewodzki Szpital, Wroclaw, 

Poland, 8 PRA International GmbH, Berlin, Germany 

1308. Opportunistic Infections in Patients with Rheumatoid 

Arthritis Treated with Rituximab: Data From the 

Autoimmunity and Rituximab Registry. Jacques-Eric 

Gottenberg 1 , Philippe Ravaud 2 , Thomas Bardin 3 , Patrice P. 

Cacoub Sr. 4 , Alain G. Cantagrel 5 , Bernard Combe 6 , Maxime 

Dougados 7 , Rene-Marc Flipo 8 , Bertrand Godeau 9 , Loic 

Guillevin 10 , Xavier X. Le Loet 11 , Eric Hachulla 12 , Thierry 

Schaeverbeke 13 , Jean Sibilia 14 , Isabelle Pane 15 , Gabriel 

Baron 16 and Xavier Mariette 17 , 1 Strasbourg University 

Hospital, Strasbourg, France, 2 Hopital Hotel Dieu, Paris 

Descartes University, Paris, France, 3 Hôpital Lariboisière, 

Paris, France, 4 Assistance Publique-Hôpitaux de Paris, 

Hopital Pitié-Salpétrière, Paris, France, 5 Place du Docteur 

Baylac, Toulouse, France, 6 Hopital Lapeyronie, Montpellier, 

France, 7 Rheumatology B Department, Paris-Descartes 

University, Cochin Hospital, Paris, France, 8 Hopital R 

Salengro CHRU, Lille CEDEX, France, 9 Service de médecine 

interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor 

Créteil, France, Creteil, France, 10 Department of Internal 

Medicine, Referral Center for Rare Autoimmune and 

Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris 

Descartes, Paris, France, Paris, France, 11 CHU de ROUEN, 

Rouen, France, 12 Department of Internal Medicine, Claude 

Huriez Hospital, University of Lille, Lille CEDEX, France, 

13 


Hautepierre, Strasbourg, France, 15 Hotel Dieu University 

Hospital Paris, France, 16 Strasbourg, France, 17 Université 

Paris-Sud, Le Kremlin Bicetre, France 

1309. Predictive Risk Factors of Serious Infections in RA Patients 

Treated with Abatacept in Real Life: Results in the Orencia 

and Rheumatoid Arthritis (ORA) Registry. Jacques-Eric 

Gottenberg 1 , Philippe Ravaud 2 , Alain G. Cantagrel 3 , Bernard 

Combe 4 , René-Marc Flipo 5 , Thierry Schaeverbeke 6 , Eric 

Houvenagel 7 , Philippe Gaudin 8 , Damien Loeuille 9 , Stephanie 

Rist 10 , Maxime Dougados 11 , Jean Sibilia 12 , Xavier Le Loet 13 , 

Christian Marcelli 14 , Thomas Bardin 15 , Isabelle Pane 16 , 

Elodie Perrodeau 17 , Gabriel Baron 18 and Xavier Mariette 19 , 

1 

Strasbourg University Hospital, Strasbourg, France, 2 Hopital 

Hotel Dieu, Paris Descartes University, Paris, France, 3 Place 

du Docteur Baylac, Toulouse, France, 4 Hopital Lapeyronie, 

Montpellier, France, 5 Rheumatology Department, Lille 

University Hospital, Lille, France, 6 Groupe Hospitalier 

Pellegrin, Bordeaux, France, 7 St Philibert Hospital, Lomme 

5946 2 , France, 8 CHU Hôpital Sud, Grenoble Teaching 

Hospital, Echirolles, France, 9 CHU Brabois, Vandoeuvre 

les Nancy, France, 10 Hospital University Orléans, France, 

11 

Paris-Descartes University, APHP, Cochin Hospital, Paris, 

France, 12 CHU Hautepierre, Strasbourg, France, 13 CHU de


ROUEN, Rouen, France, 14 Rheumatology Department, 

Caen University Hospital, 15 Hôpital Lariboisière, Paris, 

France, 16 Hotel Dieu University Hospital Paris, France, 

17 

Epidemiologist, Paris, France, 18 Epidemiology, Paris, France, 

19 

Université Paris-Sud, Le Kremlin Bicetre, France 

1310. Analysis of Anti-JC Polyomavirus T-Cell Immune Response 

with JC-Feron in Patients with Rheumatoid Arthritis 

Treated with Rituximab or Anti-TNF. Raphaèle Seror 1 , 

Houria Chavez 2 , anne-Aurélie Mazet 1 , Jeremie Sellam 3 , 

Bruno Fautrel 4 , Maxime Dougados 5 , Yassine Taoufik 2 and 

Xavier Mariette 6 , 1 Bicetre university hospital, LE Kremlin- 

Bicetre, France, 2 Hopital Bicetre, Université Paris Sud, 

AP-HP, France, 3 Hopital Saint-Antoine, Pierre et Marie 

Curie University Paris 6 , AP-HP, 75012, France, 4 APHP-Pitie 

Salpetriere Hospital / UPMC, Paris, France, 5 Paris-Descartes 

University, APHP, Cochin Hospital, Paris, France, 6 Université 

Paris-Sud, Le Kremlin Bicetre, France 

1311. A Novel Individualized Treatment Approach in Open- 

Label Extension Study of Ozoralizumab (ATN-103) in 

Subjects with Rheumatoid Arthritis On a Background of 

Methotrexate. Roy M. Fleischmann 1 , Steven De Bruyn 2 , 

Christian Duby 2 , Katrien Verschueren 2 , Judith Baumeister 2 , 

Laura Sargentini-Maier 2 , Cedric Ververken 2 and Josefin- 

Beate Holz 2 , 1 University of Texas, Dallas, TX, 2 Ablynx N.V., 

Zwijnaarde, Belgium 

1312. Clinical Response At 12 Weeks Predicts Long-Term 

Remission and the Extent of Radiographic Progression 

in Japanese Patients with Rheumatoid Arthritis Treated 

with Certolizumab Pegol with and without Methotrexate 

Coadministration. Tsutomu Takeuchi 1 , Kazuhiko Yamamoto 2 , 

Hisashi Yamanaka 3 , Naoki Ishiguro 4 , Yoshiya Tanaka 5 , 

Katsumi Eguchi 6 , Akira Watanabe 7 , Hideki Origasa 8 , 

Toshiharu Shoji 9 , Nobuyuki Miyasaka 10 and Takao Koike 11 , 

1 

Keio University School of Medicine, Tokyo, Japan, 

2 


Bunkyo-ku, Tokyo, Japan, 3 Institute of Rheumatology, 

Tokyo Women’s Medical University, Tokyo, Japan, 4 Nagoya 

University, Graduate School & Faculty of Medicine, 

Nagoya, Aichi, Japan, 5 University of Occupational and 

Environmental Health, Japan, Kitakyushu, Japan, 6 Sasebo 

City General Hospital, Sasebo, Nagasaki, Japan, 7 Institute of 

Development, Aging and Cancer, Tohoku University, Sendai, 

Miyagi, Japan, 8 University of Toyama School of Medicine, 

Toyama, Toyama, Japan, 9 Otsuka Pharmaceutical Co., Ltd, 

Shinagawa-ku, Tokyo, Japan, 10 Tokyo Medical and Dental 

University, Tokyo, Japan, 11 Sapporo medical center NTT EC, 

Sapporo, Japan 

1313. Tolerance of Rituximab in Patients with a History of Cancer: 

Data from the Registry Air. Jacques-Eric Gottenberg 1 , Marie- 

Odile Duzanski 2 , Thomas Bardin 3 , Patrice P. Cacoub Sr. 4 , 

Alain G. Cantagrel 5 , Bernard Combe 6 , Maxime Dougados 7 , 

Rene-Marc Flipo 8 , Bertrand Godeau 9 , Loic Guillevin 10 , Eric 

Hachulla 11 , Xavier Le Loet 12 , Thierry Schaeverbeke 13 , Jean 

Sibilia 14 , Isabelle Pane 15 , Philippe Ravaud 16 , Gabriel Baron 17 

and Xavier Mariette 18 , 1 Strasbourg University Hospital, 

Strasbourg, France, 2 Hôpitaux Universitaires de Strasbourg, 

Strasbourg, France, 3 Hôpital Lariboisière, Paris, France, 

4 

Assistance Publique-Hôpitaux de Paris, Hopital Pitié- 

Salpétrière, Paris, France, 5 Hopital Purpan, Toulouse CEDEX 

9 

, France, 6 Hopital Lapeyronie, Montpellier, France, 7 Paris- 

Descartes University, APHP, Cochin Hospital, Paris, France, 

8 

Hopital R Salengro CHRU, Lille CEDEX, France, 9 Service de 

médecine interne, Université Paris Est Créteil, AP-HP, Hôpital 

Mondor Créteil, France, Creteil, France, 10 Department of 

Internal Medicine, Referral Center for Rare Autoimmune 


Paris Descartes, Paris, France, Paris, France, 11 Department 

of Internal Medicine, Claude Huriez Hospital, University of 

Lille, Lille CEDEX, France, 12 CHU de ROUEN, Rouen, France, 

13 


Hautepierre, Strasbourg, France, 15 Hotel Dieu University 

Hospital Paris, France, 16 Hopital Hotel Dieu, Paris Descartes 

University, Paris, France, 17 Epidemiology, Paris, France, 

18 

Université Paris-Sud, Le Kremlin Bicetre, France 

1314. Validation of Algorithms Using Genome-Wide SNP 

Analysis for Prediction of Remission or Low Disease 

Activity for Infliximab or Etanercept-Treated RA Patients. 

Tsukasa Matsubara 1 , Satoru Koyano 2 , Keiko Funahashi 2 , 

James E. Middleton 2 , Takako Miura 1 , Kosuke Okuda 1 , 

Takeshi Nakamura 1 , Akira Sagawa 3 , Takeo Sakurai 4 , Hiroaki 

Matsuno 5 , Tomomaro Izumihara 6 , Eisuke Shono 7 , Kou 

Katayama 8 , Toyomitsu Tsuchida 9 , Mitsuyoshi Iwahashi 10 , 

Tomomi Tsuru 11 and Motohiro Oribe 12 , 1 Matsubara 

Mayflower Hospital, Kato, Japan, 2 Research Institute of Joint 

Diseases, Kobe, Japan, 3 Sagawa Akira Rheumatology Clinic, 

Sapporo, Japan, 4 Inoue Hospital, Takasaki, Japan, 5 Toyama, 

Japan, 6 Izumihara Rheumatic and Medical Clinic, Kagoshima, 

Japan, 7 Shono Rheumatology Clinic, Fukuoka, Japan, 

8 

Katayama Orthopedic Rheumatology Clinic, Asahikawa, 

Japan, 9 Tsuchida Clinic, Chiba, Japan, 10 Higashi-Hiroshima 

Memorial Hospital, Higashi-hiroshima, Japan, 11 PS Clinic, 

Fukuoka, Japan, 12 Oribe Rheumatism and Internal Medicine 

Clinic, Oita, Japan 

1315. Gene Expression Profiling and Pathway Changes Associated 

with Clinical Response to Tabalumab Blockade of 

Membrane Bound and Soluble B Cell Activating Factor 

in Rheumatoid Arthritis. Wendy J. Komocsar 1 , Mark C. 

Genovese 2 , Ernst R. Dow 1 , Poulabi Banerjee 1 , Michelle 

A. Penny 1 , Eric P. Nantz 1 , Sergey Stepaniants 3 , Anne Ho 3 , 

Pierre-Yves Berclaz 1 and Robert W. Hoffman 1 , 1 Eli Lilly and 

Company, Indianapolis, IN, 2 Stanford University Medical 

Center, Palo Alto, CA, 3 Covance Genomics Laboratory LLC, 

Seattle, WA 

1316. Long-Term Safety and Efficacy of 4-Weekly Certolizumab 

Pegol Combination and Monotherapy in Rheumatoid 

Arthritis: 5 Year Results from an Open Label Extension 

Study. Roy M. Fleischmann 1 , Ronald F. van Vollenhoven 2 , 

Jiri Vencovsky 3 , Rieke Alten 4 , Owen Davies 5 , Christian 

Stach 6 , Marc de Longueville 5 , Brenda Van Lunen 7 and Ernest 

Choy 8 , 1 University of Texas Southwestern Medical Center at 



236 

Dallas, Dallas, TX, 2 Karolinska Institute, Stockholm, Sweden, 

3 

Institute of Rheumatology, Prague, Czech Republic, 

4 

Schlosspark Klinik, University Medicine Berlin, Berlin, 

Germany, 5 UCB Pharma, Brussels, Belgium, 6 UCB Pharma, 

Monheim, Germany, 7 UCB Pharma, Raleigh, NC, 8 Cardiff 

University School of Medicine, Cardiff, United Kingdom 

1317. One-Year Results From the Canadian Methotrexate 

and Etanercept Outcome Study: A Randomized Trial of 

Etanercept and Methotrexate Versus Etanercept Alone in 

Rheumatoid Arthritis. Janet E. Pope 1 , Boulos Haraoui 2 , J. 

Carter Thorne 3 , Melanie Poulin-Costello 4 , Andrew Vieira 4 

and Edward Keystone 5 , 1 St. Joseph Health Care London, 

University of Western Ontario, London, ON, 2 Institut de 

Rhumatologie de Montréal, Montreal, QC, 3 Southlake 

Regional Health Centre, Newmarket, ON, 4 Amgen Canada 

Inc., Mississauga, ON, 5 University of Toronto, Toronto, ON 

1318. Long-Term Benefits of 4-Weekly Certolizumab Pegol 

Combination and Monotherapy On Household Productivity 

and Social Participation in Rheumatoid Arthritis: 5 Year 

Results from an Open Label Extension Study. Vibeke 

Strand 1 , Oana Purcaru 2 , Ronald F. van Vollenhoven 3 , Ernest 

Choy 4 and Roy Fleischmann 5 , 1 Stanford University, Portola 

Valley, CA, 2 UCB Pharma, Brussels, Belgium, 3 Karolinska 

Institute, Stockholm, Sweden, 4 Cardiff University School 

of Medicine, Cardiff, United Kingdom, 5 University of Texas 


1319. Certolizumab Pegol Plus Methotrexate Is Similarly Effective 

in Active Rheumatoid Arthritis Secondary Non-Responders 

to Anti-TNF Inhibitors: Post-Hoc Analysis of a Phase Iiib 

Trial. Daniel Furst 1 , Saeed A. Shaikh 2 , Maria W. Greenwald 3 , 

Michael H. Schiff 4 , Barbara Bennett 5 , Owen Davies 6 , 

Fabienne Staelens 6 , Will Koetse 7 and Philippe Bertin 8 , 

1 


2 

McMaster University, St Catharines, ON, 3 Desert Medical 

Advances, Palm Desert, CA, 4 University of Colorado, Denver, 

CO, 5 BABennett Consulting, LLC, Marietta, GA, 6 UCB Pharma, 

Brussels, Belgium, 7 UCB Pharma, Rtp, NC, 8 Dupuytren 

Hospital, Limoges, France 

1320. Sarilumab, a Subcutaneously-Administered, Fully-Human 

Monoclonal Antibody Inhibitor of the IL-6 Receptor: 

Effects On Hemoglobin Levels in a Clinical Trial for the 

Treatment of Moderate-to-Severe Rheumatoid Arthritis. 

Mark C. Genovese 1 , Roy M. Fleischmann 2 , Martine 

Jasson 3 , Allen R. Radin 4 , Jennifer Hamilton 5 and Tom W.J. 

Huizinga 6 , 1 Stanford University Medical Center, Palo Alto, 

CA, 2 University of Texas, Dallas, TX, 3 Sanofi, Paris, France, 

4 

Regeneron Pharmaceuticals Inc, Tarrytown, NY, 5 Regeneron 

Pharmaceuticals, Inc., Tarrytown, NY, 6 Leiden University 


1321. C-Type Lectin Domain Family 4 , Member C Gene Expression 

Level Helps Predict Future Clinical Response to Tabalumab 

Blockade of B Cell Activating Factor in Rheumatoid 

Arthritis. Ernst R. Dow 1 , Poulabi Banerjee 1 , Michelle A. 

Penny 1 , Eric P. Nantz 1 , Sergey Stepaniants 2 , Anne Ho 2 , Wendy 


J. Komocsar 1 , Pierre-Yves Berclaz 1 and Robert W. Hoffman 1 , 

1 

Eli Lilly and Company, Indianapolis, IN, 2 Covance Genomics 

Laboratory LLC, Seattle, WA 

1322. Coadministration of ASP015K, a Novel Janus Kinase 

Inhibitor with Methotrexate Demonstrates Tolerability 

and Lack of Pharmacokinetic Interactions in Patients 

with Rheumatoid Arthritis. Tong Zhu 1 , Kazuo Oda 2 , Udaya 

Valluri 1 , Bogie Moore 1 , Ying Cao 1 , Vishala Chindalore 3 and 

Bola Akinlade 1 , 1 Astellas Pharma Global Development, 

Inc., Northbrook, IL, 2 Astellas Pharma Inc., Osaka, Japan, 

3 

Pinnacle Research Group/Anniston Medical Clinic, Anniston, 

AL 

1323. Effects of Dose Escalation of Tocilizumab in Combination 

with Nonbiologic Disease-Modifying Antirheumatic 

Drugs: Sub-Analysis of a 24-Week Study in a United States 

Population. M. E. Weinblatt 1 , Herbert S. B. Baraf 2 , Ara H. 

Dikranian 3 , Andrew M. Anisfeld 4 , Jenny Devenport 4 and 

Sheldon Cooper 5 , 1 Rheumatology & Immunology, Brigham 

& Women’s Hospital, Boston, MA, 2 Arthritis & Rheumatism 

Associates, Wheaton, MD, 3 San Diego Arthritis Medical 

Clinic, San Diego, CA, 4 Genentech, South San Francisco, CA, 

5 

Univ Vermont College of Med, Burlington, VT 

1324. Golimumab, A Human Anti-TNF Monoclonal Antibody, 

Administered Subcutaneously Every Four Weeks As 

Monotherapy in Patients with Active Rheumatoid Arthritis 

Despite Disease Modifying Antirheumatic Drug Therapy: 

Week 104 Results of Clinical, Radiographic and Safety 

Assessments. Tsutomu Takeuchi 1 , Masayoshi Harigai 2 , 

Yoshiya Tanaka 3 , Hisashi Yamanaka 4 , Naoki Ishiguro 5 , 

Kazuhiko Yamamoto 6 , Minoru Kanazawa 7 , Yoshinori 

Murakami 8 , Toru Yoshinari 9 , Daniel Baker 10 , Nobuyuki 

Miyasaka 2 and Takao Koike 11 , 1 Keio University School 

of Medicine, Tokyo, Japan, 2 Tokyo Medical and Dental 

University, Tokyo, Japan, 3 University of Occupational and 

Environmental Health, Japan, Kitakyushu, Japan, 4 Institute 

of Rheumatology, Tokyo Women’s Medical University, 

Tokyo, Japan, 5 Nagoya University, Graduate School & Faculty 

of Medicine, Nagoya, Aichi, Japan, 6 Graduate School of 

Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, 

7 

Director of Respiratory Center Professor of Respiratory, 

Medicine Saitama Medical University, Moroyama, Iruma- 

Gun, Saimata, Japan, 8 Janssen Pharmaceutical KK, Tokyo, 

Japan, 9 Mitsubishi Tanabe Pharma Corporation, Osaka, 

Japan, 10 Janssen Research and Development, LLC, Spring 

House, PA, 11 Sapporo medical center NTT EC, Sapporo, Japan 

1325. Prevention of Joint Destruction in Patients with High 

Disease Activity or High C - reactive protein. Yoshiya 

Tanaka 1 , Masayoshi Harigai 2 , Tsutomu Takeuchi 3 , Hisashi 

Yamanaka 4 , Naoki Ishiguro 5 , Kazuhiko Yamamoto 6 , Yutaka 

Ishii 7 , Daniel Baker 8 , Nobuyuki Miyasaka 2 and Takao 

Koike 9 , 1 University of Occupational and Environmental 

Health, Japan, Kitakyushu, Japan, 2 Tokyo Medical and 

Dental University, Tokyo, Japan, 3 Keio University School 

of Medicine, Tokyo, Japan, 4 Institute of Rheumatology, 

Tokyo Women’s Medical University, Tokyo, Japan, 5 Nagoya


University, Graduate School & Faculty of Medicine, Nagoya, 

Aichi, Japan, 6 Graduate School of Medicine, The University 

of Tokyo, Bunkyo-ku, Tokyo, Japan, 7 Janssen Pharmaceutical 

K.K, Tokyo, Japan, 8 Janssen Research and Development, LLC, 

Spring House, PA, 9 Sapporo medical center NTT EC, Sapporo, 

Japan 

1326. Efficacy of Different Biologic Agents for Improving 

Physical Function As Measured by the Health Assessment 

Questionnaire: A Meta-Analysis with Indirect Comparisons. 

Lillian J. Barra 1 , Andrew Ha 2 , Louise Sun 3 , Catarina Fonseca 4 

and Janet Pope 1 , 1 Schulich School of Medicine and Dentistry, 

Western University, London, ON, 2 The University of 

Toronto, Toronto, ON, 3 University of Ottawa, Ottawa, ON, 

4 

Universidade de Lisboa, Lisbon, Portugal 

1327. Comparison of Four Different Intensive Treatment 

Strategies in Patients with Early Rheumatoid Arthritis 

in Korea. Mi-Il Kang, Yoon Kang, Hee-Jin Park, Hyang-Sun 

Lee, Sang-Won Lee, Yong-Beom Park and Soo-Kon Lee, 

Department of Internal Medicine, Yonsei University College 

of Medicine, Seoul, South Korea 

1328. The Higher and Faster Increasing Schedule of Methotrexate 

May Not Be the Best: The Accumulation of Intracellular 

Longer Chain Methotrexate Polyglutamates Was Facilitated 

by the Extra-Low-Dose Methotrexate Treatment. Yoshinobu 

Koyama 1 , Kazunori Hase 2 , Daisuke Hidaka 2 , Shuji Nagano 2 , 

Toshiyuki Ota 2 and Ayumi Uchino 2 , 1 Okayama Red Cross 

General Hospital, Okayama, Japan, 2 Iizuka Hospital, Iizuka, 

Japan 

1329. Differential Effect of 4 and 8 Mg/Kg Tocilizumab in 

Combination with Methotrexate On Serum Biomarkers 

of Cartilage, Connective Tissue and Bone Turnover. Anne 

C. Bay-Jensen 1 , Inger Byrjalsen 2 , Andrew Kenwright 3 , 

Thierry Sornasse 4 , Claus Christiansen 5 and Morten Asser 

Karsdal 1 , 1 Nordic Bioscience A/S, Herlev, Denmark, 2 Nordic 

Bioscience, Herlev, Denmark, 3 Roche, Welwyn Garden City, 

United Kingdom, 4 Genentech, South San Francisco, 5 CCBR, 

Ballerup, Denmark 

1330. High Body Mass Index Is Associated with Decreased 

Response to Initial Combination Therapy in Recent Onset 

RA Patients. Marianne van den Broek 1 , L. Heimans 1 , S. 

le Cessie 1 , B. Siegerink 1 , H.K Ronday 2 , K.H. Han 3 , P.J.S.M. 

Kerstens 4 , T.W.J. Huizinga 1 , W.F. Lems 5 and C.F. Allaart 1 , 

1 


2 

Haga Hospital, The Hague, Netherlands, 3 MCRZ hospital, 

Rotterdam, Netherlands, 4 Jan van Breemen Research 

Institute | Reade, Amsterdam, Netherlands, 5 VU University 

medical center, Amsterdam, Netherlands 

1331. Once Daily High Dose Regimens of GLPG0634 in Healthy 

Volunteers Are Safe and Provide Continuous Inhibition of 

JAK1 but Not JAK2. Florence Namour 1 , René Galien 1 , Lien 

Gheyle 2 , Frédéric Vanhoutte 3 , Béatrice Vayssière 1 , Annegret 

Van der Aa 3 , Bart Smets 3 and Gerben van ‘t Klooster 3 , 

1 

Galapagos SASU, Romainville, France, 2 SGS Clinical 

Pharmacology Unit, Antwerp, Belgium, 3 Galapagos NV, 

Mechelen, Belgium 

1332. The Incidence of Exacerbation of Pre-Existing Interstitial 

Lung Disease (ILD) Is Higher in TNF Blockers Than in Non- 

TNF Blockers in RA. Tamao Nakashita 1 , Shinji Motojima 2 , 

Natsuki Fujio 2 and Akira Jibatake 2 , 1 Kameda Medical Center, 

Kamogawa City, Japan, 2 Kameda Medical Center, Kamogawa 

city, Japan 

1333. The Predictive Value of CD64 Counts for Infectious 

Disease in Patients Treated with Tocilizumab On the 

Infectious Disease Risk Management Cohort (ACT4Ustudy). 

Atsushi Ihata 1 , Hiroyuki Hagiyama 2 , Shouhei 

Nagaoka 3 , Junichi Obata 4 , Kiyomitsu Miyachi 5 , Hidehiro 

Yamada 6 , Shunsei Hirohata 7 , Norihiko Koido 8 , Masaomi 

Yamasaki 9 , Kenichi Miyagi 10 , Shigeru Ohno 11 , Daiga 

Kishimoto 1 , Reikou Watanabe 1 , Takeaki Uehara 1 , Kaoru 

Takase 1 , Maasa Hama 1 , Ryusuke Yoshimi 1 , Atsuhisa Ueda 1 , 

Mitsuhiro Takeno 1 and Yoshiaki Ishigatsubo 1 , 1 Yokohama 

City University Graduate School of Medicine, Yokohama, 

Japan, 2 Yokohama-city Bay Red Cross Hospital, Yokohama, 

Japan, 3 Yokohama Minami Kyosai Hospital, Yokohama, 

Japan, 4 Hikarichuo Clinic, Kawasaki, Japan, 5 Keigu Clinic, 

Kawasaki, Japan, 6 St. Marianna University, Kawasaki, Japan, 

7 

Kitasato University School of Medicine, Sagamihara, 

Japan, 8 Kawasaki Rheumatism & Internal Medecine Clinic, 

Kawasaki, 9 St Marianna University, Yokohama City Seibu 

Hospital, Yokohama, Japan, 10 Miyagi Naika Clinic, Yokohama, 

11 

Yokohama City University Medical Center, Yokohama, 

Japan 

1334. Intra-Articular Etanercept Treatment in Inflammatory 

Arthritis: A Randomized Double-Blind Placebo-Controlled 

Trial. Caroline J. Aalbers 1 , Danielle M. Gerlag 1 , Koen Vos 1 , 

Gertjan Wolbink 2 , R. Landewe 1 and Paul P. Tak 3 , 1 Academic 



Amsterdam, Netherlands, 3 Academic Medical Center, 

University of Amsterdam and GlaxoSmithKline, Amsterdam, 

Netherlands 

1335. Remission Induction in Early Active Rheumatoid Arthritis: 

Comparison of Tocilizumab Versus Methotrexate 

Monotherapy. Patrick Durez, Geneviève Depresseux, 

Marie Avaux, Adrien Nzeusseu Toukap, Bernard Lauwerys, 

Laurent Meric de Bellefon, Maria S. Stoenoiu and Frédéric 

A. Houssiau, Université catholique de Louvain, Brussels, 

Belgium 

1336. Changes in the Levels of Anti-Cyclic Citrullinated Protein 

Antibody and Immunoglobulins in Rheumatoid Arthritis 

Patients After Administration of Tocilizumab. Masao Sato, 

Masao Takemura, Ryuki Shinohe, Tsuneo Watanabe and 

Katsuji Shimizu, Gifu University, Gifu, Japan 

1337. Sarilumab, a Subcutaneously-Administered, Fully- 

Human Monoclonal Antibody Inhibitor of the IL-6 

Receptor: Pharmacokinetic Profile and Its Relationship 

to Changes in Pharmacodynamic Markers in Patients 

with Rheumatoid Arthritis. Pavel Belomestnov 1 , Jennifer 

Hamilton 1 , A. Thomas DiCioccio 1 , Martine Jasson 2 and Allen 

R. Radin 3 , 1 Regeneron Pharmaceuticals, Inc., Tarrytown, 



NY, 2 Sanofi, Paris, France, 3 Regeneron Pharmaceuticals Inc, 

Tarrytown, NY 

1338. Anti-Tumor Necrosis Factor Therapy Reduces Serum 

Levels of Chemerin in Rheumatoid Arthritis: A New 

Mechanism by which Anti-Tumor Necrosis Factor Might 

Reduce Inflammation. M.M. Herenius 1 , A.S.F. Oliveira 1 , C.A. 

Wijbrandts 1 , D. Gerlag 1 , Paul P. Tak 2 and Maria C. Lebre 1 , 

1 


Amsterdam, Netherlands, 2 Academic Medical Center, 

University of Amsterdam and GlaxoSmithKline, Amsterdam, 

Netherlands 

1339. A Pilot Study Investigating the Tolerability and 

Pharmacodynamic Effect of Single Intravenous/ 

Subcutaneous Doses of Olokizumab, an Anti-Interleukin-6 

Monoclonal Antibody, in Patients with Rheumatoid 

Arthritis. Roy Fleischmann 1 , Alan J. Kivitz 2 , Frank Wagner 3 , 

Jeffrey A. Feinstein 4 , Uwe Fuhr 5 , Jürgen Rech 6 , Jagdev Sidhu 7 , 

Philip L. Hill 8 , Ruth Oliver 8 and Kosmas Kretsos 9 , 1 University 

of Texas Southwestern Medical Center, Dallas, TX, 2 Altoona 

Center for Clinical Research, Duncansville, PA, 3 Charité 

Research Org GmbH, Berlin, Germany, 4 San Antonio, TX, 

5 

Hospital of the University of Cologne (AöR), Köln, Germany, 

6 

University of Erlangen-Nuremberg, Erlangen, Germany, 7 CSL 

Limited, Parkville, Australia, 8 UCB Celltech, Slough, United 

Kingdom, 9 UCB, Slough, United Kingdom 

1340. Effects of Subcutaneous Abatacept or Adalimumab On 

Remission and Associated Changes in Physical Function 

and Radiographic Outcomes: One Year Results From the 

Ample (Abatacept Versus Adalimumab Comparison in 

Biologic-Naive RA Subjects with Background Methotrexate) 

Trial. Roy Fleischmann 1 , Michael H. Schiff 2 , Michael E. 

Weinblatt 3 , Michael A. Maldonado 4 , Elena M. Massarotti 5 

and Yusuf Yazici 6 , 1 University of Texas Southwestern 

Medical Center, Dallas, TX, 2 University of Colorado, Denver, 

CO, 3 Rheumatology & Immunology, Brigham & Women’s 

Hospital, Boston, MA, 4 Bristol-Myers Squibb, Princeton, NJ, 

5 


Boston, MA, 6 New York University, New York, NY 

1341. Beneficial Effect of Anti-TNF Therapy in the Lipoprotein 

Atherogenic Risk Profile in Comparison with DMARD 

Standard Therapy in RA Patients. Jaime Calvo-Alen 1 , Ignacio 

Villa 2 , Victor M. Martinez-Taboada 3 , Jose Luis Peña-Sagredo 4 , 

Mario Agudo 4 , Ana Carmen García 5 and Juan Gomez- 

Gerique 6 , 1 Hospital Universitario Sierrallana, Torrelavega, 

Spain, 2 Hospital Sierrallana, Torrelavega, Spain, 3 Hospital 

Universitario Marques de Valdecilla. IFIMAV, Santander, 

Spain, 4 Hospital Universitario Marqués de Valdecilla. IFIMAV, 

Santander, Spain, 5 Fundación 12 de Octubre, Madrid, Spain, 

6 

Hospital Universitario Marqués de Valdecilla, Santander, 

Spain 

1342. Changes in Patient Reported Outcomes in Response to 

Subcutaneous Abatacept or Adalimumab in Rheumatoid 

Arthritis: Results From the Ample (Abatacept Versus 

Adalimumab Comparison in Biologic Naive RA Subjects 

with Background Methotrexate) Trial. Roy Fleischmann 1 , 

Michael E. Weinblatt 2 , Michael H. Schiff 3 , Dinesh Khanna 4 , 

Daniel Furst 5 and Michael A. Maldonado 6 , 1 University 

of Texas Southwestern Medical Center, Dallas, TX, 

2 


Hospital, Boston, MA, 3 University of Colorado, Denver, 

CO, 4 University of Michigan, Ann Arbor, MI, 5 University of 

California at Los Angeles, Los Angeles, CA, 6 Bristol-Myers 

Squibb, Princeton, NJ 


and Treatment 

1343. EARLY Improvements in the Lower Limbs Enthesis by 

Ultrasound Predicting Later Favorable Responses in 

TNF Inhibotors-Treated Patients with Spondyloarthritis. 

Kensuke Kume 1 , Kanzo Amano 1 , Kuniki Amano 2 , Hiroyuki 

Ohta 3 and Noriko Kuwaba 4 , 1 Hiroshima Clinic, Hiroshima, 

Japan, 2 Sky Clinic, Hiroshima, Japan, 3 Hiroshima, Japan, 

4 

Sanki Clinical Link, Hiroshima, Japan 

1344. Diagnostic Value of High Sensitivity C Reactive Protein for 

Early Axial Spondyloarthritis: Results From the Devenir 

Des Spondylarthopathies Indifferenciees Recentes Cohort. 

Victoria Navarro-Compán 1 , Désirée van der Heijde 1 , Bernard 

Combe 2 , Claudine Cosson 3 and Floris van Gaalen 1 , 1 Leiden 

University Medical Center, Leiden, Netherlands, 2 Hopital 

Lapeyronie, Montpellier, France, 3 Hôpital Bicêtre, Assistance 

Publique Hôpitaux de Paris, Paris, France 

1345. Validation of the Health Assessment Questionnaire for 

Spondyloarthritis in Patients with Non-Radiographic Axial 

Spondyloarthritis. Dennis Revicki 1 , Wen-Hung Chen 1 , Ying 

Jin 1 , Sumati Rao 2 , Philip Mease 3 and Mary Cifaldi 2 , 1 United 

Biosource Corporation, Bethesda, MD, 2 Abbott Laboratories, 

Abbott Park, IL, 3 Swedish Rheumatology Research Group, 

Seattle, WA 

1346. Comparison of Three Screening Tools in Psoriatic Arthritis: 

The Contest Study. Laura C. Coates 1 , Tariq Aslam 1 , A. D. 

Burden 2 , Esther Burden-Teh 3 , Anna R. Caperon 4 , Rino 

Cerio 5 , Chandra Chattopadhyay 6 , Hector Chinoy 7 , Mark J. 

D. Goodfield 8 , Lesley Kay 9 , Bruce W. Kirkham 10 , Christopher 

R. Lovell 11 , Helena Marzo-Ortega 12 , Neil McHugh 13 , Ruth 

Murphy 3 , Costantino Pitzalis 14 , NJ Reynolds 9 , Catherine H. 

Smith 15 , Elizabeth Stewart 6 , Richard B. Warren 7 , Hilary E. 

Wilson 16 and Philip S. Helliwell 17 , 1 Division of Rheumatic and 

Musculoskeletal Disease, LIMM, University of Leeds, Leeds, 

United Kingdom, 2 Western Infirmary, Dumbarton Road, 

United Kingdom, 3 Nottingham Independent Treatment 

Centre, Nottingham, United Kingdom, 4 University of Leeds 

and NIHR Leeds Musculoskeletal Biomedical Research Unit, 

Leeds, United Kingdom, 5 Bart’s and The London NHS Tust, 

United Kingdom, 6 Wrightington, Wigan and Leigh NHS 

Foundation Trust, Wigan, United Kingdom, 7 The University 

of Manchester, Manchester, United Kingdom, 8 Leeds 

Teaching Hospitals NHS Trust, Leeds, United Kingdom, 

9 

Newcastle upon Tyne Hospitals NHS Foundation Trust, 

Newcastle upon Tyne, United Kingdom, 10 4th Fl Thomas Guy 

238 

2012 Program Book


House, London, United Kingdom, 11 Royal United Hospital, 

Bath, United Kingdom, 12 University of Leeds, Leeds, United 

Kingdom, 13 Royal National Hospital for Rheumatic Diseases, 

Bath, United Kingdom, 14 Barts and The London School of 

Medicine and Dentistry, London, United Kingdom, 15 London, 

16 

NHS Greater Glasgow and Clyde, Glasgow, United 

Kingdom, 17 NIHR Leeds Biomedical Research Unit, University 

of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, 


1347. Anti-TNFá Discontinuation in Psoriatic Arthritis: Is It 

Possible After Achieving Minimal Disease Activity? Amir 

Haddad, Arane Thavaneswaran, Vinod Chandran and Dafna 



1348. Diffuse Idiopathic Skeletal Hyperostosis (DISH) in Psoriatic 

Arthritis. Amir Haddad 1 , Arane Thavaneswaran 1 , Sergio M.A. 

Toloza 2 , Vinod Chandran 1 and Dafna D. Gladman 1 , 1 Toronto 


2 

Hospital San Juan Bautista, Catamarca, Argentina 

1349. Trends in Incidence and Clinical Features of Ankylosing 

Spondylitis in Olmsted County (1980-2009): A Population 

Based Study. Kerry Wright, Cynthia S. Crowson, Clement J. 

Michet and Eric L. Matteson, Mayo Clinic, Rochester, MN 

1350. Inflammatory Biomarkers in Psoriatic Arthritis. Ibrahim 

AlHomood, Arane Thavaneswaran, D. D. Gladman and Vinod 

Chandran, Toronto Western Hospital and University of 


1351. Ultrasonographic Entheseal Abnormalities among Patients 

with Psoriatic Arthritis, Psoriasis Alone and Healthy 

Individuals and Their Correlation with Disease-Related 

Variables. Lihi Eder 1 , Jai Jayakar 2 , Arane Thavaneswaran 3 , 

Amir Haddad 3 , Daniel Pereira 3 , Sutharshini Shanmugarajah 3 , 

David Salonen 4 , Cheryl Rosen 3 , Vinod Chandran 3 and 

Dafna D. Gladman 3 , 1 Carmel Medical Center, Haifa, Israel, 

2 

University of Western Ontario, London, ON, 3 Toronto 


4 

University Health Network, Toronto, ON 

1352. Adalimumab Significantly Reduces Recurrence Rate of 

Anterior Uveitis in Patients with Ankylosing Spondylitis. 

J. Christiaan van Denderen 1 , Ingrid M. Visman 1 , M. T. 

Nurmohamed 2 , Maria S.A. Suttorp-Schulten 3 and Irene 

E. van der Horst-Bruinsma 4 , 1 Jan van Breemen Research 

Institute | Reade, Amsterdam, Netherlands, 2 VU University 

Medical Center/Jan van Bremen Research Institute, 

Amsterdam, Netherlands, 3 Onze Lieve Vrouwe Gasthuis, 

Amsterdam, Netherlands, 4 VU University Medical Centre, 

Department of Rheumatology, Amsterdam, Netherlands 

1353. Improvement in Physical Function, Health-Related Quality 

of Life, and Work Productivity with Adalimumab Treatment 

in Nonradiographic Axial Spa: Wk-52 Results From 

Ability-1. Désirée van der Heijde 1 , Philip Mease 2 , Aileen L. 

Pangan 3 , Sumati Rao 4 , Naijun Chen 4 and Mary A. Cifaldi 4 , 

1 


2 

Swedish Rheumatology Research Group, Seattle, WA, 

3 

Abbott, Abbott Park, IL, 4 Abbott Laboratories, Abbott Park, 

IL 

1354. The Prevalence of Psoriatic Arthritis Based On 

Rheumatologists’ Clinical Assessment Before and After 

Laboratory and Radiographic Tests in Psoriasis Patients 

in European/North American Dermatology Clinics. Dafna 

D. Gladman 1 , Philip J. Mease 2 , Rafat Y. Faraawi 3 , Eustratios 

Bananis 4 , Andrew S. Koenig 4 , Robert Northington 4 , 

Joanne Fuiman 4 and Daniel Alvarez 4 , 1 Toronto Western 

Research Institute, University of Toronto, University Health 

Network, Toronto, ON, 2 Swedish Medical Center, Seattle, 

WA, 3 McMaster University, Kitchener, ON, 4 Pfizer Inc., 

Collegeville, PA 

1355. Hand Bone Loss Is Arrested in Early Psoriatic Arthritis but 

Not in Rheumatoid Arthritis Following Anti-Rheumatic 

Treatment Assessed by Digital X-Ray Radiogrammetry. 

Agnes Szentpetery 1 , Muhammad Haroon 2 , Phil Gallagher 3 , 

Martina Cooney 1 , Eric J. Heffernan 4 and Oliver M. 

FitzGerald 5 , 1 Department of Rheumatology, St. Vincent’s 

University Hospital, Dublin, Ireland, 2 Dublin Academic 

Medical Center, St. Vincent’s University Hospital, Dublin, 

Ireland, 3 Academic Medical Centre, St. Vincent’s University 

Hospital, Dublin, Ireland, 4 Department of Radiology, St. 

Vincent’s University Hospital, Dublin, Ireland, 5 Dublin 



1356. Gender Differences Among Spondylitis Associated with 

Psoriasis, Inflammatory Bowel Disease and Primary 

Ankylosing Spondylitis. Margarita Landi 1 , Hernan 

Maldonado-Ficco 1 , Jose A. Maldonado-Cocco 1 , Gustavo 

Citera 2 , Pablo Arturi 1 , Percival Sampaio-Barros 3 , Diana 

Flores 4 , Ruben Burgos-Vargas 5 , Helena Santos 6 , Jose Chavez- 

Corrales 7 , Daniel Palleiro 8 , Miguel A. Gutierrez 9 , Elsa Vieira- 

Sousa 10 , Fernando Pimentel-Santos 11 , Sergio O. Paira 12 , 

Alberto Berman Sr. 13 , Janitzia Vazquez-Mellado 14 , Eduardo 

Collantes-Estevez 15 and On behalf of RESPONDIA Group 16 , 

1 

Instituto de Rehabilitacion Psicofisica and Fundacion 

Reumatologica Argentina, Buenos Aires, Argentina, 2 Instituto 

de Rehabilitación Psicofísica., Buenos Aires, Argentina, 

3 

University of Sao Paulo School of Medicine, Sao Paulo, 

Brazil, 4 Hospital Universitario “Dr. José Eleuterio González”, 

Monterrey, Mexico, 5 Hospital General de Mexico, Mexico 

DF, Mexico, 6 Instituto Português de Reumatologia, Lisboa, 

Portugal, 7 Hospital Nacional E. Rebagliti-ESSALUD, Lima, 

Peru, 8 Instituto Nacional de Reumatologia, Montevideo, 

Uruguay, 9 Pontificia Universidad Catolica de Chile, Santiago, 

Chile, 10 Instituto de Medicina Molecular, Faculdade de 

Medicina da Universidade de Lisboa, Lisbon, Portugal, 

11 

Centro Hospitalar de Lisboa Ocidental, Hospital Egas 

Moniz, Lisboa, Portugal, 12 Hospital Jose Maria Cullen, Santa 

Fe SFE S3000BFP, Argentina, 13 Hospital Padilla, Tucuman, 

Argentina, 14 Hospital General de Mexico, Mexico city, 

Mexico, 15 IMIBIC-Reina Sofia Hospital, Cordoba 140 12 , Spain, 

16 

Buenos Aires 



1357. Psoriatic Arthritis and Biologic Therapy: Treatment 

Response, Drug Survival and Outcome After Switching. 

Dinny Wallis 1 , Deepak Jadon 2 , William Tillett 2 , Nicola 

Waldron 2 , Charlotte Cavill 3 , Neil McHugh 2 and Eleanor 

Korendowych 2 , 1 Royal National Hospital for Rheumatic 

Diseases NHS Foundation Trust, Bath, United Kingdom, 

2 

Royal National Hospital for Rheumatic Diseases, Bath, 

United Kingdom, 3 Bath Institute for Rheumatic Disease, 

Bath, United Kingdom 

1358. Performance of Remission Criteria and Activity Indices 

in Psoriatic Arthritis. Maria L. Acosta Felquer 1 , Leandro 

Ferreyra Garrott 1 , Erika Catay 1 , Josefina Marin 2 , Marina 

Scolnik 2 , Maria Victoria Garcia 2 , Santiago Ruta 2 , Mirtha 

Sabelli 3 , Zaida Bedran 3 , Javier Rosa 1 , Luis J. Catoggio 4 and 

Enrique R. Soriano 4 , 1 Rheumatology Section, Hospital 

Italiano de Buenos Aires, Buenos Aires, Argentina, 

2 


Italiano de Buenos Aires, Buenos Aires, Argentina, 3 Hospital 

Italiano de Buenos Aires, Buenos Aires, Argentina, 

4 



Italiano de Buenos Aires, and Fundacion PM. Catoggio, 


1359. Comparison of Sacroiliac MRI Evaluation Versus Sacroiliac 

x-Rays in Peripheral Psoriatic Arthritis: Evidence of 

Silent Disease and Lack of Association to HLA-B27. Jose 

Luis Fernandez-Sueiro 1 , JA Pinto 1 , S. Pertega-Diaz 1 , E. 

Gonzalez 1 and Francisco J. Blanco 2 , 1 Complejo Hospitalario 

Universitario La Coruña, La Coruña, Spain, 2 INIBIC-Hospital 

Universitario A Coruña, A Coruña, Spain 

1360. Spinal Involvement in Axial Psoriatic Artritis Is Not 

Determined by the Presence of HLA-B27. Is the HLA-B27 

Arm of the Axial Spa Criteria Reliable for Classifying Axial 

Psoriatic Arthritis? Jose Luis Fernandez-Sueiro 1 , JA Pinto 1 , S. 

Pertega-Diaz 1 , E. Gonzalez 1 , Ignacio Rego-Perez 2 , Francisco 

J. de Toro-Santos 3 and Francisco J. Blanco 4 , 1 Complejo 

Hospitalario Universitario La Coruña, La Coruña, Spain, 

2 

INIBIC-Hospital Universitario A Coruña. Genomic Group. 

Rheumatology Division., A Coruña, Spain, 3 Complejo 

Hospitalario Universitario Juan Canalejo, Universidad de la 

Coruña, La Coruña, Spain, 4 INIBIC-Hospital Universitario A 

Coruña, A Coruña, Spain 

1361. Disease Burden Is Comparable in Patients with Non- 

Radiographic Axial Spondyloarthritis and Ankylosing 

Spondylitis. Joachim Sieper 1 , Désirée van der Heijde 2 , Dirk 

Elewaut 3 , Aileen L. Pangan 4 and Jaclyn K. anderson 4 , 1 Charité 

Universitätesmedizin Berlin, Berlin, Germany, 2 Leiden 

University Medical Center, Leiden, Netherlands, 3 Ghent 

University Hospital, Ghent, Belgium, 4 Abbott Laboratories, 


1362. Evaluation of Spondyloarthritis activity by the Patients 

and the Physicians: ASDAS, Basdai, PASS and Flare. Marie 

Godfrin-Valnet 1 , Clément Prati 2 , Marc Puyraveau 1 , Eric 

Toussirot 3 , Helene Letho-Gyselinck 4 and Daniel Wendling 4 , 

1 

CHU, Besançon, France, 2 CHU J Minjoz, Besancon, France, 

3 

CIC Biotherapy 50 6 and Rheumatology and EA 4266 

Pathogens and Inflammation, Besançon, France, 4 Minjoz 

University Hospital, Besancon, France 

1363. Validation of the Self-Administered Comorbidity 

Questionnaire in Patients with Ankylosing Spondylitis. 

Carmen Stolwijk 1 , A.M. Van Tubergen 1 , Sofia Ramiro 2 , Ivette 

Essers 1 , Marc Blaauw 1 , Désirée van der Heijde 3 , Robert B. 

M. Landewé 4 , Filip Van den Bosch 5 , Maxime Dougados 6 

and Annelies Boonen 1 , 1 Maastricht University Medical 

Center, Maastricht, Netherlands, 2 Academic Medical Center, 


Garcia de Orta, Almada, Portugal, 3 Leiden University 

Medical Center, Leiden, Netherlands, 4 Academic Medical 


Amsterdam, Netherlands, 5 Ghent University Hospital, Ghent, 

Belgium, 6 Paris-Descartes University, APHP, Cochin Hospital, 

Paris, France 

1364. Development, Sensibility and Reliability of a New Case- 

Finding Questionnaire, the Toronto Axial Spondyloarthritis 

Questionnaire in Inflammatory Bowel Disease. Khalid 

A. Alnaqbi 1 , Zahi Touma 1 , Laura A. Passalent 1 , Sindhu R. 

Johnson 1 , George A. Tomlinson 2 , Adele Carty 1 and R. D. 

Inman 1 , 1 Toronto Western Hospital, Toronto, ON, 2 Toronto 

General Hospital, Toronto, ON 

1365. Double-Blind, Placebo-Controlled, 28-Week Trial of Efficacy 

and Safety of Infliximab Plus Naproxen Vs Naproxen 

Alone: Results From the Infliximab As First Line Therapy 

in Patients with Early, Active Axial Spondyloarthritis Trial, 

Part I. Joachim Sieper 1 , Jan Lenaerts 2 , Jürgen Wollenhaupt 3 , 

Vadim Mazurov 4 , L. Myasoutova 5 , Sung-Hwan Park 6 , 

Yeong W. Song 7 , Ruji Yao 8 , Denesh Chitkara 8 and Nathan 

Vastesaeger 9 , 1 Charité, University Medicine Berlin, Berlin, 

Germany, 2 Reuma-instituut, Hasselt, Belgium, 3 Schön-Klinik, 

Hamburg, Germany, 4 St. Petersburg Medical Academy, St. 

Petersburg, Russia, 5 Kazan State Medical University, Kazan, 

Russia, 6 Catholic University of Korea, Seoul, South Korea, 

7 

Seoul National University, Seoul, South Korea, 8 Merck Sharp 

and Dohme, Kenilworth, NJ, 9 Merck Sharp and Dohme, 

Brussels, Belgium 

1366. Golimumab Administered Subcutaneously Every 4 Weeks 

in Chinese Patients with Active Ankylosing Spondylitis: 

Week 24 Safety and Efficacy Results From a Randomized, 

Placebo - Controlled Study. Chunde Bao 1 , Feng Huang 2 , 

Muhammad Asim Khan 3 , Kaiyin Fei 4 , Zhong Wu 4 and 

Elizabeth C. Hsia 5 , 1 Shanghai Renji Hospital, Shanghai, China, 

2 

Chinese PLA General Hospital, Beijing, China, 3 Case Western 

Reserve University Hospital, Cleveland, OH, 4 Janssen 

Research & Development, LLC, Spring House, PA, 5 Janssen 

Research & Development, LLC/U of Penn, Spring House/ 

Phila, PA 

1367. Clinical Features and Treatment Results of Japanese 

Patients with SAPHO (Synovitis-Acne-Pustulosis- 

Hyperostosis-Osteitis) Syndrome. Hiroki Yabe 1 , Takashi 

240 

2012 Program Book


Kuroiwa 1 , Aya Nonaka 1 , Tomomi Tsutsumi 1 , Tadashi Sakurai 1 , 

Masato Moriguchi 1 , Hisaji Oshima 2 , Kensuke Ochi 3 and 

Chihiro Terai 1 , 1 Jichi Medical University Saitama Medeical 

Center, Saitama City, Japan, 2 Tokyo Medical Ctr, Tokyo, 

Japan, 3 Institute of Rheumatology, Tokyo Women’s Medical 


1368. Psoriatic Arthritis in South Asians- Comparison with 

Caucasians of European Descent. Vinod Chandran, Arane 

Thavaneswaran and Dafna D. Gladman Gladman, Toronto 

Western Hospital and University of Toronto, Toronto, ON 

1369. Severe Joint Damage in Psoriatic Arthritis: Mutilans and 

Ankylosis. Amir Haddad, Arane Thavaneswaran, Dafna D. 

Gladman Gladman and Vinod Chandran, Toronto Western 


1370. Clinical and Ultrasonographic Features of Nail Disease 

in Psoriasis and Psoriatic Arthritis. Amir Haddad, Arane 

Thavaneswaran, Vinod Chandran and Dafna D. Gladman 

Gladman, Toronto Western Hospital and University of 


1371. Predictors of Erosion-Free Psoriatic Arthritis. Zahi Touma, 

Arane Thavaneswaran, Vinod Chandran and D. D. Gladman, 

Toronto Western Hospital and University of Toronto, 

Toronto, ON 

1372. Increased Participation in Daily Activities After 24 Weeks 

of Certolizumab Pegol Treatment of Axial Spondyloarthritis 

Patients, Including Patients with Ankylosing Spondylitis: 

Results of a Phase 3 Double-Blind Randomized Placebo- 

Controlled Study. Désirée van der Heijde 1 , Jurgen Braun 2 , 

Martin Rudwaleit 3 , Oana Purcaru 4 and Arthur Kavanaugh 5 , 

1 


2 

Rheumazentrum Ruhrgebiet, Herne, Germany, 

3 

Endokrinologikum Berlin, Berlin, Germany, 4 UCB Pharma, 

Braine, Belgium, 5 UCSD School of Medicine, La Jolla, CA 

1373. Influence of Early Onset on the Clinical Characteristics and 

Prognosis of Ankylosing Spondylitis. Maria Aparicio 1 , Jesús 

Rodríguez-Moreno 1 , Paula Estrada 1 , Irene Martín-Esteve 1 , 

Laura López-Vives 1 , Vicenç Torrente 2 , Jordi Anton 3 , Joan 

Miquel Nolla 1 and Xavier Juanola 1 , 1 Hospital Universitari 

de Bellvitge, Barcelona, Spain, 2 Hospital Sant Joan de Déu, 

Barcelona, Spain, 3 Paediatric Rheumatology International 

Trials Organization (PRINTO), Istituto Giannina Gaslini, 

Genova, Italy 

1374. Value of C - reactive protein Level at Diagnosis of Psoriatic 

Arthritis in Predicting the Future Need for Treatment with 

Tumor Necrosis Factor-á Inhibitors. Yair Molad 1 and Shachaf 

Ofer-Shiber 2 , 1 Beilinson Hospital, Rabin Medical Center and 

Sackler Faculty of Medicine, Tel Aviv University, Petah-Tikva, 

Israel, 2 Beilinson Hospital, Rabin Medical Center and Sackler 

Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel 

1375. Depression and Anxiety in Psoriatic Disease: Prevalence 

and Associated Factors. Emily McDonough 1 , Arane 

Thavaneswaran 2 , Adele Carty 3 , Sutharshini Shanmugarajah 2 , 

Renise Ayearst 2 , Lihi Eder 4 , Vinod Chandran 5 , Cheryl Rosen 2 

and Dafna Gladman 2 , 1 University of Toronto, Ontario, 


Toronto, ON, 3 Toronto Western Hospital, Toronto, ON, 

4 

Carmel Medical Center, Haifa, Israel, 5 Toronto Western 

Hospital, University of Toronto, Toronto, ON 

1376. Development of A Health Index for Patients with 

Ankylosing Spondylitis - First Steps of A Global Initiative 

Based On the ICF Guided by ASAS. Uta Kiltz 1 , Désirée 

van der Heijde 2 , Annelies Boonen 3 , Alarcos Cieza 4 , Gerold 

Stucki 5 , Muhammad Asim Khan 6 , Walter P. Maksymowych 7 , 

Helena Marzo-Ortega 8 , John D. Reveille 9 , William Taylor 10 , 

Cristina Bostan 11 and Jügen Braun 1 , 1 Rheumazentrum 

Ruhrgebiet, Herne, Germany, 2 Leiden University Medical 

Center, Leiden, Netherlands, 3 University Hospital Maastricht, 

Maastricht, Netherlands, 4 Munich, Germany, 5 University of 

Lucerne, Lucerne, Switzerland, 6 CASE at MetroHealth Med 

Center, Cleveland, OH, 7 University of Alberta, Edmonton, AB, 

8 

University of Leeds, Leeds, United Kingdom, 9 Univ of Texas 

Health Science Center at Houston, Houston, TX, 10 University 

of Otago, Wellington, New Zealand, 11 Paraplegic Research 

Unit, Nottwil, Switzerland 

1377. Prevalence of Spondyloarthritis-Related Comorbidities, 

Osteoporosis and Fractures in Ankylosing Spondylitis: a 

Systematic Literature Review. Carmen Stolwijk 1 , A.M. 

Van Tubergen 1 , Jose Dionisio Castillo-Ortiz 2 and Annelies 

Boonen 1 , 1 Maastricht University Medical Center, Maastricht, 

Netherlands, 2 Unidad de Investigacion en Enfermedades 

Cronico-Degenerativas, Guadalajara, Mexico 

1378. Validity of Ankylosing Spondylitis Disease Activity Score 

(ASDAS) in Patients with Early Spondyloarthritis. Cruz 

Fernández-Espartero 1 , Eugenio De Miguel 2 , Milena Gobbo 3 , 

Carmen Martínez 4 , Miguel A. Descalzo 3 , Estíbaliz Loza Sr. 5 

and Esperanza Group 6 , 1 Hospital Universitario de Móstoles, 

Madrid, Spain, 2 Hospital Universitario La Paz, Madrid, Spain, 

3 

Spanish Society of Rheumatology, Madrid, Spain, 4 Sociedad 

Española de Reumatología, Madrid, Spain, 5 Research Unit. 

Sociedad Española de Reumatología, Madrid, Spain, 6 Madrid 

1379. Ultrasonographic Is More Sensitive Than Traditional 

Clinical Evaluation in the Detection of Hands and Wrists 

Synovitis and Digital Soft Tissue Involvement in Early 

Psoriatic Arthritis. Francesca Bandinelli 1 , Valentina Denaro 1 , 

Francesca Prignano 2 , Diletta Bonciani 2 , Ledio Collaku 3 and 

Marco Matucci-Cerinic 1 , 1 University of Florence, Florence, 

Italy, 2 Florence, Italy, 3 University of Tirana, Tirana, Albania 

1380. A Spondyloarthritis Research Consortium of Canada 

Score Cut-off ≥3 As Best Match for the Assessment of 

Spondyloarthritis International Society Definition of a 

Positive MRI of the Sacroiliac Joints. Rosaline van den Berg, 

Manouk de Hooge, Victoria Navarro-Compán, Monique 

Reijnierse, Floris van Gaalen, Tom Huizinga and Désirée 

van der Heijde, Leiden University Medical Center, Leiden, 

Netherlands 

1381. Non-Radiographic Spondyloarthritis Has Greater Work 

Instability Than Other Spondyloarthritis Subtypes in a 



National Database. Sherry Rohekar 1 , Robert D. Inman 2 , 

Renise Ayearst 3 , Proton Rahman 4 , Walter P. Maksymowych 5 

and Dafna D. Gladman 6 , 1 St. Joseph’s Hospital, London, 

ON, 2 Toronto Western Research Institute, University Health 

Network and University of Toronto, Toronto, ON, 3 Toronto 


4 

Memorial University, St. Johns, NF, 5 University of Alberta, 

Edmonton, AB, 6 Toronto Western Research Institute, 

University of Toronto, University Health Network, Toronto, 

ON 

1382. A Comparison of Three Methods of Measuring 

Intermalleolar Distance in Patients with Ankylosing 

Spondylitis. Buse Ozata 1 , Burak Uyar 2 , Dilek Solmaz 2 , 

Ismail Sari 2 , Servet Akar 3 and Nurullah Akkoc 4 , 1 Dokuz 

Eylul University School of Medicine, Izmir, 2 Dokuz Eylul 

University School of Medicine, Izmir, Turkey, 3 Dokuz Eylul 

University School of Medicine Department of Internal 

Medicine Division of Rheumatology, Izmir, Turkey, 4 Dokuz 

Eylul University School Of Medicine, Department Of Internal 

Medicine, Division Of Rheumatology, Izmir, Turkey 

1383. The Burden of Ankylosing Spondylitis and the Cost- 

Effectiveness of Anti-Tumor Necrosis Factor α Agents 

in Romania. Ioan Ancuta 1 , Catalin Codreanu 2 , Ruxandra 

Ionescu 3 , Magda Parvu 4 and Mihai Bojinca 1 , 1 “Dr. I. 

Cantacuzino” Hospital, Bucharest, Romania, 2 “Dr. I. Stoia” 

Center for Rheumatic Diseases, Bucharest, Romania, 3 Clinic 

Hospital Sf. Maria, Bucharest, Romania, 4 “N.Gh. Lupu” 

Clinical Hospital, Bucharest, Romania 

1384. The Frequency of Non-Radiographic Axial Spondyloarthritis 

in Relation to Symptom Duration in Patients Referred 

Because of Chronic Back Pain: Results From the Berlin 

Early Spondyloarthritis Clinic. Denis Poddubnyy 1 , Henning 

Brandt 1 , Janis Vahldiek 1 , Inge Spiller 1 , In-Ho Song 1 , 

Martin Rudwaleit 2 and Joachim Sieper 3 , 1 Charité Medical 

University, Campus Benjamin Franklin, Berlin, Germany, 

2 

Endokrinologikum Berlin, Berlin, Germany, 3 Charité 


1385. Increased Body Mass Index in Ankylosing Spondylitis Is 

Associated with a Greater Burden of Symptoms and Poor 

Perceptions of the Benefits of Exercise. Laura J. Durcan 1 , 

Fiona Wilson 2 , Richard Conway 1 , Gaye Cunnane 1 and Finbar 

(Barry) D. O’Shea 1 , 1 St James’s Hospital, Dublin, Ireland, 

2 

Trinity College, Dublin, Ireland 


1386. Genetic Variation and Coronary Atherosclerosis in 

Patients with Systemic Lupus Erythematosus. Cecilia P. 

Chung 1 , Joseph F. Solus 1 , Annette Oeser 1 , Chun Li 1 , Paolo 

Raggi 2 , Jeffrey R. Smith 1 and C. Michael Stein 1 , 1 Vanderbilt 

University, Nashville, TN, 2 Emory University, Atlanta, GA 

1387. Hospitalizations and Reasons for Admission in a Clinical 

SLE Cohort. Alaa Dekis 1 , Kenjey Chan 1 , Christian A. Pineau 2 , 

Evelyne Vinet 2 , Emil P. Nashi 2 , Sasha Bernatsky 3 and Ann E. 

Clarke 3 , 1 McGill University, Montreal, QC, 2 McGill University 

Health Centre, Montreal, QC, 3 Research Institute of the 

McGill University Health Centre, Montreal, QC 

1388. Diagnostic Accuracy of Anti-dsDNA Antibodies in 

Unselected Patients with Recent Onset of Rheumatic 

Symptoms. Michele Compagno 1 , Søren Jacobsen 2 , Ole 

Petter Rekvig 3 , Lennart Truedsson 4 , Niels H. H. Heegaard 5 , 

Johannes C. Nossent 6 , Andreas Jönsen 1 , Rasmus Sleimann 

Jacobsen 2 , Gro Østli Eilertsen 6 , Gunnar K. Sturfelt 1 and 

anders Bengtsson 1 , 1 Lund University, Lund, Sweden, 

2 


3 

University Hospital, Tromsø, Norway, 4 Department of 

Laboratory Medicine, Section of Microbiology, Immunology 

and Glycobiology, Lund, Sweden, 5 Statens Serum Institut, 

Copenhagen S, Denmark, 6 University of Tromsø, Tromso, 

Norway 

1389. Erythrocyte Sedimentation Rate Is a Predictor of Renal 

and Overall Systemic Lupus Erythematosus Disease 

Activity. George Stojan 1 , Hong Fang 1 , Laurence S. Magder 2 

and Michelle Petri 1 , 1 Johns Hopkins University School 

of Medicine, Baltimore, MD, 2 University of Maryland, 

Baltimore, MD 

1390. Vitamin D Deficiency Is Not Associated with Nor Does It 

Predict Progression of Coronary Artery Calcium or Carotid 

Intima-Media Thickness in Systemic Lupus Erythematosus. 

Adnan Kiani 1 , Hong Fang 1 , Ehtisham Akhter 1 , Laurence S. 

Magder 2 and Michelle Petri 1 , 1 Johns Hopkins University 

School of Medicine, Baltimore, MD, 2 University of Maryland, 

Baltimore, MD 

1391. Anti-Ku Autoantibodies in Systemic Lupus Erythematosus 

versus Autoimmune Myositis As Measured by a Novel 

Chemiluminescence Assay. Michael Mahler 1 , Jason Wu 2 , 

Magdalena Szmyrka-Kaczmarek 3 , Andreas Swart 4 , Marvin 

J. Fritzler 5 , Jean-Luc Senécal 6 and John G. Hanly 7 , 1 INOVA 

Diagnostics, Inc., San Diego, CA, 2 INOVA Diagnostics, San 

Diego, 3 Wroclaw Medical University, Wroclaw, Poland, 

4 

Rheumatology clinic Neuss, Neuss, Germany, 5 University 

of Calgary, Calgary, AB, 6 Hôpital Notre-Dame du CHUM, 

Montréal, QC, 7 Dalhousie University and Capital Health, 

Halifax, NS 

1392. Clinical Correlation with Anti Double Stranded 

Deoxyribonucleic Acid via Enzyme Linked Immunoassay 

Versus Multiplex Immunoassay. Megan L. Krause, Melissa 

R. Snyder, Cynthia S. Crowson, Abigail B. Green and Kevin G. 

Moder, Mayo Clinic, Rochester, MN 

1393. Predictors of Panniculitis in Systemic Lupus Erythematosus. 

Ashika Odhav 1 , Michelle Petri 2 and Hong Fang 2 , 1 University 

of Missouri Kansas City School of Medicine, Kansas, MO, 

2 

Johns Hopkins University School of Medicine, Baltimore, 

MD 

1394. Health Status Burden and Impact of Fatigue on Patient 

Functioning in SLE Patients from a Phase 1b Study. 

Michelle Petri 1 , Ariane K. Kawata 2 , Ancilla W. Fernandes 3 , 

Kavita Gajria 3 , Warren Greth 4 and Asha Hareendran 5 , 

1 


242 

2012 Program Book


MD, 2 United Biosource Corporation, Bethesda, MD, 

3 

MedImmune LLC, Gaithersburg, MD, 4 MedImmune, LLC, 

Gaithersburg, MD, 5 United Biosource Corporation, London, 


1395. The Validation of a New Simple Disease Activity Tool in 

Systemic Lupus Erythematosus (SLE): The Lupus Activity 

Scoring Tool (LAST) As Compared to the Sledai Selena 

Modification. Majed M. Khraishi 1 , Rana Aslanov 2 and Krista 

Fudge 3 , 1 Memorial University of Newfoundland, St Johns, 

NF, 2 Memorial University of Newfoundland, St.John’s, NF, 

3 

Corner Brook, NF 

1396. Associates of a History of Thrombosis in Systemic Lupus 

Erythematosus. Melissa Nastacio 1 , Hong Fang 1 , Thomas 

Kickler 1 , Jayesh Jani 1 , Laurence S. Magder 2 and Michelle 

Petri 1 , 1 Johns Hopkins University School of Medicine, 

Baltimore, MD, 2 University of Maryland, Baltimore, MD 

1397. Risk Factors Associated with Early Central Nervous System 

Damage Detected Through Perfusion MRI in Patients with 

Systemic Lupus Erythematosus. Paola Tomietto 1 , Federica 

Casagrande 2 , Maja Ukmar 2 , Luca Weis 2 , Pia Morassi 1 , 

Rita Moretti 3 , Gianni Biolo 3 , Carlo Giansante 3 and Maria 

Assunta Cova 2 , 1 AOU Ospedali Riuniti di Trieste, Trieste, 

Italy, 2 Radiology Department, University of Trieste, Trieste, 

Italy, 3 Internal Medicine Department, University of Trieste, 

Trieste, Italy 

1398. Inflammatory Back Pain Is Increased in SLE and Associated 

with Anti-Sm Antibodies. Neslihan Yilmaz 1 , Ayten Yazici 2 , 

Sibel Z. Aydin 3 and Sule Yavuz 4 , 1 Marmara University, 

Faculty of Medicine, Istanbul, Turkey, 2 Sakarya Research and 

Training Hospital, Sakarya, Turkey, 3 Medeniyet University, 

Goztepe Training and Research Hospital, Istanbul, Turkey, 

4 

Marmara University, Istanbul, Turkey 

1399. Regional Fat Distribution Is Independently Associated with 

Damage Accrual in Systemic Lupus Erythematosus Female 

Patients. Manuel F. Ugarte-Gil, Rocio V. Gamboa-Cardenas, 

Karim E. Diaz-Deza, Mariela Medina-Chinchon, J. Mariano 

Cucho-Venegas, Risto A. Perich-Campos, Jose L. Alfaro- 

Lozano, Alfredo A. Sanchez-Torres, Zoila Rodriguez-Bellido, 

Sheyla Rodriguez-Ulloa and Cesar A. Pastor-Asurza, Hospital 

Almenara, Lima, Peru 

1400. Predictors of Obesity in Systemic Lupus Erythematosus. 

Michelle Petri, Sesha Adusumilli and Hong Fang, Johns 


1401. Characterization of Clinical Photosensitivity in Cutaneous 

Lupus Erythematosus. Kristen Foering 1 , Aileen Y. 

Chang 2 , Evan W. Piette 2 , Joyce Okawa 3 and Victoria 

P. Werth 4 , 1 University of Pennsylvania, Philadelphia 

VAMC, Philadelphia, PA, 2 University of Pennsylvania, 

Philadelphia, PA, 3 Perelman School of Medicine at the 

University of Pennsylvania and Philadelphia V.A. Medical 

Center, Philadelphia, PA, 4 University of Pennsylvania and 

Philadelphia V.A. Medical Center, Philadelphia, PA 

1402. Anti-ApoA1 Antibodies Associate with Disease 

Activity in Lupus and Are Lower in Patients Taking 

Hydroxychloroquine: A Longitudinal Analysis of 398 

Samples. Sara Croca, Ian Giles, David A. Isenberg, Yiannis 

Ioannou and Anisur Rahman, University College London, 


1403. Anti-Nucleosome Antibodies Are Associated with Disease 

Activity and Hydroxychloroquine Use in Patients with 

Lupus: A Longitudinal, Multivariate Analysis of 398 

Samples. Sara Croca, Ian Giles, David A. Isenberg, Yiannis 

Ioannou and Anisur Rahman, University College London, 


1404. There Is an Association Between Disease Activity and Risk 

of Thromboembolism in SLE. Reem Jan, Emily E. Lewis, Ting 

Ting Lu, Emily Siegwald and W. Joseph McCune, University 

of Michigan, Ann Arbor, MI 

1405. Real World Experience Comparing Multiplex Immunobead 

Assay versus Immunoflorescence Assay for Anti-Nuclear 

Antibody Detection At a University Hospital. Neha Dang, 

Brock E. Harper, Emilio B. Gonzalez, Silvia S. Pierangeli, 

Trisha M. Parekh, Michael J. Loeffelholz and Kimberly K. 

Bufton, University of Texas Medical Branch, Galveston, TX 

1406. The Cost of Management of Adult Active Systemic Lupus 

Erythematosus in the UK. Munther A. Khamashta 1 , Christina 

Donatti 2 , Ian N. Bruce 3 , Caroline Gordon 4 , David A. Isenberg 5 

and Ateka-Barrutia Oier 1 , 1 Lupus Research Unit, The Rayne 

Institute, Kings College London School of Medicine, London, 

United Kingdom, 2 IMS Health, United Kingdom, 3 Arthritis 

Research UK Epidemiology Unit and NIHR Manchester 

Musculoskeletal Biomedical Research Unit, Manchester, 

United Kingdom, 4 University of Birmingham, Birmingham, 

United Kingdom, 5 University College London, London, 


1407. The Effect of the Antiphospholipid Syndrome (APS) On 

Survival in Chinese Patients with SLE: A Prospective Study 

of 679 Patients. Chi Chiu Mok, Ling Yin Ho, Ka Lung Yu and 

Chi Hung To, Tuen Mun Hospital, Hong Kong, Hong Kong 

1408. Monitoring Patients with Systemic Lupus Erythematosus in 

Clinical Practice: Have You Already Checked the Vaccination 

Status in Your Patients? Olga Malysheva, Jean-Philipp 

Ivanov, Sybille Arnold and Christoph G. Baerwald, University 

Hospital, Leipzig, Germany 

1409. A Multicentre Clinical Study of Umbilical Cord 

Mesenchymal Stem Cells Transplantation in Active 

Systemic Lupus Erythematosus. Lingyun Sun 1 , Dandan 

Wang 1 , Jing Li 2 , Miao Zhang 3 , Yu Zhang 4 and Xia Li 1 , 

1 

Department of Rheumatology and Immunology, the 

Affiliated Drum Tower Hospital of Nanjing University Medical 

School, Nanjing, China, 2 Department of Rheumatology, 

Affiliated Hospital of Jiangsu University, Zhenjiang, China, 

3 

Department of Rheumatology, Jiangsu Provincial People’s 

Hospital, Nanjing, China, 4 Department of Rheumatology, 

Subei People’s Hospital of Jiangsu Province, Yangzhou, China 



1410. Relationship between Individual Organ Damage and 

Mortality of Systemic Lupus Erythematosus (SLE): A 

Prospective Cohort Study of 679 Patients. Chi Chiu Mok, 

Ling Yin Ho and Ka Lung Yu, Tuen Mun Hospital, Hong Kong, 

Hong Kong 

1411. Equivalence of Various Language Versions of Lupus 

Specific Patient Reported Outcomes Measure (LupusPRO). 

Meenakshi Jolly 1 , Mark Kosinski 2 , Sergio M.A. Toloza 3 , Joel 

A. Block 1 , Rachel A. Mikolaitis 1 , Sergio Durán-Barragan 4 , 

Ana M. Bertoli 5 , Ivana Blazevic 6 , Luis M. Vila 7 , Dilrukshie 

Cooray 8 , Emmanuel P. Katsaros 9 , Karina Marianne D. 

Torralba 10 , Ioana Moldovan 11 , Arif Kaya 12 , Berna Goker 12 , 

Seminur Haznedaroglu 12 , Mehmet E. Tezcan 12 , Josiane 

Bourré-Tessier 13 , Sasha Bernatsky 14 , Ann E. Clarke 15 , Michael 

H. Weisman 16 , Sandra V. Navarra 17 , Daniel J. Wallace 16 and 

Graciela S. Alarcon 18 , 1 Rush University Medical Center, 

Chicago, IL, 2 QualityMetric Inc, Lincoln, RI, 3 Hospital 

San Juan Bautista, Catamarca, Argentina, 4 Unidad de 

Investigacion en Enfermedades Cronico-Degenerativas, 

Guadalajara, Mexico, 5 Instituto Reumatológico Strusberg, 

Cordoba, Cordoba, Argentina, 6 University of Buenos Aires, 

Buenos Aries, Argentina, 7 University of PuertoRico Medical 

Sciences Campus, San Juan, PR, 8 Harbor UCLA Medical 

Center, Torrance, CA, 9 Loma Linda Univ, Loma Linda, CA, 

10 

USC Keck Schl of Medicine, Los Angeles, CA, 11 Loma Linda 

Univ Medical Center, Loma Linda, CA, 12 Gazi University 

Medical School, Ankara, Turkey, 13 McGill University, 

Montréal, QC, 14 Research Institute of the McGill University 

Health Ctre, Montreal, QC, 15 MUHC, Montreal, QC, 16 Cedars- 

Sinai Medical Center, Los Angeles, CA, 17 University of Santo 

Tomas Hospital, Manila, Philippines, 18 University of Alabama 

at Birmingham, Birmingham, AL 

1412. Vascular Cell Adhesion Molecule (VCAM-1) and Angiostatin 

in Systemic Lupus Erythematosus. Adnan Kiani 1 , Hong 

Fang 1 , Tianfu Wu 2 , Chandra Mohan 3 and Michelle Petri 1 , 

1 


MD, 2 University of Texas, Southwestern Medical Center at 

Dallas, Dallas, TX, 3 University of Texas Southwestern Medical 

Center, Dallas, TX 

1413. Clinical Presentation, Treatment and Outcome of 

Membranous Nephropathy in SLE: A Comparison with 

Proliferative Lupus Glomerulonephritis in 141 Patients. Chi 

Chiu Mok, Ling Yin Ho and Ka Lung Yu, Tuen Mun Hospital, 

Hong Kong, Hong Kong 

1414. Combination of Mycophenolate Mofetil and Tacrolimus 

for Refractory Lupus Nephritis: A 12-Month Open-Labeled 

Trial. Chi Chiu Mok, Pak To Chan, Ling Yin Ho and Ka Lung Yu, 

Tuen Mun Hospital, Hong Kong, Hong Kong 

1415. Effect of Renal Disease On Survival of Patients with 

Systemic Lupus Erythematosus: A Prospective Cohort 

Study of 694 Patients. Chi Chiu Mok 1 , Raymond Kwok 2 

and Paul Yip 2 , 1 Tuen Mun Hospital, Hong Kong, Hong Kong, 

2 

University of Hong Kong, Hong Kong, Hong Kong 

1416. Tumor Necrosis Factor Alpha Is Associated with Mood 

Disorders in Patients with Systemic Lupus Erythematosus. 

Mariana Postal 1 , Aline T. Lapa 1 , Nailu A. Sinicato 1 , Karina 

Peliçari 1 , Lilian Costallat 2 and Simone Appenzeller 3 , 1 State 

University of Campinas, Campinas, Brazil, 2 Faculdade de 

Ciencias Medicas, Universidade Estadual de Campinas, 

Campinas, Brazil, 3 State University of Campinas, São Paulo, 

Brazil 

1417. Favorable Response to Belimumab At Three Months. 

Katrina M. Shum 1 , Jill P. Buyon 1 , H. Michael Belmont 1 , 

Andrew G. Franks 2 , Richard Furie 3 , Diane L. Kamen 4 , Susan 

Manzi 5 , Michelle Petri 6 , Rosalind Ramsey-Goldman 7 , 

Chung-E Tseng 1 , Ronald F. van Vollenhoven 8 , Daniel 

Wallace 9 and Anca Askanase 1 , 1 NYU School of Medicine, 

New York, NY, 2 New York University, New York, NY, 3 North 

Shore-LIJ Health System, Lake Success, NY, 4 Arthritis & 


Foundation, Charleston, SC, 5 West Penn Allegheny Health 

System, Pittsburgh, PA, 6 Johns Hopkins University School 

of Medicine, Baltimore, MD, 7 Northwestern University 

Feinberg School of Medicine, Chicago, IL, 8 The Karolinska 

Institute, Stockholm, Sweden, 9 Cedars-Sinai/UCLA, Los 

Angeles, CA 

1418. Directed Intuitive Assessment of Lupus (the DIAL system 

for real world clinics) Correlates Well with BILAG and 

SLEDAI. Anca D. Askanase 1 , Katrina M. Shum 1 , Stan Kamp 2 , 

Fredonna C. Carthen 2 , Teresa J. Aberle 2 and J.T. Merrill 2 , 

1 

NYU School of Medicine, New York, NY, 2 Oklahoma Medical 

Research Foundation, Oklahoma City, OK 

1419. Infections Increase Risk of Arterial and Venous Thromboses 

in Systemic Lupus Erythematosus Patients: 4925 Patient 

Years of Follow-up. Renata Baronaite Hansen 1 and Søren 

Jacobsen 2 , 1 Copenhagen University Hospital Rigshospitalet, 

Copenhagen, Denmark, 2 Copenhagen University Hospital, 


1420. Ethnicity and B Cell Depletion Therapy in Systemic Lupus 

Erythematosus. A. Lois-Iglesias 1 , J. Ishorari 2 and D.A. 

Isenberg 2 , 1 University Hospital Ramón y Cajal, Madrid, 

Spain. University College London, London, United Kingdom, 

2 

University College London, London, United Kingdom 

1421. Antimalarials Protect Systemic Lupus Erythematosus 

Patients From Damage Accrual During the First Five 

Years of the Disease. Ioana Ruiz-Arruza, D. D. Gladman, 

Dominique Ibanez and Murray B. Urowitz, Toronto Western 


1422. Clinical Associations of Anti-Smith Antibodies in Profile: 

A Multiethnic Lupus Cohort. Yesenia C. Santiago-Casas 1 , 

Luis M. Vila 1 , Gerald McGwin Jr. 2 , Ryan S. Cantor 2 , Michelle 

Petri 3 , Rosalind Ramsey-Goldman 4 , John D. Reveille 5 , Robert 

P. Kimberly 2 , Graciela S. Alarcon 2 and Elizabeth E. Brown 2 , 

1 

University of Puerto Rico Medical Sciences Campus, 

San Juan, PR, 2 University of Alabama at Birmingham, 

Birmingham, AL, 3 Johns Hopkins University School of 

Medicine, Baltimore, MD, 4 Northwestern University 

244 

2012 Program Book


Feinberg School of Medicine, Chicago, IL, 5 Univ of Texas 

Health Science Center at Houston, Houston, TX 

1423. Vascular Thrombosis and Pregnancy Morbidity in Patients 

with Systemic Lupus Erythematosus with Positive 

Antiphospholipid Profile and Thrombocytopenia. Amir 

Haddad, Murray B. Urowitz, Dominique Ibanez and D. 



1424. Prevalence and Clinical Significance of Severe Infection in 

Patients with Systemic Lupus Erythematosus: Preliminary 

Data From Relesser (Registry of lupus of the Spanish 

Society of Rheumatology). José M. Pego-Reigosa 1 , Íñigo 

Rúa-Figueroa 2 , Francisco J. López-Longo 3 , María Galindo 4 , 

Jaime Calvo-Alén 5 , Alejandro Olivé 6 , Loreto Horcada 7 , 

Esther Uriarte 8 , Eva Tomero 9 , Ana Sánchez-Atrio 10 , Carlos 

Montilla 11 , José Rosas 12 , Antonio Fernández-Nebro 13 , 

Paloma Vela 14 , Mercedes Freire 15 , Lucía Silva 16 , Elvira 

Díez-Álvarez 17 , Carlos Marras 18 , Antonio Zea 19 , Javier 

Narváez 20 , Jose Luis Marenco 21 , Monica Fernández de 

Castro 22 , Olaia Fernánde-Berrizbeitia 23 , Marian Gantes2 4 

and Celia Erausquin2 5 , 1 Hospital do Meixoeiro, Vigo, Spain, 

2 

Hospital Universitario Dr Negrín, Las Palmas de Gran 

Canaria, Spain, 3 Hospital Gregorio Marañón, Madrid, Spain, 

4 

Instituto de Investigación Hospital 12 de Octubre, Madrid, 

Spain, 5 Hospital Sierrallana, Torrelavega, Spain, 6 Hospital 

Universitario Germans Trias i Pujol, Badalona, Spain, 

7 

Hospital de Navarra, Spain, 8 Hospital de Donosti, Donosti, 

Spain, 9 Hospital Universitario La Princesa, Madrid, Spain, 

10 

Hospital Príncipe de Asturias, Madrid, Spain, 11 Hospital 

Universitario de Salamanca, Salamanca, Spain, 12 Hospital 

de Marina Baixa, Alicante, Spain, 13 Hospital Carlos Haya, 

Malaga, Spain, 14 Hospital General de Alicante, Alicante, 

Spain, 15 Hospital Universitario Juan Canalejo, La Coruña, 

Spain, 16 Hospital de Guadalajara, Guadalajara, Spain, 

17 

Hospital de León, León, Spain, 18 Hospital Universitario 

Virgen de la Arrixaca, Murcia, Spain, 19 Hospital Universitario 

Ramon y Cajal, Madrid, Spain, 20 Hospital de Bellvitge, 

Barcelona, Spain, 21 Hospital de Valme, Seville, Spain, 

22 

Hospital Puerta del Hierro-Majadahonda, Madrid, Spain, 

23 

Hospital de Basurto, Basurto, Spain, 24 Hospital Clinico de 

Tenerife, Spain, 25 Hospital de Gran Canaria Dr Negrin, Las 

Palmas GC, Spain 

1425. Circulating Free Protein S Levels May Be Linked to 

Cardiovascular Events and Venous Thrombosis in SLE. 

Gregg J. Silverman 1 , John Jung 1 , Ehtisham Akhter 2 , Michelle 

Petri 2 and Caroline Grönwall 1 , 1 NYU School of Medicine, 

New York, NY, 2 Johns Hopkins University School of Medicine, 

Baltimore, MD 

1426. The Clinical Relevance of a “False Negative” Enzyme Linked 

Immunoassay: Which Antinuclear Antibody Screening Test 

Is Preferred by Rheumatologists in an Integrated Health 

System? Rachita Bansal, David Bulbin, Alfred E. Denio, 

Sandi Kelsey and Harold Harrison, Geisinger Medical Center, 

Danville, PA 

1427. Late Onset Systemic Lupus Erythematosus: Is It Actually 

A Milder Variant? Juan G. Ovalles-Bonilla 1 , Julia Martínez- 

Barrio 1 , Javier Lopez-Longo 1 , Inmaculada de la Torre 1 , Carlos 

Gonzalez Fernandez 1 , María Montoro Álvarez 1 , Francisco 

Aramburu 1 , Carolina Marin 1 , Lina Martinez-Estupiñan 1 , 

Juan C. Nieto 2 , Michelle Hinojosa 1 , Natalia Bello 1 , Indalecio 

Monteagudo 1 and Luis Carreño 1 , 1 Gregorio Marañón 

Hospital, Madrid, Spain, 2 Istituto Giannina Gaslini, Genova, 

Italy 

1428. Long-Term Outcomes of Children Born to Women with 

Systemic Lupus Erythematosus. Evelyne Vinet 1 , Mohammed 

Kaouache 2 , Christian A. Pineau 1 , Ann E. Clarke 3 , Caroline 

P. Gordon 4 , Robert W. Platt 5 and Sasha Bernatsky 2 , 1 McGill 

University Health Centre, Montreal, QC, 2 Research Institute 

of the McGill University Health Ctre, Montreal, QC, 3 MUHC, 

Montreal, QC, 4 Medical School, Birmingham, United 

Kingdom, 5 McGill University, Montreal, QC 

1429. Women with Systemic Lupus Erythematosus (SLE) May 

Have Different Predictors of Risk for Progression of 

Aorta Calcium (AS) Than Women without SLE. Apinya 

Lertratanakul 1 , Peggy W. Wu 1 , Alan Dyer 1 , William Pearce 1 , 

George Kondos 2 , Daniel Edmundowicz 3 , James Carr 4 and 

Rosalind Ramsey-Goldman 4 , 1 Northwestern University, 

Chicago, IL, 2 University of Illinois at Chicago, Chicago, 

IL, 3 Temple University School of Medicine, Philadelphia, 

4 


Chicago, IL 

1430. Women with Systemic Lupus Erythematosus (SLE) May 

Have Different Predictors of Risk for Progression of 

Coronary Artery Calcium (CAC) Than Women without SLE. 

Apinya Lertratanakul 1 , Peggy W. Wu 1 , Alan Dyer 1 , William 

Pearce 1 , George Kondos 2 , Daniel Edmundowicz 3 , James Carr 4 

and Rosalind Ramsey-Goldman 4 , 1 Northwestern University, 

Chicago, IL, 2 University of Illinois at Chicago, Chicago, 

IL, 3 Temple University School of Medicine, Philadelphia, 

4 


Chicago, IL 

1431. Single Photon Emission Computed Tomography 

Contributes to Clinical Assessments in Neuropsychiatric 

Systemic Lupus Erythematosus Patients. Maasa Hama, 

Mitsuhiro Takeno, Atsushi Ihata, Daiga Kishimoto, Reikou 

Watanabe, Takeaki Uehara, Ryusuke Yoshimi, Yukiko Asami, 

Atsuhisa Ueda and Yoshiaki Ishigatsubo, Yokohama City 

University Graduate School of Medicine, Yokohama, Japan 

1432. Safety and Efficacy of Etanercept in Systemic LUPUS 

Erythematosus. Josefina Cortes-Hernandez 1 , Natalia Egri 1 , 

Miquel Vilardell-Tarres 1 and Josep Ordi-Ros 2 , 1 Hospital 

Universitari Vall dxHebron, Institut de Recerca (VHIR),, 

Barcelona, Spain, 2 Vall De Hebron General Hospt, Barcelona, 

Spain 

1433. Persistent Dyslipidemia Is a Risk Factor of Progression to 

Chronic Kidney Disease in Patients with Lupus Nephritis. 

Dong-Jin Park, Kyung-Eun Lee, Tae-Jong Kim, Yong-Wook 

Park and Shin-Seok Lee, Chonnam National University 

Medical School, Gwangju, South Korea 



246 

1434. Cardiovascular Morbidity in a Long-Term Follow-up Cohort 

of Systemic Lupus Erythematosus Patients in Southern 

Sweden. Ragnar Ingvarsson 1 , Ola Nived 2 , Gunnar Sturfelt 1 , 

anders Bengtsson 3 and Andreas Jönsen 4 , 1 Department of 

Clinical Sciences Lund, Section of Rheumatology, Lund, 

Sweden, 2 University Hospital - Lund, Lund, Sweden, 

3 

University Hospital Lund, Lund, Sweden, 4 Section of 

Rheumatology, Lund, Sweden 

1435. Identifying Systemic Lupus Erythematosus Patients At 

Higher Risk of Coronary Artery Disease. Dominique Ibanez, 

D. D. Gladman and Murray B. Urowitz, Toronto Western 


1436. Application of European League Against Rheumatism 

Recommendations for the Management of Systemic Lupus 

Erythematosus Patients with Neuropsychiatric Involvement 

May Limit Unnecessary Diagnostic Testing and Curve 

Intensification of Immunosuppressive Therapy of Unclear 

Benefit. Cristina Pamfil 1 , Antonios Fanouriakis 2 , Argyro 

Repa 2 , Maria Melissourgaki 2 , Prodromos Sidiropoulos 2 , 

Ileana Filipescu 3 , Mirela Rinzis 3 , Simona Rednic 3 , George 

Bertsias 2 and Dimitrios Boumpas 4 , 1 University of Medicine 

and Pharmacy, Cluj, Romania, 2 University of Crete, Iraklion, 

Greece, 3 Emergency County Clinical Hospital Cluj Napoca, 

Cluj-Napoca, Romania, 4 Panepistimio Kritis, Rethymnon, 

Greece 

1437. Majority of Lupusqol Domains Are Negatively Correlated 

with Systemic Lupus Activity Questionnaire (SLAQ) Score. 

Wendy Marder 1 , Martha Ganser 1 , Margaret Hyzy 2 and 

Emily C. Somers 1 , 1 University of Michigan, Ann Arbor, MI, 

2 

Universitiy of Michigan, Ann Arbor, MI 


1438. Development of Systemic Lupus Erythematosus (SLE) 

in NZM 2328 Mice in the Absence of Any Single BAFF 

Receptor. Chaim O. Jacob 1 , Ning Yu 2 , Shunhua Guo 2 , 

Noam Jacob 2 , William J. Quinn III 3 , Michael P. Cancro 3 , 

Beatrice Goilav 4 , Chaim Putterman 5 , Thi-Sau Migone 6 and 

William Stohl 2 , 1 Department of Medicine, Keck School of 

Medicine, University of Southern California, Los Angeles, 

CA, 2 University of Southern California Keck School of 

Medicine, Los Angeles, CA, 3 University of Pennsylvania 

School of Medicine, Philadelphia, PA, 4 Children’s Hospital at 

Montefiore, Bronx, NY, 5 Albert Einstein College of Medicine, 

Bronx, NY, 6 Human Genome Sciences, Rockville, MD 

1439. CTL-Promoting Effects of IL-21 Results in B Cell Elimination 

and Disease Improvement in a Murine Model of Lupus. 

Vinh Nguyen 1 , Daniel Veizaga-Udaeta 2 , Horea Rus 3 and 

Violeta Rus 3 , 1 University of Maryland School of Medicine, 

Baltimore, MD, 2 University of Maryland at Baltimore County, 

MD, 3 University of Maryland School of Medicine and 

Veteran Affairs Medical Center, Baltimore, MD 

1440. Lupus-Prone Mice Demonstrate Enhanced Neutrophil 

Extracellular Trap Formation: Implications for 

Autoantibody Formation and Organ Damage. Jason 


S. Knight 1 , Alexander A. O’Dell 1 , Wenpu Zhao 1 , Ritika 

Khandpur 1 , Srilakshmi Yalavarthi 2 and Mariana J. Kaplan 2 , 

1 

University of Michigan Rheumatology, Ann Arbor, MI, 

2 


1441. Epstein Barr Virus CD40 Functional Mimic Latent 

Membrane Protein-1 Drives Cellular Molecular Mimicry 

in the Presence of Epstein Barr Virus Nuclear Antigen-1 in 

a Novel Murine Model of Lupus-Like Disease. Melissa E. 

Munroe 1 , Jourdan R. anderson 1 , Timothy F. Gross 1 , Laura 

L. Stunz 2 , Gail A. Bishop 2 and Judith A. James 3 , 1 Oklahoma 

Medical Research Foundation, Oklahoma City, OK, 2 The 

University of Iowa, Iowa City, IA, 3 Oklahoma Medical 

Research Foundation; University of Oklahoma Health 

Sciences Center, Oklahoma City, OK 

1442. IRF-1 Deficient Lupus-Prone MRL/Lpr Mice Show Reduced 

Glomerulonephritis but Develop Severe Interstitial 

Nephritis, Renal Vasculitis and Pulmonary Granulomas 

with Propensity for Th2 Polarity. Hidemaru Sekine 1 , Takeshi 

Machida 1 , Natsumi Sakamoto 1 , Eiji Suzuki 2 , Xian Zhang 3 , 

Christopher Reilly 4 and Gary S. Gilkeson 2 , 1 Fukushima 

Medical University, Fukushima, Japan, 2 Medical University 

of South Carolina, Charleston, SC, 3 Medical University of 

South Carolina and Ralph H. Johnson VA Medical Center, 

Charleston, SC, 4 Virginia Tech, Blacksburg, VA 

1443. Caspase-1 Modulates Endothelial Dysfunction and Vascular 

Repair in Murine Lupus. J. Michelle Kahlenberg, Wenpu 

Zhao, Srilakshmi Yalavarthi and Mariana J. Kaplan, University 

of Michigan, Ann Arbor, MI 

1444. HLA-DR3 Controls Autoantibody Response to Sm 

in NZM2328.DR3+.AE0 Transgenic Mice. Vaidehi R. 

Chowdhary 1 , Chao Dai 2 , Shu Man Fu 2 and Chella S. David 1 , 

1 

Mayo Clinic, Rochester, MN, 2 University of Virginia Health 

System, Charlottesville, VA 

1445. Shared and Unique Molecular Features of Nephritis in 

3 Models of Murine SLE. Ramalingam Bethunaickan 1 , 

Celine C. Berthier 2 , Matthias Kretzler 3 and Anne Davidson 4 , 

1 

Feinstein Institute for Medical research, Manhasset, NY, 

2 

University of Michigan, Ann Arbor, MI, 3 University of 

Michigan, MI, 4 Feinstein Institute for Medical Research, 

Manhasset, NY 

1446. The Granulocyte Signature and Organ Inflammation 

in TLR7 Responsive Mice Is RNA and Type 1 Interferon 

Dependent. Xizhang Sun 1 , Alice Wiedeman 2 , Thomas H. 

Teal 2 , Nalini Agrawal 2 , Jeffrey Duggan 2 , Matt B. Buechler 3 , 

Jeffrey A. Ledbetter 2 , Denny Liggitt 2 , Jessica A. Hamerman 4 

and Keith B. Elkon 2 , 1 Division of Rheumatology, Department 

of Medicine, University of Washington, Seattle, WA, 

2 

University of Washington, Seattle, WA, 3 Benaroya Research 

Institute at Virginia Mason, Seattle, WA, Seattle, 4 Benaroya 

Research Institute at Virginia Mason, Seattle, WA 

1447. A Synthetic Triterpenoid CDDO-Me Prevents and Reverses 

Murine Lupus Nephritis. Tianfu Wu 1 , Yujin Ye 1 , Mei Yan 1 , Xin 

J. Zhou 2 , Michael andreef 3 and Chandra Mohan 1 , 1 University 

of Texas, Southwestern Medical Center at Dallas, Dallas, TX,


2 

University of Texas Southwestern Medical Center at Dallas, 

Dallas, TX, 3 The University of Texas M. D. anderson Cancer 


1448. Inhibition of Calcium/Calmodulin-Dependent Protein 

Kinase IV Suppresses the Autoimmunity in Lupus-Prone 

Mice. Kunihiro Ichinose 1 , Atsushi Kawakami 1 and George C. 

Tsokos 2 , 1 Nagasaki University Graduate School of Biomedical 

Sciences, Nagasaki, Japan, 2 Beth Israel Deaconess Medical 

Center, Harvard Medical School, Boston, MA 

1449. Numbers of Splenic Long-Lived Plasma Cells in 

Autoimmune and Pre-Autoimmune Lupus Mice Are Linked 

to a Hyper-Responsive Variant of the Thrombopoietin 

Receptor and Enhanced Megakaryopoiesis. Oliver Winter 1 , 

Katrin Moser 2 , Rudolf A. Manz 3 and Falk Hiepe 4 , 1 Charité 

- University Medicine Berlin, Berlin, Germany, 2 German 

Arthritis Research Center (DRFZ Berlin), Berlin, Germany, 

3 

University of Lübeck, Lübeck, Germany, 4 Charité University 


1450. MEDI-551 Depletes a Majority of Murine B Cells and 

Reduces Serum Titers of Autoantibodies in the SLE1- 

huCD19 TG Mice. Sandra Gallagher, Yue Wang, Isharat 

Yusuf, Thomas McCaughtry, Ronald Herbst and Laura Carter, 

MedImmune, Gaithersburg, MD 

1451. Estrogen Receptor Alpha Deficiency Protects Against 

Cognitive Defects in Murine Lupus. Melissa A. 

Cunningham 1 , Osama S. Naga 2 , Heather A. Boger 2 , Ann- 

Charlotte E. Granholm-Bentley 2 and Gary S. Gilkeson 3 , 

1 

MUSC, Charleston, SC, 2 Medical University of SC, 

Charleston, SC, 3 Medical University of South Carolina, 


1452. Inherent Strain-Based Differences in Qualitative CD4 T Cell 

Responses Determine Lupus Severity. Kateryna Soloviova, 

Maksym Puliaiev and Charles S. Via, Uniformed Services 

University of Health Sciences, Bethesda, MD 

1453. Estrogen Receptor Alpha Impacts Th17 Expansion in 

Murine Lupus. Melissa A. Cunningham 1 , Osama S. Naga 2 , 

Jackie G. Eudaly 2 and Gary S. Gilkeson 3 , 1 MUSC, Charleston, 

SC, 2 Medical University of SC, Charleston, SC, 3 Medical 

University of South Carolina, Charleston, SC 

1454. Characterization of Renal Mononuclear Phagocyte 

Populations in Murine SLE Nephritis. Ranjit Sahu 1 , 

Ramalingam Bethunaickan 2 and Anne Davidson 1 , 1 Feinstein 

Institute for Medical Research, Manhasset, NY, 2 Feinstein 

Institute for Medical research, Manhasset, NY 

1455. Mitochondrial Dysfunction in the Liver of Lupus-Prone 

MRL/Lpr Mice Prior to Disease Onset. Zachary A. Oaks 1 , 

Tiffany Telarico 2 and andras Perl 3 , 1 SUNY, Syracuse, NY, 

2 

SUNY Upstate Medical University, Syracuse, NY, 3 Upstate 

Medical University, Syracuse, NY 

1456. A Tolerogenic Peptide Down-Regulates the Expression 

of Interferon-a in Murine and Human Systemic Lupus 

Erythematosus. Zev M. Sthoeger 1 , Heidy Zinger 2 , Amir 

Sharabi 2 , Ilan Asher 1 and Edna Mozes 2 , 1 Kaplan Hospital, 

Rehovot, Israel, 2 The Weizmann institute of Science, 

Rehovot, Israel 

1457. A Novel Small Molecular Anti-Rheumatic Drug, T-6 14 , 

Ameliorates Lupus-Like Disease in MRL/Lpr Mice by 

Suppressing B Cell Functions. Qingran Yan, Fang Du and 

Chunde Bao, Renji Hospital, Shanghai, China 



1458. Left Ventricular Diastolic Dysfunction May Play a Role in 

Pathophysiology and Poor Prognosis of Pulmonary Arterial 

Hypertension Associated with Systemic Sclerosis. Sumiaki 

Tanaka 1 , Eisuke Ogawa 1 , Tatsuhiko Wada 1 , Tatsuo Nagai 1 , 

Jun Okada 2 and Shunsei Hirohata 1 , 1 Kitasato University 

School of Medicine, Sagamihara, Japan, 2 Kitasato University, 

Sagamihara, Japan 

1459. Limited Utility of Pulmonary Function Tests and B-Type 

Natriuretic Peptide As Screening Tools for Pre-Capillary 

Pulmonary Hypertension in Patients with Systemic 

Sclerosis. Yuichiro Shirai 1 , Yuichi Tamura 1 , Hidekata Yasuoka 1 , 

Tsutomu Takeuchi 1 , Toru Satoh 2 and Masataka Kuwana 1 , 

1 

Keio University School of Medicine, Tokyo, Japan, 2 Kyorin 

University School of Medicine, Tokyo, Japan 

1460. Unmasking Latent Pulmonary Arterial Hypertension by 

Fluid Challenge in Patients with Systemic Sclerosis. Amee 

Sonigra 1 , Melanie Hurford 2 , Patricia Lewis 3 , David Kilpatrick 1 , 

Nathan Dwyer 1 and Jane Zochling 3 , 1 Royal Hobart Hospital, 

Hobart, Australia, 2 Menzies Research Institute, Hobart, 

Australia, 3 Menzies Research Institute Tasmania, Hobart, 

Australia 

1461. Clinical Outcomes of Scleroderma Patients At High Risk 

for Pulmonary Hypertension. Analysis of the Pulmonary 

Hyparternsion Assessment and Recognition of Outcomes 

in Scleroderma Registry. Avram Z. Goldberg 1 , Vivien M. 

Hsu 2 and Virginia D. Steen 3 , 1 North Shore-LIJ Health System, 

Lake Success, NY, 2 RWJ Med Schl Scleroderma Prog, 

New Brunswick, NJ, 3 Georgetown Univ Medical Center, 


1462. Expert Consensus for Performing Right Heart 

Catheterization in Suspicion of Pulmonary Arterial 

Hypertension Associated with Systemic Sclerosis: A Delphi 

Consensus Study with Cluster Analysis From the Eposs 

Group. Jerome Avouac 1 , Dörte Huscher 2 , Daniel E. Furst 3 , 

Oliver Distler 4 and Yannick Allanore 1 , 1 Paris Descartes 

University, Rheumatology A department, Cochin Hospital, 

Paris, France, 2 German Rheumatism Research Centre 

and Charité University Medicine, Berlin, Germany, 3 UCLA 

Medical School, Los Angeles, CA, 4 University Hospital Zurich, 


1463. Pulmonary Hypertension and Interstitial Lung Disease 

within Pharos: Impact of Extent of Fibrosis and Pulmonary 

Physiology On Cardiac Hemodynamic Parameters. Aryeh 

Fischer 1 , Stephen C. Mathai 2 , Marcy B. Bolster 3 , Lorinda 

Chung 4 , Mary Ellen Csuka 5 , Robyn T. Domsic 6 , Tracy M. 



Frech 7 , Monique E. Hinchcliff 8 , Vivien M. Hsu 9 , Laura 

K. Hummers 2 , Jason R. Kolfenbach 10 , Mardi Gomberg- 

Maitland 11 , Aida Manu 12 , Robert W. Simms 13 and Virginia D. 

Steen 14 , 1 National Jewish Health, Denver, CO, 2 Johns Hopkins 

University, Baltimore, MD, 3 Medical Univ of South Carolina, 

Charleston, SC, 4 Stanford Univ Medical Center, Palo Alto, CA, 

5 

Medical College of Wisconsin, Milwaukee, WI, 6 University 

of Pittsburgh, Pittsburgh, PA, 7 University of Utah School of 

Medicine, SLC, UT, 8 Northwestern Univ Med School, Chicago, 

IL, 9 RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, 

10 

Univ of Colorado School of Med, Aurora, CO, 11 University 

of Chicago, Chicago, 12 Rheumatology, Georgetown University 

Medical Center, Disrict of Columbia, 13 Boston University 

School of Medicine, Boston, MA, 14 Georgetown Univ 


1464. Comparison of Baseline Characteristics of the Combined 

Response Index for Systemic Sclerosis (CRISS) Cohort 

to Patients Enrolled in Clinical Trials of Diffuse Systemic 

Sclerosis. Heather Gladue 1 , De Furst 2 , Veronica Berrocal 1 , 

James R. Seibold 3 , Peter A. Merkel 4 , Maureen D. Mayes 5 , 

Kristine Phillips 6 , Robert W. Simms 7 , Shervin Assassi 8 , Philip J. 

Clements 9 , Paul Maranian 10 and Dinesh Khanna 1 , 1 University 

of Michigan, Ann Arbor, MI, 2 University of California at 

Los Angeles, Los Angeles, CA, 3 Scleroderma Research 

Consultants LLC, Avon, CT, 4 University of Pennsylvania, 

Philadelphia, PA, 5 University of Texas Health Science 

Center at Houston, Houston, TX, 6 University of Michigan 

Medical School, Ann Arbor, MI, 7 Boston University School 

of Medicine, Boston, MA, 8 Univ of Texas Health Science 

Houston, Houston, TX, 9 UCLA School of Medicine, Los 

Angeles, CA, 10 UCLA Medical School, Los Angeles, CA 

1465. World Health Organization Classification of Pulmonary 

Hypertension and Survival in Systemic Sclerosis Patients 

in the Pharos Cohort. Jessica K. Gordon 1 , Lorinda Chung 2 , 

Robyn T. Domsic 3 , Wei-Ti Huang 4 , Stephen L. Lyman 1 , Evelyn 

M. Horn 5 , Virginia D. Steen 6 and PHAROS Investigators 7 , 

1 

Hospital for Special Surgery, New York, NY, 2 Stanford Univ 

Medical Center, Palo Alto, CA, 3 University of Pittsburgh, 

Pittsburgh, PA, 4 Hospital for Special Surgery, New York, 

5 

New York Presbyterian Hospital/Weill Cornell Medical 

College, New York, NY, 6 Georgetown Univ Medical Center, 

Washington, DC, 7 Washington, DC 

1466. Patients with Systemic Sclerosis Are Dying of Non-Systemic 

Sclerosis Related Causes, However Interstitial Lung Disease 

Remains the Predominant Systemic Sclerosis Related Cause 

of Death. Rebecca L. Batten and Bridget Griffiths, Freeman 

Hospital, Newcastle Upon Tyne, United Kingdom 

1467. Association of Gastroesophageal Factors and Progression 

of Interstitial Lung Disease in the Canadian Scleroderma 

Research Group, a Large, Multicenter Database. Xuli Jerry 

Zhang 1 , Ashley Bonner 2 , Murray Baron 3 , Marie Hudson 4 , 

Janet E. Pope 5 and Canadian Scleroderma Research Group 6 , 

1 

Western University, London, ON, 2 McMaster University, 

Hamilton, ON, 3 Jewish General Hospital, Montreal, QC, 

4 

McGill University, Montreal, QC, 5 St. Joseph Health Care 

London, University of Western Ontario, London, ON, 

6 

Montreal 

1468. Patient Perspective Informs Core Sets, Constructs of 

Metrics and Communication Tools for Patients with 

Connective Tissue Disease Related Interstitial Lung 

Disease. Shikha Mittoo 1 , Sid Frankel 2 , Daphne LeSage 3 , 

Flavia V. Castelino 4 , Lisa Christopher-Stine 5 , Sonye Danoff 6 , 

Aryeh Fischer 7 , Laura K. Hummers 5 , Ami A. Shah 5 , Jeffery J. 

Swigris 7 , Spohia Cena 8 , Sancia Ferguson 9 , Ignacio Garcia- 

Valladares 8 , Maithy Tran 1 , Harmanjot K. Grewal 10 and 

Lesley Ann Saketkoo 8 , 1 University of Toronto, Toronto, ON, 

2 

University of Manitoba, Winnipeg, 3 Center for CCH at State 

of Louisiana, New Orleans, LA, 4 Massachusetts General 

Hospital, Boston, MA, 5 Johns Hopkins University, Baltimore, 

MD, 6 Johns Hopkins School of Medicine, Baltimore, MD, 

7 

National Jewish Health, Denver, CO, 8 Louisiana State 

University Health Science Center, New Orleans, LA, 9 Tulane 

University School of Medicine, 10 Lousiana State University 

Health Sciences Center, New Orleans, LA 


1470. Clinical Features Associated with Anti-Th/to in Non- 

Scleroderma Patients - Sine Scleroderma? Ann D. Chauffe, 

Minoru Satoh, Angela Ceribelli, Edward K.L. Chan, Yi Li, Eric 

S. Sobel, Westley H. Reeves and Michael R. Bubb, University 


1471. Differential Expression of Hepatocyte Growth Factor (HGF) 

in Patients with Systemic Sclerosis-Associated Pulmonary 

Arterial Hypertension. Lorinda Chung 1 , Catriona Cramb 2 , 

William H. Robinson 3 , Virginia D. Steen 4 and Roham T. 

Zamanian 3 , 1 Stanford Univ Medical Center, Palo Alto, CA, 2 VA 

Palo Alto Heatlh Care System and Stanford University, Palo 

Alto, CA, 3 Stanford University, Palo Alto, CA, 4 Georgetown 

Univ Medical Center, Washington, DC 

1472. Enhanced Liver Fibrosis Test: A Further Step Toward 

Depiction of Fibrotic Process in Very Early Diagnosis 

of Systemic Sclerosis. Francesca Ingegnoli 1 , Roberta 

Gualtierotti 1 , Tommaso Schioppo 1 , Annalisa Orenti 2 , 

Patrizia Boracchi 2 , Chiara Lubatti 1 , Sara Lodi Rizzini 1 , 

Antonella Murgo 1 , Silvana Zeni 1 , Claudio Mastaglio 3 , 

Valentina Galbiati 3 , Claudia Grossi 4 , Maria Borghi 4 , 

William M. Rosenberg 5 and Pier Luigi Meroni 6 , 1 Division 

of Rheumatology, Istituto G. Pini, University of Milan, 

Milano, Italy, 2 Medical Statistics and Biometry, University 

of Milan, Milano, Italy, 3 Rheumatology Unit, Ospedale 

Moriggia-Pelascini, Italia Hospital, Gravedona, Italy, 4 Lab of 

immunology, IRCCS Istituto Auxologico Italiano, Milano, Italy, 

5 

Centre for Hepatology - UCL, London, United Kingdom, 

6 

Istituto G. Pini, University of Milan, Milano, Italy 

1473. Sub-Analysis of ELF Score Biomarkers Components 

Indicates a Specific Correlation with Different Organ 

Involvement in Systemic Sclerosis. Giuseppina Abignano 1 , 

Giovanna Cuomo 2 , Maya H. Buch 1 , William M. Rosenberg 3 , 

Gabriele Valentini 2 , Paul Emery 1 and Francesco Del Galdo 1 , 

1 

University of Leeds, Leeds Institute of Molecular Medicine 

248 

2012 Program Book


and LMBRU, Leeds, United Kingdom, 2 Second University 

of Naples, Rheumatology Unit, Naples, Italy, 3 Centre for 

Hepatology - UCL, London, United Kingdom 

1474. Interferon-Inducible Chemokines Correlate with Disease 

Severity in Systemic Sclerosis. Xiaochun Liu 1 , Maureen D. 

Mayes 1 , Filemon K. Tan 1 , Minghua Wu 1 , John D. Reveille 2 , 

Brock E. Harper 3 , Hilda T. Draeger 4 , Emilio B. Gonzalez 3 

and Shervin Assassi 5 , 1 University of Texas Health Science 

Center at Houston, Houston, TX, 2 Univ of Texas Health 

Science Center at Houston, Houston, TX, 3 University of Texas 

Medical Branch, Galveston, TX, 4 Univ of TX Health Sci Ctr, 

San Antonio, TX, 5 Univ of Texas Health Science Houston, 

Houston, TX 

1475. Does Skin Gene Expression Profile Predict Response 

to Imatinib? Shervin Assassi 1 , Jeffrey T. Chang 1 , Dinesh 

Khanna 2 , Xiaochun Liu 1 , Daniel Furst 3 and Maureen D. 

Mayes 1 , 1 Univ of Texas Health Science Center at Houston, 

Houston, TX, 2 University of Michigan, Ann Arbor, MI, 

3 


1476. Caveolin-1 Deficiency May Play a Role in the Predisposition 

of African Americans to SSc ILD. Elena Tourkina 1 , Charles 

Reese 2 , Beth Perry 2 , Shanice Dyer 2 , Michael Bonner 2 , Richard 

P. Visconti 2 , Jing Zhang 2 , Richard M. Silver 3 and Stanley 

Hoffman 3 , 1 Medical University of South Carolina, Charleston, 

SC, 2 Medical University of SC, Charleston, SC, 3 Medical 

University of SC, Charleston 

1477. Skin Autofluorescence As a Measure of Oxidative Stress 

in Systemic Sclerosis Is Not Affected by Skin Thickness, 

Erythema or Melanin. Andrea Murray 1 , T. Moore 1 , J. 

Manning 2 , Christopher E.M Griffiths 3 and Ariane Herrick 4 , 

1 

School of Translational Medicine, University of Manchester, 

Manchester Academic Health Science Centre, Salford 

Royal NHS Foundation Trust, Manchester, United Kingdom, 

2 

Department of Clinical Rheumatology, Salford Royal NHS 

Foundation Trust, Salford, United Kingdom, 3 Dermatology 

Centre, University of Manchester, Manchester Academic 

Health Science Centre, Salford Royal NHS Foundation Trust, 


Salford, United Kingdom 

1478. Gender-Associated Differences in Disease Characteristics 

and Outcome in Systemic Sclerosis. Svetlana I. Nihtyanova 1 , 

Voon H. Ong 2 and Christopher P. Denton 3 , 1 Royal Free 

Hospital, Medical School, London, England, 2 UCL Medical 

School, London, England, 3 UCL, London, United Kingdom 

1479. Early Versus Late Onset Systemic Sclerosis: Analysis of 

1037 Patients From Rescle Registry. Marco A. Alba 1 , Juan 

Carlos Mejia 2 , Gerard Espinosa 3 , María-Victoria Egurbide 4 , 

Carles Tolosa 5 , Luis Trapiella 6 , Carmen Pilar Simeon 7 , 

Vicent Fonollosa 8 and and RESCLE investigators 9 , 1 Vasculitis 

Research Unit. Hospital Clínic. University of Barcelona. 

IDIBAPS, Barcelona, Spain, 2 Hospital Clinic University 

Barcelona, Barcelona, Spain, 3 Hospital Clínic of Barcelona, 

Barcelona, Spain, 4 Hospital de Cruces, UPV/EHU, Barakaldo, 

Spain, Barakaldo, Spain, 5 Corporación Sanitaria Universitaria 

Parc Taulí, Barcelona, Spain, 6 Hospital Universitario Central 

de Asturias, Asturias, Spain, 7 Hospital Valle de Hebron, 

Barcelona, Spain, 8 Hospital Vall dxHebron, Barcelona, Spain, 

9 

RESCLE, Barcelona, Spain 

1480. The 15% Rule in Scleroderma: A Systematic Review of the 

Frequency of Organ Complications in Systemic Sclerosis. 

Chayawee Muangchan 1 , Murray Baron 2 , Janet E. Pope 3 

and Canadian Scleroderma Research Group 4 , 1 Mahidol 

University, Siriraj Hospital, Bangkok, Thailand, 2 Jewish 

General Hospital, Montreal, QC, 3 St. Joseph Health Care 

London, University of Western Ontario, London, ON, 

4 

Montreal, QC 

1481. A Double-Blind Placebo-Controlled Crossover Trial of 

the Alpha-2C Adrenoceptor Antagonist Orm-12741 for 

Prevention of Cold-Induced Vasospasm in Patients with 

Systemic Sclerosis. Ariane Herrick 1 , Andrea Murray 2 , 

Angela Ruck 3 , Juha Rouru 4 , Tonia Moore 2 , John Whiteside 3 , 

Pasi Hakulinen 4 , Fredrick M. Wigley 5 and Amir Snapir 4 , 

1 

University of Manchester, Salford, United Kingdom, 2 School 

of Translational Medicine, University of Manchester, 

Manchester Academic Health Science Centre, Salford Royal 

NHS Foundation Trust, Manchester, United Kingdom, 3 Orion 

Pharma UK, Research & Development, Nottingham, United 

Kingdom, 4 Orion Corporation Orion Pharma, Turku, Finland, 

5 


1482. Laser Speckle Contrast Imaging May Help in the Differential 

Diagnosis of Raynaud’s Phenomenon. Alessandra Della 

Rossa 1 , Massimiliano Cazzato 1 , Walter Bencivelli 1 , Anna 

d’Ascanio 2 , Marta Mosca 1 and Stefano Bombardieri 1 , 

1Rheumatology Unit, Pisa, Italy, 2 Rheumatology Unit, 

University of Pisa, Pisa, Italy 

1483. Predictors of Digital Ulcers in Systemic Sclerosis: 

Correlation between Clinical and Hemodynamic Features, 

Capillaroscopy, Endothelium Dysfunction and Angiogenesis 

Biomarkers. Ivone Silva 1 , Isabel Almeida 1 , António Marinho 2 

and Carlos Vasconcelos 3 , 1 Raynaud Clinics, Porto, Portugal, 

2 

Unidade de Imunologia Clínica, Porto, Portugal, 3 Hospital 

Geral Santo Antonio, Porto, Portugal 

1484. Investigating Determinants of Subjective and Objective 

Assessments of Peripheral Vascular Function in Primary 

Raynaud’s Phenomenon and Systemic Sclerosis. John D. 

Pauling, Jacqueline A. Shipley, Nigel Harris and Neil McHugh, 

Royal National Hospital for Rheumatic Diseases, Bath, 


1485. Patients with Very Early Diagnosis of Systemic Sclerosis 

(VEDOSS) Present Esophageal and Anorectal Involvement: 

Data from a Single Centre. Gemma Lepri 1 , Silvia Bellando- 

Randone 2 , Serena Guiducci 1 , Iacopo Giani 3 , Cosimo Bruni 1 , 

Giulia Carnesecchi 4 , Jelena Blagojevic 2 , Alessandra Radicati 2 , 

Filippo Pucciani 5 and Marco Matucci Cerinic 1 , 1 Department 

of Biomedicine, Division of Rheumatology AOUC, Excellence 

Centre for Research, Florence, Italy, 2 University of Florence, 

Florence, Italy, 3 General Surgery, ASL 8 , Arezzo, Italy, Arezzo, 

Italy, 4 Department of Internal Medicine, Rheumatology 



Section, University of Florence, Florence, Italy, 5 General 

and Urgency Surgery, University of Florence, Florence, Italy, 

Florence, Italy 

1486. Poor Outcome in Patients with Systemic Sclerosis and 

Myocardial Involvement: A Combined Approach Based On 

Clinical and Laboratory Findings, EKG-Holter and Cardiac 

Magnetic Resonance. Silvia Laura Bosello, Giacomo De Luca, 

Antonella Laria, Giorgia Berardi and Gianfranco Ferraccioli, 

Division of Rheumatology, Institute of Rheumatology and 

Affine Sciences, Catholic University of the Sacred Heart, 

Rome, Italy 

1487. Incidence of Fibromyalgia Syndrome in Systemic Sclerosis 

and Rheumatoid Arthritis. Comparative Results According 

to Clinical Diagnosis, Screening Test with Fibromyalgia Rapid 

Screening Tool, Diagnosis with ACR1990 and ACR 2010 

Criteria. Serge Perrot 1 , Mariana Peixoto 2 , Philippe Dieude 3 , 

Eric Hachulla 4 , Sébastien Ottaviani 5 and Yannick Allanore 6 , 

1 

Hopital Hotel Dieu, Paris, France, 2 Cochin Hospital, Paris, 

France, 3 APHP, Hopital Bichat, Paris, France, 4 Department of 

Internal Medicine, Claude Huriez Hospital, University of Lille, 

Lille CEDEX, France, 5 APHP, Paris, France, 6 Paris Descartes 

University, Rheumatology A department, Cochin Hospital, 

Paris, France 

1488. Prevalence and Risk Factors of Low Bone Mineral Density 

in Chinese Patients with Systemic Sclerosis: A Case-Control 

Study. Chi Chiu Mok, Pak To Chan, Kar Li Chan, Ling Yin Ho 

and Chi Hung To, Tuen Mun Hospital, Hong Kong, Hong Kong 

1489. Peripheral Neuropathy: A Complication of Systemic 

Sclerosis. Melissa Reily 1 , Tracy M. Frech 2 , Maureen 

Murtaugh 2 , Jason Penrod 3 and Barry M. Stults 4 , 1 University 

of Utah, Salt Lake City, UT, 2 University of Utah School of 

Medicine, SLC, UT, 3 University of Utah, Salt Lake City, 4 Salt 

Lake City Veterans Affairs Medical Center and University of 

Utah, Salt Lake City, UT 


Pathogenesis, Animal Models and Genetics 

1490. Dysregulation of Angiogenic Homeostasis in Systemic 

Sclerosis. Naglaa Y. Assaf 1 , Hanan M. Farouk 2 and Iman 

M. Aly 1 , 1 Faculty of Medicine, Ain-Shams University, Cairo, 

Egypt, 2 Ain-Shams University, Cairo, Egypt 

1491. Systemic Sclerosis – Effects of Agonistic Autoantibodies 

Directed Against the Angiotensin Receptor Type 1 and the 

Endothelin Receptor Type A On Effector Cells. Jeannine 

Guenther 1 , Angela Kill 2 , Mike O. Becker 3 and Gabriela 

Riemekasten 4 , 1 Charite University Hosptial, Berlin, Germany, 

2 

Charité University Hospital and German Rheumatism 

Research Centre, a Leibniz Institute, Berlin, Germany, 

3 

Charité University Hospital, Berlin, Germany, 4 Charité 

University Hospital, German Rheumatology Research Center, 

a Leibniz Institute, Berlin, Germany 

1492. IL-13 Receptors and Signaling in the Dermal Fibroblasts 

From Patients with Systemic Sclerosis. Yuko Ota 1 , Yasushi 

Kawaguchi 1 , Atsushi Kitani 2 , Kae Takagi 1 , Hisae Ichida 1 , 

Yasuhiro Katsumata 1 , Takahisa Gono 1 , Masanori Hanaoka 1 , 

Yuko Okamoto 1 and Hisashi Yamanaka 1 , 1 Institute of 


Japan, 2 Mucosal Immunity Section, NIAID/NIH, Bethesda, 

MD 

1493. Transforming Growth Factor-β and Endothelin-1 Induce 

Endothelial-to-Mesenchymal Transition in Cultured Human 

Endothelial Cells. Stefano Soldano 1 , Paola Montagna 1 , 

Renata Brizzolara 1 , Barbara Villaggio 2 , Alberto Sulli 3 and 

Maurizio Cutolo 1 , 1 Research Laboratory and Academic Unit 

of Clinical Rheumatology, Department of Internal Medicine, 

University of Genova, Genova, Italy, Genova, Italy, 2 Research 

Laboratory of Nephrology, Department of Internal Medicine, 

University of Genova, Genova, Italy, 3 Research Laboratory 

and Academic Unit of Clinical Rheumatology, Department of 

Internal Medicine, University of Genova, Genova, Italy 

1494. CD40 Signaling Results in Microvascular Endothelial 

Dysfunction: A Possible Clue to the Pathogenesis of 

Scleroderma Vasculopathy. Bashar Kahaleh and Yongqing 

Wang, University of Toledo, Toledo, OH 

1495. Platelet Aggregability, Eicosanoid Biosynthesis and 

Oxidative Stress in Primary Raynaud’s Phenomenon and 

Systemic Sclerosis. John D. Pauling and Neil McHugh, Royal 

National Hospital for Rheumatic Diseases, Bath, United 

Kingdom 

1496. Downregulated Expression of Metallothionein Genes in 

Response to the Gadolinium Contrast Agent Omniscan in 

Normal Human Differentiated Macrophages and Dermal 

Fibroblasts. Peter J. Wermuth 1 , Francesco Del Galdo 2 , 

Sankar Addya 3 , Paolo Fortina 3 and Sergio A. Jimenez 1 , 

1 

Jefferson Institute of Molecular Medicine, Division of 

Connective Tissue Diseases and Scleroderma Center,Thomas 

Jefferson University, Philadelphia, PA, 2 University of Leeds, 

Leeds Institute of Molecular Medicine and LMBRU, Leeds, 

United Kingdom, 3 Kimmel Cancer Center, Thomas Jefferson 


1497. Activation of Sirt1 Attenuates Bleomycin Induced 

Scleroderma Through Inhibiting Mammalian Target of 

Rapamycin Activation. Xiaoxia Zhu 1 , Jianhua Qiu 2 , Qiong 

Liu 3 , Minrui Liang 4 and Hejian Zou 5 , 1 Huashan Hospital, 

Fudan University, Shanghai, China, 2 Neuroscience Center, 

Massachusetts General Hospital, Harvard Medical 

School, Massachusetts, USA, Boston, MA, 3 Institute of 

Rheumatology, Immunology and Allergy,Shanghai Medical 

College, Fudan University, Shanghai, China, 4 Huashan 

Hospital,Fudan University,Shanghai, Shanghai, China, 

5 

Huashan Hospital, Shanghai, China 

1498. Wisp-1 Neutralization Reduces Gvhd-Induced Skin Fibrosis 

by Altering TSLP-OX40L Axis-Dependent Th2 Responses. 

Raphael Lemaire, Tim Burwell, Rachel Griffin, Julie Bakken, 

Joseph Madary, Lynne Murray, Ronald Herbst and Jane 

Connor, MedImmune LLC, Gaithersburg, MD 

250 

2012 Program Book


1499. The Soluble Guanylate Cyclase Mediates Its Anti-Fibrotic 

Effects by Inhibiting TGF-β Signaling. Christian Beyer 1 , Sonia 

C. Schindler 2 , Alfiya Distler 1 , Clara Dees 1 , Helena Reichert 2 , 

Hümeyra Akan 2 , Peter Sandner 3 , Oliver Distler 4 , Georg 

Schett 5 and Joerg HW Distler 6 , 1 Department of Internal 

Medicine 3 and Institute for Clinical Immunology, University 

of Erlangen-Nuremberg, Erlangen, Germany, 2 University of 

Erlangen-Nuremberg, Erlangen, Germany, 3 Bayer Health 

Care, Global Drug Discovery – Common Mechanism 

Research, Wuppertal, Germany, 4 University Hospital Zurich, 

Zurich, Switzerland, 5 Institute for Clinical Immunology, 


6 

Department of Internal Medicine III and Institute for Clinical 


Germany 

1500. Activation of Pregnane X Receptor Induces Regression 

of Experimental Dermal Fibrosis. Christian Beyer 1 , Alla 

Skapenko 2 , Alfiya Distler 1 , Clara Dees 1 , Helena Reichert 3 , 

Louis E. Munoz 1 , Jan Leipe 4 , Hendrik Schulze-Koops 2 , Oliver 

Distler 5 , Georg Schett 6 and Joerg HW Distler 7 , 1 Department 

of Internal Medicine 3 and Institute for Clinical Immunology, 


2 

University of Munich, Munich, Germany, 3 University of 

Erlangen-Nuremberg, Erlangen, Germany, 4 Division of 

Rheumatology and Clinical Immunology, Munich, Germany, 

5 

University Hospital Zurich, Zurich, Switzerland, 6 Institute 


Erlangen, Germany, 7 Department of Internal Medicine 

III and Institute for Clinical Immunology, University of 


1501. Increased Periostin Levels in Patients with Systemic 

Sclerosis. Yukie Yamaguchi 1 , Junya Ono 2 , Miho Masuoka 3 , 

Shoichiro Ohta 4 , Kenji Izuhara 3 , Zenro Ikezawa 5 , Michiko 

Aihara 1 and Kazuo Takahashi 1 , 1 Yokohama City University 

Graduate School of Medicine, Yokohama, Japan, 2 Shino-Test 

Corporation, Sagamihara, Japan, 3 Saga Medical School, Saga, 

Japan, 4 Saga medical School, Saga, Japan, 5 International 

University of Health and Welfare Atami Hospital, Atami, 

Japan 

1502. Hedgehog Signaling in Murine Chronic Sclerodermatous 

Graft-Versus-Host Disease. Pawel Zerr 1 , Katrin Palumbo- 

Zerr 1 , Alfiya Distler 1 , Michal Tomcik 2 , Stefan Vollath 1 , 

Louis E. Munoz 1 , Christian Beyer 1 , Clara Dees 1 , Friederike 

Egberts 3 , Ilaria Tinazzi 4 , Francesco Del Galdo 4 , Oliver Distler 5 , 

Georg Schett 1 , Bernd M. Spriewald 6 and Joerg HW Distler 7 , 

1 

Department of Internal Medicine 3 and Institute for Clinical 


Germany, 2 Institute of Rheumatology, Department of 

Rheumatology, 1 st Faculty of Medicine, Charles University, 

Prague 2 , Czech Republic, 3 Department of Dermatology, 

Schleswig-Holstein University Hospital, Campus Kiel, Kiel, 

Germany, 4 Scleroderma Research Program, Leeds Institute 

of Molecular Medicine, Division of Musculoskeletal 

Diseases, University of Leeds, Leeds, United Kingdom, 

5 

Center of Experimental Rheumatology and Zurich Center 

of Integrative Human Physiology, University Hospital Zurich, 

Zurich, Switzerland, 6 Department of Internal Medicine V, 


7 

Department of Internal Medicine III and Institute for Clinical 


Germany 

1503. Effect of Thiol Antioxidants On the Profibrotic Phenotype 

of Scleroderma Dermal Fibroblasts. Pei-Suen Tsou 1 , Beatrix 

Balogh 1 , Adam J. Pinney 1 , Elena Schiopu 1 , Dinesh Khanna 2 

and Alisa E. Koch 1 , 1 University of Michigan Medical School, 

Ann Arbor, MI, 2 University of Michigan, Ann Arbor, MI 

1504. A Possible Contribution of Visfatin to the Resolution of 

Skin Sclerosis in Patients with Diffuse Cutaneous Systemic 

Sclerosis Via a Direct Anti-Fibrotic Effect On Dermal 

Fibroblasts and Th1 Polarization of the Immune Response. 

Tetsuo Toyama, Yoshihide Asano, Yuri Masui, Sayaka Shibata, 

Kaname Akamata, Shinji Noda, Naohiko Aozasa, Takashi 

Taniguchi, Takehiro Takahashi, Yohei Ichimura, Hayakazu 

Sumida, Koichi Yanaba, Takafumi Kadono and Shinichi Sato, 

University of Tokyo Graduate School of Medicine, Tokyo, 

Japan 

1505. Inactivation of Tankyrases Ameliorates Canonical Wnt 

Signaling and Prevents Experimental Fibrosis. Alfiya 

Distler 1 , Lisa Deloch 2 , Jingang Huang 2 , Clara Dees 1 , Neng Yu 

Lin 2 , Christian Beyer 1 , Oliver Distler 3 , Georg A. Schett 4 and 

Joerg HW Distler 4 , 1 Department of Internal Medicine 3 and 


Nuremberg, Erlangen, Germany, 2 University of Erlangen- 

Nuremberg, Erlangen, Germany, 3 University Hospital Zurich, 

Zurich, Switzerland, 4 Department of Internal Medicine 



1506. Primary Human Scleroderma Dermal Endothelial Cells 

Exhibit Defective Angiogenesis. Pei-Suen Tsou 1 , Bradley 

J. Rabquer 1 , Beatrix Balogh 1 , Ann Kendzicky 1 , Bashar 

Kahaleh 2 , Elena Schiopu 1 , Dinesh Khanna 3 and Alisa E. Koch 1 , 

1 

University of Michigan Medical School, Ann Arbor, MI, 

2 

University of Toledo, Toledo, OH, 3 University of Michigan, 

Ann Arbor, MI 

1507. Propylthiouracil Reduces Fibrosis in Chronic Oxidant 

Stress Mouse Model of Scleroderma. Gianluca Bagnato 1 , 

Alessandra Bitto 1 , Natasha Irrera 1 , Gabriele Pizzino 1 , Neal 

Roberts 2 , Maurizio Cinquegrani 1 , Donatella Sangari 1 , 

Francesco Squadrito 1 , Gianfilippo Bagnato 1 and Antonino 

Saitta 1 , 1 University of Messina, Messina, Italy, 2 Medical 

College of Virginia, Richmond, VA 

1508. Simvastatin Attenuates Pulmonary Fibrosis in a Murine 

Model of Systemic Sclerosis. Gianluca Bagnato 1 , Alessandra 

Bitto 1 , Natasha Irrera 1 , Gabriele Pizzino 1 , Donatella Sangari 1 , 

Maurizio Cinquegrani 1 , Neal Roberts 2 , Gianfilippo Bagnato 1 , 

Francesco Squadrito 1 and Antonino Saitta 1 , 1 University 

of Messina, Messina, Italy, 2 Medical College of Virginia, 

Richmond, VA 



252 

1509. Correlates of Skin Gene Expression Profile in Systemic 

Sclerosis. Shervin Assassi 1 , Jeffrey T. Chang 1 , Filemon K. 

Tan 1 , Minghua Wu 1 , Gloria A. Salazar Cintora 1 , Irum Zaheer 2 , 

Dinesh Khanna 3 , Daniel E. Furst 4 and Maureen D. Mayes 1 , 

1 

Univ of Texas Health Science at Houston, Houston, TX, 

2 

Methodist Hospital, Houston, TX, 3 University of Michigan, 

Ann Arbor, MI, 4 UCLA Medical School, Los Angeles, CA 

1510. Critical Role of the Adhesion Receptor Dnax Accessory 

Molecule-1 (DNAM-1) in the Development of 

Inflammation-Driven Dermal Fibrosis in Mouse Model 

of Systemic Sclerosis. Jerome Avouac 1 , Muriel Elhai 2 , 

Michal Tomcik 3 , Manuel Friese 4 , Marco Colonna 5 , Günter 

Bernhardt 6 , andre Kahan 1 , Gilles Chiocchia 7 , Joerg HW 

Distler 8 and Yannick Allanore 1 , 1 Paris Descartes University, 

Rheumatology A department, Cochin Hospital, Paris, 

France, 2 Paris Descartes University, INSERM U10 16 , Institut 

Cochin, Sorbonne Paris Cité, Paris, France, 3 Institute 

of Rheumatology, Department of Rheumatology, 1 st 

Faculty of Medicine, Charles University, Prague 2 , Czech 

Republic, 4 Zentrum für Molekulare Neurobiologie, 

Universitätsklinikum Hamburg-Eppendorf, Hamburg, 

Germany, 5 Department of Immunology, St. Louis, MO, 

6 

Institute of Immunology, Hannover Medical School, 

Hannover, Germany, 7 Institut Cochin - INSERM U1016 - 

CNRS (UMR 8104), Paris, France, 8 Department of Internal 

Medicine III and Institute for Clinical Immunology, University 

of Erlangen-Nuremberg, Erlangen, Germany 

1511. Low Circulating Endothelial Progenitor Cell Levels and High 

VEGF Serum Levels Are Associated with the Late Nailfold 

Capillaroscopic Pattern in Systemic Sclerosis. Jerome 

Avouac 1 , Maeva Vallucci 2 , Vanessa Smith 3 , Barbara Ruiz 2 , 

Alberto Sulli 4 , Carmen Pizzorni 4 , Gilles Chiocchia 5 , Maurizio 

Cutolo 4 and Yannick Allanore 1 , 1 Paris Descartes University, 

Rheumatology A department, Cochin Hospital, Paris, 

France, 2 Paris Descartes University, INSERM U1016, Institut 

Cochin, Sorbonne Paris Cité, Paris, France, 3 Department of 

Rheumatology, Ghent University Hospital, Ghent, Belgium, 

4 

Research Laboratory and Academic Unit of Clinical 

Rheumatology, Department of Internal Medicine, University 

of Genova, Genova, Italy, 5 Institut Cochin - INSERM U1016 - 

CNRS (UMR 8104), Paris, France 

1512. Bleomycin Delivery by Osmotic Pump: A Superior Model 

for Human ILD. Rebecca Lee, Michael Bonner, Charles 

Reese, Elena Tourkina, Zoltan Hajdu, Jing Zhang, Richard 

Visconti and Stanley Hoffman, Medical University of South 

Carolina, Charleston, SC 

1513. TSLP Receptor Deficiency Reduces IL-13 Expression and 

Prevents Fibrosis in Experimental Scleroderma. Alicia 

Usategui 1 , Vanessa Miranda 1 , Gabriel Criado 1 , Manuel J. 

Del Rey 1 , Elena Izquierdo 1 , Warren J. Leonard 2 and Jose L. 

Pablos 1 , 1 Instituto de Investigación Hospital 12 de Octubre 

(I+12), Madrid, Spain, 2 National Heart, Lung, and Blood 

Institute, National Institutes of Health, Bethesda, MD 


1514. Differences in the Activation Levels and Expression 

Patterns of the Molecular Targets of Tyrosine Kinase 

Inhibitors May Account for the Heterogeneous Treatment 

Responses. Britta Maurer 1 , Alfiya Akhmetshina 2 , Renate E. 

Gay 1 , Beat A. Michel 1 , Steffen Gay 3 , Joerg H. W. Distler 2 and 

Oliver Distler 1 , 1 Department of Rheumatology and Center 

of Experimental Rheumatology, University Hospital Zurich, 

Zurich, Switzerland, 2 Department of Internal Medicine 


Erlangen-Nuremberg, Erlangen, Germany, 3 Center of 



Switzerland, Zurich, Switzerland 

1515. Pharmacological Blockade of Adenosine A2A Receptors 

(A2AR) Prevents Radiation-Induced Dermal Injury. Miguel 

Perez Aso 1 , Yee C. Low 2 , Obinna Ezeamuzie 2 , Jamie Levine 2 

and Bruce N. Cronstein 3 , 1 NYU School of Medicine, New 

York, NY, 2 New York Univ Medical Center, New York, NY, 3 NYU 

School of Medicine, Division of Rheumatology, New York, NY 

1516. TSLP Upregulation in Human SSc Skin and Induction of 

Overlapping Profibrotic Genes and Intracellular Signaling 

with IL-13 and TGFb. Romy Christmann, Allison Mathes, 

Giuseppina Stifano, Alsya J. Affandi, andreea Bujor, Cristina 

Padilla and Robert Lafyatis, Boston University, Boston, MA 

1517. TLR9 Signaling in Fibroblasts Promotes Pro-Fibrotic 

Responses Via TGF-Beta. Yang Yang 1 , Feng Fang 2 , Lei Liu 1 , 

Junjie Shangguan 2 , Boping Ye 1 and John Varga 2 , 1 China 

Pharmaceutical University, Nanjing, China, 2 Northwestern 


1518. Damage-Associated Endogenous TLR4 Ligand Fibronectin- 

EDA Is Overexpressed in Scleroderma and Drives Persistent 

Fibrosis Via TLR 4 and Inhibition of TLR4 Prevents and 

Reverses Experimental Dermal Fibrosis: Novel Target 

for Scleroderma Therapy. Swati Bhattacharyya 1 , Zenshiro 

Tamaki 2 , Wenxia Wang 3 , Paul Hoover 3 , Adam Booth 4 , Alyssa 

Dreffs 5 , Monique E. Hinchcliff 6 , Feng Fang 3 , Spiro Getsios 3 , 

Hang Yin 7 , Eric S. White 5 and John Varga 8 , 1 Northwestern 

University, Feinberg School of Medicine, Chicago, IL, 

2 

Northwestern Univ Med School, Chicago, IL, Chicago, 

IL, 3 Northwestern University, Chicago, IL, 4 Ann Arbor, MI, 

5 

University of Michigan Medical School, Ann Arbor, MI, 

6 

Northwestern Univ Med School, Chicago, IL, 7 University of 

Colorado at Boulder, Boulder, CO, 8 Northwestern University 

Medical School, Chicago, IL 

1519. Heterogeneous Nuclear RNP-K Is a Novel Cold-Related 

Autoantigen in Patients with Raynaud’s Phenomenon. 

Satoshi Serada, Minoru Fujimoto and Tetsuji Naka, National 

Institute of Biomedical Innovation, Ibaraki, Japan 

1520. Role of 12/15-Lipoxygenase (LOX) in Patients with Systemic 

Sclerosis. Hirahito Endo, Makoto Kabraki, Koutarou Shikano, 

Sei Muraoka, Nahoko Tanaka, Tatsuhiro Yamamoto, Kanako 

Kitahara, Kaichi Kaneko, Yoshie Kusunoki, Natsuko Kusunoki, 

Kenji Takagi, Tomoko Hasunuma and Shinichi Kawai, School 

of Medicine, Faculty of Medicine, Toho University, Tokyo, 

Japan


1521. A Possible Contribution of Decreased Cathepsin V 

Expression to the Development of Dermal Fibrosis, 

Proliferative Vasculopathy, and Altered Keratinocyte 

Phenotype in Systemic Sclerosis. Yoshihide Asano, Shinji 

Noda, Takehiro Takahashi, Sayaka Shibata, Kaname Akamata, 

Naohiko Aozasa, Takashi Taniguchi, Yohei Ichimura, Tetsuo 

Toyama, Hayakazu Sumida, Yoshihiro Kuwano, Koichi Yanaba 

and Shinichi Sato, University of Tokyo Graduate School of 


1522. Differential Response to Endoplasmic Reticulum Stress 

between Alveolar Epithelial Cells and Lung Fibroblasts 

in Systemic Sclerosis. Jun Liang 1 , Tanjina Akter 1 , Ilia 

Atanelishvili 1 , Richard M. Silver 2 and Galina S. Bogatkevich 1 , 

1 

Medical University of SC, Charleston, SC, 2 Medical 

University of SC, Charleston 

Vasculitis 

1523. Systemic Vasculitis and Pregnancy: a Multicenter 

Study on Maternal and Neonatal Outcome of 43 

Prospectively Followed Pregnancies. Micaela Fredi 1 , 

Maria Grazia Lazzaroni 1 , Chiari Tani 2 , Véronique Ramoni 3 , 

Maria Gerosa 4 , Flora Inverardi 5 , Laura andreoli 1 , Laura 

Trespidi 6 , Mario Motta 7 , Andrea Lojacono 8 , Renato Sinico 9 , 

Antonio Brucato 10 , Roberto Caporali 5 , Pier Luigi Meroni 4 , 

Carlomaurizio Montecucco 5 , Marta Mosca 2 and Angela 

Tincani 1 , 1Rheumatology Unit, University of Brescia, 

Brescia, Italy, 2 Rheumatology Unit, Internal Medicine, 

University of Pisa, Pisa, Italy, 3 IRCCS Policlinico San Matteo 

Foundation and University of Pavia and USC Internal 

Medicine, Bergamo, Italy, 4 Division of Rheumatology, 

Istituto Ortopedico Gaetano Pini, Department of Clinical 

Sciences and Community Health, University of Milan, 

Milan, Italy, 5 Division of Rheumatology, IRCCS Policlinico 

San Matteo Foundation and University of Pavia, Pavia, Italy, 

6 

Milan, 7 Neonathology and NICU, Spedali Civili, Brescia, 

Italy, 8 Obstetric and Gynecology of Brescia, Brescia, Italy, 

9 

Ospedale San Carlo Borromeo, Milano, Italy, 10 USC Internal 

Medicine, Ospedali Riuniti, Bergamo, Italy 

1524. The Use of the International Classification of Function, 

Disability and Health As a Conceptual Framework for 

Comparison of the Content of Core Outcome Instruments 

with the Patient Perspective in Vasculitis. Nataliya Milman 1 , 

Peter A. Merkel 2 , Annelies Boonen 3 , Lee Strunin 4 , Ryan Borg 4 

and Peter Tugwell 5 , 1 Ottawa Hospital, Riverside Campus, 

Ottawa, ON, 2 University of Pennsylvania, Philadelphia, PA, 

3 

University Hospital Maastricht, Maastricht, Netherlands, 

4 

Boston University School of Public Health, Boston, MA, 

5 

University of Ottawa, Ottawa General Hospital, Ottawa, ON 

1525. Determinants of Poor Quality of Life in ANCA Associated 

Vasculitis (AAV). Neil Basu 1 , Andrew McClean 2 , Raashid 

Luqmani 3 , Lorraine Harper 2 , Oliver Flossmann 4 , David Jayne 5 , 

Mark Little 6 , Esther N. Amft 7 , Neeraj Dhaun 8 , John McLaren 9 , 

Vinod Kumar 10 , Lars Erwig 1 , Gareth T. Jones 1 , David M. 

Reid 1 and Gary J. Macfarlane 1 , 1 University of Aberdeen, 

Aberdeen, United Kingdom, 2 University of Birmingham, 

Birmingham, United Kingdom, 3 University of Oxford, Oxford, 

United Kingdom, 4 Royal Berkshire Hospital, Reading, United 

Kingdom, 5 Addenbrookes Hospital University of Cambridge, 

Cambridge, United Kingdom, 6 Trinity College Dublin, Dublin, 

Ireland, 7 Western General Hospital, Edinburgh, United 

Kingdom, 8 Edinburgh Royal Infirmary, Edinburgh, United 

Kingdom, 9 NHS Fife, Whyteman’s Brae Hospital, Kirkcaldy, 

United Kingdom, 10 Ninewells Hospital, Dundee, United 

Kingdom 

1526. Patient Reported Outcomes in ANCA-Associated Vasculitis. 

A Prospective Comparison Between Birmingham Vasculitis 

Activity Score and Routine Assessment of Patient Index Data 

3. Osama ElSallabi, Joel A. Block and Antoine Sreih, Rush 

University Medical Center, Chicago, IL 

1527. Patient Global Assessments for Disease Activity Are 

Predictive of Future Flare in Granulomatosis with 

Polyangiitis (Wegener’s). Gunnar Tomasson 1 , John C. Davis 

Jr. 2 , Gary S. Hoffman 3 , W. Joseph McCune 4 , Ulrich Specks 5 , 

Robert F. Spiera 6 , E. William St. Clair 7 , John H. Stone 8 and 

Peter A. Merkel 9 , 1 University of Iceland, Reykjavik, Iceland, 

2 

Genentech, Inc, South San Francisco, CA, 3 Cleveland Clinic, 

Cleveland, OH, 4 University of Michigan, Ann Arbor, MI, 

5 

Mayo Clinic, Rochester, MN, 6 Hospital for Special Surgery, 

New York, NY, 7 Duke University Medical Center, Durham, NC, 

8 

Massachusetts General Hospital, Boston, MA, 9 University of 


1528. Assessing Fatigue in Systemic Vasculitis from the Patient’s 

Perspective. Peter C. Grayson 1 , Naomi Amudala 1 , Carol 

McAlear 2 , Renée Leduc 3 , Denise Shereff 3 , Rachel Richesson 3 , 

Liana Fraenkel 4 and Peter A. Merkel 5 , 1 Boston University 

Medical Center, Boston, MA, 2 Vasculitis Clinical Research 

Consortium, University of Pennsylvania, Philadelphia, 

3 

University of South Florida, Tampa, FL, 4 Yale University 

School of Medicine, Veterans Affairs Connecticut Healthcare 

System, New Haven, CT, 5 University of Pennsylvania, 


1529. Upper Airway Gene Expression Profiling in Granulomatosis 

with Polyangiitis. Peter C. Grayson 1 , Katrina Steiling 1 , Paul 

A. Monach 2 , Ji Xiao 3 , Xiaohui Zhang 1 , Yuriy Alekseyev 1 , 

Stephano Monti 3 , Avrum Spira 1 and Peter A. Merkel 4 , 

1 

Boston University Medical Center, Boston, MA, 2 Boston 

University, Boston, MA, 3 Boston University Medial Center, 

Boston, MA, 4 University of Pennsylvania, Philadelphia, PA 

1530. Plasma Cell Analysis As a Biomarker for Disease Activity 

in Patients with Granulomatosis with Polyangiitis. Bimba 

F. Hoyer 1 , Adriano Taddeo 2 , Maika Rothkegel 2 , Gerd 

R. Burmester 3 , Andreas H. Radbruch 2 and Falk Hiepe 4 , 

1 

Charite University Hospital, Berlin, Germany, 2 Deutsches 

Rheumaforschungszentrum, Berlin, Germany, 3 Charité 

– University Medicine Berlin, Berlin, Germany, 4 Charité 

University Hospital Berlin, Berlin, Germany 

1531. Comparative Proteomic Analysis of Neutrophils between 

Microscopic Polyangiitis and Granulomatosis with 

Polyangiitis. Teisuke Uchida 1 , Kouhei Nagai 2 , Toshiyuki Sato 1 , 



Mitsumi Arito 1 , Nobuko Iizuka, Manae Kurokawa 1 , Naoya 

Suematsu 2 , Kazuki Okamoto 2 , Shoichi Ozaki 4 and Tomohiro 

Kato 2 , 1 Clinical Proteomics and Molecular Medicine, 

St. Marianna University Graduate School of Medicine,, 

Kawasaki, Japan, 2 St. Mariannna University Graduate School 

of Medicine., Kawasaki, Japan, 3 St. Marianna University 

School of Medicine., Kawasaki, Japan 

1532. Serum Angiopoietin-2 Level Reflects the Disease Activity 

and Renal Function in Antineutrophilic Cytoplasmic 

Antibody-Associated Vasculitis. Yoko Wada 1 , Hiroe Sato 1 , 

Takeshi Nakatsue 1 , Shuichi Murakami 1 , Takeshi Kuroda 2 , 

Masaaki Nakano 3 and Ichiei Narita 1 , 1 Niigata University 

Graduate School of Medical and Dental Sciences, Niigata, 

Japan, 2 Niigata University, Niigata, Japan, 3 School of Health 

Sciences, Faculty of Medicine, Niigata University, Niigata, 

Japan 

1533. Increased Circulating FoxP3+ T-Cells in Patients with 

Granulomatosis with Polyangiitis Are Attributed to an 

Increase in the Non-Suppressor FoxP3Low CD45RO+ 

TReg Cell Subpopulation. Wayel H. Abdulahad 1 , Coen A. 

Stegeman 1 , Minke G. Huitema 1 , Abraham Rutgers 1 , Peter 

Heeringa 2 , Pieter C. Limburg 1 and Cees G.M. Kallenberg 1 , 

1 


Netherlands, 2 University Medical Center Groningen, 

Netherlands 

1534. IgG4 Plasma Cell Infiltration in Granulomatosis with 

Polyangiitis (formerly Wegener’s) Lung Biopsies. Mollie 

Carruthers, Shweta Shinagare, Arezou Khosroshahi, Vikram 

Deshpande and John H. Stone, Massachusetts General 

Hospital, Boston, MA 

1535. Genetic Background of Antineutrophil Cytoplasmic 

Antibody-Associated Vasculitis in a Japanese Population: 

Association of STAT4 with Myeloperoxidase Antineutrophil 

Cytoplasmic Antibody-Positive Vasculitis. Aya Kawasaki 1 , 

Naoya Inoue 1 , Chihiro Ajimi 1 , Ikue Ito 1 , Ken-ei Sada 2 , Shigeto 

Kobayashi 3 , Hidehiro Yamada 4 , Hiroshi Furukawa 5 , Makoto 

Tomita 6 , Takayuki Sumida 1 , Shigeto Tohma 5 , Nobuyuki 

Miyasaka 6 , Shoichi Ozaki 4 , Hiroshi Hashimoto 7 , Hiroshi 

Makino 2 , Masayoshi Harigai 6 and Naoyuki Tsuchiya 1 , 

1 

University of Tsukuba, Tsukuba, Japan, 2 Okayama 

University, Okayama, Japan, 3 Juntendo University Koshigaya 

Hospital, Tokyo, Japan, 4 St. Marianna University, Kawasaki, 

Japan, 5 Sagamihara National Hospital, National Hospital 

Organization, Sagamihara, Japan, 6 Tokyo Medical and Dental 

University, Tokyo, Japan, 7 Juntendo University School of 


1536. Clinical Features of Patients with Anti-Neutrophil 

Cytoplasmic Autoantibodies Targeting Native 

Myeloperoxidase Antigen. Yuji Yamanishi 1 , Toshiko 

Ito-Ihara 2 , Shigeto Kobayashi 3 , Peter Y. Shane 4 , Gary S. 

Firestein 5 , Hiroshi Hashimoto 6 and Kazuo Suzuki 7 , 1 Hiroshima 

Rheumatology Clinic, Hiroshima, Japan, 2 Kyoto University 

Hospital, Kyoto, Japan, 3 Juntendo University Koshigaya 

Hospital, Tokyo, Japan, 4 Tokyo Medical and Dental 

University, Tokyo, Japan, 5 UCSD School of Medicine, La Jolla, 

CA, 6 Juntendo Tokyo Koto Geriatric Center, Tokyo, Japan, 

7 

National Institute of Infectious Diseases, Tokyo, Japan 

1537. Pathogenesis of Atherosclerosis in Granulomatosis 

Polyangiitis. Rula Hajj-Ali 1 , Roy L. Silverstein 2 , Gary 

S. Hoffman 3 and Carol A. Langford 4 , 1 Cleveland Clinic 

Foundation, Cleveland, OH, 2 Medical College of Wisconsin, 

Milwaukee, WI, 3 Cleveland Clinic Found A50, Cleveland, OH, 

4 

Cleveland Clinic, Cleveland, OH 

1538. ANCA-Associated Vasculitis in Hispanic Americans: 

An Unrecognized Severity. Ranadeep Mandhadi 1 , Fadi 

Aldaghlawi 2 , Asad Khan 2 , Vajiha Irshad 3 , Joel A. Block 2 and 

Antoine Sreih 2 , 1 Mount Sinai Hospital, Chicago, IL, 2 Rush 

University Medical Center, Chicago, IL, 3 Stroger Hospital of 

Cook County, Chicago, IL 

1539. Microscopic Polyangiitis: A Large Single Center Series. 

Leslie D. Wilke 1 , Guy P. Fiocco 2 and Marilyn Prince-Fiocco 3 , 

1 

Scott & White Memorial Center, Temple, TX, 2 Scott & White 

Clinic, Temple, TX, 3 Temple, TX 

1540. Practice Patterns in the Treatment of ANCA-Associated 

Vasculitis: Exploring Differences among Subspecialties at a 

Single Academic Medical Center. Lindsy J. Forbess 1 , Kenneth 

W. Griffin 2 and Robert F. Spiera 3 , 1 Cedars-Sinai Medical 

Center, Los Angeles, CA, 2 Weill Cornell Medical College, New 

York, NY, 3 Hospital for Special Surgery, New York, NY 

1541. Does Leflunomide Have a Place As Remission Maintenance 

Therapy in ANCA-Associated Vasculitis? A Bayesian 

Network Meta-Analysis with Hypothesis Driven Sensitivity 

Analyses to Adjust for Potential Biases. Glen S. Hazlewood 1 , 

Claudia Metzler 2 , George A. Tomlinson 1 , Wolfgang L. Gross 3 , 

Brian M. Feldman 4 , Loic Guillevin 5 and Christian Pagnoux 6 , 

1 

University of Toronto, Toronto, ON, 2 University of Lubeck, 

Bad Branstedy, Germany, 3 Medical University at Lubeck, 

Lubeck, Germany, 4 The Hospital for Sick Children, Toronto, 

ON, 5 Cochin University Hospital, Paris, France, 6 Mount Sinai 

Hospital, Toronto, ON 

1542. The Efficacy of Rituximab Vs Cyclophosphamide for 

Treatment of Renal Disease in ANCA-Associated Vasculitis: 

The RAVE Trial Geetha D, Fervenza FC for the RAVE-Itn 

Research Group. Duvuru Geetha 1 and Fernando Fervenza 2 , 

1 

Johns Hopkins University, Baltimore, MD, 2 Mayo Clinic, 

Rochester, MN 

1543. Rituximab for ANCA-Associated Vasculitis: A Meta-Analysis 

of Randomized Trials. Carolina Mejia 1 and Carlos J. Lozada 2 , 

1 

Mount Sinai Medical Center, Miami, FL, 2 University of 

Miami Miller School of Medicine, Miami, FL 

1544. Long-Term Outcome of Patients with Granulomatosis 

with Polyangiitis (Wegener’s) Treated with Rituximab. 

Lama Azar 1 , Jason Springer 1 , Meng Xu 1 , Tiffany M. Clark 1 , 

Carol A. Langford 2 and Gary S. Hoffman 1 , 1 Cleveland Clinic 

Foundation, Cleveland, OH, 2 Cleveland Clinic, Cleveland, OH 

1545. Long-Term Follow-up of 118 Polyarteritis Nodosa and 

Microscopic Polyangiitis without Poor-Prognosis Factors. 

254 

2012 Program Book


Maxime Samson 1 , Xavier Puechal 2 , Hervé Devilliers 3 , Camillo 

Ribi 4 , Pascal Cohen 5 , Boris Bienvenu 6 , Christian Pagnoux 7 , 

Luc Mouthon 8 , Loic Guillevin 9 and French Vasculitis Study 

Group FVSG 5 , 1 Hôpital Cochin, University Paris Descartes, 

Paris, France, 2 Hôpital Cochin, Paris, France, 3 CHU Dijon, 

Dijon, France, 4 Hôpital Universitaire Cantonal de Genève, 

Geneve, Switzerland, 5 Service de médecine interne, Centre 

de Références des Vascularites, Université Paris Descartes, 

APHP, Hôpital Cochin, 7 5005 Paris, France., Paris, France, 

6 

Division of Internal Medicine, Centre Hospitalier Régional 

Universitaire de Caen, Côte de Nacre, Caen, France, 7 Mount 

Sinai Hospital, Toronto, ON, 8 Hopital Cochim, Paris, France, 

9 

Division of Internal Medicine, Hôpital Cochin, University 

Paris Descartes, Paris, France 

1546. Rhinosinusits and Nasal Polyps in the Diagnosis and Follow 

up of Patients with Eosinophilic Granulomatosis with 

Polyangitis (ex-Churg Strauss Syndrome). Chiara Baldini 1 , 

Veronica Seccia 2 , Manuela Latorre 3 , Paolo Iannicelli 2 , 

Daniela Martini 1 , Francesco Ferro 1 , Nicoletta Luciano 1 , 

Antonio Tavoni 1 , Stefano Sellari Franceschini 2 and Stefano 

Bombardieri 1 , 1Rheumatology Unit, University of Pisa, 

Pisa, Italy, 2 Unit of Otorhinolaryngology, Department of 

Neuroscience, University of Pisa, Pisa, Italy, Pisa, Italy, 

3 

Pneumology Unit, Italy 

1547. A 4 Plus 2 Infusion Protocol of Rituximab Provides Long- 

Term Beneficial Effects in Patients with HCV-Associated 

Mixed Cryoglobulinemia with Membranoproliferative 

Nephritis and Severe Polyneuropathy. Dario Roccatello 1 , 

Savino Sciascia 2 , Simone Baldovino 1 and Daniela 

Rossi 1 , 1 Centro di Ricerche di Immunologia Clinica ed 

Immunopatologia e Documentazione su Malattie Rare 

(CMID), Università di Torino, Torino, Italy, 2 Lupus Research 

Unit, The Rayne Institute, Kings College London School of 

Medicine, London, United Kingdom 

1548. Cutaneous Vasculitis as a Paraneoplastic Syndrome. Javier 

Loricera, Vanesa Calvo-Rio, Francisco Ortiz Sanjuan, Marcos 

Antonio Gonzalez-Lopez, Hector Fernandez-Llaca, Javier 

Rueda-Gotor, Carmen Gonzalez-Vela, Cristina Mata-Arnaiz, 

Miguel A. Gonzalez-Gay and Ricardo Blanco, Hospital 


Spain 

1549. Sibling Relative Risk and Heritability of Kawasaki Disease: 

A Nationwide Population Study in Taiwan. I-Jun Chou 1 , 

Chang-Fu Kuo 2 , Jing-Long Huang 1 , Chang-Teng Wu 1 , Shao- 

Hsuan Hsia 1 and Hsiao-Chun Chang 1 , 1 Chang Gung Memorial 

Hospital, Taoyuan, Taiwan, 2 University of Nottingham, 

Nottingham, United Kingdom 

1550. Long-Term Outcomes of Patients with Reversible Cerebral 

Vasoconstriction Syndromes (RCVS). Seby John, Leonard H. 

Calabrese, Stewart Tepper, Mark Stillman, Ken Uchino and 

Rula Hajj-Ali, Cleveland Clinic Foundation, Cleveland, OH 

1551. Primary Angiitis of the Central Nervous System: 

Description of the First 52 Adult Patients Enrolled in the 

French COVAC’ Cohort. Hubert de Boysson 1 , Mathieu 

Zuber 2 , Olivier Naggara 3 , Jean-Philippe Neau 4 , Françoise 

Gray 5 , Marie-Germaine Bousser 6 , Isabelle Crassard 6 , 

Emmanuel Touze 7 , Pierre-Olivier Couraud 8 , Philippe 

Kerschen 9 , Catherine Oppenheim 3 , Olivier Detante 10 , 

Anthony Faivre 11 , Nicolas Gaillard 12 , Caroline Arquizan 13 , 

Boris Bienvenu 14 , Antoine Neel 15 , Loic Guillevin 1 , Christian 

Pagnoux 16 and French Vasculitis Study Group and 

NeuroVascular Society 17 , 1 Division of Internal Medicine, 

Hôpital Cochin, University Paris Descartes, Paris, 

France, 2 Department of Neurology, Groupe Hospitalier 

Saint-Joseph, Université Paris Descartes, Paris, France, 

3 

Department of Neuroradiology, Hôpital Sainte-Anne, Paris, 

France, 4 Department of Neurology, Centre Hospitalier 

Universitaire La Milétrie, Poitiers, France, 5 Department 

of Pathology, APHP Hôpital Lariboisière, Université Paris 

Diderot, Paris, France, 6 Department of Neurology, APHP 

Hôpital Lariboisière, Université Paris Diderot, Paris, 

France, 7 Department of Neurology, Hôpital Sainte-Anne, 

Université Paris Descartes, Paris, France, 8 Department of 

Cellular Biology, Institut Cochin, Paris, France, 9 Department 

of Neurology, Centre Hospitalier Universitaire Henri 

Mondor, Créteil, France, 10 Department of Neurology, 

Centre Hospitalier Universitaire de Grenoble, Grenoble, 

France, 11 Department of Neurology, Hôpital d’Instruction 

des Armées Saint-Anne, Toulon, France, 12 Department of 

Neurology, Centre Hospitalier de Perpignan, Perpignan, 

France, 13 Department of Neurology, Hôpital Gui de Chauliac, 

Université Montpellier, Montpellier, France, 14 Division of 

Internal Medicine, Centre Hospitalier Régional Universitaire 

de Caen, Côte de Nacre, Caen, France, 15 Department of 

Internal Medicine, Centre Hospitalier Universitaire de 

Nantes, Nantes, France, 16 Mount Sinai Hospital, Toronto, ON, 

17 

Paris, France 

1552. Clinical Correlates, Treatment Outcomes and Predictors 

of Vasculitis Associated with Rheumatoid Arthritis in the 

‘Biologic Era’: A Case-Control Study. Ashima Makol, Cynthia 

S. Crowson, Eric L. Matteson and Kenneth J. Warrington, 


Clinical Practice/Patient Care 

1553. The Effect of Knee Replacement on Participation 

Outcomes: The Multicenter Osteoarthritis Study and 

Osteoarthritis Initiative. Jessica L. Maxwell 1 , Jingbo Niu 2 , 

Julie J. Keysor 1 , Tuhina Neogi 2 , Tianzhong Yang 2 , Michael 

C. Nevitt 3 , Jasvinder A. Singh 4 , Laura Frey-Law 5 and David 

T. Felson 2 , 1 Boston Univ Sargent College, Boston, MA, 

2 

Boston Univ School of Medicine, Boston, MA, 3 University 

of California-San Francisco, San Francisco, CA, 4 University 

of Alabama at Birmingham, Birmingham, AL, 5 University of 

Iowa, Iowa City, IA 

1554. Clusters of Fatigue- a Comparison between Persons with 

Systemic Lupus Erythematosus and Age and Gender 

Matched Controls. Susanne Pettersson 1 , Karin Eriksson 2 , 

Carina Boström 2 , Elisabet Svenungsson 3 , Iva Gunnarsson 3 

and Elisabet MB Welin Henriksson 4 , 1 Karolinska University 



Hospital, Stockholm, Sweden, 2 Division of Physiotherapy, 

Karolinska Institutet Huddinge, Stockholm, Sweden, 

3 

Rheumatology Unit, Karolinska Institutet, Stockholm, 

Sweden, 4 Karolinska Institutet Rheum, Stockholm, Sweden 

1555. Minimal Clinically Important Difference for Seven 

Measures of Fatigue in Patients with Systemic Lupus 

Erythematosus – Results From a Swedish Setting. Susanne 

Pettersson 1 , Ingrid E. Lundberg 2 and Elisabet MB Welin 

Henriksson 3 , 1 Karolinska University Hospital, Stockholm, 

Sweden, 2 Karolinska Institutet, Stockholm, Sweden, 

3 

Karolinska Institutet Rheum, Stockholm, Sweden 

1556. The Effect of Ginger Therapy on Symptoms of 

Osteoarthritis: An Open Pilot Study. Tessa Therkleson, Edith 

Cowan University, Perth, Australia 

1557. What Percentage of Postmenopausal Women Younger 

Than Age 65 Years Have Low Bone Mineral Density At a 

Family Health Center? Marvin Vaishnani and Feyrouz T. Al- 

Ashkar, Cleveland Clinic,Lorain Institute, Lorain, OH 

1558. “It Gets Me Down Every Single Day”: Are Men with 

Rheumatoid Arthritis Getting the Support They Need? 

Caroline A. Flurey 1 , Marianne Morris 1 , Jon Pollock 1 , 

Rodney A. Hughes 2 , Pamela Richards 3 and Sarah Hewlett 1 , 

1 

University of the West of England, Bristol, United Kingdom, 

2 

St. Peters Hospital, Chertsey Surrey, United Kingdom, 

3 

University of Bristol, Bristol, United Kingdom 

1559. Treatment Outcomes from a Nurse-Led Rheumatology 

Clinic in Monitoring of anti-TNF Therapy – a Randomised 

Controlled Trial. Ingrid Larsson 1 , Bengt Fridlund 1 , Barbro 

Arvidsson 2 , Annika Teleman 3 and Stefan Bergman 4 , 1 School 

of Health Sciences, Jönköping University, Jönköping, 

Sweden, 2 School of Social and Health Sciences, Halmstad 

University, Halmstad, Sweden, 3 Spenshults Hosp of Rheum 

Dis, Oskarstrom, Sweden, 4 R&D Center, Spenshult Hospital, 

Oskarström, Sweden 

1560. What Will Determine Adherence to Pharmaceutical 

Treatment for Rheumatoid Arthritis? A Systematic 

Review. Annelieke Pasma 1 , Adriaan van ‘t Spijker 2 , Jan van 

Busschbach 2 , Johanna M.W. Hazes 3 and Jolanda J. Luime 2 , 

1 

Erasmus MC University Medical Centre, Rotterdam, 

Netherlands, 2 Erasmus MC - University Medical Center, 

Rotterdam, Netherlands, 3 Erasmus Medical Center, 


1561. Factors Influencing Implementation of Intensive Treatment 

Strategies for Early Rheumatoid Arthritis. Sabrina 

Meyfroidt 1 , Diederik De Cock 1 , Kristien Van der Elst 1 , Laura 

van Hulst 2 , Marlies Hulscher 2 , Johan Joly 1 , Rene Westhovens 1 

and Patrick Verschueren 1 , 1 University Hospitals KULeuven, 

Leuven, Belgium, 2 Radboud University Nijmegen Medical 

Centre, Nijmegen, Netherlands 

1562. Benign Joint Hypermobility Syndrome More Common 

Than Expected, Both in Controls and in SLE Patients. Pia 

Malcus-Johnsson 1 , Lotta Köhlin 1 , Gunnar K. Sturfelt 2 and Ola 

Nived 3 , 1 Department of Rheumatology, University Hospital, 

Lund, Sweden, 2 Lund University, Lund, Sweden, 3 University 

Hospital - Lund, Lund, Sweden 

1563. Is Automated DATA Capture As Reliable As Manual DATA 

Entry in Survey Based Research? Rachel A. Mikolaitis, 

Jessica Cornejo, Chris Alonzo, Joel A. Block and Meenakshi 

Jolly, Rush University Medical Center, Chicago, IL 

1564. Misperceptions of FMS Patients about Their Disease. 

Robert S. Katz 1 , Hannah Bond 2 , Jessica L. Polyak 2 , Lauren 

Kwan 2 and Susan Shott 1 , 1 Rush University Medical Center, 

Chicago, IL, 2 Rheumatology Associates, Chicago, IL 

1565. How FMS Patients Become Workaholics. Robert S. Katz 1 , 

Hannah Bond 2 , Jessica L. Polyak 2 , Lauren Kwan 2 and Susan 

Shott 1 , 1 Rush University Medical Center, Chicago, IL, 

2 

Rheumatology Associates, Chicago, IL 

1566. Fibromyalgia’s Impact on Relationships. Robert S. Katz 1 , 

Alexandra Small 2 , Sharon M. Ferbert 3 and Susan Shott 1 , 

1 

Rush University Medical Center, Chicago, IL, 2 University of 

Illinois Medical School, 3 Advocates for Funding Fibromyalgia 

Treatment, Education and Research(AFFTER), Libertyville, IL 

1567. Sleep Study with Armband Device in Fibromyalgia Patients: 

Fibromyalgia Patients Don’t Rest Their Weary Muscles. 

Robert S. Katz 1 , Alexandra Small 2 , Ben J. Small 3 and Jessica 

L. Polyak 4 , 1 Rush University Medical Center, Chicago, IL, 

2 

University of Illinois Medical School, 3 Rush University 

Medical School, Chicago, IL, 4 Rheumatology Associates, 

Chicago, IL 

1568. A Survey Study of Methotrexate Use by Rheumatologists 

and Their Patients with Rheumatoid Arthritis. Peter Nash 1 

and Dave Nicholls 2 , 1 University of Queensland, Brisbane, 

Australia, 2 Coast Joint Care, Maroochydore, Australia 

1569. Optimizing Care for Patients with Rheumatoid Arthritis 

Newly Treated with Biologics by Evaluating Health Status 

with AIMS-2. Mie Fusama 1 , Hideko Nakahara 2 , Keisuke 

Kawamoto 2 , Satoko Nozato 2 , Midori Taguchi 2 , Kohji 

Nishioka 2 , Shinji Higa 2 , Eiji Takeuchi 2 , Kayoko Higashi 2 , Masao 

Yukioka 3 , Tsuyoshi Igarashi 2 , Taro Kuritani 2 , Keiji Maeda 2 and 

Yasushi Miura 1 , 1 Kobe University, Kobe, Japan, 2 NTT West 

Osaka Hospital, Osaka, Japan, 3 Yukioka Hospital, Osaka, 

Japan 

1570. Discrepancies between Disease Activity and Disease 

Burden. Margot J.M. Walter 1 , Adriaan van ‘t Spijker 1 , 

Annelieke Pasma 2 , Johanna M.W. Hazes 3 and Jolanda 

J. Luime 1 , 1 Erasmus MC - University Medical Center, 

Rotterdam, Netherlands, 2 Erasmus MC University Medical 

Centre, Rotterdam, Netherlands, 3 Erasmus Medical Center, 


1571. “Pain and Fatigue in Adult Patients with Rheumatoid 

Arthritis - Associations with Demographic Factors, 

Disease Related Factors, Body Awareness, Emotional and 

Psychosocial Factors”. Helena Lööf 1 , Fredrik Saboonchi 2 , 

Elisabet Welin Henriksson 3 , Staffan Lindblad 4 and Unn- 

Britt Johansson 1 , 1 Karolinska Institutet, Department of 

Clinical Sciences, Danderyd Hospital, Stockholm, Sweden, 

256 

2012 Program Book


2 

Karolinska Institutet, Department of Clinical Sciences, 

Danderyd Hospital, Division of Medicine, Stockholm, 

Sweden, 3 Karolinska Institutet, Department of Neurobiology, 

Care Sciences and Society., Stockholm, Sweden, 4 Karolinska 

University Hospital, Stockholm, Sweden 

1572. Developing a Health Literacy Universal Precautions Toolkit 

for Rheumatology. Leigh F. Callahan 1 , Victoria Hawk 2 , 

Kimberly A. Broucksou 2 , Betsy Hackney 2 , Deb MacDonald 3 , 

Lindsay Penny Prizer 1 , Beth L. Jonas 2 , Thomas K. Bauer 4 , 

Rima E. Rudd 5 , Cindy Brach 6 and Darren Dewalt 2 , 1 University 

of North Carolina, Chapel Hill, NC, 2 University of North 

Carolina at Chapel Hill, Chapel Hill, NC, 3 University of North 

Carolina Chapel Hill, Chapel Hill, NC, 4 Winston Salem, NC, 

5 

Harvard School of Public Health, Boston, MA, 6 Agency for 

Health Care Research and Quality, Rockville, MD 

1573. Baseline Screening Recommendations for Rheumatoid 

Arthritis Patients Treated with Disease Modifying Anti- 

Rheumatic Drugs: Does an Educational Intervention 

Change Practice in an Outpatient Clinic? Debra C. Lloyd 1 , 

John N. Mecchella 2 and Daniel Albert 3 , 1 Dartmouth- 

Hitchcock Med Ctr, Lebanon, NH, 2 Dartmouth Hitchcock 

Medical Center, Lebanon, NH, 3 Dartmouth-Hitchcock 

Medical Center, Geisel School of Medicine, Lebanon, NH 

1574. The Correlation of Disease Activity, Functional Status and 

Quality of Life with Sleep Disturbance and Balance Status 

in Ankylosing Spondylitis (AS). Mehmet Tuncay Duruoz, 

Zuhre Sari Surmeli and Esra Topcu, Celal Bayar University 

Medical School, Manisa, Turkey 

1575. The Impact of Targeted Exercise Intervention on Health 

Outcomes in Rheumatoid Arthritis. Laura J. Durcan 1 , Fiona 

Wilson 2 , Finbar (Barry) D. O’Shea 1 and Gaye Cunnane 1 , 1 St 

James’s Hospital, Dublin, Ireland, 2 Trinity College, Dublin, 

Ireland 

1576. Identifying Subgroups of Rheumatoid Arthritis Patients 

Based On Levels of Pain, Disability, and Depression. Taylor 

Draper 1 , Sarah R. Ormseth 1 , M. Custodio 2 , M.H. Weisman 3 , 

M.R. Irwin 2 and Perry M. Nicassio 2 , 1 Loma Linda University, 

Loma Linda, CA, 2 UCLA, Los Angeles, CA, 3 Cedars-Sinai 

Medical Center, Los Angeles, CA 

1577. Barriers to Recruit Unaffected Family Members of 

Patients with Rheumatoid Arthritis. Axel Finckh 1 , A. 

Debost-Legrand 2 , Martin Soubrier 3 , I. von Muehlenen 4 , I. 

Creveaux 2 , JJ Dubost 3 , MH Papon 2 , H. Ayadi 5 , P. Migliorini 6 , 

E. Petit-Teixeira 7 , F. Cornélis 2 and Eprac 8 , 1 Geneva University 

Hospitals, Geneva 14 , Switzerland, 2 GenHotel-Auvergne, 

Clermon-Ferrand, France, 3 CHU CLERMONT-FERRAnd, 

Clermont-Ferrand, France, 4 Universitäts-Poliklinik, Felix- 

Platter Spital, Basel, Switzerland, 5 Sfax university, Sfax, 

Tunisia, 6 Pisa university hospital, Pisa, Italy, 7 GenHotel-Evry- 

EA388 6 , Evry, France, 8 Clermont-Ferrand, France 

1578. How Disease Activity Trajectories Affect the Willingness 

to Change Treatment. Paul Falzer 1 and Liana Fraenkel 2 , 

1 

VA Connecticut Healthcare System, New Haven, CT, 2 Yale 


Healthcare System, New Haven, CT 

Rehabilitation Sciences 

1579. Why Do We Need to Pilot Interventions? Essential 

Refinements Identified During Pilots of a Fatigue 

Intervention. Emma Dures 1 , Nicholas Ambler 2 , Debbie 

Fletcher 3 , Denise Pope 3 , Frances Robinson 4 , Royston Rooke 4 

and Sarah Hewlett 1 , 1 University of the West of England, 

Bristol, United Kingdom, 2 Frenchay Hospital, Bristol, United 

Kingdom, 3 University Hospitals Bristol, United Kingdom, 

4 

University of Bristol, Bristol, United Kingdom 

1580. The Relationship between Perceived Cognitive Dysfunction 

and Objective Neuropsychological Performance in Persons 

with Rheumatoid Arthritis. So Young Shin, Patricia P. Katz 

and Laura J. Julian, University of California San Francisco, 

San Francisco, CA 

1581. The Association between Symptoms, Pain Coping 

Strategies, and Physical Activity among People with 

Symptomatic Knee and Hip Osteoarthritis. Susan L. 

Murphy 1 , Anna Kratz 1 , David A. Williams 2 and Michael E. 

Geisser 1 , 1 University of Michigan, Ann Arbor, MI, 2 Univ of MI 

Hlth System-Lobby M, Ann Arbor, MI 

1582. Long Term Costs and Cost-Effectiveness of an Integrated 

Rehabilitation Programme for Chronic Knee Pain. Mike 

Hurley 1 and Dr Nicola E. Walsh 2 , 1 St George’s University of 

London, London, United Kingdom, 2 University of the West of 


1583. Therapist and Patient Perspectives On Exercise Adherence: 

Are We On the Same Page? Jill R. Blitz 1 , Talitha Cox 2 

and Amber Richards 3 , 1 Children’s Hospital Los Angeles, 

Los Angeles, CA, 2 Children’s Hospital of Los Angeles, Los 

Angeles, CA, 3 Children’s Hospital, Los Angeles California, Los 

Angeles, CA 

1584. Validity of the Nurses Health Study II Physical Activity 

Questionnaire (NHSPAQ) in Estimating Physical Activity in 

Adults with Rheumatoid Arthritis (RA). Maura D. Iversen 1 , 

Thomas Quinn 2 and Michelle A. Frits 3 , 1 Northeastern 

University, Department of Physical Therapy, and Brigham 

& Women’s Hospital, Harvard Medical School, Boston, 

MA, 2 Northeastern University, Boston, MA, 3 Brigham and 


1585. Physical Activity and Timing of Discharge from Physical 

Therapy Following Total Knee Replacement. Carol A. Oatis 1 , 

Wenjun Li 2 , Milagros Rosal 2 , David Ayers 2 and Patricia D. 

Franklin 2 , 1 Arcadia University, Glenside, PA, 2 University of 

Massachusetts Medical School, Worcester, MA 

1586. Resistance Exercise Training for Fibromyalgia: A Systematic 

Review. Angela J. Busch 1 , Sandra Webber 1 , Rachel Richards 2 , 

Julia Bidonde 1 , Candice Schachter 1 , Laurel Schafer 3 , 

Adrienne Danyliw 4 , Anuradha Sawant 5 , Vanina Dal Bello 

Haas 6 and Tamara Rader 7 , 1 University of Saskatchewan, 

Saskatoon, SK, 2 North Vancouver, BC, 3 Central Avenue 



Physiotherapy, Swift Current, SK, 4 Health Quality Council, SK, 

5 

London Health Sciences Center, ON, 6 McMaster University, 

Hamilton, ON, 7 University of Ottawa, Ottawa, ON 

1587. Despite Low Disease Activity Patients with Poly- and 

Dermatomyositis Perceive Activity Limitation, Reduced 

Grip Force and Quality of Life Longitudinally. Malin 

Regardt 1 , Marie-Louise Schult 2 , Ingrid E. Lundberg 3 and 

Elisabet MB Welin Henriksson 4 , 1 Karolinska University 

Hospital, Karolinska Institutet, Stockholm, Sweden, 

2 

Department of Clinical Sciences, Danderyd Hospital, 

Karolinska Institutet., Stockholm, Sweden, 3 Karolinska 

Institutet, Stockholm, Sweden, 4 Karolinska Institutet Rheum, 


1588. Relationship Over Time between Beliefs, Motivation, 

and Worries about Physical Activity and Physical Activity 

Participation in Persons with Knee Osteoarthritis. Linda S. 

Ehrlich-Jones 1 , Jungwha Lee 2 , Dorothy D. Dunlop 2 , Pamela 

A. Semanik 2 , Min-Woong Sohn 2 , Jing Song 2 and Rowland 

W. Chang 2 , 1 Rehabilitation Institute Chicago, Chicago, IL, 

2 

Northwestern University, Chicago, IL 

1589. Obesity and Rehabilitation Outcomes after Lower 

Extremity Arthroplasty. Soham Al Snih, Amol Karmarkar, 

Timothy A. Reistetter, Jinhyung Lee, Amit Kumar, James E. 

Graham and Kenneth J. Ottenbacher, University of Texas 

Medical Branch, Galveston, TX 

1590. Post-Operative Rehabilitation Provides Unmet Need for 

Better Patient Support and Advice Following Lumbar Spinal 

Fusion. Michael V. Hurley 1 , James Greenwood 2 and Dr Nicola 

E. Walsh 3 , 1 St George’s University of London, London, United 

Kingdom, 2 University College Hospital London, London, 

United Kingdom, 3 University of the West of England Bristol, 

Bristol, United Kingdom 

1591. Efficacy of Neoprene Wrist Supports for Patients with 

Rheumatoid Arthritis. Kinue Matsuo 1 , Koji Tateishi 2 , Natsuko 

Nakagawa 2 and Yasushi Miura 1 , 1 Kobe University Graduate 

School of Health Sciences, Kobe, Japan, 2 Konan Kakogawa 

Hospital, Kakogawa, Japan 

1592. A Novel Approach to the Early Detection of Axial 

Spondyloarthritis in Patients with Inflammatory Bowel 

Disease: The Implementation of an Advanced Practice 

Physiotherapist Led Screening Program. Laura A. Passalent 1 , 

Rebecca Morton 1 , Khalid A. Alnaqbi 2 , Nigil Haroon 3 , 

Stephen Wolman 4 , Mark Silverberg 5 , A. Hillary Steinhart 5 

and Robert D. Inman 3 , 1 Allied Health, Toronto Western 

Hospital, Toronto, ON, 2 Toronto Western Hospital, Toronto, 

ON, 3 Toronto Western Research Institute, University Health 

Network and University of Toronto, Toronto, ON, 4 Toronto 

General Hospital, Toronto, ON, 5 Zane Cohen Centre for 

Digestive Diseases, Mount Sinai Hospital, Toronto, ON 

258 

2012 Program Book

ACR POSTER SESSION C 

Tuesday, NOVEMBER 13, 2012 



1724. Pandemic Influenza Immunization in Primary 

Antiphospholipid Syndrome (PAPS): A Trigger to 

Autoantibody Production? Danielle M. Medeiros 1 , Cleonice 

Bueno 1 , Ana Cristina M. Ribeiro 1 , Ana L. G. Calich 1 , Karina 

Rossi Bonfiglioli 1 , Vilma S. Viana 1 , Jozelio F. Carvalho 1 , Clovis 

Artur Silva 2 and Eloisa Bonfá 1 , 1 Faculdade de Medicina da 

Universidade de São Paulo, São Paulo, Brazil, 2 Paediatric 



1725. ANTI-Factor Xa Antibodies ARE Significantly Increased 

in Patients with Systemic LUPUS Erythematosus and 

Antiphospholipid Syndrome. Bahar Artim-Esen, Charis 

Pericleous, Ian Mackie, Yiannis Ioannou, Anisur Rahman, 

David A. Isenberg and Ian Giles, University College London, 


1726. Lack of Correlation between Mannose-Binding Lectin 

Gene Polymorphisms and the Thickness of the Carotid 

Artery Intima-Media (IMT) in Primary Antiphspholipid 

Syndrome. Antonio Barrera-Cruz 1 , Luis J. Jara-Quezada 2 , 

Gabriela Medina 3 and Miguel A. Saavedra Salinas 4 , 1 Instituto 

Mexicano del Seguro Social, México, Mexico, 2 Hospital de 

Especialidades Centro Médico La Raza, IMSS, Mexico City, 

Mexico, 3 Hospital de Especialidades Centro Medico Nacional 

La Raza, Mexico City, Mexico, 4 Hospital de Especialidades, 


1727. Affinity Purified Antibodies Directed to Domain I of 

β2GPI Are Pathogenic in a Mouse Model of Thrombosis. 

Charis Pericleous 1 , Patricia Ruiz-Limon 2 , Zurina Romay- 

Penabad 2 , Ana Laura Carrera Marin 2 , Acely Garza-Garcia 3 , 

Lucy Murfitt 3 , Paul C. Driscoll 4 , Ian Giles 1 , Yiannis Ioannou 1 , 

Anisur Rahman 1 and Silvia S. Pierangeli 2 , 1 University College 

London, London, United Kingdom, 2 University of Texas 

Medical Branch, Galveston, TX, 3 MRC National Institute of 

Medical Research, London, London, United Kingdom, 4 MRC 

National Institute of Medical Research, London, United 

Kingdom 

1728. Purified IgG From Antiphospholipid Syndrome Patients 

with Pregnancy Morbidity Alone Inhibit Trophoblast 

Migration and Activate a TLR4 MyD88 Independent 

Pathway. Katie Poulton, Vera Ripoll, Charis Pericleous, 

Yiannis Ioannou, Anisur Rahman and Ian Giles, University 


1729. Ribophorin II Is Involved in the Tissue Factor Expression 

Mediated by Phosphatidylserine-Dependent 

Antiprothrombin Antibody On Monocytes. Yuichiro 

Fujieda 1 , Olga Amengual 1 , Yusaku Kanetsuka 1 , Toshio 

Odani 1 , Kotaro Otomo 1 , Kenji Oku 1 , Toshiyuki Bohgaki 1 , 

Tetsuya Horita 1 , Shinsuke Yasuda 1 , Kimiko Kuroki 2 , Katsumi 

Maenaka 2 , Masaki Matsumoto 3 , Shigetsugu Hatakeyama 4 

and Tatsuya Atsumi 1 , 1 Hokkaido University,Medicine 

II, Sapporo, Japan, 2 Hokkaido University,Laboratory 

of Biomolecular Science, Sapporo, Japan, 3 Kyusyu 

University,Divison of proteomics, Multi-scale Reserch 

Center for Prevention of Medical Science, Fukuoka, Japan, 

4 

Hokkaido University,Biochemistry, Sapporo, Japan 

1730. Antiphosphatidylethanolamine Is Not Associated 

with Thrombosis or Pregnancy Loss in Systemic Lupus 

Erythematosus. Ehtisham Akhter 1 , Hong Fang 1 , Nathalie 

Bardin 2 , Marielle San Marco 2 and Michelle Petri 1 , 1 Johns 

Hopkins University School of Medicine, Baltimore, MD, 

2 

Hopital de la Conception, Marseille, France 

1731. IgA Anti-β2glycoprotein I Antibodies Are Pathogenic in a 

Mouse Model of APS. Patricia Ruiz Limon 1 , Zurina Romay- 

Penabad 2 , Ana Laura Carrera Marin 1 , Elizabeth Papalardo 2 

and Silvia S. Pierangeli 1 , 1 University of Texas Medical Branch, 

Galveston, TX, 2 Univ of TX Medical Branch, Galveston, TX 

1732. Annexin A5 Resistance Identifies a Subset of Thrombosis 

Patients in Systemic Lupus Erythematosus. Ehtisham 

Akhter 1 , Hong Fang 1 , Xiao Xuan Wu 2 , Jacob Rand 2 and 

Michelle Petri 1 , 1 Johns Hopkins University School of 

Medicine, Baltimore, MD, 2 Montefiore Medical Center, 

Bronx, NY 

1733. Effect of Hydroxychloroquine (HCQ) On the Annexin A5 

Resistance Assay (AnxA5-RA) in Antiphospholipid Antibody 

(aPL)-Positive Patients: Preliminary Results of an Ongoing 

Prospective Study. Alana B. Levine 1 , Jacob H. Rand 2 , Xiao 

Xuan Wu 2 , JoAnn Vega 1 , Glendalee Ramon 1 , Stephen L. 

Lyman 1 , Doruk Erkan 1 and Michael D. Lockshin 1 , 1 Hospital for 

Special Surgery, New York, NY, 2 Montefiore Medical Center, 

Bronx, NY 

1734. Clinical Accuracy for Diagnosis of Antiphospholipid 

Syndrome in Systemic Lupus Erythematosus: Evaluation of 

23 Possible Combinations of Antiphospholipid Antibody 

Specificities. Savino Sciascia 1 , Veronica Murru 1 , Giovanni 

Sanna 2 , Dario Roccatello 3 , Munther A. Khamashta 1 and 

Maria Laura Bertolaccini 1 , 1 Lupus Research Unit, The 

Rayne Institute, Kings College London School of Medicine, 

London, United Kingdom, 2 Louise Coote Lupus Unit, St. 

Thomas’ Hospital, London, United Kingdom, 3 Centro di 

Ricerche di Immunologia Clinica ed Immunopatologia e 

Documentazione su Malattie Rare (CMID), Università di 

Torino, Torino, Italy 

1735. Independent Validation of the Antiphospholipid Score 

(aPL-S) for the Diagnosis of Antiphospholipid Syndrome 

(APS). Savino Sciascia 1 , Maria Laura Bertolaccini 1 , Dario 

Roccatello 2 and Munther A. Khamashta 1 , 1 Lupus Research 

Unit, The Rayne Institute, Kings College London School 

of Medicine, London, United Kingdom, 2 Centro di 

Ricerche di Immunologia Clinica ed Immunopatologia e 

Documentazione su Malattie Rare (CMID), Università di 

Torino, Torino, Italy 

1736. The Estimated Prevalence of Antiphospholipid Antibodies 

in the General Population with Pregnancy Morbidity. 

Cecilia B. Chighizola 1 , Guilherme Ramires de Jesus 2 , Laura 



260 

andreoli 3 , Alessandra Banzato 4 , Guillermo J. Pons-Estel 5 , 

Michael D. Lockshin 6 , Doruk Erkan 6 and On Behalf of APS 

Action 7 , 1 Istituto Auxologico Italiano, University of Milan, 

Milan, Italy, 2 Department of Obstetrics, Universidade 

do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 

3 

Rheumatology Unit, University of Brescia, Brescia, 

Italy, 4 (2) Department of Cardiac Thoracic and Vascular 

Sciences, University of Padua, Padua Italy, Padua, Italy, 5 (4) 

Department of Autoimmune Diseases, Institut Clìnic de 

Medicina i Dermatologia, Hospital Clìnic, Barcelona, Spain, 

6 

Hospital for Special Surgery, New York, NY, 7 . 

1737. Diffuse Alveolar Hemorrhage Caused by Primary 

Antiphospholipid Syndrome. Rodrigo Cartin-Ceba, Tobias 

Peikert, Karina Keogh, Steven R. Ytterberg, Aneel Ashrani 

and Ulrich Specks, Mayo Clinic, Rochester, MN 

1738. Myocardial Dysfunction and Valvulopathy Worsens with 

Time in Patients with Antiphospholipid Syndrome: A 

10-Year Follow-up Study. MG Tektonidou 1 , CF Kampolis 1 , 

I. Moyssakis 2 , GE Tzelepis 1 , Haralampos M. Moutsopoulos 1 

and P. Vlachoyiannopoulos 1 , 1 University of Athens Medical 

School, Laiko Hospital, Athens, Greece, 2 Laiko Hospital, 


1739. Primary and Secondary Antiphospholipid Syndrome in 

Childhood. Senq-J Lee, Leonardo Brandao, Earl D. Silverman, 

Mahendranath Moharir, Julie Barsalou and Deborah M. 

Levy, The Hospital for Sick Children, Toronto, ON 

1740. Impairment of Quality of Life in Patients with 

Antiphospholipid Syndrome. Stephane Zuily 1 , Francis 

Guillemin 2 , Veronique Regnault 3 , Pierre Kaminsky 4 , 

Patrick Mismetti 5 , Jacques Ninet 6 , Nicolas Baillet 7 , Nadine 

Magy-Bertrand 8 , Bernard Lorcerie 9 , Jean-Louis Pasquali 10 , 

Thomas Lecompte 11 , Anne-Christine Rat1 2 and Denis 

Wahl 13 , 1 Vascular Medicine Unit and Regional Competence 

Center For Rare Vascular and Systemic Autoimmune 

Diseases, Vandoeuvre-Les-Nancy, France, 2 INSERM, Centre 

d’Investigation Clinique - Epidémiologie Clinique (CIC-EC) 

CIE 6 , Nancy, France, 3 INSERM U96 1 , Université de Lorraine, 

Nancy, France, 4 Orphan disease Unit, Nancy, France, 5 CHU 

Saint-Etienne, Unité de Pharmacologie Clinique, Groupe 

de Recherche sur la Thrombose (EA 3065), Saint Etienne, 

France, 6 Department of Nephrology and Internal Medicine, 

Hôpital Edouard Herriot, Lyon, France, Lyon, France, 

7 

Hôpitaux civils de Colmar, Service de Médecine interne, 

Colmar, France, 8 CHU Jean-Minjoz, Service de médecine 

interne et immunologie clinique, Besançon, France, 9 Hopital 

Du Bocage, Service de Médecine Interne et Immunologie 

Clinique, Dijon, France, 10 Hôpitaux Universitaires de 

Strasbourg, Hôpital civil, Service de médecine interne 

et immunologie clinique, Strasbourg, France, 11 Hôpitaux 

Universitaires de Genève, Département d’hématologie, 

Genève, France, 12 Université de Lorraine, INSERM, CIC-EC 

CIE 6 , Rheumatology, Epidemiology, Nancy, France, 13 Nancy 

University Hospital and INSERM U961, Vascular medicine 

division and Regional Competence Center For Rare Vascular 

and Systemic Autoimmune Diseases, Nancy, France 



1741. Suppression of Glomerulonephritis in NZB/W F1 Mice by 

a Selective Inhibitor of Bruton’s Tyrosine Kinase (RN486). 

Paola Mina-Osorio, Jacob LaStant, Natalie Keirstead, Toni 

Whittard, Stella Stefanova, Alka Patel, Jennifer Postelnek, 

John Woods, Soo Min, Yong Kim, Julie Demartino, Satwant 

Narula and Daigen Xu, Hoffmann-La Roche, Nutley, NJ 

1742. A Novel Murine Model of B Cell-Mediated Proteinuria 

Suggests Cytokines Mediate Podocyte Injury. Alfred H. Kim 1 

and andrey S. Shaw 2 , 1 Washington Univ School of Med, St. 

Louis, MO, 2 Washington University School of Medicine, Saint 

Louis, MO 

1743. IL-5-Induced FasL+ Regulatory B Cells Are Inhibited by 

IL- 4 and Cyclosporine. Matthew W. Klinker 1 , Brian R. 

Alzua 1 , Tamra J. Reed 1 , David A. Fox 2 and Steven K. Lundy 1 , 

1 

University of Michigan, Ann Arbor, MI, 2 Univ of Michigan 

Med Ctr, Ann Arbor, MI 

1744. Regulatory B Cells Supress the Progression of Fatal 

Autoimmunity in Lupus-Prone Mice. Yuriy Baglaenko 1 , 

Nan-Hua Chang 1 , Evelyn Pau 2 and Joan E. Wither 1 , 1 Toronto 

Western Research Institute, University Health Network, 

Toronto, ON, 2 Toronto Western Hospital, University Health 

Network, Toronto, ON 

1745. Amelioration of Experimental Autoimmune Arthritis by 

Adoptive Transfer of Foxp3-Expressing Regulatory B Cells 

Is Associated with the Regulatory T Cell/T helper 17 cell 

Balance. Young Ok Jung 1 , Yu Jung Heo 2 , Mi Kyung Park 3 , Mi- 

La Cho 4 , Seung Ki Kwok 5 , Ji Hyeon Ju 2 , Kyung Su PARK 2 , Sung 

Hwan PARK 2 , Ho Youn Kim 2 and Jun-Ki Min 6 , 1 Seoul, South 

Korea, 2 Catholic University, Seoul, South Korea, 3 The Catholic 

University of Korea, Seoul, South Korea, 4 Catholic University 

of Korea, Seoul, South Korea, 5 The Catholic University, 

Seoul, South Korea, 6 Division of Rheumatology, Department 

of Internal Medicine, School of Medicine, The Catholic 

University of Korea, Seoul, South Korea 

1746. Semaphorin 3A Increases the Regulatory Characteristics of 

B-Regulatory Cells. Zahava Vadasz 1 , Aharon Kessel 2 and Elias 

Toubi 2 , 1 Bnai-Zion Medical Center, Haifa, Israel, 2 Bnai-Zion 

Medical Center, Israel 

1747. Gemin5 Is a New Target of Autoantibodies That Are 

Produced in Tight Connection with Antibodies to Snrnps 

and Survival of Motor Neuron (SMN) Complex. Jason YF 

Chan, Yi Li, Angela Ceribelli, Eric S. Sobel, Westley H. Reeves, 

Edward K.L. Chan and Minoru Satoh, University of Florida, 

Gainesville, FL 

1748. Antibody Secreting Cells Arising After Vaccination of 

Lupus Patients May Produce High Affinity Autoantibodies. 

Kenneth Smith 1 , Jennifer Muther 1 , Angie Duke 1 , Emily 

McKee 1 , Alina Lorant 1 , Patrick C. Wilson 2 and Judith A. 

James 3 , 1 Oklahoma Medical Research Foundation, Oklahoma 

City, OK, 2 University of Chicago, Chicago, IL, 3 Oklahoma 

Medical Research Foundation and Oklahoma University 

Health Sciences Center, Oklahoma City, OK


1749. Targeting of CD22 by Epratuzumab Potentially Raises the 

Threshold of B Cell Receptor Activation. N. Sieger 1 , S.J. 

Fleischer 1 , K. Reiter 1 , H.E. Mei 1 , A. Shock 2 , G. Burmester 1 , C. 

Daridon 1 and T. Dorner 1 , 1 Charité University Medicine Berlin, 

Berlin, Germany, 2 UCB Pharma, Slough, United Kingdom 

1750. Phosphoprotein Changes Induced with Epratuzumab, an 

Antibody Targeting CD22 On B Cells. S. Lumb 1 , N. Torbett 2 , 

I. Vandrell 2 , H. Turner 2 , M. Page 1 , P. Hales 1 , A. Maloney 1 , B. 

Vanhaesebroeck 2 , P. Cutillas 2 and A. Shock 1 , 1 UCB Pharma, 

Slough, United Kingdom, 2 Activiomics Ltd., London, United 

Kingdom 

1751. Effect of Repeated Infusions of Rituximab in Patients with 

Primary Sjögren’s Syndrome. Maria Perez-Ferro, Sheila 

Recuero, Fredeswinda I. Romero, Cristina Serrano, Maria 

J. Rodriguez-Nieto, Julio Gomez-Seco, Teresa Presa, Javier 

R. Godo, Gabriel Herrero-Beaumont and Olga Sanchez- 

Pernaute, Jimenez Díaz Foundation University Hospital, 

Madrid, Spain 

1752. Depletion of CD4-Effector Memory T Cells and Clonally 

Expanded IgG4 Memory B Cells May Explain the 

Therapeutic Efficacy of Rituximab in IgG4-Related 

Disease: Studies Using Flow Cytometry and Single-Cell 

Sequencing. Hamid Mattoo 1 , Arezou Khosroshahi 2 , Vinay 

Mahajan 1 , Mollie Carruthers 2 , John Stone 1 and Shiv Pillai 2 , 

1 

Massachusetts General Hospital, Harvard Medical School, 

Boston, MA, 2 Massachusetts General Hospital, Boston, MA 

1753. A Rheumatoid Factor Paradox: Inhibition of Rituximab- 

Induced Complement Dependent Cytotoxicity of B Cells. 

Jonathan D. Jones 1 , Irene Shyu 1 , Marianna M. Newkirk 2 

and William F. C. Rigby 1 , 1 Dartmouth-Hitchcock Med Ctr, 

Lebanon, NH, 2 McGill University Health Centr, Montreal, QC 

1754. Disruption of Dominant B-Cell and Plasma Cell Clones in 

Rheumatoid Arthritis Synovium by Rituximab Correlates 

with Treatment Response. Marieke E. Doorenspleet 1 , Paul 

L. Klarenbeek 1 , Maartje J. Boumans 1 , Rogier M. Thurlings 1 , 

Rebecca E. Esveldt 1 , Barbera D. van Schaik 1 , Antoine H. van 

Kampen 1 , Danielle M. Gerlag 2 , Frank Baas 1 , Paul-Peter Tak 1 , 

Robert M. Plenge 3 and Niek de Vries 1 , 1 Academic Medical 

Center of the University of Amsterdam, Amsterdam, 


Amsterdam, Amsterdam, Netherlands, 3 Brigham and 


1755. The Alternative ΔCD20 Transcript Variant Is Not 

Expressed in B Cells and Synovial Tissue from Patients 

with Rheumatoid Arthritis. Clémentine Gamonet 1 , 

Marina Deschamps 2 , Béatrice Gaugler 3 , Philippe Saas 4 , 

Isabelle Auger 5 , Christophe Ferrand 6 , Eric Toussirot 7 and 

CIC BT506 8 , 1 INSERM UMR1098/ Etablissement Français 

du Sang / Université de Franche Comté, France, 2 INSERM 

UMR1098 / Etablissement Français du Sang/ Université 

de Franche Comté, Besançon, France, 3 INSERM UMR1098 

/ Etablissement Français du Sang / Université de Franche 

Comté, Besançon, France, 4 INSERM UMR1098 / Plateforme 

de Biomonitoring, Besançon, France, 5 INSERM UMR109 7 , 

Marseille, France, 6 INSERM UMR1098 Etablissement 

Français du Sang / Université de Franche Comté, Besançon, 

France, 7 CIC Biotherapy 50 6 and Rheumatology and EA 4266 

Pathogens and Inflammation, Besançon, France, 8 Clinical 

Investigation Center Biotherapy 50 6 , Besançon, France 

1756. Peripheral Blood B Cell Subsets and BAFF/APRIL Receptor 

Expression, Together with Circulating BAFF and APRIL 

Levels, Are Disturbed in Rheumatoid Arthritis but Not 

in Ankylosing Spondylitis. Béatrice Gaugler 1 , Caroline 

Laheurte 2 , Ewa Bertolini 3 , Daniel Wendling 4 , Philippe 

Saas 5 , Eric Toussirot 6 and CIC BT506 7 , 1 INSERM UMR1098 

/ Etablissement Français du Sang / Université de Franche 

Comté, Besançon, France, 2 INSERM UMR1098 / Plateforme 

Biomonitoring, Besançon, France, 3 Rheumatology, 

Besançon, France, 4 Minjoz University Hospital, Besancon, 

France, 5 INSERM UMR1098 / Plateforme de Biomonitoring, 

Besançon, France, 6 CIC Biotherapy 506 and Rheumatology 

and EA 4266 Pathogens and Inflammation, Besançon, 

France, 7 Clinical Investigation Center Biotherapy, Besançon, 

France 

1757. B Cell Activating Factor Receptor Expression After 

Rituximab: Comparison of Patients with Rheumatoid 

Arthritis and Thrombotic Thrombocytopenic Purpura. 

Elena Becerra 1 , Maria J. Leandro 1 , Edward O. Heelas 2 , John 

P. Westwood 2 , Inmaculada de la Torre 3 , Marie A. Scully 2 and 

Geraldine Cambridge 1 , 1 Rheumatology, University College 

London, London, United Kingdom, 2 Hematology, University 

College London, London, United Kingdom, 3 Rheumatology, 

Gregorio Marañón Hospital, Madrid, Spain 

1758. Serum BAFF Levels and Relationship with BAFF Binding 

Receptors in Patients with Rheumatoid Arthritis Relapsing 

after B Cell Depletion Therapy. Elena Becerra 1 , Inmaculada 

de la Torre 2 , Maria J. Leandro 1 and Geraldine Cambridge 1 , 

1 

University College London, London, United Kingdom, 

2 

Gregorio Marañón Hospital, Madrid, Spain 

1759. Expression of Surface APRIL and Its Receptor, TACI, 

Is Upregulated On B Cells From Systemic Lupus 

Erythematosus and Rheumatoid Arthritis Patients. Abby 

Jones Weldon 1 , Sheri Hsu 2 , Seyed K. Nazeri 3 , Saru Sachdeva 2 , 

Jennifer Gonzalez 1 , Andrea D. Parra 1 , Abigail Benitez 1 , Keith 

K. Colburn 4 , Ioana Moldovan 4 and Kimberly J. Payne 1 , 1 Loma 

Linda University, Loma Linda, CA, 2 Loma Linda University 

Medical Center, Loma Linda, CA, 3 Loma Lida University 

Medical Center, Loma Lida, CA, 4 Loma Linda Univ Medical 

Center, Loma Linda, CA 

1760. A Gene Expression Signature to Monitor Depletion 

of Plasma Cells Following MEDI-551 (anti-CD19) 

Administration. Katie Streicher, Chris Morehouse, 

Christopher Groves, Bhargavi Rajan, Fernanda Pilataxi, 

Kim Lehmann, Philip Brohawn, Kathleen McKeever, Volker 

Knappertz, Ronald Herbst, Yihong Yao and Koustubh 

Ranade, MedImmune, LLC, Gaithersburg, MD 



1761. Suppression of Rheumatoid Arthritis B Cells by XmAb5871, 

an Anti-CD19 Monoclonal Antibody That Co-Engages 

the B Cell Antigen Receptor and the FcγRIIb Inhibitory 

Receptor. Seung Y. Chu 1 , Karen Yeter 2 , Roshan Kotha 2 , Erik 

Pong 1 , Yvonne Miranda 1 , Hsing Chen 1 , Sung-Hyung Lee 1 , 

Irene Leung 1 , John R. Desjarlais 1 , William Stohl 2 and David 

E. Szymkowski 1 , 1 Xencor, Inc., Monrovia, CA, 2 University of 

Southern California Keck School of Medicine, Los Angeles, 

CA 

1762. IL-6 Receptor Inhibition by Tocilizumab Modulates Double 

Negative (CD19+IgD-CD27-) B Cells in RA. Zafar Mahmood 1 , 

Khalid Muhammad 1 , Petra Roll 1 , Stefan Kleinert 1 , Thomas 

Dörner 2 and Hans Peter Tony 1 , 1 University of Würzburg, 

Würzburg, Germany, 2 Charite Universitätsmedizin Berlin and 

DRFZ,, Berlin,, Germany 

1763. The Role of SYK in Human B CELL Activation and Its 

Relevance to Autoimmune Diseases. Shigeru Iwata 1 , 

Kunihiro Yamaoka 1 , Hiroaki Niiro 2 , Kazuhisa Nakano 1 , Sheau- 

Pey Wang 1 , Koichi Akashi 2 and Yoshiya Tanaka 1 , 1 University 

of Occupational and Environmental Health, Kitakyushu, 

Japan, Kitakyushu, Japan, 2 Graduate School of Medical 

Sciences, Kyushu University, Fukuoka, Japan, Fukuoka, Japan 

1764. B Cells in Early Rheumatoid Arthritis: ZAP-70 More Than 

SYK Characterize Seropositive Disease. Anna Laura Fedele, 

Barbara Tolusso, Elisa Gremese, Silvia Laura Bosello, Angela 

Carbonella, Silvia Canestri and Gianfranco Ferraccioli, 

Division of Rheumatology, Institute of Rheumatology and 

Affine Sciences, Catholic University of the Sacred Heart, 

Rome, Italy 

1765. Rheumatoid Arthritis Is Associated with Signaling 

Alterations in Naturally Occurring Autoreactive 

B-Lymphocytes. Taras Lyubchenko, Ganna Liubchenko, Holly 

C. Appleberry, Christopher C. Striebich, Karen E. Franklin, 

Lezlie A. Derber and V. Michael Holers, University of 

Colorado Denver, Aurora, CO 

1766. Synovial Gene Expression and Response to Rituximab: 

Preliminary Data. Yasser El-Sherbiny 1 , Sarah Churchman 1 , 

Frederique Ponchel 1 , Paul Emery 2 and Edward M. Vital 1 , 

1 

NIHR Leeds Biomedical Research Unit, University of Leeds 

and Leeds Teaching Hospitals NHS Trust, Leeds, United 

Kingdom, 2 University of Leeds, Leeds, United Kingdom 

1767. Circulating Plasmablasts as a Source of Anti-Citrullinated 

Protein Antibodies in Patients with Rheumatoid Arthritis. 

Priscilla Kerkman, Ellen I.H. van der Voort, Leendert 

A. Trouw, Tom W.J. Huizinga, René E.M. Toes and Hans 

Ulrich Scherer, Leiden University Medical Center, Leiden, 

Netherlands 

1768. The Absolute Concentration of Anti Citrullinated Protein 

Antibodies in Serum and Synovial Fluid in Relation to Total 

Immunoglobulin-Concentrations. Annemiek Willemze, Jing 

Shi, Marlies Mulder, Gerrie Stoeken-Rijsbergen, Tom W. J. 

Huizinga, René E. M. Toes and Leendert A. Trouw, Leiden 


1769. Affinity Purification and Characterisation of Anti- 

CCP Antibodies from Plasma and Synovial Fluids of 

Patients with Rheumatoid Arthritis. Elena Ossipova 1 , 

Catia Cerqueira 1 , Evan Reed 1 , Nastya Kharlamova 1 , Lena 

Israelsson 1 , Rikard Holmdahl 2 , Anca Irinel Catrina 1 , Vivianne 

Malmström 3 , Yngve Sommarin 4 , Lars Klareskog 1 , Per 

Johan Jakobsson 1 and Karin Lundberg 1 , 1Rheumatology 

Unit, Department of Medicine, Karolinska Institutet, 

Stockholm, Sweden, 2 Department of Medical Biochemistry 


3 

Rheumatology unit, Karolinska University Hospital, 

Karolinska Institute, Stockholm, Sweden, 4 Euro-Diagnostica 

AB, Malmö, Sweden 

1770. Recognition of Citrullinated and Carbamylated Proteins by 

Human Antibodies: Specificity, Cross-Reactivity and the 

“AMC-Senshu” Method. Jing Shi 1 , George Janssen 1 , Peter 

van Veelen 1 , Janwouter Drijfhout 1 , Antony Cerami 1 , Tom 

Huizinga 2 , Leendert A. Trouw 3 and René E.M. Toes 3 , 1 LUMC, 

Leiden, Netherlands, 2 Leiden University Medical Center, 

Leiden, Netherlands, 3 Leiden University Medical Centre, 


1771. Anti Carbamylated Protein Antibodies (Anti-CarP) Are 

Present in Arthralgia Patients and Predict the Development 

of Rheumatoid Arthritis. Jing Shi 1 , Lotte van de Stadt 2 , 

Nivine Levarht 1 , T.W.J. Huizinga 3 , R. E. M. Toes 3 , Leendert 

A. Trouw 4 and Dirkjan van Schaardenburg 2 , 1 LUMC, Leiden, 


Amsterdam, Netherlands, 3 Leiden University Medical Center, 

Leiden, Netherlands, 4 Leiden University Medical Centre, 


1772. Expansion of Autoreactive Unresponsive CD21-/Low B Cells 

in Sjögren’s Syndrome Associated Lymphoproliferation. 

David Saadoun 1 , Benjamin Terrier Sr. 2 , J. Bannock Sr. 3 , T. 

Vazquez Sr. 4 , C. Massad Sr. 3 , Florence Joly Sr. 5 , Michelle 

Rosenzwajg Sr. 6 , Damien Sene Sr. 7 , Philippe Benech Sr. 5 , 

David Klatzmann Sr. 6 , Eric Meffre Sr. 3 and Patrice Cacoub 

Sr. 8 , 1 Department of Internal Medicine and Laboratory 

I3 “Immunology, Immunopathology, Immunotherapy”, 

UMR CNRS 72 11 , INSERM U95 9 , Groupe Hospitalier Pitié- 

Salpetrière, Université Pierre et Marie Curie, Paris 6 , Paris, 

France, Paris, France, 2 Cochin Hospital, Paris, France, 3 Yale 

University School of Medicine, New Haven, CT, 4 CNRS UMR 

72 11 and INSERM U95 9 , Paris, France, 5 Prediguard, Marseille, 

France, 6 Laboratory I3 “Immunology, Immunopathology, 

Immunotherapy”, UMR CNRS 72 11 , INSERM U95 9 , Paris, 

France, 7 Groupe Hospitalier Pitié-Salpétrière, Université 

Pierre et Marie Curie, Paris, France, 8 CHU Pitié-Salpêtrière, 

Paris, France 

1773. Hyperammaglobulinemia in Primary Sjögren’s Syndrome 

Is Induced by Triggering of TLR 7 and 9. Susanna Brauner 1 , 

Marika Kvarnstrom 1 , Gunnel Nordmark 2 and Marie Wahren- 

Herlenius 1 , 1 Karolinska Institutet, Stockholm, Sweden, 

2 

Rheumatology, Uppsala, Sweden 

262 

2012 Program Book


1774. Identification of Target Antigens of Anti-Endothelial Cell 

Antibodies in Patients with ANCA-Associated Systemic 

Vasculitis: A Proteomic Approach. Alexis Régent 1 , Hanadi 

Dib 2 , Guillaume Bussone 1 , Mathieu C. Tamby 1 , Nicolas 

Tamas 2 , Christian Federici 3 , Cédric Broussard 3 , Loic Guillevin 4 

and Luc Mouthon Sr. 1 , 1 Hopital Cochin, Paris, France, 

2 

Université Paris Descartes, Paris, France, 3 INSERM U1016, 

Institut Cochin, CNRS UMR 810 4 , Paris, France, 4 Department 

of Internal Medicine, Referral Center for Rare Autoimmune 


Paris Descartes, Paris, France, Paris, France 


1775. The Phosphoinositide 3-Kinase Pathway Regulates 

Fibroblast-Like Synoviocyte Invasion. Beatrix Bartok 1 , 

Deepa Hammaker 2 and Gary S. Firestein 3 , 1 UCSD, La Jolla, 

CA, 2 Univ of California San Diego, La Jolla, CA, 3 UCSD School 

of Medicine, La Jolla, CA 

1776. Anti-SSA/Ro Mediated Injury to the Endothelium via 

Urokinase Plasminogen Activator Receptor/Tgfbeta 

Activation: Implications in the Pathogenesis of Congenital 

Heart Block. Paraskevi Briasouli 1 , Mark Halushka 2 , Jill P. 

Buyon 3 and Robert M. Clancy 4 , 1 New York University Medical 

Center, New York, NY, 2 John Hopkins PAthology, Baltmore, 

MD, 3 NYU School of Medicine, New York, NY, 4 New York 


1777. The Bioenergetic Role of HIF-1 and HIF-2 during 

Angiogenesis of Human Microvascular Endothelial 

Cells. Martin Hahne 1 , Cindy Strehl 1 , Manuela Jakstadt 1 , 

Paula Hoff 1 , Timo Gaber 1 , Gerd R. Burmester 1 and Frank 

Buttgereit 2 , 1 Charité University Medicine, Berlin, Germany, 

2 

Charite University Med-Berlin, Berlin, Germany 

1778. Adenosine A2A Receptor (A2AR) Activation Stimulates 

Increased Expression of Collagen- 1 and Collagen-3 by 

Different Signaling Pathways in Normal Human Dermal 

Fibroblasts. Miguel Perez Aso 1 and Bruce N. Cronstein 2 , 

1 

NYU Univ Medical Center, New York, NY, 2 NYU School of 

Medicine, Division of Rheumatology, New York, NY 

1779. The Loss of Syndecan-4 Aggravates Inflammatory Colitis in 

Mice. Athanasios Stratis 1 , Dominik Bettenworth 1 , Mareike 

Fröhling 1 , Peter Paruzel 1 , Adelheid Korb-Pap 1 , Corinna 

Wehmeyer 1 , Berno Dankbar 1 , Frank Echtermeyer 2 , Andreas 

Lügering 1 and Thomas Pap 1 , 1 University Hospital Muenster, 

Muenster, Germany, 2 University Hospital Hannover, 

Hanover, Germany 

1780. Association between Chondrocyte Hypertrophy and 

Angiogenesis of Cartilage in Osteoarthritis. Laurence 

Pesesse 1 , Christelle Sanchez 2 , Jean-Pierre Delcour 3 , Caroline 

Baudouin 4 , Philippe Msika 4 and Yves Henrotin 5 , 1 University 

of Liège, Liège, Belgium, 2 Bone and Cartilage Research Unit, 

Liege, Belgium, 3 Centre hospitalier du Bois de l’Abbaye, 

Seraing, Belgium, 4 Laboratoires Expanscience, Epernon, 

France, 5 Univ of Liege/Pathology Inst, Liege, Belgium 

1781. Functional Analysis of the Primary Cilium in Rheumatoid 

Arthritis Synovial Fibroblasts. Kerstin Klein 1 , Beat A. 

Michel 1 , Alexander Vogetseder 2 , Renate Gay 1 , Steffen 

Gay 1 and Caroline Ospelt 1 , 1 Center of Experimental 


of Integrative Human Physiology (ZIHP), Zurich, Switzerland, 

2 

Department of Pathology, University Hospital Zurich, 



1782. Dual Effects of Soluble FasL and Membrane Bound FasL On 

Fibroblast-Like Synoviocytes Cells (FLS) From Rheumatoid 

Arthritis (RA) Patients. Rachel Audo 1 , Flavia Calmon- 

Hamaty 1 , Bernard Combe 2 , Michael Hahne 1 and Jacques 

Morel 2 , 1 IGMM, CNRS UMR5535, Montpellier, Montpellier, 

France, 2 Hopital Lapeyronie, Montpellier, France 

1783. TNFα Influences RasGRP1 and RasGRP3 Expression Levels 

in PBMC, B and T Cells. Marie-Laure Potier 1 , Martine Hiron 1 , 

Clément Guillou 1 , Céline Derambure 1 , Olivier Boyer 2 , Xavier 

Le Loët 3 , Olivier Vittecoq 3 and Thierry Lequerré 3 , 1 Inserm 

905 & Institute for Biomedical Research, University of 

Rouen, Rouen, France, 2 Inserm 905, Institute for Biomedical 

research, University of Rouen, Rouen, France, 3 Department 

of Rheumatology, Rouen University Hospital & Inserm 905, 

Institute for Biomedical Research, University of Rouen, 

Rouen Cedex, France 

1784. Dual Function of Interleukin-33 in Fibroblast-Like 

Synoviocytes in Patients with Rheumatoid Arthritis. Min 

W. So 1 , Bon S. Koo 1 , You J. Kim 1 , You-G Kim 1 , Wook J. Seo 2 , 

Chang-K Lee 1 and Bin Yoo 1 , 1 University of Ulsan College of 

Medicine, Asan Medical Center, Seoul, South Korea, 2 Seoul 

Veterans Hospital, Seoul, South Korea 

1785. MiR-30* Family Negatively Regulates B-Cell Activating 

Factor (BAFF) Synthesis in Rheumatoid Synoviocytes. 

Ghada Alsaleh 1 , Antoine Francois 1 , Lucas Philippe 1 , Jean 

Sibilia 1 , Jacques-Eric Gottenberg 1 , Philippe Georgel 2 

and Dominique Wachsmann 1 , 1 EA4438 Laboratoire 

Physiopathologie des Arthrites, Illkirch-Strasbourg, France, 

2 

Laboratoire d’ImmunoGénétique Moléculaire Humaine, 

Strasbourg, France 

1786. Targeting CD1c-Expressing mDCs to Inhibit Increased 

Thymus and Activation Regulated Chemokine Levels in RA. 

M.R. Hillen, F.M. Moret, F.P.J.G. Lafeber, C.E. Hack, T.R.D.J. 

Radstake and J.A.G. van Roon, University Medical Center 

Utrecht, Utrecht, Netherlands 

1787. Evolution of the Cytokine and Chemokine Profile in 

Patients Receiving Oral Daily Vitamin D: Results from 

a Randomized Controlled Trial. Benjamin Terrier Sr. 1 , 

Marlène Garrido 2 and Patrice Cacoub Sr. 3 , 1 Cochin Hospital, 

Paris, France, 2 Pitié-Salpétrière, Paris, France, 3 CHU Pitié- 


1788. TSLP Induces TNFα Production by CD1c Myeloid Dendritic 

Cells and Myeloid DC-Activated T Cells From Rheumatoid 

Arthritis Patients. F.M. Moret, T.R.D.J. Radstake, J.W.J. 



264 

Bijlsma, F.P.J.G. Lafeber and J.A.G. van Roon, University 

Medical Center Utrecht, Utrecht, Netherlands 

1789. Evidence for an Additive Effect of Tumor Necrosis 

Factor Alpha and Hypoxia to Promote Bone Destruction 

in Arthritis. Shankar Revu 1 , Akilan Krishnamurthy 1 , 

Vivekananda Sunkari 2 , Ileana R. Botusan 2 , Xiaowei 

Zheng 2 , Sergiu-Bogdan Catrina 2 and Anca Irinel Catrina 1 , 

1Rheumatology Unit, Karolinska University Hospital, 

Karolinska Institute, Stockholm, Sweden, 2 Karolinska 

University Hospital, Karolinska Institute, Stockholm, Sweden 

1790. Notch Promotes Matrix Metalloproteinase 13 Expression 

by Inducing Interleukin-6 in Primary Murine Chondrocytes. 

Stefano Zanotti and Ernesto Canalis, Saint Francis Hospital 

and Medical Center, Hartford, CT 

1791. Different Mechanisms Responsible for IVIG Inhibition of 

Immune Complex versus TLR Stimulated Interferon-Alpha. 

Alice Wiedeman 1 , Fabian Käsermann 2 , Sylvia Miescher 2 and 

Keith B. Elkon 1 , 1 University of Washington, Seattle, WA, 2 CSL 

Behring, Bern, Switzerland 

1792. Identification of the Antimicrobial Peptide LL-37 As 

a Potential Mediator of Synovial Inflammation in 

Rheumatoid Arthritis. Petra Neregård 1 , Marianne 

Engström 1 , Erik Af Klint 1 , Birgitta Agerberth 2 and Anca Irinel 

Catrina 1 , 1Rheumatology Unit, Department of Medicine, 

Karolinska Institute, Karolinska University Hospital, 


Sweden, Stockholm, Sweden 

1793. The Cyclooxygenase/Prostaglandin-E2 Pathway Is Critical 

for Autocrine IL-17A Production by Th17 Cells Upon 

Synovial Fibroblast Interaction. Sandra M.J. Paulissen 1 , 

Jan Piet van Hamburg 2 , Nadine Davelaar 1 , Patrick S. 

Asmawidjaja 3 , Johanna M.W. Hazes 4 and Erik Lubberts 3 , 

1 

Erasmus MC, University Medical Center, Rotterdam, 

Rotterdam, Netherlands, 2 Erasmus MC, Rotterdam, 

Netherlands, 3 Erasmus MC, University Medical Center, 

Rotterdam, Netherlands, 4 Erasmus Medical Center, 


1794. Matrix Metalloproteinase 3 and Acute Phase Proteins as 

Markers of Disease Activity and Radiographic Damage in 

Early Rheumatoid Arthritis. Mahmood MTM Ally 1 , Bridget 

Hodkinson 2 , Pieter W.A Meyer 1 , Eustasius Musenge 3 , 

Mohammed Tikly 4 and Ronald anderson 1 , 1 University 

of Pretoria, Pretoria, South Africa, 2 University of the 

Witwatersrand, Johannesburg, South Africa, 3 University 

of Witwatersrand, Johannesburg, South Africa, 4 Division 

of Rheumatology, University of the Witwatersrand, 

Johannesburg, South Africa 

1795. Correction for Basophil and Monocyte Frequencies 

Identifies Specific Gene Expression Differences Associated 

with SLE Disease Flare: Interim Report From the Bold 

(Biomarkers of Lupus Disease) Study. Mikhail G. Dozmorov 1 , 

Nicolas Dominguez 1 , Stan Kamp 2 , Cory Giles 1 , Jonathan D. 

Wren 1 , Sudhakar T. Sridharan 3 , Joan T. Merrill 1 , Judith A. 

James 4 and Joel M. Guthridge 1 , 1 Oklahoma Medical Research 


Foundation, Oklahoma City, OK, 2 Oklahoma Medical 

Research Foundation, Oklahoma CIty, OK, 3 Pfizer Inc, 

Collegeville, PA, 4 Oklahoma Medical Research Foundation 

and Oklahoma University Health Sciences Center, Oklahoma 

City, OK 

1796. Anti-IL-20 Targets Local Tissue Inflammation As Opposed 

to Systemic Inflammation. Amanda L. Blasius 1 , Joshua N. 

Beilke 1 , Hal Blumberg 1 , John Bui 1 , Jennifer H. Cox 1 , Tom Cox 1 , 

Heidi J. Jessup 1 , Phillip L. Kong 1 , Steven D. Levin 1 , Valerie 

H. Odegard 1 , Jason A. Stucky 1 , Evan P. Thomas 1 , Joseph 

A. Wahle 1 and John Rømer 2 , 1 Novo Nordisk Inflammation 

Research Center, Seattle, WA, 2 Novo Nordisk, Måløv, 

Denmark 

1797. Wnt Signaling Pathway Status, Determined by Serum 

Dkk-1 and R-Spondin 1 Levels, in Rheumatoid Arthritis and 

Ankylosing Spondylitis. Byoong Yong Choi 1 , Hyon Joung 

Cho 1 , Eun Ha Kang 1 , Yeong Wook Song 2 and Yun Jong Lee 1 , 

1 

Seoul National University Bundang Hospital, Seongnam-si, 

South Korea, 2 Seoul National University Hospital, Seoul, 

South Korea 

1798. Macrophage Migration Inhibitory Factor Regulates Dual- 

Specificity Phosphatases Via Glucocorticoid Induced 

Leucine Zipper. Huapeng Fan, Devi Ngo, Ran Gu and Eric 

Morand, Monash University, Melbourne, Australia 

1799. ONO-4059 - A Novel Small Molecule Bruton’s 

Tyrosine Kinase (Btk) Inhibitor, Suppresses Osteoclast 

Differentiation and Activation. Yuko Ariza, Toshio 

Yoshizawa, Yoshiko Ueda, Shingo Hotta, Masami Narita and 

Kazuhito Kawabata, Ono Pharmaceutical Co., Ltd., Osaka, 

Japan 

1800. Macrophages in Hypoxic Rheumatoid Joints Preferentially 

Express Hypoxia Inducible Transcription Factor-2. Sarah 

Aynsley 1 , Ursula Fearon 2 , Anthony G. Wilson 3 and Munitta 

Muthana 4 , 1 University of Sheffield, Sheffield, United 

Kingdom, 2 Translation Research Group, Dublin Academic 

Medical Centre, St. Vincent’s University Hospital, Dublin, 

Ireland, 3 Section of Musculoskeletal Sciences, University of 

Sheffield, Sheffield, United Kingdom, 4 University of sheffield, 

Sheffield, United Kingdom 

1801. Biological Roles of C5orf30 in Rheumatoid Arthritis. 

Munitta Muthana 1 , Sachin Khetan 2 , Gbadebo Adeleke 

Adeleke 2 , Simon Tazzyman 2 , Sarah Aynsley 1 , Fiona Morrow 1 , 

Sarah Hawtree 1 , Barbara Ciani 1 and Anthony G. Wilson 3 , 

1 

University of Sheffield, Sheffield, United Kingdom, 2 Dr, 

Sheffield, United Kingdom, 3 Section of Musculoskeletal 

Sciences, University of Sheffield, Sheffield, United Kingdom 

1802. Interleukin-29 Modulates Proinflammatory Cytokine 

Production in Synovial Inflammation of Rheumatoid 

Arthritis. Miaojia Zhang, Fang Wang, Lingxiao Xu and 

Wenfeng Tan, the First Affiliated Hospital of Nanjing Medical 

University, Nanjing, CHINA., Nanjing, China 

1803. Chemokine-Like Receptor 1 (CMKLR1), a G Protein Coupled 

Receptor Expressed On Proinflammatory Monocytes in


Arthritis, Is Negatively Regulated by GRK3. D. Stephen 

Serafin 1 , Roman Timoshchenko 2 , Marcus W. McGinnis 3 and 

Teresa K. Tarrant 4 , 1 Thurston Arthritis Research Center, 

Chapel Hill, NC, 2 University of North Carolina at Chapel Hill, 

Chapel Hill, NC, 3 University of North Carolina Sch of Med, 

Chapel Hill, NC, 4 UNC School of Medicine, Chapel Hill, NC 

1804. TNF-Like Protein 1A/Death Receptor 3 Pathway Regulates 

Osteoclastogenesis and Is Associated with Erosive Disease 

in Rheumatoid Arthritis. Fraser L. Collins 1 , Michael D. 

Stone 2 , Rhian Goodfellow 3 , Ernest Choy 4 , Edward C. Wang 1 

and Anwen S. Williams 1 , 1 Cardiff University, Institute of 

Infection and Immunity, Cardiff, United Kingdom, 2 University 

Hospital Llandough, Cardiff & Vale University Health 

Board, Cardiff, United Kingdom, 3 Cardiff University, Cardiff, 

ENGLAnd, United Kingdom, 4 Cardiff University School of 

Medicine, Cardiff, United Kingdom 

1805. The Pro-Fibrotic Cytokines IL-33 and IL-13 Modulates 

Dermal Fibrosis Via the A2A Adenosine Receptor. Ross C. 

Radusky 1 , Jessica L. Feig 2 , Bruce N. Cronstein 3 , Andrew G. 

Franks 4 and Edwin SL Chan 1 , 1 New York University School 

of Medicine, New York, NY, 2 New York Univ School of 

Medicine, New York, NY, 3 NYU School of Medicine, Division 

of Rheumatology, New York, NY, 4 New York University, New 

York, NY 

1806. A Novel Angiopoetin2/TEK Tyrosine Kinase Receptor 

Mediated Effect on Leukocyte Cell Influx and Oxidative 

Damage in Inflammatory Arthritis. Emese Balogh 1 , Chin T. 

Ng 1 , Douglas J. Veale 2 , Ursula Fearon 1 and Monika Biniecka 1 , 

1 

Translation Research Group, Dublin Academic Medical 

Centre, St. Vincent’s University Hospital, Dublin, Ireland, 

2 

Dublin Academic Medical Centre, St. Vincent’s University 



1808. Immune Activating Effects of Co-Stimulation of TLR 

Agonists and Cytokines on Primary and Immortalized 

Keratinocytes From a Patient with a CARD14 Mediated 

Pustular Psoriasis (CAMPS) and Healthy Controls. Yongqing 

Chen 1 , Yin Liu 2 , Yan Huang 1 , Carole Yee 3 , Alison MacBride 4 , 

Anne Bowcock 5 , Michelle Lowes 6 and Raphaela T. Goldbach- 

Mansky 7 , 1 Translational Autoinflammatory Disease Section, 

Office of the Clinical Director NIAMS, Bethesda, MD, 

2 

NIAMS, Bethesda, MD, 3 NCI, NIH, Bethesda, MD, 4 NIAID, 

NIH, Bethesda, MD, 5 Washington University, St. Louis, MO, 

6 

Laboratory for Investigative Dermatology, The Rockefeller 

University, New York, NY, 7 Translational Autoinflammatory 

Diseases Section NIAMS NIH, Bethesda, MD 

1809. Serum IFNα Activity in Systemic Lupus Erythematosus 

Drops in Response to Immunosuppressive Therapy Only 

When There Is Concurrent Clinical Response. Elzbieta E. 

Jacek 1 , Elena Gkrouzman 1 , Mikhail Olferiev 2 , Nancy Pan 1 , 

Roland Duculan 3 , Kyriakos A. Kirou 3 and Mary K. Crow 3 , 

1 

Mary Kirkland Center for Lupus Research, Hospital for 

Special Surgery, New York, New York, NY, 2 Mary Kirkland 

Center for Lupus Research, Hospital for Special Surgery, New 

York, NY, 3 Hospital for Special Surgery, New York, NY 

1810. Identification and Characterization of Synthetic Small 

Molecule Macrocycle Antagonists of Human IL17A. David 

Livingston, Sethu Alexander, Julian Bond, Timothy Briggs, 

Andrew Fraley, Stephen Hale, Tanya Landsman, Richard 

Martinelli, Kelley Shortsleeves, Nick Terrett and Nathan 

Walsh, Ensemble Therapeutics, Cambridge, MA 

1811. On the Origin of the Type I Interferon Signature in 

Rheumatoid Arthritis. T.D. de Jong 1 , Saskia Vosslamber 1 , 

Maija-Leena Eloranta 2 , Lars Rönnblom 2 , Kyra Gelderman 1 , 

Mary von Blomberg 1 , Irene Bultink 1 , Alexandre Voskuyl 1 

and Cornelis L. Verweij 1 , 1 VU University Medical Center, 

Amsterdam, Netherlands, 2 Section of Rheumatology, 

Uppsala University, Uppsala, Sweden 

Epidemiology and Health Services Research: Rheumatic Disease 

Pharmacoepidemiology 

1812. A Retrospective Evaluation of the Clinical and Economic 

Implications of Gout in Nursing Home Residents in Hawaii 

Treated with Allopurinol. Joy Higa 1 , Gregory Reardon 2 and 

Gregory Tong 3 , 1 Long Term Care Research Center, Kaneohe, 

HI, 2 Informagenics, LLC, Worthington, OH, 3 Deerfield, IL 

1813. Accuracy of Veterans Affairs Database for Gout-Related 

Health Care Utilization. Jasvinder A. Singh, University of 

Alabama at Birmingham, Birmingham, AL 

1814. Comparing Clinical Characteristics and Comorbidities of 

Gout Patients Treated with Allopurinol or Febuxostat. 

Michael A. Becker 1 , Xiangyang Ye 2 , Kasem S. Akhras 3 , 

Rima H. Tawk 4 , Sudhir Unni 2 , Jason Young 2 and Carl V. 

Asche 5 , 1 University of Chicago, Chicago, IL, 2 University 

of Utah College of Pharmacy, Salt Lake City, UT, 3 Takeda 

Pharmaceuticals International, Inc., Deerfield, IL, 4 University 

of Illinois at Chicago, Chicago, IL, 5 University of Illinois 

College of Medicine at Peoria, Peoria, IL 

1815. Factors Associated with a Prolonged Hospital Length 

of Stay for Patients with Acute Gout. Rebecca Sharim 1 , 

Meghan Musselman 2 and Marissa Blum 2 , 1 Temple University 

Hospital, Philadelphia, PA, 2 Temple University School of 

Medicine, Philadelphia, PA 

1816. Relationship Between Race, Uric Acid Levels, Urate- 

Lowering Therapy and Resource Use in Patients with 

Gout. Kim Coley, Melissa Saul and Karen Pater, University of 

Pittsburgh, Pittsburgh, PA 

1817. The Role of Repeating Tuberculin Skin Tests During Biologic 

Therapy. Joseph R. Lutt 1 and Kevin L. Winthrop 2 , 1 Colorado 

Center for Arthritis & Osteoporosis, Boulder, CO, 2 Oregon 

Health & Science University, Portland, OR 

1818. Latent Tuberculosis Detection and Tuberculosis 

Reactivation in Patients Receiving Anti-TNFá Drugs: A 

Nationwide Italian Survey. Fabrizio Cantini 1 , Ennio Lubrano 2 , 

Alessandro Mathieu 3 , Antonio Marchesoni 4 , Carlo Salvarani 5 , 

Raffaele Scarpa 6 and Antonio Spadaro 7 , 1 Ospedale 

Misericordia e Dolce di Prato, Prato, Italy, 2 Università del 



266 

Molise, Campobasso, Italy, 3 University of Cagliari, Cagliari, 

Italy, 4 Istituto Ortopedico Gaetano Pini, Milano, Italy, 

5 

Arcispedale S Maria Nuova. IRCCS, Reggio Emilia, Italy, 6 Via 

Pansini 5 , Naples, Italy, 7 Univeristà La Sapienza di Roma, 

Roma, Italy 

1819. Predictors of Pneumococcal Vaccination in Patients with 

Rheumatoid Arthritis and Systemic Lupus Erythematosus. 

Anna Gramling 1 , Kaleb Michaud 2 , Harlan Sayles 3 , Frederick 

Wolfe 4 and Michelene Hearth-Holmes 5 , 1 University of 

Nebraska Medical Center, Omaha, NE, 2 National Data Bank 


Center, Omaha, NE, 3 University of Nebraska Medical School, 

Omaha, NE, 4 National Data Bank for Rheumatic Diseases, 

Wichita, KS, 5 Univ. of Nebraska Medical Center, Omaha, NE 

1820. Human Papillomavirus Vaccine [Types 6, 11, 16, 18] 

(Gardasil®) and Autoimmune Disorders: Safety Assessment 

Using the Pharmacoepidemiologic General Research 

Extension System. Lamiae Grimaldi-Bensouda 1 , Michel 

Rossignol 2 , Elodie Aubrun 1 , Pamela Leighton 3 , Didier 

Guillemot 4 , Alfred Mahr 5 , Jacques Benichou 6 , Paul-Henri 

Lambert 7 , Bertrand Godeau 8 and Lucien Abenhaim 9 , 

1 

LA-SER, Paris, France, 2 LA-SER, Centre for Risk Research, 

Montreal, 3 LA-SER Europe Ltd., London, United Kingdom, 

4 

Institut Pasteur (PhEMI)/ INSERM U657 & Université Paris- 

Ile de France Ouest, Paris, France, 5 Hospital Saint-Louis, 

Paris, France, 6 INSERM U657 Pharmacoepidemiology and 

evaluation of the impact of health products on human 

health, France, and Department of Biostatistics, University 

Hospital of Rouen, Rouen, France, Rouen, France, 7 Centre 

of Vaccinology & neonatal immunology, University of 

Geneva, Geneva, Switzerland, 8 Service de médecine interne, 

Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, 

France, Creteil, France, 9 LA-SER Europe Ltd, London, United 

Kingdom 

1821. Clinical Predictors of Methotrexate-Induced Liver Enzyme 

Elevation in Patients with Rheumatoid Arthritis in an 

Electronic Medical Record. Monica Ramirez 1 , Bing Lu 1 , 

Michelle A. Frits 1 , Anne H. Fossel 2 , Katherine P. Liao 1 , Robert 

M. Plenge 1 , Jonathan S. Coblyn 3 , Nancy A. Shadick 4 and 

Elizabeth W. Karlson 5 , 1 Brigham and Women’s Hospital, 

Boston, MA, 2 Brigham & Womens Hospital, Boston, MA, 

3 

Brigham & Womens Hosp, Boston, MA, 4 Department of 

Medicine, Division of Rheumatology, Immunology and 

Allergy, Brigham and Women’s Hospital, Boston, MA, 

5 


Boston, MA 

1822. Liver Toxicity Monitoring and Its Impact On Methotrexate 

Discontinuation in a National Cohort of Veterans. 

Gabriela Schmajuk 1 , Yinghui Miao 2 , Jinoos Yazdany 3 , Mary 

Margaretten 1 and Michael Steinman 2 , 1 UCSF, San Francisco, 

CA, 2 San Francisco Veterans Affairs Medical Center, San 

Francisco, CA, 3 University of California San Francisco, San 

Francisco, CA 


1823. Short Periods of Glucocorticoid Use Increase the Risk of 

Gastrointestinal Bleeding. Steven C. Vlad 1 , David T. Felson 1 , 

Donald R. Miller 2 and Yuqing Zhang 1 , 1 Boston University, 

Boston, MA, 2 Edith Nourse Rogers Memorial VA Hospital, 

Bedford, MA 

1824. Do Statins Reduce the Incidence of Connective Tissue 

Disease? A Retrospective Cohort Study. Thomas W. 

Schmidt 1 , Daniel F. Battafarano 1 , Christopher R. Frei 2 , Eric M. 

Mortensen 3 and Ishak Mansi 4 , 1 San Antonio Military Medical 

Center, San Antonio, TX, 2 University of Texas Health Science 

Center at San Antonio, San Antonio, TX, 3 University of Texas 

Southwestern Medical Center, Dallas, TX, 4 San Antonio 

Military Medical Center, San Antonio 

1825. Work Disability and Work Limitations in Rheumatoid 

Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Are 

Equal and Increase with Comorbidities. Chanseok Rhee 1 , 

Janet E. Pope 2 , Andrew E. Thompson 3 , Nicole G. H. Le Riche 4 , 

Gina Rohekar 4 and Sherry Rohekar 4 , 1 Schulich School of 

Medicine and Dentisty, Western University, London, ON, 2 St. 


London, ON, 3 St. Josephs Health Ctr, London, ON, 4 St. 

Joseph’s Hospital, London, ON 

1826. Intravenously Administered Golimumab Significantly 

Improves Health Related Quality of Life and Work 

Productivity in Patients with Rheumatoid Arthritis: Results 

of a Phase III, Placebo Controlled Trial. Rene Westhovens 1 , 

Michael Weinblatt 2 , Chenglong Han 3 , Tim Gathany 3 , 

Lilianne Kim 4 , Michael Mack 4 , Jiandong Lu 4 , Daniel Baker 4 , 

Alan Mendelsohn 4 and Clifton O. Bingham III 5 , 1 University 

Hospital KU Leuven, Leuven, Belgium, 2 Rheumatology & 

Immunology, Brigham & Women’s Hospital, Boston, MA, 

3 

Johnson & Johnson Pharmaceutical Services, LLC, Malvern, 

PA, 4 Janssen Research & Development, LLC, Spring House, 

PA, 5 Johns Hopkins University, Baltimore, MD 

1827. Factors That Impact Work Productivity in the Preserve 

Trial: A Randomized Controlled Trial of Combination 

Etanercept-Methotrexate Therapy in Patients with 

Moderately Active Rheumatoid Arthritis. Vibeke Strand 1 , 

Thomas V. Jones 2 , Wenzhi Li 3 , Andrew S. Koenig 3 and Sameer 

Kotak 4 , 1 Stanford University, Portola Valley, CA, 2 Pfizer, Inc, 

Collegeville, PA, 3 Pfizer Inc., Collegeville, PA, 4 Pfizer Inc., New 

York, NY 

1828. Smoking Is Associated with Worse and More Widespread 

Pain, Worse Fatigue, General Health and Quality of Life 

in a Swedish Population Based Cohort of Patients with 

Psoriatic Arthritis. Ann B. I. Bremander 1 , Lennart TH 

Jacobsson 2 , Stefan Bergman 3 , Emma Haglund 4 and Ingemar 

F. Petersson 5 , 1 Halmstad University School of Business 

and Engineering, Halmstad, Sweden, 2 Department of 


Academy at University of Gothenburg, Gothenburg, Sweden, 

3 

R&D Center Spenshult, Oskarström, Sweden, 4 Spenshult 

Hospital for Rheumatic Diseases, Halmstad, Sweden, 

5 


University, Lund, Sweden


1829. Cost of Etanercept, Adalimumab, and Infliximab in Patients 

with Rheumatoid Arthritis with Employer Provided Health 

Insurance. Machaon Bonafede 1 , Crystal Watson 2 , George 

Joseph 2 , Nicole Princic 1 and David J. Harrison 2 , 1 Thomson 

Reuters Healthcare, Cambridge, MA, 2 Amgen Inc., Thousand 

Oaks, CA 

1830. Drugs Are the Major Cost Driver of Rheumatoid Arthritis As 

Soon As the First Year of the Disease: An Economic Analysis 

Based On the Espoir Cohort Data. Bruno Fautrel 1 , Sandy 

Lucier 2 , Georges Haour 2 , Hassani Maoulida 2 , Stephanie 

Harvard 1 , Alain Saraux 3 , Xavier Mariette 4 , Francis Guillemin 5 , 

Isabelle Durand-Zaleski 2 and Karine Chevreul 2 , 1 APHP-Pitie 

Salpetriere Hospital / UPMC, Paris, France, 2 APHP - URC Eco, 

Paris, France, 3 Université Brest Occidentale, Brest, France, 

4 

Université Paris-Sud, Le Kremlin Bicetre, France, 5 Faculte de 

Medecin/BP 18 4 , Vandoeuvre-les-Nancy, France 

1831. Evaluation of the Cost-Effectiveness of Rheumatoid 

Arthritis Treatment with Biologic Agents Using the IORRA 

Cohort Database. Eiichi Tanaka, Eisuke Inoue, Daisuke 

Hoshi, Akiko Kobayashi, Naoki Sugimoto, Kumi Shidara, Eri 

Sato, Yasushi Inoue, Yohei Seto, Ayako Nakajima, Shigeki 

Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute 

of Rheumatology, Tokyo Women’s Medical University, Tokyo, 

Japan 

1832. Evaluating the Cost-Effectiveness of Personalized 

Treatment with Adalimumab Using Serum Drug Levels in 

Rheumatoid Arthritis Patients. Charlotte L. M. Krieckaert 1 , 

Sandhya C. Nair 2 , M. T. Nurmohamed 3 , Carlo J.J. van 

Dongen 1 , Willem F. Lems 4 , Floris P.J.G. Lafeber 2 , J.W.J. 

Bijlsma 2 , Gertjan Wolbink 1 and Paco M.J. Welsing 2 , 1 Jan 

van Breemen Research Institute | Reade, Amsterdam, 

Netherlands, 2 University Medical Center Utrecht, Utrecht, 

Netherlands, 3 VU University Medical Center/Jan van Bremen 

Research Institute, Amsterdam, Netherlands, 4 VU University 

Medical Center, Amsterdam, Netherlands 

1833. Healthcare Costs in Psoriatic Arthritis Patients Newly 

Initiated On a Biologic Disease-Modifying Anti-Rheumatic 

Drug or Methotrexate. Frank Zhang 1 , Robert Hiscock 2 and 

Jeffrey Curtis 3 , 1 Celgene Corporation, Warren, NJ, 2 Analysis 

Group, Inc., Montreal, QC, 3 University of Alabama at 


1834. Utilization and Expected Cost of Rheumatoid Arthritis 

Patients Treated with Golimumab: A Specialty Pharmacy 

Perspective. Lorie Ellis 1 , Susan Bolge 1 , Heidi Hanna 2 , 

Christina White 2 and Patricia Rice 3 , 1 Janssen Scientific 

Affairs, LLC, Horsham, PA, 2 Diplomat Specialty Pharmacy, 

Flint, MI, 3 CliniRx Research, Naperville, IL 

1835. Prescription of Biologics in Rheumatoid Arthritis (RA), 

Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) in 

4 Norwegian Regions 2002-2011: A Study of Prescription 

Rates and Baseline Disease Activity. Elisabeth Lie 1 , Karen M. 

Fagerli 1 , Knut Mikkelsen 2 , Åse S. Lexberg 3 , Erik Rødevand 4 , 

Till Uhlig 1 and Tore K. Kvien 1 , 1 Diakonhjemmet Hospital, Oslo, 

Norway, 2 Lillehammer Hospital for Rheumatic Diseases, 

Lillehammer, Norway, 3 Drammen Hospital, Drammen, 

Norway, 4 St. Olavs Hospital, Trondheim, Norway 

1836. Early Versus Delayed Initiation of Disease-Modifying 

Antirheumatic Drugs in Rheumatoid Arthritis. Sharon Van 

Doornum 1 , Lynden Roberts 2 , Mark D. Reed 3 and Danny 

Liew 1 , 1 The University of Melbourne, Melbourne, Australia, 

2 

James Cook University, Townsville, Australia, 3 Sir Charles 

Gairdiner Hospital, Nedlands, Australia 

1837. Which Rheumatoid Arthritis, Ankylosing Spondylitis 

and Juvenile Idiopathic Arthritis Patients Initiate Anti- 

TNFá Therapy? Alain Saraux 1 , Jacques Benichou 2 , Chantal 

Deslandre 3 , Loic Guillevin 4 , Latifa Idbrik 5 , Jean Sibilia 6 , Marc 

Soudan 5 , Daniel Wendling 7 and Francis Guillemin 5 , 1 CHU de 

la Cavale Blanche and Université Bretagne occidentale, Brest 

Cedex, France, 2 EA4438 Laboratoire Physiopathologie des 

Arthrites, Rouen, France, 3 Cochin Hospital, Paris, France, 

4 


Paris Descartes, Paris, France, 5 Faculte de Medecin/BP 

184, Vandoeuvre-les-Nancy, France, 6 EA4438 Laboratoire 

Physiopathologie des Arthrites, Illkirch-Strasbourg, France, 

7 

Minjoz University Hospital, Besancon, France 

1838. 10-Year Trends in the Use of Disease Modifying Anti- 

Rheumatic Drugs (DMARDs) and Biologic Agents in 

Rheumatoid Arthritis: A National Veteran Affairs Study. 

Bernard Ng 1 , Nancy Petersen 1 , Hong-Jen Yu 1 , Myrna Khan 1 

and Maria E. Suarez-Almazor 2 , 1 Michael E. DeBakey VA 

Medical Center Health Services Research and Development 

Center of Excellence, Houston, TX, 2 University of Texas MD 

anderson Cancer Center, Houston, TX 

1839. The Progression of the Rate of Biologic Initiation in Early 

Rheumatoid Arthritis Is Constant Over the First 5 Years 

in the Espoir Cohort. Stéphanie Emilie 1 , Cécile Gaujoux- 

Viala 2 , Benjamin Granger 3 , Anne-Christine Rat 4 , Bernard 

Combe 5 and Bruno Fautrel 6 , 1 Paris 6,Pierre and Marie Curie 

University, AP-HP, Pitié-Salpêtrière Hospital, Department 

of Rheumatology, Paris, France, 2 Paris 6 – Pierre et Marie 

Curie University; Rheumatology, Pitié-Salpêtrière Hospital, 

Paris, France, 3 Université Pierre et Marie Curie - Paris 6 ; 

AP-HP, Paris, France, 4 Université de Lorraine, Paris Descartes 

University, APEMAC, EA 4360, F- 54 000, Nancy, France, 

5 

Hopital Lapeyronie, Montpellier, France, 6 APHP-Pitie 

Salpetriere Hospital / UPMC, Paris, France 

1840. Treatment Patterns in Psoriatic Arthritis Patients Newly 

Initiated On Non-Biologic Disease-Modifying Anti- 

Rheumatic Drugs. Jeffrey Curtis 1 , Genevieve Gauthier 2 , 

Robert Hiscock 2 and Frank Zhang 3 , 1 University of Alabama 

at Birmingham, Birmingham, AL, 2 Analysis Group, Inc., 

Montreal, QC, 3 Celgene Corporation, Warren, NJ 

1841. Lower Than Expected Levels of DMARD Acquisition 

Immediately Pre and Post Biologic Initiation in Rheumatoid 

Arthritis Patients. Denis Choquette 1 , Oliver Thomas 2 and 

Mark Arundine 2 , 1 University of Montreal, Notre-dame 

Hospital, Montreal, QC, 2 Roche, Toronto, ON 



1842. Disease Activity and Treatment Strategies in Moderate 

Rheumatoid Arthritis Patient Population: Data from 

the Consortium of Rheumatology Researchers of North 

America. Sameer Kotak 1 , Andrew S. Koenig 2 , David H. 

Collier 3 , Katherine C. Saunders 4 , Ping He 5 , Joel M. Kremer 6 

and George W. Reed 7 , 1 Pfizer Inc., New York, NY, 2 Pfizer 

Inc., Collegeville, PA, 3 Amgen Inc., Thousand Oaks, CA, 

4 

CORRONA, Inc., Southborough, MA, 5 UMASS Medical 

School, Worcester, MA, 6 Albany Medical College and 

The Center for Rheumatology, Albany, NY, 7 University of 


1843. Predictors of Starting and Stopping Disease Modifying 

Anti-Rheumatic Drugs for Rheumatoid Arthritis: A 23 Year 

Longitudinal Cohort. Daniel H. Solomon 1 , Edward Yelin 2 , 

Jeffrey N. Katz 3 , Chris Tonner 4 , M. Alan Brookhart 5 , Seoyoung 

C. Kim 1 , Bing Lu 1 and John Z. Ayanian 6 , 1 Brigham and 

Women’s Hospital, Boston, MA, 2 University of California San 

Francisco, San Francisco, CA, 3 Brigham & Women’s Hospital, 

Boston, MA, 4 UCSF, San Francisco, CA, 5 University of North 

Carolina, 6 Brigham and Women’s Hospital 

1844. Inequities in Access to Biologic Disease-Modifying Anti- 

Rheumatic Drugs for Patients with Rheumatoid Arthritis 

Across 46 European Countries. Polina Putrik 1 , Sofia Ramiro 2 , 

Milena Pavlova 1 , Tore K. Kvien 3 , Tuulikki Sokka 4 , Till Uhlig 3 , 

Annelies Boonen 5 and Equity In Access To Treatment of 

RA Across Europe 6 , 1 Maastricht University, Maastricht, 

Netherlands, 2 Academic Medical Center, University of 

Amsterdam, The Netherlands and Hospital Garcia de Orta, 

Almada, Portugal, 3 Diakonhjemmet Hospital, Oslo, Norway, 

4 

Jyvaskyla Central Hospital, Jyvaskyla, Finland, 5 University 

Hospital Maastricht, Maastricht, Netherlands, 6 European 

Region 

1845. Inequalities Across 46 European Countries in Clinical 

Eligibility Criteria for the Start of A First (Reimbursed) 

Biologic in Patients with Rheumatoid Arthritis. Polina 

Putrik 1 , Sofia Ramiro 2 , Tore K. Kvien 3 , Tuulikki Sokka 4 , Till 

Uhlig 3 , Annelies Boonen 5 and Equity in Clinical Eligibility 

Criteria for RA treatment 6 , 1 Maastricht University, 

Maastricht, Netherlands, 2 Academic Medical Center, 


Garcia de Orta, Almada, Portugal, 3 Diakonhjemmet Hospital, 

Oslo, Norway, 4 Jyvaskyla Central Hospital, Jyvaskyla, Finland, 

5 

University Hospital Maastricht, Maastricht, Netherlands, 

6 

European Region 

1846. Observation of Persistence Rates and Potential Costs 

Savings Associated with Certolizumab Pegol Treatment 

for Rheumatoid Arthritis in England, Wales and Northen 

Ireland Clinical Practice. Mike Russell 1 , Jen Timoshanko 1 , 

Graeme Duncan 2 , Angela Spandley 1 and Samantha Roskell 3 , 

1 

UCB Pharma, Slough, United Kingdom, 2 Healthcare at Home 

Ltd, Burton on Trent, United Kingdom, 3 Rheumatology, 

Cannock Chase Hospital, Cannock, United Kingdom 

1847. Status of the Rheumatology Clinical Trials Portfolio: Data 

from Clinicaltrials.Gov. Ankoor Shah 1 , Samuel Broderick 2 , 

Karen Chiswell 2 , Asba Tasneem 2 and John S. Sundy 1 , 1 Duke 

University Medical Center, Durham, NC, 2 Duke University 

Medical Center, Durham 

1848. Impact of Biologics On Total Knee Replacement and Total 

Hip Replacement Rates in Rheumatoid Arthritis Patients: 

Results From US Marketscan Database. Andrew S. Koenig 1 , 

Jack Mardekian 2 and Sameer Kotak 3 , 1 Pfizer Inc., Collegeville, 

PA, 2 Pfizer Inc, New York, NY, 3 Pfizer Inc., New York, NY 

1849. Value of Matrices Developed to Identify Early Rheumatoid 

Arthritis Patients with Rapid Radiographic Progression 

Despite Methotrexate Therapy: A Comparison of Their 

Performance in the Early Rheumatoid Arthritis Espoir 

Cohort. Bruno Fautrel 1 , Benjamin Granger 2 , Bernard 

Combe 3 , Francis Guillemin 4 , Alain Saraux 5 and Xavier Le 

Loët 6 , 1 APHP-Pitie Salpetriere Hospital / UPMC, Paris, 

France, 2 Université Pierre et Marie Curie - Paris 6 ; AP-HP, 

Paris, France, 3 Lapeyronie Hospital, Montpellier, France, 

4 

Faculte de Medecin/BP 184, Vandoeuvre-les-Nancy, 

France, 5 Université Brest Occidentale, Brest, France, 6 Rouen 

University Hospital and Inserm U 90 5 , Rouen, France 

1850. Association of Clinical Trial Characteristics with Positive 

Study Outcome Reporting in Randomized Controlled Trials 

of Rheumatoid Arthritis Therapy. Fatima M. Khan 1 , Juan 

I. Lombeida 2 , Horace Spencer 1 , Karina D. Torralba 3 , Winnie 

K. Pang 3 and Nasim A. Khan 4 , 1 University of Arkansas for 

Medical Sciences, Little Rock, AR, 2 Mercy Medical Center, 

Rogers, AR, 3 University of Southern California Keck School 

of Medicine, Los Angeles, CA, 4 University of Arkansas for 

Medical Sciences and Central Arkansas Veterans Healthcare 

System, Little Rock, AR 

1851. Exploring the Relationship of Anti-Tumor Necrosis Factor 

Drugs and Methicillin Resistant Staphylococcus Aureus 

Nasal Colonization in Patients with Rheumatologic 

Conditions and Psoriasis. Daniel E. Kreutz 1 , Santosh P. 

Reddy 1 , Guy P. Fiocco 2 , Colleen Colbert 1 and Juhee Song 1 , 

1 

Scott & White Healthcare/Texas A&M University, Temple, 

TX, 2 Scott & White Clinic, Temple, TX 

1852. Tumour Necrosis Factor-Alpha Antagonists and Alopecia: A 

Case/Non-Case Study in a Nationwide Pharmacovigilance 

Database. Johana Béné 1 , Guillaume Moulis 2 , Marine 

Auffret 1 , Claire Fessier 1 , Guillaume Lefevre 3 and Sophie 

Gautier 1 , 1 Lille University Hospital, Lille Pharmacovigilance 

Regional Centre, Lille, France, 2 Toulouse University Hospital, 

Clinical Pharmacology Department, University of Toulouse, 

UMR INSERM-UPS 102 7 , Toulouse, France, 3 Lille University 

Hospital, Internal Medicine Department, Lille, France 

1853. Rheumatoid Arthritis Patients’ Experiences of Medication 

Side Effects and Subsequent Decision Making about 

Medications. Yomei Shaw 1 , Ilinca D. Metes 2 , Susan L. 

Zickmund 2 , Dawn McBride 2 , Kelly A. Reckley 2 , Stephen R. 

Wisniewski 1 , Larry W. Moreland 2 , Mark S. Roberts 1 and Marc 

C. Levesque 2 , 1 University of Pittsburgh, Graduate School 

of Public Health, Pittsburgh, PA, 2 University of Pittsburgh 

School of Medicine, Pittsburgh, PA 

268 

2012 Program Book


1854. The Safety of Anti-TNF Biologic Agents in Rheumatoid 

Arthritis - A Meta-Analysis of 35 RCTs. Tzuyu Lin 1 , Tatyana 

Shamliyan 1 , Hyon Choi 2 , Young Hee Rho 2 and Karen Kuntz 1 , 

1 

Division of Health Policy and Management, School of Public 

Health, University of Minnesota, Minneapolis, MN, 2 Boston 

University School of Medicine, Boston, MA 

1855. Prevalence of Potential Drug-Drug and Drug-Condition 

Interactions in Fibromyalgia Patients Newly-Initiating 

Pregabalin or Duloxetine. Stephen Johnston 1 , Margarita 

Udall 2 , Joseph C. Cappelleri 3 , Barbara H. Johnson 1 , George 

Shrady 1 and Stuart L. Silverman 4 , 1 Truven Health Analytics, 

Washington, DC, 2 Pfizer Inc., New York, NY, 3 Pfizer Inc., 

Groton, CT, 4 Cedars-Sinai Medical Center, UCLA Center of 

Excellence, Beverly Hills, CA 

1856. Burden of Adverse Events Associated with 

Immunosuppressant Therapy for the Treatment of 

Systemic Lupus Erythematosus: A Systematic Literature 

Review. Alan Oglesby 1 , Arthur Weinstein 2 , Greg Dennis 3 , 

Alissa Shaul 4 , Tiffany Pokora 4 , Clark Paramore 5 , Lael Cragin 6 

and Siva Narayanan 3 , 1 GlaxoSmithKline, Research Triangle 

Park, NC, 2 Washington Hospital Center, Washington, DC, 

3 

Human Genome Sciences, Inc., Rockville, MD, 4 United 

BioSource Corporation, Bethesda, MD, 5 United BioSource 

Corporation, Lexington, MA, 6 United BioSource, Bethesda, 

MD 


1857. Identifying Core Symptom Domains in the Fibromyalgia 

Impact Questionnaire: Principal Component Analysis of 

Data from Milnacipran Clinical Studies. Philip Mease 1 , 

Robert M. Bennett 2 , Robert H. Palmer 3 and Yong Wang 3 , 

1 

Swedish Medical Center and University of Washington, 

Seattle, WA, 2 Oregon Health & Science Univ, Portland, OR, 

3 

Forest Research Institute, Jersey City, NJ 

1858. Hypervigiliance in Fibromyalgia. Robert S. Katz 1 , Ben 

J. Small 2 , Susan Shott 1 and Sharon M. Ferbert 3 , 1 Rush 

University Medical Center, Chicago, IL, 2 Rush University 

Medical School, Chicago, IL, 3 Advocates for Funding 

Fibromyalgia Treatment, Education and Research(AFFTER), 

Libertyville, IL 

1859. The Polysymptomatic Distress Scale and the Effect of Age 

On Polysymptomatic Distress and Fibromyalgia: A Survey 

in a Representative Population Sample. Winfried Häuser 1 , 

Frederick Wolfe 2 , Johannes Rasker 3 , Elmar Brähler 4 and 

Heide Glaesmer 4 , 1 Technische Universität München, Munich, 

Germany, 2 National Data Bank for Rheumatic Diseases, 

Wichita, KS, 3 University Twente, Enschede, Netherlands, 

4 

University of Leipzig, Leipzig, Germany 

1860. Fibromyalgia and the Disease and Statistical Manual 

Classification As a Somatic Symptom Disorder. Frederick 

Wolfe 1 , Brian T. Walitt 2 and Winfried Häuser 3 , 1 National Data 

Bank for Rheumatic Diseases, Wichita, KS, 2 Washington 

Hospital Center, Washington, DC, 3 Technische Universität 

München, Munich, Germany 

1861. Efficacy and Safety of Pregabalin in Japanese Patients with 

Fibromyalgia: A Randomized, Double-Blind, Multicenter, 

Placebo-Controlled Phase III Trial and Open-Label 

Extension Study. Hiroyoshi Ohta 1 , Masayuki Ohkura 1 , 

Makoto Suzuki 1 , Hiroshi Oka 2 , Chie Usui 3 and Kusuki 

Nishioka 4 , 1 Pfizer Japan Inc, Tokyo, Japan, 2 Tokyo Medical 

University Hachioji Medical Center, Tokyo, Japan, 3 Juntendo 

University Nerima Hospital, Tokyo, Japan, 4 Tokyo Medical 


1862. The 2012 Canadian Fibromyalgia Guidelines: Clinically 

Applicable Recommendations for the Management 

of Fibromyalgia. Mary-Ann Fitzcharles 1 , Peter A. Ste- 

Marie 2 , Don L. Goldenberg 3 , John X. Pereira 4 , Susan 

Abbey 5 , Manon Choinière 2 , Gordon Ko 5 , Dwight Moulin 6 , 

Pantelis Panopalis 7 , Johanne Proulx 8 and Yoram Shir 1 , 

1 

McGill University, Montreal, QC, 2 University of Montreal, 

Montreal, QC, 3 Newton-Wellesley Hosp, Newton, MA, 

4 

University of Calgary, Calgary, AB, 5 University of Toronto, 

Toronto, ON, 6 University of Western Ontario, London, ON, 

7 

McGill University Health Center, Montreal, QC, 8 Patient 

Representative, Montreal, QC 

1863. Resetting the Naming Speed Clock with Methylphenidate 

(Ritalin). Robert S. Katz and Frank Leavitt, Rush University 

Medical Center, Chicago, IL 

1864. Swimming Is As Effective As Walking for Treating 

Fibromyalgia: A Randomized Controlled Trial. Giovana 

Fernandes, Fabio Jennings, Michele V. Nery, Ana Leticia P. de 

Buosi and Jamil Natour, Universidade Federal de Sao Paulo, 

Sao Paulo, Brazil 

1865. Emotional Pain and Catastrophizing Influence Quality of 

Life in Fibromyalgia. Neda Faregh 1 , Peter A. Ste-Marie 2 and 

Mary-Ann Fitzcharles 1 , 1 McGill University, Montreal, QC, 

2 

University of Montreal, Montreal, QC 

1866. Association of Opioid Use with Symptom Severity and 

Quality of Life in Patients with Fibromyalgia. Terry H. Oh 1 , 

Chul H. Kim 2 , Connie A. Luedtke 1 , Jeffrey Thompson 1 , W. 

Michael Hooten 1 and Ann Vincent 1 , 1 Mayo Clinic, Rochester, 

MN, 2 Kyungpook National University, Daegu, South Korea 

1867. Assessment of ART Therapy Program for Women with 

Fibromyalgia: Randomized, Controlled, Blinded Study. 

andreia S. Baptista 1 , Anamaria Jones 1 , Fernanda P. Cardoso 1 , 

Betina C. Schaffir 1 , Elisa R. W. Coelho 1 , Aline Orlandi 1 and 

Jamil Natour 2 , 1 Universidade Federal de Sao Paulo, Sao 


Brazil 

1868. Clinical Outcome in Fibromyalgia Patients Treated with 

Milnacipran Is Largely Independent of Symptom Duration. 

Philip Mease 1 , Robert M. Bennett 2 , Robert H. Palmer 3 

and Yong Wang 3 , 1 Swedish Medical Center and University 

of Washington, Seattle, WA, 2 Oregon Health & Science 

University, Portland, OR, 3 Forest Research Institute, Jersey 

City, NJ 



270 

1869. Predictors of Fatigue in Fibromyalgia. Ann Vincent 1 , Mary 

O. Whipple 1 , Debra L. Barton 1 , Daniel J. Clauw 2 , David A. 

Williams 3 , Terry H. Oh 1 and Loren L. Toussaint 4 , 1 Mayo Clinic, 

Rochester, MN, 2 University of Michigan, Ann Arbor, MI, 

3 

Univ of MI Hlth System-Lobby M, Ann Arbor, MI, 4 Luther 

College, Decorah, IA 

1870. Financial Conflicts of Interest and Industry Sponsorship 

Are Associated with Positive Outcomes in Fibromyalgia 

Randomized Controlled Trials. Winnie K. Pang 1 , Karen 

Yeter 1 , Nasim A. Khan 2 and Karina D. Torralba 1 , 1 University of 


CA, 2 University of Arkansas for Medical Sciences and Central 

Arkansas Veterans Healthcare System, Little Rock, AR 

1871. Tender Point Count and Pressure Pain Threshold As 

Predictors of Chronic Widespread Pain and Health Status 

in a Seven Year Prospective Study. Emma Jacobsen 1 and 

Stefan Bergman 2 , 1 R&D center Spenshult, Oskarström, 

Sweden, 2 R&D Center Spenshult, Oskarström, Sweden 

1872. Quality of Reporting in Pharmacological Randomized 

Controlled Trials for Fibromyalgia. Karen Yeter 1 , Winnie 

Pang 1 , Nasim A. Khan 2 and Karina D. Torralba 1 , 1 University of 


CA, 2 University of Arkansas for Medical Sciences and Central 

Arkansas Veterans Healthcare System, Little Rock, AR 

1873. Clinical Characteristics and Health Care Utilization Patterns 

Among Patients with Fibromyalgia Newly Prescribed 

Amitriptyline, Duloxetine, Gabapentin or Pregabalin: A 

Large Cohort Study. Seoyoung C. Kim, Joan E. Landon and 

Daniel H. Solomon, Brigham and Women’s Hospital, Boston, 

MA 

1874. Genomic Categories of Fatigue in Women with 

Fibromyalgia. Nada Lukkahatai 1 , Brian T. Walitt 2 , Majors 

Benjamin 1 , Gelio Alves 3 and Leorey Saligan 1 , 1 National 

Institute of Nursing Research, National Institutes of Health, 

Bethesda, MD, 2 Washington Hospital Center, Washington, 

DC, 3 National Center for Biotechnology Information, 

National Library of Medicine, Bethesda, MD 

1875. A Patient and Physician Survey of Impact and Management 

of Fibromyalgia Across Latin America and Europe. Patricia 

Clark, Hospital Infantil de México Federico Gómez, Mexico 

City, Mexico 

1876. The Assessment and Treatment of Nonsurgical Periarticular 

Post-Traumatic Soft Tissue Injuries of the Knee. Dan 

Nemes 1 , Elena Amaricai 1 , Liliana Catan 1 , Daniel Popa 1 , 

Simona Cerbu 2 and Paula Bicov 1 , 1 ”Victor Babes” University 

of Medicine and Pharmacy, Timisoara, Romania, 2 Telescan 

Imaging Centre, Timisoara, Romania 

1877. Is the Amount of T and B Lymphocytes, Natural Killer 

Cells and Macrophages in Biopsies From Non-Ruptured 

Chronic Tendinopathic Achilles Tendons Predictive for 

Long Term Outcome? A >3 Years Prospective Study of 

37 Patients. Maja S. Kragsnæs 1 , Ulrich Fredberg 2 , Katrine 

Stribolt 3 , Søren G. Kjær 1 , Knud Bendix 3 and Torkell Ellingsen 1 , 

1 

Region Hospital Silkeborg, Silkeborg, Denmark, 2 Diagnostic 


Centre Region Hospital Silkeborg Denmark, 8600 Silkeborg, 

Denmark, 3 Aarhus University Hospital, Aarhus, Denmark 

1878. Cognitive Manifestations of Fibromyalgia and Lupus. 

Robert S. Katz and Frank Leavitt, Rush University Medical 

Center, Chicago, IL 

1879. Work Related Injuries Causing or Aggravating Fibromyalgia 

in the Medicolegal Arena: A Jurisprudential Analysis. 

Mary-Ann Fitzcharles 1 , Peter A. Ste-Marie 2 and Yoram Shir 1 , 

1 

McGill University, Montreal, QC, 2 University of Montreal, 

Montreal, QC 

1880. A Brazilian Portuguese Validation of the Revised 

Fibromyalgia Impact Questionnaire (FIQR). Eduardo S. 

Paiva 1 , Roberto E. Heymann 2 , Marcelo C. Rezende 3 , Milton 

Helfenstein Jr. 4 , José E. Martinez 5 , José R. Provenza 6 , Aline 

Ranzolin 7 , Marcos Renato Assis 8 , Vivian D. Pasqualin 9 and 

Robert M. Bennett 10 , 1 Universidade Federal do Paraná, 

Curitiba, Brazil, 2 Universidade Federal de São Paulo, São 

Paulo, Brazil, 3 Santa Casa de Campo Grande, Campo 

Grande, Brazil, 4 Universidade Federal de de São Paulo, 

São Paulo, Brazil, 5 Pontifícia Universidade Católica de São 

Paulo, Sorocaba, Brazil, 6 Pontifícia Universidade Católica 

de Campinas, Campinas, Brazil, 7 Universidade Federal de 

Pernambuco, Recife, Brazil, 8 Faculdade de Medicina de 

Marilia, Marilia, Brazil, 9 Pontifícia Universidade Católica do 

Paraná, Curitiba, Brazil, 10 Oregon Health & Science Univ, 

Portland, OR 

1881. Increased Psychosocial Stress Is a Major Component of 

Fibromyalgia Triggers. Emma K. Guymer 1 , Kathleen Elford 2 

and Geoffrey O. Littlejohn 1 , 1 Monash Medical Centre and 

Monash University, Clayton, Victoria, Australia, 2 Monash 

Medical Centre, Clayton, Victoria, Australia 

1882. Predictors of a Favorable Outcome in Patients with 

Fibromyalgia: Results from the 1-Year Follow-up. Dong- 

Jin Park 1 , Shin-Seok Lee 1 , Seong-Ho Kim 2 , Seong-Su Nah 3 , 

Ji Hyun Lee 4 , Seong-Kyu Kim 5 , Yeon-Ah Lee 6 , Seung-Jae 

Hong 6 , Hyun-Sook Kim 7 , Hye-Soon Lee 8 , Hyoun Ah Kim 9 , 

Chung-Il Joung 10 and Sang-Hyon Kim 11 , 1 Chonnam National 

University Medical School, Gwangju, South Korea, 2 Inje 

University Haeundae Paik Hospital, Busan, South Korea, 

3 

Soonchunhyang University, South Korea, 4 Maryknoll 

Medical Center, Busan, South Korea, 5 and Autoimmunity 

Research Center, Catholic University of Daegu School of 

Medicine, Daegu, South Korea, 6 Kyung Hee University, 

Seoul, South Korea, 7 Internal Medicine, Chosun University 

Hospital, Gwangju, South Korea, 8 Hanyang University Guri 

Hospital, Guri, South Korea, 9 Ajou University School of Med, 

Suwon, South Korea, 10 Konyang University Medical School, 

Daejeon, South Korea, 11 Dongsan Medical Center, Keimyung 

University, Daegu, South Korea 

1883. Efficacy and Safety of Joint and Soft Tissue Injections; A 

Retrospective Study. Jenny Cabas-Vargas 1 , Leah Alon 2 , Nina 

Ramessar 2 , Dimitre Stefanov 2 , Jose B. Toro and Deana M. 

Lazaro 4 , 1 SUNY Downstate, Brooklyn, NY, 2 SUNY Downstate 

Medical Center, Brooklyn, NY, 3 Brooklyn VA, Brooklyn, NY


1884. Fibromyalgia Patients Who Meet the ACR 1990 Criteria 

Have More Severe Disease. Carmen E. Gota 1 , Benjamin 

Nutter 2 and William Wilke 3 , 1 The Cleveland Clinic Desk A50, 

Cleveland, OH, 2 Cleveland Clinic, Cleveland, OH, 3 Cleveland 

Clinic Foundation, Cleveland, OH 


1885. Rheumatologists’ Ultrasound Confidence and 

Interpretation of Normal Anatomy Are Improved by a 

Cadaver Based Sonoanatomy Course. Iain Goff 1 , David 

Wright 2 and Debra Patten 3 , 1 Newcastle University, Newcastle 

upon Tyne, United Kingdom, 2 Sunderland Royal Hospital, 

Sunderland, United Kingdom, 3 School of Medical Sciences 

Education and Development, Newcastle upon Tyne, United 

Kingdom 

1886. Evaluation of a New Educational Tool: A Resident’s Guide 

to Pediatric Rheumatology. Tania Cellucci and Ronald M. 

Laxer, The Hospital for Sick Children, Toronto, ON 

1887. Facebook Support Groups in Systemic Lupus 

Erythematosus: Content Analysis. Evelyne Vinet 1 , William 

Shihao Lao 2 , Christian A. Pineau 1 , Ann E. Clarke 3 and Sasha 

Bernatsky 4 , 1 McGill University Health Centre, Montreal, QC, 

2 

McGill University, Montreal, QC, 3 MUHC, Montreal, QC, 

4 

Research Institute of the McGill University Health Ctre, 

Montreal, QC 

1888. Immunology for Rheumatology Residents: Working 

towards a National Curriculum Consensus. Shirley L. Chow 1 , 

Dharini Mahendira 2 , Sari Herman-Kideckel 3 and Heather 

McDonald-Blumer 4 , 1 University of Toronto, Toronto, ON, 

2 

St Michael’s Hospital, Toronto, ON, 3 University of Toronto, 

North York, ON, 4 Mt. Sinai Hospital, Toronto, ON 

1889. The Effects of Physical & Mental Health Rehabilitation 

Program (PMHRP) for Hemophilic Arthritis Patients. Won 

Sook BAK 1 , Myung Chul Yoo 1 , Nam Su Cho 1 , Sang Hack Lee 1 , 

Yoon Hee Kim 2 and Ki Young Yoo 1 , 1 Kyung Hee University 

Hospital at Gangdong, Seoul, South Korea, 2 Seoul, South 

Korea 

1890. The Current State of Mentoring Among Pediatric 

Rheumatology Fellows and Junior Faculty in the United 

States and Canada. Meredith P. Riebschleger 1 , Eyal Muscal 2 , 

Matthew M. Davis 3 , Hermine Brunner 4 , B. Anne Eberhard 5 , 

C.J. Inman 6 , Marisa S. Klein-Gitelman 7 , Lakshmi N. Moorthy 8 , 

Marc D. Natter 9 , Sampath Prahalad 10 , Rayfel Schneider 11 and 

Peter A. Nigrovic 12 , 1 University of Michigan Health System, 

Ann Arbor, MI, 2 Baylor College of Medicine, Houston, TX, 

3 

University of Michigan, Ann Arbor, MI, 4 Cincinnati Children’s 

Hospital Medical Center and PRSCG, Cincinnati, OH, 5 Cohen 

Children’s Hospital Medical Center, New Hyde Park, NY, 

6 

University of Utah, Salt Lake City, UT, 7 Ann & Robert H. Lurie 

Children’s Hospital of Chicago, Chicago, IL, 8 Robert Wood 

Johnson-UMDNJ, New Brunswick, NJ, 9 Children’s Hospital 

Boston, Boston, MA, 10 Emory Children’s Center, Atlanta, GA, 

11 

The Hospital for Sick Children, Toronto, ON, 12 Brigham and 


1891. Teaching Medical Students Principles of Chronic Disease: 

Medicine of the 4th and 5th Dimension at Weill-Cornell. 

Michael D. Lockshin 1 , Greg McDermott 2 , Lester Zambrana 2 

and Alana B. Levine 1 , 1 Hospital for Special Surgery, New York, 

NY, 2 Weill-Cornell Medical College, New York 

1892. Impact of a Lupus Patient Education Event on 

Knowledge about Systemic Lupus Erythematosus. Mithu 

Maheswaranathan 1 , Melissa A. Cunningham 2 , Sharon 

Wolf 1 and Diane L. Kamen 3 , 1 Medical University of South 

Carolina, Charleston, SC, 2 MUSC, Charleston, SC, 3 Arthritis & 


Foundation, Charleston, SC 

1893. Eliciting Prescribing Choices of Anti-Tumour Necrosis Factor 

Therapy from Rheumatology Trainees. Rodney A. Hughes 1 

and Alison J. Carr 2 , 1 St. Peters Hospital, Chertsey Surrey, 

United Kingdom, 2 Hamell Communications, London, United 

Kingdom 

1894. Factors Associated with Confidence Level of Rheumatology 

Fellows in Joint Procedural Skills. Tara J. Rizvi, Min Xu and 

Nancy Searle, Baylor College of Medicine, Houston, TX 

1895. Safety Competences Knowledge and Behavioural Skills of 

Patients Treated by Biologics in Rheumatology. Anne- 

Christine Rat 1 , Bruno Fautrel 2 , Elisabeth Flipon 3 , Laure 

Gossec 4 , Benoit-Damien Caritey 5 , Laurent Marguerie 6 , 

Henri Nataf 7 , Beatrice Pallot Prades 8 , Rose Marie Poilvert 9 , 

Valerie Royant 10 , Fathia Sadji 11 , Christelle Sordet 12 , Corinne 

Thevenot 13 and Catherine Beauvais 14 , 1 Université de 

Lorraine, Paris Descartes University, APEMAC, EA 4360, 

F- 54 000, Nancy, France, 2 APHP-Pitie Salpetriere Hospital 

/ UPMC, Paris, France, 3 Cochin hospital, Paris, France, 

4 

Paris-Descartes University, Cochin Hospital, Paris, France, 

5 

Université de lorraine, Nancy, France, 6 Institut Calot, Berck, 

France, 7 Mantes-la-Jolie, Mantes-la-Jolie, France, 8 Saint 

Etienne university hospital, Saint Etienne, France, 9 Saint 

Antoine Hospital, Paris, France, 10 Chartres, Chartres, 11 Victor 

Jousselin Hospital, Dreux, France, 12 Strasbourg University 

Hospital, Strasbourg, France, 13 Laon hospital, Laon, France, 

14 

Saint Antoine, Paris, France 

1896. Variation in US Pediatric Rheumatology Fellowship 

Training. Anjali Patwardhan 1 , Michael Henrickson 2 , Sandy D. 

Hong 3 , ‘Laura Laskosz and Charles H. Spencer 1 , 1 Nationwide 

Childrens Hospital, Columbus, OH, 2 Cincinnati Children’s 

Hospital Medical Center, Cincinnati, OH, 3 U of Iowa 

Children’s Hosp, Iowa City, IA 

1897. Pregnancy and Contraception in Adolescents and Teens 

with SLE: Are pediatric rheumatologists adequately 

screening and Educating Their Patients? Deirdre I. De 

Ranieri 1 , Karen Onel 1 , Linda Wagner-Weiner 2 and Melissa 

S. Tesher 1 , 1 University of Chicago, Chicago, IL, 2 University of 

Chicago Hospital, Chicago, IL 

1898. A Competence-Based Model for Teaching Rheumatology in 

Undergraduate Medical Students in Pontificia Universidad 

Católica De Chile: A Five Years Experience. Pamela Díaz, 



272 

Carolina Cuellar, Miguel Gutiérrez and Marcela Cisternas, 

Pontificia Universidad Católica de Chile, Santiago, Chile 

1899. Factors Contributing to Non-Publication of Abstracts 

Presented At the American College of Rheumatology/ 

Association of Rheumatology Health Professionals 

Annual Meeting. Jennifer M.P. Woo 1 , De Furst 2 , Deborah 

K. McCurdy 1 , Olivia I. Lund 3 , Rotem Eyal 3 , Cijin Piao 3 and 

Gil Amarilyo 1 , 1 Mattel Children’s Hospital, University of 

California, Los Angeles, Los Angeles, CA, 2 University of 

California at Los Angeles, Los Angeles, CA, 3 David Geffen 

School of Medicine at UCLA, Los Angeles, CA 

1900. Mormed Project: A New 21st Century Web Platform 

for Multilingual Communication in systemic Lupus 

Erythematosus and Antiphospholipid Syndrome. Oier 

Ateka-Barrutia 1 , Adriane Rinsche 2 , Maria Laura Bertolaccini 1 , 

Munther A. Khamashta 1 and MORMED consortium 3 , 1 Lupus 

Research Unit, The Rayne Institute, Kings College London 

School of Medicine, London, United Kingdom, 2 Language 

Technology Center Ltd., Kingston, United Kingdom, 3 EU 


1901. Chronic Gout. Improvement According to Outcome 

Meaures in Rheumatology Domains in Daily Clinical 

Practice. Janitzia Vazquez-Mellado 1 , Betsabé Serrano 1 , Jaime 

Mendoza 2 , Sergio Garcia-Mendez 1 , V.Chantal Hernández 1 , 

Virginia Pascual Ramos 2 , Ruben Burgos-Vargas 1 and Marina 

Rull-Gabayet 2 , 1 Hospital General de Mexico, Mexico city, 

Mexico, 2 Instituto Nacional de Ciencias Médicas y Nutrición 

Salvador Zubirán, Mexico City, Mexico 

1902. What Factors Are Associated with Target Serum Urate 

Concentrations in Patients with Gout? Nicola Dalbeth 1 , 

Meaghan House 1 , Anne Horne 1 , Keith J. Petrie 1 , Fiona M. 

McQueen 1 and William Taylor 2 , 1 University of Auckland, 

Auckland, New Zealand, 2 University of Otago, Wellington, 

New Zealand 

1903. Oxidation of Urate to Allantoin by Myeloperoxidase 

in Gout. Lisa K. Stamp, Irada Khalilova, Mei Zhang, 

Rufus Turner and Anthony Kettle, University of Otago, 

Christchurch, Christchurch, New Zealand 

1904. Patterns of Gout Treatment and Related Outcomes in 

US Community Rheumatology Practices: the Relation 

between Gout Flares, Time in Treatment, Serum Uric Acid 

Level and Urate Lowering Therapy. Max I. Hamburger 1 , 

John RP Tesser 2 , John L. Skosey 3 , Allan H. Morton 4 and Karl 

M. Kilgore 5 , 1 Rheumatology Associates, Melville, NY, 2 AZ 

Arthritis Rheum Assoc, Paradise Valley, AZ, 3 Illinois Bone & 

Joint Institut, Chicago, IL, 4 Warren, MI, 5 Cetus Group, LLC, 

Hunt Valley, MD 

1905. Increase of Thyroid Stimulating Hormone in Patients On 

Febuxostat Treatment. Fernando Perez-Ruiz 1 and Ana M. 

Herrero-Beites 2 , 1 Hospital Universitario Cruces, Baracaldo, 

Spain, 2 Hospital de Gorliz, Gorliz, Spain 


1906. Changes in Gout patient´s Clinical Profile in the Last Two 

Decades. Fernando Perez-Ruiz 1 and Ana M. Herrero-Beites 2 , 

1 

Hospital Universitario Cruces, Baracaldo, Spain, 2 Hospital de 

Gorliz, Gorliz, Spain 

1907. Pharmacological Management of Gout in Italy in the Years 

2005-2009: A Nationwide, Population-Based Study. Lorenzo 

Cavagna 1 , Gianluca Trifirò 2 , Roberto Caporali 3 , P. Morabito 2 , 

C. Ferrajolo 4 , S. Pecchioli 5 , M. Simonetti 5 , G. Medea 6 , 

C. Cricelli 7 , A. Caputi 2 , G. Mazzaglia 5 and Carlomaurizio 

Montecucco 8 , 1 University and IRCCS Foundation Policlinico 

S. Matteo, Pavia, Italy, 2 University of Messina, Italy, 3 Division 

of Rheumatology, IRCCSPoliclinico S. Matteo Foundation, 

Pavia, Italy, 4 Second University of Naples, Naples, Italy, 

5 

Italian College of General Practitioners, Italy, 6 Italian college 

of General Practitioner, Italy, 7 Italian college of General 

Practitioner, Pavia (italy), Italy, 8 University of Pavia School of 


Italy 

1908. Multinational Evidence-Based Recommendations 

for Diagnosis and Management of Gout: Integrating 

Systematic Literature Research and Expert Opinion of 

a Broad Panel of Rheumatologists in the 3E Initiative. 

Mariano andres 1 , Francisca Sivera 2 , Alison Kydd 3 , John 

Moi 4 , Rakhi Seth 5 , Melonie K. Sriranganathan 6 , Caroline 

van Durme 7 , Irene AAM van Echteld 8 , Ophir Vinik 9 , Mihir D. 

Wechalekar 10 , Daniel Aletaha 11 , Claire Bombardier 9 , Rachelle 

Buchbinder 12 , Loreto Carmona 13 , Christopher J. Edwards 14 , R. 

Landewe 15 and Désirée van der Heijde 16 , 1 Hospital General 

Universitario de Alicante, Alicante, Spain, 2 Hospital General 

de Elda, Alicante, Spain, 3 University of British Columbia, 

Vancouver, BC, 4 Royal Melbourne Hospital, Melbourne, 

Australia, 5 University Hospital Southampton NHS Foundation 

Trust, Southampton, United Kingdom, 6 St. Mary’s Hospital, 

Isle of Wight, United Kingdom, 7 Maastricht University 

Medical Centre, Maastricht, Netherlands, 8 Atrium Medical 

Center, Heerlen, Netherlands, 9 University of Toronto, 

Toronto, ON, 10 Flinders University School of Medicine, 

Adelaide, Australia, 11 Medical University of Vienna, Vienna, 

Austria, 12 Monash Department of Clinical Epidemiology 

at Cabrini Hospital, Department of Epidemiology and 

Preventive Medicine, Monash University, Malvern, Australia, 

Malvern, Victoria, Australia, 13 Universidad Camilo José 

Cela, Villanueva de la Cañada, Spain, 14 University Hospital 

Southampton, Southampton, United Kingdom, 15 Academic 



Netherlands 

1909. Use of Uric Lowering Therapies within a Large Health Care 

System. Robert A. Overman 1 , Brian F. Mandell 2 and Chad 

L. Deal 3 , 1 Cleveland Clinic Foundation, Cleveland, OH, 2 The 

Cleveland Clinic, Cleveland, OH, 3 Cleveland Clinic, Cleveland, 

OH 

1910. Regulation of Microrna 223 Expression in a Gouty Arthritis. 

Gianina Statache 1 , Ashleigh-Ann Rainey 1 , Seth Masters 2 , 

andra Balanescu 3 , Iain B. McInnes 1 and Mariola Kurowska-


Stolarska 4 , 1 University of Glasgow, Glasgow, United Kingdom, 

2 

Trinity College Dublin, Dublin, United Kingdom, 3 University 

of Medicine and Pharmacy, Bucharest, Romania, 4 Institute 

of Infection,Immunity and Inflammation, College of Medical, 

Veterinary and Life Sciences, University of Glasgow,, 

Glasgow, United Kingdom 

1911. Efficacy and Safety of Canakinumab Vs Triamcinolone 

Acetonide in Patients with Gouty Arthritis Unable to Use 

Nonsteroidal Anti-Inflammatory Drugs and Colchicine, 

and On Stable Urate Lowering Therapy (ULT) or Unable to 

Use ULT. T. Bardin 1 , A. So 2 , R. Alten 3 , M. Bloch 4 , M. R. John 5 , 

G. Krammer 5 , J. M. Nebesky 5 , A. Tao 6 and N. Schlesinger 7 , 

1 

Service de Rhumatologie, Hôpital Lariboisière, Paris, 

France, 2 Centre Hospitalier Universitaire Vaudois, University 

of Lausanne, Lausanne, Switzerland, 3 Charité Univ Medicine, 

Berlin, Germany, 4 Holdsworth House Medical Practice, 

Sydney, Australia, 5 Novartis Pharma AG, Basel, Switzerland, 

6 

Novartis Pharmaceuticals Corporation, East Hanover, 

NJ, 7 UMDNJ-Robert Wood Johnson Medical School, New 

Brunswick, NJ 

1912. Colchicine, As Assessed by Target Joint Pain Scores, Is 

Effective At 16 Hours in Patients with Acute Gout Flares. 

Suman Wason, Thomas Lauterio, Steve Crockett and 

Matthew W. Davis, URL Pharma, Philadelphia, PA 

1913. Complete Tophus Response in Patients with Chronic Gout 

Initiating Pegloticase Treatment. Michael A. Becker 1 , 

Neil J. Gonter 2 , Janet E. Pope 3 , Raymond L. Malamet 4 and 

Herbert S. B. Baraf 5 , 1 University of Chicago, Chicago, IL, 

2 

Rheumatology Associates of North Jersey, Teaneck, NJ, 3 St. 


London, ON, 4 Savient Pharmaceuticals, Inc., East Brunswick, 

NJ, 5 Arthritis & Rheumatism Associates, Wheaton, MD 

1914. The Diagnosis and Management of Gout in 2012: Survey 

of US and Canadian Rheumatologists. John J. Cush 1 and 

Robert T. Keenan 2 , 1 Baylor Research Institute, Dallas, TX, 

2 

Duke University, Durham, NC 

1915. Elevated Serum Homocysteine Levels Were Related Not 

with Serum Uric Acid Levels but with Decreased Renal 

Function in Chronic Gouty Patients. Sang Tae Choi 1 , Jung- 

Soo Song 2 , Jin Su Kim 1 , Eun-Jin Kang 3 , Kwang-Hoon Lee 4 and 

You-Jung Ha 5 , 1 Chung-Ang University School of Medicine, 

Seoul, South Korea, 2 Chung-Ang University College of 

Medicine, Seoul, South Korea, 3 Busan Medical Center, 

Busan, South Korea, 4 Dongguk University Ilsan Hospital, 

Goyang, South Korea, 5 Kwandong University college of 

Medicine, Goyang, South Korea 

1916. Serum Uric Acid As a Biomarker for Mitigation of 

Infusion Reactions in Patients Treated with Pegloticase 

for Refractory Chronic Gout. Herbert S. B. Baraf 1 , Robert 

A. Yood 2 , John S. Sundy 3 , Faith D. Ottery 4 and Michael A. 

Becker 5 , 1 Arthritis & Rheumatism Associates, Wheaton, MD, 

2 

Reliant Medical Group, Worcester, MA, 3 Duke University 

Medical Center, Durham, NC, 4 Savient Pharmaceuticals, Inc., 

East Brunswick, NJ, 5 University of Chicago, Chicago, IL 

Miscellaneous Rheumatic and Inflammatory Diseases 

1917. Long-Term Follow-up of IgG4-Related Diseases Presenting 

with Lacrimal and Salivary Gland Involvement. Hiroki 

Takahashi 1 , Motohisa Yamamoto 1 , Tetsuya Tabeya 1 , Chisako 

Suzuki 1 , Yasuyoshi Naishiro 1 , Yasuhisa Shinomura 1 and 

Kohzoh Imai 2 , 1 Sapporo Medical University School of 

Medicine, Sapporo, Japan, 2 The University of Tokyo, Tokyo, 

Japan 

1918. Cluster Analysis of Organ Involvements Patients with 

Serum IgG4 Elevation; IgG4–related Disease Is a Distinct 

Subtype of Patients with Hyper-IgG4. Masamitsu Tatewaki, 

Kazuhiro Kurasawa, Ayae Tanaka, Junya Nagasawa, Satoko 

Arai, Reika Maezawa, Takayoshi Owada and Takeshi Fukuda, 

Dokkyo Medical University, Mibu, Tochigi, Japan 

1919. Regulatory T Cells in IgG4-Related Disease Patients 

Presenting with Sclerosing Sialadenitis and Dacryoadenitis. 

Winnie K. Pang, Ya Liu, Julie Wang, Song Guo Zheng, Kiran 

Qidwai, Russell K. Brynes and Francisco P. Quismorio Jr., 

University of Southern California Keck School of Medicine, 


1920. Spectrum of IgG4-Related Disease and Diagnostic Value 

of Serum IgG4 Determinations. Emma Kotisalmi 1 , Tom 

Pettersson 2 , Aaro Miettinen 3 , Johanna Arola 4 and Martti 

Färkkilä 2 , 1 University of Helsinki, Helsinki, Finland, 2 Helsinki 

University Central Hospital, Helsinki, Finland, 3 Huslab, 

Helsinki, Finland, 4 University of Helsinki and Huslab, 

Helsinki, Finland 

1921. Diagnostic Utility of Serum IgG4 in IgG4-Related Disease. 

Mollie Carruthers 1 , Tamara Augustin 2 , John H. Stone 1 and 

Arezou Khosroshahi 1 , 1 Massachusetts General Hospital, 

Boston, MA, 2 Internal Medicine, Northshore Medical Center, 

Salem, MA 

1922. Articular Involvement in Relapsing Polychondritis: A Case 

Series. Laura O. Damian 1 , Linda Ghib 1 , Ioana Felea 2 , Alma 

Maniu 3 , Nadia Radics 1 , Simona Falaus 1 , Ileana Filipescu 4 , 

Siao-pin Simon 3 and Simona Rednic 4 , 1 Emergency County 

Clinical Hospital Cluj Napoca, Cluj Napoca, Romania, 

2 

Emergency County Clinical Hospital Cluj Napoca, Cluj- 

Napoca, Romania, 3 University of Medicine and Pharmacy 

“Iuliu Hatieganu” Cluj Napoca, Cluj Napoca, Romania, 

4 

University of Medicine and Pharmacy “Iuliu Hatieganu” Cluj 

Napoca, Cluj-Napoca, Romania 

1923. Biologics in Relapsing Polychondritis: A Single Center Case- 

Series. Guillaume Moulis 1 , Laurent Sailler 2 , Grégory Pugnet 3 , 

Leonardo Astudillo 1 and Philippe Arlet 1 , 1 Toulouse University 

Hospital, University of Toulouse, Toulouse, France, 2 Toulouse 

University Hospital, University of Toulouse, INSERM UR 

1027, Toulouse, France, 3 Toulouse University Hospital, 

University of Toulouse, INSERM UMR 1027, Toulouse, France 

1924. What Do Patients with Polmyalgia Rheumatica Mean 

When They Describe Stiffness? A Qualitative Study. 

Rodney A. Hughes 1 , Sarah Mackie 2 , John R. Kirwan 3 , Colin T. 

Pease 4 , Margaret Walsh 1 and Marianne Morris 5 , 1 St. Peters 



274 

Hospital, Chertsey Surrey, United Kingdom, 2 University of 

Leeds, Leeds, United Kingdom, 3 Bristol Royal Infirmary, 

Bristol, United Kingdom, 4 Leeds Teaching Hospitals NHS 

Trust, Harrogate, United Kingdom, 5 University of the West of 

England, Bristol, United Kingdom 

1925. Patient Satisfaction and Experience with Golimumab, 

Adalimumab, and Etanercept for the Treatment of 

Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing 

Spondylitis. Susan Bolge 1 , Helen Eldridge 2 , Dilesh 

Doshi 1 , Lorie Ellis 1 , Barbara Roland 3 and John Woelfel 3 , 

1 

Janssen Scientific Affairs, LLC, Horsham, PA, 2 Janssen 

Pharmaceuticals, Inc, Titusville, NJ, 3 The Dominion Group, 

Reston, VA 

1926. Evaluation of Strategies to Taper Anti-TNF Drugs in Patients 

with Inflammatory Rheumatic Disease (Rheumatoid 

Arthritis, Ankyloing Spondylitis, Psoriatic Arthritis, Adultage 

Juvenile Idiopatic Arthritis) in Long-Term Remission. 

Jakub Zavada, Katarina Hviscova, Katerina Jarosova, Sarka 

Forejtova, Jiri Stolfa, Liliana Sedova, Dana Tegzova, Jiri 

Vencovsky and Karel Pavelka, Institute of Rheumatology, 

Prague, Czech Republic 

1927. Inflammatory Meningeal Involvement in Patients with 

Rheumatic Diseases Responsive to Rituximab. Jane Park 1 , 

Eyal Kedar 1 , Ingeborg Sacksen 1 , John Henson 2 and Gregory C. 

Gardner 1 , 1 University of Washington, Seattle, WA, 2 Swedish 

Neuroscience Institute, Seattle, WA 

1928. Evaluating the Therapeutic Effects of B Cell Depletion 

Therapy with Rituximab in a Longitudinal Cohort of Mixed 

Connective Tissue Disease Patients. Ragnar Gunnarsson, 

Inge-Margrethe Gilboe, Torhild Garen and Øyvind Molberg, 

Oslo University Hospital Rikshospitalet, Oslo, Norway 

1929. Pernicious Anemia and Vitamin B-12 Deficiency in 

Autoimmune Disease: Neglecting the Feet Will Lead You 

Astray. Michael R. Lovy, Desert Oasis Healthcare, Palm 

Springs, CA 

1930. Progranulin Plays a Protective Role in the Pathogenesis 

of Inflammatory Bowel Disease. Fanhua Wei 1 , Jinlong 

Jian 1 , Yuying Zhang 1 , Jiqiang Lin 1 , Juan Lafaille 2 , Michael 

Dustin 3 , Lloyd Mayer 4 and Chuanju Liu 5 , 1 NYU Hospital for 

Joint Diseases, New York, NY, 2 New York, NY, 3 NYU School of 

Medicine, New York, NY, 4 Mount Sinai Medical Center, New 

York, NY, 5 New York University, New York, NY 

1931. Influence of Trough Serum Drug Level and Immunogenicity 

on the Lack of Response to Adalimumab Therapy in 

Inflammatory Bowel Disease Patients. Shui Long Wang 1 , 

Scott Hauenstein 1 , Linda Ohrmund 1 , Reshma Shringarpure 1 , 

Douglas C. Wolf 2 , Isam A. Diab 3 , Jared Salbato 1 , Rukmini 

Reddy 1 , Kevin McCowen 1 , Shawn Shah 1 , Steven Lockton 1 , 

Emil Chuang 1 and Sharat Singh 1 , 1 Prometheus Laboratories, 

San Diego, CA, 2 Atlanta Gastroenterology Associates, 

Atlanta, GA, 3 Paramount Medical Research & Consulting, 

Middleburg Heights, OH 


1932. Clinical Features of an Aromatase Inhibitor Associated 

Syndrome Presenting as Rheumatoid Arthritis Ronald 

J. anderson, MD, Brigham &Women’s Hospital. Ronald J. 

anderson, Brigham & Womens Hospital, Boston, MA 

1933. Incidence and Early Detection of Retinal Toxicity in Patients 

Treated with Chloroquine and Hydroxichloroquine in 

Rheumatology Practice. Sandra Soro Marin 1 , Ana del 

Carmen Haro Martínez 1 , Deseada Palma Sanchez 1 , María del 

Rocío Gonzalez Molina 1 , Marta Mayor Gonzalez 2 and Elena 

Rubio Velazquez 3 , 1 Rafael Mendez Hospital, Spain., Lorca 

(Murcia), Spain, 2 Rafael Mendez Hospital, Lorca (Murcia), 

Spain, 3 Rafael Mendez Hospital, Lorca (Murcia) 

1934. Improvement in Cryoglobulin Detection Employing a 

Temperature Controlled Sample Transporter. W. Winn 

Chatham, Moon Nahm and William H. Benjamin Jr., 


Muscle Biology, Myositis and Myopathies: Genetics, 

Autoantibodies and other Molecular Aspects of Idiopathic 

Inflammatory Myopathies and Models 

1935. Longitudinal Peripheral Blood Lymphocyte Subsets 

Correlate with Decreased Disease Activity in Juvenile 

Dermatomyositis. Floranne C. Ernste 1 , Cynthia S. Crowson 2 , 

Consuelo Lopez de Padilla 2 , Molly Hein 2 , Abigail B. Green 2 

and Ann M. Reed 2 , 1 Mayo Clinic Rochester, Rochester, MN, 

2 


1936. The human leukocyte antigen DRB1*13:02-DQB1*06:04 

- DPB1*04:01 haplotype isclosely associated with 

dermatomyositis patients with Anti-CADM-140 (melanoma 

differentiation-associated protein 5: MDA5) Antibody. Yuji 

Hosono 1 , Chikashi Terao 2 , Ran Nakashima 1 , Yoshitaka Imura 1 , 

Naoichiro Yukawa 1 , Hajime Yoshifuji 1 , Motomu Hashimoto 1 , 

Koichiro Ohmura 1 , Takao Fujii 1 and Tsuneyo Mimori 1 , 

1 

Graduate School of Medicine, Kyoto University, Kyoto, 

Japan, 2 Kyoto University, Kyoto, Japan 

1937. HLA-DRB1*0101/*0405 Is Associated with Susceptibility 

to Anti-MDA5 Antibody-Positive Dermatomyositis in the 

Japanese Population. Takahisa Gono 1 , Yasushi Kawaguchi 1 , 

Masataka Kuwana 2 , Tomoko Sugiura 1 , Takefumi Furuya 1 , 

Kae Takagi 1 , Hisae Ichida 1 , Yasuhiro Katsumata 1 , Masanori 

Hanaoka 1 , Yuko Okamoto 1 , Yuko Ota 1 , Sayuri Kataoka 1 and 

Hisashi Yamanaka 1 , 1 Institute of Rheumatology, Tokyo 

Women’s Medical University, Tokyo, Japan, 2 Keio University 


1938. A New Enzyme-Linked Immunosorbent Assay System for 

Detecting Autoantibodies to Aminoacyl-tRNA Synthetases: 

Clinical Usefulness in Myositis and Interstitial Pneumonia. 

Ran Nakashima 1 , Yoshitaka Imura 2 , Minae Seto 3 , Akihiro 

Murakami 3 , Yuji Hosono 2 , Kizuku Watanabe 4 , Tomohiro 

Handa 4 , Michiaki Mishima 4 , Michito Hirakata 5 , Tsutomu 

Takeuchi 6 , Keishi Fujio 7 , Kazuhiko Yamamoto 8 , Hitoshi 

Kohsaka 9 , Yoshinari Takasaki 10 , Noriyuki Enomoto 11 , Kingo 

Chida 11 , Toshihiro Nukiwa1 2 and Tsuneyo Mimori 1 , 1 Graduate 

School of Medicine, Kyoto University, Kyoto, Japan, 2 Kyoto 

University Graduate School of Medicine, Kyoto, Japan,


3 

Medical & Biological Laboratories Co., Ltd., Ina, Japan, 

4 

Department of Respiratory Medicine, Graduate School 

of Medicine, Kyoto University, Kyoto, Japan, Kyoto, Japan, 

5 

Keio University, Tokyo, Japan, 6 Keio University School of 

Medicine, Tokyo, Japan, 7 Graduate school of Medicine, 

The University of Tokyo, Tokyo, Japan, 8 Graduate School of 

Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, 

9 

Graduate School of Medical and Dental Sciences, Tokyo 

Medical and Dental University, Tokyo, Japan, 10 Division of 

Rheumatology, Department of Internal Medicine, Juntendo 

University, Tokyo, Japan, 11 Hamamatsu University School of 

Medicine, Hamamatsu, Japan, 12 Department of Respiratory 

Medicine, Tohoku University Graduate School of Medicine, 

Sendai, Japan 

1939. Overexpression of Ankyrin Repeat Domain Containing 

Protein 1 Gene (ANKRD1) in Dermatomyositis Muscle 

Biopsies Is Correlated to Hypoxia and Perifascicular 

Atrophy. Samuel K. Shinjo, Sueli M. Oba-Shinjo, Miyuki 

Uno and Suely K. N. Marie, Faculdade de Medicina da 

Universidade de São Paulo, São Paulo, Brazil 

1940. A Comprehensive Study of Novel Serum Markers of ILD 

Associated with Inflammatory Myopathies. Fang Chen, 

Xiaoming Shu, Xin Lu and Guochun Wang, China-Japan 

Friendship Hospital, Beijing, China 

1941. Clinical Evaluation of Anti-Aminoacyl tRNA Synthetase 

Antibodies in Japanese Patients with Connective Tissue 

Diseases. Masakazu Matsushita, Toshio Kawamoto, Ken 

Yamaji, Naoto Tamura and Yoshinari Takasaki, Juntendo 


1942. Increased Levels of Eotaxin and MCP-1 in Juvenile 

Dermatomyositis Median 17 Years after Diagnosis; 

Associations with Disease Activity, Duration and Organ 

Damage. Helga Sanner 1 , Thomas Schwartz 2 , Berit Flatø 1 , 

Maria Vistnes 2 , Geir Christensen 2 and Ivar Sjaastad 1 , 1 Oslo 

University Hospital, Oslo, Norway, 2 University of Oslo, Oslo, 

Norway 

1943. Autophagy Expressions Were Decreased in Circulating T 

Cells in Inflammatory Myopathies Patients. Fang Chen, 

Xiaoming Shu, Xin Lu and Guochun Wang, China-Japan 

Friendship Hospital, Beijing, China 

1944. Expression of Human Leukocyte Antigen-G in Polymyositis 

or Dermatomyositis. Xiaolan Tian, Xiaoming Shu, Xin Lu, 

Qinglin Peng and Guochun Wang, China-Japan Friendship 

Hospital, Beijing, China 

1945. Anti-Transcription Intermediary Factor 1-Gamma (TIF1-Υ) 

Autoantibody Detection by ELISA and Immunoprecipitation 

in a Prospective Myositis Cohort: Predictive Value for 

Cancer Associated Myositis. Rohit Aggarwal, Noreen Fertig, 

Danielle Goudeau, Chad Stephans, Qi Zengbiao, Diane 

Koontz, Mary Lucas, Marc C. Levesque and Chester V. Oddis, 


1946. Effect of Immunosuppressive Treatment On Gene 

Expression in Patients with Polymyositis and 

Dermatomyositis. Ingela M. Loell 1 , Yi-Wen Chen 2 , Marina 

Korotkova 1 , Kanneboyina Nagaraju 3 and Ingrid E. Lundberg 1 , 

1 

Karolinska Institutet, Stockholm, Sweden, 2 Children’s 

National Medical Center, Washington, 3 Children’s National 


1947. Muscle Wasting in HTNFtg Mice, an Animal Model for 

Rheumatoid Arthritis, Due to Increased Cathepsin L and 

LC3B Expression. Martin Willburger 1 , Birgit Niederreiter 1 , 

Ewald Unger 1 , Josef S. Smolen 2 , Kurt Redlich 1 and Silvia 

Hayer 1 , 1 Medical University of Vienna, Vienna, Austria, 

2 


Austria 

1948. Decreased C4A Gene Copy Numbers in Children with 

Juvenile Dermatomyositis: Association with Decreased 

C4 Protein and Lower Absolute Number of CD3 Negative 

CD16/56+ Natural Killer Cells. Lauren M. Pachman 1 , 

Katherine E. Lintner 2 , Yee Ling Wu 2 , Lori J. Ferguson 3 , 

Gabrielle A. Morgan 3 , Chiang-Ching Huang 4 and C. Yung 

Yu 2 , 1 Division of Pediatric Rheumatology, Northwestern 

University Feinberg School of Medicine, Chicago, IL, 2 The 

Research Institute at Nationwide Children’s Hospital and The 

Ohio State University, Columbus, OH, 3 Children’s Hospital of 

Chicago Research Center, Cure JM Myositis Center, Chicago, 

IL, 4 Department of Preventive Medicine, Northwestern 

University Feinberg School of Medicine, Chicago, IL 

1949. Anti-Transcription Intermediary Factor 1-Gamma (TIF1-Υ) 

Autoantibody ELISA Development and Validation. Rohit 

Aggarwal, Chester V. Oddis, Noreen Fertig, Danielle 

Goudeau, Diane Koontz, Chad Stephans, Zengbiao Qi and 

Marc C. Levesque, University of Pittsburgh, Pittsburgh, PA 

1950. Anti-Signal Recognition Particle Autoantibody ELISA 

Development and Validation: Utility in Patients with 

Necrotizing Myopathy. Rohit Aggarwal, Chester V. Oddis, 

Danielle Goudeau, Chad Stephans, Noreen Fertig, Qi 

Zengbiao, Diane Koontz and Marc C. Levesque, University of 

Pittsburgh, Pittsburgh, PA 

1951. Elevated Level of Tumor Necrosis Factor-Like Weak 

Inducer of Apoptosis in Patients with Polymyositis or 

Dermatomyositis. Qinglin Peng, Xin Lu, Ning Zu, Lu Zhang 

and Guochun Wang, China-Japan Friendship Hospital, 

Beijing, China 

1952. The Effect of CXCL10 Blockade in C Protein-Induced 

Myositis. Jinhyun Kim 1 , Jiyong Choi 2 , Sung Hae Chang 3 , Ki 

Chul Shin 2 , Sung-Hye Park 2 , Hye Won Kim 4 , Hye Jin Oh 2 , 

Myeong Jae Yoon 4 , Bong Seung Ku 5 , Eun Young Lee 2 , Eun 

Bong Lee 3 , Hiroshi Kawachi 6 , Hitoshi Kohsaka 7 and Yeong 

Wook Song 3 , 1 Chungnam National University School of 

Medicine, Daejeon, South Korea, 2 Seoul National University 

College of Medicine, Seoul, South Korea, 3 Seoul National 

University Hospital, Seoul, South Korea, 4 Department of 

Internal Medicine, School of Medicine, Seoul National 

University, Seoul, South Korea, 5 Department of Internal 



276 

Medicine, School of Medicine, Seoul National University 

Hospital, Seoul, Korea, Seoul, South Korea, 6 Niigata 

University Graduate School of Medical and Dental Sciences, 

Niigata, Japan, 7 Graduate School of Medical and Dental 

Sciences, Tokyo Medical and Dental University, Tokyo, Japan 

1953. Antibodies to NXP- 2 and Transcriptional Intermediary 

Factor-Gamma Identify Patients with Cancer-Associated 

Dermatomyositis. David Fiorentino 1 , Lisa Christopher-Stine 2 , 

Lorinda Chung 3 , Bharathi Lingala 4 , Andrew L. Mammen 5 , 

Antony Rosen 6 and Livia Casciola-Rosen 2 , 1 Stanford 

University School of Medicine, Redwood City, CA, 2 Johns 

Hopkins University, Baltimore, MD, 3 Stanford Univ Medical 

Center, Palo Alto, CA, 4 Stanford University, Redwood City, 

CA, 5 Johns Hopkins, Baltimore, MD, 6 The Johns Hopkins 


1954. Immune Responses to NXP-2 and TIF-g Are Associated 

with Distinct Clinical Phenotypes and Prognosis for Skin 

Disease in Dermatomyositis Patients. David Fiorentino 1 , 

Lorinda Chung 2 , Lisa Zaba 1 , Bharathi Lingala 3 , Antony Rosen 4 

and Livia Casciola-Rosen 5 , 1 Stanford University School of 

Medicine, Redwood City, CA, 2 Stanford Univ Medical Center, 

Palo Alto, CA, 3 Stanford University, Redwood City, CA, 4 The 

Johns Hopkins University, Baltimore, MD, 5 Johns Hopkins 


1955. Is the Pattern of Capillary Deposition of Complement 

Membrane Attack COPMLEX Useful in the Differential 

Diagnosis of Inflammatory? Patrick Gordon 1 , Nuria Villagra 2 , 

Istvan Bodi 2 , Andrew King 2 , Stefan Buk 2 , Tibor Hortobagyi 2 

and Safa Al-Sarraj 2 , 1 Department of Rheumatology, King’s 

College London, London, United Kingdom, 2 Department of 

Clinical Neuropathology, King’s College Hospital, London, 


1956. A New Linked Set of Autoantibodies in Dermatomyositis: 

Anti-Mi-2 and Anti-Transcription Intermediary Factor 

(TIF) 1alpha. Minoru Satoh 1 , Jason YF Chan 1 , Yi Li 1 , Monica 

Vázquez-Del Mercado 2 , Marcelo Petri 3 , Luis J. Jara 4 , Miguel 

A. Saavedra 5 , Claudia Cruz-Reyes 6 , Eric S. Sobel 1 , Westley H. 

Reeves 1 , Angela Ceribelli 1 and Edward K.L. Chan 1 , 1 University 

of Florida, Gainesville, FL, 2 Universidad de Guadalajara, 

Guadalajara, Jalisco, México, Mexico, 3 Universidad de 

Guadalajara, Guadalajara, Jalisco, Mexico, Mexico, 4 Hospital 

de Especialidades Centro Medico La Raza, México City, 

Mexico, 5 Centro Medico La Raza Instituto Mexicano del 

Seguro Social Mexico D.F., México D.F., Mexico, 6 Centro 

Medico La Raza Instituto Mexicano del Seguro Social Mexico 

D.F., Mexico D. F., Mexico 


1957. Prevalence and Associated Factors of Vitamin D 

Insufficiency and Deficiency in 4,793 Japanese Patients 

with Rheumatoid Arthritis. Takefumi Furuya 1 , Takayuki 

Hosoi 2 , Eiichi Tanaka 1 , Ayako Nakajima 1 , Atsuo Taniguchi 1 , 

Shigeki Momohara 1 and Hisashi Yamanaka 1 , 1 Institute of 


Japan, 2 National Center for Geriatrics and Gerontology, 

Aichi, Japan 


1958. Bone Mineral Density in Lupus Erythematosus Women 

One Year after Rituximab Therapy. Claudia Mendoza- 

Pinto 1 , Mario Garcia-Carrasco 1 , Mario Jiménez-Hernández 1 , 

Alma Rodríguez-Gallegos 2 , Socorro Méndez-Martínez 1 

and Aurelio Lopez-Colombo 3 , 1 HGR 36 CMN Manuel Ávila 

Camacho, Instituto Mexicano del Seguro Social, Puebla, 

Mexico, 2 Laboratorios Clínicos de Puebla, Puebla, Mexico, 

3 

Delegación Estatal, Instituto Mexicano del Seguro Social, 

Puebla, Mexico 

1959. Low Fracture Incidence Is Maintained in Postmenopausal 

Women ≥75 Years with Osteoporosis with Long-Term 

Denosumab Treatment. Socrates Papapoulos 1 , Michael 

R. McClung 2 , Nathalie Franchimont 3 , Jonathan D. Adachi 4 , 

Henry G. Bone 5 , Claude-Laurent Benhamou 6 , Jordi 

Farrerons 7 , JC Gallagher 8 , Johan Halse 9 , Kurt Lippuner 10 , 

Salvatore Minisola 11 , Ove Törring 12 , Nadia Daizadeh 3 , Andrea 

Wang 3 , Rachel B. Wagman 3 and Steven Boonen 13 , 1 Leiden 

University Medical Center, Leiden, Netherlands, 2 Oregon 

Osteoporosis Center, Portland, OR, 3 Amgen Inc., Thousand 

Oaks, CA, 4 Charlton Medical Centre, Hamilton, ON, 

5 

Michigan Bone and Mineral Clinic, Detroit, MI, 6 EA 4708 

University Orleans, Orleans, France, 7 Hospital de la Santa 

Creu I Sant Pau, Barcelona, Spain, 8 Creighton University 

Medical Center, Omaha, NE, 9 Osteoporoseklinikken, Oslo, 

Norway, 10 University Hospital, Bern, Switzerland, 11 Sapienza, 

Università di Roma, Rome, Italy, 12 Karolinska Institutet 

Sodersjukhuset, Stockholm, Sweden, 13 Leuven University, 

Leuven, Belgium 

1960. Initiation of Tumor Necrosis Factor Alpha (TNFα) 

Antagonists and Risk of Fractures in Patients with Selected 

Rheumatic and Autoimmune Diseases. Vivian K. Kawai 1 , 

Carlos Grijalva 1 , Patrick Arbogast 1 , Jeffrey R. Curtis 2 , 

Daniel H. Solomon 3 , Elizabeth S. Delzell 2 , Lang Chen 2 , Lisa 

Herrinton 4 , Liyan Liu 4 , Edward F. Mitchell Jr. 1 , C. Michael 

Stein 5 and Marie Griffin 1 , 1 Vanderbilt University, Nashville, 

TN, 2 University of Alabama at Birmingham, Birmingham, 

AL, 3 Brigham and Women’s Hospital, Boston, MA, 4 Kaiser 

Permanente, Oakland, CA, 5 Vanderbilt Medical Center, 

Nashville, TN 

1961. In Postmenopausal Women with Osteoporosis, 

Denosumab Significantly Improved Trabecular Bone Score 

(TBS), an Index of Trabecular Microarchitecture. Michael 

R. McClung 1 , Kurt Lippuner 2 , Maria Luisa Brandi 3 , Jean-Marc 

Kaufman 4 , Jose R. Zanchetta 5 , Marc-Antoine Krieg 6 , Henry 

G. Bone 7 , Roland Chapurlat 8 , Didier Hans 6 , Andrea Wang 9 , 

Jang Yun 9 , Carol Zapalowski 9 and Cesar Libanati 9 , 1 Oregon 

Osteoporosis Center, Portland, OR, 2 University of Berne, 

Berne, Switzerland, 3 University of Florence, Florence, Italy, 

4 

University Hospital of Ghent, Ghent, Belgium, 5 Instituto 

de Investigaciones Metabólicas and University of Salvador, 

Buenos Aires, Argentina, 6 Lausanne University Hospital, 

Lausanne, Switzerland, 7 Michigan Bone and Mineral Clinic, 

Detroit, MI, 8 Hôpital Edouard Herriot, Lyon, France, 9 Amgen 

Inc., Thousand Oaks, CA


1962. The Specific Role of Glutaredoxin2 Isoform b (Glrx2b) in 

RANKL-Induced Osteoclastogenesis through Activation of 

the p38-MAPK Signaling Pathway. Chang-Hoon Lee 1 , Wan- 

Hee Yoo 2 , Jin-Jung Choi 3 , Myong-Joo Hong 2 , Ji-Min Kim 4 and 

Jeong-Tae Yeon 5 , 1 Department of Internal Medicine, School 

of medicine, Wonkwang university, Iksan, Chonbuk, South 

Korea, 2 Department of Internal Medicine, Chonbuk National 

University Medical School and Research Institute of Clinical 

Medicine, Jeonju, South Korea, 3 CHA University Hospital, 

Seongnam, South Korea, 4 Division of Rheumatology, 

Department of Internal Medicine, Pusan National University 

Yangsan Hospital, Pusan National University School of 

Medicine, Yangsan, South Korea, 5 Department of anatomy, 

school of medicine, Wonkwang university, Iksan, Chonbuk, 

South Korea 

1963. Fracture Sites, Frequencies and Causes in 9,720 Japanese 

Patients with Rheumatoid Arthritis: A Prospective 

Observational Cohort Study. Kensuke Ochi, Takefumi 

Furuya, Eisuke Inoue, Katsunori Ikari, Atsuo Taniguchi, 

Shigeki Momohara and Hisashi Yamanaka, Institute of 


Japan 

1964. Rolofylline, an Adenosine A1R Antagonist, Acts As an 

Inverse Agonist to Inhibit Osteoclast Differentiation. 

Wenjie He 1 and Bruce N. Cronstein 2 , 1 NYU, New York, NY, 

2 

NYU School of Medicine, Division of Rheumatology, New 

York, NY 

1965. Adenosine Regulates Bone Metabolism Via A 1 , A2A and 

A2B Receptors in Bone Marrow Cells From Normal and 

Patients with Multiple Myeloma. Wenjie He 1 , Amitabha 

Mazumder 2 and Bruce N. Cronstein 3 , 1 NYU, New York, NY, 

2 

NYU Cancer Center, New York, NY, 3 NYU School of Medicine, 

Division of Rheumatology, New York, NY 

1966. Cost-Effectiveness of Bazedoxifene Compared with 

Raloxifene in the Treatment of Postmenopausal 

Osteoporotic Women. Mickaël Hiligsmann, Wafa Ben 

Sedrine and J.-Y. Reginster, University of Liege, Liege, 

Belgium 

1967. Hypophosphatemic Osteomalacia Induced by Tenofovir in 

Patients with Human Immunodeficiency Virus Infection. 

Beatriz Tejera 1 , Lourdes Mateo-Soria 1 , Susana Holgado 1 , 

Luisa Mariñoso 2 , Ricard Pérez 1 , Anna Bonjoch 1 , Melania 

Martínez-Morillo 1 , Dolors Grados 1 and Alejandro Olivé 1 , 

1 

Hospital Universitario Germans Trias i Pujol, Badalona, 

Spain, 2 Hospital del Mar, Barcelona, Spain 

1968. The Specific Role of Vesicle-Associated Membrane 

Protein-Associated Protein B/C(VapB) As a Regulator of 

Osteoclastogenesis Via Modulation of Phospholipase 

Cã(PLCã2-Ca2+-NFAT Signaling. Chang-Hoon Lee 1 , Wan- 

Hee Yoo 2 , Jin-Jung Choi 3 , Myong-Joo Hong 2 , Ji-Min Kim 4 and 

Sik-Won Choi 5 , 1 Department of Internal Medicine, School 

of medicine, Wonkwang university, Iksan, Chonbuk, South 

Korea, 2 Department of Internal Medicine, Chonbuk National 

University Medical School and Research Institute of Clinical 

Medicine, Jeonju, South Korea, 3 CHA University Hospital, 

Seongnam, South Korea, 4 Division of Rheumatology, 

Department of Internal Medicine, Pusan National University 

Yangsan Hospital, Pusan National University School of 

Medicine, Yangsan, South Korea, 5 School of medicine, 

Wonkwang university, Iksan, Chonbuk, South Korea 

1969. Correction of Vitamin D Insufficiency with the Fixed Daily 

Combination Strontium Ranelate 2 g/Vitamin D3 1000 IU 

Over 12 Months. René Rizzoli 1 , Bess Dawson-Hughes 2 , Jean- 

Marc Kaufman 3 , Patrice Fardellone 4 , Maria Luisa Brandi 5 , 

Bruno Vellas 6 , Julien Collette 7 and Jean-Yves Reginster 8 , 

1 

Geneva University Hospitals and Faculty of Medicine, 

Geneva, Switzerland, 2 Bone Metabolism Laboratory, Tufts 

University, Boston, MA, 3 University Hospital of Ghent, 

Ghent, Belgium, 4 Hôpital Nord, C.H.U. d’Amiens, Amiens, 

France, 5 University of Florence, Firenze, Italy, 6 CHU La 

Grave, Toulouse, France, 7 Labo RIA, CHU Sart Tilman, Liege, 

Belgium, 8 University of Liege, Liege, Belgium 

1970. Utility of Spine Bone Mineral Density in Fracture Prediction 

within the Fracture Risk Assessment Tool (FRAX). Tristan 

Blackburn 1 , Diantha Howard 2 and Edward S. Leib 1 , 1 Fletcher 

Allen Health Care, University of Vermont College of 

Medicine, Burlington, VT, 2 Vermont Center for Clinical and 

Translational Science, Burlington, VT 

1971. Resolution of Effects On Bone Turnover Markers and 

Bone Mineral Density After Discontinuation of Long-Term 

Bisphosphonate Use. Kenneth G. Saag 1 , Claude-Laurent 

Benhamou 2 , Tobias De Villiers 3 , C. Conrad Johnston Jr. 4 , 

Bente Langdahl 5 , Andrew Denker 6 , Annpey Pong 6 , John 

P. McGinnis 6 , Elizabeth Rosenberg 6 and Arthur Santora 6 , 

1 

Univ of Alabama-Birmingham, Birmingham, AL, 2 EA 

4708 University Orleans, Orleans, France, 3 Mediclinic 

Panorama, Cape Town, South Africa, 4 Indiana University 

School of Medicine, Indianapolis, IN, 5 Aarhus University 

Hospital, Aarhus, Denmark, 6 Merck Sharp & Dohme Corp., 

Whitehouse Station, NJ 

1972. Assessment of Fracture Risk in Postmenopausal Women 

with Rheumatoid Arthritis. Sina Esmaeilzadeh, Nurten 

Eskiyurt, Ekin Sen and Merih Akpinar, Istanbul University, 

Istanbul Faculty of Medicine, Istanbul, Turkey 

1973. Effect of Adalimumab On the Serum Level of 

Undercarboxylated Osteocalcin (ucOC), Bone Biochemical 

Markers and Bone Mineral Density. Yoshitada Sakai 1 , Akira 

Hashiramoto 1 , Takaichi Okano 1 , Yoshiko Kawasaki 1 , Nao 

Shibanuma 2 and Masahiro Kurosaka 3 , 1 Kobe University 

Hospital, Kobe, Japan, 2 The Center for Rheumatic Diseases, 

Kobe University Hospital / Departmant of Orthopaedic 

Surgery, Kobe Kaisei Hospital, Kobe, Japan, 3 Kobe University 

Graduate School of Medicine, Kobe, Japan 

1974. Incidence of Atypical Femur Fractures Associated with 

Bisphosphonate Use for Osteoporosis: A Systematic 

Review of the Literature. John N. Mecchella 1 , John A. 



278 

Batsis 1 , Robin J. Larson 2 and Gautham Suresh 1 , 1 Dartmouth 

Hitchcock Medical Center, Lebanon, NH, 2 The Dartmouth 

Institute for Health Policy and Clinical Practice, Lebanon, NH 

1975. Mortality After Fragility Hip Fracture in Middle Aged and 

Elderly Men and Women in Southern Norway. Andreas P. 

Diamantopoulos 1 , Mari Hoff 2 , Marc C. Hochberg 3 and Glenn 

Haugeberg 1 , 1 Hospital of Southern Norway HF, Kristiansand, 

Norway, 2 and St Olavs Hospital, Trondheim, Norway, 

3 

University of Maryland, Baltimore, MD 

1976. Treatment Satisfaction in Postmenopausal Women 

Previously Treated with Bisphosphonates Who 

Transitioned to Denosumab Vs Ibandronate Therapy in an 

Open-Label Study. Santiago Palacios 1 , Giovanni Iolascon 2 , 

Irene Agodoa 3 , Hema Viswanathan 3 , Prayashi Ghelani 4 , 

Irene Ferreira 5 , Cynthia O’Malley 3 , Rachel B. Wagman 6 

and Sydney Bonnick 7 , 1 Instituto Palacios, Madrid, Spain, 

2 

Seconda Universita di Napoli, Naples, Italy, 3 Amgen Inc, 

Thousand Oaks, CA, 4 Ovatech Solutions, London, United 

Kingdom, 5 Amgen Inc., Cambridge, United Kingdom, 6 Amgen 

Inc., Thousand Oaks, CA, 7 Clinical Research Center of North 

Texas, Denton, TX 

1977. Relationship Between Baseline Bone Turnover Marker 

Levels and Bone Mineral Density Changes in Men with 

Low Bone Mineral Density Receiving Denosumab or 

Placebo. Eric Orwoll 1 , Ugis Gruntmanis 2 , Steven Boonen 3 , 

Yu-Ching Yang 4 , Rachel B. Wagman 4 , Jesse W. Hall 4 and Paul 

D. Miller 5 , 1 Oregon Health and Science University, Portland, 

OR, 2 Dallas Veterans Affairs Medical Center and University 

of Texas Southwestern Medical Center, Dallas, TX, 3 Leuven 

University, Leuven, Belgium, 4 Amgen Inc., Thousand Oaks, 

CA, 5 Colorado Center for Bone Research, Lakewood, CO 

1978. A Web-Based Intervention Aimed to Improve Bone Health 

Among Individuals On Chronic Glucocorticoids. Amy H. 

Warriner 1 , Ryan C. Outman 1 , Nathan Markward 2 , Ronald 

Aubert 2 , Jeffrey R. Curtis 3 , Robert Epstein 2 , Felix Freuh 2 , Julia 

McEachern 2 , David T. Redden 1 , Monika M. Safford 1 , Eric 

Stanek 2 , Amy Steinkellner 2 and Kenneth G. Saag 3 , 1 University 

of Alabama at Birmingham, Birmingham, AL, 2 Medco, 

Bethesda, MD, 3 Univ of Alabama-Birmingham, Birmingham, 

AL 

1979. Care Gap in the Treatment of Patients with High Risk for 

Fractures in a Single Canadian Academic Center. Arthur 

N. Lau 1 , Michael Branch 2 , Robert Bensen 3 , Jonathan D. 

Adachi 4 , Alexandra Papaioannou 1 , William Wong-Pack 5 and 

William G. Bensen 6 , 1 McMaster University, Hamilton, ON, 

2 

CEO, Inovex, Oakville, ON, 3 Rheumatology Health Team, 

Dr. Bensen’s Rheumatology Clinic, Hamilton, ON, 4 Charlton 

Medical Centre, Hamilton, ON, 5 Hamilton, ON, 6 St. Joseph’s 

Hospital and McMaster University, Hamilton, ON, Hamilton, 

ON 

1980. Intermittent Nitrate Use and Risk of Hip Fracture. Devyani 

Misra 1 , Christine Peloquin 1 , Hyon Choi 1 , Tuhina Neogi 2 and 

Yuqing Zhang 1 , 1 Boston University School of Medicine, 

Boston, MA, 2 Boston Univ School of Medicine, Boston, MA 


1981. Low Body Mass Index, Medication Use and Social Factors 

Such As Smoking but Not Secondary Medical Disorders or 

Older Age May Be More Prevalent in Males with Low Bone 

Mineral Density. Vandana J. Vedanarayanan, Allison V. Jones 

and Vikas Majithia, University of Mississippi Medical Center, 

Jackson, MS 

1982. Five Years of Treatment to Target in Early Active 

Rheumatoid Arthritis: Prevalence and Predictors of 

Vertebral Fractures. L. Dirven 1 , M. van den Broek 1 , A.J. 

Peeters 2 , N. Riyazi 3 , P.J.S.M. Kerstens 4 , T.W.J. Huizinga 1 , C.F. 

Allaart 1 and W. F. Lems 5 , 1 Leiden University Medical Center, 

Leiden, Netherlands, 2 Reinier de Graaf Gasthuis, Delft, 

Netherlands, 3 Haga Hospital, The Hague, Netherlands, 

4 

Jan van Breemen Research Institute | Reade, Amsterdam, 

Netherlands, 5 VU University medical center, Amsterdam, 

Netherlands 

1983. Comparative Risk of Fracture in Men and Women with 

Human Immunodeficiency Virus. Lydia Gedmintas 1 , 

Elizabeth Wright 2 , Jeffrey N. Katz 3 , Elena Losina 3 and Daniel 

H. Solomon 3 , 1 Brigham’s Women’s Hospital, Boston, MA, 

2 

Orthopedic and Arthritis Center for Outcomes Research, 



1984. Orally Administered Parathyroid Hormone Analog Tablets 

in a Randomized Phase 2 Study Demonstrated Consistent 

Exposure and Increased Bone Mineral Density. Morten 

Asser Karsdal 1 , Nozer M. Mehta 2 , William Stern 2 , Amy M. 

Sturmer 2 , Sheela J. Mitta 2 , Roxanne Tavakkol 2 , Ali Bolat 2 , 

Jenna Giacchi 2 , Kim Henriksen 1 , Lorraine A. Fitzpatrick 3 , 

Claus Christiansen 4 , Jeffrey A. Wald 3 , Antonio J. Nino 3 , 

Peter Alexandersen 4 , Bente J. Riis 5 , Jeppe andersen 1 , Ivo 

Valter 6 , Bettina Nedergaard 4 , Christence Teglbjaerg 4 , Felicia 

Cosman 7 and John M. Trang 8 , 1 Nordic Bioscience A/S, Herlev, 

Denmark, 2 Unigene Laboratories, Inc., Boonton, NJ, 3 GSK, 

King of Prussia, PA, 4 CCBR, Ballerup, Denmark, 5 Nordic 

Bioscience, Herlev, Denmark, 6 Ctr for Clinical & Basic Rsrch, 

Tallinn, Estonia, 7 Helen Hayes Hospital, West Haverstraw, NY, 

8 

PK/PD International Inc., Tucson, AZ 

1985. The Effect of Calcium and Vitamin D on Bone Loss in an 

Epileptic Population. Philip Dussault 1 , Samuel Davis Jr. 1 and 

Antonio A. Lazzari 2 , 1 Boston VA HCS, Boston, MA, 2 Boston VA 

Medical Center, Boston, MA 

1986. Impaired Endothelial Function in Post-Menopausal Women 

with Osteoporosis. Auleen M. Millar 1 , Aaron McCann 2 , 

Vivian McClenaghan 2 , Paul Hamilton 2 , Caroline Bleakley 2 , 

Kristopher Lyons 2 and Gary McVeigh 2 , 1 Musgrave Park 

Hospital, Belfast, United Kingdom, 2 Belfast, United Kingdom 

1987. A Comparison of Unilateral and Bilateral Hip BMD. Steven 

C. Schaub 1 , Edward S. Leib 1 and Diantha Howard 2 , 1 U of 

Vermont College of Med, Burlington, VT, 2 Vermont Center 

for Clinical and Translational Science, Burlington, VT 

1988. Zoledronate Efficacy and Safety in Active Paget’s Disease 

Long-Term Follow-up and Retreatment in Clinical 

Practice. Elsa Vieira-Sousa 1 , Ana M. Rodrigues 1 , Joana


Caetano-Lopes 2 , Susana Capela 3 , Filipa Ramos 3 , Ricardo 

Figueira 3 , Joaquim Polido-Pereira 1 , Cristina Ponte 1 , Raquel 

Campanilho-Marques 1 , Rita Barros 3 , JC Romeu 3 and José 

A. Pereira da Silva 3 , 1 Rheumatology and Metabolic Bone 

Diseases Department, Hospital de Santa Maria, CHLN 

and Rheumatology Research Unit, Instituto de Medicina 

Molecular, Faculdade de Medicina da Universidade de 

Lisboa, Lisbon, Portugal, 2 Rheumatology Research Unit, 

Instituto de Medicina Molecular, Faculdade de Medicina da 

Universidade de Lisboa, Lisbon, Portugal, 3 Rheumatology 

and Metabolic Bone Diseases Department, Santa Maria 

Hospital,CHLN, Lisbon, Portugal 

1989. Risk Factors for Vertebral Fractures in Patients with 

Rheumatoid Arthritis - the Tomorrow Study -. Tadashi 

Okano, Tatsuya Koike, Masahiro Tada, Kenji Mamoto, Yuko 

Sugioka, Atsuko Kamiyama and Hiroaki Nakamura, Osaka 

City University Medical School, Osaka, Japan 

1990. Risk of Falling Is Equivalent between Patients with 

Rheumatoid Arthritis and Healthy Individuals – the 

Tomorrow Study-. Kenji Mamoto, Tatsuya Koike, Tadashi 

Okano, Atsuko Kamiyama, Yuko Sugioka, Masahiro Tada and 

Hiroaki Nakamura, Osaka City University Graduate School of 

Medicine, Osaka, Japan 

1991. Effects of Odanacatib on the Distal Radius and Tibia in 

Postmenopausal Women: Improvements in Cortical 

Geometry and Estimated Bone Strength. Roland Chapurlat 1 , 

K. Brixen 2 , A.M. Cheung 3 , Sharmila Majumdar 4 , B. 

Dardzinski 5 , A. Cabal 6 , N. Verbruggen 7 , S. Ather 6 , Elizabeth 

Rosenberg 5 and A. de Papp 5 , 1 Hôpital Edouard Herriot, Lyon, 

France, 2 University of Southern Denmark, Odense, Denmark, 

3 

University of Toronto, Ontario, 4 University of California San 

Francisco, San Francisco, CA, 5 Merck Sharp & Dohme Corp., 

Whitehouse Station, NJ, 6 Merck Sharp & Dohme Corp., 

Whitehouse Station, 7 MSD Belgium, Brussels, Belgium 

1992. Anti-TNF Therapies Improve Bone Mineral Density At 

the Lumbar Spine of RA Patients by Decreasing Disease 

Activity and Suppressing Serum RANKL Levels. Allen P. 

Anandarajah 1 , Jennifer Hossler 2 , Kate Burns 2 , Kelly Callahan 2 , 

Yahui Grace Chiu 2 and Jennifer H. Anolik 2 , 1 Univ of Rochester 

Medical Ctr, Rochester, NY, 2 University of Rochester, 

Rochester, NY 

1993. Contribution of Lifestyle Factors to Healthy-Adherer Bias in 

Prevalent Users of Osteoporotic Drugs. Mitsuyo Kinjo 1 and 

Daniel H. Solomon 2 , 1 Okinawa Chubu Hospital, Uruma City 

Okinawa, Japan, 2 Brigham and Women’s Hospital, Boston, 

MA 

1994. The Influence of Percentage Body Fat On Bone Mineral 

Density in Thin Patients. Andrew Blanshard 1 and Marwan 

Bukhari 2 , 1 Lancaster University, Lancaster, United Kingdom, 

2 

Royal Lancaster Infirmary, Lancaster, United Kingdom 

1995. What Are the Most Clinically Relevant and Feasible 

Pragmatic Osteoporosis Clinical Trial Designs? Nicole C. 

Wright 1 , Ana Oliveira 1 , Amy H. Warriner 1 , Jeffrey Curtis 1 , 

Neil Binkley 2 , Steven R. Cummings 3 , Marc C. Hochberg 4 , 

Andrea LaCroix 5 , E. Michael Lewiecki 6 , John T. Schousboe 7 , 

Daniel H. Solomon 8 , Robert B. Wallace 9 and Kenneth G. 

Saag 1 , 1 University of Alabama at Birmingham, Birmingham, 

AL, 2 University of Wisconsin, Madison, WI, 3 San Francisco 

Coordinating Center, CPMC Research Institute, San 

Francisco, CA, 4 University of Maryland, Baltimore, MD, 

5 

Fred Hutchinson Cancer Research Center, Seattle, WA, 

6 

New Mexico Clinical Research & Osteoporosis Center, 

Albuquerque, NM, 7 Park Nicollet Health Services, 

Minneapolis, MN, 8 Brigham and Women’s Hospital, Boston, 

MA, 9 University of Iowa, Iowa City, IA 

1996. Are Changes in Bone Mineral Density Different Between 

Groups of Early Rheumatoid Arthritis Patients Treated 

According to a Tight Control Strategy with or without 

Prednisone, If Osteoporosis Prophylaxis Is Applied? 

Marlies C. van der Goes 1 , Johannes W.G. Jacobs 1 , Maud 

S. Jurgens 1 , Marije F. Bakker 1 , Maaike J. van der Veen 2 , 

Jacobine H. van der Werf 3 , Paco M.J. Welsing 1 and Johannes 

W.J. Bijlsma 1 , 1 University Medical Center Utrecht, Utrecht, 

Netherlands, 2 St. Jansdal hospital, Harderwijk, Netherlands, 

3 

Diakonessenhuis, Utrecht, Netherlands 

1997. Safety and Efficacy of Denosumab Vs Ibandronate in 

Postmenopausal Women Sub-Optimally Treated with Daily 

or Weekly Bisphosphonates: A Randomized, Open-Label 

Study. Michael A. Bolognese 1 , Edward Czerwinski 2 , Henry 

G. Bone 3 , Sydney Bonnick 4 , Neil Binkley 5 , Alfred Moffett Jr. 6 , 

Suresh Siddhanti 7 , Irene Ferreira 8 , Prayashi Ghelani 9 , Rachel 

Wagman 7 , Jesse W. Hall 7 and Chris Recknor 10 , 1 Bethesda 

Health Research Center, Bethesda, MD, 2 Krakow Medical 

Center, Krakow, Poland, 3 Michigan Bone and Mineral Clinic, 

Detroit, MI, 4 Clinical Research Center of North Texas, 

Denton, TX, 5 University of Wisconsin, Madison, WI, 6 OB- 

GYN Associates of Mid Florida, PA, Leesburg, FL, 7 Amgen 

Inc., Thousand Oaks, CA, 8 Amgen Inc., Cambridge, United 

Kingdom, 9 Ovatech Solutions, London, United Kingdom, 

10 

United Osteoporosis Centers, Gainesville, GA 

1998. Relationship between Changes in Bone Mineral Density 

and Incidence of Fracture with 6 Years of Denosumab 

Treatment. Michael A. Bolognese 1 , Paul D. Miller 2 , Jean- 

Yves Reginster 3 , Nathalie Franchimont 4 , Gerolamo Bianchi 5 , 

Roland Chapurlat 6 , Federico G. Hawkins 7 , David L. Kendler 8 , 

Beatriz Oliveri 9 , Jose R. Zanchetta 10 , Nadia Daizadeh 4 , Andrea 

Wang 4 , Rachel B. Wagman 4 and Socrates Papapoulos 11 , 

1 

Bethesda Health Research Center, Bethesda, MD, 

2 

University of Colorado Health Sciences Center and Colorado 

Center for Bone Research, Lakewood, CO, 3 University of 

Liège, Liège, Belgium, 4 Amgen Inc., Thousand Oaks, CA, 

5 

Azienda Sanitaria Genovese, Genoa, Italy, 6 Hôpital Edouard 

Herriot, Lyon, France, 7 Hospital Universitario, Madrid, Spain, 

8 

University of British Columbia, Vancouver, BC, 9 Laboratorio 

Enfermedades Metabólicas Oseas, Hospital de Clínicas, 

INIGEM UBA-CONICET, Buenos Aires, Argentina, 10 Instituto 

de Investigaciones Metabólicas and University of Salvador, 

Buenos Aires, Argentina, 11 Leiden University Medical Center, 





Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic 

Diseases 

1999. Immunogenicity and Safety of Two Doses of Influenza 

A H1N1⁄2009 Vaccine in Young Autoimmune Rheumatic 

Diseases Patients Under 9 Years Old. Guilherme Trudes 1 , 

Nadia E. Aikawa 1 , Lucia M. Campos 2 , Rosa M.R. Pereira 1 , 

Julio C. B. Moraes 1 , Ana Cristina Ribeiro 1 , Joao Miraglia 3 , 

Maria do Carmo S. Timenetsky 4 , Eloisa Bonfa 1 and Clovis 

Artur Silva 5 , 1 Faculdade de Medicina da Universidade de São 

Paulo, Sao Paulo, Brazil, 2 University of São Paulo Medical 

School, São Paulo, Brazil, 3 Fundação Butantan, São Paulo, 

Brazil, 4 Instituto Adolfo Lutz - Faculdade de Medicina da 

Universidade de São Paulo, São Paulo, Brazil, 5 Paediatric 



2000. Whole Body Magnetic Resonance Imaging in Evaluation of 

Enthesitis in Spondyloarthropathy. Hemalatha Srinivasalu 1 , 

Suvimol C. Hill 2 , Gina A. Montealegre Sanchez 1 , April D. 

Brundidge 1 , Michael M. Ward 1 and Robert A. Colbert 1 , 

1 

NIAMS NIH, Bethesda, MD, 2 NIH Clinical Center, Bethesda, 

MD 

2001. Methotrexate and Injectable Tumor Necrosis Factor 

Alpha Inhibitor Adherence and Persistence in Children 

with Rheumatic Diseases. Sarah Ringold 1 , Shannon Grant 2 , 

Charmaine Girdish 3 , Carol A. Wallace 4 and Sean Sullivan 5 , 

1 

Seattle Children’s Hospital, Seattle, WA, 2 Axio Research 

LLC, Seattle, WA, 3 CVS Caremark, Scottsdale, AZ, 4 Seattle 

Childrens Hospital, Seattle, WA, 5 University of Washington, 

Seattle, WA 

2002. Randomized Clinical Trial in Pediatric Rheumatology: 

Are Parents and Patients in Equipoise? Petra C.E. Hissink 

Muller 1 , Bahar Yildiz 1 , Cornelia F. Allaart 1 , Danielle M.C. 

Brinkman 2 , Marion A. J. Van Rossum 3 , J. Merlijn Van den 

Berg 4 , Lisette W.A. Van Suijlekom-Smit 5 , Rebecca Ten 

Cate 1 and Martine C. de Vries 1 , 1 Leiden University Medical 

Center, Leiden, Netherlands, 2 Rijnland Hospital, Leiderdorp, 

Netherlands, 3 Emma Children’s Hospital / Academic Medical 

Center and Reade Institute, Amsterdam, Netherlands, 

4 

Emma Children’s Hospital / Academic Medical Centre and 

Reade Institute, Amsterdam, Netherlands, 5 Erasmus MC 

Sophia Children’s Hospital, Rotterdam, Netherlands 

2003. Colchicine As a Therapeutic Option in Periodic Fever 

Aphtous Stomatitis, Pharingitis Syndrome and Cervical 

Adenitis (PFAPA). Yonatan butbul Aviel 1 , Sameh Tatour 2 , 

Ruth Gershoni 3 and Riva Brik 4 , 1 Rambam Medical center, 

Haifa, Israel, 2 Rambam Medical Center, Israel, 3 Rambam, 

Israel, 4 Rambam Medical center 

2004. Do We Need Minimum Standards in Care for Children 

with Localized Scleroderma- Result of the Consensus 

Meeting in Hamburg Germany On the 11th of December 

2011. Part I. Diagnosis and Assessment of the Disease. Ivan 

Foeldvari 1 , Tamás Constantin 2 , Peter Hoeger 3 , Monika Moll 4 , 

Clare Pain 5 , Dana Nemcova 6 , Kathryn S. Torok 7 , Lisa Weibel 8 

and Philip J. Clements 9 , 1 Hamburger Zentrum Kinder-und 

Jugendrheumatologie, Hamburg, Germany, 2 Semmelweis 

Egyetem, AOK, II.sz. Gyermekgyogyaszati Klinika, Budapest, 

Hungary, 3 Kinderkrankenhaus Wilhelmstift, Hamburg, 

Germany, 4 University Childrenxsxhospital, Tübingen, 

Germany, 5 University Childrenxsxhospital, Liverpool, United 

Kingdom, 6 University Childrenxsxhospital, Prague, Czech 

Republic, 7 Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 

8 

University Childrenxs Hospital, Zurich, Switzerland, 9 UCLA 

School of Medicine, Los Angeles, CA 

2005. Clinical Course and Outcomes of Children with Juvenile 

Idiopathic Arthritis-Associated Uveitis and Idiopathic 

Uveitis. Sheila T. Angeles-Han 1 , Steven Yeh 1 , Courtney 

McCracken 1 , Larry B. Vogler 1 , Kelly Rouster-Stevens 2 , 

Christine W. Kennedy 2 , Matthew Kent 1 , Kirsten Jenkins 3 , 

Scott Lambert 1 , Carolyn Drews-Botsch 4 and Sampath 

Prahalad 2 , 1 Emory Univ School of Medicine, Atlanta, GA, 

2 

Emory Children’s Center, Atlanta, GA, 3 Children’s Healthcare 

of Atlanta, Atlanta, GA, 4 Emory University School of Public 

Health, Atlanta, GA 

2006. Sexual Health and Substance Abuse in Adolescents with 

Rheumatic Conditions. Sara M. Stern, Rhina Castillo, 

Katherine AB Marzan, Jennifer Jackson, Mona Desai, Ellen 

Iverson, Leslie F. Clark and Diane Tanaka, Children’s Hospital 

Los Angeles, Los Angeles, CA 

2007. Radiological Peripheral Involvement At Hands, Feet and 

Hips in Young Adults with Polyarticular Idiopathic Juvenile 

Arthritis. Muriel Elhai 1 , Ramin Bazeli 2 , Veronique Freire 2 , 

Antoine Feydy 2 , andre Kahan 1 , Chantal Job-Deslandre 1 and 

Julien Wipff 1 , 1 Rheumatology A, Paris Descartes University, 

Cochin Hospital, APHP, Paris, France, 2 Radiology B, Paris 

Descartes University, Cochin Hospital, APHP, Paris, France 

2008. Initial Evaluation of a Localized Scleroderma (LS) Clinical 

Activity Measure. Suzanne C. Li 1 , Kathryn S. Torok 2 , Christina 

Kelsey 2 , Mara L. Becker 3 , Fatma Dedeoglu 4 , Robert C. 

Fuhlbrigge 5 , Gloria C. Higgins 6 , Sandy D. Hong 7 , Maria F. 

Ibarra 3 , Ronald M. Laxer 8 , Thomas G. Mason II 9 , Marilynn 

G. Punaro 10 , Elena Pope 11 , Egla C. Rabinovich1 2 and Katie G. 

Stewart 10 , 1 Joseph M Sanzari Children’s Hospital, Hackensack 

University Medical Center, Hackensack, NJ, 2 Univ of 

Pittsburgh Med Ctr, Pittsburgh, PA, 3 Children’s Mercy 

Hospital, Kansas City, MO, 4 Boston Childrens Hosp, Boston, 

MA, 5 Childrens Hospital, Boston, MA, 6 Nationwide Childrens 

Hosp, Columbus, OH, 7 U of Iowa Children’s Hosp, Iowa City, 

IA, 8 The Hospital for Sick Children, Toronto, ON, 9 Mayo Clinic 

Rochester, Rochester, MN, 10 Texas Scottish Rite Hospital, 

Dallas, TX, 11 Hospital for Sick Children, Toronto, ON, 12 Duke 

University Medical Center, Durham, NC 

2009. Does Breastfeeding Influence the Presentation of Juvenile 

Idiopathic Arthritis? Results from the Childhood Arthritis 

Prospective Study. Hannah Pickford 1 , Eileen Baildam 2 , Alice 

Chieng 3 , Joyce Davidson 4 , Helen E. Foster 5 , Janet Gardner- 

Medwin 4 , Lucy R. Wedderburn 6 , Wendy Thomson 1 and 

Kimme L. Hyrich 1 , 1 Arthritis Research UK Epidemiology 

280 

2012 Program Book


Unit, Manchester, United Kingdom, 2 Alder Hey Children’s 

Foundation NHS Trust, Liverpool, United Kingdom, 

3 

Manchester Children’s Hospital, Manchester, United 

Kingdom, 4 Royal Hospital for Sick Children, Glasgow, United 

Kingdom, 5 Musculoskeletal Research Group, Newcastle upon 

Tyne, United Kingdom, 6 University College London (UCL), 


2010. Administration of Routine Preventative Vaccinations 

in Children with Juvenile Idiopathic Arthritis Receiving 

Adalimumab. Neelufar Mozaffarian and Vipin Arora, Abbott, 


2011. ACR Criteria, Providers’ Global Rating of Change and Role 

of Patient Self-Report in Evaluating Change in Disease 

Over Time: A Patient Reported Outcomes Measurement 

Information System Study. Bin Huang 1 , Jennifer Farrell 1 , 

Adam Carle 1 , Stacey Niehaus 1 , Hermine Brunner 2 , Alexei 

A. Grom 1 , Michael Henrickson 1 , Jennifer L. Huggins 1 , D. J. 

Lovell 3 , Tracy V. Ting 1 and Esi M. Morgan DeWitt 1 , 1 Cincinnati 

Children’s Hospital Medical Center, Cincinnati, OH, 

2 

Cincinnati Children’s Hospital Medical Center and PRSCG, 

Cincinnati, OH, 3 Cincinnati Children’s Hospital, Cincinnati, 

OH 

2012. Pediatric Rheumatology Productivity: Results of the 

American Academy of Pediatrics 2010 Workforce Survey. 

Michael Henrickson 1 and Laura Laskosz 2 , 1 Cincinnati 

Children’s Hospital Medical Center, Cincinnati, OH, 2 The 

American Academy of Pediatrics, Elk Grove Village, IL 

2013. Cross-Sectional and Longitudinal comparison of Bone Mass 

Status, Using pQCT, in a Large Cohort of Juvenile Idiopathic 

Arthritis and Juvenile Onset Systemic Lupus Erythematosus 

Patients. Fernanda Falcini 1 , Stefano Stagi 2 , Loredana Cavalli 3 , 

Giulia Carnesecchi 4 , Federico Bertini 1 , Laura Masi 3 , Marco 

Matucci-Cerinic 5 and Maria Luisa Brandi 3 , 1 Department of 

Internal Medicine, Rheumatology Section, University of 

Florence, Florence, Italy, 2 Mugello’s Hospital, Borgo San 

Lorenzo, Firenze, Italy, 3 University of Florence, Firenze, 

Italy, 4 University of Florence, Florence, Italy, 5 Univ Florence, 

Firenze, Italy 

2014. Serum 25(OH)D Levels in Adolescents and Young Adults 

with Juvenile Idiopathic Arthritis and Juvenile Onset 

Systemic Lupus Erythematosus: Prevalence and Association 

with Disease Activity. Fernanda Falcini 1 , Stefano Stagi 2 , 

Loredana Cavalli 3 , Giulia Carnesecchi 1 , Federico Bertini 1 , 

Laura Masi 3 , Marco Matucci-Cerinic 1 and Maria Luisa 

Brandi 3 , 1 Department of Internal Medicine, Rheumatology 

Section, Transition Clinic, University of Florence, Florence, 

Italy, 2 Pediatric Unit, Mugello’s Hospital, Borgo San 

Lorenzo, Firenze, Italy, 3 Department of Internal Medicine, 

Endocrinology Unit, University of Florence, Firenze, Italy 

2015. Recognizing Two Distinct Clinical Phenotypes in Muckle- 

Wells Syndrome. J B. Kuemmerle-Deschner 1 , Samuel 

Dembi Samba 1 , Isabelle Kone-Paut 2 , Isabelle Marie 2 , Pascal 

N. Tyrrell 3 and Susanne M. Benseler 3 , 1 University Hospital 

Tuebingen, Tuebingen, Germany, 2 CHU Bicêtre, Paris, France, 

3 

The Hospital for Sick Children, Toronto, ON 

2016. Primary Raynaud’s Phenomenon in a Multicenter Cohort 

of Italian Children and Adolescents: Which Prognostic 

Relevance for Serological Tests? Fernanda Falcini 1 , Valentina 

Denaro 1 , Federica Cuoco 2 , Giorgia Martini 3 , Susanna 

Cappelli 1 , Antonella Petaccia 2 , Fabrizia Corona 2 , Giulia 

Carnesecchi 1 , Francesco La Torre 4 , Marco Matucci-Cerinic 5 

and Donato Rigante 6 , 1 Department of Internal Medicine, 

Rheumatology Section, University of Florence, Firenze, 

Italy, 2 Department of Pediatrics, University of Milan, Milan, 

Italy, 3 University of Padua, Padua, Italy, 4 DIMIMP-University, 

Rheumatologic Section, Bari, Italy, 5 University of Florence, 

Florence, Italy, 6 Università Cattolica Sacro Cuore, Rome, Italy 

2017. Orthopaedic Treatment of Temporomandibular Joint 

(TMJ) Damage in Adolescents with Juvenile Idiopathic 

Arthritis (JIA): Longitudinal Evaluation. Fernanda Falcini 1 , 

Daniela Melchiorre 1 , Giulia Carnesecchi 1 , Federico Bertini 1 , 

Katia Biondi 2 , Mario Bosco 3 and Marco Matucci-Cerinic 4 , 

1 

Department of Internal Medicine, Rheumatology Section, 

University of Florence, Florence, Italy, 2 Department of 

Odontostomatologic Sciences, University of Pavia, Pavia, 

Italy, 3 Pavia, Italy, 4 University of Florence, Florence, Italy 

2018. Juvenile Idiopathic Arthritis in Adulthood: Evaluation of 

Disease Activity, Damage and Quality of Life. Alessandra 

Salmaso 1 , Lorenzo Ceri 2 , Serena Capannini 2 , Francesco 

La Torre 3 , Maurizio Gattinara 1 , Irene Pontikaki 1 , Pier 

Luigi Meroni 4 , Fernanda Falcini 2 and Valeria Gerloni 1 , 

1 

Pediatric Rheumatology, G. Pini Institute, Department 

and Chair of Rheumatology, Milan, Italy, 2 Department 

of Internal Medicine, Rheumatology Section, Transition 

Clinic, University of Florence, Firenze, Italy, 3 DIMIMP- 

University, Rheumatologic Section, Bari, Italy, 4 Division of 

Rheumatology, Istituto G. Pini, University of Milan, Milano, 

Italy 

2019. A Novel MRI Scoring System for the Evaluation of Early- 

Stage Disease Activity of the Wrist in Juvenile Idiopathic 

Arthritis. Charlotte M. Nusman 1 , Robert Hemke 1 , Taco W. 

Kuijpers 2 , Eline E. Deurloo 1 , Dieneke Schonenberg 2 , J. Merlijn 

Van den Berg 3 , Koert M. Dolman 4 , Marion A.J. Van Rossum 3 

and Mario Maas 1 , 1 Academic Medical Center, Amsterdam, 

Netherlands, 2 Emma Children’s Hospital / Academic Medical 

Center (AMC), Amsterdam, Netherlands, 3 Emma Children’s 

Hospital / Academic Medical Center and Reade Institute, 

Amsterdam, Netherlands, 4 St. Lucas Andreas Hospital and 

Reade Institute, Amsterdam, Netherlands 

2020. Assessment of Procedure Safety and Cannula Position in 

Temporomandibular Joint Puncture Evaluated by Cone 

Beam Computerized Tomography. Thomas K. Pedersen 1 , 

Kasper D. Kristensen 1 , Per Alstergren 2 , Peter Stoustrup 1 , 

Annelise Küseler 1 and Troels Herlin 3 , 1 University of Aarhus, 

Aarhus C, Denmark, 2 Karolinska Institutet, Huddinge, 

Sweden, 3 Aarhus University Hospital Skejby, Aarhus N, 

Denmark 



282 

2021. The Schedule of Administration of Canakinumab in 

Cryopyrin Associated Periodic Syndrome Is Driven by the 

Phenotype Severity Rather Than the Age. Roberta Caorsi 1 , 

Loredana Lepore 2 , Francesco Zulian 3 , Maria Alessio 4 , Achille 

Stabile 5 , Antonella Insalaco 6 , Martina Finetti 1 , Antonella 

Battagliese 4 , Giorgia Martini 3 , Chiara Bibalo 2 , Alberto 

Martini 7 and Marco Gattorno 1 , 1 G. Gaslini Institute, Genova, 

Italy, 2 Ospedale-Infantile Trieste, Trieste, Italy, 3 University 

of Padua, Padova, Italy, 4 Federico II Hospital, Napoli, Italy, 

5 

DipartimentoPediatria, Policlinico Gemelli, Roma, Italy, 

6 

Ospedale Pediatrico Bambino Gesù, Roma, Italy, 7 Pediatric 

Rheumatology Collaborative Study Group [PRSCG], 


2022. Individual Disease Burden in Children and Adolescents 

with Chronic Musculoskeletal Pain – Multilevel-Analysis 

of a Nationwide Prospective Longitudinal Observation 

Study. Kerstin Gerhold 1 , Rebecca Muckelbauer 2 , Jacqueline 

Müller-Nordhorn 2 , Angelika Thon 3 , Thomas Müller 4 , Gerd 

Ganser 5 , Martina Niewerth 1 and Kirsten Minden 6 , 1 German 

Rheumatism Research Center, a Leipniz Institute, Berlin, 

Germany, 2 Charité - Universitätsmedizin Berlin, Berlin, 

Germany, 3 Kinderklinik der Medizinischen Hochschule 

Hannover, Hannover, Germany, 4 Universitätsklinikum 

Halle (Saale), Halle (Saale), Germany, 5 Sankt Josef Stift, 

Sendenhorst, Germany, 6 German Rheumatism Research 

Center, a Leibniz Institute, Berlin, Germany 

2023. Should Joint Ultrasound Contribute to Therapeutic 

Decisions in Juvenile Idiopathic Arthritis? Marie Halbwachs, 

Geraldine Durand, Caroline Robin, Catherine Gambert 

Abdel Rahman, Pierre Ingrand and Elisabeth Solau-Gervais, 

University Hospital, Poitiers, France 

2024. Articular Symptoms in Cryopyrin-Associated Periodic 

Syndrome: Retrospective French Study. Laetitia Houx 1 , 

Pierre Quartier 2 , Isabelle Kone-Paut 3 , Xavier Guennoc 4 , 

Pascal Pillet 5 , Thierry Lequerre 6 , Irene Lemelle 7 , Mohamed 

Hamidou 8 , Gilles Grateau 9 , Eric Hachulla 10 , Jean-Marie 

Berthelot 11 , Benedicte Neven 12 , Christophe Richez 13 , Anne 

Pagnier 14 , Veronique Hentgen 15 and Valerie Devauchelle- 

Pensec 16 , 1 Brest, France, 2 Necker-Enfants Malades Hospital,, 

Paris, France, 3 Hospital Kremlin Bicêre, Kremlin-Bicêtre, 

France, 4 Hopital de Saint Brieuc, France, 5 Paediatry, CHU, 

Bordeaux, France, 6 Rouen, France, 7 Paediatry, CHU, Nancy, 

France, 8 Hôtel Dieu, Hôpital Universitaire de Nantes, Nantes, 

France, 9 Hopital Tenon, Paris, France, 10 Department of 

Internal Medicine, Claude Huriez Hospital, University of Lille, 

Lille CEDEX, France, 11 Nantes University Hospital, Nantes, 

France, 12 Inserm U76 8 , Paris, France, 13 Hôpital Pellegrin 

and Université Victor Segalen Bordeaux, Bordeaux, France, 

14 

Service de pediatrie, Grenoble, France, 15 Paediatric Unit, 

Le Chesnay, France, 16 Brest Occidentale university, Brest, 

France 

2025. Clinical Characteristics and Therapy Response in a Large 

Single-Centre Cohort of Patients with Periodic Fever with 

Aphtous Stomatitis, Pharyngitis and Cervical Adenitis 

Syndrome. Francesca Ricci 1 , Antonella Meini 1 , Lucio 


Verdoni 1 , Laura Dotta 1 , Marta Bolis 1 , Marco Berlucchi 2 , 

Gianfranco Savoldi 3 and Marco Cattalini 1 , 1 Pediatric 

Immunology and Rheumatology Unit, Brescia, Italy, 

2 

Department of Pediatric Otorhinolaryngology, Brescia, Italy, 

3 

Angelo Nocivelli Institute of Molecular Medicine, Brescia, 

Italy 

2026. High Prevalence of Cervical Spine and Temporomandibular 

Joint Involvement in Patients with Juvenile Idiopathic 

Arthritis. Nikolay Tzaribachev 1 , Catrin Tzaribachev 1 

and Bernd Koos 2 , 1 Center for Rheumatic Diseases, Bad 

Bramstedt, Germany, 2 University Medical Center Schleswig- 

Holstein, Campus Kiel, Kiel, Germany 

2027. Chronic Nonbacterial Osteomyelitis of the Mandible in 

Children: a Tertiary Center Experience. Daniela S. Ardelean 1 

and Ronald M. Laxer 2 , 1 Hospital for Sick Children, Toronto, 

ON, 2 The Hospital for Sick Children, Toronto, ON 

2028. Medication Adherence and Quality of Life in Children with 

Rheumatic Disease. Stacey E. Tarvin 1 , Lisa M. Macharoni 2 , 

Christine M. Raches 1 and Nicole M. Taylor 2 , 1 Riley Hospital 

for Children, Indianapolis, IN, 2 University of Indianapolis, 

Indianapolis, IN 

2029. Reliability of Scoring a Disease Damage Measure for 

Juvenile Localized Scleroderma. Kathryn S. Torok 1 , Suzanne 

C. Li 2 , Christina Kelsey 1 , Mara L. Becker 3 , Fatma Dedeoglu 4 , 

Robert C. Fuhlbrigge 5 , Gloria Higgins 6 , Sandy D. Hong 7 , 

Maria F. Ibarra 3 , Ronald M. Laxer 8 , Thomas G. Mason II 9 , 

Marilynn G. Punaro 10 , Elena Pope 11 , Egla C. Rabinovich1 2 and 

Katie G. Stewart 10 , 1 Univ of Pittsburgh Med Ctr, Pittsburgh, 

PA, 2 Joseph M Sanzari Children’s Hospital, Hackensack 

University Medical Center, Hackensack, NJ, 3 Children’s Mercy 

Hospital, Kansas City, MO, 4 Boston Childrens Hosp, Boston, 

MA, 5 Childrens Hospital, Boston, MA, 6 PRCSG-Cincinnati 

Children’s Hospital Medical Center, Columbus, OH, 7 U of 

Iowa Children’s Hosp, Iowa City, IA, 8 The Hospital for Sick 

Children, Toronto, ON, 9 Mayo Clinic Rochester, Rochester, 

MN, 10 Texas Scottish Rite Hospital, Dallas, TX, 11 Hospital 

for Sick Children, Toronto, ON, 12 Duke University Medical 

Center, Durham, NC 

2030. A Multi-Modal Amplified Musculoskeletal Pain Treatment 

Program: Associations of Previous Pharmacotherapy with 

Subsequent Outcomes. Cara M. Hoffart 1 , Pamela Weiss 1 , 

David D. Sherry 2 , Chris Feudtner 3 and Margaret Stineman 4 , 

1 

The Children’s Hospital of Philadelphia, Philadelphia, 

PA, 2 Children’s Hospital of Philadelphia, Philadelphia, 

PA, 3 Division of General Pediatrics, Children’s Hospital of 

Philadelphia; University of Pennsylvania Center for Clinical 

Epidemiology and Biostatistics, Philadelphia, PA, 4 The 

University of Pennsylvania, Philadelphia, PA 

2031. Safety and Efficacy of Anakinra in Patients with Deficiency 

of Interleukin-1 Receptor Antagonist. Gina A. Montealegre 1 , 

Adriana Almeida de Jesus 2 , Dawn C. Chapelle 1 , Paul 

Dancey 3 , Joost Frenkel 4 , Annet van Royen-Kerkhoff 4 , 

Ronit Herzog 5 , Giovanna Ciocca 6 , Rafael F. Rivas-Chacon 6 , 

Ann M. Reed 7 , Nicole Plass 8 , Ivona Aksentijevich 9 , Polly J.


Ferguson 10 , Suvimol C. Hill 11 , Edward Cowen1 2 and Raphaela 

T. Goldbach-Mansky 13 , 1 NIAMS, Bethesda, MD, 2 National 

Institute of Arthritis Musculoskeletal and Skin Disease, 

National Institutes of Health, Bethesda, MD, 3 Memorial 

University of Newfoundland, St Johns, 4 University of 

Utrecht, Utrecht, Netherlands, 5 Cornell University, New 

York, NY, 6 Miami Children’s Hospital, Miami, FL, 7 Mayo 

Clinic, Rochester, MN, 8 National Institutes of Health Clinical 

Center, Bethesda, MD, 9 National Human Genome Research 

Institute, National Institutes of Health, Bethesda, MD, 

10 

University of Iowa Carver College of Medicine, Iowa City, 

IA, 11 NIH Clinical Center, Bethesda, MD, 12 NCI/NIH, Bethesda, 

MD, 13 Translational Autoinflammatory Diseases Section 

NIAMS NIH, Bethesda, MD 

2032. Results from a Multicentre International Registry of 

Familial Mediterranean Fever: Impact of Genetic and 

Environment Factors On the Expression of a Monogenic 

Disease in Children. Seza Ozen 1 , Erkan Demirkaya 2 , Gayane 

Amaryan 2 , Isabelle Koné-Paut 2 , Adem Polat 2 , Turker Turker 2 , 

Patricia Woo 2 , Yosef Uziel 2 , Consuelo Modesto 2 , Martina 

Finetti 2 , Pierre Quartier 2 , Efimia Papadopoulou-Alataki 2 , 

Sulaiman Al-Mayouf 2 , Giovanna Fabio 2 , Romina Gallizzi 2 , 

Luca Cantarini 2 , Joost Frenkel 2 , Susan Nielsen 2 , Michael 

Hofer 2 , Antonella Insalaco 2 , Huri Ozdogan 2 , Nicolino 

Ruperto 2 and Marco Gattorno 2 , 1 Hacettepe University, 

Ankara, Turkey, 2 Paediatric Rheumatology International 

Trials Organization (PRINTO), Istituto Giannina Gaslini, 

Genova, Italy 

2033. Infliximab Is an Effective Therapy in Pediatric Renal 

Sarcoidosis. Elisa Wershba, Laura Lewandowski, Heather 

Van Mater and Egla C. Rabinovich, Duke University Medical 

Center, Durham, NC 

2034. Magnetic Resonance Imaging Is a Reliable Tool to 

Monitor Chronic Non-Bacterial Osteomyelitis in Children. 

Grazia Minardo 1 , Giulia Zanon 1 , Simone Corradin 1 , Pietro 

Zucchetta 1 , Giorgia Martini 1 , Fabio Vittadello 1 and Francesco 

Zulian 2 , 1 University of Padua, Padua, Italy, 2 University of 

Padua, Padova, Italy 

2035. Performance of Icbd (International Criteria for Behcet’s 

Disease) in Iranian Children with Behcet’s Disease. Nahid 

Shafaie, Bahar Sadeghi Abdollahi and Fereydoun Davatchi, 

Shariati Hospital-Tehran Univ, Tehran, Iran 

2036. Children’s Hospital of Pittsburgh Pediatric Onset En Coup 

De Sabre and Parry-Romberg Syndrome Cohort. Kristin 

M. Brown 1 , Darren Smith 2 , Christina Kelsey 3 , Katherine 

Kurzinski 4 and Kathryn S. Torok 3 , 1 University of Pittsburgh, 

Pittsburgh, PA, 2 university of Pittsburgh Division of 

Plastic and Reconstructive Surgery, Children’s Hospital 

of Pittsburgh, Pittsburgh, 3 Univ of Pittsburgh Med Ctr, 

Pittsburgh, PA, 4 Children’s Hospital of Pittsburgh of UPMC, 


Quality Measures and Innovations in Practice Management and 

Care Delivery 

2037. Poor Quality of Gout Care Is Strongly Associated with 

Higher Gout-Related Health Care Utilization. Jasvinder 

A. Singh 1 and Joshua Richman 2 , 1 University of Alabama at 

Birmingham, Birmingham, AL, 2 UAB School of Medicine, 


2038. Expanding Access in Rheumatology Specialty Care in New 

Mexico Via an Innovative Community Outreach Program. 

Arthur Bankhurst 1 , Sanjeev Arora 1 , Summers Kalishman 1 , 

Jeannie F. Boyle 1 , Cynthia Olivas 1 , Rebecca Monette 1 , Dara 

Som 2 and Yolanda Hubbard 1 , 1 University of New Mexico 

School of Medicine, Albuquerque, NM, 2 University of New 

Mexico School of Medicine, Albuquerque 

2039. Uveitis Surveillance through Lean-Six Sigma for Quality 

Assurance in Juvenile Idiopathic Arthritis. Anjali 

Patwardhan 1 , Kelly Kelleher 1 , Jeffery Hoffman 1 , Karla 

B. Jones 2 , Stacy P. Ardoin 3 and Charles H. Spencer 1 , 

1 

Nationwide Childrens Hospital, Columbus, OH, 2 Nationwide 

Children’s Hospital, Columbus, OH, 3 Ohio State University, 

Columbus, OH 

2040. Provisions of Quality Driven Care in Childhood-Onset 

Systemic Lupus Erythematosus. Matthew C. Hollander 1 , 

Jessica M. Sage 2 , Alexandria J. Greenler 2 , Tadej Avcin 3 , 

Michael W. Beresford 4 , Graciela Espada 5 , Marisa S. Klein- 

Gitelman 6 , Michael Henrickson 2 , Tsz-Leung Lee 7 , Joshua 

D. Pendl 2 , Marilynn G. Punaro 8 , Jennifer L. Huggins 2 , Anne 

M. Stevens 9 and Hermine I. Brunner 2 , 1 Seattle Children’s 

Hospital, Seattle, WA, 2 Cincinnati Children’s Hospital 

Medical Center, Cincinnati, OH, 3 International Investigator 

Consortium for MAS Diagnostic Criteria, Ljubljana, Slovenia, 

4 

Alder Hey Children’s NHS Foundation Trust, Liverpool, 

United Kingdom, 5 Childrens Hosp Ricardo Gutierrez, Buenos 

Aires, Argentina, 6 Ann & Robert H. Lurie Children’s Hospital 

of Chicago, Chicago, IL, 7 Queen Mary Hospital, Hong 

Kong, Hong Kong, 8 Texas Scottish Rite Hospital, Dallas, TX, 

9 

University of Washington, Seattle, WA 

2041. Improving Access and Patient Education in Rheumatology: 

the Gout Shared Medical Appointment; a Quality 

Improvement Initiative. Alicia J. Zbehlik 1 and Nicole M. 

Orzechowski 2 , 1 Dartmouth-Hitchcock Medical Center, 

Lebanon, NH, 2 Dartmouth-Hitchcock Med Ctr, Lebanon, NH 

2042. Enhancing Shared Decision-Making in Juvenile Idiopathic 

Arthritis. Jessica M. Sage, Ellen A. Lipstein, William B. 

Brinkman, Carole M. Lannon and Esi M. Morgan DeWitt, 

Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 

2043. Documentation of Improvement Over 2 Months 

in Osteoarthritis, Systemic Lupus Erythematosus, 

Spondyloarthropathy and Gout Similarly to Rheumatoid 

Arthritis According to Function, Pain, Patient Global 

Estimate and RAPID3 On a Multidimensional Health 

Assessment Questionnaire (MDHAQ). Isabel Castrejón 1 , 

Martin J. Bergman 2 and Theodore Pincus 1 , 1 NYU Hospital for 

Joint Diseases, New York, NY, 2 Taylor Hospital, Ridley Park, PA 



284 

2044. Trying to Improve Care: A Review of the Morbidity and 

Mortality Conference in the Division of Rheumotology. 

Michelle Batthish 1 , Shirley Tse 1 , Brian M. Feldman 1 , G. Ross 

Baker 2 and Ronald M. Laxer 1 , 1 The Hospital for Sick Children, 

Toronto, ON, 2 The University of Toronto, Toronto, ON 

2045. Treatment Patterns and Monitoring of Serum Uric Acid 

Levels in a Large Cohort of Gout Patients in the United 

States: Is There Room for Improvement? Yong Chen 1 , 

Kasem S. Akhras 2 , Michael Grabner 1 , Rima H. Tawk 3 and 

Ralph Quimbo 1 , 1 HealthCore, Inc., Wilmington, DE, 2 Takeda 

Pharmaceuticals International, Inc., Deerfield, IL, 3 University 

of Illinois at Chicago, Chicago, IL 

2046. Matching of Patients’ Actual and Desired Roles in 

Treatment Decision Making and Trust in Physicians. Akiko 

Aoki 1 , Akiko Suda 2 , Shouhei Nagaoka 3 , Mitsuhiro Takeno 4 , 

Yoshiaki Ishigatsubo 4 , Tatsuto Ashizawa 5 , Osamu Takahashi 6 , 

Sachiko Ohde 7 and Sadayoshi Ohbu 8 , 1 Tokyo Medical 

University Hachioji Medical Center, Tokyo, Japan, 2 Yokohama 

Minami Kyousai Hospital, Yokohama, Japan, 3 Yokohama 

Minami Kyosai Hospital, Yokohama, Japan, 4 Yokohama 

City University Graduate School of Medicine, Yokohama, 

Japan, 5 Tokyo Medical University Hachioji Medical Center, 

Chuo-ku,Tokyo, Japan, 6 St Luke’s life science instutute, Chuoku,Tokyo, 

Japan, 7 St.Luke’s Life of Science Institute, Tokyo, 

Japan, 8 Rikkyo University, Tokyo, Japan 

2047. Impact of a Rheumatology Consultation Service in 

Hospitalized Patients. Shirley L. Chow 1 , Dafna D. Gladman 

Gladman 2 and Heather McDonald-Blumer 3 , 1 University 

of Toronto, Toronto, ON, 2 Toronto Western Hospital and 

University of Toronto, Toronto, ON, 3 Mt. Sinai Hospital, 

Toronto, ON 

2048. Four Physician Global Assessments for Overall Status, 

Inflammation, Damage, and Unexplained Symptoms 

Are Useful in Usual Care of Patients with Osteoarthritis, 

Fibromyalgia, Systemic Lupus Erythematosus, and 

Spondyloarthropathy, As Well As Rheumatoid Arthritis. 

Isabel Castrejón 1 , Martin J. Bergman 2 and Theodore Pincus 1 , 

1 

NYU Hospital for Joint Diseases, New York, NY, 2 Taylor 

Hospital, Ridley Park, PA 

2049. Improving Pneumococcal Vaccination and Documentation 

for Immunosuppressed Patients At a University-Based 

Rheumatology Clinic. Christine Peoples 1 , Rohit Aggarwal 1 , 

Heena Sheth 1 , Aarat Patel 1 , Daniel Lupash 1 , Christine 

McBurney 1 , Ashima Malik 1 , Swati Modi 1 , Ximena D. Ruiz 2 

and Douglas W. Lienesch 1 , 1 University of Pittsburgh, 

Pittsburgh, PA, 2 University of Pittsburgh Medical Center, 


2050. Are Patients Meeting the Updated Physical 

Activity Guidelines? Physical Activity Participation, 

Recommendation, and Preferences among Adults with 

Rheumatic Diseases. Victoria L. Manning 1 , Michael V. 

Hurley 2 , David L. Scott 1 and Lindsay M. Bearne 1 , 1 King’s 

College London, London, United Kingdom, 2 St George’s 

University of London, London, United Kingdom 


2051. Standardized Data Collection Supports Reliable Reporting 

of Rheumatoid Arthritis (RA) Measures for the Medicare 

Physicians’ Quality Reporting System. J. Timothy 

Harrington 1 , George Reed 2 , Katherine C. Saunders 3 , Lisa 

Lemire 3 , Aimee Whitworth 3 , Jeffrey D. Greenberg 4 and Joel 

M. Kremer 5 , 1 University of Wisconsin (retired), Madison, 

WI, 2 UMass Medical School, Worcester, MA, 3 CORRONA, 

Inc., Southborough, MA, 4 New York University School of 

Medicine, New York, NY, 5 Albany Medical College and The 

Center for Rheumatology, Albany, NY 

2052. Effect of Community Characteristics on Quality of Care 

in Systemic Lupus Erythematosus. Edward Yelin 1 , Laura 

Trupin 2 , Chris Tonner 3 and Jinoos Yazdany 1 , 1 University 

of California San Francisco, San Francisco, CA, 2 UC San 

Francisco, San Francisco, CA, 3 UCSF, San Francisco, CA 

2053. Tele-Rheumatology: The Future Is Now. Daniel Albert 1 , 

Krista Merrihew 2 and Sarah Pletcher 2 , 1 Dartmouth-Hitchcock 

Medical Center, Geisel School of Medicine, Lebanon, NH, 

2 

Dartmouth-Hitchcock Medical Center, Lebanon, NH 

2054. Safety of Joint and Soft Tissue Injections in Patients on 

Warfarin Anti-Coagulation. Richard Conway, Finbar (Barry) 

D. O’Shea, Gaye Cunnane and Michele Doran, St James’s 


2055. TEAM-Managed Care of Biological Patients at A Canadian 

Centre. Melissa Deamude 1 , Dawn Heap 2 , Melanie Kanellos 2 , 

Debbie Kislinsky 3 , Kathy Kislinsky 3 , Cynthia Mech 4 , Helena 

Ross 3 , Peggy Saldanha 3 , Lauri Vanstone 3 , Kathleen Brown 3 

and William G. Bensen 5 , 1 Dr. William G. Bensen Medicine 

Professional Corporation, Hamilton, ON, 2 Dr. Bensen’s 

Rheumatology Clinic, Hamilton, ON, 3 Dr. William Bensen 

Rheumatology Clinic, Hamilton, ON, 4 Rheumatology Health 

Team, Dr. Bensen’s Rheumatology Clinic, Hamilton, ON, 5 St. 

Joseph’s Hospital and McMaster University, Hamilton, ON, 

Hamilton, ON 

2056. Effectiveness of a Focused Educational Intervention in 

Improving the Supplementation of Vitamin D Deficiency 

and Insufficiency. Candice Low, Richard Conway, Gaye 

Cunnane, Michele Doran and Finbar (Barry) D. O’Shea, St 

James’s Hospital, Dublin, Ireland 

2057. Analysis of the Adherence to the Monitoring of 

Glucocorticoid Eye Toxicity and of the Prevalence of 

Cataracts and Glaucoma Among Patients with Systemic 

Lupus Erythematosus. Linda Carli 1 , Chiari Tani 1 , Francesca 

Querci 1 , Alessandra Della Rossa 1 , Sabrina Vagnani 1 , 

Anna d’Ascanio 1 , Rossella Neri 1 , Antonio Tavoni 2 , Stefano 

Bombardieri 1 and Marta Mosca 1 , 1Rheumatology Unit, 

Department of Internal Medicine, University of Pisa, PISA, 

Italy, 2 Immunoallergology Unit, Department of Internal 

Meicine, University of Pisa, PISA, Italy 

2058. Differences in Psychological Characteristics between 

Patients with Rheumatoid and Psoriatic Arthritis. Panagiota 

Tsitsi 1 , Athina Theodoridou 1 , Foteini Lada 1 , Konstantinos 

Papanikolaou 2 , Despina Dimopoulou 1 , Georgios 

Garyfallos 3 , Alexios Benos 4 and Alexandros Garyfallos 1 ,


14 

th Department of Internal Medicine,Medical School, 

Aristotle University of Thessaloniki, Thessaloniki, Greece, 

2 

Psychiatric Hospital of Petra Olympus, Katerini, Greece, 

Katerini, Greece, 3 2nd Department of Psychiatry, Medical 

School, Aristotle University of Thessaloniki, Thessaloniki, 

Greece, 4 Department of Hygiene, Medical School, Aristotle 

University of Thessaloniki, Thessaloniki, Greece 

2059. The Efficacy of Clinical Guidelines in Promoting Co- 

Prescription of Bone Protection with Glucocorticoids 

Among Hospital Doctors Treating Inpatients. Leonard 

C. Harty 1 , James Clare 2 , Dylan Finnerty 2 , Susan Van Der 

Kamp 2 , Fionnuala Kennedy 3 , Malachi McKenna 4 and Oliver 

M. FitzGerald 1 , 1 Dublin Academic Medical Centre, St. 

Vincent’s University Hospital, Dublin, Ireland, 2 Department 


Ireland, 3 Pharmacy Department, St. Vincent’s University 

Hospital, Dublin, Ireland, 4 Department of Endocrinology & 

Metabolic Bone Disease, St. Vincent’s University Hospital, 


2060. Using the Electronic Medical Record to Increase Rates of 

Physician Assessment of Lipids in Patients with Systemic 

Lupus Erythematosus and Rheumatoid Arthritis: A 

Quality Improvement Initiative. Astrud Lorraine Leyva, 

Laura L. Tarter, Elizabeth Blair Solow and David R. Karp, UT 


2061. Physician Variation in Documentation of Rheumatoid 

Arthritis Quality Measures and Evaluation of Relationship 

with Radiographic Progression. Sonali Desai 1 , Jinoos 

Yazdany 2 , Nancy A. Shadick 3 , Siri Lillegraven 4 , Chih-Chin Liu 5 , 

Michelle A. Frits 6 , Tabatha Norton 7 , Jonathan S. Coblyn 8 , 

Michael Weinblatt 5 and Daniel H. Solomon 6 , 1 Boston, MA, 

2 

University of California San Francisco, San Francisco, 

CA, 3 Department of Medicine, Division of Rheumatology, 

Immunology and Allergy, Brigham and Women’s Hospital, 

Boston, MA, 4 Diakonhjemmet Hospital, Oslo, Norway, 

5 


Hospital, Boston, MA, 6 Brigham and Women’s Hospital, 

Boston, MA, 7 Brigham and Women’s Hospital, Harvard 

Medical School, Boston, MA, 8 Brigham & Womens Hosp, 

Boston, MA 

2062. Increasing Pneumococcal Vaccination for 

Immunosuppressed Patients: A Cluster Quality 

Improvement Trial. Sonali Desai 1 , Lara Szent-gyorgyi 1 , 

Alexander Turchin 1 , Bing Lu 2 , Anna A. Bogdanova 1 , Michael 

Weinblatt 3 , Jonathan S. Coblyn 4 , Jeffrey O. Greenberg 1 , Allen 

Kachalia 1 and Daniel H. Solomon 5 , 1 Boston, MA, 2 Brigham 

and Women’s Hospital, Harvard Medical School, Boston, 

MA, 3 Rheumatology & Immunology, Brigham & Women’s 

Hospital, Boston, MA, 4 Brigham & Womens Hosp, Boston, 

MA, 5 Brigham and Women’s Hospital, Boston, MA 

2063. Detection of Inflammatory Arthritis and Musculoskeletal 

Conditions in a First Nations Community: Results of an 

Onsite Screening Program. Cheryl Barnabe 1 , Carrissa Low 

Horn 2 , Margaret Kargard 2 , Stephen Mintsioulis 2 , Sharon 

Leclercq 1 , Dianne P. Mosher 1 , Hani S. El-Gabalawy 3 , Tyler 

White 2 and Marvin J. Fritzler 1 , 1 University of Calgary, Calgary, 

AB, 2 Siksika Health Services, Siksika, AB, 3 University of 

Manitoba, Winnipeg, MB 

2064. Regular Measure of Disease Activity during the Routine 

Care of Rheumatoid Arthritis Patients Involves Some 

Extra Work but Positive Results. Lissiane K. N. Guedes, 

Ana Cristina Medeiros Ribeiro, Karina Rossi Bonfiglioli, 

Diogo Domiciano, Carolina Reither Vizioli, Gilmara Franco 

da Cunha, andressa Silva Abreu, Filipi M. Mello, Ana Luiza 

de Aguiar Foelkel, Celio R. Gonçalves and Ieda Laurindo, 


Paulo, Brazil 

2065. Uptake of the American College of Rheumatology’s (ACR) 

Rheumatology Clinical Registry (RCR): Quality Measure 

Summary Data. Salahuddin Kazi 1 , Itara Barnes 2 , Jinoos 

Yazdany 3 and Rachel Myslinski 2 , 1 UT Southwestern Medical 

Center, Dallas, TX, 2 American College of Rheumatology, 

Atlanta, GA, 3 University of California San Francisco, San 

Francisco, CA 

2066. Improving Outpatient Follow-up for Osteoporosis 

Management After a Hip Fracture. Anika Alarakhia 1 and 

Robert Quinet 2 , 1 Ochsner Medical Center, New Orleans, LA, 

2 

Ochsner Medical Center - New Orleans, New Orleans, LA 

2067. Access to Technology and Interest in Mobile “app” for 

Disease Management Among Patients with Systemic Lupus 

Erythematosus Seeking Care At a Large Referral Center. 

Wendy Marder 1 , Holly Witteman 2 , Margaret Hyzy 3 , Martha 

Ganser 1 , Emily C. Somers 1 and Lawrence An 3 , 1 University of 

Michigan, Ann Arbor, MI, 2 University of Michigan Medical 

School, Ann Arbor, MI, 3 Universitiy of Michigan, Ann Arbor, 

MI 

2068. Is There a Difference in Rheumatology Patient Reported 

Outcomes When Measured At Home Versus the Clinic 

Setting? C.J. Inman 1 , Frederick Wolfe 2 and Kaleb Michaud 3 , 

1 

University of Utah, Salt Lake City, UT, 2 National Data Bank 

for Rheumatic Diseases, Wichita, KS, 3 National Data Bank 


Center, Omaha, NE 


2069. Proteinase Activated Receptor-4 Stimulation Promotes 

Leukocyte Adhesion in the Rat Knee Joint. Jason J. 

McDougall, Dalhousie University, Halifax, NS 

2070. Myeloid-Derived Suppressor Cells Accumulated in Spleens 

of Mice with Collagen-Induced Arthritis and Inhibited 

Immune Response of CD4+ T Cells. Wataru Fujii 1 , Eishi 

Ashihara 2 , Hideyo Hirai 3 , Hidetake Nagahara 1 , Kazuki 

Fujioka 1 , Ken Murakami 1 , Kaoru Nakamura 1 , Takahiro Seno 1 , 

Aihiro Yamamoto 1 , Hidetaka Ishino 1 , Masataka Kohno 1 , 

Taira Maekawa 3 and Yutaka Kawahito 1 , 1 Graduate School of 

Medical Science, Kyoto Prefectural University of Medicine, 

Kyoto, Japan, 2 Kyoto Pharmaceutical University, Kyoto, 

Japan, 3 Kyoto University Hospital, Kyoto, Japan 



286 

2071. The Potent, Highly Selective and Orally Bioavailable Spleen 

Tyrosine Kinase Inhibitor GSK143 Demonstrates Efficacy 

in B Cell Receptor and Fc Receptor Signalling in Models 

of Inflammatory and Autoimmune Disease. Marion C. 

Dickson, Nicholas Smithers, Huw Lewis, Cesar Ramirez- 

Molina, Scott McCleary, Mike Barker and John Liddle, GSK, 

Stevenage, United Kingdom 

2072. Bone Formation and Resorption Are Both Increased in 

Autoimmune Arthritis. Kresten K. Keller 1 , Jesper Skovhus 

Thomsen 2 , Kristian Stengaard-Pedersen 1 , Frederik Dagnæs- 

Hansen 3 , Jens R. Nyengaard 4 and Ellen-Margrethe Hauge 1 , 

1 

Department of Rheumatology, Aarhus University Hospital, 

Aarhus, Denmark, 2 Institute of Anatomy, Aarhus University, 

3 

Institute of Medical Microbiology and Immunology, Aarhus 

University, Aarhus, Denmark, 4 Stereology and Electron 

Microscopy Laboratory, Centre for Stochastic Geometry and 

Advanced Bioimaging. Aarhus University hospital, Aarhus, 

Denmark 

2073. Green Tea Epigallocatechin-3-Gallate Ameliorates Murine 

Arthritis by Inducing IDO Producing Dendritic Cells Via 

Nrf2 Antioxidant Pathway. Soyoun Min, Mei Yan, Kamala 

Vanarsa, Anna Bashmakov and Chandra Mohan, University 

of Texas Southwestern Medical Center, Dallas, TX 

2074. Combined Effects of a c-Fos/AP-1 Inhibitor T-5224 and 

Methotrexate On Collagen-Induced Arthritis in Mice. 

Tomomi Date 1 , Yukihiko Aikawa 1 , Tetsuya Yamamoto 1 , 

Hirokazu Narita 1 , Shuichi Hirono 2 and Shunichi Shiozawa 3 , 

1 

Research Laboratories, Toyama Chemical Co., Ltd, Toyama, 

Japan, 2 Department of Pharmaceutical Sciences, School of 

Pharmacy, Kitasato University, Tokyo, Japan, 3 Department 

of Medicine & Rheumatology, Kyushu University Beppu 

Hospital, Beppu, Japan 

2075. CCR6+ Foxp3+ Regulatory T Cells Regulate the 

Development of Collagen Induced Arthritis in T Cell 

Specific RORγt Transgenic Mice. Yuya Kondo, Masahiro 

Tahara, Mana Iizuka, Hiroto Tsuboi, Satoru Takahashi, Isao 

Matsumoto and Takayuki Sumida, University of Tsukuba, 

Tsukuba, Japan 

2076. Efficacy of the Potent PI3K-δ,γ Inhibitor IPI-145 in Rat 

Adjuvant Arthritis. David L. Boyle, Katharyn Topoleweski 

and Gary S. Firestein, UCSD School of Medicine, La Jolla, CA 

2077. IL-6 Blockade Augments the Anti-Inflammatory Effect 

without Increasing the Side Effects of Steroids in Collagen- 

Induced Arthritis. Miho Suzuki 1 , Hiroto Yoshida 1 , Misato 

Hashizume 1 , Masashi Shiina 1 , Keisuke Tanaka 1 and Yoshihiro 

Matsumoto 2 , 1 Chugai Pharmaceutical Co., Ltd., Gotemba, 

Shizuoka, Japan, 2 Chugai Pharmaceutical Co., Ltd., Gotemba, 

Japan 

2078. Low-Density Lipoprotein Receptor Deficiency Ameliorates 

the Development of Inflammatory Arthritis. Shawn Rose 

and Harris R. Perlman, Northwestern University, Chicago, IL 

2079. Anti-Interleukin-6 Receptor Antibody Improves Systemic 

Osteoporosis in a Mice Model of Glucose-6-Phosphate 


Isomerase-Induced Arthritis. Hiroto Yoshida 1 , Miho Suzuki 1 , 

Misato Hashizume 1 , Keisuke Tanaka 1 , Masashi Shiina 1 , Isao 

Matsumoto 2 , Takayuki Sumida 2 and Yoshihiro Matsumoto 1 , 

1 

Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan, 

2 

University of Tsukuba, Tsukuba City, Japan 

2080. IL-20 Is Not Involved in Mouse Collagen Induced 

Arthritis. Christina andersson 1 , Kyle Serikawa 2 , Hermann 

Pelzer 1 , Peter Thygesen 1 , Patricia Smith 2 , Kim Kruse 2 , 

Shameek Biswas 2 , Brian Fox 2 , anders Milner 1 , Peter Kvist 1 , 

Josephine Hebsgaard 1 , Jesper Pass 1 and John Rømer 1 , 

1 

Biopharmaceutical Research Unit, Novo Nordisk A/S, Måløv, 

Denmark, 2 Biopharmaceutical Research Unit, Novo Nordisk 

A/S, Seattle, WA 

2081. Avβ3 Integrin Inhibition with Cilengitide Both Prevents 

and Treats Collagen Induced Arthritis. Despoina Sykoutri 1 , 

Nisha Geetha 1 , Silvia Hayer 1 , Peter Mandl 1 , Josef S. Smolen 2 , 

Gerald Prager 1 and Kurt Redlich 1 , 1 Medical University of 

Vienna, Vienna, Austria, 2 Medical University of Vienna and 

Hietzing Hospital, Vienna, Austria 

2082. Peripheral and Local Effects of Anti-C5aR Treatment in the 

Collagen Induced Arthritis Model. Christina andersson, 

Carola Wenander, Pernille Usher, Josephine Hebsgaard 

and Lars Hornum, Biopharmaceutical Research Unit, Novo 

Nordisk A/S, Måløv, Denmark 

2083. New Treatment Approach of Rheumatoid Arthritis 

Based On Inhibition of Cyclin Dependent Kinase-9. 

Annelie Hellvard 1 , Lutz Zeitlmann 2 , Ulrich Heiser 3 , andré 

Niestroj 3 , Hans-Ulrich Demuth 3 , Jan Potempa 4 and Piotr 

Mydel 1 , 1 Broegelmann Research Laboratory, The Gade 

Institute, University of Bergen, Bergen, Norway, 2 Ingenium 

Pharmaceuticals GmbH, Martinsried, Germany, 3 Probiodrug 

AG, Halle/Saale, Germany, 4 Jagiellonian University, Krakow, 

Poland 

2084. ASP015K: A Novel JAK Inhibitor Demonstrated Potent 

Efficacy in Adjuvant-Induced Arthritis Model in Rats. Shunji 

Yamazaki, Masamichi Inami, Misato Ito, Yasutomo Fujii, 

Kaori Hanaoka, Kaoru Yamagami, Kenji Okuma, Yoshiaki 

Morita, Shohei Shirakami, Takayuki Inoue, Susumu Miyata 

and Yasuyuki Higashi, Astellas Pharma Inc., Tsukuba, Japan 

2085. T Cell-Mediated Murine Antigen-Induced Arthritis Is 

Resistant to Transgenic Disruption of Glucocorticoid 

Signaling in Osteoblasts and Osteocytes in Vivo. Cornelia 

M. Spies 1 , Edgar Wiebe 1 , Jinwen W. Tu 2 , Aiqing Li 2 , Timo 

Gaber 1 , Dörte Huscher 1 , Markus J. Seibel 2 , Hong Zhou 2 and 

Frank Buttgereit 3 , 1 Charité University Medicine, Berlin, 

Germany, 2 ANZAC Research Institute, The University of 

Sydney, Concord, Australia, 3 Charite University Med-Berlin, 

Berlin, Germany 

2086. PI3-Kinase Controls Inflammatory Bone Destruction by 

Regulating the Osteoclastogenic Potential of Myeloid Cells. 

Stephan Blueml 1 , Gernot Schabbauer 2 , Antonia Puchner 2 , 

Emine Sahin 2 , Victoria Saferding 1 , Birgit Niederreiter 1 , Josef 

S. Smolen 3 and Kurt Redlich 1 , 1 Medical University of Vienna, 

Vienna, Austria, 2 Medical University Vienna, Vienna, Austria,


3 


Austria 

2087. Regulatory Effect of the Combination of Methotrexate and 

1,25-Dihydroxyvitamin D3 On the Balance of Treg and Th17 

in Collagen-Induced Arthritis. Jing Luo, the Second Hospital 

of Shanxi Medical University, Taiyuan, China 

2088. Annexin A1 Receptor Agonist Suppresses Development 

of Inflammatory Arthritis. Yuan Hang Yang 1 , Yuan Jia 2 , 

Wenping Kao 1 , Wuqi Song 3 , Zhan-guo Li 2 and Eric F. 

Morand 1 , 1 Monash University, Melbourne, Australia, 2 Peking 

University People’s Hospital, Beijing, China, 3 Harbin Medical 

University, Harbin, China 

2089. High Local Cathepsin Activity in a Murine Rheumatoid 

Arthritis Model, but Not in an Osteoarthritis Model, 

Explains the Difference in Cartilage Vdipen Neoepitope 

Formation. Eline A. Vermeij, Marije I. Koenders, Onno J. 

Arntz, Miranda B. Bennink, Arjen B. Blom, Peter L.E.M. 

van Lent, Wim B. van den Berg and Fons A.J. van de Loo, 

Rheumatology Research and Advanced Therapeutics, 

Department of Rheumatology, Radboud University 

Nijmegen Medical Centre, Nijmegen, Netherlands 

2090. Orchestrating the Orchestrators: Blockade of Flt3L 

Signaling-Dependent Dendritic Cells Protects Against 

Collagen Induced Arthritis. Maria I. Martins Ramos 1 , 

Karpus O.N. Karpus 1 , Pleun Broekstra 1 , Saïda Aarrass 1 , Paul 

P. Tak 2 and Maria C. Lebre 1 , 1 Academic Medical Center, 

University of Amsterdam, Amsterdam, Netherlands, 

2 



2091. The Effect of Pretreatment with Capsaicin On 

Measurement of Arthritis Pain by Dynamic Weight Bearing 

and Evoked Pain Responses in an Acute Murine Arthritis 

Model. Hollis E. Krug 1 , Christopher W. Dorman 2 , Sandra 

Frizelle 2 and Maren L. Mahowald 3 , 1 VA Health Care System, 

Minneapolis, MN, 2 Minneapolis VA Health Care System, 

Minneapolis, MN, 3 University of Minnesota Medical School 

and Minneapolis VA Health Care System, Minneapolis, MN 

Rheumatoid Arthritis - Clinical Aspects III: Infections/Risk Factors 

for Incident Rheumatoid Arthritis/Metrology/Classification/ 

Biomarkers/Predictors of Rheumatolid Arthritis Activity & 

Severity 

2092. No Significant Effect of Hepatitis B Virus Infection 

On Disease Activity, Synovitis or Joint Destruction in 

Rheumatoid Arthritis. Chan Juan Zou, Yan Hua Li, Ying Qian 

Mo, Lang Jing Zhu, Dong Hui Zheng, Jian Da Ma, Xia Ouyang 

and Lie Dai, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen 

University, Guangzhou, China 

2093. Rates of Opportunistic Infections among Rheumatoid 

Arthritis Patients Switching Biologic Therapy. John 

Baddley 1 , Shuo Yang 1 , Klye Brizendine 2 , Scott DuVall 3 , Kevin 

L. Winthrop 4 , Mary J. Burton 5 , Nivedita M. Patkar 6 , Elizabeth 

S. Delzell 1 , Monika M. Safford 1 , Jasvinder A. Singh 1 , Iris E. 

Navarro 1 , Grant W. Cannon 7 , Ted R. Mikuls 8 , Lang Chen 1 , 

Kenneth G. Saag 6 , Kimberly Alexander 9 , Pavel Napalkov 9 , 

Aaron Kamauu 10 and Jeffrey R. Curtis 6 , 1 University of 

Alabama at Birmingham, Birmingham, AL, 2 Birmingham, 

AL, 3 VA Salt Lake City Health Care System and University of 

Utah School of Medicine, Salt Lake City, UT, 4 Oregon Health 

& Science University, Portland, OR, 5 VA Hospital, Jackson, 

6 

Univ of Alabama-Birmingham, Birmingham, AL, 7 George 

E. Wahlen VA Medical Center, Salt Lake City, UT, 8 Omaha 

VA and University of Nebraska Medical Center, Omaha, 

NE, 9 Genentech, Inc., South San Francisco, CA, 10 Anolinx, 

Bountiful, UT 

2094. Reactivation of Hepatitis B Virus in Autoimmune Disease 

Patients Receiving Immunosuppressive Agents. Daisuke 

Kobayashi 1 , Satoshi Ito 1 , Megumi Unno 1 , Ichiei Narita 2 and 

Akira Murasawa 1 , 1 Niigata Rheumatic Center, Niigata, Japan, 

2 

Niigata University Graduate School of Medical and Dental 

Sciences, Niigata, Japan 

2095. Identifying Arthralgia Patients At Risk for Rheumatoid 

Arthritis in the Rotterdam Early Arthritis Cohort. M. van 

der Veer 1 , D. van Zeben 2 , A.E.A.M. Weel 3 , P.J. Barendregt 3 , 

A.H. Gerards 4 , Johanna M.W. Hazes 5 and Jolanda J. Luime 6 , 

1 

ErasmusMC, Rotterdam, Netherlands, 2 Sint Franciscus 

Gasthuis, Rotterdam, Netherlands, 3 Maasstad Hospital, 

Rotterdam, Netherlands, 4 Vlietland Hospital, Schiedam, 

Netherlands, 5 Erasmus Medical Center, Rotterdam, 

Netherlands, 6 Erasmus MC - University Medical Center, 


2096. A Prediction Rule for the Progression to Rheumatoid 

Arthritis Applied in a Mexican Mestizo Cohort with 

Undifferentiated Arthritis. Ana Arana Guajardo, Lorena 

Pérez Barbosa, David Vega Morales, Janett Riega Torres, 

Roberto Negrete López, Jacqueline Rodríguez Amado, 

Jorge Esquivel Valerio, Cassandra Skinner Taylor, Diana 

Flores Alvarado, Dionicio Galarza Delgado, Miguel Villarreal 

Alarcon and Mario Garza Elizondo, Hospital Universitario, 

UANL, Monterrey, Mexico 

2097. Adiponectin Is Associated with Pro-Inflammatory 

Cytokines in Autoantibody Positive First-Degree Relatives 

(FDRs) of Patients with Rheumatoid Arthritis. Jan M. 

Hughes-Austin 1 , Kevin D. Deane 2 , Lezlie A. Derber 3 , Gary 

O. Zerbe 1 , Dana M. Dabelea 1 , Jeremy Sokolove 4 , William H. 

Robinson 5 , V. Michael Holers 2 and Jill M. Norris 6 , 1 Colorado 

School of Public Health / University of Colorado Anschutz 

Medical Campus, Aurora, CO, 2 University of Colorado School 

of Medicine, Aurora, CO, 3 University of Colorado Anschutz 

Medical Campus, Aurora, CO, 4 VA Palo Alto Health Care 

System and Stanford University, Palo Alto, CA, 5 Stanford 

University, Palo Alto, CA, 6 Colorado School of Public Health, 

Aurora, CO 

2098. Patient Report Outcomes Variance Between Centers Is 

Much Lower Than Physician and Laboratory Assessed 

Measures of Rheumatoid Arthritis Activity: Results From 

a Multinational Study. Nasim A. Khan 1 , Horace Spencer 2 , 

Tuulikki Sokka 3 and QUEST-RA 4 , 1 University of Arkansas for 



288 

Medical Sciences and Central Arkansas Veterans Healthcare 

System, Little Rock, AR, 2 University of Arkansas for Medical 

Sciences, Little Rock, AR, 3 Jyvaskyla Central Hospital, 

Jyvaskyla, Finland, 4 Jyväskylä 

2099. Patient Self-Assessments and Selected Patient Reported 

Outcomes May Reliably Identify Rheumatoid Disease 

Flare in Early Rheumatoid Arthritis Patients. Vivian P. 

Bykerk 1 , CO Bingham III 2 , Ernest Choy 3 , Juan Xiong 4 , Gilles 

Boire 5 , Carol A. Hitchon 6 , Janet E. Pope 7 , J. Carter Thorne 8 , 

Boulos Haraoui 9 , Edward Keystone 10 and Susan J. Bartlett 11 , 

1 

Hospital for Special Surgery, New York, NY, 2 Johns Hopkins 

University, Baltimore, MD, 3 Cardiff University School of 

Medicine, Cardiff, United Kingdom, 4 Mount Sinai Hospital, 

Toronto, ON, 5 CHUS - Sherbrooke University, Sherbrooke, 

QC, 6 University of Manitoba, Winnipeg, MB, 7 St. Joseph 

Health Care London, University of Western Ontario, London, 

ON, 8 Southlake Regional Health Centre, Newmarket, ON, 

9 

Osteoarthritis Research Unit, University of Montreal 


10 

University of Toronto, Toronto, ON, 11 McGill University, 

Montreal, QC 

2100. Relative, Reliability-Adjusted Diagnostic Test Accuracy of 

Erosion Detection between Magnetic Resonance Imaging 

and Radiography in Rheumatoid Arthritis. Ruben Tavares 1 , 

Naveen Parasu 2 , Karen Finlay 2 , Erik Jurriaans 2 , Hao Wu 1 , 

Karen A. Beattie 1 , Maggie Larche 1 , Lawrence E. Hart 3 , 

William G. Bensen 4 , Raja S. Bobba 1 , Alfred A. Cividino 1 , Colin 

E. Webber 5 , Jean-Eric Tarride 6 and Jonathan D. Adachi 7 , 

1 

McMaster University, Hamilton, ON, 2 Hamilton Health 

Sciences, Hamilton, 3 St. Joseph’s Health Care, Hamilton, ON, 

4 


ON, Hamilton, ON, 5 Hamilton Health Sciences, Hamilton, 

ON, 6 Programs for Assessment of Technology in Health 

(PATH) Research Institute, Hamilton, ON, 7 Charlton Medical 

Centre, Hamilton, ON 

2101. How Much Patient Can Reported Outcomes Improve 

Among Rheumatoid Arthritis Patients Who Have a Clinical 

Response to Biologic Therapy but Have Not Attained Low 

Disease Activity? Jeffrey Curtis 1 , Ying Shan, Jie Zhang 1 , 

Jeffrey D. Greenberg 3 and George W. Reed 4 , 1 University 

of Alabama at Birmingham, Birmingham, AL, 2 New York 

University School of Medicine, New York, NY, 3 University of 


2102. Patient versus Physician Global Assessments in Ethnic 

Patients Wtih Rheumatoid Arthritis. Gail S. Kerr 1 , Yusuf 

Yazici 2 , Christopher J. Swearingen 3 , Luis R. Espinoza 4 , Edward 

L. Treadwell 5 , Yvonne R. S. Sherrer 6 , Angelia D. Mosley- 

Williams 7 , Akgun Ince 8 , Raj G. Nair 9 , Theresa Lawrence 

Ford 10 , Jeffrey Huang 11 and Carl A. Nunziato 11 , 1 Washington 

DC VAMC, Georgetown and Howard University, Washington, 

DC, 2 New York University, New York, NY, 3 University of 

Arkansas, Little Rock, AR, 4 Louisiana State University, New 

Orleans, LA, 5 East Carolina University, Greenville, NC, 

6 

Centre Rheum Immunol Arthritis, Fort Lauderdale, FL, 7 John 

Dingell VAMC, Detroit, MI, 8 Saint Louis University, St. Louis, 


MO, 9 Washington Hospital Center, Washington DC, DC, 

10 

North Georgia Rheumatology, Lawrenceville, GA, 11 Howard 

University Hospital, Washington, DC 

2103. Reliability of DAS28 in Rheumatoid Arthritis When Based 

On Patient Self-Assessment of Tender and Swollen Joints. 

Ole Rintek Madsen and Cecilie Heegaard, Copenhagen 

University Hospital Gentofte, Hellerup, Denmark 

2104. Quantitation in Patients with Rheumatoid Arthritis of 

Inflammation, Joint Damage and “Unexplained Symptoms” 

(e.g., Fibromyalgia) in Addition to Overall Status, According 

to 4 Physician Global Estimates Scored 0-10. Isabel 

Castrejón 1 , Martin J. Bergman 2 and Theodore Pincus 1 , 1 NYU 

Hospital for Joint Diseases, New York, NY, 2 Taylor Hospital, 

Ridley Park, PA 

2105. Significant Correlation between ACR/EULAR Remission 

Criteria and a Simplified Measure Using RAPID 3 and Careful 

Joint Examination without a Formal Joint Count. Martin J. 

Bergman 1 , Isabel Castrejón 2 and Theodore Pincus 2 , 1 Taylor 

Hospital, Ridley Park, PA, 2 NYU Hospital for Joint Diseases, 

New York, NY 

2106. Patient Characteristics Associated with Discrepancies in 

Evaluator-Reported and Patient-Reported Outcomes in 

U.S. Veterans with Rheumatoid Arthritis. Archana Jain 1 , 

Rebecca Belsom 1 , Jeffrey Curtis 2 , Shuo Yang 2 , Ted R. Mikuls 3 , 

Lang Chen 2 and Angelo L. Gaffo 4 , 1 University of Alabama, 


Birmingham, AL, 3 Omaha VA and University of Nebraska 

Medical Center, Omaha, NE, 4 Birmingham VA Medical Center 

and University of Alabama at Birmingham, Birmingham, AL 

2107. Assessing Subclinical Synovitis in Rheumatoid Arthritis: 

Arthrosonographic Findings in Patients with Good 

Response to Therapy. Matthias Witt, Felix Mueller, Axel 

Nigg, Christiane Reindl, Hendrik Schulze-Koops and Mathias 

Grunke, Division of Rheumatology and Clinical Immunology, 

Medizinische Klinik und Poliklinik IV, University of Munich, 

Munich, Germany 

2108. Identification of Four Parameters That Drive the 

Discordance between the Patient and Physician Global 

Assessment in Rheumatoid Arthritis. William Bensen 1 , 

Denis Choquette 2 , Milton F. Baker 3 , Susan M. Otawa 4 and 

Hayssam Khalil 4 , 1 St. Joseph’s Hospital and McMaster 

University, Hamilton, ON, 2 University of Montreal, Notredame 

Hospital, Montreal, QC, 3 University of Victoria, 

Victoria, BC, 4 Janssen Canada Inc, Toronto, ON 

2109. Discrepancy Between Patient and Physician Global 

Assessments Over Time in Early Rheumatoid Arthritis. 

Pooneh Akhavan 1 , Vivian P. Bykerk 2 , Juan Xiong 3 , Janet 

Pope 4 , Boulos Haraoui 5 , J. Carter Thorne 6 , Gilles Boire 7 , Carol 

A. Hitchon 8 , Diane Tin 6 , E. Keystone 3 and CATCH 9 , 1 University 

of Toronto, Toronto, ON, 2 Hospital for Special Surgery, New 

York, NY, 3 Mount Sinai Hospital, Toronto, ON, 4 Schulich 

School of Medicine and Dentistry, Western University, 

London, ON, 5 Osteoarthritis Research Unit, University of 

Montreal Hospital Research Centre (CRCHUM), Montreal,


QC, 6 Southlake Regional Health Centre, Newmarket, ON, 

7 

CHUS - Sherbrooke University, Sherbrooke, QC, 8 University 

of Manitoba, Winnipeg, MB, 9 Toronto 

2110. Prospective Assessement of Bone Texture Parameters At 

the Hand in Rheumatoid Arthritis. Laetitia Sparsa 1 , Sami 

Kolta 1 , Karine Briot 1 , Simon Paternotte 1 , Rashra Masri 2 , 

Damien Loeuille 2 , Piet P. Geusens 3 and Christian Roux 1 , 

1 

Paris Descartes University, Cochin hospital, Paris, France, 

2 

CHU Brabois, Vandoeuvre les Nancy, France, 3 Maastricht 

University, Maastricht, Netherlands 

2111. Diagnostic Performance of the 2010 American College 

of Rheumatology/European League against Rheumatism 

Classification Criteria for Rheumatoid Arthritis: Systematic 

Literature Review and Meta-Analysis. Garifallia Sakellariou 1 , 

Carlo Alberto Scirè 2 , Roberto Caporali 1 and Carlomaurizio 

Montecucco 3 , 1 Division of Rheumatology, University of 

Pavia School of Medicine, IRCCS Policlinico San Matteo 

Foundation, Pavia, Italy, 2 Epidemiology Unit , Italian 

Society for Rheumatology (SIR), Milano, Italy, 3 University 

of Pavia School of Medicine, IRCCS Policlinico San Matteo 

Foundation, Pavia, Italy 

2112. Combination of Magnetic Resonance Imaging (MRI)-Proven 

Osteitis with 2010 RA Classification Criteria Improves the 

Diagnostic Probability of Rheumatoid Arthritis (RA). Mami 

Tamai 1 , Yoshikazu Nakashima 1 , Takahisa Suzuki 2 , Yoshiro 

Horai 2 , Akitomo Okada 2 , Junko Kita 2 , Shin-ya Kawashiri 2 , 

Naoki Iwamoto 1 , Kunihiro Ichinose 2 , Kazuhiko Arima 1 , Hideki 

Nakamura 1 , Tomoki Origuchi 2 , Masataka Uetani 2 , Kiyoshi 

Aoyagi 2 , Katsumi Eguchi 3 and Atsushi Kawakami 2 , 1 Nagasaki 

University, Nagasaki, Japan, 2 Nagasaki University Graduate 

School of Biomedical Sciences, Nagasaki, Japan, 3 Sasebo City 

General Hospital, Sasebo, Nagasaki, Japan 

2113. Performance of the New ACR/EULAR Classification Criteria 

for Rheumatoid arthritis– a Systematic Literature Review. 

Helga Radner 1 , Josef Smolen 2 and Daniel Aletaha 3 , 1 Medical 

University Vienna, Vienna, Austria, 2 Medical University of 

Vienna and Hietzing Hospital, Vienna, Austria, 3 Medical 

University of Vienna, Vienna, Austria 

2114. Joint Damage Progression in Rheumatoid Arthritis: Role 

of the HLA-DRB1 Shared Epitope and Anti-CCP. Jose Felix 

Restrepo 1 , Inmaculada del Rincon 1 , Roy W. Haas 1 , Daniel F. 

Battafarano 2 and Agustin Escalante 1 , 1 University of Texas 

Health Science Center at San Antonio, San Antonio, TX, 

2 

Brooke Army Medical Ctr, San Antonio, TX 

2115. Altered Serum Levels of Bone Metabolism Markers in 

Rheumatoid Arthritis. Lang Jing Zhu, Xia Ouyang, Lie Dai, 

Dong Hui Zheng, Ying Qian Mo, Xiu Ning Wei, Chan Juan Zou 

and Bai Yu Zhang, Sun Yat-Sen Memorial Hospital, Sun Yat- 

Sen University, Guangzhou, China 

2116. The Associations of HLA-DR Shared Epitope Alleles 

and Serum Cytokines among Postmenopausal Women 

with Rheumatoid Factor and Anti-Citrullinated Protein 

Antibody-Positive Rheumatoid Arthritis. Mehret Birru 

Talabi 1 , Rachel Mackey 2 , Larry W. Moreland 2 , Jan Dorman 3 , 

Kevin D. Deane 4 , Jeremy Sokolove 5 , V. Michael Holers 4 , 

William H. Robinson 6 , Brian Wallitt 7 and Lewis Kuller 2 , 

1 

University of Pittsburgh Medical Center, Pittsburgh, PA, 

2 

University of Pittsburgh, Pittsburgh, PA, 3 University of 

Pittsburgh School of Nursing, Pittsburgh, PA, 4 University 

of Colorado School of Medicine, Aurora, CO, 5 VA Palo Alto 

Health Care System and Stanford University, Palo Alto, CA, 

6 

Stanford University, Palo Alto, CA, 7 Washington Hospital 

Center, Baltimore, MD 

2117. Algorithm Using Genome-Wide SNP Analysis for Prediction 

of Radiographic Progression per Year in RA Patients 

From Multiple Medical Cohorts. Tsukasa Matsubara 1 , 

Satoru Koyano 2 , Yoshitada Sakai 3 , Keiko Funahashi 2 , 

James E. Middleton 2 , Takako Miura 1 , Kosuke Okuda 1 , 

Takeshi Nakamura 1 , Akira Sagawa 4 , Takeo Sakurai 5 , Hiroaki 

Matsuno 6 , Tomomaro Izumihara 7 and Eisuke Shono 8 , 

1 

Matsubara Mayflower Hospital, Kato, Japan, 2 Research 

Institute of Joint Diseases, Kobe, Japan, 3 Kobe University 

Hospital, Kobe, Japan, 4 Sagawa Akira Rheumatology Clinic, 

Sapporo, Japan, 5 Inoue Hospital, Takasaki, Japan, 6 Matsuno 

Clinic for Rheumatic Diseases, Toyama, Japan, 7 Izumihara 

Rheumatic and Medical Clinic, Kagoshima, Japan, 8 Shono 

Rheumatology Clinic, Fukuoka, Japan 

2118. Validation of Prognostic Biomarkers for RA: Testing of 

14-3-3 Eta According to the Omeract Soluble Biomarker 

Criteria. Walter P. Maksymowych 1 , Désirée van der Heijde 2 , 

R. Landewe 3 , George A. Wells 4 , Joan M. Bathon 5 , CO 

Bingham III 6 , Vivian P. Bykerk 7 , Mikkel Ostergaard 8 , Hilde 

B. Hammer 9 , Maarten Boers 10 , Paul Peter Tak 11 , Oliver M. 

FitzGerald 12 , Christopher T. Ritchlin 13 , Dafna Gladman 14 , 

Philip Mease 15 , Dirkjan van Schaardenburg 16 , Marina 

Backhaus 17 , Bernard Combe 18 , Gianfranco Ferraccioli 19 and 

Anthony Marotta 20 , 1 University of Alberta, Edmonton, AB, 

2 


3 

Academic Medical Center / University of Amsterdam, 

Amsterdam, Netherlands, 4 Univ of Ottawa Faculty of Med, 

Ottawa, ON, 5 Columbia University Medical Center, New 

York, NY, 6 Johns Hopkins University, Baltimore, MD, 7 Hospital 

for Special Surgery, New York, NY, 8 Copenhagen University 

Hospital at Glostrup, Glostrup, Denmark, 9 Diakonhjemmet 

Hospital, Oslo, Norway, 10 VU University Medical Center, 

Amsterdam, Netherlands, 11 Academic Medical Center/ 

University of Amsterdam, Amsterdam, Netherlands, 12 Dublin 


Dublin, Ireland, 13 University of Rochester Medical Center, 

Rochester, NY, 14 Toronto Western Hospital and University of 

Toronto, Toronto, ON, 15 Swedish Rheumatology Research 

Group, Seattle, WA, 16 Jan van Breemen Research Institute 

| Reade, Amsterdam, Netherlands, 17 Charite University 

Hospital, Berlin, Germany, 18 Hopital Lapeyronie, Montpellier, 

France, 19 Division of Rheumatology, Catholic University of 

the Sacred Heart, Rome, Italy, 20 Augurex Life Sciences Corp, 

North Vancouver, BC 



119. Interleukin-6 as a Biomarker for the Clinical and 

Radiological Effectiveness of Methotrexate in Rheumatoid 

Arthritis. Naoshi Nishina, Hideto Kameda, Yuko Kaneko, 

Masataka Kuwana and Tsutomu Takeuchi, Keio University 


2120. Predictive Value of Anti-CCP Positivity on Disease Course 

and Response to Therapy in Early Rheumatoid Arthritis. 

Results from the Swedish EIRA Study. Saedis Saevarsdottir 1 , 

Marie Holmqvist 2 , Johan Askling 2 , Lars Alfredsson 3 and 

Lars Klareskog 2 , 1Rheumatology Unit, Karolinska University 

Hospital, Karolinska Institute, Stockholm, Sweden, 

2 

Karolinska Institute, Stockholm, Sweden, 3 Institute of 

Environmental Medicine, Karolinska Institutet, Stockholm, 

Sweden 

2121. A Multi-Biomarker Disease Activity (VECTRA DA 

Algorithm) Score Reflects Clinical Disease Activity and 

Structural Changes in Rheumatoid Arthritis Patients 

Treated with Tocilizumab. Yoshiya Tanaka 1 , Kentaro 

Hanami 1 , Hisashi Tasaka 1 , Shunsuke Fukuyo 1 , Douglas J. 

Haney 2 , Nadine Defranoux 2 , Rebecca Bolce 2 , Guy Cavet 2 , 

David Chernoff 2 , Kunihiro Yamaoka 1 , Kazuyoshi Saito 1 

and Shintaro Hirata 1 , 1 University of Occupational and 

Environmental Health, Japan, Kitakyushu, Japan, 2 Crescendo 

Bioscience Inc., South San Francisco, CA 

2122. Plasma chemerin as a Useful Marker for Disease Activity 

in Patients with Rheumatoid Arthritis. Sang Tae Choi 1 , 

You-Jung HA 2 , Eun-Jin Kang 3 , Kwang-Hoon Lee 4 and Jung-Soo 

Song 1 , 1 Chung-Ang University College of Medicine, Seoul, 

South Korea, 2 Kwanding University College of Medicine, 

Myongji Hospital, Goyang, South Korea, 3 Busan Medical 

Center, Busan, South Korea, 4 Dongguk University Ilsan 

Hospital, Goyang, South Korea 

2123. Circulating Mir-223 Is Associated with Disease Activity and 

May Predict the Response to Therapy in Treatment naïve 

Patients with Early Rheumatoid Arthritis. Maria Filkova 1 , 

Caroline Ospelt 1 , Serena Vettori 1 , Ladislav ŠEnolt 2 , Herman 

F. Mann 2 , Beat A. Michel 3 , Jiri Vencovsky 2 , Karel Pavelka 2 , 

Renate E. Gay 1 , Steffen Gay 1 and Astrid Jüngel 1 , 1 Center of 



Switzerland, Zurich, Switzerland, 2 Institute of Rheumatology, 

Department of Clinical and Experimental Rheumatology of 

the 1st Faculty of Medicine, Charles University in Prague, 

Prague, Czech Republic, 3 Department of Rheumatology, 


2124. Serum Concentrations of Soluble Interferon Receptor in 

Patients with Rheumatoid Arthritis. Masao Sato, Masao 

Takemura, Ryuki Shinohe, Tsuneo Watanabe and Katsuji 

Shimizu, Gifu University, Gifu, Japan 

2125. Response to Methotrexate Plus Prednisone in Camera II 

Using a Multi-Biomarker Disease Activity (VectraTM DA) 

Test and DAS28-ESR. J.W.J. Bijlsma 1 , M. Verhoef-Jurgens 1 , 

M.F. Bakker 1 , J.W.G. Jacobs 1 , F.P.J.G. Lafeber 1 , P.M.J. 

Welsing 1 , G. Cavet 2 , D. Chernoff 2 and D.J. Haney 2 , 1 University 

Medical Center Utrecht, Utrecht, Netherlands, 2 Crescendo 

Bioscience, Inc., South San Francisco, CA 

2126. Changes of Serological Markers in the Course of Traditional 

and Biological Disease Modifying Therapy of Rheumatoid 

Arthritis. Christoph Böhler 1 , Helga Radner 1 , Josef S. Smolen 2 

and Daniel Aletaha 1 , 1 Medical University of Vienna, Vienna, 

Austria, 2 Medical University of Vienna and Hietzing Hospital, 


2127. Rheumatoid Arthritis (RA) Patients Discordant for 

Rheumatoid Factor and Anti-CCP Positivity Have Different 

Clinical and Laboratory Features Than RA Patients 

Seropositive or Seronegative for Both Markers. Swati 

Modi 1 , Yona Cloonan 1 , Danielle Goudeau 1 , Donald M. Jones 2 , 

Christine L. Amity 3 , Lynne M. Frydrych 2 , Kelly A. Reckley 4 , 

Heather Eng 3 , Stephen R. Wisniewski 5 , Larry W. Moreland 1 

and Marc C. Levesque 1 , 1 University of Pittsburgh, Pittsburgh, 

PA, 2 Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 3 Univ of 

Pittsburgh, Pittsburgh, PA, 4 University of Pittsburgh School of 

Medicine, Pittsburgh, PA, 5 University of Pittsburgh, Graduate 

School of Public Health, Pittsburgh, PA 

2128. Matrix Metalloproteinase 3: A Biomarker of Disease 

Activity in Rheumatoid Arthritis. Sandra Reuter 1 , Torsten 

Matthias 2 and Bruno Larida 3 , 1 AIRA e.V., AESKU.KIPP 

Institute, Wendelsheim, Germany, 2 AESKU.Diagnostics 

GmbH & Co. KG, Wendelsheim, Germany, 3 AESKU. 

DIAGNOSTICS INC, Oakland, CA 

2129. Dickkopf-1 Is Increased in Rheumatoid Arthritis of Recent 

Onset and Might Be a New Biomarker of Structural 

Progression. Data from the Espoir Cohort. Raphaèle Seror 1 , 

Stephan Pavy 2 , Thierry Schaeverbeke 3 , Alain Saraux 4 , Xavier 

Mariette 5 and Corinne Miceli-Richard 1 , 1 Université Paris Sud, 

Le Kremlin Bicêtre, France, 2 Hopital Bicetre, Paris, France, 

3 

Groupe Hospitalier Pellegrin, Bordeaux, France, 4 CHU de la 

Cavale Blanche, Brest Cedex, France, 5 Université Paris-Sud, 

Le Kremlin Bicetre, France 

2130. Studies of Disease and Therapy-Response Biomarkers in 

Early Rheumatoid Arthritis Treated with Methotrexate. 

Aase Haj Hensvold 1 , Saedis Saevarsdottir* 1 , Wanyiang 

Li* 2 , Vivianne Malmström 1 , Guy Cavet 3 , Lars Klareskog 4 

and Anca Irinel Catrina 1 , 1Rheumatology Unit, Karolinska 

University Hospital, Karolinska Institute, Stockholm, Sweden, 

2 

Crescendo Bioscience Inc. 341 Oyster Point Blvd South 

San Francisco, CA 94080, San Francisco, CA, 3 Crescendo 

Bioscience Inc., South San Francisco, CA, 4 Karolinska 

Institute, Stockholm, Sweden 

2131. An Evaluation of Prognostic Factors for Orthopaedic 

Joint Surgery in Rheumatoid Arthritis. Results From Two 

Multicentre UK Inception Cohorts (1986-2011). Elena 

Nikiphorou 1 , Lewis Carpenter 2 , Sam Norton 3 , David James 4 , 

Patrick D. Kiely 5 , David Walsh 6 , Richard Williams 7 and 

Adam Young 8 , 1 ERAS, St Albans City Hospital & University 

College London (UCL), London, United Kingdom, 2 University 

of Hertfordshire, Hatfield, United Kingdom, 3 ERAS, St 

Albans City Hospital, St Albans, United Kingdom, 4 Diana 

290 

2012 Program Book


Princess of Wales Hospital, Grimsby, United Kingdom, 5 St. 

Georges Hospital, London, United Kingdom, 6 City Hospital, 

Nottingham, United Kingdom, 7 County Hospital, Hereford, 

United Kingdom, 8 St Albans City Hospital, St Albans, United 

Kingdom 

2132. Disease Activity and Anti-CCP Status, but Not 

Sociodemographic Factors or Patient Comorbidities, Affect 

Time to Diagnosis in Early Rheumatoid Arthritis. Cheryl 

Barnabe 1 , Juan Xiong 2 , Gilles Boire 3 , Carol A. Hitchon 4 , 

Boulos Haraoui 5 , Janet E. Pope 6 , J. Carter Thorne 7 , Edward 

Keystone 8 , Diane Tin 7 , Vivian P. Bykerk 9 and Canadian 

ArThritis CoHort 10 , 1 University of Calgary, Calgary, AB, 

2 

University of Toronto, Toronto, 3 CHUS - Sherbrooke 

University, Sherbrooke, QC, 4 University of Manitoba, 

Winnipeg, MB, 5 Osteoarthritis Research Unit, University of 

Montreal Hospital Research Centre (CRCHUM), Montreal, 

QC, 6 St. Joseph Health Care London, University of Western 

Ontario, London, ON, 7 Southlake Regional Health Centre, 

Newmarket, ON, 8 University of Toronto, Toronto, ON, 

9 

Hospital for Special Surgery, New York, NY, 10 Toronto 

2133. Relationship between Clinical Response and Radiographic 

Outcomes in Patients with Moderate Rheumatoid 

Arthritis. Josef S. Smolen 1 , Ronald F. van Vollenhoven 2 , 

Andrew S. Koenig 3 , Ronald Pedersen 3 , Annette Szumski 3 

and Eustratios Bananis 3 , 1 Medical University of Vienna and 

Hietzing Hospital, Vienna, Austria, 2 The Karolinska Institute, 

Stockholm, Sweden, 3 Pfizer Inc., Collegeville, PA 

2134. The Changed Prognosis of Patients with Early Rheumatoid 

Arthritis. Karin Britsemmer 1 and D. van Schaardenburg 2 , 

1 

Jan van Breemen Research Institute / Reade, Amsterdam, 



2135. Trabecular Bone Texture parameters are Correlated with 

Magnetic Resonance Imaging (MRI) bone Edema At Hand 

and Wrist in Active Rheumatoid Arthritis (RA). Thao Pham 1 , 

Sophie Trijau 1 , Roland Chapurlat 2 , Damien Loeuille 3 , Thierry 

Schaeverbeke 4 , Christian Roux 5 , Claude-Laurent Benhamou 6 , 

Olivier Vittecoq 7 , Jean Sibilia 8 , Frederic Mistretta 9 and Cécile 

Hacquard-Bouder 10 , 1 Sainte Marguerite Hospital, Marseille, 

France, 2 Hôpital Edouard Herriot, Lyon, France, 3 CHU 

Brabois, Vandoeuvre les Nancy, France, 4 Groupe Hospitalier 

Pellegrin, Bordeaux, France, 5 Paris Descartes University, 

Paris, France, 6 EA 4708 University Orleans, Orleans, France, 

7 

Rouen University Hospital & Inserm905, University of 

Rouen, Rouen Cedex, France, 8 CHU Hautepierre, Strasbourg, 

France, 9 Lyon, France, 10 Abbott France, Rungis, France 

2136. Alcohol Use and Radiographic Disease Progression 

in African Americans with Recent Onset Rheumatoid 

Arthritis. Marshall Davis 1 , Kaleb Michaud 1 , Harlan Sayles 1 , 

Doyt L. Conn 2 , Larry W. Moreland 3 , S. Louis Bridges Jr. 4 and 

Ted R. Mikuls 1 , 1 University of Nebraska Medical Center, 

Omaha, NE, 2 Emory Univ School of Medicine, Atlanta, 

GA, 3 University of Pittsburgh, Pittsburgh, PA, 4 Marguerite 

Jones Harbert-Gene V. Ball, MD Professor of Medicine, and 

Director, Division of Clinical Immunology and Rheumatology, 


2137. Contribution of Disease Activity, Joint Damage and 

Comorbidity to Impairment (SOFI) and Disability (HAQ) 

in Rheumatoid Arthritis Patients Over 20 Years. Meliha C. 

Kapetanovic 1 , Elisabet Lindqvist 2 , Jan-Åke Nilsson 3 , Pierre 

Geborek 4 , Tore Saxne 5 and Kerstin Eberhardt 2 , 1 Dept of 

Clinical Sciences Lund, Section of Rheumatology, Lund 

University, Lund, Sweden, 2 Department of Clinical Sciences 

Lund, Section of Rheumatology, Skåne University Hospital, 

Lund University, Lund, Sweden, Lund, Sweden, 3 Lund 

University, Malmö, Sweden, 4 Sweden, 5 Dept of Clinical 

Sciences Lund, Section of Rheumatology, Lund, Sweden 

2138. Racial and Ethnic Disparities in Rheumatoid Arthritis 

Outcomes in Community-Based U.S. Rheumatology 

Practices: Results From the Consortium of Rheumatology 

Researchers of North America Registry. Jeffrey D. 

Greenberg 1 , Tanya Spruill 2 , Gbenga Ogedebe 3 , Joel M. 

Kremer 4 , Ying Shan 5 , Katherine C. Saunders 6 , Yusuf Yazici 7 

and Leslie R. Harrold 5 , 1 NYU Hospital for Joint Diseases, 

New York, NY, 2 NYU School of Medicine, New York, NY, 3 New 

York University School of Medicine, New York, NY, 4 Albany 

Medical College and The Center for Rheumatology, Albany, 

NY, 5 UMass Medical School, Worcester, MA, 6 CORRONA, Inc., 

Southborough, MA, 7 New York University, New York, NY 

2139. Smoking Is Associated with Worsening Functional Status 

Over Time in a Diverse Cohort of Patients with Rheumatoid 

Arthritis. Matthew Reimert 1 , Laura Trupin 2 , Patricia P. Katz 3 , 

Edward Yelin 3 , Jennifer Barton 4 and John B. Imboden 5 , 

1 

University of CA San Francisco, San Francisco, CA, 2 UC 

San Francisco, San Francisco, CA, 3 University of California 

San Francisco, San Francisco, CA, 4 UCSF, San Francisco, CA, 

5 

University of California, San Francisco, San Francisco, CA 

2140. A Longitudinal Study of Prognostic Factors in Patients with 

Early RA Providing Direction for Future Clinical Treatment- 

Predict Study. Paul Bird 1 , David Nicholls 2 , Julien P. de Jager 3 , 

Hedley Griffiths 4 , Lynden Roberts 5 , Kathleen Tymms 6 , Jane 

Zochling 7 , Mark H. Arnold 8 , Geoffrey O. Littlejohn 9 and OPAL 

Consortium 10 , 1 Combined Rheumatology Practice, Sydney, 

Australia, 2 Coast Joint Care, Maroochydore, Australia, 

3 

Suite 2 , Osler House, Southport, Australia, 4 Barwon 

Rheumatology Service, Geelong, Australia, 5 James Cook 

University, Townsville, Australia, 6 Canberra Rheumatology, 

Canberra, Australia, 7 Menzies Research Institute Tasmania, 

Hobart, Australia, 8 Level 2 The Gallery, Chatswood, 

Australia, 9 Monash Medical Center, Melbourne, Australia, 

10 

Melbourne, Australia 

2141. Effects of Cigarette Smoking On EARLY Arthritis 

(CONAART). Maria Haye Salinas 1 , Ana C. Alvarez 1 , Rafael 

Chaparro del Moral 2 , Mariana Benegas 2 , Christian A. 

Waimann 3 , Rodolfo Perez Alamino 3 , Rodrigo Garcia Salinas 4 , 

Ana Lucía Barbaglia 5 , Veronica Bellomio 5 , Josefina Marcos 6 , 

Adrian Salas 6 , Cristian Quiroz 7 , Federico Ceccato 8 , Sergio 

Paira 8 , Dora Lia Vazquez 9 , Gabriela Salvatierra 10 , M. Crespo 11 , 



292 

Edson Javier Velozo 12 , Oscar L. Rillo 13 , Enrique Soriano 14 , 

Antonio Catalan Pellet 4 , Alberto Berman Sr. 5 , Juan Carlos 

Marcos 6 , Gustavo Citera 15 and Francisco Caeiro 16 , 1 Hospital 

Privado, Córdoba, Argentina, 2 Hospital Tornu, Buenos 

Aires, Argentina, 3 Instituto de Rehabilitación Psicofísica, 

Buenos Aires, Argentina, 4 Hospital Rivadavia, Buenos Aires, 

Argentina, 5 Hospital Padilla, Tucuman, Argentina, 6 Hospital 

San Martin, La Plata, Argentina, 7 Rheumatology Section, 


8 

Hospital Jose Maria Cullen, Santa Fe, Argentina, 9 Centro 

Integral de Reumatologia, Santiago del Estero, Argentina, 

10 

Centro de enfermedades Reumaticas, Santiago Del Estero, 

Argentina, 11 Hospital Señor del Milagro, Salta, Argentina, 

12 

Sanatorio Adventista del Plata, Entre Rios, Argentina, 

13 

Hospital Tornú, Buenos Aires, Argentina, 14 Hospital Italiano 

de Buenos Aires, Buenos Aires, Argentina, 15 Instituto 

de Rehabilitación Psicofísica., Buenos Aires, Argentina, 

16 

Hospital privado de Cordoba, Cordoba, Argentina 

2142. Magnetic Resonance Imaging-Proven Osteitis At Baseline 

Predicts the Early Rheumatoid Arthritis Patients Who Will 

Develop Rapid Radiographic Progression: MRI Is Beneficial 

to Find the Window of Opportunity in Early RA. Mami 

Tamai 1 , Yoshikazu Nakashima 2 , Takahisa Suzuki 2 , Yoshiro 

Horai 2 , Akitomo Okada 2 , Junko Kita 2 , Shin-ya Kawashiri 2 , 

Naoki Iwamoto 1 , Kunihiro Ichinose 2 , Kazuhiko Arima 1 , Hideki 

Nakamura 1 , Tomoki Origuchi 2 , Masataka Uetani 2 , Kiyoshi 

Aoyagi 2 , Katsumi Eguchi 3 and Atsushi Kawakami 2 , 1 Nagasaki 

University, Nagasaki, Japan, 2 Nagasaki University Graduate 

School of Biomedical Sciences, Nagasaki, Japan, 3 Sasebo City 

General Hospital, Sasebo, Nagasaki, Japan 

2143. Analysis of Factors Associated with the Health Assessment 

Questionnaire Score Change in Five Years. Shinji Yoshida 1 , 

Katsunori Ikari 2 , Kensuke Ochi 1 , Yoshiaki Toyama 3 , Atsuo 

Taniguchi 1 , Hisashi Yamanaka 1 and Shigeki Momohara 1 , 

1 

Institute of Rheumatology, Tokyo Women’s Medical 

University, Tokyo, Japan, 2 Institute of Rheumatology, Tokyo 

Women’s Medical University, Shinjuku-ku, Japan, 3 Keio 

University, Shinjuku, Japan 

2144. Early RA Patients Fulfilling the New 2010 ACR/EULAR 

Criteria, Display Better Clinical Responses to DMARD 

Therapy but Have Higher Radiographic Damage 

Progression Than Patients with Early RA Not Fulfilling the 

2010 ACR/EULAR Criteria. Ruediger Mueller 1 , Toni Kaegi 1 , 

Axel Finckh 2 and Johannes von Kempis 1 , 1 MD, St. Gallen, 

Switzerland, 2 Geneva University Hospitals, Geneva 14 , 

Switzerland 

2145. Age at Onset Determines Severity and choice of Treatment 

in Early Rheumatoid Arthritis. Lena Innala 1 , Bozena 

Möller 2 , Lotta Ljung 1 , Torgny Smedby 3 , Anna Södergren 1 , 

Staffan Magnusson 4 , Ewa H. Berglin 1 , Solbritt M. Rantapää- 

Dahlqvist 1 and Solveig Wållberg-Jonsson 1 , 1 Institution 

of Public health and clinical medicine/ Rheumatology, 

University of Umeå, Umeå, Sweden, 2 Department of 

Rheumatology, Sunderby Hospital, Luleå, Sweden, 

3 

Department of Rheumatology, Östersund hospital, 


Östersund, Sweden, 4 Department of Internal Medicine, 

Sundsvall Hospital, Sundsvall, Sweden 

2146. Impact of Severity Index for Rheumatoid Arthritis 

on Healthcare Costs and Utilizations in Patients with 

Rheumatoid Arthritis. Onur Baser 1 , Li Wang 2 , Juan Du 3 , Hai 

Wang 3 and Lin Xie 3 , 1 STATinMED Research/The University of 

Michigan, Ann Arbor, MI, 2 STATinMED Research, Dallas, TX, 

3 

STATinMED Research, Ann Arbor, MI 

2147. Risks to Visit Emergency Room in Patients with 

Rheumatoid Arthritis: A Two-Year Retrospective Study. 

Yoshiki Nagai, Naoto Yokogawa, Kota Shimada and Shoji 

Sugii, Tokyo Metropolitan Tama Medical Center, Tokyo, 

Japan 

2148. Peer to Peer Mentoring for Individuals with Early 

Inflammatory Arthritis: Feasibility Pilot. Mary J. Bell 1 , Paula 

Veinot 2 , Gayathri Embuldeniya 2 , Joyce Nyhof-Young 3 , Joanna 

Sale 4 , Joan Sargeant 5 , Peter Tugwell 6 , Sydney Brooks 7 , Susan 

Ross 7 , Ruth Tonon 7 , Sharron Sandhu 2 , Dawn Richards 8 , 

Jennifer Boyle 7 , Kerry Knickle 9 , Nicky Britten 10 , Emma Bell 2 , 

Fiona Webster 9 and Mary Cox-Dublanski 11 , 1 Sunnybrook 

Health Sciences Centre and University of Toronto, Toronto, 

ON, 2 Sunnybrook Health Sciences Centre, Toronto, ON, 

3 

University Health Network, University of Toronto, Toronto, 

ON, 4 University of Toronto, St. Michael’s Hospital, Toronto, 

ON, 5 Dalhousie University, Halifax, NS, 6 University of Ottawa, 

Ottawa General Hospital, Ottawa, ON, 7 The Arthritis Society, 

Ontario Division, Toronto, ON, 8 Canadian Arthritis Network 

Consumer Advisory Council, Toronto, ON, 9 University of 

Toronto, Toronto, ON, 10 University of Exeter, Exeter, United 

Kingdom, 11 St. Mary’s General Hospital, Kitchener, ON 


Gene Therapy 

2149. Atsttrin-â, an Engineered Protein Derived From Progranulin 

Growth Factor, Binds to TNF Receptors and Exhibits 

Potent Anti-Inflammatory Activity in Mice. Yunpeng Zhao 1 , 

Qingyun Tian 1 , Haicheng Song 1 , Fanhua Wei 1 and Chuanju 

Liu 2 , 1 NYU Hospital for Joint Diseases, New York, NY, 2 New 

York University, New York, NY 

2150. Action of Tofacitinib via Human Dendritic Cells. Satoshi 

Kubo, Kunihiro Yamaoka, Shigeru Iwata and Yoshiya Tanaka, 


Japan, Kitakyushu, Japan 


2152. Inhibition of Fucose Incorporation Abrogates the 

Development of Arthritis by Suppressing the Inflammatory 

Macrophage Development and TNF-α Production. Jun Li 1 , 

Hui-Chen Hsu 2 , PingAr Yang 1 , Qi Wu 1 , David M. Spalding 1 , W. 

Winn Chatham 1 , Robert P. Kimberly 1 , S. Louis Bridges Jr. 1 and 

John D. Mountz 2 , 1 University of Alabama at Birmingham, 

Birmingham, AL, 2 University of Alabama at Birmingham and 

Birmingham VA Medical center, Birmingham, AL 

2153. Target-Directed Development of a Proposed Biosimilar 

Rituximab (GP2013): Comparability of Antibody-


Dependent Cellular Cytotoxicity Activity and Pre-Clinical 

Pharmacokinetics and Pharmacodynamics with Originator 

Rituximab. Antonio da Silva, Ulrich Kronthaler, Ines Meyer, 

Anastassia Papandrikopoulou, Thomas Stangler and Jan 

Marinus Visser, Sandoz Biopharmaceuticals / HEXAL AG, 

Holzkirchen, Germany 

2154. Regulation of Folate Pathway Related Genes in 

Methotrexate naïve and Methotrexate Treated Patients 

with Rheumatoid Arthritis. Marjolein Blits 1 , Gerrit Jansen 1 , 

Saskia Vosslamber 1 , Yehuda G. Assaraf 2 and Cornelis L. 

Verweij 1 , 1 VU University Medical Center, Amsterdam, 

Netherlands, 2 Haifa, Israel 

2155. The Annualized Progression of Radiologic Damage in 

Placebo Arms of Rheumatoid Arthritis Trials Is Much Lower 

Than the Mean Annual Progression Since Disease Onset. 

Jean-Marie Berthelot and Celine Cozic, Nantes University 

Hospital, Nantes, France 

2156. Anti-Cyclic Citrullinated Protein Antibodies as a Predictor 

of Response to Tocilizumab in Patients with Rheumatoid 

arthritis A Prospective Study. Kensuke Kume 1 , Kanzo 

Amano 1 , Susumu Yamada 1 , Kuniki Amano 2 , Kazuhiko Hatta 3 , 

Hiroyuki Ohta 4 and Noriko Kuwaba 5 , 1 Hiroshima Clinic, 

Hiroshima, Japan, 2 Sky Clinic, Hiroshima, Japan, 3 Hatta 

Clinic, Kure, Japan, 4 Hiroshima, Japan, 5 Sanki Clinical Link, 

Hiroshima, Japan 

2157. Resveratrol Counters Pro-Atherogenic Effects of Systemic 

Lupus Erythematosus and Rheumatoid Arthritis Plasma On 

Cholesterol Efflux in Human Macrophages. Allison B. Reiss, 

Iryna Voloshyna, Ofek Hai, Michael J. Littlefield, Elise Belilos, 

Kristina B. Belostocki, Lois A. Bonetti, Gary C. Rosenblum 

and Steven E. Carsons, Winthrop University Hospital, 

Mineola, NY 

2158. Baseline Folate Related Biomarkers in Serum and 

erythrocytes Are Not Associated with Methotrexate 

Response and Adverse Events in Rheumatoid Arthritis. 

Maurits C.F.J. De Rotte 1 , Saskia M.F. Pluijm 2 , Maja Bulatovic 3 , 

Johanna M.W. Hazes 1 and Robert De Jonge 1 , 1 Erasmus 

Medical Center, Rotterdam, Netherlands, 2 Erasmus Medical 

center, Rotterdam, Netherlands, 3 University Medical Centre 

Utrecht, Netherlands 

2159. Correlation of a Multi-Biomarker Disease Activity Response 

Assessment to Disease Activity Score 28 (C - reactive 

protein) Response Assessment and Omeract Ramris Scores 

in a Placebo-Controlled Rheumatoid Arthritis Clinical Trial 

with Abatacept (ASSET). DJ Haney 1 , G. Cavet 2 , P. Durez 3 , 

R. Alten 4 , G. R. Burmester 5 , P. P. Tak 6 , Anka. I. Catrina 7 , 

C. Gaillez 8 , M. Le Bars 8 , S. Connolly 9 and R. Townsend 9 , 

1 

Crescendo Bioscience Inc., South San Francisco, CA, 

2 

Crescendo Bioscience, Inc., South San Francisco, CA, 

3 

Université Catholique de Louvain, Brussels, Belgium, 

4 

Schlosspark-Klinik, University Medicine, Berlin, Germany, 

5 

Charité-Universitätsmedizin, Berlin, Germany, 6 Academic 

Medical Center/University of Amsterdam, Amsterdam, the 

Netherlands; GlaxoSmithKline, Stevenage, United Kingdom, 

7 

Karolinska Institute, Stockholm, Sweden, 8 Bristol-Myers 

Squibb, Rueil Malmaison, France, 9 Bristol-Myers Squibb, 

Princeton, NJ 

2160. Fcγ Receptor IIIb Polymorphism Is Associated with 

Injection Reaction to Adalimumab in Patients with 

Rheumatoid Arthritis. Masako Tsukamoto 1 , Yosuke 

Hashimoto 1 , Tatsuhiro Ohshige 1 , Keiko Yoshimoto 1 , Yuko 

Kaneko 2 , Hideto Kameda 1 and Tsutomu Takeuchi 1 , 1 Keio 

University School of Medicine, Tokyo, Japan, 2 Keio Univ 

School of Medicine, Shinjuku-ku, Japan 

2161. Methotrexate Polyglutamate Concentrations in 

Erythrocytes Are a Potential Tool for Therapeutic Drug 

Monitoring of Methotrexate Response in Rheumatoid 

Arthritis. Maurits C.F.J. De Rotte 1 , Ethan den Boer 2 , Maja 

Bulatovic 3 , Saskia M.F. Pluijm 4 , Johanna M.W. Hazes 1 and 

Robert De Jonge 1 , 1 Erasmus Medical Center, Rotterdam, 

Netherlands, 2 Erasmus University Hospital, Rotterdam, 

Netherlands, 3 University Medical Centre Utrecht, 

Netherlands, 4 Erasmus Medical center, Rotterdam, 

Netherlands 

2162. Correlation of A Multi-Biomarker Disease Activity 

(VECTRA DA) Score with Clinical Disease Activity 

and Its Components with Radiographic Progression in 

Rheumatoid Arthritis Patients Treated with Tofacitinib. 

Kunihiro Yamaoka 1 , Satoshi Kubo 1 , Koshiro Sonomoto 1 , 

Shintaro Hirata 1 , Guy Cavet 2 , Rebecca Bolce 2 , Michael W. 

Rowe 2 , David Chernoff 2 , Nadine Defranoux 2 , Kazuyoshi 

Saito 1 and Yoshiya Tanaka 1 , 1 University of Occupational and 

Environmental Health, Japan, Kitakyushu, Japan, 2 Crescendo 

Bioscience Inc., South San Francisco, CA 

2163. Abatacept Monotherapy Effectively Reduces the 

Frequency of Osteoclast Precursor Cells in the Peripheral 

Blood of Patients with Rheumatoid Arthritis and Inhibits 

Their Differentiation into Osteoclasts. Sandra Mueller- 

Schmucker 1 , Roland Axmann 1 , Sonja Herman 2 , Mario Zaiss 1 , 

Manuela Le Bars 3 , Thomas Harrer 1 and Georg A. Schett 4 , 

1 


2 

Medical University of Vienna, Vienna, Austria, 3 Bristol- 

Myers Squibb, Rueil Malmaison, France, 4 Department of 

Internal Medicine III and Institute for Clinical Immunology, 

University of Erlangen-Nuremberg, Erlangen, Germany 

2164. Evidence for NF-Kb Intracellular Signaling Involvement 

Following CTLA4-Ig (Abatacept) Treatment of Human 

Macrophages. Renata Brizzolara 1 , Paola Montagna 1 , 

Stefano Soldano 1 , Alberto Sulli 1 , Bruno Seriolo 1 , Barbara 

Villaggio 2 , Pierfranco Triolo 3 , Lamberto Felli 4 and Maurizio 

Cutolo 1 , 1 Research Laboratory and Academic Unit of 

Clinical Rheumatology, Department of Internal Medicine, 

University of Genova, Genova, Italy, 2 Research Laboratory 

of Nephrology, Department of Internal Medicine, University 

of Genova, Genova, Italy, 3 Rheumatoid Arthritis Unit, 

Orthopedic Surgery Department, CTO Hospital, Turin, taly, 

Turin, Italy, 4 Orthopedic Department, University of Genova, 

Genova, Italy 



294 

2165. Utility of Vectra-DA On Assessment of Rheumatoid 

Arthritis Disease Activity and Golimumab Response: 

Results of a Pilot Study from a Phase 3 Trial in Patients 

with Active Rheumatoid Arthritis Despite Methotrexate 

Therapy. Sarah Lamberth, Yauheniya Cherkas, Carrie 

Brodmerkel and Mark Curran, Janssen Research and 

Development, LLC, Spring House, PA 

2166. Identification of Serological Biomarker Profiles Associated 

with Response to IL-6 Intervention in Rheumatoid 

Arthritis. Morten Asser Karsdal 1 , Anne C. Bay-Jensen 1 , 

Inger Byrjalsen 2 , Andrew Kenwright 3 , Adam Platt 3 , Thierry 

Sornasse 4 and Claus Christiansen 5 , 1 Nordic Bioscience A/S, 

Herlev, Denmark, 2 Nordic Bioscience, Herlev, Denmark, 

3 

Roche, Welwyn Garden City, United Kingdom, 4 Genentech, 

Inc., South San Francisco, USA, San Fransisco, CA, 5 CCBR, 


2167. Serum Based Biomarkers of Joint Destruction Can Identify 

Responders and Non-Responder to Tocilizumab. Anne 

C. Bay-Jensen 1 , Inger Byrjalsen 2 , Claus Christiansen 3 and 

Morten Asser Karsdal 1 , 1 Nordic Bioscience A/S, Herlev, 

Denmark, 2 Nordic Bioscience, Herlev, Denmark, 3 CCBR, 


2168. Tolerance and Efficacy of Rituximab in Elderly Patients 

with Rheumatoid Arthritis Enrolled in the French Society 

of Rheumatology Air Registry. Sarah Payet 1 , Jacques-Eric 

Gottenberg 2 , Xavier Mariette 3 , Philippe Ravaud 4 , Elodie 

Perrodeau 5 , Thomas Bardin 6 , Patrice P. Cacoub Sr. 7 , Alain G. 

Cantagrel 8 , Bernard Combe 9 , Maxime Dougados 10 , Rene- 

Marc Flipo 11 , Bertrand Godeau 12 , Loic Guillevin 13 , Xavier X. Le 

Loet 14 , Eric Hachulla 15 , Thierry Schaeverbeke 16 , Jean Sibilia 17 , 

Isabelle Pane 18 , Gabriel Baron 19 and Martin Soubrier 20 , 

1 

CHU G.-Montpied, Clermont-Ferrand, France, 2 Strasbourg 

University Hospital, Strasbourg, France, 3 Université Paris- 

Sud, Le Kremlin Bicetre, France, 4 Hopital Hotel Dieu, Paris 

Descartes University, Paris, France, 5 Epidemiologist, Paris, 

France, 6 Hôpital Lariboisière, Paris, France, 7 Assistance 


France, 8 Centre Hospitalier Universitaire de Toulouse, 

Toulouse, France, 9 Hopital Lapeyronie, Montpellier, France, 

10 

Paris-Descartes University, APHP, Cochin Hospital, Paris, 

France, 11 Hopital R Salengro CHRU, Lille CEDEX, France, 

12 

Service de médecine interne, Université Paris Est Créteil, 

AP-HP, Hôpital Mondor Créteil, France, Creteil, France, 

13 


Paris Descartes, Paris, France, 14 CHU de ROUEN, Rouen, 

France, 15 Department of Internal Medicine, Claude 

Huriez Hospital, University of Lille, Lille CEDEX, France, 

16 

Groupe Hospitalier Pellegrin, Bordeaux, France, 17 EA4438 

Laboratoire Physiopathologie des Arthrites, Illkirch- 

Strasbourg, France, 18 Hotel Dieu University Hospital Paris, 

France, 19 Epidemiology, Paris, France, 20 CHU CLERMONT- 

FERRAnd, Clermont-Ferrand, France 

2169. Short to Medium Term Safety of Glucocorticoid Therapy 

in Rheumatoid Arthritis: A Systematic Review and Dose- 

Response Analysis of Randomized Controlled Trials. Simon 


Tarp 1 , Daniel E. Furst 2 , John R. Kirwan 3 , Maarten Boers 4 , 

Henning Bliddal 1 , Thasia Woodworth 5 , Else Marie Bartels 1 , 

Bente Danneskiold-Samsoe 1 , Lars Erik Kristensen 6 , Steffen 

Thirstrup 7 , Mette Rasmussen 7 , Marian Kaldas 8 and Robin 

Christensen 1 , 1 The Parker Institute, Copenhagen University 

Hospital at Frederiksberg, Copenhagen F, Denmark, 2 UCLA 

Medical School, Los Angeles, CA, 3 Bristol Royal Infirmary, 

Bristol, United Kingdom, 4 VU University Medical Center, 

Amsterdam, Netherlands, 5 Leading Edge Clinical Research 

LLC, Florida, FL, 6 Lund University, Lund, Sweden, 7 University 

of Copenhagen, Copenhagen, Denmark, 8 University of 

California in Los Angeles, Los Angeles, CA 

2170. Methotrexate and Interstitial Lung Disease in Rheumatoid 

Arthritis – A Systematic Literature Review and Meta- 

Analysis. Richard Conway 1 , Candice Low 2 , Robert J. 

Coughlan 3 , Martin O’Donnell 3 and John J. Carey 3 , 1 St James’s 

Hospital, Dublin, Ireland, 2 St. James Hospital, Dublin, Ireland, 

3 

Galway University Hospitals, Galway, Ireland 

2171. Comparative Efficacy of Biologics as Monotherapy and in 

Combination with Methotrexate in Rheumatoid Arthritis 

Patients with an Inadequate Response to Conventional 

Dmards: A Network Meta-Analysis. Felicity Buckley 1 , Axel 

Finckh 2 , Tom W. J. Huizinga 3 , Fred Dejonckheere 4 and Jeroen 

P. Jansen 1 , 1 MAPI Consultancy, Boston, MA, 2 University 

Hospital of Geneva, Geneva, Switzerland, 3 Leiden University 

Medical Center, Leiden, Netherlands, 4 F. Hoffmann-La Roche 

Ltd, Basel, Switzerland 

2172. An Update of Management of Coccidioidomycosis in 

Patients on Biologic Response Modifiers and Disease- 

Modifying Antirheumatic Drugs. Susan Knowles 1 , Dominick 

Sudano 1 , Sara Taroumian 2 , Neil M. Ampel 1 , John Galgiani 3 , 

Jeffrey R. Lisse 1 and Susan E. Hoover 1 , 1 University of Arizona, 

Tucson, AZ, 2 University of California, Los Angeles, Los 

Angeles, CA, 3 Valley Fever Center for Excellence, Tucson, AZ 

2173. Pharmacoeconomic Evaluation of Tocilizumab 

Monotherapy vs. Adalimumab Monotherapy in Reducing 

Disease Activity in Patients with Rheumatoid Arthritis. 

Navarro Sarabia F 1 , Francisco J. Blanco 2 , Álvaro Gracia 

JM 3 , JA García Meijide 4 and Jl Poveda 5 , 1 Hospital. Virgen 

Macarena, Sevilla, Spain, 2 INIBIC-Hospital Universitario 

A Coruña, A Coruña, Spain, 3 H. Universitario La Princesa, 

Madrid, Spain, 4 Hospital Ntra. Sra. La Esperanza, Santiago de 

Compostela, Spain, 5 Hospital Universitario La Fe, Valencia, 

Spain 

Sjögren’s Syndrome - Clinical 

2174. Natural History of Sjögren’s Syndrome Phenotypic Features 

in the Sjögren’s International Collaborative Clinical 

Alliance Registry. Caroline Shiboski 1 , Alan N. Baer 2 , Mi Y. 

Lam 1 , Stephen Challacombe 3 , Hector Lanfranchi 4 , Morten 

Schiødt 5 , Hisanori Umehara 6 , Frederick B. Vivino 7 , Yan Zhao 8 , 

Yi Dong 8 , Bruce W. Kirkham 9 , Kenneth E. Sack 10 , Susumu 

Sugai 6 , Cristina F. Vollenweider 11 , Wen Zhang 8 , John S. 

Greenspan 1 , Troy Daniels 1 , Lindsey A. Criswell 1 and Sjögren’s 

International Collaborative Clinical Alliance 12 , 1 University of


California San Francisco, San Francisco, CA, 2 Johns Hopkins 

University, Baltimore, MD, 3 Kings College London, London, 

United Kingdom, 4 University of Buenos Aires, Buenos 

Aires, Argentina, 5 Rigshospitalet, Copenhagen, Denmark, 

6 

Kanazawa Medical University, Ishikawa, Japan, 7 Penn 

Presbyt Med Ctr, Philadelphia, PA, 8 PUMCH, Bejing, China, 

9 

Guys Hospital, London, United Kingdom, 10 Univ of Calif-San 

Francisco, San Francisco, CA, 11 German Hospital, Buenos 

Aires, Argentina, 12 University of California San Francisco, CA 

2175. Interstitial Lung Disease in Sjogren Syndrome: A 

Population-Based Study. Carlotta Nannini 1 , Adlene 

Jebakumar 2 , Jay H. Ryu 2 , Cynthia S. Crowson 2 and Eric 

Matteson 2 , 1 Prato Hospital, Prato, Italy, 2 Mayo Clinic, 

Rochester, MN 

2176. Pulmonary Manifestations and Treatment of Primary 

Sjogren’s Syndrome-Associated Lung Involvement Patients: 

A Prospective Study. Hui Gao, Xuewu Zhang, Jing He, Min 

Feng, Wei Zhao, Yan Ding and Zhan-guo Li, Peking University 

People’s Hospital, Beijing, China 

2177. The Forced Oscillation Technique Is a Sensitive Method 

for Detection of Obstructive Airway Disease in Patients 

with Primary Sjögren’s Syndrome. Anna M. Nilsson 1 , Elke 

Theander 2 , Roger Hesselstrand 3 , Per Wollmer 2 and Thomas 

Mandl 2 , 1 Skane University Hospital Malmo, Lund University, 

Malmo, Sweden, 2 Skane University Hospital Malmo, Lund 

University, Malmö, Sweden, 3 Skane University Hospital Lund, 

Lund University, Lund, Sweden 

2178. 18-Fludeoxyglucose Positron Emission Tomography Is a 

Valuable Marker of Activity of Interstitial Lung Disease 

in Primary Sjögren’s Syndrome. Camille Cohen 1 , Arsene 

Mekinian 1 , Michael Soussan 2 , Yurdagul Uzunhan 2 , Veronique 

Eder 2 , Robin Dhote 3 , Dominique Valeyre 4 and Olivier Fain 5 , 

1 

Jean Verdier Hospital, Bondy, France, 2 Bobigny, France, 

3 

Avicenne Hospital, Bobigny, France, 4 Avicenne Hospital 

(AP-HP), Bobigny, France, 5 Service de médecine interne, 

Université Paris 13, AP-HP, Hôpital Jean Verdier, 93140, 

Bondy, France., Bondy, France 

2179. High Resolution CT Findings and Concomitant 

Nontuberculosis Mycobacterial Infection (NTM) in 

Patients with the Diagnosis of Primary Sjögren’s Syndrome 

Evaluated At a Respiratory Referral Center. Mehrnaz 

Maleki-Fischbach 1 and Gloria M. Russell 2 , 1 National Jewish 

Health, Denver, CO, 2 Pontificia Universidad Católica Madre y 

Maestra, Santiago, Dominican Republic 

2180. Coronary Flow Reserve and Asymmetric Dimethylarginine 

Levels: New Measurements for Identifying Subclinical 

Atherosclerosis in Patients with Primary Sjögren’s 

Syndrome. F. Atzeni 1 , L. Boccassini 1 , M.C. Signorello 2 , MA 

Carrideo 2 , L. Gianturco 2 , V. De Gennaro Colonna 3 , L. Drago 4 , 

M. Turiel 2 and P. Sarzi-Puttini 1 , 1Rheumatology Unit, L. Sacco 

University Hospital of Milan, Milan, Italy, 2 IRCCS Galeazzi 

Orthopedic Institute, University of Milan, Department 

of Health Technologies, Cardiology Unit,, Milan, Italy, 

3 

Pharmacology Department, University of Milan, Milan, 

Italy, 4 Laboratory Unit, IRCCS Galeazzi Orthopedic Institute, 

Department of Health Technologies, University of Milan, 

Milan, Italy 

2181. Concomitant Atheosclerosis and Impaired Bone Health 

in Patients with Primary Sjogren’s Syndrome. Clio P. 

Mavragani 1 , Fotini Gravani 2 , andrianos Nezos 1 , Eleni Antypa 3 , 

Kiki Maselou 3 , Dimitrios Ioakeimidis 4 , Michael Koutsilieris 1 

and Haralampos M. Moutsopoulos 5 , 1 School of Medicine, 

University of Athens, Athens, Greece, Athens, Greece, 

2 

School of Medicine, University of Athens, Athens, Greece, 

M Asias st, Athens, Greece, Athens, Greece, 3 General 

Hospital of Athens, Greece, 4 General Hospital of Athens 

“G.Gennimatas”, Greece, Greece, 5 School of Medicine, 

University of Athens, Athens, Greece 

2182. Prevalence of Fibromyalgia Is Increased in Primary 

Sjögren’s Syndrome Compared with SLE and Associated 

with Depression and Severe Vitamin D Deficiency. Byoong 

Yong Choi, Hye Jin Oh, Jun Won Park, Bon Seung Ku, Sung 

Hae Chang, Eun Young Lee, Eun Bong Lee and Yeong Wook 

Song, Seoul National University Hospital, Seoul, South Korea 

2183. Common Features in Lymphoproliferative Complications in 

the Course of Primary Sjögren’s Syndrome: Results From 

a Multicenter Cohort of 1170 Patients. Luca Quartuccio 1 , 

Chiara Baldini 2 , Roberta Priori 3 , Elena Bartoloni Bocci 4 , 

Francesco Carubbi 5 , Miriam Isola 6 , Marta Maset 1 , Sara 

Salvin 1 , Nicoletta Luciano 2 , Giovanna Picarelli 3 , Alessia 

Alunno 4 , Roberto Giacomelli 7 , Roberto Gerli 8 , Guido 

Valesini 9 , Stefano Bombardieri 2 and Salvatore De Vita 10 , 

1 

Rheumatology Clinic, DSMB, University of Udine, Italy, 

Udine, Italy, 2 Rheumatology Unit, University of Pisa, Pisa, 

Italy, 3 Rheumatology Unit, Sapienza University of Rome, 

Rome, Italy, 4 Rheumatology Unit, Department of Clinical 

& Experimental Medicine, University of Perugia, Perugia, 

Italy, 5 Rheumatology Clinic, University of L’Aquila, L’Aquila, 

Italy, 6 Institute of Statistics, University of Udine, Udine, Italy, 

7 

Rheumatology Unit, University of Aquila, L’Aquila, Italy, 

8 

Rheumatology Unit, University of Perugia, Perugia, Italy, 

9 

Sapienza, Universita di Roma, Rome, Italy, 10 Rheumatology 

Clinic, DSMB, University of Udine, Udine, Italy 

2184. Pregnancy and Fetal Outcome in Patients with an 

Established Diagnosis of Primary Sjögren’s Syndrome. 

Roberta Priori 1 , Angelica Gattamelata 1 , Mariagrazia 

Modesti 1 , Serena Colafrancesco 1 , Marta Maset 2 , Luca 

Quartuccio 2 , Salvatore De Vita 2 , Elena Bartoloni Bocci 3 , 

Alessia Alunno 3 , Roberto Gerli 3 , Francesca Strigini 4 , Chiara 

Baldini 4 , Chiari Tani 4 , Marta Mosca 4 , Stefano Bombardieri 4 

and Guido Valesini 1 , 1Rheumatology Unit, Sapienza 

University of Rome, Rome, Italy, 2 Rheumatology Clinic, 

DSMB, University of Udine, Udine, Italy, 3 Rheumatology 

Unit, Department of Clinical & Experimental Medicine, 

University of Perugia, Perugia, Italy, 4 Rheumatology Unit, 

University of Pisa, Pisa, Italy 



296 

2185. Prevalence of Severe Extra-Glandular Manifestations in a 

Large Cohort of Patients with Primary Sjögren’s Syndrome. 

Chiara Baldini 1 , Pasquale Pepe 1 , Luca Quartuccio 2 , Roberta 

Priori 3 , Elena Bartoloni Bocci 4 , Alessia Alunno 4 , Serena 

Colafrancesco 3 , Angelica Gattamelata 3 , Marta Maset 2 , 

Mariagrazia Modesti 3 , Antonio Tavoni 1 , Salvatore De Vita 2 , 

Roberto Gerli 4 , Guido Valesini 3 and Stefano Bombardieri 1 , 


2 

Rheumatology Clinic, DSMB, University of Udine, Italy, 

Udine, Italy, 3 Rheumatology Unit, Sapienza University of 

Rome, Rome, Italy, 4 Rheumatology Unit, Department of 

Clinical & Experimental Medicine, University of Perugia, 

Perugia, Italy 

2186. Ultrasonography of Major Salivary Glands in Primary 

Sjögren’s syndrome. Malin V. Jonsson 1 , Daniel 

Hammenfors 2 , Johan G. Brun 2 and Roland Jonsson 1 , 

1 

University of Bergen, Bergen, Norway, 2 Haukeland 

University Hospital, Bergen, Norway 

2187. Safety of Minor Labial Salivary Gland Biopsy. ŽIga Rotar, 

Alojzija Hočevar, NatašA. Gašperšič, Branka Hostnik, Anita 

Antolić and Matija Tomšič, University Medical Centre 

Ljubljana, 10 00 Ljubljana, Slovenia 

2188. How to Better Define Inclusion Criteria in a Large 

Controlled Trial in Primary Sjögren Syndrome? Valerie 

Devauchelle-Pensec 1 , Xavier Mariette 2 , Jacques-Eric 

Gottenberg 3 , Raphaèle Seror 4 , Anne-Laure Fauchais 5 , Olivier 

Vittecoq 6 , Véronique Le Guern 7 , Jacques Morel 8 , JJ Dubost 9 , 

Philippe Dieude 10 , Eric Hachulla 11 , Pierre yves Hatron 12 , C. 

Larroche 13 , Aleth Perdriger 14 , Xavier Puechal 15 , Damien Sene 

Sr. 16 , Stephanie Rist 17 and Alain Saraux 18 , 1 Brest Occidentale 

university, Brest, France, 2 Université Paris-Sud, Le Kremlin 

Bicetre, France, 3 Strasbourg University Hospital, Strasbourg, 

France, 4 Bicetre university hospital, LE Kremlin-Bicetre, 

France, 5 Hospital, Limoges, France, 6 Rouen University 

Hospital & Inserm905, University of Rouen, Rouen Cedex, 

France, 7 Cochin Hospital, Paris, France, 8 Hopital Lapeyronie, 

Montpellier, France, 9 CHU CLERMONT-FERRAnd, Clermont- 

Ferrand, France, 10 APHP, Hopital Bichat, Paris, France, 

11 

Department of Internal Medicine, Claude Huriez Hospital, 

University of Lille, Lille CEDEX, France, 12 Hôpital Claude 

Huriez, Université Lille II, Lille, France, Paris, France, 

13 

Hospital University Bobigny, France, 14 Hôpital Sud, Rennes, 

France, 15 Hôpital Cochin, Paris, France, 16 Groupe Hospitalier 

Pitié-Salpétrière, Université Pierre et Marie Curie, Paris, 

France, 17 Orleans Hospital, Orleans, France, 18 Université 

Brest Occidentale, Brest, France 

2189. Efficacy of Belimumab on Non-Malignant Parotid Swelling 

and Systemic Manifestations of Sjögren’s Syndrome: 

Results of the Beliss Study. Salvatore De Vita 1 , Raphaèle 

Seror 2 , Luca Quartuccio 3 , Frederic Desmoulins 4 , Sara Salvin 3 , 

Gabriel Baron 5 , Martina Fabris 6 , Philippe Ravaud 5 , Miriam 

Isola 7 and Xavier Mariette 8 , 1 Rheumatology Clinic, DSMB, 

University of Udine, Udine, Italy, 2 Université Paris-Sud, Le 

Kremlin Bicêtre, LE Kremlin-Bicetre, France, 3 Rheumatology 

Clinic, DSMB, University of Udine,, Udine, Italy, 4 Université 


Paris-Sud, Le Kremlin Bicêtre, Le Kremlin Bicetre, France, 

5 

Université Paris-Descartes, Paris,, Paris, France, 6 Institute 

of Clinical Pathology, Udine, Italy, 7 Institute of Statistics, 

University of Udine, Udine, Italy, 8 Université Paris-Sud, Le 

Kremlin Bicetre, France 

2190. Antimalarials for Sjögren’s Syndrome Treatment in Adults, 

Meta-Analysis. Vibian A. Coy 1 , Carlos E. Granados 2 , Diana 

Gil 1 , Alejandro Junca 1 , Daniel Jaramillo 1 , Antonio A. Iglesias- 

Gamarra 3 , Jose Felix Restrepo 4 and Federico Rondon- 

Herrera 4 , 1 Fellow of Rheumatology Universidad Nacional 

de Colombia, Bogotá, Colombia, 2 Professor -Universidad 

Nacional de Colombia, Bogotá, Colombia, 3 Professor- 

Universidad Nacional de Colombia, Bogota, Colombia, 

4 

Professor -Universidad Nacional de Colombia, Bogota, 

Colombia 

2191. Secretagogue Use in Patients with Primary Sjögren’s 

Syndrome. Ghaith Noaiseh 1 , Joshua Baker 1 and Frederick B. 

Vivino 2 , 1 University of Pennsylvania, Philadelphia, PA, 2 Penn 

Presbyt Med Ctr, Philadelphia, PA 

2192. Phenotypic Features of Sjögren’s Syndrome Among 

Patients with Low-Titer SSA/B Antibodies. Mara McAdams 

DeMarco 1 , Mi Y. Lam 2 , Stephen Shiboski 2 , Lindsey A. 

Criswell 3 , Caroline Shiboski 2 and Alan N. Baer 4 , 1 Johns 

Hopkins Bloomberg School of Public Health, Baltimore, MD, 

2 


3 


4 


2193. Validity of Low Titers of SSA/B Antibodies in Predicting 

A Key Feature of Sjögren’s Syndrome. Mara McAdams 

DeMarco 1 , Mi Y. Lam 2 , Stephen Shiboski 2 , Lindsey A. 

Criswell 3 , Caroline Shiboski 2 and Alan N. Baer 4 , 1 Johns 

Hopkins Bloomberg School of Public Health, Baltimore, MD, 

2 


3 


4 


2194. Cathepsin S Activity in Tears as a Marker of Sjögren’s 

Syndrome. S.E. Whitt 1 , K. Renduchintala 1 , S. Janga 2 , M. 

Shah 2 , J. Zhu 3 , K. Silka 3 , S. Bricel 3 , D. Bach 3 , M. Heur 4 , S. 

Christianakis 3 , J. Irvine 4 , D. Arkfeld 3 , W.J. Mack 3 , William 

Stohl 3 and S.F. Hamm-Alvarez 2 , 1 University of Southern 

California Keck School of Medicine -These authors 

contributed equally to this work, Los Angeles, CA, 

2 

University of Southern California School of Pharmacy, Los 

Angeles, CA, 3 University of Southern California Keck School 

of Medicine, Los Angeles, CA, 4 Doheny Eye Institute, Los 

Angeles, CA 

2195. Long-Term Changes in Autoantibody Profile after Pandemic 

Unadjuvanted Influenza A/H1N1 Vaccine in Sjögren’s 

Syndrome. Sandra G. Pasoto 1 , Ana C. Ribeiro 1 , Vilma 

S.T. Viana 1 , Elaine P. Leon 2 , Cleonice Bueno 1 , Mauricio 

Levy Neto 1 , Alexander R. Precioso 3 , Maria do Carmo S. 

Timenetsky 4 and Eloisa Bonfa 1 , 1 Division of Rheumatology 

- Faculdade de Medicina da Universidade de São Paulo, 

São Paulo, Brazil, 2 Faculdade de Medicina da Universidade


de São Paulo, São Paulo, Brazil, 3 Fundação Butantan - 

Instituto Butantan, São Paulo, Brazil, 4 Instituto Adolfo Lutz 

- Faculdade de Medicina da Universidade de São Paulo, São 

Paulo, Brazil 

2196. Decreased Expression of TSLP in Labial Salivary Glands of 

Patients with pSS Is Associated with Local and Systemic 

Disease Parameters. M.R. Hillen, A. Bikker, A.A. Kruize, 

M. Wenting-van Wijk, F.P.J.G. Lafeber, C.E. Hack and J.A.G. 

van Roon, University Medical Center Utrecht, Utrecht, 

Netherlands 

2197. Diagnostic Value of Blood B-Cell Subset Profiling and 

Autoimmunity Markers in Anti-SSA-Negative Sjögren’s 

Syndrome Patients. Divi Cornec 1 , Alain Saraux 2 , Jacques- 

Olivier Pers 1 , Sandrine Jousse-Joulin 3 , Yves Renaudineau 1 , 

Thierry Marhadour 3 and Valerie Devauchelle-Pensec 2 , 1 Brest 

Occidentale University, Brest, France, 2 Brest Occidentale 

university, Brest, France, 3 CHU de la Cavale Blanche, Brest, 

France 

2198. Interstitial Lung Disease in Primary Sjögren’s syndrome: 

Any Association with IgG4 Related Sclerosing Disease? 

Adlene Jebakumar 1 , Carlotta Nannini 2 , Eunhee S. Yi 1 , 

Hiroshi Sekiguchi 1 , Jay H. Ryu 1 , Cynthia S. Crowson 1 and Eric 

L. Matteson 1 , 1 Mayo Clinic, Rochester, MN, 2 Prato Hospital, 

Prato, Italy 

2199. Elevated IgG4 Serum Levels among Primary Sjögren’s 

Syndrome Patients: Do They Unmask Underlying IgG4- 

Related Disease? Clio P. Mavragani 1 , George Fragoulis 2 , 

Dimitra Rontogianni 3 , Maria Kanariou 4 and Haralampos M. 

Moutsopoulos 2 , 1 School of Medicine, University of Athens, 

Athens, Greece, Athens, Greece, 2 School of Medicine, 

University of Athens, Athens, Greece, 3 Evangelismos 

General Hospital, Athens, Greece, 4 ”Aghia Sophia” Children’s 

Hospital, Athens, Greece 

2200. IgE Autoantibodies against SSA and SSB in Patients with 

Sjögren’s Syndrome and Healthy Controls. Stamatina 

Danielides 1 , Barbara Dema 2 , Juan Rivera 2 and Gabor 

G. Illei 3 , 1 NIH, Bethesda, MD, 2 Laboratory of Molecular 

Immunogenetics, NIAMS, NIH, Bethesda, MD, 3 NIDCR/ NIH, 

Bethesda, MD 

2201. Involvement of Interleukin-33 in the Pathogenesis of 

Sjögren’s Syndrome. Ahmad Awada, Valérie Gangji and 

Muhammad S. Soyfoo, Hôpital Erasme,Université Libre de 

Bruxelles, Brussels, Belgium 

2202. Classification Criteria for Sjögren’s Syndrome: Comparison 

of the Performance of the 2002 American-European 

Consensus Group Criteria (AECG) and the 2012 ACR 

Criteria. Elke Theander 1 , Peter Olsson 2 and Thomas Mandl 3 , 

1 

Skane University Hospital, Lund University, Malmö, Sweden, 

2 

Department of Rheumatology, Skåne University Hospital, 

Lund University, Malmö, Sweden, 3 Skane University Hospital 

Malmo, Lund University, Malmö, Sweden 

2203. Effects of Reclassification Using the American College 

of Rheumatology Criteria On a Large cohort Sjögren’s 

Syndrome Patients. Astrid Rasmussen 1 , John A. Ice 1 , 

He Li 2 , Kiely Grundahl 3 , Jennifer A. Kelly 1 , Lida Radfar 4 , 

Kimberly S. Hefner 5 , Donald U. Stone 4 , Juan-Manuel Anaya 6 , 

Michael Rohrer 7 , Glen D. Houston 4 , David M. Lewis 4 , 

James Chodosh 8 , John B. Harley 9 , Pamela Hughes 7 , Jacen 

S. Maier-Moore 4 , Courtney G. Montgomery 1 , Nelson L. 

Rhodus 7 , A. Darise Farris 10 , Barbara M. Segal 11 , Christopher 

J. Lessard 12 , R. Hal Scofield 10 and Kathy Moser Sivils 1 , 

1 


OK, 2 Oklahoma Medical Research Foundation, Oklahoma 

CIty, OK, 3 Oklahoma Medical Research Foundation, 

oklahoma CIty, OK, 4 University of Oklahoma Health Sciences 

Center, Oklahoma City, OK, 5 Hefner Eye Care and Optical 

Center, Oklahoma City, OK, 6 Universidad del Rosario- 

Corporacion para Investigaciones Biologicas, Bogota, 

Colombia, 7 University of Minnesota, Minneapolis, MN, 

8 

Harvard Clinical and Translational Science Center, Boston, 

MA, 9 Cincinnati Children’s Hospital Medical Center; US 


OH, 10 Oklahoma Medical Research Foun, Oklahoma City, 

OK, 11 Hennepin County Medical Center, Minneapolis, MN, 

12 

Oklahoma Medical Research Foundation; University of 


2204. Overall Agreement between Sjögrens’s Minor Salivary 

Gland Biopsy and 200 2 and 2012 Classification Criteria. 

Laura Aline Martinez 1 , Candido Flores 2 , Alberto Arana 

Fraustro 2 and Luis H. Silveira 3 , 1 Instituto Nacional de 

Cardiologia Ignacion Chavez, Mexico City, Mexico, 2 Instituto 

Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 

3 

Instituto Nacional Cardiología Ignacio Chávez, Mexico City, 

Mexico 

2205. Longitudinal Evaluation of the Performance of Different 

Classification Criteria in Patients with Primary Sjögren’s 

Syndrome. Martina Plešivčnik Novljan 1 , ŽIga Rotar 1 , Aleš 

Ambrožič 1 , Gaj Vidmar 2 and Matija Tomšič 1 , 1 University 

Medical Centre Ljubljana, 1000 Ljubljana, Slovenia, 

2 

University Rehabilitation Institute, 1000 Ljubljana, Slovenia 


and Treatment 

2206. Patients Fulfilling the Imaging-Arm and Patients Fulfilling 

the HLA-B27+ Arm of the Assessment of Spondyloarthritis 

International Society Axial Spondyloarthritis Classification 

Criteria: Are They Similar? Rosaline van den Berg, Manouk 

de Hooge, Floris van Gaalen, Monique Reijnierse, Tom 

Huizinga and Désirée van der Heijde, Leiden University 


2207. How Useful is imaging of the Sacroiliac Joints (MRI and/ 

or X-ray) in Patients with Possible Spondyloarthritis 

in the Diagnostic Work-up? Rosaline van den Berg, 

Manouk de Hooge, Victoria Navarro-Compán, Floris van 

Gaalen, Monique Reijnierse, Tom Huizinga and Désirée 


Netherlands 



2208. Referral Patterns and Diagnosis of Patients with 

Axial Spondyloarthritis: Results of an International 

Survey. Désirée van der Heijde 1 , Joachim Sieper 2 , Dirk 

Elewaut 3 , Aileen L. Pangan 4 and Dianne Nguyen 5 , 1 Leiden 

University Medical Center, Leiden, Netherlands, 2 Charité 

Universitätesmedizin Berlin, Berlin, Germany, 3 Ghent 

University Hospital, Ghent, Belgium, 4 Abbott Laboratories, 

Abbott Park, IL, 5 Abbott Laboratories, Singapore, Singapore 

2209. Assessing Active Inflammation in Sacroiliac Joints in 

Spondyloarthritis Patients: No Added Value of Gadolinium 

Compared to Short Tau Inversion Recovery Sequence. 

Manouk de Hooge, Rosaline van den Berg, Victoria Navarro- 

Compán, Floris van Gaalen, Désirée van der Heijde, Tom 

Huizinga and Monique Reijnierse, Leiden University Medical 


2210. The Canada-Denmark Fat Spondyloarthritis Spine Score: 

Validation of a New Scoring Method for the Evaluation 

of Fat Lesions in the Spine of Patients with Axial 

Spondyloarthritis. Susanne Juhl Pedersen 1 , Zheng Zhao 2 , 

Robert GW Lambert 3 , Mikkel Østergaard 1 , Ulrich Weber 4 and 

Walter P. Maksymowych 3 , 1 Glostrup Hospital, Copenhagen, 

Denmark, 2 Department of Rheumatology, University of 

Alberta and PLA General Hospital, Beijing, PR China, Beijing, 

China, 3 University of Alberta, Edmonton, AB, 4 Balgrist 

University Hospital, Zurich, Switzerland 

2211. Is It Useful to Repeat an MRI of the Sacroiliac Joints in the 

Diagnostic Work-up for Spondyloarthritis? Rosaline van den 

Berg, Manouk de Hooge, Victoria Navarro-Compán, Floris 

van Gaalen, Monique Reijnierse, Tom Huizinga and Désirée 


Netherlands 

2212. How Much Does the Spondyloarthritis Research 

Consortium of Canada Score of the Sacroiliac Joints Change 

Over a 3-Month Period in Patients On Non-Biological 

Treatment? Rosaline van den Berg, Manouk de Hooge, 

Victoria Navarro-Compán, Floris van Gaalen, Monique 

Reijnierse, Tom Huizinga and Désirée van der Heijde, Leiden 


2213. Ankylosing Spondylitis Is Strongly Related to Clinical 

Spine Fractures Independently of Drugs Use: A Register- 

Based Case-Control Study. Daniel Prieto-Alhambra 1 , Juan 

Muñoz-Ortego 2 , Cyrus Cooper 3 , Adolfo Díez-Pérez 4 and 

Peter Vestergaard 5 , 1 URFOA-IMIM, Parc de Salut Mar; Idiap 

Jordi Gol; University of Oxford; University of Southampton, 

Barcelona, Spain, 2 Hospital Sagrat Cor, Barcelona (Spain), 

Spain, 3 University of Oxford; Southampton General Hospital, 

Southampton, United Kingdom, 4 Hospital del Mar-IMIM, 

Universitat Autònoma de Barcelona, Barcelona; and 

RETICEF, ISCIII Madrid; Spain, Barcelona, Spain, 5 Aarhus 

University Hospital THG, Aarhus (Denmark), Aarhus, 

Denmark 

2214. Similar Levels of Disease Activity in Patients with 

Oligoarticular vs. Polyarticular Peripheral Spondyloarthritis. 

Filip Van den Bosch 1 , Philip Mease 2 , Désirée van der Heijde 3 , 

Martin Rudwaleit 4 , Katie Obermeyer 5 and Aileen L. Pangan 5 , 

1 

Ghent University Hospital, Ghent, Belgium, 2 Swedish 

Medical Center, Seattle, WA, 3 Leiden University Medical 

Center, Leiden, Netherlands, 4 Endokrinologikum Berlin, 

Berlin, Germany, 5 Abbott Laboratories, Abbott Park, IL 

2215. Assessment of Vascular Age in Psoriatic Arthritis Patients. 

Jl Rosales-Alexander, César Magro Checa, Juan Salvatierra, 

Jesús Cantero Hinojosa and Enrique Raya Álvarez, University 

Hospital San Cecilio, Granada, Spain 

2216. Cardiovascular Risk Assessment in Spondyloarthritis Using 

the Score Chart and Reclassification by Presence of Plaques 

on Ultrasonography. Jl Rosales-Alexander, Juan Salvatierra, 

César Magro Checa, Jesús Cantero Hinojosa and Enrique 

Raya Álvarez, University Hospital San Cecilio, Granada, Spain 

2217. Even after Pretreatment with up to Three Biologics, 

Anti-TNFs Shows Effectiveness in Active Psoriatic Arthritis 

Patients. Frank Behrens 1 , Michaela Koehm 1 , Diamant 

Thaci 2 , Brigitte Krummel-Lorenz 3 , Gerd Greger 4 , Bianca 

Wittig 4 and Harald Burkhardt 5 , 1 CIRI/Div. Rheumatology, 

J.W. Goethe-University, Frankfurt/Main, Germany, 2 Klinik 

für Dermatologie, Venerologie und Allergologie, J.W. 

Goethe University, Frankfurt/Main, Germany, 3 CIRI/ 

Endokrinologikum, Frankfurt/Main, Germany, 4 Abbott GmbH 

& Co KG, Wiesbaden, Germany, 5 CIRI/Div. Rheumatology, 

J.W. Goethe University, Frankfurt/Main, Germany 

2218. 5 Year Safety, Efficacy, and Radiographic Data in Patients 

with Active Psoriatic Arthritis Treated with Golimumab: 

Results From the Long-Term Extension of a Randomized, 

Placebo-Controlled Study. Arthur Kavanaugh 1 , Desiree M. 

van der Heijde 2 , Iain B. McInnes 3 , Philip Mease 4 , Gerald G. 

Krueger 5 , Dafna Gladman 6 , Yiying Zhou 7 , J. D. Lu 7 , Zhenhua 

Xu 7 , Lenore Noonan 7 and Anna Beutler 7 , 1 UCSD School 

of Medicine, La Jolla, CA, 2 Leiden University Medical Ctr, 

Leiden, Netherlands, 3 University of Glasgow, Glasgow, 

United Kingdom, 4 Swedish Medical Center, Seattle, WA, 

5 

University of Utah, Salt Lake City, UT, 6 Toronto Western 

Hospital and University of Toronto, Toronto, ON, 7 Janssen 

Research & Development, LLC, Spring House, PA 

2219. Patients with Ankylosing Spondylitis and Non-Radiographic 

Axial Spondyloarthritis Show Similar Response Rates after 

One Year of Treatment with Etanercept - results of the 

Esther Trial. In-Ho Song 1 , Kay-Geert A. Hermann 2 , Hildrun 

Haibel 1 , Christian Althoff 3 , Denis Poddubnyy 1 , Joachim 

Listing 4 , Anja Weiß 5 , Ekkehard Lange 6 , Bruce Freundlich 7 , 

Martin Rudwaleit 8 and Joachim Sieper 9 , 1 Charité Medical 

University, Campus Benjamin Franklin, Berlin, Germany, 

2 

Charité Medical School, Berlin, Germany, 3 Charite Medical 

School, Berlin, Germany, 4 German Rheumatism Research 

Center, Berlin, Germany, 5 German Rheumatism Research 

Centre, Berlin, Germany, 6 Berlin, Germany, 7 Villanova, 

PA, 8 Endokrinologikum Berlin, Berlin, Germany, 9 Charité 


298 

2012 Program Book


2220. Development of the Pulsar (Program to Understand 

the Longterm Outcomes in Spondyloarthritis) Registry. 

Andreas M. Reimold 1 , Liron Caplan 2 , Daniel O. Clegg 3 , Gail 

S. Kerr 4 , Elizabeth Chang 5 , Lisa A. Davis 6 , Prashant Kaushik 7 , 

Vikas Majithia 8 , J. Steuart Richards 9 , Joel D. Taurog 10 

and Jessica Walsh 11 , 1 Dallas VA and University of Texas 

Southwestern, Dallas, TX, 2 Denver VA and Univ of Colorado 

School of Medicine, Aurora, CO, 3 George E. Wahlen VA 

Medical Center, Salt Lake City, UT, 4 Washington DC VAMC, 

Georgetown and Howard University, Washington, DC, 

5 

Phoenix, AZ, 6 Denver VA and Univ of Colorado School of 

Med, Aurora, CO, 7 Sratton VAMC, Albany, NY, 8 University 

of Mississippi Medical Center, Jackson, MS, 9 Washington 

DC VA and Georgetown University, Washington, DC, 10 UT 

Southwestern Medical Center, Dallas, TX, 11 University of 

Utah Hospital, Salt Lake City, UT 

2221. Major Adverse Cardiovascular Events Are More Common 

in Rheumatoid Arthritis Than in Psoriatic Arthritis and 

Are Associated with Different Risk Factors. Allen P. 

Anandarajah 1 , Katherine C. Saunders 2 , George W. Reed 3 , 

Alina U. Onofrei 4 , Jeffrey D. Greenberg 5 and Christopher 

T. Ritchlin 6 , 1 Univ of Rochester Medical Ctr, Rochester, 

NY, 2 CORRONA, Inc., Southborough, MA, 3 University of 

Massachusetts Medical School, Worcester, MA, 4 UMass 

Medical School, Worcester, MA, 5 NYU Hospital for Joint 

Diseases, New York, NY, 6 University of Rochester Medical 

Center, Rochester, NY 

2222. Spinal Mobility Measures in Normal Individuals – the 

Mobility Study. Sofia Ramiro 1 , Carmen Stolwijk 2 , A.M. Van 

Tubergen 2 , Désirée van der Heijde 3 and Robert Landewé 4 , 

1 


The Netherlands and Hospital Garcia de Orta, Almada, 

Portugal, 2 Maastricht University Medical Center, Maastricht, 


Netherlands, 4 Academic Medical Center, University 


Netherlands 

2223. Dysregulation of Chromatin Modification Enzymes in 

Psoriatic Arthritis. Remy Pollock, Fawnda Pellett, Vinod 

Chandran and Dafna Gladman, Toronto Western Hospital 


2224. Oral Contraceptive Pill Use in Women with Ankylosing 

Spondylitis Is Associated with a Younger Age at Diagnosis. 

Dharini Mahendira 1 , Arane Thavaneswaran 2 , Adele Carty 3 , 

Nigil Haroon 4 , Ammepa Anton 3 , Laura A. Passalent 3 , Khalid 

A. Alnaqbi 3 , Laurie M. Savage 5 , Elin Aslanyan 6 and Robert 

D. Inman 7 , 1 St Michael’s Hospital, Toronto, ON, 2 Toronto 


3 

Toronto Western Hospital, Toronto, ON, 4 University Health 

Network, Toronto Western Research Institute, University of 

Toronto, Toronto, ON, 5 Spondylitis Association of America, 

Van Nuys, CA, 6 Spondylitis Association of America, Van Nuys, 

7 

Toronto Western Research Institute, University Health 

Network and University of Toronto, Toronto, ON 

2225. Improvement in Signs and Symptoms of Active Ankylosing 

Spondylitis Following Treatment with Anti-Interleukin 

(IL)-17A Monoclonal Antibody Secukinumab Are Paralleled 

by Reductions in Acute Phase Markers and Inflammatory 

Markers S100A 8 and A9 (Calgranulin A and B). Dominique 

L. Baeten 1 , Stephan Bek 2 , Jiawei Wei 3 , Arndt Brachat 4 , 

Joachim Sieper 5 , Paul Emery 6 , Jurgen Braun 7 , Desiree M. 

van der Heijde 8 , Iain B. McInnes 9 , Jacob M. van Laar 10 , R. 

Landewe 11 , Paul Wordsworth 12 , Jurgen Wollenhaupt 13 , 

Herbert Kellner 14 , Jacqueline E. Paramarta 15 , Arthur 

Bertolino 2 , Andrew Wright 4 and Hueber Wolfgang 2 , 

1 


Amsterdam, Netherlands, 2 Novartis Institutes for BioMedical 

Research, Basel, Switzerland, 3 Beijing Novartis Pharma 

Co. Ltd., Shanghai,, China, 4 Novartis Pharma AG, Basel, 

Switzerland, 5 Charité Universitätesmedizin Berlin, Berlin, 

Germany, 6 Leeds Musculoskeletal Biomedical Research 

Unit, Leeds, United Kingdom, 7 Rheumazentrum Ruhrgebiet, 

Herne, Germany, 8 Leiden University Medical Ctr, Leiden, 

Netherlands, 9 University of Glasgow, Glasgow, United 

Kingdom, 10 Musculoskeletal Research Group, Newcastle, 

United Kingdom, 11 Academic Medical Center / University 

of Amsterdam, Amsterdam, Netherlands, 12 Nuffield 

Orthopaedic Centre, Oxford, United Kingdom, 13 Schoen- 

Klinik Hamburg-Eilbek Teaching Hospital of the University 

of Hamburg, Hamburg, Germany, 14 Centre for Inflammatory 

Joint Diseases, Munich, Germany, 15 Academic Medical 

Center/University of Amsterdam, Amsterdam, Netherlands 

2226. Application of Classification Criteria for Psoriatic Arthritis 

to Patients of the Rotterdam Early Arthritis Cohort. Jos Van 

der Kaap 1 , Johanna M.W. Hazes 2 , M. Vis 3 , Ilya Tchetverikov 

and Jolanda J. Luime 5 , 1 Rotterdam, Netherlands, 2 Erasmus 

Medical Center, Rotterdam, Netherlands, 3 VU University 

medical center, Amsterdam, Netherlands, 4 Erasmus MC - 

University Medical Center, Rotterdam, Netherlands 

2227. Low Dosage with Escalating Dosage of Infliximab in 

Psoriatic Arthritis Gives the Same Treatment Results as 

Standard Dosage of Adalimumab or Etanercept: Results 

From the Nationwide Registry ICEBIO. Bjorn Gudbjornsson 1 

and Niels Steen Krogh 2 , 1 Center for Rheumatology Research, 

Reykjavik, Iceland, 2 ZiteLab ApS, Copenhagen, Denmark 

2228. The Caspar Classification Criteria and Response to 

TNF Blockade in Rheumatologists Practice: A Large 

Observational Cohort Study. Burkhard Moller 1 , Almut 

Scherer 2 , J. Dudler 3 , Bettina Weiss 4 , Nikhil Yawalkar 5 and 

Peter M. Villiger 6 , 1 Inselspital University Hospital, Bern, 

Switzerland, 2 SCQM Foundation, Zurich, Switzerland, 

3 

Cantonal Hospital Fribourg, Fribourg, Switzerland, 4 Balgrist 

University Hospital, Zurich, Switzerland, 5 MD, Bern, 

Switzerland, 6 Inselspital-University Hospital of Bern, Bern, 

Switzerland 

2229. Analysis of Clinical, CRP- and MRI- Responses to TNF- 

Blockade in Axial Spondyloarthritis Patients with Short Vs 

Long Symptom Duration. Anja Weiss 1 , In-Ho Song 2 , Hildrun 

Haibel 2 , Joachim Listing 3 and Joachim Sieper 4 , 1 German 



300 

Rheumatism Research Centre, Berlin, Germany, 2 Charité 


Germany, 3 German Rheumatism Research Center, Berlin, 


Germany 

2230. The Early Clinical Response of TNF-Alpha Blockers Is a 

Predictor of Metrology Outcome in Ankylosing Spondylitis. 

Eon Jeong Nam, Jung Soo Eun, Na Ri Kim, Jong Wan Kang, 

Churl Hyun Im and Young Mo Kang, Kyungpook National 

University School of Medicine, Daegu, South Korea 

2231. Treatment of Psoriatic Arthritis with Tumour Necrosis 

Factor á Antagonists Successfully Maintains Work Capacity: 

2 Year Results of a Prospective Cohort Study. Leonard C. 

Harty 1 , Alex Franciosi 2 , Naomi Pettysan 2 , Paul Rushe 2 and 

Oliver M. FitzGerald 1 , 1 Dublin Academic Medical Centre, St. 

Vincent’s University Hospital, Dublin, Ireland, 2 Department 


Ireland 

2232. Performance of Berlin Criteria in Patients with EARLY 

Spondyloarthritis. Beatriz E. Joven 1 , Milena Gobbo 2 , Miguel 

A. Descalzo 2 , Eugenio De Miguel 3 and Esperanza Group 4 , 

1 

HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, Madrid, Spain, 

2 

Spanish Society of Rheumatology, Madrid, Spain, 3 Hospital 

Universitario La Paz, Madrid, Spain, 4 Madrid 

2233. Assessing the Clinical and Economic Burden of U.S. Veteran 

Ankylosing Spondylitis Patients. Lin Xie 1 , Onur Baser 2 , 

Ahong Huang 3 , Lu Li 3 , Elyse K. Fritschel 3 and Li Wang 3 , 

1 

STATinMED Research, Ann Arbor, MI, 2 STATinMED Research/ 

The University of Michigan, Ann Arbor, MI, 3 STATinMED 

Research, Dallas, TX 

2234. US Treatment Patterns of Psoriatic Arthritis Patients Newly 

Initiated On Etanercept or Adalimumab. Frank Zhang 1 , Stan 

Li 1 and Jeffrey R. Curtis 2 , 1 Celgene Corporation, Warren, NJ, 

2 

Univ of Alabama-Birmingham, Birmingham, AL 

2235. How Important Is the Assessment of ASDAS in the 

Long-Term Evaluation of Disease Activity in Ankylosing 

Spondylitis? A Comparison with Currently Used Clinical 

Parameters. Xenofon Baraliakos 1 , Claudia Fritz 2 , Joachim 

Listing 3 , Hildrun Haibel 4 , Joachim Sieper 5 and Jürgen Braun 1 , 

1 

Rheumazentrum Ruhrgebiet, Herne, Germany, 2 German 

Rheumatism Research Centre, Berlin, Germany, 3 German 

Rheumatism Research Center, Berlin, Germany, 4 Charité 



Germany 


2236. Cross Cultural Validation of English and French Versions of 

a Disease Specific Patient Reported Outcome Measure for 

Lupus in Canada. Josiane Bourré-Tessier 1 , Ann E. Clarke 2 , 

Rachel A. Mikolaitis 3 , Mark Kosinski 4 , Sasha Bernatsky 5 , Joel 

A. Block 3 and Meenakshi Jolly 3 , 1 McGill University, Montréal, 

QC, 2 McGill University, Montreal, QC, 3 Rush University 

Medical Center, Chicago, IL, 4 QualityMetric Inc, Lincoln, RI, 

5 

McGill, Montreal, QC 


2237. Application and Feasibility of Proposed Systemic Lupus 

Erythematosus Reproductive Health Care Quality 

Indicators At a Public Urban Rheumatology Clinic. Itziar 

Quinzanos 1 , Angela Keniston 1 , Joann Zell 2 , Jinoos Yazdany 3 , 

Alyssa Nash 1 , Rebecca Fransen 1 , Jennifer Stichman 1 and Joel 

M. Hirsh 1 , 1 Denver Health Med Ctr, Denver, CO, 2 National 

Jewish Health, Denver, CO, 3 University of California San 


2238. Alpha-Chlorofatty Acid Does Not Correlate with Baseline 

Subclinical Cardiovascular Disease in Systemic Lupus 

Erythematosus. Mary A. Mahieu 1 , Camelia Guild 2 , 

Carolyn J. Albert 2 , George Kondos 3 , James Carr 1 , Daniel 

Edmundowicz 4 , David A. Ford 2 and Rosalind Ramsey- 

Goldman 1 , 1 Northwestern University Feinberg School of 

Medicine, Chicago, IL, 2 Saint Louis University, Saint Louis, 

MO, 3 University of Illinois at Chicago, Chicago, IL, 4 Temple 

University School of Medicine, Philadelphia 

2239. Characterization of Pure Membranous Lupus Nephritis: 

A Cohort of 150 Patients. Lucía Silva 1 , Teresa Oton 1 , Anca 

Askanase 2 , Patricia Carreira 3 , Francisco Javier López-Longo 4 , 

Anne Riveros 5 , Íñigo Rúa-Figueroa 6 , Javier Narvaez 7 , Esther 

Ruiz-Lucea 8 , Mariano andres 9 , Enrique Calvo 10 , Francisco 

Toyos 11 , Juan J. Alegre 12 , Eva Tomero 13 , Carlos Montilla 14 , 

Antonio Zea 15 , Esther Uriarte-Isacelaya 16 , Jaime Calvo-Alen 17 , 

Carlos Marras 18 , Víctor M. Martínez-Taboada 19 , María 

Ángeles Belmonte 20 , Jose Rosas 21 , Enrique Raya 22 , Gema 

Bonilla2 3 and Mercedes Freire 24 , 1 Hospital Universitario 

Puerta de Hierro Majadahonda, Majadahonda (Madrid), 

Spain, 2 NYU School of Medicine, New York, NY, 3 Hospital 

Universitario 12 de Octubre, Madrid, Spain, 4 Hospital 

General Universitario Gregorio Marañón, Madrid, Spain, 

5 

Hospital Universitario Germans Trias i Pujol, Badalona, 

Spain, 6 Hospital Universitario Dr Negrín, Las Palmas de 

Gran Canaria, Spain, 7 Hospital Universitario de Bellvitge, 

Barcelona, Spain, 8 Hospital de Basurto, Bilbao, Spain, 

9 

Hospital General Universitario de Alicante, Alicante, Spain, 

10 

Hospital Universitario Infanta Sofía, San Sebastián de los 

Reyes, Spain, 11 Hospital Universitario Virgen Macarena, 

Sevilla, Spain, 12 Hospital Universitario Dr Peset, Valencia, 

Spain, 13 Hospital Universitario La Princesa, Madrid, Spain, 

14 

Hospital Universitario de Salamanca, Salamanca, Spain, 

15 

Hospital Universitario Ramon y Cajal, Madrid, Spain, 

16 

Hospital Universitario de Donostia, Donosti, Spain, 

17 

Hospital Sierrallana, Torrelavega, Spain, 18 Hospital 

Universitario Virgen de la Arrixaca, Murcia, Spain, 19 Hospital 


Spain, 20 Hospital Universitario Carlos Haya, Málaga, Spain, 

21 

Hospital Marina Baixa, Villajoyosa, Spain, 22 University 

Hospital San Cecilio, Granada, Spain, 23 Hospital La Paz- 

IdiPaz, Madrid, Spain, 24 Hospital Universitario Juan Canalejo, 

La Coruña, Spain 

2240. Systematic Review of Skin Nontuberculous Mycobacteria 

Infection in Systemic Lupus Erythematosus: An Unusual 

Skin Infection Mimicking Lupus Vasculitis. Zahi Touma 1 , 

Amir Haddad 1 , Dafna D. Gladman 2 , Elizabeth Uleryk 3 

and Murray B. Urowitz 1 , 1 Toronto Western Hospital and


University of Toronto, Toronto, ON, 2 Toronto Western 

Research Institute, University of Toronto, University Health 

Network, Toronto, ON, 3 The Hospital for Sick Children, 

Toronto, ON 

2241. Efficacy of Belimumab in Systemic Lupus Erythematosus 

Patients with High Baseline Disease Activity. Ann E. Clarke 1 , 

Susan Manzi 2 , Michelle A. Petri 3 , Richard Furie 4 , Ronald F. 

van Vollenhoven 5 , Simon Cooper 6 , Z. John Zhong 6 , William 

W. Freimuth 6 and Arthur Weinstein 7 , 1 MUHC, Montreal, 

QC, 2 West Penn Allegheny Health System, Pittsburgh, PA, 

3 


MD, 4 North Shore-LIJ Health System, Lake Success, NY, 

5 

Karolinska University Hospital, Stockholm, Sweden, 6 Human 

Genome Sciences, Inc., Rockville, MD, 7 Washington Hospital 

Center, Washington, DC 

2242. Clinical Manifestations and Predictive Factors for Response 

to Induction Therapy and Maintenance of Remission in 

ISN/RPS Class V Lupus Nephritis. Masanori Hanaoka 1 , 

Takahisa Gono 1 , Yasushi Kawaguchi 1 , Hirotaka Kaneko 2 , Kae 

Takagi 1 , Hisae Ichida 1 , Yasuhiro Katsumata 2 , Yuko Okamoto 2 , 

Yuko Ota 1 , Sayuri Kataoka 1 and Hisashi Yamanaka 1 , 1 Institute 

of Rheumatology, Tokyo Women’s Medical University, Tokyo, 

Japan, 2 Tokyo Women’s Medical University, Tokyo, Japan 

2243. A Comparison of Systemic Lupus Erythematosus (SLE) 

Patients Achieving Prolonged Clinical Quiescence (PCQ) 

on and off Corticosteroids and/or Immunosuppressive 

Medications. Amanda J. Steiman 1 , Dafna D. Gladman 2 , 

Dominique Ibanez 1 , Anjali Papneja 3 and Murray B. 

Urowitz 1 , 1 Toronto Western Hospital and University of 

Toronto, Toronto, ON, 2 Toronto Western Research Institute, 

University of Toronto, University Health Network, Toronto, 

ON, 3 University of Toronto, Toronto, ON 

2244. Predicting Sjögren’s Syndrome at Diagnosis of Systemic 

Lupus Erythematosus. Gabriela Hernandez-Molina 1 , Tatiana 

Zamora-Legoff 1 , Juanita Romero-Diaz 1 , Carlos Alberto 

Nuñez-Alvarez 1 , Francisco Cárdenas-Velázquez 1 , Carlos 

Hernández-Hernández 1 , Maria Luisa Calderillo 1 , Martha 

Marroquín 1 , Claudia Recillas-Gispert 1 , Carmen Ávila-Casado 2 

and Jorge Sánchez-Guerrero 3 , 1 Instituto Nacional de Ciencias 

Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 

2 

University Health Network, Toronto Canada., 3 Mount Sinai 

Hospital, Toronto Canada. 

2245. Vitamin D Deficiency is associated with, but Does Not 

Predict, Change in hsCRP in Systemic Lupus Erythematosus 

(SLE). Adnan Kiani, Hong Fang and Michelle Petri, Johns 


2246. Real World Experience with Belimumab in the 

Management of Systemic Lupus Erythematosus (SLE): A 

Single Center, Observational, Post-Marketing Study. Susan 

S. Kim, Tanya Pavri, Kyriakos A. Kirou, Jane Salmon and 

Doruk Erkan, Hospital for Special Surgery, New York, NY 

2247. The First Report of Desensitization to Trimethoprim/ 

Sulfamethoxazole in Patients with Systemic Lupus 

Eryhtematosus. Yasuhiro Suyama 1 , Mitsumasa Kishimoto 1 , 

Hiroto Nakano 2 , Ken-ichi Yamaguchi 1 , Hisanori Shimizu 1 , Ryo 

Rokutanda 1 , Chisun Min 1 , Yuri Ohara 1 , Yoichiro Haji 1 , Kazuo 

Matsui 2 , Akira Takeda 1 , Yukio Matsui 1 and Masato Okada 1 , 

1 

St. Luke’s International Hospital, Tokyo, Japan, 2 Kameda 

Medical Center, Kamogawa City, Japan 

2248. Serum Phosphatidylserine-Specific Phospholipase A1 

(PS-PLA1) Identified As a Novel Biomarker for Systemic 

Lupus Erythematosus (SLE). Tetsuji Sawada 1 , Kazuhiro 

Nakamura 2 , Ryunosuke Ohkawa 2 , Aki Shoji 1 , Koichiro 

Tahara 1 , Haeru Hayashi 1 , Eri Kimura 1 , Koji Igarashi 3 , Junken 

Aoki 4 and Yutaka Yatomi 5 , 1 Tokyo Medical University, Tokyo, 

Japan, 2 The University of Tokyo Hospital, Tokyo, Japan, 

3 

TOSOH Corporation, Kanagawa, Japan, 4 Graduate School of 

Pharmaceutical Sciences, Tohoku University, Miyagi, Japan, 

5 


Tokyo, Japan 

2249. Comparison of Mycophenolate Mofetil and Intravenous 

Cyclophosphamide As Induction Therapy in Korean 

Patients with Lupus Nephritis. Dong-Jin Park, Kyung-Eun 

Lee, Tae-Jong Kim, Yong-Wook Park and Shin-Seok Lee, 

Chonnam National University Medical School, Gwangju, 

South Korea 

2250. A Clinical Analysis of Adult Patients with Autoimmune- and 

Infection-Associated Hemophagocytic Lymphohistiocytosis. 

Min W. So 1 , Bon S. Koo 1 , You J. Kim 1 , Yong-G Kim 1 , Wook J. 

Seo 2 , Chang-K Lee 1 and Bin Yoo 1 , 1 University of Ulsan College 

of Medicine, Asan Medical Center, Seoul, South Korea, 

2 

Seoul Veterans Hospital, Seoul, South Korea 

2251. High Sensitivity C - reactive protein, Disease Activity 

and Cardiovascular Risk Factors in Systemic Lupus 

Erythematosus. Chi Chiu Mok 1 , Daniel Birmingham 2 , Ling 

Yin Ho 1 and Brad H. Rovin 2 , 1 Tuen Mun Hospital, Hong 

Kong, Hong Kong, 2 Ohio State University Medical Center, 

Columbus, OH 

2252. Epratuzumab-Treated Systemic Lupus Erythematosus 

Patients Report Improvements in Health-Related Quality 

of Life: Final Results from an Open-Label Extension 

Study (SL0006). V. Strand 1 , K. Hobbs 2 , D.J. Wallace 3 , K. 

Kalunian 4 , B. Kilgallen 5 , E. Nikaï 6 , W.A. Wegener 7 and D.M. 

Goldenberg 8 , 1 Stanford University, Palo Alto, CA, 2 Denver 

Arthritis Clinic, Denver, CO, 3 Cedars-Sinai Medical Center, 

Los Angeles, CA, 4 UCSD School of Medicine, La Jolla, CA, 

5 

UCB Pharma, Smyrna, GA, 6 UCB Pharma, Brussels, Belgium, 

7 

Immunomedics Inc, Morris Plains, NJ, 8 Centre for Molecular 

Medicine and Immunology, Morris Plains, NJ 

2253. Metabolic Syndrome Is Not Only a Risk Factor for 

Cardiovascular Events in Systemic Lupus Erythematosus 

but Also Associated with Cumulative Organ Damage: A 

Cross-Sectional Analysis of 311 Patients. Semra Ertan- 

Demir 1 , Bahar Artim-Esen 1 , Yasemin Sahinkaya 1 , Özlem 

Pehlivan 1 , Nilüfer Alpay-Kanitez 1 , Ahmet Omma 1 , Burak 

Erer 2 , Sevil Kamali 1 , Ahmet Gul 1 , Orhan Aral 1 , Lale Ocal 1 

and Murat Inanc 1 , 1 Istanbul University, Istanbul Faculty of 

Medicine, Istanbul, Turkey, 2 Istanbul Faculty of Medicine, 



302 

Istanbul University, Istanbul, Turkey 

2254. Discoid Lupus in Patients with Systemic Lupus 

Erythematosus. Ghassan AlJohani, Dominique Ibanez, D. D. 

Gladman and Murray B. Urowitz, Toronto Western Hospital 


2255. Apolipoprotein B Containing Lipoprotein Subclasses and 

Subclinical Atherosclerosis in Patients with Systemic Lupus 

Erythematosus (SLE). Adnan Kiani 1 , Hong Fang 1 , Ehtisham 

Akhter 1 , Carmen Quiroga 2 , Nancy Simpson 2 , Petar Alaupovic 2 

and Michelle Petri 1 , 1 Johns Hopkins University School of 

Medicine, Baltimore, MD, 2 Oklahoma Medical Research 

Foundation, Oklahoma, OK 

2256. A Population of IL-21 Producing CD4+ T Cells Correlates 

with Disease Damage in Systemic Lupus Erythematosus 

(SLE) Patients. Babak Noamani 1 , Stacey Morrison 2 , Dafna 

Gladman 3 , Jorge Sanchez-Guerrero 4 , Murray B. Urowitz 3 , 

Joan E. Wither 5 and Carolina Landolt-Marticorena 6 , 1 Toronto 

Western Research Institute, Toronto, ON, 2 The Toronto 

Western Hospital, Toronto, ON, 3 Toronto Western Hospital 

and University of Toronto, Toronto, ON, 4 Mount Sinai 

Hospital, University Health Network, Toronto, ON, 5 Toronto 


Toronto, ON, 6 University of Toronto, Toronto, ON 

2257. Association of Low Vitamin D with High Disease Activity in 

an Australian Systemic Lupus Erythematosus Cohort. Kristy 

S. Yap 1 , Alberta Y. Hoi 2 and Eric F. Morand 2 , 1 Monash Medical 

Centre, Clayton, Australia, 2 Monash University, Melbourne, 

Australia 

2258. Risk Factors for Total Joint Replacement in Systemic Lupus 

Erythematosus Patients with Avascular Necrosis. Jennifer 

Lee 1 , Dae-Jun Kim 1 , Jae Ho Lee 1 , Seung Min Jung 1 , Seung-Ki 

Kwok 1 , Ji Hyeon Ju 2 , Kyung-Su Park 1 , Sung-Hwan Park 1 and 

Ho-Youn Kim 1 , 1 Division of Rheumatology, Department of 

Internal Medicine, Seoul St. Mary’s Hospital, The Catholic 

University of Korea College of Medicine, Seoul, South Korea, 

2 

College of Medicine, The Catholic University of Korea, 

Stanford University, Seoul, Palo Alto, CA 

2259. Limitations of Current Treatment for Systemic Lupus 

Erythematosus: A Patient and Physician Survey. V. Strand 1 , 

C. Galateanu 2 , S. Lobosco 3 , D.S. Pushparajah 2 , J. Sayers 4 and 

R.F. van Vollenhoven 5 , 1 Stanford University, Portola Valley, 

CA, 2 UCB Pharma, Brussels, Belgium, 3 Adelphi Real World 

Ltd., Macclesfield, United Kingdom, 4 Adelph Real World Ltd., 

Macclesfield, United Kingdom, 5 The Karolinska Institute, 


2260. Serum DNAse I Anti DNAse I Antibodies, CRP and 

Antibodies to CRP Relation to Disease Activity in Systemic 

Lupus Eryhtematous: Longitudinal Studies. Ramnath 

Misra 1 , Avadesh Pratap 2 , Amit Singh 1 and Amita Aggarwal 1 , 

1 

Sanjay Gandhi Postgraduate Institute of Medical Sciences, 

Lucknow, India, 2 Technician, Lucknow, India 

2261. Ovarian Reserve Markers in Reproductive Age Women with 

Systemic Lupus Erythematosus. Olívio B. Malheiro, Carolina 


P. Rezende, Gilda A. Ferreira and Fernando M. Reis, Federal 

University of Minas Gerais, Belo Horizonte, Brazil 

2262. Hypogammaglobulinemia in Pediatric Systemic Lupus 

Erythematosus. Emilina Lim 1 and Megan A. Cooper 2 , 

1 

Washington University in Saint Louis- St. Louis Children’s 

Hospital, St. Louis, MO, 2 Washington University, Saint Louis, 

MO 

2263. The Association between Prior Pregnancy Morbidity and 

Cardiovascular Events in Women with Systemic Lupus 

Erythematosus. Megan Clowse 1 , Eliza F. Chakravarty 2 , 

Jill P. Buyon 3 and Gerald McGwin Jr. 4 , 1 Duke University 

Medical Center, Durham, NC, 2 Oklahoma Medical Research 

Foundation, Oklahoma City, CA, 3 New York University 

School of Medicine, New York, NY, 4 University of Alabama at 


2264. Improving Outcomes for Pregnant Lupus Patients: Is 

There a Geographic Link? Darneesh Thornton-Johnson 1 

and Daniel Albert 2 , 1 Dartmouth Institute for Health Policy 

and Clinical Practice, Lebanon, NH, 2 Dartmouth-Hitchcock 

Medical Center, Geisel School of Medicine, Lebanon, NH 

2265. Clinical Manifestations of Systemic Lupus Erythematosus 

Vary Based On Age of Disease Onset. Flora Simmons 1 , 

Natasha M. Ruth 1 , Gary S. Gilkeson 1 and Diane L. Kamen 2 , 

1 

Medical University of South Carolina, Charleston, SC, 

2 

Arthritis & Clinical Immunology Program, Oklahoma 

Medical Research Foundation, Charleston, SC 

2266. Outcome of Renal Transplantation in Lupus Patients with 

Positive and Negative Serology: Survival of the Graft and 

Patients after Transplant. Zahi Touma, Murray B. Urowitz, 

Dominique Ibanez and D. D. Gladman, Toronto Western 



Pathogenesis 

2267. Genome-Wide Pathway Analysis of Genome-Wide 

Association Studies On Systemic Lupus Erythematosus. 

Young Ho Lee 1 , Sung Jae Choi 1 , Jong Dae Ji 1 and Gwan Gyu 

Song 2 , 1 Korea University Medical Center, Seoul, South Korea, 

2 

Korea Univ College of Med, Seoul 

2268. Hyperacetylation of Histone H4 in Systemic Lupus 

Erythematosus. Yiu Tak Leung 1 , Lihua Shi 2 , Kelly Maurer 2 , Li 

Song 2 , Zhe Zhang 3 , Michelle Petri 4 and Kathleen E. Sullivan 2 , 

1 

University of Pennsylvania, Philadelphia, PA, 2 Children’s 

Hospital of Philadelphia, Philadelphia, PA, 3 Bioinformatics, 

Children’s Hospital of Philadelphia, Philadelphia, PA, 4 Johns 


2269. The Differences of DNA Methylome and Transcriptome 

among Diverse Clinical Manifestations of Systemic Lupus 

Erythematosus. Ming Zhao 1 , Shuangyan Luo 1 , Honglong 

Wu 2 , Siyang Liu 2 , Meini Tang 1 , Wenjing Cheng 1 , Qing Zhang 1 , 

Xinhai Yu 1 , Tak Mao Chan 3 , Yudong Xia 2 , Na Yi 2 , Fei Gao 2 , Li 

Wang 2 , Ning Li 2 and Qianjin Lu 1 , 1 Second Xiangya Hospital, 

Central South University; Hunan Key Laboratory of Medical 

Epigenomics, Changsha, China, 2 Beijing Genomics Institute


at Shenzhen, Shenzhen, China, Shenzhen, China, 3 Division 

of Nephrology, Department of Medicine, University of Hong 

Kong, Queen Mary Hospital, Hong Kong, China 

2270. The DNA Methylome of Systemic Lupus Erythematosus 

(SLE) From Whole Peripheral Blood Mononuclear Cells 

(PBMCs). Robert Shoemaker 1 , Lou H. Bookbinder 2 , David 

L. Boyle 3 , Gary S. Firestein 3 , Jonathan E. Lim 2 and David W. 

anderson 1 , 1 NexDx, Inc., San Diego, CA, 2 NexDx, Inc., San 

Diego, 3 UCSD School of Medicine, La Jolla, CA 

2271. Variation of Interferon-Alpha Production in Healthy 

Individuals and Association with Autoimmune 

Susceptibility Genes. Olof Berggren 1 , andrei Alexsson 1 , 

Gunnar V. Alm 2 , Ann-Christine Syvänen 3 , Lars Rönnblom 1 

and Maija-Leena Eloranta 1 , 1 Section of Rheumatology, 

Uppsala University, Uppsala, Sweden, 2 Swedish University 

of Agricultural Sciences, Uppsala, Sweden, 3 Molecular 

Medicine, Uppsala University, Uppsala, Sweden 

2272. Gene Expression Signatures in Monocytes From Primary 

Antiphospholipd Syndrome, Systemic Lupus Erythematosus 

and Lupus with Antiphospholipid Syndrome Identify 

Specific Pathways Involved in the Pathogenesis of 

Atherosclerosis and Cardiovascular Disease. Chary Lopez- 

Pedrera 1 , Sebastiano Messineo 2 , Carlos Perez-Sanchez 1 , 

Patricia Ruiz-Limon 1 , Mª Angeles Aguirre 1 , Rosario M. 

Carretero-Prieto 1 , Antonio Rodriguez-Ariza 1 , Nuria 

Barbarroja 3 , Francisco Velasco 1 , Munther A. Khamashta 4 , 

Eduardo Collantes-Estevez 1 and Mª Jose Cuadrado 4 , 1 IMIBIC- 

Reina Sofia Hospital, Cordoba, Spain, 2 Dipartimento di 

Scienze della Salute, Universitá Magna Graecia di Catanzaro, 

Italy., Catanzaro, Italy, 3 IMABIS and Virgen de la Victoria 

Hospital, Malaga, Spain, 4 Lupus Research Unit, The Rayne 

Institute, Kings College London School of Medicine, London, 


2273. Functional Genetic Polymorphisms in Immunoglobulin- 

Like Transcript 3 Are Associated with Decreased Surface 

Expression On Dendritic Cells and Increased Serum 

Cytokines in Lupus Patients. Mark A. Jensen, Karen C. 

Patterson, Akaash A. Kumar, Marissa Kumabe, Beverly S. 

Franek and Timothy B. Niewold, University of Chicago, 

Chicago, IL 

2274. Genes Associated with Systemic Lupus Erythematosus 

Show Evidence of Selection in the Gullah African American 

Population. Paula S. Ramos 1 , Satria Sajuthi 2 , Yiqi Huang 3 , 

Diane L. Kamen 4 , Jasmin Divers 2 , Kenneth M. Kaufman 5 , 

John B. Harley 5 , Robert P. Kimberly 6 , Carl D. Langefeld 2 , 

Michèle M. Sale 3 , W. Timothy Garvey 6 and Gary S. Gilkeson 1 , 

1 

Medical University of South Carolina, Charleston, SC, 

2 

Wake Forest School of Medicine, Winston-Salem, NC, 

3 

University of Virginia, Charlottesville, VA, 4 Arthritis & 


Foundation, Charleston, SC, 5 Cincinnati Children’s Hospital 

Medical Center, Cincinnati, OH, 6 University of Alabama at 


2275. NR1H3 (LXR alpha) Gene Polymorphisms Are Associated 

with Systemic Lupus Erythematosus in Koreans. Ja-Young 

Jeon, Hyoun-Ah Kim and Chang-Hee Suh, Ajou University 

School of Medicine, Suwon, South Korea 

2276. Signature of Circulating Micro-RNA in Systemic Lupus 

Erythematosus. Anting L. Carlsen 1 , Aaron J. Schetter 2 , 

Christoffer T. Nielsen 1 , Christian Lood 3 , Steen Knudsen 4 , 

Anne Voss 5 , Curtis C. Harris 6 , Thomas Hellmark 7 , Mårten 

Segelmark 8 , Søren Jacobsen 9 , anders A. Bengtsson 10 and 

Niels H. H. Heegaard 1 , 1 Statens Serum Institut, Copenhagen 

S, Denmark, 2 National Institutes of Health, Bethesda, MD, 

3 

Department of Clinical Sciences Lund, Lund, Sweden, 

4 

Medical Prognosis Institute, Horsholm, Denmark, 5 Odense 

University Hospital, Odense C, Denmark, 6 National Cancer 

Institute NIH, Bethesda, MD, 7 Lund, Sweden, 8 Sweden, 

9 


10 

Department of Clinical Sciences Lund, Section of 

Rheumatology, Lund, Sweden 

2277. Familial Aggregation and Heritability of Systemic Lupus 

Erythematosus in Taiwan: A Nationwide Population Study. 


Hui Yu 3 , Shue-Fen Luo 3 , Ana M. Valdes 4 , Hsiao-Chun Chang 3 , 

I-Jun Chou 3 , Weiya Zhang 1 and Michael Doherty 1 , 1 University 

of Nottingham, Nottingham, United Kingdom, 2 Chang 

Gung University, Taoyuan, Taiwan, 3 Chang Gung Memorial 

Hospital, Taoyuan, Taiwan, 4 St. Thomas’ Hospital, King’s 


2278. Single Nucleotide Polymorphisms (SNPs) of Integrin-á-M 

(ITGAM) Are Associated with Susceptibility to Systemic 

Lupus Erythematosus (SLE) in an Asian Lupus Cohort. 

Weng-Giap Law 1 , Kok Ooi Kong 1 , Bernard Pui Lam Leung 1 , 

Chack-Yung Yu 2 , Yeong W. Song 3 , Yun Deng 4 , Hiok-Hee 

Chng 1 , Betty P. Tsao 5 and Hwee-Siew Howe 1 , 1 Tan Tock Seng 

Hospital, Singapore, Singapore, 2 7Center for Molecular and 

Human Genetics, The Research Institute at Nationwide 

Children’s Hospital and The Ohio State University, Columbus, 

OH, 3 Seoul National University, Seoul, South Korea, 4 David 

Geffen School of Medicine University of California Los 

Angeles, Los Angeles, CA, 5 UCLA School of Medicine, Los 

Angeles, CA 

2279. Genetic Markers for Circulating Vitamin D and the 

Associations with Risk of Systemic Lupus Erythematosus. 

Linda T. Hiraki 1 , Adrienne H. Williams 2 , Arun-Prasad 

Manoharan 3 , Peter Kraft 4 , Carl D. Langefeld 5 , Robert R. 

Graham 6 and Elizabeth W. Karlson 7 , 1 Brigham and Women’s 

Hospital, Harvard School of Public Health, Boston, MA, 

2 

Wake Forest School of Medicine, Winston-Salem, NC, 

3 

Genentech, Inc., 4 Program in Molecular and Genetic 

Epidemiology, Harvard School of Public Health, Boston, 

MA, 5 Department of Biostatistical Sciences, Wake Forest 

University Health Sciences, Winston-Salem, NC, 6 Genentech, 

Inc., South San Francisco, CA, 7 Brigham and Women’s 




2280. Serum Metabolomics As a Novel Diagnostic Approach for 

Systemic Lupus Erythematosus. Jun Saegusa 1 , Yasuhiro 

Irino 1 , Masaru Yoshida 1 , Shino Tanaka 1 , Yoshinori Kogata 1 , 

Goichi Kageyama 1 , Seiji Kawano 1 , Goh Tsuji 2 , Shunichi 

Kumagai 2 and Akio Morinobu 1 , 1 Kobe University Graduate 

School of Medicine, Kobe, Japan, 2 Shinko Hospital, Kobe, 

Japan 

2281. Tartrate-Resistant Acid Phosphatase Deficiency in the 

Predisposition to Systemic Lupus Erythematosus. Jie An 1 , 

Tracy A. Briggs 2 , Nalini Agrawal 1 , Alice Wiedeman 1 , Laurence 

Chaperot 3 , Joel Plumas 3 , Yanick J. Crow 2 and Keith B. Elkon 1 , 

1 

University of Washington, Seattle, WA, 2 University of 

Manchester, Manchester, United Kingdom, 3 Immunobiology 

& Immunotherapy of Cancers, La Tronche, France 

2282. Low Gene Copy Number for C4, C4A and C4B Is a Strong 

Risk Factor for Developing Systemic Lupus Erythematosus 

in Childhood. Luis Eduardo C. andrade 1 , Kaline M.C. Pereira 2 , 

Atila G. A. Faria 3 , Bernadete Liphaus 4 , Adriana A. Jesus 5 , 

Clovis Silva 6 and Magda Carneiro-Sampaio 5 , 1 Universidade 

Federal de São Paulo, Sao Paulo, Brazil, 2 Universidade 

Federal de São Paulo and Fleury Health and Medicine 

Laboratories, Sao Paulo, Brazil, 3 Sao Paulo, Brazil, 4 Instituto 

da Criança, Hospital das Clínicas, Faculdade de Medicina, 

Universidade de São Paulo, São Paulo, Brazil, 5 Instituto da 

Criança da Faculdade de Medicina da Universidade de São 

Paulo (FMUSP), Sao Paulo, Brazil, 6 MD; PhD, São Paulo-SP, 

Brazil 

2283. Preferential Association of Complement Receptor 2 

Variants with Anti-dsDNA Autoantibodies in Systemic 

Lupus Erythematosus. Brendan M. Giles 1 , Jian Zhao 2 , Kara 

M. Lough 1 , Patrick M. Gaffney on behalf of LLAS 23 , Marta 

E. Alarcon-Riquelme on behalf of BIOLUPUS 4 , Elizabeth E. 

Brown on behalf of PROFILE 5 , Lindsey A. Criswell 6 , Gary 

S. Gilkeson 7 , Chaim O. Jacob 8 , Judith A. James 9 , Joan T. 

Merrill 3 , Kathy L. Moser 3 , Timothy B. Niewold 10 , R. Hal 

Scofield 3 , Timothy J. Vyse 11 , John B. Harley 12 , Kenneth M. 

Kaufman 3 , Jennifer A. Kelly 3 , Carl D. Langefeld 13 , Jeffrey 

C. Edberg 14 , Robert P. Kimberly 5 , Daniela Ulgiati 15 , Betty 

P. Tsao 16 and Susan A. Boackle 1 , 1 University of Colorado 

School of Medicine, Aurora, CO, 2 David Geffen School of 

Medicine University of California Los Angeles, Los Angeles, 

CA, 3 Oklahoma Medical Research Foundation, Oklahoma 

City, OK, 4 Oklahoma Medical Research Foundation, Center 

for Genomics and Oncological Research Pfizer-University of 

Granada-Junta de andalucia, Oklahoma City, OK, 5 University 

of Alabama at Birmingham, Birmingham, AL, 6 University 

of California San Francisco, San Francisco, CA, 7 Medical 

University of South Carolina, Charleston, SC, 8 Department of 

Medicine, Keck School of Medicine, University of Southern 

California, Los Angeles, CA, 9 Oklahoma Medical Research 

Foundation and University of Oklahoma Health Sciences 

Center, Oklahoma City, OK, 10 University of Chicago, Chicago, 

IL, 11 King’s College London, Guy’s Hospital, London, United 

Kingdom, 12 Cincinnati Children’s Hospital Medical Center; US 


OH, 13 Wake Forest School of Medicine, Winston-Salem, 

NC, 14 Department of Medicine, University of Alabama at 

Birmingham, Birmingham, AL, 15 University of Western 

Australia, Perth, Western Australia, Australia, 16 UCLA School 

of Medicine, Los Angeles, CA 

2284. Epigenetic Profiling in Monozygotic Twins Discordant 

for Systemic Lupus Erythematosus Reveals Prominent 

Hypomethylation of Interferon-Inducible Genes. Paula 

S. Ramos 1 , Timothy D. Howard 2 , Miranda C. Marion 2 , 

Satria Sajuthi 2 , Jennifer A. Kelly 3 , Kathy L. Moser 3 and 

Carl D. Langefeld 2 , 1 Medical University of South Carolina, 

Charleston, SC, 2 Wake Forest School of Medicine, Winston- 

Salem, NC, 3 Oklahoma Medical Research Foundation, 


2285. Systemic Lupus Erythematosus RNA-Seq: Endogenous 

Retroviral Group K Overexpression in Monocytes. Lihua 

Shi 1 , Zhe Zhang 2 , Michelle Petri 3 and Kate Sullivan 4 , 

1 

Children’s Hospital of Philadelphia, Philadelphia, PA, 

2 

Bioinformatics, Children’s Hospital of Philadelphia, 

Philadelphia, PA, 3 Johns Hopkins University School of 

Medicine, Baltimore, MD, 4 THe Children’s Hospital of 



Pathogenesis, Animal Models and Genetics 

2286. Dysregulated Discoidin Domain Receptor 2-Microrna 

196a-Mediated Negative Feedback Against Excess Type I 

Collagen Expression in Scleroderma Dermal Fibroblasts. 

Katsunari Makino, Masatoshi Jinnin, Jun Aoi, Ikko Kajihara, 

Takamitsu Makino, Keisuke Sakai, Satoshi Fukushima, Yuji 

Inoue and Hironobu Ihn, Kumamoto University, Kumamoto, 

Japan 

2287. Altered Regulation of Metabolic Pathways in Systemic 

Sclerosis Evidenced by Metabolomics. Emmanuel Chatelus, 

Jacques-Eric Gottenberg, François-Marie Moussallieh, 

Christelle Sordet, Arnaud Theulin, Alain Meyer, Jean- 

Francois Kleimann, Jean Sibilia and Izzie Jacques Namer, 

Strasbourg University Hospital, Strasbourg, France 

2288. The Role of TCR Vä1+ NKT Cells in Systemic Sclerosis 

Patients with Interstitial Pneumonitis. Seiji Segawa, Daisuke 

Goto, Masanobu Horikoshi, Shinya Hagiwara, Naoto Umeda, 

Hiroshi Ogishima, Yuya Kondo, Hiroto Tsuboi, Makoto 

Sugihara, Taichi Hayashi, Yusuke Chino, Isao Matsumoto and 

Takayuki Sumida, University of Tsukuba, Tsukuba City, Japan 

2289. Adiponectin Has Potent Anti-Fibrotic Effects Mediated 

Via AMP Kinase: Novel Target for Fibrosis Therap. Feng 

Fang 1 , Lei Liu 2 , Yang Yang 2 , Jun Wei 1 , Swati Bhattacharyya 1 , 

Ross Summer 3 , Boping Ye 2 and John Varga 1 , 1 Northwestern 

University, Chicago, IL, 2 China Pharmaceutical University, 

Nanjing, China, 3 Boston University, Boston, MA 

2290. Type I Interferon Associated Gene IRF7 in the Pathogenesis 

of Fibrosis in Systemic Sclerosis (SSc). Minghua Wu 1 , 

Michael R. Blackburn 2 , Shervin Assassi 1 , Xiaochun Liu 1 , 

John D. Reveille 1 , Filemon K. Tan 1 , Sandeep K. Agarwal 3 and 

304 

2012 Program Book


Maureen D. Mayes 1 , 1 University of Texas Health Science 

Center at Houston, Houston, TX, 2 The University of Texas 

Medical School at Houston, Houston, TX, 3 Baylor College of 

Medicine, Houston, TX 

2291. Enhanced Release of S100A9 and Hepatocyte Growth 

Factor by the Epidermis in Systemic Sclerosis. Joanna 

Nikitorowicz Buniak 1 , Christopher P. Denton 2 , David J. 

Abraham 1 and Richard J. Stratton 1 , 1 UCL Medical School, 

London, United Kingdom, 2 UCL, London, United Kingdom 

2292. Increased Synthesis of Leukotrienes by Peripheral Blood 

Mononuclear Cells Is Associated with More Severe 

Disease and Worse Prognosis in Patients with Systemic 

Sclerosis. Otylia M. Kowal-Bielecka 1 , Anna Lapinska 2 , 

Marek Bielecki 3 , Oliver Distler 4 , Izabela Domyslawska 1 , 

Lech Chyczewski 2 , Stanislaw Sierakowski 1 , Steffen Gay 5 

and Krzysztof Kowal 6 , 1 Department of Rheumatology and 

Internal Medicine, Medical University in Bialystok, Bialystok, 

Poland, 2 Department of Medical Pathomorphology, Medical 

University in Bialystok, Bialystok, Poland, 3 Department 

of Orthopedics and Traumatology, Medical University in 

Bialystok, Bialystok, Poland, 4 Department of Rheumatology 

and Center of Experimental Rheumatology, University 

Hospital Zurich, Zurich, Switzerland, 5 Center of Experimental 


of Integrative Human Physiology (ZIHP), Switzerland, Zurich, 

Switzerland, 6 Department of Allergology and Internal 

Medicine, Medical University of Bialystok, Bialystok, Poland 

2293. Interleukin-17A Positive Cells Are Increased in Systemic 

Sclerosis Skin and Their Number Is Inversely Correlated to 

Skin Thickness. Marie-Elise Truchetet 1 , Nicolò Costantino 

Brembilla 1 , Elisa Montanari 1 , Paola Lonati 2 , Pier Luigi 

Meroni 3 and Carlo Chizzolini 1 , 1 University hospital of 

Geneva, Geneva, Switzerland, 2 Istituto G. Pini, University 

of Milan, Milan, Italy, 3 Istituto G. Pini, University of Milan, 

Milano, Italy 

2294. The Histone Deacetylase SIRT1 Is Anti-Fibrotic and 

Mediates Resveratrol Effects. Roberta G. Marangoni 1 , Archit 

Ghosh 1 , Jun Wei 2 and John Varga 3 , 1 Northwestern University, 

Feinberg School of Medicine, Chicago, IL, 2 Northwestern 

University, Chicago, IL, 3 Northwestern University Medical 

School, Chicago, IL 

2295. Caveolin-1 Deficiency Induces Spontaneous Endothelialto-Mesenchymal 

Transition (EndoMT) in Murine 

Pulmonary Endothelial Cells in Vitro. Zhaodong Li 1 , Peter 

J. Wermuth 1 , Bryan Benn 1 , Michael P. Lisanti 2 and Sergio 

A. Jimenez 1 , 1 Jefferson Institute of Molecular Medicine, 

Division of Connective Tissue Diseases and Scleroderma 

Center, Thomas Jefferson University, Philadelphia, PA, 

2 

Jefferson Stem Cell Biology and Regenerative Medicine 

Center, Kimmel Cancer Center, Thomas Jefferson University, 


2296. Platelet Release Products Mediate Endothelial Apoptosis: 

A Possible Role for Thrombospondin 1- CD36 Pathway in 

SSc-Endothelial Apoptosis. Bashar Kahaleh and Yongqing 

Wang, University of Toledo, Toledo, OH 

2297. Decrease Activity of DNA Demethylase in SSc Fibroblast 

and Microvascular Endothelial Cells: A Possible Mechanism 

for Persistence of SSc Phenotype. Bashar Kahaleh and 

Yongqing Wang, University of Toledo, Toledo, OH 

2298. The Arachidonate 5-Lipoxygenase Activating Protein 

(ALOX5AP) Polymorphism Is Associated with Risk 

of Scleroderma-Related Interstitial Lung Disease: A 

Multicenter Study From the EULAR Scleroderma Trial 

and Research Group. Otylia M. Kowal-Bielecka 1 , Sylwia 

Chwiesko-Minarowska 2 , Pawel Bernatowicz 2 , Yannick 

Allanore 3 , Timothy RD Radstake 4 , Jasper Broen 5 , Marco 

Matucci-Cerinic 6 , Roger Hesselstrand 7 , Dorota Krasowska 8 , 

Gabriela Riemekasten 9 , Madelon C. Vonk 4 , Oksana 

Kowalczuk 2 , Marek Bielecki 10 , Robert Milewski 11 , Lech 

Chyczewski 12 , Jacek Niklinski 2 and Krzysztof Kowal 13 , 

1 

Department of Rheumatology and Internal Medicine, 

Medical University in Bialystok, Bialystok, Poland, 

2 

Department of Clinical Molecular Biology, Medical 

University of Bialystok, Bialystok, Poland, 3 Paris Descartes 

University, Rheumatology A department, Cochin 

Hospital, Paris, France, 4 Radboud University Nijmegen 


Rheumatology & Clinical Immunology, University Medical 

Center, Utrecht, Netherlands, 6 University of Florence, 

Florence, Italy, 7 Skane University Hospital Lund, Lund 

University, Lund, Sweden, 8 Department of Dermatology, 

Venereology and Pediatric Dermatology, Medical University 

of Lublin, Lublin, Poland, 9 Charité University Hospital, 

German Rheumatology Research Center, a Leibniz 

Institute, Berlin, Germany, 10 Department of Orthopedics 

and Traumatology, Medical University of Bialystok, 

Bialystok, Poland, 11 Department of Statistics and Medical 

Informatics, Medical University of Bialystok, Bialystok, 

Poland, 12 Department of Medical Pathomorphology, Medical 

University in Bialystok, Bialystok, Poland, 13 Department of 

Allergology and Internal Medicine, Medical University of 

Bialystok, Bialystok, Poland 

2299. Acroosteolysis Is Associated with Increased Propensity 

for Osteoclast Formation and Higher VEGF Levels in the 

Peripheral Blood of Systemic Sclerosis Patients. Jin Kyun 

Park 1 , Andrea Fava 2 , Antony Rosen 3 and Francesco Boin 2 , 

1 

Seoul National University Hospital, Seoul, South Korea, 

2 

Johns Hopkins University, Baltimore, MD, 3 The Johns 

Hopkins University, Baltimore, MD 

2300. The Effects of Salvianolic Acid B in Fibrotic Models in Vivo 

and in Vitro. Qingmei Liu 1 , Wenyu Wu 2 , Wenzheng Tu 3 , 

Haiyan Chu 1 , Yanyun Ma 1 , Hejian Zou 2 , Xiaodong Zhou 4 and 

Jiu-Cun Wang 1 , 1 Ministry of Education Key Laboratory of 

Contemporary Anthropology, School of Life Sciences, Fudan 

University, Shanghai, China, 2 Huashan Hospital, Shanghai, 

China, 3 Shanghai Traditional Chinese Medicine-Integrated 

Hospital, Shanghai, China, 4 University of Texas-Houston 

Medical School, Houston, TX 

2301. The Interferon Type I Signature Is Increased in Monocytes 

from Systemic Sclerosis Patients. Zana Brkic 1 , Lenny van 



Bon 2 , Cornelia G. van Helden-Meeuwsen 1 , Madelon C. 

Vonk 3 , Hanneke Knaapen 3 , Wim van den Berg 3 , Paul L. Van 

Daele 1 , Virgil A. Dalm 1 , Timothy Radstake 2 and Marjan A. 

Versnel 1 , 1 Erasmus Medical Center, Rotterdam, Netherlands, 

2 

University Medical Center Utrecht/Radboud University 

Nijmegen Medical Center, Utrecht/Nijmegen, Netherlands, 

3 

Radboud University Nijmegen Medical Center, Nijmegen, 

Netherlands 

2302. Secreted Frizzled-Related Protein 4 Induces a Profibrotic 

Phenotype in Systemic Sclerosis Fibroblasts by Activating 

a Non-Canonical WNT Signaling Pathway. Justin Gillespie 1 , 

Paul Emery 2 and Francesco Del Galdo 3 , 1 University of Leeds, 

Leeds, United Kingdom, 2 Leeds Musculoskeletal Biomedical 

Research Unit, Leeds, United Kingdom, 3 University of Leeds, 

Leeds Institute of Molecular Medicine and LMBRU, Leeds, 


2303. Confirmation of TNIP1 as a Susceptibility Locus for 

Systemic Sclerosis in a Large Multicentre Study. Lara 

Bossini-Castillo 1 , Jose Ezequiel Martin 1 , Carmen Pilar 

Simeon 2 , Lorenzo Beretta 3 , Olga Y. Gorlova 4 , Madelon 

C. Vonk 5 , Patricia Carreira 6 , the Spanish Scleroderma 

Group 7 , Annemie Schuerwegh 8 , Alexandre Voskuyl 9 , Anna- 

Maria Hoffmann-Vold 10 , Roger Hesselstrand 11 , Annika 

Nordin 12 , Claudio Lunardi 13 , Jaap Van Laar 14 , Paul Shiels 15 , 

Ariane Herrick 16 , Jane Worthington 17 , Carmen Fonseca 18 , 

Christopher P. Denton 18 , Shervin Assassi 19 , Bobby P.C. 

Koeleman 20 , Maureen D. Mayes 19 , T.R.D.J. Radstake 20 and 

Javier Martin 1 , 1 Instituto de Parasitologia y Biomedicina 

Lopez-Neyra (IPBLN-CSIC), Granada, Spain, 2 Hospital Valle 

de Hebron, Barcelona, Spain, 3 IRCCS Fondazione Policlinico- 

Mangiagalli-Regina Elena & University of Milan, Milan, 

Italy, 4 UT M. D. anderson Cancer Center, Houston, TX, 

5 


Netherlands, 6 Hospital Universitario 12 de Octubre, Madrid, 

Spain, 7 Granada, Spain, 8 Leids Univ Medisch Centrum, 

Leiden, Netherlands, 9 VU University Medical Center, 

Amsterdam, Netherlands, 10 Oslo University Hospital, Oslo, 

Norway, 11 Skane University Hospital Lund, Lund University, 

Lund, Sweden, 12 Karolinska Institute, Stockholm, Sweden, 

13 

Policlinico G B Rossi, Verona, Italy, 14 Leiden University 

Hospital, Leiden, Netherlands, 15 University of Glasgow, 

Glasgow, United Kingdom, 16 University of Manchester, 

Salford, United Kingdom, 17 University of Manchester, 

Manchester, United Kingdom, 18 Royal Free and University 

College Medical School, London, United Kingdom, 

19 

University of Texas Health Science Center at Houston, 

Houston, TX, 20 University Medical Center Utrecht, Utrecht, 

Netherlands 

2304. Differential Association of IRAK1 and MECP2 with Specific 

Systemic Sclerosis Phenotypes. F. David Carmona 1 , M.C. 

Cénit 1 , L.M. Díaz-Gallo 1 , Carmen P. Simeón 2 , Patricia 

Carreira 3 , the Spanish Scleroderma Group 4 , Nicolas 

Hunzelmann 5 , Gabriela Riemekasten 6 , Torsten Witte 7 , 

Alexander Kreuter 8 , Jörg HW Distler 9 , Paul Shiels 10 , Jacob 

M. van Laar 11 , Annemie Schuerwegh 12 , Madelon C. Vonk 13 , 

Alexandre Voskuyl 14 , Carmen Fonseca 15 , Christopher 

Denton 16 , Ariane Herrick 17 , Frank C. Arnett 18 , Filemon 

K. Tan 18 , Shervin Assassi 18 , T.R.D.J. Radstake 19 , Maureen 

D. Mayes 18 and Javier Martin 1 , 1 Consejo Superior de 

Investigaciones Científicas, Armilla (Granada), Spain, 

2 

Hospital Valle de Hebron, Barcelona, Spain, 3 Hospital 

Universitario 12 de Octubre, Madrid, Spain, 4 Granada, 

Spain, 5 University of Cologne, Cologne, Germany, 6 Charité 

University Hospital, German Rheumatology Research Center, 

a Leibniz Institute, Berlin, Germany, 7 Hannover Medical 

School, Hanover, Germany, 8 Ruhr University Bochum, 

Bochum, Germany, 9 Department of Internal Medicine 3 and 


Nuremberg, Erlangen, Germany, 10 University of Glasgow, 

Glasgow, United Kingdom, 11 Musculoskeletal Research 

Group, Newcastle, United Kingdom, 12 Leids Univ Medisch 

Centrum, Leiden, Netherlands, 13 Radboud University 

Nijmegen Medical Centre, Nijmegen, Netherlands, 14 VU 

University Medical Center, Amsterdam, Netherlands, 

15 

Royal Free Hospital, London, United Kingdom, 16 Royal 

Free Hospital, London, England, 17 University of Manchester, 

Salford, United Kingdom, 18 University of Texas Health 

Science Center at Houston, Houston, TX, 19 University 


2305. A Putative Role for the TGFβ Accessory Receptors 

Betaglycan and Endoglin in pulmonary Complications of 

Scleroderma. Sarah L. Trinder, Adrian Gilbane, Markella 

Ponticos, Johanna Donovan, Christopher P. Denton, David 

J. Abraham and Alan M. Holmes, UCL, London, United 

Kingdom 

2306. Intratracheal Instillation of Omniscan in an Adenine- 

Induced Model of Chronic Renal Failure: A New Model 

of Nephrogenic Systemic Fibrosis. Peter J. Wermuth and 

Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, 

Division of Connective Tissue Diseases and Scleroderma 

Center,Thomas Jefferson University, Philadelphia, PA 

2307. Role of Endosomal and Cell Membrane Toll-Like 

Receptors in Keratinocyte Activation by Systemic Sclerosis 

Autoantibodies. James M. Watson 1 , Joanna Nikitorowicz 

Buniak 1 , Xu Shiwen 2 , David J. Abraham 1 , Christopher P. 

Denton 3 and Richard J. Stratton 1 , 1 UCL Medical School, 

London, United Kingdom, 2 Royal Free Hospital, London, 

United Kingdom, 3 Royal Free and University College Medical 

School, London, United Kingdom 

2308. CD11c+ Cells Are Necessary for Myofibroblast Maintenance 

in Bleomycin-Induced Cutaneous Fibrosis. Jennifer J. Chia 1 , 

Sha Tian 2 and Theresa T. Lu 2 , 1 Weill Cornell/Rockefeller/ 

Sloan-Kettering Tri-Institutional MD-PhD Program, New York, 

NY, 2 Hospital for Special Surgery, New York, NY 

2309. Increased Levels of Ser 181 Phosphorylated SOX9 in 

SSc Dermal Fibroblasts: A Novel Participant in the 

Pathogenesis of SSc Fibrotic Process. Sonsoles Piera- 

Velazquez, Jolanta Fertala and Sergio A. Jimenez, Jefferson 

Institute of Molecular Medicine, Division of Connective 

306 

2012 Program Book


Tissue Diseases and Scleroderma Center,Thomas Jefferson 



2310. Enhancement of CRACM1 Expression in Functionally 

Aberrant Naïve CD4+ T Cells in Active Rheumatoid 

Arthritis. Shuang Liu 1 , Shohei Watanabe 2 , Miyuki Kuno 3 , 

Hiromasa Miura 2 and Kazutaka Maeyama 1 , 1 Informational 

Biomedicine, Ehime University Graduate School of Medicine, 

Toon-shi, Ehime, Japan, 2 Ehime University Graduate School 

of Medicine, Toon, Japan, 3 Osaka City University Graduate 

School of Medicine, Osaka, Japan 

2311. Total Glucosides of Paeony Th1 and Th17 Cell 

Differentiation by Blocking STAT1 and STAT3 Activation in 

Vivo. Ningli Li 1 and JP Lin 2 , 1 Shanghai Jiao Tong University 

School of Medicine, Shanghai, China, 2 Shanghai, China 

2312. Senescent T Cells Promote Bone Loss in Rheumatoid 

Arthritis. Johannes Fessler, Rusmir Husic, Elisabeth 

Lerchbaum, Verena Schwetz, Claudia Stiegler, Barbara 

Obermayer-Pietsch, Winfried B. Graninger and Christian 

Dejaco, Medical University Graz, Graz, Austria 

2313. The Autoantibody-Inducing CD4 T Cell (aiCD4 T cell) 

Belongs to CCR4+CD45RBlo122lo CD4 Subpopulation: A 

Novel ‘Self-Organized Criticality Theory’ Explains the Cause 

of Systemic Lupus Erythematosus (SLE). Yumi Miyazaki 1 , 

Ken Tsumiyama 2 and Shunichi Shiozawa 2 , 1 Kyushu University 

Beppu Hospital/ Kobe University Graduate School of Health 

Sciences, Beppu/ Kobe, Japan, 2 Kyushu University Beppu 

Hospital, Beppu, Japan 

2314. Correlation Between Abatacept and Rheumatoid Factor 

– Can Rheumatoid Factor Be a Predictive Factor for 

Abatacept? Tomonori Kobayakawa 1 , Masatoshi Hayashi 1 , 

Toshihisa Kanamono 1 , Atsushi Kaneko 2 , Toshihisa Kojima 3 

and Naoki Ishiguro 4 , 1 Nagano Red Cross Hospital, Nagano, 

Japan, 2 Nagoya Medical Center, Nagoya, Japan, 3 Nagoya 

Univeristy, School of Medicine, Nagoya, Japan, 4 Nagoya 

University, Graduate School & Faculty of Medicine, Nagoya, 

Aichi, Japan 

2315. Foxp3+ Treg Cells Decreased in Overexpression of T-Bet 

in PD-1 Deficient Mice. Masahiro Tahara 1 , Yuya Kondo 1 , 

Hiroto Tsuboi 1 , Satoru Takahashi 2 , Isao Matsumoto 1 and 

Takayuki Sumida 1 , 1 Department of Internal Medicine, 

Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, 

Japan, 2 Department of Anatomy and Embryology, Faculty of 

Medicine, University of Tsukuba, Tsukuba city, Ibaraki, Japan 

2316. Generation of CD4+ Follicular Helper T cells by 

Complement and Immune Complexes. Anil K. Chauhan 1 , 

Richard DiPaolo 2 and Terry L. Moore 1 , 1 Saint Louis University, 

St. Louis, MO, 2 Saint Louis, MO 

2317. Protein Phosphatase 5 (PP5) Regulates Methylation 

Sensitive Gene Expression in CD4+ T Cells. Dipak R. Patel, 

Gabriela Gorelik and Bruce C. Richardson, University of 

Michigan, Ann Arbor, MI 

2318. Reduced Thymus Function and Accelerated T-Cell Aging 

in Patients with Axial Spondylarthritis. Christian Dejaco 1 , 

Wolfgang Schwinger 1 , Andrea Raicht 1 , Rusmir Husic 1 , 

Johannes Fessler 1 , Christoph G. Ammann 2 , Christina 

Duftner 3 , Winfried B. Graninger 1 and Michael Schirmer 4 , 

1 

Medical University Graz, Graz, Austria, 2 Medical Uiversity 

Innsbruck, Innsbruck, Austria, 3 Hopital Elisabethinen, 

Klagenfurt, Austria, 4 Innsbruck Medical University, 

Innsbruck, Austria 

2319. T Follicular Helper Cell and Regulatory T cell Frequencies 

Are Affected by B Cell Depletion in Patients with 

Granulomatosis with Polyangiitis. Yuan Zhao 1 , Jessica 

Thomas 1 , Shirish Sangle 2 , Pamela M.K Lutalo 3 , Lee Meng 

Choong 4 , Jennifer R. Tyler 1 , Jo Spencer 1 , Timothy Tree 1 and 

David P. D’Cruz 2 , 1 School of Medicine, King’s College London, 

London, United Kingdom, 2 Louise Coote Lupus Unit, St 

Thomas’ Hospital, London, United Kingdom, 3 Louise Coote 

Lupus Unit, St Thomas Hospital, London, United Kingdom, 

4 

St Thomas’ Hospital, London, United Kingdom 

2320. Superantigen Induces IL-17 Production From Extremely 

Polarized Th1 Clones. Kentaro Yomogida 1 , Yuan K. Chou 1 

and Cong-Qiu Chu 2 , 1 Oregon Health & Science University, 

Portland, OR, 2 Oregon Health & Science Univ and Portland 

VA Medical Center, Portland, OR 

2321. Interleukin 12 Is Involved in an Interferon Type I Signature 

through Crosstalk of CD4+ T Cells and Plasmacytoid 

Dendritic Cells. Corinne Miceli-Richard 1 , Nicolas 

Gestermann 2 , Federico Simoneta 2 , Saida Boudaoud 2 , 

Gaetane Nocturne 3 , Yann Lecluze 4 , Christine Bourgeois 2 

and Xavier Mariette 3 , 1 Université Paris-Sud, Le Kremlin 

Bicêtre, France, 2 INSERM U10 12 , Le Kremlin Bicêtre, France, 

3 

Université Paris-Sud, Le Kremlin Bicetre, France, 4 Villejuif, 

France 

2322. Dynamic Regulation of T Follicular Helper Cell 

Differentiation through STAT Signaling. Shingo 

Nakayamada 1 , Yuka Kanno 2 , Golnaz Vahedi 2 , John J. O’Shea 2 

and Yoshiya Tanaka 1 , 1 First Department of Internal Medicine, 


Kitakyushu, Japan, 2 National Institute of Arthritis and 

Musculoskeletal and Skin Diseases, NIH, Bethesda, MD 

2323. A Genetic Polymorphism on New Zealand Black 

Chromosome 1 Is Associated with Abnormal Dendritic 

Cell Function Leading to Expansion of TH 1 , TH 17 and T 

Follicular Helper (TFH) Cells. Nafiseh Talaei 1 , Carolina 

Landolt-Marticorena 2 , Babak Noamani 1 , Evelyn Pau 1 , 

Nan-Hua Chang 1 and Joan E. Wither 1 , 1 Toronto Western 

Research Institute, University Health Network, Toronto, ON, 

2 

University Health Network, Toronto, ON 

2324. An Essential Role for TNF and PD-L1 in the Generation of 

Human CD8+CD25+Foxp3+ Regulatory T Cells That Are 

More Protective in Vivo Than CD4regs. David A. Horwitz, 

Stephanie Pan, Julie Wang and Song G. Zheng, Keck School 

of Medicine of USC, Los Angeles, CA 



308 

2325. PD-1 Signaling Promotes Suppressive Function of CD4+ 

Regulatory T Cells in (New Zealand Black x New Zealand 

White) F1 Lupus-Prone Mice in a Dose-Dependent Manner. 

Maida Wong 1 , Antonio La Cava 1 and Bevra H. Hahn 2 , 

1 

University of California, Los Angeles, Los Angeles, CA, 2 UCLA 

David Geffen School of Medicine, Los Angeles, CA 

2326. Discovery of a Highly Potent, Selective Reversible Covalent 

Inhibitor of JAK3 Kinase. Ronald J. Hill 1 , Angelina Bisconte 1 , 

J. Michael Bradshaw 1 , Ken Brameld 2 , Eun Ok Kim 1 , Xiaoyan 

Li 2 , Tim Owens 2 , Erik Verner 2 and David M. Goldstein 2 , 

1 

Principia Biopharma, South San Francisco, CA, 2 Principia 

Biopharma 

2327. CGEN-15001, a Novel Negative Costimulatory Fusion 

Protein Is Effective in the Collagen-Induced Arthritis Mouse 

Model of Rheumatoid Arthritis. Iris Hecht 1 , Kay McNamee 2 , 

Ilan Vaknin 1 , Anat Oren 1 , Joseph R. Podojil 3 , Galit Rotman 1 , 

Eyal Neria 1 , Stephen D. Miller 3 and Richard O. Williams 2 , 

1 

Compugen Ltd., Tel Aviv, Israel, 2 Oxford University, London, 

United Kingdom, 3 Northwestern University, Chicago, IL 

2328. A Novel Method for Quantitative and Functional Analysis 

of Autophagy Using Flow Cytometry in Activated Human 

Primary T Cells. Ryu Watanabe, Hiroshi Fujii, Yukiko 

Kamogawa, Kyohei Nakamura, Tsuyoshi Shirai, Yumi Tajima, 

Shinichiro Saito, Tomonori Ishii and Hideo Harigae, Tohoku 

University, Sendai, Japan 

2329. Increase of CD4+CD25+FoxP3+ T cell in Patients with 

Systemic Sclerosis Could Secret IL-17 with Dysfunction of 

Immunosuppression. Xinjuan Liu 1 , Na Gao 1 , Mengtao Li 1 , 

Dong Xu 1 , Yong Hou 1 , Qian Wang 1 , Guohua Zhang 1 , Qiuning 

Sun 1 , Henghui Zhang 2 and Xiaofeng Zeng 1 , 1 Peking Union 

Medical College Hospital, Chinese Academy of Medical 

Science & Peking Union Medical College, Beijing, China, 

2 

Peking University, People’s Hospital, Beijing, China 

2330. Mucosal-Associated Invariant T Cells Are Inactivated by 

IFNα and Reduced in Systemic Lupus Erythematosus. 

Asako Chiba 1 , Naoto Tamura 2 , Ran Matsudaira 2 , Takashi 

Yamamura 1 , Yoshinari Takasaki 2 and Sachiko Miyake 1 , 

1 

National Institute of Neuroscience, National Center 

of Neurology and Psychiatry, Tokyo, Japan, 2 Juntendo 


2331. The Effects of Anti–Tumor Necrosis Factor Agents on 

the Expansion of T Helper-Type 17 Cells Driven by 

Lipopolysaccharide-Stimulated Monocytes. Gianluca 

Fossati 1 , Louise Healy 1 and Andrew Nesbitt 2 , 1 UCB Pharma, 

Slough, United Kingdom, 2 UCB Pharma, SLough, United 

Kingdom 

2332. Suppression of PP2Ac Causes DNA Hypermethylation 

through Enhanced Pmek/Perk Activity in T Cells. Katsue 

S. Watanabe 1 , Kamalpreet Nagpal 2 and George C. Tsokos 2 , 

1 

Okayama University Graduate School of Medicine, 

Dentistry, and Pharmaceutical Sciences, Okayama, Japan, 

2 

Beth Israel Deaconess Medical Center, Harvard Medical 



2333. A Novel Subset of CD4 T Cells That Provides Help for 

Human Memory B cell Responses. Sang T. Kim, Jin Young 

Choi, Begona Lainez and Joseph E. Craft, Yale University 

School of Medicine, New Haven, CT 

2334. T-Cell Cross Reactivity with Citrullinated Antigen and P. 

Gingivalis Membrane Antigen Following Infection with P. 

Gingavalis and/or Injection of Citrullinated Mouse Type II 

Collagen in DBA/1J Mice. Michael J. Duryee 1 , Anand Dusad 1 , 

Carlos D. Hunter 1 , Ke Ren 1 , Dong Wang 2 , James R. O’Dell 3 , 

Lynell W. Klassen 3 , Ted R. Mikuls 4 and Geoffrey M. Thiele 3 , 

1 

University of Nebraska Medical Center, Omaha, NE, 2 Univ 

of Nebraska Medical Ctr, Omaha, NE, 3 Univ of Nebraska 

Med Ctr, Omaha, NE, 4 Omaha VA and University of Nebraska 

Medical Center, Omaha, NE 

2335. Increased TSLP Expression in Joints of Rheumatoid Arthritis 

Patients Causes Increased Activation of Intra-Articular 

Myeloid Dendritic Cells with Enhanced Th 1 and Th17 Cell 

Activity. F.M. Moret, C.E. Hack, T.R.D.J. Radstake, J.W.J. 

Bijlsma, F.P.J.G. Lafeber and J.A.G. van Roon, University 


2336. Elevated Frequency of Synovial Interleukin-21+ CD4+ T 

Cells Co-Expressing Tumor Necrosis Factor-a in Rheumatoid 

Arthritis. Maria C. Lebre 1 , Pedro L. Vieira 2 , Saïda Aarrass 1 , 

Thomas Newsom-Davis 2 , Paul P. Tak 3 and Gavin R. Screaton 2 , 

1 

Division of Clinical Immunology and Rheumatology, 


Amsterdam The Netherlands, Amsterdam, Netherlands, 

2 

Imperial College London, London, United Kingdom, 

3 



2337. Therapeutic Promotion of CD8 CTL by CpG 

Oligodeoxynucleotides (ODN) in an Induced Model of 

Lupus. Maksym Puliaiev, Kateryna Soloviova and Charles 

S. Via, Uniformed Services University of Health Sciences, 

Bethesda, MD 

2338. 1,25(OH)2D3 Modulates the Migration Pattern of Th17 

Cells From Patients with Rheumatoid Arthritis. Wendy 

Dankers 1 , Jan Piet van Hamburg 2 , Patrick S. Asmawidjaja 1 , 

Nadine Davelaar 3 , Hoyan Wen 1 , Anne-Marie Mus 1 , Edgar 

Colin 2 , Johannes van Leeuwen 1 , Johanna M.W. Hazes 4 and 

Erik Lubberts 1 , 1 Erasmus MC, University Medical Center, 

Rotterdam, Netherlands, 2 Erasmus MC, Rotterdam, 

Netherlands, 3 Erasmus MC, University Medical Center, 

Rotterdam, Rotterdam, Netherlands, 4 Erasmus Medical 


2339. Lowering Fli1 Levels Decreases the Levels of Lipid 

Mediators in the Kidneys and T Cells of MRL/Lpr Lupus 

Prone Mice. Marlene Bunni 1 , Zainab Amani 1 , Andrew 

Mather 1 , Jennifer Berglind Schepp 1 , Leah Siskind 1 and 

Tamara K. Nowling 2 , 1 Medical University of South Carolina, 

Charleston, SC, 2 Medical University of South Carolina and 

Ralph H. Johnson VA Medical Center, Charleston, SC 

2340. A Numeric Expansion of Invariant Natural Killer T Cells 

Protects Against the Progression of Fatal Autoimmunity


in Lupus-Prone Mice. Yuriy Baglaenko 1 , Nan-Hua Chang 1 , 

Evelyn Pau 2 , Christina Loh 1 and Joan E. Wither 1 , 1 Toronto 


Toronto, ON, 2 Toronto Western Hospital, University Health 

Network, Toronto, ON 

2341. Exacerbation of Collagen-Induced Arthritis by an Anti-CD3 

Antibody Targeting Aminoterminal-Deficient CD3ε. María 

J. Pérez-Lorenzo 1 , Elena Gonzalo 1 , José M. Rojo 2 , María 

Galindo 1 , Jose L. Pablos 1 and Gabriel Criado 1 , 1 Instituto de 

Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, 

2 

Centro de Investigaciones Biológicas-CSIC, Madrid, Spain 

2342. Synovial Tissue Analysis in the Pre-Clinical Phase of 

Arthritis: T-Cell Infiltration Preceding the Development 

of Arthritis. Maria J. H. de Hair 1 , Marleen G. H. van 

de Sande 1 , Tamara H. Ramwadhdoebe 2 , Robert B. M. 

Landewé 3 , Christiaan van der Leij 4 , Mario Maas 4 , D. van 

Schaardenburg 5 , Danielle Marie Gerlag 1 , Lisa G.M. van 

Baarsen 2 and Paul P. Tak 6 , 1 Division of Clinical Immunology 

and Rheumatology, Academic Medical Center / University 

of Amsterdam, Amsterdam, Netherlands, 2 Division of 

Clinical Immunology and Rheumatology and Department 

of Experimental Immunology , Academic Medical Center 


3 

Division of Clinical Immunology and Rheumatology, 

Academic Medical Center / University of Amsterdam 

& Atrium Medical Center, Amsterdam, Netherlands, 

4 

Department of Radiology, Academic Medical Center / 

University of Amsterdam, Amsterdam, Netherlands, 5 Jan 

van Breemen Research Institute | Reade, Amsterdam, 

Netherlands, 6 Division of Clinical Immunology and 

Rheumatology, Academic Medical Center / University of 

Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands 

2343. The Therapeutic Antibody Tregalizumab (BT-061) Induces 

Activation of Regulatory T Cells by Engaging a Unique CD4 

Mediated Signaling That Strongly Differs From Signaling 

Events Induced by Standard Anti-CD4 Antibodies. Bianca 

Helling 1 , Benjamin Daelken 1 , Holger Wallmeier 2 , Silke 

Aigner 1 , Chantal Zuber 1 , Martin Koenig 1 , andre Engling 1 , 

Frank Osterroth 1 , Niklas Czeloth 1 and Christoph Uherek 1 , 

1 

Biotest AG, Dreieich, Germany, 2 Condor Scientific 

Computing & Consulting, Sulzbach, Germany 

2344. Transcriptional Regulation of Garp Expression. Sonja Haupt, 

Qihui Zhou, Johannes Thomas Kreuzer, Simon Herrmann, 

Hendrik Schulze-Koops and Alla Skapenko, University of 

Munich, Munich, Germany 

2345. HRES-1/RAB4-Mediated Loss of DRP1 Inhibits Mitophagy, 

Promotes Accumulation of Mitochondria and Serves 

As Target for Treatment in SLE. Tiffany Telarico 1 , David 

Fernandez 1 , Zachary A. Oaks 2 , Gergely Talaber 2 , Mark Haas 3 , 

Michael P. Madaio 4 and andras Perl 5 , 1 SUNY Upstate Medical 

University, Syracuse, NY, 2 SUNY, Syracuse, NY, 3 Cedars- 

Sinai Medical Center, Los Angeles, CA, 4 Medical College of 

Georgia, Augusta, GA, 5 Upstate Medical University, Syracuse, 

NY 

2346. MHC II-Independent Regulation of Intestinal Tregs. Lisa 

L. Korn and Terri M. Laufer, University of Pennsylvania, 


Vasculitis 

2347. Specificity of the New American College of Rheumatology/ 

European League Against Rheumatism Classification 

Criteria for Polymyalgia Rheumatica in Comparison 

with the Former Ones : A Single Centre Study. Pierluigi 

Macchioni 1 , Luigi Boiardi 2 , Mariagrazia Catanoso 2 , Giulia 

Pazzola 2 and Carlo Salvarani 3 , 1 Arcispedale S Maria Nuova, 

IRCCS, Reggio Emilia, Italy, 2 Arcispedale S Maria Nuova, 

Reggio Emilia, Italy, 3 Arcispedale S Maria Nuova. IRCCS, 

Reggio Emilia, Italy 

2348. Plasma Fibrinogen Better Identifies Persistent Disease 

Activity in Polymyalgia Rheumatica Than Either ESR or 

CRP. EM McCarthy 1 , Paul A. MacMullan 1 , S. Al-Mudhaffer 1 , 

Anne M. Madigan 1 , S. Donnelly 1 , C. J. McCarthy 1 , Dermot 

Kenny 2 , Eamonn S. Molloy 3 and G M. McCarthy 1 , 1 Mater 

Misericordiae University Hospital, Dublin 7 , Ireland, 2 RCSI, 

Dublin 2, Ireland, 3 Dublin Academic Medical Centre, St. 

Vincent’s University Hospital, Dublin, Ireland 

2349. Corticosterois Therapy Restaured Treg/Th17 Balance in 

Patients with Polimyalgia Rheumatica. Lorena Alvarez- 

Rodriguez 1 , Marcos Lopez-Hoyos 1 , Jaime Calvo-Alen 2 , Elena 

Aurrecoechea 3 , Teresa Ruiz Jimeno 3 , Ignacio Villa 3 , Carmen 

Gonzalez-Vela 1 and Victor M. Martinez-Taboada 1 , 1 Hospital 

Universitario Marques de Valdecilla. IFIMAV, Santander, 

Spain, 2 Hospital Universitario Sierrallana, Torrelavega, Spain, 

3 

Hospital de Sierrallana, Torrelavega, Spain 

2350. Similarities Exceeds Differences in the Pattern of Joint and 

Vascular Positron Emission/Computed Tomography Uptake 

in Polymyalgia Rheumatica and Giant Cell Arteritis. Dario 

Camellino 1 , Silvia Morbelli 2 , Francesco Paparo 3 , Michela 

Massollo 2 , Gianmario Sambuceti 2 and Marco A. Cimmino 1 , 

1 

Clinica Reumatologica, Genova, Italy, 2 Medicina Nucleare, 

Genova, Italy, 3 E.O. Ospedali Galliera, Genoa, Italy 

2351. Correlation between Hypoechoic Halo of the Temporal 

Arteries and Clinical, Laboratory, and Temporal Artery 

Biopsy Findings in Patients with Giant Cell Arteritis. 

Luigi Boiardi 1 , Giulia Pazzola 1 , Alberto Cavazza 1 , Francesco 

Muratore 1 , Giovanna Restuccia 1 , Alberto Nicolini 1 , Giuseppe 

Germanò 2 , Nicolo Pipitone 1 , Pierluigi Macchioni 1 , Niccolò 

Possemato 1 , Gianluigi Bajocchi 3 , Ilaria Padovano 1 , Olga 

Addimanda 1 , Alberto Lo Gullo 1 , Maria Grazia Catanoso 1 and 

Carlo Salvarani 3 , 1 Arcispedale S Maria Nuova, IRCCS, Reggio 

Emilia, Italy, 2 Arcispedale S Maria Nuova, Reggio Emilia, Italy, 

3 

Arcispedale S Maria Nuova. IRCCS, Reggio Emilia, Italy 

2352. Temporal Artery Biopsy Culture in Tridimensional Matrix. 

An in Vitro Model for Functional Studies in Giant-Cell 

Arteritis. Marc Corbera Bellalta 1 , Ester Planas Rigol 1 , Ester 

Lozano 1 , Marco A. Alba 2 , Itziar Tavera-Bahillo 1 , Sergio Prieto- 

González 1 , Georgina Espígol Frigolé 1 , Montserrat Butjosa 1 , 

José Hernández-Rodríguez 1 , Ana García-Martínez 2 and Maria 



310 

C. Cid 3 , 1 Hospital Clinic University Barcelona, Barcelona, 

Spain, 2 Vasculitis Research Unit. Hospital Clínic. University of 

Barcelona. IDIBAPS, Barcelona, Spain, 3 Vasculitis Research 

Unit. Department of Autoimmune Diseases. Hospital Clínic. 

University of Barcelona. IDIBAPS, Barcelona, Spain 

2353. TLR2 Activation by Acute Serum Amyloid A Induces Pro- 

Inflammatory Mechanisms in a Novel Ex Vivo Temporal 

Artery Explant Culture/Model of Giant Cell Arteritis. 

Peadar Rooney 1 , Danielle Molloy 1 , Jennifer McCormick 1 , 

Mary Connolly 1 , Sinead M. Miggin 2 , Ashwini Maratha 2 , 

Douglas J. Veale 3 , Conor Murphy 4 , Eamonn S. Molloy 3 

and Ursula Fearon 5 , 1 Dublin Academic Medical Centre, 

Dublin, Ireland, 2 Immune Signalling Laboratory, Maynooth, 

Ireland, 3 Dublin Academic Medical Centre, St. Vincent’s 

University Hospital, Dublin, Ireland, 4 Royal Victoria Eye and 

Ear Hospital, Dublin, Ireland, 5 Translation Research Group, 

Dublin Academic Medical Centre, St. Vincent’s University 


2354. The Prevalence of Low Bone Mineral Density in 

Patients with New Onset Giant Cell Arteritis. Do They 

Get Appropriate Bone Protective Treatment? Andreas 

P. Diamantopoulos and Glenn Haugeberg, Hospital of 

Southern Norway HF, Kristiansand, Norway 

2355. Increase in Duration and Cumulative Dose of 

Glucocorticoid Therapy in Recent Decades: Observations 

From a Population-Based Cohort of Patients with Giant Cell 

Arteritis. P. Deepak Udayakumar, Tanaz A. Kermani, Kenneth 

J. Warrington, Cynthia S. Crowson and Eric L. Matteson, 


2356. Visual Manifestations in Giant Cell Arteritis: Trend Over 

Five Decades. Abha G. Singh 1 , Cynthia S. Crowson 1 , Tanaz 

A. Kermani 2 , Cornelia M. Weyand 3 , Eric L. Matteson 1 and 

Kenneth J. Warrington 1 , 1 Mayo Clinic, Rochester, MN, 

2 

University of California Los Angeles, Los Angeles, 3 Stanford 

University School of Medicine, Stanford, CA 

2357. Relapses in Patients with Giant-Cell Arteritis: Prevalence, 

Characteristics and Associated Clinical Findings in a 

Prospectively Followed Cohort of 106 Patients. Marco A. 

Alba 1 , Ana García-Martínez 1 , Itziar Tavera-Bahillo 1 , Sergio 

Prieto-González 1 , Montserrat Butjosa 2 , Georgina Espígol 3 , 

Marc Corbera 3 , Ester Planas 3 , Jose Hernandez-Rodriguez 4 

and Maria C. Cid 5 , 1 Vasculitis Research Unit. Hospital Clínic. 

University of Barcelona. IDIBAPS, Barcelona, Spain, 2 Hospital 

Clinic University Barcelona, Barcelona, Spain, 3 Vasculitis 

research unit. Hospital Clínic. University of Barcelona. 

IDIBAPS, Barcelona, Spain, 4 Hospital Clínic. University of 




2358. Large Vessel Giant Cell Arteritis: A Cohort Study. Francesco 

Muratore 1 , Tanaz A. Kermani 2 , Cynthia S. Crowson 3 , Abigail 

B. Green 3 , Eric L. Matteson 3 and Kenneth J. Warrington 3 , 

1 

Arcispedale S Maria Nuova, Reggio Emilia, Italy, 2 University 

of California Los Angeles, Los Angeles, 3 Mayo Clinic, 

Rochester, MN 


2359. Outcome of Aortic Involvement in GIANT CELL Arteritis 

(GCA) After 1-Year Follow-up: Prospective Study in 35 

Patients Using Computed Tompography Angiography 

(CTA). Sergio Prieto-González 1 , Pedro Arguis 1 , Ana García- 

Martínez 1 , Itziar Tavera-Bahillo 1 , Marc Corbera-Bellalta 1 , 

Marco A. Alba 1 , Georgina Espígol-Frigolé 1 , Ester Planas- 

Rigol 1 , José Hernández-Rodríguez 1 and Maria C. Cid 2 , 

1 

Vasculitis Research Unit. Hospital Clínic. University of 




2360. Prevalence, Management and Outcomes of PET Positive 

Large Vessel Vasculitis in Difficult to Treat PMR and GCA 

Patients. Pravin Patil 1 , Shaifali Jain 1 , Katerina Achilleos 1 , 

Tochukwu Adizie 1 , Mark Williams 1 , Matthew Tam 1 and 

Bhaskar Dasgupta 2 , 1 Southend University Hospital, Westcliff 

on sea, United Kingdom, 2 Southend University Hospital, 

Westcliff-on-Sea, United Kingdom 

2361. Misdiagnosis of Giant Cell Arteritis Presenting As Fever 

of Unknown Origin. Chiara Stagnaro, Rosaria Talarico, 

Claudia Ferrari, Anna d’Ascanio and Stefano Bombardieri, 

Rheumatology Unit, University of Pisa, Pisa, Italy 

2362. Evaluation of Disease Activity Using FDG PET-CT in Patients 

with Large Vessel Vasculitis. Giulia Pazzola 1 , Luca Magnani 1 , 

Luigi Boiardi 1 , Nicolo Pipitone 1 , Annibale Versari 1 , Debora 

Formisano 1 , Olga Addimanda 1 , Riccardo Meliconi 2 , Lia 

Pulsatelli 3 , Gianluigi Bajocchi 1 , Pierluigi Macchioni 1 , Maria 

Grazia Catanoso 1 , Niccolò Possemato 1 , Ilaria Padovano 1 , 

Alberto Lo Gullo 1 and Carlo Salvarani 4 , 1 Arcispedale S Maria 

Nuova, IRCCS, Reggio Emilia, Italy, 2 Istituto Ortopedico 

Rizzoli, University of Bologna, Bologna, Italy, 3 Istituto 

Ortopedico Rizzoli, Bologna, Italy, 4 Arcispedale S Maria 

Nuova. IRCCS, Reggio Emilia, Italy 

2363. Assessment of Disease Activity in Large Vessel Vasculitis: 

Initial Results of an International Delphi Exercise. Sibel 

Z. Aydin 1 , Haner Direskeneli 2 , Eric L. Matteson 3 and Peter 

A. Merkel 4 , 1 Medeniyet University, Goztepe Training and 

Research Hospital, Istanbul, Turkey, 2 Marmara University, 

School of Medicine, Istanbul, Turkey, 3 Mayo Clinic, 

Rochester, MN, 4 University of Pennsylvania, Philadelphia, PA 

2364. CROSS-Sectional Assessment of Damage in Takayasu 

Arteritis with A Validated Tool. Ahmet Omma 1 , Burak Erer 1 , 

Omer Karadag 2 , Neslihan Yilmaz 3 , Fatma Alibaz-Oner 3 , Fatih 

Yildiz 4 , Melike Kalfa 5 , Gezmis Kimyon 6 , Sedat Kiraz 2 , Haner 

Direskeneli 3 , Eren Erken 4 , Kenan Aksu 5 , Ahmet Mesut Onat 6 , 

Ahmet Gul 1 , Lale Ocal 1 , Murat Inanc 1 and Sevil Kamali 1 , 

1 

Istanbul University, Istanbul Faculty of Medicine, Istanbul, 

Turkey, 2 Hacettepe University, Faculty of Medicine, Ankara, 

Turkey, 3 Marmara University, Faculty of Medicine, Istanbul, 

Turkey, 4 Cukurova University, Faculty of Medicine, Adana, 

Turkey, 5 Ege University, Faculty of Medicine, Izmir, Turkey, 

6 

Gaziantep University, Faculty of Medicine, Gaziantep, 

Turkey 

2365. Asymptomatic Myocardial Ischemic Disease in Takayasu’s 

Arteritis. Chloe Comarmond 1 , Odile Dessault 2 , jean-Yves


Devaux 2 , Nathalie Costedoat-Chalumeau 3 , Mathieu Resche 

Rigon 4 , Richard Isnard 5 , Fabien Koskas 6 , Patrice Cacoub Sr. 7 

and David Saadoun 3 , 1 Hôpital Pitié Salpétrière, Paris, France, 

2 

Groupe Hospitalier Saint-Antoine, Paris, France, 3 Assistance 


France, 4 Department of Internal Medicine and Laboratory 

I3 “Immunology, Immunopathology, Immunotherapy”, 

UMR CNRS 7211, INSERM U959, Groupe Hospitalier 

Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 

6 

, Paris, France, Paris, France, 5 Department of Cardiology, 

CHU Pitié-Salpêtrière, 47-83 Boulevard de l’hôpital, 75651 

Paris Cedex 13, Paris, France, Paris, France, 6 Department 

of Internal Medicine and 2Laboratory I3 « Immunology, 

Immunopathology, Immunotherapy », UMR CNRS 7211, 

INSERM U959, Groupe Hospitalier Pitié-Salpetrière, 

Université Pierre et Marie Curie, Paris 6 , Paris, France, Paris, 

France, 7 CHU Pitié-Salpêtrière, Paris, France 

2366. Aortic and Coronary Calcifications in Takayasu Arteritis. 

Emire Seyahi 1 , Ayca Ucgul 2 , Serdal Ugurlu 1 , Canan Akman 3 , 

Deniz Cebi Olgun 3 , Sebahattin Yurdakul 1 and Hasan Yazici 1 , 

1 

Istanbul University, Cerrahpasa Medical Faculty, Istanbul, 

Turkey, 2 University of Istanbul, Cerrahpasa Medical Faculty, 

Istanbul, Turkey, 3 Istanbul University, Cerrahpasa Medical 

School, Istanbul, Turkey 

2367. Presence of Fibromyalgia and Fatigue Is Not Increased 

in Patients with Takayasu’s Arteritis. Fatma Alibaz- 

Oner, Meryem Can, Birkan Ilhan, Ozge Polat and Haner 

Direskeneli, Marmara University, School of Medicine, 


2368. Tocilizumab in Refractory Takayasu’s Arteritis: 7 Patients 

Followed At a Single Italian Centre. Enrico Tombetti, Elena 

Baldissera, Stefano Franchini, Patrizia Aiello, Francesca 

Motta, Barbara Gulgielmi and Maria Grazia Sabbadini, Vita- 

Salute San Raffaele University, Milan, Italy 

2369. Aspects of Innate Immunity in Behçet´s Disease: A Model 

of Autoinflammatory Disease? Sandro F. Perazzio 1 , Paulo 

Vitor Soeiro Pereira 2 , Alexandre Wagner S. de Souza 3 , 

Antonio Condino-Neto 2 and Luis Eduardo C. andrade 4 , 

1 

Federal University of Sao Paulo, Sao Paulo, Brazil, 2 USP, 

São Paulo, Brazil, 3 University Medical Center Groningen, 


4 

Universidade Federal de São Paulo, Sao Paulo, Brazil 

2370. A Genome-Wide DNA Methylation Study Identifies 

Significant Epigenetic Changes Across the Genome and in 

Multiple HLA Loci in Behcet’s Disease. Haner Direskeneli 1 , 

Patrick S. Coit 2 , Filiz Ture-Ozdemir 1 , Fatma Alibaz-Oner 1 , 

Guher Saruhan-Direskeneli 3 , Matlock A. Jeffries 4 and Amr 

H. Sawalha 2 , 1 Marmara University, School of Medicine, 

Istanbul, Turkey, 2 University of Michigan, Ann Arbor, MI, 

3 

Istanbul University, Istanbul Faculty of Medicine, Istanbul, 

Turkey, 4 University of Oklahoma and Oklahoma Medical 

Research Foundation, Oklahoma City, OK 

2371. The Unmet Need in Behcet’s Disease: Most Patients Are 

Not in Complete Remission in the Long-Term Follow-up. 

Fatma Alibaz-Oner 1 , Gonca Mumcu 2 , Gülsen Ozen 3 , Zeynep 

Kubilay 1 , Meryem Can 1 , Sibel Yýlmaz Oner 1 , Tülin Ergun 4 

and Haner Direskeneli 1 , 1 Marmara University, School of 

Medicine, Istanbul, Turkey, 2 Marmara University,Faculty 

of Health Sciences, Department of Health Informatics and 

Technologies, Istanbul, Turkey, 3 Marmara University, School 

of Medicine., Istanbul, Turkey, 4 Marmara University School 

of Medicine, Istanbul, Turkey 

2372. Efficacy of Quantitative Analysis of Brainstem Atrophy 

On Magnetic Resonance Imaging for Diagnosis of Chronic 

Progressive Neuro-Behçet’s Disease. Hirotoshi Kikuchi 1 , 

Maki Takayama 2 , Yoshitaka Kimura 2 , Kurumi Asako 2 , Hajime 

Kono 2 , Yasuo Ono 1 and Shunsei Hirohata 3 , 1 Teikyo University 

Shool of Medicine, Tokyo, Japan, 2 Teikyo University School 

of Medicine, Tokyo, Japan, 3 Kitasato University School of 

Medicine, Sagamihara, Japan 

2373. The Clinical Course of the Acute Deep Vein Thrombosis 

of the Legs in Behçet’s Syndrome. Yesim Ozguler 1 , Melike 

Melikoglu 2 , Firat Cetinkaya 3 , Serdal Ugurlu 4 , Emire Seyahi 5 , 

Koray Tascilar 4 and Hasan Yazici 2 , 1 Istanbul University, 

Cerrahpasa Medical School, Rheumatology, Istanbul, 

Turkey, 2 Rheumatology, Istanbul, Turkey, 3 Istanbul, Turkey, 

4 

Istanbul University Cerrahpasa Medical Faculty, Istanbul, 

Turkey, 5 Cerrahpasa Faculty of Medicine, Istanbul University, 


2374. Characteristics, Treatment and Outcome of Gastrointestinal 

Involvement in Behcet’s Syndrome: Experience in A 

Dedicated Center. Ibrahim Hatemi 1 , Gulen Hatemi 2 , Yusuf 

Erzin 1 , Aykut Ferhat Celik 1 and Hasan Yazici 3 , 1 Istanbul 

University, Cerrahpasa Medical School, Gastroenterology, 

Istanbul, Turkey, 2 Istanbul University, Cerrahpasa Medical 

Faculty, Rheumatology, Istanbul, Turkey, 3 Istanbul University, 

Cerrahpasa Medical School, Rheumatology, Istanbul, Turkey 

2375. WHAT Affects the Quality of Life in Patients with BEHCET’S 

Disease? Mehmet Melikoglu 1 and Meltem Alkan Melikoglu 2 , 

1 

Health Ministry Erzurum Regional Training and Research 

Hospital, Erzurum, Turkey, 2 Ataturk University School of 

Medicine, Erzurum, Turkey 

2376. Behcet’s Disease: Combination of Pulse 

Cyclophosphamide, Azathioprine, and Prednisolone for the 

Treatment of Retinal Vasculitis; Longitudinal Study On 10 

Years. Fereydoun Davatchi, Farhad Shahram, Bahar Sadeghi 

Abdollahi, Hormoz Shams, Abdolhadi Nadji, Massoomeh 

Akhlaghi, Tahereh Faezi and Farimah Ashofteh, Shariati 

Hospital-Tehran Univ, Tehran, Iran 

2377. Impaired Endothelial Function in Patients with Takayasu’s 

Arteritis. Fatma Alibaz-Oner 1 , Selen Yurdakul 2 , Yelda 

Tayyareci 2 , Saide Aytekin 2 and Haner Direskeneli 1 , 1 Marmara 

University, School of Medicine, Istanbul, Turkey, 2 ISTANBUL 

FLORENCE NIGHTINGALE HOSPITAL, Istanbul, Turkey 

2378. Evaluation of the EULAR/ACR 2012 Classification Criteria 

for Polymyalgia Rheumatica: Comparison of the New 

Algorithms with and without Ultrasound to the Formerly 

Used Criteria. Sandra Balser 1 , Wolfgang Hartung 1 , 



Emmanuelle LeBras 1 , Boris P. Ehrenstein 1 , Martina Müller 2 

and Martin Fleck 1 , 1 Asklepios Klinikum Bad Abbach, 

Bad Abbach, Germany, 2 University Clinic Regensburg, 

Regensburg 

2379. Successful Treatment of Churg-Strauss Syndrome with 

Rituximab. Christin Dubrau 1 , Fabian Arndt 2 , Wolfgang L. 

Gross and Frank Moosig 2 , 1 University Hospital Schleswig- 

Holstein, Campus Luebeck and Klinikum Bad Bramstedt, Bad 

Bramstedt, Germany, 2 University Hospital Schleswig Holstein 

and Klinikum Bad Bramstedt, Bad Bramstedt, Germany 

2380. High Frequency of Ferritin Autoantibodies in Takayasu 

Arteritis. Niklas T. Baerlecken 1 , Katherina Große 2 , Frank 

Moosig 3 , Wolfgang L. Gross 4 , Reinhold E. Schmidt 5 and 

Torsten Witte 6 , 1 MD, Hannover, Germany, 2 Student, 

Hannover, Germany, 3 Stormarnzing 15 6 , Bad Bramstedt, 

Germany, 4 Medical University at Lubeck, Lubeck, Germany, 

5 

Hannover Medical School, Hannover, Germany, 6 Hannover 

Medical School, Hanover, Germany 

2381. Serum Level of IL-3 3 and Soluble ST 2 and Their Association 

with Disease Activity in Patients with Behcet’s Disease. 

Dae-Jun Kim 1 , Jae-Ho Lee 1 , Ji Hyeon Ju 1 , Sung-Hwan Park 2 , 

Ho-Youn Kim 1 and Seung-Ki Kwok 1 , 1 The Catholic University 

of Korea, Seoul St. Mary’s Hospital, Seoul, South Korea, 

2 

Catholic University of Korea, Seoul, South Korea 

2382. Plasma Fibrinogen is an Accurate Marker of Disease 

Activity in Patients with Polymyalgia Rheumatica. E.M. 

McCarthy 1 , Paul A. MacMullan 1 , S. Al-Mudhaffer 1 , Anne 

M. Madigan 1 , S. Donnelly 1 , C. J. McCarthy 1 , Dermot 

Kenny 2 , Eamonn S. Molloy 3 and G M. McCarthy 1 , 1 Mater 

Misericordiae University Hospital, Dublin 7 , Ireland, 2 RCSI, 

Dublin 2, Ireland, 3 Dublin Academic Medical Centre, St. 

Vincent’s University Hospital, Dublin, Ireland 

2383. Rituximab as Induction and Maintenance Therapies for 

ANCA-Associated Vasculitis: A Multicenter Retrospective 

Study On 80 Patients. Pierre Charles 1 , Antoine Néel 2 , 

Nathalie Tieulié 3 , Arnaud Hot Sr. 4 , Grégory Pugnet 5 , 

Olivier Decaux 6 , Isabelle Marie 7 , Mehdi Khellaf 8 , Jean- 

Emmanuel Kahn 9 , Alexandre Karras 10 , Jean-Marc Ziza 11 , 

Christophe Deligny 12 , Colas Tchérakian 13 and Loic Guillevin 1 , 

1 

Department of Internal Medicine, Referral Center for Rare 

Autoimmune and Systemic Diseases, Hôpital Cochin, AP– 

HP, Université Paris Descartes, Paris, France, Paris, France, 

2 

Internal Medicine, Nantes University Hospital, Nantes, 

France, 3 Service de Médecine onterne, CHU Nice, Nice, 

France, 4 Lyon hospital, Lyon, France, 5 Toulouse University 

Hospital, University of Toulouse, INSERM UMR 1027, 

Toulouse, France, 6 Hôpital Sud, Rennes, France, 7 Service 

de médecine interne, CHU de Rouen, Rouen, France., 

Rouen, France, 8 Service de médecine interne, Université 

Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, 

Creteil, France, 9 Internal Medicine, Foch Hospital, Suresnes, 

France, 10 Hôpital Européen Georges Pompidou, APHP, 

Paris, France, 11 Hopital Croix Saint Simon, Paris, France, 

12 

Centre hospitalier Universitaire de Fort de France, Fort de 

France, Martinique, 13 Service de pneumologie, hôpital Foch, 

Suresnes, France 

2384. Giant Cell Arteritis and Cardiovascular Events in the French 

Apogee Cohort. A Population-Based Study Using the French 

Health Insurance System Database. Grégory Pugnet 1 , 

Laurent Sailler 2 , Robert Bourrel 3 , Jean-Louis Montastruc 4 

and Maryse Lapeyre-Mestre 4 , 1 Toulouse University 

Hospital, University of Toulouse, INSERM UMR 1027, 

Toulouse, France, 2 Toulouse University Hospital, University 

of Toulouse, INSERM UR 1027, Toulouse, France, 3 Caisse 

Nationale de l’Assurance Maladie échelon régional, Midi- 

Pyrénées, Toulouse, France, 4 Toulouse University Hospital, 

INSERM U1027, University of Toulouse, France, Toulouse, 

France 

2385. Prognostic Impact of HLA-B*51 and HLA-A*26:01 On 

Ocular Behcet’s Disease. Jun Won Park 1 , Eun Ha Kang 2 , Hye 

Won Kim 1 , Chaerin Park 1 , Hyeong Gon Yu 1 , Eun Young Lee 1 , 

Yun Jong Lee 2 , Eun Bong Lee 1 and Yeong Wook Song 1 , 1 Seoul 

National University Hospital, Seoul, South Korea, 2 Seoul 

National University Bundang Hospital, Seongnam-si, South 

Korea 

2386. Disability and Mortality Related to Cerebrovascular 

Disease in Systemic Vasculitis. Jamal Mikdashi and Marcia 

Wozniak, University of Maryland School of Medicine, 

Baltimore, MD 

2387. Takayasu’s Arteritis: Features and Management of 216 

Patients in China. Xia Liu 1 , Tao Zhang 2 , Xiaofeng Zhuang 3 , 

Kai Yuan 1 , Xiaoming Shu 1 and Guochun Wang 1 , 1 China-Japan 

Friendship Hospital, Beijing, China, 2 Chinese PLA General 

Hospital, Beijing, China, 3 FuWai Hospital and Cardiovascular 

Institute, Beijing, China 

2388. Urticarial Vasculitis: Clinical Study. Javier Loricera 1 , Vanesa 

Calvo-Rio 1 , Francisco Ortiz Sanjuan 1 , Marcos Antonio 

Gonzalez-Lopez 1 , Hector Fernandez-Llaca 1 , Javier Rueda- 

Gotor 1 , Carmen Gonzalez-Vela 1 , Cristina Mata-Arnaiz 2 , Jose 

Luis Peña-Sagredo 1 , Miguel A. Gonzalez-Gay 1 and Ricardo 

Blanco 1 , 1 Hospital Universitario Marqués de Valdecilla. 

IFIMAV, Santander, Spain, 2 Hospital Laredo, Santander, Spain 

2389. Cutaneous Leukocytoclastic Angiitis: Study of 173 Patients. 

Javier Loricera, Vanesa Calvo-Rio, Francisco Ortiz-Sanjuan, 

Marcos Antonio Gonzalez-Lopez, Hector Fernandez-Llaca, 

Javier Rueda-Gotor, Carmen Gonzalez-Vela, Miguel A. 

Gonzalez-Gay and Ricardo Blanco, Hospital Universitario 

Marqués de Valdecilla. IFIMAV, Santander, Spain 

2390. Color Doppler Ultrasonography an Alternative to CT/MR 

Angiography for Identifying Large Vessel Involvement 

in Giant Cell Arteritis? Andreas P. Diamantopoulos 1 , 

Glenn Haugeberg 1 and Geirmund Myklebust 2 , 1 Hospital of 

Southern Norway HF, Kristiansand, Norway, 2 Hospital of 

Southern Norway, Kristiansand, Norway 

2391. New Disease Manifestations after Diagnosis in Six Types 

of Vasculitis. Peter C. Grayson 1 , David Cuthbertson 2 , 

Simon Carette 3 , Gary S. Hoffman 4 , Nader A. Khalidi 5 , Curry 

312 

2012 Program Book


L. Koening 6 , Carol A. Langford 4 , Kathleen Maksimowicz- 

McKinnon 7 , Paul A. Monach 8 , Philip Seo 9 , Ulrich Specks 10 , 

Steven R. Ytterberg 10 and Peter A. Merkel 11 , 1 Boston 

University Medical Center, Boston, MA, 2 University of South 

Florida, Tampa, FL, 3 UHN/MSH, Toronto, ON, 4 Cleveland 

Clinic, Cleveland, OH, 5 McMaster University, Hamilton, 

ON, 6 Salt Lake City Veterans Administration, Salt Lake 

City, UT, 7 University of Pittsburgh, Pittsburgh, PA, 8 Boston 

University, Boston, MA, 9 Johns Hopkins Vasculitis Center, 

Baltimore, MD, 10 Mayo Clinic, Rochester, MN, 11 University of 


2392. Blood Vessel Instability and Oxidative Damage in Giant 

Cell Arteritis. Danielle Molloy 1 , Jennifer McCormick 1 , Mary 

Connolly 1 , Muhammad Haroon 1 , Douglas J. Veale 1 , Conor 

Murphy 2 , Ursula Fearon 1 and Eamonn S. Molloy 1 , 1 Dublin 

Academic Medical Center, St. Vincent’s University Hospital, 

Dublin, Ireland, 2 Royal Victoria Eye and Ear Hospital, Dublin, 

Ireland 

2393. High Mobility Group Box 1 Levels Are Not Associated 

with Subclinical Carotid Atherosclerosis in Patients with 

Granulomatosis with Polyangiitis but Are Reduced by 

Glucocorticoids and Statins. Alexandre Wagner S. de Souza 1 , 

Karina de Leeuw 1 , Johanna Westra 2 , andries J. Smit 1 , Anne 

Marijn van der Graaf 2 , Hans L. A. Nienhuis 1 , Johan Bijzet 1 , 

Pieter C. Limburg 2 , Coen A. Stegeman 2 , Marc Bijl 3 and Cees 

G.M. Kallenberg 2 , 1 University Medical Center Groningen, 


2 


Netherlands, 3 Martini Hospital, Groningen, Netherlands 

2394. Fibromyalgia in Behçet’s Disease Is Associated with Disease 

Activity. Meryem Can 1 , Fatma Alibaz-Öner 2 , Sibel Yılmaz- 

Öner 1 , Birkan İlhan 1 , Tülin Ergun 1 , Gonca Mumcu 3 and Haner 

Direskeneli 1 , 1 Marmara University School of Medicine, 

Istanbul, Turkey, 2 Marmara University School of Medicine, 

Turkey, 3 Marmara University,Faculty of Health Sciences, 

Department of Health Informatics and Technologies, 


2395. Body Composition, Strength, and Function in Elderly 

Patients with Giant Cell Arteritis. Rebecca L. Manno 1 , 

Allan C. Gelber 1 , Philip Seo 2 , Stuart M. Levine 1 , Sharon R. 

Ghazarian 3 , Po-Han Chen 3 , Kerry J. Stewart 1 , Jeffrey Metter 4 , 

Luigi Ferrucci 4 and Kevin R. Fontaine 5 , 1 Johns Hopkins 

University, Baltimore, MD, 2 Johns Hopkins Vasculitis Center, 

Baltimore, MD, 3 Baltimore, MD, 4 National Institute on Aging, 

Baltimore, MD, 5 The University of Alabama at Birmingham, 


2396. Higher Homocysteine Levels Are Associated with 

Ischemic Arterial Events Rather Than Disease Activity 

and the Extension of Arterial Involvement in Takayasu 

Arteritis. Alexandre W.S. Souza 1 , Carla S. Lima 2 , Ana Cecilia 

D. Oliveira 3 , Luiz Samuel G. Machado 3 , Frederico A. G. 

Pinheiro 3 , Sonia Hix 4 and Vânia D’Almeida 5 , 1 Escola Paulista 

de Medicina - Universidade Federal de São Paulo, Sao Paulo, 

Brazil, 2 Escola Paulista de Medicina - Universidade Federal 

de São Paulo, São Paulo, Brazil, 3 Universidade Federal de 

São Paulo, São Paulo, Brazil, 4 Universidade Federal de 

São Paulo - Escola Paulista de Medicina, São Paulo, Brazil, 

5 

Universidade Federal de São Paulo- Escola Paulista de 

Medicina, São Paulo, Brazil 

2397. Urinary Biomarkers in Vasculitis Associated with Anti- 

Neutrophil Cytoplasmic Antibodies. Jason G. Lieberthal 1 , 

David Cuthbertson 2 , Simon Carette 3 , Gary S. Hoffman 4 , 

Nader A. Khalidi 5 , Curry L. Koening 6 , Carol A. Langford 4 , 

Kathleen Maksimowicz-McKinnon 7 , Philip Seo 8 , Ulrich 

Specks 9 , Steven R. Ytterberg 9 , Peter A. Merkel 10 and Paul 

A. Monach 11 , 1 Boston University School of Medicine, 

Boston, MA, 2 University of South Florida, Tampa, FL, 

3 

UHN/MSH, Toronto, ON, 4 Cleveland Clinic, Cleveland, 

OH, 5 McMaster University, Hamilton, ON, 6 Salt Lake City 

Veterans Administration, Salt Lake City, UT, 7 University of 

Pittsburgh, Pittsburgh, PA, 8 Johns Hopkins Vasculitis Center, 

Baltimore, MD, 9 Mayo Clinic, Rochester, MN, 10 University of 

Pennsylvania, Philadelphia, PA, 11 Boston University, Boston, 

MA 

2398. Pauci-Immune Glomerulonephritis in the Elderly: Disease 

Severity and Outcomes. Rebecca L. Manno 1 , Duvuru 

Geetha 1 , Stuart M. Levine 1 , Philip Seo 2 and Allan C. Gelber 1 , 

1 

Johns Hopkins University, Baltimore, MD, 2 Johns Hopkins 

Vasculitis Center, Baltimore, MD 


2399. Exercise on Prescription: Barriers to Participation in 

Community Based Exercise Programmes. Dr Nicola E. 

Walsh 1 and Professor Mike Hurley 2 , 1 University of the West 

of England, Bristol, United Kingdom, 2 St George’s University 

of London, London, United Kingdom 

2400. Hospital for Special Surgery Osteoarthritis Wellness 

Initiative: the Impact of a Hospital-Based Exercise Program 

On Osteoarthritis. Sandra Goldsmith, Dana Friedman, Linda 

Roberts, Dana Sperber and Laura Robbins, Hospital for 

Special Surgery, New York, NY 

2401. An International Framework for Chronic Condition Self 

Management Support: Results from an International 

Electronic Consultation Process. Teresa J. Brady 1 , Sue Mills 2 , 

Peter Sargious 3 and Shabnam Ziabakhsh 4 , 1 Centers for 

Disease Control and Prevention, Atlanta, GA, 2 University of 

British Columbia, Vancouver, BC, 3 Alberta Health Services, 

Calgary, AB, 4 BC Women’s Hospital & Health Centre, 

Vancouver, BC 

2402. Clinical Utility of the Hospital Anxiety and Depression 

Scale for an Outpatient Fibromyalgia Education Program. 

Diane Tin 1 , Lorna J. Bain 1 , J. Carter Thorne 1 , Seungree Nam 2 

and Liane Ginsburg 2 , 1 Southlake Regional Health Centre, 

Newmarket, ON, 2 York University, Toronto, ON 

2403. The Effect of a Rheumatoid Arthritis Peer Support Program 

On Clinical Outcomes. Rebecca Thrower 1 , Christine K. 

Iannaccone 1 , Hsun Tsao 2 , Michael Weinblatt 3 , Jing Cui 4 

and Nancy A. Shadick 5 , 1 Brigham and Women’s Hospital, 



Boston, MA, 2 Brigham and Women’s Hospital, Harvard 

Medical School, Boston, MA, 3 Rheumatology & Immunology, 

Brigham & Women’s Hospital, Boston, MA, 4 Brigham and 

Womens Hospital, Boston, MA, 5 Department of Medicine, 

Division of Rheumatology, Immunology and Allergy, Brigham 


2404. Cardiovascular Disease Prevention Counseling Program for 

Systemic Lupus Erythematosus and/or Antiphospholipid 

Antibody Positive Patients: Two-Year Preliminary Analysis 

of Diet and Exercise Habits. Virginia Haiduc, Monica C. 

Richey, Sotiria Everett, Aeshita Dwivedi, Lisa Konstantellis, 

Hassan Ghomrawi and Doruk Erkan, Hospital for Special 

Surgery, New York, NY 

2405. A Proof-of-Concept Study of an Animated, Web-Based 

Methotrexate Decision Aid for Patients with Rheumatoid 

Arthritis. Linda C. Li 1 , Paul M. Adam 2 , Catherine L. 

Backman 1 , Sydney Brooks 3 , Gwen A. Ellert 4 , Allyson Jones 5 , 

Otto Kamensek 6 , Cheryl Koehn 7 , Diane Lacaille 6 , Colleen 

Maloney 6 , Anne F. Townsend 6 , Elaine Yacyshyn 5 , Charlene 

Yousefi 6 and Dawn Stacey 8 , 1 University of British Columbia, 

Vancouver, BC, 2 Mary Pack Arthritis Centre, Vancouver, 

BC, 3 The Arthritis Society, Ontario Division, Toronto, 4 Trelle 

Enterprises Inc, Vancouver, BC, 5 University of Alberta, 

Edmonton, AB, 6 Arthritis Research Centre of Canada, 

Vancouver, BC, 7 Vancouver, BC, 8 University of Ottawa, 

Ottawa, ON 

2406. Implementation of a Pilot Nutrition Education Intervention 

for Culturally Diverse Teens with Lupus and Their Families 

in Hospital for Special Surgery’s Charla De Lupus /Lupus 

Chat® Teen and Parent Support Group. Jillian A. Rose 1 , 

Roberta Horton 1 , Dariana M. Pichardo 2 , Dana Friedman 1 , 

Robyn Wiesel 1 , Sandra Goldsmith 1 , Sotiria Everett 1 and Lisa 

F. Imundo 3 , 1 Hospital for Special Surgery, New York, NY, 

2 

Hospital For Special Surgery, New York, NY, 3 Morgan Stanely 

Children’s Hospital of New York-Presbyterian, Columbia 

University Medical Center, New York, NY 

2407. Perceptions of the Chronic Disease Self-Management 

Program Among Low Income African American Women 

with Lupus. Charmayne M. Dunlop-Thomas, Terrika Barham, 

Natasha DeVeauuse Brown and Cristina Drenkard, Emory 

University, Atlanta, GA 

Epidemiology and Public Health 

2408. Effects of Ground and Joint Reaction Force Exercise On 

Bone Mineral Density in Postmenopausal Women: A 

Meta-Analysis of Randomized Controlled Trials. George A. 

Kelley 1 , Kristi S. Kelley 1 and Wendy M. Kohrt 2 , 1 West Virginia 

University, Morgantown, WV, 2 University of Colorado @ 

Denver, Aurora, CO 

2409. Work Productivity in a Population Based Cohort of 

Patients with Spondyloarthritis. Emma Haglund 1 , Ann B. 

I. Bremander 2 , Stefan Bergman 1 , Lennart TH Jacobsson 3 , 

Britta Strömbeck 4 and Ingemar F. Petersson 4 , 1 R&D Center 

Spenshult, Oskarstrom, Sweden, 2 Halmstad University 

School of Business and Engineering, Halmstad, Sweden, 

3 

Department of Rheumatology, Clinical sciences, Skane 

University Hospital, Malmö, Sweden, 4 Musculoskeletal 

Sciences, Department of Orthopedics, Clinical Sciences, 

Lund, Sweden 


2411. Obesity Is Associated with Higher Levels of Fatigue 

in RA. Patricia P. Katz 1 , Vladimir Chernitskiy 1 and Mary 

Margaretten 2 , 1 University of California San Francisco, San 

Francisco, CA, 2 UCSF, San Francisco, CA 

2412. Valdiation of a Diagnosis of Gout in the Epiccare Electronic 

Medical Records. Neera Narang 1 and Eswar Krishnan 2 , 

1 

Stanford Univ Medical Center, Stanford, CA, 2 Standford 

University, Palo Alto, CA 

2413. The Impact of Asymptomatic Vertebral Fractures On 

Quality of Life in Community-Dwelling Older Women: 

The Sao Paulo Ageing & Health Study (SPAH). Jaqueline 

B. Lopes 1 , Leandro Fung 2 , Carolina C. Cha 2 , Camille P. 

Figueiredo 2 , Liliam Takayama 2 , Valéria Caparbo 2 and Rosa 

M.R. Pereira 2 , 1 Hospital das Clínicas da Faculdade de 

Medicina da Universidade de São Paulo, São Paulo, Brazil, 

2 


Paulo, Brazil 

2414. Multisite Joint Pain and Fatigue: the Role of Pain Severity 

and Sleep Problems in Adults with Arthritis. Mayilee 

Canizares 1 and E.M. Badley 2 , 1 Division of Health Care and 

Outcomes Research. Toronto Western Research Institute, 

Toronto, ON, 2 Division of Health Care and Outcomes 

Research, Toronto Western Research Institute;Dalla Lana 

School of Public Health,University of Toronto, Toronto, ON 

2415. Does Interleukin-6 Mediate the Relation Between Estrogen 

and Bone? an Epidemiologic Approach in the Framingham 

Osteoporosis Study. Robert R. McLean 1 , Xiaochun Zhang 2 , 

Andrea D. Coviello 3 , Joao D.T. Fontes 4 , L. Adrienne Cupples 5 , 

Douglas P. Kiel 1 and Marian T. Hannan 1 , 1 Hebrew SeniorLife 

& Harvard Medical School, Boston, MA, 2 Hebrew Senior Life, 

Boston, MA, 3 Boston University School of Medicine, Boston, 

MA, 4 Framingham Heart Study and Boston University, 

Framingham, MA, 5 Boston University School of Public 

Health, Boston, MA 

2416. Arthritis-Attributable Interference in Routine Life Activities. 

Kristina A. Theis 1 , Teresa J. Brady 1 , Charles G. Helmick 1 , 

Louise Murphy 2 and Kamil E. Barbour 1 , 1 Centers for Disease 

Control and Prevention, Atlanta, GA, 2 CDC, Atlanta, GA 

2417. Transitioning to Adulthood: Employment Experiences 

of Young Adults with Lupus and Juvenile Arthritis. Arif 

Jetha 1 , E. M. Badley 2 , Dorcas Beaton 3 , Paul R. Fortin 4 , Natalie 

J. Shiff 5 , Alan M. Rosenberg 6 , Lori B. Tucker 7 , Dianne P. 

Mosher 8 and M. A. Gignac 9 , 1 Health Care and Outcomes 

Research, Toronto Western Research Institute; Dalla Lana 

School of Public Health, University of Toronto, Toronto, ON, 

2 

Division of Health Care and Outcomes Research,Toronto 

Western Research Institute; Dalla Lana School of Public 

314 

2012 Program Book


Health, University of Toronto, Toronto, ON, 3 Institute for 

Work & Health; Mobility Program, Clinical Research Unit, St. 

Michaels Hospital, Toronto, ON, 4 Division of Rheumatology, 

Centre de recherche du centre hospitalier universitaire de 

Québec, Faculté de médecine de L’université Laval, Quebec 

City, QC, 5 University of Saskatchewan, Saskatoon, SK, 6 Royal 

University Hospital, Saskatoon, SK, 7 BC Childrens Hospital, 

Vancouver, BC, 8 University of Calgary, Calgary, AB, 9 Health 

Care and Outcomes Research, Toronto Western Research 


Toronto; Institute for Work & Health, Toronto, ON 

2418. The Everyday Challenge of Living with Lupus. Brenda L. 

Frie, St. Catherine University, St. Paul, MN 

2419. Novel Candidate Genes for Structural Foot Disorders: A 

Genome-Wide Association Study in an Older Caucasian 

Population. Marian T. Hannan 1 , Yi-Hsiang Hsu 2 , Chia Ho 

Cheng 2 , Youfang Liu 3 and Joanne M. Jordan 4 , 1 Hebrew 

SeniorLife & Harvard Medical School, Boston, MA, 2 Hebrew 

SeniorLife & Harvard Med Sch, Boston, MA, 3 University of 

North Carolina, Chapel Hill, NC, 4 University of North Carolina 


Pediatrics 

2420. Frequent Self-Reported Pain and Disease Symptoms in 

Juvenile Idiopathic Arthritis Persist Despite Advances in 

Medication Therapies: An Electronic Diary Study. Maggie 

H. Bromberg 1 , Mark Connelly 2 , Kelly K. Anthony 3 , Karen M. 

Gil 1 and Laura E. Schanberg 3 , 1 University of North Carolina at 

Chapel Hill, Chapel Hill, NC, 2 Children’s Mercy Hospitals and 

Clinics, Kansas City, MO, 3 Duke University Medical Center, 

Durham, NC 

2421. The Pediatric Rheumatology Nursing Network: An 

International Email MANAGED COMMUNICATION System. 

Norma L. Liburd, All Children’s Hospital, St. Petersburg, FL 

Psychology/Social Sciences 

2422. Sexual Activity and Sexual Functioning Among Women 

with Systemic Sclerosis Compared to Women From a 

Population Sample. Brooke Levis 1 , Andrea Burri 2 , Marie 

Hudson 1 , Murray Baron 3 and Brett D. Thombs 1 , 1 McGill 

University, Montreal, QC, 2 King’s College, London, United 

Kingdom, 3 Jewish General Hospital, Montreal, QC 

2423. Perceptions Regarding Cardiovascular Risk Factors and 

Barriers to Risk Reduction Among African American 

Women with Lupus. Barron Mia 1 , Lynne Nemeth 1 , Diane 

L. Kamen 2 and Youlanda C. Gibbs 1 , 1 Medical University 

of South Carolina, Charleston, SC, 2 Arthritis & Clinical 

Immunology Program, Oklahoma Medical Research 

Foundation, Charleston, SC 

2424. Sleep Disturbances in Systemic Sclerosis: Evidence for the 

Role of Gastrointestinal Symptoms, Pain, and Pruritus. 

Katherine Milette 1 , Marie Hudson 1 , Annett Koerner 1 , Murray 

Baron 2 and Brett D. Thombs 1 , 1 McGill University, Montreal, 

QC, 2 Jewish General Hospital, Montreal, QC 

2425. A Qualitative Study of Self-Image and Body Image in 

Individuals with Systemic Lupus Erythematosus. Afton 

L. Hassett 1 , Diane C. Radvanski 2 and Elizabeth Hale 3 , 

1 

University of Michigan, Ann Arbor, MI, 2 Robert Wood 

Johnson Medical School, NJ, 3 Dudley Group NHS Foundation 

Trust, Dudley, United Kingdom 

2426. Prevalence and Characteristics of Sleep Problems in 

Rheumatoid Arthritis: A Systematic Review of the 

Literature. Cassandra Coleman and Yvonne C. Lee, Brigham 


2427. Health-Related Quality of Life in Adolescents with 

Rheumatic Disease. Sandra J. Watcher 1 , Maggie Sepkowitz 1 , 

Suhas M. Radhakrishna 2 , Anusha Ramanathan 3 , Elizabeth 

Morasso 3 , Jennifer Chang 3 and Jeffrey I. Gold 4 , 1 Children’s 

Hospital of LA, Los Angeles, CA, 2 Kaiser Permananete 

Medical Group, Oakland, CA, 3 Childrens Hospital Los 

Angeles, Los Angeles, CA, 4 Keck School of Medicine, 

University of Southern California - Children’s Hospital Los 

Angeles, Los Angeles, CA 

2428. Causal Beliefs of Disease among Patients with Systemic 

Vasculitis. Peter C. Grayson 1 , Naomi Amudala 1 , Carol 

McAlear 2 , Renée Leduc 3 , Denise Shereff 3 , Rachel Richesson 3 , 

Liana Fraenkel 4 and Peter A. Merkel 5 , 1 Boston University 

Medical Center, Boston, MA, 2 Vasculitis Clinical Research 

Consortium, University of Pennsylvania, Philadelphia, 

3 

University of South Florida, Tampa, FL, 4 Yale University 

School of Medicine, Veterans Affairs Connecticut Healthcare 

System, New Haven, CT, 5 University of Pennsylvania, 


2429. Balancing Work and Health: Do Younger Workers 

Experience More Work-Health Conflict Than Middle- and 

Older-Aged Workers with Rheumatic Diseases? Arif Jetha1, 

Xingshan Cao2 and Monique A. Gignac 3 , 1 Health Care and 

Outcomes Research, Toronto Western Research Institute; 

Dalla Lana School of Public Health, University of Toronto, 

Toronto, ON, 2 Arthritis Community Research and Evaluation 

Unit , Toronto Western Research Institute, Toronto, ON, 

3 

Arthritis Community Research and Evaluation Unit , Toronto 

Western Research Institute, University of Toronto and 

Institute for Work and Health, Toronto, ON 

2430. Using the Internet in Help-Seeking As Illness Develops 

in Early Rheumatoid Arthritis. Anne F. Townsend 1 , Jenny 

Leese 2 , Catherine L. Backman 3 , Paul M. Adam 4 and Linda 

C. Li 5 , 1 Arthritis Research Centre of Canada, Vancouver, 

BC, 2 Arthritis Research Centre, Vancouver, BC, 3 University 

of British Columbia, Vancouver, BC, 4 Mary Pack Arthritis 

Centre, Vancouver, BC, 5 Arthritis Centre of Canada and 

Department of Physical Therapy, University of British 

Columbia, Vancouver, BC 


INNOVATION THEATER 

These non-CME accredited presentations have been planned and will be implemented in accordance with the requirements of the FDA 

and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. 

All Innovation Theater presentations will be held in Hall A (Booth #1451) at their designated time. 


10:30 - 11:15 am 

ACTEMRA Monotherapy: From Clinical Trial Experience to 

Clinical Practice 

Presented by Genentech, a member of the Roche Group 

2:30 - 3:15 pm 

Role of Multi-Biomarker Test in RA Patient Management 

Presented by Crescendo Bioscience 

Monday, NOVEMBER 12, 2012 

10:30 - 11:15 am 

Rituxan RA - Pivotal and Long-term Efficacy and Safety Data 

Presented by Genentech, a member of the Roche Group 


10:30 - 11:15 am 

Evaluation of Clinical Endpoints for SLE Disease Activity in 

Worldwide Clinical Trials: Optimization of Treatment Effects 

through Targeted Training and Centralized Data Review 

Presented by ReSearch Pharmaceutical Services, Inc. 

12:30 - 1:15 pm 

Are You Using Your Father’s Prednisone to Treat Your Mother’s 

RA?: New Understanding of a Familiar Therapy 

Presented by Horizon Pharma 

2:30 - 3:15 pm 

Pathophysiology of Pain: Processes, Plasticity, and Perception 

Presented by Lilly USA, LLC 

12:30 - 1:15 pm 

Introducing an Innovative New Patient Educational and 

Support Program 

Presented by Janssen Biotech, Inc. 

2:30 - 3:15 pm 

Case Studies: Practical Management of Gout 

Presented by Takeda Pharmaceuticals 

316 

2012 Program Book



6:30 PM Non-CME Symposium 

The event listed below is a non-CME Programs wholly sponsored and 

supported by the commercial entities listed. By holding the Program, the 

commercial entity has represented that the Program has been developed 

and will be implemented in accordance with the requirements of the 

FDA and applicable standards of the PhRMA Code on Interactions with 

Healthcare Professionals. The commercial entity is to observe all guidelines 

established by federal and state regulatory agencies regarding non-CME 

educational or promotional presentations throughout the duration of 

the Program. The content and views expressed during the Program are 

those of the commercial entities and presenters. The ACR by making this 

venue available does not guarantee, warrant or endorse the content of the 

Program nor the products discussed and reviewed during the Program. 

Innovative pathways in science and patient care: From genetic 

and therapeutic discovery to 15 years of clinical experience 

Developed and offered by Abbott 

Third-Party Organization: MedEd Link 

Grand Hyatt, Independence Ballroom 

Learning Objectives 

Upon completion of this activity, participants should be able to: 

• review the discovery of TNF-alpha, the role it has on the inflammatory 

process and the impact it has had on developing treatments for inflammatory 

diseases 

• review the development of HUMIRA to specifically target TNF-alpha 

and the role inhibiting TNF-alpha plays in the chronic inflammatory 

diseases 

• have a deeper understanding of the impact of 15 years of clinical trial 

experience 

6:30 - 7:00 PM 

Registration and Dinner 

7:00 - 7:05 PM 

Introductions and Program Overview 

Dr. Arthur Kavanaugh, Professor of Clinical Medicine, Director of Center 

for Innovative Therapy, UC San Diego, School of Medicine 

7:05 - 7:35 PM 

Discovery of TNF-α 

Nobel Prize Winner, Dr. Bruce Beutler, UT Southwestern Medical Center, 

Center for the Genetics of Host Defense 

7:35 - 8:00 PM 

Targeting TNF-α: Discovery and Development of HUMIRA 

Dr. Jochen Salfeld, Divisional Vice President, Abbott Bioresearch Center 

8:00 – 8:30 PM 

Patient Case Study & Clinical Review – 14 years of clinical experience 

Dr. Arthur Kavanaugh, Professor of Clinical Medicine, Director of Center for 

Innovative Therapy, UC San Diego, School of Medicine 

8:30 – 8:40 PM 

Question and Answer session with the faculty 

Led by Dr. Kavanaugh, with participation by Dr. Jochen Salfed and Dr. Bruce 

Beutler 

8:40 pm – 9:00 PM 

Dessert and Refreshments 

6:30 PM CME-Accredited Symposium 

For CME-accredited symposia, the sponsoring organization is responsible 

for planning and providing CME credit. 

Treatment of SLE: Bridging the Gap from Clinical Trials 

to Practice 

Supported by an educational grant from Human Genome Sciences, INC. 

Sponsored by Cleveland Clinic 

Grand Hyatt, Constitution Ballroom 

Physician (ACCME) Accreditation Statement 

The Cleveland Clinic Foundation Center for Continuing Education is 

accredited by the Accreditation Council for Continuing Medical Education 

(ACCME) to provide continuing medical education for physicians. 

Credit Designation Statement 

The Cleveland Clinic Foundation Center for Continuing Education 

designates this live activity for a maximum of 2.0 AMA PRA Category 1 

Credits. Physicians should claim only the credit commensurate with the 

extent of their participation in the activity. 

Needs Assessment Statement 

As research into the biologic basis of SLE pathogenesis and the therapeutic 

management of the disease rapidly moves forward, achieving optimal 

patient outcomes depends on increasing rheumatologists’ medical 

understanding of the molecular and cellular basis of SLE pathogenesis 

is crucial to improving outcomes in these patient populations. Many 

clinicians have knowledge gaps regarding the latest SLE clinical research, 

biologic agents, and targeted therapies, creating a need for an educational 

activity in which experts compile and critically appraise new evidence and 

interpret its implications for clinical practice. 



• recognize the common clinical features of SLE that are most likely to 

require therapy and describe how they affect morbidity and mortality 

• summarize the algorithms of care for generalized SLE and organ-specific 

disease associated with SLE 

• compare and contrast the efficacy and utility of instruments and techniques 

for monitoring disease activity 

• summarize leading pathogenic theories and describe the role of B cells 

in the integrated immune response as they relate to SLE pathogenesis 

• assess data from recent clinical trials of novel therapeutics targeting 

related pathways 

• describe biologic agents (including preclinical development, early to 

late stage trials, etc.) for SLE treatment, their mechanism of action, side 

effects, and clinical indications 

• highlight important long-term extension data from phase 3 trials and 

assess the potential impact on clinical practice 

6:30 - 7:30 PM 


7:30 - 7:40 PM 

Introduction – Historical Overview of SLE Therapy 

Leonard Calabrese, DO, Cleveland Clinic, Cleveland, OH 

7:40 - 8:00 PM 

SLE Unmet Medical Needs and Therapeutic Standards of Care 

Bevra Hahn, MD, David Geffen School of Medicine at UCLA, Los Angeles, 

CA 



8:00 – 8:20 PM 

Measuring Disease Activity & Severity in Clinical Trials and the Clinic- 

Same or Different? 

Michelle Petri, MD, MPH, Johns Hopkins University School of Medicine, 

Baltimore, MD 

8:20 - 8:40 PM 

B Cell Dysregulation and the Pathogenesis of SLE 

Peter Lipsky, MD, Arthritis Research and Therapy, Bethesda, MD 

8:40 - 9:00 PM 

Clinical Impact of Biologic Therapies in the Treatment of SLE 

Daniel Wallace, MD, Cedars-Sinai Medical Center, Los Angeles, CA 

9:00 - 9:30 PM 


All Faculty 














Women’s Health Issues in Rheumatology: Challenges, Concerns 

and Considerations 

Developed and offered by UCB, Inc. 

Third-Party Organization: ETHOS Health Communications 

Renaissance Hotel, Renaissance Ballroom 



• identify and discuss clinical challenges in women’s health across a 

spectrum of rheumatic diseases 

• relate the physical and emotional impact of family planning for women 

living with chronic inflammatory diseases 

• delineate future areas of research, clinical strategies and guidelines 

development in this area 

6:30 - 7:00 PM 


7:00 - 7:05 PM 

Welcome and Introductions 

Megan Clowse, MD, MPH, Duke Medical Center, Durham, NC 

7:05 - 7:20 PM 

Overview of Issues in Women’s Health in Rheumatic Disease 

Eliza Chakravarty, MD, Oklahoma Medical Research Foundation, 


7:20 - 7:30 PM 

Women and Rheumatoid Arthritis: The Patient Perspective 

Patient of Dr. Clowse and Dr. James 

7:30 - 7:50 PM 

Effects of Infertility, Pregnancy Loss and Patient Concerns on Family Size of 

Women with Rheumatoid Arthritis 


7:50 - 8:10 PM 

Obstetric Care & Complications in Rheumatic Diseases 

Andra James, MD, University of Virginia, Charlottesville, VA 

8:10 - 8:30 PM 

Preconceptional Counseling in Women with Rheumatic Disease 

Monika Østensen MD, PhD, University of Bern, Bern, Switzerland 

8:30 - 8:55 PM 

Question and Answer Session/ Panel Discussion 

9:00 PM 

Conclusion and Closing Remarks 
















Navigating the Course of Psoriatic Disease – Look Inside for a 

New Perspective 

Developed and offered by Celgene 

Third-Party Organization: Veraxis Health Communications 

Grand Hyatt, Constitution Ballroom 



• understand the burden of psoriatic disease and the design and methodology 

of the Global Psoriasis Survey 

• explain the inflammatory basis of psoriatic disease 

• discuss the diagnosis and management of psoriatic arthritis 

6:30 - 7:00 PM 

Registration/ Beverages & Hors d’oeuvres 

7:00 - 7:05 PM 

Welcome, Introductions, and Opening Remarks 

Arthur Kavanaugh, MD, University of California, San Diego School of 

Medicine, San Diego, CA 

7:05 - 7:25 PM 

Understanding the Burden of Psoriatic Disease: Design and Methodology 

of the Global Psoriasis Survey 

Arthur Kavanaugh, MD, University of California, San Diego School of 

Medicine, San Diego, CA 

318 

2012 Program Book


7:25 - 7:45 PM 

Psoriatic Arthritis: Mechanism of Disease 

Iain B. McInnes, MBCHB FRCP FMedSci, University of Glasgow, Glasgow, 

Scotland 

7:45 - 8:05 PM 

Challenges in Diagnosis and Management of Psoriatic Arthritis 

Philip Mease, MD, University of Washington, Seattle, WA 

8:05 - 8:30 PM 

Question and Answer Panel 




Osteoarthritis Update: Bridging the Gap between NSAIDs and 

Surgery 

Supported by an educational grant from Eli Lilly 

Sponsored by Creative Educational Concepts 

Renaissance Hotel, Congressional Ballroom 


Creative Educational Concepts, Inc. (CEC) is accredited by the 

Accreditation Council for Continuing Medical Education (ACCME) to 

provide continuing medical education for physicians. 


CEC designates this educational activity for a maximum of 2.0 AMA PRA 

Category 1 Credit(s). Physicians should only claim credit commensurate 

with the extent of their participation in the activity. 


Osteoarthritis (OA) is one of the leading causes of disability in the United 

States (US), and it represents a significant burden on the US healthcare 

system. Approximately half of persons over the age of 65 report having 

OA, making arthropathies the fifth most common office visit diagnosis. 

Projections regarding the rate of hip and knee revisions, which are 

typically last-line therapies, have provided that they are expected to 

expand dramatically over the coming decades. Because of this, there is a 

need for more effective methods to treat the pain associated with OA and 

this activity will provide clinicians with the tools necessary to bridge the 

chasm that exists between first-line therapies and total joint replacement. 



• identify the different pathophysiologic processes responsible for the 

generation of pain in osteoarthritis 

• differentiate how the mechanisms responsible for producing pain affect 

the appropriate selection of therapeutic agents 

• evaluate the risks and benefits of new treatment options in OA, and 

identify how they fit within the existing treatment paradigm 

6:30 - 7:00 PM 


7:00 - 7:10 PM 

Welcome and Introductions 

Marc Hochberg, MD, MPH, University of Maryland School of Medicine, 

Baltimore, MD 

7:10 - 7:35 PM 

Advances in Understanding the Mechanisms of Pain in Osteoarthritis 

C. Kent Kwoh, MD, University of Pittsburgh, Pittsburgh, PA 

7:35 - 8:00 PM 

Bridging the Gap I: Pharmaceutical Options in Patients with an Inadequate 

Response to NSAIDs 

Marc Hochberg, MD, MPH, University of Maryland School of Medicine, 

Baltimore, MD 

8:00 - 8:25 PM 

Bridging the Gap II: Intra-articular Therapies in Osteoarthritis 

Roy D. Altman, MD, University of California, Los Angeles, Los Angeles, CA 

8:25 - 9:00 PM 

Conversations with the Experts: Audience Q&A 

Moderated by Marc Hochberg, MD, MPH, University of Maryland School 


Wednesday, NOVEMBER 14, 2012 




Treatment Success in Osteoarthritis: Advances in Pharmacologic 

Therapy 

Supported by an educational grant from Bioiberica S.A. 

Sponsored by Medical Education Resources 

Renaissance Hotel, Grand Ballroom North 


This activity has been planned and implemented in accordance with the 

Essential Areas and Policies of the Accreditation Council for Continuing 

Medical Education (ACCME) through the joint sponsorship of Medical 

Education Resources (MER) and Consensus Medical Communications 

(CMC). MER is accredited by the ACCME to provide continuing medical 

education for physicians. 


MER designates this live activity for a maximum of 1.5 AMA PRA Category 

1 Credit(s). Physicians should claim only the credit commensurate with 

the extent of their participation in the activity. 


Effective treatment of OA must focus on addressing all aspects of 

pathophysiology, including preventing cartilage loss and damage to the 

joint. Current data support the use of chondroitin sulfate, alone or in 

combination with glucosamine, as an effective treatment for patients 

with OA. These substances may result in an improvement of quality of life 

for patients with OA as well as significantly reduce the costs this disease 

generates in society. This program will investigate the pathophysiology of 

osteoarthritis, review the pharmacologic actions and clinical efficacy of 

chondroitin sulfate and glucosamine, and discuss strategies to effectively 

manage patients with OA. 



• discuss the pathophysiology of osteoarthritis and identify diseasemodifying 

strategies to reduce disability 

• describe the synergistic effects of concomitant glucosamine and chondroitin 

sulfate therapy in the prevention of osteoarthritis joint damage 

• discuss currently available clinical data on the use of chondroitin sulfate, 

with or without glucosamine, in the treatment of osteoarthritis 

1:00 - 1:20 PM 

Registration and Lunch 



1:20 - 1:25 PM 

Welcome and Introduction 

Marc C. Hochberg, MD, MPH, University of Maryland School of Medicine, 

Baltimore, MD 

1:25 - 1:40 PM 

The Pathophysiology of Osteoarthritis 

Virginia Byers Kraus, MD, PhD, Duke University Medical Center, Durham, 

NC 

1:40 - 1:55 PM 

Synovitis in Osteoarthritis: How Important Is It? 

Timothy E. McAlindon, MD, MPH, Tufts University School of Medicine, 

Boston, MA 

1:55 - 2:10 PM 

Synovium Angiogenesis: A New Therapy Target for Osteoarthritis 

Treatment 

Yves Henrotin, PhD, University of Liege, Liege, Belgium 

2:10 - 2:25 PM 

Chondroitin Sulfate May Reduce Total Knee Replacement in a 12-month 

Multicentre Clinical Trial in Knee Osteoarthritis: Results from a 4- Year 

Observation 

Jean-Pierre Pelletier, MD, University of Montreal Hospital Research Centre 

(CRCHUM), Montreal, Quebec, Canada 

2:25 - 2:40 PM 

Can Chondroitin Sulfate and Glucosamine Combination Reduce Total Knee 

Replacement? 

Patrick du Souich, MD, PhD, University of Montreal, Montreal, Quebec, 

Canada 

2:40 - 2:55 PM 

Question and Answer Session 

2:55 – 3:00 PM 

Concluding Remarks 

Marc C. Hochberg, MD, MPH, University of Maryland School of Medicine, 

Baltimore, MD 




Selecting Appropriate Biologic Therapy for RA: A Practical Evaluation 

of Comparative Effectiveness Data 

Supported by an educational grant from Bristol-Myers Squibb 

Jointly sponsored by PeerView Institute for Medical Education, Inc. and 

University of Florida College of Medicine 

Renaissance Hotel, Congressional Ballroom 


The University Of Florida College Of Medicine is accredited by the 

Accreditation Council for Continuing Medical Education (ACCME) to 

provide continuing medical education for physicians. 


The University of Florida College of Medicine designates this live activity 

for a maximum of 2.0 AMA PRA Category 1 Credit(s). Physicians should 

claim only the credit commensurate with the extent of their participation 

in the activity. 


Rheumatologists and other professionals managing RA have an expanding 

range of management options available; however, it is imperative that 

these therapies are used appropriately. Although the body of evidence 

shows that biologic DMARDs are effective in treating RA, there has 

been a scarcity of head-to-head comparison studies, a barrier that 

has confounded the establishment of clear guidelines on how biologic 

DMARDs should be used and sequenced in the clinic. As an increasing 

amount of comparative effectiveness research begins to yield evidence 

which can potentially inform clinical decisions, it is essential to keep 

rheumatologists and other professionals abreast of these emerging 

studies to begin to clarify the appropriate selection of biologic therapy for 

RA with the ultimate goal of improving long term patient outcomes. It is 

imperative that rheumatologists and other clinicians managing RA remain 

updated on recent advances in the management of this disease, and are 

aware of practical strategies for implementing treatment to a main goal of 

remission. Appropriate use of biologic therapy is particularly important, as 

these drugs have the potential to change the natural history of RA. 



• recognize the impact of early treatment and tight control on long-term 

patient outcomes in RA 

• discuss the current safety and efficacy data from direct head-to-head 

comparison studies of biologic therapies for RA 

• compare and contrast the mechanisms of action and optimal use of 

biologic therapies for RA 

• individualize biologic therapy for patients with RA based on patient factors 

and treat-to-target goals 

1:00 - 1:30 PM 


1:30 - 1:40 PM 

Welcome and Introduction 

1:40 - 1:55 PM 

Comparative Effectiveness Data in Rheumatoid Arthritis: Is There A Need? 

Professor Paul Emery, University of Leeds, Leeds, United Kingdom 

1:55 - 2:20 PM 

Head-to-Head Trials Comparing Biologic Therapies in Rheumatoid 

Arthritis: Clinical Implications of the Data 

Cem Gabay, MD, University Hospitals of Geneva, Geneva, Switzerland 

2:20 - 2:35 PM 

Mid-Session Panel Discussion & Ask the Faculty 

2:35 - 2:50 PM 

Clinical Trial Design in Rheumatoid Arthritis: Past, Present, and Future 

Josef S. Smolen, MD, Center for Rheumatic Diseases, Hietzing Hospital, 


2:50 - 3:10 PM 

Case-Based Expert Roundtable Discussion: Contemporary Implementation 

of Biologic Therapies in Rheumatoid Arthritis 

All Speakers 

3:10 - 3:30 PM 

Ask the Faculty and Conclusions 

320 

2012 Program Book





Debating the Future of RA Management: Focus on the Mechanisms‐of‐Action 

and Roles of Novel Agents, A Core Symposium 

Supported by an educational grant from MedImmune, LLC 

Sponsored by North American Center for Continuing Medical Education, LLC 

(NACCME) 

Renaissance Hotel, Grand Ballroom South 


North American Center for Continuing Medical Education, LLC (NACCME), 

is accredited by the Accreditation Council for Continuing Medical 

Education, the Accreditation Council for Pharmacy Education, and the 

American Nurses Credentialing Center to provide continuing education for 

the healthcare team. 


NACCME designates this live activity for a maximum of 2.0 AMA 

PRA Category 1 Credits. Physicians should claim only the credit 

commensurate with the extent of their participation in the activity. This 

continuing nursing education activity awards 2.00 contact hours. Provider 

approved by the California Board of Registered Nursing, Provider #13255 

for 2.00 contact hours. 


Rheumatologists understand that RA is a chronic disease that requires 

aggressive treatment and monitoring; the challenge is to improve 

clinical inertia with clinical measurement tools and timing of treatment 

decisions. Education on the value of measurement tools, what constitutes 

an inadequate response, how to switch between biologic agents, and 

emerging treatment options will provide rheumatologists with the 

knowledge and confidence to adopt the necessary practice changes to 

improve patient health. 



• align RA treatment strategies with updated diseases classification and 

remission criteria 

• outline and overcome controllable factors and available therapy shortfalls 

that impact patient adherence to therapy 

• describe the safety and efficacy of newer and emerging treatment options 

for RA management 

• correlate the mechanisms-of-action of novel therapies to their potential 

role in patient-centric treatment 

1:00 - 1:30 PM 


1:30 - 3:00 PM 

Crossfire Presidential Debate 

• Pursuing updated remission criteria through aggressively treating RA 

with available agents 

• Overcoming controllable factors that impact patient adherence to 

therapy 

• Safety and efficacy of newer and emerging biologics for RA management 

• Matching the mechanisms-of-action of novel therapies to their potential 

role in patient-centric treatment 

Moderator: 

Leonard H. Calabrese, DO, Case Western Reserve University, Cleveland, 

OH 

Co-Presenters: 

Bernard Combe, MD, PhD, Université Montpellier, Montpellier, France 

Jeffrey Curtis, MD, MS, MPH, University of Alabama at Birmingham, 


Daniel E. Furst, MD David Geffen School of Medicine at UCLA, Los Angeles, 

CA 

3:00 - 3:30 PM 

Closing Arguments and Audience Voting 




Challenging Gout: Newest Recommendations and Emerging 

Treatments 

Jointly sponsored by Interstate Postgraduate Medical Association and 

MedEdRules, LLC. 

Supported by an educational grant from Savient Pharmaceuticals, Inc. 

Renaissance Hotel, Renaissance Ballroom 


This activity has been planned and implemented in accordance with the 

Essential Areas and Policies of the Accreditation Council for Continuing 

Medical Education (ACCME) through the joint sponsorship of Interstate 

Postgraduate Medical Association (IPMA) and MedEdRules, LLC. 

(MEDEDR). IPMA is accredited by the ACCME to provide continuing 

medical education for physicians. 


IPMA designates this live activity for a maximum of 2.0 AMA PRA Category 

1 Credit(s). Physicians should claim only the credit commensurate with 

the extent of their participation in the activity. 

Continuing Education Units 

IPMA is approved by the California Board of Registered Nursing, provider 

number 6971, for 2.4 contact hours. Each person should retain this 

certificate for 4 years after the course has been completed. 

RNs outside of California must verify with their licensing agency for approval 

of this course. 




IPMA and MEDEDR have completed a detailed needs assessment of the 

educational needs of clinicians who are interested in improving patient 

outcomes in gout. This needs assessment is based upon feedback from 

previously successful CME interventions, interviews with experts in the 

field, and a thorough literature search. This needs assessment shows 

awareness and knowledge transfer is needed to help the rheumatologist 

and related health care provider (including primary care, podiatrists 

and nephrologists) better manage patients with gout, including those 

with comorbid conditions as well as those who are difficult to manage 

or become refractory to therapy. Rheumatologists and other clinicians 

must be able to tailor an individualized management strategy utilizing 

the most advanced treatment options available. Educational gaps include 

the following: clinicians do not provide consistent treatment; clinicians 

may not appreciate the seriousness of the disease; clinicians may not 

recognize the debilitating effects of advanced crystal deposition in gout; 

clinicians need to identify common comorbidities in patients associated 

with advanced gout and effectively manage these patient types; clinicians 

need to keep updated on the safety, efficacy, and use of all available gout 

treatment options, including new and emerging therapies. 



• assess the ascending level of disease in 3 patient case studies, including 

evaluation of serum urate, pain and inflammation, joint destruction, 

and quality of life, and understand the evidence supporting options to 

lower urate levels, treat inflammation, and prevent joint destruction in 

refractory disease 

• devise a long-term management plan, within each case study, to treat 

the patient effectively according to their level of disease 

• select the appropriate individualized medical regimen based on the 

most recent recommendations, taking into consideration the efficacy 

and safety profiles and risk-benefit ratios of available therapies 

• discuss how emerging agents for gout might address the therapeutic 

needs of treatment-refractory patients 

1:00 - 1:30 PM 

Registration and Refreshments 

1:30 - 1:35 PM 

Welcome, Introduction, Overview 

Jonathan Kay, MD, UMass Memorial Medical Center, Worchester, MA 

1:35 - 2:05 PM 

Case Study 1: Approaching the Gout Patient with Frequent Flares 

Jonathan Kay, MD, UMass Memorial Medical Center, Worchester, MA 

2:05 - 2:35 PM 

Case Study 2: Current Modalities and Latest Recommendations for 

Treatment of Monoarticular Flares 

Robert Keenan, MD, MPH, Duke University Medical Center, Durham, NC 

2:35 - 3:10 PM 

Case Study 3: Challenging Gout - How to Treat the Refractory Patient 

Robert Terkeltaub, MD, Veterans Affairs Medical Center; San Diego, CA 

3:10 - 3:30 PM 

Summary and Question and Answer Session 

322 

2012 Program Book

CERTIFICATES OF CME CREDIT OR PARTICIPATION 

Accreditation Statement: The American College of 

Rheumatology is accredited by the Accreditation Council for 

Continuing Medical Education (ACCME) to provide continuing 

medical education for physicians. 

Designation Statement: The ACR designates this live educational 

activity for a maximum of 49.75 AMA PRA Category 1 credits. 

Physicians should claim only the credit commensurate with the 

extent of their participation in the activity. 

International Physicians: International physicians who register 

as part of a group and require AMA PRA Category 1 Credit(s), 

must provide the following information to your tour leader: full 

name, mailing address, telephone and fax numbers, and e-mail 

address. The information will be used to verify your meeting 

attendance. 

The American Medical Association has an agreement of mutual 

recognition of continuing medical education credit with the 

European Union of Medical Specialties. International physicians 

interested in converting AMA PRA Category 1 Credit to 

EACCME credit should contact the UEMS. 

Health Professionals: Participants may claim hours to receive 

a Certificate of Participation for an activity designated for AMA 

PRA Category 1 Credit(s). For non-CME sessions, attendees may 

also request a certificate of participation. 

MEETING EVALUATIONS, CME CREDIT/ 

CERTIFICATES OF PARTICIPATION 

New 

this year! 

Use My Annual Meeting and the My Annual 

Meeting APP to complete your meeting and session 

evaluations online while tracking your participation 

as you go. Access My Annual Meeting at 

www.ACRannualmeeting.org to e-mail or print 

your CME certificate or certificate of participation. 

Computers are also available for you to complete your CME/ 

Certificate of Participation and session evaluations online 

during the meeting at the CME/Internet Center located in the 

Concourse, near the entrance to the exhibit hall (Hall A). 

International physicians, requiring a Certificate of Attendance, 

can find one enclosed in your meeting bag. If your country 

recognizes AMA PRA Category 1 Credit(s) in accordance with 

AMA PRA requirements, please complete the session evaluations 

and CME application online using My Annual Meeting or the My 

Annual Meeting APP. 

Your evaluation of the meeting is very important. The ACR/ 

ARHP annual meeting planning committees use feedback from 

attendees to assist in the development of future educational 

activities; therefore, we encourage you to complete your session 

evaluations and CME/Certificate application. 

Conflict of Interest/Disclosure Statements 

As an educational provider accredited by the Accreditation 

Council for Continuing Medical Education (ACCME), the American 

College of Rheumatology must ensure balance, independence, 

objectivity and scientific rigor in all its educational activities. 

Therefore, all speakers and moderators participating in an 

ACR-sponsored activity are required to disclose to the planning 

committee and audience any financial or other relationships 

including, but not limited to: 

None: Nothing to disclose 

1. Stock, stock options or bond holdings in a for-profit 

corporation or self-directed pension plan 

2. Research grants 

3. Employment (full or part-time) 

4. Ownership or partnership 

5. Consulting fees or other remuneration (payment) 

6. Non-remunerative positions of influence such as officer, 

board member, trustee or public spokesperson 

7. Receipt of royalties 

8. Speakers’ bureau 

9. Other 

Speakers, moderators and abstract authors submitted their 

disclosure online prior to publication. Disclosures for invited 

speakers are listed in the indices by presenters’ last name. 

Abstract author disclosures are published online and in a 

supplement to the October issue of Arthritis & Rheumatism. 

Disclosures for the late-breaking abstracts are published online 

and in the December issue of Arthritis & Rheumatism. Any 

individual who refuses to disclose relevant financial relationships 

will be disqualified from being a planning committee member, 

a presenter, an author of a CME activity, and cannot have 

control of, or responsibility for, the development, management, 

presentation or evaluation of the CME activity. 

Disclosure Policy 

It is the policy of the American College of Rheumatology to 

ensure that its CME activities are independent and free of 

commercial bias. 

To ensure content objectivity and balance, and guarantee that 

the content presented is in the best interest of its learners 

and the public, the ACR requires that everyone in a position 

to control content disclose all relevant financial relationships 

with any commercial interest if the relationship is financial and 

occurred within the past 12 months. If there are relationships 

that create a conflict of interest, these must be resolved in 

accordance with the ACR’s CME Resolution of Conflict policy 

prior to the participation of the individual in the development or 

presentation of CME content. 

This annual meeting is sponsored by the American College of 

Rheumatology for educational purposes only. The material 

presented is not intended to represent the only or the best 

methods appropriate for the medical conditions being 

discussed, but rather is intended to present the opinions of 

the authors or presenters, which may be helpful to other 

healthcare professionals at arriving at their own conclusions and 

consequent application. Attendees participating in this medical 

education program do so with full knowledge that they waive 

any claim they may have against the College for reliance on any 

information presented during these educational activities. The 

College does not guarantee, warrant or endorse any commercial 

products or services. 


2012 ACR/ARHP ANNUAL MEETING LEADERSHIP 

Thank You! 

The ACR/ARHP board of directors extends its gratitude to the ACR/ARHP Annual Meeting Planning Subcommittee, ACR Abstract 

Oversight Committee, ACR Abstract Selection Committee, ARHP Abstract Review Panels, and ARHP Clinical Focus Task Force 

members for their leadership and volunteering their services to plan the 2012 annual meeting. Their significant contributions 

and expertise make the annual meeting the premier event for specialists in the field of rheumatology. 

ACR/ARHP Annual Meeting Planning 

Subcommittee 

Chester V. Oddis, MD, ACR Chair 

Mary Cronin, MD, ACR Clinical Sub-chair 

Linda S. Ehrlich-Jones, PhD, RN, ARHP Chair 

Afton Hassett, PsyD, ARHP Chair Elect 

Carol A. Langford, MD, MHS, Abstract Selection 

Chair (Clinical) 

Richard F. Loeser, MD, ACR Basic Science 

Sub-chair 

Richard M. Pope, MD, Abstract Selection 

Chair (Basic) 

Mary-Chester Wasko, MD, MSc, ACR MTP/ 

Workshop/Study Group Sub-chair 

Joel A. Block, MD, ACR Immediate Past Chair 

Joan M. Bathon, MD, A&R Editor 

Thuy T. Beam, BSN 

Elana Bernstein, MD, Fellow Representative 

Hazel L. Breland, PhD, OTR/L 

S. Louis Bridges, Jr., MD, PhD 

Richard Bucala, MD, PhD 

Andrew P. Cope, MD, PhD 

Lindsey A. Criswell, MD, MPH 

Donna K. Everix, MPA, PT 

Fernando E. Figueroa, MD 

James G. Freeman, MD 

Gregory C. Gardner, MD 

Alexei A. Grom, MD 

Raymond Hong, MD, MBA, CORC Representative 

Shelly P. Kafka, MD 

Diane Kamen, MD 

Salahuddin Kazi, MD, RHIT Representative 

Sharon L. Kolasinski, MD 

Robert A. Lafyatis, MD 

Anne-Marie Malfait, MD, PhD 

Richard W. Martin, MD, MA 

Zsuzsanna McMahan, MD 

Victoria A. Merrell, PA-C, MPT 

Tuhina Neogi, MD, PhD, Quality Measures 

Committee 

Uyen Sa D. Nguyen, DSc, MPH 

Peter A. Nigrovic, MD 

Karen Onel, MD 

Elizabeth G. Salt, PhD, ARNP 

Kenneth N. Schikler, MD 

Victoria K. Shanmugam, MBBS 

Gregg J. Silverman, MD 

Jasvinder Singh, MD, MPH 

Robert F. Spiera, MD 

Virginia D. Steen, MD 

Margaret R. Wilkes, MD 

Laura C. Wright, MBA 

Ex Officio Members 

Richard A. Furie, MD, COE Chair 

James R. O’Dell, MD, ACR President 

ACR/ARHP Abstract Oversight Committee 

Robert Fuhlbrigge, MD, PhD, Chair 

Shreyasee Amin, MD 

Emily Somers, PhD, ScM 

Steven Ytterberg, MD 

ARHP Clinical Focus Task Force 

Marie D. Westby, PT, PhD, Chair 

Jessica F. Farrell, PharmD 

Kathryn L. Lowenstein, OTR 

Taraneh Mehrani, MD 

ACR and ARHP Abstract Selection Committees 

(including category chairs and reviewers) 

Carol A. Langford, MD, MHS, ACR Clinical 

Science Chair, Abstract Selection 

Richard M. Pope, MD, ACR Basic Science Chair, 

Abstract Selection 

Elizabeth Salt, PhD, ARHP Abstract Selection 

Chair 

1. Cytokines, Mediators, and Gene Regulation 

Erik Lubberts, PhD, Co-Chair 

Michael Volin, PhD, Co-Chair 

Sarah L. Gaffen, PhD 

Katalin Mikecz, MD, PhD 

Hendrik Schutze-Koops, MD, PhD 

Zoltan Szekanecz, MD, PhD 

2. Cell-cell Adhesion, Cell Trafficking and 

Angiogenesis 

Shiva Shahrara, PhD, Co-Chair 

Douglas J. Veale, MD, Co-Chair 

Alexander D. Fraser, MD 

Charles J. Malemud, PhD 

David Walsh, MD 

Song G. Zheng, MD, PhD 

3. Innate Immunity and Rheumatic Disease 

Susan A. Boackle, MD, Co-Chair 

Diego Kyburz, MD, Co-Chair 

Maripat Corr, MD 

Mariana J. Kaplan, MD 

Timothy Radstake, MD, PhD 

Ranjeny Thomas, MBBS, MD 

4. B cell Biology and Targets in Autoimmune 

Disease 

Robert A. Eisenberg, MD, Co-Chair 

William Stohl, MD, PhD, Co-Chair 

Philip L. Cohen, MD 

Bevra H. Hahn, MD 

David A. Isenberg, MD 

Gregg J. Silverman, MD 

5. T cell Biology and Targets in Autoimmune 

Disease 

Jorg J. Goronzy, MD, PhD, Co-Chair 

Joseph Holoshitz, MD, Co-Chair 

Alison Finnegan, PhD 

Shu-Man Fu, MD, PhD 

Terri M. Laufer, MD 

Linda K. Myers, MD 

6. Biology and Pathology of Bone and Joint 

Hiroshi Asahara, MD, Co-Chair 

Mary C. Nakamura, MD, Co-Chair 

Antonios O. Aliprantis, MD 

Di Chen, MD, PhD 

Mary B. Goldring, PhD 

Mary Beth Humphrey, MD, PhD 

7. Osteoarthritis – Clinical Aspects 

Joanne M. Jordan, MD, MPH, Co-Chair 

Tuhina Neogi, MD, PhD, FRCPC, Co-Chair 

Martin Englund, MD, PhD 

William F. Harvey, MD, MSc 

Najia Shakoor, MD 

Leena Sharma, MD 

324 

2012 Program Book


8. Osteoporosis and Metabolic Bone Disease: 

Clinical Aspects and Pathogenesis 

Robin K. Dore, MD, Co-Chair 

Anthony D. Woolf, MBBS, Co-Chair 

Chad L. Deal, MD 

Andrew J. Laster, MD 

Willem F. Lems, MD, PhD 

S. Bobo Tanner, MD 

9. Fibromyalgia and Soft Tissue Disorders 

Daniel J. Clauw, MD, Co-Chair 

Mary-Ann Fitzcharles, MBChB, MD, Co-Chair 

Jacob N. Ablin, MD 

Dennis C. Ang, MD 

Chad S. Boomershine, MD, PhD 

Pier Carlo Sarzi-Puttini, MD 

10. Orthopedics, Low Back Pain, and 

Rehabilitation 

John D. FitzGerald, MD, PhD, Chair 

Jeffrey N. Katz, MD, Chair 

Erin L. Arnold, MD 

Aileen M. Davis, PhD 

M. Elaine Husni, MD, MPH 

Ernest R. Vina, MD, MSc 

11. Pediatric Rheumatology – Clinical and 

Therapeutic Aspects 

Daniel J. Lovell, MD, MPH, Co-Chair 

Rayfel Schneider, MBBCh, Co-Chair 

Emily von Scheven, MD, Co-Chair 

Carol A. Wallace, MD, Co-Chair 

Kristin M. Houghton, MD 

Daniel J. Kingsbury, MD 

Suzanne C. Li, MD, PhD 

Lakshmi N. Moorthy, MD, MS 

Karen Onel, MD 

Angelo Ravelli, MD 

Taunton R. Southwood, FRCP 

Richard K. Vehe, MD 

12. Pediatric Rheumatology – Pathogenesis and 

Genetics 

Alexei A. Grom, MD, Co-Chair 

Raphael Hirsch, MD, Co-Chair 

Abbe N. de Vallejo, PhD 

Anthony R. French, MD, PhD 

Kathryn S. Torok, MD 

James W. Verbsky, MD, PhD 

13. Infection-related Rheumatic Disease 

John D. Carter, MD, Co-Chair 

Dimitrios Vassilopoulos, MD, Co-Chair 

Leonard H. Calabrese, DO 

Prashant Kaushik, MD 

James S. Louie, MD 

Frank B. Vasey, MD 

14. Metabolic and Crystal Arthropathies 

Naomi Schlesinger, MD, Co-Chair 

John S. Sundy, MD, PhD, Co-Chair 

Michael A. Becker, MD 

Nicola Dalbeth, MBChB, MD 

Puja Khanna, MD 

H. Ralph Schumacher, MD 

15. Muscle Biology, Myositis and Myopathies 

Ingrid E. Lundberg, MD, PhD, Chair 

Lauren M. Pachman, MD, Chair 

Dana P. Ascherman, MD 

Carol B. Lindsley, MD 

Lisa G. Rider, MD 

Jiri Vencovsky, MD, PhD 

16. Imaging of Rheumatic Diseases 

John Carrino, MD, MPH, Co-Chair 

Wolfgang A. Schmidt, MD, Co-Chair 

Harry K. Genant, MD 

Ali Guermazi, MD 

Fiona M. McQueen, MBChB, MD 

Ralf G. Thiele, MD 

17. Rheumatoid Arthritis – Clinical Aspects 

Vivian P. Bykerk, MD, Chair 

Ernest Choy, MD, Chair 

Jon T. Giles, MD, Chair 

Merete L. Hetland, MD, PhD, DMSc, Chair 

Jonathan Kay, MD, Chair 

Eric L. Matteson, MD, MPH, Chair 

Rieke Alten, MD 

Neal S. Birnbaum, MD 

Lin A. Brown, MD 

Loreto Carmona, MD, PhD 

Paul F. Dellaripa, MD 

Kimme Hyrich, MD, PhD 

Shahin Jamal, MD, MSc 

Elizabeth W. Karlson, MD 

Yvonne C. Lee, MD, MMedSc 

Grant H. Louie, MD, MHS 

Eric M. Ruderman, MD 

Sergio Schwartzman, MD 

18. Rheumatoid Arthritis – Small Molecules, 

Biologics and Gene Therapy 

John J. Cush, MD, Co-Chair 

Daniel E. Furst, MD, Co-Chair 

Joseph A. Markenson, MD, Co-Chair 

Richard W. Martin, MD, MA, Co-Chair 

Josef S. Smolen, MD, Co-Chair 

Daniel H. Solomon, MD, MPH, Co-Chair 

Martin Aringer, MD 

CO Bingham, MD 

Maya H. Buch, MBChB, MRCP, PhD 

Marc D. Cohen, MD 

Aaron T. Eggebeen, MD 

Roy Fleischmann, MD 

Andrew J. Head, MD 

Kathryn Hobbs, MD 

Arthur Kavanaugh, MD 

Marc C. Levesque, MD, PhD 

Alan K. Matsumoto, MD 

Mark H. Wener, MD 

19. Rheumatoid Arthritis – Human Etiology and 

Pathogenesis 

Alisa E. Koch, MD, Co-Chair 

David S. Pisetsky, MD, PhD, Co-Chair 

Andrew P. Cope, MD, PhD 

Gary S. Firestein, MD 

Pierre Miossec, MD, PhD 

William H. Robinson, MD, PhD 

20. Rheumatoid Arthritis – Animal Models 

Harris R. Perlman, PhD, Co-Chair 

Charles S. Via, MD, Co-Chair 

Ewa Cairns, PhD 

Tibor T. Glant, MD 

Thomas Pap, MD 

Wim van den Berg, PhD 

21. Systemic Sclerosis, Fibrosing Syndromes, and 

Raynaud’s – Clinical Aspects and Therapeutics 

Murray Baron, MD, Co-Chair 

Robyn T. Domsic, MD, MPH, Co-Chair 

Tracy M. Frech, MD 

Jerry A. Molitor, MD, PhD 

Luc Mouthon, MD 

Ami A. Shah, MD, MHS 



22. Systemic Sclerosis, Fibrosing Syndromes and 

Raynaud’s – Pathogenesis, Animal Models 

and Genetics 

Arnold E. Postlethwaite, MD, Co-Chair 

Richard M. Silver, MD, Co-Chair 

Francesco Boin, MD 

Oliver Distler, MD 

Robert Lafyatis, MD 

Marco Matucci-Cerinic, MD, PhD 

23. Sjögren’s Syndrome 

Gabor G. Illei, MD, Co-Chair 

Xavier Mariette, MD, PhD, Co-Chair 

Simon J. Bowman, PhD 

Lindsey A. Criswell, MD, MPH 

E. William St. Clair, MD 

Athanasios G. Tzioufas, MD 

24. Antiphospholipid Syndrome 

Doruk Erkan, MD, Co-Chair 

Pierluigi Meroni, MD, Co-Chair 

Laura Andreoli, MD 

Maria Laura Bertolaccini, MD, PhD 

Pojen P. Chen, PhD 

Roger A. Levy, MD, PhD 

25. Systemic Lupus Erythematosus – Clinical 

Aspects and Treatment 

Maria Dall’Era, MD, Co-Chair 

Kenneth C. Kalunian, MD, Co-Chair 

Elena M. Massarotti, MD, Co-Chair 

Michelle Petri, MD, MPH, Co-Chair 

Rosalind Ramsey-Goldman, MD, Co-Chair 

Daniel J. Wallace, MD, Co-Chair 

Graciela S. Alarcon, MD, MPH 

Anca Askanase, MD, MPH 

Jose A. Gomez-Puerta, MD, PhD 

Jennifer M. Grossman, MD 

Meenakshi Jolly, MD, MS 

Diane L. Kamen, MD, MS 

S. Sam Lim, MD, MPH 

Meggan C. Mackay, MD 

Maureen A. McMahon, MD 

Juanita Romero-Diaz, MD 

Emily C. Somers, PhD, ScM 

David Wofsy, MD 

26. Systemic Lupus Erythematosus – Human 

Etiology and Pathogenesis 

Mary K. Crow, MD, Co-Chair 

Vasileios C. Kyttaris, MD, Co-Chair 

Jill P. Buyon, MD 

Judith A. James, MD, PhD 

Insoo Kang, MD 

Andras Perl, MD, PhD 

27. Systemic Lupus Erythematosus – Animal 

Models 

Keith B. Elkon, MBBCh, Co-Chair 

Ram P. Singh, PhD, Co-Chair 

Anne Davidson, MBBS 

Dwight H. Kono, MD 

Ann Marshak-Rothstein, PhD 

John D. Mountz, MD, PhD 

28. Spondylarthropathies and Psoriatic Arthritis – 

Clinical Aspects and Treatment 

Daniel O. Clegg, MD, Co-Chair 

Luis R. Espinoza, MD, Co-Chair 

Robert D. Inman, MD, Co-Chair 

Neil J. McHugh, MB, ChB, Co-Chair 

Desiree van der Heijde, MD, PhD, Co-Chair 

Michael H. Weisman, MD, Co-Chair 

Maxime Dougados, MD 

Dirk Elewaut, MD, PhD 

Oliver M. FitzGerald, MD 

Lianne S. Gensler, MD 

Jeffrey R. Lisse, MD 

Walter P. Maksymowych, MD 

Andreas M. Reimold, MD 

John D. Reveille, MD 

Enrique R. Soriano, MD, MSc 

Rafael R. Valle, MD 

Filip Van den Bosch, MD, PhD 


29. Spondylarthropathies and Psoriatic Arthritis – 


Robert A. Colbert, MD, PhD, Co-Chair 

Joachim Sieper, MD, Co-Chair 

Shervin Assassi, MD, MS 

Dominique L. Baeten, MD, PhD 

Maxime A. Breban, MD, PhD 

Siba P. Raychaudhuri, MD 

30. Vasculitis 

Rula Hajj-Ali, MD, Co-Chair 

Paul A. Monach, MD, PhD, Co-Chair 

Maria C. Cid, MD 

Loic Guillevin, MD 

Curry L. Koening, MD, MS 

Stuart M. Levine, MD 

31. Epidemiology and Health Services Research 

Karen H. Costenbader, MD, MPH, Co-Chair 

Jeffrey R. Curtis, MD, MPH, MS, Co-Chair 

Lisa A. Mandl, MD, MPH, Co-Chair 

Ted R. Mikuls, MD, MSPH, Co-Chair 

Gabriela Schmajuk, MD, MS, Co-Chair 

Jasvinder A. Singh, MBBS, Co-Chair 

Cheryl Barnabe, MD, MSc 

Liron Caplan, MD, PhD 

Mariko L. Ishimori, MD 

Nasim A. Khan, MD 

Eswar Krishnan, MD 

Elena Losina, PhD 

Kaleb Michaud, PhD 

Vk Ranganath, MD 

Lee S. Simon, MD 

Laura Tarter, MD 

Evelyne Vinet, MD 

Jie Zhang, PhD 

32. Quality Measures and Innovations in Practice 


Gary L. Bryant, MD, Co-Chair 

Salahuddin Kazi, MD, Co-Chair 

C. J. Inman, MD, MS 

Eric D. Newman, MD 

Catalina Orozco, MD 

Kara H. Prescott, MD 

33. Genetics, Genomics and Proteomics 

John B. Harley, MD, PhD, Co-Chair 

Betty P. Tsao, PhD, Co-Chair 

Gary S. Gilkeson, MD 

Robert M. Plenge, MD, PhD 

Soumya Raychaudhuri, MD, PhD 

Nan Shen, MD 

34. Education 

Robert A. Kalish, MD, Co-Chair 

Joan Marie Von Feldt, MD, MSEd, Co-Chair 

Michael J. Battistone, MD 

Richard D. Brasington, MD 

John A. Flynn, MD 

Paulette C. Hahn, MD 

326 

2012 Program Book


35. Miscellaneous Rheumatic and Inflammatory 

Diseases 

W. Winn Chatham, MD, Chair 

Kristine M. Lohr, MD, MS, Chair 

Corey M. Hatfield, DO 

Richard M. Keating, MD 

Cummins Lue, MD 

Katherine K. Temprano, MD 

36. Clinical Practice/Patient Care 

James G. Freeman, MD, Chair 

Marcia G. Chwalek, MS, RN, ANP 

Atul A. Deodhar, MD 

Beatriz Y. Hanaoka, MD 

Bernadette McNally, MS, PAC 

Leonard H. Sigal, MD 

37. Education/Community Programs 

Linda S. Ehrlich-Jones, PhD, RN, Chair 

Paul M. Adam, MSW 

Janet S. Austin, PhD 

Susan J. Blalock, PhD 

Victoria Gall, PT, MEd 

Deanna S. Yamamoto, NP 

38. Epidemiology and Public Health 

Uyen Sa D.T. Nguyen, DSc, MPH, Chair 

Alison H. Chang, PT, DPT, MS 

Yvonne M. Golightly, MS, PhD, PT 

Charles G. Helmick, MD 

Sunny Kim, PhD 


39. Health Services Research 

Mary E. Christenson, PhD, PT, Chair 

Catherine L. Backman, OT, PhD 

Laura D. Bilek, PhD, PT 

Donna K. Everix, MPA, BS, PT 

Linda J. Pine, PharmD 

Elizabeth A. Schlenk, hD, RN 

41. Psychology/Social Sciences 

Afton L. Hassett, PsyD, Chair 

E. M. Badley, PhD 

Carol M. Greco, PhD 

Vanessa L. Malcarne, PhD 

Perry M. Nicassio, PhD 

Karen L. Smarr, PhD 

42. Rehabilitation Sciences 

Hazel L. Breland, PhD, OTR/L, Chair 

Nadine M. Fisher, EdD 


Andrea S. Martin, MSN, FNP-C 

Janet L. Poole, OTR, PhD 

Mary Wright, BS, OT 

43. Research Methodology 

Elizabeth G. Salt, PhD, Chair 


Leigh F. Callahan, PhD 

Mary-Beth Coty, PhD, RN 

Kori A. Dewing, DNP, ARNP 

Una E. Makris, MD 

Basic Research Conference Abstract Reviewers 


Steffen Gay, MD 

Lionel B. Ivashkiv, MD 

John Varga, MD 

Clinical Research Conference Abstract 

Reviewers 


Danie J. Clauw, MD 


40. Pediatrics 

Thuy T. Beam, BSN, RN, Chair 

Susan Johnson, MSN 

Norma L. Liburd, MN 

Janalee Taylor, CNS, CPNP, MSN 

Akaluck Thatayatikom, MD 

Susan Tupper, PhD 


Corporate Roundtable 

The American College of 

Rheumatology Research 

Foundation has launched 

Journey to Cure — a 

$60 million multi-year 

campaign to directly invest 

in two mission priorities — 

rheumatology training and 

development, and diseasetargeted 

research. Journey to 

Cure serves as a rallying point 

to accelerate these mission 

priorities on a scale never 

before achieved. 

The Foundation thanks 

the Corporate Roundtable, 

including current Industry 

Roundtable members, for 

their exemplary support: 

† 

Within Our Reach Pinnacle Donor 

† † 

Within Our Reach Partner Donor 

* Industry Roundtable members

Educate • Network • Discover 

You can do all this and more in the 

Exhibit Hall 

Educate 

• Attend a session in the Innovation Theater 

• Listen to a missed session in the SessionSelect 

Lounge 

• Learn about the latest rheumatology products 

and services 

Network 

• Meet for lunch in the food court 

• Catch up in the networking lounges 

• Connect with employers at Career Connection 

Discover 

• New exhibitors 

• Search the web on WiFi Way 

Sunday, November 11: ................10:00 am – 5:00 pm 

Monday, November 12: ..............10:00 am – 5:00 pm 

Tuesday, November 13: ..............10:00 am – 5:00 pm

2012 Fellows Education Fund 

Through the Fellows Education Fund, the ACR 

is accelerating the education and training of 

the next generation of rheumatologists. The 

ACR Fellows Education Fund has a proven track 

record of successfully providing rheumatology 

fellows-in-training with outstanding educational 

opportunities to advance their knowledge 

and skills to treat an ever-changing patient 

population. 

The ACR thanks the following organizations 

for their support of the 2012 Fellows 

Education Fund: 

Genentech, A Member of the Roche Group 

UCB, Inc. 

Janssen Biotech, Inc.

EXHIBITORS 

Abbott 

Pharmaceuticals 

Booth #: 1005, Suite F 

www.abbott.com 

ACP/Annals of Internal Medicine 

Nonprofit Organization, Publisher 

Booth #: 214 

www.acponline.org 

ACR Simple Tasks 

Nonprofit Organization 

Booth #: 924 

www.SimpleTasks.org 

Actelion Pharmaceuticals 


Booth #: 1045 

www.actelion.com 

AESKU.DIAGNOSTICS 

Diagnostic Equipment/Products, Laboratory 

Equipment/Products 

Booth #: 420 

www.aesku.com 

American Regent, Inc. 


Booth #: 1049 

www.americanregent.com 

Amgen, Inc. 

Biotech, Pharmaceuticals 

Booth #: 900 

www.amgen.com 

Amgen, Inc. and Pfizer Inc. 


Booth #: 707 

www.amgen.com 

www.pfizer.com 

Arthritis Foundation 


Booth #: 304 

www.arthritis.org 

Arthritis Health Monitor TV 

Publisher, TV Network 

Booth #: 413 

www.healthmonitornetwork.com 

Autoimmune Diseases Association 


Booth #: 311 

www.aarda.org 

Auxilium Pharmaceuticals 


Booth #: 553, 658 

www.auxilium.com 

Besse Medical 

Distributor, Pharmaceuticals 

Booth #: 512 

www.besse.com 

BioMed Central 

Publisher 

Booth #: 438 

www.biomedcentral.com 

Bioventus, LLC 

Biotech, Therapeutic/Patient Aid Products 

Booth #: 422 

www.bioventusglobal.com 

Bristol-Myers Squibb 


Booth #: 1252 

www.bms.com 

British Society for Rheumatology 


Booth #: 206 

www.rheumatology.org.uk 

Buzzy4Shots.com 

Laboratory Equipment/Products 

Booth#: 1513 

www.Buzzy4shots.com 

Cardinal Health 

Pharmacy Services 

Booth #: 1519 

www.cardinalhealth.com 

Celgene Corporation 


Booth #: 819 

www.celgene.com 

Cellestis, a QIAGEN Company 

Biotech, Diagnostic Products 

Booth #: 843 

www.QuantiFERON.com 

Celltrion Healthcare Co., LTD 


Booth #: 361 

www.celltrionhealthcare.com 

Chugai Pharmaceutical Co., Ltd. 


Booth #: 761 

www.chugai-pharm.co.jp/hc/chugai_top_ 

en.jsp 

Cleveland Clinic 


Booth #: 221 

www.clevelandclinic.org 

Clinical and Experimental Rheumatology 

Publisher 

Booth #: 559 

www.clinexprheumatol.org 

Compulink Business Systems, Inc. 

Office Software/Equipment 

Booth #: 746 

www.compulinkadvantage.com 

ContextMedia:Health’s Rheumatoid Health 

Network 

Educational Materials for Patients 

Booth #: 1421 

www.contextmediahealth.com 

CORRONA, Inc. 

Other: Registry 

Booth #: 1509, Suite G 

www.corrona.org 

Crescendo Bioscience, Inc. 

Diagnostic Equipment/Products 

Booth #: 1247, Suite B 

www.crescendobio.com 

CuraScript SD 


Booth #: 1419 

www.curascriptonline.com 

CVS/Caremark Specialty Pharmacy 


Booth #: 639 

www.cvscaremarkspecialtyrx.com 

DePuy Mitek 

Medical Device 

Booth #: 1153 

www.depuymitek.com 

eClinicalWorks 

EHR 

Booth #: 357 

www.eclinicalworks.com 

Elsevier 

Publisher 

Booth #: 902 

www.us.elsevierhealth.com 

Esaote North America 


Booth #: 1343 

www.esaoteusa.com 

Euroimmun US 

Biotech, Diagnostic Equipment/Products 

Booth #: 506 

www.euroimmunus.com 


EXHIBITORS 

European League Against Rheumatism 

(EULAR) 


Booth #: 315 

www.eular.org 

Exhibitchek 

Market Research 

Booth #: 1142 

Ferring Pharmaceuticals Inc. 


Booth #: 514 

www.euflexxa.com 

Fidia Pharma USA 


Booth #: 641 

www.fidiapharma.us/en/ 

Forest Pharmaceuticals, Inc. 


Booth #: 747 

www.frx.com 

GE Healthcare 


Booth #: 741 

www.gehealthcare.com 

Genentech and Roche 


Booth #: 507 

www.gene.com 

Genzyme 

Biotech 

Booth #: 1146 

www.genzyme.com 

Gilead Sciences, Inc. 


Booth #: 537 

www.gilead.com 

GlaxoSmithKline, LLC 


Booth #: 1308 

www.gsk.com 

Gout & Uric Acid Education Society (GUAES) 

Nonprofit Organization, Educational 

Materials for Patients 

Booth #: 205 

www.gouteducation.org 

Hologic 

Diagnostic Equipment/Products, Medical 

Device 

Booth #: 940 

www.hologic.com 

Horizon Pharma, Inc. 


Booth #: 545 

www. horizonpharma.com 

Hospira 


Booth #: 744 

www.hospira.com 

Hospital for Special Surgery 


Booth #: 319 

www.hss.edu 

Inova Diagnostics, Inc. 

Biotech, Diagnostic Equipment/Products 

Booth #: 956 

www.inovadx.com 

Intellogics 

Biotech, Distributor 

Booth #: 1536 

www.intellogics.com 

Janssen Biotech, Inc. 


Booth #: 1023, 1226 

www.janssenbiotech.com 

Johns Hopkins Rheumatology 


Booth #: 801 

www.hopkinsrheumatology.org 

Journal of Rheumatology, The 

Publisher 

Booth #: 318 

www.jrheum.org 

La Lettre Du Rhumatologue - Edimark Santé 

Publisher 

Booth #: 601 

www.edimark.fr 

Letter to Editor Rheumatology 

Nonprofit Organization, Publisher 

Booth #: 212 

www.lettertoeditor.org 

Lilly USA, LLC. 


Booth #: 1327A, 1327B, 1327C 

www.lilly.com 

Lone Oak Medical Technology 


Device 

Booth #: 452 

www.loneoakmedical.com 

Lupus Initiative, The 


Booth #: 1043 

www.thelupusinitiative.org 

Mayo Clinic 


Booth #: 740 

www.mayoclinic.org 

McKesson Specialty Health 

Distributor 

Booth #: 1515 

www.mckessonspecialtyhealth.com 

medac pharma, Inc. 


Booth #: 847 

MedImmune, LLC 

Biotech 

Booth #: 327 

www.medimmune.com 

Merck 


Booth #: 1537 

www.merck.com 

METEOR 

Nonprofit Organization, Office Software/ 

Equipment 

Booth #: 308 

www.meteorfoundation.com 

Metro Medical Supply 


Booth #: 849 

metromedical.com 

Metroplex Clinical Research Center 

Research 

Booth #: 418 

www.mcrcdallas.com 

National Data Bank for Rheumatic Diseases 


Booth #: 215 

www.arthritis-research.org 

National Fibromyalgia Partnership 


Booth #: 305 

www.fmpartnership.org 

National Institute of Arthritis and 

Musculoskeletal and Skin Diseases 

Government 

Booth #: 213 

www.niams.nih.gov 

332 

2012 Program Book

EXHIBITORS 

National Scleroderma Core Centers 

Contract Research 

Booth #: 209 

www.bu.edu/SScores 

Novartis Pharmaceuticals Corporation 


Booth #: 1218 

www.novartis.com 

Nutramax Laboratories, Inc. 

Nutritional Products 

Booth #: 618 

www.nutramaxlabs.com 

NYU Langone Medical Center - NYU Hospital 

for Joint Diseases 


Booth #: 321 

www.med.nyu.edu/medicine/rheumatology 

OMERACT 


Booth #: 207 

www.omeract.org 

Optasia Medical, Inc 


Booth #: 1305 

www.optasiamedical.com 

Organization of Teratology Information 

Specialists 

Contract Research, Registry 

Booth #: 211 

www.otispregnancy.org 

Ossur Americas 


Booth #: 637 

www.Össur.com 

Oxford Immunotec Inc 

Diagnostic Products 

Booth #: 952 

www.oxfordimmunotec.com 

Oxford University Press 

Publisher 

Booth #: 404 

www.oup.com 

PANLAR 


Booth #: 313 

www.panlar.org 

PatientPoint 

Educational Materials for Patients, Publisher 

Booth #: 1404 

www.patientpoint.com 

Pfizer, Inc. 


Booth #: 423, 724 

www.pfizer.com 

Pulmonary Hypertension Association 


Booth #: 210 

www.PHAssociation.org 

Questcor Pharmaceuticals, Inc. 


Booth #: 1443 

www.questcor.com 

Quidel Corporation 


Booth #: 407 

www.quidel.com 

R. J. Fasenmyer Center for Clinical 

Immunology 

Nonprofit Organization, Medical Conference 

Booth #: 219 

www.clevelandclinic.org/FasenmyerCenter 

RDL Reference Laboratory 

Diagnostic Products 

Booth #: 619 

www.rdlinc.com 

Regeneron Pharmaceuticals, Inc. 


Booth #: 1147 

www.regeneron.com 

ReSearch Pharmaceutical Services 


Booth #: 1144 

www.rpsweb.com 

Rheumatoid Patient Foundation 


Booth #: 510 

www.rheum4us.org 

Rheumatology News 

Publisher 

Booth #: 1439 

www.rheumatologynews.com 

Rheumatology Nurses Society 


Booth #: 309 

www.RNSnetwork.org 

Rheumatology Practice News 

Publisher 

Booth #: 1437 

www.rheumatologypracticenews.com 

Roche 


Booth #: Suite J (1401) 

www.gene.com 

Rottapharm Ltd 


Booth #: 825 

www.rotta.com 

Sanofi Biosurgery 

Biotech 

Booth #: 645 

www.sanofi.com 

Savient Pharmaceuticals 

Biotech 

Booth #: 343, Suite C 

www.Savient.com 

Scandinavian Journal of Rheumatology 


Booth #: 320 

www.scandjrheumatol.dk 

Scleroderma Foundation 

Nonprofit Organization, Educational 

Materials for Patients 

Booth #: 303 

www.scleroderma.org 

Siemens Medical Solutions USA Inc. 

Diagnostic Equipment/Products, Imaging 

Core Lab 

Booth #: 946 

www.usa.siemens.com/rheumatology 

Silver Ring Splint Company 

Medical Device, Therapeutic/Patient Aid 

Products 

Booth #: 736 

www.SilverRingSplint.com 

Sjogren’s Syndrome Foundation 


Booth #: 204 

www.sjogrens.org 

SNBL 


Booth #: 944 

www.snbl.com 

SOBI 


Booth #: 1253 

www.sobi.com 


EXHIBITORS 

SonoSite 


Device 

Booth #: 501 

www.sonosite.com 

Spondylitis Association of America 

Educational Materials for Patients, 

Therapeutic/Patient Aid Products 

Booth #: 314 

www.spondylitis.org 

Springer 

Publisher 

Booth #: 436 

www.springer.com 

Takeda Pharmaceuticals 


Booth #: 1261 

www.tpna.com 

The JAMA Network 

Publisher 

Booth #: 339 

www.jamanetwork.com 

The Myositis Association 


Booth #: 310 

www.myositis.org 

TheraTest Laboratories, Inc. 


Booth #: 337 

www.theratest.com 

Trimer Biotech, LLC 

Biotech 

Booth #: 845 

www.trimerbio.com 

TSI Healthcare 

Rheumatology PM & EHR 

Booth #: 414 

www.tsihealthcare.com 

UCB, Inc. 

Biotech 

Booth #: 1137 

www.ucb.com 

United Regional Health Care System 

Recruitment 

Booth #: 415 

www.unitedregional.org 

UpToDate – Wolters Kluwer Health 

Office Software/Equipment, Publisher 

Booth #: 519 

www.uptodate.com 

US Pain Foundation Inc. 


Booth #: 307 

www.uspainfoundation.org 

Value-Based Care in Rheumatology 

Publisher 

Booth #: 649 

www.valuebasedrheumatology.com 

Vasculitis Foundation 


Booth #: 312 

www.vasculitisfoundation.org 

Vindico Medical Education 

Publisher 

Booth #: 353 

www.VindicoMedEd.com 

VQ OrthoCare 


Booth #: 653 

www.vqorthocare.com 

Wiley Blackwell 

Publisher 

Booth #: 841 

www.wiley.com 

334 

2012 Program Book

ACKNOWLEDGEMENTS 

The ACR, the ARHP and the Foundation wish to thank the following organizations for providing support for the 2012 ACR/ARHP Annual Meeting. 

Abbott 

Convention Center Banner 

Exhibit Hall Internet Centers 

Exhibit Hall Networking Lounges 

Amgen, Inc. 

Session Tracker 

Amgen, Inc. and Pfizer Inc 

Scientific Program Book 

Bristol-Myers Squibb Company 

Exhibit Hall Wi-Fi Way 

Exhibit Hall Aisle Signs 



Hotel Key Cards 

Pfizer, Inc. 

Poster Hall Services 

Convention Center Digital Signs 

Savient Pharmaceuticals, Inc. 


Conference Notepad 

Exhibit Hall Floor Decals 

Takeda Pharmaceuticals U.S.A., Inc. 

Clinical Scenario Challenge 

Convention Center Digital Signs 

UCB, Inc. 


Conference Shuttle Buses 

Attendee Lounge 


ACKNOWLEDGEMENTS 

In addition to the support provided for the 2012 ACR/ARHP Annual Meeting, the ACR, the ARHP and the Foundation wish to thank the following 

organizations for providing support for activities and programs held throughout the year. 

Abbott 

Corporate Roundtable, Leadership level 

Fellows Education Fund 

Winter Rheumatology Symposium 

Rheumatology Maintenance of Certification Course 

Rheumatology Training Directors’ Conference 

State-of-the-Art Clinical Symposium 

Clinical Focus Course: Targeted Approaches to Complex Pain Management 

CARE 2012 

ARHP Advanced Rheumatology Course 

ARHP Fundamentals of Rheumatology Course 

Musculoskeletal Ultrasound Course for Rheumatologists – Fundamentals 

(April and November) 

Musculoskeletal Ultrasound Course for Rheumatologists – Intermediate 

Musculoskeletal Ultrasound Course for Rheumatologists – Train-the-Trainer 

Hands-on Workshop 

Student Achievement Award 

Medical and Pediatric Resident Research Award 

Health Professional Graduate Student Research Preceptorship 

Medical Student Clinical Preceptorship 

Medical Student Research Preceptorship 

Annual Meeting Industry-Supported Symposium 

Amgen, Inc. 

Corporate Roundtable, Leadership level 







CARE 2012 








Amgen Pediatric Visiting Professorship Program 

Amgen Pediatric Research Award 

Amgen Fellowship Training Award 

ARHP Networking Forum 

Bioiberica 

Annual Meeting Industry-Supported Post-Conference Symposium 

Bristol-Myers Squibb Company 







CARE 2012 




Celgene Corporation 

Corporate Roundtable, Principal level 

Annual Meeting Industry-Supported Symposia 

Eli Lilly and Company 

Roundtable Member, Partner level* 





CARE 2012 



336 









Corporate Roundtable, Principal level 


2012 ACR/ARHP Membership Directory 






CARE 2012 



Human Genome Sciences, Inc. 


Human Genome Sciences, Inc. 

Corporate Roundtable, Partner level* 






CARE 2012 




Janssen Biotech, Inc. 



ACR REF Rheumatology Scientist Development Award 

MedImmune, LLC 


Pfizer, Inc. 







CARE 2012 








Savient Pharmaceuticals, Inc. 


UCB, Inc. 








CARE 2012 




*Industry Roundtable Member

A 

Abelson, Abby, MD 


Special Session: Clinician Scholar Educator 

Presentations ..........................62 

Disclosure: Nothing to Disclose 

Abramson, Steven B., MD 


Arthritis ..............................32 

Disclosure: Pfizer Inc., 5 

Microbiome Influence on Autoimmunity . . 101 


Adams, Harold, MD 

Update on Stroke .......................32 

Disclosure: Medical Review Ltd Japan, 8; 

Medtronic, 5; Merck Pharmaceuticals, 5; Pierre 

Fabre, 8 

Agace, William, PhD 

Molecular and Cellular Basis of Tissue 

Homing ...............................91 


Aggarwal, Rohit, MD, MS 

Plenary Session II: Discovery 2012 .........67 


Airth-Edblom, Tracey L., OTR, CHT 


What You Don’t Know Can Hurt You .......37 


Al Haj, Rany, MD 

ACR Musculoskeletal Ultrasound Course for 

Rheumatologists ....................20, 23 


Al Nahlawi, Basma, MD 

Thieves’ Market Poster Presentation - 

Development of Leprosy After Treatment With 

IL6 Blocker ............................62 


Alexanderson, Helene, PhD, RPT 


Management .........................110 


Alheresh, Rawan, OT, MSc 


Where Do We Go Next? .................89 


Ali, Joseph, JD 

Clinical Research Conference - Special Issues in 

Pain Research .........................23 


Allen, Kelli D., PhD 


Reviewed and Scored ...................79 


Alonzo, Chris 

Practice Managers: Improving Access and 

Website Marketing .....................46 


Ampel, Neil M., MD 

Fungal Infections and Tuberculosis in Patients 

with Rheumatologic Disease .............91 


Andrade, Luis Eduardo C., MD, PhD 

Making Sense of Autoantibodies in the 

Diagnosis of Systemic Rheumatic Diseases . . 129 

Disclosure: Fleury Medicine and Health 

Laboratories, 5 

Antolini, C. Ryan, MD 

Creating an Efficient Rheum Practice .......61 


Aranow, Cynthia, MD 


System (009) ...........................31 



System (076) ..........................102 


Arnold, Lesley M., MD 

Clinical Research Conference - Clinical Trials 

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 

Disclosure: Daiichi Sankyo, 5; Dainippo Sumtomo 

Pharma, 5; Eli Lilly and Company, 2; Forest 

Laboratories, 2, 5; Grunenthal, 5; Pfizer Inc, 2, 5, 

8; Takeda , 2; Theravance, 5 

Depression in Rheumatic Diseases .........80 

Disclosure: Daiichi Sankyo, 5; Dainippo Sumtomo 

Pharma, 5; Eli Lilly and Company, 2; Forest 

Laboratories, 2, 5; Grunenthal, 5; Pfizer Inc, 2, 5, 

8; Takeda , 2; Theravance, 5 

Arriens, Cristina, MD 

Thieves’ Market Poster Presentation - Stridor 

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62 



. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49 


Ascherman, Dana P., MD 


Management .........................110 


Avecilla, Sunjanel, EMT-P, CPC, CMC, CMOM, 

CMIS, CMCO 

CORC Pre-meeting Course for Practice 

Managers - Improving Accounts Receivable for 

Profitability ............................27 


CORC Pre-meeting Course for Practice Managers 

- Transforming the Practice Front End ......27 


B 

Baer, Alan N., MD 

Controversies in Sjögren’s Syndrome (053) . . 88 

Disclosure: Cellgene, 5; Merck Serono, 5 

Controversies in Sjögren’s Syndrome (002) . . 31 

Disclosure: Cellgene, 5; Merck Serono, 5 

Bahrami, Soon, MD 

Dermatology Topics for Rheumatologists: What 

You Need to Know ......................81 


Baker, Nancy A., MPH, OTR, OTR/L 

A Practical Understanding of Function in 

Rheumatoid Arthritis: A Multidisciplinary 

Perspective ............................97 


Balow, James E., MD 


Erythematosus .........................39 


Baraf, Herbert S. B., MD 

Contract Negotiations for Physicians .......93 



Managers - Deal Breakers in Payer Contract 

Negotiations ...........................27 


Bartlett, Susan J., PhD 

Clinical Focus Course - Obesity and 

Osteoarthritis: Clinicians Can Make a Difference 

in Promoting Healthier Lifestyles ..........27 


Complementary and Alternative Medicine: 

Evidence Based Options for Arthritis 

Patients ...............................39 


New and Better Habits! Facilitating Patient 

Self-management with Proven Behavior Change 

Strategies .............................59 


Bathon, Joan M., MD 

Tips for Publishing Your Work in a Peer- 

Reviewed Medical Journal ...............30 


Battistone, Michael J., MD 

Medical Education: The Year in Review .....32 






Beam, Thuy T., BSN, RN 

Forming an Education and Support Group from 

the Ground Up ........................128 


Obesity in Rheumatic Diseases of Children and 

Adults ...............................111 


Transition Tools for Patients: Pediatric to 

Adults ...............................111 


Becker, Mara L., MD, MSCE 


Rheumatologists (066) ..................92 


Crystal: Diagnosis and Management of Gout 

(031) .................................60 

Disclosure: Ardea Biociences INC, 5; 

BioCryst Pharmaceuticals Inc, 5; Metabolex 

Pharmaceuticals Inc, 5; Regeneron 

Pharmaceuticals Inc, 5; Savient Pharmaceuticals 

Inc, 5; Takeda Pharmaceuticals Inc, 5; UpToDate 

Inc, 7; URL Pharmaceuticals Inc, 5 


(062) .................................92 

Disclosure: Ardea Biociences INC, 5; 






Invited Speaker /Moderator Index 



338 

Bég, Shazia, MD 


Development: Lessons from New Medical 

Schools ...............................71 


Belza, Basia, PhD 

Distinguished Lecturer: Unraveling the “Go- 

Gene” ................................63 


Benator, Debra, MD 



Arthritis ...............................58 


Berman, Jessica, MD 





Berney, Seth M., MD 


Disclosure: Biogen/Idec, Genentech, 

Medimmune, Roche, UCB , 2; MedStudy, 8; Pfizer 

Inc, 2 

Bernstein, Elana J., MD 

Paradigm Shifts in Rheumatoid Arthritis ....93 


Preoperative Assessment and Perioperative 

Management of the Patient with Rheumatic 

Disease: What Every Rheumatologist Should 

Know (Clinical Review) ..................38 


Bethina, Narandra, MD 

ACR Knowledge Bowl - Preliminary Round . . 37 


Beukelman, Timothy, MD, MSCE 

New Developments in Systemic Juvenile 

Idiopathic Arthritis Management ..........69 

Disclosure: Genentech and Biogen IDEC Inc., 5; 

Novartis Pharmaceutical Corporation, 5; Pfizer 

Inc, 2 

Bingham III, Clifton O., MD 

Vaccinations for Patients on Biologic Therapies 

(049) .................................70 


Vaccinations for Patients on Biologic Therapies 

(090) ................................119 


Binstadt, Bryce, MD, PhD 



Biro, Frank M., MD 

Puberty, Adolescence and Rheumatologic 

Disease ...............................49 


Bloch, Donald B., MD 

Making Sense of Autoantibodies in the 

Diagnosis of Systemic Rheumatic Diseases . . 129 



Block, Joel A., MD 


Sympathetic Dystrophy: Recent Advances, 

Current Thoughts .......................70 

Disclosure: Allergan USA, Inc., 5; Pfizer, Inc., 5 


Incidence of Falls by Older Adults .........29 

Disclosure: Allergan USA, Inc., 5; Pfizer, Inc., 5 

Blythe, Margaret J., MD 


Disease ...............................49 

Disclosure: Merck Pharmaceuticals, 8 

Bode, Christina, PhD 

The Puzzle of Fatigue in Rheumatoid Arthritis: 

Putting the Pieces Together .............120 


Bonassar, Lawrence, PhD 


. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72 

Disclosure: Fidia Farmaceutici, SpA, 2 

Bong, David A., MD 


Rheumatologists - Day Two ...............23 


Borenstein, David G., MD 

Pain: Evaluation and Treatment of Back Pain 

(056) .................................88 

Disclosure: Abbott Laboratories, 5; Pfizer Inc, 5 

Clinical Research Conference - Day Two 

Introductory Remarks ...................28 


ILAR – The Current Rheumatology Workforce 

Across the Globe .......................59 


Pain: Evaluation and Treatment of Back Pain 

(025) .................................56 


Approach and Management of Back Pain in 

Older Adults ..........................104 


ACR Town Hall Meeting & Business Meeting 

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103 

Disclusure: Abbott Laboratories, 5; Pfizer Inc, 5 

Breland, Hazel L., PhD, OTR/L 

Disparities in the Use of Joint Arthroplasty: 

A Pervasive Matter Leading to Inequitable 

Care .................................58 


Osteoporosis: 2012 Update .............128 


Brenner, Michael B., MD 

Basic Research Conference - Session I: The 

Biology of Mesenchymal Cells ............22 

Disclosure: Calcimedica Inc, 5; Synovex Corp, 1, 5 

Prospects for Prevention and Cure of 

Rheumatoid Arthritis ....................39 

Disclosure: Calcimedica Inc, 5; Synovex Corp, 1, 5 

Bridges Jr., S. Louis, MD, PhD 

Osteoimmunology .....................102 


Bright, Christina, MD 



Brooks, Peter, MD 


across the Globe .......................59 


Brunner, Hermine, MBA, MD, MSc 



Neuropsychiatric Lupus in Children and 

Adolescents ...........................72 


Pediatric Rheumatology Town Hall Meeting 

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71 


Bruyn, George A. W., MD, PhD 

Musculoskeletal Ultrasound Course for 

Rheumatologists - Hand and Wrist .........21 


Bucala, Richard J., MD, PhD 

Gouty Inflammation ....................96 


Systems Immunology ...................92 


Buckley, Christopher D., PhD 

Basic Research Conference - Session IV: 

Immunity and Mesenchymal Cells .........25 


Burke, Allen, MD 

Histopathology of Vasculitis (222) .........71 


Histopathology of Vasculitis (233) .........97 


Bykerk, Vivian P., MD 


Disclosure: Amgen, Pfizer, Abbott, BMS, 

Janssen Biotech, Roche, UCB, 2; Pfizer, Astellis 

Pharmaceuticals, Boehringer Ingelheim, BMS, 

Roche, UCB, Abbott, 5 

C 

Calabrese, Leonard H., DO 

Review Course - Is It Central Nervous System 

Vasculitis or Something Else? .............25 

Disclosure: Amgen, 8; Bristol-Myers Squibb, 

5; Genentech and Biogen IDEC Inc., 5; Janssen 

Pharmaceutica Product, L.P., 5; Sanofi-Aventis 

Pharmaceutical, 5; ucb, 5 

Callahan, Leigh F., PhD 

Don’t Let the Pink Sheets Make You Blue ...91 


Carette, Simon, MD 

The Great Masqueraders: Malignancies in 

Rheumatic Disease. . . . . . . . . . . . . . . . . . . . . 112 


Carnie, Martie, AS, PFAC 

Practice Management: Patients As Partners in 

Design and Delivery .....................56 


Carrino, John, MD, MPH 


Rheumatology .........................58 

Disclosure: Carestream, Siemens, General 

Electric, 6; Medtronic, General Electric, Quality 

Medical Metrics, Vital Images, 5; Merge 

Healthcare, 1; Siemens, Toshiba, Carestream, 2

Carson, Craig W., MD 

The Guide to Meaningful Use and Beyond 

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94 


Carsons, Steven E., MD 


Syndrome .............................48 


Carter, Robert H., MD 

Career Opportunities in Rheumatology: Making 

a Choice ..............................69 


NIAMS-Sponsored Research in Rheumatology: 

2012 Highlights .......................122 


Catanese, Veronica M., MD, MBA 



Schools ...............................70 


Chakravarty, Eliza F., MD 

Pregnancy in Rheumatic Diseases (018) ....38 


Pregnancy in Rheumatic Diseases (067) ....92 


Chao, Nelson, MD 

Don’t Let the Pink Sheets Make You Blue ...91 


Chapurlat, Roland, MD 

Plenary Session I: Discovery 2012 .........35 

Disclosure: Merck Pharmaceuticals, 2, 5 

Charles-Schoeman, Christina, MD 

Diagnostic Assessments in Myopathy .....111 


Chauhan, Krati, MD, MPH 

Thieves’ Market Poster Presentation - A Case of 

Juvenile Arthritis .......................62 


Chen, Di, MD, PhD 

New Molecules in Joint Biology . .........104 


Chen, Lan, MD, PhD 


(215) .................................48 



(232) .................................92 



(237) ................................103 


Chinoy, Hector, MD, PhD 



Choi, Hyon K., DrPH, MD 


Risk Factor Paradox and Other Issues ......96 



Disease Research .......................93 


Chow, Shingpui Betty, PT, MA, OCS 

Osteoarthritis: Opportunities and Challenges 

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88 


Chowdhury, Badrul, MD, PhD 


Administration Perspective ..............122 


Christl, Leah, PhD 




Christopher-Stine, Lisa, MD, MPH 

Myopathy: Issues in Diagnosis and Treatment 

(014) .................................38 

Disclosure: Inova Diagnostics, Inc., 7; 

Medimmune, 5; Novartis Pharmaceutical 

Corporation, 5; Questcor, 5 

Myopathy: Issues in Diagnosis and Treatment 

(073) ................................102 

Disclosure: Inova Diagnostics, Inc., 7; 

Medimmune, 5; Novartis Pharmaceutical 

Corporation, 5; Questcor, 5 

Chu, Cong-Qiu, MD 

Neutrophil Extracellular Traps (NETosis) in 



Chung, Antanya, CPC, CPC-I, CRHC, CCP 

Certified Rheumatology Coder Course: Unlock 

the Mystery: A Roadmap for Rheumatology 

Coding - Day One .......................21 


Ciccarelli, Mary R., MD 

Obesity in Rheumatic Diseases of Children and 

Adults ...............................111 


Transition Tools for Patients: Pediatric to 

Adults ...............................111 


Cid, Maria C., MD 

Polymyalgia Rheumatica - Recent Advances and 

Ongoing Questions ....................101 


Clarke, John, MD 

Scleroderma Bowel Disease: From Top to 

Bottom (Clinical Review) .................71 

Disclosure: ProStrakan, 9; Wyeth 

Pharmaceuticals, 9 

Clauw, Daniel J., MD 

Clinical Research Conference - Introduction: 

State of the Field .......................22 

Disclosure: Pfizer Inc, Forest Laboratories, Merck, 

Nuvo , 2; Pfizer, Forest, Lilly, Merck, Nuvo, J and 

J , 5 

Clayburne, Gilda M., MLT 


(215) .................................48 



(232) .................................92 



(237) ................................103 


Cohen, Stanley B., MD 


Disclosure: Abbott Laboratories, 2; Amgen, 5; 

Astellas, 8; BMS, 5; Janssen Pharmaceutica 

Product, L.P., 5; Pfizer Inc;, 5; Roche 

Pharmaceuticals, 5; UCB, 2 

Rheumatoid Arthritis: Difficult Cases (036) . . 60 

Disclosure: Abbott Laboratories, 2; Amgen, 5; 

Astellas, 8; BMS, 5; Janssen Pharmaceutica 

Product, L.P., 5; Pfizer Inc;, 5; Roche 


Collier, Deborah S., MD 

The Connected Rheumatology Practice: 

Electronic Health Record and Social Media 

Implementation and Customization ........69 


Collins, Christopher E., MD 





Conaghan, Philip G., MD, PhD 


Rheumatology Practice (218) .............60 





Connelly, Mark, PhD 

Clinical Research Conference - Day Two - Break 

Out Groups ...........................29 

Disclosure: Arthritis Foundation, 2; NIAMS, 2 

Clinical Research Conference - Day Two - 

Methods for Phenotyping Pain-2 ..........28 

Disclosure: Arthritis Foundation, 2; NIAMS, 2 

Cook, Dane B., PhD 

Clinical Research Conference - Day Two - Break 

Out Groups ...........................28 


Non-pharmacological Management of 

Fibomyalgia: Your Toolbox. . . . . . . . . . . . . . . . 46 


Cope, Andrew P., MD, PhD 


Practice ..............................58 


Molecular and Cellular Basis of Tissue 

Homing ...............................91 


Visualizing the Immuno-inflammatory 

Response ............................104 


Crawford, Donah Z., BS, MA 

Highlights from the 2012 ARHP Sessions ...104 


Criscione-Schreiber, Lisa G., MD 






340 

Criswell, Lindsey A., MD, MPH 


Syndrome .............................48 


Epigenetic Factors in Autoimmune Disease . . 60 



Disease Pathogenesis ...................30 


Cronin, Mary E., MD 

Adult Inflammatory Myopathy (051) .......88 


Adult Inflammatory Myopathy (011) .......38 


Cronstein, Bruce N., MD 

Basic Research Conference - Session VI: 

Therapeutic Aspects: Biomarkers and Targeting 

Fibrosis (continued) .....................26 

Disclosure: Arthritis Foundation, SLE Foundation, 

6; Bristol-Myers Squibb, Novartis, URL, 

Regeneron, Gismo Therapeutics, 5; Canfite 

BioPharma, 1; NIH, URL Pharma, OSI, 2; Patents 

on use of adenosine receptor antagonists to treat 

or prevent fibrosis. Multiple other patents., 9 


2012 Highlights .......................122 

Disclosure: Arthritis Foundation, SLE Foundation, 

6; Bristol-Myers Squibb, Novartis, URL, 

Regeneron, Gismo Therapeutics, 5; Canfite 

BioPharma, 1; NIH, URL Pharma, OSI, 2; Patents 

on use of adenosine receptor antagonists to treat 

or prevent fibrosis. Multiple other patents., 9 

Crow, Mary K., MD 

Predictive Biomarkers: A Journey to 

Personalized Health Care ...............123 

Disclosure: Baxter, 5; Celgene, 5; EMD Merck 

Serono, 5; Genentech and Biogen IDEC Inc., 5; 

Idera, 5; Johnson & Johnson, 1; Johnson and 

Johnson, 5; MedImmune, 5; Novo Nordisk, 2; 

Pfizer Inc, 1; Takeda, 5 

Cui, Jing, PhD 

Rheumatology Research Foundation Special 

Session: Disease Targeted Research .......94 


Curtis, Jeffrey R., MD, MPH, MS 

Osteoporosis: From Bisphosphonates and 

Beyond ...............................72 

Disclosure: Roche/Genetech, UCB, Centocor, 

CORRONA, Amgen Pfizer, BMS, Crescendo, 

Abbott, 2, 5 



Directions ............................111 

Disclosure: Roche/Genetech, UCB, Centocor, 

CORRONA, Amgen Pfizer, BMS, Crescendo, 

Abbott, 2, 5 

Cush, John J., MD 

Infections with Biologics (003) ............31 

Disclosure: Genentch, Pfzer, UCB, Celgene, 

Amgen, Novartis, CORRONA, NIH, 2; Jensen, 

Savient,Pfizer, BMS,Amgen, Genetech Abbott, 

UCB, 5 

Infections with Biologics (063) ............92 




UCB, 5 


Rheumatology Roundup: Highlights from the 

2012 Annual Scientific Meeting ..........121 




UCB, 5 



Administration and Beyond ..............62 




UCB, 5 

Cyr, Lori L., BSc, OT 


Rheumatic Disease Research .............91 



Populations ............................80 


D 

Daikh, David I., MD, PhD 


Meeting .............................103 


Rheumatology Research Foundation Paul 

Klemperer, MD Memorial Lectureship: Serum 



Outcomes .............................91 


Dall’Era, Maria, MD 


Systemic Lupus Erythematosus (060) .......88 



Systemic Lupus Erythematosus (077) ......102 


Dasgupta, Bhaskar, MD 

Polymyalgia Rheumatica (017) ............38 

Disclosure: Merck Pharmaceuticals, 5 

Davidson, Anne, MBBS 





a Choice ..............................69 


Deal, Chad L., MD 


Beyond ...............................72 

Disclosure: Amgen, Lilly, 5, 8 

Review Course - Osteoporosis Update ......25 


Deane, Kevin D., MD, PhD 


Arthritis ..............................32 



Prevention ............................82 


Deane, Peter, MD 

Hereditary Angioedema (045) ............70 


DeMarco, Paul J., MD 


Rheumatologists .................20, 23, 24 

Disclosure: Abbott Immunology Pharmaceuticals, 

8; Auxilium Pharmaceuticals, 5; Sonosite Inc, 5 


Practice? .............................112 


8; Auxilium Pharmaceuticals, 5; Sonosite Inc, 5 

Dennis, Gregory J., MD 


Disclosure: Awarded stock options at Human 

Genome Sciences, 1; Was a full time employee 

of HGS, 3 

Deodhar, Atul A., MD 

Joint Injection Techniques (234)...........97 


Joint Injection Techniques (239)..........111 


Desai, Shailey S., MD 

ACR Knowledge Bowl - Final Round ........37 


Dewing, Kori A., DNP, ARNP 


Practitioners into Rheumatology Practice ...59 


Diamond, Betty, MD 


Adolescents ...........................72 


Distler, Joerg HW, MD 

Basic Research Conference - Session II: Core 

Signaling Mechanisms in Fibrosis ..........22 

Disclosure: 4D Science Gmbh, 1; Bayer Pharma, 

Celgene, Boehringer Ingelheim, JB Therapeutics, 

Anaphore, Actelion, Pfizer, Roche, 5; Bayer 

Pharma, Celgene, JB Therapeutics, Anaphore, 

Actelion, Pfizer, Roche, 8; Celgene, Bayer Pharma, 

Novartis, Array Biopharma, Pfizer, BMS , 2 

Domsic, Robyn T., MD, MPH 

Scleroderma: Systemic Sclerosis (038)......60 


Scleroderma: Systemic Sclerosis (069)......92 


Dooley, Mary Anne, MD, MPH 

Systemic Lupus Erythematosus: Novel 

Treatments (019) .......................38 

Disclosure: Cephalon, 9; GSK/HGS, 8; HGS GSK, 

9; UCB, 9 

Dougados, Maxime, MD 




Duffield, Jeremy S., MD, PhD 

Basic Research Conference - Session V: 


Fibrosis ...............................25 

Disclosure: Biogen Idec, Boehringer Ingelheim, 

BMS, GSK, Takeda, Gilead, 5; Muregen LLC, 1; 

Promedior Inc., 1; Regulus Therapeutics, 2 

Dufour, Alyssa B., MA 

Beyond the Basics: A Real Life Example of 

Multiple Imputation for Missing Data 

Problems .............................121 

Disclosure: Nothing to Disclose

Dunlop, Dorothy D., PhD 

Basic Statistical Concepts for the Medical 

Researcher (201) .......................31 

Disclosure: Pearson Publishing Company, 5 

Dures, Emma, PhD 



Strategies .............................59 


Dutz, Jan P., MD 



Disclosure: Centocor, ONO Pharmaceuticals, 9; 

Janssen-Ortho, Abbott, Amgen, Leo Pharma, 5, 8 

Dworkin, Robert H., PhD 

Clinical Research Conference - Clinical 

Trials .................................23 

Disclosure: Adynxx, Analgesic Solutions, Astellas, 

Avanir, Biogen, Bioness, Bristol-Myers Squibb, 

Depomed, Depuy, Epicept, Flexion, Johnson & 

Johnson, Lilly, Merck, MMS Holdings, NeurogesX, 

Pfizer, Sanofi-Aventis, Smith & Nephew, and 

Spinifex, 5; NIH and FDA, 2 

E 

Ehrlich-Jones, Linda S., PhD, RN 

ARHP Keynote Address: It’s Not Child’s Play: 

Growing Up With and Mastering Juvenile 

Idiopathic Arthritis from the Child’s 

Perspective ............................33 


Best Practices for Ordering Diagnostic Imaging 

in Evaluating Rheumatologic Conditions ...120 


Distinguished Lecturer: Unraveling the “Go- 

Gene” ................................63 


The 5A Approach to Physical Activity Counseling 

for Arthritis Patients ....................37 


El-Gabalawy, Hani S., MD 


Prevention ............................82 


Review Course - Setting the Stage for 



Elliott, Christine, RN 

Infusion Reactions: Management and 

Prevention ............................61 


Elson, Charles O., MD 



Embi, Peter J., MD, MS 

Designing a Website for Your Practice (208) 

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39 


Erickson, Alan R., MD 

Top 10 Compliance Risks Facing Physicians . . 101 


Erkan, Doruk, MD 

Catastrophic Antiphospholipid Syndrome 

(Clinical Review) .......................102 

Disclosure: Genentech and Biogen IDEC Inc., 2, 5; 

Human Genome Sciences, Inc., 8; Lupus Clinical 

Trials Consortium, 2 

Esdaile, John, MD, MPH 


Practice? .............................112 


Evangelisto, Amy M., MD 




2, 8 

Musculoskeletal Ultrasound (206) .........33 


2, 8 



2, 8 


Rheumatologists - Break Out Session: Adult 



2, 8 


Rheumatologists - Opening Remarks .......20 


2, 8 


Rheumatologists - The Elbow .............21 


2, 8 


Rheumatologists - The Shoulder ...........21 


2, 8 

Everix, DOnna K., MPA, BS, PT 

Early Rehabilitation for Hip and Foot 


. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88 



What You Don’t Know Can Hurt You .......37 


Total Knee Arthroplasty Rehabilitation: 

Optimizing Functional Outcomes Through 

Examination of Patient Factors, Practice 

Variation and Best Practice Recommendations 

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80 


F 

Farrell, Jessica, PharmD 

Clinical Focus Course - Breakout Session I ...26 


Clinical Focus Course - Breakout Session II . . 26 




Fearon, Douglas T., MD 




Feinstein, Amanda B., MS 

Novel Approaches to Pain Management in 

Juvenile Idiopathis Arthritis ..............89 


Ferguson, Polly J., MD 


. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90 


Fett, Nicole, MD 

Cutaneous Vasculitis (012) ...............38 


Fields, Theodore R., MD 


(023) .................................56 

Disclosure: Savient Pharmaceuticals, 5, 8; Takeda 

Pharmaceuticals, 5, 8; URL Pharmaceuticals, 5, 8 

Gout and Hyperuricemia: Diseases Beyond 

the Joint ..............................81 

Disclosure: Savient Pharmaceuticals, 5, 8; Takeda 

Pharmaceuticals, 5, 8; URL Pharmaceuticals, 5, 8 

Figueroa, Fernando E., MD 

Catastrophic Antiphospholipid Syndrome 

(Clinical Review) .......................102 


Update on Stroke .......................32 


Fillingim, Roger B., PhD 

Clinical Research Conference - Break Out 

Groups ...............................28 

Disclosure: Algynomics, 1; American Pain Society, 

6; MedScape, 5 

Clinical Research Conference - Methods for 

Phenotyping Pain-1 .....................28 

Disclosure: Algynomics, 1; American Pain Society, 

6; MedScape, 5 

Fine, Derek M., MD 

Update on Immune Mediated Glomerular 

Disease ...............................91 


Finkel, Toren, MD, PhD 

Aging and the Rheumatic Diseases ........81 


Fiorentino, David, MD, PhD 




Firestein, Gary S., MD 

Rheumatology Research Foundation Memorial 

Lectureship: Pathogenesis of Rheumatoid 

Arthritis: The Voyage from Pre-Rheumatoid 

Arthritis to Joint Destruction .............61 

Disclosure: NexDx, Inc, 9 



Fibrosis ...............................26 

Disclosure: NexDx, Inc, 9 

Fischer, Aryeh, MD 

Connective Tissue Disease Associated Interstitial 

Lung Disease. . . . . . . . . . . . . . . . . . . . . . . . . . 104 

Disclosure: Actelion Pharmaceuticals US, 5, 8; 

Gilead Pharmaceuticals, 8; NIH, 2 

Fish, Eleanor, PhD 



Fibrosis ...............................25 





Fitzgerald, G. Kelley, PhD, PT 





FitzGerald, John D., MD, PhD 


Practice? .............................112 

Disclosure: American College of Rheumatology, 2 

Fleischman, Michael, FAAHC 


- Improve Revenue Cycle Management 

Effectiveness and Optimize Cash Flow ......27 


Flemming, Donald J., MD 

X-ray Challenges in Rheumatic Diseases 

(219) .................................60 

Disclosure: Elsevier, 7 

Flood, Joseph, MD 


a Choice ..............................69 


Fox, David A., MD 






Karyopharm, 2 

Franklin, Patricia D., MD, MBA, MPH 

Clinical Focus Course - Osteoarthritis Chronic 

Disease Management in the Age of the Internet, 

Apps and Tweets .......................27 

Disclosure: Zimmer, Inc., 2 




Variation and Best Practice 

Recommendations ......................80 

Disclosure: Zimmer, Inc., 2 

Freeman, James G., MD 


in Patients Undergoing Joint Replacement . . 61 



Erythematosus ........................111 


Rheumatic Disease Update: The Approach to 

Low Back Pain .........................93 


Rheumatic Disease Update: Vasculitis ......37 


Strategies to Enhance Office Efficiencies and 

Access to Care in Rheumatology Practice ...97 


Furie, Richard A., MD 


a Choice ..............................69 


Plenary Session III: Discovery 2012 ........64 


Furner, Sylvia, PhD, MPH 

Arthritis and the Older Worker ...........120 


Furst, Daniel E., MD 

Hepatitis in Patients with Rheumatologic 

Disease ...............................93 

Disclosure: Abbott, Actelion, Amgen, BMS, 

BiogenIdec, Centocor, Gilead, GSK, NIH, 

Novartis, Pfizer, Roche/Genentech, UCB, 5; 

Abbott, Actelion, Amgen, BMS, Gilead, GSK, 

NIH, Novartis, Pfizer, Roche/Genentech, UCB, 2; 

Abbott, Actelion, UCB , 8 

Systemic Sclerosis: How to Perform Skin 

Scores (228) ...........................81 

Disclosure: Abbott, Actelion, Amgen, BMS, 

BiogenIdec, Centocor, Gilead, GSK, NIH, 

Novartis, Pfizer, Roche/Genentech, UCB, 5; 

Abbott, Actelion, Amgen, BMS, Gilead, GSK, 

NIH, Novartis, Pfizer, Roche/Genentech, UCB, 2; 

Abbott, Actelion, UCB , 8 

G 

Gabay, Odile H., PhD 

Energetics, Metabolism and Osteoarthritis . . 81 


Gabriel, Sherine E., MD, MSc 




Gaffney, Patrick M., MD 




Garber, Larry, MD 


- Innovations for the Office ...............28 


Gardner, Gregory C., MD 

Review Course .........................24 


Amyloidosis 2012 ......................129 


Joint Injections (Knee and Ankle Prosthetics) 

(216) .................................60 


Joint Injections (Shoulder and Wrist Prosthetics) 

(223) .................................70 


Garside, Paul, PhD 


Response ............................104 


Gay, Steffen, MD 



Disclosure: IAR , 2 



Disclosure: IAR , 2 

Basic Research Conference - Session III: 

Fibroblasts as Invaders and Aggressors .....25 


Geenen, Rinie, PhD 




Geissmann, Frederic, MD, PhD 


Tissue Inflammation and Fibrosis ..........72 


Gelber, Allan C., MD 


a Choice ..............................69 


Genovese, Mark C., MD 



Disclosure: Eli Lilly and Company, 2, 5 

Gerlag, Danielle M., MD 


Response ............................104 


Gilkeson, Gary S., MD 


Directions ............................122 


Gillanders, Robert, PT, DPT 

Shoulder Pain and Rotator Cuff Tear in 

Rheumatoid Arthritis ...................136 


Goebel, Andreas, MSc, PhD 


Sympathetic Dystrophy: Recent Advances, 

Current Thoughts .......................70 

Disclosure: Baxter, UK, CSL-Behring, Biotest , 2; 

CSL-Behring, 9 

Golightly, Yvonne M., MS, PhD, PT 



Problems .............................122 


Goncalves Marangoni, Roberta, MD, PhD 



Fibrosis ...............................46 


Gordon, Jessica K., MD, MSc 


Lung Disease. . . . . . . . . . . . . . . . . . . . . . . . . . 104 


Goyal, Janak R., MD 


Rheumatologists - Day Two .........20, 23, 24 


Musculoskeletal Ultrasonography: Basic 

(226) .................................80 


Grabiner, Mark D., PhD 


Incidence of Falls by Older Adults .........29 

Disclosure: University of IIllinois, 7 

Graham, Logan 

ARHP Keynote Address: It’s Not Child’s Play: 

Growing Up With and Mastering Juvenile 

Idiopathic Arthritis from the Child’s 

Perspective ............................33 


342 

2012 Program Book

Gramling, Anna, MD 


Voriconazole-Induced Periostitis ..........62 


Gravallese, Ellen M., MD 



Disclosure: Abbott Laboratories, 5; Lilly, 2 

Rheumatology Research Foundation Oscar S. 

Gluck, MD, Memorial Lectureship: Bone Wasn’t 

Built in a Day: New Insights into Destruction and 

Repair in Rheumatic Disease ..............33 

Disclosure: Abbott Laboratories, 5; Lilly, 2 

Gregersen, Peter K., MD 



Disclosure: Illumina and Amgen, 1, 9 

Griffin, Timothy M., PhD 



Grom, Alexei A., MD 



Disclosure: Novartis Pharmaceutical Corporation, 5 

Gujar, Bansari, MD 


Headaches and Heartaches. . . . . . . . . . . . . . . 62 


Thieves’ Market Poster Presentation - Mass 

Effect .................................62 


Gultekin, Sakir Humayun, MD 

Muscle Involvement in Rheumatic Diseases 

(209) .................................39 


Gutierrez, Cindy, MBA 


Managers - Deal Breakers in Payer Contract 

Negotiations ...........................27 



- Effective Marketing for Today’s Medical 

Practice ...............................27 



- How to Maximize the Use of Your Practice 

Data ..................................28 






- Transforming the Practice Front End ......27 


H 

Hafler, David A., MD 

Systems Immunology ...................92 

Disclosure: Pfizer Inc, 5; Teva Neuroscience, 5 

Hahn, Bevra H., MD 


Disclosure: Abbott, 5; Anthera, 5; Aspreva 

Pharmaceutical, 2; Eli Lilly, 5; Teva 




Disclosure: Abbott, 5; Anthera, 5; Aspreva 

Pharmaceutical, 2; Eli Lilly, 5; Teva 


Hajj-Ali, Rula, MD 

Central Nervous System Vasculitis (081) ...119 


Hannan, Marian T., DSc, MPH 


Populations ............................80 





Hant, Faye N., DO, MSCR 

Scleroderma Mimics (048) ...............70 


Harrington, J. Timothy, MD 

Rheumatoid Arthritis: Outcome Measures in 

Clinical Practice (029) ...................56 

Disclosure: Abbott Laboratories, 5, 8; American 

Orthopedic Association, 5; Consortium of 

Rheumatology Researchers of North America 

CORRONA), 5; Joiner Associates LLC, 4; Springer 

Publishers, 7; US Treat to Target Committee, 8 

Harris, Richard E., PhD 


Disclosure: Pfizer Inc, 2, 5 

Harsanyi, Andreea M., MD 


. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49, 62 


Harte, Steven E., PhD 

Clinical Research Conference - Day Two ....28 

Disclosure: Analgesic Solutions, Natick, MA, 9 

Hashkes, Philip J., MD, MSc 

Thieves’ Market: Show Me Your Best 

Cases .................................49 


Hassett, Afton L., PsyD 

Rheumatic Disease Update: Gout ..........61 

Disclosure: Bristol-Myers Squibb, 2, 5; Pfizer Inc, 

2, 5 

An Introduction to Immunology ..........121 

Disclosure: Bristol-Myers Squibb, 2, 5; Pfizer Inc, 

2, 5 

Hawker, Gillian A., MD, MSc 

Clinical Focus Course - Using Outcome Measures 

to Inform Clinical Practice ................26 




Care .................................59 


Hayat, Samina Q., MD 



IL6 Blocker ............................62 


Heimans, L., MD 



Heinegard, Dick, PhD 


Disclosure: Anamar Medical, 1; IDS Ltd, 2 

Helmick, Charles G., MD 


Arthritis ...............................56 


Hertweck, Susan Paige, MD, OB/GYN 


Disease ...............................49 


Hewlett, Sarah, MA, PhD, RN 



Strategies .............................59 





Hicks, Robert D., PhD 

Opening Lecture and Awards .............29 


Higgs, Jay B., MD 


Rheumatologists - Day Two ............20, 23 


Highland, Kristin B., MD, MSCR 


(046) .................................70 

Disclosure: Actelion Pharmaceuticals US, 9; 

Genentech and Biogen IDEC Inc., 8; Gilead 

Sciences, 9; United Therapeutics, 9 


(084) ................................119 

Disclosure: Genentech and Biogen IDEC Inc., 8 

Hillstrom, Howard J., PhD 

Knee Braces and Foot Orthosis for Knee 

Osteoarthritis (230) .....................92 


Hinz, Boris, PhD 




Hirschman, Michelle 




Hochberg, Marc C., MD, MPH 

Clinical Focus Course - 2012 ACR Guidelines 

on Osteoarthritis: A Focus on Pharmacologic 

Management ..........................26 

Disclosure: Abbott Laboratories, Astra-Zeneca, 

Bioiberica S.A., Eli Lilly Inc., Genentech/Roche, 

Merck Inc., Novartis Pharma A.G., Pfizer Inc., 

Stryker LLC, Xoma., 5 






Osteoarthritis Therapeutics: Will This be the 

Decade for Breakthroughs? .............123 








344 

Hogaboam, Cory M., PhD 



Disclosure: Medimmune Inc, 2; Novartis 

Pharmaceutical Corporation, 2 

Holers, V. Michael, MD 



Disclosure: Diagnostic Companies, 7 

Holland, Gary N., MD 


Disease ...............................46 


Hootman, Jennifer M., ATC, PhD 




The 5A Approach to Physical Activity Counseling 

for Arthritis Patients ....................37 


Houghton, Kristin M., MD 

Clinical Focus Course - Addressing Risk Factors 

for Osteoarthritis through the Lifespan: Let’s 

Start with the Kids! .....................26 


Hudson, Marie, MD, MPH 



Huisinga, Karen, MN, ARNP, FNP 

Infusion Reactions: Management and 

Prevention ............................61 

Disclosure: Pfizer Inc, 8 

Hunder, Gene G., MD 

Temporal Arteritis (030) .................56 


Temporal Arteritis (079) ................102 


Hunter, David J., MBBS, PhD 



Disclosure: DonJoy, 7; NHMRC, ARC, NIH, FNIH, 2 

Husni, M. Elaine, MD, MPH 

Psoriatic Arthritis (035) ..................60 




Hübbe, Claudia, MD 

Thieves’ Market Poster Presentation - Behçet’s 

Disease with Pulmonary Artery Aneurysms 

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95 


Ibrahim, Said, MD, MPH 



Care .................................59 


Ilowite, Norman T., MD 

Pediatric Rheumatology Town Hall 

Meeting ..............................71 



I 

Inman, Christi Joy, MD, MS 

The Unintended Consequences of Health 

Information Technology ................121 


Inman, Robert D., MD 

Spondylarthropathy: An Update (007)......31 

Disclosure: Abbott, Amgen, Merck, Pfizer, Sanofi- 

Aventis , 5 

Isaacs, John D., MD, PhD 


Practice ..............................58 

Disclosure: GSK, 2; No company, Treatment of 

chronic joint inflammation using an antibody 

against the CD3 antigen complex, 9 

Isenberg, David A., MD 

Year in Review .........................32 


Iversen, Maura D., BSc, DPT, SD, MPH 


Management .........................110 


Jacobe, Heidi, MD, MSCS 

Review Course - When Thick Skin is Not a Good 

Thing .................................24 


Jain, Nitin, MD, MSPH 

Shoulder Pain and Rotator Cuff Tear in 

Rheumatoid Arthritis ...................136 

Disclosure: AAPMU Faculty, 9; NIAMS-NIH, 2 

James, Judith A., MD, PhD 


Prevention ............................82 


Jarjour, Wael N., MD 



Disclosure: Human Genome Sciences, Inc., 9 

J 

Johnson, Richard J., MD 


the Joint ..............................81 

Disclosure: Ardea, Novartis, Biocryst, 5; NHLBI- 

NIH, 2; Univ of Florida , 9; Univ of WA,, 9 

Jolly, Meenakshi, MD, MS 

Clinical Trials: Participation and 

Recruitment ...........................61 

Disclosure: GlaxoSmithKline, 5; Lupus Foundation 

of America, 2; MedImmune, 7; The Binding Site, 2 

Jones, Kim D., PhD 




Jordan, Joanne M., MD, MPH 

Osteoarthritis: Update 2012 (032) .........60 

Disclosure: Algynomics, Inc. , 1; Eli Lilly and 

Company, 5; Interleukin Genetics, Inc. , 5; Johnson 

& Johnson, 2; Johnson and Johnson, 5; Mutual 

Pharmaceutical Company, 5 

Osteoarthritis: Update 2012 (064) .........92 


Company, 5; Interleukin Genetics, Inc. , 5; Johnson 

& Johnson, 2; Johnson and Johnson, 5; Mutual 

Pharmaceutical Company, 5 

Joshi, Reeti K., MBBS 

Thieves’ Market Poster Presentation - A Wolf in 

Sheep’s Clothing ........................95 


Jungel, Astrid, PhD 



Disclosure: IAR,Masterswitch-FP7,IMI-BTCure, 2 

K 

Kaeley, Gurjit S., MBBS, MRCP 

Musculoskeletal Ultrasonography: Basic 

(226) .................................80 

Disclosure: Esaote, Sonosite, 2 


Rheumatologists .................20, 21, 23 

Disclosure: Esaote, Sonosite, 2 

Kafka, Shelly P., MD 



Disclosure: Janssen Pharmaceutica Product, L.P., 

Abbott, Amgen, Takeda, HGSI, UCB, Forest, 8; 

Pfizer Inc, Lilly, Amgen, Jannsen,Vertex, Abbott, 

Takeda, Savient, UCB, GSK/HGSI, 2 


Spondylarthropathies ...................49 

Disclosure: Janssen Pharmaceutica Product, L.P. 

, Abbott, Amgen, Takeda, HGSI, UCB, Forest, 8; 

Pfizer Inc, Lilly, Amgen, Jannsen,Vertex, Abbott, 

Takeda, Savient, UCB, GSK/HGSI, 2 

Kalish, Robert A., MD 

Clinical Anatomy and Physical Exam: Essential 

Tools in Lower Extremity Regional Pain 

Syndromes (202) ......................103 



Tools in Upper Extremity Regional Pain 

Syndromes (235) .......................31 


Curbside Consults - Ask the Professors .....71 


Kamen, Diane L., MD, MS 




Directions ............................122 



Prevention ............................82 



. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49 


Kastner, Daniel L., MD, PhD 

Pediatrics: Periodic Fevers in Children (016) 

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38 

Disclosure: National Institutes of Health, 7 

Year in Review ........................132 


Katikaneni, Mamatha, MD 



IL6 Blocker ............................62 

Disclosure: Nothing to Disclose

Katz, Jeffrey N., MD 

Rheumatic Disease Update: The Approach to 

Low Back Pain .........................93 


Katz, Patricia P., PhD 

Demystifying the Study Section: How Grants are 




Putting the Pieces Together ..............79 


Katz, Stephen I, MD, PhD 

Clinical Research Conference - Day Two 

Introductory Remarks ...................28 


Katzman, Wendy, DSc, PT 



Kaufman, Randal J., PhD 


Response in Immunity and Inflammation ...38 

Disclosure: Proteostasis Therapeutics, Inc., 

Cambridge, MA, 6; Syndexa Pharm, Cambridge, 

MA, 6 

Kavanaugh, Arthur, MD 


Disclosure: Amgen, Abbott, BMS, Celgene, Roche, 

UCB, Janssen, Pfizer, 2 










Kay, Jonathan, MD 

Rheumatoid Arthritis: Challenging Cases 

(028) .................................56 


2; Amgen, 5; Ardea Biosciences, 2; Bristol-Myers 

Squibb, 5; Celgene, 5; Crescendo BioScience, 

5; Eli Lilly and Company, 2; Fidia Farmaceutici 

SpA, 2; fourteen22, 5; Genentech and Biogen 

IDEC Inc., 5; Horizon Pharma, 5; Janssen 

Biotech, 5; Molecular Partners AG, 5; Pfizer Inc, 

5; Roche Pharmaceuticals, 2; Sanofi-Aventis 

Pharmaceutical, 2; Savient, 5; UCB, 5 

Amyloidosis 2012 ......................129 


Rheumatoid Arthritis: Challenging Cases 

(074) ................................102 


2; Amgen, 5; Ardea Biosciences, 2; Bristol-Myers 

Squibb, 5; Celgene, 5; Crescendo BioScience, 

5; Eli Lilly and Company, 2; Fidia Farmaceutici 

SpA, 2; fourteen22, 5; Genentech and Biogen 

IDEC Inc., 5; Horizon Pharma, 5; Janssen 

Biotech, 5; Molecular Partners AG, 5; Pfizer Inc, 

5; Roche Pharmaceuticals, 2; Sanofi-Aventis 


Kay, Neil E, MD 




Kazi, Salahuddin, MD 

Getting Electronic Health Records Right 

(225) .................................80 


Rheumatoid Arthritis – Treating to Target: How 

to Incorporate Rheumatoid Arthritis Disease 

Activity Measures into Routine Practice ...130 






Keck, Tatiana, MD 



Kerr, Gail S., MD 



Arthritis ...............................58 


Kessler, Craig M., MD 

New Anticoagulants: What a Hematologist 

Thinks a Rheumatologist Needs to Know! ...61 


Keysor, Julie J., PhD, PT 




Keystone, Edward C., MD 

Physical Examination Skills for Improved 

Detection of Synovitis and Cervical 

Thoracolumbar Disorders (210) ...........39 


Rheumatoid Arthritis: Biological Agents 

(006) .................................31 

Disclosure: Abbott Laboratories, 5; Abbott 

Pharmaceutical, 8; Abbottt Laboratories, 

2; Amgen, 8; Amgen Inc., 2; Astrazeneca 

Pharmaceuticals, 5; Astrazeneca Pharmaceuticals 

LP, 2; Biotest, 5; Bristol-Myers Squibb, 2, 

8; Centocor, Inc., 2; F. Hoffman La-Roche 

Inc, 2; F. Hoffman La-Roche Ltd, 5, 8; 

Genentech and Biogen IDEC Inc., 5; Genzyme 

Corporation, 2; Janssen Pharmaceuticals, 

8; Merck Pharmaceuticals, 2, 5, 8; Novartis 

Pharmaceuticals, 2; Nycomed, 5; Pfizer 

Pharmaceuticals, 2, 5; UCB, 2, 5, 8 

Rheumatoid Arthritis: Biological Agents 

(059) .................................88 


Khamashta, Munther A., MD 

Antiphospholipid Syndrome (022) .........56 


Antiphospholipid Syndrome (052) ........122 


Khanna, Dinesh, MD, MSc 

Pulmonary Hypertension in the Rheumatic 

Diseases (027) .........................34 

Disclosure: Actelion, BMS, Gilead, Genentech, 

ISDIN, and United Therapeutics, 2, 5, 8 

Khosroshahi, Arezou, MD 


Directions ............................122 


Kikuta, Junichi, MD 



Kim, Sunny, PhD 



Problems .............................121 


Kim, Susan, MD, MPH 

Pediatrics: Dermatomyositis (004) .........31 


Kimberly, Robert P., MD 



Kimura, Yukiko, MD 




Novartis Pharmaceutical Corporation, 5 

King II, Charles M., MD 





Kissin, Eugene Y., MD 



Disclosure: SonoSite Inc., 9 





Kivitz, Alan J., MD, CPI 

Clinical Trials: Participation and 

Recruitment ...........................61 

Disclosure: Bristol-Myers Squibb, 8; Forest 

Laboratories, 8; Genentech and Biogen IDEC Inc., 

5; Pfizer Inc, 8; Takeda, 8 

Klareskog, Lars, MD, PhD 




Klein-Gitelman, Marisa S., MD, MPH 


Meeting ..............................71 


Koch, Alisa E., MD 





Koening, Curry L., MD, MS 




Kohler, Minna J., MD 


Rheumatologists - Hand and Wrist .........21 


Kolasinski, Sharon L., MD 


Evidence Based Options for Arthritis 

Patients ...............................39 







Schools ...............................70 


Kolfenbach, Jason R., MD 





Kremer, Joel M, MD 


Disclosure: Abbott, BMS, Genentech, Pfizer, HGS, 

Lilly, Novartis, 2; Amgen, BMS, Genentech, Pfizer, 

Lilly, 5 

Krishnan, Eswar, MD 


the Joint ..............................81 

Disclosure: takeda, Metabolex, URL, 2; takeda, 

URL Metabolex, 5 

Krohn, Kelly, MD 

Knee Braces and Foot Orthosis for Knee 

Osteoarthritis (230) .....................92 

Disclosure: LIlly USA, LLC, 1, 3 

L 

Lacomis, David, MD 



Lafyatis, Robert, MD 



Fibrosis ...............................25 

Disclosure: Shire, Sanofi/Genzyme, Regeneron, 

Actelion, 2; Shire, Sanofi/Genzyme, Regeneron, 

Roche/Genentech, Biogen, 5 


Response in Immunity and Inflammation ...38 




Macrophage and Dendritic cell Heterogeneity 

in Tissue Inflammation and Fibrosis ........71 




Mechanisms of Autoinflammatory 

Diseases .............................129 




Lahita, Robert G., MD, PhD 

Systemic Lupus Erythematosus: Novel 

Treatments (089) ......................119 

Disclosure: Human Genome Sciences, Inc. Glaxo 

Smith Kline, 8 

Laing, Timothy, MD 

Legislative Update from Capitol Hill ........62 


Lamande, Shireen, PhD 



Lane, Nancy E., MD 



Vitamin D and Bone Health (020) ..........38 


Langford, Carol A., MD, MHS 

ACR/ABIM Maintenance of Certification 

Learning Session - 2012 Update in 







Disclosure: Bristol-Myers Squibb, 9; Genentech 

and Biogen IDEC Inc., 9 





The Great Debate: In 2012 What are the Roles 

of Cyclophosphamide versus Rituximab in 

ANCA-Associated Vasculitis ...............39 


Lapteva, Larissa, MD, MHS 





Lawry, George V., MD 


Musculoskeletal Examination for Arthritis 

(204) .................................31 

Disclosure: McGraw-Hill Co., 7 


Musculoskeletal Examination of the Neck and 

Low Back (213) .........................48 



Musculoskeletal Examination of the Shoulder 

and Knee (220) .........................63 


Laxer, Ronald M., MD 



Disclosure: Novartis Pharmaceutical Corporation, 

2, 5 

Lazaro, Deana M., MD 





Lee, Jungwha, PhD, MPH 

Basic Statistical Concepts for the Medical 

Researcher (201) .......................31 


Lehman, Thomas J. A., MD 

Pediatrics: Spondylarthritis in Children 

(034) .................................60 

Disclosure: Abbott Immunology Pharmaceuticals, 8 

Leon-Reyes, Elyse M., BA, MPA 

Forming An Education and Support Group from 

the Ground Up ........................128 


Levesque, Marc C., MD, PhD 





Li, Zhan-Guo, MD 




Libman, Bonita S., MD 





Lichy, Jack H., MD, PhD 



Arthritis ...............................58 


Lieb, Kevin 

CORC FORUM: Achieving Economic Goals in an 

Era of Healthcare Reform ................31 


Lieberman, Judy, MD, PhD 

MicroRNA and the Rheumatic Diseases ....112 


Liles, Robert W., JD 

Top 10 Compliance Risks Facing Physicians 

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101 

Disclosure: Liles Parker, 9 

Ling, Shari M., MD 



Liu-Bryan, Ru, PhD 



Lockshin, Michael D., MD 




Loeser, Richard F., MD 



Mechanotransduction in Bone and 

Cartilage ..............................72 


Lotz, Martin K., MD 



Lovell, D. J., MD, MPH 


2012 Highlights .......................122 


5; Amgen, 9; AstraZeneca, 5; Bristol-Myers 

Squibb, 5; Centocor, Inc., 5; Forest Laboratories, 

9; Hoffmann-La Roche, Inc., 5; horizon 

pharmaceuticals, 5; Novartis Pharmaceutical 

Corporation, 5; Pfizer Inc, 5; Regeneron, 5; Wyeth 


Lowenstein, Kathryn L., OTR 





346 

2012 Program Book

Lowes, Michelle, MD, PhD 


Tissue Inflammation and Fibrosis .........72X 


Lu, Theresa T., MD, PhD 




Lundberg, Ingrid E., MD, PhD 

Review Course - Inflammatory Myositis: 

2012 .................................24 

Disclosure: Bristol-Myers Squibb, 2; MedImmune, 

5; Novartis Pharmaceutical Corporation, 5; Pfizer 

Inc, 1 

Luning Prak, ElineT., MD, PhD 

Advances in Targeting of B cell Survival 

Factors ...............................92 


Luther, Sanjiv, PhD 



Fibrosis ...............................26 


Lynch, Susan, PhD 


Disclosure: Second Genome, 6 

M 

Macfarlane, Gary J., BSc, MBChB, MD, PhD 


Groups ...............................28 


Clinical Research Conference - From Preclinical 

Models to Clinical Studies ...............28 


Magid, Steven K., MD 

The Guide to Meaningful Use and Beyond . . 93 


Maisel, Alan S., MD 



Disclosure: Alere, Abbott, Brahms-Thermofisher, 

2; Alere, Critical Diagnostics, 5 

Maixner, William, DDS, PhD 


Groups ...............................29 

Disclosure: Algynomics, 1, 4, 5; NIH, 2 



Disclosure: Algynomics, 1, 4, 5; NIH, 2 

Makol, Ashima, MD 


Cases .................................49 


Makris, Una E., MD 

Approach and Management of Back Pain in 

Older Adults ..........................103 


Maksymowych, Walter P., MD 


Spondyloarthritis: A Clinician’s Guide(224) . . 71 

Disclosure: Abbott Laboratories, 2, 5; Amgen, 2; 

Eli Lilly and Company, 5; Janssen Pharmaceutica 

Product, L.P., 2, 5; Merck Pharmaceuticals, 5; 

Pfizer Inc, 2, 5; UCB, 5 


Spondyloarthritis: A Clinician’s Guide(236) 

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103 

Disclosure: Abbott Laboratories, 2, 5; Amgen, 2; 

Eli Lilly and Company, 5; Janssen Pharmaceutica 

Product, L.P., 2, 5; Merck Pharmaceuticals, 5; 

Pfizer Inc, 2, 5; UCB, 5 

Malawista, Stephen E., MD 

Gouty Inflammation ....................92 


Malfait, Anne-Marie, MD, PhD 

Mechanisms of Pain in Rheumatic 

Diseases ..............................38 

Disclosure: NIAMS-NIH, 2 


Disclosure: NIAMS-NIH, 2 

Mammen, Andrew L., MD, PhD 



Disclosure: anti-HMGCR antibody test, 9 

Mandelin II, Arthur M., MD, PhD 

Adult Musculoskeletal Lower Examinations 

(229) .................................92 


Adult Musculoskeletal Upper Examinations 

(205) .................................33 




Directions ............................111 


Mandell, Brian F., MD, PhD 


in Patients Undergoing Joint Replacement ...61 



(215) .................................48 



(232) .................................92 



(237) ................................103 


Manson, Sharon, RN, MS, NP 

Infusion Room Information for Medical 

Professionals ..........................59 


Manzi, Susan, MD, MPH 

Review Course - Lupus - More than Nephritis: 

Treatment of Non-Nephritis Lupus 

Problems ..............................24 

Disclosure: Anthera, Bristol-Myers Squibb 

Company, Cephalon, HGS- Exagen, Human 

Genome Sciences , 2, 5; Patent Patents Examined 

and Allowed for Issuance as a Patent, 7 

Marden, Susan, MD 



Disclosure: Anthera, Bristol-Myers Squibb 

Company, Cephalon, HGS- Exagen, Human 

Genome Sciences , 2, 5; Patent Patents Examined 

and Allowed for Issuance as a Patent, 7 

Margules, Kenneth R., MD 

Joint Injections (Knee and Ankle Prosthetics) 

(216) .................................60 


Joint Injections (Shoulder and Wrist Prosthetics) 

(223) .................................71 


Maricic, Michael J., MD 

Osteoporosis: Novel Treatments (015) .....38 

Disclosure: Amgen, 5; Eli Lilly and Company, 8; 

Novartis Pharmaceutical Corporation, 8 

Rheumatology Practice 101: Starting Out in 

Practice for The Graduating Fellow (087) . . 119 


Martinez-Lavin, Manuel, MD 

Fibromyalgia and Dysautonomia (055) .....88 


Fibromyalgia and Dysautonomia (072) ....102 


Mathai, Stephen C., MD, MHS 


Lung Disease. . . . . . . . . . . . . . . . . . . . . . . . . . 104 


Bayer HealthCare, 5; Gilead Sciences, 5; United 

Therapeutics, 5 

Mathew, Anita S., MD 



IL6 Blocker ............................62 


Matteson, Eric L., MD, MPH 



Disclosure: American College of Rheumatology 

and EULAR grant to develop classification criteria 

for rheumatoid arthritis., 2; Horizon, 5; Novartis 


Maxwell, Jessica L., DPT, PT 




McAlindon, Timothy E., MD, MPH 


Practice? .............................112 

Disclosure: Arthritis and Rheumatism, 9; 

BioIberica, 9; Croma, 2; Flexion; Sanofi; 

Wintherix, 5; NIH; ACR, 2; OARSI, 6 

McBeth, John, PhD 


Groups ...............................29 








McClatchey, William M., MD 





McClung, Michael R., MD 


Disclosure: Amgen, Lilly, Merck, Novartis, 5; 

Amgen, Lilly, Novartis, Warner-Chilcott, 8; 

Amgen, Merck, 2 


Disclosure: Amgen, Lilly, Merck, Novartis, 5; 

Amgen, Lilly, Novartis, Warner-Chilcott, 8; 

Amgen, Merck, 2 

McComas, Heather, PharmD 


- How to Maximize the Use of Your Practice 

Data ..................................28 


McCurdy, Deborah K., MD 


Disease ...............................46 

McLean, Robert R., DSc, MPH 



Problems .............................122 





Highlights from the 2012 ARHP Sessions ...136 


McMahan, Zsuzsanna H., MD, MHS 









Cases .................................49 


Update on Immune Mediated Glomerular 

Disease ...............................91 


McMenamin, Terence, MA 



Mease, Philip, MD 


Spondylarthropathies ...................49 


5, 8; Abbott Laboratories, 2; Amgen, 2, 5, 8; 

Bristol Myers Squibb, 2, 5, 8; Celgene, 2, 5; 

Crescendo, 2, 5; Cresendo, 8; Forest Laboratories, 

2, 5, 8; Genentech and Biogen IDEC Inc., 2, 5, 8; 

Janssen Pharmaceutica Product, L.P., 2, 5, 8; Lilly, 

2, 5, 8; Merck Pharmaceuticals, 2, 5; Novartis 

Pharmaceutical Corporation, 2, 5; Pfizer Inc, 2, 5, 

8; UCB, 2, 5, 8 

Medsger Jr., Thomas A., MD 

Rheumatology Research Foundation Paul 

Klemperer, MD Memorial Lectureship: Serum 



Outcomes .............................91 


Melmed, Gil Y., MD 

Immunizations in Patients with Rheumatologic 

Disease ...............................96 

Disclosure: Abbott Laboratories, 8; Jannsen, 5; 

Pfizer, 2 

Melton, Alton, MD 

Immunodeficiency Syndromes (024) .......56 


Mercer, Louise K., MBChB, MRCP 



Merkel, Peter A., MD, MPH 

Vasculitis: Update (050)..................70 


Bristol-Myers Squibb, 2; Celgene, 2; Genentech 

and Biogen IDEC Inc., 2; Genzyme Corporation, 

5; Human Genome Sciences, Inc., 2; Proteon 


Vasculitis: Update (070)..................92 






Merrell, Victoria A., MPT, PA-C 




Michaud, Kaleb, PhD 





Mikuls, Ted R., MD, MSPH 


Arthritis ..............................32 



Joint .................................82 


Miller, Daniel, MD 

Dermatopathology of Rheumatic Diseases 

(203) .................................31 


Dermatopathology of Rheumatic Diseases 

(212) .................................48 


Monach, Paul A., MD, PhD 

Vasculitis: Update (040) ..................60 


Vasculitis: Update (080) .................102 


Monrad, Seetha U., MD 





Moonaz, Steffany, PhD, RYT-500 


Disclosure: Arthritis Foundation, 5; NIH, 5; Yoga 

for Arthritis, 4 

Clinical Focus Course - Breakout Session II ...26 

Disclosure: Arthritis Foundation, 5; NIH, 5; Yoga 

for Arthritis, 4 

Morgan DeWitt, Esi M., MD, MSCE 


Groups ...............................28 


Morris, Edward L., MD 

CORC FORUM: Achieving Economic Goals in an 

Era of Healthcare Reform ................31 


Murphey, Mark D., MD 

Best Practices for Ordering Diagnostic Imaging 

in Evaluating Rheumatologic Conditions ...120 


Murphy, Kenneth M., MD, PhD 


Tissue Inflammation and Fibrosis ..........71 



Arthritis ...............................56 



Groups ...............................29 



Populations ............................80 


Muscal, Eyal, MD, MS 


Adolescents ...........................72 


Müller-Ladner, Ulf, MD 



Fibrosis ...............................26 

Disclosure: German Research Foundation, 2 

N 

Naredo, Esperanza, MD 






Rheumatologists - The Shoulder ...........21 


Nelson, J. Lee, MD 


Autoimmune Pathogenesis ..............121 


Neogi, Tuhina, MD, PhD 


Rheumatic Disease Research .............91 





348 

2012 Program Book

Newman, Eric D., MD 

Strategies to Enhance Office Efficiencies and 

Access to Care in Rheumatology Practice ...97 


Nigrovic, Peter A., MD 

Advances in the Biology of Aging ..........31 





. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90 





Pediatric Rheumatology for Adult 

Rheumatologists (033) ..................60 





Nikolov, Nikolay P., MD 




Noble, Paul, MD 




Nola, Kam, PharmD, MS 


Populations ............................80 


New Medication Developments in 



Norris, Jill M., MPH, PhD 


Prevention ............................82 

Disclosure: Nothing to DiscloseO 

O’Brien, Virginia, OTD, OTR/L, CHT 


Disclosure: Books on Hand, Caring for the Painful 

Thumb, 2nd ed.,editor’s’royalty per book, 5 

Clinical Focus Course - Breakout Session II ...26 

Disclosure: Books on Hand, Caring for the Painful 

Thumb, 2nd ed.,editor’s’royalty per book, 5 

O’Connell, Ryan M., PhD 



O’Dell, James R., MD 


Meeting .............................103 








O’Rourke, Kenneth S., MD 





Joint Injection Techniques (234) ...........97 


Joint Injection Techniques (239) ..........111 


O’Toole, John, BA 




Oates, Jim, MD 

Metabolic Abnormalities in Autoimmunity . . 48 


Oatis, Carol A., PhD, PT 


Optimizing Functional Outcomes through 



. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80 


Oddis, Chester V., MD 








Year in Review .........................30 


Okada-Yim, Sarah K., MD 




Onel, Karen, MD 


Adolescents ...........................72 


Ostergaard, Mikkel, MD, PhD, DMSc 







Ostrov, Barbara E., MD 


Meeting ..............................71 


Oyoo, Omondi G., MD, MMed 




P 

Pabolu, Sangeetha, MD 


Cases .................................49 


Paget, Stephen A., MD 

Pain: Dealing with Patients with Refractory 

Pain in Musculoskeletal and Autoimmune 

Disorders (065) .........................92 


Paik, Julie J., MD 

Thieves’ Market Poster Presentation - Myalgias: 

Out of Proportion to Exam ...............95 


Pap, Thomas, MD 

Basic Research Conferance - Session III: 


Disclosure: Abbott Laboratories, 5; Artialis 

S.A., 5; Bioiberica S.A., 5; Chugai, 5; Eli Lilly and 

Company, 5; Mundipharma , 8 

Parke, Ann L., MD 


Syndrome .............................48 


Passo, Murray H., MD 

Pediatrics: Difficult to Treat Juvenile Idiopathic 

Arthritis (005)..........................31 


Thieves’ Market Poster Presentation - Neonate 

with Sclerodermatous Limbs. . . . . . . . . . . . . . 95 


Pavalko, Fredrick, PhD 

Mechanotransduction in Bone and 

Cartilage ..............................72 


Perl, Andras, MD, PhD 



Petri, Michelle, MD, MPH 


Erythematosus ........................111 

Disclosure: Anthera, 5; Genentech and Biogen 

IDEC Inc., 5; GlaxoSmithKline, 5; HGS, 5; 

Medimmune, 5; Pfizer Inc, 5; UCB, 5 

Pincus, Theodore, MD 

Patient Questionnaires: Multi-Dimensional 

Health Assessment Questionnaire/Routine 

Assessment of Patient Index Data 3 and Beyond 

toward a Standard, Scientific, Quantitative 

Patient History (227) ....................81 


Pine, Linda J., PharmD 

New Medication Developments in 


Disclosure: Amgen, 5 

Plenge, Robert M., MD, PhD 









Pope, Janet E., MD, MPH 

Raynaud’s and Digital Ischemia (047) .......70 

Disclosure: Actelion and Pfizer, 2, 5 

Raynaud’s and Digital Ischemia (085) ......119 

Disclosure: Actelion and Pfizer, 2, 5 

Pope, Richard, MD 








350 

Synovial Immunobiology and Response to 

Therapy in Rheumatoid .................58 


The Plasticity of T Regulatory Cells and their 

Role in Autoimmunity ...................32 


Porter, Janet, PhD 

Practice Management: Patients as Partners in 



Powell, Jonathan, MD, PhD 



Prockop, Darwin J., MD, PhD 




Disclosure:

Scher, Jose U., MD 



Scher, Richard K., MD, MS 




Schett, Georg A., MD, PhD 

Osteoimmunology .....................102 


Schikler, Kenneth N., MD 


Disease ...............................48 


Schlenk, Elizabeth A., PhD, RN 



Perspective ............................97 

Disclosure: UCB, 2 

Schlesinger, Naomi, MD 

Rheumatic Disease Update: Gout ..........61 

Disclosure: Novartis Pharmaceutical Corporation, 

2; Novartis Pharmaceutical Corporation; 

Takeda, Savient , 8; Novartis Pharmaceutical 

CorporationTakeda, Savient, Enzyme Rx, URL 

Pharma ;, 5; Sobi, 5; Takeda, 8 

Schmidt, Wolfgang A., MD 




2, 5, 8; Actelion Pharmaceuticals US, 2; Berlin- 

Chemie / Menarini, 5, 8; Esaote, 2; General 

Electric, 2; Medac, 8; Merck Sharp Dohme, 2, 8; 


Inc, 8; Roche Pharmaceuticals, 2, 5, 8; UCB, 8 





2, 5, 8; Actelion Pharmaceuticals US, 2; Berlin- 

Chemie / Menarini, 5, 8; Esaote, 2; General 

Electric, 2; Medac, 8; Merck Sharp Dohme, 2, 8; 


Inc, 8; Roche Pharmaceuticals, 2, 5, 8; UCB, 8 

Schneider, Rayfel, MBBCh 

Systemic Arthritis and Still’s Disease (008) ...31 

Disclosure: Hoffmann-La Roche, Inc., 5, 8; 

Innomar Strategies, 5 

Schwartzman, Sergio, MD 

Inflammatory Eye Disease/Uveitis (013) ....38 

Disclosure: Janssen, Abbott, UCB, Amgen, Pfizer, 

Genentech, Human Genome Science, 8 

Seo, Philip, MD, MHS 

Rheumatic Disease Update: Vasculitis ......37 


Serhan, Charles, PhD 



Disclosure: BayerHealth Care , 7; NIH grants, 2; 

Resolvyx Pharmaceutical, 1; Schiff, 9; Solutex 

Corporation, 5 

Seymour, Sally M., MD 





Shadick, Nancy A., MD, MPH 

Rheumatoid Arthritis: Difficult Cases (037) . . 60 


2; Amgen, 2; Crescendo Bioscience, 2; Genentech 

and Biogen IDEC Inc., 2; Medimmune, 2 

Shah, Ami A., MD, MHS 




Shahrara, Shiva, PhD 



Shanmugam, Victoria K., MBBS 



Arthritis ...............................58 

Disclosure: Spouse is a partner at the law firm 

of Williams and Connolly LLP which represents 

various pharmaceutical and medical device 

companies. The partners in the firm share in the 

profits related to representing these companies., 9 

New Anticoagulants: What a Hematologist 

Thinks a Rheumatologist Needs to Know! ...61 

Disclosure: Spouse is a partner at the law firm 

of Williams and Connolly LLP which represents 

various pharmaceutical and medical device 

companies. The partners in the firm share in the 

profits related to representing these companies. , 9 

Shapiro, Marjorie, PhD 




Sherlock, Jonathan, DM, MBBCh 


Disclosure: Merck, 3 

Shiboski, Stephen, PhD 


Syndrome .............................48 


Siegel, Richard M., MD, PhD 

Mechanisms of Autoinflammatory 

Diseases .............................129 


Sieper, Joachim, MD 

Ankylosing Spondylitis: Disease Modification 

(061) .................................91 

Disclosure: Abbott, Merck, Pfizer, Janssen, 2; 

Abbott, Merck, Pfizer, Lilly, UCB, 5; Abbott, Merck, 

Pfizer, UCB, 8 

Sigal, Leonard H., MD 

An Introduction to Immunology ..........121 


Sikorski, Simon, MD 


- Effective Marketing for Today’s Medical 

Practice ...............................27 

Disclosure: Healthcare Marketing Center of 

Excellence, 4 




Disclosure: Healthcare Marketing Center of 

Excellence, 4 

Silver, Richard M., MD 


Lung Disease. . . . . . . . . . . . . . . . . . . . . . . . . . 104 


Sanofi-Aventis Pharmaceutical, 5; Takeda , 8 

Silverman, Gregg J., MD 


Autoimmune Pathogenesis ..............121 





Silverman, Stuart L., MD 


Absorptiometry and Clinical Risk Factors: The 

New Fracture Risk Assessment Algorithm 

(214) .................................48 

Disclosure: Amgen, Genentech, Lilly, Novartis and 

Pfizer/Wyeth, 5; Amgen, Lilly, Novartis and Pfizer/ 

Wyeth , 8; Cedars-Sinai Medical Center , 3; Lilly, 

Pfizer/Wyeth , 2 


Absorptiometry and Clinical Risk Factors: The 

New Fracture Risk Assessment Algorithm 

(221) .................................63 

Disclosure: Amgen, Genentech, Lilly, Novartis and 

Pfizer/Wyeth, 5; Amgen, Lilly, Novartis and Pfizer/ 

Wyeth , 8; Cedars-Sinai Medical Center , 3; Lilly, 

Pfizer/Wyeth , 2 

Simon, Lee S., MD 

Rheumatoid Arthritis: Safety of Novel Therapies 

(075) ................................102 

Disclosure: Affinergy, Abraxxis, Alpha Rx, 

NuvoResearch, Roche, Pfizer, Novartis, PLx 

Pharma, Hisamatsu, Dr Reddys, Avanir, Cerimon, 

Leerink Swann, Alimera, Nomura, Luxor , 

Paraexel, Nitec, Bayer, Rigel, Chelsea, 5; Alder, 

Cephalon, Purdue, EMDSerono, Altea, Talagen, 

Tigenix, Antigenics, Forest, Genzyme, CaloSyn, 

King, Horizon, Pozen, ILPharma, Analgesic 

Solutions, Creabilis, Kowa, Array, Astra Zeneca, 

5; Regeneron, Cypress, Savient, Nicox, Fidelity 

, Extera, Wyeth, Asahi, Winterex, Metabolix, 

Solace, Puretechventures, White Mountain 

Pharma, Abbott, Omeros, Jazz, Takeda, Teva, 

Zydus, Proprius, Savient, 5 

Rheumatoid Arthritis: Safety of Novel Therapies 

(086) ................................119 















Singh, Jasvinder A., MBBS 


Joint .................................81 

Disclosure: Savient, Takeda, Ardea, Regeneron, 

Allergan, URL pharmaceuticals and Novartis, 5; 

Takeda and Savient, 2 













Sittig, Dean F., PhD 

The Unintended Consequences of Health 

Information Technology ................121 

Disclosure: Office of the National Coordinator for 

Health Information Technology; AHRQ, 2 

Siverling, Scott, PT, OCS 

Early Rehabiliation for Hip and Foot 


. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88 


Slusher, BArbara A., PA-C, MSW 




8; Amgen, 8; cardinal health specialty services, 5; 

Pfizer Inc, 8; UCB, 8 



Directions ............................111 


8; Amgen, 8; cardinal health specialty services, 5; 

Pfizer Inc, 8; UCB, 8 

Smarr, Karen L., PhD 



Smith, Benjamin J., PA-C 


Meeting .............................103 




Smith, Terry J., MD 




Specks, Ulrich, MD 




Disclosure: Genentech and Biogen IDEC Inc., 2, 5 

Spiegel, Lynn R., MDCM 




Spiera, Robert F., MD 


Lung Disease. . . . . . . . . . . . . . . . . . . . . . . . . . 104 








Thieves’ Market: Show Me Your Best Cases . 49 


Starz, Terence W., MD 



Perspective ............................97 


Staud, Roland, MD 


Groups ...............................28 

Disclosure: Forest Laboratories, 2; Pfizer Inc, 2 

Steen, Virginia D., MD 

Review Course - Hypermobility, Diagnosis, 

Disease Associations, Treatment ..........25 


Gilead Science, 2; Roche Pharmaceuticals, 2; 

United Therapeutics, 2 

Review Course - Inflammatory Myositis: 2012 

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 




Review Course - Lupus - More than Nephritis: 

Treatment of Non-Nephritis Lupus Problems 

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 




Review Course - When Thick Skin is Not a Good 

Thing .................................24 




Scleroderma Bowel Disease: From Top to 

Bottom (Clinical Review) .................71 









Stinson, Jennifer N., PhD, RN, CPNP 


Groups ...............................29 




Disclosure: CIHR, NIH, CAN, 2 

Stohl, William, MD, PhD 

Advances in Targeting of B cell Survival 

Factors ...............................92 

Disclosure: Eli Lilly and Company, 9; Human 

Genome Sciences, Inc., 9; Pfizer Inc, 9; Xencor, 

Inc., 2 

Stone, John H., MD, MPH 


Directions ............................122 

Disclosure: Genentech, 5 

Vasculitis Mimics (010) ..................31 

Disclosure: Genentech, 5 

Stürmer, Til, MD, MPH, PhD 



Disclosure: AHRQ, 2; GlaxoSmithKline, 2; Merck 

Pharmaceuticals, 2; NIH, 2; Sanofi-Aventis 

Pharmaceutical, 2 

Suarez-Almazor, Maria E., MD, PhD 



Care .................................59 

Disclosure: Zimmer, 5 

Szauter, Karen, MD 

Medical Education: The Year in Review .....32 


T 

Tak, Paul P., MD, PhD 

Synovial Immunobiology and Response to 

Therapy in Rheumatoid .................58 

Disclosure: GlaxoSmithKline, 3 

Tesser, John RP, MD 




Theis, Kristina A., BA, MPH 




Arthritis ...............................56 


Tillman, Melesia, CPC, CRHC, CHA 

Certified Rheumatology Coder Course: Unlock 

the Mystery: A Roadmap for Rheumatology 

Coding - Day One .......................21 


Certified Rheumatology Coding Course 

Examination: Unlock the Mystery: A Roadmap 

for Rheumatology Coding - Day Two .......29 


Tracey, Irene, MA, (Oxon), PhD 


Groups ...............................28 





Troxell, Megan, MD 


Erythematosus and Vasculitis (207) ........33 



Erythematosus and Vasculitis (211) ........39 


Tuan, Rocky S., PhD 




Tzaribachev, Nikolay, MD 


Rheumatologists - Break Out Session: Pediatric 



U 

Utrie, Paul C., MD 


Musculoskeletal Examination for Arthritis 

(204) .................................31 


352 

2012 Program Book


Musculoskeletal Examination of the Neck and 

Low Back (213) .........................48 



Musculoskeletal Examination of the Shoulder 

and Knee (220) .........................63 


V 

Valastyan, Scott J., PhD 

Basic Research Conference - Session III: 



van der Heijde, Desiree M., MD, PhD 

Review Course - Review and Update of 

Ankylosing Spondylitis ...................24 


5; Amgen, 5; AstraZeneca, 5; Bristol-Myers 

Squibb, 5; Centocor, Inc., 5; Chugai, 5; Eli Lilly 

and Company, 5; GlaxoSmithKline, 5; Merck 

Pharmaceuticals, 5; Novartis Pharmaceutical 

Corporation, 5; otsuka, 5; Pfizer Inc, 5; 

Roche Pharmaceuticals, 5; Sanofi-Aventis 

Pharmaceutical, 5; Schering-Plough, 5; UCB, 5; 

Wyeth Pharmaceuticals, 5 


Spondylarthropathies .................. 49 

Disclosure: Abbott Immunology 

Pharmaceuticals, 5; Amgen, 5; AstraZeneca, 

5; Bristol-Myers Squibb, 5; Centocor, Inc., 

5; Chugai, 5; Eli Lilly and Company, 5; 

GlaxoSmithKline, 5; Merck Pharmaceuticals, 

5; Novartis Pharmaceutical Corporation, 5; 

otsuka, 5; Pfizer Inc, 5; Roche Pharmaceuticals, 

5; Sanofi-Aventis Pharmaceutical, 5; Schering- 

Plough, 5; UCB, 5; Wyeth Pharmaceuticals, 5 

Varga, John, MD 

Basic Research Conferance - Session III: 

Fibroblasts as Invaders and Aggressors .... 25 

Disclosure: JBT, 2 


Biology of Mesenchymal Cells ........... 22 



Immunity and Mesenchymal Cells. . . . . . . . 25 




Fibrosis ............................. 25 




Fibrosis (continued) ................... 26 


Venables, Patrick, MD 


Arthritis ............................ 32 


Vignali, Dario AA, PhD 

The Plasticity of T Regulatory Cells and their 

Role in Autoimmunity ................. 32 

Disclosure: BMS, 7 

Vijg, Jan, PhD 

Advances in the Biology of Aging ........ 31 


Villasenor Ovies, Pablo, MD 


Tools in Lower Extremity Regional Pain 

Syndromes (202) ..................... 31 



Tools in Upper Extremity Regional Pain 

Syndromes (235) .................... 103 


Vincent, Ann, MD 


Putting the Pieces Together ............ 102 



. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72 


Violette, Shelia, PhD 



Fibrosis ............................. 25 

Disclosure: Bioge Idec, 1; Biogen Idec, 3 

Vivino, Frederick B., MD 


Syndrome ........................... 48 


Curbside Consults - Ask the Professors .... 71 


Vleugels, Ruth Ann, MD, MPH 

Dermatological Manifestations of Rheumatic 

Diseases (054) .........................88 


W 

Wakefield, Richard J., BM, MD 








Walston, Jeremy, MD 



Wang, Chenchen, MD, MSc 


Evidence Based Options for Arthritis Patients . 39 


Wang, Heng, MS 



Ward, Michael M., MD 




Warren, Robert W., MD, PhD, MPH 




The Guide to Meaningful Use and Beyond . . 94 


Wasko, Mary Chester M., MD, MSc 





Wasserman, Sara, MD 



Watcher, Sandra J., BSN 


the Ground Up ........................128 


Watts, Nelson B., MD 


Beyond ...............................72 

Disclosure: OsteoDynamics , 1 

Weinblatt, Michael E., MD 


Disclosure: Bristol-Myers Squibb, Abbott, 2, 5 

Weisman, Michael H., MD 

Ankylosing Spondylitis: 2012 Update (021). . 56 


Ankylosing Spondylitis: 2012 Update (041). . 70 






Wells, Alvin F., MD, PhD 



Disclosure: Terason, 5 

Westby, Marie D., PT, PhD 

Clinical Focus Course - 2012 ACR Guidelines 

on Osteoarthritis: A Focus on Pharmacologic 

Management ..........................26 


Clinical Focus Course - Addressing Risk Factors 

for Osteoarthritis through the Lifespan: Let’s 

Start with the Kids! .....................26 






Clinical Focus Course - Concluding Remarks 

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 


Clinical Focus Course - Introduction ........26 


Clinical Focus Course - Obesity and 

Osteoarthritis: Clinicians Can Make a Difference 

in Promoting Healthier Lifestyles ..........27 


Clinical Focus Course - Osteoarthritis as We 

Understand It Today ....................26 


Clinical Focus Course - Osteoarthritis 

Assessment: Thinking Outside of the Joint . . 26 


Clinical Focus Course - Osteoarthritis Chronic 

Disease Management in the Age of the Internet, 

Apps and Tweets .......................27 


Clinical Focus Course - Using Outcome Measures 

to Inform Clinical Practice ................26 






. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80 





Weyand, Cornelia M., MD, PhD 



Wiener, Aimee, ARNP, MSN 

Infusion Room Information for Medical 

Professionals ..........................59 


Wilkes, Margaret R., MD 


Beyond ...............................72 


Williams, David A., PhD 


Groups ...............................28 

Disclosure: Eli Lilly and Company, 5; Forest 

Laboratories, 5; Pfizer Inc, 5 







Strategies .............................59 







Williams, Mark, MBBS, BSc, (Hons) 

Thieves’ Market Poster Presentation - Medical 

Re-vascularisation ......................95 


Witter, James P., MD, PhD 


Groups ...............................28 



2012 Highlights .......................122 


Wolfe, Frederick, MD 




Woodward, Amy L., MD, MPH 





Woolf, Clifford, MB, BCh, PhD 

Clinical Research Conference - Introduction: 

State of the Field .......................22 

Disclosure: Abbott Laboratories, 5; Bristol-Myers 

Squibb, 5; GlaxoSmithKline, 2; Lupin Laboratories, 

5; Pfizer Inc, 5 

Mechanisms of Pain in Rheumatic Diseases 

.....................................38 


Squibb, 5; GlaxoSmithKline, 2; Lupin Laboratories, 

5; Pfizer Inc, 5 

Wright, Laura, MBA, CMPE 


- Improve Revenue Cycle Management 

Effectiveness and Optimize Cash Flow ......27 



- Improving Accounts Receivable for Profitability 

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 



- Keynote Address: The World’s Best Managers 

Do Manage Differently-Find Your Strengths for 

Efficiency! .............................27 


Practice Management: Patients As Partners in 





Disclosure: Nothing to DiscloseY 

Yazici, Hasan, MD 

Behçet’s Disease (001) ..................31 


Yelin, Edward H., PhD 


Arthritis ...............................56 



2012 Highlights .......................122 


Yeremenko, Nataliya, PhD 

Plenary Session III: Discovery 2012 .......100 


York, Michael R., MD 

Scleroderma: Systemic Sclerosis (039) ......60 


Z 

Zanin-Zhorov , Alexandra, PhD 


Response ............................104 


Zen, Yoh, MD, PhD 


Directions ............................122 


Zhang, Yuqing, DSc, MPH 







Ziegler, Jennifer A 


the Ground Up ........................128 


Zychlinsky, Arturo, PhD 

Neutrophil Extracellular Traps (NETosis) in 



354 

2012 Program Book

A 

Aakhus, S 1681 

Aalbers, CJ 1334 

Aalokken, TM 231 

Aarrass, S 2090, 2336 

Aati, O 2586 

Abaci, N 989 

Abarca, N 1632 

Abbas, AR 620 

Abbas, W 873 

Abbasi, T 342, 345 

Abbey, S 1862 

Abboud, J 2647 

Abdelnaby, R 267 

Abdollahi-Roodsaz, S 896, 2523 

Abdulahad, WH 514, 860, 1533 

Abe, T 877 

Abenhaim, L 168, 1820 

Aberle, TJ 1418 

Abignano, G 710, 1473 

Abinun, M 1166 

Abji, F 537, 581 

Ablin, JN 955 

Abouassi, H 1228 

Abraham, DJ 785, 854, 2291, 2305, 

2307 

Abrahamowicz, M 720, 1642, 2688 

Abram, F 1124 

Abramowitz, M 949 

Abrams, K 749, 759, 761 

Abramsky-Risman, S 1141 

Abramson, SB 260, 1212, 1263 

Abreu, AS 2064 

Abreu, MM 96, 927 

Abria, C 434, 1185 

Absher, D 729 

Abu-Asab, M 310 

Abu-Shakra, M 193, 1038 

Abud-Mendoza, C 1679 

Acasuso, M 567 

Acharya, S 2700 

Achenbach, SJ 822 

Achilleos, K 2360 

Acikel, C 2477 

Acosta, I 998, 999 

Acosta Felquer, ML 115, 1268, 

1358 

Acu, R 133 

Adachi, JD 1016, 1018, 1052, 

1959, 1979, 2100 

Adam, PM 1722, 2405, 2430 

Adams, AB 621 

Adams, BS 311 

Adams, M 45, 51 

Adams, RJ 61 

Adan, AM 185 

Addimanda, O 2351, 2362 

Addya, S 1496 

Adebajo, AO 57 

Adeleke, GA 1801 

Adema, G 844 

Ademowo, OS 582 

Adizie, T 2360 

Adler, A 858 

Adler, S 2553 

Adlowitz, DG 690, 2667 

Adorni, M 675 

Adrianto, I 523, 524, 525, 2671, 

2674 

Adusumilli, S 1400 

Af Klint, E 1792 

Affandi, AJ 1516 

Aga, AB 376, 395 

Agarwal, M 1680 

Agarwal, SK 2290 

Agarwal, S 772 

Agarwal, V 1017, 1054 

Agerberth, B 1792 

Aggarwal, A 309, 1166, 2260 

Aggarwal, R 207, 217, 230, 756, 

1598, 1945, 1949, 1950, 2049 

Agha, Z 917 

Aghdassi, E 2688 

Agodoa, I 922, 1976 

Agoston, G 125 

Agrawal, N 1446, 2281 

Agrawal, S 282 

Agrawal, S 1068 

Agrawal, V 1017, 1054 

Aguado, P 1175 

Agudo, M 1341 

Aguilar-Lozano, L 446 

Aguirre, MA 980, 1211, 2272 

Aguirre de Cárcer, D 2494 

Agung, E 738 

Agýldere, M 958 

Ahadieh, S 1697 

Ahearn, JM 2699 

Ahedi, H 1117 

Ahlehoff, O 1684 

Ahluwalia, V 926, 1287, 2511 

Ahmad, R 2571 

Ahmad, S 431 

Ahmadi, N 131 

Ahn, G 919 

Ahn, GE 242 

Ahn, JK 203, 425, 435, 1181, 1226 

Aiello, P 2368 

Aigner, S 2343 

Aihara, M 1501 

Aikawa, NE 533, 1999 

Aikawa, Y 2074 

Air, GM 645 

Ajeganova, S 1245 

Ajimi, C 1535 

Akaike, H 1163 

Akamata, K 708, 1504, 1521 

Akan, H 1499 

Akar, S 565, 1382 

Akashi, K 186, 1763 

Akhavan, P 403, 2109 

Akhlaghi, M 2376 

Akhmetshina, A 347, 1514 

Akhras, KS 1814, 2045 

Akhtar, N 29 

Akhter, E 619, 626, 691, 1390, 

1425, 1648, 1730, 1732, 2255 

Akikusa, J 318 

Akinlade, B 1322 

Akkineni, R 928 

Akkoc, N 565, 1382 

Akman, C 2366 

Akpinar, M 1972 

Akram, A 1624 

Aksentijevich, I 2031 

Aksu, K 181, 532, 858, 2364 

Aktay Ayaz, N 1166, 2477 

Akter, T 1522 

AL Achkar, W 420 

Al Haj, R 2592 

Al Snih, S 1257, 1589 

Al-Ashkar, FT 1557 

Al-Mayouf, S 2032, 2477 

Al-Mudhaffer, S 2348, 2382 

Al-Sarraj, S 1955 

Alam, MM 406 

Alarakhia, A 1195, 2066 

Alarcon, GS 287, 604, 671, 931, 

1411, 1422, 1665 

Alarcon-Riquelme, ME 843 

Alarcon-Riquelme on behalf of 

BIOLUPUS, ME 2283 

Alarcon-Riquelme on behalf of 

BIOLUPUS and GENLES, ME 970 

Alarcón-Riquelme on behalf of 

BIOLUPUS and GENLES network, 

ME 846 

Alarcün-Riquelme on behalf of 

BIOLUPUS and GENLES networks, 

ME 1613 

Alasti, F 421, 2608 

Alaupovic, P 2255 

Alba, MA 859, 1479, 2352, 2357, 

2359 

Albani, S 427, 2593, 2594, 2595 

Albath-Sadiki, A 1656 

Albert, CJ 2238 

Albert, D 1573, 2053, 2264 

Albert, DA 97, 928 

Albrecht, A 1019 

Albrecht, E 1630 

Alcaraz, MJ 22 

Aldag, JC 65, 66 

Aldaghlawi, F 1538 

ALE02 Study Team, 2687 

Alegre, JJ 2239 

Alekseeva, E 1143, 1148, 1597 

Alekseyev, Y 1529 

Alessandri, C 192 

Alessio, M 1166, 1676, 2021 

Aletaha, D 773 

Aletaha, D 109, 111, 405, 421, 

1908, 2113, 2126, 2608 

Alevizos, I 506, 517, 2501 

Alexander, K 2093, 2543 

Alexander, MY 623, 667 

Alexander, S 1810 

Alexander, T 686, 979 

Alexandersen, P 1984 

Alexanderson, H 208, 754 

Alexiades, M 1093, 2443 

Alexopoulos, N 1261 

Alexsson, A 2271 

Alfaro-Lozano, JL 1399 

Alfie, J 1268 

Alfredsson, L 63, 64, 753, 978, 

1604, 2120 

AlHomood, I 612, 1350 

Ali, A 2603 

Ali, J 338 

Alibaz-Oner, F 2364, 2367, 2370, 

2371, 2377 

Alibaz-Öner, F 2394 

Aliprantis, AO 30, 735 

Alivernini, S 1197 

AlJohani, G 2254 

Allaart, CF 394, 397, 469, 1330, 

1594, 1982, 2606 

Allaart, CF 2002 

Allaire, N 618, 886 

Allanore, Y 696, 1000, 1462, 1487, 

1510, 1511, 2298 

Allen, KD 795, 1113 

Allen, P 1662 

Allen, R 318 

Allenbach, Y 220, 225, 757 

Allison, J 920, 1085 

Ally, MM 1794 

Alm, GV 845, 2271 

Almagor, O 241, 2467 

Almeida, I 1483 

Almeida de Jesus, A 2031, 2653 

Alnaqbi, KA 1364, 1592, 2224 

Alon, L 1883 

Alonso, A 998, 999, 1001 

Alonzo, C 1563 

Aloush, V 611 

Alpay-Kanitez, N 1707, 2253 

Alperin, R 621 

Alpérovitch, A 168 

Alpsoy, E 858 


abstract author Index

abstract author Index 

356 

Alsaleh, G 511, 1785 

Alstergren, P 2020 

Alten, R 460, 462, 1695, 1911, 

2159, 2547 

Alten, R 144, 1274 

Alten, R 367, 772, 1316, 1640 

Althoff, C 571, 2219 

Alunno, A 2183, 2184, 2185 

Alvarez, AC 60, 2141 

Alvarez, D 1354 

Alvarez de la Rosa, D 505 

Alvarez-Rodriguez, L 2349 

Alves, C 768 

Alves, C 385 

Alves, G 1874 

Aly, IM 1490 

Alzua, BR 1743 

Amani, Z 2339 

Amano, K 444, 445, 1343, 2156 

Amano, K 98, 473, 1289 

Amano, K 444, 445, 1343, 2156 

Amara, K 2578 

Amaricai, E 1876 

Amarilyo, G 1170, 1899 

Amaryan, G 2032 

Amato, AA 753, 755 

Ambarus, C 585 

Ambarus, CA 539, 1602 

Ambler, N 1579 

Ambrožič, A 2205 

Ambrus, J Jr. 515 

Ambudkar, I 506, 517 

Amdur, RL 149 

Amengual, O 1729, 2460 

Amezcua-Guerra, LM 127, 644 

Amft, EN 1525 

Amin, MA 311, 330, 413, 737, 879, 

1603 

Amin, S 424, 820, 822 

Amital, H 2550 

Amity, CL 2127 

Amiya, E 700 

Ammann, CG 2318 

Ammitzbøll, CG 2522 

Amorosa, V 174 

Amoura, Z 225, 641, 751, 1649, 

2459, 2531, 2532 

Ampel, NM 2172 

Amudala, N 868, 1528, 2428 

An, J 2281 

An, L 2067 

Anan, R 1186 

Anandarajah, AP 1112, 1207, 

1992, 2221 

Anaya, JM 523, 524, 525, 843, 

2203, 2671, 2674 

Ancuta, I 448, 449, 1383 

Andersen, AR 361, 363 


Andersen, J 1984 

Andersen, MD 2558 

Anderson, DW 1610, 2270 

Anderson, JK 1361 

Anderson, JR 645, 740, 1441 

Anderson, M 1171 

Anderson, R 1794 

Anderson, RJ 1932 

Andersson, C 2080, 2082 

Andersson, H 231 

Andersson, ML 390, 1245 

Andhivarothai, N 486 

Andou, A 738 

Andrade, F 619, 1689 

Andrade, L 212 

Andrade, LEC 657, 1073, 2282, 

2369 

Andreef, M 1447 

Andreoli, L 1523, 1736, 2458 

Andres, M 1908, 2239 

Andres Cerezo, L 347 

Andreu, JL 980 

Andrews, C 749 

Andrieu, M 600 

Andrigueti, FV 704 

Andringa, KK 729 

Ang, DC 952, 965 

Angeles-Han, S 1157 

Angeles-Han, ST 1144, 1155, 2005 

Angerer, P 944 

Angioloni, S 2473 

Ångström, L 1244 

Anink, J 1142 

Anis, AH 1287, 2462 

Anisfeld, AM 1323 

Anolik, JH 512, 1207, 1992, 2666, 

2667, 2678 

Anouk, M 611 

Anslik, T 225 

Antal-Szalmas, P 543 

Anthony, KK 2420 

Antoch, G 1040 

Antolić, A 2187 

Anton, A 2224 

Anton, J 762, 1166, 1373, 2477 

Antypa, E 991, 2181 

Aoi, J 2286 

Aoki, A 2046 

Aoki, J 2248 

Aoyagi, K 1046, 1053, 2112, 2142 

Aozasa, N 708, 1504, 1521 

Aparicio, M 1373 

Apatira, A 329 

Apaz, M 1166 

Apaz, MT 2473 

Apkarian, AV 1082 

Appel, H 2496 

Appenzeller, S 299, 300, 1416 

Appleberry, HC 1765 

Appleton, SL 61 

APS Action, OBO 1736, 2458 

Arai, S 1918 

Aral, O 2253 

Aramburu, F 1427 

Arami, S 2454 

Arana Fraustro, A 2204 

Arana Guajardo, A 2096 

Aranow, C 649, 656, 2570, 2572, 

2619, 2687 

Araujo, D 372 

Araujo, E 1010, 2581 

Arayssi, T 420 

Arbab, A 1603 

Arbogast, P 1960 

Arce-Franco, MT 505 

Ardelean, DS 2027 

Arden, NK 781, 915, 982 

Ardoin, SP 840, 2039, 2601 

Ardouin, E 1302 

Arend, WP 1059 

Arendt, C 503 

Arendt-Nielsen, L 235 

Arentz, G 2676 

Arguis, P 2359 

Arima, K 1046, 1053, 2112, 2142 

Ariño i Torregrosa, M 171 

Arinobu, Y 186 

Arinuma, Y 2684 

Arismendi, MI 704 

Arito, M 182, 1531 

Ariza, R 538 

Ariza, Y 1660, 1799 

Arkachaisri, T 274 

Arkema, EV 1605 

Arkfeld, D 2194 

Arledge, T 777, 2613 

Arlestig, L 412 

Arlet, P 1923 

Armas-Gonzalez, E 505 

Arnaud, L 751, 2459, 2531, 2532 

Arndt, F 2379 

Arnett, DK 996, 997 

Arnett, FC 2304 

Arnett, H 1659 

Arnold, K 297 

Arnold, LM 2641 

Arnold, MH 2140 

Arnold, S 1408 

Arntz, OJ 896, 2089 

Arola, J 1920 

Arold, G 1307 

Arora, J 829 

Arora, S 2038 

Arora, V 995, 1678, 2010 

Aróstegui, JI 191 

Arquizan, C 1551 

Arribas, F 546 

Arroyo-Villa, I 1175 

Arsenyeva, S 1676 

Artim-Esen, B 1707, 1725, 2253 

Arts, EEA 1682 

Arturi, P 1356 

Arufe, MC 7 

Arundine, M 1841 

Arvidsson, B 1559 

Arvikar, SL 1204 

Asahara, H 28, 2645 

Asako, K 184, 2372 

Asami, Y 809, 1431 

Asano, Y 700, 708, 1504, 1521 

Asashima, H 518, 2529 

Aschauer, C 343 

Asche, CV 1814 

Ascherman, DP 207, 756, 1598 

Ash, E 611 

Asher, I 1456 

Ashihara, E 2070 

Ashizawa, T 2046 

Ashlock, M 1671 

Ashofteh, F 2376 

Ashrani, A 1737 

Ashruf, U 638 

Ashworth, WD 2509 

Askanase, A 1417, 2239 

Askanase, AD 1418 

Askling, J 826, 1229, 1615, 2120 

Aslam, A 1650 

Aslam, T 1346 

Aslanov, R 1246, 1395 

Aslanyan, E 2224 

Aslibekyan, S 996, 997 

Asmawidjaja, PS 1793, 2338 

Asmussen, K 580 

Assaf, NY 1490 

Assaraf, YG 2154 

Assassi, S 92, 545, 852, 1464, 

1474, 1475, 1509, 1704, 2290, 

2303, 2304 

Assis, MR 1880 

Astudillo, L 1923 

Atanelishvili, I 1522 

Atay, K 1707 

Ateka-Barrutia, O 1900 

Ather, S 1991 

Atkinson, EJ 822 

Atroshi, I 1129, 2648 

Atsumi, T 1729, 2460 

Atta, A 177 

Attur, M 1212, 1263 

Attwell, S 341 

Atzeni, F 2180

Atzeni, F 263 

Au, K 900 

Aubert, R 1978 

Aubrun, E 168, 1820 

Aubry, B Sr. 135 

Audo, R 1782 

Auffret, M 1852 

Auger, I 1755 

Auger, JL 1056, 2452 

Augustin, T 1921 

Augusto, KL 162 

Aulie, H 1681 

Aumaitre, O 641, 1652 

Aurrecoechea, E 2349 

Austad, C 90 

Austin, CR 190 

Austin, HA 2501 

Australian-Anglo-American 

Spondylitis Consortium (TASC), 

1612 

Australo-Anglo-American 

Spondyloarthritis Consortium, 

595 

Autran, B 201 

Avaux, M 1335 

Avcin, T 1166, 2040, 2473, 2598 

Avendano, C 8 

Ávila, G 980 

Avila Campos, MJ 2523 

Ávila-Casado, C 2244 

Avina-Zubieta, JA 2568, 2685 

Avins, AL 817 

Avouac, J 347, 1462, 1510, 1511 

Awada, A 2201 

Awasthi, R 1017, 1054 

Axelsen, MB 1045, 1617 

Axmann, R 2163 

Ayabe, F 28, 2645 

Ayadi, H 1577 

Ayanian, JZ 1843 

Ayano, M 186 

Aydin, SZ 710, 1398, 2363 

Ayearst, R 1375, 1381 

Ayers, D 1085, 1086, 1087, 1585, 

2651 

Aynsley, S 1800, 1801 

Aytekin, S 2377 

Ayyagari, R 75 

Azar, L 1544 

Aziz Khan, K 873 

Azuma, K 223 

Azuma, N 1281 

Baas, F 1754 

Baba, S 941, 942 

B 

Bach, D 2194 

Bach, M 146 

Bach, MH 2493 

Bachelot, A 641 

Backhaus, M 129, 2118 

Backlin, C 1229 

Backman, CL 870, 1722, 2405, 

2430 

Baddley, J 763, 1270, 2093, 2543 

Badley, EM 925, 2417, 2634 

Badley, EM 2414, 2630 

Badurski, J 1596 

Bae, J 1236 

Bae, KT 251 

Bae, SC 78, 843, 846, 970, 1013, 

1210, 1247, 2686 

Bae, S 408 

Baechler Gillespie, E 424, 658, 

2576 

Baecklund, E 1229 

Baek, IW 613, 628 

Baer, AN 101, 743, 2174, 2192, 

2193, 2672 

Baerlecken, NT 586, 2380 

Baerwald, CG 1218, 1408 

Baeten, D 574, 888 

Baeten, DL 539, 585, 737, 1602, 

2225, 2453 

Baeuerle, M 747 

Bagavant, H 2675 

Bagchi, S 935 

Bagdonas, E 438 

Bagga, A 2477 

Baggott, J 996 

Baglaenko, Y 1744, 2340 

Bagnari, V 1002 

Bagnasco, M 263 

Bagnato, G 1507, 1508 

Bagnato, G 1507, 1508 

Bahner, M 129 

Bahrt, KM 169, 170 

Baildam, E 1145, 1159, 1162, 2009 

Baillet, N 1740 

Bain, LJ 2402 

Bair, M 965 

Baird, E 621 

Bajocchi, G 2351, 2362 

BAK, WS 1889 

Baker, D 563, 812, 1292, 1301, 

1324, 1325, 1620, 1826 

Baker, GR 2044 

Baker, J 1221, 1620, 2191 

Baker, MF 2108 

Baker, NA 2435, 2438 

Bakir-Gungor, B 1005 

Bakken, J 784, 1498 

Bakker, MF 2125 

Bakker, MF 1996 

Bala, SV 390 

Balanescu, A 1910 

Balasingh, V 2578 

Balbir-Gurman, A 450 

Balci, N 1106 

Baldassari, AA 2629 

Baldi, C 1291 

Baldini, C 126, 529, 1546, 2183, 

2184, 2185 

Baldissera, E 2368 

Baldo, G 204 

Baldovino, S 1547 

Balfour, HH Jr. 2452 

Baliki, M 1082 

Balint, P 810, 811 

Balint, PV 111 

Balogh, B 1503, 1506 

Balogh, E 1191, 1806 

Balow, JE 2501 

Balsa, A 461 

Balsa, A 546, 1000, 1175, 1205 

Balser, S 120, 1047, 2378 

Bananis, E 1011, 1285, 1354, 

2133, 2661 

Bancroft, T 94, 932 

Banda, NK 1059 

Bandeira, M 296 

Bandinelli, F 1379 

Bandos, A 756 

Banerjee, P 1315, 1321 

Bang, SY 348, 1210, 1247, 2686 

Bankhurst, A 2038 

Bannock, J Sr. 1772 

Bannuru, RR 964 

Bansal, R 1426 

Bansback, N 2462 

Bantia, S 1633 

Banzato, A 1736, 2458 

Bao, C 1366, 1457 

Bao, G 935, 945, 2695 

Bao, M 2545 

Bao, Y 1242 

Baptista, AS 1867 

Baraf, HSB 159, 160, 815, 1323, 

1913, 1916 

Baraliakos, X 563, 574, 586, 780, 

1619, 2235 

Baram, N 1038 

Baratz, M 2435 

Barbaglia, AL 60, 2141 

Barbarroja, N 1211, 2272 

Barber, CE 172 

Barber, G 527 

Barbosa, JW 1018 

Barbosa, L 177 

Barbour, KE 819, 2416 

Barcellos, LF 521 

Bardelli, M 1291 

Bardin, N 1730 

Bardin, T 1911 

Bardin, T 144, 351, 1308, 1309, 

1313, 2168 

Barendregt, PJ 768, 2095 

Barham, T 2407 

Barile-Fabris, L 467 

Barinas-Mitchell, E 1711 

Barinstein, LV 621 

Barker, A 2509 

Barker, M 2071 

Barleben, M 440 

Barnabe, C 1007, 1009, 2063, 

2132 

Barnes, DE 819 

Barnes, I 2065, 2602 

Barnetche, T 352, 566, 1302 

Barohn, RJ 753, 1598 

Baron, G 1308, 1309, 1313, 2168, 

2189, 2472 

Baron, M 711, 728, 853, 1467, 

1480, 2422, 2424, 2626 

Baronaite Hansen, R 1419 

Barone, P 1166 

Barr, SG 1009, 2570 

Barra, LJ 422, 1326 

Barreira, JC 200 

Barrera, P 1180 

Barrera-Cruz, A 1726 

Barrett, R 2616 

Barriere, F 1649 

Barron, KS 179 

Barros, R 1988 

Barros, TBM 162, 210 

Barsalou, J 1739 

Barsness, LO 2576 

Bartels, CM 86, 1667 

Bartels, EM 2169 

Bartlett, SJ 476, 1216, 2099 

Bartley, Y 1644 

Bartok, B 1659, 1775 

Bartoloni Bocci, E 2183, 2184, 

2185 

Barton, A 362, 974 

Barton, B 1085 

Barton, DL 1869 

Barton, J 247, 2139, 2440 

Bartos, A 2498 

Bas, S 248 

Baser, O 2146, 2233 

Bashmakov, A 2073 

Basiaga, M 634 

Basic, J 1154 

Basra, G 2456, 2457 

Bastian, I 504, 2676 

Basu, N 1525 

Bateman, L 1228 




358 

Bathon, JM 2118, 2467, 2484, 

2539, 2659 

Batruch, I 560 

Batsis, JA 1974 

Batt, CM 1628 

Battafarano, DF 87, 1213, 1269, 

1824, 2114 

Battagliese, A 2021 

Batten, RL 1466 

Batteux, F 2565 

Batthish, M 1171, 2044 

Battisti, R 96, 927 

Battistone, MJ 2509 

Baud, L 873 

Baudouin, C 1780 

Bauer, G 343 

Bauer, TK 1572 

Baum, W 347 

Baumeister, J 336, 1311 

Baumgratz, TD 96, 927 

Bautista, E 1294 

Bautista-Caro, MB 1175 

Bay-Jensen, AC 235, 575, 591, 592, 

1329, 2166, 2167, 2615 

Baynes, KE 1036 

Bayoumi, A 1168 

Bazeli, R 2007 

Bazin, D 1657 

Bazzichi, L 1039 

Beaart-van de Voorde, LJJ 1136 

Bearne, LM 2050, 2439 

Beaton, D 2417 

Beattie, KA 1016, 1018, 1052, 

2100 

Beattie, SD 2487, 2488 

Beatty, M 89 

Beaulieu, A 1124 

Beaulieu, AD 471, 472 

Beauvais, C 1895 

Beavers, D 2534 

Beavers, D 2536 

Becerra, E 502, 1757, 1758 

Becker, ML 1151, 2008, 2029, 

2597 

Becker, MA 150, 159, 160, 1814, 

1913, 1916 

Becker, MO 1491 

Becvar, R 347 

Bedran, Z 60, 1268, 1358 

Beekman, M 1100 

Beham, AW 1209 

Behera, A 32 

Behin, A 225 

Behrbalk, E 955 

Behrens, EM 314, 1058 

Behrens, F 2217 

Behrens, TW 620 

Beier, F 42 


Beilke, JN 1796 

Beitinger, N 118 

Bejarano, V 1718 

Bek, S 761, 2225 

Belasco, J 2491 

Belenotti, P 1622 

Belilos, E 2157 

Belke-Voss, E 359 

Bell, DA 422 

Bell, E 2148 

Bell, L 1239 

Bell, MJ 2148 

Bell, SW 904 

Bell-Peter, A 284, 285 

Bellamy, N 254, 255, 1137, 1596 

Bellando Randone, S 125, 1039 

Bellando-Randone, S 1485 

Bello, AE 259 

Bello, KJ 1710 

Bello, N 1427 

Bellomio, V 2141 

Belmar, N 331 

Belmont, HM 1417 

Belmonte, M 2239 

Belmonte-Serrano, M 461 

Belomestnov, P 1337 

Belostocki, KB 2157 

Belot, A 2477 

Belsom, R 402, 2106 

Beltramo, A 2476 

Bemrich-Stolz, CJ 2655 

Ben Sedrine, W 1966 

Benavidez, J 200 

Bencivelli, W 1482 

Benda, B 773, 1277, 2485 

Benda, B 1282, 1297 

Bendix, K 1877 

Béné, J 1852 

Benech, P Sr. 1772 

Benegas, M 60, 2141 

Benessiano, J 830 

Bengtsson, A 654, 1388, 1434 

Bengtsson, AA 661, 662, 680, 930, 

2276 

Bengtsson, C 63, 64, 1604, 1607 

Bengtsson, K 463 

Benham, H 2492, 2494 

Benhamou, CL 1959, 1971, 2135 

Benhamou, M 556 

Benichou, J 1820, 1837 

Benitez, A 1759 

Benítez-del-Castillo, JM 1140 

Benito, P 1101 

Benjamin, M 1874 

Benjamin, WH Jr. 1934 

Benn, B 2295 

Bennett, B 1319 

Bennett, K 2540 

Bennett, L 1629 

Bennett, M 305, 2474 

Bennett, M 156, 1132 

Bennett, RM 801, 804, 1857, 1868, 

1880 

Bennett, TD 283 

Bennin, D 1601 

Bennink, MB 896, 2089 

Benos, A 2058 

Benseler, SM 284, 285, 295, 304, 

2015, 2478 

Bensen, R 1979 

Bensen, W 460, 472, 493, 1596 

Bensen, W 494, 2108 

Bensen, WG 384, 456, 1016, 1018, 

1979, 2055, 2100 

Benveniste, O 220, 225, 757 

Bérard, A 1169 

Berardi, G 1486 

Berclaz, PY 447, 1276, 1315, 1321, 

2487, 2488 

Berenbaum, F 1109 

Berenbaum, F 13, 18, 19, 830, 

1110, 1627 

Beresford, M 1145 

Beresford, MW 2040 

Beretta, L 2303 

Berg, KL 1196 

Bergegård, J 208 

Berger, A 2507 

Berger, J 128, 129 

Bergerhausen, HJ 365 

Berggren, O 2271 

Bergin, D 825, 1255, 1686 

Bergknut, C 73, 916 

Berglin, EH 2145 

Berglind Schepp, J 2339 

Bergman, MJ 75, 84, 2043, 2048, 

2104, 2105 

Bergman, S 95, 1559, 1828, 1871, 

2409 

Bergmann, JF 225 

Bergström, U 411, 1184 

Berinstein, J 590 

Berkun, Y 759 

Berlucchi, M 2025 

Berman, A 60, 479, 1356, 2141 

Berman, B 258 

Berman, H 60 

Berman, M 955 

Bermas, BL 608, 937 

Bernal, WE 314, 987 

Bernardi, L 1275 

Bernasconi, C 454, 2550 

Bernatowicz, P 2298 

Bernatsky, S 55, 457, 649, 926, 

1169, 1223, 1387, 1411, 1428, 

1887, 2236, 2475, 2511, 2570 

Bernelot Moens, HJ 2607, 2637 

Berner Hammer, H 810, 811 

Bernhardt, G 1510 

Bernini, F 675 

Bernstein, CN 939, 2541 

Bernstein, EJ 1712 

Bernton, E 833 

Berrocal, V 92, 158, 1464 

Bertamino, M 1158 

Bertani, L 246 

Berthelot, JM 2024, 2155, 2554 

Berthier, CC 1445, 2499 

Bertin, P 1319 

Bertini, F 2013, 2014, 2017 

Bertleff, M 1048 

Bertolaccini, ML 1734, 1735, 1900 

Bertoli, AM 1411 

Bertolini, E 873, 1756 

Bertolino, A 2225 

Bertrand, J 40 

Bertsias, G 989, 1436 

Bessette, L 457, 1124 

Bessis, N 2505 

Bethunaickan, R 1445, 1454 

Bettencourt, B 372 

Bettenworth, D 1779 

Betteridge, Z 229, 854, 1673 

Beukelman, T 763, 924, 1146, 

1168, 2601, 2655 

Beutler, A 2218 

Beyer, C 347, 1499, 1500, 1502, 

1505, 2517 

Beysen, C 1290 

Bezanahary, H 1649 

Bhadra, P 1130 

Bhangle, S 174 

Bhansing, KJ 228 

Bharadwaj, A 385 

Bharat, A 924 

Bharucha, KN 760 

Bhattacharyya, S 1518, 2289 

Bhatti, P 904 

Bhattoa, HP 543 

Bian, A 832, 1261 

Bianchi, G 1998 

Bibalo, C 2021 

Bica, BE 296, 1166 

Bicov, P 1876 

Bidonde, J 1586 

Biear, J 1207, 2667 

Bielecki, M 2292, 2298 

Bienkowska, J 618, 886 

Bienvenu, B 1545, 1551, 1656 

Bienvenu, T 1217 

Bierma-Zeinstra, S 2471 

Bierma-Zeinstra, SMA 1125, 1126 

Biermasz, NR 1100

Bierut, L 2672 

Biesen, R 686, 979 

Bijanki, V 1662 

Bijkerk, C 394 

Bijl, M 2393 

Bijlsma, JWJ 510, 1122, 1788, 

1832, 2125, 2335 

Bijlsma, JWJ 1996 

Bijlsma, JW 1126 

Bijsterbosch, J 1100 

Bijzet, J 2393 

Bikker, A 509, 510, 2196 

Bilgic, H 424, 658 

Bili, A 1231, 1241, 2604 

Billard, MJ 1663 

Binder, NB 2518 

Bingham, CO III 1284 

Bingham, CA 2601 

Bingham, CO III 459, 476, 812, 

1216, 1292, 1301, 1694, 1826, 

2480 

Bingham, C III 349, 2099, 2118 

Biniecka, M 1191, 1621, 1806 

Binkley, N 1995, 1997 

Binstadt, BA 1056, 2452 

BIOBADASER Study Group, 1641 

Biolo, G 630, 1397 

Biondi, K 2017 

Biotherapy, C 873 

Bird, H 1718 

Bird, P 387, 2140 

Birkett, R 1074, 1076, 1206, 1639, 

2524 

Birmingham, D 729, 840, 2251 

Birmingham, JD 382 

Birnbaum, J 609 

Birolo, C 1676 

Birru Talabi, M 2116 

Birt, J 488 

Bischoff, S 77 

Bisconte, A 2326 

Bishop, GA 1441 

Bissonauth, A 70 

Biswas, S 2080 

Bitman, B 1644 

Biton, J 2505 

Bitto, A 1507, 1508 

Björk, J 913, 914 

Björnådal, L 703 

Blaauw, M 1363 

Black, J 61 

Black, MA 1628 

Blackburn, MR 2290 

Blackburn, T 1970 

Blagojevic, J 1485 

Blalock, SJ 906 

Blanc, F 1657 

Blancette, N 304 

Blanch, J 781 

Blanchard-Delaunay, C 1652 

Blanco, F 1679 

Blanco, FJ 6, 7, 11, 48, 541, 988, 

993, 994, 1359, 1360, 2173 

Blanco, I 632, 838, 839, 949, 2570 

Blanco, R 980, 1140, 1548, 2388, 

2389 

Blanco Alonso, R 1205 

Blanco Garcia, FJ 41 

Blaney Davidson, EN 17, 23 

Blankenstein, K 24 

Blanshard, A 1994 

Blaschke, S 1209 

Blasius, AL 1796 

Blattes, R 733 

Blauvelt, A 552 

Blazevic, I 1411 

Bleakley, C 1986 

Bleck, E 46 

Bleijenberg, G 1232 

Bliddal, H 1042, 1045, 2169 

Blier, PR 762 

Blits, M 2154 

Blitz, JR 861, 1583 

Blizzard, L 1117, 2535 

Bloch, DB 2527 

Bloch, M 1911 

Bloch, M 144 

Block, AJ 1679 

Block, JA 234, 236, 262, 264, 265, 

1105, 1411, 1526, 1538, 1563, 

2236 

Bloem, JL 1051 

Blom, AB 17, 733, 895, 2089 

Blueml, S 2086 

Blum, A 1618 

Blum, M 1815 

Blumberg, H 1796 

Blüml, S 335, 1070 

Boackle, SA 2283 

Bobba, RS 1016, 1018, 2100 

Boccassini, L 2180 

Bochkov, V 1072 

Bochud, M 1630 

Bode, C 871 

Bodi, I 1955 

Boehm, C 347 

Boers, M 358, 1125, 1274, 2118, 

2169 

Boesen, M 1042, 1045 

Boettner, F 2479 

Bogatkevich, GS 1522 

Bogdanova, AA 2062 

Boger, HA 1451 

Bogot, N 154 

Bohgaki, T 1729, 2460 

Böhler, C 2126 

Bøhme, W 361, 363 

Bohm, M 1172, 2654 

Bohndorf, K 1027 

Bohnsack, JF 276, 283, 974, 1614, 

2657 

Boiardi, L 2347, 2351, 2362 

Boin, F 697, 2299 

Boire, G 401, 465, 769, 1216, 

1225, 1238, 2099, 2109, 2132, 

2610 

Boismenu, R 2622 

Boissier, MC 479, 844, 2505 

Bojalil, R 644 

Bojinca, M 448, 449, 1383 

Bolat, A 1984 

Bolce, R 1131, 1286, 2121, 2162, 

2664 

Bolge, S 1834, 1925 

Bolis, M 2025 

Bolognese, MA 1997, 1998 

Bolster, MB 1463 

Bolt, I 1166 

Bolten, WW 257 

Bombardier, C 55, 403, 926, 1908, 

2511 

Bombardieri, S 114, 126, 188, 529, 

1039, 1482, 1546, 2057, 2183, 

2184, 2185, 2361, 2551 

Bompane, D 246 

Bonafede, M 1829 

Bonaffini, P 133 

Bonciani, D 1379 

Bond, D 1718 

Bond, H 1564, 1565, 2698 

Bond, J 1810 

Bonderman, D 851 

Bondt, A 1176 

Bone, HG 1959, 1961, 1997 

Boneparth, M 798 

Bonetti, LA 2157 

Bonfa, E 173, 277, 533, 631, 923, 

1724, 1999, 2195, 2497, 2500, 

2530, 2618 

Bonfiglioli, KR 173, 1724, 2064 

Bongardt, S 639 

Bonilla, G 546, 1175, 2239 

Bonjoch, A 1967 

Bonner, A 381, 401, 711, 1467 

Bonner, M 1476, 1512 

Bonnet, F 1622 

Bonnick, S 727, 1976, 1997 

Bonnotte, B 1652 

Bontadelli, K 1080 

Bonvin, A 1091 

Bookbinder, LH 2270 

Boonen, A 1363, 1376, 1377, 

1524, 1844, 1845 

Boonen, S 1959, 1977 

Booth, A 1518 

Bootsma, H 514, 516, 2551 

Boracchi, P 1472 

Borah, B 574 

Borba, EF 277, 631, 2497, 2500, 

2618 

Borba Neto, EF 2530 

Borg, R 1524 

Borghi, M 1472, 2455 

Borghi, O 675 

Borgia, E 302 

Borlawsky, T 2602 

Boros, CA 317 

Bos, MI 1021 

Bos, WH 765 

Bosco, M 2017 

Bosello, SL 1486, 1764 

Bossini-Castillo, L 2303 

Bostan, C 1376 

Boström, C 1554 

Bosworth, HB 795 

Botsios, C 1275 

Bottai, M 753 

Bottini, N 1659, 2452 

Botusan, IR 1789 

Bouaziz, W 25, 44 

Boudaoud, S 2321 

Boudreau, RM 249, 250, 252, 908, 

909, 1031, 1128, 2469, 2470 

Bougault, C 13, 18, 19 

Boumans, MJ 1754 

Boumpas, D 460, 1436 

Bourgeois, C 2321 

Bourgeois, P 225 

Bourré-Tessier, J 171, 1411, 2236 

Bourrel, R 2384 

Bousser, MG 1551 

Bouta, EM 333 

Boutin, D 641 

Boutsen, Y 479 

Bouttier, R 1115 

Bowcock, A 1808 

Bowes, J 974, 1614 

Bowes, MA 732, 1034 

Bowman, EP 725 

Bowman, SJ 2551 

Box, J 462 

Boy, MG 2485 

Boy, MG 1697 

Boyd, SK 1009 

Boyer, O 220, 485, 1783 

Boyesen, P 1111 

Bøyesen, P 361, 363, 1042 

Boyle, DL 426, 878, 1610, 1659, 

2076, 2270 

Boyle, JF 2038 

Boyle, J 2148 




360 

Braakman-Jansen, A 2637 

Brabosa, R 300 

Bracciolini, G 1165, 1173 

Brach, C 1572 

Brachat, A 761, 2225 

Bradbury, LA 595 

Bradley, J 1277, 1284 

Bradley, JD 773, 2485 

Bradley, J 1014, 1290, 1297, 2486 

Bradley, JD 1282, 1283 

Bradshaw, JM 2326 

Brady, S 232 

Brady, TJ 2401, 2416, 2695 

Brahn, E 329 

Brakenhoff, LKPM 1051 

Brameld, K 2326 

Branch, M 1979 

Branch, W 1650 

Branco, JC 372 

Brand, C 164 

Brandao, L 1739 

Brandi, ML 1961, 1969, 2013, 2014 

Brandt, H 1384 

Brasil, F 1266 

Bratton, SL 283 

Brault, Y 364 

Braun, A 553 

Braun, J 553, 780 

Braun, J 574, 777, 1372, 1619, 

1705, 2225 

Braun, J 586, 1376 

Braun, J 563, 1703, 2235 

Braun, T Sr. 195 

Brauner, S 1773 

Bray, MS 997 

Breban, MA 594, 597, 598, 600 

Breda, L 1166 

Breedveld, E 331 

Breedveld, FC 1015, 1303, 1304 

Breland, HL 2633 

Bremander, ABI 73, 95, 1828, 2409 

Brembilla, NC 2293 

Brennan, M 1690 

Brennan, MT 2671 

Brennan-Speranza, TC 24 

Breton, G 225 

Breuer, GS 154, 450 

Brewer, J 881 

Brewer, M 1062 

Brey, RL 671 

Breysach, C 1209 

Briasouli, P 1776 

Bricel, S 2194 

Brickmann, K 117 

Bridges, SL Jr. 975, 996, 997, 1203, 

2136, 2152 

Briggs, L 801 


Briggs, T 1810 

Briggs, TA 2281 

Brik, R 759, 761, 2003 

Brink, M 412, 439 

Brink, P 41 

Brinkman, DMC 2002 

Brinkman, WB 2042 

Brinks, R 944 

Brinson, D 28 

Briot, K 823, 2110 

Brites, F 1256 

Britsemmer, K 2134 

Britten, N 2148 

Brixen, K 1991 

Brizendine, K 2093 

Brizzolara, R 1493, 2164 

Brkic, Z 528, 2301 

Brock, M 892 

Broderick, S 1847 

Brodmerkel, C 2165 

Broekstra, P 2090 

Broen, J 1180, 2298 

Brogan, P 1674, 2477 

Brohawn, P 755, 784, 1675, 1760, 

2681 

Bromberg, MH 2420 

Brookhart, MA 1843 

Brooks, S 1722, 2148, 2405 

Brophy, M 1287 

Broucksou, KA 1572 

Broussard, C 1774 

Brouwer, E 894, 1202 

Brouwer, J 1240 

Brown, D 278, 2653 

Brown, E 996, 997 

Brown, EE 729, 1422 

Brown, J 255 

Brown, JP 824 

Brown, K 2055 

Brown, KK 1227, 1713 

Brown, KM 2036 

Brown, MT 259 

Brown, MA 595, 1025, 1612, 2495 

Brown, M 1014 

Brown, PM 774 

Brown, RD Jr. 2566 

Brown MPH, EE 970 

Brown on behalf of PROFILE, EE 

671, 843, 846, 1613, 2283 

Browning, J 886 

Bru Morón, C 200 

Brucato, A 1523 

Bruce, IN 623, 667, 1406, 1651 

Bruges Armas, J 372 

Bruk, S 1307 

Brulhart, L 107 

Brun, JG 2186, 2551 

Brundidge, AD 2000 

Brune, T 440 

Bruner, BF 670 

Bruni, C 125, 1039, 1485 

Brunner, H 280, 281, 764, 1597, 

1890, 2011 

Brunner, HI 288, 294, 305, 312, 

759, 761, 1141, 2040, 2474, 2475, 

2603 

Bruyere, O 255 

Bruyere, O 256 

Bryceson, Y 845 

Brynes, RK 1919 

Brähler, E 1859 

BSRBR, OBOT 828, 1593 

BSRBR Control Centre Consortium, 

1593 

BSRBR Control Centre Consortium, 

BSFRBR 828 

BT506, C 1755, 1756 

Buatois, V 752 

Bubb, MR 1470 

Bucala, RJ 875 

Buch, MH 366, 1473 

Buchbender, C 1040 

Buchbinder, R 1908 

Buchdaul, AL 195 

Buckholz, JM 1606 

Buckley, B 1663 

Buckley, CD 725, 1189 

Buckley, F 2171 

Buckner, JH 72, 414, 441 

Buckner, T 2455 

Budoff, M 1251, 1685 

Buechler, MB 1446 

Buechler, Y 1671 

Bueno, C 1724, 2195 

Bufton, KK 1405 

Bugatti, S 888 

Bugni, VM 1160 

Bui, J 1080, 1796 

Buie, HR 1007, 1009 

Buie, J 681 

Bujak, DI 2533 

Bujan, J 48 

Bujor, A 1516 

Buk, S 1955 

Bukhari, M 1994 

Bukowski, J 2549 

Bulatovic, M 2158, 2161, 2654 

Bulbin, D 1426 

Bull, H 1689 

Bullard, DC 992 

Bultink, I 1811 

Bunin, VM 2497 

Bunn, C 854 

Bunn, J 1178 

Bunni, M 2339 

Buoncompagni, A 2476 

Burbage, G 1718 

Burbine, SA 911 

Burden, AD 1346 

Burden-Teh, E 1346 

Burghardt, AJ 2583, 2584 

Burgos-Vargas, R 1679 

Burgos-Vargas, R 1356, 1901 

Burguera, EF 6 

Burkhardt, H 2217 

Burkly, LC 838 

Burlingame, RW 230 

Burmester, G 1749 

Burmester, GR 460, 2159, 2545 

Burmester, GR 47, 1283, 1530, 

1777 

Burnett, H 1168 

Burns, CM 196 

Burns, K 1112, 1992 

Burri, A 2422 

Burton, MJ 2093 

Burudpakdee, C 386 

Burwell, T 784, 1498 

Busch, AJ 1586 

Buschiazzo, E 60 

Bushnell, D 2656 

Bushnell, MC 961, 2643 

Buskila, D 955 

Bussone, G 1774 

Bustabad-Reyes, S 122 

butbul Aviel, Y 2003 

Butjosa, M 2352, 2357 

Butt, D 926, 2511 

Butters, T 848 

Buttgereit, F 24, 47, 367, 1274, 

1777, 2085 

Butz, S 1638 

Buyon, JP 290, 313, 603, 614, 615, 

666, 837, 889, 1417, 1647, 1650, 

1776, 2263 

Buyske, S 866 

Bykerk, VP 381, 401, 465, 503, 

977, 1216, 1225, 1238, 2099, 2109, 

2118, 2132, 2579, 2610 

Byrjalsen, I 592, 1329, 2166, 2167 

Byrne, JC 2526 

Bzarova, T 1143, 1148 

Cabal, A 1991 

Cabas-Vargas, J 1883 

Cabrera, S 1288 

Cabrera-Perez, J 517 

Cacoub, P Sr. 1622, 1623, 1627, 

1657, 1772, 1787, 2365 

Cacoub, PP Sr. 1308, 1313, 1699, 

2168 

C

Cadet, C 1109 

Cadet, C 1110 

Cadzow, M 1628 

Caeiro, F 60, 2141 

Caetano-Lopes, J 1988 

Cai, T 1683 

Cai, W 616 

Cailotto, F 982 

Cairns, E 422 

Cakar, A 989, 1611 

Calabrese, LH 1550 

Calamia, V 988 

Calandra, S 1158 

Caldana, WI 1041 

Calderillo, ML 2244 

Caldwell, KL 1099 

Caldwell, T 8 

Calich, AL 631, 2618 

Calich, ALG 173, 1724 

Calich, AL 2530 

Callahan, K 1207, 1992 

Callahan, LF 1203, 1572, 2432, 

2629 

Callahan, M 731 

Callahan, S 2619 

Callegari, A 1266 

Callhoff, J 780 

Callon, KE 137 

Calmon-Hamaty, F 1782 

Calvo, E 2239 

Calvo, I 122, 759 

Calvo Penades, I 1597 

Calvo-Alen, J 1341, 1424, 2239, 

2349 

Calvo-Río, V 1140, 1548, 2388, 

2389 

Cambridge, G 502, 652, 1757, 

1758 

Camellino, D 2350 

Camont, L 1256 

Campana, C 596 

Campanilho-Marques, R 1988 

Campbell, A 2452 

Campbell, P 737 

Campbell, PL 330, 413, 879 

Campos, LM 1999 

Campos, LMA 277, 296 

Can, M 2367, 2371, 2394 

Canadian ArThritis CoHort, 2132 

Canadian Early Arthritis Cohort 

(CATCH) Investigators, 1225 

Canadian Scleroderma Research 

Group, 711, 1467, 1480 

Canalis, E 1790 

canas Silva, J 372 

Cançado, EL 2530 

Cancro, MP 1438 

Canestri, S 679, 1197, 1764 

Cañete, JD 998, 1183 

Cañete, JD 185, 999, 1193, 1288, 

1641, 2453 

Canhao, H 372 

Canizares, M 925, 2414, 2630 

Canna, SW 314, 1058 

Cannella, AC 676, 1287, 2589, 

2592 

Cannon, GW 89, 105, 1187, 1270, 

2093, 2482, 2483, 2509, 2543, 

2640 

Cano, L 1237 

Canova, M 1275 

Cantaert, T 2453 

Cantagrel, AG 351, 830, 1049, 

1308, 1309, 1313, 1699, 2168, 

2545 

Cantarini, L 2032 

Canter, D 280 

Cantero Hinojosa, J 1264, 2215, 

2216 

Cantini, F 1818 

Cantor, RM 1613 

Cantor, RS 1422 

Cao, X 2429 

Cao, Y 1322 

Cao, Y 2537 

Caorsi, R 2021 

Capannini, S 2018 

Caparbo, V 921, 923, 2413 

Capela, S 1988 

Caperon, AR 1346 

Caplan, L 91, 2220, 2482, 2483, 

2640 

Caporali, R 1291, 1523, 1907, 

2111, 2551 

Cappelleri, JC 1855 

Cappelli, LC 222 

Cappelli, S 2016 

Caputi, A 1907 

Caramella, D 126 

Carbone, G 1178 

Carbonella, A 1764 

Carcelain, G 201 

Cárdenas-Velázquez, F 2244 

Cardiel, M 1278 

Cardiel, MH 1277 

Cardiel, MH 1294 

Cardoso, FP 1867 

Cardozo, T 788 

Carette, S 2391, 2397 

Carey, JJ 825, 1255, 1686, 2170 

Carey, TS 1094, 1113 

Caricchio, R 839 

Caritey, BD 1895 

Carle, A 2011 

Carlens, C 1615 

Carli, L 114, 2057 

Carli, P 1699 

Carlsen, AL 2276 

Carlson, CS 731 

Carlson, JJ 2463 

Carlton, V 588 

Carmona, FD 2304 

Carmona, L 696, 1701, 1908 

Carmona-Fernandes, D 372 

Carmona-Rivera, C 2502 

Carneiro-Sampaio, M 657, 2282 

Carnesecchi, G 1485, 2013, 2014, 

2016, 2017 

Carns, MA 716 

Carpenter, L 1215, 2131 

Carpintero-Fernandez, P 41 

Carr, AJ 1893 

Carr, JJ 2534 

Carr, J 1429, 1430, 2238 

CARRA Registry Investigators, 303 

CARRAnet Investigators, 762 

Carrara, G 167 

Carrasco, S 2497 

Carreira, P 2239, 2303, 2304 

Carreira, PE 696, 980 

Carreño, L 980, 1427 

Carrera, GF 1036 

Carrera Marin, AL 1727, 1731, 

2456, 2457 

Carretero-Prieto, RM 1211, 2272 

Carrideo, M 2180 

Carron, PL 1652 

Carruthers, E 2447 

Carruthers, M 133, 1534, 1752, 

1921, 2527, 2528 

Carruthers, R 2528 

Carsons, SE 2157 

Carta, S 2658 

Carter, L 1450 

Carthen, FC 1418 

Cartin-Ceba, R 1737 

Carty, A 537, 1364, 1375, 2224 

Carubbi, F 2183 

Carvalho, JF 1724 

Casagrande, F 630, 1397 

Casali, B 858 

Casano, AV 2653 

Casciola Rosen, L 221 

Casciola-Rosen, L 526, 758, 1953, 

1954 

Casey, VA 790, 791, 792, 793 

Caspard, H 624, 940 

Casper, C 283 

Caspi, D 193, 611 

Castañeda-Sanz, S 1205 

Casteilla, L 733 

Castejón, MA 22 

Castelino, FV 1468 

Castillo, R 289, 2006 

Castillo-Gallego, C Jr. 546, 710 

Castillo-Ortiz, JD 446, 1377 

Castrejón, I 245, 2043, 2048, 2104, 

2105, 2605, 2639 

Catalan Pellet, A 60, 2141 

Catan, L 1876 

Catanoso, MG 2351, 2362 

Catanoso, M 2347 

Catay, E 119, 240, 1268, 1358 

CATCH, 1216, 1238, 2109, 2610 

CATCH Investigators, 381, 401, 

465 

Catoggio, LJ 1256, 1268, 1358 

Catrina, AI 31, 1208, 1615, 1691, 

1769, 1789, 1792, 2130 

Catrina, AI 2578 

Catrina, AI 2159 

Catrina, SB 1789 

Cats, H 895 

Cattalini, M 2025 

Cattani, P 1197 

Cauley, JA 819 

Caulfield, M 1630 

Cauli, A 498, 599 

Cavagna, L 1907 

Cavalcanti, A 296 

Cavalcanti, FS 2455 

Cavalli, L 2013, 2014 

Cavazza, A 2351 

Caversaccio, MD 2553 

Cavet, G 2125, 2159 

Cavet, G 2121, 2130, 2162, 2664 

Caviggioli, F 1717 

Cavill, C 1357 

Cawthon, P 821 

Cazenave, T 106 

Cazzato, M 1482 

Cebi Olgun, D 2366 

Ceccato, F 60, 2141 

Cedeno, C 2604 

Cederlund, I 2437 

Cefle, A 858 

Ceko, M 961, 2643 

Celik, AF 2374 

Celis, R 1193 

Cellucci, T 304, 1886, 2478 

Cena, S 1468 

Cendes, F 299, 300 

Cénit, MC 2304 

Cerami, A 1770 

Cerbu, S 1876 

Ceri, L 2018 

Ceribelli, A 642, 684, 712, 713, 

1470, 1747, 1956 

Cerio, R 1346 

Cerniglia, RM 1036 

Cerqueira, C 31, 1769 




362 

Cerrahoglu, L 1106 

Cervera, R 185, 614, 615, 2459 

Cespedes-Cruz, A 2473 

Cetinkaya, F 2373 

Cha, CC 2413 

Cha, HS 78, 203, 425, 435, 1181, 

1226, 1247 

Chaara, W 1623 

Chabra, SS 1133 

Chadha-Boreham, H 851 

Chaer, FGG 1266 

Chagadama, D 1718 

Chahal, A 282 

Chai, JY 203, 1226 

Chaisson, CE 141, 151, 741, 2650 

Chakhtoura, Z 641 

Chakravarty, EF 605, 627, 2263 

Chakravarty, K 57 

Chakravarty, SD 900 

Challacombe, S 2174, 2672 

Chalom, E 764 

Chalom, EC 1141 

Cham, WT 317 

Chamberlain, ND 328, 2454, 2669 

Chambers, CD 2466 

Champion, HC 699, 1253 

Chan, AC 2452 

Chan, CH 2630 

Chan, EKL 212, 642, 684, 712, 713, 

1470, 1747, 1956 

Chan, ES 1805 

Chan, G 1693 

Chan, H 388 

Chan, JYF 212, 223 

Chan, JY 712, 1747, 1956 

Chan, KL 1488 

Chan, K 651 

Chan, K 1387 

Chan, MO 1139 

Chan, PT 637, 1414, 1488 

Chan, S 548, 778, 1024 

Chan, TM 2269 

Chan, W 562 

Chandran, V 537, 540, 560, 573, 

581, 590, 1347, 1348, 1350, 1351, 

1368, 1369, 1370, 1371, 1375, 

2223, 2611 

Chang, AY 1401 

Chang, BY 329 

Chang, DM 846 

Chang, E 2220 

Chang, HC 1182, 1549, 2277, 2673 

Chang, HJ 796 

Chang, JT 1475, 1509 

Chang, J 2427 

Chang, KM 174 

Chang, L 692 

Chang, NH 674, 1744, 2323, 2340 


Chang, RW 242, 243, 919, 1588, 

1664 

Chang, SH 99, 215, 1188, 1952, 

2182 

Chantepie, S 1256 

Chao, CC 725 

Chao, D 331 

Chaparro del Moral, R 60, 2141 

Chapelle, DC 2031, 2653 

Chapelle, JP 43 

Chaperot, L 2281 

Chapman, J 1256 

Chapman, PT 139 

Chapurlat, R 1596 

Chapurlat, R 254, 727, 1961, 1991, 

1998, 2135 

Charles, JF 30 

Charles, PJ 233, 1200 

Charles, P 2383 

Charles-Schoeman, C 629, 1252, 

1290, 1709 

Charlier, E 43, 50 

Chartier, M 460 

Chartier-Logan, CJ 423 

Chartrand, S 720, 721 

Chartrand-Lefebvre, C 721 

Chary-Valckenaere, I 1618 

Chasnyk, V 1166, 1597 

Chataway, TK 2676 

Chatel, L 752 

Chatelus, E 2287 

Chatham, WW 603, 1934, 2152, 

2619, 2621 

Chatterton, RT 65, 66 

Chattopadhyay, C 1346 

Chaturvedi, S 58, 59 

Chatzidionysiou, K 776 

Chaudhari, AJ 337 

Chaudhary, D 1062 

Chaudhary, SH 205 

Chauffe, AD 1470 

Chauhan, AK 320, 324, 325, 2316 

Chauveheid, MP 225 

Chavez, H 1310 

Chavez, J 1679 

Chavez, J 1597 

Chavez, R 318 

Chavez-Corrales, J 1356 

Checchio, T 1697 

CHECK steering group, 1126 

Chefo, S 153 

Chen, C 616 

Chen, CY 442, 976, 1608 

Chen, C 784 

Chen, C 141, 151, 741 

Chen, F 1940, 1943 

Chen, H 1761 

Chen, J 341 

Chen, J 874 

Chen, JH 477 

Chen, J 527 

Chen, L 54, 374, 402, 489, 763, 

924, 1270, 1960, 2093, 2106, 2542, 

2543 

Chen, N 1353 

Chen, PH 2395 

Chen, SY 326 

Chen, W 629, 846, 984, 1613 

Chen, WH 1345 

Chen, X 2699 

Chen, YW 2638 

Chen, YW 1946 

Chen, Y 2045 

Chen, Y 1808, 2653 

Chen, Z 545, 1704 

Cheng, CH 2419 

Cheng, G 2452 

Cheng, L 784, 2681 

Cheng, W 2269 

Cheng, Y 2699 

Cheon, EJ 2, 10, 37 

Cheon, YH 340 

Cherkas, Y 2165 

Chernitskiy, V 2411 

Chernoff, D 2125 

Chernoff, D 2121, 2162, 2664 

Cheryk, LA 2527 

Cheung, AM 1991 

Cheung, VG 987 

Cheuret, E 2473 

Chevalier, X 255, 1596 

Chevalier, X 2472 

Chevreul, K 1830 

Chew, CS 1638 

Chew, R 1278, 2490 

Chhana, A 137 

Chia, JJ 2308 

Chiang, KP 1671 

Chiba, A 2330 

Chiche, L Sr. 1622, 2554 

Chida, AS 690 

Chida, K 1938 

Chieng, A 1159, 1162, 2009 

Chiewchengchol, D 1069 

Chighizola, CB 1736, 2458 

Childhood Myositis Heterogeneity 

Study Group, 291 

Chin, AS 721 

Chindalore, V 1322 

Chino, Y 2288 

Chinoy, H 229, 1346, 1673 

Chiocchia, G 597, 598, 600, 1000, 

1510, 1511 

Chiorini, JA 517 

Chipping, J 767 

Chiriac, R 479 

Chironi, G 2563 

Chistyakova, E 1143, 1148 

Chiswell, K 1847 

Chitkara, D 549, 779, 1365 

Chiu, YH 2616 

Chiu, YG 1992 

Chizzolini, C 2293 

Chmiel, JS 241, 2467 

Chng, HH 2278 

Cho, CS 613 

Cho, CS 628 

Cho, HJ 1797 

Cho, ML 39 

Cho, ML 21, 34, 664, 1745 

Cho, NS 1889 

Cho, SK 78, 130, 1013, 1247 

Cho, YN 1063 

Chodosh, J 523, 525, 2203, 2674 

Choe, JY 78, 967, 1236, 1247 

Choi, BY 1797, 2182 

Choi, CB 78, 1247, 2686 

Choi, D 2680 

Choi, H 151, 1630, 1854, 1980, 

2614 

Choi, HK 141, 741, 742, 849, 2559, 

2568 

Choi, IA 1219 

Choi, JY 2686 

Choi, JY 2333, 2497 

Choi, JJ 1962, 1968 

Choi, J 1952 

Choi, K 142 

Choi, ST 62, 1915, 2122 

Choi, SW 354 

Choi, SW 1968 

Choi, SJ 409, 2267 

Choi, TY 1251, 1685 

Choi, YK 1189 

Choi, YY 130, 1013 

Choi, YJ 1632 

Choinière, M 1862 

Chomakhidze, A 1143, 1148 

Chon, Y 831 

Chong, C 754 

Choo, C 658 

Choong, LM 2319 

Choong, PF 269 

Chopra, A 58, 59 

Chopra, P 84 

Chopra, R 635 

Choquette, D 171, 458, 467, 494, 

1124, 1841, 2108 

Choromanski, TL 176, 1194 

Chou, IJ 583, 1182, 1549, 2277, 

2673 

Chou, YK 8, 2320 

Choudhury, A 975 

Chow, A 496

Chow, SL 1888, 2047 

Chowdhary, VR 1444 

Chowdhury, M 1200 

Choy, E 393, 1216, 1316, 1318, 

1804, 2099, 2439, 2609 

Christensen, G 872, 1942 

Christensen, R 959, 2169, 2609 

Christensen, TG 361, 363, 580 

Christianakis, S 2194 

Christiansen, C 575, 1329, 1596, 

1984, 2166, 2167, 2615 

Christianson, TJH 2566 

Christmann, R 1516, 1713 

Christopher-Stine, L 221, 222, 

1468, 1953 

Chu, BC 389 

Chu, CQ 8, 190, 2320 

Chu, H 2300 

Chu, LH 2514 

Chu, SY 1761 

Chuang, CS 972 

Chuang, E 1931 

Chubinskaya, S 12 

Chun, L 1260 

Chung, C 456, 467, 1280 

Chung, CP 1386, 2663 

Chung, L 706, 724, 758, 1463, 

1465, 1471, 1953, 1954 

Chung, WT 78, 1247 

Churchill, MA 1294 

Churchill, S 1683 

Churchman, S 1766 

Chwiesko-Minarowska, S 2298 

Chyczewski, L 2292, 2298 

Ciancio, G 1002 

Ciani, B 1801 

Ciani, L 356 

Cibere, J 1033, 1103, 1123 

Cibo, H Sr. 1260 

Cicero-Casarrubias, A 650 

Cicutinni, F 1120 

Cicuttini, F 1117, 1118, 2535 

Cid, MC 855, 859, 2352, 2357, 

2359 

Ciesielski, R 1164 

Cieza, A 1376 

Cifaldi, M 534 

Cifaldi, M 75, 379, 468, 484, 1345 

Cifaldi, MA 84, 369, 373, 746, 

1353 

Cimaz, R 1161, 1166, 1676, 2473, 

2598 

Cimmino, MA 167, 2350 

Cinquegrani, M 1507, 1508 

Ciocca, G 2031 

Cioffi, E 114 

Cirelli, JA 2523 

Cisternas, M 1898 

Cistrone, CA 1207, 2666, 2667 

Citera, G 60, 106, 579, 1356, 2141, 

2449 

Ciullo, M 1630 

Cividino, AA 1016, 1018, 2100 

Cizgici, AY 1707 

Claessen, KMJA 1100 

Clair, A 2641 

Clancy, MM 1114 

Clancy, RM 313, 666, 837, 889, 

1776 

Clare, J 2059 

Clark, B 1035 

Clark, J 492 

Clark, LF 2006 

Clark, P 1875 

Clark, TM 1544 

Clarke, AE 649, 932, 1169, 1387, 

1411, 1428, 1887, 2236, 2241, 

2475, 2570 

Claudepierre, P 555 

Claushuis, D 595 

Clauw, DJ 158, 801, 802, 803, 805, 

806, 866, 962, 963, 1230, 1869, 

2450, 2644 

Clegg, DO 105, 545, 2220 

Cleland, LG 453 

Clement, C 323 

Clemente, G 296 

Clements, PJ 92, 1464, 2004 

Cleveland, RJ 2432, 2629 

Clewell, J 379, 468 

Cloonan, Y 724, 908, 909, 2127 

Clowse, M 1643, 2263 

Clowse, MEB 2619 

Coates, LC 535, 1346 

Cobb, J 974, 1162, 1614, 2654 

Coblyn, JS 1821, 2061, 2062 

Cobraiville, G 43 

Coca, A 512, 2619 

Cockell, SJ 774 

Codreanu, C 448, 449, 1383 

Codullo, V 1078 

Coelho, ERW 1867 

Coenen, MJH 433, 1180 

Coenen, M 869, 2627 

Coffey, BM 2526 

Coffman, C 795 

Cofield, S 54 

Coggon, D 800 

Coghlan, JG 214, 722, 851 

Cogman, A 627 

Cohen, C 2178 

Cohen, L 1649 

Cohen, P 1545, 1652, 1656 

Cohen, PL 660, 688, 1065, 1067 

Cohen, RB 1695 

Cohen, S 2485 

Cohen, SB 1277 

Cohen, SB 1280 

Cohen-Aubart, F 751 

Cohen-Solal, M 25, 44 

Coit, PS 858, 2370 

Colafrancesco, S 192, 2184, 2185 

Colbert, CJ 241 

Colbert, C 1851 

Colbert, RA 310, 545, 2000 

Colburn, KK 1693, 1759 

Cole, B 2650 

Coleman, B 137 

Coleman, C 2426 

Coley, K 1816 

Colin, E 2338 

Colin, MJ 1250 

Colina, M 1002 

Collado, P 122, 123 

Collaku, L 1379 

Collantes-Estevez, E 1211, 1356, 

1701, 2272 

Collee, G 1594 

Collette, J 256, 1969 

Collier, DH 81, 383, 495, 865, 

1698, 1842 

Collier, DS 1204 

Collins, CE 2617 

Collins, ES 582 

Collins, FL 1804 

Collins, JE 238, 735, 1090 

Colombato, LA 200 

Colonna, M 1510 

Comarmond, C 2365 

Combe, B 351, 352, 396, 471, 472, 

480, 566, 1308, 1309, 1313, 1344, 

1782, 1839, 1849, 2118, 2168, 

2472, 2549, 2605, 2639 

Combe, BG 830, 1699 

Comeau, ME 729, 970 

Comet, D 555 

Compagno, M 1388 

Company, C 1101 

Conaghan, PG 257, 732, 1034, 

1620, 2550 

Condino-Neto, A 2369 

Conn, DL 1203, 2136 

Connell, CA 1277 

Connell, C 1014 

Connell, CA 1283 

Connelly, M 2420 

Connolly, M 2353, 2392 

Connolly, S 2159 

Connor, J 784, 1498, 2681 

Connors, G 2659 

Conrad, K 2496 

Conroy, MB 2433 

Cons, L 752 

Consolaro, A 1158, 1165, 1172, 

1173, 2476 

Constantin, AL 1000, 1049 

Constantin, T 759, 2004 

Constantinescu, FM 536 

Conway, R 175, 1385, 2054, 2056, 

2170 

Cook, CE 1094 

Cooney, M 1355 

Cooper, C 254, 255, 781, 915, 

1596, 2213 

Cooper, DML 339 

Cooper, MA 2262 

Cooper, RG 229, 1673 

Cooper, S 1178, 1323 

Cooper, S 2241 

Cooray, D 1411, 1645 

Cootes, TF 271 

Corbera, M 2357 

Corbera Bellalta, M 2352 

Corbera-Bellalta, M 855, 859, 2359 

Cordero Coma, M 1700 

Cordero-Coma, M 1140 

Coresh, J 101, 743 

Corkill, D 784, 2681 

Cornec, D 2197 

Cornejo, J 1563 

Cornélis, F 1577 

Cornish, J 137 

Corona, F 1166, 2016, 2473 

Corr, M 426 

Corradin, S 2034 

Corrales, A 1205 

Cortes, A 595, 1612, 2495 

Cortes, C 1059 

Cortes Pereira, E 994 

Cortes-Hernandez, J 1432 

Cortese, A 232 

Corti, D 2578 

Cosman, F 1984 

Cossette, P 769 

Cosson, C 1344 

Costa, JA 372 

Costa, PR 2497 

Costa Reis, AP 314 

Costa Reis, P 315 

Costallat, L 1416 

Costantino, F 598 

Coste, J 918, 1115 

Costedoat-Chalumeau, N 201, 293, 

641, 1647, 1649, 2365, 2532 

Costenbader, KH 287, 307, 442, 

608, 729, 931, 937, 976, 1605, 

1608, 1609, 1665, 2570, 2600 

Cöster, L 776 Coteur, G 557, 558, 

777 

Coughlan, RJ 825, 1255, 1686, 

2170 

Couillault, G 2473 




364 

Couraud, PO 1551 

Cournia, Z 875 

Coussieu, C 641 

Coustet, B 1000 

Cova, MA 630, 1397 

Covarrubias, A 462 

Covert, K 2603 

Coviello, AD 2415 

Cowen, E 2031 

Cox, JH 1796 

Cox, T 1583 

Cox, T 1796 

Cox-Dublanski, M 2148 

Coy, VA 2190 

Coyle, A 784, 2681 

Cozic, C 2155 

Crabol, Y 178 

Craft, JE 2333, 2497 

Cragin, L 1856 

Craig, C 2591 

Craig, TJ 199 

Cramb, C 1187, 1471, 1605, 1688, 

2659 

Crassard, I 1551 

Crema, M 252, 1032, 1119, 2467 

Crespo, M 2141 

Crespo-Pagnussat, S 324, 325 

Cretu, D 560 

Creveaux, I 1577 

Criado, G 1183, 1513, 2341 

Cricelli, C 1907 

Criscione-Schreiber, LG 2619 

Crisostomo, M 2455 

Crispín, JC 2682 

Cristol, JP 480 

Criswell, LA 521, 729, 970, 997, 

2174, 2192, 2193, 2283, 2672 

Crittenden, DB 165, 166 

Croca, S 607, 652, 1402, 1403 

Crockett, S 1912 

Cron, RQ 671, 1166, 1677, 2475, 

2655 

Cronin, ME 635 

Cronstein, BN 14, 15, 16, 165, 788, 

1515, 1778, 1805, 1964, 1965, 

2516 

Crooks, MG 1200 

Crotti, TN 33, 2518 

Crow, MK 233, 653, 694, 1715, 

1809 

Crow, YJ 2281 

Crowson, CS 134, 207, 658, 709, 

754, 820, 950, 1220, 1222, 1235, 

1248, 1249, 1349, 1392, 1552, 

1935, 2175, 2198, 2355, 2356, 

2358, 2481 

Cruz, JD 342, 345 

Cruz, VG 2652 

Cruz-Dominguez, MP 701 


Cruz-Reyes, C 212, 1956 

Cryer, B 261 

Csuka, ME 1463 

Cua, D 725, 2677 

Cuadrado, MJ 1211, 2272 

Cucho-Venegas, JM 1399 

Cuda, CM 1077, 2679 

Cuellar, C 1898 

Cui, J 372, 442, 976, 981, 983, 

1605, 1609, 1683, 2403 

Cui, X 1203 

Cule, E 2654 

Cummings, SR 819, 982, 1995 

Cunha, FQ 2523 

Cunha, GFD 2064 

Cunnane, G 175, 610, 682, 1258, 

1259, 1385, 1575, 2054, 2056 

Cunningham, A 832 

Cunningham, C 907 

Cunningham, M 2636 

Cunningham, MA 1451, 1453, 

1892 

Cuoco, F 2016 

Cuomo, G 1473 

Cupples, LA 2415 

Curhan, G 1630 

Curin Serbec, V 2598 

Curran, M 2165 

Curran, ML 301, 312 

Curteis, B 2585 

Curtis, J 54, 374, 402, 489, 1270, 

1833, 1840, 1995, 2101, 2106, 

2543 

Curtis, JR 763, 920, 924, 996, 997, 

1960, 1978, 2093, 2234, 2542, 

2638 

Cush, JJ 380, 492, 503, 1629, 1914 

Custodio, M 1576, 2694 

Cuthbertson, D 1655, 2391, 2397 

Cutillas, P 1750 

Cutinha, A 88, 676 

Cutolo, M 1493, 1511, 2164 

Cuttica, R 1166 

Cuttica, RJ 1597, 2473, 2477 

Cuziol, M 96, 927 

Cymet, A 2688 

Czapiga, M 1675 

Czeloth, N 2343 

Czerwinski, E 254 

Czerwinski, E 1997 

Cziumplik, M 129 

D 

D’Agostino, M 810, 811 

D’Almeida, V 2396 

D’Angelo, G 1166 

D’Artois, J 1307 

d’Ascanio, A 188, 1482, 2057, 2361 

D’Cruz, DP 2319 

D’Onghia, S 1197 

D’souza, A 670 

da Silva, A 2153 

Da Silva, JAP 372 

Dabelea, DM 2097 

DaCosta, D 2688 

Daele, PLV 528 

Daelken, B 2343 

Dagna, L 751 

Dagnæs-Hansen, F 2072 

Dahlberg, LE 253, 913, 914 

Dai, C 1444 

Dai, D 2597 

Dai, L 2092, 2115 

Daien, CI 480 

Daigle, ME 910, 911 

Daizadeh, N 1959, 1998 

Dal Bello Haas, V 1586 

Dalbeth, N 136, 137, 148, 815, 

1035, 1180, 1628, 1902, 2585, 

2586 

Dale, J 2662 

Dall’Era, M 2617, 2619 

Dalm, VA 528, 2301 

Dalprà, S 1165 

Daluiski, A 1108 

Dalvi, S 1212 

Damian, LO 1922 

Damjanov, N 1154 

Dancey, P 2031 

Danchin, N 168 

Dang, N 1405, 2456 

Danielides, S 2200 

Daniels, T 2174, 2672 

Danila, MI 997, 1203 

Dankbar, B 346, 1779 

Dankers, W 2338 

Danko, K 229, 1673 

Danneskiold-Samsoe, B 2169 

Danoff, S 1468, 2659 

Danoff, SK 221, 222 

Danyliw, A 1586 

Dao, KH 1629 

Darbie, LM 2601 

Dardzinski, B 1991 

Daridon, C 1749 

Darrah, E 1194, 1689 

Das, L 274, 2653 

Das, R 734 

Das, S 474 

Dasgupta, B 471, 472, 2360 

DaSilva, C 727 

Dastmalchi, M 208 

Datta, K 58, 59 

Datta Mitra, A 434, 589, 1185 

Daugherty, B 960 

Daurès, JP 830 

Davatchi, F 2035, 2376 

Dave, AJ 706 

Davelaar, N 1793, 2338 

Davì, S 1166, 1173 

David, CS 1444 

Davids, ML 694, 1715 

Davidson, A 1445, 1454 

Davidson, J 1159, 1162, 2009 

Davies, O 1316, 1319 

Davies, R 828, 1145 

Davignon, I 259 

Davignon, J 1290 

Davine, A 2590 

Davis, AM 925 

Davis, EC 786 

Davis, HM 1293 

Davis, JC Jr. 620, 1527, 2622 

Davis, JM III 1248, 2481 

Davis, K 587 

Davis, LA 2220, 2482, 2483, 2640 

Davis, MM 432 

Davis, M 2136 

Davis, MM 1890 

Davis, MW 1912 

Davis, N 748, 749, 750 

Davis, S Jr. 1985 

Davis, T 835 

Davis, WE 1195 

Dawidowicz, K 478 

Dawood, MM 2498 

Dawson-Hughes, B 1969 

De, G 75 

De Benedetti, F 760, 1597, 2473 

de Bock, L 2670 

de Boysson, H 1551 

de Broucker, T 225 

De Bruyn, S 1307, 1311 

de Buck, M 394 

de Buosi, ALP 102, 807, 1864 

De Cock, D 1561 

De Domenico, I 855 

De Gennaro Colonna, V 2180 

de Hair, MJH 2342 

de Hooge, M 564, 1380, 2206, 

2207, 2209, 2211, 2212, 2612 

de Iorio, M 2654 

de Jager, JP 387, 2140 

de Jager, W 509 

de Jong, TD 1811 

De Jonge, R 2158, 2161, 2654 

De Keyser, F 1305 

de Kroon, L 23 

De La Fuente, A 7 

de la Torre, I 1427, 1757, 1758 

De La Torre Ortega, I 652

de Leeuw, K 2393 

de Longueville, M 503, 1316 

De Luca, G 1486 

De Lucia, O 1167 

de Man, YA 2609 

De Marchi, D 1039 

de Mendez, I 784 

De Miguel, E 1378, 1701, 2232 

de Min, C 752 

de Munter, W 2515 

de Pablo, P 1214 

de Papp, A 1991 

De Ranieri, DI 1897 

de Ridder, MAJ 1224 

de Rooij, M 266 

de Rooy, DPC 894 

de Rooy, DPC 973, 2670 

De Rotte, MCFJ 2158, 2161 

De Rycke, L 539 

De Sanctis, J 1257 

de Seny, D 43, 50 

de Smit, MJ 1202 

de Sonnaville, PB 394 

de Souza, AWS 2369, 2393 

de Steenwinkel, FDO 1224 

De Swert, K 1307 

De Toro, FJ 11, 48 

de Toro-Santos, FJ 541, 1360 

De Villiers, T 727, 1971 

de Visser, M 753 

De Vita, S 2183, 2184, 2185, 2189, 

2555 

de Vlam, KL 597 

de Vries, MC 2002 

de Vries, N 516, 1754 

de Vries, TJ 20 

de Wazières, B 1656 

de Wazieres, B 195 

de-Mendez, I 2681 

Deal, CL 1909 

Deamude, M 384, 2055 

Deane, KD 71, 72, 414, 423, 441, 

1692, 2097, 2116 

DeBerardine, M 165, 166 

Debost-Legrand, A 1577 

Debré, P 201 

Decaux, O 195, 1652, 2383 

Dechant, C 407 

Decker, P 844, 2505 

Decktor, D 1286 

Dedeoglu, F 2008, 2029 

Deehan, M 752 

Deelder, AM 1176, 1201 

Dees, C 347, 783, 1499, 1500, 

1502, 1505, 2517 

Defranoux, N 2121, 2162, 2664 

DeHoratius, RJ 1286 

Dejaco, C 108, 117, 1044, 2312, 

2318 

Dejaco, C 2627 

Dejonckheere, F 2171, 2463 

Dekis, A 1387 

Dekker, J 266, 1125 

Del Galdo, F 710, 1473, 1496, 

1502, 2302 

Del Papa, N 1717 

Del Rey, MJ 1183, 1193, 1513 

del Rincon, I 87, 1213, 1269, 2114 

Delaet, I 462, 1695, 2547 

Delaney, T 784, 2681 

DeLaurier, A 1171 

Delcour, JP 1780 

Delgado, E 1629 

Deligny, C 1649, 2383 

Dell, S 285 

Dell’Accio, F 40, 2517 

Della Rossa, A 1482, 2057 

Dellaripa, PF 1713 

Delle Sedie, A 114 

Deloch, L 1505 

DelVecchio, B 2604 

Delzell, ES 54, 374, 489, 763, 924, 

1270, 1960, 2093, 2542, 2543 

Dema, B 2200 

DeMartino, J 1075, 1741, 2525 

Demary, W 365 

Demattei, C 544 

Demirkaya, E 1166, 2032, 2477 

Demoruelle, MK 423, 441, 1692 

Dempsey-Robertson, M 124 

Demuth, HU 2083 

den Boer, E 2161 

den Broeder, AA 1273, 1682, 2609, 

2637 

den Heijer, M 1097, 2538 

den Uyl, D 353, 358 

Denaro, V 1379, 2016 

Dencker, D 361, 363 

Deng, X 950 

Deng, Y 846, 984, 1613, 2278 

Denio, AE 1426, 2604 

Denis, G 195 

Denisova, E 1676 

Denisova, R 1143, 1148 

Deniz, G 1707 

Denker, A 1971 

Dennis, G 945, 1856, 2617 

Denny, MF 660 

Denton, C 2304 

Denton, CD 851, 854 

Denton, CP 214, 693, 696, 698, 

722, 785, 1478, 1713, 1716, 2291, 

2303, 2305, 2307, 2625 

Deodhar, AA 545, 552, 558, 777, 

2613 

Depresseux, G 1335 

Derambure, C 1783 

Derber, LA 414, 423, 441, 1765, 

2097 

Derer, A 888 

Dernis, E 1627 

Derrett-Smith, E 785 

Dervieux, T 603 

Desai, M 2006 

Desai, S 2061, 2062 

Desai, S 854 

Descalzo, MA 1378, 1641, 1701, 

2232 

Descarreaux, M 2647 

Deschamps, M 1755 

Deshmukh, U 2675 

Deshpande, GA 399 

Deshpande, V 133, 1534, 2528 

Desjarlais, JR 1761 

Deslandre, C 1676, 1837 

Desmoulins, F 2189, 2555 

Desmurs-Clavel, H 1652 

Dessault, O 2365 

Dessole, G 498, 599 

Detante, O 1551 

Deurloo, EE 2019 

Devarajan, P 305, 2474 

Devauchelle-Pensec, V 2024, 2188, 

2197, 2554 

Devaux, JY 2365 

DeVeauuse Brown, N 2407 

Devenport, J 454, 491, 1300, 1323 

Devich, J Jr. 1128 

Devilliers, H 1545, 2531 

DeVita, P 2534 

Devogelaer, J 254 

Dewalt, D 1572 

Dewar, L 232 

DH Kim, 273 

Dhaun, N 1525 

Dhellin, O 479 

Dhir, V 499 

Dhote, R 2178 

Di Luca, G 1717 

Diab, IA 1931 

Diamandis, E 560 

Diamantopoulos, AP 121, 1975, 

2354, 2390 

Diamond, B 656, 2572, 2619, 2687 

Dias, VC 1644 

Díaz, P 1898 

Diaz-Deza, KE 1399 

Díaz-Gallo, LM 2304 

Diaz-Gonzalez, F 505 

Díaz-Llopis, M 1140 

Diaz-Prado, S 11, 48 

Dib, H 1774 

DiCarlo, JC 2488 

DiCioccio, AT 1337 

Dickson, MC 2071 

Dieffenbach, B 426 

Diehl, S 1178 

Dieppe, PA 269 

Dietrich, T 1214 

Dietz, HC 786 

Dieude, P 478, 1000, 1487, 2188 

Díez-Álvarez, E 1424 

Díez-Pérez, A 781, 915, 2213 

Dijkmans, BAC 358 

Dikranian, AH 772, 1323 

Dillon, AM 159, 160 

Dillon, SP 670, 677 

Dima, C 2455 

Dimopoulou, D 2058 

Dinant, HJ 539 

Ding, C 1118, 1120, 2535, 2537 

Ding, L 2567 

Ding, Y 2176 

DiNitto, JP 338 

Dinsdale, G 695 

Diogo, D 1595, 1683 

Diot, E 1649, 1656 

DiPaolo, R 2316 

DiPonio, L 2591 

Direskeneli, H 858, 2363, 2364, 

2367, 2370, 2371, 2377, 2394 

Dirven, L 469, 1982 

Distler, A 783, 1499, 1500, 1502, 

1505, 2517 

Distler, JHW 1514 

Distler, JH 347, 783, 1499, 1500, 

1502, 1505, 1510, 2517 

Distler, JH 2304 

Distler, O 347, 717, 783, 851, 902, 

1462, 1499, 1500, 1502, 1505, 

1514, 1713, 2292, 2517 

Divers, J 2274 

Dixon, WG 828, 1593 

Do, H 2573 

Do, MHT 1671 

do Prado, LL 162 

Dobarro, D 214, 722 

Doelberg, M 851 

Doering Maurer, K 526 

Doheny, K 2672 

Doherty, M 583, 814, 1182, 2277, 

2673 

Dohi, M 98 

Dokoupilova, E 836 

Dolezalova, P 2654 

Dolhain, RJEM 76, 1176, 1224, 

1240 

Dolman, KM 2019 

Domiciano, D 2064 




366 

Domiciano, DS 921, 923 

Dominguez, N 1795 

Dominguez-Gutierrez, PR 642, 684 

Dominguez-Luis, MJ 505 

Domino, SE 330, 879 

Domsic, RT 698, 699, 724, 1463, 

1465 

Domyslawska, I 2292 

Donati, V 529 

Donatti, C 1406 

Dong, Y 2174, 2672 

Donnell-Fink, L 2650 

Donnelly, S 2348, 2382 

Donovan, J 2305 

Doobay, K 694, 1715 

Dooley, MA 2570 

Doorenspleet, ME 516, 1754 

Doornbos-van der Meer, B 1202 

Dorais, M 1124 

Doran, M 175, 610, 682, 2054, 

2056 

Dore, D 1117, 1118, 1120 

Dorfleutner, A 2524 

Dorgham, K 751, 2532 

Doria, AS 124 

Dorman, CW 2091 

Dorman, J 2116 

Dorner, T 1749, 2551 

Dörner, T 1762 

Doschak, MR 38 

Doshi, D 1925 

Dotta, L 2025 

Dougados, M 351, 544, 555, 556, 

593, 777, 830, 1308, 1309, 1310, 

1313, 1363, 1699, 2168, 2550, 

2605, 2639 

Dougados, MR 1280 

Doveri, M 1039 

Dow, ER 1315, 1321 

Dower, K 1081 

Dowsey, M 269 

Doyle, A 815, 1035, 2585, 2586 

Doyle, K 1246 

Doyle, MK 80, 569, 2557, 2562 

Doyle, TM 190 

Dozmorov, MG 1795 

Draeger, HT 852, 1474 

Drago, L 2180 

Dragone, LL 2507, 2596 

Drake, J 139 

Dranitzki, Z 193 

Draper, T 1576, 2694 

Dreffs, A 1518 

Drenkard, C 935, 945, 2407, 2695 

Drescher, E 2487 

Dressler, F 2473 

Drews-Botsch, C 1155, 2005 

Drexhage, HA 528 


Dreyer, L 79, 1271, 1684 

Driban, J 745 

Driban, JB 239, 798, 1121, 2512 

Drijfhout, J 1770 

Driscoll, PC 1727 

Drosos, AA 2552 

Droz, N 1627 

Druce, K 1161 

Druey, KM 2575 

Drynda, S 440, 1004 

Du, F 1457 

Du, J 2146 

Du, X 875 

du Bois, R 854 

Dua, AB 234, 236 

Duarte, C 372 

Duarte, CW 970 

Dubko, M 1676 

DuBois, MS 1036 

Dubost, J 1577, 2188, 2554 

Dubourg, O 225 

Dubrau, C 2379 

Dubreuil, M 849, 2614 

Duby, C 1311 

Ducret, M 1652 

Ducreux, J 2548 

Duculan, R 847, 1809 

Duda, G 47 

Dudler, J 2228 

Dudler, J 368 

Duer, A 1617 

Duff, GW 985 

Duffy, CM 1169, 2475 

Duffy, S 28 

Dufour, AB 789, 790, 791, 792, 793 

Duftner, C 2318 

Duggan, D 986 

Duggan, J 1446 

Duhaut, P 641 

Duke, A 1748 

Dunbar, J 338 

Duncan, G 1846 

Duncan, M 321 

Dunlop, DD 239, 241, 242, 243, 

919, 1588, 2467 

Dunlop-Thomas, CM 2407, 2695 

Dunne, A 1631 

Dunne, E 1239 

Dunne, R 1258, 1259 

Dunstan, CR 24 

Dupin, N 201 

Dupuy Gorce, AM 480 

Dür, M 869, 2627 

Duran, S 671 

Durán-Barragan, S 1411 

Durand, G 2023 

Durand-Zaleski, I 1830 

Durcan, LJ 1385, 1575 

Durden, E 933, 934 

Dures, E 1579 

Durez, P 462, 2159, 2547 

Durez, P 471, 472, 479, 1305, 

1335, 1694, 2548 

Duruoz, MT 1574 

Durusoy, R 181 

Duruöz, MT 2690 

Duryea, JW 2470, 2533 

Duryee, MJ 26, 27, 2334 

Dusad, A 26, 27, 2334 

Dussault, P 1985 

Dusser, DJ 1217 

Dustin, M 1930 

Dutmer, E 1273 

Duval, X 2565 

DuVall, S 2093, 2543 

DuVall, SL 149, 1270 

Duyckaerts, C 225 

Duzanski, MO 351, 1313 

Duzgun, N 858 

Dvergsten, JA 316 

Dvorchik, I 306 

Dwivedi, A 2404 

Dwyer, N 1460 

Dwyer, T 2535 

Dyer, A 1429, 1430 

Dyer, S 1476 

E 

E Smedby, K 1229 

EASIC, 780 

Easley, K 2695 

Eathakkattu Antony, BS 2535, 2537 

Eaton, C 239, 242, 243, 745, 2467, 

2512 

Ebbing, PCC 704 

Ebbo, M 1627 

Eberhard, BA 294, 1890 

Eberhardt, K 2137 

Eberl, G 725 

Ebina, K 500 

Echtermeyer, F 40, 1779 

Eckstein, F 249, 250, 252, 2469, 

2470, 2534 

Eda, H 738 

Edberg, JC 729, 843, 970, 992, 

1613, 2283 

Eder, L 537, 547, 1351, 1375 

Eder, V 2178 

Edgerton, S 124 

Edison, J 441 

Edmundowicz, D 1429, 1430, 2238 

Edwan, JH 310 

Edwards, CJ 1908 

Edwards, JA 2527 

Edwards, K 2437 

Edwards, RR 1230 

Edwards, S 1069 

Edworthy, SM 2570 

Egberts, F 1502 

Egelston, C 1061 

Eggebeen, AT 382 

Egholm, CL 79 

Egri, N 1432 

Eguchi, K 370, 1312, 2112, 2142 

Egurbide, MV 1479 

Ehrenfeld, MZ 450 

Ehrenstein, BP 118, 120, 128, 

1047, 2378 

Ehrlich-Jones, LS 243, 919, 1588 

Ehst, B 552 

Eilertsen, G 1388 

Einarsson, JT 481 

Eisuke, O 669 

Ekholm, L 233 

Eklund, A 1691 

Ekman, EF 259 

El Torgomen, N 190 

El-Gabalawy, HS 1179, 1194, 1688, 

2063 

El-Sherbiny, Y 1766 

Elashoff, D 391, 1252 

Elboudwarej, E 521 

Eldridge, H 1925 

Elewaut, D 597, 1361, 2208 

Elford, K 1881 

Elgeioushi, N 692 

Elhai, M 1510, 2007 

Elkayam, J 244 

Elkayam, O 193 

Elkon, KB 1446, 1791, 2281 

Ellert, GA 1722, 2405 

Ellingsen, T 79, 416, 959, 1254, 

1877, 2522 

Elliott-Penry, L 1228 

Ellis, J 318 

Ellis, L 1834, 1925 

Elmesmari, A 881 

Elmore, KB 65, 66 

Eloranta, ML 522, 845, 1811, 2271 

ElSallabi, O 1526 

Elvin, K 2574 

Emans, PJ 1122 

Embi, PJ 2602 

Embuldeniya, G 2148 

Emery, P 80, 366, 368, 369, 373, 

456, 459, 467, 474, 487, 574, 710, 

772, 775, 1011, 1280, 1473, 1620, 

1718, 1766, 2225, 2302, 2488, 

2549 

Emilie, S 1839 

Emir, B 2641

Emmungil, H 181, 532 

Emond, P 1018 

Emrence, Z 989, 1611 

Endo, H 1520 

Eng, H 2127 

Engel-Nitz, NM 378 

Engelke, K 1008, 2582 

Englbrecht, M 594, 1019, 2581, 

2582 

Engler, A 437 

Engling, A 2343 

English, C 1255 

Englund, M 73, 253, 826, 913, 914, 

916, 1032, 1129 

Engström, M 1792, 2578 

Ennis, H 695 

Enocsson, H 617 

Enomoto, N 1938 

Ensrud, KE 819 

Epis, O 356 

Eprac, 1577 

Epstein, R 1978 

Equity In Access To Treatment of 

RA Across Europe, 1844 

Equity in Clinical Eligibility Criteria 

for RA treatment, 1845 

Erausquin, C 1424 

Erba, G 356 

Erdogan, M 532 

Erer, B 750 

Erer, B 989, 1611, 2253, 2364 

Ergen, A 858 

Ergun, T 2371, 2394 

Erguven, M 759 

Erickson, AR 676, 1287 

Erika, M 984 

Eriksson, C 665 

Eriksson, J 826 

Eriksson, K 1554 

Eriksson, P 522 

Eriksson, S 662 

Erkan, D 1733, 1736, 2246, 2404, 

2456, 2457, 2458, 2696, 2697 

Erken, E 2364 

Ernste, F 709 

Ernste, FC 754, 1935, 2588 

Erondu, N 831 

Erra, A 998, 999 

Ertan-Demir, S 1707, 2253 

Erten, G 1707 

Ervin, D 2602 

Erwig, L 1525 

Erwin, J 2437 

Erzin, Y 2374 

Esaki, K 899 

Esbensen, BA 2689 

Escalante, A 87, 671, 1213, 1269, 

2114 

Escorpizo, R 717 

Escudero, P 1101 

Esdaile, J 172, 1642 

Eshed, I 1026, 1616, 1617 

Eskehave, TN 235 

Eskelinen, A 1095 

Eskiyurt, N 1972 

Eskra, D 2603 

Esmaeilzadeh, S 1972 

Espada, G 760, 2040, 2477 

Esperanza Group, 1378, 1701, 

2232 

Espesen, J 361, 363 

Espígol, G 2357 

Espígol Frigolé, G 2352 

Espígol-Frigolé, G 859, 2359 

Espiño- Lorenzo, P 1237 

Espinosa, G 185, 1479 

Espinosa, M 656 

Espinoza, LR 2102 

Esquivel Valerio, J 2096 

Essers, I 1363 

Estensen, ME 1681 

Estrada, P 1373 

Estrela, GBQ 116 

Esveldt, RE 516, 1754 

Etau, P 2437 

Etchepare, F 470, 823 

Eudaly, JG 1453 

EUMUSC.net working group WP 

5, 1721 

EuMyoNet, 229, 1673 

Eun, JS 2230 

Eustar, 696 

Evangelisto, AM 2592 

Evans, DS 982 

Evans, D 595, 1612 

Evans, RR 152, 813 

Evans-Young, G 2440 

Everett, S 2404, 2406, 2697 

Everts, V 20 

Ewing, E 1201 

Eyal, R 1899 

Eymard, B 225 

Ezealah, E 1207 

Ezeamuzie, O 1515 

Ezzat, AM 1103, 2434 

F 

F, NS 2173 

Fabi, M 200 

Fabio, G 2032 

Fabreguet, I 135 

Fabris, M 2189, 2555 

Faccin, F 487, 1303 

Faezi, T 2376 

Fagerland, M 834 

Fagerli, KM 395, 501, 1835, 2560, 

2561 

Faham, M 588 

Fahmi, H 730 

Faia, K 338 

Fain, O 195, 225, 1649, 1699, 2178 

Faivre, A 1551 

Faivre, B 751, 2532 

Falaus, S 1922 

Falcini, F 1676, 2013, 2014, 2016, 

2017, 2018 

Falgarone, G 195 

Falzer, P 1578, 2636 

Fan, H 1798 

Fang, F 787, 1517, 1518, 2289 

Fang, H 609, 618, 619, 626, 633, 

640, 691, 886, 938, 1389, 1390, 

1393, 1396, 1400, 1412, 1648, 

1710, 1730, 1732, 2245, 2255, 

2569, 2571 

Fanouriakis, A 1436 

Faraawi, RY 1354 

Fardellone, P 830, 1969 

Faré, R 1183, 1193 

Faregh, N 1865 

Farewell, D 393 

Farge, D 220, 641 

Fargetti, S 631 

Faria, AGA 2282 

Farina, I 1002 

Färkkilä, M 1920 

Farkouh, M 1250, 1263 

Farmani, NL 1693 

Farouk, HM 1490 

Farrell, J 2011, 2603 

Farrerons, J 1959 

Farris, AD 2203 

Farrokhi, S 1127 

Fauchais, AL 2188 

Faucherre, M 135 

Faust, E 369 

Fautrel, B 82, 83, 364, 396, 479, 

830, 918, 1310, 1627, 1830, 1839, 

1849, 1895, 2605, 2639 

Fava, A 2299 

Favari, E 675 

Favors, K 2533 

Fayad, Z 1250, 1263 

Fearon, U 1191, 1621, 1658, 1800, 

1806, 2353, 2392 

Fedele, AL 1764 

Federici, C 1774 

Feehan, LM 1007, 2447 

Feely, J 1258, 1259 

Feghali-Bostwick, CA 319, 1714 

Fei, K 1366 

Feig, JL 788, 1805 

Feinstein, JA 1339 

Feitosa de Oliveira, SK 296, 762 

Feld, J 547 

Feldman, BM 951, 1168, 1171, 

1541, 1598, 2044 

Feldman, CH 287, 931, 2570, 2600 

Feldman, D 2545 

Feldman, DE 1169 

Felea, I 1922 

Felli, L 2164 

Felson, DT 271, 796, 799, 1098, 

1104, 1114, 1119, 1553, 1666, 

1823, 2631 

Fenaux, P 195 

Feng, M 2176 

Fengxiao, Z 1260 

Ferbert, SM 867, 1566, 1858 

Ferguson, C 731 

Ferguson, JE 695 

Ferguson, LJ 301, 1948 

Ferguson, PJ 2031 

Ferguson, S 1468 

Ferlin, W 752 

Fermont, L 1649 

Fernánde-Berrizbeitia, O 1424 

Fernandes, AW 94, 932, 1394, 

2638 

Fernandes, AJ 769 

Fernandes, ARC 1233 

Fernandes, G 1864 

Fernandes, P 342, 345 

Fernandez, D 2345 

Fernández, JA 531 

Fernandez, NC 200 

Fernández de Castro, M 1424 

Fernandez Garcia, JL 993 

Fernandez Moreno, M 994 

Fernandez-Cid, JC 1140 

Fernández-Espartero, C 1378 

Fernández-Gutierrez, B 1006, 1205 

Fernandez-Llaca, H 1548, 2388, 

2389 

Fernandez-Lopez, C 541, 551, 993, 

994 

Fernandez-Moreno, M 993 

Fernández-Nebro, A 980, 998, 999, 

1237, 1424 

Fernandez-Perez, ER 1227 

Fernandez-Puente, P 41, 988 

Fernandez-Rodriguez, B 2578 

Fernandez-Sueiro, JL 541, 550, 

551, 567, 998, 999, 1359, 1360 

Fernandez-Tajes, J 993, 994 

Ferraccioli, G 679, 1197, 1486, 

1764, 2118 

Ferracin, M 1002 

Ferrajolo, C 1907 

Ferrand, C 1755 

Ferrari, C 188, 2361 

Ferrari, C 1173 




Ferreira, GA 2261 

Ferreira, I 1976, 1997 

Ferreira, VP 1059 

Ferreira, WG 299 

Ferrell, EG 1144, 1157 

Ferreyra Garrott, L 115, 1268, 

1358 

Ferri, C 456 

Ferriani, VP 296 

Ferro, F 126, 529, 1546 

Ferrucci, L 2395 

Fert, I 600 

Fertala, J 2309 

Fertig, N 230, 1945, 1949, 1950 

Ferucci, ED 176, 1194, 1688 

Fervenza, F 1542, 2567 

Feslon, DT 1032 

Fesmire, J 677 

Fessier, C 1852 

Fessler, J 2312, 2318 

Fetrow, JS 731 

Feudtner, C 2030 

Feydy, A 556, 2007 

Fichtner, A 777, 1705 

Fidder, HH 1051 

Fidelus-Gort, RK 2487 

Fiehn, C 359 

Fielding, R 794 

Figgie, MP 1093, 2443, 2479, 

2573, 2649 

Figueira, R 1988 

Figueiredo, CP 921, 923, 2413 

Figus, M 188 

Filer, A 1189 

Filgueira-Fernandez, P 41 

Filho, MAGP 162 

Filipescu, I 1436, 1922 

Filippucci, E 810, 811 

Filkova, M 2123 

Fill Malfertheiner, S 440 

Finckh, A 248, 456, 467, 482, 766, 

770, 1102, 1577, 2144, 2171 

Fine, JS 2525 

Fine, MJ 698 

Finès, P 2462 

Finetti, M 2021, 2032 

Finkenstaedt, M 466 

Finlay, K 1016, 2100 

Finnegan, S 321 

Finnerty, D 2059 

Finzel, S 594, 1008, 1010, 1019, 

2581, 2582 

Fiocco, GP 1539, 1851 

Fiorentino, D 706, 755, 758, 1953, 

1954 

Firestein, GS 426, 878, 1536, 1610, 

1659, 1775, 2076, 2270 

Fischbach, M 2473 

Fischer, A 213 

Fischer, A 1227, 1463, 1468 

Fischer, L 482 

Fischer, MA 287, 931, 2600 

Fischer, S 4 

Fisheleva, E 1694 

Fisher, BA 1200 

Fisher, MC 166, 1204 

Fitz-Patrick, D 150 

Fitzcharles, MA 961, 1862, 1865, 

1879, 2643 

Fitzgerald, GK 1127 

FitzGerald, JD 629, 1252, 1709 

FitzGerald, OM 535, 543, 582, 

1003, 1355, 2059, 2118, 2231, 

2540, 2549 

Fitzpatrick, JD 1306 

Fitzpatrick, LA 1984 

Flaherty, K 1713 

Flannery, MP 288 

Flato, B 760 

Flatø, B 872, 1681, 1942 

Flavin, NE 964 

Fleck, M 118, 120, 128, 1047, 2378 

Fleckner, J 653 

Fleischer, SJ 1749 

Fleischmann, R 2547 

Fleischmann, RM 1277 

Fleischmann, R 80, 487, 775, 1285, 

1318, 1339, 1340, 1342, 2449 

Fleischmann, RM 459, 557, 1286, 

1290, 1311, 1316, 1320, 2486, 

2613, 2661 

Fleisher, TA 206 

Fleming, M 1081 

Fletcher, D 1579 

Fletcher, J 317 

Fleury, T 668 

Fligelstone, K 717 

Flipo, RM 82, 83, 351, 830, 1308, 

1309, 1313, 2168 

Flipon, E 1895 

Flondell, M 2648 

Florentinus, S 373, 487, 775, 1303, 

1304 

Flores, C 2204 

Flores, D 1356 

Flores Alvarado, D 2096 

Flores Nunez, A 1679 

Flores-Suarez, LF 1294 

Flossmann, O 1525 

Flurey, CA 864, 1558 

Flynn, E 974, 2654 

Foeldvari, I 1679 

Foeldvari, I 1156, 2004 

Foelkel, ALDA 2064 

Foerger, F 2553 

Foering, K 1401 

Fogg, LF 262, 264 

Foltz, V 1049, 2472 

Fong, HHS 258 

Fonollosa, V 1479 

Fonollosa Calduch, A 1140 

Fonseca, C 2303, 2304 

Fonseca, C 1326 

Fonseca, JE 372 

Font, P 1211 

Fontaine, KR 2395 

Fontes, JDT 2415 

for the CARRA Registry 

Investigators, 279 

for the Vasculitis Clinical Research 

Consortium, 1655 

Forastiero, R 2459 

Forbess, LJ 1540 

Ford, DA 2238 

Ford, J 1293 

Forejtova, S 1926 

Förger, F 766 

Formisano, D 2362 

Førre, T 834 

Forsblad-d’Elia, H 463, 522 

Forslind, K 390 

Forsthoefel, A 818 

Fortin, I 494 

Fortin, PR 403, 674, 2417, 2570, 

2688 

Fortina, P 1496 

Fossati, G 2331 

Fossel, AH 1821 

Foster, HE 1139, 1159, 1162 

Foster, HE 1145, 2009 

Foucher, KC 262, 797, 1133 

Fowler, R 389 

Fox, B 2080 

Fox, C 1630 

Fox, DA 311, 883, 1743 

Fox, E 690 

Fraenkel, L 868, 907, 1083, 1528, 

1578, 2428, 2444, 2636 

Fragoulis, G 2199 

Fraley, A 1810 

Frallonardo, P 596 

Frampton, C 139 

Francès, C 641 

Franchimont, N 1959, 1998 

Franchini, S 2368 

Franciosi, A 2231 

Francis, L 2498 

Francois, A 1785 

Frane, J 760 

Franek, BS 2273 

Frank, MB 523, 525, 2674 

Frank, MM 2521 

Frank Bertoncelj, M 902 

Franke, B 433, 1180 

Frankel, S 1468 

Franklin, KE 1765 

Franklin, PD 1085, 1086, 1087, 

1585, 2651 

Franks, AG 1417, 1805 

Fransen, J 1232 

Fransen, J 136, 853, 1682, 2635, 

2637 

Fransen, R 2237 

Fransoo, R 939, 2541 

Fraser, AR 881 

Fraser, A 1195 

Freburger, JK 1094 

Frech, TM 692, 1463, 1489 

Fredberg, U 959, 1877 

Frederiksen, KS 653 

Fredi, M 1523 

Freedman, BI 729, 970, 1613 

Freedman, JE 2567 

Freeman, T 1196 

Freeston, JE 366 

Frei, CR 1824 

Freimuth, WW 614, 615, 616, 

2241, 2621 

Freire, M 1424, 2239 

Freire, V 556, 2007 

Freire González, M 980 

French, J 1697 

French Vasculitis Study Group 

(FVSG), 1652, 1656, 2563 

French Vasculitis Study Group and 

NeuroVascular Society, 1551 

Frenkel, J 2031, 2032 

Freuh, F 1978 

Freundlich, B 571, 2219 

Frey, S 888 

Frey-Law, L 1553 

Friday, RP 1661 

Friday, SC 883 

Fridlund, B 1559 

Frie, BL 2418 

Friedman, A 678, 840, 1672 

Friedman, D 2400, 2406 

Friedman, D 290, 1647 

Friend, SF 2507 

Friese, M 1510 

Frits, MA 798, 954, 1584, 1821, 

2061, 2660 

Fritschel, EK 2233 

Fritschy, D 248 

Fritz, C 2235 

Fritzler, MJ 1194, 1391, 1688, 

2063 

Frizelle, S 2091 

Frobell, R 916 

Frommer, K 890 

Frommer, KW 891 

368 

2012 Program Book

Frost, J 975 

Frostegård, J 1245 

Frydrych, LM 2127 

Frye, LL 1062 

Fröhling, M 1779 

Fu, SM 1444 

Fu, SM 2675 

Fudge, K 1395 

Fuentes, IM 48 

Fuentes, M 968 

Fuentes-Boquete, IM 11 

Fuentes-Silva, Y 1257 

Fuhlbrigge, RC 2008, 2029 

Fuhr, U 1339 

Fuhrman, C 217 

Fuiman, J 1354 

Fujieda, Y 1729, 2460 

Fujii, H 2328, 2665 

Fujii, T 216, 1296, 1936 

Fujii, W 2070 

Fujii, Y 2084 

Fujimoto, M 226 

Fujimoto, M 1519 

Fujio, K 1938 

Fujio, N 1332 

Fujioka, K 2070 

Fujishiro, M 332 

Fujita, K 1281 

Fujita, M 418 

Fukuda, T 370 

Fukuda, T 1918 

Fukushima, S 2286 

Fukuyo, S 3, 771, 1634, 2121 

Fuller, R 162, 2618 

Funahashi, K 1314, 2117 

Funauchi, M 1296 

Funck-Brentano, T 25, 44 

Fung, L 2413 

Funk, RS 1151, 2597 

Funke, R 783 

Furer, V 1250, 1263 

Furie, R 603, 1417, 2241 

Furie, RA 2621 

Furst, D 93 

Furst, DE 1050 

Furst, D 1319, 1342, 1475 

Furst, DE 92, 94, 459, 468, 932, 

1242, 1462, 1509, 2169 

Furst, D 486, 728, 1170, 1464, 

1899 

Furtado, RNV 102, 104, 116, 452, 

807, 808 

Furtado, RN 1160 

Furu, M 430 

Furukawa, H 1000, 1535 

Furukawa, KI 360 

Furusawa-Carballeda, J 513 

Furuya, T 1937, 1957, 1963 

Fusama, M 1569 

Futai, K 1084 

FVSG, FVSG 1545 

G 

Gabay, C 248, 772 

Gaber, T 47, 1777, 2085 

Gabriel, B 357 

Gabriel, SE 820, 822, 1220, 1222, 

1248, 1249, 2481 

Gabriel, S 420 

Gachályi, B 1307 

Gaedigk, R 2597 

Gaffen, SL 736 

Gaffney, PM 524, 843, 846, 970, 

1613, 2671 

Gaffney on behalf of LLAS2, PM 

2283 

Gaffo, AL 402, 2106 

Gage, JR 1644 

Gago-Fuentes, R 41 

Gaich, CL 488, 490 

Gaillard, N 1551 

Gaillez, C 810, 811, 2159 

Gainer, V 1683 

Gait, AD 271 

Gajalakshmi, V 59 

Gajria, K 932, 1394 

Galarza Delgado, D 2096 

Galateanu, C 2259 

Galbiati, V 1472 

Galeazzi, M 460, 810, 811 

Galeazzi, M 1291 

Galgiani, J 2172 

Galicier, L 641 

Galien, R 1331 

Galindo, M 1424, 2341 

Gallagher, J 1959 

Gallagher, P 1355 

Gallagher, S 1450 

Gallegos-Nava, S 644 

Gallizzi, R 2032 

Gallo, A 506, 529 

Gallo, G 364 

Gallo, MC 1158, 1173 

Galloway, JB 828, 1593 

Gambert Abdel Rahman, C 2023 

Gamble, G 137, 2585 

Gamboa-Cardenas, RV 1399 

Gamez-Nava, J 212 

Gamir, M 122, 123 

Gamonet, C 1755 

Gan, JB 264 

Gan, RW 71, 72 

Gandavadi, S 875 

Gande, A 1107 

Gandjbakhch, F 1049 

Gangji, V 2201 

Ganguli, A 379, 484 

Gannon, W Jr. 833 

Ganser, G 1149, 2022 

Ganser, M 1437, 2067 

Gantes, M 1424 

Ganz, R 1116 

Gao, A 2585 

Gao, F 2269 

Gao, H 2176 

Gao, N 2329 

Gao, W 1191, 1658 

Garau, P 498, 599 

Garay, SM 200 

Garay, SM 2477 

Garces, A 735 

García, AC 1341 

García, ML 122 

Garcia, MV 1268, 1358 

García, N 1101 

Garcia, R 2498 

Garcia, S 901, 1602 

Garcia de Aquino, S 2523 

García Meijide, J 2173 

Garcia Salinas, R 2141 

García-Aparicio, M 1140 

García-Bermúdez, M 1205 

Garcia-Carazo, S 546 

Garcia-Carrasco, M 606, 1958 

García-Martínez, A 2352, 2357, 

2359 

Garcia-Melchor, E 191 

Garcia-Mendez, S 1901 

Garcia-Monaco, R 115, 119, 240 

Garcia-Valladares, I 1468 

Garcia-Verdugo, J 505 

García-Vicuña, C 1140 

García-Vicuña, R 461 

Gardette, A 478 

Gardner, GC 146, 1927 

Gardner-Medwin, J 1159, 1162, 

2009 

Garen, T 231, 1928 

Garg, A 736 

Garg, N 552 

Garg, V 391 

Gargani, L 125, 1039 

Garland, A 939, 2541 

Garnero, P 580 

Garrido, M 1787 

Garris, C 943, 946 

Gärtner, M 109 

Garvey, WT 2274 

Garyfallos, A 2058 

Garyfallos, G 2058 

Garza Elizondo, M 2096 

Garza-Garcia, A 1727 

Gascon, C 713 

Gasparello de Almeida, R 296 

Gathany, T 1292, 1826 

Gattamelata, A 2184, 2185 

Gattinara, M 1167, 2018 

Gattorno, M 749, 2021, 2032, 

2657, 2658 

Gauba, V 1671 

Gaudin, P 470, 823, 1309 

Gaugler, B 1755, 1756 

Gaujoux-Viala, C 82, 83, 918, 1839 

Gaur, P 309 

Gauri, L 58, 59 

Gauthier, G 1840 

Gautier, S 1852 

Gay, R 1781 

Gay, RE 419, 437, 438, 892, 902, 

1514, 2123 

Gay, S 419, 437, 438, 892, 902, 

1514, 1781, 2123, 2292, 2670 

Gaydukova, I 561 

Gaylord, S 368, 2549 

Gašperšič, N 2187 

Geborek, P 481, 826, 2137 

Gebretsadik, T 1261 

Gedmintas, L 1983 

Gee, A 824 

Geetha, D 1542, 2398 

Geetha, N 2081 

Geier, JL 1697 

Geisser, ME 1581 

Geitz, K 1156 

Gelber, AC 697, 2395, 2398 

Gelderman, K 1811 

Gelfand, J 2559, 2614 

Genant, H 1596 

Genin, E 1000, 1217 

Genovese, MC 462, 1695, 2547 

Genovese, MC 80, 490, 1315, 

1320, 1640, 2487, 2488 

Gensler, LS 782 

Gent, YYJ 131 

Geoffroy, V 25 

Georgantas, R III 1675 

George, M 138 

Georgel, P 1785 

Georgiopoulos, G 1626 

Geppert, TD 692 

Geraldino-Pardilla, L 2539 

Gerards, AH 768, 2095 

Gerber, EE 786 

Gerdes, VEA 353 

Gerhold, K 365, 2022 

Geri, G 1623 

Gerlag, D 1338 




370 

Gerlag, DM 582, 737, 1189, 1334, 

1754 

Gerlag, DM 1078, 2342 

Gerli, R 2183, 2184, 2185, 2551 

Gerloni, V 1679 

Gerloni, V 760, 761, 762, 1167, 

2018, 2473 

Germanò, G 2351 

Gerona, D 652 

Gerosa, M 675, 1523 

Gerritsen, M 266 

Gershell, L 960 

Gershoni, R 2003 

Gertner, E 197, 1265 

Gesner, EM 341 

Gestermann, N 2321 

Getsios, S 1518 

Geusens, PP 2110 

Gewanter, HL 275 

Ghazarian, SR 2395 

Ghelani, P 1976, 1997 

Gheyle, L 1331 

Ghib, L 1922 

Ghomrawi, H 2404 

Ghoreishi-Haack, N 734 

Ghorpade, R 58, 59 

Ghosh, A 58, 59 

Ghosh, A 2294 

Ghosh, P 146 

Giacchi, J 1984 

Giacobbe, L 2576 

Giacomelli, C 529 

Giacomelli, R 2183 

Giacuzzo, S 356 

Giampoli, E 1112 

Giani, I 1485 

Giannelou, M 991 

Giannini, C 2566 

Giannini, E 764 

Giannini, EH 1141 

Giansante, C 630, 1397 

Gianturco, L 2180 

Gibbs, YC 2423 

Gibofsky, A 379 

Gibson, DS 321 

Gibson, K 217 

Gibson, R 453 

Giclas, PC 475 

Gieger, C 1630 

Gierut, AK 1077 

Gigante, MR 679 

Gignac, MA 2417 

Gignac, MA 2429, 2634 

Giguére, PM 1663 

Gil, D 2190 

Gil, KM 2420 

Gilardin, L 1627 


Gilbane, A 2305 

Gilboe, IM 1928 

Gilchrist, DS 881 

Giles, BM 2283 

Giles, C 1795 

Giles, I 1402, 1403, 1725, 1727, 

1728 

Giles, JT 1003, 1689, 2484, 2539, 

2659 

Gilkeson, GS 286, 668, 673, 846, 

970, 1442, 1451, 1453, 1613, 2265, 

2274, 2283 

Gill, G 478 

Gill, TM 2444 

Gill, TK 61 

Gillespie, J 2302 

Gilliam, B 320, 324, 325 

Gilliland, WR 441 

Ginsburg, L 2402 

Ginzler, EM 2570 

Ginzler, EM 837, 2621 

Giovannoni, L 1291 

Giraldez, T 505 

Girdish, C 2001 

Giugliani, R 204 

Giwercman, A 1184 

Gkrouzman, E 653, 1809 

Glace, B Sr. 1302 

Gladman, DD 537, 612, 625, 646, 

647, 648, 841, 842, 951, 1350, 

1371, 1421, 1423, 1435, 1706, 

2254, 2266 

Gladman, D 560, 573, 590, 1375, 

2118, 2218, 2223, 2256, 2611, 

2616 

Gladman, DD 540, 557, 581, 674, 

1347, 1348, 1351, 1354, 1381, 

2240, 2243, 2570, 2683 

Gladman, DDG 535, 1368, 1369, 

1370, 1651, 2047 

Gladue, H 1464 

Glaesmer, H 1859 

Glant, TT 1061 

Glaser, N 1048 

Glass, DN 1614 

Glass, JM 2644 

Glenn, SB 523, 524, 525, 2674 

Glintborg, B 79, 361, 363, 1271, 

2558 

Gloetzner, M 1004 

Gnanasakthy, A 142 

Gnann, H 553 

Gobbo, M 1378, 1701, 2232 

Gobert, P 1652 

Godeau, B 1308, 1313, 1627, 

1820, 2168 

Godfrin-Valnet, M 1362 

Godmann, L 19, 40 

Godmer, P 1652, 1656 

Godo, JR 1751 

Goeb, V 2554 

Goekoop, R 2606 

Goff, I 1885 

Goffin, L 759 

Gofita, I 2453 

Goilav, B 1438 

Goker, B 1105, 1411 

Gold, JI 2427 

Goldbach-Mansky, RT 310, 1808, 

2031, 2653, 2656 

Goldberg, AZ 692, 1461 

Goldberg, G 41 

Goldblum, R 1272 

Goldenberg, DM 639, 2252 

Goldenberg, DL 1862 

Goldenstein-Schainberg, C 162 

Goldfarb, DS 153 

Goldfien, RD 817 

Goldhaber-Fiebert, J 2461 

Golding, A 2506 

Goldman, JA 1286 

Goldmuntz, EA 2619, 2687 

Goldring, SR 33, 2518 

Goldsmith, DP 1141 

Goldsmith, S 2400, 2406 

Goldstein, BL 1605 

Goldstein, DM 2326 

Golightly, YM 789 

Gomar, F 22 

Gomberg-Maitland, M 1463 

Gombert, B 195 

gomez Rosso, L 1256 

Gomez-Caballero, ME 1288 

Gomez-Gerique, J 1341 

Gomez-Gracia, I 1211 

Gomez-Puerta, JA 608, 1288, 1665 

Gomez-Reino, J 1278 

Gomez-Reino, JJ 454 

Gomez-Seco, J 1751 

Gómez-Vaquero, C 1205 

Goncalves, CR 2064, 2497 

Goncalves Marangoni, R 787 

Gong, K 337 

Gong, W 327 

Gong, Y 511 

Gono, T 714, 941, 942, 1492, 

1937, 2242 

Gonter, NJ 1913 

Gonzalez, C 998 

Gonzalez, CM 999 

Gonzalez, E 541, 550, 1359, 1360 

Gonzalez, EB 691, 852, 1405, 

1474, 2456, 2457 

Gonzalez, J 1759 

Gonzalez, MI 1172 

Gonzalez, S 89 

Gonzalez, T 200 

Gonzalez Della Valle, A 1093 

Gonzalez Fernandez, C 1427 

Gonzalez Molina, MDR 1933 

González-Álvaro, I 1205 

Gonzalez-Gay, MA 1548, 2388, 

2389 

González-Gay, MA 1000, 1140, 

1205 

Gonzalez-Hernandez, MJ 311 

González-Juanatey, C 1205 

Gonzalez-Lopez, L 212 

Gonzalez-Lopez, MA 1548, 2388, 

2389 

Gonzalez-Pulido, C 607 

Gonzalez-Roca, E 191 

González-Rodríguez, C 538 

Gonzalez-Vela, C 1548, 2349, 

2388, 2389 

Gonzalo, E 2341 

Goode, AP 237, 1094, 1113 

Goodfellow, R 1804 

Goodfield, MJD 1346 

Goodman, SM 1093, 2443, 2479 

Goodwin, KA 190 

Gopalakrishnan, R 523, 524, 525, 

2674 

Gordon, C 1406, 2570 

Gordon, CP 1428 

Gordon, C 1018 

Gordon, JK 694, 724, 1465, 1712, 

1715 

Gordon, P 1955 

Gordon, TP 504 

Gordon, T 2676 

Gorelik, A 164 

Gorelik, G 2317 

Gorelik, M 2656 

Gorlova, OY 2303 

Gorman, D 725 

Gorn, AH 629, 1709 

Gorochov, G 751, 2532 

Goronzy, JJ 857, 2665 

Gosciniak, P 125 

Gossec, L 556, 1895 

Gosset, M 13, 18, 19 

Gota, CE 1884 

Göthberg, M 836 

Goto, D 2288 

Gottenberg, JE 351, 456, 467, 511, 

1308, 1309, 1313, 1699, 1785, 

2168, 2188, 2287, 2551, 2554 

Gottlieb, AB 569, 2557, 2562 

Gottlieb, BS 1141, 2601 

Gou, P 721 

Goudeau, D 756, 1945, 1949, 

1950, 2127 

Goudie, CT 1306 

Goulabchand, R 566 

Goules, AV 1190, 2552

Goules, JD 1190 

Goulet, JR 720, 721 

Goulvestre, C 2565 

Goupille, PM 593 

Goupille, PM 830 

Gourzi, VC 507, 508 

Govind, N 975 

Govoni, M 167, 356, 1002 

Gow, PJ 1628 

Gowdie, PJ 304 

Goyal, JR 2592 

Goyal, P 499 

Grabner, M 2045 

Gracely, R 237, 952 

Gracey, E 1625 

Grader, A 798 

Grados, D 191, 1967 

Graffin, B Sr. 1622 

Graham, GJ 881 

Graham, JE 1589 

Graham, RR 2279 

Graham, T 545 

Grahn, A 367, 1274 

Grainge, MJ 583, 814, 1182, 2277, 

2673 

Grainger, AJ 1020 

Gram, H 761 

Gramling, A 1819 

Grammatikos, AP 739 

Gran, JT 231 

Graña, J Sr. 122, 211 

Granados, CE 2190 

Granger, B 1839, 1849 

Granholm-Bentley, ACE 1451 

Graninger, WB 108, 1044, 2312, 

2318 

Grant, S 377, 379, 383, 468, 2001, 

2480 

GRAPPA Composite Exercise 

(GRACE) collaboration, 535 

Gratacós, J 998, 999 

Grateau, G 2024 

Graudal, N 361, 363 

Gravani, F 2181 

Gray, F 1551 

Graybill, JL 632 

Grayson, PC 868, 1528, 1529, 

2391, 2428, 2592 

Grazio, S 451, 479 

Greaves, J 2624 

Greco, CM 2699 

Green, AB 207, 658, 754, 1249, 

1392, 1935, 2358 

Green, D 926 

Green, J 772 

Green, S 1718 

Green, SM 1029, 1030, 1031 

Greenberg, JD 165, 379, 380, 464, 

491, 829, 1250, 1263, 1300, 2051, 

2101, 2138, 2221, 2510, 2577 

Greenberg, JO 2062 

Greenberg, SA 755, 1675 

Greene, M 9 

Greenhill, Y 2693 

Greenlees, L V 1675 

Greenler, AJ 288, 2040 

Greenspan, JS 2174, 2672 

Greenwald, MW 447, 1276, 1319 

Greenwood, J 1590 

Greenwood, J 1062 

Greger, G 2217 

Gregersen, PK 72, 894, 1203 

Gregersen, PK 71, 414, 441, 973, 

975, 2572, 2670, 2687 

Gregson, CK 483 

Greidinger, EL 527 

Grein, J 725 

Gremese, E 679, 1197, 1764 

Greth, W 94, 755, 932, 1394 

Gretler, J 108, 117, 1044 

Greve, JM 1671 

Grevers, LC 20 

Grewal, HK 1468 

Griffin, KW 1540 

Griffin, M 1960 

Griffin, N 2601 

Griffin, R 1498 

Griffiths, B 1466 

Griffiths, CEM 695, 1477 

Griffiths, G 89 

Griffiths, H 387, 2140 

Grifka, J 118, 553 

Grigorian, M 347 

Grigoriev, G 874 

Grijalva, C 763, 1960 

Grillet, BA 394, 1594, 2606 

Grimaldi, L 641 

Grimaldi-Bensouda, L 168, 1820 

Grodzicky, T 720, 721 

Grogan, S 28 

Grom, AA 2011, 2657 

Gronwall, C 2577 

Gross, AJ 2440 

Gross, KD 794, 799, 1104 

Gross, RL 603 

Gross, T 670 

Gross, TF 1441 

Gross, WL 1541, 2379, 2380 

Grossbard, EB 329 

Grossi, C 675, 1472, 2455 

Grossman, JM 629, 846, 984, 1709 

Grotzke, M 2509 

Grouard-Vogel, G 479 

Groves, C 1760, 2681 

Große, K 2380 

Gruben, D 773, 1277, 2485 

Gruben, D 1014, 1282, 1283, 

1297, 2486, 2546 

Gruenke, M 554, 747 

Grundahl, K 2203 

Grunewald, J 1691 

Grunke, M 110, 272, 407, 2107 

Gruntmanis, U 1977 

Grün, JR 686, 979 

Grünig, E 851 

Grützkau, A 686, 979 

Grönwall, C 1263, 1425 

Gu, R 1798 

Gu, Y 1075 

Gualtierotti, R 1472 

Guan, W 424 

Gudbjornsson, B 2227 

Guedes, LKN 173, 2064 

Guennoc, X 2024 

Guenther, J 1491 

Guerin, A 84 

Guermazi, A 249, 250, 252, 273, 

1027, 1029, 1030, 1031, 1032, 

1104, 1114, 1119, 1123, 2467, 

2469, 2470, 2534 

Guerne, PA 482 

Guerra, MM 1650 

Guettrot-Imbert, G 293, 641, 1649 

Guiducci, S 125, 1039, 1485 

Guiguet, M 220 

Guild, C 2238 

Guillemin, F 82, 83, 830, 918, 

1740, 1830, 1837, 1849, 2639 

Guillemot, D 1820 

Guillén, MI 22 

Guillevin, L 201, 1308, 1313, 1541, 

1545, 1551, 1627, 1652, 1656, 

1774, 1837, 2168, 2383, 2563 

Guillou, C 485, 1783 

Gul, A 750, 1278 

Gul, A 1005, 2253, 2364 

Gül, A 989, 1611 

Gulati, N 2491 

Gulgielmi, B 2368 

Gullstrand, B 662 

Gulseth, HC 834 

Guma, M 878 

Gumus, S 251 

Gunawardena, H 229, 1673 

Gunawardhana, L 153 

Gunay, N 565 

Gunn, G 1286 

Gunnarsson, I 1554, 2574 

Gunnarsson, R 1928 

Gunraj, N 2511 

Guo, S 1438 

Guo, X 218 

Guochun, W 1260 

Gupta, N 420 

Gupta, RK 1017, 1054 

Gupta, S 847, 880 

Gupta, V 666 

Guralnik, JM 800 

Gurner, D 727 

Gustafson, N 2435 

Gustafsson, J 2574 

Guthery, S 974, 1614 

Guthridge, JM 627, 645, 673, 1795 

Gutierrez, MJ 199 

Gutiérrez, M 1898 

Gutierrez, MA 1356 

Gutierrez-Achury, J 858 

Gutierrez-Alamillo, L 526 

Gutierrez-Cruz, G 1611 

Guymer, EK 1881 

Guzman P., RN 1683 

Guzmán Úbeda, MA 461 

Gvozdenovic, E 397, 469 

H 

Ha, A 1326 

Ha, CM 413, 1603 

Ha, YJ 1915, 2122 

Haas, JP 974, 1149, 1153, 1614 

Haas, M 2345 

Haas, R 1213 

Haas, RW 87, 1269, 2114 

Haavardsholm, EA 376, 395, 2660 

Hachulla, E 220, 748, 1308, 1313, 

1487, 2024, 2168, 2188, 2551, 

2554 

Hack, CE 1064, 1786, 2196, 2335 

Hackney, B 1572, 2432 

Hackshaw, KV 969 

Hacquard-Bouder, C 555, 2135 

Haddad, A 573, 1347, 1348, 1351, 

1369, 1370, 1423, 2240 

Hadziyannis, E 1626 

Haecke, E 516 

Haffizulla, K 527 

Hafström, I 390, 1245 

Haga, S 659, 683 

Hagberg, N 845 

Hagedorn, TJ 790, 791, 792, 793 

Hagel, S 73 

Hagelberg, S 2473 

Hagerty, D 140, 143 

Hagihara, K 500 

Hagiwara, S 2288 

Hagiwara, Y 1298 

Hagiyama, H 98, 1333 

Haglund, E 95, 1828, 2409 




372 

Hahn, BH 629, 846, 984, 1613, 

1709, 2325, 2451 

Hahne, M 47, 1777 

Hahne, M 1782 

Hai, O 2157 

Haibel, H 561, 571, 1703, 2219, 

2229, 2235, 2496 

Haiduc, V 2404, 2697 

Haines, GK III 344, 879, 1603, 

1639, 2679 

Haines, KA 294, 2475 

Haiying, C 1260 

Haj Hensvold, A 1615, 1691, 2130 

Hajdu, Z 1512 

Haji, Y 399, 948, 2247 

Hajj-Ali, R 1537, 1550 

Hakimiyan, A 12 

Hakulinen, P 1481 

Halbwachs, M 2023 

Hale, C 1718 

Hale, E 2425 

Hale, S 1810 

Hales, P 1750 

Hall, C 453 

Hall, C 848 

Hall, JP 1081 

Hall, JW 1977, 1997 

Hall, JC 221 

Hall, M 1258, 1259 

Hall, PC 818 

Hall, S 2486, 2545 

Halse, J 1959 

Halushka, M 1776 

Halvorsen, A 2588 

Hama, M 809, 1333, 1431 

Hamaguchi, Y 226 

Hämäläinen, M 882 

Hamann, J 1189 

Hamburger, MI 1904 

Hamer, C 124 

Hamerman, JA 1446 

Hamidou, M 1649, 1652, 2024 

Hamilton, BC III 27 

Hamilton, J 1320, 1337 

Hamilton, P 1986 

Hamm-Alvarez, SF 2194 

Hammaker, D 878, 1775 

Hammam, N 705 

Hammenfors, D 2186 

Hammer, HB 2118 

Hammer, M 1149 

Hammond, A 2446, 2693 

Hamoudeh, M 2549 

Hampson, JP 802, 803, 805, 806, 

2644 

Han, C 80, 569, 1292, 1826 

Han, J 429 


Han, KH 1330 

Han, K 469 

Han, L 2444 

Han, MK 130, 1013 

Han, S 42 

Hanami, K 2121 

Hanaoka, K 2084 

Hanaoka, M 714, 941, 942, 1492, 

1937, 2242 

Hanci, I 187 

Hanczko, R 2498 

Handa, R 58, 59 

Handa, T 1938 

Handler, C 214, 722 

Haney, DJ 2125 

Haney, D 2159 

Haney, DJ 2121, 2664 

Hanidu, A 1196 

Hanly, JG 53, 622, 1391 

Hanna, H 1834 

Hanna, MG 232 

Hannan, MT 789, 790, 791, 792, 

793, 2415, 2419 

Hannon, MJ 249, 250, 251, 252, 

908, 909, 1029, 1030, 1031, 1128, 

2469, 2470 

Hans, D 1961 

Hansell, D 722 

Hansen, A 361, 363, 1271 

Hansen, HC 341 

Hansen, MS 1271 

Hansen, PR 1684 

Hansson, M 411, 412, 439, 1615 

Haour, G 1830 

Haq, S 693 

Haqqi, TM 29, 2519 

Haque, UJ 476 

Hara, T 748 

Harada, Y 194 

Haraoui, B 381, 384, 401, 458, 

465, 1124, 1216, 1225, 1238, 1317, 

2099, 2109, 2132, 2610 

Harari, O 1597 

Harbers, JB 394 

Hare, AA 875 

Hareendran, A 1394 

Harel, L 761 

Hargrove, JB 801 

Harigae, H 2328 

Harigai, M 98, 371, 1324, 1325, 

1535 

Harju, A 1691 

Harlé, JR 641 

Harley, ITW 670 

Harley, JB 523, 524, 525, 673, 729, 

740, 846, 970, 1606, 1613, 2203, 

2274, 2283, 2671, 2674 

Harman, L 1633 

Haro Martínez, ADC 1933 

Haroche, J 751, 2532 

Haroldson, KL 762 

Haroon, M 1003, 1355, 2392 

Haroon, N 542, 782, 1592, 2224 

Harper, BE 691, 852, 1405, 1474 

Harper, L 1525 

Harre, U 31, 1010 

Harrer, T 2163 

Harriman, G 1062 

Harrington, JT 2051 

Harrington, TM 2604 

Harris, CC 2276 

Harris, EL 2672 

Harris, JK 1692 

Harris, J 401 

Harris, L 635 

Harris, N 1484 

Harris, RE 802, 803, 805, 806, 866, 

2450, 2644 

Harris, TB 800, 2513 

Harris, ZL 863 

Harris-Love, M 1598 

Harrison, A 1180, 1628 

Harrison, DJ 386, 495, 1698, 1829 

Harrison, H 1426 

Harrold, LR 464, 1085, 1087, 2138, 

2510 

Harsanyi, AM 1120 

Hart, DM 1688 

Hart, LE 1016, 1018, 1052, 2100 

Hart, SP 1200 

Harte, S 802 

Harte, SE 805, 806, 866 

Hartkamp, A 1273 

Hartkamp, LM 901, 2525 

Hartlage, GR 1261 

Hartman, T 331 

Hartmann, B 857 

Hartung, W 118, 120, 128, 1047, 

2378 

Harty, LC 1621, 2059, 2231, 2540 

Harvard, S 1830 

Harvey, BP 5 

Harvey, E 284 

Harvey, P 2688 

Harvey, WF 964 

Hase, K 1328 

Haseeb, A 2519 

Hasegawa, A 2645 

Hasegawa, H 1060 

Hasegawa, M 226 

Hashimoto, A 36 

Hashimoto, H 1296 

Hashimoto, H 1535, 1536 

Hashimoto, J 194 

Hashimoto, M 216, 1936 

Hashimoto, N 1281 

Hashimoto, Y 2160 

Hashiramoto, A 428, 1973 

Hashizume, M 899, 2077, 2079 

Hasni, SA 2501, 2506 

Hassanali, A 349 

Hassett, AL 866, 2425 

Hasunuma, T 1520 

Hatakeyama, S 1729 

Hatano, M 700 

Hatemi, G 2374 

Hatemi, I 2374 

Hatron, PY 1652, 2188 

Hatta, K 444, 445, 2156 

Hatta, K 1296 

Hatzara, C 1626 

Hauenstein, S 1931 

Hauge, EM 2072 

Haugeberg, G 121, 1975, 2354, 

2390 

Haugen, IK 1111 

Häupl, T 686, 979 

Häuser, W 953, 1859, 1860, 2642 

Haupt, S 2344, 2508 

Hawk, V 1572 

Hawker, GA 239, 244, 799, 907 

Hawkins, C 295 

Hawkins, FG 1998 

Hawkins, P 180 

Hawtree, S 1801 

Hay, E 25, 44 

Hayashi, D 1027, 1029, 1030, 1032 

Hayashi, H 2248 

Hayashi, M 2314, 2465 

Hayashi, T 2288 

Hayat, S 57 

Haye Salinas, M 60, 2141 

Hayem, G 2554 

Hayer, S 335, 343, 1947, 2081 

Hayes, KW 241 

Haynes, K 374, 2559 

Hays, T 158 

Hazel, E 1169 

Hazelhurst, S 975 

Hazen, MM 762 

Hazes, J 1048 

Hazes, JMW 76, 768, 1176, 1224, 

1240, 1560, 1570, 1793, 2095, 

2158, 2161, 2226, 2338 

Hazlewood, GS 401, 465, 1541 

Haznedaroglu, S 1411 

He, J 2176 

He, P 1842 

He, T 75 

He, W 1964, 1965 

Head, AJ 382 

Healy, L 2331 

Healy, M 1258, 1259

Heap, D 2055 

Hearth-Holmes, M 676, 1819 

Hebert, D 284 

Hebert, L 840 

Hebsgaard, J 2080, 2082 

Hecht, C 2581 

Hecht, I 2327 

Hedemann-Andersen, A 1254 

Heegaard, C 2103 

Heegaard, NHH 680, 1388, 2276 

Heelas, EO 1757 

Heeringa, P 860, 1533 

Heezen, K 528 

Heffernan, EJ 1355, 1621 

Hefner, K 524 

Hefner, KS 523, 525, 2203, 2674 

Heiberg, MS 2560, 2561 

Heijda, TF 539 

Heike, T 748 

Heimans, L 394, 1330, 1594, 2606 

Heimbürger, M 776 

Hein, M 207, 658, 1935 

Heintzman, N 917 

Heinze, E 1693 

Heinzl, H 851 

Heiser, U 2083 

Heitzmann, M 1638 

Heldmann, F 586, 780, 1619 

Helfenstein, M Jr. 1880 

Hellbacher, E 2574 

Hellgren, K 1229 

Helling, B 2343 

Helliwell, PS 474, 535, 1020, 1346 

Hellmark, T 2276 

Hellvard, A 2083 

Helmer, Q 2670 

Helmick, CG 1099, 2416 

Helsen, MM 2515 

Hemke, R 1021, 2019 

Hemmati, I 1123 

Henchoz, Y 1234, 2647 

Hendler, T 611 

Hendrickson, AF 1150 

Hendrikx, J 2635 

Hendrikz, J 1137 

Henrickson, M 294, 1896, 2011, 

2012, 2040 

Henriksen, K 1984 

Henrotin, Y 1780 

Henson, J 1927 

Hentgen, V 2024 

Heo, YJ 1745 

Her, YM 21 

Herbein, G 873 

Herborn, G 357 

Herbst, R 784, 1450, 1498, 1760, 

2681 

Herenius, MM 1338 

Herlin, T 2020 

Herman, S 2163 

Herman-Kideckel, S 1888 

Hermann, J 108, 117, 1044 

Hermann, KGA 563, 2219 

Hermine, O Sr. 1622 

Hernandez, C 446 

Hernández, MV 185 

Hernández, MV 1288, 1641 

Hernández, VC 1901 

Hernández-Cruz, B 538 

Hernández-Díaz, C 127 

Hernández-Hernández, C 2244 

Hernandez-Molina, G 513, 2244 

Hernandez-Molinero, M 1006 

Hernández-Rodríguez, J 855, 859, 

2352, 2357, 2359 

Herrera-Garcia, A 505 

Herrero de Padura, I 567 

Herrero-Beaumont, G 1751 

Herrero-Beites, AM 145, 1905, 

1906 

Herrick, A 695, 1477, 1481, 2303, 

2304 

Herrinton, L 1960 

Herrmann, K 1082 

Herrmann, M 1072 

Herrmann, S 2344 

Hersh, AO 276, 283, 298 

Herson, S 220, 225 

Hervier, B 751 

Herz, B 1019 

Herzog, R 2031 

Heslop, PS 1719 

Hesselstrand, R 2177, 2298, 2303 

Hester, CG 2521 

Hetland, ML 79, 121, 361, 363, 

416, 433, 1045, 1271, 2522, 2558 

Heur, M 2194 

Hewitt, S 2688 

Hewlett, S 864, 1558, 1579, 1723 

Heymann, RE 1880 

Heymans, MW 1125 

Heynen, G 1102 

Hidaka, D 1328 

Hidaka, T 370 

Hides, JA 2628 

Hiepe, F 686, 979, 1449, 1530 

Higa, J 1812 

Higa, S 1569 

Higami, K 1296 

Higashi, K 1569 

Higashi, Y 2084 

Higgins, G 2029 

Higgins, GC 2008 

Higgs, BW 218, 755, 1675 

Higgs, JB 2589, 2592 

Highton, J 1180, 1628 

Hilário, M 761 

Hilario, MO 296, 1041 

Hilderson, D 862 

Hiligsmann, M 1966 

Hill, CL 61 

Hill, J 1718 

Hill, J 33, 1196, 2518 

Hill, J 387 

Hill, PL 1339 

Hill, RJ 2326 

Hill, SC 2000, 2031 

Hillegass, WB 2542 

Hillen, J 1638 

Hillen, MR 1786, 2196 

Hilliard, BA 688 

Hilligoss, J 952 

Hillstrom, HJ 789, 790, 792 

Hilton-Jones, D 232 

Hinchcliff, ME 716, 787, 1463, 

1518 

Hinks, A 974, 1614, 2654 

Hinojosa, M 1427 

Hinojosa-Azaola, A 650 

Hinsch-Gylvin, L 456, 467 

Hinson, G 1131 

Hirai, H 2070 

Hirakata, M 1938 

Hiraki, LT 287, 442, 931, 976, 1608, 

1609, 2279 

Hirano, F 371 

Hirano, T 500 

Hirata, S 771, 2121, 2162, 2664 

Hirata, Y 700 

Hirohata, S 36, 1333, 1458, 2372, 

2684 

Hiron, M 485, 1783 

Hirono, S 2074 

Hirsch, JD 142 

Hirsch, R 2656 

Hirsh, JM 91, 655, 2237 

Hisamoto, S 186 

Hiscock, A 232 

Hiscock, R 1833, 1840 

Hishitani, Y 500 

Hissink Muller, PCE 2002 

Hitchon, CA 381, 401, 465, 939, 

1179, 1216, 1225, 1238, 2099, 

2109, 2132, 2541, 2610 

Hix, S 2396 

Hjalte, F 930 

Hmamouchi, I 396 

Ho, A 1315, 1321 

Ho, HE 2497 

Ho, LY 1407, 1410, 1413, 1414, 

1488, 2251 

Hočevar, A 2187 

Hobbs, K 639, 2252 

Hobday, PM 1056 

Hochberg, MC 1695 

Hochberg, MC 239, 258, 260, 744, 

912, 919, 986, 1975, 1995, 2467, 

2533 

Hodgson, RJ 1020 

Hodkinson, B 975, 1794 

Hoeck, HC 235 

Hoeger, P 2004 

Hoehle, M 466 

Hoekstra, M 2607 

Hoeltzel, MF 2597 

Hoepken, B 777, 1705, 2613 

Hoese, G 77 

Hoetjes, N 131 

Hofbauer, A 668 

Hofer, M 2648 

Hofer, M 759, 1679, 2032 

Hoff, M 1975 

Hoff, P 47, 1777 

Hoffart, CM 2030 

Hoffman, GS 855, 1527, 1537, 

1544, 1653, 1655, 2391, 2397, 

2567 

Hoffman, H 180 

Hoffman, HM 2656 

Hoffman, I 1305 

Hoffman, J 804 

Hoffman, J 2039 

Hoffman, M 1132 

Hoffman, RW 1315, 1321 

Hoffman, S 1476, 1512 

Hoffmann, N 944 

Hoffmann, PM 179 

Hoffmann-Vold, AM 2303 

Hoffmeyer, P 248, 1091 

Hoffstetter, P 128, 1047 

Hoftman, AD 303 

Hoganson, DD 709 

Hoh, SF 274 

Hoi, AY 2257 

Hokken-Koelega, ACS 1224 

Holers, VM 71, 72, 414, 423, 441, 

1059, 1692, 1765, 2097, 2116 

Holgado, S 1967 

Holla, JFM 1125 

Hollan, I 834 

Holland-Fischer, M 2558 

Hollander, MC 2040 

Hollister, AS 150, 1633 

Hollister, JR 2596 

Holmdahl, R 411, 412, 439, 1769 

Holmes, AM 2305 

Holmqvist, M 2120 

Holz, JB 336, 1307, 1311 

Hommes, DW 1051 


Hömmö, T 882Honda, F 856 



374 

Honda, S 370 

Hong, MJ 884, 1962, 1968 

Hong, SD 1896, 2008, 2029 

Hong, SJ 78, 967, 1247, 1262, 

1882 

Hong, SY 2680 

Hong, YS 34 

Hong, YK 884 

Hooper, M 1644 

Hooten, WM 1866 

Hoover, P 1518 

Hoover, SE 2172 

Hopkinson, D 732, 1034 

Horai, Y 370, 1053, 2112, 2142 

Horcada, L 1424 

Horikoshi, M 2288 

Horita, T 1729, 2460 

Horiuchi, T 186 

Horkayne-Szakaly, I 206 

Horn, EM 1465, 1712 

Hörnberg, K 1244 

Horne, A 1166 

Horne, A 1902 

Horneff, G 759, 760, 1147, 1149, 

1152, 1153, 1597 

Hornum, L 2082 

Horslev-Petersen, K 416 

Hørslev-Petersen, K 1045, 2522 

Hortobagyi, T 1955 

Horton, R 2406 

Horton, SC 366 

Horwitz, DA 2324, 2503 

Hoshi, D 392, 400, 1831 

Hosoi, T 1957 

Hosono, O 1600 

Hosono, Y 216, 1936, 1938 

Hosoya, T 371 

Hosseini, K 82, 83, 918 

Hossler, J 1207, 1992, 2667, 2678 

Hostnik, B 2187 

Hot, A Sr. 1622, 2383 

Hotchkiss, RN 1108 

Hotta, S 1660, 1799 

Hou, Y 2329 

Houard, X 13, 18, 19 

Houghton, K 761 

Houk, C 2604 

House, M 1902 

Houssiau, FA 1335, 2548 

Houston, GD 523, 524, 525, 2203, 

2674 

Houvenagel, E 1309 

Houwing-Duistermaat, J 973 

Houwing-Duistermaat, JJ 2670 

Houx, L 2024 

Howard, D 1970, 1987 

Howard, DG 610, 682 


Howard, TD 313, 2284 

Howe, HS 2278 

Howsmon, R 322 

Howson, TL 169, 170 

Hoyer, BF 1530 

Hoyles, R 785 

Hoyt, J 338 

Hsia, EC 80, 1366, 1620 

Hsia, SH 1549 

Hsieh, C 603 

Hsu, B 563 

Hsu, HC 2152, 2575, 2677 

Hsu, S 1759 

Hsu, VM 692, 1461, 1463 

Hsu, YH 2419 

Hu, C 1293 

Hu, F 1065 

Hu, X 900 

Hua, C 352 

Huang, A 2233 

Huang, B 2011 

Huang, B 1181 

Huang, CC 301, 1948 

Huang, CH 972 

Huang, F 1366 

Huang, J 2102, 2482 

Huang, JL 1549 

Huang, J 1505, 2517 

Huang, QQ 1074, 1076, 1206, 

1639 

Huang, Q 2524 

Huang, WT 1465 

Huang, Y 1808, 2653 

Huang, Y 2274 

Hubbard, Y 2038 

Huber, AM 291 

Huber, KA 155 

Huber, LC 892 

Hubert, P 201 

Hudson, M 711, 728, 1467, 2422, 

2424, 2626 

Hueber, AJ 888, 1010, 2582 

Huemer, C 1679 

Huffman, KM 268, 1228 

Huggins, JL 281, 312, 2011, 2040, 

2603 

Hughes, LB 997 

Hughes, P 523, 525, 2203, 2674 

Hughes, RA 488, 864, 1558, 1893, 

1924 

Hughes, T 858 

Hughes-Austin, JM 71, 414, 2097 

Huhtala, TA 2509 

Huie, TJ 1227 

Huitema, MG 514, 1533 

Huizinga, TWJ 397, 894, 1136, 

1330, 1771, 1982, 2550 

Huizinga, T 394, 564, 1380, 1594, 

1770, 2206, 2207, 2209, 2211, 

2212, 2606, 2612 

Huizinga, TWJ 973, 1768, 2171, 

2670 

Huizinga, TWJ 1201, 1320, 1767 

Hulscher, M 1561 

Hulsey, TC 602 

Hummel, J 280, 281, 305, 312, 

2474 

Hummers, LK 697, 719, 723, 1463, 

1468 

Humphreys, J 767, 2544 

Hunder, GG 2566 

Hung, K 812 

Hung, MY 2513 

Hungerford, DS 260 

Hunter, CD 27, 2334 

Hunter, D 249 

Hunter, DJ 141, 151, 250, 252, 741, 

1027, 2469, 2470, 2534 

Hunzelmann, N 2304 

Huppertz, H 1679 

Hurford, M 1460 

Hurley, MV 1590, 2050, 2439 

Hurley, M 1582, 2436, 2448, 2632 

Hurley, PM 2399 

Huscher, D 77, 1462, 1713, 2085 

Husic, R 108, 117, 1044, 2312, 

2318 

Huso, DL 786 

Hutcheson, J 2679 

Hutchinson, CE 271 

Huttenlocher, A 1601 

Huvard, M 12 

Hviscova, K 1926 

Hwang, J 203, 425, 435, 1181, 

1226 

Hwe, A 817 

Hübbe-Tena, C 644 

Hyrich, K 767 

Hyrich, KL 362, 828, 1145, 1159, 

1162, 1593, 2009 

Hyun, DS 1236 

Hyzy, M 1437, 2067 

Iagnocco, A 810, 811 

Iaiani, G 192 

Iannaccone, CK 954, 2403, 2660 

Iannicelli, P 1546 

Ibanez, D 612, 625, 646, 647, 648, 

841, 842, 1421, 1423, 1435, 1706, 

2243, 2254, 2266, 2683 

Ibanez Estrella, A 2477 

Ibarra, MF 2008, 2029, 2597 

Ibba, V 498, 599 

Ibrahim, S 908, 909 

I 

Ice, JA 523, 524, 525, 2203, 2671, 

2674 

Ichesco, E 802, 805, 806, 2644 

Ichida, H 714, 941, 942, 1492, 

1937, 2242 

Ichihara, H 1600 

Ichimura, Y 700, 708, 1504, 1521 

Ichinose, K 1046, 1053, 1448, 

2112, 2142, 2682 

Ichinose, S 332 

Ichise, Y 1298 

Ickinger, C 975 

Idbrik, L 1837 

Idrees, IM 1231 

Iga, S 371 

Igarashi, K 2248 

Igarashi, T 1569 

IGAS, IGOASC 1612 

Iglesias-Gamarra, AA 2190 

Ignatenko, S 1279 

Igney, A 844 

Ihata, A 809, 1333, 1431 

Ihn, H 2286 

Iizuka, M 518, 2075, 2529 

Iizuka, N 182, 1531 

Ikari, K 1089, 1963, 2143 

Ikawa, T 1296 

Ikeda, K 112 

Ikeda, K 332 

Ikezawa, Z 1501 

Ilhan, B 2367 

Ilhan, B 2394 

Illei, GG 506, 2200, 2501, 2506, 

2671 

Ilowite, N 764 

Ilowite, NT 323, 2657 

Im, CH 406, 1267, 2230 

Imai, K 1917 

Imamura, PM 1268 

Imanaka, H 1163 

Imboden, JB 2139, 2440, 2583, 

2584 

Imundo, LF 2406 

Imura, Y 216, 1936, 1938 

Inal, V 532 

Inami, M 2084 

Inanc, M 1707, 2253, 2364 

Inase, N 98 

Ince, A 2102 

Inciarte-Mundo, J 1288 

Ing, S 1195 

Ingegnoli, F 675, 1472 

Ingrand, P 2023 

Ingvarsson, R 654, 930, 1434 

Inman, CJ 1890, 2068 

Inman, RD 172, 587, 588, 1364, 

1625

Inman, RD 542, 782, 1381, 1592, 

1624, 2224 

Innala, L 2145 

Inoue, A 1635 

Inoue, E 392, 400, 1831, 1963 

Inoue, N 1535 

Inoue, T 2084 

Inoue, Y 186, 392, 400, 1831 

Inoue, Y 2286 

Insalaco, A 2021, 2032 

International RA Consortium on 

Therapy (InteRACT), 983 

International Scleroderma Renal 

Crisis Study Investigaots, 728 

International Spondyloarthritis 

Genetics Consortium, 2495 

Inverardi, F 1523 

Ioakeimidis, D 991, 2181 

Ioan-Fascinay, A 1097 

Ioannidis, G 1018 

Ioannou, Y 1402, 1403, 1725, 

1727, 1728 

Iolascon, G 1976 

Ionescu, R 448, 449, 1383 

Iorga, SR 94, 932 

Ipseiz, N 903 

Irazoque, F 456 

Irigoyen, MV 1237 

Irino, Y 2280 

Irrera, N 1507, 1508 

Irrgang, JJ 1107 

Irshad, V 1538 

Irvine, J 2194 

Irwin, MR 1576, 2694 

Isaacs, J 362 

Isaacs, JD 103, 774 

Isayeva, K 1143, 1148 

Isenberg, DA 607, 1420, 2570 

Isenberg, DA 652, 848, 1402, 

1403, 1406, 1725 

Isgro, J 847 

Ishida, MA 2618 

Ishigatsubo, Y 809, 989, 1333, 

1431, 1611, 2046 

Ishiguro, N 1312, 1324, 1325, 

2314, 2465 

Ishii, M 726 

Ishii, T 370, 2328 

Ishii, Y 1325 

Ishikawa, M 430 

Ishimori, ML 673 

Ishino, H 2070 

Ishizaka, Y 659, 683 

Ishizaki, J 1060 

Ishizaki, T 371 

Ishorari, J 1420 

Isnard, R 2365 

Isobe, M 856 

Isobe, T 431 

Isola, M 2183, 2189 

Isozaki, T 330, 413, 737, 879, 1603 

Israelsson, L 1208, 1615, 1769, 

2578 

Ito, H 430 

Ito, H 415 

Ito, I 1535 

Ito, M 2084 

Ito, S 2094 

Ito-Ihara, T 1536 

Itoh, K 2504 

Iung, B 2565 

Ivan Polk, B 2483, 2640 

Ivanco, D 699 

Ivanov, JP 1408 

Ivashkiv, LB 874, 900, 1188, 1196 

Ivers, N 926, 2511 

Iversen, C 608, 937 

Iversen, LV 680 

Iversen, MD 798, 1584 

Iversen, P 386 

Iverson, E 2006 

Iwabuchi, K 332 

Iwahashi, M 1314 

Iwamoto, K 1084 

Iwamoto, N 1046, 1053, 2112, 

2142 

Iwamoto, T 1089 

Iwamoto, T 112 

Iwata, S 1600 

Iwata, S 1763, 2150 

Iyer, R 2514 

Izac, B 597, 598 

Izmirly, PM 290, 1250, 1647 

Izquierdo, E 1183, 1193, 1513 

Izuhara, K 1501 

Izumi, K 455 

Izumihara, T 1314, 2117 

J.M Kerkhof, H 982 

Jaakkimainen, RL 926, 2511 

Jabbar-Lopez, Z 2660 

Jacek, EE 1809 

Jackson, J 2006 

Jackson, M 2676 

Jackson, MW 504 

Jackson, R 242 

Jackson, RD 239, 986, 2467 

Jackson, SW 2580 

Jacob, CO 843, 846, 970, 1438, 

1613, 2283 

Jacob, N 1438 

Jacobs, JWG 2125 

Jacobs, JWG 1048, 1996 

Jacobs, S 336 

J 

Jacobsen, E 1871 

Jacobsen, S 680, 1388, 1419, 2276, 

2570 

Jacobsson, LTH 411, 826, 905, 

1184 

Jacobsson, LT 95, 463, 1828, 2409 

Jacques, C 13, 18, 19 

Jacquot, S 220 

Jadon, D 1357 

Jahagirdar, R 341 

Jain, A 402, 2106 

Jain, M 1250, 1263 

Jain, MS 206 

Jain, S 2360 

Jain, V 835 

Jajoria, P 691 

Jakicic, JM 1029, 1030, 1031 

Jakobsen, MS 1271 

Jakobsson, K 905 

Jakobsson, PJ 31, 411, 412, 439, 

1769 

Jakstadt, M 1777 

Jallal, B 755, 1675 

Jallouli, M 1649 

James, D 74, 1215, 2131 

James, JA 524, 627, 645, 670, 673, 

729, 740, 846, 970, 1441, 1606, 

1613, 1748, 1795, 2283, 2671 

James, MT 172 

James, M 453 

Jan, R 1404 

Jandali, R 377 

Jang, SI 506, 2501 

Janga, S 2194 

Jani, J 1396 

Janini, ACR 96, 927 

Janow, GL 323 

Jansen, AV 206, 1037 

Jansen, G 2154 

Jansen, JP 2171 

Jansen, TL 136, 1273 

Janssen, G 1770 

Janssen, KMJ 1202 

Jara, LJ 1956 

Jara-Quezada, LJ 212, 701, 1726 

Jaramillo, D 2190 

Jaremko, J 38, 1033 

Jariwala, M 1680 

Jarjour, WN 678, 840, 1672 

Jarosova, K 764, 1926 

Jarraya, M 1029, 1030, 1032 

Jarrin, J 124 

Jaskal, K 2455 

Jasson, M 1320, 1337 

Jatwani, S 2456 

Javaid, MK 781, 915 

Jayakar, J 1351 

Jayne, D 1525, 2564 

Jebakumar, A 134, 1220, 2175, 

2198 

Jefferies, C 610, 682, 2526 

Jeffries, MA 2370 

Jenkins, K 1155, 2005 

Jenks, S 690 

Jennings, F 1092, 1233, 1864, 

2652 

Jennum, P 2689 

Jensen, DV 361, 363, 2558 

Jensen, MA 2273 

Jensen, MP 952 

Jensen, P 840 

Jensen, P 959 

Jensen, TD 361 

Jensen-Urstad, K 703 

Jensenius, JC 2522 

Jeon, CH 425, 1181 

Jeon, JY 2275 

Jeong, H 203 

Jessep, S 2436 

Jessup, HJ 1796 

Jesus, AA 2282 

Jetanalin, P 917 

Jetha, A 2417, 2429 

Jeudy, A 873 

Jhangri, GS 1088 

Jhingran, PM 945 

Ji, JD 409, 2267 

Jia, Y 2088 

Jian, J 1930 

Jiang, H 2521 

Jiang, W 1068 

Jiang, X 978 

Jiang, X 1196 

Jibatake, A 1332 

Jimenez, JL 2466 

Jimenez, SA 1496, 2295, 2306, 

2309 

Jimenez- Núñez, FG 1237 

Jiménez-Hernández, M 1958 

Jin, HM 1063 

Jin, JP 1206 

Jin, Y 1345 

Jinnin, M 2286 

Jinying, L 1260 

Jiries, N 193 

JM, G 2173 

Job Deslandre, C 1679 

Job-Deslandre, C 2007 

Jog, N 839 

Johansen, J 2522 

Johansen, JS 433, 580 

Johansson, I 2692 

Johansson, UB 1571 

John, A 464, 491, 1300 

John, MR 1911 




376 

John, MR 144, 249, 250, 252, 2470 

John, S 1550 

Johns, C 197 

Johnson, BH 1855 

Johnson, BK 2479 

Johnson, DL 2466 

Johnson, H 1667 

Johnson, L 490 

Johnson, MR 1203 

Johnson, SR 853, 1364 

Johnson, VM 307 

Johnston, S 389, 1855 

Johnston Jr., CC 1971 

Jolly, M 1411, 1563, 2236 

Joly, F Sr. 1772 

Joly, J 1561 

Joly, M 1302 

Jonas, BL 1203, 1572 

Jonas-Dwyer, D 2590 

Jones, AV 1981 

Jones, A 1722, 2405 

Jones, A 1092, 1233, 1867 

Jones, A 179 

Jones, CA 1088 

Jones, DM 2127 

Jones, GT 601, 966, 1161, 1525 

Jones, G 454, 1117, 1118, 1120, 

2535, 2537 

Jones, H 398 

Jones, JD 1753 

Jones, KB 2039 

Jones, KL 2466 

Jones, KD 804 

Jones, M 2650 

Jones, OY 282 

Jones, PBB 1628 

Jones, RV 282 

Jones, TV 1827 

Jones-Taha, R 447, 1276 

Jönsen, A 654, 662, 930, 1388, 

1434 

Jonsson, MV 520, 2186 

Jonsson, R 520, 522, 2186, 2671 

Joos, R 761, 862 

Jordan, JM 237, 789, 986, 1094, 

1099, 1113, 2419, 2468 

Jorgensen, C 733, 2505 

Jorgensen, WL 875 

Jorns, JM 311 

Joseph, G 386, 495, 1698, 1829 

Joseph, R 422 

Joshi, V 58, 59 

Joshua, V 1208, 1691 

Jouen, F 220, 485 

Joung, CI 967, 1882 

Jousse-Joulin, S 2197, 2554 

Joven, BE 696, 2232 


Joyce-Shaikh, B 725 

JP Lin, 2311 

Ju, JH 436, 664, 1745, 2258, 2381 

Ju, Y 334 

Juan, M 191 

Juanola, X 1373, 1700 

Judge, A 781, 915 

Juengel, A 902 

Juhl Pedersen, S 1617 

Julià, A 980, 998, 999, 1001 

Julian, BA 729 

Julian, LJ 1580 

Jun, JB 78, 1247 

Junca, A 2190 

Juneau, P 933, 934 

Junfang, L 1260 

Jung, HA 37 

Jung, J 1425, 2577 

Jung, KJ 1236 

Jung, LK 1141 

Jung, M 711 

Jung, SM 664, 2258 

Jung, YO 1745 

Jung, Y 42 

Jungel, A 438 

Junker, P 416, 1045, 2522 

Junker, S 890 

Jurgens, MS 1996 

Jurriaans, E 1016, 2100 

Jury, EC 848 

Juvenile Dermatomyositis Research 

Group, 297 

Jüngel, A 2123 

Jüni, P 1116 

K 

Kabasakal, Y 532 

Kabraki, M 1520 

Kaburaki, J 850 

Kachalia, A 2062 

Kachaochana, A 1670 

Kadi, A 597, 598 

Kadono, T 1504 

Kaegi, T 770, 2144 

Kaeley, GS 2589, 2592 

Kaffenberger, B 1672 

Kageyama, G 2280 

Kahaleh, B 1494, 1506, 2296, 2297 

Kahan, A 1510, 2007 

Kahlenberg, JM 1443, 2502 

Kahn, JE 641, 1622, 2383 

Kaieda, S 897 

Kaine, J 1695, 2547 

Kaine, J 1294 

Kairys, AE 802, 805, 806, 866, 

2644 

Kaiser, MJ 1305 

Kaji, K 226 

Kajihara, I 2286 

Kalabic, J 486 

Kalampokis, I 316 

Kaldas, M 2169 

Kale, M 2475 

Kalfa, M 181, 532, 2364 

Kalishman, S 2038 

Kallas, EG 2497 

Källberg, H 978, 1607, 2574 

Kalled, S 618, 886 

Kallenberg, CGM 860, 1533, 2393, 

2567 

Kallinich, T 759 

Kalliolias, GD 874, 1196 

Kalluru, R 2586 

Kalstad, S 404, 2560, 2561 

Kalunian, K 639, 2252, 2622 

Kalunian, KC 603 

Kamali, S 2253, 2364 

Kamath, T 389 

Kamauu, A 2093, 2543 

Kamble, S 984 

Kamdar, AA 475 

Kameda, H 455, 473, 877, 2119, 

2160 

Kamen, DL 673, 729, 843, 846, 

970, 1417, 1613, 1892, 2265, 2274, 

2423, 2619, 2687 

Kamen, LA 1057 

Kamensek, O 1722, 2405 

Kaminski, N 217 

Kaminsky, P 1740 

Kamiyama, A 113, 1012, 1989, 

1990 

Kamogawa, Y 2328 

Kamp, S 1418, 1795 

Kampolis, C 1738 

Kan, H 945 

Kan, M 1009 

Kanamono, T 2314, 2465 

Kanariou, M 2199 

Kanazawa, M 1324 

Kandiah, DA 2590 

Kandili, A 1626 

Kandimalla, ER 1068 

Kaneko, A 2314 

Kaneko, H 1634 

Kaneko, H 2242 

Kaneko, K 1520 

Kaneko, T 132 

Kaneko, Y 98, 455, 1186, 2119, 

2160 

Kanellos, M 2055 

Kanetsuka, Y 1729, 2460 

Kang, EH 1797, 2385 

Kang, EJ 1915, 2122 

Kang, JS 408 

Kang, JH 406 

Kang, JW 1267, 2230 

Kang, J 1664 

Kang, MI 1327 

Kang, Y 1327 

Kang, YM 78, 406, 1267, 2230 

Kanno, Y 2322 

Kantarci, A 1204 

Kao, AH 1690, 1711, 2699 

Kao, W 2088 

Kaouache, M 649, 1169, 1428 

Kapeller, R 1062 

Kapetanovic, MC 481, 2137 

Kaplan, I 1290 

Kaplan, J 855 

Kaplan, MJ 311, 660, 1440, 1443, 

2499, 2502 

Kapoor, M 730 

Kapsogeorgou, EK 507, 508, 526 

Karabulut, G 532 

Karadag, O 2364 

Karberg, K 77 

Kargard, M 2063 

Karimi, R 1691 

Karin, M 426 

Karlson, EW 372, 442, 937, 976, 

981, 1230, 1605, 1608, 1609, 1664, 

1683, 1821, 2279 

Karmarkar, A 1589 

Karouzakis, E 419, 438 

Karp, DR 673, 685, 2060 

Karp, G 1038 

Karpouzas, GA 629, 1251, 1645, 

1685 

Karpus, KON 2090 

Karpus, ON 1189 

Karras, A 1652, 1657, 2383 

Karsdal, MA 235, 575, 591, 592, 

1329, 1984, 2166, 2167, 2615 

Kasapcopur, O 750 

Käsermann, F 1791 

Kaskari, D 958 

Kåss, A 834 

Kassoumeri, L 2654 

Kast, M 2455 

Kastelein, R 725 

Kastner, DL 179, 989, 1005, 1611, 

2657 

Katada, Y 194 

Kataoka, S 714, 1937, 2242 

Katashima, Y 1281 

Katayama, K 1314 

Katayama, M 194 

Katayose, T 1600 

Kates, S 1112 

Kato, T 182, 1531 

Katsaros, EP 1411

Katsicas, MM 302, 1174 

Katsumata, Y 714, 941, 942, 1492, 

1937, 2242 

Katz, BJ 855 

Katz, C 956 

Katz, JD 282 

Katz, JN 238, 910, 911, 1090, 1108, 

1843, 1983, 2650 

Katz, PP 247, 791, 871, 1580, 

2139, 2411 

Katz, RS 605, 867, 953, 956, 1564, 

1565, 1566, 1567, 1858, 1863, 

1878, 2642, 2698 

Kauffman, M 2678 

Kaufman, JM 1961, 1969 

Kaufman, KM 843, 846, 970, 1613, 

2274, 2283 

Kaufmann, C 404 

Kaul, I 1147 

Kaul, P 70 

Kauppi, MJ 67, 68 

Kaushik, P 829, 2220 

Kautiainen, H 67, 68, 375 

Kavanaugh, A 373, 380, 487, 569, 

772, 775, 995, 1303, 1372, 2218, 

2557, 2562 

Kawabata, K 1660, 1799 

Kawabata, T 1278, 1284, 2490 

Kawachi, H 1952 

Kawaguchi, Y 98, 714, 941, 942, 

1492, 1937, 2242 

Kawahito, Y 1296, 2070 

Kawai, S 1520 

Kawai, T 1204 

Kawai, VK 1960 

Kawakami, A 370, 1046, 1053, 

1448, 2112, 2142 

Kawamoto, K 1569 

Kawamoto, T 209, 1941 

Kawano, S 410, 2280 

Kawarasaki, S 700 

Kawasaki, A 1535 

Kawasaki, H 1600 

Kawasaki, M 332 

Kawasaki, Y 1973 

Kawashima, H 112 

Kawashiri, SY 1046, 1053, 2112, 

2142 

Kawata, AK 1394 

Kawatkar, AA 2514 

Kay, L 1346, 1718 

Kaya, A 1411 

Kaya, D 251 

Kaymakcalan, Z 5 

Kayser, C 704 

Kazi, S 2065 

Kazkaz, L 420 

Keane, C 1597 

Kearns, GM 610, 682, 2526 

Kearsley-Fleet, L 1145 

Keating, RM 72, 414, 441 

Kedar, E 1927 

Keddache, M 1614 

Kee, SJ 1063 

Keeling, SO 70 

Keen, KJ 717 

Keenan, G 2617 

Keenan, RT 166, 1914 

Kehler, T 479 

Keir, G 722 

Keirstead, N 1741 

Keiserman, M 462 

Keith, MP 740 

Kekow, J 440, 1004 

Kekow, M 440 

Kelleher, K 2039 

Keller, KK 2072 

Kelley, GA 2408 

Kelley, KS 2408 

Kellner, H 272, 574, 2225 

Kelly, JA 523, 524, 525, 846, 970, 

1613, 2203, 2283, 2284, 2674 

Kelly, S 2547 

Kelly, VM 1132 

Kelsey, C 319, 2008, 2029, 2036 

Kelsey, S 1426 

Keltsev, V 1597 

Kendler, DL 1998 

Kendzerska, T 244 

Kendzicky, A 1506 

Keniston, A 655, 2237 

Kennedy, A 1621 

Kennedy, AC 447 

Kennedy, CW 1144, 1155, 1157, 

2005 

Kennedy, F 2059 

Kennedy, M 540 

Kennedy, WP 620, 2622 

Kenny, D 1239, 2348, 2382 

Kent, M 1155, 2005 

Kenwright, A 760, 1329, 1597, 

2166 

Keogh, JC 818 

Keogh, K 1737 

Keren, R 929 

Kerkman, P 1767 

Kermani, TA 754, 2355, 2356, 2358 

Kerola, AM 67, 68 

Kerola, T 67, 68 

Kerr, GS 89, 149, 536, 1187, 2102, 

2220, 2482, 2483, 2640 

Kerschen, P 1551 

Kerstens, PJSM 358, 1330, 1982 

Keränen, T 882 

Keser, G 181, 532, 858 

Kessel, A 1746 

Kessler, E 762 

Kettle, A 1903 

Ketzer, JB 1227 

Key, JD 602 

Keyes-Elstein, L 2619 

Keysor, JJ 796, 1553 

Keystone, E 80, 1216, 1277, 1695, 

2109 

Keystone, E 381, 401, 459, 465, 

490, 1225, 1238, 1280, 1287, 1299, 

1317, 2099, 2132, 2487, 2488, 

2610 

Keystone, EC 1015, 1303, 1304 

Keyßer, G 1696 

Khakban, A 93 

Khalidi, NA 2391, 2397 

Khalil, H 493, 494, 496, 497, 2108 

Khalilova, I 1903 

Khamashta, MA 1406, 1647, 1734, 

1735, 1900, 2272 

Khan, A 1538 

Khan, FM 1850 

Khan, HI 1118 

Khan, K 785 

Khan, MA 559, 1366, 1376 

Khan, M 1838 

Khan, NA 1850, 1870, 1872, 2098 

Khandpur, R 1440 

Khanna, D 92, 93, 140, 147, 159, 

160, 718, 728, 851, 1342, 1464, 

1475, 1503, 1506, 1509, 1713, 

2623 

Khanna, P 140, 147, 158 

Khanna on behalf of ACR/EULAR 

Classification Criteria SSc, D 853 

Kharlamova, N 1769 

Khellaf, M 2383 

Khetan, S 1801 

Khim, S 2580 

Khosroshahi, A 133, 1534, 1752, 

1921, 2527, 2528 

Khoutra, C 1652 

Khraishi, MM 496, 1246, 1395 

Khubchandani, R 2477 

Khun, H 950 

Kiani, A 626, 1390, 1412, 2245, 

2255 

Kichikawa, Y 1600 

Kick-off of the Italina Network for 

Gout (KING) Study Group, 167 

Kickler, T 1396 

Kieffer, NA 2482 

Kiel, DP 2415 

Kielar, D 777, 1705, 2613 

Kiely, PD 74, 1215, 2131 

Kievit, W 433, 1273, 2635, 2637 

Kikly, K 2492 

Kikuchi, H 184, 2372 

Kikuta, J 726 

Kilgallen, B 639, 2252 

Kilgore, KM 1904 

Kilgore, M 920 

Kill, A 1491 

Kilpatrick, D 1460 

Kiltz, U 553, 1376 

Kim, AH 1742 

Kim, BM 39 

Kim, CH 1866 

Kim, DJ 2258, 2381 

Kim, D 664 

Kim, D 2686 

Kim, EO 2326 

Kim, G 165 

Kim, G 42 

Kim, HR 39 

Kim, HJ 1188 

Kim, HY 1745 

Kim, HY 21, 664, 2258, 2381 

Kim, H 215 

Kim, HW 215, 1188, 1219, 1952, 

2385 

Kim, HE 917 

Kim, HA 1882 

Kim, HA 2275 

Kim, HA 2, 10, 37, 273, 967 

Kim, HS 967, 1882 

Kim, IJ 273 

Kim, IS 406 

Kim, JH 1236 

Kim, JS 1188 

Kim, JY 130, 1013 

Kim, JH 2680 

Kim, JM 1962, 1968 

Kim, JY 613 

Kim, J 803 

Kim, JS 1915 

Kim, JH 1219 

Kim, J 1952 

Kim, J 78, 426, 435, 1247 

Kim, J 172 

Kim, KJ 613, 628 

Kim, KW 21, 39 

Kim, KC 1114 

Kim, KH 1219 

Kim, KH 1267 

Kim, L 812, 1292, 1301, 1826 

Kim, NR 1267, 2230 

Kim, NH 876 

Kim, ST 2333 

Kim, SH 1882 

Kim, SJ 1709 

Kim, SH 1882 

KIM, SHK 967 

Kim, SK 967, 1236, 1247, 1882 

Kim, SC 1687, 1843, 1873 

Kim, SJ 328, 2669 




378 

Kim, S 643, 1262 

Kim, SS 2246 

Kim, TY 348 

Kim, TH 78, 1247 

Kim, TJ 78, 1063, 1433, 2249 

Kim, TY 443 

Kim, WU 613, 628 

Kim, Y 1741 

Kim, YG 2250 

Kim, YG 354 

Kim, YH 1889 

Kim, Y 989, 1611 

Kim, YJ 1784, 2250 

Kim, YJ 354 

Kim, YG 1784 

Kim, YJ 1267 

Kim, Y 436 

Kim, YA 1238 

Kimberly, RP 729, 843, 846, 970, 

997, 1422, 1613, 2152, 2274, 2283 

Kimberly on behalf of PROFILE 

investigators, RP 671 

Kimmel, JC 165 

Kimura, E 2248 

Kimura, F 2504 

Kimura, M 36 

Kimura, Y 184, 2372 

Kimura, Y 762, 1146 

Kimyon, G 2364 

Kindred, C 536 

Kinds, MB 1122 

King, A 1955 

Kingsbury, D 761 

Kingsbury, DJ 1678 

Kinjo, M 1993 

Kiraz, S 2364 

Kirchner, HL 1231 

Kiridly, J 2670 

Kirino, Y 989, 1611 

Kirkham, BW 1346, 2174 

Kirou, KA 603, 653, 847, 1809, 

2246, 2696 

Kirwan, JR 1274, 1723, 1924, 2169 

Kishimoto, D 809, 1333, 1431 

Kishimoto, M 183, 399, 948, 2247 

Kislinsky, D 2055 

Kislinsky, K 2055 

Kissel, K 2550 

Kissin, EY 2592 

Kita, J 2112, 2142 

Kitahara, K 1520 

Kitani, A 1492 

Kitano, M 1281, 1296 

Kitano, S 1281 

Kitchin, E 920 

Kivity, S 193 

Kivitz, A 1679 


Kivitz, AJ 349, 558, 1339 

Kiyokawa, T 223 

Kjær, SG 1877 

Klammer, A 117 

Klarenbeek, PL 516, 1754 

Klareskog, L 31, 63, 64, 411, 412, 

439, 978, 1208, 1604, 1615, 1691, 

1769, 2120, 2130, 2578 

Klassen, LW 26, 27, 676, 2334 

Klatt, S 49 

Klatzman, D 757 

Klatzmann, D Sr. 1623, 1772 

Klearman, M 349, 772 

Kleimann, JF 2287 

Klein, I 2565 

Klein, K 1781, 2670 

Klein, M 233 

Klein-Gitelman, MS 280, 281, 294, 

312, 1890, 2040 

Kleinert, S 1762 

Kleyer, A 1010 

Klinger, M 1717 

Klinker, MW 1743 

Klinkhoff, AV 494 

Kloppenburg, M 1136 

Kloppenburg, M 1097, 1100, 1126, 

2538 

Klotsche, J 1149, 1152, 1153 

Kluger, E 580 

Knaapen, H 2301 

Knappertz, V 1760 

Kneissel, M 346 

Knevel, R 894 

Knevel, R 2670 

Knickle, K 2148 

Knight, A 929 

Knight, A 776 

Knight, JS 1440 

Knoop, H 1232 

Knoop, J 266 

Knowles, S 2172 

Knudsen, S 2276 

Ko, G 1862 

Ko, K 689 

Kobayakawa, T 2314, 2465 

Kobayashi, A 392, 400, 1831 

Kobayashi, D 2094 

Kobayashi, H 1243 

Kobayashi, N 292 

Kobayashi, S 1535, 1536 

Kobayashi, T 183 

Kobayashi, T 132 

Kobayashi, Y 1243 

Kocanaogullari, H 532 

Koch, AE 311, 330, 413, 737, 879, 

1503, 1506, 1603 

Koch, T 944 

Kodera, T 370 

Koehm, M 2217 

Koehn, C 1722, 2405 

Koehoorn, M 1103 

Koeleman, BPC 894 

Koeleman, BPC 2303 

Koelling, S 1209 

Koenders, MI 2089, 2523 

Koenig, AS 81, 368, 383, 398, 865, 

1011, 1285, 1354, 1827, 1842, 

1848, 2133, 2549, 2661 

Koenig, M 720, 721 

Koenig, M 2343 

Koening, CL 855, 2391, 2397 

Koerner, A 2424 

Koerner, M 2553 

Koes, B 2471 

Koessler, RE 1074, 1639, 2524 

Koetse, W 1319 

Koetter, I 858 

Koevoets, R 397 

Koga, T 370, 2682 

Kogata, Y 2280 

Koh, EM 78, 203, 425, 435 

Koh, E 1181, 1226, 1247 

Koh, MX 1018 

Kohane, I 1683 

Köhlin, L 1562 

Kohno, M 2070 

Kohrt, WM 2408 

Kohsaka, H 1938, 1952 

Koido, N 1333 

Koike, R 98 

Koike, T 1312, 1324, 1325 

Koike, T 113, 1012, 1989, 1990 

Kojima, M 877 

Kojima, T 2314, 2465 

Kokkonen, H 439 

Koldobskaya, Y 689 

Kolfenbach, JR 1463 

Kolhatkar, N 2580 

Kollerup, G 361, 363 

Kolta, S 2110 

Komocsar, W 1276 

Komocsar, WJ 1315, 1321 

Komuro, Y 1282 

Koncz, T 2486 

Kondo, M 1634 

Kondo, Y 518, 2075, 2288, 2315, 

2529 

Kondos, G 1429, 1430, 2238 

Kone-Paut, I 2015, 2024, 2032 

Kong, HH 206 

Kong, KO 2278 

Kong, PL 1796 

Kono, H 184, 2372 

Kono, M 2460 

Konstantellis, L 2404 

Kontush, A 1256 

Koo, BS 1784, 2250 

Koo, BS 354 

Koolwijk, P 1599 

Koontz, D 217, 230, 756, 1945, 

1949, 1950 

Koopman, FA 451 

Koos, B 1164, 2026 

Kopec, JA 2462, 2568 

Korb-Pap, A 1638, 1779 

Korchynskyi, O 737 

Korean Observational Study 

Network for Arthritis (KORONA), 

1247 

Korendowych, E 1357 

Koretzky, GA 519 

Korevaar, JC 52 

Korhonen, R 882, 1095, 2520 

Korkosz, M 1307 

Korn, LL 2346 

Kornyat, T 124 

Korotkova, M 1946 

Kosco-Vilbois, M 752 

Kosinski, M 1411, 2236 

Koskas, F 2365 

Koskinen, A 2520 

Kosmac, M 2598 

Kostik, M 1172 

Kostine, M 1302 

Kostman, J 174 

Kosutic, G 1643 

Kotak, S 81, 368, 865, 1827, 1842, 

1848 

Kotha, R 1761 

Kothari, KK 1121 

Kotisalmi, E 1920 

Kotkin, S 2572 

Kötter, I 844 

Kottgen, A 101 

Köttgen, A 1630 

Kottyan, LC 843, 1606 

Koumpouras, F 2619 

Koutsilieris, M 991, 2181 

Kowal, K 2292, 2298 

Kowal-Bielecka, OM 1713, 2292, 

2298 

Kowalczuk, O 2298 

Kowalski, M 79 

Koyama, Y 1328 

Koyano, S 1314, 2117 

Kozaci, DL 565 

Kozu, KT 277 

Krabben, A 894 

Kracht, K 764 

Kraft, P 2279 

Kragsnæs, MS 1877 

Kral, MC 286 

Kramer, I 346

Kramers-de Quervain, IA 1669 

Krammer, G 1911 

Krammer, G 144 

Krantz, E 833 

Krasnokutsky Samuels, S 1250 

Krasowska, D 2298 

Krastins, B 735 

Kratz, A 1581 

Kraus, S 2582 

Kraus, VB 268 

Kraus, WE 268, 1228 

Krause, D 359 

Krause, DM 357 

Krause, K 1307 

Krause, L 600 

Krause, ML 1392 

Krausz, S 1602 

Kreiger, PA 519, 1058 

Kremer, JM 1277 

Kremer, JM 81, 380, 383, 464, 468, 

491, 829, 865, 1280, 1300, 1640, 

1842, 2051, 2138 

Kretsos, K 1339 

Kretzler, M 1445, 2499 

Kreuter, A 2304 

Kreutz, DE 1851 

Kreuzer, JT 2344, 2508 

Krieckaert, CLM 1832 

Krieg, MA 1961 

Krintel, SB 433 

Krischer, J 1655 

Krishnamurthy, A 31, 1789 

Krishnan, E 156, 157, 706, 816, 

1132, 1690, 2412, 2461 

Krishnaswami, S 773, 1277, 2485, 

2490 

Krishnaswami, S 1297, 1697, 2486 

Kristensen, KD 2020 

Kristensen, LE 2169 

Kristensen, LE 463 

Kristensen, L 1254 

Kristensen, SL 1684 

Krivitzky, A 201 

Kroenke, G 347 

Kroese, F 514, 516 

Krogh, NS 1271, 2227, 2558 

Krogh, T 959 

Krol, P 1674 

Kronke, G 903, 1072 

Kronthaler, U 2153 

Kroon, HM 1100 

Krueger, GG 2218 

Krueger, JG 2491 

Krug, HE 2091 

Kruize, AA 509, 510, 2196, 2551 

Krumbholz, G 890 

Krummel-Lorenz, B 2217 

Krumsiek, J 1630 

Kruse, K 2080 

Ku, BS 1219, 2182 

Ku, BS 215, 1952 

Ku, J 552 

Kubassova, O 1042, 1045 

Kubilay, Z 2371 

Kubo, S 771, 2150, 2162 

Kubota, T 1163 

Kudo, T 1043 

Kudo-Tanaka, E 194 

Kuemmerle-Deschner, JB 2015 



Kuh, D 800 

Kuhn, K 1662 

Kuijpers, TW 1021, 2019 

Kulakodlu, M 378 

Kuller, L 2116 

Kumabe, M 2273 

Kumagai, S 410, 418, 707, 1298, 

2280 

Kumanogoh, A 500 

Kumar, AA 2273 

Kumar, A 1589 

Kumar, T 58, 59 

Kumar, V 1525 

Kume, K 444, 445, 1343, 2156 

Kunjeer, V 58, 59 

Kunkel, GA 105, 1287 

Kuno, M 2310 

Kuntz, K 1854 

Kunugiza, Y 500, 1084 

Kuo, CF 583, 814, 1182, 1549, 

2277, 2673 

Kuper, IH 2607, 2637 

Kupper, H 487, 764, 775, 995, 

1303, 1304, 1678 

Kurasawa, K 1918 

Kurasawa, T 473 

Kurien, BT 670, 677 

Kurita, M 1084 

Kurita, T 98, 2460 

Kuritani, T 1569 

Kuriya, B 2610 

Kurko, J 1061 

Kuroda, T 1532 

Kuroiwa, T 1296 

Kuroiwa, T 1367 

Kurokawa, M 182, 1531 

Kuroki, K 1729 

Kurosaka, M 1973 

Kurowska-Stolarska, M 881, 1910 

Kurreeman, F 973 

Kurzinski, K 319, 2036 

Kusaba, A 415 

Küseler, A 2020 

Kusunoki, N 1520 

Kusunoki, Y 1520 

Kutty, S 293 

Kuwaba, N 444, 445, 1343, 2156 

Kuwana, M 455, 850, 1186, 1459, 

1937, 2119 

Kuwano, Y 708, 1521 

Kvarnstrom, M 1773 

Kvien, TK 69, 90, 376, 395, 404, 

501, 1111, 1180, 1835, 1844, 1845, 

2560, 2561, 2660 

Kvist, P 2080 

Kwan, C 388 

Kwan, L 1564, 1565, 2698 

Kwoh, CK 239, 243, 249, 250, 251, 

252, 698, 908, 909, 1029, 1030, 

1031, 1128, 2433, 2467, 2469, 

2470 

Kwok, R 1415 

Kwok, SK 1745 

Kwok, SK 664, 2258, 2381 

Kwon, H 331 

Kwon, YJ 443 

Kyburz, D 1669 

Kydd, A 1908 

Kyndt, X 1656 

Kyogoku, C 686, 979 

Kyriakidis, NC 507, 508 

La Cava, A 2325 

La Monica, N 1068 

La Torre, F 1676, 2016, 2018 

Laavola, M 882 

Labitigan, M 949 

Labrecque, J 2475 

Labroquère, K 600 

Lacaille, D 1642, 1722, 2405, 2568 

Lacerda, AP 486 

Lachaine, J 457 

Lachenbruch, PA 282, 291 

Lachmann, HJ 748, 749 

Lacomis, D 230 

Lacraz, A 1622 

LaCroix, A 1995 

Lada, F 2058 

LaFace, D 725 

Lafaille, J 1930 

Lafeber, FPJG 509, 510, 1064, 

1122, 1786, 1788, 2125, 2196, 

2335 

Lafeber, FPJG 1832 

Lafleur, J 922 

Laforgue, P 2472 

Lafyatis, R 1516 

Laheurte, C 1756 

Lahey, LJ 1690 

L 

Lai, Z 517 

Lai, ZW 2498 

Laiguillon, MC 13 

Lainez, B 2333 

Lajeunesse, D 730 

Lakhanpal, A 685 

Lakos, G 2455 

Lale, R 142 

Lam, C 1069 

Lam, KH 1048 

Lam, MY 2174, 2192, 2193, 2672 

Lamas, JR 990, 1006 

Lambert, M 2459 

Lambert, PH 1820 

Lambert, RG 38, 542, 548, 577, 

578, 591, 592, 778, 1024, 1028, 

1033, 2210, 2615 

Lambert, S 1155, 2005 

Lamberth, S 2165 

Lambotte, O 641 

Lan, Q 1079 

Lanata, L 263 

Lanciano, E 356 

Lancioni, E 1268 

Land, J 860 

Landewe, R 469, 574, 977, 1334, 

1908, 2118, 2225, 2579 

Landewé, R 495, 563, 572, 576, 

1015, 1023, 1698, 2222 

Landewé, RBM 397, 558, 777, 

1014, 1078, 1363, 1705, 2342, 

2546 

Landi, M 1356 

Landolt-Marticorena, C 674, 2256, 

2323, 2683 

Landon, JE 1873 

Landsittel, DP 1253 

Landsman, T 1810 

Lane, NE 821, 982, 2468 

Lanfranchi, H 2174, 2672 

Lang, V 1010 

Langdahl, B 1971 

Lange, E 2219 

Langefeld, CD 313, 843, 846, 970, 

974, 1613, 1614, 2274, 2279, 2283, 

2284, 2657 

Langenberg, P 258 

Langer, HE 129 

Langfeld, CD 729 

Langford, CA 1537, 1544, 1653, 

1655, 2391, 2397, 2567 

Lanni, S 1158, 1172 

Lannon, CM 2042 

Lao, L 258 

Lao, WS 1887 

Laor, A 547 

Lapa, AT 299, 300, 1416 

Lapeyre-Mestre, M 2384 

Lapinska, A 2292 




380 

Larche, M 1016, 1018, 1052, 2100 

Larcombe, L 1179 

Laria, A 1486 

Larida, B 2128 

Larroca, V 1632 

Larroche, C 2188 

Larson, RJ 1974 

Larsson, I 1559 

Larsson, P 776 

Laskin, CA 1650 

Laskosz, 1896 

Laskosz, L 2012 

Lasky, A 2597 

Lassen, E 439 

LaStant, J 1741 

Latorre, M 1546 

Lau, AN 1018, 1979 

Lau, CS 393 

Laufer, TM 2346 

Laughlin, S 295, 2478 

Launay, D 195 

Laura, D 2658 

Laurent, DD 574 

Laurent, V 1618 

Laurie, C 2672 

Laurindo, I 173, 2064 

Lauterio, T 1912 

Lauwerys, B 1335, 2548 

LaValley, MP 794 

Lavan, BE 1632 

Laven, JSE 1240 

Law, A 101 

Law, G 2569 

Law, WG 2278 

Lawrence, N 985 

Lawrence Ford, T 2102 

Lawson, EF 276, 298 

Lawson, V 969 

Laxer, RM 284, 1171, 1886, 2008, 

2027, 2029, 2044, 2601 

Lazarevic, D 1154 

Lazaro, DM 1883 

Lazarou, I 482 

Lazzari, AA 1985 

Lazzaroni, MG 1523 

Le, C 755 

Le Bailly De Tilleghem, C 727 

Le Bars, M 460, 810, 811, 2159 

Le Bars, M 2163 

Le Bidois, J 1649 

le Cessie, S 1330 

Le Guern, V 641, 2188, 2554 

Le Loët, X 396, 1309, 1313, 1783, 

1849 

Le Loet, XX 830, 1308, 2168 

Le Marshall, KF 269 

Le Riche, NGH 1825 


Leandro, M 652 

Leandro, MJ 502, 1757, 1758 

Learch, TJ 542, 782 

Leary, B 338 

Leavitt, F 1863, 1878 

Leberruyer, PY 1656 

Leboime, A 597, 598 

LeBras, E 120, 1047, 2378 

Lebray, P Sr. 1657 

Lebre, MC 1066 

Lebre, MC 1338, 2090, 2336 

Leclerc-Jacob, S 1618 

Leclercq, S 2063 

Lecluze, Y 2321 

Lecompte, T 1740 

Ledbetter, JA 1446 

Lederman, H 1041 

Lederman, S 960 

Leduc, R 868, 1528, 2428 

Lee, A 874 

Lee, A 453 

Lee, AT 975 

Lee, CH 884, 1962, 1968 

Lee, CK 1784, 2250 

Lee, CK 354 

Lee, C 629 

Lee, CH 447, 490, 1276, 2487, 

2488 

Lee, CK 1247 

Lee, CK 78 

Lee, D 1671 

Lee, DYW 258 

Lee, EB 1284 

Lee, EB 99, 1188, 1219, 1282, 

1952, 2182, 2385, 2486 

Lee, EY 215, 1188, 1219, 1952, 

2182, 2385 

Lee, EG 884 

Lee, E 42 

Lee, H 967, 1236 

Lee, HS 1327 

Lee, HS 78, 348, 967, 1210, 1247, 

1882 

Lee, HW 62 

Lee, I 839 

Lee, JH 664, 2258 

Lee, JH 2381 

Lee, JS 21 

Lee, J 78, 425, 435, 1181, 1226 

Lee, J 664, 2258 

Lee, JL 2475 

Lee, JH 967, 1882 

Lee, J 1589 

Lee, J 78, 1247 

Lee, JY 1219 

Lee, JH 1013 

Lee, JA 291 

Lee, J 242, 243, 919, 1588 

Lee, KL 388 

Lee, K 1081 

Lee, K 666 

Lee, KH 1915, 2122 

Lee, KH 406 

Lee, KW 1210 

Lee, KE 1433, 2249 

Lee, L 133 

Lee, M 943, 946 

Lee, MS 884 

Lee, P 322 

Lee, R 1512 

Lee, R 610, 682 

Lee, SH 1889 

Lee, SH 39, 1247 

Lee, SH 643, 1262 

Lee, SI 340 

Lee, SW 443, 1327, 2680 

Lee, SJ 295, 951, 1739 

Lee, SY 21 

Lee, S 1013 

Lee, SS 78, 967, 1247, 1433, 1882, 

2249 

Lee, SK 62, 443, 2680 

Lee, SK 1327 

Lee, SW 78 

Lee, SH 1761 

Lee, SJ 1063 

Lee, SJ 917 

Lee, TL 2040 

Lee, TC 762 

Lee, YA 78, 643, 1262, 1882 

Lee, YM 1219 

Lee, YH 409, 2267 

Lee, YY 1252 

Lee, YJ 1797, 2385 

Lee, YC 954, 1230, 2426 

Leeder, JS 2597 

Leeder, JS 1151 

Leesch, D 1004 

Leese, J 1722, 2430, 2434, 2447 

Lefevre, G 1852 

Leffers, H 1271 

Legare, J 384 

Legault, C 2534 

Legendre, M 311 

Léger, JM 1622 

Legerton, C III 462 

Lehane, PB 459, 1280, 1694 

Lehman, AJ 493 

Lehman, TJA 621 

Lehmann, K 1760 

Lehr, A 4, 890, 891 

Leib, ES 1970, 1987 

Leighton, P 1820 

Leipe, J 407, 1500 

Leirisalo-Repo, M 1286 

Leiss, H 1070 

Lemaire, R 784, 1498 

Lemeiter, D 2505 

Lemelle, I 2024 

Lemire, L 2051 

Lemonnier, I 1134 

Lems, WF 1982 

Lems, WF 358, 469, 1330 

Lems, WF 266, 353, 1125, 1832 

Len, C 2657 

Len, CA 1160 

Lenaerts, J 549, 779, 1365 

Leng, L 875 

Leo, P 595, 1612 

Leo-Summers, L 2444 

Leon, EP 2195, 2500, 2530 

Leon, G 462 

Leonard, MB 1221 

Leonard, WJ 1513 

Lepley, D 454 

Lepore, L 2021 

Leport, C 225 

Lepri, G 1485 

Lepse, N 860 

Lequerré, T 485, 1783, 2024 

Lerchbaum, E 2312 

Lerman, MA 279 

Lerner, V 1090 

Lertratanakul, A 1429, 1430 

LeSage, D 1468 

Lesende-Rodriguez, IA 7 

Lessa, M 296 

Lessard, CJ 523, 524, 525, 2203, 

2671, 2674 

Lessard, JA 523, 524, 525, 2671, 

2674 

Leszczynski, P 2545 

Letho-Gyselinck, H 1362 

Letschert, K 553 

Leu, JH 1293 

Leung, A 269, 727 

Leung, AM 393 

Leung, AYF 2447 

Leung, B 70 

Leung, BPL 2278 

Leung, I 1761 

Leung, YT 2268 

Leunig, M 1116 

Levarht, N 1771 

Levesque, K 293, 1649 

Levesque, MC 56, 207, 756, 1253, 

1598, 1853, 1945, 1949, 1950, 

2127, 2619 

Levin, SD 1796 

Levine, A 969 

Levine, AB 1733, 1891

Levine, J 1515 

Levine, SM 2395, 2398 

Levine, T 969 

Levine, Y 451 

Levis, B 2422 

Levy, AR 746 

Levy, A 534 

Levy, B 2650 

Levy, DM 280, 294, 1739 

Levy, O 193 

Levy, RA 96 

Levy, RA Sr. 614, 615, 927 

Levy Neto, M 2195 

Lew, R 1287 

Lewallen, D 1096, 2445 

Lewandowski, L 2033 

Lewiecki, EM 1995 

Lewis, CE 794, 799, 1032 

Lewis, CE 796, 1098, 1104, 1119 

Lewis, C 1086, 1087 

Lewis, DM 523, 524, 525, 2203, 

2674 

Lewis, EE 1404 

Lewis, H 2071 

Lewis, J 374 

Lewis, M 1718 

Lewis, P 1460, 2628 

Lewis, W 616 

Lexberg, S 1835, 2560, 2561 

Leyva, AL 2060 

Lheritier, K 759 

Lhomme, M 1256 

Li, A 2085 

Li, C 1386, 2663 

Li, C 261 

Li, D 855 

Li, E 1693 

Li, G 1595 

Li, H 2677 

Li, H 523, 524, 525, 2203, 2671, 

2674 

Li, J 2622 

Li, J 331 

Li, J 624, 940 

Li, J 1409 

Li, J 33, 2152, 2575, 2677 

Li, LC 1007, 1103, 1722, 2405, 

2430, 2434, 2447 

Li, L 1027 

Li, L 2233 

Li, M 2329 

Li, N 429, 2269 

Li, N 2311 

Li, R 984 

Li, S 569, 2557, 2562 

Li, S 2234 

Li, SC 124, 2008, 2029 

Li, T 674 

Li, W 2664 

Li, W 1085, 1086, 1087, 1585, 

2651 

Li, W 1827 

Li, X 636, 687, 1192, 1409, 1646 

Li, X 663 

Li, X 2583, 2584 

Li, X 663 

Li, X 2326 

Li, YH 2092 

Li, Y 684, 712, 1470, 1747, 1956 

Li, YT 326 

Li, ZG 2088, 2176 

Li, Z 1065 

Li, Z 2295 

Li*, W 2130 

Liang, J 1522 

Liang, KP 905, 1253 

Liang, MH 753 

Liang, M 1497 

Liang, P 769 

Liang, WM 477 

Lianza, AC 533 

Liao, J 857 

Liao, KP 981, 1683, 1821 

Libanati, C 824, 1961 

Liburd, NL 2421 

Lichuaco, JJ 2572 

Lidar, M 193 

Lidar, Z 955 

Liddle, J 2071 

Lidove, O 1656 

Lidtke, RH 262, 264, 265, 1105 

Lie, BA 1180 

Lie, E 376, 395, 404, 501, 1835, 

2560, 2561, 2609 

Lieberman, SM 519 

Lieberthal, JG 2397 

Liebhaber, A 365 

Liebling, MS 124 

Liedmann, I 1153 

Lienesch, DW 2049 

Liew, D 1836 

Liggitt, D 1446 

Lilleby, V 1681 

Lillegraven, S 501, 2061, 2660 

Lim, AR 338 

Lim, E 2262 

Lim, JE 2270 

Lim, JH 2442 

Lim, KK 269 

Lim, LSH 951 

Lim, MK 417, 584, 971 

Lim, SS 935, 945, 2695 

Lim, SY 2442 

Lima, CS 2396 

Lima, G 513 

Lima, I 177 

Limacher, A 1116 

Limal, N 1652 

Limaye, VS 205 

Limburg, PC 1533, 2393 

Lin, G 2599 

Lin, H 901 

Lin, H 25, 44 

Lin, J 1930 

Lin, K 331 

Lin, LL 1081 

Lin, NY 1505 

Lin, NY 2517 

Lin, SL 831 

Lin, T 1854 

Linan, MK 688 

Lindau, D 844 

Lindblad, S 1571 

Linde, L 1684 

Lindegaard, HM 361, 363, 2558 

Lindell, K 217 

Lindhardsen, J 1684 

Lindop, R 2676 

Lindquist, JH 795 

Lindqvist, E 894 

Lindqvist, E 73, 776, 2137 

Lindsley, HB 1131 

Lindwall, E 1195 

Lingala, B 706, 1132, 1953, 1954 

Link, TM 2583, 2584 

Linsenmeyer, KD 1114 

Lintner, KE 1948 

Liphaus, B 2282 

Lipman, TH 760 

Lippuner, K 1959, 1961 

Lipson, A 1261 

Lipstein, EA 2042 

Lira, FS 2652 

Lisanti, MP 2295 

Lisse, JR 2172 

Listing, J 365, 571, 780, 1703, 

2219, 2229, 2235 

Litinsky, I 611 

Little, M 1525 

Littlefield, MJ 2157 

Littlejohn, GO 387, 957, 1881, 

2140 

Liu, CC 2699 

Liu, CC 2061 

Liu, C 1930, 2149 

Liu, F 2468 

Liu, H 280 

Liu, J 287, 931, 1665, 1687, 2600 

Liu, K 1664 

Liu, L 1517, 2289 

Liu, L 1960 

Liu, MF 326 

Liu, P 1663 

Liu, Q 2300 

Liu, Q 1497 

Liu, R 1136 

Liu, R 1192 

Liu, S 2310 

Liu, S 1015, 1303, 1304 

Liu, S 2269 

Liu, X 2387 

Liu, X 852, 1474, 1475, 2290 

Liu, X 517 

Liu, X 2329 

Liu, Y 1919, 2503 

Liu, Y 1808, 2653 

Liu, Y 986, 2419 

Liu, ZA 244 

Liubchenko, G 1765 

Liufu, C 1260 

Livingston, D 1810 

Livingston, SE 176 

Ljung, L 2145 

Llorca, J 1205 

Llorens, V 185 

Llorente, L 513 

Lloyd, A 488 

Lloyd, DC 1573 

Lloyd, TE 222 

Lo, GH 239, 1121, 2512 

Lo, MS 307 

Lo Gullo, A 2351, 2362 

Lo Nigro, A 596 

Lo Re, V 174 

Lo-Ciganic, WH 2433 

Lobosco, S 2259 

Locher, JL 920 

Lockshin, MD 1650, 1733, 1736, 

1891, 2458 

Lockton, S 1931 

Lodi Rizzini, S 1472 

Loef, M 1097, 2538 

Loeffelholz, MJ 1405 

Loell, IM 1946 

Loeppenthin, K 2689 

Loeser, RF 9, 731, 2534, 2536 

Loeuille, D 544, 1033, 1309, 1618, 

2110, 2135, 2472 

Loft, AG 580, 2558 

Logeart, I 830 

Løgstrup, B 1254 

Lögters, T 46 

Loh, C 2340 

Lohan, D 825, 1255, 1686 

Lois-Iglesias, A 1420 

Lojacono, A 1523 

Lojo, L 546 

Lombardi, M 1039 




382 

Lombeida, JI 1850 

Lonati, P 2293 

Long, L 901 

Longson, A 870 

Loo, C 562 

Lood, C 662, 680, 2276 

Lööf, H 1571 

Looney, RJ 1207 

Lopes, JB 921, 923, 2413 

Lopez, JA 2657 

Lopez, LR 2455 

Lopez, M 735 

Lopez de Padilla, C 207, 658, 1935 

Lopez-Colombo, A 606, 1958 

Lopez-Hoyos, M 2349 

López-Lasanta, MA 980, 998, 999, 

1237 

López-Longo, FJ 1424 

López-Longo, FJ 2239 

Lopez-Longo, J 1427 

López-Mejías, R 1205 

Lopez-Pedrera, C 1211, 2272 

Lopez-Reyes, A 127 

Lopez-Robledillo, JC 123 

López-Vives, L 1373 

Lorant, A 1748 

Lorcerie, B 1740 

Lorenz, HM 460 

Lorenzen, T 79, 1271 

Lorenzi, AR 103 

Lorenzin, M 596 

Loricera, J 1140, 1548, 2388, 2389 

Lories, R 2615 

Lories, RJ 982 

Lortholary, O 201 

Losina, E 238, 735, 910, 911, 1090, 

1983, 2650 

Lotz, MK 28, 988, 2645 

Louder, AM 163 

Lough, KM 2283 

Louie, GH 222 

Louie, JS 2491 

Louis-Plence, P 2505 

Lourenco, E 629, 1709, 2451 

Lourido, L 988 

Louw, I 471, 472 

Love, T 2559, 2614 

Loveless, JE 1280 

Lovell, CR 1346 

Lovell, DJ 759, 760, 761, 764, 

1141, 1597, 1679, 2011, 2593, 

2594, 2601 

LoVerde, ZJ 2479 

Lovy, MR 1929 

Low, AS 828, 1593 

Low, C 2056, 2170 

Low, YC 1515 


Low Horn, C 2063 

Lowes, M 1808 

Loza, E Sr. 211, 1378 

Loza Cortina, E 461 

Lozada, CJ 1543 

Lozano, E 859, 2352 

Lu, B 745, 937, 976, 1230, 1608, 

1821, 1843, 2062 

Lu, C 986 

Lu, G 1075 

Lu, H 198 

Lu, JD 1620, 2218 

Lu, J 812, 1292, 1301, 1826 

Lu, L 1646 

Lu, PY 1606 

Lu, Q 2269 

Lu, TT 2308 

Lu, TT 1404 

Lu, X 1940, 1943, 1944, 1951 

Lu, Z 687 

Lubatti, C 1472 

Lubbers, J 2668 

Lubberts, E 1793, 2338 

Lubrano, E 1818 

Luca, N 1168 

Lucas, J 798 

Lucas, M 1714, 1945 

Lucena, J 1266 

Lucero, E 479 

Luchi, ME 2487, 2488 

Luciano, N 126, 529, 1546, 2183 

Lucier, S 1830 

Luckey, D 1636 

Lucman, A 1632 

Lucron, H 1649 

Ludivico, CL 2545 

Luedtke, CA 962, 1866 

Lugli, EB 1200 

Lui, LY 819 

Luijtens, K 503 

Luime, JJ 768, 1048, 1560, 1570, 

2095, 2226 

Lukas, C 396, 566 

Lukkahatai, N 1874 

Lumb, S 1750 

Lunardi, C 2303 

Lund, OI 1899 

Lundberg, IE 208, 229, 233, 753, 

1555, 1587, 1673, 1946 

Lundberg, K 31, 1769 

Lundsgaard, D 653 

Lundy, SK 1743 

Luneburg, P 744 

Lunt, M 767, 828, 1593, 1651, 

2544 

Luo, B 2575 

Luo, J 2087 

Luo, S 2269 

Luo, SF 583, 814, 1182, 2277, 2673 

Luo, Y 426 

Luo, Y 2466 

Luo, Z 1290 

Luong, M 1081 

Luong, ML 2432 

Lupash, D 2049 

Lupus Nephritis-ESRD Consortium, 

729 

Luqmani, R 1525 

Lurati, A 246 

Luster, AD 1661 

Lutalo, PMK 2319 

Luthra, HS 1636 

Lutt, JR 1817 

Lutteri, L 43 

Lux, G 1618 

Luz, KR 104, 808 

Lübbeke, A 248, 1091 

Lügering, A 1779 

Lüring, C 118 

Lyles, M 2534, 2536 

Lyman, SL 694, 1108, 1465, 1715, 

1733, 2649 

Lynch, JA 1032, 1104, 2468, 2512 

Lyon, K 24 

Lyons, K 1986 

Lyubchenko, T 1765 

M 

Ma, JD 2092 

Ma, T 429 

Ma, Y 2300 

Ma, Y 963 

Maas, M 1021, 2019, 2342 

MacBride, A 1808 

Macchioni, P 2347, 2351, 2362 

MacDermott, EJ 621 

Macdonald, C 2447 

MacDonald, D 1572 

MacDonald, PA 153 

Macfarlane, GJ 601, 966, 1161, 

1525 

Machado, FS 102, 807 

Machado, LG 921, 923 

Machado, LSG 2396 

Machado, NP 452 

Machado, P 232, 563 

Macharoni, LM 2028 

Machida, T 1442 

Machold, KP 109 

Macias, W 2487, 2488, 2653 

Maciuca, R 620, 2622 

MacIver, H 474 

Mack, M 1292, 1301, 1826 

Mack, WJ 2194 

Mackay, M 656, 2572 

Mackay, MC 649, 2619, 2687 

Mackey, R 2116 

Mackie, I 1725 

Mackie, S 1924 

MacMullan, PA 1239, 2348, 2382 

MacPherson, KE 2434 

Madaio, MP 2345 

Madary, J 1498 

Madaule, S 195 

Madeo, A 2476 

Madger, L 604 

Madigan, AM 1239, 2348, 2382 

Madsen, OR 1026, 1616 

Maeda, A 223 

Maeda, K 1296, 1569 

Maekawa, T 2070 

Maenaka, K 1729 

Maestre, M 1659 

Maetzel, A 150, 1633 

Maeyama, K 2310 

Maezawa, R 1918 

Magder, LS 640, 1389, 1390, 1396, 

1648, 1708, 1710, 2569, 2571 

Magee, AI 848 

Magee, K 319 

Magnani, L 2362 

Magner, RP 464 

Magnusson, PK 1615 

Magnusson, S 2145 

Magrey, MN 559 

Magro, C 694, 1715 

Magro Checa, C 1264, 2215, 2216 

Maguire, C 512 

Magy-Bertrand, N 1740 

Mahadevan, U 1643 

Mahajan, A 58, 59 

Mahajan, V 1752 

Mahendira, D 1888, 2224 

Mahendranath, K 58, 59 

Maheswaranathan, M 1892 

Maheu, E 1109 

Maheu, E 1110, 2472 

Mahieu, MA 2238 

Mahler, M 713, 1391 

Mahmood, Z 1762 

Mahowald, ML 2091 

Mahr, A 1820, 2564, 2565 

Mai, B 1209 

Maier-Moore, JS 670, 2203 

Maisonobe, T 225 

Majgaard, O 361, 363 

Majithia, V 1981, 2220 

Majka, DS 1664 

Major, GA 1720 

Majumdar, S 1991

Makino, H 1535 

Makino, K 2286 

Makino, T 2286 

Makol, A 1235, 1552, 2481 

Makris, UE 2444 

Maksimowicz-McKinnon, K 2391, 

2397 

Maksymowych, WP 38, 534, 542, 

548, 556, 568, 575, 577, 578, 591, 

592, 746, 777, 778, 977, 1024, 

1025, 1028, 1033, 1376, 1381, 

1705, 2118, 2210, 2579, 2615 

Malah, V 1256 

Malaise, D 43 

Malaise, MG 43, 50 

Malaise, O 43, 50 

Malamet, RL 170, 1913 

Malattia, C 2476 

Malaviya, AP 1306 

Malchus, AM 554 

Malcus-Johnsson, P 1562 

Maldini, C 2564 

Maldonado, M 2547 

Maldonado, MA 1340, 1342, 2449 

Maldonado Ficco, H 60 

Maldonado-Cocco, JA 579, 1356 

Maldonado-Ficco, H 579, 1356 

Maleki-Fischbach, M 237, 2179 

Malfait, AM 734 

Malheiro, OB 2261 

Malheiros, DM 2500 

Malik, A 230, 2049 

Malik, F 355 

Malin, K 957 

Malmström, V 31, 1208, 1615, 

1769, 2130, 2578 

Malone, DG 2592 

Malone, M 124 

Maloney, A 1750 

Maloney, C 1722, 2405 

Malpeso, J 1251, 1685 

Malspeis, S 442, 976, 1605, 1609 

Maltret, A 293, 1649 

Malul, G 2595 

Malvar Fernandez, B 1602 

Malvin, NP 1662 

Malysheva, O 1218, 1408 

Mamchaoui, K 1674 

Mammen, AL 222, 1953 

Mamoto, K 113, 1012, 1989, 1990 

Mamyrova, G 282, 291 

Man, A 742, 849, 2614 

Manara, M 167 

Mandell, BF 1909 

Mandhadi, R 1538 

Mandl, LA 1093, 1108, 1712, 2443, 

2479, 2573, 2649, 2650 

Mandl, P 109, 111, 335, 2081 

Mandl, T 2177, 2202 

Mangalam, A 1636 

Manger, B 1010 

Manheim, L 243 

Mani, V 1250, 1263 

Maniaci, B 8 

Manieri, NA 1662 

Maniu, A 1922 

Mankee, A 1648 

Mann, AD 2483, 2640 

Mann, HF 2123 

Manning, G 321 

Manning, J 1477 

Manning, VL 2050, 2439 

Mannion, AA 1669 

Mannion, ML 763 

Manno, RL 697, 2395, 2398, 2480 

Manoharan, AP 2279 

Manoussakis, MN 507 

Manrique-Arija, S 1237 

Mansi, I 1824 

Mansour, A 1082 

Manu, A 1463 

Manz, RA 1449 

Manzi, S 1417, 1711, 2241, 2570, 

2699 

Maoulida, H 1830 

Marak, R 1054 

Marangoni, RG 2294 

Maranian, P 1050 

Maranian, P 93, 391, 1464 

Maratha, A 2353 

Marcelli, C 1309 

March, L 254, 2535 

Marchesoni, A 1818 

Marchetti, S 1197 

Marchi, S 177 

Marcos, J 60, 2141 

Marcos, JC 60, 2141 

Marcuz, J 1171 

Mardekian, J 1848 

Marder, W 1437, 2067 

Marenco, JL 980, 1424 

Margaretten, M 247, 1822, 2411 

Margolis, P 2601 

Marguerie, L 1895 

Margulis, A 12 

Marhadour, T 2197 

Maria, NI 528 

Mariampillai, K 220 

Marie, I 220, 1622, 2015, 2383 

Marie, SKN 1939 

Marietta, E 1636 

Mariette, X 351, 479, 503, 593, 

830, 1308, 1309, 1310, 1313, 1622, 

1699, 1830, 2129, 2168, 2188, 

2189, 2321, 2551, 2554, 2555, 

2671 

Marijnissen, ACA 1122 

Marin, C 1427 

Marin, J 1358 

Marinho, A 1483 

Marini, R 299, 300 

Marino, L 60 

Mariñoso, L 1967 

Marion, MC 313, 843, 1614, 2284 

Marjanovic, EJ 271 

Märker-Hermann, E 1703 

Markovitz, D 311 

Markt, J 89 

Markward, N 1978 

Maron, DD 149 

Marotta, A 568, 977, 2118, 2579 

Marra, CA 93 

Marras, C 461 

Marras, C 1424, 2239 

Marrazza, M 246 

Marri, R 202 

Marrie, RA 939, 2541 

Marroquín, M 2244 

Marsal, S 980, 998, 999, 1001 

Marshall, L 1285, 2661 

Marshall, T 767, 2544 

Marsolo, K 2601 

Martel-Pelletier, J 730, 1118, 1120, 

1124 

Martin, C 338 

Martin, DA 1294 

Martin, J 1000, 1205, 2303, 2304 

Martin, JE 2303 

Martin, KR 800, 2513 

Martin, L 1009 

Martin, RW 382, 1294 

Martin, S 2650 

Martin, TM 190, 595 

Martin Marquez, T 212 

Martín-Esteve, I 1373 

Martin-Mola, E 546 

Martín-Mola, E 1175, 2550 

Martinelli, B 204 

Martinelli, R 1810 

Martínez, C 1378, 1701 

Martinez, F 1211 

Martinez, JE 1880 

Martinez, LA 968, 2204 

Martínez Taboada, V 456, 467 

Martínez-Barrio, J 1427 

Martinez-Estupiñan, L 1427 

Martinez-Godinez, MA 701 

Martinez-Jimeno, C 505 

Martinez-Lavin, M 968 

Martinez-Lopez, J Sr. 211 

Martínez-Morillo, M 1967 

Martinez-Sanchez, AH 11, 48 

Martínez-Taboada, VM 980, 1341, 

2239, 2349 

Martini, A 1679, 2476 

Martini, A 759, 760, 761, 764, 

1158, 1165, 1166, 1172, 1173, 

1597, 2021, 2473, 2477, 2657, 

2658 

Martini, D 529, 1546 

Martini, G 2016, 2021, 2034 

Martins Ramos, MI 2090 

Marx, R 2650 

Marzan, KA 278, 289, 861, 2006 

Marzo-Ortega, H 1346, 1376 

Masatlioglu-Pehlivan, S 187 

Masdar, H 585 

Maselou, K 2181 

Maset, M 2183, 2184, 2185 

Masetto, A 769 

Mashmoushi, A 668 

Mashour, G 801 

Masi, AT 65, 66 

Masi, L 2013, 2014 

Maskeri, B 1611 

Mason, TG II 2008, 2029 

Masri, R 2110 

Massad, C Sr. 1772 

Massarotti, EM 603, 608, 1340, 

2619 

Masse, CE 1062 

Massollo, M 2350 

Mastaglio, C 1472 

Masteller, EL 901 

Masters, S 1910 

Mastrovic, K 479 

Masui, Y 1504 

Masuoka, M 1501 

Mata-Arnaiz, C 1548, 2388 

Mateo Bernardo, I 461 

Mateo-Soria, L 1967 

Mateos, J 7, 988 

Mathai, SC 723, 1463 

Mather, A 2339 

Mathes, A 1516 

Mathews, A 58, 59 

Mathian, A 2459, 2532 

Mathieu, A 356, 498, 599, 1818 

Mathsson, L 411, 412, 439 

Matsubara, T 1289, 1314, 2117 

Matsuda, S 430 

Matsudaira, R 2330 

Matsui, K 183, 2247 

Matsui, K 1281, 1296 

Matsui, Y 399, 948, 2247 

Matsukawa, T 2645 

Matsumoto, I 518, 1635, 2075, 

2079, 2288, 2315, 2529 

Matsumoto, M 1729 

Matsumoto, T 1060 




Matsumoto, Y 899, 2077, 2079 

Matsuno, H 1314, 2117 

Matsuo, K 1591 

Matsushima, K 856 

Matsushita, M 209, 1941 

Matsushita, M 194 

Matsushita, R 36 

Matsushita, T 226 

Matsutani, T 1296 

Matte, U 204 

Mattes-György, K 1040 

Matteson, E 709, 2175 

Matteson, EL 134, 905, 1220, 

1222, 1235, 1248, 1249, 1349, 

1552, 1713, 2198, 2355, 2356, 

2358, 2363, 2481 

Matthias, T 2128 

Mattoo, H 1752 

Matucci Cerinic, M 125, 1039, 

1485 

Matucci-Cerinic, M 167, 696, 853, 

1379, 2013, 2014, 2016, 2017, 

2298 

Maugars, Y 2472 

Maurer, B 1514 

Maurer, K 2268 

Maurier, F 1652 

Maurouard, T 1629 

Mautz, AP 1036 

Mavragani, CP 233, 991, 2181, 

2199 

Maxwell, JR 362, 985 

Maxwell, JL 1553 

Mayan, MD 41 

Mayer, F 204 

Mayer, L 1930 

Mayes, MD 92, 852, 1464, 1474, 

1475, 1509, 2290, 2303, 2304 

Maynard, JW 101, 743 

Mayor Gonzalez, M 1933 

Mazet, AA 1310 

Mazieres, B 1115 

Mazumder, A 1965 

Mazur, M 2489 

Mazurov, V 549, 779, 1365 

Mazzaglia, G 1907 

Mazzoni, M 2476 

Mc Bride, P 1667 

McAdams DeMarco, M 101, 743, 

2192, 2193 

McAlear, C 868, 1528, 1655, 2428 

McAlindon, T 745 

McAlindon, TE 239, 964, 1121, 

2512 

McBride, D 1853 

McBride, E 202 

McBride, JM 620, 2622 

McBurney, C 217, 2049 

McCann, A 1986 

McCann, L 759, 761 

McCarthy, CJ 2348, 2382 

McCarthy, EM 2382 

McCarthy, E 260 

McCarthy, E 2348 

McCarthy, EM 610, 682, 2526 

McCarthy, GM 2348, 2382 

McCarthy, GM 1239, 1631 

McCarty, GA 1138 

McCaskill, R 379 

McCaughtry, T 1450 

McCauley, D 2678 

McClanahan, T 725 

McClean, A 1525 

McCleary, S 2071 

McClenaghan, V 1986 

McCloud, P 387 

McClung, MR 824, 1959, 1961 

McConnachie, A 2662 

McCormick, J 2353, 2392 

McCowen, K 1931 

McCracken, C 1155, 2005 

McCune, WJ 1404, 1527 

McCurdy, DK 303, 936, 1170, 1899 

McDaniel, GE 1228 

McDermott, G 1891 

McDonald, FS 2588 

McDonald, G 848 

McDonald-Blumer, H 1888, 2047 

McDonough, E 1375 

McDougall, JJ 2069 

McEachern, J 1978 

McGinnis, JP 1971 

McGinnis, MW 1663, 1803 

McGonagle, D 710 

McGowan, D 89 

McGuckin, M 2492, 2494 

McGuire, MB 2617 

McGwin, G Jr. 604, 671, 1422, 

2263 

McHugh, C 2672 

McHugh, G 1204 

McHugh, KP 33, 2518 

McHugh, N 229, 854, 1346, 1357, 

1484, 1495, 1673 

McHugh, NJ 535 

McInnes, IB 569, 574, 881, 1290, 

1910, 2218, 2225, 2557, 2562, 

2662 

McIntosh, D 693 

McIvor, E 1718 

McKay, HA 1007 

McKay, JD 2621 

McKee, C 338 

McKee, E 1748 

McKeever, K 1760 

McKenna, M 2059 

Mckernan, P 748 

McLaren, J 1525 

McLaughlin, V 851 

McLean, L 153 

McLean, RR 791, 2415 

McLure, KG 341 

McMahan, ZH 719 

McMahon, BJ 176 

McMahon, MA 629, 1252, 1709 

McNamee, K 2327 

McNulty, MA 731 

McQueen, FM 137, 815, 1035, 

1619, 1902, 2585, 2586 

McQueenie, R 881 

McSherry, T 986 

McVeigh, G 1986 

McWherter, CA 1632 

McWilliams, L 453 

Meade, T 1022 

Means, TK 1661 

Mease, P 535, 557, 570, 963, 

1345, 1353, 1857, 1868, 2118, 

2214, 2218, 2613 

Mease, PJ 1354 

Mebus, C 773 

Mebus, CA 2485 

Mebus, CA 1283, 1297 

Mecchella, JN 1573, 1974 

Mech, C 2055 

Medea, G 1907 

Medeiros, DM 1724 

Mediero, A 14, 15, 16, 2516 

Medina, G 1726 

Medina-Chinchon, M 1399 

Medsger, TA Jr. 698, 699, 1714 

Meednu, N 1207, 2666 

Meek, IL 161 

Meekings, A 710 

Meffre, E Sr. 1772, 2578 

Meguro, A 1005, 1611 

Mehbob, A 459 

Mehta, A 328 

Mehta, G 1059 

Mehta, NM 1984 

Mei, HE 1749 

Meijers, JCM 353 

Meijide Failde, R 6 

Meikinian, A 1627 

Meiners, PM 514 

Meini, A 749, 2025 

Mejia, C 1543 

Mejia, JC 1479 

Mekinian, A 195, 2178 

Melander, O 905 

Melchiorre, D 2017 

Melguizo-Madrid, E 538 

Meliconi, R 2362 

Melikoglu, M 2375 

Melikoglu, M 2373 

Melikoglu, MA 2375 

Melissourgaki, M 1436 

Mellins, ED 2657 

Mello, FM 162, 2064 

Melo, M 1266 

Melo-Gomes, JA 1679 

Melton, LJ III 820, 822 

Mendelsohn, A 569, 812, 1292, 

1293, 1301, 1826, 2557, 2562 

Mendelson, CF 2623, 2624 

Méndez-Martínez, S 1958 

Mendlein, J 1671 

Mendoza, J 1901 

Mendoza Pinto, C 606 

Mendoza-Pinto, C 1958 

Menon, S 1697 

Mercer, LK 828, 1593 

Meric de Bellefon, L 1335 

Merino, R 122, 123 

Merkel, PA 92, 279, 868, 1464, 

1524, 1527, 1528, 1529, 1655, 

2363, 2391, 2397, 2428, 2441, 

2567 

Merola, JF 608, 937 

Meroni, PL 675, 1167, 1472, 1523, 

2018, 2293, 2455 

Meroño, T 1256 

Merrihew, K 2053 

Merrill, JT 1418 

Merrill, JT 627, 645, 729, 843, 

1650, 1795, 2283, 2621, 2622 

Merriman, ME 1180, 1628 

Merriman, TR 1180, 1628 

Mersten, JN 1715 

Mertelsmann-Voss, C 2573, 2649 

Mertens, MT 1265 

Merwe, JPVD 528 

Mesdaghinia, S 1037 

Mesquida, M 185 

Messbacher, ME 888 

Messier, SP 2534, 2536 

Messineo, S 2272 

Messing, SP 829 

Messuti, L 679 

Metes, ID 56, 1853 

Metter, J 2395 

Metzler, C 1541 

Meulenbelt, I 1100 

Meurer, L 204 

Meyer, A 2287 

Meyer, I 2153 

Meyer, O 478, 830, 1649, 1699 

Meyer, PWA 1794 

Meyfroidt, S 1561 

Meyhoas, MC 225 

Meysami, A 196 

384 

2012 Program Book

Mia, B 2423 

Miao, Y 1822 

Miceli-Richard, C 593, 2129, 2321, 

2671 

Michael, D 517 

Michaelson, JS 838 

Michaud, K 88, 495, 605, 1698, 

1819, 2068, 2136, 2482 

Michel, BA 419, 437, 438, 892, 

902, 1514, 1781, 2123 

Michels, H 764 

Michet, CJ 1349 

Middleton, JE 1314, 2117 

Midtgaard, J 2689 

Miescher, S 1791 

Miese, F 1040 

Miettinen, A 1920 

Miggin, SM 2353 

Migliorini, P 1577 

Migone, TS 1438 

Miguel, L 848 

Mihalko, S 2534 

Mihu, R 219 

Mikage, H 223 

Mikdashi, J 638, 2386 

Mikecz, K 1061 

Miki, K 1296 

Mikkelsen, K 404, 1835, 2560, 

2561 

Mikolaitis, RA 234, 236, 262, 264, 

1411, 1563, 2236 

Mikuls, TR 26, 27, 72, 89, 402, 

414, 441, 676, 1187, 1270, 1287, 

2093, 2106, 2136, 2334, 2483, 

2543, 2640 

Milad, M 1290 

Milette, K 2424 

Milewski, R 2298 

Miliar-Garcia, A 701 

Miljko, S 451 

Millar, AM 1986 

Miller, A 232 

Miller, DR 1666, 1823 

Miller, E 2512 

Miller, FW 206, 282, 291, 753, 

1037, 1598 

Miller, GD 2534 

Miller, L 720, 721 

Miller, ML 2601 

Miller, PD 1977, 1998 

Miller, PSJ 483 

Miller, RE 734 

Miller, RJ 734 

Miller, SD 2327 

Milligan, A 1035 

Millner, J 2628 

Mills, E 1631 

Mills, K 1631 

Mills, S 2401 

Milman, N 1524 

Milner, A 2080 

Miloslavsky, E 1654 

Mimori, A 659, 683 

Mimori, T 216, 1296, 1936, 1938 

Min, C 399, 948, 2247 

Min, JK 34, 1745 

Min, S 1741 

Min, S 2073 

Mina, R 294, 305, 2474, 2603 

Mina-Osorio, P 1741 

Minardo, G 2034 

Minden, K 1679 

Minden, K 1149, 1152, 1153, 2022 

Miniaci, A 2650 

Minisola, G 167 

Minisola, S 1959 

Minniti, A 192 

Minoda, M 183 

Minoia, F 1166 

Minopetrou, M 1626 

Minor, L 1144, 1157 

Mintsioulis, S 2063 

Miosge, N 1209 

Mirabet, V 22 

Miraglia, J 1999, 2618 

Miranda, P 505 

Miranda, P 479 

Miranda, V 1183, 1513 

Miranda, Y 1761 

Miranda-Carús, ME 1175 

Miranda-Filloy, JA 1205 

Mirel, D 420 

Mirrasoul, N 2466 

Mischler, R 140, 143 

Miserocchi, E 1676 

Misharin, AV 344, 1077, 2679 

Mishima, M 1938 

Mismetti, P 1740 

Misra, D 1098, 1980 

Misra, R 2260 

Mistretta, F 2135 

Mitchell, BD 744, 912, 986 

Mitchell, EF Jr. 1960 

Mitenko, E 1143, 1148 

Mitomi, H 223, 415 

Mitra, A 337, 434, 1185 

Mitraud, SDAV 1160 

Mitsui, H 2491 

Mitta, SJ 1984 

Mittoo, S 1468 

Miura, H 2310 

Miura, N 856 

Miura, T 1314, 2117 

Miura, Y 1569, 1591 

Mix, KS 898 

Miyabe, C 856 

Miyabe, Y 856 

Miyachi, K 1333 

Miyagi, K 1333 

Miyake, S 2330 

Miyaki, S 28 

Miyasaka, N 98, 371, 856, 1289, 

1312, 1324, 1325, 1535 

Miyashita, T 36 

Miyata, S 2084 

Miyazaki, M 708 

Miyazaki, Y 98 

Miyazaki, Y 885, 2313 

Miyoshi, H 1662 

Mizuguchi, K 431 

Mizui, M 2682 

Mizuki, N 1005, 1611 

Mizushima, M 223, 227 

Mladenovic, Z 13 

Mo, YQ 2092, 2115 

Moazedi-Fürst, F 117 

Mociran, E 479 

Moder, KG 950, 1392 

Modesti, M 2184, 2185 

Modesti, V 596 

Modesto, C 123, 2032 

Modi, S 2049, 2127 

Modica, RF 275 

Moehling, K 2435, 2438 

Moeller, B 107 

Moffett, A Jr. 1997 

Moggi Pignone, A 125 

Mohammad, A 825, 1255, 1686 

Mohammadi, S 2700 

Mohan, C 672, 1412, 1447, 2073, 

2679 

Mohan, S 857, 2665 

Mohanta, A 124 

Moharir, M 1739 

Moi, J 1908 

Moi, JH 164 

Moilanen, E 882, 1095, 2520 

Moilanen, T 1095, 2520 

Mojazi Amiri, H 2442 

Mok, CC 224, 388, 637, 651, 1407, 

1410, 1413, 1414, 1415, 1488, 

2251 

Molad, Y 1374 

Molberg, O 231, 1681 

Molberg, 1928 

Moldovan, I 1411, 1759 

Molenaar, THE 394, 469, 2606 

Moll, M 2004 

Moller, B 766, 2228 

Möller, B 2145 

Moller, I 810, 811 

Møller, JM 1026, 1616 

Møller, JM 1042, 1045, 1617 

Möller, S 2574 

Molloy, D 2353, 2392 

Molloy, ES 2348, 2353, 2382, 

2392, 2526 

Molta, CT 945, 2617 

Moltó, A 555, 556 

Momohara, S 392, 400, 1089, 

1831, 1957, 1963, 2143 

Monach, PA 1529, 1655, 2391, 

2397, 2567 

Moncrieffe, H 2654 

Mondéjar-García, R 538 

Mondot, S 2494 

Monette, R 2038 

Monfort, J 1101 

Monrad, SU 2591 

Montagna, P 1493, 2164 

Montanari, E 2293 

Montañés, F 1101 

Montastruc, JL 2384 

Monteagudo, I 123, 1427 

Montealegre, GA 2031, 2653 

Montealegre Sanchez, GA 2000 

Montecucco, C 167, 888, 1523, 

1907, 2111 

Monteiro de Castro, T 1041 

Montes García, S 1264 

Montes-Cortes, DH 701 

Montgomery, CG 523, 524, 525, 

2203, 2671, 2674 

Monti, S 1529 

Montilla, C 998, 999, 1424, 2239 

Montoro Álvarez, M 1427 

Mookherjee, N 1179 

Moon, SJ 34, 436 

Moon, YM 21 

Mooney, S 825, 1255, 1686 

Moons, P 862 

Moore, B 1322 

Moore, CE 1029, 1030, 1031 

Moore, GF 676 

Moore, KF 2596 

Moore, T 1477 

Moore, TL 320, 321, 324, 325, 

2316 

Moore, T 695, 1481 

Moorehead, S 2616 

Moorthy, A 57 

Moorthy, LN 621, 1890 

Moosig, F 2379, 2380 

Moots, R 1069 

Mor-Vaknin, N 311 

Mora, T 968 

Morabito, P 1907 

Moraes, JCB 173, 533, 1999 

Moraes, MT 210 

Moraitis, E 297 

Morales, K 929 




386 

Morales, M 1268 

Morales-Torres, J 446 

Moran, RC 1645 

Morand, E 1798 

Morand, EF 2088, 2257 

Morassi, P 630, 1397 

Morasso, E 2427 

Morbach, H 2578 

Morbelli, S 2350 

Morehouse, C 755, 1675, 1760, 

2681 

Moreira, E 1092, 1233 

Moreira-Navarrete, V 538 

Morel, J 351, 352, 480, 566, 1782, 

2188, 2554 

Morel, N 641, 1649 

Moreland, LW 56, 996, 997, 1203, 

1253, 1853, 2116, 2127, 2136 

Moreno, M 531 

Moret, FM 1064, 1786, 1788, 2335 

Moretti, R 630, 1397 

Morgacheva, O 1050 

Morgan, AW 362 

Morgan, GA 301, 1670, 1948 

Morgan, SL 996, 997 

Morgan DeWitt, EM 288, 1146, 

2011, 2042, 2601, 2603 

Mörgelin, M 661 

Moriguchi, M 1367 

Moriguichi, Y 1637 

Morimoto, A 620, 2622 

Morimoto, C 1600 

Morimoto, S 332 

Morin, F 1124 

Morinobu, A 410, 418, 707, 2280 

Morio, T 856 

Morioka, M 332 

Morita, S 1296 

Morita, Y 2084 

Moriyama, M 2529 

Morlandt, AB 1677 

Morley, MP 987 

Morlock, R 140, 143 

MORMED consortium, 1900 

Morris, M 864, 1558, 1723, 1924 

Morris, PW 1141 

Morris, S 74 

Morrison, M 2494 

Morrison, S 2256, 2688 

Morros, R 270 

Morrow, F 1801 

Morrow, J 232 

Morrow, O 427 

Mortensen, E 1278, 2490 

Mortensen, EM 1824 

Morton, AH 1904 

Morton, LE 601 


Morton, R 1592 

Morvan, J 1115 

Mosca, M 1482, 1523, 2057, 2184 

Moser, KL 2283, 2284 

Moser, K 1449 

Moser Sivils, K 523, 524, 525, 673, 

729, 843, 846, 970, 1613, 2203, 

2551, 2671, 2674 

Mosher, DP 2063, 2417 

Moshref, M 2593, 2594 

Mosley-Williams, AD 2102 

Mosquera Rey, A 993 

Motojima, S 1332 

Motta, F 2368 

Motta, M 1523 

Mouassess, F 420 

Moulin, D 1862 

Moulis, G 1852, 1923 

Moulton, VR 739 

Mountz, JD 2152, 2575, 2677 

Mouritzen, U 1279 

Moussallieh, FM 2287 

Mouterde, G 566 

Mouthon, L Sr. 201, 1545, 1627, 

1652, 1656, 1774, 2563 

Moutsopoulos, HM 507, 508, 991, 

1738, 2181, 2199, 2552 

Mouy, R 1679 

Mowbray, K 1145 

Moyssakis, I 1738 

Mozaffarian, N 379, 468, 486, 764, 

1015, 1678, 2010 

Mozes, E 1456 

Mpofu, C 454, 456 

MrOS Investigators Group, 821 

Msika, P 1780 

Mu, R 1065 

Muangchan, C 1480 

Muckelbauer, R 2022 

Mudano, A 920 

Muehlbauer, M 1228 

Mueller, BA 904 

Mueller, DL 424, 2576 

Mueller, F 110, 2107 

Mueller, GA 1209 

Mueller, R 770, 1102, 2144 

Mueller-Schmucker, S 2163 

Muhammad, K 1762 

Muiños, E 48 

Muiños-Lopez, E 11 

Mukai, M 1289 

Mukhopadhyay, P 595 

Mulani, PM 1242 

Mulder, M 1768 

Mulero, J 1701 

Mulleman, D 2472 

Muller, S 2620 

Mullikin, J 1611 

Mulukutla, SR 1253 

Mumcu, G 2371, 2394 

Munoz, LE 1500, 1502 

Munoz, S 1251, 1685 

Muñoz-Fernandez, S 211, 998, 999 

Muñoz-Ortego, J 781, 2213 

Munro, J 318 

Munroe, ME 645, 673, 740, 1441 

Muntner, PM 2542 

Mura, T 480 

Murad, S 63 

Murakami, A 1938 

Murakami, K 2070 

Murakami, K 1296 

Murakami, S 1532 

Murakami, Y 1324 

Muraoka, S 1520 

Murasawa, A 2094 

Murata, K 430 

Muratore, F 2351, 2358 

Muratore, V 1172 

Murfitt, L 1727 

Murgo, A 1472 

Murphy, C 322 

Murphy, C 2353, 2392 

Murphy, EA 1081 

Murphy, L 2416 

Murphy, R 1346 

Murphy, SN 1683 

Murphy, SL 1581 

Murray, A 695, 1477, 1481 

Murray, F 2578 

Murray, JA 1636 

Murray, L 1498 

Murru, V 1734 

Murtaugh, M 1489 

Murthy, VL 2456, 2457 

Mus, AM 2338 

Muscal, E 280, 1890 

Musenge, E 1794 

Museyko, O 1008 

Mussard, J 844 

Musselman, D 772 

Musselman, M 1815 

Musset, L 220 

Mustelin, T 1659 

Muth, T 944 

Muthana, M 1800, 1801 

Muther, J 1748 

Mwaniki, L 2437 

Myasoedova, E 1249 

Myasoutova, L 549, 779, 1365 

Mydel, P 2083 

Myklebust, G 121, 2390 

Myles, A 309 

Müller, M 118, 120, 128, 1047, 

2378 

Müller, T 2022 

Müller-Ladner, U 4, 272, 696, 851, 

890, 891 

Müller-Nordhorn, J 2022 

Myones, BL 475, 760 

Mysiw, A 242 

Mysiw, WJ 986, 2467 

Mysler, E 462 

Myslinski, R 2065, 2602 

N 

Nab, H 364, 1285 

Nabozny, GH 32, 33, 1196, 2518 

Naden, RP 853 

Nadji, A 2376 

Nafees, B 488 

Naga, OS 1451, 1453 

Nagafuchi, H 223 

Nagahara, H 2070 

Nagai, K 182, 1531 

Nagai, R 700 

Nagai, T 36, 1458 

Nagai, Y 2147 

Nagakura, T 1163 

Nagano, S 1328 

Nagaoka, S 1333, 2046 

Nagaraju, K 1946 

Nagasaka, K 98 

Nagasawa, H 473 

Nagasawa, J 1918 

Naggara, O 1551 

Nagore, D 546 

Nagpal, K 2332 

Nah, SS 967, 1882 

Nahm, M 1934 

Naiman, B 2681 

Nair, A 12 

Nair, P 342, 345 

Nair, RG 2102 

Nair, SC 1832 

Naishiro, Y 1917 

Naka, T 1519 

Nakagawa, N 1591 

Nakagomi, D 112 

Nakahara, H 1296, 1569 

Nakahara, H 28, 2645 

Nakajima, A 392, 400, 1831, 1957 

Nakajima, H 112 

Nakamura, H 1046, 1053, 2112, 

2142 

Nakamura, H 113, 1012, 1989, 

1990 

Nakamura, H 1282 

Nakamura, K 2070 

Nakamura, K 2248 

Nakamura, K 2328

Nakamura, MC 30 

Nakamura, S 2529 

Nakamura, T 1314, 2117 

Nakamura, Y 360 

Nakano, H 182, 223 

Nakano, H 183, 2247 

Nakano, K 3, 1634, 1763 

Nakano, M 1532 

Nakao, T 700 

Nakashima, M 370 

Nakashima, R 216, 1936, 1938 

Nakashima, Y 1046, 1053, 2112, 

2142 

Nakashita, T 1332 

Nakatani, T 1296 

Nakatsue, T 1532 

Nakayamada, S 1634, 2322 

Nalesso, G 40 

Nam, EJ 406, 1267, 2230 

Nam, S 2402 

Namer, IJ 2287 

Namiki, M 1296 

Namiuchi, S 1296 

Namjou, B 843 

Namour, F 1331 

Nangle, L 1671 

Nanki, T 98, 856 

Nannini, C 2175, 2198 

Nantz, EP 1315, 1321 

Naot, D 137 

Napadow, V 803 

Napalkov, P 2093, 2543 

Narang, N 758, 2412 

Narayanan, S 933, 934, 943, 946, 

1856, 2617 

Narazaki, M 500 

Nardi, G 200 

Naredo, E 810, 811 

Narimatsu, S 116 

Narita, H 2074 

Narita, I 1532, 2094 

Narita, M 1660, 1799 

Narula, S 1741, 2525 

Narváez, J 191, 1424, 2239 

Nash, A 2237 

Nash, P 462, 1695, 2547 

Nash, PT 1277 

Nash, P 1568 

Nashi, EP 649, 1387 

Nasonov, E 462, 1596 

Nasr, R 197 

Nasrallah, M 857 

Nassikas, N 1230 

Nastacio, M 1396 

Nataf, H 1895 

Naterop, J 76 

Natour, J 102, 104, 116, 452, 807, 

808, 1092, 1160, 1233, 1864, 1867, 

2652 

Natter, MD 1890 

Navarra, SV 614, 615, 1411 

Navarro, F 1596 

Navarro, IE 2093, 2542 

Navarro-Compán, V 538, 1344, 

1380, 2207, 2209, 2211, 2212, 

2612 

Navarro-Millan, I 1270 

Navarro-Sarabia, F 538 

Navarta, DA 119, 240, 1268 

Nawata, M 771 

Nazeri, SK 1759 

Ndosi, M 1718 

Nduaka, CI 1282 

Neau, JP 1551 

Nebesky, JM 180, 1911 

Nebesky, JM 144 

Nedergaard, B 1984 

Neel, A 1551, 2383 

Negrete López, R 2096 

Negrini, M 1002 

Negro, G 1165, 1173 

Neidhart, M 419, 438 

Nelson, AE 1099, 1113, 2468 

Nelson, JL 904 

Nelson, RE 2509 

Nelson, S 288, 294, 305, 312, 2474 

Nemcova, D 764, 2004 

Nemes, D 1876 

Nemeth, L 2423 

Neogi, T 136, 141, 151, 234, 236, 

741, 742, 794, 799, 1098, 1553, 

1980, 2631 

Neovius, M 826 

Neregård, P 1792 

Neri, D 1291 

Neri, R 2057 

Neria, E 2327 

Nerome, Y 1163 

Nery, MV 1864 

Nesbitt, A 2331 

Nesher, G 154 

Neumann, E 4, 890, 891 

Neuville, S 43, 50 

Neven, B 2024 

Neville, C 2688 

Nevitt, MC 239, 794, 796, 799, 

919, 982, 1032, 1098, 1104, 1119, 

1553, 2467, 2470 

New, JS 2575 

Newell, J 825, 1255, 1686 

Newkirk, MM 1179, 1194, 1688, 

1753 

Newman, AB 819, 2433 

Newman, ED 2604 

Newman, S 2654 

Newmark, R 831 

Newsom-Davis, T 2336 

Nezos, A 2181 

Ng, B 1838 

Ng, CT 1806 

Ng, CT 1191, 1621 

Ng, MS 817 

Ng, R 55 

Ng, WF 2551, 2671 

Ngcozana, T 2625 

Ngian, GS 702 

Ngo, D 1798 

Nguyen, D 2442 

Nguyen, D 2208 

Nguyen, H 1049 

Nguyen, V 1439 

Ni Gabhann, J 610, 682, 2526 

Ni Mhuircheartaigh, O 754, 820 

Nicassio, PM 1576, 2694 

Nicholls, D 387, 1568 

Nicholls, D 2140 

Nicklas, BJ 2534, 2536 

Nicolaou, S 1123 

Nicolini, A 2351 

Niddrie, F 1720 

Niederreiter, B 343, 1947, 2086 

Niehaus, S 2011 

Nielen, MMJ 52 

Nielsen, CT 680, 2276 

Nielsen, S 2032 

Niemi, E 30 

Nieminen, T 67, 68 

Nienhuis, HLA 2393 

Niestroj, A 2083 

Nieto, JC 1172, 1427 

Nieves, L 1237 

Niewerth, M 1149, 1153, 2022 

Niewold, TB 673, 689, 729, 740, 

846, 970, 1613, 2273, 2283 

Nigg, A 2107 

Nigg, AP 407, 554 

Nigon, D 1302 

Nigrovic, PA 897, 1890 

Nihtyanova, S 698, 722 

Nihtyanova, SI 1478, 1716 

Niiro, H 186, 1763 

Nikaï, E 2252 

Nikiphorou, E 74, 1215, 2131 

Nikishina, I 1597, 1676 

Nikitorowicz Buniak, J 2291, 2307 

Niklinski, J 2298 

Nilsson, AM 2177 

Nilsson, J 1184, 2137 

Ninet, J 1656, 1740 

Ning, B 327 

Ning, T 268 

Nino, AJ 1984 

Nirmala, NR 761 

Nishi, K 1043 

Nishida, J 1177 

Nishikawa-Matsumura, T 431 

Nishimoto, N 1296 

Nishimoto, T 1186 

Nishimura, R 1693 

Nishina, N 2119 

Nishio, MJ 2592 

Nishioka, K 1569 

Nishioka, K 1861 

Nishioka, Y 98 

Nistala, K 1674 

Nititham, J 2672 

Niu, J 141, 799, 1032, 1119, 1553, 

2631 

Nived, O 654, 661, 930, 1434, 

1562, 2570 

Noaiseh, G 2191 

Noamani, B 2256, 2323 

Noble, P 1086, 1087 

Nocturne, G 593, 2321 

Noda, S 708, 1504, 1521 

Noddings, R 1723 

Nolla, JM 1, 980, 1373 

Nomoto, S 415 

Nonaka, A 1367 

Nonaka, Y 1163 

Noonan, L 812, 2218 

Noort, AR 1066, 1599 

Nordin, A 703 

Nordin, A 2303 

Nordin, H 79, 2558 

Nordmark, G 520, 522, 1773, 2671 

Norek, K 341 

Noronha, IL 2500 

Nørregaard, J 580 

Norris, JM 71, 72, 414, 423, 441, 

673, 1692, 2097 

Northington, R 1354 

Norton, S 1215, 2131 

Norton, T 608, 937, 2061 

Nossent, JC 1388 

Nourissat, G 13 

Novack, DV 1599 

Novack, V 1038 

Noveck, RJ 818 

Nowak, E 2554 

Nowik, M 679 

Nowling, TK 286, 2339 

Noworolski, SM 2583 

Noyes Essex, M 261, 1130 

Nozaki Shibata, T 415 

Nozato, S 1569 

Nozawa, K 332 

Nugent, K 2442 

Nukiwa, T 1938 




388 

Nuñez-Alvarez, CA 2244 

Nunna, R 305 

Nuño, L 546, 1175 

Nunziato, CA 149, 2102 

Nurmohamed, MT 353, 460, 1352, 

1832 

Nurmohamed, M 1242 

Nurmohamed, MT 350, 358, 827, 

1668, 1702 

Nusman, CM 2019 

Nutter, B 1653, 1884 

Nyengaard, JR 2072 

Nyhof-Young, J 2148 

Nyman, E 483 

Nyren, S 1691 

Nüßlein, H 460 

Nzeusseu Toukap, A 1335, 2548 

O 

O’Connell, PG 610, 682 

O’Connor, M 1258, 1259 

O’Dell, AA 1440 

O’Dell, JR 26, 27, 72, 414, 441, 

676, 996, 997, 1287, 2334 

O’Donnell, JL 139 

O’Donnell, M 825, 1255, 1686, 

2170 

O’Hearn, P 338 

O’Leary, DH 1269 

O’Malley, C 1976 

O’Neil, KM 294, 2475 

O’Neill, T 667 

O’Reilly, A 835 

O’Riordan, M 2595 

O’Seaghdha, C 1630 

O’Shea, FD 175, 1385, 1575, 2054, 

2056 

O’Shea, JJ 2322 

O’Toole, G 2540 

Oaks, ZA 1455, 2345 

Oates, J 668, 681 

Oatis, CA 1585, 2651 

Oba-Shinjo, SM 1939 

Obata, J 1333 

Obermayer-Pietsch, B 2312 

Obermeyer, K 570, 2214 

Obici, L 749 

Ocal, L 2253, 2364 

Ocampo-Torres, MC 650 

Ochi, K 1089, 1367, 1963, 2143 

Ochi, S 98 

Ochs, W 77, 272 

Oda, K 1322 

Odani, T 1729, 2460 

Oddis, CV 206, 207, 217, 230, 756, 

1598, 1713, 1945, 1949, 1950 

Oddone, EZ 795 


Odegard, VH 1796 

Odhav, A 1393 

Odio, A 727 

Oei, E 2471 

Oen, K 2475 

Oeser, A 1386, 2663 

Oeser, AM 832, 1261 

Ofer-Shiber, S 1374 

Oflaz, H 1707 

Ogale, S 378, 2463 

Ogata, A 500, 1295 

Ogata, H 877 

Ogawa, E 1458, 2684 

Ogawa, H 223 

Ogdie, A 174, 2559, 2614 

Ogedebe, G 2138 

Ogishima, H 2288 

Oglesby, A 933, 934, 943, 946, 

1856, 2617 

Oh, BM 215 

Oh, C 1250, 1263 

Oh, HJ 215, 1952, 2182 

Oh, HJ 21 

Oh, H 1219 

Oh, JS 354 

Oh, TH 962, 1866, 1869 

Ohara, Y 183, 399, 948, 2247 

Ohbu, S 2046 

Ohde, S 399, 2046 

Ohkawa, R 2248 

Ohkura, M 1861 

Ohmura, K 216, 1296, 1936 

Ohno, N 856 

Ohno, S 1333 

Ohno-Macado, L 917 

Ohrmund, L 1931 

Ohshige, T 2160 

Ohshima, S 194 

Ohta, H 1861 

Ohta, H 444, 445, 1343, 2156 

Ohta, S 1501 

Ohta, S 1289 

Ohta, SI 186 

Oier, AB 1406 

Oka, H 1861 

Okada, A 370, 1046, 2112, 2142 

Okada, J 1458 

Okada, M 399, 948, 2247 

Okada, N 1298 

Okada, Y 3, 1634 

Okada, Y 420 

Okamoto, K 182, 1531 

Okamoto, Y 714, 941, 942, 1492, 

1937, 2242 

Okamura, K 132 

Okamura, R 2442 

Okano, T 113, 1012, 1989, 1990 

Okano, T 428, 1973 

Okano, Y 1043 

Okawa, J 947, 1401 

Okazaki, T 223 

Oksel, F 532 

Oksenhendler, E 201 

Oku, K 1729 

Okubo, A 112 

Okuda, K 1314, 2117 

Okuma, K 2084 

Okuno, H 370 

Olea, JL 1140 

Olenginski, TP 2604 

Olex, AL 731 

Olferiev, M 653, 1809 

Olin, AI 661 

Olivas, C 2038 

Olivé, A 191, 980, 1424, 1967 

Oliveira, ASF 1338 

Oliveira, A 1995 

Oliveira, ACD 2396 

Oliveira, HA 1092, 1233, 2652 

Oliveira, P 204 

Oliveira, R 177 

Oliveira, S 2473, 2477 

Oliveira, SK 2657 

Oliver, R 1339 

Oliveri, B 1998 

Olofsson, T 826 

Olschowka, N 2455 

Olsen, H 1691 

Olsen, IC 69 

Olsen, NJ 685 

Olson, AL 1227 

Olsson, P 2202 

Ombrello, AK 179 

Ombrello, MJ 989, 1611, 2657 

Omdal, R 522, 2671 

Omenetti, A 2658 

OMERACT Flare Working Group, 

1216 

OMERACT Ultrasound Task Force, 

811 

OMERACT-US Task Force, 810 

Ometto, F 1275 

Omma, A 2253, 2364 

On behalf of RESPONDIA Group, 

1356 

Onat, AM 2364 

Onel, K 294, 760, 762, 1141, 1897, 

2601 

Ong, HL 506 

Ong, V 2625 

Ong, VH 1478, 1716 

Onishi, A 707 

Onishi, S 1060 

Ono, J 1501 

Ono, Y 2372 

Onofrei, AU 2221 

Ooka, S 182, 223 

Oomatia, A 609 

OPAL Consortium, 387, 2140 

Opitz, S 124 

Opoka-Winiarska, V 1597 

Oppenheim, C 1551 

Orabi, H 705 

ORAL Scan Investigators, 1277 

Ørnbjerg, LM 361, 363 

Ordi-Ros, J 1432 

Ordoñez-Cañizares, MC 1237 

Oreiro, N 993, 994 

Orellana, C 1604 

Orellana, C 1101 

Oren, A 2327 

Orenti, A 1472 

Oribe, M 1314 

Origasa, H 1312 

Origuchi, T 1046, 1053, 2112, 2142 

Orlandi, A 1867 

Ormseth, MJ 832, 1261 

Ormseth, SR 1576, 2694 

Orquevaux, P 1649 

Ortego, N 1140 

Ortiz Sanjuan, F 1548, 2388 

Ortiz-Sanjuan, F 2389 

Ortolan, A 596 

Orwoll, E 821, 1977 

Orzechowski, NM 2041 

Osborn, T 709 

Oshikawa, H 183 

Oshima, H 1367 

Oshita, K 3 

Oskolkova, O 1072 

Ospelt, C 437, 438, 1781, 2123, 

2670 

Ossipova, E 31, 1769 

Ostendorf, B 1040 

Ostendorf, B 46 

Osteoarthritis Initiative 

Investigators, 2470 

Ostergaard, M 416, 548, 578, 778, 

810, 811, 1024, 2118 

Østergaard, M 361, 363, 577, 580, 

1026, 1042, 1045, 1271, 1616, 

1617, 1620, 2210, 2522, 2558, 

2689 

Østergaard, O 680 

Osterroth, F 2343 

Ostor, AJ 1306 

Ostrowski, RA 202 

Oswald, M 2572, 2687 

Ota, T 1328 

Ota, Y 714, 941, 942, 1492, 1937, 

2242 

Otabe, K 28, 2645

Otawa, SM 493, 494, 496, 2108 

OTIS Research Group, 2466 

Otomo, K 1729, 2460 

Oton, T 2239 

Ottaviani, S 478, 1487 

Otten, MH 1142 

Ottenbacher, KJ 1589 

Ottery, FD 147, 159, 160, 169, 

1916 

Ottosson, C 208 

Ou, P 293 

Ouary, S 479 

Oukka, M 2677 

Outcalt, S 965 

Outman, RC 920, 1978 

Ouyang, W 2622 

Ouyang, X 2092, 2115 

Ovalles-Bonilla, JG 1427 

Overman, RA 1909 

Owada, T 1918 

Owen, T 1207, 2666, 2667, 2678 

Owens, T 2326 

Oyoo, OG 2437 

Ozaki, S 182, 223, 227, 415, 1531, 

1535 

Ozarka, N 2455 

Ozata, B 1382 

Ozdogan, H 750 

Ozdogan, H 187, 759, 761, 2032 

Ozeki, A 700 

Ozen, G 2371 

Ozen, S 2032, 2477, 2657 

Ozguler, Y 2373 

Ozyazgan, Y 989, 1611 

P 

Pablos, JL 1183, 1193, 1513, 2341 

Pace, AV 1718 

Pachecho, RA 985 

Pacheco-Tena, C 462 

Pachman, LM 301, 1670, 1948 

Pack, JW 1121 

Padilla, C 1516 

Padilla-Ibarra, J 446 

Padova, H 193 

Padovan, M 356 

Padovano, I 2351, 2362 

Padyukov, L 233, 978, 1607 

Paessler, ME 314, 1058 

Page, C 269 

Page, M 1750 

Pagès-Castellà, A 915 

Pagnier, A 2024 

Pagnini, I 2598 

Pagnoux, C 284, 1541, 1545, 1551, 

1652, 1656, 2563 

Pahau, H 1198 

Pain, C 2004 

Paira, S 60, 2141 

Paira, SO 1356 

Paiva, ES 1880 

Pal, S 58, 59 

Pal, S 471, 472 

Palacios, S 727, 1976 

Palanichamy, A 1207, 2667 

Palazzo, E 478 

Palleiro, D 1356 

Pallot Prades, B 1699, 1895 

Palma Sanchez, D 1933 

Palmer, E 690 

Palmer, L 922 

Palmer, RH 963, 1857, 1868 

Palmisani, E 1165 

Palmisano, J 2650 

Palombella, VJ 338 

Palumbo-Zerr, K 347, 783, 1502 

Pamfil, C 1436 

Pan, N 1809 

Pan, S 2324 

Pan, TJ 2573, 2649 

Panahifar, A 38 

Panchal, S 57 

Pande, I 57 

Pandey, A 1057 

Pandey, C 1017, 1054 

Pane, I 1308, 1309, 1313, 1699, 

2168 

Pang, J 2512 

Pang, WG 174 

Pang, W 1872 

Pang, WK 1850, 1870, 1919 

Pangan, AL 570, 1025, 1353, 1361, 

2208, 2214 

Pangburn, MK 1059 

Panicker, S 1075 

Panopalis, P 1862 

Pantell, M 2513 

Paoli, CJ 922 

Paolicchi, A 126 

Pap, T 19, 40, 346, 1638, 1779 

Papac, D 1633 

Papadaki, I 991 

Papadopoulou, C 1172 

Papadopoulou-Alataki, E 2032 

Papaioannou, A 1979 

Papalardo, E 1731 

Papandrikopoulou, A 2153 

Papanikolaou, K 2058 

Papapoulos, S 1959, 1998 

Paparo, F 2350 

Papneja, A 540, 2243 

Papo, T 2565 

Papon, M 1577 

Pappas, DA 491, 1300, 2480, 2659 

Pappu, R 2617 

Paramarta, JE 539, 2225 

Paramore, C 1856 

Paran, D 450, 611 

Parasu, N 1016, 1052, 2100 

Parekh, TM 1405 

Parikh, K 484 

Parimi, N 821, 982 

Parish, M 423, 441 

Park, C 2385 

Park, DJ 1063, 1433, 1882, 2249 

Park, E 2622 

Park, EJ 203, 1181 

Park, HJ 1327 

Park, H 42 

Park, H 417, 584, 971 

Park, J 146, 1927 

Park, JA 408 

Park, JK 99, 2299 

Park, JW 2182, 2385 

Park, K 2634 

Park, KH 2680 

PARK, KS 1745 

Park, KS 21, 664, 2258 

Park, MK 1745 

Park, MC 443 

Park, SH 1278 

Park, SY 2686 

Park, SJ 2, 10, 37 

Park, SJ 613 

Park, SH 1236 

PARK, SH 1745 

Park, SH 78 

Park, SH 21, 34, 549, 664, 779, 

1365, 2258, 2381 

Park, SH 1952 

Park, S 2680 

Park, YB 62, 443, 1327, 2680 

Park, YW 1063, 1433, 2249 

Park-Min, KH 1188 

Parker, B 623, 1651 

Parker, C 1633 

Parker, L 2625 

Parkes, MJ 271 

Parperis, KM 1036 

Parra, AD 1759 

Parton, M 232 

Parton, S 51 

Paruzel, P 1779 

Parvu, M 448, 449, 1383 

Pascale, R 126 

Pascual, MV 1629 

Pascual Ramos, V 1901 

Pascual-Salcedo, D 546 

Pasma, A 1560, 1570 

Pasoto, SG 631, 2195, 2497, 2618 

Pasquali, JL 1740 

Pasqualin, VD 1880 

Pasqualoni, E 1652 

Pass, J 2080 

Passalent, LA 1364, 1592, 2224 

Passo, MH 286, 602, 762, 2601 

Pastor-Asurza, CA 1399 

Patel, A 2049 

Patel, AM 56 

Patel, A 1741 

Patel, DR 2317 

Patel, G 1678 

Patel, G 935 

Patel, J 656 

Patel, J 1212 

Patel, K 2513 

Patel, N 729 

Patel, PJ 202 

Patel, RD 165 

Patel, R 1636 

Patel, S 2547 

Patel, S 713 

Patel, T 666, 837 

Pater, K 1816 

Paternotte, S 555, 556, 2110 

Paterson, JM 55, 926, 2511 

Patil, P 2360 

Patkar, NM 763, 1270, 2093, 2543 

Patki, A 970 

Patrick, F 2654 

Patten, D 1885 

Patterson, KC 2273 

Patterson, OV 149 

Patwardhan, A 275, 306, 1896, 

2039 

Pau, E 1744, 2323, 2340 

Paudyal, P 966 

Pauer, L 2641 

Paukkeri, EL 1095 

Paul, B 58, 59 

Paul, S 1198 

Paul, S 2455 

Pauling, JD 1484, 1495 

Paulissen, SMJ 1793 

Paulus, HE 391 

Pauly, T 46 

Pavelka, K 254 

Pavelka, K 460, 831, 1926, 2123 

Pavenstädt, H 1638 

Pavlova, M 1844 

Pavri, T 2246 

Pavri, TM 847 

Pavy, S 593, 2129 

Payet, S 2168 

Payne, J 89 

Payne, KJ 1759 

Payne, PRO 2602 




Paz, E 1679 

Pazzola, G 2347, 2351, 2362 

Pearce, W 1429, 1430 

Pease, CT 1924 

Peat, G 916 

Pecchioli, S 1907 

Pedersen, R 368, 1011, 2133, 

2549, 2661 

Pedersen, SJ 548, 577, 578, 580, 

778, 1024, 1026, 1042, 1616, 2210 

Pedersen, TK 2020 

Pederzoli, S 1173, 2476 

Pedraza, I 423 

Peeters, AJ 1594, 1982 

Pego-Reigosa, JM 211, 980, 1424 

Pehlivan, 1707, 2253 

Peikert, T 1737 

Peiteado, D 546 

Peixoto, M 1487 

Pelck, R 361, 363 

Pelegrin, L 185 

Peliçari, K 1416 

Pelletier, JP 1118, 1124 

Pelletier, JP 730, 1120 

Pellett, F 537, 560, 573, 581, 590, 

2223 

Peloquin, C 849, 1980 

Pelzek, AJ 2577 

Pelzer, H 2080 

Peña-Sagredo, JL 1341, 2388 

Pendl, JD 2040 

Peng, Q 1944, 1951 

Peng, SL 692, 2531 

Pengo, V 2459 

Pennaforte, JL 1649 

Pennington, SR 321, 582 

Penny, MA 1315, 1321 

Penny Prizer, L 1572 

Penrod, J 1489 

Peoples, C 1714, 2049 

Pepe, P 2185 

Pepmueller, PH 377 

Peralta-Sastre, A 1006 

Perazzio, SF 657, 1073, 2369 

Perdriger, A 470, 823, 2188, 2554 

Pereira, AM 1100 

Pereira, D 540, 1351 

Pereira, DF 452 

Pereira, JX 1862 

Pereira, KMC 2282 

Pereira, PVS 2369 

Pereira, RMR 277, 921, 923, 1999, 

2413 

Pereira da Silva, JA 1988 

Pereira Silva, JA 372 

Pérez, R 1967 

Perez Alamino, R 2141 

Perez Aso, M 1515, 1778 

Pérez Barbosa, L 2096 

Pérez Pampin, E 461 

Perez Venegas, J 998, 999 

Pérez Venegas, JJ 980 

Perez-Aso, M 788 

Perez-Ferro, M 1751 

Pérez-Lorenzo, MJ 2341 

Perez-Ruiz, F 145, 1905, 1906 

Perez-Sanchez, C 1211, 2272 

Perich-Campos, RA 1399 

Pericleous, C 1725, 1727, 1728 

Perka, C 47 

Perl, A 1455, 2345, 2498 

Perl, Y 1038 

Perlman, HR 344, 1022, 1074, 

1076, 1077, 1639, 2078, 2679 

Pernis, AB 847, 880 

Peron, CR 1135 

Perricone, C 192 

Perrodeau, E 1309, 1656, 2168 

Perrot, S 1487 

Perry, B 1476 

Pers, JO 2197, 2554 

Pers, YM 2505 

Persson, U 930 

Pertega-Diaz, S 541, 550, 551, 567, 

1359, 1360 

Pertuiset, E 1699 

Peschken, C 939, 2541, 2570 

Peschken, CA 1179 

Pesesse, L 1780 

Pesu, M 1095 

Petaccia, A 2016 

Peter, HH 460 

Peter, R 1091 

Peter, WF 266 

Peterfy, CG 2488 

Peters, MJL 827, 1668, 1702 

Petersen, N 1838 

Peterson, EJ 424, 2452, 2576 

Peterson, LK 2507 

Petersson, IF 73, 95, 253, 826, 913, 

914, 930, 1828, 2409 

Petinoit, L 1141 

Petit-Teixeira, E 1577 

Petri, M 212, 1956 

Petri, M 604, 609, 618, 619, 626, 

633, 640, 658, 671, 691, 886, 938, 

1389, 1390, 1393, 1394, 1396, 

1400, 1412, 1417, 1422, 1425, 

1648, 1650, 1708, 1710, 1730, 

1732, 2245, 2255, 2268, 2285, 

2569, 2570, 2571 

Petri, MA 614, 615, 729, 843, 

2241, 2621 

Petricca, L 679, 1197 

Petrie, KJ 1902 

Petterle, GS 104, 808 

Pettersson, S 1554, 1555, 2574 

Pettersson, T 1920 

Pettysan, N 2231 

Peyrin-Biroulet, L 1618 

Pezic, A 318 

Pfirrmann, CW 1116 

PGRx MI Group, 168 

Pham, T 2135 

Phan, A 1645 

PHAROS Investigators, 718, 724, 

1465 

Phibbs, C 1287 

Philippe, L 1785 

Philippski, P 46 

Phillips, K 92, 1294, 1464, 1713 

Phillips, PE 2498 

Phippard, DJ 2567 

Phipps-Green, A 1180, 1628 

Pialoux, G 1657 

Pianta, M 1028 

Piao, C 1899 

Picano, E 125, 1039 

Picarelli, G 2183 

Pichardo, DM 2406 

Pichavant, M 1144, 1157 

Piché, M 2647 

Pickford, H 2009 

Pickles, D 366 

Pieper, C 268 

Piera-Velazquez, S 2309 

Pierangeli, SS 691, 1405, 1727, 

1731, 2455, 2456, 2457 

Pierce, R 725 

Piette, AM 1627 

Piette, EW 1401 

Piette, JC 641, 1647, 1649, 2532 

Piga, M 498, 599 

Pikwer, M 411, 1184 

Pilataxi, F 1760 

Pilkington, C 297 

Pilkington, CA 753 

Pillai, S 1752 

Pillen, S 228 

Pillet, P 2024 

Pillinger, MH 165, 166 

Pimentel-Santos, F 372, 1356 

Pimienta, O 1050 

Pincus, T 79, 245, 2043, 2048, 

2104, 2105, 2605, 2639 

Pine, P 329 

Pineau, CA 649, 1169, 1223, 1387, 

1428, 1887, 2688 

Pineda, C 127 

Ping, Z 1260 

Pingitore, A 1039 

Pinheiro, FAG 2396 

Pinheiro, MM 104, 808 

Pink, M 338 

Pinney, AJ 1503 

Pinney, SM 1606 

Pinot, E 480 

Pinto, J 541, 550, 551, 567, 1359, 

1360 

Pipitone, N 2351, 2362 

Piqueras, L 1101 

Pisetsky, DS 902 

Pisoni, C 1647 

Pistorio, A 2473 

Pittrow, D 1713 

Pitts, L 1640 

Pitzalis, C 1346 

Pizzino, G 1507, 1508 

Pizzorni, C 1511 

Plaisier, E 1622, 1657 

Planas, E 2357 

Planas Rigol, E 2352 

Planas-Rigol, E 859, 2359 

Plant, D 362 

Plasencia, C 546 

Plass, N 2031, 2653 

Platas, J 22 

Platt, A 2166 

Platt, PN 103 

Platt, RW 649, 1428 

Plenge, RM 372, 420, 976, 981, 

997, 1595, 1630, 1683, 1754, 1821 

Plestilova, L 229, 233, 1673 

Pletcher, S 2053 

Plešivčnik Novljan, M 2205 

Pluijm, SMF 2158, 2161 

Plumas, J 2281 

PLUS, 641 

Poddubnyy, D 561, 1384, 1703, 

2219, 2496 

Podenphant, J 416 

Pødenphant, J 1045, 2522 

Podlusky, S 716 

Podojil, JR 2327 

Poelmans, S 336 

Poggenborg, RP 1026, 1042, 1616 

Poilvert, RM 1895 

Pointon, J 595 

Pokora, T 1856 

Pol, S 1627, 1657 

Polak, JF 1269 

Polasek, E 447 

Polat, A 2032 

Polat, O 2367 

Polido Pereira, J 372 

Polido-Pereira, J 1988 

Pollock, J 864, 1558, 1723 

Pollock, R 537, 581, 590, 2223 

Polyak, JL 1564, 1565, 1567, 2698 

Ponce de Leon, D 1278 

390 

2012 Program Book

Poncet, C 460 

Ponchel, F 1766 

Ponder, L 1144, 1157 

Pong, A 1971 

Pong, E 1761 

Pons-Estel, GJ 1736, 2458 

Ponsonby, AL 318 

Ponte, C 1988 

Ponticos, M 2305 

Pontikaki, I 1167, 2018 

Pool, B 137 

Pool, C 1286 

Poole, JL 2623, 2624 

Poole, K 824 

Popa, C 1682 

Popa, D 1876 

Pope, D 1579 

Pope, E 2008, 2029 

Pope, J 465, 1238, 1326, 2109 

Pope, JE 55, 381, 401, 711, 851, 

853, 1216, 1225, 1317, 1467, 1480, 

1825, 1913, 2099, 2132, 2610, 

2688 

Pope, RM 1074, 1076, 1206, 1639, 

1664, 2524 

Popovich, J 219 

Porcelli, SA 323 

Porrini, AA 579 

Porru, G 498, 599 

Portales, P 2505 

Porter, D 2662 

Porter, JR 338 

Porter, V 483 

Portugal, C 2514 

Possemato, N 2351, 2362 

Postal, M 299, 300, 1416 

Postelnek, J 1741 

Posthumus, MD 2607 

Potapov, A 2660 

Potempa, J 2083 

Potier, ML 485, 1783 

Pottel, T 1696 

Pouchot, J 918, 1115 

Poulin-Costello, M 1317 

Poulsen, UE 361, 363 

Poulton, K 1728 

Pourrat, J 641 

Poveda, J 2173 

Powe, T 627 

Powell, TC 671 

Prager, G 2081 

Prahalad, S 974, 1144, 1155, 1157, 

1614, 1890, 2005, 2657 

Pratali, L 125 

Pratap, A 2260 

Prati, C 544, 1362 

Pratt, AG 103, 774 

Pratt, IV 339 

Precioso, AR 2195 

Preissner, KT 4 

Presa, T 1751 

Pressman, A 817 

Prestigiacomo, T 2455 

Prevel, N 757 

Priam, S 13, 18 

Price, LL 239, 2512 

Prieto-Alhambra, D 270, 781, 915, 

2213 

Prieto-González, S 859, 2352, 

2357, 2359 

Prieto-Parra, RE 212 

Prignano, F 1379 

Primiano, MJ 1081 

Prince, JM 384 

Prince-Fiocco, M 1539 

Princic, N 1829 

Prinz, JC 554 

Priori, R 192, 2183, 2184, 2185, 

2551 

Prisco, E 1291 

Proctor, J 338 

Prodinger, B 2431 

Proft, F 747 

Proglhof, JEP 116 

Propert, K 947 

Prots, I 407 

Proudman, S 205, 453 

Proulx, J 1862 

Provenza, JR 1135, 1880 

Providenti, A 2476 

Provost, Y 721 

Prowse, R 136 

Pruijn, GJ 2523 

Puato, M 596 

Pucciani, F 1485 

Puchner, A 1070, 2086 

Puechal, X 1217, 1545, 1652, 

1656, 2188, 2554 

Pugnet, G 1923, 2383, 2384 

Puig, J 2455 

Puig, L 569, 2557, 2562 

Puig-Kröger, A 1175 

Puliaiev, M 1452, 2337 

Pullenayegum, E 951 

Pullman-Mooar, SW 138 

Pulsatelli, L 2362 

Punaro, MG 294, 762, 2008, 2029, 

2040 

Pundole, X 198 

Punzi, L 255 

Punzi, L 596, 1275 

Puolakka, K 67, 68, 375 

Purcaru, O 1318, 1372 

Purdue, PE 33, 2518 

Purves, D 2662 

Pushparajah, DS 2259 

Puskas, GJ 248 

Putrik, P 1844, 1845 

Putterman, C 603, 632, 838, 839, 

1438 

Puyraveau, M 1362 

Pyne, L 381 

Q 

Qaiyumi, S 536 

Qi, J 337 

Qi, L 2474 

Qi, Z 230, 1714, 1949 

Qidwai, K 1919 

Qiu, J 1497 

Qiu, X 1065 

Quach, D 521 

Quach, HL 521 

Quadrini, NA 200 

Quan, J 685 

Quartier, P 759, 761, 1597, 1678, 

2024, 2032, 2473, 2477 

Quartuccio, L 2183, 2184, 2185, 

2189, 2555 

Quasthoff, S 117 

Queiro, R 998, 999 

Quemeneur, T 1622, 1652, 1656 

Querci, F 2057 

Quesada Calvo, F 43, 50 

QUEST-RA, 2098 

Quillinan, NP 693 

Quimbo, R 2045 

Quinet, R 1195, 2066 

Quinn, H 1718 

Quinn, T 1584 

Quinn, WJ III 1438 

Quinteros, A 60 

Quintin, E 478 

Quinzanos, I 91, 655, 2237 

Quiroga, C 2255 

Quiroz, C 115, 1268, 2141 

Quismorio, FP Jr. 1919 

Qvist, P 591 

R 

Rabinovich, EC 762, 2008, 2029, 

2033 

Rabois, E 1302 

Rabquer, BJ 311, 1506 

Rabsteyn, A 844 

Racewicz, A 1284 

Raches, CM 2028 

Rachlis, AC 1171 

Radbruch, A 686, 979 

Radbruch, AH 1530 

Rader, T 1586 

Radfar, L 523, 524, 525, 2203, 

2674 

Radford, K 574 

Radhakrishna, SM 289, 2427 

Radhakrishnan, S 342, 345 

Radicati, A 1485 

Radics, N 1922 

Radin, AR 1320, 1337 

Radin, D 259 

Radner, H 109, 111, 2113, 2126, 

2608 

Radstake, TRDJ 1064, 1786, 1788, 

2303, 2304, 2335 

Radstake, T 1180, 2301 

Radstake, TR 2298 

Radusky, RC 1805 

Radvanski, DC 2425 

Raffeiner, B 1275 

Raffray, L 195 

Ragavendra, N 1709 

Raggi, P 1261, 1386, 2663 

Rahbar, M 545, 1704 

Rahim, A 58, 59 

Rahman, A 1402, 1403, 1725, 

1727, 1728, 2570 

Rahman, M 2462 

Rahman, P 569, 570, 1381, 2557, 

2562 

Rahme, E 457 

Raicht, A 2318 

Rainer, F 460 

Rainey, AA 1910 

Rainis, CA 1127 

Rajan, B 1760 

Rajendran, C 59 

Ram, S 244 

Ramanathan, A 621, 2427 

Ramessar, N 1883 

Ramires de Jesus, G 1736, 2458 

Ramirez, F 2545 

Ramirez, G 2644 

Ramirez, J 1288 

Ramirez, M 1821 

Ramirez-Molina, C 2071 

Ramiro, S 495, 572, 576, 1023, 

1363, 1698, 1844, 1845, 2222 

Ramji, F 124 

Rammensee, HG 844 

Ramon, G 1733 

Ramonda, R 596 

Ramoni, V 1523 

Ramos, F 1988 

Ramos, PS 313, 889, 2274, 2284 

Ramos-Casals, M 2551 

Ramos-Remus, C 446 

Ramsay, M 975 

Ramsey-Goldman, R 2570 




392 

Ramsey-Goldman, R 603, 671, 

729, 843, 1417, 1422, 1429, 1430, 

2238, 2475 

Ramwadhdoebe, TH 2342 

Rana, N 517 

Ranade, K 1675, 1760 

Rand, J 1732 

Rand, JH 1733 

Ranganath, VK 1050 

Ranganath, VK 391, 1252 

Ranganathan, P 355 

Rangaraj, MJ 2545 

Rangel-Moreno, J 2678 

Ranieri, E 317 

Rannou, F 556 

Rantapaa-Dahlqvist, SM 412, 439 

Rantapää Dahlqvist, S 665, 2692 

Rantapää-Dahlqvist, SM 2145 

Rantz, T 1632 

Ranzolin, A 1880 

Rao, S 534, 746, 1345, 1353 

Rao, VR 1081 

Rappaport, L 12 

Rask, K 935 

Rasker, J 1859 

Rasmussen, A 524, 2203 

Rasmussen, C 79 

Rasmussen, M 2169 

Rat, AC 82, 83, 918, 1115, 1134, 

1618, 1740, 1839, 1895 

Raterman, HG 358 

Rathmann, SS 487, 775, 1025 

Rathore, RKS 1017, 1054 

Rau, R 357, 359 

Rauch, C 460 

Rauch, TA 1061 

Rauer, B 180 

Ravaud, P 830, 1308, 1309, 1313, 

1652, 1656, 1699, 2168, 2189, 

2472, 2555 

RAVE/ITN Research Group, 1654 

Ravelli, A 1158, 1165, 1166, 1172, 

1173, 2473 

Ravetch, JV 1056 

Ravindra, L 280 

Rawlings, DJ 2580 

Ray, DW 667 

Raya, E 2239 

Raya Álvarez, E 1264, 2215, 2216 

Raychaudhuri, SP 337, 434, 589, 

1185 

Raychaudhuri, SK 337, 434, 589, 

1185 

Raynauld, JP 458, 1124 

Razykov, I 2626 

Re, KA 246 

Reardon, G 1812 

Reaume, M 1171 


Rech, J 272, 1010, 1019, 2581, 

2582 

Rech, J 594, 1339 

Recillas-Gispert, C 2244 

Reckley, KA 1853, 2127 

Recknor, C 1997 

Recuero, S 1751 

Redden, D 1203 

Redden, DT 996, 997, 1978 

Reddy, R 1931 

Reddy, SP 1851 

Reddy, SM 1250 

Reddy, ST 1252 

Reddy, V 652 

Redegeld, F 509 

Redlich, K 335, 343, 1070, 1947, 

2081, 2086 

Redman, R 89 

Redmond, AC 1020 

Rednic, S 1436, 1922 

Reed, AM 207, 424, 658, 754, 756, 

1598, 1935, 2031 

Reed, E 1769 

Reed, G 380, 829, 2051, 2480 

Reed, GW 81, 379, 464, 491, 865, 

1300, 1842, 2101, 2221, 2510 

Reed, JH 666, 889 

Reed, MD 1836 

Reed, TJ 1743 

Reedquist, KA 901, 1602, 2525 

Reese, C 1476, 1512 

Reeves, Q 2585 

Reeves, WH 642, 684, 712, 1470, 

1747, 1956 

Refino, C 342, 345 

Regardt, M 1587 

Régent, A 201, 1774 

Regev, G 955 

Reginster, JY 1966 

Reginster, JY 255, 256, 1596, 1969, 

1998 

Reginster, J 254 

Regnault, V 1740 

Rego-Perez, I 993, 994, 1360 

Rehart, S 4, 890, 891 

Rehaume, L 2492, 2494 

Rehman, AA 65, 66 

Reichenbach, S 1116 

Reichert, H 1499, 1500 

Reichlin, M 677 

Reichlin, M 677 

Reichmann, WM 238, 735 

Reid, DM 1525 

Reiff, A 278 

Reiff, AO 289 

Reijman, M 2471 

Reijnierse, M 1051 

Reijnierse, M 564, 1380, 2206, 

2207, 2209, 2211, 2212, 2538, 

2612 

Reilly, C 1442 

Reily, M 1489 

Reimert, M 2139 

Reimold, AM 89, 1187, 2220, 

2483, 2640 

Reindl, C 2107 

Reindl, CS 407 

Reinhardt, AL 2653 

Reinke, E 2650 

Reis, E 177 

Reis, FM 2261 

Reis, MG 177 

Reis, RC 1266 

Reis, SE 1253 

Reiss, AB 2157 

Reiss, W 389, 464 

Reistetter, TA 1589 

Reiter, K 1749 

Reiter, K 2461 

Reksten, TR 520 

Rekvig, OP 1388 

Relaño-Fernandez, S 994 

Relic, B 43, 50 

Remmers, E 1005, 2657 

Remmers, EF 989, 1611 

Ren, K 2334 

Renaudineau, Y 2197 

Renduchintala, K 2194 

Rennebohm, RM 762 

Renner, J 237, 1094, 1113 

Renner, JB 986, 1099, 2468 

Reny, JL 1656 

Repa, A 1436 

Repping-Wuts, H 1232 

Resche Rigon, M 2365 

Resche-Rigon, M 2564 

RESCLE investigators, A 1479 

Resnick, EM 2641 

Restrepo, JF 1213, 2114, 2190 

Restuccia, G 2351 

Reuter, S 2128 

Reuwer, AQ 1078 

Reveille, JD 545, 595, 671, 782, 

843, 852, 1376, 1422, 1474, 1704, 

2290 

Revicki, D 1345 

Revu, S 1789 

Reyes-Leyva, J 606 

Reyes-Salazar, A 701 

Reyes-Thomas, J 603 

Reynisdottir, G 1691 

Reynolds, JA 667 

Reynolds, N 1346 

Reynolds, RJ 975, 996, 997, 1203 

Rezende, CP 2261 

Rezende, GM 2500 

Rezende, MC 1880 

Rhee, C 1825 

Rhee, RL 2441 

Rheumatoid Arthritis Consortium 

International (RACI), 1595 

Rho, YH 849, 1854, 2614 

Rhodus, NL 523, 524, 525, 2203, 

2671, 2674 

Rialland, A 2472 

Ribeiro, AC 2195 

Ribeiro, ACM 173, 533 

Ribeiro, AC 1999 

Ribeiro, ACM 1724 

Ribeiro, ACM 2064 

Ribi, C 482, 1545 

Ribon, M 844 

Ricci, F 2025 

Rice, P 367, 1274, 1834 

Rich, E 720, 721 

Richards, A 861, 1583 

Richards, D 2148 

Richards, JS 149, 2220, 2482 

Richards, JS 536 

Richards, P 864, 1558 

Richards, R 1586 

Richardson, BC 620, 2317 

Richardson, C 690 

Richesson, R 868, 1528, 2428 

Richette, P 255, 544 

Richette, P 168, 2472 

Richey, MC 2404, 2696, 2697 

Richez, C 1302, 2024 

Richman, J 2037 

Richman, L 755, 1675 

Richter, A 365 

Richter, JG 944 

Rickert, M 4, 890 

Rider, LG 206, 282, 291, 753, 1037, 

1598 

Riebschleger, MP 762, 1890 

Riega Torres, J 2096 

Riemekasten, G 1491, 2298, 2304 

Riente, L 114 

Riera, E 191 

Riese, R 1278, 1284, 2485, 2490 

Riese, R 1282, 1290, 1697 

Rigante, D 2016 

Rigby, WFC 1753 

Rigolet, A 220, 1627 

Riis, BJ 1984 

Rillo, OL 60, 200, 479, 2141 

Rincheval, N 830 

Rincon, M 1178 

Ringold, S 322, 1150, 2001, 2595 

Ringsdal, VS 361, 363 

Rinsche, A 1900

Rintek Madsen, O 79, 361, 363, 

1042, 2103 

Rinzis, M 1436 

Rioja, J 1237 

Ripoll, V 1728 

Rischmueller, M 453, 2671 

Riskowski, JL 790, 791, 792, 793 

Rist, S 1309, 2188 

Ritchlin, CT 333, 334, 569, 2118, 

2221, 2557, 2562, 2616 

Ritter, SY 735 

Rivas-Chacon, RF 2031 

Rivera, J 2200 

Rivera, Y 513 

Riveros, A 2239 

Rivière, S 1627 

Rivoire, J 2583 

Riyazi, N 1982 

Rizo Rodriguez, JC 490 

Rizvi, TJ 1894, 2587 

Rizzo, WC 349 

Rizzoli, R 1969 

Roane, G 2545 

Robazzi, T 296 

Robbins, L 2400 

Roberts, C 164 

Roberts, K 1069 

Roberts, L 2400 

Roberts, L 387, 1836, 2140 

Roberts, MS 1853 

Roberts, MEP 512 

Roberts, N 1507, 1508 

Roberts, VC 627, 645 

Robertson, JM 740 

Robertson, S 1199 

Robillard, P 1256 

Robin, C 2023 

Robinson, DB 1194, 1688 

Robinson, F 1579 

Robinson, G 722 

Robinson, P 1612, 2495 

Robinson, SM 1719 

Robinson, S 1062 

Robinson, WH 1187, 1471, 1605, 

1688, 1690, 2097, 2116, 2539, 

2659 

Roccatello, D 1547, 1734, 1735 

Rocha, F 372 

Rocha, FA 1135 

Rødevand, E 404, 1835, 2560, 

2561 

Rodrigues, AM 372, 1988 

Rodrigues, JF 496 

Rodriguez, GR 200 

Rodriguez, J 998 

Rodriguez, MA 1257 

Rodriguez, VA 1081 

Rodríguez Amado, J 2096 

Rodriguez Moreno, J 999 

Rodriguez-Ariza, A 1211, 2272 

Rodriguez-Bellido, Z 1399 

Rodríguez-Gallegos, A 1958 

Rodríguez-García, V 1237 

Rodríguez-Gómez, M 461 

Rodríguez-Moreno, J 1373 

Rodriguez-Nieto, MJ 1751 

Rodriguez-Pla, A 1629 

Rodriguez-Rodriguez, L 2670 

Rodriguez-Ulloa, S 1399 

Roebuck-Spencer, T 280, 281 

Roemer, F 249, 250, 252, 1027, 

1029, 1030, 1031, 1032, 1033, 

1104, 1119, 2467, 2469, 2470 

Roger, VL 820, 1248 

Rohekar, G 1825 

Rohekar, S 1381, 1825 

Rohrer, M 523, 524, 525, 2203, 

2674 

Roig, D 998, 999 

Rojkovich, B 1307 

Rojo, JM 2341 

Rokutanda, R 399, 948, 2247 

Roland, B 1925 

Roll, P 1762 

Rollefstad, S 69 

Rollins, M 12 

Romas, E 35 

Romay-Penabad, Z 1727, 1731 

Rombouts, Y 1201 

Rome, BN 1090 

Rømer, J 1796, 2080 

Romera-Baures, M Sr. 1 

Romero, D 1062 

Romero, FI 1751 

Romero Silva, AB 461 

Romero-Barco, CM 1237 

Romero-Diaz, J 650, 2244 

Romeu, J 1988 

Romijn, HA 1100 

Romviel, S 266 

Ronda, N 675 

Ronday, HK 1330 

Ronday, HK 1594 

Rondon-Herrera, F 2190 

Rong, M 1260 

Ronis, T 2601 

Rönnblom, L 522, 845, 1811, 2271 

Ronnelid, J 412 

Rönnelid, J 411, 439 

Rontogianni, D 2199 

Rooke, R 1579 

Rooney, C 582 

Rooney, M 321 

Rooney, P 2353 

Roorda, LD 266, 1125 

Rosa, J 115, 119, 240, 1268, 1358 

Rosal, M 1085, 1585, 2651 

Rosales-Alexander, J 1264, 2215, 

2216 

Rosario, V 1288 

Rosas, J 1424, 2239 

Rose, JA 2406 

Rose, S 2078 

Rose, SM 1022 

Rosemffet, MG 106 

Rosen, A 526, 758, 1194, 1689, 

1953, 1954, 2299 

Rosen, C 537, 1351, 1375 

Rosen, P 1038 

Rosenbaum, JT 595, 2493 

Rosenberg, AM 339, 2417, 2475 

Rosenberg, A 512 

Rosenberg, DM 851 

Rosenberg, E 1971, 1991 

Rosenberg, WM 1472, 1473 

Rosenblum, GC 2157 

Rosendaal, FR 1097, 2538 

Rosenfeld, A 116 

Rosenthal, AK 155, 635 

Rosenthal, PB 1250 

Rosenzwajg, M Sr. 1623, 1772 

Rosenzweig, E 689 

Rosina, S 1165 

Roskell, S 1846 

Rosner, I 193, 450 

Ross, H 2055 

Ross, S 2148 

Rossen, RD 219 

Rossenu, S 336 

Rossetti, M 427, 2593, 2594 

Rossi, C 529 

Rossi, D 1547 

Rossignol, M 168, 1820 

Rotar, 2187, 2205 

Roth, J 733, 1674 

Rothe, T 1072 

Rother, I 213 

Rother, M 213, 257 

Rothkegel, M 1530 

Rotman, G 2327 

Rottinghaus, S 1284 

Rouanet, S 470, 823 

Rouru, J 1481 

Roussos, C 1091 

Roussy, JP 457 

Rouster-Stevens, K 275, 1157, 

2005 

Rouster-Stevens, KA 1144, 1155 

Roux, C 470, 593, 823, 2110, 2135, 

2472 

Rovin, BH 840, 2251 

Rowe, MW 2162 

Royant, V 1895 

Royston, P 576 

Rozadilla, A Sr. 1 

Rozman, B 902 

Rua-Figueroa, I 211 

Rúa-Figueroa, 1424, 2239 

Rubartelli, A 2658 

Rubbert-Roth, A 456, 467, 1640, 

2545 

Rubell, A 1693 

Rubinstein, E 2435 

Rubio Velazquez, E 1933 

Rubio-Perez, N 1679 

Rubio-Perez, N 1597 

Ruck, A 1481 

Rudd, RE 61, 1572 

Rudwaleit, M 555, 571, 777, 1372, 

1384, 1703, 2214, 2219, 2496 

Rueda-Gotor, J 1548, 2388, 2389 

Ruffatti, A 2459 

Rufibach, K 548, 1024 

Ruiz, B 1511 

Ruiz, XD 2049 

Ruiz Jimeno, T 2349 

Ruiz Limon, P 1731, 2456, 2457 

Ruiz-Arruza, I 1421 

Ruiz-Esquide, V 1288 

Ruiz-Irastorza, G 2570 

Ruiz-Limon, P 1211, 1727, 2272 

Ruiz-Lucea, E 2239 

Ruiz-Martin, J 531 

Ruiz-Romero, C 988 

Rull-Gabayet, M 1901 

Rullo, OJ 303, 1170 

Rundell, SD 1094 

Runhaar, J 2471 

Ruperto, N 1679 

Ruperto, N 1166 

Ruperto, N 759, 760, 761, 764, 

1158, 1597, 2032, 2473, 2477 

Rus, H 1439 

Rus, V 1439 

Rushe, P 2231 

Russell, CB 1294 

Russell, GM 1227, 2179 

Russell, M 1846 

Russo, P 315 

Russo, R 302, 2473 

Russo, RAG 1174, 2657 

Ruta, S 115, 119, 240, 1358 

Rutgers, A 860, 1533 

Ruth, JH 330, 413, 737, 879, 1603 

Ruth, NM 280, 286, 602, 2265 

Rutkowska-Sak, L 759, 761 

Ruutu, M 2492, 2494 

Ruyssen-Witrand, A 1049 

Ryan, HS 176 




Ryan, J 1621 

Ryan, LM 155, 1036 

Ryan, S 1718 

Rydberg, B 776 

Ryu, JH 2175, 2198 

Ryu, JA 1013 

S 

Sa, KH 406 

Saad, CGS 173, 533 

Saad-Magalhaes, C 1679 

Saad-Magalhães, C 2477 

Saadoun, D 1623, 1657, 1772, 

2365 

Saag, KG 54, 148, 374, 489, 763, 

920, 924, 1274, 1971, 1978, 1995, 

2093, 2543 

Saas, P 1755, 1756 

Saavedra, MA 1956 

Saavedra Salinas, MA 1726 

Saavedra-Salinas, MA 212 

Sabbadini, MG 2368 

Sabelli, M 1268, 1358 

Saber, R 1077, 2679 

Saboonchi, F 1571 

Saccenti, E 1002 

Sacchetti, S 296 

Sachdeva, S 1759 

Sack, KE 2174 

Sacksen, I 1927 

Sacli, FS 989, 1611 

Sacre, K 641 

Sada, KE 1535 

Sadatsafavi, M 93 

Sadeghi Abdollahi, B 2035, 2376 

Sadik, CD 1661 

Sadji, F 1895 

Saegusa, J 410, 418, 1298, 2280 

Saeki, Y 194 

Saevarsdottir, S 1607, 2120 

Saevarsdottir*, S 2130 

Saferding, V 335, 1070, 2086 

Safford, MM 1270, 1978, 2093, 

2542, 2543 

Safran-Norton, C 2650 

Sagar, V 499 

Sagawa, A 1314, 2117 

Sage, JM 2040, 2042, 2603 

Saha, AK 311 

Saha, C 952 

Sahakian, L 629, 1709 

Sahani, D 133 

Sahhar, J 702 

Sahin, E 2086 

Sahinkaya, Y 1707, 2253 

Sahl, S 1647 

Sahoo, P 1054 

Sahu, R 1454 

Said-Nahal, R 594, 597, 598 

Sailler, L 1923, 2384 

Saito, K 771, 2121, 2162, 2664 

Saito, S 2328 

Saitou, A 1089 

Saitta, A 1507, 1508 

Sajuthi, S 313, 2274, 2284 

Sakai, K 2286 

Sakai, R 98 

Sakai, Y 1973, 2117 

Sakamoto, N 1442 

Sakellariou, G 2111 

Saketkoo, LA 717, 1468, 1713 

Sakuma, Y 1089 

Sakurai, D 846, 984, 1613 

Sakurai, T 1367 

Sakurai, T 1314, 2117 

Salaffi, F 167 

Salas, A 2141 

Salas, E 2466 

Salazar Cintora, GA 1509 

Salazar-Paramo, M 212 

Salbato, J 1931 

Saldanha, P 2055 

Sale, J 2148 

Sale, MM 2274 

Saligan, L 1874 

Salinger, DH 1294 

Sallum, AM 277, 296 

Salmaso, A 1167, 2018 

Salmon, J 2246 

Salmon, JE 424, 729, 847, 880, 

1238, 1650 

Salmon, JH 1699 

Salom, D 1140 

Salomao, R 657, 1073 

Salomon, B 757 

Salonen, D 542, 1351 

Saluja, M 58, 59 

Salvarani, C 858, 1818, 2347, 

2351, 2362, 2566 

Salvat, C 18, 19 

Salvatierra, G 60, 2141 

Salvatierra, J 1264, 2215, 2216 

Salvin, S 2183, 2189, 2555 

Samanta, A 57 

Samba, SD 2015 

Sambataro, D 1717 

Sambrook, P 1596 

Sambuceti, G 2350 

Samedy, LA 221 

Sammaritano, LR 1650 

Sampaio-Barros, P 1356 

Samson, M 1545 

Samuels, J 1250 

Samuelson, T 369 

San Marco, M 1730 

Sanayama, Y 112 

Sanchez, C 1780 

Sánchez-Atrio, A 1424 

Sanchez-Guerrero, J 650, 674, 

2244, 2256, 2572 

Sanchez-Pernaute, O 1751 

Sanchez-Torres, AA 1399 

Sanderson, T 1723 

Sandhu, S 2148 

Sandner, P 1499 

Sandorfi, N 1713 

Sandoval-Castro, C 446 

Sands, GH 1130 

Sangari, D 1507, 1508 

Sangle, S 2319 

Sanjurjo-Rodriguez, C 11, 48 

Sanmarti, R 185, 998, 999, 1288, 

1641 

Sanna, G 1734 

Sanner, H 872, 1942 

Sano, H 1281, 1296 

Santambrogio, L 323 

Santiago, M 177 

Santiago-Casas, YC 671, 1422 

Santini, E 529 

Santora, A 1971 

Santos, H 372, 1356 

Santos, MC 296 

Santos, MJ 372 

Santos-Rey, J 531 

Sanz, I 690, 1207, 2667 

Sanz, I 512 

Sanz, MJ 1101 

Saperstein, D 969 

Saracbasi, E 553 

Saraon, P 560 

Saraux, A 351, 830, 1115, 1830, 

1837, 1849, 2129, 2188, 2197, 

2551, 2554 

Sardano, E 114 

Sargeant, J 2148 

Sargentini-Maier, L 1307, 1311 

Sargious, P 2401 

Sari, I 565, 1382 

Sari Surmeli, Z 1574 

Sarkin, A 142 

Sarmukkadam, S 58, 59 

Sarracino, D 735 

Saruhan-Direskeneli, G 858, 2370 

Sarvagil-Maman, H 193 

Sarzi-Puttini, P 2180 

Sarzi-Puttini, PC 263 

Sarzi-Puttini, P 467 

Sassolas, F 1649 

Satake, M 1634 

Sathe, M 725 

Sato, C 1281 

Sato, E 1831 

Sato, H 1532 

Sato, H 1243 

Sato, M 1336, 2124 

Sato, S 700, 708, 1504, 1521 

Sato, S 292 

Sato, T 182, 1531 

Satoh, M 212, 223, 227, 642, 684, 

712, 713, 1470, 1747, 1956 

Satoh, T 1459 

Satorius, C 989, 1611, 2657 

Saucedo, C 1256, 1268 

Saul, M 56, 1816 

Saunders, KC 81, 377, 379, 380, 

464, 491, 829, 865, 1300, 1842, 

2051, 2138, 2221, 2480, 2510 

Sauvageau, D 458 

Savage, LM 545, 2224 

Savoldi, G 2025 

Sawada, T 2248 

Sawalha, AH 858, 2370 

Sawant, A 1586 

Sawhney, S 1680 

Sawitzke, AD 1650 

Saxena, A 290, 1647 

Saxne, T 894 

Saxne, T 481, 2137 

Sayers, J 2259 

Sayles, H 89, 1819, 2136, 2482 

Sayre, EC 1033, 1103, 1123, 1642, 

2462, 2568 

Scali, JJ 1640 

Scalzi, L 634 

Scanzello, CR 12 

Scarpa, R 1818 

Scarpellini, M 246 

Schabbauer, G 2086 

Schabert, VF 386 

Schachter, C 1586 

Schaeverbeke, T 351, 470, 823, 

830, 1000, 1302, 1308, 1309, 1313, 

2129, 2135, 2168 

Schafer, L 1586 

Schafer, P 45, 51 

Schaffir, BC 1867 

Schanberg, LE 288, 1146, 2420, 

2475 

Schantz, A 1286 

Schaub, SC 1987 

Scheffer, H 433 

Schelbergen, R 733 

Schellevis, FG 52 

Scher*, JU 1212 

Scherer, A 107, 2228 

Scherer, A 1040 

Scherer, HU 1201, 1767 

394 

2012 Program Book

Scherrer, CB 1669 

Schett, G 31, 272, 1010, 1019, 

1072, 1214, 1499, 1500, 1502, 

2581, 2582 

Schett, GA 347, 594, 783, 888, 

890, 903, 1008, 1505, 2163, 2517, 

2550 

Schetter, AJ 2276 

Schiappapietra, B 1165 

Schiff, M 1272, 2547 

Schiff, MH 1319, 1340, 1342, 2449 

Schillinger, D 2440 

Schindler, SC 1499 

Schiodt, M 2672 

Schioppo, T 1472 

Schiopu, E 692, 718, 1503, 1506 

Schipper, I 1240 

Schirmer, M 2318 

Schirner, M 129 

Schiødt, M 2174 

Schlager, J 2474 

Schlemmer, A 361, 363 

Schlenk, EA 2433 

Schlesinger, N 1911 

Schlesinger, N 144 

Schlichting, DE 490, 2487, 2488 

Schlottmann, I 783 

Schmajuk, G 247, 1822, 2464, 

2599 

Schmidmaier, G 47 

Schmidt, I 594 

Schmidt, KM 275 

Schmidt, RE 2380 

Schmidt, S 594, 2581, 2582 

Schmidt, TW 1824 

Schmidt-Bleek, K 47 

Schmidt-Wilcke, T 802, 805, 806, 

2644 

Schneider, F 217 

Schneider, M 46, 272, 365, 944, 

1040 

Schneider, R 285, 759, 761, 1146, 

1890 

Schnittker, J 553 

Schnitzer, TJ 1082 

Schoen, P 1307 

Schoenhoff, F 719 

Schoettler, N 329 

Scholtysek, C 347 

Schonenberg, D 2019 

Schonkeren, J 2670 

Schouffoer, AA 394 

Schousboe, JT 1995 

Schramm, MA 407 

Schreiber, BE 214, 722 

Schreiner, B 118 

Schroeder, LL 1241 

Schue, JR 1131 

Schuerwegh, A 2303, 2304 

Schult, ML 1587 

Schulze-Koops, H 110, 407, 471, 

472, 554, 747, 995, 1500, 2107, 

2344, 2508 

Schumacher, HR 136, 148 

Schumacher, HR 138, 144, 174, 

813, 2441 

Schumacher, M 761 

Schur, PH 608, 937 

Schwartz, G 1168 

Schwartz, H 1290 

Schwartz, MA 2580 

Schwartz, N 837 

Schwartz, T 872, 1942 

Schwartz, TA 1099, 2468 

Schwartzman, S 492 

Schwarz, EM 333, 334, 2616 

Schweinhardt, P 961, 2643 

Schweizer, HP 855 

Schwetz, V 2312 

Schwinger, W 2318 

Schädel-Höpfner, M 46 

Schäfer, C 1696 

Schäfer, VS 128, 1047 

Schäffler, A 891 

Sciascia, S 1547, 1734, 1735 

Scinocca, M 422 

Scirè, CA 167, 2111 

Scofield, RH 523, 524, 525, 2203, 

2283, 2671, 2674 

Scofield, RH 670, 677, 970, 1613 

Scolnik, M 115, 1268, 1358 

Scotland and Ireland Registry for 

Ankylosing Spondylitis, 601 

Scott, B 727 

Scott, DL 2050, 2439 

Scott, JC 387 

Scott, K 1258, 1259 

Screaton, GR 2336 

Scully, MA 1757 

Searle, N 1894, 2587 

Sebba, A 454, 1640 

Seccia, V 1546 

Secco, A 60 

Sedlis, SP 165 

Sedova, L 1926 

See, LC 583, 814, 1182, 2277, 2673 

Seebach, J 482 

Seel, W 117 

Segal, BM 523, 524, 525, 2203, 

2671, 2674 

Segal, M 729 

Segal, N 1104 

Segawa, S 2288 

Segelmark, M 2276 

Segers, P 1681 

Seibel, MJ 24, 2085 

Seibold, JR 92, 851, 1464, 1713 

Seidel, EJ 213 

Seki, Y 738 

Sekigawa, I 332 

Sekiguchi, H 2198 

Sekiguchi, M 1281, 1296 

Sekine, H 1442 

Sellam, J 13, 1310 

Sellari Franceschini, S 1546 

Selles, RW 1048 

Selman, MHJ 1176, 1201 

Selvaag, AM 1681 

Selvi, E 1291 

Semanik, PA 242, 243, 919, 1588 

Semb, AG 69 

Semerano, L 2505 

Sen, E 1972 

Sendo, S 1298 

Sene, D Sr. 641, 1623, 1772, 2188 

Senécal, JL 720, 721, 1391 

Senet, P 1622 

Seno, T 2070 

Senolt, L 347 

ŠEnolt, L 836, 2123 Seo, P 1655, 

2391, 2395, 2397, 2398, 2567 

Seo, WJ 1784, 2250 

Sepkowitz, M 2427 

SER group for the study of systemic 

autoimmune diseases, 211 

Serada, S 1519 

Serafin, DS 1803 

Seri, M 1002 

Serikawa, K 2080 

Seriolo, B 2164 

Serne, EH 1702 

Sernissi, F 529 

Seror, R 1310, 2129, 2188, 2189, 

2551, 2555 

Serra-Bonett, N 1257 

Serrano, B 1901 

Serrano, C 1751 

Serre, GB 411 

Sesseng, S 1111 

Sessoms, SL 219 

Seta, N 455, 1186 

Seth, R 1908 

Seto, M 1938 

Seto, Y 392, 400, 1831 

Seve, P 1649 

Sevgi, S 750 

Sewerin, P 46, 1040 

Seyahi, E 187, 989, 1611, 2366, 

2373 

Sezerman, OU 1005 

Sfriso, P 1275 

Sha, J 996, 997 

Shacham, S 2678 

Shackleton, DP 768 

Shadakshari, A 2498 

Shademan, A 1037 

Shadick, NA 954, 981, 1821, 2061, 

2403, 2660 

Shafaie, N 2035 

Shah, AA 697, 1468 

Shah, A 1847 

Shah, B 165 

Shah, M 2194 

Shah, M 282 

Shah, SJ 716 

Shah, S 1931 

Shah, U 2443 

Shah, V 1674 

Shaham, B 278 

Shahram, F 2376 

Shahrara, S 328, 2454, 2669 

Shahzad, F 798 

Shaikh, SA 493, 1319 

Shakoor, N 234, 236, 262, 264, 

1133 

Shamliyan, T 1854 

Shams, H 2376 

Shan, Y 2101, 2138, 2510 

Shane, PY 1536 

Shangguan, J 1517 

Shankar, G 1286 

Shanmugarajah, S 537, 1351, 1375 

Shao, WH 1067 

Shao, W 1065 

Shaoxian, H 1260 

Shapira-Lichter, I 611 

Sharabi, A 1456 

Share, O 1690 

Sharif, B 2462 

Sharif, MI 474 

Sharim, R 1815 

Sharma, A 499 

Sharma, A 377 

Sharma, K 1017, 1054 

Sharma, L 241, 242, 243, 2467, 

2470 

Sharma, R 1672 

Sharma, SK 499 

Sharma, TS 2700 

Shaul, A 1856 

Shaw, AS 1742 

Shaw, J 379, 468 

Shaw, JW 75, 84, 369, 373 

Shaw, Y 1853 

Sheane, BJ 1258, 1259 

Sheen, D 417, 584, 971 

Sheikh, S 284, 295, 304, 2478 

Shelef, I 1038 

Shelef, MA 1601 

Shelley, M 1062 




Shen, L 515 

Shen, Z 2518 

Sheng, S 812 

Shenoi, S 904 

Shenoy, N 341 

Shereff, D 868, 1528, 2428 

Sheridan, WP 150 

Sheriff, MK 493 

Sherlock, J 725 

Sherrer, YRS 2102 

Sherry, DD 2030 

Sherwood, J 40 

Sheth, H 2049 

Shevach, EM 2506 

Shewade, A 464, 491 

Shewede, A 1300 

Shi, B 2524 

Shi, J 1768, 1770, 1771 

Shi, K 500, 1084 

Shi, L 1065 

Shi, L 2268, 2285 

Shi, N 389 

Shi, XA 237, 1099 

Shiau, AL 326 

Shibanuma, N 428, 1973 

Shibata, S 1504, 1521 

Shibata, T 223 

Shiboski, C 2174, 2192, 2193, 2672 

Shiboski, S 2192, 2193, 2672 

Shibuya, H 430 

Shidara, K 392, 400, 1831 

Shields, KJ 1711 

Shiels, P 2303, 2304 

Shiff, NJ 2417 

Shiina, M 2077, 2079 

Shikano, K 1520 

Shim, J 1247, 2686 

Shim, SC 417, 584, 971 

Shim, SC 1247 

Shima, Y 738 

Shima, Y 500 

Shimada, K 2147 

Shimizu, H 399, 948, 2247 

Shimizu, K 1336, 2124 

Shimizu, N 1084 

Shin, J 1081 

Shin, KC 1952 

Shin, K 408 

Shin, SY 1580 

Shinagare, S 1534, 2528 

Shingler, W 474 

Shinjo, SK 210, 631, 1135, 1939 

Shinohe, R 1336, 2124 

Shinomura, Y 1917 

Shinozaki, N 1177 

Shintani, A 832, 1261 

Shiozawa, S 428, 885, 1055, 2074, 

2313 

Shipley, JA 1484 

Shir, Y 1862, 1879 

Shirai, T 2328 

Shirai, Y 1459 

Shirakami, S 2084 

Shiwen, X 2307 

Shiyanov, P 2474 

Shock, A 1749, 1750 

Shoemaker, R 1610, 2270 

Shojania, K 1007 

Shoji, A 2248 

Shoji, T 1312 

Shono, E 1314, 2117 

Shortsleeves, K 1810 

Shott, S 867, 956, 1564, 1565, 

1566, 1858, 2698 

Shourt, C 2588 

Shoushtari, A 699 

Shoyama, FM 2452 

Shrader, JA 206, 1037 

Shrady, G 1855 

Shringarpure, R 1931 

Shu, X 1940, 1943, 1944, 2387 

Shuling, H 1260 

Shum, KM 1417, 1418 

Shuman, SA 1603 

Shunsei, H 669 

Shyu, I 1753 

Sibilia, J 351, 511, 830, 1308, 

1309, 1313, 1699, 1785, 1837, 

2135, 2168, 2287, 2554 

Sicari, R 125 

SICCA, 2672 

Siddhanti, S 1997 

Siddle, HJ 1020 

Siderovski, DP 1663 

Sidhu, J 1339 

Sidiropoulos, P 1436 

Siebuhr, AS 575 

Siegelman, SS 2659 

Sieger, N 1749 

Siegerink, B 1330 

Siegrist, J 944 

Siegwald, E 1404 

Siemerink, MJ 1599 

Sieper, J 574 

Sieper, J 549, 558, 561, 570, 571, 

777, 779, 1025, 1361, 1365, 1384, 

1703, 2208, 2219, 2225, 2229, 

2235, 2496 

Sierakowski, S 2292 

Sigmon, K 818 

Signorello, MC 2180 

Signorovitch, J 75, 84, 369, 1242 

Silka, K 2194 

Silva, CA 1679 

Silva, C 372 

Silva, C 2500 

Silva, C 296, 2282 

Silva, CA 1597 

Silva, CA 277, 533, 1724, 1999, 

2477, 2530 

Silva, I 1483 

Silva, JM 1135 

Silva, L 1424, 2239 

Silva, NA 2500 

Silva, NP 657, 1073 

Silveira, LH 2204 

Silver, L 690 

Silver, RM 1476, 1522 

Silver, TI 339 

Silverberg, M 1592 

Silverfield, JC 1282 

Silverman, ED 951, 1597, 1739, 

2475 

Silverman, G 1263 

Silverman, GJ 1425, 1694, 2577 

Silverman, SL 1855 

Silverstein, RL 1537 

Simard, JF 2574 

Simeón, CP 2304 

Simeon, CP 1479, 2303 

Simkin, PA 146 

Simmet, NE 117 

Simmons, F 2265 

Simms, RW 92, 692, 849, 1463, 

1464 

Simon, A 2563 

Simon, LS 261 

Simon, SP 1922 

Simon-Campos, JA 462 

Simonelli, PF 2604 

Simoneta, F 2321 

Simonetti, M 1907 

Simonini, G 1161, 2598 

Simonsen, O 235 

Simpson, N 2255 

Sims, NA 35 

Singer, J 1123 

Singer, NG 294, 2593, 2595 

Singh, AG 2356 

Singh, A 2260 

Singh, G 261, 342, 345 

Singh, JA 143, 148, 753, 1096, 

1270, 1553, 1813, 2037, 2093, 

2445, 2543 

Singh, N 660 

Singh, R 58, 59 

Singh, S 1931 

Singla, M 499 

Sinha, U 1057 

Sinha, V 2700 

Sinicato, NA 299, 300, 1416 

Sinico, R 1523 

Sinissen, P 2670 

Siskind, L 2339 

Sivera, F 1908 

Six, A 1623 

Sjaastad, I 872, 1942 

Sjögren’s International 

Collaborative Clinical Alliance, 

2174 

Sjöwall, C 617, 661 

Skaggs, B 629, 1709, 2451 

Skapenko, A 407, 995, 1500, 2344, 

2508 

Skedgel, C 53 

Skinner Taylor, C 2096 

Skipper, B 2623 

Skoedt, J 580 

Skogh, T 617, 661 

Skold, M 1691 

Skoniecki, DJ 2650 

Skopouli, FN 2552 

Skosey, JL 1904 

Skrumsager, BK 1279 

Slagboom, PE 1100 

Slan, S 286 

Slatkowsky-Christensen, B 1111 

Sleimann Jacobsen, R 1388 

Sleptsova, T 1143, 1148 

SLICC, 647, 648, 1706 

Sloëtjes, AW 2515 

Slot, O 1042 

Small, A 867, 956, 1566, 1567 

Small, BJ 1567, 1858 

Smart, D 454 

Smedby, T 2145 

Smets, B 1331 

Smit, AJ 2393 

Smith, CK 2502 

Smith, CH 1346 

Smith, D 2036 

Smith, DM 922 

Smith, DD 1131 

Smith, JR 1386, 2663 

Smith, K 1748 

Smith, MD 1180 

Smith, M 1667 

Smith, M 2525 

Smith, MD 259, 260 

Smith, M 2616 

Smith, P 2080 

Smith, S 610, 682 

Smith, V 150 

Smith, V 1511 

Smithers, N 2071 

Smolen, JS 773 

Smolen, J 2113 

396 

2012 Program Book

Smolen, JS 80, 109, 111, 335, 343, 

373, 405, 421, 487, 490, 775, 869, 

995, 1721, 1947, 2081, 2086, 2126, 

2133, 2431, 2608, 2627 

Smolik, I 1194, 1688 

Smulders, YM 827, 1668, 1702 

Snapir, A 1481 

Snir, O 2578 

Snyder, B 1085, 1086, 1087 

Snyder, MR 950, 1392 

So, A 1911 

So, A 144, 1234 

So, AK Sr. 135 

So, MW 1784, 2250 

So, MW 354 

Soares, MB 1670 

Sobel, ES 642, 684, 712, 1470, 

1747, 1956 

Sobel, RE 1141, 1150 

Soep, JB 2596 

Sofat, N 1199 

Soglia, J 338 

Sohn, JH 348 

Sohn, MW 919, 1588 

Sokka, T 375, 1844, 1845, 2098 

Sokoll, K 474 

Sokolove, J 1187, 1605, 1688, 

1690, 2097, 2116, 2539, 2659 

Sokolovic, S 451 

Solakov, P 479 

Solans-Laqué, R 2551 

Solari, N 1165, 1173 

Solau-Gervais, E 2023 

Soldano, S 1493, 2164 

Solini, A 529 

Solmaz, D 565, 1382 

Solomon, DH 372, 1230, 1665, 

1687, 1843, 1873, 1960, 1983, 

1993, 1995, 2061, 2062, 2660 

Solomon, DH 2650 

Solomon, JJ 1227 

Solomons, N 837 

Soloviova, K 1452, 2337 

Solow, EB 2060 

Solus, JF 1386, 2663 

Som, D 2038 

Soma, K 1284 

Soma, K 1282 

Somers, EC 603, 1437, 2067 

Somers, K 2670 

Somers, V 2670 

Sommarin, Y 1769 

Son, KM 37, 273 

Son, MBF 307 

Song, GG 409, 2267 

Song, H 2149 

Song, IH 561, 571, 1384, 2219, 

2229 

Song, JS 1188 

Song, J 239, 241, 242, 243, 919, 

1588 

Song, J 1851 

Song, JS 62, 426, 1915, 2122 

Song, L 2268 

Song, R 643, 1262 

Song, SNJ 431 

Song, W 2088 

Song, Y 1277 

Song, YW 549, 779, 1365, 2278 

Song, YW 273, 408, 846, 1188, 

1797, 1952, 2182, 2385 

Song, YW 1219 

Sonigra, A 1460 

Sonnaville, PBJ 1594 

Sonomoto, K 3, 1634, 2162 

Soo, Y 152 

Sordet, C 1895, 2287 

Soriano, E 60, 1256, 1268, 2141 

Soriano, ER 115, 119, 240, 1358 

Sorkin, JD 2533 

Sornasse, T 1329, 2166 

Soro Marin, S 1933 

Sorroche, P 1256, 1268 

Soto, R 1075 

Soto Saez, L 479 

Soto-Hermida, A 994 

Soubrier, M 351, 1577, 2168 

Soudan, M 1837 

Sousa, MC 2652 

Soussan, M 2178 

Southwood, TR 1145 

Souza, AWS 2396 

Souza, B 1266 

Souza, D 32 

Souza, FHC 173, 210 

Souza, T 1081 

Soyfoo, MS 530, 2201 

Spadaro, A 1818 

Spalding, DM 2152 

Spandley, A 1846 

Spargo, L 453 

Sparsa, L 2110 

Specker, C 1040 

Specks, U 1527, 1654, 1655, 1737, 

2391, 2397, 2567 

Spector, T 1596 

Spector, TD 982 

Spencer, CH 275, 306, 1896, 2039 

Spencer, H 1850, 2098 

Spencer, J 2319 

Sperber, D 2400 

Sperber, NR 795 

Speyer, I 394 

Spieler, W 272, 368 

Spiera, RF 694, 1527, 1540, 1712, 

1715, 2567 

Spies, CM 2085 

Spijkervet, F 516 

Spiller, I 1384 

Spindler, A 1597 

Spindler, KP 2650 

Spira, A 1529 

Spits, H 2453 

Spoonamore, J 1595 

Spratt, KF 196 

Spreafico, R 427, 2593, 2594 

Spriewald, BM 1502 

Springer, J 1544, 1653 

Spronk, S 1142 

Spruill, T 2138, 2510 

Squadrito, F 1507, 1508 

Sramek, P 1307 

Sreih, A 1526, 1538 

Sridharan, ST 1795 

Srikhum, W 2583, 2584 

Srinivasalu, H 2000 

Srinivasan, D 1075 

Srinivasan, M 2672 

Sriranganathan, MK 1908 

Srivastava, R 283 

Srivastava, S 2603 

St. Clair, EW 1228, 1527, 2567 

Stabile, A 2021 

Stacey, D 1722, 2405 

Stacey, K 2526 

Stach, C 777, 1316, 1643, 1705, 

2613 

Staelens, F 1319 

Stagi, S 2013, 2014 

Stagnaro, C 188, 2361 

Stahl, E 1595 

Stahl de Castrillon, F 1164 

Stamm, TA 869, 1721, 2431, 2627 

Stamp, LK 139, 1180, 1628, 1903 

Stancati, A 759 

Stanek, E 1978 

Stanford, S 1659, 2452 

Stange, R 40 

Stangler, T 2153 

Stannus, O 2537 

Stansfield, RB 2591 

Stappenbeck, TS 1662 

Starling, GC 331 

Statache, G 1910 

Ste-Marie, PA 1862, 1865, 1879 

Steel, KJA 974 

Steel, KJA 1614 

Steen, J 2578 

Steen, VD 718, 723, 724, 1461, 

1463, 1465, 1471 

Steensberg, A 1279 

Steer, S 1180 

Steere, AC 1204 

Stefanik, JJ 1104 

Stefanov, D 1883 

Stefanova, S 1741 

Steffey, A 624, 940 

Steg, AD 1203 

Stegeman, CA 860, 1533, 2393 

Stehlik, C 2524 

Steiling, K 1529 

Steiman, AJ 2243, 2683 

Stein, CM 832, 1261, 1386, 1960, 

2663 

Stein, N 747 

Steinberg, G 470, 823 

Steiner, JL 952 

Steinhart, AH 1592 

Steinkasserer, A 1072 

Steinkellner, A 1978 

Steinman, M 1822 

Steinmeyer, J 890 

Stemmer-Rachamimov, A 2528 

Stengaard-Pedersen, K 416, 959, 

1045, 2072, 2522 

Stepaniants, S 1315, 1321 

Stephans, C 1945, 1949, 1950 

Stephens, G 1057 

Sterba, G 2473 

Sterling, KL 490 

Stern, SM 278, 861, 2006 

Stern, W 1984 

Steultjens, MPM 266, 1125 

Steup-Beekman, G 1594 

Stevens, AM 322, 843, 2040 

Stevens, E 1294 

Stevens, W 2602 

Stewart, E 1346 

Stewart, KG 2008, 2029 

Stewart, KJ 2395 

Sthoeger, ZM 1456 

Stichman, J 655, 2237 

Stiegler, C 2312 

Stifano, G 1516 

Stillman, M 1550 

Stineman, M 2030 

Stock, JA 2601 

Stoeken-Rijsbergen, G 894 

Stoeken-Rijsbergen, G 1768, 2670 

Stoenoiu, MS 1335 

Stoffer, M 1721, 2431 

Stohl, W 1438, 1761, 2194, 2621 

Stojan, G 640, 1389 

Stolfa, J 1926 

Stoll, ML 1677 

Stolwijk, C 572, 576, 1023, 1363, 

1377, 2222 

Stomp, W 1051 




Stone, D 2653 

Stone, DU 523, 524, 525, 2203, 

2674 

Stone, J 1752 

Stone, JH 133, 1527, 1534, 1654, 

1921, 2527, 2528, 2567 

Stone, MD 1804 

Storgard, C 140, 143 

Stoustrup, P 2020 

Straaten van der, T 1100 

Stradner, M 117 

Strand, V 639, 2252, 2259 

Strand, V 535, 1011, 1283, 1318, 

1713, 1827 

Strangfeld, A 365 

Stratis, A 346, 1779 

Stratton, RJ 2291, 2307 

Straub, RH 49 

Strehl, C 47, 1777 

Streicher, K 1675, 1760 

Stribolt, K 1877 

Striebich, CC 1765 

Strigini, F 2184 

Strle, K 1204 

Strojny, L 2678 

Strunin, L 1524 

Strutton, G 2492 

Strömbeck, B 2409 

Stucki, G 1376 

Stucky, JA 1796 

Studenic, P 405 

Stuijver, DJF 353 

Stults, BM 1489 

Stunz, LL 1441 

Sturfelt, G 654, 661, 662, 1434 

Sturfelt, GK 1388, 1562 

Sturmer, AM 1984 

Su, K 676 

Su, L 432 

Suarez-Almazor, ME 1088, 1838 

Suarez-de-Figueroa, M 1140 

Suarez-Farinas, M 2491 

Subich, D 616 

Suda, A 2046 

Sudano, D 2172 

Sudman, M 1614 

Suematsu, N 182, 1531 

Suemori, K 1060 

Suffia, C 1166 

Sugai, S 2174, 2672 

Sugamoto, K 1084 

Sugihara, M 2288 

Sugihara, T 98, 371 

Sugii, S 2147 

Sugimoto, N 392, 400, 1831 

Sugioka, Y 113, 1012, 1989, 1990 

Sugita, M 708 

Sugiura, T 1937 

Sugiyama, D 707 

Sugiyama, H 98 

Suh, CH 2275 

Sulcs, E 943, 946 

Sulli, A 1493, 1511, 2164 

Sullivan, K 2285 

Sullivan, KE 314, 315, 2268 

Sullivan, S 2001, 2463 

Sumida, H 708, 1504, 1521 

Sumida, T 518, 1535, 1635, 2075, 

2079, 2288, 2315, 2529, 2551 

Summer, R 2289 

Sun, HW 1611 

Sun, K 243, 919 

Sun, L 636, 687, 1192, 1409, 1646, 

2556 

Sun, L 1326 

Sun, Q 2329 

Sun, W 1081 

Sun, X 1446 

Sun, Y 1299 

Sundaram, S 483 

Sundstrom, C 1229 

Sundström, B 2692 

Sundy, JS 159, 160, 815, 818, 

1847, 1916 

Sung, MS 884 

Sung, YK 78, 130, 1013, 1247 

Sunkari, V 1789 

Suntharaligam, J 722 

Supp, G 109, 111 

Suppiah, R 1619 

Suresh, G 1974 

Suresh, L 515 

Susic, G 1154 

Suter, LG 907, 1083 

Sutton-Tyrrell, K 1711 

Suttorp-Schulten, MSA 1352 

Suva, D 248 

Suyama, Y 399, 948, 2247 

Suzuki, C 1917 

Suzuki, E 1442 

Suzuki, JI 856 

Suzuki, K 877 

Suzuki, K 1536 

Suzuki, M 1861 

Suzuki, M 2077, 2079 

Suzuki, N 182 

Suzuki, T 1046, 1053, 2112, 2142 

Suzuki, Y 292 

Svensson, B 390 

Svenungsson, E 703, 1554, 2574 

Sverzelatti, N 722 

Swaim, B 517 

Swantek, J 32, 1196 

Swantek, JL 2518 

Swart, A 1391 

Swearingen, CJ 2102 

Swedler, W 2669 

Sweiss, NJ 328 

Swigris, JJ 1468 

Swigris, JJ 1227 

Syed, A 2700 

Syed, RH 325 

Sykoutri, D 335, 2081 

Sylvester, K 798 

Symmons, D 767 

Symmons, DP 828, 1593 

Symmons, DPM 2544 

Syrbe, U 2496 

Systemic Lupus International 

Collaborating Clincs, 622 


Collaborating Clinic (SLICC), 1651 


Collaborating Clinics (SLICC), 647 

Syverson, GD 275 

Syvänen, AC 2271 

Szabo, S 534, 746 

Szalai, A 992 

Szczepanski, L 447 

Szczerba, B 2675 

Szekanecz, Z 543 

Szent-gyorgyi, L 2062 

Szentpetery, A 543, 1355 

Szmyrka-Kaczmarek, M 1391 

Sztajnbok, F 296 

Szumski, A 398, 1285, 2133, 2661 

Szymanski, KA 163 

Szymkowski, DE 1761 

Szymula, A 2675 

Södergren, A 2145 

Sørensen, IJ 580, 1026, 1042, 1616 

T 

‘t Hart, B 336 

‘t Hart, BA 331 

Tabechian, D 1207, 2592 

Tabera-Bahillo, I 859 

Tabeya, T 1917 

Taboada-Cole, A 606 

Tacey, M 164 

Tachmazidou, I 2657 

Tada, M 113, 1012, 1989, 1990 

Taddeo, A 1530 

Taghavi-Zadeh, S 646 

Taguchi, H 1043 

Taguchi, M 1569 

Tahami, A 497 

Tahara, K 2248 

Tahara, M 2075, 2315 

Tai, M 1661 

Tajima, Y 2328 

Tak, PP 1066, 1599, 2159 

Tak, PP 539, 582, 585, 737, 901, 

1334, 1338, 1602, 2090, 2336, 

2342, 2453, 2525 

Tak, PP 568, 1078, 1189, 2118 

Tak, PP 451, 516, 1754 

Takada, S 28 

Takada, Y 410 

Takagi, K 714, 941, 942, 1492, 

1937, 2242 

Takagi, K 1520 

Takagishi, K 132 

Takahashi, H 1917 

Takahashi, K 1501 



Takahashi, O 2046 

Takahashi, R 2504 

Takahashi, RD 102, 807 

Takahashi, S 518, 1635, 2075, 2315 

Takahashi, T 700, 708, 1504, 1521 

Takahashi, Y 370 

Takahashi, Y 659, 683 

Takakuwa, Y 182 

Takao, M 1177 

Takasaki, Y 98, 209, 332, 1938, 

1941, 2330 

Takase, K 1333 

Takayama, L 921, 923, 2413 

Takayama, M 2372 

Takeda, A 399, 948, 2247 

Takehara, K 226 

Takei, S 1163 

Takemura, M 1336, 2124 

Takeno, M 809, 989, 1333, 1431, 

1611, 2046 

Takeshita, S 738 

Takeuchi, A 184 

Takeuchi, E 1569 

Takeuchi, K 132 

Takeuchi, T 455, 473, 850, 877, 

1186, 1289, 1312, 1324, 1325, 

1459, 1938, 2119, 2160 

Takezaki, T 1163 

Talaber, G 2345 

Talaei, N 2323 

Talarico, R 188, 2361 

Tam, LS 388 

Tam, M 2360 

Tamai, M 1046, 1053, 2112, 2142 

Tamaki, Z 700, 708, 1518 

Tamariz, L 163 

Tamas, N 1774 

Tamayo Novas, M 993 

Tamborrini, G 107 

Tamby, MC 1774 

Tamura, N 209, 1941, 2330 

Tamura, Y 1459 

Tan, FK 1474, 1509, 2290, 2304 

398 

2012 Program Book

Tan, SL 1075 

Tan, W 1802 

Tanaka, A 2529 

Tanaka, A 186 

Tanaka, A 1918 

Tanaka, D 2006 

Tanaka, E 392, 400, 1831, 1957 

Tanaka, H 1600 

Tanaka, K 2077, 2079 

Tanaka, M 877 

Tanaka, M 98 

Tanaka, N 1520 

Tanaka, S 410, 418, 2280 

Tanaka, S 1458 

Tanaka, T 500 

Tanaka, Y 1277 

Tanaka, Y 3, 98, 771, 1289, 1312, 

1324, 1325, 1634, 1763, 2121, 

2150, 2162, 2322, 2664 

Tanaka, Y 1635 

Tandon, M 506, 2501 

Taneja, V 1636 

Tang, I 331 

Tang, MW 1078 

Tang, M 2269 

Tang, X 1241 

Tani, C 1523, 2057, 2184 

Taniguchi, A 392, 400, 1831, 1957, 

1963, 2143 

Taniguchi, T 700, 708, 1504, 1521 

Tanner, SB 832 

Tanriverdi, K 2567 

Tansley, S 229, 1673 

Tao, A 1911 

Tao, A 144 

Tao, J 663 

Taoufik, Y 1310 

Tardif, JC 2688 

Targoff, IN 291, 670 

Taroumian, S 2172 

Tarp, S 2169 

Tarp, U 361, 363, 1271, 2558 

Tarrant, TK 1663, 1803 

Tarride, JE 1016, 2100 

Tarter, LL 2060 

Tarvin, SE 2028 

Tas, SW 1066, 1599 

Tasaka, H 2121 

Tascilar, K 100, 2373 

Tashjian, RZ 2509 

Tashman, S 1127 

Tasneem, A 1847 

Tateishi, K 1591 

Tatewaki, M 1918 

Tatibouet, S 728 

Tatouli, IP 2552 

Tatour, S 2003 

Tatsuo, N 669 

Taubenheim, B 1633 

Taurog, JD 2220, 2493 

Taurok, D 2431 

Tavakkol, R 1984 

Tavares, R 1016, 1018, 1052, 2100 

Tavera-Bahillo, I 2352, 2357, 2359 

Taverna, DM 986 

Tavoni, A 1546, 2057, 2185 

Tawfik, O 1131 

Tawk, RH 1814, 2045 

Taylor, J 2603 

Taylor, J 1718 

Taylor, KE 2672 

Taylor, LH 985 

Taylor, MB 391, 1252 

Taylor, NM 2028 

Taylor, P 490, 2487, 2488 

Taylor, T 1287 

Taylor, W 136, 148, 1376, 1902 

Tayyareci, Y 2377 

Tazzyman, S 1801 

Tchao, N 2567 

Tchérakian, C 2383 

Tchetverikov, I 2226 

Teal, TH 1446 

Teare, MD 985 

Tecktonidou, M 2459 

Tedder, T 316 

Teerawattanapong, S 1677 

Teglbjaerg, C 1984 

Tegzova, D 1277 

Tegzova, D 1926 

Tehrani, R 202 

Tejera, B 1967 

Tektonidou, M 1738 

Telarico, T 1455, 2345, 2498 

Teleman, A 776, 1559 

Ten Cate, DF 1048 

Ten Cate, R 2002 

ten Dijke, P 23 

Tenner, CT 165 

Tensfeldt, T 1697 

Teodorescu, MC 1664, 2455 

Tepper, S 1550 

ter Huurne, MC 733 

ter Wee, MM 353, 358 

Terai, C 1367 

Terao, C 1936 

Terashima, Y 856 

Terkeltaub, R 150, 813 

Terpstra, I 1643 

Terrabuio, DR 2530 

Terreri, MT 296, 1041, 1160 

Terrett, N 1810 

Terricabras, M Sr. 1 

Terrier, B Sr. 201, 1622, 1623, 

1627, 1772, 1787, 2563 

Teruel, M 1000, 1205 

Teruel Antolin, JR 2583 

Tesher, MS 1897 

Teshigawara, S 194 

Tesser, JR 1272, 1904 

Tétreau, C 2647 

Teumer, A 1630 

Tezcan, ME 1411 

Thaci, D 2217 

Thakkar, A 202 

Thakuria, B 58, 59 

Thamsborg, G 580 

Thanarajasingam, U 2588 

Thavaneswaran, A 540, 573, 590, 

1347, 1348, 1350, 1351, 1368, 

1369, 1370, 1371, 1375, 2224, 

2611 

the Arthritis Research UK Working 

Group on Complementary and, 

966 

the Childhood Myositis 

Heterogeneity Group, 282 

the CSP551 RACAT Research 

Group, 1287 

The Global Urate Genetics 

Consortium (GUGC), 1630 

the International Myositis 

Classification Criteria Project, 753 

the MUSASHI study group, 1295 

the ORAL Start Investigators, 2486 

the RIM Study Group, 1598 

the RPDAI study group, 2531 

the Spanish Scleroderma Group, 

2303, 2304 

The Swedish-Norwegian Sjögren’s 

syndrome Network, 520 

Theander, E 522, 2177, 2202, 2551 

Theis, KA 2416 

Theodoridou, A 2058 

Theorell, J 845 

Therkleson, T 1556 

Therneau, TM 1248, 2481 

Theulin, A 1649, 2287 

Thevenot, C 1895 

Thiel, S 2522 

Thiele, GM 26, 27, 1187, 2334 

Thiele, K 77 

Thiele, RG 1207 

Thiolat, A 2505 

Thirstrup, S 2169 

Thomas, EC 280, 281, 312 

Thomas, EP 1796 

Thomas, H 1069 

Thomas, J 2319 

Thomas, O 1841 

Thomas, R 1198, 2492, 2494 

Thomas, T 274 

Thomas, W 2526 

Thombs, BD 2422, 2424, 2626 

Thome, D 32 

Thompson, AE 1825 

Thompson, J 1866 

Thompson, JM 962 

Thompson, K 53 

Thompson, LF 645 

Thompson, SD 974, 1614, 2595, 

2657 

Thomsen, JS 2072 

Thomsen, T 2689 

Thomson, W 974, 1145, 1159, 

1162, 1614, 2009, 2654, 2657 

Thon, A 2022 

Thonhofer, R 117 

Thormann, A 361, 363 

Thorne, A 1123 

Thorne, JC 55, 381, 384, 401, 465, 

493, 926, 1216, 1238, 1317, 2099, 

2109, 2132, 2402, 2511, 2610 

Thornton-Johnson, D 2264 

Thorp, LE 262, 264, 1105 

Thorstensson, CA 266 

Thrower, R 2403 

Thurgood, L 2676 

Thurlings, RM 1754 

Thygesen, P 2080 

Tian, A 280 

Tian, Q 2149 

Tian, S 2308 

Tian, X 1944 

Tian, X 602 

Tieulié, N 2383 

Tikly, M 975, 1794 

Tillett, W 1357 

Tillotson, B 338 

Tilson, H 180 

Tily, HI 2498 

Timenetsky, MDCS 1999, 2195 

Timlin, H 640 

Timoshanko, J 1846 

Timoshchenko, R 1663, 1803 

Tin, D 465, 1216, 1238, 2109, 

2132, 2402, 2610 

Tinazzi, I 1502 

Tincani, A 1523 

Ting, TV 2011, 2603 

Tio, L 1101 

Tipton, C 690 

Tissot, M 873 

Titcombe, P 2576 

Tive, L 260 

Tivon, D 788 

Tiwari, H 970 

Tiwari, P 431 

Tjarnlund, A 233 

Tjärnlund, A 753 




400 

To, CH 224, 637, 1407, 1488 

Toda, E 856 

Todd, J 1263 

Todesco, S 1275 

Todiere, G 1039 

Toepfer, D 1008 

Toes, REM 894, 1771 

Toes, REM 1768 

Toes, REM 973, 1201, 1767, 1770, 

2670 

Tohma, S 98, 399, 1000, 1289, 

1535 

Tokuda, Y 948 

Tolliday, N 1595 

Tolosa, C 1479 

Toloza, SMA 671, 1348, 1411 

Tolusso, B 679, 1197, 1764 

Tomasson, G 1527, 2567 

Tombetti, E 2368 

Tomcik, M 347, 1502, 1510 

Tomero, E 1424, 1701, 2239 

Tomic, K 922 

Tomietto, P 630, 1397 

Tomita, M 1535 

Tomita, RB 162 

Tomita, T 500, 1084, 1637 

Tomlinson, GA 403, 926, 1364, 

1541 

Tomomi Date, 2074 

Tomsic, M 2551 

Tomšič, M 2187, 2205 

Toncheva, A 479 

Tong, G 1812 

Tonkin, BA 35 

Tonner, C 871, 1843, 2052, 2464, 

2599 

Tonon, R 2148 

Tony, HP 1762 

Too, CL 63 

Topcu, E 1574 

Toplak, N 2598 

Topless, R 1180, 1628 

Topoleweski, K 2076 

Topolewski, K 878 

Torbett, N 1750 

Torbey, S 1082 

Torjesen, P 834 

Tormey, V 749 

Torner, J 794, 796, 799, 1032, 

1098, 1119 

Tornero-Esteban, P 1006 

Toro, JB 1883 

Torok, KS 319, 2004, 2008, 2029, 

2036 

Torp-Pedersen, C 1684 

Torralba, KD 1850, 1870, 1872, 

2589 

Torralba, KMD 1411 


Torre-Alonso, JC 531, 998, 999 

Torrelo, A 2653 

Torrente, V 1373 

Törring, O 1959 

Tortosa, R 980, 998, 999, 1001 

Totaro, MC 1197 

Toubi, E 1746 

Touma, Z 646, 841, 842, 1364, 

1371, 2240, 2266 

Tourkina, E 1476, 1512 

Tourtellotte, W 787 

Toussaint, LL 962, 1869 

Toussirot, E 195, 873, 1362, 1755, 

1756 

Touze, E 1551 

Tovar Beltrán, JV 461 

Townsend, AF 1722, 2405, 2430 

Townsend, MJ 620, 2622 

Townsend, R 2159 

Townshend-Bulson, LJ 176 

Toyama, T 700, 708, 1504, 1521 

Toyama, Y 2143 

Toyos, F 2239 

Tracey, K 451 

Trad, S 641 

Tran, M 1468 

Tran, P 734 

Tran, TM 310 

Tran, TN 624, 940 

Trang, JM 1984 

Trapiella, L 1479 

Trautmann, S 1209 

Treadwell, EL 2102 

Tree, T 2319 

Treece, G 824 

Trenkmann, M 419, 892 

Trespidi, L 1523 

Treudler, R 190 

Trifirò, G 1907 

Trijau, S 2135 

Trinder, SL 2305 

Triolo, P 2164 

Tripathi, D 1017, 1054 

Tripathi, LP 431 

Trivedi, AN 2599 

Trotta, F 1002 

Troum, O 1050, 2550 

Trouw, LA 1767, 1768, 1770, 1771 

Troxel, A 2559 

Truchetet, ME 2293 

Trudes, G 1999 

Truedsson, L 662, 1388 

Trugman, JM 963 

Truong, B 552 

Trupin, L 247, 298, 871, 2052, 

2139, 2440 

Tryniszewska, B 1061 

Tsai, A 2585 

Tsao, BP 729, 843, 846, 970, 984, 

1613, 2278, 2283 

Tsao, H 608, 2403 

Tsao, PH 937 

Tse, S 2044 

Tse, SM 1171 

Tseng, CE 1417 

Tsikrika, S 1626 

Tsitsi, P 2058 

Tsokos, GC 739, 740, 1448, 2332, 

2682 

Tsonaka, R 973 

Tsou, PS 1503, 1506 

Tsuboi, H 518, 2075, 2288, 2315, 

2529 

Tsuboi, R 856 

Tsuchida, K 223 

Tsuchida, T 1314 

Tsuchiya, N 1000, 1535 

Tsuji, G 1298, 2280 

Tsuji, S 194 

Tsukamoto, H 186 

Tsukamoto, M 2160 

Tsumiyama, K 885, 1055, 2313 

Tsunoda, S 1281 

Tsuru, T 1314 

Tsutsumi, T 1367 

Tsuzaka, K 1177 

Tsuzuki, S 2529 

Tu, JW 2085 

Tu, K 55, 926, 2511 

Tu, W 2300 

Tubiana, S 2565 

Tucker, LB 294, 2417 

Tudor-Locke, C 794 

Tufan, A 1105 

Tugal-Tutkun, I 989, 1611 

Tugwell, P 1524, 2148 

Tunceli, O 2638 

Turchin, A 2062 

Ture-Ozdemir, F 2370 

Turesson, C 411, 776, 905, 1184 

Turiel, M 2180 

Turker, T 2032, 2477 

Turkiewicz, A 253, 913, 914, 1129 

Turnbull, EM 2475 

Turner, H 1750 

Turner, ML 206 

Turner, R 1903 

Turner, S 725, 1290 

Tustumi, F 2530 

Tuylu, T 565 

Twickler, MT 1078 

Twilt, M 284, 285, 304 

Tyler, JR 2319 

Tymms, K 387, 2140 

Tyndall, AG 853 

Tyrrell, H 1280 

Tyrrell, PN 304, 2015, 2478 

Tyson, N 459, 1694 

Tyson, S 2446, 2693 

Tytus, S 1018 

Tytus, SR 1052 

Tzaribachev, C 2026 

Tzaribachev, N 1164, 2026 

Tzelepis, G 1738 

Tzioufas, AG 507, 508, 526, 1190, 

2551, 2552 

U 

Ucar, U 2690 

Ucgul, A 2366 

Uchida, T 1531 

Uchino, A 1328 

Uchino, K 1550 

Udall, M 1855 

Udayakumar, PD 134, 2355 

Udayakumar, PD 1220 

Uderhardt, S 903, 1072 

Ueda, A 809, 1333, 1431, 1611 

Ueda, N 186 

Ueda, S 186 

Ueda, Y 1660, 1799 

Uehara, T 809, 1333, 1431 

Ueki, N 186 

Ueki, Y 370 

Ueng, J 625 

Uetani, M 1046, 2112, 2142 

Ugarte-Gil, MF 1399 

Ugurlu, S 750 

Ugurlu, S 187, 2366, 2373 

Uherek, C 2343 

Uhlig, T 90, 376, 395, 404, 501, 

1835, 1844, 1845 

UK JDRG, 229, 1673 

Ukmar, M 630, 1397 

Uleryk, E 2240 

Ulgiati, D 2283 

Ulici, V 42 

Ulrichts, H 336 

Umeda, N 1635, 2288 

Umehara, H 2174, 2672 

Umicevic-Mirkov, M 433 

Ungar, W 1168 

Unger, E 1947 

Unni, S 1814 

Unno, M 2094 

Uno, M 1939 

Unson, V 2700 

Upmanyu, R 349 

Urata, Y 360 

Urbina, EM 71

Ureña, I 1237 

Uriarte, E 1424 

Uriarte-Isacelaya, E 2239 

Urowitz, MB 612, 625, 646, 647, 

648, 674, 841, 842, 1421, 1423, 

1435, 1651, 1706, 2240, 2243, 

2254, 2256, 2266, 2570, 2683 

Ursu, S 2654 

Ursum, J 52 

Usategui, A 1183, 1193, 1513 

Usher, P 2082 

Usmani, SE 42 

Ustek, D 989, 1611 

Usui, C 1861 

Uyar, B 1382 

Uziel, Y 2032 

Uzunhan, Y 2178 

V 

Vacca, A 498, 599 

Vadasz, Z 1746 

Vaglio, A 751, 857 

Vagnani, S 2057 

Vahedi, G 2322 

Vahldiek, J 1384 

Vaishnani, M 1557 

Vaknin, I 2327 

Valdazo-De Diego, P 531 

Valdes, AM 583, 814, 982, 1182, 

2277, 2673 

Valdez, H 1278, 2490 

Valdivielso, P 1237 

Valencia, X 836 

Valente, R 462 

Valente, R 2449 

Valentin, MA 225 

Valentin, MA 761 

Valentini, G 1473 

Valesini, G 192, 2183, 2184, 2185 

Valeyre, D 2178 

Vali, S 342, 345 

Valieva, S 1143, 1148 

Valim, V 2551 

Valiunas, V 41 

Vallejo-Ruiz, V 606 

Valls-Garcia, R Sr. 1 

Vallucci, M 1511 

Valluri, U 1322 

Valter, I 1984 

van ‘t Klooster, G 1331, 2489 

van ‘t Spijker, A 1560, 1570 

van Baarsen, LGM 2342 

van Beuningen, HM 17 

van Bon, L 2301 

van Busschbach, J 1560 

van Caam, AP 23 

Van Daele, PL 2301 

van Dartel, S 1232 

van de Laar, MAFJ 161, 433, 2607, 

2637 

van de Loo, FA 17, 2523 

van de Loo, FAJ 896, 2089 

van de Sande, MGH 2342 

van de Stadt, LA 1202 

van de Stadt, L 765, 1201, 1771 

van de Stadt, LA 2668 

van den Bemt, BJF 1273 

Van den Berg, JM 2002, 2019 

van den Berg, R 564, 1380, 2206, 

2207, 2209, 2211, 2212, 2612 

van den Berg, W 2301 

van den Berg, WB 17, 20, 23, 733, 

895, 896, 2089, 2515, 2523 

Van den Bosch, F 570, 1363, 2214 

van den Bosch, MH 17, 895 

van Den Brand, BT 896 

van den Broek, M 469, 1982 

van den Broek, M 1330 

van den Hoogen, FHJ 853 

van den Oever, IAM 350, 353, 827, 

1668 

van Denderen, JC 1352 

Van der Aa, A 1331, 2489 

Van Der Broek, T 427 

Van der Elst, K 1561 

van der Esch, M 266 

van der Goes, MC 1996 

van der Graaf, AM 2393 

van der Heijde, D 574, 1051, 1203, 

1277 

van der Heijde, D 69, 397, 495, 

555, 563, 564, 572, 576, 593, 777, 

977, 1014, 1015, 1023, 1025, 1111, 

1283, 1303, 1344, 1353, 1361, 

1363, 1372, 1376, 1380, 1698, 

1705, 1908, 2118, 2206, 2207, 

2208, 2209, 2211, 2212, 2214, 

2218, 2222, 2225, 2449, 2546, 

2560, 2561, 2579, 2612, 2613, 

2661 

van der Helm - van Mil, AHM 2670 

van der Helm-van Mil, AHM 894 

van der Helm-van Mil, AHM 973 

van der Horst-Bruinsma, IE 1352 

Van der Kaap, J 2226 

Van Der Kamp, S 2059 

van der Kraan, PM 17, 23, 895 

van der Laken, CJ 131 

van der Leeden, M 266, 1125 

van der Leij, C 2342 

van der Maas, A 1273, 2609 

van der Poll, T 180 

van der Veen, MJ 1996 

van der Veer, M 2095 

van der Voort, EIH 1767 

van der Werf, JH 1996 

van Dillen, N 358 

Van Domelen, D 2513 

van Dongen, CJJ 1832 

Van Doornum, S 164, 702, 1836 

van Duivenvoorde, LM 585 

van Durme, C 1908 

van Echteld, IA 1908 

van Eijk, IC 1702 

van Engelen, BGM 228 

van Es, IE 901, 2525 

van Eyk, J 719 

van Gaalen, FA 1051 

van Gaalen, F 564, 1344, 1380, 

2206, 2207, 2209, 2211, 2212, 

2612 

van Geffen, EW 23 

Van Gelder, RN 2493 

Van Groenendael, JHLM 1594 

van Haandel, L 1151, 2597 

van Halm, VP 827, 1668 

van Hamburg, JP 1793, 2338 

van Helden-Meeuwsen, CG 528, 

2301 

van Herwaarden, N 1273 

Van Holder, K 810, 811 

van Hoogmoed, D 1232 

van Hulst, L 1561 

van Kampen, AH 1754 

van Kuijk, AW 568, 582 

van Laar, J 574 

Van Laar, J 2303 

van Laar, JM 2225, 2304 

van Leeuwen, J 2338 

van Lent, PL 17 

van Lent, PLEM 20, 733, 895, 

2089, 2515 

Van Lunen, B 1316 

Van Mater, H 2033 

van Meurs, JB 982 

van Middelkoop, M 2471 

van Nies, JAB 894 

van Nies, J 2670 

van Oosterhout, M 1594 

van Osch, G 2471 

Van Riel, P 1180 

van Riel, PLC 1232 

van Riel, PLCM 433, 1273, 1682, 

2607, 2609, 2635, 2637 

Van Riel, PL 228 

van Roon, JAG 509, 510, 1064, 

1786, 1788, 2196, 2335 

Van Rossum, MAJ 1021, 2002 

Van Rossum, MAJ 2019 

Van Roy, M 336 

van Royen-Kerkhoff, A 2031 

van Schaardenburg, D 353, 358, 

1201, 1202, 2134, 2342 

van Schaardenburg, D 765, 1771, 

2118, 2668 

van Schaik, BD 1754 

van Sijl, AM 827, 1668, 1702 

Van Suijlekom-Smit, LWA 1142, 

2002 

van Tok, MN 585, 2453 

Van Tubergen, AM 558, 572, 576, 

1023, 1363, 1377, 2222 

van Veelen, P 1770 

van Veenendaal, M 1021 

van Vollenhoven, RF 2259 

van Vollenhoven, R 503 

van Vollenhoven, RF 369, 373, 

459, 487, 614, 615, 772, 775, 776, 

1297, 1303, 1316, 1318, 1417, 

1640, 1694, 2133, 2241, 2486 

van Winkelhoff, AJ 1202 

van Zaane, B 353 

van Zeben, D 2095 

van Zelst, BD 2654 

van Zoest, KPM 1066, 1599 

Vanarsa, K 2073 

Vandam, W 2455 

Vandenhende, F 574 

Vandepapeliere, P 479 

Vander Bilt, J 2433 

Vandrell, I 1750 

Vanhaesebroeck, B 1750 

Vanhille, P 1656 

Vanhoutte, F 1331, 2489 

Vanin, EF 1670 

Vanstone, L 2055 

Varela Guidetti, F 1268 

Varga, A 125 

Varga, J 716, 787, 1517, 1518, 

2289, 2294 

Vargas, A 127, 968 

Vargas-Serafin, C 446 

Vargo, J 330 

Vargova, V 764 

Varisco, PA 135 

Varnier, GC 1158 

Varsani, H 1674 

Vas, J 2577 

Vasama, K 1095 

Vasconcelos, C 1483 

Vassiliadis, E 575, 2615 

Vassilopoulos, D 1626 

Vastesaeger, N 471, 472, 549, 779, 

1365 

Vaughan, D 881 

Vaughn, S 843 

Vayssière, B 1331 

Vazquez, DL 2141 

Vazquez, T Sr. 1772 

Vazquez Mosquera, ME 994 


Vazquez-Del Mercado, M 212, 

1956 



Vazquez-Mellado, J 159, 160, 

1356, 1901 

Veale, DJ 1191, 1621, 1658, 1806, 

2353, 2392 

Vedanarayanan, VJ 1981 

Veenhuizen, M 447, 1276 

Vega, J 1733, 2456, 2457 

Vega Morales, D 2096 

Vega-Fernandez, P 280, 281 

Veinot, P 2148 

Veizaga-Udaeta, D 1439 

Vela, P 980, 1424 

Vela Anero, A 6 

Velasco, F 2272 

Velasco, J 2492, 2494 

Vellas, B 1969 

Velozo, EJ 60, 2141 

Venables, PJ 1200 

Vencovsky, J 229, 233, 1316, 1673, 

1926, 2123 

Vende, F 1652 

Vendramini, M 2618 

Venn, A 2535 

Venugopalan, A 58, 59 

Vera-Lastra, O 701 

Vera-Lastra, OL 212 

Verazza, S 1158 

Verbeek, JS 20, 1056 

Verbruggen, N 1991 

Verburg, KM 259, 260 

Verdet, M 485 

Verdoni, L 2025 

Vergnaud, P 2472 

Verheyden, G 336 

Verhoef-Jurgens, M 2125 

Verma, SM 947 

Vermeer, M 2607, 2637 

Vermeij, EA 896, 2089 

Vermeulen, SH 433 

Verner, E 2326 

Vernon, E 1640 

Verrouil, E 1115 

Versari, A 2362 

Verschueren, K 1307, 1311 

Verschueren, P 1561 

Versnel, MA 528, 2301 

Verstappen, G 514 

Verstappen, S 767, 1159, 1162, 

2544 

Ververken, C 1311 

Verweij, CL 233, 1811, 2154, 2668 

Vester, JC 257 

Vestergaard, P 781, 2213 

Vestweber, D 1638 

Vettori, S 2123 

Vezzari, C 1275 

Via, CS 1452, 2337 

Viana, VS 277, 1724 

Viana, VST 2500, 2530 

Viana, VST 2195, 2618 

Vicena, V 1632 

Vidal, E 641 

Videm, V 1198 

Vidmar, G 2205 

Vidva, R 342, 345 

Vieira, A 1317 

Vieira, PL 2336 

Vieira-Sousa, E 1078, 1356, 1988 

Vierboom, M 336 

Vierboom, MPM 331 

Viergever, MA 1122 

Vignon, EP 260 

Vikerfors, A 2574 

Vila, LM 671, 843, 1411, 1422 

Vila, OM 2454 

Vila Fayos, V 461 

Vila-Inda, C 632 

Vilardell-Tarres, M 1432 

Villa, I 1341, 2349 

Villa-Forte, A 1653 

Villafuertes, E 1006 

Villaggio, B 1493, 2164 

Villagra, N 1955 

Villain, E 293, 1649 

Villalba, A 546 

Villanueva, FS 1253 

Villarreal, A 2455 

Villarreal Alarcon, M 2096 

Villarroel, I 302 

Villeneuve, S 2555 

Villiger, PM 766, 2228, 2553 

Vina, ER 908, 909 

Vincent, A 280 

Vincent, A 962, 1866, 1869 

Vincent, GR 732, 1034 

Vinci, V 1717 

Vincze, M 229, 1673 

Vinet, E 649, 1169, 1223, 1387, 

1428, 1887 

Vinik, O 1908 

Viola, S 2476 

Virayavanich, W 2584 

Virta, LJ 67, 68 

Vis, M 2226 

Visconti, R 1512 

Visconti, RP 1476 

Visman, IM 1352 

Visser, AW 1097, 2538 

Visser, A 516 

Visser, JM 2153 

Visser, K 394, 1594, 2606 

Vissink, A 1202 

Vissink, A 514 

Vista, EG 523, 525, 2674 

Vistnes, M 872, 1942 

Viswanathan, H 1976 

Vital, EM 474, 1766 

Vitali, C 2551 

Vitart, V 1630 

Vittadello, F 2034 

Vittecoq, D 225 

Vittecoq, O 810, 811, 1000 

Vittecoq, O 351, 485, 1783, 2135, 

2188 

Vitters, EL 23 

Vivar Pomiano, N 31 

Vivino, FB 2174, 2191, 2672 

Vizioli, CR 2064 

Vlachoyiannopoulos, P 1738 

Vlad, SC 1114, 1666, 1823 

Vlahos, B 368, 2549 

Vlak, T 479 

Voelker, K 86, 1667 

Vogetseder, A 1781 

Vogl, T 733, 1674 

Vogler, LB 1144, 1155, 1157, 2005 

Vogt, M 1669 

Vojinovic, J 1154 

Volin, M 328, 2454, 2669 

Volkov, S 2454, 2669 

Vollath, S 1502 

Vollenweider, CF 2174, 2551 

Volochayev, R 206 

Voloshyna, I 2157 

von Blomberg, M 1811 

Von Feldt, JM 1221, 2441 

von Hinüber, U 77 

von Kempis, J 770, 1102, 2144 

von Muehlenen, I 1577 

von Scheven, E 276, 298, 303, 

2475 

Vonk, MC 228, 851, 2298, 2301, 

2303, 2304 

Vonkeman, HE 161 

Voorneman, RE 266 

Vora, S 2601 

Vordenbäumen, S 46 

Vos, K 539, 1334 

Voskuyl, AE 131 

Voskuyl, A 358, 1811, 2303, 2304 

Voskuyl, AE 827, 1668 

Voss, A 680, 2276 

Vosslamber, S 233, 1811, 2154, 

2668 

Vostretsova, K 2685 

Vray, M 470, 823 

Vroegindeweij, D 2471 

Vrtovsnik, F 2565 

Vu, K 198 

Vu, THT 1664 

Vuillemin, A 1134 

Vuolteenaho, K 2520 

Vyse, TJ 843, 846, 970, 1613, 2283 

W 

Wachsmann, D 1785 

Wada, T 1458 

Wada, Y 1532 

Wade, JP 384 

Wagman, R 1997 

Wagman, RB 1959, 1976, 1977, 

1998 

Wagner, F 1339 

Wagner, GS 341 

Wagner-Weiner, L 1897 

Wahl, D 1740, 2459 

Wahle, J 1080 

Wahle, JA 1796 

Wahren-Herlenius, M 522, 1773, 

2671 

Waikar, S 1665 

Waimann, CA 60, 106, 2141 

Waisberg, MG 173 

Waisman, G 1268 

Wait, R 1199 

Waite, PD 1677 

Wakefield, R 810, 811 

Wakefield, RJ 1020 

Wald, JA 1984 

Waldman, G 797 

Waldron, N 1357 

Walgreen, B 2515 

Walitt, BT 1860, 1874, 2642 

Walker, D 1719 

Walker, R 2455 

Walker, UA 180, 696 

Wallace, C 2594, 2595 

Wallace, CA 762, 1150, 2001, 2593 

Wallace, DJ 639, 2252 

Wallace, D 1417, 2570 

Wallace, DJ 629, 673, 1294, 1411, 

2620, 2621 

Wallace, RB 1995 

Wallace, ZS 2528 

Wållberg Jonsson, S 1244 

Wållberg-Jonsson, S 2145 

Wallenstein, G 1277, 2485 

Wallenstein, G 1283, 2486 

Wallis, D 1357 

Wallitt, B 953, 2116 

Wallmeier, H 2343 

Walsh, D 74, 1215, 2131 

Walsh, DNE 1582, 1590, 2399, 

2436, 2448, 2632 

Walsh, JB 1258, 1259 

402 

2012 Program Book

Walsh, J 2220 

Walsh, M 1924 

Walsh, N 1810 

Walsh, NC 35 

Walter, MJM 1570 

Walton, NR 2536 

Wan Tain, WR 1180 

Wang, A 824, 1959, 1961, 1998 

Wang, B 692 

Wang, C 798, 2646 

Wang, CR 326 

Wang, D 636, 1409, 1646, 2556 

Wang, D 26, 27, 2334 

Wang, EC 1804 

Wang, F 1802 

Wang, F 1671 

Wang, G 1940, 1943, 1944, 1951, 

2387 

Wang, H 2146 

Wang, H 670, 2450 

Wang, J 1286 

Wang, JC 2300 

Wang, JH 2575 

Wang, J 1644, 1919, 2324 

Wang, JX 897 

Wang, K 1104 

Wang, L 2146, 2233, 2269 

Wang, L 1282 

Wang, M 663 

Wang, M 926 

Wang, Q 2329 

Wang, SP 1763 

Wang, SL 1931 

Wang, S 2556 

Wang, W 1610 

Wang, W 2667, 2678 

Wang, W 1518 

Wang, Y 2452 

Wang, Y 1857, 1868 

Wang, Y 1494, 2296, 2297 

Wang, Y 1450 

Wang, Y 569, 2557, 2562 

Wang, Z 249, 250, 252, 1128, 

2469, 2470 

Wang, Z 818 

Wangjam, K 58, 59 

Waraich, SA 1645 

Ward, M 163 

Ward, MM 542, 782, 2000, 2600 

Ward, RJ 1121 

Wardemann, H 2578 

Waris, M 528 

Warner, AJ 2544 

Warren, RB 1346 

Warren, S 1287 

Warriner, AH 1978, 1995 

Warrington, KJ 857, 905, 1552, 

2355, 2356, 2358 

Wasan, A 1230 

Wasko, MCM 1241, 1690 

Wason, S 1912 

Wassenberg, S 359 

Watanabe, A 194 



Watanabe, K 98 

Watanabe, KS 2332 

Watanabe, K 1938 

Watanabe, M 700 

Watanabe, R 809, 1333, 1431 

Watanabe, R 370, 2328 

Watanabe, S 2310 

Watanabe, T 2460 

Watanabe, T 1336, 2124 

Watcher, SJ 2427 

Waters, EA 1022 

Watkins, M 2455 

Watson, C 386, 1829 

Watson, JM 2307 

Watson, K 1593 

Watson, KD 828 

Watts, A 1723 

Watts, S 1062 

Webb-Detiege, TA 1195 

Webber, CE 1016, 1052, 2100 

Webber, M 214 

Webber, S 1586 

Weber, D 1299 

Weber, U 548, 778, 1024, 1028, 

1033, 2210 

Webster, F 2148 

Wechalekar, MD 1908 

Wedderburn, LR 229, 1159, 1162, 

1614, 1673, 1674, 2009, 2654, 

2657 

Weel, AEAM 2095 

Wegener, WA 639, 2252 

Wehmeyer, C 346, 1779 

Wei, F 1930, 2149 

Wei, JC 972 

Wei, J 327 

Wei, J 2225 

Wei, J 787, 2289, 2294 

Wei, N 2491 

Wei, X 2622 

Wei, XN 2115 

Weibel, L 2004 

Weichselbaum, L 530 

Weinberger, M 795 

Weinblatt, M 954, 2547 

Weinblatt, ME 1323, 1695 

Weinblatt, M 812, 981, 1292, 

1301, 1826, 2061, 2062, 2403, 

2660 

Weinblatt, ME 1340, 1342, 2449 

Weinstein, A 603 

Weinstein, AM 910 

Weinstein, A 1856, 2241, 2621 

Weinstein, SP 152, 813 

Weis, L 1083 

Weis, L 630, 1397 

Weisbart, RH 1693 

Weisman, MH 1576, 2694 

Weisman, MH 71, 72, 414, 423, 

441, 542, 545, 629, 673, 782, 1411, 

1704 

Weiss, A 2229 

Weiss, B 2228 

Weiss, JE 762, 1141, 1146, 2601 

Weiss, P 929, 2030 

Weiß, A 571, 2219 

Weldon, AJ 1759 

Welin Henriksson, E 1571 

Welin Henriksson, EM 1554, 1555, 

1587 

Weller, M 517 

Wells, AU 722, 854, 1713 

Wells, GA 2118 

Welsch, G 1019 

Welsing, PMJ 1122, 2125 

Welsing, PMJ 1832, 1996 

Wen, H 2338 

Wenander, C 2082 

Wendling, D 544, 873, 1362, 1627, 

1756, 1837, 2472 

Wener, MH 176 

Weng, H 471, 472 

Weng, S 838 

Wenkert, D 383, 1644 

Wenting-van Wijk, M 2196 

Werlen, S 1116 

Wermuth, PJ 1496, 2295, 2306 

Werner, SG 129 

Wershba, E 2033 

Werth, VP 753, 947, 1401 

Wessel, MD 1062 

Wesseling, J 1126 

Wesseling, JG 2668 

West, CR 259, 260 

Wester, RT 1062 

Westhoff, G 1214 

Westhovens, R 812, 862, 1292, 

1301, 1305, 1561, 1826 

Westmacott, R 304 

Westman, K 2564 

Westra, J 1202 

Westra, J 2393 

Westwood, B 731 

Westwood, JP 1757 

Wetterö, J 617, 661 

Wevers-de Boer, KVC 394, 1594, 

2606 

Weyand, CM 857, 2356, 2665 

Whelton, SA 536 

Whipple, MO 962, 1869 

Whitbred, JM 2595 

White, C 1834 

White, CJ 165 

White, DK 794, 799 

White, ES 1518 

White, J 1718 

White, K 338 

White, T 2063 

White, W 218, 755 

Whiteside, J 1481 

Whitmore, M 798 

Whitney-Mahoney, KJ 1171 

Whitt, IZ 709 

Whitt, SE 2194 

Whittard, T 1741 

Whitworth, A 2051 

Whyte, A 2676 

Wichuk, S 575, 578, 591, 592, 

2615 

Wick, JA 1131 

Wicks, I 702 

Widdifield, J 55, 926, 2511 

Widmer, A 748 

Wiebe, E 2085 

Wiedeman, A 1446, 1791, 2281 

Wiell, C 1042 

Wiesel, R 2406 

Wigerinck, P 2489 

Wigley, FM 697, 719, 786, 1481 

Wijbrandts, CA 1338 

Wijmenga, C 858 

Wiland, P 368 

Wilder, T 2516 

Wildi, LM 1124 

Wildman, HF 694, 1715 

Wiley, GB 524 

Wilke, LD 1539 

Wilke, W 1884 

Wilkinson, B 1284 

Wilkinson, B 1297 

Wilkinson, BE 2486 

Willburger, M 1947 

Willemze, A 1768 

Williams, AH 2279 

Williams, AS 1804 

Williams, DA 158, 866, 962, 1581, 

1869 

Williams, M 2360 

Williams, M 2585 

Williams, R 1215, 2131 

Williams, RO 2327 




Williams, SA 483 

Williams, S 1643 

Williams, T 368, 2549 

Williamson, JD 2534 

Willim, M 930 

Willis, CR 510 

Willis, R 691, 2455, 2456, 2457 

Willis, VC 423 

Wills, AK 800 

Wilson, AG 894 

Wilson, AG 362, 985, 1800, 1801 

Wilson, A 1178 

Wilson, F 1385, 1575 

Wilson, G 103, 774 

Wilson, HE 1346 

Wilson, KL 933, 934 

Wilson, PC 1748 

Wilson-Gerwing, TD 339 

Wimmer, MA 262 

Winchester, R 1003, 2659 

Winkelmayer, WC 287, 931, 1665 

Winkler, A 1081 

Winkler, DG 338 

Winkler, S 594 

Winter, O 1449 

Winterstein, A 1027 

Winther, SA 1684 

Winthrop, KL 1284, 2490 

Winthrop, KL 54, 763, 1278, 1817, 

2093 

Wipff, J 2007 

Wirth, W 2470 

Wise, B 821 

Wisniewski, SR 56, 698, 1853, 

2127 

Wither, JE 674, 1744, 2256, 2323, 

2340, 2683 

Witt, M 110, 407, 747, 2107 

Witte, BI 765 

Witte, D 305 

Witte, T 586, 2304, 2380, 2671 

Witteman, H 2067 

Witter, JP 545 

Wittig, B 2217 

Wittkowski, H 1674 

Wittkowski, KM 124 

Wittsack, HJ 1040 

Woelfel, J 1925 

Wolak, A 1038 

Wolak, T 1038 

Wolbink, G 1334, 1832 

Wolf, DC 1643, 1931 

Wolf, G 1209 

Wolf, JM 1129 

Wolf, S 1892 

Wolfe, F 88, 495, 605, 953, 1698, 

1819, 1859, 1860, 2068, 2642 

Wolfe, S 1108 

Wolff, M 2565 

Wolff, RK 2483 

Wolff, V 472 

Wolfgang, H 574, 2225 

Wolfson, M 170 

Wollenhaupt, J 574, 1282, 2225 

Wollenhaupt, J 471, 472, 549, 779, 

1365, 2613 

Wollmer, P 2177 

Wolman, S 1592 

Wolstenholme, CB 732, 1034 

Wolterbeek, R 397 

Woltering, F 557, 558, 2613 

Wong, B 1171 

Wong, BR 901 

Wong, EE 1121 

Wong, H 2462 

Wong, JB 2646 

Wong, M 2325, 2451 

Wong, P 1280 

Wong, RH 972 

Wong-Pack, W 1979 

Woo, J 331 

Woo, JMP 303, 1170, 1899 

Woo, P 762, 2032, 2657 

Woo, YJ 21 

Wood, J 278 

Wood, R 333, 334 

Wood, S 1284 

Wood, SP 1282 

Woodhead, F 854 

Woods, A 697 

Woods, D 710 

Woods, J 1741, 2525 

Woodward, AL 863 

Woodward, TC 2638 

Woodworth, T 1050 

Woodworth, T 2169 

Woodworth, TG 2609 

Woody, SE 2433 

Wooley, PH 327 

Woolf, AD 1721, 2431, 2437 

Wootton, J 288 

Wordsworth, P 574, 595, 781, 

2225 

Worthington, J 2303 

Wouters, C 764 

Wouters, CH 862 

Wozniak, M 2386 

Wren, JD 1795 

Wright, A 574, 2225 

Wright, D 1885 

Wright, E 1983 

Wright, H 1069 

Wright, J 2650 

Wright, K 1222, 1349 

Wright, NC 54, 1995 

Wright, R 2650 

Wrobel, J 1058 

WTCCC 1612 

Wu, CT 1549 

Wu, CL 326 

Wu, D 1595 

Wu, EQ 369, 484 

Wu, EY 2521 

Wu, H 1016, 2100 

Wu, H 2269 

Wu, J 341 

Wu, J 1391 

Wu, J 992 

Wu, J 965 

Wu, LC 678 

Wu, L 51 

Wu, M 1474, 1509, 2290 

Wu, PW 1429, 1430 

Wu, P 838 

Wu, Q 587 

Wu, Q 2152, 2575, 2677 

Wu, R 813 

Wu, S 8 

Wu, T 672, 1412, 1447 

Wu, W 2300 

Wu, XX 1732, 1733 

Wu, YL 1948 

Wu, Z 1366 

Wuhrer, M 1176, 1201 

Wulffraat, N 759, 761, 2473 

Wulffraat, NM 762, 2654 

Wunrau, C 346 

Wyllie, R 1139 

Wyman, B 1277 

Wynant, W 2688 

X 

Xavier, R 1597 

Xavier, RM 204, 2550 

Xia, Y 2269 

Xiangyuan, L 1260 

Xiao, J 1529 

Xiaofeng, L 1260 

Xiaomin, L 1260 

Xie, C 1606 

Xie, F 54, 374, 489, 763, 924 

Xie, J 484 

Xie, L 2146, 2233 

Xing, L 333, 334, 1074, 2666 

Xingfu, L 1260 

Xiong, J 1216, 1238, 1299, 2099, 

2109, 2132, 2610 

Xiuyan, Y 1260 

Xu, AP 2503 

Xu, D 1741 

Xu, D 1670, 2329 

Xu, J 626, 633, 938 

Xu, J 2556 

Xu, L 1027, 1029 

Xu, L 1802 

Xu, M 1544 

Xu, M 1894, 2587 

Xu, Z 1293 

Xu, Z 2218 

Xu, Z 1671 

Y 

Yılmaz-Öner, S 2394 

Yabe, H 1367 

Yacyshyn, E 1722, 2405 

Yaffe, K 819 

Yagüe, J 191 

Yahya, A 63 

Yalavarthi, S 1440, 1443 

Yamada, H 223, 227, 415, 1333, 

1535 

Yamada, S 444, 445, 2156 

Yamagami, K 2084 

Yamagata, M 112 

Yamaguchi, A 332 

Yamaguchi, KI 399, 948, 2247 

Yamaguchi, Y 1501 

Yamaji, K 209, 1941 

Yamamoto, A 2070 

Yamamoto, K 1312, 1324, 1325, 

1938 

Yamamoto, M 1917 

Yamamoto, T 738 




Yamamura, T 2330 

Yamanaka, H 392, 400, 714, 941, 

942, 1289, 1312, 1324, 1325, 1492, 

1831, 1937, 1957, 1963, 2143, 

2242 

Yamanishi, Y 1536 

Yamaoka, K 3, 771, 1634, 1763, 

2121, 2150, 2162, 2664 

Yamasaki, M 227, 1333 

Yamasaki, Y 223, 227, 415 

Yamasaki, Y 1163 

Yamashita, H 415 

Yamashita, S 28 

Yamatou, T 1163 

Yamazaki, H 98 

Yamazaki, K 292 

404 

2012 Program Book

Yamazaki, S 2084 

Yamazaki, T 1084 

Yan, M 1447, 2073 

Yan, Q 1457 

Yan, Z 2672 

Yanaba, K 708, 1504, 1521 

Yanagida, M 332 

Yancopoulos, GD 152 

Yang, H 484 

Yang, HI 1262 

Yang, P 2152, 2575, 2677 

Yang, SY 327 

Yang, S 402, 489, 1270, 2093, 

2106, 2543 

Yang, T 796, 1553 

Yang, Y 1517, 2289 

Yang, YC 1977 

Yang, YH 2088 

Yang, Z 2665 

Yao, L 1037 

Yao, Q 189 

Yao, R 471, 472, 549, 779, 1365 

Yao, Y 218, 692, 755, 1675, 1760 

Yap, KS 2257 

Yargucu Zihni, F 181 

Yarlina, A 1196 

Yasuda, S 98, 1729, 2460 

Yasuda, T 893 

Yasukawa, M 1060 

Yasuoka, H 455, 1459 

Yatomi, Y 2248 

Yau, MS 912, 986 

Yavuz, S 1398 

Yawalkar, N 2228 

Yazdany, J 247, 298, 655, 931, 

1822, 2052, 2061, 2065, 2237, 

2464, 2599, 2600 

Yazici, A 858, 1398 

Yazici, H 100, 187, 2366, 2373, 

2374 

Yazici, Y 245, 1340, 2102, 2138 

Ye, B 1517, 2289 

Ye, S 331 

Ye, X 1814 

Ye, Y 672, 1447 

Yearley, J 725 

Yee, B 269 

Yee, C 1808 

Yeh, S 1155, 2005 

Yelin, E 247, 276, 1843, 2052, 

2139, 2570 

Yelin, EH 298, 2440 

Yen, EY 936 

Yeo, AE 169, 170 

Yeo, KJ 972 

Yeon, JT 1962 

Yeremenko, N 585, 2453 

Yerges-Armstrong, L 744, 912, 986 

Yeter, K 1761, 1870, 1872 

Yeung, RS 2657 

Yi, ES 2198 

Yi, H 436 

Yi, N 2269 

Yi, W 1260 

Yildiz, B 2002 

Yildiz, F 2364 

Yilmaz, N 1398, 2364 

Yilmaz, V 858 

Yin, H 1518 

Yin, H 517 

Yin, S 1260 

Ying, J 281, 294, 312 

Ying, KY 224 

Yip, AL 206, 1037 

Yip, GM 817 

Yip, M 224, 562 

Yip, P 651, 1415 

Yokoe, I 1243 

Yokogawa, N 2147 

Yokota, S 748 

Yokoyama, W 371 

Yomogida, K 8, 2320 

Yonemoto, Y 132 

Yonezawa, T 2645 

Yongfu, W 1260 

Yoo, B 354, 1784, 2250 

Yoo, DH 78, 1247 

Yoo, KY 1889 

Yoo, MC 1889 

Yoo, S 692 

Yoo, WH 78, 884, 1247, 1962, 

1968 

Yood, RA 159, 160, 1916 

Yoon, BY 21, 78, 1247 

Yoon, CH 613, 628 

Yoon, MJ 215, 1219, 1952 

Yoshida, H 2077, 2079 

Yoshida, K 183 



Yoshida, M 2280 

Yoshida, S 1089, 2143 

Yoshifuji, H 216, 1936 

Yoshii, I 1296 

Yoshikawa, H 1084 

Yoshikawa, T 1281 

Yoshimi, R 809, 1333, 1431 

Yoshimoto, K 877, 2160 

Yoshimura, A 2504 

Yoshimura, M 194 

Yoshinari, T 1324 

Yoshioka, T 182 

Yoshitomi, H 430 

Yoshiyuki, A 669 

Yoshizaki, K 431 

Yoshizawa, T 1660, 1799 

Young, A 74, 1215, 2131 

Young, D 1677 

Young, J 926 

Young, JP 1141 

Young, J 1814 

Young, KA 414 

Young, N 678, 840, 1672 

Young, PR 341 

Yousefi, C 1722, 2405 

Ytterberg, J 1691 

Ytterberg, SR 1655, 1737, 2391, 

2397 

Yu, A 2584 

Yu, CY 1948 

Yu, CY 2278 

Yu, D 1068 

Yu, HJ 1838 

Yu, HG 2385 

Yu, J 2498 

Yu, KL 1407, 1410, 1413, 1414 

Yu, KH 583, 814, 1182, 2277, 2673 

Yu, N 663, 1438 

Yu, X 2269 

Yu, Y 676 

Yu, Z 965 

Yuan, K 2387 

Yuan, W 880 

Yucel, AE 958 

Yukawa, N 216, 1936 

Yukioka, M 1569 

Yun, H 489 

Yun, J 1961 

Yura, A 194 

Yurdakul, S 2366 

Yurdakul, S 2377 

Yurgin, N 922 

Yurkovich, M 2685 

Yusuf, I 1450 

Yýlmaz Oner, S 2371 

Z 

Zaba, L 1954 

Zaccara, E 1717 

Zagatti, B 1002 

Zaheer, I 1509 

Zaiss, M 2163 

Zakem, JM 1195 

Zaki, A 623 

Zaman, S 685 

Zamanian, RT 1471 

Zamanpoor, M 1180 

Zambrana, L 1891 

Zamir, B 547 

Zamora-Legoff, T 2244 

Zanchetta, JR 1961, 1998 

Zannin, ME 1676 

Zanon, G 2034 

Zanoteli, E 1041 

Zanotti, S 1790 

Zapalowski, C 1961 

Zarco, P 998, 999, 1701 

Zarnitsky, C 2554 

Zarotsky, V 483 

Zauner, D 117 

Zavada, J 1926 

Zavadil, J 889 

Zazzetti, F 200 

Zbehlik, AJ 2041 

Zea, A 980, 1424, 2239 

Zeddou, M 50 

Zeft, A 2657 

Zeggini, E 2657 

Zeidler, H 1703 

Zeitlmann, L 2083 

Zelko, F 280, 281 

Zell, J 655, 2237 

Zeller, J 2591 

Zeng, X 2329 

Zengbiao, Q 756, 1945, 1950 

Zeni, S 1472 

Zerbe, GO 72, 2097 

Zerbini, C 1277 

Zerbini, C 471, 472 

Zerbini, CAF 1283 

Zerr, P 347, 783, 1502 

Zgibor, JC 2433 

Zhai, G 1118 

Zhan, JY 972 

Zhang, BY 2115 

Zhang, F 1833, 1840, 2234 

Zhang, G 2329 

Zhang, H 2329 

Zhang, H 2666 

Zhang, H 2593, 2594 

Zhang, H 636 

Zhang, J 54, 374, 1270, 2101, 2542 

Zhang, J 1476, 1512 

Zhang, L 1951 

Zhang, M 1903 

Zhang, M 1409 

Zhang, M 1802 

Zhang, M 2655 

Zhang, Q 2269 

Zhang, S 124 

Zhang, T 2387 

Zhang, W 583, 814, 1182, 2277, 

2673 

Zhang, W 2174 

Zhang, X 1442 

Zhang, X 3, 1634 

Zhang, X 2415 




Zhang, X 1529 

Zhang, X 840 

Zhang, X 1195 

Zhang, X 2176 

Zhang, XJ 1467 

Zhang, Y 1409 

Zhang, Y 141, 151, 741, 849, 1032, 

1119, 1666, 1823, 1980, 2614, 

2631 

Zhang, Y 1930 

Zhang, Z 2268, 2285 

Zhanguo, L 1260 

Zhao, C 2449 

Zhao, J 846, 984, 1613, 2283 

Zhao, M 2269 

Zhao, W 2176 

Zhao, W 1440, 1443, 2499 

Zhao, Y 2174 

Zhao, Y 2319 

Zhao, Y 2149 

Zhao, Z 578, 591, 592, 778, 2210, 

2615 

Zhenbin, L 1260 

Zheng, DH 2092, 2115 

Zheng, J 32 

Zheng, SG 1079, 2324, 2503 

Zheng, SG 1919 

Zheng, S 429 

Zheng, TS 838 

Zheng, X 1789 

Zhernakova, A 894 

Zhernakova, S 973 

Zhong, ZJ 614, 615, 616, 2241, 

2621 

Zhou, H 1293 

Zhou, H 24, 2085 

Zhou, H 2501 

Zhou, J 337 

Zhou, JJ 1671 

Zhou, J 429 

Zhou, Q 2344, 2508 

Zhou, Q 1611 

Zhou, S 2638 

Zhou, W 2452 

Zhou, X 2300 

Zhou, XJ 1447 

Zhou, Y 992 

Zhou, Y 2218 

Zhu, F 1068 

Zhu, J 2194 

Zhu, J 1065 

Zhu, LJ 2092, 2115 

Zhu, T 1322 

Zhu, W 218, 755, 1675 

Zhu, X 1497 

Zhu, Y 742, 849, 2614 

Zhu, Y 8 

Zhuang, X 2387 

Zhuoli, Z 1260 

Ziabakhsh, S 2401 

Zickert, A 2574 

Zickmund, SL 1853 

Zijlstra, TR 2637 

Zimetti, F 675 

Zimmer, R 2620 

Zimmermann, B 4 

Zimmermann, D 1091 

Zinger, H 1456 

Zink, A 77, 365, 1214 

Zinser, E 1072 

Zisman, D 450, 547 

Ziswiler, HR 107 

Zitnik, R 451 

Ziza, JM 195, 2383 

Zizzo, G 688 

Zlotnick, S 464 

Zochling, J 387, 1460, 2140, 2628 

Zollars, E 618 

Zoller, E 843 

Zou, CJ 2092, 2115 

Zou, H 1497, 2300 

Zu, N 1951 

Zubarev, R 1691 

Zuber, C 2343 

Zuber, M 1551 

Zuber, Z 1597 

Zubieta, JK 2450 

Zubler, V 548, 778, 1024, 1033 

Zucchetta, P 2034 

Zuckerman, A 1290 

Zuckerman, SH 2653 

Zufferey, P 107, 135, 1234 

Zuily, S 1740, 2459 

Zulian, F 1676, 2021, 2034, 2473, 

2477 

Zwillich, SH 773, 1277, 1284, 2485 

Zwillich, SH 1282, 1283, 1297, 

2486 

406 

2012 Program Book

A 

Alarcon, Graciela S., MD, MPH 

Systemic Lupus Erythematosus - Clinical Aspects 

and Treatment II: Clinical Aspects/Pregnancy 


Aletaha, Daniel, MD, MSc 

Rheumatoid Arthritis Treatment - Small 

Molecules, Biologics and Gene Therapy: Safety 

& Efficacy of Janus Activated-Kinase (JAK) 

Inhibitors 


Aliprantis, Antonios O., MD 


Regulation of Bone Cells 


Aringer, Martin, MD 


Molecules, Biologics and Gene Therapy: Safety 

& Efficacy of Janus Activated-Kinase (JAK) 

Inhibitors 


Pharmaceuticals, 5; Pfizer Inc, 5; Roche 


Asahara, Hiroshi, MD 




Askanase, Anca, MD, MPH 


and Treatment I: Renal 


Assassi, Shervin, MD, MS 




B 

Barnabe, Cheryl, MD, MSc 

Epidemiology and Health Services Research 

I: Epidemiology and Outcomes in Rheumatic 

Disease 

Disclosure: Amgen, Pfizer, Bristol-Myers Squibb, 

Roche, UCB, 5 

Baron, Murray, MD 




Battistone, Michael J., MD 



Beam, Thuy T., BSN, RN 



Becker, Michael A., MD 


Disclosure: Ardea Biociences Inc, 5; 






Belza, Basia, PhD 



Birnbaum, Neal S., MD 


Drugs for Rheumatoid Arthritis: New 

Insights on Comorbidities and Adverse Events 

Disclosure: Amgen, Pfizer, Janssen, Abbott, 8 

Blalock, Susan J., PhD 

Programs and Literacy in Patients with 

Rheumatologic Diseases 


Blitz, Jill R., PT, DPT 

Doing Is Believing: Health Beliefs Before 

and After an Exercised-Based Rehabilitation 

Programme for Chronic Knee Pain 





Brady, Teresa J., PhD 



Bykerk, Vivian P., MD 

Rheumatoid Arthritis - Clinical Aspects I: Risk 

Factors and Prediction of Rheumatoid Arthritis 


C 

Calabrese, Leonard H., DO 


Disclosure: Amgen, 8; Bristol-Myers Squibb, 

5; Genentech and Biogen IDEC Inc., 5; Janssen 

Pharmaceutica Product, L.P., 5; Sanofi-Aventis 

Pharmaceutical, 5; ucb, 5 

Callahan, Leigh F., PhD 

Clinical and Rehabilitative Aspects of 



Caplan, Liron, MD, PhD 

Epidemiology and Health Services Research 

I: Epidemiology and Outcomes in Rheumatic 

Disease 


Carrino, John, MD, MPH 



Disclosure: Carestream, Siemens, General 

Electric, 6; Medtronic, General Electric, Quality 

Medical Metrics, Vital Images, 5; Merge 

Healthcare, 1; Siemens, Toshiba, Carestream, 2 

Chatham, W. Winn, MD 


Disclosure: Centocor, Inc., 2; GlaxoSmithKline, 

9; Human Genome Sciences, Inc., 2, 5; UCB 

Pharma, 2 

Chow, Shingpui Betty, PT, MA, OCS 

Associations of Foot Forces and Pressures to 

Regional Foot Pain: The Framingham Foot Study 




Choy, Ernest, MD 

Rheumatoid Arthritis - Clinical Aspects VI: 

Remission and Flare in Rheumatoid Arthritis 

Disclosure: Chugai, 5, 8; Daiichi Pharmaceutical 

Corporation, 5; Eli Lilly and Company, 5; 

Ferring Pharmaceuticals, 5; GSK, 5; Jazz 

Pharmaceuticals, 5; MedImmune, 5; Merck 

Pharmaceuticals, 5, 8; NovImmune, 5; Pfizer Inc, 

5, 8; Roche Pharmaceuticals, 2, 5, 8; UCB, 2, 5, 8 

Cid, Maria C., MD 



Clauw, Daniel J., MD 


Disclosure: Pfizer Inc, Forest Laboratories, 

Merck, Nuvo , 2; Pfizer, Forest, Lilly, Merck, 

Nuvo, J and J , 5 

Cohen, Philip L., MD 

B-cell Biology and Targets in Autoimmune 

Disease 


Colbert, Robert A., MD, PhD 




Cook, Dane B., PhD 



Costenbader, Karen H., MD, MPH 

ACR/ARHP Combined Epidemiology Abstract 

Session 


Coty, Mary-Beth, PhD, RN 

Beliefs, Perceptions and Coping 


Criswell, Lindsey A., MD, MPH 



Crow, Mary K., MD 

Systemic Lupus Erythematosus - Human Etiology 

and Pathogenesis II 

Disclosure: Baxter, 5; Celgene, 5; EMD Merck 

Serono, 5; Genentech and Biogen IDEC Inc., 5; 

Idera, 5; Johnson & Johnson, 1; Johnson and 

Johnson, 5; MedImmune, 5; Novo Nordisk, 2; 

Pfizer Inc, 1; Takeda, 5 

Curtis, Jeffrey, MD, MPH, MS 


Rheumatoid Arthritis Management in the Treatto-Target 

Era 


Deal, Chad L., MD 



Dellaripa, Paul F., MD 



Disclosure: Genentech and Biogen IDEC Inc., 

2; Intermune, Inc., 2; Novartis Pharmaceutical 

Corporation, 2; Stomedix, Inc., 2 

D 

Abstract Moderator disclosure 


Deodhar, Atul A., MD 



Dewing, Kori A., DNP, ARNP 

Research 


Domsic, Robyn T., MD, MPH 




Dunlop, DOrothy D., PhD 

ARHP Epidemiology & Public Health Oral Session 

2-Lifestyle Factors in Relation to Arthritis 


Clinical and Rehabilitative Aspects of 



E 

Eggebeen, Aaron T., MD 


Molecules, Biologics and Gene Therapy: Efficacy 

of Approved Biologics 


Eisenberg, Robert A., MD 

B-cell Biology and Targets in Autoimmune 

Disease 


Elewaut, Dirk, MD, PhD 

Spondylarthropathies and Psoriatic Arthritis 

- Clinical Aspects and Treatment: Psoriatic 

Arthritis and Spondyloarthritis 


Elkon, Keith B., MBBCh 



Englund, Martin, MD, PhD 

Osteoarthritis - Clinical Aspects II: Structural 

Risks for Osteoarthritis End-points and Potential 

Treatments 


Escalante, Agustin, MD 



French, Anthony R., MD, PhD 

Pediatric Rheumatology - Pathogenesis and 

Genetics 


Furie, Richard A., MD 

Plenary Session III: Discovery 2012 


G 

Gall, Victoria, PT, MEd 

Programs and Literacy in Patients with 

Rheumatologic Diseases 


Genovese, Mark C., MD 


Molecules, Biologics and Gene Therapy: 

Comparative Efficacy and Novel Treatment 

Strategies in Rheumatoid Arthritis 

Disclosure: Eli Lilly and Company, 2, 5 

Gensler, Lianne S., MD 

Spondylarthropathies and Psoriatic 

Arthritis - Clinical Aspects and Treatment: 

Spondyloarthritis I 



Giles, Jon T., MD 

Rheumatoid Arthritis - Clinical Aspects III: 

Rheumatoid Arthritis and Cardiovascular 

Disease 

Disclosure: Roche/Genentech, 5 

Gilkeson, Gary S., MD 



Goldenberg, DOn L., MD 


Disclosure: Forest , Lilly, Pfizer Inc, 5; Pfizer Inc, 2 

Goldring, Mary B., PhD 



Disclosure: Abbott Laboratories, 2; Biogen Idec, 

2; Fidia Farmaceutici S.p.A., 5; Merck-Serono, 2 

Gomez-Puerta, Jose A., MD, PhD 


and Treatment IV: Therapeutics 


Greco, Carol M., PhD 


Disclosure: NIAMS-NIH, 2; Pfizer Inc, 1 


Disclosure: NIAMS-NIH, 2; Pfizer Inc, 1 

Grisanti, Joseph M., MD 


Molecules, Biologics and Gene Therapy: Safety II 


Grom, Alexei A., MD 

Pediatric Rheumatology - Pathogenesis and 

Genetics 

Disclosure: Novartis Pharmaceutical 

Corporation, 5; NovImmune, 9; Roche 


Gross, K. Douglas, DPT, MSc 

ARHP Epidemiology & Public Health Oral 

Session 3-Biomechanics & Foot Disorders 


Grossman, Jennifer M., MD 


and Treatment I: Renal 

Disclosure: medimmune, UCB, Pfizer, TEVA, 

Cephalon, American College of Rheumatology, 

Eli Lilly, 2 

Guccione, Andrew A., DPT, PhD 


1- Predictors & Consequences of Arthritis 


Guermazi, Ali, MD, PhD 



Disclosure: AstraZeneca, 5; Boston Imaging Core 

Lab, 1; Genzyme Corporation, 5; Merck Serono, 

5; Novartis Pharmaceutical Corporation, 5; 

Stryker, 5 

Guillevin, Loic P., MD 


Disclosure: Roche Pharmaceuticals, 2, 5 

H 

Hajj- Ali, Rula, MD 



Hanaoka, Beatriz Y., MD 



Hannan, Marian T., DSc, MPH 

ARHP Epidemiology & Public Health Oral 

Session 3-Biomechanics & Foot Disorders 


Haqqi, Tariq M., PhD 


Regulation of Bone Cells 


Hassett, Afton L., PsyD 



Head, Andrew J., MD 



and Safety of Novel Entities 


Helfgott, Simon M., MD 


Molecules, Biologics and Gene Therapy: Safety I 


Pharmaceuticals, 5; Roche Pharmaceuticals, 5 

Helmick, Charles G., MD 




F 

Fitzcharles, Mary-Ann, MBChB, MD 


Disclosure: Pfizer Inc, Lilly, Purdue, Valeant, 5 

FitzGerald, John D., MD, PhD 

ACR/ARHP Combined Rehabilitation Abstract 

Session 


Forbess, Lindsy J., MD 

ACR/REF Edmond L. Dubois, MD Memorial 

Lectureship: Hydroxychloroquine Reduces 

Thrombosis in Systemic Lupus Erythematosus, 

Particularly in Antiphospholipid Positive Patients 


Hetland, Merete L., MD, PhD, DMSc 

Rheumatoid Arthritis - Clinical Aspects VII: 

Prediction of Outcome in Rheumatoid Arthritis 


Squibb, 5; MSD, 5; Pfizer Inc, 5; Roche, 5; UCB 

Nordic, 5 

408 

2012 Program Book

Hobbs, Kathryn, MD 



and Safety of Novel Entities 

Disclosure: HGS, UCB, 6 

Hootman, Jennifer M., ATC, PhD 


2-Lifestyle Factors in Relation to Arthritis 




Education/Research/Health Services Research 


Hyrich, Kimme, MD, PhD 

Rheumatoid Arthritis - Clinical Aspects III: 

Rheumatoid Arthritis and Cardiovascular 

Disease 


Rheumatoid Arthritis - Clinical Aspects II: 

Long-term Outcome of Rheumatoid Arthritis, 



I 

Ishimori, Mariko L., MD 


Rheumatic Diseases and Cardiovascular Disease 

and Risk Assessment 


Iversen, Maura D., BSc, DPT, SD, MPH 

Doing Is Believing: Health Beliefs Before 

and After an Exercised-Based Rehabilitation 

Programme for Chronic Knee Pain 





J 

Jamal, Shahin, MD, MSc 

Rheumatoid Arthritis - Clinical Aspects VI: 

Remission and Flare in Rheumatoid Arthritis 

Disclosure: Abbott, Amgen, Pfizer, Janssen, 

Roche, BMS, UCB, 5 

Jolly, Meenakshi, MD, MS 


and Treatment II: Clinical Aspects/Pregnancy 

Disclosure: GlaxoSmithKline, 5; Lupus 

Foundation of America, 2; MedImmune, 7; The 

Binding Site, 2 

Jordan, Joanne M., MD, MPH 

Osteoarthritis - Clinical Aspects I: Weight, 

Activity, and Metabolic Effects on Osteoarthritis 


Company, 5; Interleukin Genetics, Inc. , 5; 

Johnson & Johnson, 2; Johnson and Johnson, 5; 

Mutual Pharmaceutical Company, 5 

K 

Kalunian, Kenneth C., MD 


and Treatment V: Clinical Aspects 


Kaplan, Mariana J., MD 


Disclosure: Boehringer Ingelheim, 5 


and Pathogenesis II 

Disclosure: Takeda, Boehringer-Ingelheim, 9 

Karlson, Elizabeth, MD 

Rheumatoid Arthritis - Clinical Aspects I: Risk 

Factors and Prediction of Rheumatoid Arthritis 


Katz, Patricia P., PhD 

Consequences of Stress and Depression 


Kay, Jonathan, MD 


Drugs for Rheumatoid Arthritis: New 

Insights on Comorbidities and Adverse Events 


Pharmaceuticals, 2; Amgen, 5; Ardea 

Biosciences, 2; Bristol-Myers Squibb, 5; 

Celgene, 5; Crescendo BioScience, 5; Eli Lilly 

and Company, 2; Fidia Farmaceutici SpA, 2; 

fourteen22, 5; Genentech and Biogen IDEC 

Inc., 5; Horizon Pharma, 5; Janssen Biotech, 

5; Molecular Partners AG, 5; Pfizer Inc, 5; 

Roche Pharmaceuticals, 2; Sanofi-Aventis 


Keating, Richard M., MD 



Keysor, Julie J., PhD, PT 

ACR/ARHP Combined Rehabilitation Abstract 

Session 


Khan, Nasim A., MD 


Epidemiologic Risk Factors in the Development 

of Rheumatic Disease 


Kivitz, Alan J., MD, CPI 


Molecules, Biologics and Gene Therapy: Safety II 


Koch, Alisa E., MD 

Rheumatoid Arthritis - Human Etiology 

and Pathogenesis I: Early Pathogenesis of 



Krishnan, Eswar, MD, MPhil 

ACR/ARHP Epidemiology Abstract Session 


Kyburz, Diego, MD 



Kyttaris, Vasileios C., MD 


and Pathogenesis I 

Disclosure: Nothing to DiscloseL 

Langford, Carol A., MD, MHS 

Plenary Session II: Discovery 2012 



Lee, Yvonne C., MD, MMedSc 

Rheumatoid Arthritis - Clinical Aspects VII: 

Prediction of Outcome in Rheumatoid Arthritis 

Disclosure: China Med Tech, 1; Cubist 

Pharmaceuticals, 1; Elan Corporation, 1; Forest 

Laboratories, 2; Given Imaging, 1; Medco Health 

Solutions, 1; Merck Pharmaceuticals, 1; Novartis 


Lems, Willem F., MD 



Levy, Roger, MD 



Li, Suzanne C., MD, PhD 

Pediatric Rheumatology: Clinical and 

Therapeutic Disease IV: Childhood Therapeutics 

and Response 


Lisse, Jeffrey R., MD 



Arthritis 

Disclosure: UCB Pharmaceuticals, 5 

Lohr, Kristine M., MD, MS 




Losina, Elena, PhD 




Louie, James S., MD 



Lovell, Daniel J., MD, MPH 


Therapeutic Disease II: Juvenile Idiopathic 

Arthritis II 


Lubberts, Erik, PhD 





Lundberg, Ingrid E., MD, PhD 


Classification, Treatment and Outcome in 

Idiopathic Inflammatory Myopathies 

Disclosure: Bristol-Myers Squibb, 2; 

MedImmune, 5; Novartis Pharmaceutical 

Corporation, 5; Pfizer Inc, 1 




M 

Manzi, Susan, MD, MPH 


and Treatment III: Cardiovascular 

Disclosure: SEE ATTACHED, 2, 5, 7 

Mariette, Xavier, MD, PhD 



Markenson, Joseph A., MD 


Molecules, Biologics and Gene Therapy: 

Comparative Efficacy and Novel Treatment 

Strategies in Rheumatoid Arthritis 


Pharmaceuticals, 8; Amgen, 8; Bristol-Myers 

Squibb, 8; Genentech and Biogen IDEC Inc., 8; 

Janssen Pharmaceutica Product, L.P., 8; Novartis 

Pharmaceutical Corporation, 8; Pfizer Inc, 8; 

Roche Pharmaceuticals, 8; UCB , 8 

Martin, Richard W., MD, MA 



of Approved Biologics 


Matteson, Eric L., MD 




McMahon, Maureen A., MD 


and Treatment III: Cardiovascular 

Disclosure: Glaxo Smith Klein, 8; Human 

Genome Sciences, Inc., 8 


and Treatment V: Clinical Aspects 

Disclosure: Glaxo Smith Klein, 8; Human 

Genome Sciences, Inc., 8 

McQueen, Fiona M., MBChB, MD 


Tomography 


McTigue, Joan C., PA-C, MS 



Merkel, Peter A., MD, MPH 







Meroni, Pier Luigi, MD 



Michaud, Kaleb, PhD 




Miossec, Pierre, MD, PhD 



Arthritis and Novel Rheumatoid Arthritis 

Genome-Wide Association Studies 


Monach, Paul A., MD, PhD 



Morgan DeWitt, Esi M., MD, MSCE 




Mouthon Sr., Luc, MD 




N 

Neogi, Tuhina, MD, PhD 

Osteoarthritis - Clinical Aspects II: Structural 

Risks for Osteoarthritis End-points and Potential 

Treatments 


Nguyen, Uyen Sa D.T., DSc, MPH 



Nicassio, Perry M., PhD 

Beliefs, Perceptions and Coping 


O’Dell, James R., MD 

Plenary Session I: Discovery 2012 


Oddis, Chester V., MD 

Plenary Session III: Discovery 2012 


Onel, Karen, MD 


Therapeutic Disease III: Childhood Systemic 

Lupus Erythematosus and Other Vasculidities 


Pachman, Lauren M., MD 


Pathogenesis in Idiopathic Inflammatory 

Myopathies 

Disclosure: NIH- R0-1 ; Education grant from 

Behring for $5,000, 2 

Perez-Ruiz, Fernando, MD, PhD 


Disclosure: Ardea Biosciences, 5, 8; Menarini, 

5, 8; Metabolex, 5; Novartis Pharmaceutical 

Corporation, 5, 8; Savient, 5, 8 

Perlman, Harris R., PhD 



O 

P 

Pernis, Alessandra, MD 


and Pathogenesis I 


Pillinger, Michael H., MD 



Metabolic and Crystal Arthropathies: Basic 

Science 

Disclosure: 1. Takeda Inc; 2. Savient Inc, 5 

Pisetsky, David S., MD, PhD 



Arthritis and Novel Rheumatoid Arthritis 

Genome-Wide Association Studies 

Disclosure: Bio-Rad, 5; Pfizer Inc, 5 

Poole, Janet L., OTR, PhD 

Independence At Home: Real or Perceived 


Pope, Richard M., MD 

Plenary Session II: Discovery 2012 


Q 

Quismorio Jr. , Francisco P., MD 

ACR/REF Edmond L. Dubois, MD Memorial 

Lectureship: Hydroxychloroquine Reduces 

Thrombosis in Systemic Lupus Erythematosus, 

Particularly in Antiphospholipid Positive Patients 


R 

Ranganath, Veena K., MD, MS 

ACR/ARHP Epidemiology Abstract Session 

Disclosure: BMS, 2; Cellgene, 2; UCB, 2, 9 

Rao, Smita, PT, PhD 

Associations of Foot Forces and Pressures to 

Regional Foot Pain: The Framingham Foot Study 




Ravelli, Angelo, MD 


Therapeutic Disease I: Juvenile Idiopathic 

Arthritis I 


Reimold, Andreas M., MD 






Arthritis 


Rider, Lisa G., MD 


Classification, Treatment and Outcome in 

Idiopathic Inflammatory Myopathies 


410 

2012 Program Book

Robinson, William H., MD, PhD 

Rheumatoid Arthritis - Human Etiology 

and Pathogenesis I: Early Pathogenesis of 



Rose, Jillian A., LMSW 

Independence At Home: Real or Perceived 


Ruderman, Eric M., MD 

Rheumatoid Arthritis - Clinical Aspects II: 

Long-term Outcome of Rheumatoid Arthritis, 



Pharmaceuticals, 2, 5; Amgen, 5; Bristol-Myers 

Squibb, 5; Celgene, 2; CVS/Caremark, 5; Pfizer 

Inc, 2, 5; The Rheumatology Education Group, 4 

S 

Salt, Elizabeth G., PhD 




Schett, Georg A., MD, PhD 


Tomography 


Schmidt, Wolfgang A., MD 

Imaging of Rheumatic Diseases I: Ultrasound 

and X-ray 


Pharmaceuticals, 2, 5, 8; Actelion 

Pharmaceuticals US, 2; Berlin-Chemie / 

Menarini, 5, 8; Esaote, 2; General Electric, 2; 

Medac, 8; Merck Sharp Dohme, 2, 8; Novartis 

Pharmaceutical Corporation, 2; Pfizer Inc, 8; 

Roche Pharmaceuticals, 2, 5, 8; UCB, 8 

Schneider, Rayfel, MBBCh 


Therapeutic Disease I: Juvenile Idiopathic 

Arthritis I 

Disclosure: Hoffmann-La Roche, Inc., 2, 5, 8; 

Innomar Strategies, 5; Novartis Pharmaceutical 

Corporation, 2 

Schulze-Koops, Hendrik, MD, PhD 


Disclosure: Abbott, AB Science, Astra-Zeneca, 

BMS, Biotest, Celgene, Cephalon, Chugai, 

Essex, Haspira, Janssen biologics, MSD, Merck, 

Novartis, Pfizer, Roche, UCB, 2; Abbott, Actelion, 

Biotest, BMS, Chugai, Essex, GSK, MSD, Medac, 

Merck, Mundai Pharma, Novartis, Nycomed, 

Pfizer, Roche, UCB , 5 

Shah, Ami A., MD, MHS 




Shahrara, Shiva, PhD 

Cell-cell Adhesion, Cell Trafficking and 

Angiogenesis 


Sharma, Leena, MD 



Osteoarthritis - Clinical Aspects I: Weight, 

Activity, and Metabolic Effects on Osteoarthritis 


Shen, Nan, MD 



Simon, Lee S., MD 


Rheumatoid Arthritis Management in the Treatto-Target 

Era 















Singh, Jasvinder A., MBBS 

ACR/ARHP Combined Epidemiology Abstract 

Session 

Disclosure: OMERACT, 9; Savient, Takeda, Ardea, 

Regeneron, Allergan, URL pharmaceuticals and 

Novartis, 5; Takeda and Savient, 2 



Smarr, Karen L., PhD 

Consequences of Stress and Depression 




Smith, Benjamin J., PA-C 

Plenary Session I: Discovery 2012 


Smolen, Josef S., MD 


Molecules, Biologics and Gene Therapy: Safety I 

Disclosure: Abbott, Astra-Zeneca, Bristol-Myers 

Squibb, Celgene, GlaxoSmithKline, MedImmune, 

MSD, Novo-Nordisk, Pfizer, Inc., Roche, Sandoz, 

Sanofi, UCB, 5; Abbott, Bristol-Myers Squibb, 

MSD, Pfizer, Inc., Roche, UCB, 2; Rheumatology 

Textbook, Mosby-Elsevier, 7 

Somers, Emily C., PhD, ScM 


1- Predictors & Consequences of Arthritis 





Soriano, Enrique R., MD, MSc 



Spondyloarthritis II 


Pharmaceuticals, 2; Bristol-Myers Squibb, 

2; Genzyme Corporation, 2; Janssen 

Pharmaceutica Product, L.P., 8; Pfizer Inc, 8 

Southwood, Taunton R., BM, BS 


Therapeutic Disease IV: Childhood Therapeutics 

and Response 


St.Clair, E. William, MD 


Disclosure: Biogen Idec, 9; Bristol-Myers Squibb, 

1; Merck Pharmaceuticals, 1 

Stone, John, MD, MPH 


Disclosure: Genentech and Biogen IDEC Inc., 2, 

5; Roche Pharmaceuticals, 2, 5 

Sundy, John S., MD, PhD 

Metabolic and Crystal Arthropathies: Basic 

Science 


T 

Tarter, Laura L., MD 


Rheumatic Diseases and Cardiovascular Disease 

and Risk Assessment 


Taylor, Janalee, CNS, CPNP, MSN 



Temprano, Katherine K., MD 




Thiele, Ralf G., MD 

Imaging of Rheumatic Diseases I: Ultrasound 

and X-ray 

Disclosure: Abbott Laboratories, 8; American 

College of Rheumatology, 6; Amgen, 8; 

Equipment support, 9 

Trojanowska, Maria, PhD 



Genetics 


Tsokos, George C., MD 

T-cell Biology and Targets in Autoimmune 

Disease 


Tzioufas, Athanasios G., MD 





V 

W 


Valle-Oñate, Rafael, MD 



Arthritis and Spondyloarthritis 


Van den Bosch, Filip, MD, PhD 



Spondyloarthritis II 


Varga, John, MD 



Genetics 


Veale, DOuglas J., MD 

Cell-cell Adhesion, Cell Trafficking and 

Angiogenesis 


Vehe, Richard K., MD 


Therapeutic Disease II: Juvenile Idiopathic 

Arthritis II 


Vencovsky, Jiri, MD, DSc 


Pathogenesis in Idiopathic Inflammatory 

Myopathies 


Via, Charles S., MD 



Vinet, Evelyne, MD 


Epidemiologic Risk Factors in the Development 

of Rheumatic Disease 


Volin, Michael, PhD 



von Scheven, Emily, MD 


Therapeutic Disease III: Childhood Systemic 

Lupus Erythematosus and Other Vasculidities 


Wallace, Daniel J., MD 


and Treatment IV: Therapeutics 


Ward, Michael M., MD 



Spondyloarthritis I 


Weyand, Cornelia M., MD, PhD 

T-cell Biology and Targets in Autoimmune 

Disease 


412 

2012 Program Book

Notes

Notes

Prescription Enbrel ® (etanercept) is administered by injection. 

IMPORTANT SAFETY INFORMATION 

SERIOUS INFECTIONS 

Patients treated with ENBREL are at increased risk for 

developing serious infections that may lead to hospitalization 

or death. Most patients who developed these infections were 

taking concomitant immunosuppressants such as methotrexate 

or corticosteroids or were predisposed to infection because of 

their underlying disease. ENBREL should not be initiated in the 

presence of sepsis, active infections, or allergy to ENBREL or 

its components. ENBREL should be discontinued if a patient 

develops a serious infection or sepsis. Reported infections 

include: 1) Active tuberculosis (TB), including reactivation of 

latent TB. Patients with TB have frequently presented with 

disseminated or extrapulmonary disease. Patients should 

be tested for latent TB before ENBREL use and periodically 

during therapy. Treatment for latent infection should be 

initiated prior to ENBREL use, 2) Invasive fungal infections, 

including histoplasmosis, coccidioidomycosis, candidiasis, 

aspergillosis, blastomycosis, and pneumocystosis. Patients 

with histoplasmosis or other invasive fungal infections may 

present with disseminated, rather than localized, disease. 

Antigen and antibody testing for histoplasmosis may be 

negative in some patients with active infection. Empiric 

antifungal therapy should be considered in patients at risk for 

invasive fungal infections who develop severe systemic illness, 

and 3) Bacterial, viral, and other infections due to opportunistic 

pathogens, including Legionella and Listeria. 

The risks and benefits of treatment with ENBREL should be 

carefully considered prior to initiating therapy in patients 

1) with chronic or recurrent infection, 2) who have been exposed 

to TB, 3) who have resided or traveled in areas of endemic 

TB or endemic mycoses, or 4) with underlying conditions that 

may predispose them to infections such as advanced or poorly 

controlled diabetes. Patients should be closely monitored 

for the development of signs and symptoms of infection 

during and after treatment with ENBREL, including the 

possible development of TB in patients who tested negative 

for latent TB prior to initiating therapy. 

MALIGNANCIES 

Lymphoma and other malignancies, some fatal, have been 

reported in children and adolescent patients treated with 

tumor necrosis factor (TNF) blockers, including ENBREL. 

In adult clinical trials of all TNF blockers, more cases of 

lymphoma were seen compared to control patients. The risk of 

lymphoma may be up to several-fold higher in RA and psoriasis 

patients. The role of TNF blocker therapy in the development of 

malignancies is unknown. 

Cases of acute and chronic leukemia have been reported in 

association with postmarketing TNF blocker use in RA and 

other indications. The risk of leukemia may be higher in patients 

with RA (approximately 2-fold) than the general population. 

Melanoma and non-melanoma skin cancer (NMSC) have been 

reported in patients treated with TNF blockers, including 

ENBREL. Periodic skin examinations should be considered for 

all patients at increased risk for skin cancer. 

Pediatric Patients 

In patients who initiated therapy at ≤18 years of age, approximately 

half of the reported malignancies were lymphomas (Hodgkin’s 

and non-Hodgkin’s lymphoma). Other cases included rare 

malignancies usually associated with immunosuppression and 

malignancies that are not usually observed in children and 

adolescents. Most of the patients were receiving concomitant 

immunosuppressants. 

NEUROLOGIC EVENTS 

Treatment with TNF-blocking agents, including ENBREL, has been 

associated with rare (

When you have decided a biologic is the next step 

Choose 

ENBREL 

for appropriate moderate 

to severe RA patients 

Visit us at 

booth 707 

ENBREL provided rapid and sustained efficacy 

in patients with moderate to severe RA 

ACR 20 Responses at Week 2, Year 1, and Year 3 (NRI) were 1 : 

44%, 75%, and 52% for ENBREL + MTX* 

19%, 59%, and 33% for MTX only 

*P

PRE-MEETING COURSES - American College of Rheumatology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?